data_1whh_residue save_MolProbity _Software.Sf_category software _Software.Sf_framecode MolProbity _Software.Entry_ID ? _Software.ID 1 _Software.Name MolProbity _Software.Version 4.0 _Software.Details . save_ save_CYRANGE _Software.Sf_category software _Software.Sf_framecode CYRANGE _Software.Entry_ID ? _Software.ID 2 _Software.Name CYRANGE _Software.Version 2.0 _Software.Details . save_ save_Structure_validation_residue _Structure_validation_residue.Sf_category structure_validation _Structure_validation_residue.Sf_framecode Structure_validation_residue _Structure_validation_residue.Entry_ID ? _Structure_validation_residue.List_ID 1 _Structure_validation_residue.PDB_accession_code 1whh _Structure_validation_residue.Date_analyzed 2016-10-07 loop_ _Residue_analysis_software.Software_ID _Residue_analysis_software.Software_label _Residue_analysis_software.Method_ID _Residue_analysis_software.Method_label _Residue_analysis_software.Entry_ID _Residue_analysis_software.Structure_validation_oneline_list_ID 1 MolProbity . . ? 1 2 CYRANGE . . ? 1 stop_ loop_ _Residue_analysis.ID _Residue_analysis.PDB_model_num _Residue_analysis.Hydrogen_positions _Residue_analysis.MolProbity_flips _Residue_analysis.Cyrange_core_flag _Residue_analysis.Two_letter_chain_ID _Residue_analysis.PDB_strand_ID _Residue_analysis.PDB_residue_no _Residue_analysis.PDB_ins_code _Residue_analysis.PDB_residue_name _Residue_analysis.Assembly_ID _Residue_analysis.Entity_assembly_ID _Residue_analysis.Entity_ID _Residue_analysis.Comp_ID _Residue_analysis.Comp_index_ID _Residue_analysis.Clash_value _Residue_analysis.Clash_source_PDB_atom_name _Residue_analysis.Clash_destination_PDB_atom_name _Residue_analysis.Clash_destination_PDB_strand_ID _Residue_analysis.Clash_destination_PDB_residue_no _Residue_analysis.Clash_destination_PDB_ins_code _Residue_analysis.Clash_destination_PDB_residue_name _Residue_analysis.Cbeta_deviation_value _Residue_analysis.Rotamer_score _Residue_analysis.Rotamer_name _Residue_analysis.Ramachandran_phi _Residue_analysis.Ramachandran_psi _Residue_analysis.Ramachandran_score _Residue_analysis.Ramachandran_evaluation _Residue_analysis.Ramachandran_type _Residue_analysis.Bond_outlier_count _Residue_analysis.Worst_bond _Residue_analysis.Worst_bond_value _Residue_analysis.Worst_bond_sigma _Residue_analysis.Angle_outlier_count _Residue_analysis.Worst_angle _Residue_analysis.Worst_angle_value _Residue_analysis.Worst_angle_sigma _Residue_analysis.RNA_phosphate_perpendicular_outlier _Residue_analysis.RNA_suitness_score _Residue_analysis.RNA_suite_conformer _Residue_analysis.RNA_suite_triage _Residue_analysis.Max_b_factor _Residue_analysis.Tau_angle _Residue_analysis.Omega_dihedral _Residue_analysis.Disulfide_chi1 _Residue_analysis.Disulfide_chi2 _Residue_analysis.Disulfide_chi3 _Residue_analysis.Disulfide_ss_angle _Residue_analysis.Disulfide_ss _Residue_analysis.Disulfide_ss_angle_prime _Residue_analysis.Disulfide_chi2prime _Residue_analysis.Disulfide_chi1prime _Residue_analysis.Outlier_count_separate_geometry _Residue_analysis.Outlier_count _Residue_analysis.Entry_ID _Residue_analysis.Structure_validation_residue_list_ID . 001 nuclear orig core ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.231 0.11 0 CA-C-O 120.761 0.315 . . . . 0.0 111.164 . . . . . . . . . 0 0 . 1 . 001 nuclear orig core ' A' A ' 27' ' ' GLU . . . . . . . . . . . . . 2.1 mm-40 -149.14 167.56 25.59 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.941 -179.992 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 21.8 t -68.6 125.02 25.54 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 CA-C-N 116.176 -0.465 . . . . 0.0 111.106 -179.975 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 98.39 29.66 7.36 Favored Glycine 0 N--CA 1.451 -0.347 0 C-N-CA 120.724 -0.751 . . . . 0.0 112.446 -179.991 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -138.76 147.96 43.27 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-O 120.814 0.34 . . . . 0.0 110.845 -179.928 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 31' ' ' GLN . . . . . . . . . . . . . 0.7 OUTLIER -72.65 127.25 32.0 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.963 179.977 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 22.2 m -130.16 179.9 3.79 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 CA-C-N 116.265 -0.425 . . . . 0.0 111.192 179.973 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 33' ' ' LEU . . . . . . . . . . . . . 15.7 tp -139.52 109.33 6.32 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.262 -0.426 . . . . 0.0 110.963 -179.993 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 23.1 t -76.57 121.12 28.08 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.261 -0.427 . . . . 0.0 111.138 -180.0 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 35' ' ' ALA . . . . . . . . . . . . . . . 59.22 26.61 15.42 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.244 179.976 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . 56.74 36.64 73.01 Favored Glycine 0 N--CA 1.45 -0.387 0 C-N-CA 120.74 -0.743 . . . . 0.0 112.639 179.954 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 37' ' ' GLN . . . . . . . . . . . . . 35.3 mt-30 -146.98 -71.42 0.23 Allowed 'General case' 0 C--N 1.329 -0.325 0 CA-C-O 120.796 0.331 . . . . 0.0 110.948 -179.998 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 38' ' ' LYS . . . . . . . . . . . . . 13.2 mttm -67.83 114.79 6.71 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.879 -179.995 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 39' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -90.14 125.98 35.64 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.922 179.935 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -152.77 -175.61 24.45 Favored Glycine 0 N--CA 1.451 -0.347 0 C-N-CA 120.715 -0.755 . . . . 0.0 112.5 -179.971 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 4.3 mt -127.64 128.79 69.94 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.272 0 CA-C-O 120.8 0.333 . . . . 0.0 111.02 -179.948 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 42' ' ' VAL . . . . . . . . . . . . . 21.6 t -59.99 124.42 14.28 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.253 -0.431 . . . . 0.0 111.084 179.975 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 43' ' ' ARG . . . . . . . . . . . . . 45.0 mmt-85 -110.57 -30.24 7.71 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.23 -0.441 . . . . 0.0 111.077 -179.993 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 44' ' ' PHE . . . . . . . . . . . . . 35.7 t80 -143.61 118.6 10.02 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.318 -0.401 . . . . 0.0 110.993 -179.958 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 45' ' ' TYR . . . . . 0.455 ' CE1' ' CZ ' ' A' ' 56' ' ' TYR . 22.2 t80 -115.08 114.9 25.96 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.845 179.899 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 176.8 162.96 28.27 Favored Glycine 0 N--CA 1.45 -0.382 0 C-N-CA 120.699 -0.763 . . . . 0.0 112.441 179.944 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 47' ' ' LYS . . . . . 0.418 ' HG3' ' CE1' ' A' ' 54' ' ' TYR . 22.7 mttt -65.98 137.32 57.05 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.865 0.364 . . . . 0.0 110.852 179.97 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 48' ' ' THR . . . . . . . . . . . . . 41.2 p -95.67 -175.35 3.41 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.902 179.918 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 4.6 t70 -106.58 -30.87 8.76 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.893 179.987 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 50' ' ' PHE . . . . . 0.418 ' CE1' ' HB1' ' A' ' 51' ' ' ALA . 44.3 p90 -71.29 -36.22 71.58 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.867 -179.985 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 51' ' ' ALA . . . . . 0.418 ' HB1' ' CE1' ' A' ' 50' ' ' PHE . . . -132.69 148.17 68.48 Favored Pre-proline 0 C--N 1.33 -0.274 0 CA-C-N 116.236 -0.438 . . . . 0.0 111.188 179.978 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 52' ' ' PRO . . . . . . . . . . . . . 59.9 Cg_endo -72.25 -170.07 0.53 Allowed 'Trans proline' 0 C--N 1.344 0.34 0 C-N-CA 122.601 2.201 . . . . 0.0 112.336 -179.97 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 59.26 -161.01 15.5 Favored Glycine 0 N--CA 1.452 -0.283 0 C-N-CA 120.746 -0.74 . . . . 0.0 112.537 179.976 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 54' ' ' TYR . . . . . 0.418 ' CE1' ' HG3' ' A' ' 47' ' ' LYS . 12.8 m-85 -106.19 157.8 17.3 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-O 120.844 0.354 . . . . 0.0 110.855 -179.95 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 55' ' ' TRP . . . . . 0.41 ' CZ3' ' HD3' ' A' ' 88' ' ' PRO . 69.5 m95 -144.37 159.71 42.27 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.898 179.988 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 56' ' ' TYR . . . . . 0.455 ' CZ ' ' CE1' ' A' ' 45' ' ' TYR . 5.7 m-85 -116.36 115.26 25.55 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.878 -179.951 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 57' ' ' GLY . . . . . 0.443 ' CA ' ' CE1' ' A' ' 86' ' ' PHE . . . -82.27 65.72 4.02 Favored Glycine 0 N--CA 1.451 -0.307 0 C-N-CA 120.75 -0.738 . . . . 0.0 112.431 -179.973 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 58' ' ' ILE . . . . . . . . . . . . . 5.5 mt -72.67 143.66 13.75 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-O 120.816 0.341 . . . . 0.0 111.074 179.986 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 8.0 tt0 -104.23 143.04 33.49 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.836 179.95 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 60' ' ' LEU . . . . . . . . . . . . . 82.1 mt -96.11 173.18 7.54 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.929 -179.957 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 7.9 t0 -97.12 -33.19 11.6 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.954 179.991 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 62' ' ' GLN . . . . . . . . . . . . . 2.7 mt-30 -116.14 146.36 36.99 Favored Pre-proline 0 C--N 1.329 -0.319 0 CA-C-N 116.18 -0.463 . . . . 0.0 110.936 179.97 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 48.1 Cg_exo -55.83 86.75 0.04 OUTLIER 'Trans proline' 0 C--N 1.346 0.409 0 C-N-CA 122.548 2.165 . . . . 0.0 112.172 179.955 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 64' ' ' THR . . . . . . . . . . . . . 80.8 p -157.3 30.44 0.29 Allowed 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.251 -0.431 . . . . 0.0 110.984 -179.979 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . -89.62 175.54 42.29 Favored Glycine 0 N--CA 1.451 -0.363 0 C-N-CA 120.708 -0.758 . . . . 0.0 112.491 179.957 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 66' ' ' LYS . . . . . . . . . . . . . 48.5 mttm -78.61 -30.47 46.57 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 120.693 0.282 . . . . 0.0 110.865 179.94 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 67' ' ' HIS . . . . . . . . . . . . . 7.4 p80 -148.38 -178.98 6.61 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.898 -179.961 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 9.2 p30 -105.25 48.49 0.84 Allowed 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.952 179.999 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 94.02 -45.91 2.27 Favored Glycine 0 N--CA 1.452 -0.294 0 C-N-CA 120.738 -0.744 . . . . 0.0 112.512 -179.964 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 70' ' ' SER . . . . . . . . . . . . . 1.6 p -98.96 136.58 38.73 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-O 120.821 0.344 . . . . 0.0 110.901 179.985 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 21.4 t -114.41 110.64 32.8 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.253 -0.431 . . . . 0.0 111.131 179.969 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 72' ' ' PHE . . . . . . . . . . . . . 60.6 m-85 60.47 31.89 20.41 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.22 -0.446 . . . . 0.0 110.961 179.967 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 98.85 -30.18 10.25 Favored Glycine 0 N--CA 1.451 -0.355 0 C-N-CA 120.685 -0.769 . . . . 0.0 112.556 -179.962 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 21.4 t -77.95 117.63 23.52 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-O 120.823 0.344 . . . . 0.0 111.127 179.904 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 75' ' ' ARG . . . . . . . . . . . . . 5.1 ttt180 -95.33 149.52 21.27 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.988 -179.864 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 76' ' ' TYR . . . . . . . . . . . . . 35.9 m-85 -129.94 -45.6 1.15 Allowed 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.25 -0.432 . . . . 0.0 110.947 179.951 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 77' ' ' PHE . . . . . . . . . . . . . 38.1 p90 -146.72 164.72 31.85 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.31 -0.405 . . . . 0.0 110.997 179.945 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 51.7 p -96.18 123.49 39.82 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.921 -179.97 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 79' ' ' CYS . . . . . . . . . . . . . 7.5 p -148.02 170.57 17.47 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.877 179.891 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 80' ' ' ALA . . . . . . . . . . . . . . . -71.73 162.48 72.93 Favored Pre-proline 0 C--N 1.329 -0.289 0 CA-C-N 116.163 -0.471 . . . . 0.0 111.079 -179.952 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 81' ' ' PRO . . . . . . . . . . . . . 53.0 Cg_exo -52.4 118.46 4.66 Favored 'Trans proline' 0 C--N 1.344 0.3 0 C-N-CA 122.632 2.221 . . . . 0.0 112.294 179.971 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 82' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER 60.27 63.53 1.38 Allowed 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.869 179.972 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 83' ' ' HIS . . . . . . . . . . . . . 3.3 m-70 -132.3 -46.02 0.91 Allowed 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.13 -0.486 . . . . 0.0 110.911 -179.975 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . -63.73 141.69 45.74 Favored Glycine 0 N--CA 1.451 -0.362 0 C-N-CA 120.709 -0.757 . . . . 0.0 112.52 179.996 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 85' ' ' VAL . . . . . . . . . . . . . 6.1 m -142.15 120.14 8.24 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-O 120.768 0.318 . . . . 0.0 111.166 -179.974 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 86' ' ' PHE . . . . . 0.443 ' CE1' ' CA ' ' A' ' 57' ' ' GLY . 12.4 m-85 -100.38 115.39 29.9 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.868 179.994 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 87' ' ' ALA . . . . . . . . . . . . . . . -137.8 145.57 49.04 Favored Pre-proline 0 C--N 1.328 -0.336 0 CA-C-N 116.28 -0.418 . . . . 0.0 111.143 179.924 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 88' ' ' PRO . . . . . 0.425 ' O ' ' N ' ' A' ' 91' ' ' ARG . 47.4 Cg_exo -56.02 139.14 84.51 Favored 'Trans proline' 0 C--N 1.345 0.388 0 C-N-CA 122.454 2.103 . . . . 0.0 112.336 -179.977 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -48.01 -50.91 26.03 Favored 'General case' 0 C--N 1.333 -0.122 0 CA-C-N 116.109 -0.496 . . . . 0.0 110.272 179.862 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 90' ' ' SER . . . . . . . . . . . . . 17.7 m -55.76 -24.49 35.65 Favored 'General case' 0 N--CA 1.454 -0.259 0 CA-C-N 115.687 -0.688 . . . . 0.0 109.766 178.816 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 91' ' ' ARG . . . . . 0.425 ' N ' ' O ' ' A' ' 88' ' ' PRO . 0.6 OUTLIER -88.3 -15.14 36.53 Favored 'General case' 0 N--CA 1.455 -0.188 0 CA-C-N 115.831 -0.622 . . . . 0.0 110.473 179.02 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 92' ' ' ILE . . . . . . . . . . . . . 33.3 mt -104.37 157.89 5.5 Favored 'Isoleucine or valine' 0 C--N 1.334 -0.097 0 CA-C-N 116.379 -0.373 . . . . 0.0 110.973 179.924 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 93' ' ' GLN . . . . . . . . . . . . . 2.2 mt-30 -128.3 166.34 18.81 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.889 -179.912 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 94' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -107.15 145.36 32.64 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.846 -179.994 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 95' ' ' ILE . . . . . . . . . . . . . 23.4 mt . . . . . 0 C--N 1.329 -0.299 0 CA-C-N 116.211 -0.449 . . . . 0.0 111.13 179.902 . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.231 0.101 0 CA-C-O 120.877 0.37 . . . . 0.0 111.081 . . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' A' A ' 27' ' ' GLU . . . . . . . . . . . . . 6.0 mt-10 -148.03 173.37 12.98 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.252 -0.431 . . . . 0.0 110.911 179.98 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 21.5 t -70.83 110.28 3.72 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.087 179.974 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 113.01 36.24 1.54 Allowed Glycine 0 N--CA 1.452 -0.296 0 C-N-CA 120.736 -0.745 . . . . 0.0 112.503 179.97 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 2.1 m-20 -150.06 138.05 20.23 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 120.852 0.358 . . . . 0.0 110.866 -179.978 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 31' ' ' GLN . . . . . . . . . . . . . 0.7 OUTLIER -62.94 132.88 53.57 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.125 -0.489 . . . . 0.0 110.871 179.998 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 12.6 m -132.99 178.81 5.12 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.149 179.99 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 33' ' ' LEU . . . . . . . . . . . . . 40.4 tp -140.14 101.22 4.1 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.9 179.931 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 21.6 t -72.55 127.68 34.75 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.218 -0.446 . . . . 0.0 111.175 -179.928 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 35' ' ' ALA . . . . . . . . . . . . . . . 57.68 25.33 11.62 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.139 -0.482 . . . . 0.0 111.266 179.937 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . 56.07 27.96 52.75 Favored Glycine 0 N--CA 1.453 -0.224 0 C-N-CA 120.686 -0.769 . . . . 0.0 112.638 179.979 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 37' ' ' GLN . . . . . . . . . . . . . 29.5 mt-30 -138.1 -72.83 0.41 Allowed 'General case' 0 C--N 1.33 -0.279 0 CA-C-O 120.797 0.332 . . . . 0.0 110.944 -179.906 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 38' ' ' LYS . . . . . . . . . . . . . 3.7 mttt -69.02 111.81 5.25 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.265 -0.425 . . . . 0.0 110.965 179.991 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 39' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -92.98 130.5 38.53 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.086 -0.506 . . . . 0.0 110.905 -179.997 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -152.04 -171.0 19.33 Favored Glycine 0 N--CA 1.45 -0.38 0 C-N-CA 120.812 -0.709 . . . . 0.0 112.52 -179.988 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 29.8 mt -123.4 131.92 72.29 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 CA-C-O 120.825 0.345 . . . . 0.0 111.172 179.973 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 42' ' ' VAL . . . . . . . . . . . . . 21.6 t -59.44 126.87 17.85 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.336 0 CA-C-N 116.24 -0.436 . . . . 0.0 111.105 -179.999 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 43' ' ' ARG . . . . . . . . . . . . . 8.7 mmm180 -111.81 -42.56 3.78 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.932 -179.999 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 44' ' ' PHE . . . . . . . . . . . . . 46.0 t80 -138.66 113.24 8.95 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.937 -179.937 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 45' ' ' TYR . . . . . 0.426 ' CE1' ' CE1' ' A' ' 56' ' ' TYR . 35.8 t80 -113.08 138.56 49.73 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.956 179.98 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 152.71 -169.57 31.79 Favored Glycine 0 N--CA 1.449 -0.45 0 C-N-CA 120.783 -0.722 . . . . 0.0 112.489 179.957 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 47' ' ' LYS . . . . . . . . . . . . . 28.7 mttm -78.21 147.35 34.49 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-O 120.847 0.356 . . . . 0.0 110.844 -179.954 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 48' ' ' THR . . . . . 0.412 ' HB ' ' CE2' ' A' ' 50' ' ' PHE . 34.8 p -118.88 171.52 8.17 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.913 179.985 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -98.88 -35.79 9.99 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.885 179.972 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 50' ' ' PHE . . . . . 0.418 ' CD1' ' HB3' ' A' ' 51' ' ' ALA . 27.0 p90 -61.61 -31.39 71.46 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.92 179.907 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 51' ' ' ALA . . . . . 0.418 ' HB3' ' CD1' ' A' ' 50' ' ' PHE . . . -152.11 146.42 18.52 Favored Pre-proline 0 C--N 1.329 -0.294 0 CA-C-N 116.26 -0.427 . . . . 0.0 111.117 179.997 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 52' ' ' PRO . . . . . . . . . . . . . 60.9 Cg_endo -72.86 175.82 9.84 Favored 'Trans proline' 0 C--N 1.345 0.368 0 C-N-CA 122.573 2.182 . . . . 0.0 112.334 179.973 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 84.11 -158.79 35.03 Favored Glycine 0 N--CA 1.45 -0.369 0 C-N-CA 120.716 -0.754 . . . . 0.0 112.541 179.986 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 54' ' ' TYR . . . . . . . . . . . . . 20.2 m-85 -118.74 124.64 47.78 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-O 120.872 0.368 . . . . 0.0 110.897 179.982 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 55' ' ' TRP . . . . . . . . . . . . . 36.4 m95 -118.19 162.89 17.49 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.911 179.988 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 56' ' ' TYR . . . . . 0.426 ' CE1' ' CE1' ' A' ' 45' ' ' TYR . 8.4 m-85 -110.69 125.37 53.4 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.934 -179.91 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 57' ' ' GLY . . . . . 0.416 ' HA3' ' CE1' ' A' ' 77' ' ' PHE . . . -88.01 53.28 4.21 Favored Glycine 0 N--CA 1.451 -0.365 0 C-N-CA 120.72 -0.752 . . . . 0.0 112.423 179.97 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 58' ' ' ILE . . . . . . . . . . . . . 3.8 mt -64.64 142.33 17.03 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.266 0 CA-C-O 120.834 0.349 . . . . 0.0 111.164 -179.981 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 2.4 tm-20 -115.12 108.11 16.2 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.118 -0.492 . . . . 0.0 110.836 -179.947 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 60' ' ' LEU . . . . . . . . . . . . . 48.0 mt -67.75 176.28 2.57 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.906 -179.964 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -100.86 -32.87 10.46 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.852 -179.995 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 62' ' ' GLN . . . . . . . . . . . . . 0.2 OUTLIER -101.37 154.69 37.07 Favored Pre-proline 0 C--N 1.328 -0.332 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.917 179.976 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 58.3 Cg_endo -71.85 68.13 3.09 Favored 'Trans proline' 0 C--N 1.344 0.308 0 C-N-CA 122.584 2.189 . . . . 0.0 112.275 -179.965 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 64' ' ' THR . . . . . . . . . . . . . 73.4 p -139.54 34.25 2.04 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.901 -179.994 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . -88.33 -129.11 3.15 Favored Glycine 0 N--CA 1.452 -0.295 0 C-N-CA 120.732 -0.747 . . . . 0.0 112.579 179.948 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 66' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -144.96 -47.33 0.23 Allowed 'General case' 0 C--N 1.328 -0.353 0 CA-C-O 120.785 0.326 . . . . 0.0 110.845 -179.991 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 67' ' ' HIS . . . . . . . . . . . . . 7.6 p80 -119.94 170.02 9.64 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.213 -0.448 . . . . 0.0 110.839 179.973 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 39.0 m-20 -98.42 34.04 2.09 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.862 -179.983 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 94.62 -42.72 2.39 Favored Glycine 0 N--CA 1.451 -0.329 0 C-N-CA 120.737 -0.744 . . . . 0.0 112.586 -179.939 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 70' ' ' SER . . . . . . . . . . . . . 5.6 p -100.8 134.67 43.42 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-O 120.833 0.349 . . . . 0.0 110.946 -179.984 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 71' ' ' VAL . . . . . 0.414 HG11 ' CD2' ' A' ' 72' ' ' PHE . 21.3 t -114.92 102.95 14.57 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.156 -0.474 . . . . 0.0 111.062 -179.913 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 72' ' ' PHE . . . . . 0.414 ' CD2' HG11 ' A' ' 71' ' ' VAL . 33.2 m-85 61.75 30.8 18.52 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.191 -0.458 . . . . 0.0 110.935 179.929 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 104.21 -30.09 10.81 Favored Glycine 0 N--CA 1.451 -0.362 0 C-N-CA 120.703 -0.76 . . . . 0.0 112.513 179.973 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 21.4 t -77.82 116.87 22.04 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.345 0 CA-C-O 120.749 0.309 . . . . 0.0 111.173 179.978 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 75' ' ' ARG . . . . . . . . . . . . . 10.1 ttm180 -96.62 143.24 27.77 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.272 -0.422 . . . . 0.0 110.898 -179.956 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 76' ' ' TYR . . . . . 0.408 ' CE2' HG21 ' A' ' 48' ' ' THR . 20.0 m-85 -118.69 -40.48 2.88 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.933 179.926 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 77' ' ' PHE . . . . . 0.416 ' CE1' ' HA3' ' A' ' 57' ' ' GLY . 16.0 p90 -160.07 157.55 28.79 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.956 179.972 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 18.8 m -83.9 111.51 19.3 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.836 -179.974 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 79' ' ' CYS . . . . . . . . . . . . . 30.5 p -132.74 174.24 10.52 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.901 179.941 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 80' ' ' ALA . . . . . . . . . . . . . . . -91.91 171.58 7.61 Favored Pre-proline 0 C--N 1.33 -0.281 0 CA-C-N 116.161 -0.472 . . . . 0.0 111.151 179.997 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 81' ' ' PRO . . . . . . . . . . . . . 50.7 Cg_exo -53.77 116.14 2.81 Favored 'Trans proline' 0 C--N 1.344 0.301 0 C-N-CA 122.592 2.194 . . . . 0.0 112.322 179.988 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 82' ' ' ARG . . . . . . . . . . . . . 3.4 mtp85 61.1 52.31 4.06 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.896 179.901 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 83' ' ' HIS . . . . . . . . . . . . . 6.0 m170 -120.99 -43.02 2.47 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.793 179.936 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . -75.2 144.4 31.97 Favored Glycine 0 N--CA 1.45 -0.383 0 C-N-CA 120.817 -0.706 . . . . 0.0 112.495 179.938 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 85' ' ' VAL . . . . . . . . . . . . . 6.6 m -147.77 127.39 4.44 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-O 120.806 0.336 . . . . 0.0 111.231 179.978 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 86' ' ' PHE . . . . . . . . . . . . . 6.1 m-85 -106.71 110.74 23.01 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.886 179.975 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 87' ' ' ALA . . . . . . . . . . . . . . . -132.27 150.96 77.45 Favored Pre-proline 0 C--N 1.33 -0.268 0 CA-C-N 116.189 -0.459 . . . . 0.0 111.106 -179.957 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 88' ' ' PRO . . . . . 0.405 ' O ' ' N ' ' A' ' 91' ' ' ARG . 32.1 Cg_exo -58.4 138.09 83.94 Favored 'Trans proline' 0 C--N 1.344 0.338 0 C-N-CA 122.518 2.146 . . . . 0.0 112.285 -179.972 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -48.05 -51.29 24.85 Favored 'General case' 0 CA--C 1.522 -0.124 0 CA-C-N 116.106 -0.497 . . . . 0.0 110.331 179.845 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 90' ' ' SER . . . . . . . . . . . . . 70.3 p -55.96 -24.41 38.14 Favored 'General case' 0 N--CA 1.453 -0.296 0 CA-C-N 115.714 -0.675 . . . . 0.0 109.769 178.809 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 91' ' ' ARG . . . . . 0.405 ' N ' ' O ' ' A' ' 88' ' ' PRO . 1.3 mtt180 -88.43 -14.6 37.57 Favored 'General case' 0 N--CA 1.453 -0.282 0 CA-C-N 115.852 -0.613 . . . . 0.0 110.535 178.992 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 92' ' ' ILE . . . . . . . . . . . . . 26.0 mt -107.02 146.01 13.85 Favored 'Isoleucine or valine' 0 C--O 1.23 0.076 0 CA-C-N 116.302 -0.408 . . . . 0.0 111.014 179.935 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 93' ' ' GLN . . . . . . . . . . . . . 2.1 mt-30 -115.53 177.2 4.75 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.904 179.973 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 94' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER -115.81 148.23 40.12 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.923 179.971 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 95' ' ' ILE . . . . . . . . . . . . . 28.8 mm . . . . . 0 C--N 1.328 -0.358 0 CA-C-N 116.259 -0.428 . . . . 0.0 111.082 -179.935 . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.231 0.111 0 CA-C-O 120.784 0.326 . . . . 0.0 111.143 . . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' A' A ' 27' ' ' GLU . . . . . . . . . . . . . 3.0 mt-10 -115.25 -173.28 2.29 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.899 179.967 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 21.4 t -80.18 98.31 3.36 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.312 -0.404 . . . . 0.0 111.05 179.978 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 111.78 29.72 3.25 Favored Glycine 0 N--CA 1.451 -0.312 0 C-N-CA 120.807 -0.711 . . . . 0.0 112.417 179.912 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 1.2 t70 -122.81 146.03 47.91 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 120.832 0.348 . . . . 0.0 110.894 179.981 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 31' ' ' GLN . . . . . . . . . . . . . 18.1 mt-30 -60.76 131.46 50.75 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.821 179.953 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 14.5 m -140.3 171.81 12.8 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.156 -0.475 . . . . 0.0 111.137 179.978 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 33' ' ' LEU . . . . . . . . . . . . . 17.8 tp -134.21 110.54 9.61 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.903 -179.963 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 21.6 t -77.95 120.43 28.68 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 116.221 -0.445 . . . . 0.0 111.09 -179.937 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 35' ' ' ALA . . . . . . . . . . . . . . . 58.25 27.05 14.65 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.163 -0.471 . . . . 0.0 111.192 179.981 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . 56.77 31.33 60.73 Favored Glycine 0 N--CA 1.452 -0.282 0 C-N-CA 120.709 -0.758 . . . . 0.0 112.606 179.931 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 37' ' ' GLN . . . . . . . . . . . . . 91.5 mt-30 -140.28 -73.27 0.36 Allowed 'General case' 0 C--N 1.33 -0.272 0 CA-C-O 120.833 0.349 . . . . 0.0 110.962 -179.992 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 38' ' ' LYS . . . . . . . . . . . . . 34.1 mttp -68.22 104.27 1.78 Allowed 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.855 179.977 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 39' ' ' GLN . . . . . . . . . . . . . 0.4 OUTLIER -85.34 136.07 33.63 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.252 -0.431 . . . . 0.0 110.839 179.905 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -164.56 -163.7 18.21 Favored Glycine 0 N--CA 1.451 -0.356 0 C-N-CA 120.771 -0.728 . . . . 0.0 112.539 179.965 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 41' ' ' ILE . . . . . 0.431 HD12 HG23 ' A' ' 41' ' ' ILE . 32.4 mt -131.12 139.51 50.84 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-O 120.79 0.328 . . . . 0.0 111.156 179.994 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 42' ' ' VAL . . . . . . . . . . . . . 23.2 t -69.18 124.36 24.8 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.334 0 CA-C-N 116.187 -0.46 . . . . 0.0 111.059 -179.952 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 43' ' ' ARG . . . . . . . . . . . . . 27.8 mmt180 -105.58 -32.57 8.42 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.178 -0.464 . . . . 0.0 110.984 -179.956 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 44' ' ' PHE . . . . . . . . . . . . . 51.0 t80 -143.08 118.11 10.05 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 116.189 -0.459 . . . . 0.0 110.962 -179.93 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 45' ' ' TYR . . . . . 0.494 ' CE1' ' CZ ' ' A' ' 56' ' ' TYR . 15.5 t80 -113.02 117.94 33.41 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.867 179.965 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 172.74 170.25 36.26 Favored Glycine 0 N--CA 1.452 -0.26 0 C-N-CA 120.657 -0.782 . . . . 0.0 112.487 179.979 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 47' ' ' LYS . . . . . 0.415 ' HG3' ' CE1' ' A' ' 54' ' ' TYR . 19.5 mttt -67.09 148.08 52.33 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 120.837 0.351 . . . . 0.0 110.942 179.983 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 48' ' ' THR . . . . . . . . . . . . . 16.6 p -109.15 170.85 7.79 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.893 179.988 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 8.3 t0 -98.3 -31.12 12.21 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.869 179.989 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 50' ' ' PHE . . . . . 0.435 ' CD1' ' N ' ' A' ' 51' ' ' ALA . 18.1 p90 -66.54 -32.23 73.45 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.935 -179.962 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 51' ' ' ALA . . . . . 0.435 ' N ' ' CD1' ' A' ' 50' ' ' PHE . . . -148.94 151.72 35.34 Favored Pre-proline 0 C--N 1.329 -0.299 0 CA-C-N 116.271 -0.422 . . . . 0.0 111.096 179.996 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 52' ' ' PRO . . . . . . . . . . . . . 56.8 Cg_endo -70.67 -167.94 0.29 Allowed 'Trans proline' 0 C--N 1.344 0.31 0 C-N-CA 122.598 2.198 . . . . 0.0 112.289 179.997 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 65.2 -176.39 12.82 Favored Glycine 0 N--CA 1.45 -0.38 0 C-N-CA 120.791 -0.719 . . . . 0.0 112.481 179.971 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 54' ' ' TYR . . . . . 0.415 ' CE1' ' HG3' ' A' ' 47' ' ' LYS . 7.6 m-85 -106.57 128.97 54.55 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-O 120.828 0.347 . . . . 0.0 110.928 179.974 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 55' ' ' TRP . . . . . . . . . . . . . 35.0 m95 -116.2 174.29 6.13 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.846 -179.969 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 56' ' ' TYR . . . . . 0.494 ' CZ ' ' CE1' ' A' ' 45' ' ' TYR . 16.8 m-85 -125.35 121.64 34.51 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.92 -179.963 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 57' ' ' GLY . . . . . 0.403 ' N ' ' CE1' ' A' ' 86' ' ' PHE . . . -82.11 62.03 4.61 Favored Glycine 0 N--CA 1.451 -0.33 0 C-N-CA 120.776 -0.726 . . . . 0.0 112.417 179.928 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 58' ' ' ILE . . . . . . . . . . . . . 21.2 mt -68.67 139.71 20.14 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-O 120.809 0.338 . . . . 0.0 111.122 -179.993 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 4.7 tm-20 -111.99 112.52 24.22 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.91 179.959 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 60' ' ' LEU . . . . . . . . . . . . . 84.7 mt -72.53 177.34 4.73 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.967 -179.992 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -100.42 -32.37 10.85 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.815 179.998 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 62' ' ' GLN . . . . . . . . . . . . . 4.7 mm100 -106.62 155.33 39.08 Favored Pre-proline 0 C--N 1.328 -0.34 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.829 179.999 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 57.7 Cg_endo -71.51 68.11 2.82 Favored 'Trans proline' 0 C--N 1.345 0.354 0 C-N-CA 122.544 2.163 . . . . 0.0 112.399 179.907 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 64' ' ' THR . . . . . . . . . . . . . 12.4 p -136.0 31.18 3.0 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.871 -179.999 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . -92.95 -139.75 9.46 Favored Glycine 0 N--CA 1.451 -0.349 0 C-N-CA 120.754 -0.736 . . . . 0.0 112.548 -179.956 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 66' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -128.63 -45.75 1.31 Allowed 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 120.848 0.356 . . . . 0.0 110.924 179.961 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 67' ' ' HIS . . . . . . . . . . . . . 7.2 p80 -127.1 169.89 12.93 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.233 -0.44 . . . . 0.0 110.871 179.974 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 10.3 p-10 -98.56 36.51 1.63 Allowed 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.935 179.964 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 105.88 -50.37 0.82 Allowed Glycine 0 N--CA 1.45 -0.391 0 C-N-CA 120.756 -0.735 . . . . 0.0 112.502 179.964 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 70' ' ' SER . . . . . . . . . . . . . 80.5 p -93.26 151.84 19.56 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 120.836 0.35 . . . . 0.0 110.832 -179.945 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 71' ' ' VAL . . . . . 0.42 HG11 ' CD2' ' A' ' 72' ' ' PHE . 20.0 t -141.35 110.47 2.77 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 CA-C-N 116.226 -0.443 . . . . 0.0 111.069 -180.0 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 72' ' ' PHE . . . . . 0.42 ' CD2' HG11 ' A' ' 71' ' ' VAL . 67.6 m-85 60.17 31.17 20.43 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.903 -179.968 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 87.07 28.37 25.83 Favored Glycine 0 N--CA 1.451 -0.312 0 C-N-CA 120.747 -0.739 . . . . 0.0 112.498 179.98 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 74' ' ' VAL . . . . . 0.407 HG12 ' CZ ' ' A' ' 76' ' ' TYR . 21.4 t -128.35 104.27 11.38 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-O 120.901 0.381 . . . . 0.0 111.085 -179.988 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 75' ' ' ARG . . . . . . . . . . . . . 11.3 ttt180 -84.0 134.2 34.65 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.861 -179.934 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 76' ' ' TYR . . . . . 0.407 ' CZ ' HG12 ' A' ' 74' ' ' VAL . 56.5 m-85 -118.2 -41.51 2.86 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.883 179.973 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 77' ' ' PHE . . . . . . . . . . . . . 12.8 p90 -158.98 163.31 36.58 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.145 -0.48 . . . . 0.0 110.87 179.987 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 1.2 p -89.6 109.1 20.08 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.926 179.97 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 79' ' ' CYS . . . . . . . . . . . . . 28.6 p -138.41 166.19 24.88 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.921 -179.988 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 80' ' ' ALA . . . . . 0.416 ' HB3' ' CE1' ' A' ' 83' ' ' HIS . . . -77.51 168.93 23.75 Favored Pre-proline 0 C--N 1.329 -0.316 0 CA-C-N 116.227 -0.442 . . . . 0.0 111.07 -179.97 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 81' ' ' PRO . . . . . . . . . . . . . 32.5 Cg_exo -58.11 122.93 12.55 Favored 'Trans proline' 0 C--N 1.344 0.308 0 C-N-CA 122.582 2.188 . . . . 0.0 112.29 -179.929 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 82' ' ' ARG . . . . . . . . . . . . . 14.8 mtt-85 64.17 46.54 3.59 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.155 -0.475 . . . . 0.0 111.123 179.908 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 83' ' ' HIS . . . . . 0.416 ' CE1' ' HB3' ' A' ' 80' ' ' ALA . 9.4 m170 -119.29 -45.18 2.55 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.796 179.892 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . -75.49 138.96 23.99 Favored Glycine 0 N--CA 1.452 -0.295 0 C-N-CA 120.742 -0.742 . . . . 0.0 112.47 179.955 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 85' ' ' VAL . . . . . . . . . . . . . 18.0 m -141.72 119.72 8.78 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.361 0 CA-C-O 120.818 0.342 . . . . 0.0 111.108 -179.91 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 86' ' ' PHE . . . . . 0.403 ' CE1' ' N ' ' A' ' 57' ' ' GLY . 9.3 m-85 -97.69 110.57 23.11 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.872 179.928 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 87' ' ' ALA . . . . . . . . . . . . . . . -128.78 151.19 76.81 Favored Pre-proline 0 C--N 1.33 -0.273 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.163 -179.989 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 88' ' ' PRO . . . . . 0.404 ' O ' ' N ' ' A' ' 91' ' ' ARG . 31.8 Cg_exo -58.72 136.24 72.53 Favored 'Trans proline' 0 C--N 1.345 0.36 0 C-N-CA 122.619 2.213 . . . . 0.0 112.252 -179.925 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -48.05 -51.25 25.02 Favored 'General case' 0 C--N 1.333 -0.124 0 CA-C-N 116.154 -0.476 . . . . 0.0 110.277 179.91 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 90' ' ' SER . . . . . . . . . . . . . 5.5 m -55.94 -24.36 37.54 Favored 'General case' 0 N--CA 1.454 -0.249 0 CA-C-N 115.724 -0.671 . . . . 0.0 109.757 178.81 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 91' ' ' ARG . . . . . 0.404 ' N ' ' O ' ' A' ' 88' ' ' PRO . 0.6 OUTLIER -89.11 -14.09 37.04 Favored 'General case' 0 N--CA 1.455 -0.21 0 CA-C-N 115.818 -0.628 . . . . 0.0 110.487 179.064 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 92' ' ' ILE . . . . . . . . . . . . . 28.1 mt -108.26 146.25 14.35 Favored 'Isoleucine or valine' 0 C--O 1.231 0.091 0 CA-C-N 116.391 -0.368 . . . . 0.0 111.034 179.834 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 93' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -106.19 164.49 11.96 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.218 -0.447 . . . . 0.0 110.817 -179.993 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 94' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -116.35 119.27 35.14 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.887 -179.995 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 95' ' ' ILE . . . . . . . . . . . . . 22.2 mt . . . . . 0 C--N 1.329 -0.307 0 CA-C-N 116.18 -0.464 . . . . 0.0 111.197 179.96 . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.231 0.091 0 CA-C-O 120.836 0.35 . . . . 0.0 111.122 . . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' A' A ' 27' ' ' GLU . . . . . . . . . . . . . 1.1 pm0 -116.75 158.39 23.94 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.888 -179.988 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 36.7 t -67.85 82.69 0.11 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.035 179.911 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 136.24 43.95 0.1 OUTLIER Glycine 0 N--CA 1.451 -0.366 0 C-N-CA 120.745 -0.74 . . . . 0.0 112.537 -179.981 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -149.18 167.69 25.28 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-O 120.838 0.352 . . . . 0.0 110.893 -179.984 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 31' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -78.12 130.73 36.73 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.942 -179.962 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 4.7 m -132.76 172.48 16.37 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.326 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.112 179.944 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 33' ' ' LEU . . . . . . . . . . . . . 16.7 tp -143.52 112.36 6.58 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.196 -0.457 . . . . 0.0 110.856 -179.942 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 21.5 t -81.09 124.25 38.57 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.245 -0.434 . . . . 0.0 111.11 -179.849 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 35' ' ' ALA . . . . . . . . . . . . . . . 57.94 26.65 13.65 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.067 -0.515 . . . . 0.0 111.294 179.99 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . 57.05 33.45 64.25 Favored Glycine 0 N--CA 1.452 -0.29 0 C-N-CA 120.759 -0.734 . . . . 0.0 112.562 179.959 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 37' ' ' GLN . . . . . . . . . . . . . 37.7 mt-30 -144.36 -70.44 0.29 Allowed 'General case' 0 C--N 1.328 -0.35 0 CA-C-O 120.87 0.367 . . . . 0.0 111.075 -179.867 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 38' ' ' LYS . . . . . . . . . . . . . 2.8 mmpt? -68.08 114.61 6.74 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.925 -179.871 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 39' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -93.88 128.64 40.27 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.9 179.985 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -152.82 -172.88 21.64 Favored Glycine 0 N--CA 1.451 -0.335 0 C-N-CA 120.759 -0.734 . . . . 0.0 112.534 179.973 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 25.4 mm -125.33 138.07 55.57 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.269 0 CA-C-O 120.818 0.342 . . . . 0.0 111.136 -179.932 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 42' ' ' VAL . . . . . . . . . . . . . 21.5 t -69.32 122.33 20.56 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.185 -0.461 . . . . 0.0 111.082 -179.99 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 43' ' ' ARG . . . . . . . . . . . . . 8.0 mmt180 -113.55 -35.88 5.1 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.926 -179.998 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 44' ' ' PHE . . . . . . . . . . . . . 64.6 t80 -139.05 111.45 7.53 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.941 -179.983 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 45' ' ' TYR . . . . . 0.485 ' CE1' ' CE1' ' A' ' 56' ' ' TYR . 13.3 t80 -107.28 136.88 46.36 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.857 179.879 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 153.51 -163.08 30.6 Favored Glycine 0 N--CA 1.451 -0.352 0 C-N-CA 120.746 -0.74 . . . . 0.0 112.479 179.988 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 47' ' ' LYS . . . . . . . . . . . . . 21.1 mttp -88.64 167.69 13.16 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-O 120.799 0.333 . . . . 0.0 110.875 -179.944 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 48' ' ' THR . . . . . 0.41 HG22 ' CZ ' ' A' ' 50' ' ' PHE . 29.1 p -129.48 -173.88 3.13 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.846 179.965 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -110.37 -31.58 7.24 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.855 -179.97 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 50' ' ' PHE . . . . . 0.427 ' CD1' ' N ' ' A' ' 51' ' ' ALA . 18.3 p90 -67.84 -36.09 79.74 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.259 -0.428 . . . . 0.0 110.992 -179.924 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 51' ' ' ALA . . . . . 0.427 ' N ' ' CD1' ' A' ' 50' ' ' PHE . . . -148.4 146.04 21.81 Favored Pre-proline 0 C--N 1.329 -0.283 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.175 179.979 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 52' ' ' PRO . . . . . . . . . . . . . 69.2 Cg_endo -74.39 173.77 13.67 Favored 'Trans proline' 0 C--N 1.345 0.391 0 C-N-CA 122.573 2.182 . . . . 0.0 112.315 -179.985 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 92.43 172.62 41.47 Favored Glycine 0 N--CA 1.452 -0.289 0 C-N-CA 120.762 -0.733 . . . . 0.0 112.48 179.905 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 54' ' ' TYR . . . . . . . . . . . . . 10.5 m-85 -90.14 110.31 21.33 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-O 120.814 0.34 . . . . 0.0 110.868 -179.993 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 55' ' ' TRP . . . . . 0.422 ' CZ3' ' HD3' ' A' ' 88' ' ' PRO . 66.7 m95 -105.17 159.25 16.01 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.906 179.967 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 56' ' ' TYR . . . . . 0.485 ' CE1' ' CE1' ' A' ' 45' ' ' TYR . 12.6 m-85 -114.9 117.34 30.4 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.98 -179.824 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . -79.75 68.06 3.28 Favored Glycine 0 N--CA 1.451 -0.34 0 C-N-CA 120.684 -0.77 . . . . 0.0 112.341 179.934 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 58' ' ' ILE . . . . . . . . . . . . . 38.0 mt -73.3 137.89 22.44 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.39 0 CA-C-O 120.829 0.347 . . . . 0.0 111.192 -179.911 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 1.3 tm-20 -104.29 107.12 17.88 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.79 179.926 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 60' ' ' LEU . . . . . . . . . . . . . 36.6 mt -60.11 170.43 1.25 Allowed 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.971 -179.935 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 2.9 m-20 -100.45 -31.6 11.21 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.882 -179.991 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 62' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -120.24 147.31 44.63 Favored Pre-proline 0 C--N 1.331 -0.23 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.839 -179.93 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 50.6 Cg_exo -53.07 90.5 0.03 OUTLIER 'Trans proline' 0 C--N 1.345 0.389 0 C-N-CA 122.479 2.119 . . . . 0.0 112.405 179.949 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 64' ' ' THR . . . . . . . . . . . . . 4.9 t -164.7 39.4 0.07 Allowed 'General case' 0 C--N 1.327 -0.384 0 CA-C-N 116.296 -0.411 . . . . 0.0 110.911 179.989 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . -100.66 -149.07 22.99 Favored Glycine 0 N--CA 1.451 -0.325 0 C-N-CA 120.741 -0.742 . . . . 0.0 112.515 179.946 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 66' ' ' LYS . . . . . . . . . . . . . 0.6 OUTLIER -121.47 -42.65 2.43 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-O 120.825 0.345 . . . . 0.0 110.918 -179.948 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 67' ' ' HIS . . . . . . . . . . . . . 6.8 p80 -128.53 172.15 11.44 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.917 179.964 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 4.9 m-20 -98.36 33.67 2.17 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.922 -179.971 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 99.47 -41.89 2.1 Favored Glycine 0 N--CA 1.451 -0.316 0 C-N-CA 120.636 -0.792 . . . . 0.0 112.491 179.995 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 70' ' ' SER . . . . . . . . . . . . . 77.3 p -104.82 148.62 26.44 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 120.835 0.35 . . . . 0.0 110.918 -179.974 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 21.5 t -135.45 122.59 35.31 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.146 -0.479 . . . . 0.0 111.105 179.958 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 72' ' ' PHE . . . . . . . . . . . . . 33.5 m-85 60.28 33.85 20.89 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.924 -179.992 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 80.4 27.92 50.09 Favored Glycine 0 N--CA 1.452 -0.25 0 C-N-CA 120.692 -0.766 . . . . 0.0 112.533 -179.97 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 21.4 t -131.61 100.71 4.58 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-O 120.767 0.317 . . . . 0.0 111.078 -179.997 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 75' ' ' ARG . . . . . . . . . . . . . 20.5 ttt85 -77.45 119.75 21.49 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.26 -0.427 . . . . 0.0 110.949 -179.968 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 76' ' ' TYR . . . . . . . . . . . . . 25.4 m-85 -92.28 -48.86 6.46 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.835 -179.995 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 77' ' ' PHE . . . . . . . . . . . . . 16.8 p90 -148.65 161.97 40.65 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.752 179.936 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -88.34 108.5 19.37 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.971 -179.963 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 79' ' ' CYS . . . . . . . . . . . . . 30.4 p -132.93 174.11 10.68 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.867 -179.976 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 80' ' ' ALA . . . . . . . . . . . . . . . -81.95 166.73 35.53 Favored Pre-proline 0 C--N 1.329 -0.311 0 CA-C-N 116.198 -0.455 . . . . 0.0 111.056 179.978 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 81' ' ' PRO . . . . . . . . . . . . . 51.9 Cg_exo -54.34 117.49 3.99 Favored 'Trans proline' 0 C--N 1.343 0.267 0 C-N-CA 122.57 2.18 . . . . 0.0 112.304 179.994 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 82' ' ' ARG . . . . . . . . . . . . . 3.3 mpt_? 60.99 52.97 3.86 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.116 -0.493 . . . . 0.0 110.96 179.99 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 83' ' ' HIS . . . . . . . . . . . . . 7.2 m170 -122.41 -42.15 2.36 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.119 -0.491 . . . . 0.0 110.915 179.989 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . -64.24 144.56 48.75 Favored Glycine 0 N--CA 1.452 -0.261 0 C-N-CA 120.632 -0.794 . . . . 0.0 112.426 179.968 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 85' ' ' VAL . . . . . . . . . . . . . 15.4 m -152.54 121.32 0.77 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-O 120.833 0.349 . . . . 0.0 111.101 179.997 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 86' ' ' PHE . . . . . 0.403 ' CD1' ' HB3' ' A' ' 55' ' ' TRP . 2.5 m-85 -100.69 118.73 37.4 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.945 179.971 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 87' ' ' ALA . . . . . . . . . . . . . . . -139.91 145.72 43.79 Favored Pre-proline 0 C--N 1.329 -0.316 0 CA-C-N 116.258 -0.428 . . . . 0.0 111.094 179.936 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 88' ' ' PRO . . . . . 0.422 ' HD3' ' CZ3' ' A' ' 55' ' ' TRP . 36.0 Cg_exo -57.27 138.2 85.16 Favored 'Trans proline' 0 C--N 1.346 0.441 0 C-N-CA 122.46 2.107 . . . . 0.0 112.336 -179.952 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -47.63 -51.9 19.84 Favored 'General case' 0 C--N 1.333 -0.115 0 CA-C-O 121.112 0.482 . . . . 0.0 110.367 179.902 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 90' ' ' SER . . . . . . . . . . . . . 5.9 m -55.52 -24.48 32.11 Favored 'General case' 0 N--CA 1.454 -0.246 0 CA-C-N 115.657 -0.701 . . . . 0.0 109.754 178.769 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 91' ' ' ARG . . . . . 0.413 ' N ' ' O ' ' A' ' 88' ' ' PRO . 0.6 OUTLIER -88.41 -16.36 33.1 Favored 'General case' 0 N--CA 1.454 -0.234 0 CA-C-N 115.829 -0.623 . . . . 0.0 110.416 179.066 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 92' ' ' ILE . . . . . . . . . . . . . 51.6 mt -104.51 145.09 13.57 Favored 'Isoleucine or valine' 0 C--N 1.333 -0.121 0 CA-C-N 116.379 -0.373 . . . . 0.0 111.035 179.869 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 93' ' ' GLN . . . . . . . . . . . . . 1.8 mt-30 -112.83 -179.96 3.8 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.228 -0.442 . . . . 0.0 111.009 -179.949 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 94' ' ' ARG . . . . . . . . . . . . . 0.6 OUTLIER -126.88 138.96 53.39 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.947 -179.895 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 95' ' ' ILE . . . . . . . . . . . . . 3.8 mp . . . . . 0 C--N 1.33 -0.252 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.059 179.967 . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.23 0.06 0 CA-C-O 120.839 0.352 . . . . 0.0 111.076 . . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' A' A ' 27' ' ' GLU . . . . . . . . . . . . . 28.5 mt-10 -143.2 -172.59 3.72 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.918 -179.996 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 30.6 t -78.46 111.65 15.55 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.236 -0.438 . . . . 0.0 111.078 -179.979 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 106.16 42.73 1.6 Allowed Glycine 0 N--CA 1.452 -0.255 0 C-N-CA 120.729 -0.748 . . . . 0.0 112.52 179.967 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 2.3 m-20 -150.12 136.77 19.14 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-O 120.813 0.34 . . . . 0.0 110.823 179.979 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 31' ' ' GLN . . . . . . . . . . . . . 2.6 mt-30 -60.03 141.02 56.42 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.88 179.92 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 6.3 m -146.57 179.58 0.92 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.356 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.188 179.992 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 33' ' ' LEU . . . . . . . . . . . . . 25.7 tp -142.09 109.89 5.8 Favored 'General case' 0 C--N 1.331 -0.239 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.846 179.991 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 21.5 t -77.72 123.54 34.59 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.266 0 CA-C-N 116.181 -0.463 . . . . 0.0 111.182 -179.969 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 35' ' ' ALA . . . . . . . . . . . . . . . 57.63 26.64 13.14 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.198 -0.456 . . . . 0.0 111.235 -179.964 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . 57.07 29.38 59.42 Favored Glycine 0 N--CA 1.451 -0.327 0 C-N-CA 120.734 -0.746 . . . . 0.0 112.613 179.953 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 37' ' ' GLN . . . . . . . . . . . . . 20.1 mt-30 -141.29 -74.59 0.32 Allowed 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 120.85 0.357 . . . . 0.0 110.966 -179.964 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 38' ' ' LYS . . . . . . . . . . . . . 21.8 mmtm -63.47 103.19 0.49 Allowed 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.861 -179.959 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 39' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -82.55 135.35 35.11 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.939 179.931 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -164.73 -176.01 36.04 Favored Glycine 0 N--CA 1.452 -0.288 0 C-N-CA 120.677 -0.773 . . . . 0.0 112.49 179.965 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 2.6 mt -127.34 137.01 59.03 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 CA-C-O 120.82 0.343 . . . . 0.0 111.085 -179.979 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 42' ' ' VAL . . . . . . . . . . . . . 21.4 t -59.62 123.38 11.91 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.202 -0.454 . . . . 0.0 111.12 179.971 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 43' ' ' ARG . . . . . . . . . . . . . 17.3 mmt85 -111.3 -33.99 6.27 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.902 179.903 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 44' ' ' PHE . . . . . 0.416 ' CD1' ' HB3' ' A' ' 76' ' ' TYR . 60.4 t80 -142.75 110.31 5.78 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.965 -179.979 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 45' ' ' TYR . . . . . . . . . . . . . 15.3 t80 -107.54 119.62 39.93 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.196 -0.457 . . . . 0.0 110.861 179.974 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 175.52 177.14 44.35 Favored Glycine 0 N--CA 1.451 -0.347 0 C-N-CA 120.801 -0.714 . . . . 0.0 112.561 179.971 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 47' ' ' LYS . . . . . . . . . . . . . 16.0 mtmt -77.02 168.14 20.6 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-O 120.886 0.374 . . . . 0.0 110.856 179.975 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 48' ' ' THR . . . . . 0.412 HG22 ' CZ ' ' A' ' 50' ' ' PHE . 23.6 p -125.58 -179.66 4.74 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.868 179.953 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 1.5 t70 -106.74 -31.84 8.24 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.939 179.974 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 50' ' ' PHE . . . . . 0.416 ' CD1' ' HB2' ' A' ' 51' ' ' ALA . 48.8 p90 -70.19 -35.86 74.22 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.924 -179.988 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 51' ' ' ALA . . . . . 0.416 ' HB2' ' CD1' ' A' ' 50' ' ' PHE . . . -141.09 144.16 33.85 Favored Pre-proline 0 C--N 1.328 -0.333 0 CA-C-N 116.218 -0.446 . . . . 0.0 111.087 -179.981 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 52' ' ' PRO . . . . . . . . . . . . . 70.8 Cg_endo -74.74 -176.85 3.02 Favored 'Trans proline' 0 C--N 1.345 0.389 0 C-N-CA 122.531 2.154 . . . . 0.0 112.309 179.99 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 76.78 -175.68 53.36 Favored Glycine 0 N--CA 1.45 -0.376 0 C-N-CA 120.745 -0.74 . . . . 0.0 112.567 179.993 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 54' ' ' TYR . . . . . . . . . . . . . 34.5 m-85 -88.58 158.35 18.31 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-O 120.847 0.356 . . . . 0.0 110.916 179.967 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 55' ' ' TRP . . . . . 0.409 ' HB3' ' CD1' ' A' ' 86' ' ' PHE . 94.2 m95 -154.06 140.96 19.21 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.154 -0.475 . . . . 0.0 110.867 179.96 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 56' ' ' TYR . . . . . . . . . . . . . 36.2 m-85 -102.57 122.31 44.13 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.902 -179.927 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 57' ' ' GLY . . . . . 0.447 ' N ' ' CE1' ' A' ' 86' ' ' PHE . . . -87.79 59.08 4.31 Favored Glycine 0 N--CA 1.451 -0.357 0 C-N-CA 120.754 -0.736 . . . . 0.0 112.468 -179.978 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 58' ' ' ILE . . . . . . . . . . . . . 7.8 mt -64.14 152.48 8.28 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-O 120.829 0.347 . . . . 0.0 110.964 -179.957 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 1.7 tm-20 -122.94 102.94 8.3 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.925 179.988 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 60' ' ' LEU . . . . . . . . . . . . . 54.8 mt -63.16 162.72 11.32 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.904 -179.957 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 2.7 t0 -92.78 -30.91 15.25 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.916 -179.981 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 62' ' ' GLN . . . . . . . . . . . . . 7.1 mt-30 -100.35 152.0 37.7 Favored Pre-proline 0 C--N 1.329 -0.311 0 CA-C-N 116.231 -0.44 . . . . 0.0 110.952 -179.994 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 71.9 Cg_endo -75.45 97.9 1.13 Allowed 'Trans proline' 0 C--N 1.344 0.316 0 C-N-CA 122.595 2.196 . . . . 0.0 112.309 -179.892 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 64' ' ' THR . . . . . . . . . . . . . 9.9 t -173.68 36.27 0.01 OUTLIER 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.9 -179.989 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . -90.09 -159.52 35.6 Favored Glycine 0 N--CA 1.451 -0.335 0 C-N-CA 120.731 -0.747 . . . . 0.0 112.544 179.985 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 66' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -110.47 -31.71 7.17 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 120.819 0.342 . . . . 0.0 110.846 -179.947 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 67' ' ' HIS . . . . . . . . . . . . . 6.6 p80 -140.83 173.57 11.36 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.893 179.954 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 2.6 m-20 -97.98 37.09 1.46 Allowed 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.834 -179.915 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 98.79 -28.61 14.33 Favored Glycine 0 N--CA 1.451 -0.362 0 C-N-CA 120.676 -0.773 . . . . 0.0 112.486 179.967 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 70' ' ' SER . . . . . . . . . . . . . 88.7 p -110.4 161.32 15.77 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-O 120.841 0.353 . . . . 0.0 110.842 -179.92 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 21.5 t -146.41 126.75 6.02 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.256 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.063 -179.981 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 72' ' ' PHE . . . . . . . . . . . . . 11.3 m-85 60.58 27.05 16.73 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.163 -0.472 . . . . 0.0 111.026 179.974 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 95.65 -29.82 9.23 Favored Glycine 0 N--CA 1.452 -0.284 0 C-N-CA 120.752 -0.737 . . . . 0.0 112.537 179.952 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 25.5 t -80.98 116.58 25.53 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.343 0 CA-C-O 120.8 0.333 . . . . 0.0 111.141 -179.976 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 75' ' ' ARG . . . . . . . . . . . . . 2.1 ttt-85 -88.49 148.36 24.19 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.86 -179.933 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 76' ' ' TYR . . . . . 0.416 ' HB3' ' CD1' ' A' ' 44' ' ' PHE . 53.8 m-85 -120.09 -50.81 2.24 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.933 -179.963 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 77' ' ' PHE . . . . . . . . . . . . . 26.9 p90 -146.04 161.78 39.35 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.9 179.978 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 4.9 m -91.93 121.98 34.03 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.099 -0.501 . . . . 0.0 110.941 179.979 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 79' ' ' CYS . . . . . . . . . . . . . 26.1 p -144.57 158.12 43.91 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.252 -0.431 . . . . 0.0 110.87 -179.952 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 80' ' ' ALA . . . . . . . . . . . . . . . -59.59 164.03 6.06 Favored Pre-proline 0 C--N 1.329 -0.306 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.135 179.913 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 81' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_exo -52.31 116.19 2.67 Favored 'Trans proline' 0 C--N 1.345 0.358 0 C-N-CA 122.558 2.172 . . . . 0.0 112.322 -179.982 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 82' ' ' ARG . . . . . . . . . . . . . 16.1 mtt180 58.91 62.49 1.87 Allowed 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.874 -179.962 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 83' ' ' HIS . . . . . . . . . . . . . 4.3 m170 -127.12 -43.78 1.64 Allowed 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.088 -0.506 . . . . 0.0 110.859 179.957 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . -68.2 138.51 32.76 Favored Glycine 0 N--CA 1.45 -0.37 0 C-N-CA 120.706 -0.759 . . . . 0.0 112.473 179.976 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 85' ' ' VAL . . . . . . . . . . . . . 16.9 m -143.3 113.91 2.43 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-O 120.894 0.378 . . . . 0.0 111.108 -179.994 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 86' ' ' PHE . . . . . 0.447 ' CE1' ' N ' ' A' ' 57' ' ' GLY . 5.4 m-85 -89.11 119.81 29.95 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.843 -179.964 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 87' ' ' ALA . . . . . . . . . . . . . . . -139.48 143.86 37.41 Favored Pre-proline 0 C--N 1.329 -0.303 0 CA-C-N 116.263 -0.426 . . . . 0.0 111.146 179.991 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 88' ' ' PRO . . . . . 0.427 ' O ' ' N ' ' A' ' 91' ' ' ARG . 46.8 Cg_exo -55.94 140.45 85.85 Favored 'Trans proline' 0 C--N 1.346 0.43 0 C-N-CA 122.541 2.161 . . . . 0.0 112.379 179.959 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -47.83 -50.3 26.59 Favored 'General case' 0 CA--C 1.521 -0.158 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.264 179.896 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 90' ' ' SER . . . . . . . . . . . . . 8.0 m -55.59 -24.37 32.51 Favored 'General case' 0 N--CA 1.454 -0.266 0 CA-C-N 115.769 -0.651 . . . . 0.0 109.796 178.859 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 91' ' ' ARG . . . . . 0.427 ' N ' ' O ' ' A' ' 88' ' ' PRO . 2.3 mtm-85 -89.74 -15.22 32.93 Favored 'General case' 0 N--CA 1.455 -0.19 0 CA-C-N 115.813 -0.631 . . . . 0.0 110.524 179.063 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 92' ' ' ILE . . . . . . . . . . . . . 49.9 mt -103.08 144.87 13.2 Favored 'Isoleucine or valine' 0 C--O 1.232 0.16 0 CA-C-N 116.402 -0.363 . . . . 0.0 111.094 179.858 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 93' ' ' GLN . . . . . . . . . . . . . 0.5 OUTLIER -115.71 154.3 29.81 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.905 -179.976 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 94' ' ' ARG . . . . . . . . . . . . . 7.6 mtp180 -96.96 138.54 34.34 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.868 179.978 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 95' ' ' ILE . . . . . . . . . . . . . 16.9 mt . . . . . 0 C--N 1.329 -0.286 0 CA-C-N 116.15 -0.477 . . . . 0.0 111.108 179.97 . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.23 0.078 0 CA-C-O 120.799 0.333 . . . . 0.0 111.142 . . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' A' A ' 27' ' ' GLU . . . . . . . . . . . . . 6.3 mm-40 -142.46 -179.18 6.13 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.935 179.956 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 21.5 t -66.95 123.34 19.8 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.127 -180.0 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 84.7 46.34 5.76 Favored Glycine 0 N--CA 1.451 -0.326 0 C-N-CA 120.767 -0.73 . . . . 0.0 112.529 -179.993 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 4.6 t0 -146.16 134.28 21.59 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 120.879 0.371 . . . . 0.0 110.892 -179.998 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 31' ' ' GLN . . . . . . . . . . . . . 1.9 mt-30 -60.31 139.23 57.74 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.912 179.974 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 19.2 m -145.17 176.02 2.31 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.28 -0.418 . . . . 0.0 111.133 -179.975 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 33' ' ' LEU . . . . . . . . . . . . . 30.4 tp -134.5 100.04 4.53 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.145 -0.48 . . . . 0.0 110.898 179.988 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 21.5 t -69.11 126.58 29.42 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.205 -179.853 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 35' ' ' ALA . . . . . . . . . . . . . . . 57.06 25.34 10.67 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.321 179.941 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . 56.07 35.03 63.04 Favored Glycine 0 N--CA 1.451 -0.33 0 C-N-CA 120.722 -0.751 . . . . 0.0 112.58 179.941 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 37' ' ' GLN . . . . . . . . . . . . . 48.8 mt-30 -147.51 -68.3 0.25 Allowed 'General case' 0 C--N 1.329 -0.295 0 CA-C-O 120.862 0.363 . . . . 0.0 110.949 -179.929 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 38' ' ' LYS . . . . . . . . . . . . . 64.5 mttp -73.77 106.85 5.69 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.919 -179.966 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 39' ' ' GLN . . . . . . . . . . . . . 0.9 OUTLIER -85.16 135.02 34.14 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.923 179.89 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -157.87 -170.43 22.65 Favored Glycine 0 N--CA 1.45 -0.389 0 C-N-CA 120.683 -0.77 . . . . 0.0 112.505 -179.998 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 14.5 mt -126.38 131.54 71.33 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-O 120.842 0.353 . . . . 0.0 111.132 -179.959 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 42' ' ' VAL . . . . . . . . . . . . . 38.2 t -65.52 119.73 10.87 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.02 -179.964 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 43' ' ' ARG . . . . . . . . . . . . . 25.5 mmt180 -104.13 -31.46 9.64 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.259 -0.428 . . . . 0.0 110.966 179.895 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 44' ' ' PHE . . . . . . . . . . . . . 69.2 t80 -143.77 117.52 9.28 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.875 -179.929 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 45' ' ' TYR . . . . . 0.464 ' CE1' ' CZ ' ' A' ' 56' ' ' TYR . 21.5 t80 -113.13 133.82 54.85 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.264 -0.426 . . . . 0.0 110.925 179.988 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 154.17 174.87 24.76 Favored Glycine 0 N--CA 1.451 -0.35 0 C-N-CA 120.799 -0.715 . . . . 0.0 112.523 179.937 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 47' ' ' LYS . . . . . . . . . . . . . 1.9 mmtp -60.06 160.53 7.93 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 120.81 0.338 . . . . 0.0 110.938 -179.996 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 48' ' ' THR . . . . . 0.408 HG22 ' CE2' ' A' ' 50' ' ' PHE . 38.4 p -124.82 -179.09 4.38 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.872 179.938 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -107.65 -34.75 6.9 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.883 -179.989 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 50' ' ' PHE . . . . . 0.435 ' CD1' ' N ' ' A' ' 51' ' ' ALA . 15.9 p90 -63.33 -31.46 72.62 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.154 -0.475 . . . . 0.0 110.986 180.0 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 51' ' ' ALA . . . . . 0.435 ' N ' ' CD1' ' A' ' 50' ' ' PHE . . . -156.27 148.16 17.28 Favored Pre-proline 0 C--N 1.33 -0.244 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.117 -179.999 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 52' ' ' PRO . . . . . . . . . . . . . 58.3 Cg_endo -71.47 162.63 41.68 Favored 'Trans proline' 0 C--N 1.344 0.326 0 C-N-CA 122.624 2.216 . . . . 0.0 112.335 179.987 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 102.28 177.42 27.57 Favored Glycine 0 N--CA 1.45 -0.407 0 C-N-CA 120.769 -0.729 . . . . 0.0 112.501 179.939 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 54' ' ' TYR . . . . . . . . . . . . . 37.1 m-85 -97.22 112.31 24.17 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 120.813 0.34 . . . . 0.0 110.958 179.996 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 55' ' ' TRP . . . . . 0.42 ' CZ3' ' HD3' ' A' ' 88' ' ' PRO . 42.1 m95 -107.93 161.76 14.63 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.898 179.989 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 56' ' ' TYR . . . . . 0.464 ' CZ ' ' CE1' ' A' ' 45' ' ' TYR . 11.3 m-85 -113.61 122.49 47.37 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.26 -0.427 . . . . 0.0 110.918 -179.98 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . -84.19 56.71 5.04 Favored Glycine 0 N--CA 1.45 -0.368 0 C-N-CA 120.801 -0.714 . . . . 0.0 112.511 179.861 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 58' ' ' ILE . . . . . . . . . . . . . 3.7 mt -68.32 137.99 23.39 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-O 120.84 0.352 . . . . 0.0 111.092 -179.937 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 0.8 OUTLIER -101.39 141.55 34.09 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.947 179.998 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 60' ' ' LEU . . . . . . . . . . . . . 59.6 mt -97.78 174.13 6.76 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.883 179.99 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 1.3 t0 -101.55 -30.91 11.12 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.176 -0.466 . . . . 0.0 110.959 179.965 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 62' ' ' GLN . . . . . . . . . . . . . 7.5 mt-30 -104.17 153.16 39.15 Favored Pre-proline 0 C--N 1.33 -0.273 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.912 -179.972 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 66.1 Cg_endo -73.97 65.34 5.07 Favored 'Trans proline' 0 C--N 1.345 0.352 0 C-N-CA 122.576 2.184 . . . . 0.0 112.29 -179.902 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 64' ' ' THR . . . . . . . . . . . . . 3.9 t -148.76 39.38 0.86 Allowed 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.882 179.933 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . -83.64 -99.63 0.57 Allowed Glycine 0 N--CA 1.451 -0.305 0 C-N-CA 120.705 -0.759 . . . . 0.0 112.525 179.906 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 66' ' ' LYS . . . . . . . . . . . . . 5.8 mttt -168.76 -44.69 0.02 OUTLIER 'General case' 0 C--N 1.33 -0.251 0 CA-C-O 120.845 0.355 . . . . 0.0 110.871 179.952 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 67' ' ' HIS . . . . . . . . . . . . . 10.1 p80 -125.5 170.28 11.58 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.903 179.91 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 17.1 t0 -103.49 52.36 0.77 Allowed 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.934 179.951 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 90.55 -75.64 1.65 Allowed Glycine 0 N--CA 1.45 -0.403 0 C-N-CA 120.741 -0.742 . . . . 0.0 112.445 179.982 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 70' ' ' SER . . . . . . . . . . . . . 93.1 p -84.4 154.7 22.67 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-O 120.875 0.369 . . . . 0.0 110.848 179.982 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 21.5 t -129.37 122.69 56.29 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.141 179.993 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 72' ' ' PHE . . . . . . . . . . . . . 37.7 m-85 60.74 30.03 19.42 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.898 179.98 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 96.5 -30.05 9.37 Favored Glycine 0 N--CA 1.451 -0.362 0 C-N-CA 120.759 -0.734 . . . . 0.0 112.573 -179.969 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 28.0 t -79.4 122.61 34.96 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-O 120.833 0.349 . . . . 0.0 111.087 -179.992 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 75' ' ' ARG . . . . . . . . . . . . . 21.8 ttt-85 -91.89 142.99 26.95 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.98 179.948 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 76' ' ' TYR . . . . . . . . . . . . . 24.3 m-85 -118.78 -41.72 2.77 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.271 -0.422 . . . . 0.0 110.869 -179.973 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 77' ' ' PHE . . . . . . . . . . . . . 50.9 p90 -160.29 161.7 33.4 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.828 -179.998 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 3.3 m -89.86 123.51 33.88 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.987 179.865 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 79' ' ' CYS . . . . . . . . . . . . . 30.3 p -145.88 -177.94 5.85 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.885 179.997 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 80' ' ' ALA . . . . . . . . . . . . . . . -92.1 164.47 23.23 Favored Pre-proline 0 C--N 1.329 -0.319 0 CA-C-N 116.2 -0.455 . . . . 0.0 111.124 179.988 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 81' ' ' PRO . . . . . . . . . . . . . 52.9 Cg_exo -52.48 116.29 2.76 Favored 'Trans proline' 0 C--N 1.345 0.344 0 C-N-CA 122.55 2.167 . . . . 0.0 112.275 179.993 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 82' ' ' ARG . . . . . . . . . . . . . 7.3 mtm180 61.9 58.79 1.85 Allowed 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.178 -0.464 . . . . 0.0 110.834 -179.997 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 83' ' ' HIS . . . . . . . . . . . . . 5.6 m170 -128.98 -47.55 1.23 Allowed 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.92 179.925 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . -66.64 147.58 49.82 Favored Glycine 0 N--CA 1.45 -0.4 0 C-N-CA 120.8 -0.714 . . . . 0.0 112.471 179.906 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 85' ' ' VAL . . . . . . . . . . . . . 5.2 m -152.99 123.07 0.82 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-O 120.804 0.335 . . . . 0.0 111.153 179.921 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 86' ' ' PHE . . . . . . . . . . . . . 29.8 m-85 -99.87 121.23 41.01 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.834 -179.938 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 87' ' ' ALA . . . . . . . . . . . . . . . -140.56 147.38 48.94 Favored Pre-proline 0 C--N 1.33 -0.261 0 CA-C-N 116.248 -0.433 . . . . 0.0 111.093 -179.988 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 88' ' ' PRO . . . . . 0.42 ' HD3' ' CZ3' ' A' ' 55' ' ' TRP . 32.4 Cg_exo -57.97 138.33 85.46 Favored 'Trans proline' 0 C--N 1.345 0.388 0 C-N-CA 122.561 2.174 . . . . 0.0 112.258 -179.979 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 89' ' ' ALA . . . . . 0.419 ' HB1' ' CE1' ' A' ' 56' ' ' TYR . . . -47.98 -51.71 22.72 Favored 'General case' 0 C--N 1.332 -0.161 0 CA-C-O 121.137 0.494 . . . . 0.0 110.278 179.84 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 90' ' ' SER . . . . . . . . . . . . . 3.6 t -55.87 -24.45 37.07 Favored 'General case' 0 C--N 1.332 -0.186 0 CA-C-N 115.693 -0.685 . . . . 0.0 109.701 178.826 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 91' ' ' ARG . . . . . 0.416 ' N ' ' O ' ' A' ' 88' ' ' PRO . 0.0 OUTLIER -88.5 -14.35 38.02 Favored 'General case' 0 N--CA 1.454 -0.246 0 CA-C-N 115.911 -0.586 . . . . 0.0 110.49 179.058 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 92' ' ' ILE . . . . . . . . . . . . . 36.3 mt -110.83 156.13 12.05 Favored 'Isoleucine or valine' 0 C--N 1.334 -0.065 0 CA-C-O 120.908 0.385 . . . . 0.0 111.063 179.906 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 93' ' ' GLN . . . . . . . . . . . . . 2.3 mp0 -123.67 173.84 7.84 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.116 -0.493 . . . . 0.0 110.811 179.987 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 94' ' ' ARG . . . . . . . . . . . . . 1.1 mtp180 -115.48 140.02 49.53 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.899 179.968 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 95' ' ' ILE . . . . . . . . . . . . . 21.7 mm . . . . . 0 C--N 1.33 -0.267 0 CA-C-N 116.154 -0.476 . . . . 0.0 111.124 179.946 . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.231 0.13 0 CA-C-O 120.862 0.363 . . . . 0.0 111.089 . . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' A' A ' 27' ' ' GLU . . . . . . . . . . . . . 3.6 mm-40 -135.55 -178.73 5.25 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.841 179.946 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 21.5 t -83.08 104.98 12.42 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.164 -0.471 . . . . 0.0 111.119 179.993 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 107.35 30.58 4.07 Favored Glycine 0 N--CA 1.452 -0.288 0 C-N-CA 120.779 -0.724 . . . . 0.0 112.487 -179.948 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 3.4 m-20 -124.84 144.21 50.42 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 120.793 0.33 . . . . 0.0 110.895 179.952 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 31' ' ' GLN . . . . . . . . . . . . . 5.0 mp0 -65.28 130.4 43.19 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.806 -179.97 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 20.7 m -136.13 175.23 10.95 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 CA-C-N 116.2 -0.454 . . . . 0.0 111.079 179.993 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 33' ' ' LEU . . . . . . . . . . . . . 14.1 tp -139.11 100.06 3.92 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.105 -0.498 . . . . 0.0 110.912 179.98 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 21.5 t -64.5 121.02 12.74 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 116.234 -0.439 . . . . 0.0 111.179 179.991 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 35' ' ' ALA . . . . . . . . . . . . . . . 58.71 26.87 15.14 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.3 179.998 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . 56.66 27.79 55.61 Favored Glycine 0 N--CA 1.451 -0.32 0 C-N-CA 120.779 -0.724 . . . . 0.0 112.601 -179.976 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 37' ' ' GLN . . . . . . . . . . . . . 38.9 mt-30 -139.66 -72.08 0.38 Allowed 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.775 0.321 . . . . 0.0 110.892 -179.993 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 38' ' ' LYS . . . . . . . . . . . . . 55.6 mttt -65.17 114.53 4.73 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.259 -0.428 . . . . 0.0 110.924 179.995 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 39' ' ' GLN . . . . . . . . . . . . . 5.8 tm0? -85.53 130.07 34.67 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.886 179.952 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -157.08 173.56 34.66 Favored Glycine 0 N--CA 1.451 -0.302 0 C-N-CA 120.66 -0.781 . . . . 0.0 112.481 179.993 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 33.5 mt -121.13 133.18 68.56 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 CA-C-O 120.802 0.334 . . . . 0.0 111.033 -179.969 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 42' ' ' VAL . . . . . . . . . . . . . 21.4 t -61.99 121.73 11.06 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.146 -0.479 . . . . 0.0 111.097 179.979 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 43' ' ' ARG . . . . . . . . . . . . . 14.8 mmt180 -108.0 -30.92 8.19 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.903 179.878 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 44' ' ' PHE . . . . . . . . . . . . . 28.9 t80 -149.73 109.57 4.07 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.25 -0.432 . . . . 0.0 110.934 -179.976 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 45' ' ' TYR . . . . . 0.49 ' CE1' ' CZ ' ' A' ' 56' ' ' TYR . 22.7 t80 -106.76 130.5 54.46 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.289 -0.414 . . . . 0.0 110.865 179.964 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 167.02 -161.17 35.02 Favored Glycine 0 N--CA 1.451 -0.35 0 C-N-CA 120.679 -0.772 . . . . 0.0 112.488 -179.976 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 47' ' ' LYS . . . . . . . . . . . . . 40.3 mttt -84.74 175.83 8.93 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 120.748 0.309 . . . . 0.0 110.949 179.94 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 48' ' ' THR . . . . . 0.412 HG22 ' CE2' ' A' ' 50' ' ' PHE . 71.1 p -143.9 -177.42 5.42 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.938 -179.974 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 3.5 t0 -110.8 -35.03 6.08 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.284 -0.416 . . . . 0.0 110.914 -179.961 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 50' ' ' PHE . . . . . 0.438 ' CD1' ' N ' ' A' ' 51' ' ' ALA . 16.1 p90 -60.06 -31.36 69.92 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.917 179.996 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 51' ' ' ALA . . . . . 0.438 ' N ' ' CD1' ' A' ' 50' ' ' PHE . . . -159.84 141.73 9.62 Favored Pre-proline 0 C--N 1.329 -0.319 0 CA-C-N 116.264 -0.426 . . . . 0.0 111.092 179.911 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 52' ' ' PRO . . . . . . . . . . . . . 72.6 Cg_endo -74.77 154.7 43.86 Favored 'Trans proline' 0 C--N 1.346 0.405 0 C-N-CA 122.497 2.131 . . . . 0.0 112.39 179.991 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 121.39 -160.34 15.75 Favored Glycine 0 N--CA 1.45 -0.393 0 C-N-CA 120.752 -0.737 . . . . 0.0 112.555 179.988 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 54' ' ' TYR . . . . . . . . . . . . . 33.4 m-85 -113.2 110.49 20.49 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-O 120.81 0.338 . . . . 0.0 110.887 179.997 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 55' ' ' TRP . . . . . . . . . . . . . 51.2 m95 -112.96 160.5 18.03 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.888 179.955 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 56' ' ' TYR . . . . . 0.49 ' CZ ' ' CE1' ' A' ' 45' ' ' TYR . 4.8 m-85 -118.07 128.13 54.46 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.954 -179.972 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 57' ' ' GLY . . . . . 0.42 ' HA3' ' CE1' ' A' ' 77' ' ' PHE . . . -88.25 59.42 4.14 Favored Glycine 0 N--CA 1.451 -0.305 0 C-N-CA 120.744 -0.741 . . . . 0.0 112.344 179.855 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 58' ' ' ILE . . . . . . . . . . . . . 12.6 mt -68.98 148.55 11.61 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.367 0 CA-C-O 120.864 0.364 . . . . 0.0 111.113 -179.895 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -119.15 120.47 37.18 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.891 179.932 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 60' ' ' LEU . . . . . . . . . . . . . 56.7 mt -71.88 -179.96 2.93 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.852 -179.997 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 21.0 m-20 -104.96 -29.55 10.39 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.283 -0.417 . . . . 0.0 110.935 -179.928 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 62' ' ' GLN . . . . . . . . . . . . . 2.1 mt-30 -114.87 147.95 39.39 Favored Pre-proline 0 C--N 1.329 -0.31 0 CA-C-N 116.312 -0.404 . . . . 0.0 110.871 -179.907 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 36.6 Cg_exo -60.02 91.2 0.08 OUTLIER 'Trans proline' 0 C--N 1.345 0.391 0 C-N-CA 122.515 2.143 . . . . 0.0 112.264 179.924 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 64' ' ' THR . . . . . . . . . . . . . 10.1 t -172.72 39.22 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.271 -0.422 . . . . 0.0 110.992 -179.994 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . -91.37 -104.84 1.38 Allowed Glycine 0 N--CA 1.451 -0.3 0 C-N-CA 120.695 -0.764 . . . . 0.0 112.459 -179.979 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 66' ' ' LYS . . . . . . . . . . . . . 3.0 mtmt -159.99 -49.3 0.05 Allowed 'General case' 0 C--N 1.328 -0.336 0 CA-C-O 120.795 0.331 . . . . 0.0 110.791 -179.992 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 67' ' ' HIS . . . . . . . . . . . . . 7.5 p80 -128.92 171.96 11.8 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.244 -0.435 . . . . 0.0 110.868 -179.937 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 16.8 t0 -98.18 32.47 2.44 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.255 -0.43 . . . . 0.0 110.88 179.926 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 95.4 -41.47 2.48 Favored Glycine 0 N--CA 1.451 -0.32 0 C-N-CA 120.73 -0.748 . . . . 0.0 112.506 -179.936 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 70' ' ' SER . . . . . . . . . . . . . 99.2 p -98.85 126.51 44.52 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 120.762 0.315 . . . . 0.0 110.978 179.976 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 21.5 t -112.88 114.27 46.49 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.354 0 CA-C-N 116.198 -0.456 . . . . 0.0 111.114 -179.908 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 72' ' ' PHE . . . . . . . . . . . . . 14.7 m-85 61.49 30.77 18.96 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.917 -179.976 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 98.42 -29.75 10.87 Favored Glycine 0 N--CA 1.452 -0.288 0 C-N-CA 120.741 -0.742 . . . . 0.0 112.511 179.985 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 21.5 t -77.2 124.22 35.22 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-O 120.752 0.311 . . . . 0.0 111.111 -179.978 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 75' ' ' ARG . . . . . . . . . . . . . 10.3 ttt180 -104.71 136.76 43.63 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.939 179.996 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 76' ' ' TYR . . . . . . . . . . . . . 36.3 m-85 -112.84 -43.47 3.42 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.965 179.963 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 77' ' ' PHE . . . . . 0.42 ' CE1' ' HA3' ' A' ' 57' ' ' GLY . 40.9 p90 -153.29 165.06 36.91 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.935 -179.995 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 2.6 t -93.6 121.62 35.2 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.176 -0.466 . . . . 0.0 110.853 -179.994 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 79' ' ' CYS . . . . . . . . . . . . . 10.0 p -142.45 154.2 44.35 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.22 -0.445 . . . . 0.0 111.002 -179.98 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 80' ' ' ALA . . . . . . . . . . . . . . . -58.94 165.45 3.35 Favored Pre-proline 0 C--N 1.328 -0.34 0 CA-C-N 116.166 -0.47 . . . . 0.0 111.025 179.956 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 81' ' ' PRO . . . . . . . . . . . . . 17.9 Cg_endo -59.6 115.94 2.95 Favored 'Trans proline' 0 C--N 1.344 0.332 0 C-N-CA 122.53 2.153 . . . . 0.0 112.095 179.985 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 82' ' ' ARG . . . . . . . . . . . . . 57.1 mtp180 63.96 55.36 1.59 Allowed 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.812 -179.883 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 83' ' ' HIS . . . . . . . . . . . . . 6.4 m170 -126.75 -47.43 1.54 Allowed 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.907 179.97 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . -59.04 142.41 46.51 Favored Glycine 0 N--CA 1.452 -0.261 0 C-N-CA 120.738 -0.744 . . . . 0.0 112.511 -179.99 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 85' ' ' VAL . . . . . . . . . . . . . 5.3 m -146.86 115.91 1.29 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.272 0 CA-C-O 120.804 0.335 . . . . 0.0 111.113 179.955 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 86' ' ' PHE . . . . . . . . . . . . . 10.4 m-85 -93.41 124.95 37.75 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.862 179.936 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 87' ' ' ALA . . . . . . . . . . . . . . . -144.55 144.86 26.46 Favored Pre-proline 0 C--N 1.329 -0.303 0 CA-C-N 116.27 -0.423 . . . . 0.0 111.101 179.93 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 88' ' ' PRO . . . . . 0.424 ' O ' ' N ' ' A' ' 91' ' ' ARG . 31.9 Cg_exo -58.38 142.13 97.51 Favored 'Trans proline' 0 C--N 1.345 0.387 0 C-N-CA 122.429 2.086 . . . . 0.0 112.243 179.956 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -47.58 -51.84 19.72 Favored 'General case' 0 C--N 1.333 -0.114 0 CA-C-O 121.088 0.471 . . . . 0.0 110.388 179.983 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 90' ' ' SER . . . . . . . . . . . . . 64.3 m -55.88 -24.29 36.28 Favored 'General case' 0 C--N 1.331 -0.235 0 CA-C-N 115.701 -0.681 . . . . 0.0 109.81 178.839 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 91' ' ' ARG . . . . . 0.424 ' N ' ' O ' ' A' ' 88' ' ' PRO . 0.5 OUTLIER -89.33 -13.83 37.06 Favored 'General case' 0 N--CA 1.455 -0.197 0 CA-C-N 115.876 -0.602 . . . . 0.0 110.484 179.095 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 92' ' ' ILE . . . . . . . . . . . . . 46.8 mt -109.92 141.11 26.17 Favored 'Isoleucine or valine' 0 C--O 1.231 0.126 0 CA-C-N 116.493 -0.321 . . . . 0.0 111.034 179.883 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 93' ' ' GLN . . . . . . . . . . . . . 1.4 mt-30 -107.72 171.45 7.38 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.816 179.992 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 94' ' ' ARG . . . . . . . . . . . . . 5.5 ttt180 -122.1 125.58 46.51 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.919 179.982 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 95' ' ' ILE . . . . . . . . . . . . . 5.5 mt . . . . . 0 C--N 1.329 -0.29 0 CA-C-N 116.273 -0.421 . . . . 0.0 111.037 -179.965 . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.231 0.118 0 CA-C-O 120.829 0.347 . . . . 0.0 111.16 . . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' A' A ' 27' ' ' GLU . . . . . . . . . . . . . 5.6 mp0 -130.46 177.87 7.03 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.886 -179.96 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 26.9 t -64.9 92.21 0.11 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.231 -0.44 . . . . 0.0 111.132 179.95 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 114.86 41.86 0.82 Allowed Glycine 0 N--CA 1.452 -0.251 0 C-N-CA 120.746 -0.74 . . . . 0.0 112.403 -179.928 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 37.5 t70 -134.93 144.14 47.3 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-O 120.841 0.353 . . . . 0.0 110.945 179.979 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 31' ' ' GLN . . . . . . . . . . . . . 2.4 mp0 -64.43 134.98 55.61 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.254 -0.43 . . . . 0.0 110.811 -179.996 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 13.7 m -147.96 173.41 1.99 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.358 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.21 179.981 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 33' ' ' LEU . . . . . . . . . . . . . 15.0 tp -134.32 108.53 8.26 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.222 -0.444 . . . . 0.0 110.899 -179.969 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 26.0 t -73.74 122.59 27.11 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.115 179.967 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 35' ' ' ALA . . . . . . . . . . . . . . . 59.13 25.2 13.65 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.117 -0.492 . . . . 0.0 111.194 -179.992 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . 55.27 27.49 46.97 Favored Glycine 0 N--CA 1.452 -0.253 0 C-N-CA 120.779 -0.724 . . . . 0.0 112.592 179.938 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 37' ' ' GLN . . . . . . . . . . . . . 12.8 mt-30 -141.87 -63.05 0.45 Allowed 'General case' 0 C--N 1.329 -0.286 0 CA-C-O 120.781 0.324 . . . . 0.0 110.876 -179.988 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 38' ' ' LYS . . . . . . . . . . . . . 11.4 mttp -71.26 111.97 7.03 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.25 -0.432 . . . . 0.0 110.889 179.989 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 39' ' ' GLN . . . . . . . . . . . . . 0.9 OUTLIER -82.27 131.24 35.23 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.854 -179.991 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -163.28 179.06 38.67 Favored Glycine 0 N--CA 1.451 -0.336 0 C-N-CA 120.775 -0.726 . . . . 0.0 112.504 -179.994 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 28.0 mt -128.63 137.74 56.49 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-O 120.842 0.354 . . . . 0.0 111.125 179.929 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 42' ' ' VAL . . . . . . . . . . . . . 21.5 t -62.19 127.16 21.68 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-N 116.174 -0.467 . . . . 0.0 111.161 -179.997 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 43' ' ' ARG . . . . . . . . . . . . . 10.1 mmt180 -111.76 -34.67 5.96 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.909 179.955 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 44' ' ' PHE . . . . . . . . . . . . . 39.4 t80 -143.52 112.28 6.53 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.897 -179.988 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 45' ' ' TYR . . . . . 0.485 ' CE1' ' CZ ' ' A' ' 56' ' ' TYR . 12.9 t80 -105.39 122.29 45.68 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.919 179.932 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 166.02 173.13 34.16 Favored Glycine 0 N--CA 1.452 -0.265 0 C-N-CA 120.757 -0.735 . . . . 0.0 112.485 179.953 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 47' ' ' LYS . . . . . . . . . . . . . 14.5 mttm -70.15 155.46 40.6 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 120.842 0.353 . . . . 0.0 110.911 -179.995 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 48' ' ' THR . . . . . 0.407 ' HB ' ' CE1' ' A' ' 50' ' ' PHE . 42.8 p -118.12 -177.75 3.35 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.13 -0.486 . . . . 0.0 110.874 179.969 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 4.8 t0 -105.98 -30.75 9.12 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.922 179.98 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 50' ' ' PHE . . . . . 0.407 ' CE1' ' HB ' ' A' ' 48' ' ' THR . 53.8 p90 -71.02 -40.75 71.58 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.941 -179.95 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 51' ' ' ALA . . . . . . . . . . . . . . . -137.0 144.47 46.5 Favored Pre-proline 0 C--N 1.329 -0.294 0 CA-C-N 116.187 -0.461 . . . . 0.0 111.211 -179.934 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 52' ' ' PRO . . . . . . . . . . . . . 73.3 Cg_endo -76.16 169.76 21.4 Favored 'Trans proline' 0 C--N 1.345 0.357 0 C-N-CA 122.54 2.16 . . . . 0.0 112.366 -179.975 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 90.39 178.78 44.07 Favored Glycine 0 N--CA 1.452 -0.294 0 C-N-CA 120.738 -0.744 . . . . 0.0 112.464 179.906 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 54' ' ' TYR . . . . . . . . . . . . . 14.1 m-85 -91.17 115.7 28.23 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-O 120.813 0.34 . . . . 0.0 110.935 179.977 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 55' ' ' TRP . . . . . . . . . . . . . 73.8 m95 -109.91 147.22 33.8 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.89 179.973 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 56' ' ' TYR . . . . . 0.485 ' CZ ' ' CE1' ' A' ' 45' ' ' TYR . 8.1 m-85 -104.62 120.98 42.57 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.966 -179.89 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 57' ' ' GLY . . . . . 0.445 ' N ' ' CE1' ' A' ' 86' ' ' PHE . . . -80.72 62.78 4.34 Favored Glycine 0 N--CA 1.451 -0.325 0 C-N-CA 120.758 -0.734 . . . . 0.0 112.365 179.929 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 58' ' ' ILE . . . . . . . . . . . . . 21.6 mt -70.76 138.94 20.84 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-O 120.866 0.365 . . . . 0.0 111.141 -179.906 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -109.13 130.63 55.48 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.877 -179.97 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 60' ' ' LEU . . . . . . . . . . . . . 84.2 mt -85.54 173.21 10.37 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.871 179.959 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 1.5 t70 -103.11 -31.03 10.36 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.943 -179.961 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 62' ' ' GLN . . . . . . . . . . . . . 2.4 mm-40 -114.43 147.81 38.82 Favored Pre-proline 0 C--N 1.33 -0.272 0 CA-C-N 116.298 -0.41 . . . . 0.0 110.911 -179.986 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 31.9 Cg_exo -58.24 84.32 0.05 OUTLIER 'Trans proline' 0 C--N 1.346 0.399 0 C-N-CA 122.564 2.176 . . . . 0.0 112.25 179.928 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 64' ' ' THR . . . . . . . . . . . . . 13.4 t -157.0 35.02 0.29 Allowed 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.297 -0.411 . . . . 0.0 110.946 179.988 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . -95.96 -159.98 32.65 Favored Glycine 0 N--CA 1.452 -0.292 0 C-N-CA 120.745 -0.741 . . . . 0.0 112.503 179.911 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 66' ' ' LYS . . . . . . . . . . . . . 0.5 OUTLIER -110.03 -31.31 7.42 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 120.861 0.363 . . . . 0.0 110.922 179.977 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 67' ' ' HIS . . . . . . . . . . . . . 13.1 p80 -145.96 -178.74 6.28 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.877 -179.975 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 26.6 t0 -114.87 73.08 0.81 Allowed 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.944 179.986 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 79.41 -72.75 2.47 Favored Glycine 0 N--CA 1.451 -0.352 0 C-N-CA 120.761 -0.733 . . . . 0.0 112.476 -179.982 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 70' ' ' SER . . . . . . . . . . . . . 97.2 p -86.62 151.5 23.39 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-O 120.841 0.353 . . . . 0.0 110.907 -179.981 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 71' ' ' VAL . . . . . 0.411 HG13 ' CD2' ' A' ' 72' ' ' PHE . 21.5 t -128.03 117.9 47.08 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.162 -0.472 . . . . 0.0 111.095 179.977 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 72' ' ' PHE . . . . . 0.411 ' CD2' HG13 ' A' ' 71' ' ' VAL . 59.8 m-85 60.91 31.12 19.98 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.879 179.962 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 99.74 -30.0 10.9 Favored Glycine 0 N--CA 1.452 -0.281 0 C-N-CA 120.687 -0.768 . . . . 0.0 112.563 179.984 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 21.3 t -75.66 116.35 18.45 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-O 120.888 0.375 . . . . 0.0 111.093 179.981 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 75' ' ' ARG . . . . . . . . . . . . . 26.2 ttt85 -93.83 148.03 22.51 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.858 179.969 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 76' ' ' TYR . . . . . 0.404 ' CZ ' HG22 ' A' ' 48' ' ' THR . 89.9 m-85 -133.24 -47.69 0.84 Allowed 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.165 -0.471 . . . . 0.0 110.948 179.946 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 77' ' ' PHE . . . . . . . . . . . . . 22.5 p90 -155.2 154.67 32.6 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.9 -179.979 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 9.0 t -84.6 140.7 31.19 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.169 -0.468 . . . . 0.0 110.847 179.955 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 79' ' ' CYS . . . . . . . . . . . . . 22.7 p -164.7 162.39 21.25 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.922 179.921 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 80' ' ' ALA . . . . . . . . . . . . . . . -59.24 166.16 3.12 Favored Pre-proline 0 C--N 1.33 -0.254 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.002 179.949 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 81' ' ' PRO . . . . . . . . . . . . . 28.1 Cg_endo -62.66 122.63 11.05 Favored 'Trans proline' 0 C--N 1.346 0.397 0 C-N-CA 122.468 2.112 . . . . 0.0 112.253 -180.0 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 82' ' ' ARG . . . . . . . . . . . . . 0.5 OUTLIER 61.01 53.36 3.72 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.91 -179.875 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 83' ' ' HIS . . . . . . . . . . . . . 7.4 m170 -123.21 -45.54 2.1 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.11 -0.495 . . . . 0.0 110.85 179.958 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . -59.8 146.01 45.09 Favored Glycine 0 N--CA 1.451 -0.341 0 C-N-CA 120.646 -0.788 . . . . 0.0 112.501 -179.971 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 85' ' ' VAL . . . . . . . . . . . . . 6.1 m -150.04 114.88 0.67 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-O 120.815 0.34 . . . . 0.0 111.098 -179.938 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 86' ' ' PHE . . . . . 0.445 ' CE1' ' N ' ' A' ' 57' ' ' GLY . 3.7 m-85 -97.53 108.29 20.98 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.929 179.998 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 87' ' ' ALA . . . . . . . . . . . . . . . -128.5 145.4 55.79 Favored Pre-proline 0 C--N 1.328 -0.344 0 CA-C-N 116.233 -0.439 . . . . 0.0 111.139 179.982 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 88' ' ' PRO . . . . . 0.417 ' O ' ' N ' ' A' ' 91' ' ' ARG . 32.3 Cg_exo -57.96 142.57 96.66 Favored 'Trans proline' 0 C--N 1.345 0.362 0 C-N-CA 122.519 2.146 . . . . 0.0 112.259 -179.984 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 89' ' ' ALA . . . . . 0.424 ' HB1' ' CE1' ' A' ' 56' ' ' TYR . . . -47.85 -51.18 23.93 Favored 'General case' 0 CA--C 1.521 -0.141 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.329 179.872 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 90' ' ' SER . . . . . . . . . . . . . 23.6 t -55.83 -24.4 36.24 Favored 'General case' 0 N--CA 1.454 -0.266 0 CA-C-N 115.747 -0.661 . . . . 0.0 109.815 178.76 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 91' ' ' ARG . . . . . 0.417 ' N ' ' O ' ' A' ' 88' ' ' PRO . 0.0 OUTLIER -89.37 -14.14 36.24 Favored 'General case' 0 N--CA 1.455 -0.215 0 CA-C-N 115.932 -0.576 . . . . 0.0 110.513 179.04 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 92' ' ' ILE . . . . . . . . . . . . . 48.9 mt -105.85 156.59 6.62 Favored 'Isoleucine or valine' 0 C--O 1.231 0.12 0 CA-C-N 116.396 -0.365 . . . . 0.0 110.971 179.753 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 93' ' ' GLN . . . . . . . . . . . . . 50.8 mt-30 -121.42 175.0 6.4 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.262 -0.426 . . . . 0.0 110.881 -179.979 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 94' ' ' ARG . . . . . . . . . . . . . 0.6 OUTLIER -122.03 110.41 15.76 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.855 -179.972 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 95' ' ' ILE . . . . . . . . . . . . . 32.5 mt . . . . . 0 C--N 1.329 -0.317 0 CA-C-N 116.262 -0.427 . . . . 0.0 111.073 179.97 . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.231 0.128 0 CA-C-O 120.827 0.346 . . . . 0.0 111.106 . . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' A' A ' 27' ' ' GLU . . . . . . . . . . . . . 8.8 mt-10 -125.01 167.74 14.3 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.251 -0.431 . . . . 0.0 110.885 179.992 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 28.3 t -70.55 100.41 0.73 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 CA-C-N 116.165 -0.471 . . . . 0.0 111.077 -179.963 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 116.94 39.68 0.8 Allowed Glycine 0 N--CA 1.451 -0.334 0 C-N-CA 120.692 -0.766 . . . . 0.0 112.504 -179.977 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 1.8 m-20 -142.35 146.94 35.51 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-O 120.836 0.35 . . . . 0.0 110.89 -179.992 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 31' ' ' GLN . . . . . . . . . . . . . 77.1 mt-30 -59.96 136.26 57.96 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.861 179.966 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 5.8 m -148.91 162.46 5.01 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.129 179.968 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 33' ' ' LEU . . . . . . . . . . . . . 20.5 tp -130.23 104.96 7.6 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.825 -179.956 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 21.7 t -72.98 125.01 31.09 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-N 116.178 -0.464 . . . . 0.0 111.263 -179.955 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 35' ' ' ALA . . . . . . . . . . . . . . . 57.17 25.88 11.48 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.169 -0.469 . . . . 0.0 111.24 179.914 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . 56.54 32.01 60.74 Favored Glycine 0 N--CA 1.452 -0.244 0 C-N-CA 120.726 -0.749 . . . . 0.0 112.613 179.971 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 37' ' ' GLN . . . . . . . . . . . . . 29.9 mt-30 -142.2 -66.71 0.39 Allowed 'General case' 0 C--N 1.329 -0.284 0 CA-C-O 120.781 0.324 . . . . 0.0 110.975 179.96 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 38' ' ' LYS . . . . . . . . . . . . . 25.1 mmtp -72.95 112.22 8.78 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.244 -0.434 . . . . 0.0 110.902 -179.957 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 39' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -92.62 130.28 38.3 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.891 -179.967 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -161.16 -169.41 24.38 Favored Glycine 0 N--CA 1.451 -0.324 0 C-N-CA 120.749 -0.739 . . . . 0.0 112.56 179.977 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 8.9 mt -128.62 132.71 67.58 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-O 120.769 0.319 . . . . 0.0 111.087 -179.993 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 42' ' ' VAL . . . . . . . . . . . . . 21.5 t -59.53 125.2 15.2 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.361 0 CA-C-N 116.2 -0.454 . . . . 0.0 111.153 179.932 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 43' ' ' ARG . . . . . . . . . . . . . 10.1 mmt180 -110.51 -32.52 6.88 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.882 -179.954 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 44' ' ' PHE . . . . . . . . . . . . . 86.9 t80 -144.4 113.73 7.0 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.909 -179.995 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 45' ' ' TYR . . . . . 0.439 ' CE1' ' CZ ' ' A' ' 56' ' ' TYR . 27.1 t80 -113.15 111.73 22.6 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.925 179.989 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . -169.52 -150.38 6.76 Favored Glycine 0 N--CA 1.45 -0.391 0 C-N-CA 120.808 -0.711 . . . . 0.0 112.545 179.984 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 47' ' ' LYS . . . . . 0.416 ' HD3' ' CE1' ' A' ' 54' ' ' TYR . 2.2 mmmp? -96.77 168.84 10.26 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.792 0.33 . . . . 0.0 110.879 -179.93 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 48' ' ' THR . . . . . 0.416 HG22 ' CE2' ' A' ' 50' ' ' PHE . 64.6 p -132.43 178.15 7.05 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.837 179.947 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 32.3 t70 -112.55 -35.41 5.55 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.961 -179.975 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 50' ' ' PHE . . . . . 0.422 ' CE1' ' HB2' ' A' ' 51' ' ' ALA . 30.1 p90 -62.73 -31.04 71.9 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.949 -179.942 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 51' ' ' ALA . . . . . 0.422 ' HB2' ' CE1' ' A' ' 50' ' ' PHE . . . -151.74 151.96 29.38 Favored Pre-proline 0 C--N 1.329 -0.299 0 CA-C-N 116.237 -0.438 . . . . 0.0 111.107 -179.962 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 52' ' ' PRO . . . . . . . . . . . . . 58.2 Cg_endo -71.58 -176.89 2.17 Favored 'Trans proline' 0 C--N 1.345 0.347 0 C-N-CA 122.559 2.173 . . . . 0.0 112.3 179.928 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 75.12 -177.07 48.92 Favored Glycine 0 N--CA 1.451 -0.348 0 C-N-CA 120.756 -0.735 . . . . 0.0 112.54 -179.922 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 54' ' ' TYR . . . . . 0.416 ' CE1' ' HD3' ' A' ' 47' ' ' LYS . 10.1 m-85 -107.8 132.45 53.4 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 120.815 0.34 . . . . 0.0 110.916 179.994 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 55' ' ' TRP . . . . . 0.423 ' CZ3' ' HD3' ' A' ' 88' ' ' PRO . 19.0 m95 -120.07 173.31 7.16 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.852 -179.989 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 56' ' ' TYR . . . . . 0.439 ' CZ ' ' CE1' ' A' ' 45' ' ' TYR . 10.8 m-85 -117.21 127.51 54.17 Favored 'General case' 0 C--N 1.331 -0.235 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.948 -179.904 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . -90.6 65.12 2.76 Favored Glycine 0 N--CA 1.45 -0.426 0 C-N-CA 120.746 -0.74 . . . . 0.0 112.426 -179.998 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 58' ' ' ILE . . . . . . . . . . . . . 25.3 mt -71.64 139.43 19.82 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-O 120.779 0.323 . . . . 0.0 111.135 -179.928 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 0.2 OUTLIER -108.49 111.0 22.64 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.826 -179.965 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 60' ' ' LEU . . . . . . . . . . . . . 63.2 mt -63.93 167.89 5.73 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.308 -0.406 . . . . 0.0 110.846 -179.969 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -96.84 -26.1 15.23 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.947 -179.995 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 62' ' ' GLN . . . . . . . . . . . . . 64.9 mm-40 -124.26 152.36 67.56 Favored Pre-proline 0 C--N 1.329 -0.284 0 CA-C-N 116.369 -0.378 . . . . 0.0 110.908 -179.895 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 63' ' ' PRO . . . . . 0.408 ' HA ' ' CD2' ' A' ' 83' ' ' HIS . 32.2 Cg_exo -58.19 92.52 0.06 OUTLIER 'Trans proline' 0 C--N 1.346 0.401 0 C-N-CA 122.579 2.186 . . . . 0.0 112.293 179.954 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 64' ' ' THR . . . . . . . . . . . . . 13.4 t -165.74 36.49 0.05 Allowed 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 116.283 -0.417 . . . . 0.0 110.932 179.873 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . -99.12 -140.11 11.26 Favored Glycine 0 N--CA 1.451 -0.344 0 C-N-CA 120.78 -0.724 . . . . 0.0 112.442 -179.993 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 66' ' ' LYS . . . . . . . . . . . . . 1.7 mttm -132.21 -46.55 0.92 Allowed 'General case' 0 C--N 1.328 -0.34 0 CA-C-O 120.822 0.344 . . . . 0.0 110.87 179.97 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 67' ' ' HIS . . . . . . . . . . . . . 12.4 p80 -127.27 174.69 8.75 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.233 -0.44 . . . . 0.0 110.92 179.901 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 1.6 m-20 -98.46 48.68 0.98 Allowed 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.928 179.998 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 84.44 -61.51 4.7 Favored Glycine 0 N--CA 1.451 -0.31 0 C-N-CA 120.715 -0.755 . . . . 0.0 112.486 -179.997 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 70' ' ' SER . . . . . . . . . . . . . 31.4 p -80.26 152.15 29.22 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-O 120.774 0.321 . . . . 0.0 110.802 -179.992 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 21.5 t -134.32 118.08 26.42 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.111 179.982 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 72' ' ' PHE . . . . . . . . . . . . . 28.8 m-85 60.58 31.05 20.16 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.884 179.937 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 98.35 -28.41 14.94 Favored Glycine 0 N--CA 1.451 -0.316 0 C-N-CA 120.741 -0.742 . . . . 0.0 112.462 -179.998 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 21.5 t -73.64 130.56 35.78 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-O 120.805 0.336 . . . . 0.0 111.133 179.998 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 75' ' ' ARG . . . . . . . . . . . . . 48.4 ttt-85 -93.71 144.23 25.59 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.901 179.963 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 76' ' ' TYR . . . . . . . . . . . . . 58.4 m-85 -124.85 -44.82 1.92 Allowed 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.867 -179.985 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 77' ' ' PHE . . . . . . . . . . . . . 32.7 p90 -166.91 177.44 6.37 Favored 'General case' 0 C--N 1.327 -0.383 0 CA-C-N 116.18 -0.463 . . . . 0.0 110.908 179.978 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 1.7 t -98.96 124.83 44.18 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.833 -179.93 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 79' ' ' CYS . . . . . . . . . . . . . 27.0 p -150.98 155.01 38.2 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.847 179.952 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 80' ' ' ALA . . . . . 0.405 ' HB3' ' CD2' ' A' ' 83' ' ' HIS . . . -67.99 166.84 20.4 Favored Pre-proline 0 C--N 1.328 -0.349 0 CA-C-N 116.159 -0.473 . . . . 0.0 111.049 179.956 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 81' ' ' PRO . . . . . . . . . . . . . 53.3 Cg_exo -52.63 117.07 3.31 Favored 'Trans proline' 0 C--N 1.345 0.362 0 C-N-CA 122.538 2.159 . . . . 0.0 112.324 -179.92 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 82' ' ' ARG . . . . . . . . . . . . . 2.9 ttm180 63.12 57.7 1.56 Allowed 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.978 179.985 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 83' ' ' HIS . . . . . 0.408 ' CD2' ' HA ' ' A' ' 63' ' ' PRO . 6.3 m170 -126.96 -46.98 1.52 Allowed 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.091 -0.504 . . . . 0.0 110.94 179.957 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . -62.86 139.31 44.85 Favored Glycine 0 N--CA 1.45 -0.388 0 C-N-CA 120.722 -0.752 . . . . 0.0 112.541 179.989 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 85' ' ' VAL . . . . . . . . . . . . . 5.5 m -147.21 124.18 3.19 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.257 0 CA-C-O 120.871 0.367 . . . . 0.0 111.062 -179.942 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 86' ' ' PHE . . . . . . . . . . . . . 13.5 m-85 -100.77 121.12 41.14 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.081 -0.508 . . . . 0.0 110.9 179.999 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 87' ' ' ALA . . . . . . . . . . . . . . . -140.75 144.84 37.47 Favored Pre-proline 0 C--N 1.328 -0.33 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.161 179.975 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 88' ' ' PRO . . . . . 0.423 ' HD3' ' CZ3' ' A' ' 55' ' ' TRP . 47.6 Cg_exo -56.06 141.25 87.11 Favored 'Trans proline' 0 C--N 1.345 0.394 0 C-N-CA 122.607 2.204 . . . . 0.0 112.224 -179.9 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -47.96 -50.97 25.48 Favored 'General case' 0 CA--C 1.521 -0.149 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.295 179.854 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 90' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -55.83 -24.6 37.41 Favored 'General case' 0 C--N 1.331 -0.217 0 CA-C-N 115.68 -0.691 . . . . 0.0 109.673 178.841 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 91' ' ' ARG . . . . . 0.416 ' N ' ' O ' ' A' ' 88' ' ' PRO . 0.0 OUTLIER -87.6 -15.37 37.54 Favored 'General case' 0 N--CA 1.454 -0.244 0 CA-C-N 115.856 -0.611 . . . . 0.0 110.423 179.032 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 92' ' ' ILE . . . . . . . . . . . . . 33.0 mt -104.63 145.89 12.61 Favored 'Isoleucine or valine' 0 C--N 1.333 -0.126 0 CA-C-N 116.397 -0.365 . . . . 0.0 111.066 179.864 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 93' ' ' GLN . . . . . . . . . . . . . 0.7 OUTLIER -114.83 -179.96 3.78 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.991 -179.973 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 94' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -126.08 142.88 51.33 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.877 -179.968 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 95' ' ' ILE . . . . . . . . . . . . . 3.3 mp . . . . . 0 C--N 1.329 -0.287 0 CA-C-N 116.108 -0.496 . . . . 0.0 111.172 179.981 . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.231 0.1 0 CA-C-O 120.833 0.349 . . . . 0.0 111.134 . . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' A' A ' 27' ' ' GLU . . . . . . . . . . . . . 28.7 mt-10 -139.41 178.31 7.29 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.946 179.972 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 28.9 t -72.31 115.7 13.18 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.219 -0.446 . . . . 0.0 111.049 -179.979 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 102.43 33.96 4.33 Favored Glycine 0 N--CA 1.452 -0.298 0 C-N-CA 120.716 -0.754 . . . . 0.0 112.443 179.969 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 13.3 m-20 -141.42 148.35 39.42 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-O 120.822 0.344 . . . . 0.0 110.912 179.92 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 31' ' ' GLN . . . . . . . . . . . . . 3.5 mp0 -72.74 137.33 45.82 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.955 179.975 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 14.8 m -146.55 177.53 1.3 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 116.262 -0.426 . . . . 0.0 111.112 179.984 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 33' ' ' LEU . . . . . . . . . . . . . 21.7 tp -134.15 112.36 11.06 Favored 'General case' 0 C--N 1.33 -0.283 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.794 -179.998 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 21.9 t -76.03 123.74 32.77 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.145 -0.479 . . . . 0.0 111.127 -179.949 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 35' ' ' ALA . . . . . . . . . . . . . . . 59.28 25.56 14.22 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.153 -0.476 . . . . 0.0 111.229 179.979 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . 55.95 27.88 51.88 Favored Glycine 0 N--CA 1.452 -0.252 0 C-N-CA 120.759 -0.734 . . . . 0.0 112.633 -179.993 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 37' ' ' GLN . . . . . . . . . . . . . 24.9 mt-30 -142.64 -69.23 0.35 Allowed 'General case' 0 C--N 1.329 -0.285 0 CA-C-O 120.885 0.374 . . . . 0.0 110.925 179.957 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 38' ' ' LYS . . . . . . . . . . . . . 19.3 mttp -67.15 119.73 12.56 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.929 179.985 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 39' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -87.09 133.03 33.65 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.886 -179.999 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -162.33 169.76 37.75 Favored Glycine 0 N--CA 1.45 -0.371 0 C-N-CA 120.742 -0.742 . . . . 0.0 112.557 -179.969 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 23.2 mt -116.03 146.22 20.75 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.352 0 CA-C-O 120.799 0.333 . . . . 0.0 111.061 -179.99 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 42' ' ' VAL . . . . . . . . . . . . . 33.3 t -69.49 124.95 26.51 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.212 -0.449 . . . . 0.0 111.042 179.946 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 43' ' ' ARG . . . . . . . . . . . . . 2.9 mmm180 -111.84 -43.39 3.62 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.894 179.99 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 44' ' ' PHE . . . . . . . . . . . . . 49.7 t80 -136.7 113.16 10.02 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.86 -179.897 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 45' ' ' TYR . . . . . 0.495 ' CE1' ' CE1' ' A' ' 56' ' ' TYR . 14.1 t80 -112.9 131.57 55.67 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.272 -0.422 . . . . 0.0 110.872 179.965 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 156.17 -172.45 34.05 Favored Glycine 0 N--CA 1.451 -0.364 0 C-N-CA 120.763 -0.732 . . . . 0.0 112.524 -179.968 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 47' ' ' LYS . . . . . 0.412 ' HG3' ' CZ ' ' A' ' 54' ' ' TYR . 98.5 mttt -69.01 155.86 39.62 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 120.768 0.318 . . . . 0.0 110.915 179.968 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 48' ' ' THR . . . . . . . . . . . . . 7.2 p -122.69 170.08 10.41 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.858 -179.943 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -102.33 -31.28 10.59 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.93 179.957 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 50' ' ' PHE . . . . . 0.413 ' CD1' ' HB2' ' A' ' 51' ' ' ALA . 18.0 p90 -73.66 -31.63 63.58 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.915 179.951 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 51' ' ' ALA . . . . . 0.413 ' HB2' ' CD1' ' A' ' 50' ' ' PHE . . . -140.51 147.95 51.45 Favored Pre-proline 0 C--N 1.33 -0.269 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.096 -179.895 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 52' ' ' PRO . . . . . . . . . . . . . 60.0 Cg_endo -72.25 176.9 7.93 Favored 'Trans proline' 0 C--N 1.344 0.32 0 C-N-CA 122.578 2.185 . . . . 0.0 112.402 179.902 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 72.45 -155.97 51.73 Favored Glycine 0 N--CA 1.45 -0.397 0 C-N-CA 120.771 -0.728 . . . . 0.0 112.592 179.947 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 54' ' ' TYR . . . . . 0.412 ' CZ ' ' HG3' ' A' ' 47' ' ' LYS . 10.8 m-85 -115.86 137.63 51.91 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-O 120.894 0.378 . . . . 0.0 110.856 -179.989 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 55' ' ' TRP . . . . . . . . . . . . . 52.0 m95 -126.37 164.25 21.48 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.835 179.977 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 56' ' ' TYR . . . . . 0.495 ' CE1' ' CE1' ' A' ' 45' ' ' TYR . 25.9 m-85 -114.42 120.88 41.81 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.968 179.963 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 57' ' ' GLY . . . . . 0.414 ' HA3' ' CE1' ' A' ' 77' ' ' PHE . . . -83.07 61.25 4.81 Favored Glycine 0 N--CA 1.45 -0.387 0 C-N-CA 120.73 -0.748 . . . . 0.0 112.401 179.995 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 58' ' ' ILE . . . . . 0.425 HG21 HD11 ' A' ' 58' ' ' ILE . 45.2 mt -69.33 145.13 13.43 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-O 120.827 0.346 . . . . 0.0 111.098 -179.899 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 5.6 tm-20 -112.83 132.77 55.13 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.797 -179.961 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 60' ' ' LEU . . . . . . . . . . . . . 39.3 mt -93.1 158.76 15.61 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.202 -0.453 . . . . 0.0 110.93 -179.994 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 32.6 t0 -100.26 31.17 3.49 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.918 179.931 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 62' ' ' GLN . . . . . . . . . . . . . 1.8 pm0 -157.46 149.05 17.02 Favored Pre-proline 0 C--N 1.33 -0.276 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.846 179.965 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 56.4 Cg_endo -70.28 63.67 2.09 Favored 'Trans proline' 0 C--N 1.344 0.314 0 C-N-CA 122.631 2.221 . . . . 0.0 112.284 -179.994 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 64' ' ' THR . . . . . . . . . . . . . 5.4 p -145.23 30.84 1.12 Allowed 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.972 179.901 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . -79.37 -159.26 15.92 Favored Glycine 0 N--CA 1.451 -0.361 0 C-N-CA 120.714 -0.755 . . . . 0.0 112.48 179.989 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 66' ' ' LYS . . . . . . . . . . . . . 7.0 mtpm? -111.53 -33.74 6.29 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 120.813 0.34 . . . . 0.0 110.928 179.969 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 67' ' ' HIS . . . . . . . . . . . . . 6.0 p80 -139.12 174.07 10.9 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.911 179.921 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 1.3 t70 -97.85 37.07 1.44 Allowed 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.951 179.973 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 95.19 -65.21 1.33 Allowed Glycine 0 N--CA 1.451 -0.337 0 C-N-CA 120.703 -0.76 . . . . 0.0 112.511 -179.965 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 70' ' ' SER . . . . . . . . . . . . . 3.1 p -89.57 133.34 34.65 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 120.807 0.337 . . . . 0.0 110.836 -179.931 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 71' ' ' VAL . . . . . 0.413 HG11 ' CD2' ' A' ' 72' ' ' PHE . 21.5 t -114.21 114.76 47.62 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.202 -0.454 . . . . 0.0 111.111 -179.982 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 72' ' ' PHE . . . . . 0.413 ' CD2' HG11 ' A' ' 71' ' ' VAL . 13.9 m-85 60.73 31.11 20.09 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.949 179.99 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 98.8 -29.36 11.81 Favored Glycine 0 N--CA 1.451 -0.324 0 C-N-CA 120.752 -0.737 . . . . 0.0 112.485 -179.956 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 21.5 t -76.97 123.56 33.74 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-O 120.797 0.332 . . . . 0.0 111.092 -179.944 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 75' ' ' ARG . . . . . . . . . . . . . 11.4 ttm180 -101.1 134.04 44.7 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.884 179.996 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 76' ' ' TYR . . . . . . . . . . . . . 51.7 m-85 -109.67 -31.15 7.57 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.998 179.922 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 77' ' ' PHE . . . . . 0.414 ' CE1' ' HA3' ' A' ' 57' ' ' GLY . 27.0 p90 -172.85 156.39 3.4 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.941 179.98 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 12.3 m -85.75 111.2 19.92 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.798 179.968 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 79' ' ' CYS . . . . . . . . . . . . . 27.1 p -134.86 164.31 27.86 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.31 -0.405 . . . . 0.0 110.995 -179.929 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 80' ' ' ALA . . . . . . . . . . . . . . . -63.55 165.86 10.72 Favored Pre-proline 0 C--N 1.328 -0.337 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.949 179.879 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 81' ' ' PRO . . . . . . . . . . . . . 20.5 Cg_endo -60.85 114.97 2.39 Favored 'Trans proline' 0 C--N 1.345 0.364 0 C-N-CA 122.58 2.187 . . . . 0.0 112.146 179.876 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 82' ' ' ARG . . . . . . . . . . . . . 49.7 mtt180 64.4 58.69 1.06 Allowed 'General case' 0 C--N 1.331 -0.232 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.752 -179.969 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 83' ' ' HIS . . . . . . . . . . . . . 5.7 m-70 -130.7 -48.56 1.05 Allowed 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.899 179.927 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . -60.48 140.29 48.06 Favored Glycine 0 N--CA 1.452 -0.273 0 C-N-CA 120.741 -0.742 . . . . 0.0 112.531 -179.99 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 85' ' ' VAL . . . . . . . . . . . . . 10.1 m -142.59 130.52 20.12 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-O 120.823 0.344 . . . . 0.0 111.096 179.937 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 86' ' ' PHE . . . . . 0.409 ' CE1' ' CA ' ' A' ' 57' ' ' GLY . 8.6 m-85 -103.66 114.0 27.93 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.924 -179.963 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 87' ' ' ALA . . . . . . . . . . . . . . . -134.28 145.4 55.23 Favored Pre-proline 0 C--N 1.331 -0.237 0 CA-C-N 116.259 -0.428 . . . . 0.0 111.067 -179.949 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 88' ' ' PRO . . . . . 0.41 ' O ' ' N ' ' A' ' 91' ' ' ARG . 36.5 Cg_exo -57.45 140.57 93.58 Favored 'Trans proline' 0 C--N 1.345 0.356 0 C-N-CA 122.527 2.151 . . . . 0.0 112.236 -179.981 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -48.24 -50.27 30.13 Favored 'General case' 0 CA--C 1.521 -0.162 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.262 179.809 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 90' ' ' SER . . . . . . . . . . . . . 2.7 m -55.9 -24.51 37.82 Favored 'General case' 0 N--CA 1.455 -0.223 0 CA-C-N 115.706 -0.679 . . . . 0.0 109.789 178.767 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 91' ' ' ARG . . . . . 0.41 ' N ' ' O ' ' A' ' 88' ' ' PRO . 0.2 OUTLIER -88.54 -14.19 38.29 Favored 'General case' 0 N--CA 1.455 -0.177 0 CA-C-N 115.865 -0.607 . . . . 0.0 110.391 179.1 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 92' ' ' ILE . . . . . . . . . . . . . 21.4 mt -108.12 139.82 28.88 Favored 'Isoleucine or valine' 0 C--O 1.232 0.154 0 CA-C-N 116.45 -0.341 . . . . 0.0 111.061 179.808 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 93' ' ' GLN . . . . . . . . . . . . . 8.7 mt-30 -106.7 171.72 7.21 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.892 179.997 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 94' ' ' ARG . . . . . . . . . . . . . 3.4 ttt-85 -111.79 154.18 25.45 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.902 179.929 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 95' ' ' ILE . . . . . . . . . . . . . 31.8 mt . . . . . 0 C--N 1.328 -0.326 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.155 179.997 . . . . . . . . 0 0 . 1 . 011 nuclear orig core ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.231 0.117 0 CA-C-O 120.776 0.322 . . . . 0.0 111.143 . . . . . . . . . 0 0 . 1 . 011 nuclear orig core ' A' A ' 27' ' ' GLU . . . . . . . . . . . . . 30.4 mt-10 -145.56 -178.36 6.04 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.901 -179.992 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 21.5 t -75.85 116.62 19.08 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.211 -0.449 . . . . 0.0 111.144 -179.954 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 101.35 36.65 3.77 Favored Glycine 0 N--CA 1.45 -0.416 0 C-N-CA 120.766 -0.73 . . . . 0.0 112.47 -179.992 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -144.79 151.67 39.17 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 120.778 0.323 . . . . 0.0 110.898 -179.991 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 31' ' ' GLN . . . . . . . . . . . . . 2.7 mp0 -72.11 125.78 28.14 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.233 -0.439 . . . . 0.0 110.891 179.984 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 27.5 m -127.04 174.57 10.57 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.138 -0.483 . . . . 0.0 111.143 179.964 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 33' ' ' LEU . . . . . . . . . . . . . 25.8 tp -143.22 102.54 4.0 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.852 -179.923 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 21.4 t -72.65 128.57 35.6 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.148 -0.478 . . . . 0.0 111.147 -179.92 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 35' ' ' ALA . . . . . . . . . . . . . . . 57.18 25.08 10.54 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.065 -0.516 . . . . 0.0 111.304 179.936 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . 56.38 31.22 59.53 Favored Glycine 0 N--CA 1.451 -0.344 0 C-N-CA 120.752 -0.737 . . . . 0.0 112.604 -179.986 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 37' ' ' GLN . . . . . . . . . . . . . 81.6 mt-30 -146.3 -70.86 0.25 Allowed 'General case' 0 C--N 1.329 -0.29 0 CA-C-O 120.79 0.329 . . . . 0.0 110.906 -179.92 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 38' ' ' LYS . . . . . . . . . . . . . 12.6 mttt -61.71 105.05 0.5 Allowed 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.905 -179.988 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 39' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -85.1 132.02 34.37 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.902 179.942 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -158.39 -170.19 22.78 Favored Glycine 0 N--CA 1.451 -0.358 0 C-N-CA 120.709 -0.758 . . . . 0.0 112.438 179.977 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 32.2 mt -129.55 129.74 66.87 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-O 120.798 0.332 . . . . 0.0 111.046 -179.959 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 42' ' ' VAL . . . . . . . . . . . . . 21.4 t -58.46 125.22 14.12 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.172 179.973 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 43' ' ' ARG . . . . . . . . . . . . . 36.6 mmt180 -108.18 -31.53 7.87 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.87 -179.973 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 44' ' ' PHE . . . . . . . . . . . . . 41.0 t80 -148.78 113.81 5.47 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.922 179.926 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 45' ' ' TYR . . . . . 0.471 ' CE1' ' CZ ' ' A' ' 56' ' ' TYR . 33.7 t80 -112.3 142.93 44.2 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.884 179.974 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 148.92 -168.99 29.4 Favored Glycine 0 N--CA 1.451 -0.327 0 C-N-CA 120.732 -0.747 . . . . 0.0 112.492 -179.982 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 47' ' ' LYS . . . . . 0.41 ' HE2' ' CZ ' ' A' ' 54' ' ' TYR . 22.2 mttm -87.39 141.58 28.53 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-O 120.851 0.357 . . . . 0.0 110.869 -179.98 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 48' ' ' THR . . . . . 0.441 ' CB ' ' CE2' ' A' ' 50' ' ' PHE . 63.6 p -102.18 -177.12 3.31 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.85 179.983 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 1.3 t70 -112.85 15.86 19.67 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.159 -0.473 . . . . 0.0 111.242 -179.958 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 50' ' ' PHE . . . . . 0.445 ' CD1' ' N ' ' A' ' 51' ' ' ALA . 29.2 p90 -116.38 -36.65 3.94 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-O 120.727 0.299 . . . . 0.0 110.996 179.846 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 51' ' ' ALA . . . . . 0.445 ' N ' ' CD1' ' A' ' 50' ' ' PHE . . . -140.26 146.71 47.04 Favored Pre-proline 0 C--N 1.328 -0.332 0 CA-C-N 116.249 -0.432 . . . . 0.0 111.126 179.924 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 52' ' ' PRO . . . . . . . . . . . . . 60.0 Cg_endo -72.42 170.81 18.37 Favored 'Trans proline' 0 C--N 1.345 0.388 0 C-N-CA 122.505 2.137 . . . . 0.0 112.353 -179.957 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 90.66 -154.08 23.01 Favored Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.778 -0.725 . . . . 0.0 112.525 179.939 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 54' ' ' TYR . . . . . 0.41 ' CZ ' ' HE2' ' A' ' 47' ' ' LYS . 57.4 m-85 -125.23 124.45 41.71 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 120.872 0.368 . . . . 0.0 110.867 179.963 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 55' ' ' TRP . . . . . . . . . . . . . 65.3 m95 -115.13 161.83 17.86 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.936 179.95 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 56' ' ' TYR . . . . . 0.471 ' CZ ' ' CE1' ' A' ' 45' ' ' TYR . 10.8 m-85 -117.68 120.07 36.89 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.211 -0.449 . . . . 0.0 110.92 -179.887 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 57' ' ' GLY . . . . . 0.45 ' CA ' ' CE1' ' A' ' 86' ' ' PHE . . . -84.71 63.8 4.35 Favored Glycine 0 N--CA 1.452 -0.298 0 C-N-CA 120.681 -0.771 . . . . 0.0 112.392 179.997 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 58' ' ' ILE . . . . . . . . . . . . . 3.3 mt -70.24 146.95 11.87 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.23 0 CA-C-O 120.807 0.337 . . . . 0.0 111.128 -179.966 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 3.7 tm-20 -116.91 109.8 17.51 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.841 -179.979 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 60' ' ' LEU . . . . . . . . . . . . . 96.0 mt -63.55 172.84 1.87 Allowed 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.912 179.932 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -98.5 -32.54 11.41 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.289 -0.414 . . . . 0.0 110.924 -179.978 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 62' ' ' GLN . . . . . . . . . . . . . 4.7 mm-40 -118.42 151.34 49.44 Favored Pre-proline 0 C--N 1.33 -0.264 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.94 -179.998 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 52.1 Cg_exo -54.66 99.95 0.06 OUTLIER 'Trans proline' 0 C--N 1.345 0.362 0 C-N-CA 122.485 2.123 . . . . 0.0 112.286 -179.958 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 64' ' ' THR . . . . . . . . . . . . . 9.8 t -176.98 39.01 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.872 179.983 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . -95.87 -125.43 4.73 Favored Glycine 0 N--CA 1.45 -0.37 0 C-N-CA 120.713 -0.756 . . . . 0.0 112.475 179.98 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 66' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -144.17 -47.71 0.27 Allowed 'General case' 0 C--N 1.329 -0.284 0 CA-C-O 120.825 0.345 . . . . 0.0 110.833 -179.869 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 67' ' ' HIS . . . . . . . . . . . . . 6.4 p80 -122.84 177.43 5.48 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.191 -0.458 . . . . 0.0 110.884 179.984 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -100.15 35.35 2.09 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.891 -179.987 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 100.99 -70.18 0.42 Allowed Glycine 0 N--CA 1.451 -0.365 0 C-N-CA 120.756 -0.735 . . . . 0.0 112.465 179.944 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 70' ' ' SER . . . . . . . . . . . . . 78.4 p -81.68 148.85 28.79 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 120.85 0.357 . . . . 0.0 110.868 179.987 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 27.3 t -127.67 125.94 66.17 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.167 -0.47 . . . . 0.0 111.11 179.93 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 72' ' ' PHE . . . . . . . . . . . . . 47.7 m-85 60.08 28.02 17.52 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.99 -179.929 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 95.97 -30.03 9.11 Favored Glycine 0 N--CA 1.451 -0.307 0 C-N-CA 120.628 -0.796 . . . . 0.0 112.538 179.951 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 21.6 t -80.47 122.95 36.59 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-O 120.784 0.326 . . . . 0.0 111.074 -179.939 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 75' ' ' ARG . . . . . . . . . . . . . 21.2 ttm180 -88.96 146.26 25.01 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.224 -0.443 . . . . 0.0 110.922 -179.997 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 76' ' ' TYR . . . . . 0.415 ' CE2' HG22 ' A' ' 48' ' ' THR . 37.0 m-85 -119.26 -47.75 2.45 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.185 -0.462 . . . . 0.0 110.897 -179.977 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 77' ' ' PHE . . . . . . . . . . . . . 34.8 p90 -152.79 171.4 18.3 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.922 179.972 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 4.6 p -97.26 122.56 40.42 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.904 -179.97 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 79' ' ' CYS . . . . . . . . . . . . . 27.3 p -143.87 176.74 9.03 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.906 179.963 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 80' ' ' ALA . . . . . 0.404 ' HB2' ' CD2' ' A' ' 83' ' ' HIS . . . -90.43 168.95 13.02 Favored Pre-proline 0 C--N 1.329 -0.308 0 CA-C-N 116.229 -0.441 . . . . 0.0 111.077 179.96 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 81' ' ' PRO . . . . . . . . . . . . . 52.7 Cg_exo -52.59 113.6 1.3 Allowed 'Trans proline' 0 C--N 1.344 0.303 0 C-N-CA 122.557 2.171 . . . . 0.0 112.261 179.93 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 82' ' ' ARG . . . . . . . . . . . . . 9.2 mmt180 61.27 53.59 3.47 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.907 -179.987 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 83' ' ' HIS . . . . . 0.404 ' CD2' ' HB2' ' A' ' 80' ' ' ALA . 5.5 m170 -121.17 -42.4 2.48 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.125 -0.489 . . . . 0.0 110.918 179.989 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . -63.7 154.67 45.67 Favored Glycine 0 N--CA 1.45 -0.368 0 C-N-CA 120.745 -0.741 . . . . 0.0 112.511 179.933 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 85' ' ' VAL . . . . . . . . . . . . . 15.2 m -156.27 127.27 0.87 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-O 120.84 0.352 . . . . 0.0 111.191 -179.96 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 86' ' ' PHE . . . . . 0.45 ' CE1' ' CA ' ' A' ' 57' ' ' GLY . 7.9 m-85 -112.53 102.09 10.21 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.818 179.942 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 87' ' ' ALA . . . . . . . . . . . . . . . -123.19 145.86 47.45 Favored Pre-proline 0 C--N 1.329 -0.297 0 CA-C-N 116.245 -0.434 . . . . 0.0 111.119 -179.956 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 88' ' ' PRO . . . . . 0.41 ' O ' ' N ' ' A' ' 91' ' ' ARG . 32.3 Cg_exo -58.02 141.94 96.5 Favored 'Trans proline' 0 C--N 1.346 0.4 0 C-N-CA 122.498 2.132 . . . . 0.0 112.235 179.991 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 89' ' ' ALA . . . . . 0.413 ' HB1' ' CE1' ' A' ' 56' ' ' TYR . . . -47.9 -51.44 23.24 Favored 'General case' 0 CA--C 1.522 -0.116 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.346 179.859 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 90' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -55.99 -24.29 37.84 Favored 'General case' 0 N--CA 1.454 -0.27 0 CA-C-N 115.759 -0.655 . . . . 0.0 109.789 178.836 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 91' ' ' ARG . . . . . 0.41 ' N ' ' O ' ' A' ' 88' ' ' PRO . 0.0 OUTLIER -89.77 -14.08 35.34 Favored 'General case' 0 N--CA 1.455 -0.208 0 CA-C-N 115.945 -0.571 . . . . 0.0 110.526 179.029 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 92' ' ' ILE . . . . . 0.443 HD11 HG21 ' A' ' 92' ' ' ILE . 52.4 mt -110.56 156.04 11.73 Favored 'Isoleucine or valine' 0 C--O 1.23 0.077 0 CA-C-O 120.904 0.383 . . . . 0.0 111.04 179.864 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 93' ' ' GLN . . . . . . . . . . . . . 1.9 mt-30 -124.31 179.98 4.69 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.78 179.93 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 94' ' ' ARG . . . . . . . . . . . . . 4.2 ttt180 -126.08 142.18 51.63 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.936 179.993 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 95' ' ' ILE . . . . . . . . . . . . . 3.4 mt . . . . . 0 C--N 1.329 -0.292 0 CA-C-N 116.246 -0.434 . . . . 0.0 111.088 179.982 . . . . . . . . 0 0 . 1 . 012 nuclear orig core ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.457 -0.076 0 CA-C-O 120.85 0.357 . . . . 0.0 111.088 . . . . . . . . . 0 0 . 1 . 012 nuclear orig core ' A' A ' 27' ' ' GLU . . . . . . . . . . . . . 50.8 mt-10 -133.24 -177.82 4.7 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.924 179.983 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 27.4 t -71.31 121.53 21.51 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.096 179.924 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 89.72 52.98 2.51 Favored Glycine 0 N--CA 1.452 -0.293 0 C-N-CA 120.7 -0.762 . . . . 0.0 112.424 179.954 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -155.45 142.1 18.83 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 120.795 0.331 . . . . 0.0 110.887 179.968 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 31' ' ' GLN . . . . . . . . . . . . . 15.3 mt-30 -59.97 134.95 57.52 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.256 -0.429 . . . . 0.0 110.923 -179.971 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 5.5 m -141.83 179.31 2.12 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.346 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.12 -179.982 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 33' ' ' LEU . . . . . . . . . . . . . 30.6 tp -142.76 108.0 5.0 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.791 179.98 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 22.0 t -78.29 124.67 37.03 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.156 179.995 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 35' ' ' ALA . . . . . . . . . . . . . . . 58.46 26.15 13.86 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.052 -0.522 . . . . 0.0 111.231 179.952 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . 56.57 28.48 56.21 Favored Glycine 0 N--CA 1.451 -0.333 0 C-N-CA 120.773 -0.727 . . . . 0.0 112.598 -179.999 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 37' ' ' GLN . . . . . . . . . . . . . 34.3 mt-30 -140.34 -70.88 0.38 Allowed 'General case' 0 C--N 1.328 -0.327 0 CA-C-O 120.749 0.309 . . . . 0.0 110.924 -179.998 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 38' ' ' LYS . . . . . . . . . . . . . 2.1 mttt -69.76 108.45 3.93 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.263 -0.426 . . . . 0.0 110.902 -179.948 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 39' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -88.15 136.98 32.72 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.908 179.974 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -160.52 -163.49 13.89 Favored Glycine 0 N--CA 1.451 -0.319 0 C-N-CA 120.727 -0.749 . . . . 0.0 112.463 180.0 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 33.2 mt -133.67 131.6 56.9 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-O 120.742 0.306 . . . . 0.0 111.084 -179.905 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 42' ' ' VAL . . . . . . . . . . . . . 21.4 t -60.06 125.43 16.17 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.345 0 CA-C-N 116.209 -0.45 . . . . 0.0 111.123 179.988 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 43' ' ' ARG . . . . . . . . . . . . . 13.6 mmt180 -110.34 -32.72 6.85 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.908 179.951 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 44' ' ' PHE . . . . . . . . . . . . . 72.2 t80 -143.05 111.05 6.0 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.248 -0.433 . . . . 0.0 110.912 -179.919 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 45' ' ' TYR . . . . . 0.5 ' CE1' ' CZ ' ' A' ' 56' ' ' TYR . 18.6 t80 -108.0 122.95 47.88 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.855 -179.99 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 164.94 -179.61 39.47 Favored Glycine 0 N--CA 1.451 -0.32 0 C-N-CA 120.767 -0.73 . . . . 0.0 112.534 179.928 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 47' ' ' LYS . . . . . . . . . . . . . 18.6 mttt -69.4 153.18 43.97 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 120.817 0.341 . . . . 0.0 110.879 -179.975 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 48' ' ' THR . . . . . . . . . . . . . 1.3 p -111.24 177.6 4.61 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.892 179.98 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -104.5 -31.33 9.51 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.835 179.992 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 50' ' ' PHE . . . . . 0.415 ' CE2' ' HB1' ' A' ' 51' ' ' ALA . 54.1 p90 -75.53 -39.19 58.7 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.262 -0.427 . . . . 0.0 110.918 -179.965 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 51' ' ' ALA . . . . . 0.415 ' HB1' ' CE2' ' A' ' 50' ' ' PHE . . . -131.61 147.13 64.81 Favored Pre-proline 0 C--N 1.33 -0.273 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.093 -179.946 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 52' ' ' PRO . . . . . . . . . . . . . 61.0 Cg_endo -72.96 -172.58 1.01 Allowed 'Trans proline' 0 C--N 1.345 0.372 0 C-N-CA 122.508 2.138 . . . . 0.0 112.395 179.974 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 67.94 -165.48 45.23 Favored Glycine 0 N--CA 1.452 -0.291 0 C-N-CA 120.738 -0.744 . . . . 0.0 112.511 179.973 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 54' ' ' TYR . . . . . . . . . . . . . 69.3 m-85 -107.69 141.55 39.04 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-O 120.84 0.352 . . . . 0.0 110.876 -179.963 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 55' ' ' TRP . . . . . 0.418 ' CZ3' ' HD3' ' A' ' 88' ' ' PRO . 52.6 m95 -132.61 167.17 20.52 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.917 -179.897 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 56' ' ' TYR . . . . . 0.5 ' CZ ' ' CE1' ' A' ' 45' ' ' TYR . 3.7 m-85 -121.18 117.09 26.23 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.323 -0.399 . . . . 0.0 110.912 179.997 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 57' ' ' GLY . . . . . 0.446 ' N ' ' CE1' ' A' ' 86' ' ' PHE . . . -81.2 68.26 3.47 Favored Glycine 0 N--CA 1.451 -0.331 0 C-N-CA 120.789 -0.72 . . . . 0.0 112.402 -179.967 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 58' ' ' ILE . . . . . . . . . . . . . 19.6 mt -73.53 138.04 22.09 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-O 120.807 0.337 . . . . 0.0 111.113 179.998 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -103.63 114.18 28.25 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.841 -179.967 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 60' ' ' LEU . . . . . . . . . . . . . 77.8 mt -69.51 -179.94 1.87 Allowed 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.154 -0.475 . . . . 0.0 110.885 179.972 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 4.9 m-20 -109.41 -34.09 6.63 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.951 -179.977 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 62' ' ' GLN . . . . . . . . . . . . . 4.1 mm-40 -108.14 146.63 33.94 Favored Pre-proline 0 C--N 1.329 -0.3 0 CA-C-N 116.321 -0.4 . . . . 0.0 110.942 -179.975 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 31.7 Cg_exo -58.88 91.93 0.07 OUTLIER 'Trans proline' 0 C--N 1.345 0.368 0 C-N-CA 122.62 2.213 . . . . 0.0 112.172 -179.966 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 64' ' ' THR . . . . . . . . . . . . . 10.1 t -172.89 38.88 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.913 -179.979 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . -93.42 -128.97 5.1 Favored Glycine 0 N--CA 1.45 -0.37 0 C-N-CA 120.786 -0.721 . . . . 0.0 112.48 -179.976 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 66' ' ' LYS . . . . . . . . . . . . . 1.1 mtpm? -135.89 -50.8 0.72 Allowed 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 120.881 0.372 . . . . 0.0 110.874 180.0 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 67' ' ' HIS . . . . . . . . . . . . . 7.1 p80 -128.18 178.99 5.85 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.884 179.911 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 15.5 t0 -101.46 36.46 2.02 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.966 179.999 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 95.66 -37.85 3.3 Favored Glycine 0 N--CA 1.451 -0.351 0 C-N-CA 120.707 -0.759 . . . . 0.0 112.495 -179.997 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 70' ' ' SER . . . . . . . . . . . . . 75.2 p -102.73 162.33 13.02 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-O 120.947 0.403 . . . . 0.0 110.842 -179.91 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 21.4 t -148.07 117.14 1.15 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-N 116.132 -0.485 . . . . 0.0 111.168 179.953 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 72' ' ' PHE . . . . . . . . . . . . . 5.1 m-85 60.4 35.56 20.47 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.14 -0.482 . . . . 0.0 111.002 -179.977 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 80.91 28.26 46.78 Favored Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.679 -0.772 . . . . 0.0 112.597 -179.972 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 74' ' ' VAL . . . . . 0.402 ' O ' ' CE1' ' A' ' 76' ' ' TYR . 21.5 t -133.63 104.89 6.78 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-O 120.799 0.333 . . . . 0.0 111.098 -179.975 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 75' ' ' ARG . . . . . . . . . . . . . 3.6 ttt-85 -77.41 131.47 38.04 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.246 -0.433 . . . . 0.0 111.001 -179.979 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 76' ' ' TYR . . . . . 0.402 ' CE1' ' O ' ' A' ' 74' ' ' VAL . 11.7 m-85 -106.86 -45.63 4.14 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.178 -0.464 . . . . 0.0 110.858 179.956 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 77' ' ' PHE . . . . . 0.418 ' CE1' ' HA3' ' A' ' 57' ' ' GLY . 36.8 p90 -156.29 156.55 34.21 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.924 179.985 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 1.9 t -80.0 114.51 18.97 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.25 -0.432 . . . . 0.0 110.89 179.955 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 79' ' ' CYS . . . . . . . . . . . . . 29.4 p -147.15 152.48 38.5 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.973 -179.936 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 80' ' ' ALA . . . . . 0.406 ' CB ' ' HD2' ' A' ' 81' ' ' PRO . . . -58.45 166.73 2.09 Favored Pre-proline 0 C--N 1.329 -0.29 0 CA-C-N 116.143 -0.48 . . . . 0.0 111.002 179.93 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 81' ' ' PRO . . . . . 0.406 ' HD2' ' CB ' ' A' ' 80' ' ' ALA . 20.5 Cg_endo -60.76 120.95 8.95 Favored 'Trans proline' 0 C--N 1.344 0.29 0 C-N-CA 122.545 2.164 . . . . 0.0 112.168 179.936 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 82' ' ' ARG . . . . . . . . . . . . . 78.1 mtt180 63.11 50.36 3.1 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.143 -0.48 . . . . 0.0 110.876 -179.832 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 83' ' ' HIS . . . . . . . . . . . . . 5.8 m170 -123.33 -48.8 1.95 Allowed 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.934 179.933 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . -66.5 121.82 18.68 Favored Glycine 0 N--CA 1.451 -0.304 0 C-N-CA 120.629 -0.796 . . . . 0.0 112.401 179.857 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 85' ' ' VAL . . . . . . . . . . . . . 5.9 m -126.35 132.4 70.43 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-O 120.911 0.386 . . . . 0.0 111.194 -179.98 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 86' ' ' PHE . . . . . 0.446 ' CE1' ' N ' ' A' ' 57' ' ' GLY . 12.9 m-85 -103.66 118.05 35.83 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.991 179.958 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 87' ' ' ALA . . . . . . . . . . . . . . . -134.69 143.61 47.19 Favored Pre-proline 0 C--N 1.33 -0.279 0 CA-C-N 116.215 -0.448 . . . . 0.0 111.058 179.992 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 88' ' ' PRO . . . . . 0.418 ' HD3' ' CZ3' ' A' ' 55' ' ' TRP . 32.5 Cg_exo -57.71 142.1 95.81 Favored 'Trans proline' 0 C--N 1.346 0.401 0 C-N-CA 122.451 2.101 . . . . 0.0 112.397 179.972 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -47.94 -50.98 25.28 Favored 'General case' 0 CA--C 1.521 -0.156 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.255 179.867 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 90' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER -55.87 -24.39 36.72 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 115.716 -0.674 . . . . 0.0 109.801 178.859 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 91' ' ' ARG . . . . . 0.418 ' N ' ' O ' ' A' ' 88' ' ' PRO . 1.0 OUTLIER -90.98 -13.15 33.93 Favored 'General case' 0 N--CA 1.455 -0.219 0 CA-C-N 115.944 -0.571 . . . . 0.0 110.522 179.154 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A ' 92' ' ' ILE . . . . . 0.421 HG21 HD11 ' A' ' 92' ' ' ILE . 62.9 mt -107.09 147.8 11.99 Favored 'Isoleucine or valine' 0 C--O 1.231 0.101 0 CA-C-N 116.432 -0.349 . . . . 0.0 110.895 179.836 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 93' ' ' GLN . . . . . . . . . . . . . 5.7 mt-30 -118.04 168.97 10.05 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.972 179.934 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 94' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -111.48 152.36 27.54 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.859 -179.997 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 95' ' ' ILE . . . . . . . . . . . . . 23.1 mt . . . . . 0 C--N 1.329 -0.297 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.155 179.909 . . . . . . . . 0 0 . 1 . 013 nuclear orig core ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.457 -0.078 0 CA-C-O 120.822 0.344 . . . . 0.0 111.063 . . . . . . . . . 0 0 . 1 . 013 nuclear orig core ' A' A ' 27' ' ' GLU . . . . . . . . . . . . . 14.3 mt-10 -142.57 168.42 19.78 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.938 179.991 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 27.4 t -68.58 85.06 0.14 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.049 179.957 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 132.62 43.86 0.15 Allowed Glycine 0 N--CA 1.452 -0.265 0 C-N-CA 120.677 -0.773 . . . . 0.0 112.462 179.975 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 2.2 t0 -149.81 152.86 35.86 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 120.774 0.321 . . . . 0.0 110.902 -179.915 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 31' ' ' GLN . . . . . . . . . . . . . 1.6 mt-30 -69.03 141.92 54.72 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.918 179.943 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 5.7 m -143.27 174.84 4.43 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-N 116.247 -0.433 . . . . 0.0 111.141 179.96 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 33' ' ' LEU . . . . . . . . . . . . . 13.8 tp -141.25 105.15 4.75 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.843 179.986 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 21.7 t -73.73 123.49 28.98 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.153 -179.982 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 35' ' ' ALA . . . . . . . . . . . . . . . 56.99 25.04 10.19 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.304 179.96 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . 57.29 37.0 78.65 Favored Glycine 0 N--CA 1.45 -0.374 0 C-N-CA 120.803 -0.713 . . . . 0.0 112.572 179.912 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 37' ' ' GLN . . . . . . . . . . . . . 39.0 mt-30 -148.55 -70.17 0.21 Allowed 'General case' 0 C--N 1.33 -0.279 0 CA-C-O 120.731 0.3 . . . . 0.0 110.971 179.98 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 38' ' ' LYS . . . . . . . . . . . . . 62.3 mttt -67.73 105.78 2.03 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.913 179.973 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 39' ' ' GLN . . . . . . . . . . . . . 2.3 tm0? -82.2 132.51 35.24 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.886 -179.996 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -158.08 -174.64 28.04 Favored Glycine 0 N--CA 1.451 -0.333 0 C-N-CA 120.658 -0.782 . . . . 0.0 112.53 179.923 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 15.7 mt -127.41 135.2 63.98 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-O 120.845 0.355 . . . . 0.0 111.046 -179.967 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 42' ' ' VAL . . . . . . . . . . . . . 21.5 t -62.82 120.97 10.71 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.175 179.956 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 43' ' ' ARG . . . . . . . . . . . . . 30.9 mmt180 -110.08 -32.1 7.13 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 116.178 -0.464 . . . . 0.0 110.932 -179.991 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 44' ' ' PHE . . . . . . . . . . . . . 63.4 t80 -147.4 115.53 6.55 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.896 179.924 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 45' ' ' TYR . . . . . 0.496 ' CE1' ' CE1' ' A' ' 56' ' ' TYR . 22.1 t80 -113.1 113.54 25.55 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.967 179.887 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . -175.96 -161.06 24.51 Favored Glycine 0 N--CA 1.452 -0.293 0 C-N-CA 120.712 -0.756 . . . . 0.0 112.474 -179.967 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 47' ' ' LYS . . . . . 0.418 ' HE2' ' CE1' ' A' ' 54' ' ' TYR . 27.2 mttm -88.4 168.95 12.22 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 120.795 0.331 . . . . 0.0 110.893 -179.925 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 48' ' ' THR . . . . . 0.407 HG23 ' CE2' ' A' ' 50' ' ' PHE . 67.1 p -140.04 175.09 9.88 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.949 -179.974 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 3.9 t70 -109.2 -31.52 7.55 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.931 179.994 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 50' ' ' PHE . . . . . 0.419 ' CD1' ' N ' ' A' ' 51' ' ' ALA . 28.2 p90 -65.52 -36.07 82.74 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.97 179.959 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 51' ' ' ALA . . . . . 0.419 ' N ' ' CD1' ' A' ' 50' ' ' PHE . . . -140.98 148.13 50.8 Favored Pre-proline 0 C--N 1.329 -0.318 0 CA-C-N 116.209 -0.45 . . . . 0.0 111.097 -179.99 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 52' ' ' PRO . . . . . . . . . . . . . 59.7 Cg_endo -72.6 176.05 9.35 Favored 'Trans proline' 0 C--N 1.345 0.364 0 C-N-CA 122.508 2.139 . . . . 0.0 112.281 -179.981 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 67.72 175.19 8.33 Favored Glycine 0 N--CA 1.452 -0.286 0 C-N-CA 120.727 -0.749 . . . . 0.0 112.493 -179.934 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 54' ' ' TYR . . . . . 0.418 ' CE1' ' HE2' ' A' ' 47' ' ' LYS . 5.9 m-85 -83.71 148.91 26.81 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-O 120.829 0.347 . . . . 0.0 110.944 -179.983 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 55' ' ' TRP . . . . . . . . . . . . . 72.0 m95 -134.44 164.48 27.34 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.923 -179.978 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 56' ' ' TYR . . . . . 0.496 ' CE1' ' CE1' ' A' ' 45' ' ' TYR . 27.0 m-85 -113.55 112.41 23.5 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.908 179.979 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . -77.21 65.93 2.96 Favored Glycine 0 N--CA 1.451 -0.324 0 C-N-CA 120.727 -0.749 . . . . 0.0 112.396 179.909 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 58' ' ' ILE . . . . . . . . . . . . . 22.5 mt -74.65 152.34 6.78 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.271 0 CA-C-O 120.774 0.321 . . . . 0.0 111.215 -179.976 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 10.8 tm-20 -121.67 120.93 36.15 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 116.258 -0.428 . . . . 0.0 110.862 -179.968 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 60' ' ' LEU . . . . . . . . . . . . . 71.6 mt -79.88 -179.9 7.21 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-N 116.13 -0.486 . . . . 0.0 110.953 179.998 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -108.35 -29.0 9.08 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.028 -179.953 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 62' ' ' GLN . . . . . . . . . . . . . 8.2 mt-30 -108.63 143.41 27.46 Favored Pre-proline 0 C--N 1.329 -0.313 0 CA-C-N 116.382 -0.372 . . . . 0.0 110.973 -179.924 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 63' ' ' PRO . . . . . 0.408 ' HA ' ' CD2' ' A' ' 83' ' ' HIS . 39.4 Cg_exo -60.5 89.87 0.08 OUTLIER 'Trans proline' 0 C--N 1.346 0.4 0 C-N-CA 122.488 2.126 . . . . 0.0 112.18 179.928 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 64' ' ' THR . . . . . . . . . . . . . 10.2 t -170.89 35.97 0.02 OUTLIER 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.294 -0.412 . . . . 0.0 110.967 -179.976 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . -87.02 -95.3 0.88 Allowed Glycine 0 N--CA 1.451 -0.362 0 C-N-CA 120.684 -0.769 . . . . 0.0 112.522 -179.994 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 66' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -172.91 -47.42 0.02 OUTLIER 'General case' 0 C--N 1.328 -0.353 0 CA-C-O 120.854 0.359 . . . . 0.0 110.887 -179.982 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 67' ' ' HIS . . . . . . . . . . . . . 11.5 p80 -135.38 167.5 20.93 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.871 179.915 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -95.8 42.68 1.09 Allowed 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.898 179.945 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 87.33 -53.39 4.4 Favored Glycine 0 N--CA 1.452 -0.295 0 C-N-CA 120.717 -0.754 . . . . 0.0 112.492 179.966 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 70' ' ' SER . . . . . . . . . . . . . 93.8 p -79.05 143.82 35.23 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-O 120.773 0.32 . . . . 0.0 110.952 -179.992 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 71' ' ' VAL . . . . . 0.413 HG13 ' CD2' ' A' ' 72' ' ' PHE . 21.4 t -138.24 112.13 8.06 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.329 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.125 -179.981 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 72' ' ' PHE . . . . . 0.413 ' CD2' HG13 ' A' ' 71' ' ' VAL . 48.0 m-85 60.94 31.04 19.96 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.273 -0.421 . . . . 0.0 110.951 -179.933 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 86.11 29.49 25.36 Favored Glycine 0 N--CA 1.451 -0.304 0 C-N-CA 120.715 -0.755 . . . . 0.0 112.528 -179.997 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 21.5 t -136.77 110.33 8.82 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-O 120.849 0.357 . . . . 0.0 111.103 -179.946 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 75' ' ' ARG . . . . . . . . . . . . . 25.8 ttm-85 -81.47 143.81 31.81 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.132 -0.486 . . . . 0.0 110.91 -179.979 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 76' ' ' TYR . . . . . . . . . . . . . 24.5 m-85 -120.4 -44.48 2.47 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.837 179.992 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 77' ' ' PHE . . . . . . . . . . . . . 8.2 p90 -157.19 156.51 32.73 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.907 -179.891 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 1.2 m -84.64 95.63 8.95 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.117 -0.492 . . . . 0.0 110.883 179.912 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 79' ' ' CYS . . . . . . . . . . . . . 13.9 p -122.85 159.3 28.44 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.288 -0.414 . . . . 0.0 110.976 -179.942 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 80' ' ' ALA . . . . . 0.416 ' HB2' ' CG ' ' A' ' 83' ' ' HIS . . . -59.05 166.68 2.48 Favored Pre-proline 0 C--N 1.328 -0.343 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.011 179.944 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 81' ' ' PRO . . . . . . . . . . . . . 35.7 Cg_endo -65.09 118.26 5.28 Favored 'Trans proline' 0 C--N 1.345 0.365 0 C-N-CA 122.491 2.127 . . . . 0.0 112.196 179.958 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 82' ' ' ARG . . . . . . . . . . . . . 1.1 mtm-85 62.1 46.71 6.16 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.844 -179.944 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 83' ' ' HIS . . . . . 0.416 ' CG ' ' HB2' ' A' ' 80' ' ' ALA . 8.7 m170 -120.68 -43.36 2.48 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.899 179.98 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . -61.07 151.5 41.91 Favored Glycine 0 N--CA 1.451 -0.326 0 C-N-CA 120.708 -0.758 . . . . 0.0 112.494 -179.983 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 85' ' ' VAL . . . . . . . . . . . . . 15.2 m -151.55 129.4 2.49 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-O 120.861 0.362 . . . . 0.0 111.236 -179.929 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 86' ' ' PHE . . . . . . . . . . . . . 8.4 m-85 -102.45 121.87 43.18 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.81 179.985 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 87' ' ' ALA . . . . . . . . . . . . . . . -143.0 145.52 33.47 Favored Pre-proline 0 C--N 1.33 -0.258 0 CA-C-N 116.171 -0.468 . . . . 0.0 111.161 179.943 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 88' ' ' PRO . . . . . . . . . . . . . 32.0 Cg_exo -58.29 137.0 78.22 Favored 'Trans proline' 0 C--N 1.345 0.365 0 C-N-CA 122.575 2.183 . . . . 0.0 112.235 -179.972 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -48.38 -50.96 28.67 Favored 'General case' 0 CA--C 1.521 -0.145 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.316 179.82 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 90' ' ' SER . . . . . . . . . . . . . 51.2 p -55.96 -24.48 38.67 Favored 'General case' 0 N--CA 1.454 -0.246 0 CA-C-N 115.701 -0.681 . . . . 0.0 109.782 178.692 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 91' ' ' ARG . . . . . . . . . . . . . 1.0 OUTLIER -88.22 -14.66 37.96 Favored 'General case' 0 N--CA 1.455 -0.199 0 CA-C-N 115.808 -0.633 . . . . 0.0 110.405 179.062 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 92' ' ' ILE . . . . . . . . . . . . . 22.2 mt -108.45 150.29 11.22 Favored 'Isoleucine or valine' 0 C--O 1.231 0.114 0 CA-C-O 120.84 0.353 . . . . 0.0 111.089 179.887 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 93' ' ' GLN . . . . . . . . . . . . . 1.8 mp0 -110.95 169.68 8.6 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.87 179.98 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 94' ' ' ARG . . . . . . . . . . . . . 9.3 ttt-85 -121.59 119.27 31.42 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.189 -0.459 . . . . 0.0 110.876 -179.99 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 95' ' ' ILE . . . . . . . . . . . . . 4.5 mt . . . . . 0 C--N 1.329 -0.289 0 CA-C-N 116.185 -0.461 . . . . 0.0 111.115 -180.0 . . . . . . . . 0 0 . 1 . 014 nuclear orig core ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.231 0.119 0 CA-C-O 120.804 0.335 . . . . 0.0 111.075 . . . . . . . . . 0 0 . 1 . 014 nuclear orig core ' A' A ' 27' ' ' GLU . . . . . . . . . . . . . 41.7 mt-10 -140.64 174.87 10.09 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.871 -179.972 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 21.5 t -75.27 105.48 4.27 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.247 -0.433 . . . . 0.0 111.136 179.961 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 114.51 35.63 1.4 Allowed Glycine 0 N--CA 1.452 -0.291 0 C-N-CA 120.699 -0.762 . . . . 0.0 112.537 -179.969 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -149.0 150.88 33.57 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-O 120.749 0.309 . . . . 0.0 110.934 -179.952 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 31' ' ' GLN . . . . . . . . . . . . . 8.8 mp0 -70.0 151.35 45.67 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.282 -0.417 . . . . 0.0 110.831 -179.995 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 14.0 m -152.38 179.46 0.43 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.261 -0.427 . . . . 0.0 111.153 179.998 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 33' ' ' LEU . . . . . . . . . . . . . 44.3 tp -143.39 117.86 9.71 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.856 179.943 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 21.7 t -85.57 129.6 37.7 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.207 -0.452 . . . . 0.0 111.278 -179.839 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 35' ' ' ALA . . . . . . . . . . . . . . . 53.93 25.91 5.8 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.149 -0.478 . . . . 0.0 111.394 179.893 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . 57.61 33.82 68.16 Favored Glycine 0 N--CA 1.451 -0.353 0 C-N-CA 120.725 -0.75 . . . . 0.0 112.551 179.958 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 37' ' ' GLN . . . . . . . . . . . . . 94.2 mt-30 -146.91 -70.6 0.24 Allowed 'General case' 0 C--N 1.33 -0.281 0 CA-C-O 120.847 0.356 . . . . 0.0 110.993 -179.951 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 38' ' ' LYS . . . . . . . . . . . . . 2.7 mtmp? -67.11 110.41 3.42 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.947 -179.98 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 39' ' ' GLN . . . . . . . . . . . . . 1.3 tm0? -91.35 137.98 31.94 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.921 179.964 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -164.14 -173.22 32.56 Favored Glycine 0 N--CA 1.45 -0.371 0 C-N-CA 120.82 -0.705 . . . . 0.0 112.564 179.939 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 26.6 mt -122.63 132.01 72.08 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-O 120.804 0.335 . . . . 0.0 111.146 179.958 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 42' ' ' VAL . . . . . . . . . . . . . 33.8 t -59.53 124.29 13.53 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.081 179.986 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 43' ' ' ARG . . . . . . . . . . . . . 1.6 mmm-85 -109.77 -31.11 7.56 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.957 179.985 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 44' ' ' PHE . . . . . . . . . . . . . 28.9 t80 -147.59 112.14 5.31 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.892 179.966 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 45' ' ' TYR . . . . . 0.495 ' CE1' ' CZ ' ' A' ' 56' ' ' TYR . 15.2 t80 -113.27 141.9 46.46 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.894 -179.955 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 144.95 -174.53 24.99 Favored Glycine 0 N--CA 1.451 -0.329 0 C-N-CA 120.757 -0.735 . . . . 0.0 112.501 179.951 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 47' ' ' LYS . . . . . 0.414 ' HG3' ' CD1' ' A' ' 54' ' ' TYR . 13.6 mttm -74.02 161.54 29.96 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-O 120.797 0.332 . . . . 0.0 110.88 -179.966 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 48' ' ' THR . . . . . 0.428 HG21 ' CE2' ' A' ' 50' ' ' PHE . 75.2 p -119.07 -176.91 3.22 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.853 -179.975 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 1.8 t0 -113.41 15.65 19.09 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.378 -179.985 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 50' ' ' PHE . . . . . 0.45 ' CD1' ' N ' ' A' ' 51' ' ' ALA . 42.8 p90 -124.79 -41.28 2.13 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 120.74 0.305 . . . . 0.0 110.955 -179.993 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 51' ' ' ALA . . . . . 0.45 ' N ' ' CD1' ' A' ' 50' ' ' PHE . . . -129.25 149.21 72.06 Favored Pre-proline 0 C--N 1.329 -0.306 0 CA-C-N 116.311 -0.404 . . . . 0.0 111.106 -179.995 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 52' ' ' PRO . . . . . . . . . . . . . 55.6 Cg_endo -70.19 178.04 5.25 Favored 'Trans proline' 0 C--N 1.344 0.306 0 C-N-CA 122.608 2.205 . . . . 0.0 112.274 -179.971 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 72.96 -169.91 52.35 Favored Glycine 0 N--CA 1.451 -0.345 0 C-N-CA 120.717 -0.754 . . . . 0.0 112.542 -179.95 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 54' ' ' TYR . . . . . 0.414 ' CD1' ' HG3' ' A' ' 47' ' ' LYS . 99.7 m-85 -111.28 134.38 52.91 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-O 120.849 0.357 . . . . 0.0 110.932 179.933 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 55' ' ' TRP . . . . . . . . . . . . . 42.1 m95 -120.43 157.81 28.53 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.893 179.984 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 56' ' ' TYR . . . . . 0.495 ' CZ ' ' CE1' ' A' ' 45' ' ' TYR . 4.1 m-85 -110.61 123.82 50.7 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.944 -179.901 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . -89.52 64.11 3.23 Favored Glycine 0 N--CA 1.452 -0.253 0 C-N-CA 120.768 -0.729 . . . . 0.0 112.416 179.891 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 58' ' ' ILE . . . . . . . . . . . . . 4.8 mt -71.72 144.7 13.01 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-O 120.783 0.325 . . . . 0.0 111.098 179.988 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 1.4 tm-20 -109.08 137.56 46.8 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.187 -0.461 . . . . 0.0 110.891 179.961 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 60' ' ' LEU . . . . . . . . . . . . . 65.1 mt -93.89 168.88 10.69 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.892 -179.931 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 20.2 t0 -95.79 -31.34 13.23 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.917 179.974 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 62' ' ' GLN . . . . . . . . . . . . . 5.5 pt20 -111.27 153.41 44.04 Favored Pre-proline 0 C--N 1.33 -0.274 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.865 -179.879 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 56.6 Cg_endo -70.67 80.05 1.17 Allowed 'Trans proline' 0 C--N 1.344 0.328 0 C-N-CA 122.605 2.203 . . . . 0.0 112.302 179.943 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 64' ' ' THR . . . . . . . . . . . . . 65.5 p -156.73 31.33 0.31 Allowed 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.075 -0.511 . . . . 0.0 110.823 -179.993 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . -83.85 -114.62 0.61 Allowed Glycine 0 N--CA 1.451 -0.309 0 C-N-CA 120.699 -0.762 . . . . 0.0 112.521 -179.969 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 66' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -151.68 -48.16 0.11 Allowed 'General case' 0 C--N 1.329 -0.293 0 CA-C-O 120.851 0.357 . . . . 0.0 110.904 -179.963 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 67' ' ' HIS . . . . . . . . . . . . . 7.2 p80 -124.37 175.92 6.79 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.973 -179.982 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 1.3 m-20 -97.94 37.25 1.43 Allowed 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.231 -0.44 . . . . 0.0 110.924 179.97 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 91.03 -50.94 3.14 Favored Glycine 0 N--CA 1.451 -0.325 0 C-N-CA 120.723 -0.751 . . . . 0.0 112.489 -179.998 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 70' ' ' SER . . . . . . . . . . . . . 21.4 p -88.31 143.3 27.1 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-O 120.79 0.328 . . . . 0.0 110.927 -179.938 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 71' ' ' VAL . . . . . 0.421 HG13 ' CD2' ' A' ' 72' ' ' PHE . 24.6 t -127.32 114.6 37.23 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.219 -0.446 . . . . 0.0 111.078 179.982 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 72' ' ' PHE . . . . . 0.421 ' CD2' HG13 ' A' ' 71' ' ' VAL . 25.3 m-85 60.32 31.04 20.3 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.956 -179.917 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 86.48 28.56 26.89 Favored Glycine 0 N--CA 1.451 -0.325 0 C-N-CA 120.685 -0.769 . . . . 0.0 112.475 179.969 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 21.5 t -130.16 100.2 4.92 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-O 120.91 0.386 . . . . 0.0 111.161 179.991 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 75' ' ' ARG . . . . . . . . . . . . . 4.8 ttt180 -80.26 112.37 17.52 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.116 -0.493 . . . . 0.0 110.879 -179.942 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 76' ' ' TYR . . . . . . . . . . . . . 58.0 m-85 -88.16 -40.37 13.79 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.911 -180.0 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 77' ' ' PHE . . . . . . . . . . . . . 23.3 p90 -154.1 153.39 31.78 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.889 179.892 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 5.1 t -82.97 111.56 18.95 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.145 -0.48 . . . . 0.0 110.812 -179.999 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 79' ' ' CYS . . . . . . . . . . . . . 18.4 p -143.1 170.71 15.21 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.959 -179.977 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 80' ' ' ALA . . . . . . . . . . . . . . . -70.67 167.06 30.42 Favored Pre-proline 0 C--N 1.329 -0.307 0 CA-C-N 116.121 -0.49 . . . . 0.0 110.969 179.938 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 81' ' ' PRO . . . . . . . . . . . . . 34.7 Cg_endo -64.86 126.83 17.33 Favored 'Trans proline' 0 C--N 1.345 0.356 0 C-N-CA 122.433 2.089 . . . . 0.0 112.224 179.934 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 82' ' ' ARG . . . . . . . . . . . . . 76.2 mtt180 62.03 39.34 13.32 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.132 -0.486 . . . . 0.0 110.957 -179.914 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 83' ' ' HIS . . . . . . . . . . . . . 9.1 m170 -114.55 -37.66 4.23 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.868 179.971 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . -76.91 152.77 41.03 Favored Glycine 0 N--CA 1.451 -0.332 0 C-N-CA 120.746 -0.74 . . . . 0.0 112.529 179.997 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 85' ' ' VAL . . . . . . . . . . . . . 16.1 m -153.9 135.22 5.23 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.329 0 CA-C-O 120.82 0.343 . . . . 0.0 111.12 179.934 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 86' ' ' PHE . . . . . . . . . . . . . 7.2 m-85 -111.09 117.09 32.34 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.99 -179.989 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 87' ' ' ALA . . . . . . . . . . . . . . . -135.42 145.25 52.87 Favored Pre-proline 0 C--N 1.329 -0.324 0 CA-C-N 116.262 -0.426 . . . . 0.0 111.053 179.906 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 88' ' ' PRO . . . . . 0.409 ' O ' ' N ' ' A' ' 91' ' ' ARG . 33.6 Cg_exo -59.62 145.0 99.29 Favored 'Trans proline' 0 C--N 1.344 0.337 0 C-N-CA 122.562 2.174 . . . . 0.0 112.313 -179.978 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -48.45 -50.91 29.43 Favored 'General case' 0 CA--C 1.521 -0.158 0 CA-C-N 116.187 -0.461 . . . . 0.0 110.247 179.84 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 90' ' ' SER . . . . . . . . . . . . . 1.2 m -56.0 -24.37 38.51 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 115.681 -0.69 . . . . 0.0 109.749 178.766 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 91' ' ' ARG . . . . . 0.409 ' N ' ' O ' ' A' ' 88' ' ' PRO . 0.0 OUTLIER -89.75 -13.9 35.78 Favored 'General case' 0 N--CA 1.454 -0.226 0 CA-C-N 115.926 -0.579 . . . . 0.0 110.515 179.125 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' A' A ' 92' ' ' ILE . . . . . . . . . . . . . 48.7 mt -110.31 153.51 12.07 Favored 'Isoleucine or valine' 0 C--O 1.23 0.074 0 CA-C-N 116.378 -0.374 . . . . 0.0 111.072 179.814 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 93' ' ' GLN . . . . . . . . . . . . . 0.6 OUTLIER -116.24 179.81 3.89 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.805 -179.98 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 94' ' ' ARG . . . . . . . . . . . . . 4.1 ttp180 -122.76 144.08 49.41 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.885 -179.983 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 95' ' ' ILE . . . . . . . . . . . . . 22.0 mt . . . . . 0 C--N 1.33 -0.265 0 CA-C-N 116.174 -0.466 . . . . 0.0 111.177 179.931 . . . . . . . . 0 0 . 1 . 015 nuclear orig core ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.231 0.101 0 CA-C-O 120.829 0.347 . . . . 0.0 111.121 . . . . . . . . . 0 0 . 1 . 015 nuclear orig core ' A' A ' 27' ' ' GLU . . . . . . . . . . . . . 4.8 mt-10 -124.31 179.51 4.88 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.953 179.976 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 21.4 t -75.21 104.98 3.83 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.241 -0.436 . . . . 0.0 111.172 179.951 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 108.13 34.55 2.72 Favored Glycine 0 N--CA 1.451 -0.328 0 C-N-CA 120.732 -0.747 . . . . 0.0 112.529 -179.941 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -138.06 145.29 41.59 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-O 120.814 0.34 . . . . 0.0 110.879 180.0 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 31' ' ' GLN . . . . . . . . . . . . . 0.7 OUTLIER -60.01 144.78 48.48 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.932 -179.962 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 12.0 m -150.02 174.46 1.08 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.372 0 CA-C-N 116.286 -0.415 . . . . 0.0 111.208 179.953 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 33' ' ' LEU . . . . . . . . . . . . . 28.8 tp -138.71 107.1 5.81 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.886 -179.958 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 21.5 t -77.32 125.58 37.17 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-N 116.236 -0.438 . . . . 0.0 111.22 -179.978 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 35' ' ' ALA . . . . . . . . . . . . . . . 58.2 26.23 13.55 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.163 -0.471 . . . . 0.0 111.333 -179.967 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . 56.14 31.39 59.01 Favored Glycine 0 C--N 1.331 0.279 0 C-N-CA 120.775 -0.726 . . . . 0.0 112.607 179.973 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 37' ' ' GLN . . . . . . . . . . . . . 37.3 mt-30 -145.3 -70.42 0.27 Allowed 'General case' 0 C--N 1.329 -0.287 0 CA-C-O 120.795 0.331 . . . . 0.0 110.877 -179.944 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 38' ' ' LYS . . . . . . . . . . . . . 32.0 mttt -67.57 104.05 1.5 Allowed 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.927 179.958 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 39' ' ' GLN . . . . . . . . . . . . . 4.2 tt0 -82.93 148.03 27.9 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.875 -179.972 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -175.68 -164.13 29.59 Favored Glycine 0 N--CA 1.451 -0.363 0 C-N-CA 120.787 -0.721 . . . . 0.0 112.541 179.945 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 3.8 mp -134.61 139.14 48.33 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-O 120.856 0.36 . . . . 0.0 111.156 179.986 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 42' ' ' VAL . . . . . . . . . . . . . 31.0 t -70.47 127.08 31.91 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.029 179.953 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 43' ' ' ARG . . . . . . . . . . . . . 15.6 mmt180 -110.72 -32.35 6.89 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.207 -0.452 . . . . 0.0 110.923 -179.957 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 44' ' ' PHE . . . . . . . . . . . . . 72.6 t80 -141.21 108.23 5.45 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.859 179.978 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 45' ' ' TYR . . . . . 0.497 ' CE1' ' CZ ' ' A' ' 56' ' ' TYR . 12.5 t80 -109.53 131.96 54.58 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.881 179.949 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 158.82 -137.71 5.33 Favored Glycine 0 N--CA 1.451 -0.36 0 C-N-CA 120.68 -0.771 . . . . 0.0 112.53 -179.968 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 47' ' ' LYS . . . . . . . . . . . . . 11.1 mttm -104.18 154.16 20.08 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-O 120.815 0.341 . . . . 0.0 110.922 179.996 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 48' ' ' THR . . . . . . . . . . . . . 25.5 p -117.86 -179.22 3.69 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.224 -0.443 . . . . 0.0 110.874 179.875 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 2.2 t0 -110.91 -26.55 9.25 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.212 -0.449 . . . . 0.0 111.026 -179.836 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 50' ' ' PHE . . . . . 0.451 ' CD1' ' N ' ' A' ' 51' ' ' ALA . 22.6 p90 -72.32 -34.12 67.86 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.422 -0.354 . . . . 0.0 111.117 -179.831 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 51' ' ' ALA . . . . . 0.451 ' N ' ' CD1' ' A' ' 50' ' ' PHE . . . -148.9 147.81 25.43 Favored Pre-proline 0 C--N 1.329 -0.3 0 CA-C-N 116.3 -0.409 . . . . 0.0 111.237 -179.931 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 52' ' ' PRO . . . . . . . . . . . . . 74.0 Cg_endo -75.3 165.34 31.06 Favored 'Trans proline' 0 C--N 1.344 0.327 0 C-N-CA 122.651 2.234 . . . . 0.0 112.366 179.954 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 99.68 -168.98 21.9 Favored Glycine 0 N--CA 1.451 -0.317 0 C-N-CA 120.734 -0.746 . . . . 0.0 112.56 179.917 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 54' ' ' TYR . . . . . . . . . . . . . 64.9 m-85 -102.31 125.87 49.15 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-O 120.825 0.345 . . . . 0.0 110.893 179.994 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 55' ' ' TRP . . . . . 0.418 ' CZ3' ' HD3' ' A' ' 88' ' ' PRO . 63.9 m95 -127.02 156.77 41.11 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.912 179.976 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 56' ' ' TYR . . . . . 0.497 ' CZ ' ' CE1' ' A' ' 45' ' ' TYR . 4.2 m-85 -113.32 122.71 48.24 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.254 -0.43 . . . . 0.0 110.95 -179.961 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 57' ' ' GLY . . . . . 0.447 ' CA ' ' CE1' ' A' ' 86' ' ' PHE . . . -84.04 68.03 3.6 Favored Glycine 0 N--CA 1.45 -0.404 0 C-N-CA 120.775 -0.726 . . . . 0.0 112.427 179.865 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 58' ' ' ILE . . . . . . . . . . . . . 19.7 mt -73.58 138.59 20.97 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-O 120.812 0.339 . . . . 0.0 111.138 -179.955 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -114.07 112.38 23.15 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.915 179.948 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 60' ' ' LEU . . . . . . . . . . . . . 8.1 mt -73.21 173.06 9.99 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.246 -0.434 . . . . 0.0 110.865 -179.972 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 8.3 p-10 -102.0 -31.59 10.58 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.856 179.957 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 62' ' ' GLN . . . . . . . . . . . . . 4.1 pt20 -106.5 157.49 34.92 Favored Pre-proline 0 C--N 1.329 -0.301 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.835 -179.974 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 37.2 Cg_endo -65.86 82.58 0.25 Allowed 'Trans proline' 0 C--N 1.345 0.345 0 C-N-CA 122.533 2.155 . . . . 0.0 112.263 179.937 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 64' ' ' THR . . . . . . . . . . . . . 9.1 t -156.01 34.55 0.34 Allowed 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.108 -0.496 . . . . 0.0 110.839 -179.995 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . -97.84 -131.51 7.15 Favored Glycine 0 N--CA 1.45 -0.407 0 C-N-CA 120.732 -0.747 . . . . 0.0 112.547 179.956 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 66' ' ' LYS . . . . . . . . . . . . . 4.3 mtmm -144.6 -58.36 0.36 Allowed 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 120.819 0.343 . . . . 0.0 110.9 -179.969 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 67' ' ' HIS . . . . . . . . . . . . . 6.9 p80 -110.72 164.51 12.68 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.887 179.945 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 45.6 t0 -97.76 36.52 1.52 Allowed 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.209 -0.451 . . . . 0.0 110.946 -179.997 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 96.75 -32.1 6.91 Favored Glycine 0 N--CA 1.45 -0.369 0 C-N-CA 120.766 -0.73 . . . . 0.0 112.47 179.955 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 70' ' ' SER . . . . . . . . . . . . . 12.2 p -114.13 141.93 46.86 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-O 120.885 0.374 . . . . 0.0 110.844 179.988 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 71' ' ' VAL . . . . . 0.403 HG13 ' CD2' ' A' ' 72' ' ' PHE . 21.6 t -131.07 111.26 19.43 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.252 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.137 179.929 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 72' ' ' PHE . . . . . 0.403 ' CD2' HG13 ' A' ' 71' ' ' VAL . 53.4 m-85 61.09 30.88 19.7 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.999 -179.952 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 98.8 -27.62 18.97 Favored Glycine 0 N--CA 1.452 -0.26 0 C-N-CA 120.728 -0.749 . . . . 0.0 112.454 -179.971 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 22.8 t -75.55 135.35 27.29 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-O 120.834 0.35 . . . . 0.0 111.09 -179.934 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 75' ' ' ARG . . . . . . . . . . . . . 19.2 ttt180 -107.71 144.44 34.81 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.911 179.992 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 76' ' ' TYR . . . . . 0.403 ' CD1' ' N ' ' A' ' 76' ' ' TYR . 3.9 m-85 -123.42 -44.06 2.15 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.944 179.932 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 77' ' ' PHE . . . . . . . . . . . . . 28.5 p90 -162.88 177.7 9.03 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.866 179.97 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -99.67 113.16 25.43 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.913 179.921 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 79' ' ' CYS . . . . . . . . . . . . . 30.2 p -142.9 152.66 42.32 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.27 -0.423 . . . . 0.0 110.924 179.955 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 80' ' ' ALA . . . . . . . . . . . . . . . -66.79 168.26 11.09 Favored Pre-proline 0 C--N 1.329 -0.325 0 CA-C-N 116.215 -0.448 . . . . 0.0 111.054 -179.984 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 81' ' ' PRO . . . . . . . . . . . . . 41.7 Cg_exo -56.91 122.49 11.91 Favored 'Trans proline' 0 C--N 1.344 0.293 0 C-N-CA 122.584 2.19 . . . . 0.0 112.306 -179.991 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 82' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER 62.37 51.91 3.23 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.169 -0.469 . . . . 0.0 111.082 179.845 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 83' ' ' HIS . . . . . . . . . . . . . 7.0 m170 -124.77 -50.42 1.72 Allowed 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.861 179.92 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . -66.05 142.36 43.04 Favored Glycine 0 N--CA 1.451 -0.338 0 C-N-CA 120.748 -0.739 . . . . 0.0 112.536 179.928 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 85' ' ' VAL . . . . . . . . . . . . . 6.9 m -146.99 129.04 6.93 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-O 120.862 0.363 . . . . 0.0 111.076 179.957 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 86' ' ' PHE . . . . . 0.447 ' CE1' ' CA ' ' A' ' 57' ' ' GLY . 17.0 m-85 -108.12 114.9 29.14 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.106 -0.497 . . . . 0.0 110.85 -179.977 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 87' ' ' ALA . . . . . . . . . . . . . . . -136.68 146.7 56.49 Favored Pre-proline 0 C--N 1.33 -0.281 0 CA-C-N 116.14 -0.482 . . . . 0.0 111.178 179.916 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 88' ' ' PRO . . . . . 0.423 ' O ' ' N ' ' A' ' 91' ' ' ARG . 34.5 Cg_exo -57.7 142.84 96.06 Favored 'Trans proline' 0 C--N 1.345 0.352 0 C-N-CA 122.561 2.174 . . . . 0.0 112.324 -179.942 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 89' ' ' ALA . . . . . 0.425 ' HB3' ' CE1' ' A' ' 56' ' ' TYR . . . -48.04 -50.75 26.82 Favored 'General case' 0 C--O 1.231 0.117 0 CA-C-N 116.101 -0.5 . . . . 0.0 110.261 179.853 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 90' ' ' SER . . . . . . . . . . . . . 42.6 m -55.75 -24.43 35.27 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 115.708 -0.678 . . . . 0.0 109.733 178.828 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 91' ' ' ARG . . . . . 0.423 ' N ' ' O ' ' A' ' 88' ' ' PRO . 3.4 mtm180 -89.41 -14.81 34.65 Favored 'General case' 0 N--CA 1.456 -0.172 0 CA-C-N 115.857 -0.611 . . . . 0.0 110.472 179.059 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 92' ' ' ILE . . . . . . . . . . . . . 48.2 mt -107.03 158.3 6.99 Favored 'Isoleucine or valine' 0 C--O 1.231 0.128 0 CA-C-N 116.379 -0.373 . . . . 0.0 111.014 179.793 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 93' ' ' GLN . . . . . . . . . . . . . 5.2 mt-30 -130.18 176.82 7.79 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.964 -179.973 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 94' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -118.16 154.23 32.51 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.903 179.971 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 95' ' ' ILE . . . . . . . . . . . . . 4.4 mt . . . . . 0 C--N 1.329 -0.312 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.102 179.957 . . . . . . . . 0 0 . 1 . 016 nuclear orig core ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.231 0.08 0 CA-C-O 120.9 0.381 . . . . 0.0 110.984 . . . . . . . . . 0 0 . 1 . 016 nuclear orig core ' A' A ' 27' ' ' GLU . . . . . . . . . . . . . 13.8 mt-10 -141.28 174.26 10.7 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.154 -0.476 . . . . 0.0 110.881 -179.973 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 22.1 t -76.18 117.96 21.68 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.129 179.871 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 109.39 28.65 4.25 Favored Glycine 0 N--CA 1.452 -0.281 0 C-N-CA 120.776 -0.726 . . . . 0.0 112.491 -179.95 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 7.8 t0 -143.21 142.23 31.35 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 120.807 0.336 . . . . 0.0 110.863 -179.931 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 31' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -61.62 150.35 36.6 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.843 179.931 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 15.2 m -154.14 170.6 0.81 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.351 0 CA-C-N 116.222 -0.444 . . . . 0.0 111.182 179.971 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 33' ' ' LEU . . . . . . . . . . . . . 28.9 tp -134.88 106.02 6.68 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.94 179.968 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 21.7 t -74.48 124.82 32.85 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.169 -179.918 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 35' ' ' ALA . . . . . . . . . . . . . . . 57.38 26.08 12.06 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.138 -0.483 . . . . 0.0 111.298 179.953 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . 55.81 26.95 48.76 Favored Glycine 0 N--CA 1.452 -0.284 0 C-N-CA 120.723 -0.751 . . . . 0.0 112.647 179.959 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 37' ' ' GLN . . . . . . . . . . . . . 77.9 mt-30 -138.15 -68.37 0.46 Allowed 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 120.842 0.353 . . . . 0.0 110.931 -179.949 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 38' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -69.7 111.14 5.28 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.906 -179.996 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 39' ' ' GLN . . . . . . . . . . . . . 1.9 tt0 -89.25 135.39 33.6 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.154 -0.476 . . . . 0.0 110.976 179.933 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -165.5 -167.97 26.94 Favored Glycine 0 N--CA 1.451 -0.304 0 C-N-CA 120.7 -0.762 . . . . 0.0 112.513 180.0 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 23.5 mt -129.52 143.19 41.89 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-O 120.789 0.328 . . . . 0.0 111.16 -179.959 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 42' ' ' VAL . . . . . . . . . . . . . 21.9 t -68.22 112.04 2.98 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.247 -0.433 . . . . 0.0 111.114 179.961 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 43' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -96.19 -41.21 8.8 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.965 -179.986 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 44' ' ' PHE . . . . . . . . . . . . . 21.0 t80 -135.74 119.02 16.66 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.895 179.985 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 45' ' ' TYR . . . . . 0.423 ' CE1' ' CZ ' ' A' ' 56' ' ' TYR . 38.0 t80 -123.04 136.75 54.96 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.115 -0.493 . . . . 0.0 110.844 -179.989 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 157.86 -155.3 26.31 Favored Glycine 0 N--CA 1.451 -0.346 0 C-N-CA 120.747 -0.739 . . . . 0.0 112.478 179.914 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 47' ' ' LYS . . . . . . . . . . . . . 2.1 mtpt -83.35 150.12 26.3 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-O 120.844 0.354 . . . . 0.0 110.891 179.999 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 48' ' ' THR . . . . . 0.417 HG22 ' CE2' ' A' ' 50' ' ' PHE . 6.3 p -115.04 178.01 4.44 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.814 -179.981 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -115.01 -37.48 4.13 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.974 -179.997 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 50' ' ' PHE . . . . . 0.417 ' CE2' HG22 ' A' ' 48' ' ' THR . 27.4 p90 -63.78 -32.35 73.82 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.191 -0.458 . . . . 0.0 110.951 -179.936 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 51' ' ' ALA . . . . . 0.401 ' HB1' ' CD1' ' A' ' 50' ' ' PHE . . . -149.62 152.08 34.3 Favored Pre-proline 0 C--N 1.33 -0.269 0 CA-C-N 116.226 -0.443 . . . . 0.0 111.156 -179.997 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 52' ' ' PRO . . . . . . . . . . . . . 57.6 Cg_endo -71.33 168.98 21.88 Favored 'Trans proline' 0 C--N 1.344 0.321 0 C-N-CA 122.562 2.175 . . . . 0.0 112.262 179.99 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 89.87 -160.15 28.46 Favored Glycine 0 N--CA 1.45 -0.37 0 C-N-CA 120.707 -0.758 . . . . 0.0 112.562 -179.972 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 54' ' ' TYR . . . . . . . . . . . . . 59.5 m-85 -123.67 125.73 45.31 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 120.841 0.353 . . . . 0.0 110.839 -179.928 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 55' ' ' TRP . . . . . 0.412 ' CZ3' ' HD3' ' A' ' 88' ' ' PRO . 37.3 m95 -112.34 169.8 8.62 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.22 -0.446 . . . . 0.0 110.835 179.987 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 56' ' ' TYR . . . . . 0.423 ' CZ ' ' CE1' ' A' ' 45' ' ' TYR . 9.2 m-85 -118.9 117.43 28.81 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.965 -179.96 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . -82.35 61.37 4.72 Favored Glycine 0 N--CA 1.45 -0.367 0 C-N-CA 120.752 -0.737 . . . . 0.0 112.402 179.956 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 58' ' ' ILE . . . . . . . . . . . . . 13.2 mt -69.91 137.94 23.07 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-O 120.911 0.386 . . . . 0.0 111.079 -179.949 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER -106.28 133.73 50.52 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.859 179.927 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 60' ' ' LEU . . . . . . . . . . . . . 53.5 mt -100.48 171.64 7.62 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.915 -179.969 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 61' ' ' ASP . . . . . 0.404 ' O ' ' CE1' ' A' ' 83' ' ' HIS . 0.7 OUTLIER -97.28 -30.8 12.76 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.095 -0.502 . . . . 0.0 110.919 179.987 . . . . . . . . 3 3 . 1 . 016 nuclear orig core ' A' A ' 62' ' ' GLN . . . . . . . . . . . . . 6.5 mm-40 -97.49 155.35 37.38 Favored Pre-proline 0 C--N 1.328 -0.331 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.974 -179.974 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 74.3 Cg_endo -75.44 60.63 5.81 Favored 'Trans proline' 0 C--N 1.344 0.324 0 C-N-CA 122.648 2.232 . . . . 0.0 112.262 -179.961 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 64' ' ' THR . . . . . . . . . . . . . 26.7 p -132.85 33.26 3.73 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.253 -0.431 . . . . 0.0 110.932 -179.95 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . -85.47 -127.51 1.86 Allowed Glycine 0 N--CA 1.451 -0.338 0 C-N-CA 120.689 -0.767 . . . . 0.0 112.489 -179.968 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 66' ' ' LYS . . . . . . . . . . . . . 0.3 OUTLIER -150.24 -49.08 0.13 Allowed 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.824 0.345 . . . . 0.0 110.865 -179.961 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 67' ' ' HIS . . . . . . . . . . . . . 5.7 p80 -119.5 169.92 9.62 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.143 -0.48 . . . . 0.0 110.854 -179.962 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -97.08 39.8 1.17 Allowed 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.87 -179.987 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 99.43 -36.34 4.13 Favored Glycine 0 N--CA 1.451 -0.337 0 C-N-CA 120.735 -0.745 . . . . 0.0 112.537 179.907 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 70' ' ' SER . . . . . . . . . . . . . 11.7 p -115.32 163.52 15.58 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 120.8 0.333 . . . . 0.0 110.957 179.986 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 21.4 t -137.88 116.25 13.62 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 116.137 -0.483 . . . . 0.0 111.125 179.984 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 72' ' ' PHE . . . . . . . . . . . . . 32.3 m-85 60.6 30.76 19.96 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.928 179.973 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 99.58 -30.03 10.8 Favored Glycine 0 N--CA 1.451 -0.341 0 C-N-CA 120.641 -0.79 . . . . 0.0 112.568 179.988 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 21.5 t -77.5 114.94 18.64 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.34 0 CA-C-O 120.896 0.379 . . . . 0.0 111.068 179.991 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 75' ' ' ARG . . . . . . . . . . . . . 12.6 ttm180 -95.27 126.49 40.62 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.911 179.967 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 76' ' ' TYR . . . . . . . . . . . . . 12.8 m-85 -100.17 -50.75 3.86 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.797 -179.96 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 77' ' ' PHE . . . . . . . . . . . . . 11.3 p90 -144.3 173.34 11.86 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.946 -179.96 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 41.6 p -103.94 122.08 44.45 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.266 -0.425 . . . . 0.0 110.904 179.917 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 79' ' ' CYS . . . . . . . . . . . . . 27.8 p -145.13 172.53 12.96 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.849 -179.988 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 80' ' ' ALA . . . . . . . . . . . . . . . -78.64 166.66 41.09 Favored Pre-proline 0 C--N 1.33 -0.268 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.115 179.988 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 81' ' ' PRO . . . . . . . . . . . . . 50.1 Cg_exo -53.57 116.35 2.93 Favored 'Trans proline' 0 C--N 1.345 0.362 0 C-N-CA 122.587 2.191 . . . . 0.0 112.333 179.959 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 82' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER 61.94 53.4 3.08 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.879 179.923 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 83' ' ' HIS . . . . . 0.404 ' CE1' ' O ' ' A' ' 61' ' ' ASP . 7.4 m170 -123.45 -44.46 2.12 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.915 179.921 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . -71.02 150.0 46.91 Favored Glycine 0 N--CA 1.451 -0.359 0 C-N-CA 120.699 -0.762 . . . . 0.0 112.535 179.948 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 85' ' ' VAL . . . . . . . . . . . . . 10.8 m -148.94 139.27 16.57 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-O 120.817 0.342 . . . . 0.0 111.157 -179.962 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 86' ' ' PHE . . . . . . . . . . . . . 4.1 m-85 -115.93 109.03 17.01 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.839 179.988 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 87' ' ' ALA . . . . . . . . . . . . . . . -130.84 142.85 47.04 Favored Pre-proline 0 C--N 1.33 -0.261 0 CA-C-N 116.259 -0.428 . . . . 0.0 111.126 -179.953 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 88' ' ' PRO . . . . . 0.421 ' O ' ' N ' ' A' ' 91' ' ' ARG . 44.3 Cg_exo -56.26 143.7 84.49 Favored 'Trans proline' 0 C--N 1.345 0.391 0 C-N-CA 122.516 2.144 . . . . 0.0 112.22 179.938 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 89' ' ' ALA . . . . . 0.417 ' HB1' ' CE1' ' A' ' 56' ' ' TYR . . . -47.89 -50.88 25.26 Favored 'General case' 0 C--N 1.333 -0.134 0 CA-C-O 121.113 0.482 . . . . 0.0 110.308 179.807 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 90' ' ' SER . . . . . . . . . . . . . 1.1 m -55.72 -24.76 36.63 Favored 'General case' 0 C--N 1.331 -0.215 0 CA-C-N 115.639 -0.71 . . . . 0.0 109.721 178.765 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 91' ' ' ARG . . . . . 0.421 ' N ' ' O ' ' A' ' 88' ' ' PRO . 0.0 OUTLIER -87.9 -16.28 34.34 Favored 'General case' 0 N--CA 1.454 -0.244 0 CA-C-N 115.833 -0.622 . . . . 0.0 110.393 179.044 . . . . . . . . 3 3 . 1 . 016 nuclear orig core ' A' A ' 92' ' ' ILE . . . . . . . . . . . . . 44.1 mt -104.2 153.74 6.19 Favored 'Isoleucine or valine' 0 C--O 1.231 0.114 0 CA-C-N 116.344 -0.389 . . . . 0.0 111.063 179.882 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 93' ' ' GLN . . . . . . . . . . . . . 0.3 OUTLIER -120.43 142.57 49.1 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.922 -179.976 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 94' ' ' ARG . . . . . . . . . . . . . 12.9 ttt180 -89.96 116.44 28.02 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.222 -0.444 . . . . 0.0 110.868 179.996 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 95' ' ' ILE . . . . . . . . . . . . . 35.2 mt . . . . . 0 C--N 1.329 -0.285 0 CA-C-N 116.136 -0.484 . . . . 0.0 111.143 179.99 . . . . . . . . 0 0 . 1 . 017 nuclear orig core ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.231 0.107 0 CA-C-O 120.883 0.373 . . . . 0.0 111.14 . . . . . . . . . 0 0 . 1 . 017 nuclear orig core ' A' A ' 27' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -123.91 168.1 13.24 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.848 -179.963 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 25.2 t -73.43 111.42 8.24 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.097 179.951 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 112.72 27.96 3.62 Favored Glycine 0 N--CA 1.452 -0.285 0 C-N-CA 120.752 -0.737 . . . . 0.0 112.516 -179.966 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -136.57 145.53 45.08 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-O 120.757 0.313 . . . . 0.0 110.895 179.995 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 31' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -68.56 136.01 52.41 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.887 179.978 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 12.7 m -136.66 179.67 3.66 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.181 -0.463 . . . . 0.0 111.093 179.993 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 33' ' ' LEU . . . . . . . . . . . . . 15.7 tp -137.91 114.1 10.11 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.914 179.959 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 21.5 t -83.82 123.22 38.67 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.343 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.104 179.997 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 35' ' ' ALA . . . . . . . . . . . . . . . 59.34 26.39 15.24 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.197 179.979 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . 56.13 27.78 52.66 Favored Glycine 0 N--CA 1.452 -0.299 0 C-N-CA 120.774 -0.727 . . . . 0.0 112.579 179.999 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 37' ' ' GLN . . . . . . . . . . . . . 41.7 mt-30 -137.17 -70.6 0.45 Allowed 'General case' 0 C--N 1.328 -0.336 0 CA-C-O 120.858 0.361 . . . . 0.0 110.987 -179.965 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 38' ' ' LYS . . . . . . . . . . . . . 11.5 mttm -70.4 124.6 24.57 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.923 179.969 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 39' ' ' GLN . . . . . . . . . . . . . 0.1 OUTLIER -99.13 129.57 45.39 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.861 179.993 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -151.88 -173.78 21.92 Favored Glycine 0 N--CA 1.452 -0.276 0 C-N-CA 120.702 -0.761 . . . . 0.0 112.49 179.955 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 32.7 mt -125.15 138.05 55.58 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-O 120.77 0.319 . . . . 0.0 111.125 -179.984 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 42' ' ' VAL . . . . . . . . . . . . . 26.5 t -67.17 113.98 3.63 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.226 -0.443 . . . . 0.0 111.02 179.956 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 43' ' ' ARG . . . . . . . . . . . . . 14.7 mmt180 -102.6 -31.45 10.38 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.933 179.995 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 44' ' ' PHE . . . . . . . . . . . . . 80.7 t80 -146.26 116.71 7.51 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.895 179.943 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 45' ' ' TYR . . . . . 0.488 ' CE1' ' CZ ' ' A' ' 56' ' ' TYR . 17.7 t80 -114.52 117.53 31.2 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.922 179.936 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 173.58 170.44 37.07 Favored Glycine 0 N--CA 1.451 -0.339 0 C-N-CA 120.746 -0.74 . . . . 0.0 112.534 -179.943 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 47' ' ' LYS . . . . . . . . . . . . . 85.5 mttt -65.33 148.27 51.99 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-O 120.819 0.342 . . . . 0.0 110.899 -179.922 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 48' ' ' THR . . . . . 0.411 HG21 ' CZ ' ' A' ' 50' ' ' PHE . 0.9 OUTLIER -103.03 -177.08 3.27 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.909 179.989 . . . . . . . . 3 3 . 1 . 017 nuclear orig core ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 12.5 t0 -109.21 -31.53 7.55 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.246 -0.434 . . . . 0.0 110.985 -179.999 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 50' ' ' PHE . . . . . 0.411 ' CZ ' HG21 ' A' ' 48' ' ' THR . 19.8 p90 -80.01 -31.19 39.66 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.979 180.0 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 51' ' ' ALA . . . . . . . . . . . . . . . -134.8 139.99 33.92 Favored Pre-proline 0 C--N 1.329 -0.306 0 CA-C-N 116.269 -0.423 . . . . 0.0 111.078 -179.957 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 52' ' ' PRO . . . . . . . . . . . . . 72.0 Cg_endo -76.82 167.06 25.95 Favored 'Trans proline' 0 C--N 1.346 0.434 0 C-N-CA 122.469 2.113 . . . . 0.0 112.292 -179.974 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 92.21 -167.85 30.64 Favored Glycine 0 N--CA 1.45 -0.372 0 C-N-CA 120.734 -0.746 . . . . 0.0 112.562 179.898 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 54' ' ' TYR . . . . . . . . . . . . . 31.0 m-85 -103.31 124.27 48.34 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-O 120.868 0.366 . . . . 0.0 110.833 -179.969 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 55' ' ' TRP . . . . . . . . . . . . . 75.2 m95 -117.29 160.61 20.84 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.865 -179.997 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 56' ' ' TYR . . . . . 0.488 ' CZ ' ' CE1' ' A' ' 45' ' ' TYR . 5.7 m-85 -118.45 115.81 25.4 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.963 -179.96 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . -82.04 69.53 3.3 Favored Glycine 0 N--CA 1.452 -0.283 0 C-N-CA 120.646 -0.788 . . . . 0.0 112.437 179.933 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 58' ' ' ILE . . . . . . . . . . . . . 3.9 mt -75.67 141.05 16.36 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-O 120.8 0.333 . . . . 0.0 111.099 -179.976 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 3.1 tt0 -105.63 119.38 38.98 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.925 179.956 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 60' ' ' LEU . . . . . . . . . . . . . 92.7 mt -77.94 172.25 13.76 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.935 179.993 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -101.32 -29.2 12.19 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.895 -179.984 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 62' ' ' GLN . . . . . . . . . . . . . 0.3 OUTLIER -106.65 155.63 38.58 Favored Pre-proline 0 C--N 1.33 -0.259 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.936 179.965 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 55.0 Cg_endo -69.73 70.29 1.57 Allowed 'Trans proline' 0 C--N 1.344 0.335 0 C-N-CA 122.526 2.151 . . . . 0.0 112.296 179.993 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 64' ' ' THR . . . . . . . . . . . . . 42.9 p -147.75 43.76 1.08 Allowed 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 116.112 -0.494 . . . . 0.0 110.826 179.998 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . -95.49 -127.74 5.32 Favored Glycine 0 N--CA 1.451 -0.322 0 C-N-CA 120.777 -0.725 . . . . 0.0 112.561 179.968 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 66' ' ' LYS . . . . . . . . . . . . . 0.6 OUTLIER -148.16 -50.04 0.17 Allowed 'General case' 0 C--N 1.328 -0.346 0 CA-C-O 120.833 0.349 . . . . 0.0 110.83 179.999 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 67' ' ' HIS . . . . . . . . . . . . . 6.7 p80 -123.1 168.06 12.87 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.154 -0.476 . . . . 0.0 110.833 179.969 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 9.2 p-10 -98.89 31.29 3.02 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.253 -0.431 . . . . 0.0 110.914 -179.984 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 100.36 -28.09 17.4 Favored Glycine 0 N--CA 1.451 -0.312 0 C-N-CA 120.653 -0.784 . . . . 0.0 112.486 -179.979 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 70' ' ' SER . . . . . . . . . . . . . 33.2 p -122.47 139.74 53.53 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-O 120.795 0.331 . . . . 0.0 110.867 -179.981 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 21.5 t -124.99 116.81 48.27 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.224 -0.444 . . . . 0.0 111.029 179.988 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 72' ' ' PHE . . . . . . . . . . . . . 13.7 m-85 60.96 30.92 19.9 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.901 179.965 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 98.45 -28.52 14.5 Favored Glycine 0 N--CA 1.451 -0.33 0 C-N-CA 120.756 -0.735 . . . . 0.0 112.498 179.933 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 21.5 t -77.05 122.42 31.55 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.272 0 CA-C-O 120.876 0.369 . . . . 0.0 111.109 179.998 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 75' ' ' ARG . . . . . . . . . . . . . 3.4 ttt180 -95.3 146.34 24.44 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.925 179.982 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 76' ' ' TYR . . . . . . . . . . . . . 72.8 m-85 -122.05 -45.0 2.27 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.884 179.968 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 77' ' ' PHE . . . . . . . . . . . . . 17.1 p90 -162.23 165.25 27.06 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.883 179.945 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 1.0 OUTLIER -89.65 103.05 15.73 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.976 179.974 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 79' ' ' CYS . . . . . . . . . . . . . 28.4 p -127.69 153.73 46.14 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.887 -179.969 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 80' ' ' ALA . . . . . 0.409 ' HB2' ' CG ' ' A' ' 83' ' ' HIS . . . -61.91 164.21 10.89 Favored Pre-proline 0 C--N 1.329 -0.308 0 CA-C-N 116.136 -0.484 . . . . 0.0 111.137 179.975 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 81' ' ' PRO . . . . . . . . . . . . . 51.0 Cg_exo -54.11 115.59 2.46 Favored 'Trans proline' 0 C--N 1.345 0.385 0 C-N-CA 122.578 2.185 . . . . 0.0 112.293 -179.949 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 82' ' ' ARG . . . . . . . . . . . . . 0.7 OUTLIER 61.59 53.64 3.25 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.852 179.953 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 83' ' ' HIS . . . . . 0.409 ' CG ' ' HB2' ' A' ' 80' ' ' ALA . 6.1 m170 -125.15 -44.52 1.89 Allowed 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.145 -0.479 . . . . 0.0 110.879 179.882 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . -67.23 130.24 29.43 Favored Glycine 0 N--CA 1.451 -0.311 0 C-N-CA 120.714 -0.755 . . . . 0.0 112.434 179.934 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 85' ' ' VAL . . . . . . . . . . . . . 5.1 m -134.29 121.67 37.98 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-O 120.856 0.36 . . . . 0.0 111.174 179.966 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 86' ' ' PHE . . . . . . . . . . . . . 7.9 m-85 -96.25 112.33 24.1 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.916 179.937 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 87' ' ' ALA . . . . . . . . . . . . . . . -129.74 143.74 50.23 Favored Pre-proline 0 C--N 1.33 -0.28 0 CA-C-N 116.257 -0.429 . . . . 0.0 111.025 -179.94 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 88' ' ' PRO . . . . . 0.419 ' O ' ' N ' ' A' ' 91' ' ' ARG . 46.9 Cg_exo -56.03 140.52 86.5 Favored 'Trans proline' 0 C--N 1.346 0.406 0 C-N-CA 122.52 2.146 . . . . 0.0 112.317 -179.995 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -47.96 -51.61 22.97 Favored 'General case' 0 CA--C 1.521 -0.136 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.255 179.901 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 90' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -55.82 -24.47 36.45 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 115.76 -0.655 . . . . 0.0 109.709 178.87 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 91' ' ' ARG . . . . . 0.419 ' N ' ' O ' ' A' ' 88' ' ' PRO . 0.0 OUTLIER -87.8 -15.31 37.24 Favored 'General case' 0 N--CA 1.455 -0.225 0 CA-C-N 115.834 -0.621 . . . . 0.0 110.415 179.022 . . . . . . . . 3 3 . 1 . 017 nuclear orig core ' A' A ' 92' ' ' ILE . . . . . . . . . . . . . 41.7 mt -108.66 150.57 11.28 Favored 'Isoleucine or valine' 0 N--CA 1.457 -0.105 0 CA-C-N 116.376 -0.375 . . . . 0.0 111.071 179.898 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 93' ' ' GLN . . . . . . . . . . . . . 10.5 mt-30 -120.06 161.4 21.03 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.918 -179.991 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 94' ' ' ARG . . . . . . . . . . . . . 1.1 mtt180 -101.15 126.35 47.85 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.247 -0.433 . . . . 0.0 110.885 179.963 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 95' ' ' ILE . . . . . . . . . . . . . 26.1 mm . . . . . 0 C--N 1.33 -0.275 0 CA-C-N 116.15 -0.477 . . . . 0.0 111.171 179.968 . . . . . . . . 0 0 . 1 . 018 nuclear orig core ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.458 -0.055 0 CA-C-O 120.861 0.362 . . . . 0.0 111.071 . . . . . . . . . 0 0 . 1 . 018 nuclear orig core ' A' A ' 27' ' ' GLU . . . . . . . . . . . . . 3.7 mt-10 -138.84 171.38 14.42 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.084 -0.507 . . . . 0.0 110.841 -179.964 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 28.1 t -65.97 109.71 1.16 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 116.097 -0.501 . . . . 0.0 111.02 -179.999 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 112.85 29.85 2.96 Favored Glycine 0 N--CA 1.452 -0.254 0 C-N-CA 120.756 -0.735 . . . . 0.0 112.516 -179.986 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 1.2 t0 -137.48 164.69 28.09 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-O 120.823 0.344 . . . . 0.0 110.878 179.942 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 31' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -83.11 131.72 35.13 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.25 -0.432 . . . . 0.0 110.927 179.966 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 15.3 m -139.74 179.53 2.75 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 116.329 -0.396 . . . . 0.0 111.136 179.957 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 33' ' ' LEU . . . . . . . . . . . . . 22.7 tp -143.45 102.02 3.88 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.158 -0.473 . . . . 0.0 110.812 179.97 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 21.5 t -70.5 124.19 26.11 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.202 -0.454 . . . . 0.0 111.2 179.99 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 35' ' ' ALA . . . . . . . . . . . . . . . 58.57 25.51 13.24 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.228 -0.442 . . . . 0.0 111.264 179.942 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . 55.42 27.22 47.0 Favored Glycine 0 N--CA 1.452 -0.242 0 C-N-CA 120.852 -0.69 . . . . 0.0 112.587 179.984 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 37' ' ' GLN . . . . . . . . . . . . . 64.5 mt-30 -138.22 -64.86 0.52 Allowed 'General case' 0 C--N 1.329 -0.311 0 CA-C-O 120.704 0.287 . . . . 0.0 110.927 179.948 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 38' ' ' LYS . . . . . . . . . . . . . 64.3 mttt -72.38 112.64 8.62 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 116.294 -0.412 . . . . 0.0 110.877 179.954 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 39' ' ' GLN . . . . . . . . . . . . . 1.4 tm0? -91.82 117.26 29.61 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.836 179.991 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -145.14 -166.07 11.52 Favored Glycine 0 N--CA 1.451 -0.304 0 C-N-CA 120.747 -0.739 . . . . 0.0 112.468 -179.993 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 31.3 mt -131.17 132.58 63.25 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.25 0 CA-C-O 120.839 0.352 . . . . 0.0 111.105 -179.992 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 42' ' ' VAL . . . . . . . . . . . . . 21.5 t -60.4 121.46 8.27 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.261 -0.427 . . . . 0.0 111.086 179.962 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 43' ' ' ARG . . . . . . . . . . . . . 3.6 mmm-85 -104.14 -31.48 9.62 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.898 -179.941 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 44' ' ' PHE . . . . . 0.424 ' CD1' ' HB3' ' A' ' 76' ' ' TYR . 41.3 t80 -148.3 115.6 6.2 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.97 -179.947 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 45' ' ' TYR . . . . . 0.454 ' CE1' ' CE1' ' A' ' 56' ' ' TYR . 25.8 t80 -114.7 123.35 49.06 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.895 -179.986 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 171.03 -149.3 12.16 Favored Glycine 0 N--CA 1.451 -0.361 0 C-N-CA 120.671 -0.776 . . . . 0.0 112.449 179.956 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 47' ' ' LYS . . . . . . . . . . . . . 7.0 mttt -99.15 164.59 12.09 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-O 120.849 0.357 . . . . 0.0 110.975 -179.962 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 48' ' ' THR . . . . . 0.421 HG21 ' CZ ' ' A' ' 50' ' ' PHE . 13.2 p -129.68 -176.02 3.78 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.823 -179.982 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -112.98 -33.41 6.06 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.973 -179.89 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 50' ' ' PHE . . . . . 0.421 ' CZ ' HG21 ' A' ' 48' ' ' THR . 8.7 p90 -67.31 -30.51 70.37 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.24 -0.436 . . . . 0.0 111.016 -179.893 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 51' ' ' ALA . . . . . 0.42 ' N ' ' CD1' ' A' ' 50' ' ' PHE . . . -148.44 146.2 22.13 Favored Pre-proline 0 C--N 1.329 -0.314 0 CA-C-N 116.324 -0.398 . . . . 0.0 111.17 -179.906 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 52' ' ' PRO . . . . . . . . . . . . . 72.3 Cg_endo -74.95 -178.46 4.17 Favored 'Trans proline' 0 C--N 1.345 0.371 0 C-N-CA 122.584 2.189 . . . . 0.0 112.352 -179.991 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 76.78 -168.01 54.63 Favored Glycine 0 N--CA 1.451 -0.363 0 C-N-CA 120.778 -0.725 . . . . 0.0 112.515 179.954 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 54' ' ' TYR . . . . . . . . . . . . . 20.6 m-85 -101.59 149.56 23.99 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-O 120.837 0.351 . . . . 0.0 110.87 -179.929 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 55' ' ' TRP . . . . . . . . . . . . . 69.4 m95 -145.81 156.41 43.56 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.187 -0.461 . . . . 0.0 110.943 179.946 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 56' ' ' TYR . . . . . 0.454 ' CE1' ' CE1' ' A' ' 45' ' ' TYR . 25.2 m-85 -110.24 124.92 52.49 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.288 -0.415 . . . . 0.0 110.947 -179.947 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . -90.08 60.39 3.43 Favored Glycine 0 N--CA 1.45 -0.368 0 C-N-CA 120.768 -0.73 . . . . 0.0 112.414 179.9 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 58' ' ' ILE . . . . . . . . . . . . . 21.2 mt -73.53 137.68 22.82 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-O 120.871 0.367 . . . . 0.0 111.073 -179.957 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 0.2 OUTLIER -103.89 133.27 49.14 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.084 -0.507 . . . . 0.0 110.845 -179.991 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 60' ' ' LEU . . . . . . . . . . . . . 56.5 mt -88.15 174.75 8.05 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.903 179.952 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 2.7 m-20 -100.59 -30.8 11.57 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.976 179.963 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 62' ' ' GLN . . . . . . . . . . . . . 0.8 OUTLIER -106.4 153.5 40.43 Favored Pre-proline 0 C--N 1.331 -0.239 0 CA-C-N 116.178 -0.464 . . . . 0.0 110.924 -179.971 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 73.6 Cg_endo -75.81 64.22 6.72 Favored 'Trans proline' 0 C--N 1.344 0.31 0 C-N-CA 122.613 2.209 . . . . 0.0 112.323 -179.857 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 64' ' ' THR . . . . . . . . . . . . . 7.5 t -147.01 38.55 0.99 Allowed 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.899 179.975 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . -86.57 -111.72 0.86 Allowed Glycine 0 N--CA 1.451 -0.313 0 C-N-CA 120.767 -0.73 . . . . 0.0 112.559 179.98 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 66' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -147.71 -47.27 0.17 Allowed 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.819 0.343 . . . . 0.0 110.893 179.992 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 67' ' ' HIS . . . . . 0.415 ' CE1' ' CG2' ' A' ' 71' ' ' VAL . 15.7 p80 -141.99 -176.0 4.63 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.865 179.96 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -89.32 -168.83 2.28 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.833 179.987 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . -63.39 -27.6 71.01 Favored Glycine 0 N--CA 1.451 -0.363 0 C-N-CA 120.695 -0.765 . . . . 0.0 112.473 -179.934 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 70' ' ' SER . . . . . . . . . . . . . 4.0 p -116.98 147.66 42.11 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 120.8 0.333 . . . . 0.0 110.897 -179.94 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 71' ' ' VAL . . . . . 0.415 ' CG2' ' CE1' ' A' ' 67' ' ' HIS . 28.2 t -127.12 119.86 53.89 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.103 179.929 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 72' ' ' PHE . . . . . . . . . . . . . 5.4 m-85 60.57 30.82 20.02 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.887 -179.948 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 94.91 -15.76 62.72 Favored Glycine 0 N--CA 1.451 -0.318 0 C-N-CA 120.713 -0.756 . . . . 0.0 112.721 -179.999 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 25.3 t -87.9 113.08 24.48 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-O 120.807 0.337 . . . . 0.0 111.169 -179.938 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 75' ' ' ARG . . . . . . . . . . . . . 6.4 ttm105 -95.06 114.7 26.54 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.762 179.885 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 76' ' ' TYR . . . . . 0.424 ' HB3' ' CD1' ' A' ' 44' ' ' PHE . 26.0 m-85 -96.7 -34.97 11.17 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.988 -179.853 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 77' ' ' PHE . . . . . . . . . . . . . 51.6 p90 -162.6 159.52 24.7 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 116.316 -0.402 . . . . 0.0 111.021 -179.907 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 26.0 m -87.62 140.82 29.13 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.922 179.917 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 79' ' ' CYS . . . . . . . . . . . . . 30.7 p -164.67 -175.6 3.9 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.263 -0.426 . . . . 0.0 110.915 179.965 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 80' ' ' ALA . . . . . . . . . . . . . . . -96.62 166.45 14.05 Favored Pre-proline 0 C--N 1.328 -0.328 0 CA-C-N 116.166 -0.47 . . . . 0.0 111.102 -179.97 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 81' ' ' PRO . . . . . . . . . . . . . 50.6 Cg_exo -53.21 120.55 7.92 Favored 'Trans proline' 0 C--N 1.344 0.298 0 C-N-CA 122.627 2.218 . . . . 0.0 112.297 179.96 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 82' ' ' ARG . . . . . . . . . . . . . 37.8 mtp85 62.45 61.46 1.25 Allowed 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.953 -179.967 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 83' ' ' HIS . . . . . . . . . . . . . 4.5 m-70 -130.79 -51.13 1.05 Allowed 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.866 -179.985 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . -63.51 143.54 48.21 Favored Glycine 0 N--CA 1.45 -0.367 0 C-N-CA 120.753 -0.736 . . . . 0.0 112.541 179.972 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 85' ' ' VAL . . . . . . . . . . . . . 5.1 m -145.92 118.16 2.12 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-O 120.829 0.347 . . . . 0.0 111.061 -179.974 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 86' ' ' PHE . . . . . . . . . . . . . 6.6 m-85 -96.45 105.93 18.1 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.847 179.973 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 87' ' ' ALA . . . . . . . . . . . . . . . -126.0 142.76 43.35 Favored Pre-proline 0 C--N 1.328 -0.339 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.091 179.954 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 88' ' ' PRO . . . . . 0.411 ' O ' ' N ' ' A' ' 91' ' ' ARG . 31.2 Cg_exo -58.88 146.18 94.28 Favored 'Trans proline' 0 C--N 1.347 0.461 0 C-N-CA 122.468 2.112 . . . . 0.0 112.344 -179.999 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -48.38 -51.31 27.1 Favored 'General case' 0 C--N 1.333 -0.133 0 CA-C-O 121.08 0.467 . . . . 0.0 110.263 179.769 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 90' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -56.02 -24.4 38.93 Favored 'General case' 0 N--CA 1.454 -0.225 0 CA-C-N 115.648 -0.705 . . . . 0.0 109.789 178.732 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 91' ' ' ARG . . . . . 0.411 ' N ' ' O ' ' A' ' 88' ' ' PRO . 0.1 OUTLIER -88.44 -15.01 36.53 Favored 'General case' 0 N--CA 1.454 -0.254 0 CA-C-N 115.876 -0.602 . . . . 0.0 110.348 179.077 . . . . . . . . 3 3 . 1 . 018 nuclear orig core ' A' A ' 92' ' ' ILE . . . . . . . . . . . . . 43.1 mt -108.77 158.31 8.65 Favored 'Isoleucine or valine' 0 C--O 1.231 0.081 0 CA-C-N 116.334 -0.394 . . . . 0.0 111.017 179.784 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 93' ' ' GLN . . . . . . . . . . . . . 3.4 mt-30 -124.78 162.72 23.67 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.246 -0.434 . . . . 0.0 110.898 -179.886 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 94' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -112.65 127.17 56.03 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.113 -0.494 . . . . 0.0 110.838 -179.993 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 95' ' ' ILE . . . . . . . . . . . . . 33.0 mt . . . . . 0 C--N 1.329 -0.316 0 CA-C-N 116.187 -0.461 . . . . 0.0 111.022 179.962 . . . . . . . . 0 0 . 1 . 019 nuclear orig core ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.457 -0.095 0 CA-C-O 120.843 0.354 . . . . 0.0 111.105 . . . . . . . . . 0 0 . 1 . 019 nuclear orig core ' A' A ' 27' ' ' GLU . . . . . . . . . . . . . 16.4 mt-10 -133.92 179.77 6.04 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.917 -179.975 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 21.5 t -75.32 93.16 0.85 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.091 -179.981 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 121.72 44.84 0.36 Allowed Glycine 0 N--CA 1.451 -0.36 0 C-N-CA 120.843 -0.694 . . . . 0.0 112.489 179.972 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -144.77 158.21 43.87 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-O 120.832 0.349 . . . . 0.0 110.933 -179.991 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 31' ' ' GLN . . . . . . . . . . . . . 0.2 OUTLIER -77.56 126.03 30.26 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.82 -179.911 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 16.2 m -129.34 175.63 10.11 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.262 -0.427 . . . . 0.0 111.158 179.983 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 33' ' ' LEU . . . . . . . . . . . . . 25.6 tp -144.92 101.86 3.69 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.244 -0.434 . . . . 0.0 110.926 179.936 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 21.5 t -69.42 123.02 22.13 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.171 -179.958 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 35' ' ' ALA . . . . . . . . . . . . . . . 58.2 25.73 12.93 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.279 179.977 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . 56.13 32.75 60.2 Favored Glycine 0 N--CA 1.452 -0.294 0 C-N-CA 120.731 -0.747 . . . . 0.0 112.636 -179.99 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 37' ' ' GLN . . . . . . . . . . . . . 30.9 mt-30 -142.9 -73.9 0.29 Allowed 'General case' 0 C--N 1.329 -0.319 0 CA-C-O 120.847 0.356 . . . . 0.0 110.974 -179.968 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 38' ' ' LYS . . . . . . . . . . . . . 4.6 mttp -64.35 109.6 1.97 Allowed 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.918 -179.973 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 39' ' ' GLN . . . . . . . . . . . . . 14.3 tm0? -85.32 129.38 34.82 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.254 -0.43 . . . . 0.0 110.905 179.982 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -156.13 -178.15 30.02 Favored Glycine 0 N--CA 1.45 -0.371 0 C-N-CA 120.683 -0.77 . . . . 0.0 112.524 -179.971 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 41' ' ' ILE . . . . . 0.484 HD13 HG22 ' A' ' 41' ' ' ILE . 27.9 mm -123.12 138.18 53.98 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-O 120.731 0.3 . . . . 0.0 111.114 -179.983 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 42' ' ' VAL . . . . . . . . . . . . . 26.2 t -62.79 121.11 10.96 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 116.252 -0.431 . . . . 0.0 111.101 179.982 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 43' ' ' ARG . . . . . . . . . . . . . 3.1 mmt180 -107.33 -34.16 7.17 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.922 -179.983 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 44' ' ' PHE . . . . . . . . . . . . . 25.8 t80 -145.04 116.27 7.96 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.905 -179.978 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 45' ' ' TYR . . . . . . . . . . . . . 15.4 t80 -111.09 127.1 55.45 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.901 -179.985 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 166.88 -161.49 35.3 Favored Glycine 0 N--CA 1.45 -0.384 0 C-N-CA 120.774 -0.726 . . . . 0.0 112.531 179.992 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 47' ' ' LYS . . . . . . . . . . . . . 46.5 mttt -96.88 158.11 15.58 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-O 120.816 0.341 . . . . 0.0 110.837 -179.975 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 48' ' ' THR . . . . . 0.419 ' HB ' ' CE2' ' A' ' 50' ' ' PHE . 28.4 p -120.75 168.25 11.62 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.165 -0.471 . . . . 0.0 110.848 179.895 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -91.69 -29.18 16.99 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.207 -0.452 . . . . 0.0 110.972 179.969 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 50' ' ' PHE . . . . . 0.419 ' CE2' ' HB ' ' A' ' 48' ' ' THR . 37.5 p90 -74.92 -32.33 61.77 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.273 -0.421 . . . . 0.0 111.055 -179.929 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 51' ' ' ALA . . . . . 0.418 ' HB3' ' CE1' ' A' ' 50' ' ' PHE . . . -142.1 143.35 27.55 Favored Pre-proline 0 C--N 1.33 -0.264 0 CA-C-N 116.304 -0.407 . . . . 0.0 111.128 -179.965 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 52' ' ' PRO . . . . . . . . . . . . . 73.8 Cg_endo -77.33 -168.06 0.55 Allowed 'Trans proline' 0 C--N 1.346 0.404 0 C-N-CA 122.669 2.246 . . . . 0.0 112.325 -179.978 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 70.94 -155.15 52.68 Favored Glycine 0 N--CA 1.451 -0.346 0 C-N-CA 120.722 -0.751 . . . . 0.0 112.527 179.917 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 54' ' ' TYR . . . . . . . . . . . . . 41.4 m-85 -119.04 125.23 48.85 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-O 120.793 0.33 . . . . 0.0 110.906 -179.982 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 55' ' ' TRP . . . . . 0.411 ' CZ3' ' HD3' ' A' ' 88' ' ' PRO . 63.8 m95 -117.4 168.5 10.3 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.909 179.967 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 56' ' ' TYR . . . . . 0.42 ' CE1' ' HB3' ' A' ' 89' ' ' ALA . 6.5 m-85 -124.6 119.56 29.4 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.254 -0.43 . . . . 0.0 110.939 -179.951 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 57' ' ' GLY . . . . . 0.454 ' CA ' ' CE1' ' A' ' 86' ' ' PHE . . . -84.1 62.43 4.59 Favored Glycine 0 N--CA 1.451 -0.366 0 C-N-CA 120.771 -0.728 . . . . 0.0 112.543 179.956 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 58' ' ' ILE . . . . . . . . . . . . . 7.2 mt -68.53 142.84 15.77 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-O 120.868 0.366 . . . . 0.0 111.035 179.995 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 4.7 tm-20 -109.13 110.1 21.25 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.921 179.948 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 60' ' ' LEU . . . . . . . . . . . . . 84.2 mt -68.6 176.33 3.0 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.863 -179.973 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -101.33 -32.18 10.6 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.896 -179.948 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 62' ' ' GLN . . . . . . . . . . . . . 6.3 mt-30 -102.2 162.78 19.25 Favored Pre-proline 0 C--N 1.329 -0.285 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.927 -179.97 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 98.7 Cg_endo -79.52 58.26 6.88 Favored 'Trans proline' 0 C--N 1.344 0.332 0 C-N-CA 122.663 2.242 . . . . 0.0 112.477 -179.996 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 64' ' ' THR . . . . . . . . . . . . . 20.8 p -133.4 32.12 3.69 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.949 179.993 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . -81.98 -117.28 0.48 Allowed Glycine 0 N--CA 1.451 -0.308 0 C-N-CA 120.751 -0.738 . . . . 0.0 112.454 179.976 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 66' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -155.17 -48.05 0.08 Allowed 'General case' 0 C--N 1.33 -0.263 0 CA-C-O 120.868 0.366 . . . . 0.0 110.899 179.917 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 67' ' ' HIS . . . . . . . . . . . . . 7.9 p80 -127.08 169.5 13.33 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 116.156 -0.474 . . . . 0.0 110.81 179.923 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 1.8 m-20 -97.81 36.07 1.59 Allowed 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.255 -0.43 . . . . 0.0 110.91 179.969 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 95.81 -39.57 2.81 Favored Glycine 0 N--CA 1.451 -0.355 0 C-N-CA 120.697 -0.763 . . . . 0.0 112.549 -179.984 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 70' ' ' SER . . . . . . . . . . . . . 11.6 p -101.1 127.23 47.73 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 120.741 0.305 . . . . 0.0 110.911 179.982 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 21.5 t -115.07 111.01 34.06 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.349 0 CA-C-N 116.202 -0.454 . . . . 0.0 111.128 179.964 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 72' ' ' PHE . . . . . . . . . . . . . 30.2 m-85 61.44 30.66 18.99 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.891 179.966 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 99.1 -28.79 13.66 Favored Glycine 0 N--CA 1.451 -0.356 0 C-N-CA 120.741 -0.742 . . . . 0.0 112.463 179.951 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 27.8 t -80.55 121.71 34.47 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-O 120.881 0.372 . . . . 0.0 111.075 179.952 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 75' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -106.35 142.07 36.64 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.817 -179.937 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 76' ' ' TYR . . . . . . . . . . . . . 8.2 m-85 -115.42 -46.8 2.86 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.123 -0.49 . . . . 0.0 110.855 179.954 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 77' ' ' PHE . . . . . 0.42 ' CE1' ' HA3' ' A' ' 57' ' ' GLY . 35.1 p90 -146.9 177.29 9.25 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 116.263 -0.426 . . . . 0.0 110.879 179.982 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 0.9 OUTLIER -104.69 124.36 49.23 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.875 -179.964 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 79' ' ' CYS . . . . . . . . . . . . . 10.8 p -144.97 167.42 22.68 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.118 -0.492 . . . . 0.0 110.893 179.977 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 80' ' ' ALA . . . . . . . . . . . . . . . -75.51 166.44 45.3 Favored Pre-proline 0 C--N 1.33 -0.255 0 CA-C-N 116.228 -0.442 . . . . 0.0 111.075 -179.958 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 81' ' ' PRO . . . . . . . . . . . . . 51.2 Cg_exo -52.85 116.6 3.01 Favored 'Trans proline' 0 C--N 1.345 0.346 0 C-N-CA 122.572 2.181 . . . . 0.0 112.318 179.916 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 82' ' ' ARG . . . . . . . . . . . . . 0.5 OUTLIER 61.39 56.74 2.54 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.84 179.897 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 83' ' ' HIS . . . . . . . . . . . . . 6.2 m170 -126.36 -47.76 1.58 Allowed 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.925 179.953 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . -61.91 139.33 46.43 Favored Glycine 0 N--CA 1.451 -0.353 0 C-N-CA 120.699 -0.763 . . . . 0.0 112.56 179.915 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 85' ' ' VAL . . . . . . . . . . . . . 5.8 m -140.28 127.99 24.25 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.326 0 CA-C-O 120.774 0.321 . . . . 0.0 111.126 -179.911 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 86' ' ' PHE . . . . . 0.454 ' CE1' ' CA ' ' A' ' 57' ' ' GLY . 9.1 m-85 -110.26 112.45 24.42 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.189 -0.459 . . . . 0.0 110.871 179.926 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 87' ' ' ALA . . . . . . . . . . . . . . . -134.86 149.45 70.6 Favored Pre-proline 0 C--N 1.329 -0.286 0 CA-C-N 116.303 -0.408 . . . . 0.0 111.213 179.966 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 88' ' ' PRO . . . . . 0.42 ' O ' ' N ' ' A' ' 91' ' ' ARG . 32.5 Cg_exo -58.08 140.53 94.41 Favored 'Trans proline' 0 C--N 1.345 0.356 0 C-N-CA 122.596 2.197 . . . . 0.0 112.27 -179.92 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 89' ' ' ALA . . . . . 0.42 ' HB3' ' CE1' ' A' ' 56' ' ' TYR . . . -47.79 -51.69 21.61 Favored 'General case' 0 C--N 1.332 -0.165 0 CA-C-O 121.06 0.457 . . . . 0.0 110.299 179.916 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 90' ' ' SER . . . . . . . . . . . . . 14.9 m -55.71 -24.5 35.06 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 115.731 -0.668 . . . . 0.0 109.734 178.788 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 91' ' ' ARG . . . . . 0.42 ' N ' ' O ' ' A' ' 88' ' ' PRO . 0.2 OUTLIER -88.76 -15.14 35.46 Favored 'General case' 0 N--CA 1.454 -0.229 0 CA-C-N 115.889 -0.596 . . . . 0.0 110.438 179.089 . . . . . . . . 3 3 . 1 . 019 nuclear orig core ' A' A ' 92' ' ' ILE . . . . . . . . . . . . . 48.4 mt -107.03 144.88 15.26 Favored 'Isoleucine or valine' 0 C--N 1.334 -0.104 0 CA-C-N 116.413 -0.358 . . . . 0.0 111.047 179.913 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 93' ' ' GLN . . . . . . . . . . . . . 9.1 mt-30 -115.65 -179.94 3.79 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.167 -0.469 . . . . 0.0 110.866 -179.997 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 94' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -125.77 134.99 51.55 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.202 -0.453 . . . . 0.0 110.996 -179.954 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 95' ' ' ILE . . . . . . . . . . . . . 5.0 mt . . . . . 0 C--N 1.329 -0.31 0 CA-C-N 116.22 -0.446 . . . . 0.0 111.108 179.952 . . . . . . . . 0 0 . 1 . 020 nuclear orig core ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.231 0.098 0 CA-C-O 120.88 0.372 . . . . 0.0 111.072 . . . . . . . . . 0 0 . 1 . 020 nuclear orig core ' A' A ' 27' ' ' GLU . . . . . . . . . . . . . 7.4 mp0 -133.74 -178.63 5.1 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.955 179.994 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 25.6 t -73.43 98.96 1.05 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.061 -179.993 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 117.94 39.63 0.75 Allowed Glycine 0 N--CA 1.451 -0.327 0 C-N-CA 120.789 -0.72 . . . . 0.0 112.449 179.924 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 20.7 t70 -146.25 137.68 24.66 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-O 120.842 0.353 . . . . 0.0 110.899 -179.978 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 31' ' ' GLN . . . . . . . . . . . . . 0.8 OUTLIER -59.96 137.33 58.11 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.121 -0.491 . . . . 0.0 110.961 179.938 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 6.2 m -141.28 171.67 11.77 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 116.234 -0.439 . . . . 0.0 111.11 -179.938 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 33' ' ' LEU . . . . . . . . . . . . . 33.9 tp -136.61 111.31 8.71 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.125 -0.488 . . . . 0.0 110.875 179.943 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 21.5 t -79.15 125.77 38.64 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-N 116.226 -0.443 . . . . 0.0 111.25 -179.978 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 35' ' ' ALA . . . . . . . . . . . . . . . 56.58 25.47 9.93 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.346 179.97 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . 57.54 31.69 63.73 Favored Glycine 0 N--CA 1.451 -0.306 0 C-N-CA 120.736 -0.745 . . . . 0.0 112.565 179.898 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 37' ' ' GLN . . . . . . . . . . . . . 9.3 mt-30 -142.98 -74.28 0.28 Allowed 'General case' 0 C--N 1.33 -0.28 0 CA-C-O 120.818 0.342 . . . . 0.0 111.006 -179.971 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 38' ' ' LYS . . . . . . . . . . . . . 46.0 mttp -63.51 112.59 2.84 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.896 -179.892 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 39' ' ' GLN . . . . . . . . . . . . . 2.1 mt-30 -87.6 139.6 30.37 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.837 179.926 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -172.87 171.42 44.39 Favored Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.697 -0.763 . . . . 0.0 112.512 179.993 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 3.2 mp -111.88 143.7 21.14 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-O 120.875 0.369 . . . . 0.0 111.114 179.978 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 42' ' ' VAL . . . . . . . . . . . . . 21.5 t -69.29 123.2 22.36 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.153 -0.476 . . . . 0.0 111.138 -179.995 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 43' ' ' ARG . . . . . . . . . . . . . 4.0 mmm180 -106.73 -31.54 8.38 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.891 -179.973 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 44' ' ' PHE . . . . . 0.405 ' CG ' ' HB3' ' A' ' 76' ' ' TYR . 15.2 t80 -147.82 106.26 3.78 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.879 -179.928 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 45' ' ' TYR . . . . . 0.496 ' CE1' ' CE1' ' A' ' 56' ' ' TYR . 14.3 t80 -111.03 123.88 51.06 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.294 -0.412 . . . . 0.0 110.935 179.893 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 171.54 -142.79 7.19 Favored Glycine 0 N--CA 1.45 -0.371 0 C-N-CA 120.649 -0.786 . . . . 0.0 112.462 -179.98 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 47' ' ' LYS . . . . . . . . . . . . . 24.7 mtpt -95.06 175.01 6.8 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-O 120.773 0.321 . . . . 0.0 110.906 179.993 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 48' ' ' THR . . . . . 0.414 ' HB ' ' CE1' ' A' ' 50' ' ' PHE . 44.8 p -138.79 -177.8 5.04 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.846 -179.996 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 4.4 t70 -129.04 17.59 6.13 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.154 -0.476 . . . . 0.0 111.259 179.924 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 50' ' ' PHE . . . . . 0.418 ' CD2' ' HB3' ' A' ' 51' ' ' ALA . 49.5 p90 -126.81 -44.98 1.62 Allowed 'General case' 0 C--N 1.331 -0.217 0 CA-C-N 116.447 -0.342 . . . . 0.0 110.892 179.961 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 51' ' ' ALA . . . . . 0.418 ' HB3' ' CD2' ' A' ' 50' ' ' PHE . . . -123.5 145.37 46.72 Favored Pre-proline 0 C--N 1.329 -0.324 0 CA-C-N 116.291 -0.413 . . . . 0.0 111.122 179.944 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 52' ' ' PRO . . . . . . . . . . . . . 64.4 Cg_endo -73.59 164.7 34.26 Favored 'Trans proline' 0 C--N 1.345 0.36 0 C-N-CA 122.565 2.176 . . . . 0.0 112.32 -179.926 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 83.51 -177.2 52.65 Favored Glycine 0 N--CA 1.452 -0.287 0 C-N-CA 120.725 -0.75 . . . . 0.0 112.478 179.855 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 54' ' ' TYR . . . . . . . . . . . . . 7.8 m-85 -97.63 131.84 43.83 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-O 120.818 0.342 . . . . 0.0 110.862 -179.979 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 55' ' ' TRP . . . . . 0.423 ' CZ3' ' HD3' ' A' ' 88' ' ' PRO . 24.8 m95 -123.41 157.74 32.74 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.907 -179.994 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 56' ' ' TYR . . . . . 0.496 ' CE1' ' CE1' ' A' ' 45' ' ' TYR . 11.9 m-85 -109.69 126.84 54.12 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.977 -179.948 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . -84.46 62.08 4.62 Favored Glycine 0 N--CA 1.451 -0.36 0 C-N-CA 120.733 -0.746 . . . . 0.0 112.419 179.921 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 58' ' ' ILE . . . . . . . . . . . . . 15.9 mt -71.32 141.05 17.26 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-O 120.816 0.341 . . . . 0.0 111.108 -179.985 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER -109.89 122.14 46.85 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.885 179.951 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 60' ' ' LEU . . . . . . . . . . . . . 63.1 mt -82.69 170.3 15.26 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.945 -179.929 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 1.1 m-20 -100.6 -26.52 13.79 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.95 -179.97 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 62' ' ' GLN . . . . . . . . . . . . . 10.8 pt20 -110.41 152.16 43.13 Favored Pre-proline 0 C--N 1.329 -0.292 0 CA-C-N 116.299 -0.41 . . . . 0.0 110.922 -179.967 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 49.7 Cg_endo -68.91 84.1 0.53 Allowed 'Trans proline' 0 C--N 1.345 0.357 0 C-N-CA 122.599 2.199 . . . . 0.0 112.312 179.971 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 64' ' ' THR . . . . . . . . . . . . . 2.2 p -156.97 35.83 0.3 Allowed 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.213 -0.448 . . . . 0.0 110.894 -179.923 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . -91.65 -158.6 34.72 Favored Glycine 0 N--CA 1.451 -0.359 0 C-N-CA 120.757 -0.735 . . . . 0.0 112.443 -179.961 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 66' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -114.07 -36.69 4.67 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-O 120.735 0.303 . . . . 0.0 110.889 -179.997 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 67' ' ' HIS . . . . . . . . . . . . . 6.9 p80 -127.08 170.26 12.54 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.261 -0.427 . . . . 0.0 110.909 -179.903 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 5.4 m-20 -98.8 30.87 3.15 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.165 -0.471 . . . . 0.0 110.85 179.973 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 105.46 -42.76 1.82 Allowed Glycine 0 N--CA 1.452 -0.257 0 C-N-CA 120.667 -0.777 . . . . 0.0 112.457 179.915 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 70' ' ' SER . . . . . . . . . . . . . 63.4 p -108.62 141.76 40.08 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.798 0.333 . . . . 0.0 110.92 179.966 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 21.5 t -117.45 109.9 29.17 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 116.25 -0.432 . . . . 0.0 111.112 179.957 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 72' ' ' PHE . . . . . . . . . . . . . 40.7 m-85 60.66 30.58 19.82 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.932 -179.972 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 101.08 -30.02 11.26 Favored Glycine 0 N--CA 1.451 -0.353 0 C-N-CA 120.705 -0.759 . . . . 0.0 112.51 179.999 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 21.5 t -78.66 117.88 24.94 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-O 120.764 0.316 . . . . 0.0 111.152 -179.977 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 75' ' ' ARG . . . . . . . . . . . . . 10.3 ttm180 -98.33 145.67 26.45 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.894 -179.984 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 76' ' ' TYR . . . . . 0.405 ' HB3' ' CG ' ' A' ' 44' ' ' PHE . 12.6 m-85 -119.93 -42.36 2.61 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.852 -179.96 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 77' ' ' PHE . . . . . . . . . . . . . 26.6 p90 -153.13 158.89 42.52 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.875 179.991 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 12.0 p -89.96 99.53 12.52 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.91 -180.0 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 79' ' ' CYS . . . . . . . . . . . . . 30.5 p -117.93 173.95 6.48 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.85 179.977 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 80' ' ' ALA . . . . . . . . . . . . . . . -80.72 168.0 28.49 Favored Pre-proline 0 C--N 1.329 -0.308 0 CA-C-N 116.149 -0.478 . . . . 0.0 111.061 -179.975 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 81' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_exo -52.14 112.18 0.8 Allowed 'Trans proline' 0 C--N 1.345 0.347 0 C-N-CA 122.554 2.169 . . . . 0.0 112.296 179.974 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 82' ' ' ARG . . . . . . . . . . . . . 12.9 mtp180 59.97 56.56 3.38 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.872 179.977 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 83' ' ' HIS . . . . . . . . . . . . . 5.1 m170 -121.48 -41.78 2.48 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.949 179.967 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . -71.44 142.22 33.59 Favored Glycine 0 N--CA 1.451 -0.301 0 C-N-CA 120.786 -0.721 . . . . 0.0 112.516 179.997 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 85' ' ' VAL . . . . . . . . . . . . . 22.3 m -144.48 124.03 7.27 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-O 120.785 0.326 . . . . 0.0 111.089 179.943 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 86' ' ' PHE . . . . . . . . . . . . . 24.1 m-85 -101.28 121.26 41.56 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.974 179.927 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 87' ' ' ALA . . . . . . . . . . . . . . . -138.64 146.54 51.03 Favored Pre-proline 0 C--N 1.329 -0.3 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.102 179.981 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 88' ' ' PRO . . . . . 0.431 ' O ' ' N ' ' A' ' 91' ' ' ARG . 41.8 Cg_exo -56.92 139.15 88.79 Favored 'Trans proline' 0 C--N 1.345 0.379 0 C-N-CA 122.487 2.125 . . . . 0.0 112.313 -179.934 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -48.08 -48.39 33.58 Favored 'General case' 0 C--O 1.232 0.141 0 CA-C-N 116.076 -0.511 . . . . 0.0 110.24 179.818 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 90' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -55.53 -24.54 32.62 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 115.681 -0.69 . . . . 0.0 109.779 178.779 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 91' ' ' ARG . . . . . 0.431 ' N ' ' O ' ' A' ' 88' ' ' PRO . 0.7 OUTLIER -92.13 -13.55 30.53 Favored 'General case' 0 N--CA 1.455 -0.195 0 CA-C-N 115.877 -0.601 . . . . 0.0 110.62 179.201 . . . . . . . . 3 3 . 1 . 020 nuclear orig core ' A' A ' 92' ' ' ILE . . . . . 0.409 HD13 HG22 ' A' ' 92' ' ' ILE . 50.1 mt -105.74 154.39 7.01 Favored 'Isoleucine or valine' 0 C--N 1.333 -0.12 0 CA-C-O 120.836 0.35 . . . . 0.0 111.013 179.796 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 93' ' ' GLN . . . . . . . . . . . . . 0.3 OUTLIER -124.07 176.93 6.06 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.911 -179.978 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 94' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER -111.47 160.98 16.61 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.845 -179.989 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 95' ' ' ILE . . . . . . . . . . . . . 30.8 mt . . . . . 0 C--N 1.329 -0.284 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.097 179.961 . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.211 0 N-CA-C 112.463 -0.255 . . . . 0.0 112.463 . . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 7.3 p 62.32 121.17 0.01 OUTLIER 'General case' 0 C--N 1.33 -0.252 0 CA-C-O 120.872 0.367 . . . . 0.0 110.962 -179.992 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 3.6 m -59.62 -62.54 1.8 Allowed 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.921 179.936 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -150.01 -147.63 4.58 Favored Glycine 0 N--CA 1.45 -0.387 0 C-N-CA 120.713 -0.756 . . . . 0.0 112.458 179.962 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 42.3 t -94.14 -63.11 1.23 Allowed 'General case' 0 C--N 1.329 -0.293 0 CA-C-O 120.845 0.355 . . . . 0.0 110.895 -179.967 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 20.9 p -102.05 -51.11 3.47 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.876 -179.979 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 157.16 -177.76 33.86 Favored Glycine 0 N--CA 1.452 -0.29 0 C-N-CA 120.695 -0.764 . . . . 0.0 112.464 179.949 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 10.2 tttm -157.01 31.58 0.3 Allowed 'General case' 0 C--N 1.33 -0.259 0 CA-C-O 120.827 0.346 . . . . 0.0 110.922 179.981 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 10.3 t -94.93 145.19 29.1 Favored Pre-proline 0 C--N 1.33 -0.281 0 CA-C-N 116.178 -0.464 . . . . 0.0 110.826 -179.955 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 65.5 Cg_endo -73.52 146.25 39.0 Favored 'Trans proline' 0 C--N 1.345 0.342 0 C-N-CA 122.647 2.232 . . . . 0.0 112.348 -179.972 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -81.48 -31.32 32.99 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.871 179.915 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 32.7 p -136.92 154.57 76.26 Favored Pre-proline 0 C--N 1.329 -0.312 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.847 179.879 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 39.9 Cg_endo -67.02 88.97 0.3 Allowed 'Trans proline' 0 C--N 1.345 0.363 0 C-N-CA 122.577 2.185 . . . . 0.0 112.233 179.959 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 83.6 p -123.24 147.5 46.85 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.931 179.969 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 3.8 tp -136.17 -177.04 4.53 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.174 -0.467 . . . . 0.0 110.812 179.954 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -58.28 -34.02 72.65 Favored Glycine 0 N--CA 1.451 -0.327 0 C-N-CA 120.625 -0.798 . . . . 0.0 112.43 179.982 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 3.8 p -177.49 109.32 0.07 Allowed 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.803 0.335 . . . . 0.0 110.878 179.889 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 12.2 mt -153.8 31.58 0.45 Allowed 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.853 -179.988 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 19' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -154.13 31.75 0.44 Allowed 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.806 179.945 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 20' ' ' GLN . . . . . . . . . . . . . 1.9 mt-30 -87.72 176.08 7.57 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.959 179.977 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 9.8 mmt180 -100.97 105.8 17.06 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.944 -179.98 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 4.0 mt-10 60.47 31.96 20.43 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.968 179.98 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -71.07 157.58 53.55 Favored Glycine 0 N--CA 1.45 -0.37 0 C-N-CA 120.724 -0.75 . . . . 0.0 112.497 -179.992 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -170.2 155.06 5.2 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-O 120.781 0.324 . . . . 0.0 111.077 -179.945 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 0.6 OUTLIER -86.75 -46.49 9.95 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.988 179.957 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -107.84 -177.99 3.49 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.116 -0.493 . . . . 0.0 111.164 179.94 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 27' ' ' GLU . . . . . . . . . . . . . 2.1 mm-40 -149.14 167.56 25.59 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.941 -179.992 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 21.8 t -68.6 125.02 25.54 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 CA-C-N 116.176 -0.465 . . . . 0.0 111.106 -179.975 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 98.39 29.66 7.36 Favored Glycine 0 N--CA 1.451 -0.347 0 C-N-CA 120.724 -0.751 . . . . 0.0 112.446 -179.991 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -138.76 147.96 43.27 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-O 120.814 0.34 . . . . 0.0 110.845 -179.928 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 31' ' ' GLN . . . . . . . . . . . . . 0.7 OUTLIER -72.65 127.25 32.0 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.963 179.977 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 22.2 m -130.16 179.9 3.79 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 CA-C-N 116.265 -0.425 . . . . 0.0 111.192 179.973 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 33' ' ' LEU . . . . . . . . . . . . . 15.7 tp -139.52 109.33 6.32 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.262 -0.426 . . . . 0.0 110.963 -179.993 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 23.1 t -76.57 121.12 28.08 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.261 -0.427 . . . . 0.0 111.138 -180.0 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 35' ' ' ALA . . . . . . . . . . . . . . . 59.22 26.61 15.42 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.244 179.976 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . 56.74 36.64 73.01 Favored Glycine 0 N--CA 1.45 -0.387 0 C-N-CA 120.74 -0.743 . . . . 0.0 112.639 179.954 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 37' ' ' GLN . . . . . . . . . . . . . 35.3 mt-30 -146.98 -71.42 0.23 Allowed 'General case' 0 C--N 1.329 -0.325 0 CA-C-O 120.796 0.331 . . . . 0.0 110.948 -179.998 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 38' ' ' LYS . . . . . . . . . . . . . 13.2 mttm -67.83 114.79 6.71 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.879 -179.995 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 39' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -90.14 125.98 35.64 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.922 179.935 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -152.77 -175.61 24.45 Favored Glycine 0 N--CA 1.451 -0.347 0 C-N-CA 120.715 -0.755 . . . . 0.0 112.5 -179.971 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 4.3 mt -127.64 128.79 69.94 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.272 0 CA-C-O 120.8 0.333 . . . . 0.0 111.02 -179.948 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 42' ' ' VAL . . . . . . . . . . . . . 21.6 t -59.99 124.42 14.28 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.253 -0.431 . . . . 0.0 111.084 179.975 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 43' ' ' ARG . . . . . . . . . . . . . 45.0 mmt-85 -110.57 -30.24 7.71 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.23 -0.441 . . . . 0.0 111.077 -179.993 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 44' ' ' PHE . . . . . . . . . . . . . 35.7 t80 -143.61 118.6 10.02 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.318 -0.401 . . . . 0.0 110.993 -179.958 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 45' ' ' TYR . . . . . 0.455 ' CE1' ' CZ ' ' A' ' 56' ' ' TYR . 22.2 t80 -115.08 114.9 25.96 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.845 179.899 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 176.8 162.96 28.27 Favored Glycine 0 N--CA 1.45 -0.382 0 C-N-CA 120.699 -0.763 . . . . 0.0 112.441 179.944 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 47' ' ' LYS . . . . . 0.418 ' HG3' ' CE1' ' A' ' 54' ' ' TYR . 22.7 mttt -65.98 137.32 57.05 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.865 0.364 . . . . 0.0 110.852 179.97 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 48' ' ' THR . . . . . . . . . . . . . 41.2 p -95.67 -175.35 3.41 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.902 179.918 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 4.6 t70 -106.58 -30.87 8.76 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.893 179.987 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 50' ' ' PHE . . . . . 0.418 ' CE1' ' HB1' ' A' ' 51' ' ' ALA . 44.3 p90 -71.29 -36.22 71.58 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.867 -179.985 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 51' ' ' ALA . . . . . 0.418 ' HB1' ' CE1' ' A' ' 50' ' ' PHE . . . -132.69 148.17 68.48 Favored Pre-proline 0 C--N 1.33 -0.274 0 CA-C-N 116.236 -0.438 . . . . 0.0 111.188 179.978 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 52' ' ' PRO . . . . . . . . . . . . . 59.9 Cg_endo -72.25 -170.07 0.53 Allowed 'Trans proline' 0 C--N 1.344 0.34 0 C-N-CA 122.601 2.201 . . . . 0.0 112.336 -179.97 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 59.26 -161.01 15.5 Favored Glycine 0 N--CA 1.452 -0.283 0 C-N-CA 120.746 -0.74 . . . . 0.0 112.537 179.976 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 54' ' ' TYR . . . . . 0.418 ' CE1' ' HG3' ' A' ' 47' ' ' LYS . 12.8 m-85 -106.19 157.8 17.3 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-O 120.844 0.354 . . . . 0.0 110.855 -179.95 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 55' ' ' TRP . . . . . 0.41 ' CZ3' ' HD3' ' A' ' 88' ' ' PRO . 69.5 m95 -144.37 159.71 42.27 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.898 179.988 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 56' ' ' TYR . . . . . 0.455 ' CZ ' ' CE1' ' A' ' 45' ' ' TYR . 5.7 m-85 -116.36 115.26 25.55 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.878 -179.951 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 57' ' ' GLY . . . . . 0.443 ' CA ' ' CE1' ' A' ' 86' ' ' PHE . . . -82.27 65.72 4.02 Favored Glycine 0 N--CA 1.451 -0.307 0 C-N-CA 120.75 -0.738 . . . . 0.0 112.431 -179.973 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 58' ' ' ILE . . . . . . . . . . . . . 5.5 mt -72.67 143.66 13.75 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-O 120.816 0.341 . . . . 0.0 111.074 179.986 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 8.0 tt0 -104.23 143.04 33.49 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.836 179.95 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 60' ' ' LEU . . . . . . . . . . . . . 82.1 mt -96.11 173.18 7.54 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.929 -179.957 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 7.9 t0 -97.12 -33.19 11.6 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.954 179.991 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 62' ' ' GLN . . . . . . . . . . . . . 2.7 mt-30 -116.14 146.36 36.99 Favored Pre-proline 0 C--N 1.329 -0.319 0 CA-C-N 116.18 -0.463 . . . . 0.0 110.936 179.97 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 48.1 Cg_exo -55.83 86.75 0.04 OUTLIER 'Trans proline' 0 C--N 1.346 0.409 0 C-N-CA 122.548 2.165 . . . . 0.0 112.172 179.955 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 64' ' ' THR . . . . . . . . . . . . . 80.8 p -157.3 30.44 0.29 Allowed 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.251 -0.431 . . . . 0.0 110.984 -179.979 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . -89.62 175.54 42.29 Favored Glycine 0 N--CA 1.451 -0.363 0 C-N-CA 120.708 -0.758 . . . . 0.0 112.491 179.957 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 66' ' ' LYS . . . . . . . . . . . . . 48.5 mttm -78.61 -30.47 46.57 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 120.693 0.282 . . . . 0.0 110.865 179.94 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 67' ' ' HIS . . . . . . . . . . . . . 7.4 p80 -148.38 -178.98 6.61 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.898 -179.961 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 9.2 p30 -105.25 48.49 0.84 Allowed 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.952 179.999 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 94.02 -45.91 2.27 Favored Glycine 0 N--CA 1.452 -0.294 0 C-N-CA 120.738 -0.744 . . . . 0.0 112.512 -179.964 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 70' ' ' SER . . . . . . . . . . . . . 1.6 p -98.96 136.58 38.73 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-O 120.821 0.344 . . . . 0.0 110.901 179.985 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 21.4 t -114.41 110.64 32.8 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.253 -0.431 . . . . 0.0 111.131 179.969 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 72' ' ' PHE . . . . . . . . . . . . . 60.6 m-85 60.47 31.89 20.41 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.22 -0.446 . . . . 0.0 110.961 179.967 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 98.85 -30.18 10.25 Favored Glycine 0 N--CA 1.451 -0.355 0 C-N-CA 120.685 -0.769 . . . . 0.0 112.556 -179.962 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 21.4 t -77.95 117.63 23.52 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-O 120.823 0.344 . . . . 0.0 111.127 179.904 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 75' ' ' ARG . . . . . . . . . . . . . 5.1 ttt180 -95.33 149.52 21.27 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.988 -179.864 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 76' ' ' TYR . . . . . . . . . . . . . 35.9 m-85 -129.94 -45.6 1.15 Allowed 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.25 -0.432 . . . . 0.0 110.947 179.951 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 77' ' ' PHE . . . . . . . . . . . . . 38.1 p90 -146.72 164.72 31.85 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.31 -0.405 . . . . 0.0 110.997 179.945 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 51.7 p -96.18 123.49 39.82 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.921 -179.97 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 79' ' ' CYS . . . . . . . . . . . . . 7.5 p -148.02 170.57 17.47 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.877 179.891 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 80' ' ' ALA . . . . . . . . . . . . . . . -71.73 162.48 72.93 Favored Pre-proline 0 C--N 1.329 -0.289 0 CA-C-N 116.163 -0.471 . . . . 0.0 111.079 -179.952 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 81' ' ' PRO . . . . . . . . . . . . . 53.0 Cg_exo -52.4 118.46 4.66 Favored 'Trans proline' 0 C--N 1.344 0.3 0 C-N-CA 122.632 2.221 . . . . 0.0 112.294 179.971 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 82' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER 60.27 63.53 1.38 Allowed 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.869 179.972 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 83' ' ' HIS . . . . . . . . . . . . . 3.3 m-70 -132.3 -46.02 0.91 Allowed 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.13 -0.486 . . . . 0.0 110.911 -179.975 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . -63.73 141.69 45.74 Favored Glycine 0 N--CA 1.451 -0.362 0 C-N-CA 120.709 -0.757 . . . . 0.0 112.52 179.996 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 85' ' ' VAL . . . . . . . . . . . . . 6.1 m -142.15 120.14 8.24 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-O 120.768 0.318 . . . . 0.0 111.166 -179.974 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 86' ' ' PHE . . . . . 0.443 ' CE1' ' CA ' ' A' ' 57' ' ' GLY . 12.4 m-85 -100.38 115.39 29.9 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.868 179.994 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 87' ' ' ALA . . . . . . . . . . . . . . . -137.8 145.57 49.04 Favored Pre-proline 0 C--N 1.328 -0.336 0 CA-C-N 116.28 -0.418 . . . . 0.0 111.143 179.924 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 88' ' ' PRO . . . . . 0.425 ' O ' ' N ' ' A' ' 91' ' ' ARG . 47.4 Cg_exo -56.02 139.14 84.51 Favored 'Trans proline' 0 C--N 1.345 0.388 0 C-N-CA 122.454 2.103 . . . . 0.0 112.336 -179.977 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -48.01 -50.91 26.03 Favored 'General case' 0 C--N 1.333 -0.122 0 CA-C-N 116.109 -0.496 . . . . 0.0 110.272 179.862 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 90' ' ' SER . . . . . . . . . . . . . 17.7 m -55.76 -24.49 35.65 Favored 'General case' 0 N--CA 1.454 -0.259 0 CA-C-N 115.687 -0.688 . . . . 0.0 109.766 178.816 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 91' ' ' ARG . . . . . 0.425 ' N ' ' O ' ' A' ' 88' ' ' PRO . 0.6 OUTLIER -88.3 -15.14 36.53 Favored 'General case' 0 N--CA 1.455 -0.188 0 CA-C-N 115.831 -0.622 . . . . 0.0 110.473 179.02 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 92' ' ' ILE . . . . . . . . . . . . . 33.3 mt -104.37 157.89 5.5 Favored 'Isoleucine or valine' 0 C--N 1.334 -0.097 0 CA-C-N 116.379 -0.373 . . . . 0.0 110.973 179.924 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 93' ' ' GLN . . . . . . . . . . . . . 2.2 mt-30 -128.3 166.34 18.81 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.889 -179.912 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 94' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -107.15 145.36 32.64 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.846 -179.994 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 95' ' ' ILE . . . . . . . . . . . . . 23.4 mt -115.58 -36.94 2.2 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.211 -0.449 . . . . 0.0 111.13 179.902 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . -105.4 146.47 16.08 Favored Glycine 0 N--CA 1.451 -0.339 0 C-N-CA 120.782 -0.723 . . . . 0.0 112.514 179.971 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 97' ' ' SER . . . . . . . . . . . . . 85.9 p -134.95 40.95 2.89 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-O 120.849 0.357 . . . . 0.0 110.841 179.998 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 98' ' ' GLY . . . . . . . . . . . . . . . 172.76 99.22 0.12 Allowed Glycine 0 N--CA 1.451 -0.32 0 C-N-CA 120.717 -0.754 . . . . 0.0 112.461 -179.994 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 99' ' ' PRO . . . . . . . . . . . . . 43.0 Cg_endo -67.75 -27.84 37.48 Favored 'Trans proline' 0 C--N 1.346 0.405 0 C-N-CA 122.431 2.088 . . . . 0.0 112.295 179.94 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 100' ' ' SER . . . . . . . . . . . . . 13.3 p -133.34 79.0 1.81 Allowed 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.949 179.974 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -144.1 170.8 15.27 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.906 -179.956 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.249 1.032 0 CA-C-O 118.335 -1.259 . . . . 0.0 112.449 -179.964 . . . . . . . . 0 0 . 1 . 002 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.17 0 N-CA-C 112.474 -0.251 . . . . 0.0 112.474 . . . . . . . . . 0 0 . 1 . 002 nuclear orig full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 2.1 p -83.03 134.61 35.03 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-O 120.925 0.393 . . . . 0.0 110.941 -179.88 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -120.49 -51.28 2.18 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.075 -0.511 . . . . 0.0 110.77 179.827 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -110.31 100.69 1.31 Allowed Glycine 0 N--CA 1.451 -0.347 0 C-N-CA 120.728 -0.748 . . . . 0.0 112.488 179.9 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 9.4 p -167.79 35.1 0.03 OUTLIER 'General case' 0 C--N 1.33 -0.269 0 CA-C-O 120.746 0.308 . . . . 0.0 110.932 -179.875 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 40.1 t -76.97 -61.02 2.12 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.315 -0.402 . . . . 0.0 110.881 179.952 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 84.27 -121.2 5.47 Favored Glycine 0 N--CA 1.451 -0.326 0 C-N-CA 120.677 -0.773 . . . . 0.0 112.534 179.968 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 17.3 mmtt -148.3 127.74 13.13 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-O 120.769 0.319 . . . . 0.0 110.884 -179.945 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 12.8 p -159.99 99.78 1.46 Allowed Pre-proline 0 C--N 1.329 -0.306 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.903 -179.967 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 44.0 Cg_endo -68.01 106.32 1.32 Allowed 'Trans proline' 0 C--N 1.345 0.369 0 C-N-CA 122.44 2.093 . . . . 0.0 112.258 -179.98 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 26.7 t -115.48 44.39 1.87 Allowed 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.896 179.929 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -161.93 89.4 1.46 Allowed Pre-proline 0 C--N 1.329 -0.292 0 CA-C-N 116.1 -0.5 . . . . 0.0 110.988 179.939 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 64.7 Cg_exo -51.12 108.6 0.24 Allowed 'Trans proline' 0 C--N 1.345 0.389 0 C-N-CA 122.518 2.145 . . . . 0.0 112.29 179.951 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 23.1 t -145.86 -45.47 0.21 Allowed 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.248 -0.433 . . . . 0.0 111.062 -179.965 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 6.3 mp -116.87 -77.61 0.57 Allowed 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.268 -0.424 . . . . 0.0 110.973 -179.926 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -92.54 85.15 1.17 Allowed Glycine 0 N--CA 1.45 -0.375 0 C-N-CA 120.714 -0.755 . . . . 0.0 112.421 179.966 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -59.01 -168.53 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 120.792 0.33 . . . . 0.0 110.889 -179.945 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 1.0 OUTLIER -134.06 34.58 3.33 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.271 -0.422 . . . . 0.0 110.904 180.0 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 19' ' ' GLN . . . . . . . . . . . . . 5.4 tm0? -59.82 -38.21 81.35 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.881 179.933 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 20' ' ' GLN . . . . . . . . . . . . . 0.6 OUTLIER -133.54 145.45 50.12 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.838 -180.0 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 10.4 ptp180 -114.01 39.93 2.6 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.265 -0.425 . . . . 0.0 110.94 -179.974 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 24.6 mt-10 -106.18 178.11 4.66 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.918 179.916 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 174.28 -121.17 0.83 Allowed Glycine 0 N--CA 1.451 -0.319 0 C-N-CA 120.742 -0.742 . . . . 0.0 112.527 -179.923 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -108.92 130.9 55.45 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-O 120.81 0.338 . . . . 0.0 111.098 179.982 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 1.6 tttp -70.73 -35.49 72.73 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.874 179.985 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -138.63 -176.8 4.6 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.209 -0.45 . . . . 0.0 111.081 179.985 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 27' ' ' GLU . . . . . . . . . . . . . 6.0 mt-10 -148.03 173.37 12.98 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.252 -0.431 . . . . 0.0 110.911 179.98 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 21.5 t -70.83 110.28 3.72 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.087 179.974 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 113.01 36.24 1.54 Allowed Glycine 0 N--CA 1.452 -0.296 0 C-N-CA 120.736 -0.745 . . . . 0.0 112.503 179.97 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 2.1 m-20 -150.06 138.05 20.23 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 120.852 0.358 . . . . 0.0 110.866 -179.978 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 31' ' ' GLN . . . . . . . . . . . . . 0.7 OUTLIER -62.94 132.88 53.57 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.125 -0.489 . . . . 0.0 110.871 179.998 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 12.6 m -132.99 178.81 5.12 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.149 179.99 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 33' ' ' LEU . . . . . . . . . . . . . 40.4 tp -140.14 101.22 4.1 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.9 179.931 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 21.6 t -72.55 127.68 34.75 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.218 -0.446 . . . . 0.0 111.175 -179.928 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 35' ' ' ALA . . . . . . . . . . . . . . . 57.68 25.33 11.62 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.139 -0.482 . . . . 0.0 111.266 179.937 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . 56.07 27.96 52.75 Favored Glycine 0 N--CA 1.453 -0.224 0 C-N-CA 120.686 -0.769 . . . . 0.0 112.638 179.979 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 37' ' ' GLN . . . . . . . . . . . . . 29.5 mt-30 -138.1 -72.83 0.41 Allowed 'General case' 0 C--N 1.33 -0.279 0 CA-C-O 120.797 0.332 . . . . 0.0 110.944 -179.906 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 38' ' ' LYS . . . . . . . . . . . . . 3.7 mttt -69.02 111.81 5.25 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.265 -0.425 . . . . 0.0 110.965 179.991 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 39' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -92.98 130.5 38.53 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.086 -0.506 . . . . 0.0 110.905 -179.997 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -152.04 -171.0 19.33 Favored Glycine 0 N--CA 1.45 -0.38 0 C-N-CA 120.812 -0.709 . . . . 0.0 112.52 -179.988 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 29.8 mt -123.4 131.92 72.29 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 CA-C-O 120.825 0.345 . . . . 0.0 111.172 179.973 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 42' ' ' VAL . . . . . . . . . . . . . 21.6 t -59.44 126.87 17.85 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.336 0 CA-C-N 116.24 -0.436 . . . . 0.0 111.105 -179.999 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 43' ' ' ARG . . . . . . . . . . . . . 8.7 mmm180 -111.81 -42.56 3.78 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.932 -179.999 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 44' ' ' PHE . . . . . . . . . . . . . 46.0 t80 -138.66 113.24 8.95 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.937 -179.937 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 45' ' ' TYR . . . . . 0.426 ' CE1' ' CE1' ' A' ' 56' ' ' TYR . 35.8 t80 -113.08 138.56 49.73 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.956 179.98 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 152.71 -169.57 31.79 Favored Glycine 0 N--CA 1.449 -0.45 0 C-N-CA 120.783 -0.722 . . . . 0.0 112.489 179.957 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 47' ' ' LYS . . . . . . . . . . . . . 28.7 mttm -78.21 147.35 34.49 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-O 120.847 0.356 . . . . 0.0 110.844 -179.954 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 48' ' ' THR . . . . . 0.412 ' HB ' ' CE2' ' A' ' 50' ' ' PHE . 34.8 p -118.88 171.52 8.17 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.913 179.985 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -98.88 -35.79 9.99 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.885 179.972 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 50' ' ' PHE . . . . . 0.418 ' CD1' ' HB3' ' A' ' 51' ' ' ALA . 27.0 p90 -61.61 -31.39 71.46 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.92 179.907 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 51' ' ' ALA . . . . . 0.418 ' HB3' ' CD1' ' A' ' 50' ' ' PHE . . . -152.11 146.42 18.52 Favored Pre-proline 0 C--N 1.329 -0.294 0 CA-C-N 116.26 -0.427 . . . . 0.0 111.117 179.997 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 52' ' ' PRO . . . . . . . . . . . . . 60.9 Cg_endo -72.86 175.82 9.84 Favored 'Trans proline' 0 C--N 1.345 0.368 0 C-N-CA 122.573 2.182 . . . . 0.0 112.334 179.973 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 84.11 -158.79 35.03 Favored Glycine 0 N--CA 1.45 -0.369 0 C-N-CA 120.716 -0.754 . . . . 0.0 112.541 179.986 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 54' ' ' TYR . . . . . . . . . . . . . 20.2 m-85 -118.74 124.64 47.78 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-O 120.872 0.368 . . . . 0.0 110.897 179.982 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 55' ' ' TRP . . . . . . . . . . . . . 36.4 m95 -118.19 162.89 17.49 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.911 179.988 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 56' ' ' TYR . . . . . 0.426 ' CE1' ' CE1' ' A' ' 45' ' ' TYR . 8.4 m-85 -110.69 125.37 53.4 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.934 -179.91 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 57' ' ' GLY . . . . . 0.416 ' HA3' ' CE1' ' A' ' 77' ' ' PHE . . . -88.01 53.28 4.21 Favored Glycine 0 N--CA 1.451 -0.365 0 C-N-CA 120.72 -0.752 . . . . 0.0 112.423 179.97 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 58' ' ' ILE . . . . . . . . . . . . . 3.8 mt -64.64 142.33 17.03 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.266 0 CA-C-O 120.834 0.349 . . . . 0.0 111.164 -179.981 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 2.4 tm-20 -115.12 108.11 16.2 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.118 -0.492 . . . . 0.0 110.836 -179.947 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 60' ' ' LEU . . . . . . . . . . . . . 48.0 mt -67.75 176.28 2.57 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.906 -179.964 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -100.86 -32.87 10.46 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.852 -179.995 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 62' ' ' GLN . . . . . . . . . . . . . 0.2 OUTLIER -101.37 154.69 37.07 Favored Pre-proline 0 C--N 1.328 -0.332 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.917 179.976 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 58.3 Cg_endo -71.85 68.13 3.09 Favored 'Trans proline' 0 C--N 1.344 0.308 0 C-N-CA 122.584 2.189 . . . . 0.0 112.275 -179.965 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 64' ' ' THR . . . . . . . . . . . . . 73.4 p -139.54 34.25 2.04 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.901 -179.994 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . -88.33 -129.11 3.15 Favored Glycine 0 N--CA 1.452 -0.295 0 C-N-CA 120.732 -0.747 . . . . 0.0 112.579 179.948 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 66' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -144.96 -47.33 0.23 Allowed 'General case' 0 C--N 1.328 -0.353 0 CA-C-O 120.785 0.326 . . . . 0.0 110.845 -179.991 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 67' ' ' HIS . . . . . . . . . . . . . 7.6 p80 -119.94 170.02 9.64 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.213 -0.448 . . . . 0.0 110.839 179.973 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 39.0 m-20 -98.42 34.04 2.09 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.862 -179.983 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 94.62 -42.72 2.39 Favored Glycine 0 N--CA 1.451 -0.329 0 C-N-CA 120.737 -0.744 . . . . 0.0 112.586 -179.939 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 70' ' ' SER . . . . . . . . . . . . . 5.6 p -100.8 134.67 43.42 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-O 120.833 0.349 . . . . 0.0 110.946 -179.984 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 71' ' ' VAL . . . . . 0.414 HG11 ' CD2' ' A' ' 72' ' ' PHE . 21.3 t -114.92 102.95 14.57 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.156 -0.474 . . . . 0.0 111.062 -179.913 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 72' ' ' PHE . . . . . 0.414 ' CD2' HG11 ' A' ' 71' ' ' VAL . 33.2 m-85 61.75 30.8 18.52 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.191 -0.458 . . . . 0.0 110.935 179.929 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 104.21 -30.09 10.81 Favored Glycine 0 N--CA 1.451 -0.362 0 C-N-CA 120.703 -0.76 . . . . 0.0 112.513 179.973 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 21.4 t -77.82 116.87 22.04 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.345 0 CA-C-O 120.749 0.309 . . . . 0.0 111.173 179.978 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 75' ' ' ARG . . . . . . . . . . . . . 10.1 ttm180 -96.62 143.24 27.77 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.272 -0.422 . . . . 0.0 110.898 -179.956 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 76' ' ' TYR . . . . . 0.408 ' CE2' HG21 ' A' ' 48' ' ' THR . 20.0 m-85 -118.69 -40.48 2.88 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.933 179.926 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 77' ' ' PHE . . . . . 0.416 ' CE1' ' HA3' ' A' ' 57' ' ' GLY . 16.0 p90 -160.07 157.55 28.79 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.956 179.972 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 18.8 m -83.9 111.51 19.3 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.836 -179.974 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 79' ' ' CYS . . . . . . . . . . . . . 30.5 p -132.74 174.24 10.52 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.901 179.941 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 80' ' ' ALA . . . . . . . . . . . . . . . -91.91 171.58 7.61 Favored Pre-proline 0 C--N 1.33 -0.281 0 CA-C-N 116.161 -0.472 . . . . 0.0 111.151 179.997 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 81' ' ' PRO . . . . . . . . . . . . . 50.7 Cg_exo -53.77 116.14 2.81 Favored 'Trans proline' 0 C--N 1.344 0.301 0 C-N-CA 122.592 2.194 . . . . 0.0 112.322 179.988 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 82' ' ' ARG . . . . . . . . . . . . . 3.4 mtp85 61.1 52.31 4.06 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.896 179.901 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 83' ' ' HIS . . . . . . . . . . . . . 6.0 m170 -120.99 -43.02 2.47 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.793 179.936 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . -75.2 144.4 31.97 Favored Glycine 0 N--CA 1.45 -0.383 0 C-N-CA 120.817 -0.706 . . . . 0.0 112.495 179.938 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 85' ' ' VAL . . . . . . . . . . . . . 6.6 m -147.77 127.39 4.44 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-O 120.806 0.336 . . . . 0.0 111.231 179.978 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 86' ' ' PHE . . . . . . . . . . . . . 6.1 m-85 -106.71 110.74 23.01 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.886 179.975 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 87' ' ' ALA . . . . . . . . . . . . . . . -132.27 150.96 77.45 Favored Pre-proline 0 C--N 1.33 -0.268 0 CA-C-N 116.189 -0.459 . . . . 0.0 111.106 -179.957 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 88' ' ' PRO . . . . . 0.405 ' O ' ' N ' ' A' ' 91' ' ' ARG . 32.1 Cg_exo -58.4 138.09 83.94 Favored 'Trans proline' 0 C--N 1.344 0.338 0 C-N-CA 122.518 2.146 . . . . 0.0 112.285 -179.972 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -48.05 -51.29 24.85 Favored 'General case' 0 CA--C 1.522 -0.124 0 CA-C-N 116.106 -0.497 . . . . 0.0 110.331 179.845 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 90' ' ' SER . . . . . . . . . . . . . 70.3 p -55.96 -24.41 38.14 Favored 'General case' 0 N--CA 1.453 -0.296 0 CA-C-N 115.714 -0.675 . . . . 0.0 109.769 178.809 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 91' ' ' ARG . . . . . 0.405 ' N ' ' O ' ' A' ' 88' ' ' PRO . 1.3 mtt180 -88.43 -14.6 37.57 Favored 'General case' 0 N--CA 1.453 -0.282 0 CA-C-N 115.852 -0.613 . . . . 0.0 110.535 178.992 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 92' ' ' ILE . . . . . . . . . . . . . 26.0 mt -107.02 146.01 13.85 Favored 'Isoleucine or valine' 0 C--O 1.23 0.076 0 CA-C-N 116.302 -0.408 . . . . 0.0 111.014 179.935 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 93' ' ' GLN . . . . . . . . . . . . . 2.1 mt-30 -115.53 177.2 4.75 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.904 179.973 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 94' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER -115.81 148.23 40.12 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.923 179.971 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 95' ' ' ILE . . . . . . . . . . . . . 28.8 mm -96.51 -53.95 7.58 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.358 0 CA-C-N 116.259 -0.428 . . . . 0.0 111.082 -179.935 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . -123.74 156.31 17.94 Favored Glycine 0 N--CA 1.45 -0.368 0 C-N-CA 120.775 -0.726 . . . . 0.0 112.479 -179.961 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 97' ' ' SER . . . . . . . . . . . . . 33.6 t -170.2 -173.97 1.62 Allowed 'General case' 0 C--N 1.329 -0.301 0 CA-C-O 120.852 0.358 . . . . 0.0 110.884 -179.988 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 98' ' ' GLY . . . . . . . . . . . . . . . -127.88 70.28 0.51 Allowed Glycine 0 N--CA 1.451 -0.313 0 C-N-CA 120.814 -0.708 . . . . 0.0 112.487 -179.954 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 99' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_exo -52.23 -30.47 42.1 Favored 'Trans proline' 0 C--N 1.344 0.308 0 C-N-CA 122.588 2.192 . . . . 0.0 112.359 -179.99 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 100' ' ' SER . . . . . . . . . . . . . 12.7 p 58.57 175.45 0.07 Allowed 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.108 -0.496 . . . . 0.0 110.978 179.98 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 46.0 p -168.48 35.31 0.03 OUTLIER 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.857 -179.991 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.249 1.093 0 CA-C-O 118.393 -1.226 . . . . 0.0 112.54 -179.997 . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.28 0 N-CA-C 112.482 -0.247 . . . . 0.0 112.482 . . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 21.8 t -158.64 167.08 30.51 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-O 120.783 0.325 . . . . 0.0 110.924 -179.952 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 32.8 t -119.76 -42.34 2.63 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.813 -179.97 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 150.02 -162.4 29.17 Favored Glycine 0 N--CA 1.451 -0.363 0 C-N-CA 120.752 -0.737 . . . . 0.0 112.471 -179.963 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 1.4 m -110.24 -42.6 4.11 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-O 120.773 0.321 . . . . 0.0 110.856 179.963 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 2.0 m -144.34 -179.32 6.46 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.797 179.978 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -169.79 -123.81 0.7 Allowed Glycine 0 N--CA 1.45 -0.368 0 C-N-CA 120.707 -0.759 . . . . 0.0 112.527 -179.999 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 12.5 tttm -91.14 130.35 37.04 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-O 120.76 0.314 . . . . 0.0 110.837 -179.958 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER 59.79 84.83 0.19 Allowed Pre-proline 0 C--N 1.329 -0.301 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.956 179.991 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 51.9 Cg_exo -52.79 151.76 18.98 Favored 'Trans proline' 0 C--N 1.345 0.35 0 C-N-CA 122.595 2.197 . . . . 0.0 112.295 -179.996 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 20.3 m -141.39 -60.54 0.48 Allowed 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.178 -0.464 . . . . 0.0 110.906 179.973 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 24.3 t -165.98 63.33 0.84 Allowed Pre-proline 0 C--N 1.329 -0.294 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.922 179.951 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 52.3 Cg_exo -52.72 -49.09 18.71 Favored 'Trans proline' 0 C--N 1.345 0.36 0 C-N-CA 122.641 2.227 . . . . 0.0 112.298 -179.959 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 1.3 m -109.87 152.94 25.14 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.147 -0.478 . . . . 0.0 110.892 -179.947 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 0.6 OUTLIER -151.67 73.98 1.1 Allowed 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.872 179.986 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 67.08 -115.35 7.11 Favored Glycine 0 N--CA 1.452 -0.291 0 C-N-CA 120.713 -0.756 . . . . 0.0 112.463 -179.971 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -177.02 37.8 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 120.856 0.36 . . . . 0.0 110.923 -179.953 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -131.16 -67.82 0.69 Allowed 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.189 -0.459 . . . . 0.0 110.938 179.944 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 19' ' ' GLN . . . . . . . . . . . . . 3.4 mp0 60.43 -178.24 0.1 Allowed 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.908 -179.976 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 20' ' ' GLN . . . . . . . . . . . . . 0.4 OUTLIER -148.8 117.55 6.64 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.916 179.961 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -127.56 159.63 34.02 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.838 -179.957 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 4.3 mm-40 60.17 35.53 21.08 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.884 179.989 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 78.46 -123.89 6.45 Favored Glycine 0 N--CA 1.451 -0.327 0 C-N-CA 120.715 -0.755 . . . . 0.0 112.502 -179.963 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . 59.77 79.8 0.22 Allowed 'General case' 0 C--N 1.329 -0.325 0 CA-C-O 120.731 0.301 . . . . 0.0 111.105 179.949 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -86.86 -39.86 15.44 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.823 -179.986 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -118.41 168.16 10.9 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.176 -0.465 . . . . 0.0 111.143 179.909 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 27' ' ' GLU . . . . . . . . . . . . . 3.0 mt-10 -115.25 -173.28 2.29 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.899 179.967 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 21.4 t -80.18 98.31 3.36 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.312 -0.404 . . . . 0.0 111.05 179.978 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 111.78 29.72 3.25 Favored Glycine 0 N--CA 1.451 -0.312 0 C-N-CA 120.807 -0.711 . . . . 0.0 112.417 179.912 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 1.2 t70 -122.81 146.03 47.91 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 120.832 0.348 . . . . 0.0 110.894 179.981 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 31' ' ' GLN . . . . . . . . . . . . . 18.1 mt-30 -60.76 131.46 50.75 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.821 179.953 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 14.5 m -140.3 171.81 12.8 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.156 -0.475 . . . . 0.0 111.137 179.978 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 33' ' ' LEU . . . . . . . . . . . . . 17.8 tp -134.21 110.54 9.61 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.903 -179.963 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 21.6 t -77.95 120.43 28.68 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 116.221 -0.445 . . . . 0.0 111.09 -179.937 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 35' ' ' ALA . . . . . . . . . . . . . . . 58.25 27.05 14.65 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.163 -0.471 . . . . 0.0 111.192 179.981 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . 56.77 31.33 60.73 Favored Glycine 0 N--CA 1.452 -0.282 0 C-N-CA 120.709 -0.758 . . . . 0.0 112.606 179.931 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 37' ' ' GLN . . . . . . . . . . . . . 91.5 mt-30 -140.28 -73.27 0.36 Allowed 'General case' 0 C--N 1.33 -0.272 0 CA-C-O 120.833 0.349 . . . . 0.0 110.962 -179.992 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 38' ' ' LYS . . . . . . . . . . . . . 34.1 mttp -68.22 104.27 1.78 Allowed 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.855 179.977 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 39' ' ' GLN . . . . . . . . . . . . . 0.4 OUTLIER -85.34 136.07 33.63 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.252 -0.431 . . . . 0.0 110.839 179.905 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -164.56 -163.7 18.21 Favored Glycine 0 N--CA 1.451 -0.356 0 C-N-CA 120.771 -0.728 . . . . 0.0 112.539 179.965 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 41' ' ' ILE . . . . . 0.431 HD12 HG23 ' A' ' 41' ' ' ILE . 32.4 mt -131.12 139.51 50.84 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-O 120.79 0.328 . . . . 0.0 111.156 179.994 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 42' ' ' VAL . . . . . . . . . . . . . 23.2 t -69.18 124.36 24.8 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.334 0 CA-C-N 116.187 -0.46 . . . . 0.0 111.059 -179.952 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 43' ' ' ARG . . . . . . . . . . . . . 27.8 mmt180 -105.58 -32.57 8.42 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.178 -0.464 . . . . 0.0 110.984 -179.956 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 44' ' ' PHE . . . . . . . . . . . . . 51.0 t80 -143.08 118.11 10.05 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 116.189 -0.459 . . . . 0.0 110.962 -179.93 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 45' ' ' TYR . . . . . 0.494 ' CE1' ' CZ ' ' A' ' 56' ' ' TYR . 15.5 t80 -113.02 117.94 33.41 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.867 179.965 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 172.74 170.25 36.26 Favored Glycine 0 N--CA 1.452 -0.26 0 C-N-CA 120.657 -0.782 . . . . 0.0 112.487 179.979 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 47' ' ' LYS . . . . . 0.415 ' HG3' ' CE1' ' A' ' 54' ' ' TYR . 19.5 mttt -67.09 148.08 52.33 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 120.837 0.351 . . . . 0.0 110.942 179.983 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 48' ' ' THR . . . . . . . . . . . . . 16.6 p -109.15 170.85 7.79 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.893 179.988 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 8.3 t0 -98.3 -31.12 12.21 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.869 179.989 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 50' ' ' PHE . . . . . 0.435 ' CD1' ' N ' ' A' ' 51' ' ' ALA . 18.1 p90 -66.54 -32.23 73.45 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.935 -179.962 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 51' ' ' ALA . . . . . 0.435 ' N ' ' CD1' ' A' ' 50' ' ' PHE . . . -148.94 151.72 35.34 Favored Pre-proline 0 C--N 1.329 -0.299 0 CA-C-N 116.271 -0.422 . . . . 0.0 111.096 179.996 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 52' ' ' PRO . . . . . . . . . . . . . 56.8 Cg_endo -70.67 -167.94 0.29 Allowed 'Trans proline' 0 C--N 1.344 0.31 0 C-N-CA 122.598 2.198 . . . . 0.0 112.289 179.997 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 65.2 -176.39 12.82 Favored Glycine 0 N--CA 1.45 -0.38 0 C-N-CA 120.791 -0.719 . . . . 0.0 112.481 179.971 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 54' ' ' TYR . . . . . 0.415 ' CE1' ' HG3' ' A' ' 47' ' ' LYS . 7.6 m-85 -106.57 128.97 54.55 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-O 120.828 0.347 . . . . 0.0 110.928 179.974 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 55' ' ' TRP . . . . . . . . . . . . . 35.0 m95 -116.2 174.29 6.13 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.846 -179.969 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 56' ' ' TYR . . . . . 0.494 ' CZ ' ' CE1' ' A' ' 45' ' ' TYR . 16.8 m-85 -125.35 121.64 34.51 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.92 -179.963 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 57' ' ' GLY . . . . . 0.403 ' N ' ' CE1' ' A' ' 86' ' ' PHE . . . -82.11 62.03 4.61 Favored Glycine 0 N--CA 1.451 -0.33 0 C-N-CA 120.776 -0.726 . . . . 0.0 112.417 179.928 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 58' ' ' ILE . . . . . . . . . . . . . 21.2 mt -68.67 139.71 20.14 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-O 120.809 0.338 . . . . 0.0 111.122 -179.993 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 4.7 tm-20 -111.99 112.52 24.22 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.91 179.959 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 60' ' ' LEU . . . . . . . . . . . . . 84.7 mt -72.53 177.34 4.73 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.967 -179.992 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -100.42 -32.37 10.85 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.815 179.998 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 62' ' ' GLN . . . . . . . . . . . . . 4.7 mm100 -106.62 155.33 39.08 Favored Pre-proline 0 C--N 1.328 -0.34 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.829 179.999 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 57.7 Cg_endo -71.51 68.11 2.82 Favored 'Trans proline' 0 C--N 1.345 0.354 0 C-N-CA 122.544 2.163 . . . . 0.0 112.399 179.907 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 64' ' ' THR . . . . . . . . . . . . . 12.4 p -136.0 31.18 3.0 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.871 -179.999 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . -92.95 -139.75 9.46 Favored Glycine 0 N--CA 1.451 -0.349 0 C-N-CA 120.754 -0.736 . . . . 0.0 112.548 -179.956 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 66' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -128.63 -45.75 1.31 Allowed 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 120.848 0.356 . . . . 0.0 110.924 179.961 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 67' ' ' HIS . . . . . . . . . . . . . 7.2 p80 -127.1 169.89 12.93 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.233 -0.44 . . . . 0.0 110.871 179.974 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 10.3 p-10 -98.56 36.51 1.63 Allowed 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.935 179.964 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 105.88 -50.37 0.82 Allowed Glycine 0 N--CA 1.45 -0.391 0 C-N-CA 120.756 -0.735 . . . . 0.0 112.502 179.964 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 70' ' ' SER . . . . . . . . . . . . . 80.5 p -93.26 151.84 19.56 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 120.836 0.35 . . . . 0.0 110.832 -179.945 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 71' ' ' VAL . . . . . 0.42 HG11 ' CD2' ' A' ' 72' ' ' PHE . 20.0 t -141.35 110.47 2.77 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 CA-C-N 116.226 -0.443 . . . . 0.0 111.069 -180.0 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 72' ' ' PHE . . . . . 0.42 ' CD2' HG11 ' A' ' 71' ' ' VAL . 67.6 m-85 60.17 31.17 20.43 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.903 -179.968 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 87.07 28.37 25.83 Favored Glycine 0 N--CA 1.451 -0.312 0 C-N-CA 120.747 -0.739 . . . . 0.0 112.498 179.98 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 74' ' ' VAL . . . . . 0.407 HG12 ' CZ ' ' A' ' 76' ' ' TYR . 21.4 t -128.35 104.27 11.38 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-O 120.901 0.381 . . . . 0.0 111.085 -179.988 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 75' ' ' ARG . . . . . . . . . . . . . 11.3 ttt180 -84.0 134.2 34.65 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.861 -179.934 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 76' ' ' TYR . . . . . 0.407 ' CZ ' HG12 ' A' ' 74' ' ' VAL . 56.5 m-85 -118.2 -41.51 2.86 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.883 179.973 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 77' ' ' PHE . . . . . . . . . . . . . 12.8 p90 -158.98 163.31 36.58 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.145 -0.48 . . . . 0.0 110.87 179.987 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 1.2 p -89.6 109.1 20.08 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.926 179.97 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 79' ' ' CYS . . . . . . . . . . . . . 28.6 p -138.41 166.19 24.88 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.921 -179.988 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 80' ' ' ALA . . . . . 0.416 ' HB3' ' CE1' ' A' ' 83' ' ' HIS . . . -77.51 168.93 23.75 Favored Pre-proline 0 C--N 1.329 -0.316 0 CA-C-N 116.227 -0.442 . . . . 0.0 111.07 -179.97 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 81' ' ' PRO . . . . . . . . . . . . . 32.5 Cg_exo -58.11 122.93 12.55 Favored 'Trans proline' 0 C--N 1.344 0.308 0 C-N-CA 122.582 2.188 . . . . 0.0 112.29 -179.929 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 82' ' ' ARG . . . . . . . . . . . . . 14.8 mtt-85 64.17 46.54 3.59 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.155 -0.475 . . . . 0.0 111.123 179.908 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 83' ' ' HIS . . . . . 0.416 ' CE1' ' HB3' ' A' ' 80' ' ' ALA . 9.4 m170 -119.29 -45.18 2.55 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.796 179.892 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . -75.49 138.96 23.99 Favored Glycine 0 N--CA 1.452 -0.295 0 C-N-CA 120.742 -0.742 . . . . 0.0 112.47 179.955 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 85' ' ' VAL . . . . . . . . . . . . . 18.0 m -141.72 119.72 8.78 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.361 0 CA-C-O 120.818 0.342 . . . . 0.0 111.108 -179.91 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 86' ' ' PHE . . . . . 0.403 ' CE1' ' N ' ' A' ' 57' ' ' GLY . 9.3 m-85 -97.69 110.57 23.11 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.872 179.928 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 87' ' ' ALA . . . . . . . . . . . . . . . -128.78 151.19 76.81 Favored Pre-proline 0 C--N 1.33 -0.273 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.163 -179.989 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 88' ' ' PRO . . . . . 0.404 ' O ' ' N ' ' A' ' 91' ' ' ARG . 31.8 Cg_exo -58.72 136.24 72.53 Favored 'Trans proline' 0 C--N 1.345 0.36 0 C-N-CA 122.619 2.213 . . . . 0.0 112.252 -179.925 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -48.05 -51.25 25.02 Favored 'General case' 0 C--N 1.333 -0.124 0 CA-C-N 116.154 -0.476 . . . . 0.0 110.277 179.91 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 90' ' ' SER . . . . . . . . . . . . . 5.5 m -55.94 -24.36 37.54 Favored 'General case' 0 N--CA 1.454 -0.249 0 CA-C-N 115.724 -0.671 . . . . 0.0 109.757 178.81 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 91' ' ' ARG . . . . . 0.404 ' N ' ' O ' ' A' ' 88' ' ' PRO . 0.6 OUTLIER -89.11 -14.09 37.04 Favored 'General case' 0 N--CA 1.455 -0.21 0 CA-C-N 115.818 -0.628 . . . . 0.0 110.487 179.064 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 92' ' ' ILE . . . . . . . . . . . . . 28.1 mt -108.26 146.25 14.35 Favored 'Isoleucine or valine' 0 C--O 1.231 0.091 0 CA-C-N 116.391 -0.368 . . . . 0.0 111.034 179.834 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 93' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -106.19 164.49 11.96 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.218 -0.447 . . . . 0.0 110.817 -179.993 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 94' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -116.35 119.27 35.14 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.887 -179.995 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 95' ' ' ILE . . . . . . . . . . . . . 22.2 mt -91.89 -61.88 1.86 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.18 -0.464 . . . . 0.0 111.197 179.96 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . 68.48 -72.36 0.34 Allowed Glycine 0 N--CA 1.451 -0.301 0 C-N-CA 120.738 -0.744 . . . . 0.0 112.413 179.89 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 97' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -155.06 -69.6 0.12 Allowed 'General case' 0 C--N 1.328 -0.34 0 CA-C-O 120.795 0.331 . . . . 0.0 110.864 -179.954 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 98' ' ' GLY . . . . . . . . . . . . . . . 99.72 -97.2 1.75 Allowed Glycine 0 N--CA 1.451 -0.304 0 C-N-CA 120.752 -0.737 . . . . 0.0 112.507 179.976 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 99' ' ' PRO . . . . . . . . . . . . . 50.0 Cg_exo -53.68 138.43 67.53 Favored 'Trans proline' 0 C--N 1.345 0.378 0 C-N-CA 122.507 2.138 . . . . 0.0 112.301 -179.986 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 100' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -81.12 152.27 27.88 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.874 -179.96 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -137.37 31.86 2.59 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.837 -179.96 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.249 1.058 0 CA-C-O 118.334 -1.259 . . . . 0.0 112.526 -179.997 . . . . . . . . 0 0 . 1 . 004 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.488 2.126 0 N-CA-C 112.518 -0.233 . . . . 0.0 112.518 . . . . . . . . . 0 0 . 1 . 004 nuclear orig full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 1.3 m -149.62 -179.95 7.51 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-O 120.858 0.361 . . . . 0.0 110.827 -179.902 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -145.49 -47.45 0.22 Allowed 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.794 -179.995 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 170.54 -168.42 41.47 Favored Glycine 0 N--CA 1.451 -0.308 0 C-N-CA 120.794 -0.717 . . . . 0.0 112.501 -179.991 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 50.5 m -106.62 35.8 2.85 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-O 120.853 0.359 . . . . 0.0 110.877 179.982 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 12.3 t -122.2 93.62 4.04 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.903 179.917 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 132.06 -130.85 6.05 Favored Glycine 0 N--CA 1.451 -0.3 0 C-N-CA 120.735 -0.745 . . . . 0.0 112.415 179.939 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 15.5 tttp -60.56 91.88 0.02 OUTLIER 'General case' 0 C--N 1.328 -0.346 0 CA-C-O 120.788 0.328 . . . . 0.0 110.846 -179.877 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 9' ' ' SER . . . . . 0.405 ' N ' ' CD ' ' A' ' 10' ' ' PRO . 0.4 OUTLIER -85.63 -52.92 0.46 Allowed Pre-proline 0 C--N 1.329 -0.294 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.965 179.984 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 10' ' ' PRO . . . . . 0.405 ' CD ' ' N ' ' A' ' 9' ' ' SER . 75.5 Cg_exo -50.59 147.34 17.74 Favored 'Trans proline' 0 C--N 1.345 0.36 0 C-N-CA 122.615 2.21 . . . . 0.0 112.344 -179.963 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 17.2 p 57.84 105.76 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.98 179.972 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 45.6 t -160.6 145.58 10.85 Favored Pre-proline 0 C--N 1.329 -0.31 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.874 179.898 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 52.5 Cg_exo -54.55 -169.39 0.02 OUTLIER 'Trans proline' 0 C--N 1.346 0.43 0 C-N-CA 122.531 2.154 . . . . 0.0 112.384 179.985 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 1.2 m -150.6 -46.95 0.12 Allowed 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.868 -179.995 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -165.09 32.06 0.06 Allowed 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.871 179.979 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 109.03 41.22 1.44 Allowed Glycine 0 N--CA 1.452 -0.278 0 C-N-CA 120.686 -0.769 . . . . 0.0 112.447 -179.924 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 16.4 m -68.26 113.62 6.03 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-O 120.774 0.321 . . . . 0.0 110.907 -179.954 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 5.1 tt -151.32 -48.66 0.12 Allowed 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.282 -0.417 . . . . 0.0 110.846 179.872 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 19' ' ' GLN . . . . . . . . . . . . . 24.7 mp0 -66.39 111.9 3.77 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.926 179.925 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 20' ' ' GLN . . . . . . . . . . . . . 28.5 mt-30 -59.84 -63.86 1.15 Allowed 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.178 -0.464 . . . . 0.0 110.884 -179.929 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 2.4 mmm180 60.16 33.64 21.12 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.902 179.923 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 3.5 tt0 -167.22 -44.42 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.886 179.907 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 84.13 90.56 0.76 Allowed Glycine 0 N--CA 1.45 -0.418 0 C-N-CA 120.742 -0.742 . . . . 0.0 112.507 179.934 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -156.13 167.29 30.89 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.798 0.332 . . . . 0.0 111.021 179.985 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 5.4 mmtt -142.94 -48.55 0.33 Allowed 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.941 179.916 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -121.77 168.12 12.19 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.122 179.946 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 27' ' ' GLU . . . . . . . . . . . . . 1.1 pm0 -116.75 158.39 23.94 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.888 -179.988 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 36.7 t -67.85 82.69 0.11 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.035 179.911 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 136.24 43.95 0.1 OUTLIER Glycine 0 N--CA 1.451 -0.366 0 C-N-CA 120.745 -0.74 . . . . 0.0 112.537 -179.981 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -149.18 167.69 25.28 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-O 120.838 0.352 . . . . 0.0 110.893 -179.984 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 31' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -78.12 130.73 36.73 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.942 -179.962 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 4.7 m -132.76 172.48 16.37 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.326 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.112 179.944 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 33' ' ' LEU . . . . . . . . . . . . . 16.7 tp -143.52 112.36 6.58 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.196 -0.457 . . . . 0.0 110.856 -179.942 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 21.5 t -81.09 124.25 38.57 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.245 -0.434 . . . . 0.0 111.11 -179.849 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 35' ' ' ALA . . . . . . . . . . . . . . . 57.94 26.65 13.65 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.067 -0.515 . . . . 0.0 111.294 179.99 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . 57.05 33.45 64.25 Favored Glycine 0 N--CA 1.452 -0.29 0 C-N-CA 120.759 -0.734 . . . . 0.0 112.562 179.959 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 37' ' ' GLN . . . . . . . . . . . . . 37.7 mt-30 -144.36 -70.44 0.29 Allowed 'General case' 0 C--N 1.328 -0.35 0 CA-C-O 120.87 0.367 . . . . 0.0 111.075 -179.867 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 38' ' ' LYS . . . . . . . . . . . . . 2.8 mmpt? -68.08 114.61 6.74 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.925 -179.871 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 39' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -93.88 128.64 40.27 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.9 179.985 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -152.82 -172.88 21.64 Favored Glycine 0 N--CA 1.451 -0.335 0 C-N-CA 120.759 -0.734 . . . . 0.0 112.534 179.973 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 25.4 mm -125.33 138.07 55.57 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.269 0 CA-C-O 120.818 0.342 . . . . 0.0 111.136 -179.932 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 42' ' ' VAL . . . . . . . . . . . . . 21.5 t -69.32 122.33 20.56 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.185 -0.461 . . . . 0.0 111.082 -179.99 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 43' ' ' ARG . . . . . . . . . . . . . 8.0 mmt180 -113.55 -35.88 5.1 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.926 -179.998 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 44' ' ' PHE . . . . . . . . . . . . . 64.6 t80 -139.05 111.45 7.53 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.941 -179.983 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 45' ' ' TYR . . . . . 0.485 ' CE1' ' CE1' ' A' ' 56' ' ' TYR . 13.3 t80 -107.28 136.88 46.36 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.857 179.879 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 153.51 -163.08 30.6 Favored Glycine 0 N--CA 1.451 -0.352 0 C-N-CA 120.746 -0.74 . . . . 0.0 112.479 179.988 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 47' ' ' LYS . . . . . . . . . . . . . 21.1 mttp -88.64 167.69 13.16 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-O 120.799 0.333 . . . . 0.0 110.875 -179.944 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 48' ' ' THR . . . . . 0.41 HG22 ' CZ ' ' A' ' 50' ' ' PHE . 29.1 p -129.48 -173.88 3.13 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.846 179.965 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -110.37 -31.58 7.24 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.855 -179.97 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 50' ' ' PHE . . . . . 0.427 ' CD1' ' N ' ' A' ' 51' ' ' ALA . 18.3 p90 -67.84 -36.09 79.74 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.259 -0.428 . . . . 0.0 110.992 -179.924 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 51' ' ' ALA . . . . . 0.427 ' N ' ' CD1' ' A' ' 50' ' ' PHE . . . -148.4 146.04 21.81 Favored Pre-proline 0 C--N 1.329 -0.283 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.175 179.979 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 52' ' ' PRO . . . . . . . . . . . . . 69.2 Cg_endo -74.39 173.77 13.67 Favored 'Trans proline' 0 C--N 1.345 0.391 0 C-N-CA 122.573 2.182 . . . . 0.0 112.315 -179.985 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 92.43 172.62 41.47 Favored Glycine 0 N--CA 1.452 -0.289 0 C-N-CA 120.762 -0.733 . . . . 0.0 112.48 179.905 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 54' ' ' TYR . . . . . . . . . . . . . 10.5 m-85 -90.14 110.31 21.33 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-O 120.814 0.34 . . . . 0.0 110.868 -179.993 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 55' ' ' TRP . . . . . 0.422 ' CZ3' ' HD3' ' A' ' 88' ' ' PRO . 66.7 m95 -105.17 159.25 16.01 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.906 179.967 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 56' ' ' TYR . . . . . 0.485 ' CE1' ' CE1' ' A' ' 45' ' ' TYR . 12.6 m-85 -114.9 117.34 30.4 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.98 -179.824 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . -79.75 68.06 3.28 Favored Glycine 0 N--CA 1.451 -0.34 0 C-N-CA 120.684 -0.77 . . . . 0.0 112.341 179.934 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 58' ' ' ILE . . . . . . . . . . . . . 38.0 mt -73.3 137.89 22.44 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.39 0 CA-C-O 120.829 0.347 . . . . 0.0 111.192 -179.911 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 1.3 tm-20 -104.29 107.12 17.88 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.79 179.926 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 60' ' ' LEU . . . . . . . . . . . . . 36.6 mt -60.11 170.43 1.25 Allowed 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.971 -179.935 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 2.9 m-20 -100.45 -31.6 11.21 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.882 -179.991 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 62' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -120.24 147.31 44.63 Favored Pre-proline 0 C--N 1.331 -0.23 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.839 -179.93 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 50.6 Cg_exo -53.07 90.5 0.03 OUTLIER 'Trans proline' 0 C--N 1.345 0.389 0 C-N-CA 122.479 2.119 . . . . 0.0 112.405 179.949 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 64' ' ' THR . . . . . . . . . . . . . 4.9 t -164.7 39.4 0.07 Allowed 'General case' 0 C--N 1.327 -0.384 0 CA-C-N 116.296 -0.411 . . . . 0.0 110.911 179.989 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . -100.66 -149.07 22.99 Favored Glycine 0 N--CA 1.451 -0.325 0 C-N-CA 120.741 -0.742 . . . . 0.0 112.515 179.946 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 66' ' ' LYS . . . . . . . . . . . . . 0.6 OUTLIER -121.47 -42.65 2.43 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-O 120.825 0.345 . . . . 0.0 110.918 -179.948 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 67' ' ' HIS . . . . . . . . . . . . . 6.8 p80 -128.53 172.15 11.44 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.917 179.964 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 4.9 m-20 -98.36 33.67 2.17 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.922 -179.971 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 99.47 -41.89 2.1 Favored Glycine 0 N--CA 1.451 -0.316 0 C-N-CA 120.636 -0.792 . . . . 0.0 112.491 179.995 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 70' ' ' SER . . . . . . . . . . . . . 77.3 p -104.82 148.62 26.44 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 120.835 0.35 . . . . 0.0 110.918 -179.974 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 21.5 t -135.45 122.59 35.31 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.146 -0.479 . . . . 0.0 111.105 179.958 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 72' ' ' PHE . . . . . . . . . . . . . 33.5 m-85 60.28 33.85 20.89 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.924 -179.992 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 80.4 27.92 50.09 Favored Glycine 0 N--CA 1.452 -0.25 0 C-N-CA 120.692 -0.766 . . . . 0.0 112.533 -179.97 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 21.4 t -131.61 100.71 4.58 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-O 120.767 0.317 . . . . 0.0 111.078 -179.997 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 75' ' ' ARG . . . . . . . . . . . . . 20.5 ttt85 -77.45 119.75 21.49 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.26 -0.427 . . . . 0.0 110.949 -179.968 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 76' ' ' TYR . . . . . . . . . . . . . 25.4 m-85 -92.28 -48.86 6.46 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.835 -179.995 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 77' ' ' PHE . . . . . . . . . . . . . 16.8 p90 -148.65 161.97 40.65 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.752 179.936 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -88.34 108.5 19.37 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.971 -179.963 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 79' ' ' CYS . . . . . . . . . . . . . 30.4 p -132.93 174.11 10.68 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.867 -179.976 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 80' ' ' ALA . . . . . . . . . . . . . . . -81.95 166.73 35.53 Favored Pre-proline 0 C--N 1.329 -0.311 0 CA-C-N 116.198 -0.455 . . . . 0.0 111.056 179.978 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 81' ' ' PRO . . . . . . . . . . . . . 51.9 Cg_exo -54.34 117.49 3.99 Favored 'Trans proline' 0 C--N 1.343 0.267 0 C-N-CA 122.57 2.18 . . . . 0.0 112.304 179.994 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 82' ' ' ARG . . . . . . . . . . . . . 3.3 mpt_? 60.99 52.97 3.86 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.116 -0.493 . . . . 0.0 110.96 179.99 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 83' ' ' HIS . . . . . . . . . . . . . 7.2 m170 -122.41 -42.15 2.36 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.119 -0.491 . . . . 0.0 110.915 179.989 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . -64.24 144.56 48.75 Favored Glycine 0 N--CA 1.452 -0.261 0 C-N-CA 120.632 -0.794 . . . . 0.0 112.426 179.968 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 85' ' ' VAL . . . . . . . . . . . . . 15.4 m -152.54 121.32 0.77 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-O 120.833 0.349 . . . . 0.0 111.101 179.997 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 86' ' ' PHE . . . . . 0.403 ' CD1' ' HB3' ' A' ' 55' ' ' TRP . 2.5 m-85 -100.69 118.73 37.4 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.945 179.971 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 87' ' ' ALA . . . . . . . . . . . . . . . -139.91 145.72 43.79 Favored Pre-proline 0 C--N 1.329 -0.316 0 CA-C-N 116.258 -0.428 . . . . 0.0 111.094 179.936 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 88' ' ' PRO . . . . . 0.422 ' HD3' ' CZ3' ' A' ' 55' ' ' TRP . 36.0 Cg_exo -57.27 138.2 85.16 Favored 'Trans proline' 0 C--N 1.346 0.441 0 C-N-CA 122.46 2.107 . . . . 0.0 112.336 -179.952 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -47.63 -51.9 19.84 Favored 'General case' 0 C--N 1.333 -0.115 0 CA-C-O 121.112 0.482 . . . . 0.0 110.367 179.902 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 90' ' ' SER . . . . . . . . . . . . . 5.9 m -55.52 -24.48 32.11 Favored 'General case' 0 N--CA 1.454 -0.246 0 CA-C-N 115.657 -0.701 . . . . 0.0 109.754 178.769 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 91' ' ' ARG . . . . . 0.413 ' N ' ' O ' ' A' ' 88' ' ' PRO . 0.6 OUTLIER -88.41 -16.36 33.1 Favored 'General case' 0 N--CA 1.454 -0.234 0 CA-C-N 115.829 -0.623 . . . . 0.0 110.416 179.066 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 92' ' ' ILE . . . . . . . . . . . . . 51.6 mt -104.51 145.09 13.57 Favored 'Isoleucine or valine' 0 C--N 1.333 -0.121 0 CA-C-N 116.379 -0.373 . . . . 0.0 111.035 179.869 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 93' ' ' GLN . . . . . . . . . . . . . 1.8 mt-30 -112.83 -179.96 3.8 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.228 -0.442 . . . . 0.0 111.009 -179.949 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 94' ' ' ARG . . . . . . . . . . . . . 0.6 OUTLIER -126.88 138.96 53.39 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.947 -179.895 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 95' ' ' ILE . . . . . . . . . . . . . 3.8 mp -113.2 -57.91 3.74 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.252 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.059 179.967 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . 73.09 167.98 12.51 Favored Glycine 0 N--CA 1.451 -0.303 0 C-N-CA 120.837 -0.697 . . . . 0.0 112.519 179.955 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 97' ' ' SER . . . . . . . . . . . . . 54.7 p -145.61 -64.75 0.32 Allowed 'General case' 0 C--N 1.33 -0.279 0 CA-C-O 120.825 0.345 . . . . 0.0 110.894 179.99 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 98' ' ' GLY . . . . . . . . . . . . . . . 127.72 143.2 5.66 Favored Glycine 0 N--CA 1.452 -0.299 0 C-N-CA 120.838 -0.696 . . . . 0.0 112.463 179.962 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 99' ' ' PRO . . . . . . . . . . . . . 50.1 Cg_exo -53.54 126.22 21.07 Favored 'Trans proline' 0 C--N 1.345 0.376 0 C-N-CA 122.569 2.18 . . . . 0.0 112.358 179.937 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 100' ' ' SER . . . . . . . . . . . . . 89.1 p -149.08 -47.52 0.14 Allowed 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.906 179.959 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER 63.77 90.5 0.08 Allowed 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.132 -0.486 . . . . 0.0 110.946 179.934 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.25 1.103 0 CA-C-O 118.365 -1.242 . . . . 0.0 112.515 179.933 . . . . . . . . 0 0 . 1 . 005 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.248 0 N-CA-C 112.502 -0.239 . . . . 0.0 112.502 . . . . . . . . . 0 0 . 1 . 005 nuclear orig full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 3.5 m -150.9 166.26 31.12 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-O 120.874 0.369 . . . . 0.0 110.809 -179.952 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 14.1 m -119.43 115.16 23.5 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.125 -0.488 . . . . 0.0 110.964 -179.985 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 77.97 -131.19 10.76 Favored Glycine 0 N--CA 1.451 -0.356 0 C-N-CA 120.754 -0.736 . . . . 0.0 112.564 179.957 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 9.2 t -127.82 137.01 52.23 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-O 120.853 0.358 . . . . 0.0 110.933 -179.922 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 82.7 p -111.51 143.06 42.96 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.879 179.982 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -179.56 -45.08 0.08 OUTLIER Glycine 0 N--CA 1.451 -0.334 0 C-N-CA 120.742 -0.742 . . . . 0.0 112.485 -179.985 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 15.8 ttpt -109.42 -64.34 1.26 Allowed 'General case' 0 C--N 1.329 -0.323 0 CA-C-O 120.867 0.365 . . . . 0.0 110.93 179.955 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 2.8 m -124.66 148.08 57.93 Favored Pre-proline 0 C--N 1.33 -0.262 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.877 179.982 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 58.2 Cg_endo -71.76 -45.17 0.79 Allowed 'Trans proline' 0 C--N 1.344 0.338 0 C-N-CA 122.536 2.157 . . . . 0.0 112.342 179.971 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 1.8 p -78.06 125.26 29.08 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.248 -0.433 . . . . 0.0 110.856 -179.967 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 1.9 m -128.89 134.44 26.32 Favored Pre-proline 0 C--N 1.33 -0.26 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.859 179.974 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 74.1 Cg_endo -75.48 80.92 2.42 Favored 'Trans proline' 0 C--N 1.345 0.362 0 C-N-CA 122.518 2.145 . . . . 0.0 112.289 -179.958 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER 59.9 109.57 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.989 179.944 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 1.6 mt -141.14 30.35 1.79 Allowed 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.899 179.994 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 95.34 28.7 9.5 Favored Glycine 0 N--CA 1.451 -0.323 0 C-N-CA 120.701 -0.762 . . . . 0.0 112.539 -179.972 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 5.0 t -79.64 112.73 17.19 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-O 120.872 0.368 . . . . 0.0 110.901 -179.98 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 10.1 tp -119.79 -44.63 2.52 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.857 179.976 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 19' ' ' GLN . . . . . . . . . . . . . 3.2 mp0 -80.13 93.4 5.81 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.924 179.996 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 20' ' ' GLN . . . . . . . . . . . . . 3.4 pt20 -106.07 122.27 45.82 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.843 -179.924 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 2.1 mtt180 -108.9 80.3 1.31 Allowed 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.209 -0.451 . . . . 0.0 110.86 179.924 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 48.0 tt0 -156.92 129.46 7.54 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.931 179.95 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -175.37 141.43 5.71 Favored Glycine 0 N--CA 1.451 -0.319 0 C-N-CA 120.733 -0.746 . . . . 0.0 112.522 -179.965 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -73.13 134.16 44.36 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-O 120.733 0.301 . . . . 0.0 111.077 -179.969 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 8.7 tptp -79.37 -46.13 18.22 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.899 179.969 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -142.0 -179.37 6.18 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.277 -0.419 . . . . 0.0 111.076 179.994 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 27' ' ' GLU . . . . . . . . . . . . . 28.5 mt-10 -143.2 -172.59 3.72 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.918 -179.996 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 30.6 t -78.46 111.65 15.55 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.236 -0.438 . . . . 0.0 111.078 -179.979 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 106.16 42.73 1.6 Allowed Glycine 0 N--CA 1.452 -0.255 0 C-N-CA 120.729 -0.748 . . . . 0.0 112.52 179.967 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 2.3 m-20 -150.12 136.77 19.14 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-O 120.813 0.34 . . . . 0.0 110.823 179.979 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 31' ' ' GLN . . . . . . . . . . . . . 2.6 mt-30 -60.03 141.02 56.42 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.88 179.92 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 6.3 m -146.57 179.58 0.92 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.356 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.188 179.992 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 33' ' ' LEU . . . . . . . . . . . . . 25.7 tp -142.09 109.89 5.8 Favored 'General case' 0 C--N 1.331 -0.239 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.846 179.991 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 21.5 t -77.72 123.54 34.59 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.266 0 CA-C-N 116.181 -0.463 . . . . 0.0 111.182 -179.969 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 35' ' ' ALA . . . . . . . . . . . . . . . 57.63 26.64 13.14 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.198 -0.456 . . . . 0.0 111.235 -179.964 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . 57.07 29.38 59.42 Favored Glycine 0 N--CA 1.451 -0.327 0 C-N-CA 120.734 -0.746 . . . . 0.0 112.613 179.953 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 37' ' ' GLN . . . . . . . . . . . . . 20.1 mt-30 -141.29 -74.59 0.32 Allowed 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 120.85 0.357 . . . . 0.0 110.966 -179.964 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 38' ' ' LYS . . . . . . . . . . . . . 21.8 mmtm -63.47 103.19 0.49 Allowed 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.861 -179.959 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 39' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -82.55 135.35 35.11 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.939 179.931 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -164.73 -176.01 36.04 Favored Glycine 0 N--CA 1.452 -0.288 0 C-N-CA 120.677 -0.773 . . . . 0.0 112.49 179.965 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 2.6 mt -127.34 137.01 59.03 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 CA-C-O 120.82 0.343 . . . . 0.0 111.085 -179.979 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 42' ' ' VAL . . . . . . . . . . . . . 21.4 t -59.62 123.38 11.91 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.202 -0.454 . . . . 0.0 111.12 179.971 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 43' ' ' ARG . . . . . . . . . . . . . 17.3 mmt85 -111.3 -33.99 6.27 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.902 179.903 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 44' ' ' PHE . . . . . 0.416 ' CD1' ' HB3' ' A' ' 76' ' ' TYR . 60.4 t80 -142.75 110.31 5.78 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.965 -179.979 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 45' ' ' TYR . . . . . . . . . . . . . 15.3 t80 -107.54 119.62 39.93 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.196 -0.457 . . . . 0.0 110.861 179.974 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 175.52 177.14 44.35 Favored Glycine 0 N--CA 1.451 -0.347 0 C-N-CA 120.801 -0.714 . . . . 0.0 112.561 179.971 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 47' ' ' LYS . . . . . . . . . . . . . 16.0 mtmt -77.02 168.14 20.6 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-O 120.886 0.374 . . . . 0.0 110.856 179.975 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 48' ' ' THR . . . . . 0.412 HG22 ' CZ ' ' A' ' 50' ' ' PHE . 23.6 p -125.58 -179.66 4.74 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.868 179.953 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 1.5 t70 -106.74 -31.84 8.24 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.939 179.974 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 50' ' ' PHE . . . . . 0.416 ' CD1' ' HB2' ' A' ' 51' ' ' ALA . 48.8 p90 -70.19 -35.86 74.22 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.924 -179.988 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 51' ' ' ALA . . . . . 0.416 ' HB2' ' CD1' ' A' ' 50' ' ' PHE . . . -141.09 144.16 33.85 Favored Pre-proline 0 C--N 1.328 -0.333 0 CA-C-N 116.218 -0.446 . . . . 0.0 111.087 -179.981 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 52' ' ' PRO . . . . . . . . . . . . . 70.8 Cg_endo -74.74 -176.85 3.02 Favored 'Trans proline' 0 C--N 1.345 0.389 0 C-N-CA 122.531 2.154 . . . . 0.0 112.309 179.99 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 76.78 -175.68 53.36 Favored Glycine 0 N--CA 1.45 -0.376 0 C-N-CA 120.745 -0.74 . . . . 0.0 112.567 179.993 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 54' ' ' TYR . . . . . . . . . . . . . 34.5 m-85 -88.58 158.35 18.31 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-O 120.847 0.356 . . . . 0.0 110.916 179.967 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 55' ' ' TRP . . . . . 0.409 ' HB3' ' CD1' ' A' ' 86' ' ' PHE . 94.2 m95 -154.06 140.96 19.21 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.154 -0.475 . . . . 0.0 110.867 179.96 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 56' ' ' TYR . . . . . . . . . . . . . 36.2 m-85 -102.57 122.31 44.13 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.902 -179.927 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 57' ' ' GLY . . . . . 0.447 ' N ' ' CE1' ' A' ' 86' ' ' PHE . . . -87.79 59.08 4.31 Favored Glycine 0 N--CA 1.451 -0.357 0 C-N-CA 120.754 -0.736 . . . . 0.0 112.468 -179.978 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 58' ' ' ILE . . . . . . . . . . . . . 7.8 mt -64.14 152.48 8.28 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-O 120.829 0.347 . . . . 0.0 110.964 -179.957 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 1.7 tm-20 -122.94 102.94 8.3 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.925 179.988 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 60' ' ' LEU . . . . . . . . . . . . . 54.8 mt -63.16 162.72 11.32 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.904 -179.957 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 2.7 t0 -92.78 -30.91 15.25 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.916 -179.981 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 62' ' ' GLN . . . . . . . . . . . . . 7.1 mt-30 -100.35 152.0 37.7 Favored Pre-proline 0 C--N 1.329 -0.311 0 CA-C-N 116.231 -0.44 . . . . 0.0 110.952 -179.994 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 71.9 Cg_endo -75.45 97.9 1.13 Allowed 'Trans proline' 0 C--N 1.344 0.316 0 C-N-CA 122.595 2.196 . . . . 0.0 112.309 -179.892 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 64' ' ' THR . . . . . . . . . . . . . 9.9 t -173.68 36.27 0.01 OUTLIER 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.9 -179.989 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . -90.09 -159.52 35.6 Favored Glycine 0 N--CA 1.451 -0.335 0 C-N-CA 120.731 -0.747 . . . . 0.0 112.544 179.985 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 66' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -110.47 -31.71 7.17 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 120.819 0.342 . . . . 0.0 110.846 -179.947 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 67' ' ' HIS . . . . . . . . . . . . . 6.6 p80 -140.83 173.57 11.36 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.893 179.954 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 2.6 m-20 -97.98 37.09 1.46 Allowed 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.834 -179.915 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 98.79 -28.61 14.33 Favored Glycine 0 N--CA 1.451 -0.362 0 C-N-CA 120.676 -0.773 . . . . 0.0 112.486 179.967 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 70' ' ' SER . . . . . . . . . . . . . 88.7 p -110.4 161.32 15.77 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-O 120.841 0.353 . . . . 0.0 110.842 -179.92 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 21.5 t -146.41 126.75 6.02 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.256 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.063 -179.981 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 72' ' ' PHE . . . . . . . . . . . . . 11.3 m-85 60.58 27.05 16.73 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.163 -0.472 . . . . 0.0 111.026 179.974 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 95.65 -29.82 9.23 Favored Glycine 0 N--CA 1.452 -0.284 0 C-N-CA 120.752 -0.737 . . . . 0.0 112.537 179.952 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 25.5 t -80.98 116.58 25.53 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.343 0 CA-C-O 120.8 0.333 . . . . 0.0 111.141 -179.976 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 75' ' ' ARG . . . . . . . . . . . . . 2.1 ttt-85 -88.49 148.36 24.19 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.86 -179.933 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 76' ' ' TYR . . . . . 0.416 ' HB3' ' CD1' ' A' ' 44' ' ' PHE . 53.8 m-85 -120.09 -50.81 2.24 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.933 -179.963 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 77' ' ' PHE . . . . . . . . . . . . . 26.9 p90 -146.04 161.78 39.35 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.9 179.978 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 4.9 m -91.93 121.98 34.03 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.099 -0.501 . . . . 0.0 110.941 179.979 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 79' ' ' CYS . . . . . . . . . . . . . 26.1 p -144.57 158.12 43.91 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.252 -0.431 . . . . 0.0 110.87 -179.952 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 80' ' ' ALA . . . . . . . . . . . . . . . -59.59 164.03 6.06 Favored Pre-proline 0 C--N 1.329 -0.306 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.135 179.913 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 81' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_exo -52.31 116.19 2.67 Favored 'Trans proline' 0 C--N 1.345 0.358 0 C-N-CA 122.558 2.172 . . . . 0.0 112.322 -179.982 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 82' ' ' ARG . . . . . . . . . . . . . 16.1 mtt180 58.91 62.49 1.87 Allowed 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.874 -179.962 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 83' ' ' HIS . . . . . . . . . . . . . 4.3 m170 -127.12 -43.78 1.64 Allowed 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.088 -0.506 . . . . 0.0 110.859 179.957 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . -68.2 138.51 32.76 Favored Glycine 0 N--CA 1.45 -0.37 0 C-N-CA 120.706 -0.759 . . . . 0.0 112.473 179.976 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 85' ' ' VAL . . . . . . . . . . . . . 16.9 m -143.3 113.91 2.43 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-O 120.894 0.378 . . . . 0.0 111.108 -179.994 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 86' ' ' PHE . . . . . 0.447 ' CE1' ' N ' ' A' ' 57' ' ' GLY . 5.4 m-85 -89.11 119.81 29.95 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.843 -179.964 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 87' ' ' ALA . . . . . . . . . . . . . . . -139.48 143.86 37.41 Favored Pre-proline 0 C--N 1.329 -0.303 0 CA-C-N 116.263 -0.426 . . . . 0.0 111.146 179.991 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 88' ' ' PRO . . . . . 0.427 ' O ' ' N ' ' A' ' 91' ' ' ARG . 46.8 Cg_exo -55.94 140.45 85.85 Favored 'Trans proline' 0 C--N 1.346 0.43 0 C-N-CA 122.541 2.161 . . . . 0.0 112.379 179.959 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -47.83 -50.3 26.59 Favored 'General case' 0 CA--C 1.521 -0.158 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.264 179.896 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 90' ' ' SER . . . . . . . . . . . . . 8.0 m -55.59 -24.37 32.51 Favored 'General case' 0 N--CA 1.454 -0.266 0 CA-C-N 115.769 -0.651 . . . . 0.0 109.796 178.859 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 91' ' ' ARG . . . . . 0.427 ' N ' ' O ' ' A' ' 88' ' ' PRO . 2.3 mtm-85 -89.74 -15.22 32.93 Favored 'General case' 0 N--CA 1.455 -0.19 0 CA-C-N 115.813 -0.631 . . . . 0.0 110.524 179.063 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 92' ' ' ILE . . . . . . . . . . . . . 49.9 mt -103.08 144.87 13.2 Favored 'Isoleucine or valine' 0 C--O 1.232 0.16 0 CA-C-N 116.402 -0.363 . . . . 0.0 111.094 179.858 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 93' ' ' GLN . . . . . . . . . . . . . 0.5 OUTLIER -115.71 154.3 29.81 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.905 -179.976 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 94' ' ' ARG . . . . . . . . . . . . . 7.6 mtp180 -96.96 138.54 34.34 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.868 179.978 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 95' ' ' ILE . . . . . . . . . . . . . 16.9 mt -111.02 -30.3 2.33 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.15 -0.477 . . . . 0.0 111.108 179.97 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . -58.97 -28.48 63.66 Favored Glycine 0 N--CA 1.452 -0.289 0 C-N-CA 120.745 -0.741 . . . . 0.0 112.475 179.974 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 97' ' ' SER . . . . . . . . . . . . . 7.2 p -74.78 88.27 2.26 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-O 120.778 0.323 . . . . 0.0 110.952 179.882 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 98' ' ' GLY . . . . . . . . . . . . . . . 151.13 87.13 0.06 OUTLIER Glycine 0 N--CA 1.451 -0.337 0 C-N-CA 120.736 -0.745 . . . . 0.0 112.482 179.992 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 99' ' ' PRO . . . . . . . . . . . . . 53.0 Cg_exo -52.32 -40.75 69.69 Favored 'Trans proline' 0 C--N 1.343 0.274 0 C-N-CA 122.604 2.203 . . . . 0.0 112.394 179.933 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 100' ' ' SER . . . . . . . . . . . . . 46.1 p -140.59 37.67 1.84 Allowed 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.93 179.988 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 1.3 m -132.47 -62.8 0.81 Allowed 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.145 -0.48 . . . . 0.0 110.853 -179.95 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.249 1.065 0 CA-C-O 118.344 -1.253 . . . . 0.0 112.488 179.993 . . . . . . . . 0 0 . 1 . 006 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.208 0 N-CA-C 112.476 -0.249 . . . . 0.0 112.476 . . . . . . . . . 0 0 . 1 . 006 nuclear orig full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 48.3 m -139.34 162.46 34.97 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-O 120.877 0.37 . . . . 0.0 110.899 -179.971 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 15.3 m -134.64 -58.07 0.82 Allowed 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.884 179.981 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 91.86 144.92 14.24 Favored Glycine 0 N--CA 1.45 -0.406 0 C-N-CA 120.749 -0.738 . . . . 0.0 112.504 179.979 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 1.3 m -102.61 -176.02 2.98 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-O 120.817 0.342 . . . . 0.0 110.867 -179.953 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER 60.63 100.01 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.132 -0.485 . . . . 0.0 110.864 179.954 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -163.67 101.37 0.19 Allowed Glycine 0 N--CA 1.451 -0.358 0 C-N-CA 120.758 -0.734 . . . . 0.0 112.485 -179.998 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -93.45 -178.74 4.82 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-O 120.825 0.345 . . . . 0.0 110.926 179.956 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 50.7 m -128.48 59.94 45.12 Favored Pre-proline 0 C--N 1.329 -0.288 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.885 179.954 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 52.0 Cg_endo -69.49 -168.02 0.24 Allowed 'Trans proline' 0 C--N 1.344 0.317 0 C-N-CA 122.609 2.206 . . . . 0.0 112.212 -179.936 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 1.3 m -102.77 114.05 27.98 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.964 179.981 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -152.54 146.15 18.02 Favored Pre-proline 0 C--N 1.329 -0.301 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.863 179.982 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 50.9 Cg_exo -53.06 91.07 0.03 OUTLIER 'Trans proline' 0 C--N 1.344 0.338 0 C-N-CA 122.577 2.185 . . . . 0.0 112.325 179.959 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -140.93 108.25 5.53 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.944 179.998 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 9.4 tp -176.79 121.6 0.14 Allowed 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.912 -179.998 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 74.4 -70.42 1.62 Allowed Glycine 0 N--CA 1.45 -0.368 0 C-N-CA 120.745 -0.74 . . . . 0.0 112.502 -179.977 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER 64.45 -78.9 0.03 OUTLIER 'General case' 0 C--N 1.33 -0.265 0 CA-C-O 120.778 0.323 . . . . 0.0 110.934 -179.997 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -164.64 92.36 0.61 Allowed 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.274 -0.421 . . . . 0.0 110.807 179.988 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 19' ' ' GLN . . . . . . . . . . . . . 0.2 OUTLIER -145.83 127.92 15.61 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.247 -0.433 . . . . 0.0 110.973 179.995 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 20' ' ' GLN . . . . . . . . . . . . . 48.6 mm-40 -104.61 -49.46 3.53 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.877 179.986 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER 61.0 35.75 18.84 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.872 -179.989 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 2.9 tp10 -155.88 -59.51 0.1 Allowed 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.926 179.979 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 100.73 164.75 28.1 Favored Glycine 0 N--CA 1.451 -0.36 0 C-N-CA 120.705 -0.76 . . . . 0.0 112.43 179.99 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -163.08 -169.34 1.99 Allowed 'General case' 0 C--N 1.33 -0.274 0 CA-C-O 120.868 0.366 . . . . 0.0 111.057 179.966 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 1.0 OUTLIER -146.41 -50.85 0.22 Allowed 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.905 -179.992 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -115.97 -178.05 3.31 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.162 -0.472 . . . . 0.0 111.142 179.992 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 27' ' ' GLU . . . . . . . . . . . . . 6.3 mm-40 -142.46 -179.18 6.13 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.935 179.956 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 21.5 t -66.95 123.34 19.8 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.127 -180.0 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 84.7 46.34 5.76 Favored Glycine 0 N--CA 1.451 -0.326 0 C-N-CA 120.767 -0.73 . . . . 0.0 112.529 -179.993 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 4.6 t0 -146.16 134.28 21.59 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 120.879 0.371 . . . . 0.0 110.892 -179.998 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 31' ' ' GLN . . . . . . . . . . . . . 1.9 mt-30 -60.31 139.23 57.74 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.912 179.974 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 19.2 m -145.17 176.02 2.31 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.28 -0.418 . . . . 0.0 111.133 -179.975 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 33' ' ' LEU . . . . . . . . . . . . . 30.4 tp -134.5 100.04 4.53 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.145 -0.48 . . . . 0.0 110.898 179.988 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 21.5 t -69.11 126.58 29.42 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.205 -179.853 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 35' ' ' ALA . . . . . . . . . . . . . . . 57.06 25.34 10.67 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.321 179.941 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . 56.07 35.03 63.04 Favored Glycine 0 N--CA 1.451 -0.33 0 C-N-CA 120.722 -0.751 . . . . 0.0 112.58 179.941 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 37' ' ' GLN . . . . . . . . . . . . . 48.8 mt-30 -147.51 -68.3 0.25 Allowed 'General case' 0 C--N 1.329 -0.295 0 CA-C-O 120.862 0.363 . . . . 0.0 110.949 -179.929 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 38' ' ' LYS . . . . . . . . . . . . . 64.5 mttp -73.77 106.85 5.69 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.919 -179.966 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 39' ' ' GLN . . . . . . . . . . . . . 0.9 OUTLIER -85.16 135.02 34.14 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.923 179.89 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -157.87 -170.43 22.65 Favored Glycine 0 N--CA 1.45 -0.389 0 C-N-CA 120.683 -0.77 . . . . 0.0 112.505 -179.998 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 14.5 mt -126.38 131.54 71.33 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-O 120.842 0.353 . . . . 0.0 111.132 -179.959 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 42' ' ' VAL . . . . . . . . . . . . . 38.2 t -65.52 119.73 10.87 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.02 -179.964 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 43' ' ' ARG . . . . . . . . . . . . . 25.5 mmt180 -104.13 -31.46 9.64 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.259 -0.428 . . . . 0.0 110.966 179.895 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 44' ' ' PHE . . . . . . . . . . . . . 69.2 t80 -143.77 117.52 9.28 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.875 -179.929 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 45' ' ' TYR . . . . . 0.464 ' CE1' ' CZ ' ' A' ' 56' ' ' TYR . 21.5 t80 -113.13 133.82 54.85 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.264 -0.426 . . . . 0.0 110.925 179.988 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 154.17 174.87 24.76 Favored Glycine 0 N--CA 1.451 -0.35 0 C-N-CA 120.799 -0.715 . . . . 0.0 112.523 179.937 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 47' ' ' LYS . . . . . . . . . . . . . 1.9 mmtp -60.06 160.53 7.93 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 120.81 0.338 . . . . 0.0 110.938 -179.996 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 48' ' ' THR . . . . . 0.408 HG22 ' CE2' ' A' ' 50' ' ' PHE . 38.4 p -124.82 -179.09 4.38 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.872 179.938 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -107.65 -34.75 6.9 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.883 -179.989 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 50' ' ' PHE . . . . . 0.435 ' CD1' ' N ' ' A' ' 51' ' ' ALA . 15.9 p90 -63.33 -31.46 72.62 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.154 -0.475 . . . . 0.0 110.986 180.0 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 51' ' ' ALA . . . . . 0.435 ' N ' ' CD1' ' A' ' 50' ' ' PHE . . . -156.27 148.16 17.28 Favored Pre-proline 0 C--N 1.33 -0.244 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.117 -179.999 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 52' ' ' PRO . . . . . . . . . . . . . 58.3 Cg_endo -71.47 162.63 41.68 Favored 'Trans proline' 0 C--N 1.344 0.326 0 C-N-CA 122.624 2.216 . . . . 0.0 112.335 179.987 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 102.28 177.42 27.57 Favored Glycine 0 N--CA 1.45 -0.407 0 C-N-CA 120.769 -0.729 . . . . 0.0 112.501 179.939 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 54' ' ' TYR . . . . . . . . . . . . . 37.1 m-85 -97.22 112.31 24.17 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 120.813 0.34 . . . . 0.0 110.958 179.996 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 55' ' ' TRP . . . . . 0.42 ' CZ3' ' HD3' ' A' ' 88' ' ' PRO . 42.1 m95 -107.93 161.76 14.63 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.898 179.989 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 56' ' ' TYR . . . . . 0.464 ' CZ ' ' CE1' ' A' ' 45' ' ' TYR . 11.3 m-85 -113.61 122.49 47.37 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.26 -0.427 . . . . 0.0 110.918 -179.98 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . -84.19 56.71 5.04 Favored Glycine 0 N--CA 1.45 -0.368 0 C-N-CA 120.801 -0.714 . . . . 0.0 112.511 179.861 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 58' ' ' ILE . . . . . . . . . . . . . 3.7 mt -68.32 137.99 23.39 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-O 120.84 0.352 . . . . 0.0 111.092 -179.937 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 0.8 OUTLIER -101.39 141.55 34.09 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.947 179.998 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 60' ' ' LEU . . . . . . . . . . . . . 59.6 mt -97.78 174.13 6.76 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.883 179.99 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 1.3 t0 -101.55 -30.91 11.12 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.176 -0.466 . . . . 0.0 110.959 179.965 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 62' ' ' GLN . . . . . . . . . . . . . 7.5 mt-30 -104.17 153.16 39.15 Favored Pre-proline 0 C--N 1.33 -0.273 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.912 -179.972 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 66.1 Cg_endo -73.97 65.34 5.07 Favored 'Trans proline' 0 C--N 1.345 0.352 0 C-N-CA 122.576 2.184 . . . . 0.0 112.29 -179.902 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 64' ' ' THR . . . . . . . . . . . . . 3.9 t -148.76 39.38 0.86 Allowed 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.882 179.933 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . -83.64 -99.63 0.57 Allowed Glycine 0 N--CA 1.451 -0.305 0 C-N-CA 120.705 -0.759 . . . . 0.0 112.525 179.906 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 66' ' ' LYS . . . . . . . . . . . . . 5.8 mttt -168.76 -44.69 0.02 OUTLIER 'General case' 0 C--N 1.33 -0.251 0 CA-C-O 120.845 0.355 . . . . 0.0 110.871 179.952 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 67' ' ' HIS . . . . . . . . . . . . . 10.1 p80 -125.5 170.28 11.58 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.903 179.91 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 17.1 t0 -103.49 52.36 0.77 Allowed 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.934 179.951 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 90.55 -75.64 1.65 Allowed Glycine 0 N--CA 1.45 -0.403 0 C-N-CA 120.741 -0.742 . . . . 0.0 112.445 179.982 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 70' ' ' SER . . . . . . . . . . . . . 93.1 p -84.4 154.7 22.67 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-O 120.875 0.369 . . . . 0.0 110.848 179.982 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 21.5 t -129.37 122.69 56.29 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.141 179.993 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 72' ' ' PHE . . . . . . . . . . . . . 37.7 m-85 60.74 30.03 19.42 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.898 179.98 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 96.5 -30.05 9.37 Favored Glycine 0 N--CA 1.451 -0.362 0 C-N-CA 120.759 -0.734 . . . . 0.0 112.573 -179.969 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 28.0 t -79.4 122.61 34.96 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-O 120.833 0.349 . . . . 0.0 111.087 -179.992 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 75' ' ' ARG . . . . . . . . . . . . . 21.8 ttt-85 -91.89 142.99 26.95 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.98 179.948 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 76' ' ' TYR . . . . . . . . . . . . . 24.3 m-85 -118.78 -41.72 2.77 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.271 -0.422 . . . . 0.0 110.869 -179.973 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 77' ' ' PHE . . . . . . . . . . . . . 50.9 p90 -160.29 161.7 33.4 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.828 -179.998 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 3.3 m -89.86 123.51 33.88 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.987 179.865 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 79' ' ' CYS . . . . . . . . . . . . . 30.3 p -145.88 -177.94 5.85 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.885 179.997 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 80' ' ' ALA . . . . . . . . . . . . . . . -92.1 164.47 23.23 Favored Pre-proline 0 C--N 1.329 -0.319 0 CA-C-N 116.2 -0.455 . . . . 0.0 111.124 179.988 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 81' ' ' PRO . . . . . . . . . . . . . 52.9 Cg_exo -52.48 116.29 2.76 Favored 'Trans proline' 0 C--N 1.345 0.344 0 C-N-CA 122.55 2.167 . . . . 0.0 112.275 179.993 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 82' ' ' ARG . . . . . . . . . . . . . 7.3 mtm180 61.9 58.79 1.85 Allowed 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.178 -0.464 . . . . 0.0 110.834 -179.997 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 83' ' ' HIS . . . . . . . . . . . . . 5.6 m170 -128.98 -47.55 1.23 Allowed 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.92 179.925 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . -66.64 147.58 49.82 Favored Glycine 0 N--CA 1.45 -0.4 0 C-N-CA 120.8 -0.714 . . . . 0.0 112.471 179.906 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 85' ' ' VAL . . . . . . . . . . . . . 5.2 m -152.99 123.07 0.82 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-O 120.804 0.335 . . . . 0.0 111.153 179.921 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 86' ' ' PHE . . . . . . . . . . . . . 29.8 m-85 -99.87 121.23 41.01 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.834 -179.938 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 87' ' ' ALA . . . . . . . . . . . . . . . -140.56 147.38 48.94 Favored Pre-proline 0 C--N 1.33 -0.261 0 CA-C-N 116.248 -0.433 . . . . 0.0 111.093 -179.988 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 88' ' ' PRO . . . . . 0.42 ' HD3' ' CZ3' ' A' ' 55' ' ' TRP . 32.4 Cg_exo -57.97 138.33 85.46 Favored 'Trans proline' 0 C--N 1.345 0.388 0 C-N-CA 122.561 2.174 . . . . 0.0 112.258 -179.979 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 89' ' ' ALA . . . . . 0.419 ' HB1' ' CE1' ' A' ' 56' ' ' TYR . . . -47.98 -51.71 22.72 Favored 'General case' 0 C--N 1.332 -0.161 0 CA-C-O 121.137 0.494 . . . . 0.0 110.278 179.84 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 90' ' ' SER . . . . . . . . . . . . . 3.6 t -55.87 -24.45 37.07 Favored 'General case' 0 C--N 1.332 -0.186 0 CA-C-N 115.693 -0.685 . . . . 0.0 109.701 178.826 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 91' ' ' ARG . . . . . 0.416 ' N ' ' O ' ' A' ' 88' ' ' PRO . 0.0 OUTLIER -88.5 -14.35 38.02 Favored 'General case' 0 N--CA 1.454 -0.246 0 CA-C-N 115.911 -0.586 . . . . 0.0 110.49 179.058 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 92' ' ' ILE . . . . . . . . . . . . . 36.3 mt -110.83 156.13 12.05 Favored 'Isoleucine or valine' 0 C--N 1.334 -0.065 0 CA-C-O 120.908 0.385 . . . . 0.0 111.063 179.906 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 93' ' ' GLN . . . . . . . . . . . . . 2.3 mp0 -123.67 173.84 7.84 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.116 -0.493 . . . . 0.0 110.811 179.987 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 94' ' ' ARG . . . . . . . . . . . . . 1.1 mtp180 -115.48 140.02 49.53 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.899 179.968 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 95' ' ' ILE . . . . . . . . . . . . . 21.7 mm -82.22 -39.92 16.75 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 CA-C-N 116.154 -0.476 . . . . 0.0 111.124 179.946 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . -87.15 -178.45 48.75 Favored Glycine 0 N--CA 1.451 -0.324 0 C-N-CA 120.714 -0.755 . . . . 0.0 112.442 -179.985 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 97' ' ' SER . . . . . . . . . . . . . 41.6 m -88.39 -48.17 7.83 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-O 120.871 0.367 . . . . 0.0 110.971 -179.922 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 98' ' ' GLY . . . . . . . . . . . . . . . 143.76 93.7 0.18 Allowed Glycine 0 N--CA 1.45 -0.381 0 C-N-CA 120.713 -0.756 . . . . 0.0 112.472 179.958 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 99' ' ' PRO . . . . . . . . . . . . . 63.5 Cg_exo -51.32 155.09 7.25 Favored 'Trans proline' 0 C--N 1.344 0.303 0 C-N-CA 122.562 2.175 . . . . 0.0 112.394 -179.997 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 100' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -119.53 100.43 7.28 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.895 -179.999 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 40.4 t -166.55 -48.05 0.03 OUTLIER 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.143 -0.48 . . . . 0.0 110.923 -179.922 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.249 1.069 0 CA-C-O 118.346 -1.252 . . . . 0.0 112.479 -179.981 . . . . . . . . 0 0 . 1 . 007 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.189 0 N-CA-C 112.547 -0.221 . . . . 0.0 112.547 . . . . . . . . . 0 0 . 1 . 007 nuclear orig full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 29.1 t -171.44 -49.61 0.02 OUTLIER 'General case' 0 C--N 1.328 -0.34 0 CA-C-O 120.827 0.346 . . . . 0.0 110.968 -179.944 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 1.6 p -141.8 91.45 2.36 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.862 179.991 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -68.43 108.93 2.65 Favored Glycine 0 N--CA 1.451 -0.363 0 C-N-CA 120.694 -0.765 . . . . 0.0 112.428 -179.983 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 0.6 OUTLIER -128.55 -46.85 1.3 Allowed 'General case' 0 C--N 1.329 -0.29 0 CA-C-O 120.827 0.346 . . . . 0.0 110.845 179.993 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 1.8 m -81.57 113.89 19.9 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.911 179.998 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 141.67 53.42 0.04 OUTLIER Glycine 0 N--CA 1.451 -0.34 0 C-N-CA 120.76 -0.733 . . . . 0.0 112.526 -179.983 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 2.8 mmmm -144.69 -179.38 6.54 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 120.744 0.307 . . . . 0.0 110.951 179.967 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 45.9 m -129.39 81.06 70.96 Favored Pre-proline 0 C--N 1.329 -0.31 0 CA-C-N 116.286 -0.415 . . . . 0.0 111.032 -179.957 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 56.7 Cg_endo -70.74 -166.44 0.22 Allowed 'Trans proline' 0 C--N 1.345 0.346 0 C-N-CA 122.634 2.223 . . . . 0.0 112.29 -179.942 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 8.1 t 70.08 -67.57 0.23 Allowed 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.945 179.956 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 15.5 m -162.91 161.91 18.66 Favored Pre-proline 0 C--N 1.329 -0.302 0 CA-C-N 116.371 -0.377 . . . . 0.0 110.967 179.984 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 51.9 Cg_exo -54.37 -171.0 0.02 OUTLIER 'Trans proline' 0 C--N 1.344 0.302 0 C-N-CA 122.553 2.169 . . . . 0.0 112.286 179.937 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 3.5 t -134.48 107.43 7.55 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.899 -179.961 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 4.3 mm? -85.76 -63.45 1.32 Allowed 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.836 179.977 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -145.67 25.08 1.81 Allowed Glycine 0 N--CA 1.451 -0.301 0 C-N-CA 120.77 -0.728 . . . . 0.0 112.579 179.979 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER 58.4 174.33 0.06 Allowed 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 120.767 0.318 . . . . 0.0 110.975 179.963 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 13.3 mt 60.45 46.39 9.82 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.89 179.922 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 19' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -140.51 84.48 1.95 Allowed 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.847 -179.968 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 20' ' ' GLN . . . . . . . . . . . . . 2.5 tp-100 59.66 29.96 19.55 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.925 -179.964 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -144.26 92.13 2.28 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.262 -0.426 . . . . 0.0 110.998 179.98 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -61.74 -70.05 0.21 Allowed 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.264 -0.426 . . . . 0.0 110.852 -179.96 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 73.1 86.84 0.2 Allowed Glycine 0 N--CA 1.451 -0.303 0 C-N-CA 120.734 -0.746 . . . . 0.0 112.554 179.987 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -166.21 145.82 6.06 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 120.758 0.313 . . . . 0.0 111.097 -179.958 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 29.7 mmmt -85.45 -45.12 12.14 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.924 179.946 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -118.97 -174.76 2.77 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.089 179.983 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 27' ' ' GLU . . . . . . . . . . . . . 3.6 mm-40 -135.55 -178.73 5.25 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.841 179.946 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 21.5 t -83.08 104.98 12.42 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.164 -0.471 . . . . 0.0 111.119 179.993 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 107.35 30.58 4.07 Favored Glycine 0 N--CA 1.452 -0.288 0 C-N-CA 120.779 -0.724 . . . . 0.0 112.487 -179.948 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 3.4 m-20 -124.84 144.21 50.42 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 120.793 0.33 . . . . 0.0 110.895 179.952 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 31' ' ' GLN . . . . . . . . . . . . . 5.0 mp0 -65.28 130.4 43.19 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.806 -179.97 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 20.7 m -136.13 175.23 10.95 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 CA-C-N 116.2 -0.454 . . . . 0.0 111.079 179.993 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 33' ' ' LEU . . . . . . . . . . . . . 14.1 tp -139.11 100.06 3.92 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.105 -0.498 . . . . 0.0 110.912 179.98 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 21.5 t -64.5 121.02 12.74 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 116.234 -0.439 . . . . 0.0 111.179 179.991 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 35' ' ' ALA . . . . . . . . . . . . . . . 58.71 26.87 15.14 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.3 179.998 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . 56.66 27.79 55.61 Favored Glycine 0 N--CA 1.451 -0.32 0 C-N-CA 120.779 -0.724 . . . . 0.0 112.601 -179.976 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 37' ' ' GLN . . . . . . . . . . . . . 38.9 mt-30 -139.66 -72.08 0.38 Allowed 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.775 0.321 . . . . 0.0 110.892 -179.993 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 38' ' ' LYS . . . . . . . . . . . . . 55.6 mttt -65.17 114.53 4.73 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.259 -0.428 . . . . 0.0 110.924 179.995 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 39' ' ' GLN . . . . . . . . . . . . . 5.8 tm0? -85.53 130.07 34.67 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.886 179.952 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -157.08 173.56 34.66 Favored Glycine 0 N--CA 1.451 -0.302 0 C-N-CA 120.66 -0.781 . . . . 0.0 112.481 179.993 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 33.5 mt -121.13 133.18 68.56 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 CA-C-O 120.802 0.334 . . . . 0.0 111.033 -179.969 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 42' ' ' VAL . . . . . . . . . . . . . 21.4 t -61.99 121.73 11.06 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.146 -0.479 . . . . 0.0 111.097 179.979 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 43' ' ' ARG . . . . . . . . . . . . . 14.8 mmt180 -108.0 -30.92 8.19 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.903 179.878 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 44' ' ' PHE . . . . . . . . . . . . . 28.9 t80 -149.73 109.57 4.07 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.25 -0.432 . . . . 0.0 110.934 -179.976 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 45' ' ' TYR . . . . . 0.49 ' CE1' ' CZ ' ' A' ' 56' ' ' TYR . 22.7 t80 -106.76 130.5 54.46 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.289 -0.414 . . . . 0.0 110.865 179.964 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 167.02 -161.17 35.02 Favored Glycine 0 N--CA 1.451 -0.35 0 C-N-CA 120.679 -0.772 . . . . 0.0 112.488 -179.976 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 47' ' ' LYS . . . . . . . . . . . . . 40.3 mttt -84.74 175.83 8.93 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 120.748 0.309 . . . . 0.0 110.949 179.94 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 48' ' ' THR . . . . . 0.412 HG22 ' CE2' ' A' ' 50' ' ' PHE . 71.1 p -143.9 -177.42 5.42 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.938 -179.974 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 3.5 t0 -110.8 -35.03 6.08 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.284 -0.416 . . . . 0.0 110.914 -179.961 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 50' ' ' PHE . . . . . 0.438 ' CD1' ' N ' ' A' ' 51' ' ' ALA . 16.1 p90 -60.06 -31.36 69.92 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.917 179.996 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 51' ' ' ALA . . . . . 0.438 ' N ' ' CD1' ' A' ' 50' ' ' PHE . . . -159.84 141.73 9.62 Favored Pre-proline 0 C--N 1.329 -0.319 0 CA-C-N 116.264 -0.426 . . . . 0.0 111.092 179.911 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 52' ' ' PRO . . . . . . . . . . . . . 72.6 Cg_endo -74.77 154.7 43.86 Favored 'Trans proline' 0 C--N 1.346 0.405 0 C-N-CA 122.497 2.131 . . . . 0.0 112.39 179.991 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 121.39 -160.34 15.75 Favored Glycine 0 N--CA 1.45 -0.393 0 C-N-CA 120.752 -0.737 . . . . 0.0 112.555 179.988 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 54' ' ' TYR . . . . . . . . . . . . . 33.4 m-85 -113.2 110.49 20.49 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-O 120.81 0.338 . . . . 0.0 110.887 179.997 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 55' ' ' TRP . . . . . . . . . . . . . 51.2 m95 -112.96 160.5 18.03 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.888 179.955 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 56' ' ' TYR . . . . . 0.49 ' CZ ' ' CE1' ' A' ' 45' ' ' TYR . 4.8 m-85 -118.07 128.13 54.46 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.954 -179.972 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 57' ' ' GLY . . . . . 0.42 ' HA3' ' CE1' ' A' ' 77' ' ' PHE . . . -88.25 59.42 4.14 Favored Glycine 0 N--CA 1.451 -0.305 0 C-N-CA 120.744 -0.741 . . . . 0.0 112.344 179.855 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 58' ' ' ILE . . . . . . . . . . . . . 12.6 mt -68.98 148.55 11.61 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.367 0 CA-C-O 120.864 0.364 . . . . 0.0 111.113 -179.895 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -119.15 120.47 37.18 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.891 179.932 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 60' ' ' LEU . . . . . . . . . . . . . 56.7 mt -71.88 -179.96 2.93 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.852 -179.997 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 21.0 m-20 -104.96 -29.55 10.39 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.283 -0.417 . . . . 0.0 110.935 -179.928 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 62' ' ' GLN . . . . . . . . . . . . . 2.1 mt-30 -114.87 147.95 39.39 Favored Pre-proline 0 C--N 1.329 -0.31 0 CA-C-N 116.312 -0.404 . . . . 0.0 110.871 -179.907 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 36.6 Cg_exo -60.02 91.2 0.08 OUTLIER 'Trans proline' 0 C--N 1.345 0.391 0 C-N-CA 122.515 2.143 . . . . 0.0 112.264 179.924 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 64' ' ' THR . . . . . . . . . . . . . 10.1 t -172.72 39.22 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.271 -0.422 . . . . 0.0 110.992 -179.994 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . -91.37 -104.84 1.38 Allowed Glycine 0 N--CA 1.451 -0.3 0 C-N-CA 120.695 -0.764 . . . . 0.0 112.459 -179.979 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 66' ' ' LYS . . . . . . . . . . . . . 3.0 mtmt -159.99 -49.3 0.05 Allowed 'General case' 0 C--N 1.328 -0.336 0 CA-C-O 120.795 0.331 . . . . 0.0 110.791 -179.992 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 67' ' ' HIS . . . . . . . . . . . . . 7.5 p80 -128.92 171.96 11.8 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.244 -0.435 . . . . 0.0 110.868 -179.937 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 16.8 t0 -98.18 32.47 2.44 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.255 -0.43 . . . . 0.0 110.88 179.926 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 95.4 -41.47 2.48 Favored Glycine 0 N--CA 1.451 -0.32 0 C-N-CA 120.73 -0.748 . . . . 0.0 112.506 -179.936 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 70' ' ' SER . . . . . . . . . . . . . 99.2 p -98.85 126.51 44.52 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 120.762 0.315 . . . . 0.0 110.978 179.976 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 21.5 t -112.88 114.27 46.49 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.354 0 CA-C-N 116.198 -0.456 . . . . 0.0 111.114 -179.908 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 72' ' ' PHE . . . . . . . . . . . . . 14.7 m-85 61.49 30.77 18.96 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.917 -179.976 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 98.42 -29.75 10.87 Favored Glycine 0 N--CA 1.452 -0.288 0 C-N-CA 120.741 -0.742 . . . . 0.0 112.511 179.985 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 21.5 t -77.2 124.22 35.22 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-O 120.752 0.311 . . . . 0.0 111.111 -179.978 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 75' ' ' ARG . . . . . . . . . . . . . 10.3 ttt180 -104.71 136.76 43.63 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.939 179.996 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 76' ' ' TYR . . . . . . . . . . . . . 36.3 m-85 -112.84 -43.47 3.42 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.965 179.963 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 77' ' ' PHE . . . . . 0.42 ' CE1' ' HA3' ' A' ' 57' ' ' GLY . 40.9 p90 -153.29 165.06 36.91 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.935 -179.995 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 2.6 t -93.6 121.62 35.2 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.176 -0.466 . . . . 0.0 110.853 -179.994 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 79' ' ' CYS . . . . . . . . . . . . . 10.0 p -142.45 154.2 44.35 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.22 -0.445 . . . . 0.0 111.002 -179.98 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 80' ' ' ALA . . . . . . . . . . . . . . . -58.94 165.45 3.35 Favored Pre-proline 0 C--N 1.328 -0.34 0 CA-C-N 116.166 -0.47 . . . . 0.0 111.025 179.956 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 81' ' ' PRO . . . . . . . . . . . . . 17.9 Cg_endo -59.6 115.94 2.95 Favored 'Trans proline' 0 C--N 1.344 0.332 0 C-N-CA 122.53 2.153 . . . . 0.0 112.095 179.985 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 82' ' ' ARG . . . . . . . . . . . . . 57.1 mtp180 63.96 55.36 1.59 Allowed 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.812 -179.883 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 83' ' ' HIS . . . . . . . . . . . . . 6.4 m170 -126.75 -47.43 1.54 Allowed 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.907 179.97 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . -59.04 142.41 46.51 Favored Glycine 0 N--CA 1.452 -0.261 0 C-N-CA 120.738 -0.744 . . . . 0.0 112.511 -179.99 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 85' ' ' VAL . . . . . . . . . . . . . 5.3 m -146.86 115.91 1.29 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.272 0 CA-C-O 120.804 0.335 . . . . 0.0 111.113 179.955 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 86' ' ' PHE . . . . . . . . . . . . . 10.4 m-85 -93.41 124.95 37.75 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.862 179.936 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 87' ' ' ALA . . . . . . . . . . . . . . . -144.55 144.86 26.46 Favored Pre-proline 0 C--N 1.329 -0.303 0 CA-C-N 116.27 -0.423 . . . . 0.0 111.101 179.93 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 88' ' ' PRO . . . . . 0.424 ' O ' ' N ' ' A' ' 91' ' ' ARG . 31.9 Cg_exo -58.38 142.13 97.51 Favored 'Trans proline' 0 C--N 1.345 0.387 0 C-N-CA 122.429 2.086 . . . . 0.0 112.243 179.956 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -47.58 -51.84 19.72 Favored 'General case' 0 C--N 1.333 -0.114 0 CA-C-O 121.088 0.471 . . . . 0.0 110.388 179.983 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 90' ' ' SER . . . . . . . . . . . . . 64.3 m -55.88 -24.29 36.28 Favored 'General case' 0 C--N 1.331 -0.235 0 CA-C-N 115.701 -0.681 . . . . 0.0 109.81 178.839 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 91' ' ' ARG . . . . . 0.424 ' N ' ' O ' ' A' ' 88' ' ' PRO . 0.5 OUTLIER -89.33 -13.83 37.06 Favored 'General case' 0 N--CA 1.455 -0.197 0 CA-C-N 115.876 -0.602 . . . . 0.0 110.484 179.095 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 92' ' ' ILE . . . . . . . . . . . . . 46.8 mt -109.92 141.11 26.17 Favored 'Isoleucine or valine' 0 C--O 1.231 0.126 0 CA-C-N 116.493 -0.321 . . . . 0.0 111.034 179.883 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 93' ' ' GLN . . . . . . . . . . . . . 1.4 mt-30 -107.72 171.45 7.38 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.816 179.992 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 94' ' ' ARG . . . . . . . . . . . . . 5.5 ttt180 -122.1 125.58 46.51 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.919 179.982 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 95' ' ' ILE . . . . . . . . . . . . . 5.5 mt -96.32 -58.25 3.9 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.273 -0.421 . . . . 0.0 111.037 -179.965 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . 66.6 62.7 4.37 Favored Glycine 0 N--CA 1.451 -0.311 0 C-N-CA 120.78 -0.724 . . . . 0.0 112.434 -179.992 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 97' ' ' SER . . . . . . . . . . . . . 50.6 p -108.49 158.09 17.85 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-O 120.868 0.366 . . . . 0.0 110.869 179.993 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 98' ' ' GLY . . . . . . . . . . . . . . . 140.51 -178.47 19.96 Favored Glycine 0 N--CA 1.451 -0.311 0 C-N-CA 120.739 -0.743 . . . . 0.0 112.513 179.995 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 99' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_exo -52.26 171.16 0.2 Allowed 'Trans proline' 0 C--N 1.345 0.351 0 C-N-CA 122.59 2.193 . . . . 0.0 112.28 -179.947 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 100' ' ' SER . . . . . . . . . . . . . 8.6 t -155.54 -61.43 0.11 Allowed 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.93 179.981 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 62.9 m -148.58 175.72 10.93 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.218 -0.447 . . . . 0.0 110.876 179.978 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.249 1.083 0 CA-C-O 118.357 -1.246 . . . . 0.0 112.531 179.981 . . . . . . . . 0 0 . 1 . 008 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.488 2.15 0 N-CA-C 112.57 -0.212 . . . . 0.0 112.57 . . . . . . . . . 0 0 . 1 . 008 nuclear orig full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 64.0 m -139.4 142.45 37.5 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-O 120.823 0.344 . . . . 0.0 110.902 -179.982 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -102.62 98.43 8.48 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.945 179.945 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -71.31 -173.05 15.25 Favored Glycine 0 N--CA 1.451 -0.338 0 C-N-CA 120.797 -0.716 . . . . 0.0 112.478 -179.985 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -167.52 167.16 13.82 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-O 120.827 0.346 . . . . 0.0 110.946 -179.934 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 36.2 p -105.73 -53.51 2.63 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.863 -179.994 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -125.04 -77.11 0.29 Allowed Glycine 0 N--CA 1.452 -0.293 0 C-N-CA 120.726 -0.75 . . . . 0.0 112.425 179.985 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 8.0 pttt -128.75 -54.61 1.23 Allowed 'General case' 0 C--N 1.329 -0.299 0 CA-C-O 120.784 0.326 . . . . 0.0 110.85 179.919 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER 53.87 85.97 0.18 Allowed Pre-proline 0 C--N 1.329 -0.297 0 CA-C-N 116.227 -0.442 . . . . 0.0 111.054 179.861 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 52.1 Cg_exo -52.82 89.31 0.03 OUTLIER 'Trans proline' 0 C--N 1.345 0.344 0 C-N-CA 122.551 2.167 . . . . 0.0 112.254 179.987 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 20.9 m -139.52 -54.67 0.56 Allowed 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.268 -0.424 . . . . 0.0 110.923 -179.961 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 87.1 p -140.25 154.24 69.73 Favored Pre-proline 0 C--N 1.329 -0.287 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.846 179.973 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 53.2 Cg_endo -69.54 86.9 0.54 Allowed 'Trans proline' 0 C--N 1.345 0.39 0 C-N-CA 122.551 2.167 . . . . 0.0 112.24 -179.994 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -119.52 136.7 54.23 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.274 -0.421 . . . . 0.0 110.887 179.979 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 1.6 mt -165.48 -171.13 2.03 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.776 -179.995 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -55.17 106.42 0.55 Allowed Glycine 0 N--CA 1.452 -0.263 0 C-N-CA 120.796 -0.716 . . . . 0.0 112.588 179.949 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -59.4 108.39 0.7 Allowed 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 120.892 0.377 . . . . 0.0 110.944 -179.952 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 6.8 mt -112.34 -35.37 5.61 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.857 179.964 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 19' ' ' GLN . . . . . . . . . . . . . 4.3 mt-30 -65.83 136.15 55.8 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.833 -179.958 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 20' ' ' GLN . . . . . . . . . . . . . 4.1 tt0 -144.33 -47.4 0.26 Allowed 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.896 179.958 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 0.9 OUTLIER -103.64 117.01 33.42 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.18 -0.463 . . . . 0.0 110.839 179.989 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 8.4 mp0 -113.72 -62.48 1.59 Allowed 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.876 179.919 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 106.22 -59.93 0.39 Allowed Glycine 0 N--CA 1.451 -0.33 0 C-N-CA 120.715 -0.755 . . . . 0.0 112.496 179.995 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -78.49 129.67 35.13 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-O 120.826 0.346 . . . . 0.0 111.116 -179.932 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -87.6 -64.19 1.19 Allowed 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.865 -179.987 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -98.83 179.85 4.52 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.185 -0.461 . . . . 0.0 111.16 179.941 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 27' ' ' GLU . . . . . . . . . . . . . 5.6 mp0 -130.46 177.87 7.03 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.886 -179.96 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 26.9 t -64.9 92.21 0.11 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.231 -0.44 . . . . 0.0 111.132 179.95 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 114.86 41.86 0.82 Allowed Glycine 0 N--CA 1.452 -0.251 0 C-N-CA 120.746 -0.74 . . . . 0.0 112.403 -179.928 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 37.5 t70 -134.93 144.14 47.3 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-O 120.841 0.353 . . . . 0.0 110.945 179.979 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 31' ' ' GLN . . . . . . . . . . . . . 2.4 mp0 -64.43 134.98 55.61 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.254 -0.43 . . . . 0.0 110.811 -179.996 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 13.7 m -147.96 173.41 1.99 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.358 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.21 179.981 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 33' ' ' LEU . . . . . . . . . . . . . 15.0 tp -134.32 108.53 8.26 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.222 -0.444 . . . . 0.0 110.899 -179.969 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 26.0 t -73.74 122.59 27.11 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.115 179.967 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 35' ' ' ALA . . . . . . . . . . . . . . . 59.13 25.2 13.65 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.117 -0.492 . . . . 0.0 111.194 -179.992 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . 55.27 27.49 46.97 Favored Glycine 0 N--CA 1.452 -0.253 0 C-N-CA 120.779 -0.724 . . . . 0.0 112.592 179.938 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 37' ' ' GLN . . . . . . . . . . . . . 12.8 mt-30 -141.87 -63.05 0.45 Allowed 'General case' 0 C--N 1.329 -0.286 0 CA-C-O 120.781 0.324 . . . . 0.0 110.876 -179.988 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 38' ' ' LYS . . . . . . . . . . . . . 11.4 mttp -71.26 111.97 7.03 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.25 -0.432 . . . . 0.0 110.889 179.989 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 39' ' ' GLN . . . . . . . . . . . . . 0.9 OUTLIER -82.27 131.24 35.23 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.854 -179.991 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -163.28 179.06 38.67 Favored Glycine 0 N--CA 1.451 -0.336 0 C-N-CA 120.775 -0.726 . . . . 0.0 112.504 -179.994 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 28.0 mt -128.63 137.74 56.49 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-O 120.842 0.354 . . . . 0.0 111.125 179.929 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 42' ' ' VAL . . . . . . . . . . . . . 21.5 t -62.19 127.16 21.68 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-N 116.174 -0.467 . . . . 0.0 111.161 -179.997 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 43' ' ' ARG . . . . . . . . . . . . . 10.1 mmt180 -111.76 -34.67 5.96 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.909 179.955 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 44' ' ' PHE . . . . . . . . . . . . . 39.4 t80 -143.52 112.28 6.53 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.897 -179.988 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 45' ' ' TYR . . . . . 0.485 ' CE1' ' CZ ' ' A' ' 56' ' ' TYR . 12.9 t80 -105.39 122.29 45.68 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.919 179.932 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 166.02 173.13 34.16 Favored Glycine 0 N--CA 1.452 -0.265 0 C-N-CA 120.757 -0.735 . . . . 0.0 112.485 179.953 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 47' ' ' LYS . . . . . . . . . . . . . 14.5 mttm -70.15 155.46 40.6 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 120.842 0.353 . . . . 0.0 110.911 -179.995 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 48' ' ' THR . . . . . 0.407 ' HB ' ' CE1' ' A' ' 50' ' ' PHE . 42.8 p -118.12 -177.75 3.35 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.13 -0.486 . . . . 0.0 110.874 179.969 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 4.8 t0 -105.98 -30.75 9.12 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.922 179.98 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 50' ' ' PHE . . . . . 0.407 ' CE1' ' HB ' ' A' ' 48' ' ' THR . 53.8 p90 -71.02 -40.75 71.58 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.941 -179.95 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 51' ' ' ALA . . . . . . . . . . . . . . . -137.0 144.47 46.5 Favored Pre-proline 0 C--N 1.329 -0.294 0 CA-C-N 116.187 -0.461 . . . . 0.0 111.211 -179.934 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 52' ' ' PRO . . . . . . . . . . . . . 73.3 Cg_endo -76.16 169.76 21.4 Favored 'Trans proline' 0 C--N 1.345 0.357 0 C-N-CA 122.54 2.16 . . . . 0.0 112.366 -179.975 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 90.39 178.78 44.07 Favored Glycine 0 N--CA 1.452 -0.294 0 C-N-CA 120.738 -0.744 . . . . 0.0 112.464 179.906 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 54' ' ' TYR . . . . . . . . . . . . . 14.1 m-85 -91.17 115.7 28.23 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-O 120.813 0.34 . . . . 0.0 110.935 179.977 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 55' ' ' TRP . . . . . . . . . . . . . 73.8 m95 -109.91 147.22 33.8 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.89 179.973 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 56' ' ' TYR . . . . . 0.485 ' CZ ' ' CE1' ' A' ' 45' ' ' TYR . 8.1 m-85 -104.62 120.98 42.57 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.966 -179.89 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 57' ' ' GLY . . . . . 0.445 ' N ' ' CE1' ' A' ' 86' ' ' PHE . . . -80.72 62.78 4.34 Favored Glycine 0 N--CA 1.451 -0.325 0 C-N-CA 120.758 -0.734 . . . . 0.0 112.365 179.929 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 58' ' ' ILE . . . . . . . . . . . . . 21.6 mt -70.76 138.94 20.84 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-O 120.866 0.365 . . . . 0.0 111.141 -179.906 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -109.13 130.63 55.48 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.877 -179.97 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 60' ' ' LEU . . . . . . . . . . . . . 84.2 mt -85.54 173.21 10.37 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.871 179.959 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 1.5 t70 -103.11 -31.03 10.36 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.943 -179.961 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 62' ' ' GLN . . . . . . . . . . . . . 2.4 mm-40 -114.43 147.81 38.82 Favored Pre-proline 0 C--N 1.33 -0.272 0 CA-C-N 116.298 -0.41 . . . . 0.0 110.911 -179.986 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 31.9 Cg_exo -58.24 84.32 0.05 OUTLIER 'Trans proline' 0 C--N 1.346 0.399 0 C-N-CA 122.564 2.176 . . . . 0.0 112.25 179.928 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 64' ' ' THR . . . . . . . . . . . . . 13.4 t -157.0 35.02 0.29 Allowed 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.297 -0.411 . . . . 0.0 110.946 179.988 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . -95.96 -159.98 32.65 Favored Glycine 0 N--CA 1.452 -0.292 0 C-N-CA 120.745 -0.741 . . . . 0.0 112.503 179.911 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 66' ' ' LYS . . . . . . . . . . . . . 0.5 OUTLIER -110.03 -31.31 7.42 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 120.861 0.363 . . . . 0.0 110.922 179.977 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 67' ' ' HIS . . . . . . . . . . . . . 13.1 p80 -145.96 -178.74 6.28 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.877 -179.975 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 26.6 t0 -114.87 73.08 0.81 Allowed 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.944 179.986 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 79.41 -72.75 2.47 Favored Glycine 0 N--CA 1.451 -0.352 0 C-N-CA 120.761 -0.733 . . . . 0.0 112.476 -179.982 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 70' ' ' SER . . . . . . . . . . . . . 97.2 p -86.62 151.5 23.39 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-O 120.841 0.353 . . . . 0.0 110.907 -179.981 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 71' ' ' VAL . . . . . 0.411 HG13 ' CD2' ' A' ' 72' ' ' PHE . 21.5 t -128.03 117.9 47.08 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.162 -0.472 . . . . 0.0 111.095 179.977 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 72' ' ' PHE . . . . . 0.411 ' CD2' HG13 ' A' ' 71' ' ' VAL . 59.8 m-85 60.91 31.12 19.98 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.879 179.962 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 99.74 -30.0 10.9 Favored Glycine 0 N--CA 1.452 -0.281 0 C-N-CA 120.687 -0.768 . . . . 0.0 112.563 179.984 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 21.3 t -75.66 116.35 18.45 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-O 120.888 0.375 . . . . 0.0 111.093 179.981 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 75' ' ' ARG . . . . . . . . . . . . . 26.2 ttt85 -93.83 148.03 22.51 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.858 179.969 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 76' ' ' TYR . . . . . 0.404 ' CZ ' HG22 ' A' ' 48' ' ' THR . 89.9 m-85 -133.24 -47.69 0.84 Allowed 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.165 -0.471 . . . . 0.0 110.948 179.946 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 77' ' ' PHE . . . . . . . . . . . . . 22.5 p90 -155.2 154.67 32.6 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.9 -179.979 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 9.0 t -84.6 140.7 31.19 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.169 -0.468 . . . . 0.0 110.847 179.955 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 79' ' ' CYS . . . . . . . . . . . . . 22.7 p -164.7 162.39 21.25 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.922 179.921 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 80' ' ' ALA . . . . . . . . . . . . . . . -59.24 166.16 3.12 Favored Pre-proline 0 C--N 1.33 -0.254 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.002 179.949 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 81' ' ' PRO . . . . . . . . . . . . . 28.1 Cg_endo -62.66 122.63 11.05 Favored 'Trans proline' 0 C--N 1.346 0.397 0 C-N-CA 122.468 2.112 . . . . 0.0 112.253 -180.0 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 82' ' ' ARG . . . . . . . . . . . . . 0.5 OUTLIER 61.01 53.36 3.72 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.91 -179.875 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 83' ' ' HIS . . . . . . . . . . . . . 7.4 m170 -123.21 -45.54 2.1 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.11 -0.495 . . . . 0.0 110.85 179.958 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . -59.8 146.01 45.09 Favored Glycine 0 N--CA 1.451 -0.341 0 C-N-CA 120.646 -0.788 . . . . 0.0 112.501 -179.971 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 85' ' ' VAL . . . . . . . . . . . . . 6.1 m -150.04 114.88 0.67 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-O 120.815 0.34 . . . . 0.0 111.098 -179.938 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 86' ' ' PHE . . . . . 0.445 ' CE1' ' N ' ' A' ' 57' ' ' GLY . 3.7 m-85 -97.53 108.29 20.98 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.929 179.998 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 87' ' ' ALA . . . . . . . . . . . . . . . -128.5 145.4 55.79 Favored Pre-proline 0 C--N 1.328 -0.344 0 CA-C-N 116.233 -0.439 . . . . 0.0 111.139 179.982 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 88' ' ' PRO . . . . . 0.417 ' O ' ' N ' ' A' ' 91' ' ' ARG . 32.3 Cg_exo -57.96 142.57 96.66 Favored 'Trans proline' 0 C--N 1.345 0.362 0 C-N-CA 122.519 2.146 . . . . 0.0 112.259 -179.984 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 89' ' ' ALA . . . . . 0.424 ' HB1' ' CE1' ' A' ' 56' ' ' TYR . . . -47.85 -51.18 23.93 Favored 'General case' 0 CA--C 1.521 -0.141 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.329 179.872 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 90' ' ' SER . . . . . . . . . . . . . 23.6 t -55.83 -24.4 36.24 Favored 'General case' 0 N--CA 1.454 -0.266 0 CA-C-N 115.747 -0.661 . . . . 0.0 109.815 178.76 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 91' ' ' ARG . . . . . 0.417 ' N ' ' O ' ' A' ' 88' ' ' PRO . 0.0 OUTLIER -89.37 -14.14 36.24 Favored 'General case' 0 N--CA 1.455 -0.215 0 CA-C-N 115.932 -0.576 . . . . 0.0 110.513 179.04 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 92' ' ' ILE . . . . . . . . . . . . . 48.9 mt -105.85 156.59 6.62 Favored 'Isoleucine or valine' 0 C--O 1.231 0.12 0 CA-C-N 116.396 -0.365 . . . . 0.0 110.971 179.753 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 93' ' ' GLN . . . . . . . . . . . . . 50.8 mt-30 -121.42 175.0 6.4 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.262 -0.426 . . . . 0.0 110.881 -179.979 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 94' ' ' ARG . . . . . . . . . . . . . 0.6 OUTLIER -122.03 110.41 15.76 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.855 -179.972 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 95' ' ' ILE . . . . . . . . . . . . . 32.5 mt -83.0 -32.32 9.54 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.262 -0.427 . . . . 0.0 111.073 179.97 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . -64.75 -141.8 0.02 OUTLIER Glycine 0 N--CA 1.451 -0.367 0 C-N-CA 120.783 -0.723 . . . . 0.0 112.541 179.95 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 97' ' ' SER . . . . . . . . . . . . . 5.5 m 60.23 92.44 0.05 OUTLIER 'General case' 0 C--N 1.328 -0.331 0 CA-C-O 120.862 0.363 . . . . 0.0 110.927 179.984 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 98' ' ' GLY . . . . . . . . . . . . . . . 107.62 151.98 17.27 Favored Glycine 0 N--CA 1.452 -0.297 0 C-N-CA 120.725 -0.75 . . . . 0.0 112.517 179.919 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 99' ' ' PRO . . . . . . . . . . . . . 55.4 Cg_endo -69.84 93.74 0.53 Allowed 'Trans proline' 0 C--N 1.345 0.347 0 C-N-CA 122.562 2.175 . . . . 0.0 112.3 179.962 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 100' ' ' SER . . . . . . . . . . . . . 10.7 t -72.07 139.35 48.41 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.883 -179.947 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -77.1 -173.74 2.89 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.913 179.99 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.248 1.007 0 CA-C-O 118.365 -1.242 . . . . 0.0 112.49 179.953 . . . . . . . . 0 0 . 1 . 009 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.267 0 N-CA-C 112.529 -0.228 . . . . 0.0 112.529 . . . . . . . . . 0 0 . 1 . 009 nuclear orig full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 1.3 m -173.15 140.3 0.86 Allowed 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 120.871 0.367 . . . . 0.0 110.925 179.952 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 2.9 p -142.96 159.76 41.64 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.899 -179.982 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 158.44 45.8 0.01 OUTLIER Glycine 0 N--CA 1.451 -0.34 0 C-N-CA 120.777 -0.725 . . . . 0.0 112.515 -179.919 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -105.82 136.66 45.05 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 120.724 0.297 . . . . 0.0 110.926 -179.962 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -60.98 110.19 1.28 Allowed 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.864 179.994 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 140.68 154.41 6.23 Favored Glycine 0 N--CA 1.45 -0.38 0 C-N-CA 120.776 -0.726 . . . . 0.0 112.52 -179.994 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 7.6 mttt -142.71 83.18 1.8 Allowed 'General case' 0 C--N 1.328 -0.331 0 CA-C-O 120.847 0.356 . . . . 0.0 110.921 179.975 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 1.5 t -149.34 88.35 5.05 Favored Pre-proline 0 C--N 1.329 -0.316 0 CA-C-N 116.213 -0.448 . . . . 0.0 110.931 -179.993 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 49.8 Cg_endo -68.8 -28.06 30.61 Favored 'Trans proline' 0 C--N 1.345 0.358 0 C-N-CA 122.547 2.165 . . . . 0.0 112.321 179.954 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 53.2 p -82.05 128.05 33.71 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.883 -179.985 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 2.6 m -77.34 150.44 80.0 Favored Pre-proline 0 C--N 1.329 -0.3 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.878 -179.952 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_exo -52.2 -51.53 10.93 Favored 'Trans proline' 0 C--N 1.345 0.367 0 C-N-CA 122.62 2.214 . . . . 0.0 112.249 -179.96 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 1.2 m -136.2 170.5 15.92 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.275 -0.421 . . . . 0.0 110.902 179.996 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 0.6 OUTLIER -162.99 33.25 0.1 Allowed 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.211 -0.449 . . . . 0.0 110.831 -179.995 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 122.95 40.53 0.48 Allowed Glycine 0 N--CA 1.452 -0.28 0 C-N-CA 120.768 -0.73 . . . . 0.0 112.478 179.978 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 1.1 m -80.12 -42.8 22.82 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 120.733 0.302 . . . . 0.0 110.847 -179.935 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -109.9 38.96 2.24 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.884 -179.974 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 19' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -97.43 107.53 20.05 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.145 -0.48 . . . . 0.0 110.875 -179.99 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 20' ' ' GLN . . . . . . . . . . . . . 3.6 mm-40 60.31 32.37 20.7 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.114 -0.493 . . . . 0.0 110.909 179.926 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 1.0 OUTLIER -166.79 169.91 12.86 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.145 -0.48 . . . . 0.0 110.903 179.904 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 0.2 OUTLIER -111.64 165.73 11.77 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.264 -0.426 . . . . 0.0 110.899 179.989 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -112.78 112.33 2.95 Favored Glycine 0 N--CA 1.451 -0.354 0 C-N-CA 120.701 -0.762 . . . . 0.0 112.537 179.882 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -88.31 136.37 33.01 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-O 120.813 0.34 . . . . 0.0 111.125 179.94 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -91.56 -45.14 8.66 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.034 -179.986 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -108.98 166.25 10.97 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.215 -0.448 . . . . 0.0 111.106 179.981 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 27' ' ' GLU . . . . . . . . . . . . . 8.8 mt-10 -125.01 167.74 14.3 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.251 -0.431 . . . . 0.0 110.885 179.992 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 28.3 t -70.55 100.41 0.73 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 CA-C-N 116.165 -0.471 . . . . 0.0 111.077 -179.963 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 116.94 39.68 0.8 Allowed Glycine 0 N--CA 1.451 -0.334 0 C-N-CA 120.692 -0.766 . . . . 0.0 112.504 -179.977 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 1.8 m-20 -142.35 146.94 35.51 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-O 120.836 0.35 . . . . 0.0 110.89 -179.992 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 31' ' ' GLN . . . . . . . . . . . . . 77.1 mt-30 -59.96 136.26 57.96 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.861 179.966 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 5.8 m -148.91 162.46 5.01 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.129 179.968 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 33' ' ' LEU . . . . . . . . . . . . . 20.5 tp -130.23 104.96 7.6 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.825 -179.956 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 21.7 t -72.98 125.01 31.09 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-N 116.178 -0.464 . . . . 0.0 111.263 -179.955 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 35' ' ' ALA . . . . . . . . . . . . . . . 57.17 25.88 11.48 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.169 -0.469 . . . . 0.0 111.24 179.914 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . 56.54 32.01 60.74 Favored Glycine 0 N--CA 1.452 -0.244 0 C-N-CA 120.726 -0.749 . . . . 0.0 112.613 179.971 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 37' ' ' GLN . . . . . . . . . . . . . 29.9 mt-30 -142.2 -66.71 0.39 Allowed 'General case' 0 C--N 1.329 -0.284 0 CA-C-O 120.781 0.324 . . . . 0.0 110.975 179.96 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 38' ' ' LYS . . . . . . . . . . . . . 25.1 mmtp -72.95 112.22 8.78 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.244 -0.434 . . . . 0.0 110.902 -179.957 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 39' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -92.62 130.28 38.3 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.891 -179.967 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -161.16 -169.41 24.38 Favored Glycine 0 N--CA 1.451 -0.324 0 C-N-CA 120.749 -0.739 . . . . 0.0 112.56 179.977 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 8.9 mt -128.62 132.71 67.58 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-O 120.769 0.319 . . . . 0.0 111.087 -179.993 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 42' ' ' VAL . . . . . . . . . . . . . 21.5 t -59.53 125.2 15.2 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.361 0 CA-C-N 116.2 -0.454 . . . . 0.0 111.153 179.932 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 43' ' ' ARG . . . . . . . . . . . . . 10.1 mmt180 -110.51 -32.52 6.88 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.882 -179.954 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 44' ' ' PHE . . . . . . . . . . . . . 86.9 t80 -144.4 113.73 7.0 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.909 -179.995 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 45' ' ' TYR . . . . . 0.439 ' CE1' ' CZ ' ' A' ' 56' ' ' TYR . 27.1 t80 -113.15 111.73 22.6 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.925 179.989 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . -169.52 -150.38 6.76 Favored Glycine 0 N--CA 1.45 -0.391 0 C-N-CA 120.808 -0.711 . . . . 0.0 112.545 179.984 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 47' ' ' LYS . . . . . 0.416 ' HD3' ' CE1' ' A' ' 54' ' ' TYR . 2.2 mmmp? -96.77 168.84 10.26 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.792 0.33 . . . . 0.0 110.879 -179.93 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 48' ' ' THR . . . . . 0.416 HG22 ' CE2' ' A' ' 50' ' ' PHE . 64.6 p -132.43 178.15 7.05 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.837 179.947 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 32.3 t70 -112.55 -35.41 5.55 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.961 -179.975 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 50' ' ' PHE . . . . . 0.422 ' CE1' ' HB2' ' A' ' 51' ' ' ALA . 30.1 p90 -62.73 -31.04 71.9 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.949 -179.942 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 51' ' ' ALA . . . . . 0.422 ' HB2' ' CE1' ' A' ' 50' ' ' PHE . . . -151.74 151.96 29.38 Favored Pre-proline 0 C--N 1.329 -0.299 0 CA-C-N 116.237 -0.438 . . . . 0.0 111.107 -179.962 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 52' ' ' PRO . . . . . . . . . . . . . 58.2 Cg_endo -71.58 -176.89 2.17 Favored 'Trans proline' 0 C--N 1.345 0.347 0 C-N-CA 122.559 2.173 . . . . 0.0 112.3 179.928 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 75.12 -177.07 48.92 Favored Glycine 0 N--CA 1.451 -0.348 0 C-N-CA 120.756 -0.735 . . . . 0.0 112.54 -179.922 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 54' ' ' TYR . . . . . 0.416 ' CE1' ' HD3' ' A' ' 47' ' ' LYS . 10.1 m-85 -107.8 132.45 53.4 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 120.815 0.34 . . . . 0.0 110.916 179.994 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 55' ' ' TRP . . . . . 0.423 ' CZ3' ' HD3' ' A' ' 88' ' ' PRO . 19.0 m95 -120.07 173.31 7.16 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.852 -179.989 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 56' ' ' TYR . . . . . 0.439 ' CZ ' ' CE1' ' A' ' 45' ' ' TYR . 10.8 m-85 -117.21 127.51 54.17 Favored 'General case' 0 C--N 1.331 -0.235 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.948 -179.904 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . -90.6 65.12 2.76 Favored Glycine 0 N--CA 1.45 -0.426 0 C-N-CA 120.746 -0.74 . . . . 0.0 112.426 -179.998 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 58' ' ' ILE . . . . . . . . . . . . . 25.3 mt -71.64 139.43 19.82 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-O 120.779 0.323 . . . . 0.0 111.135 -179.928 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 0.2 OUTLIER -108.49 111.0 22.64 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.826 -179.965 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 60' ' ' LEU . . . . . . . . . . . . . 63.2 mt -63.93 167.89 5.73 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.308 -0.406 . . . . 0.0 110.846 -179.969 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -96.84 -26.1 15.23 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.947 -179.995 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 62' ' ' GLN . . . . . . . . . . . . . 64.9 mm-40 -124.26 152.36 67.56 Favored Pre-proline 0 C--N 1.329 -0.284 0 CA-C-N 116.369 -0.378 . . . . 0.0 110.908 -179.895 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 63' ' ' PRO . . . . . 0.408 ' HA ' ' CD2' ' A' ' 83' ' ' HIS . 32.2 Cg_exo -58.19 92.52 0.06 OUTLIER 'Trans proline' 0 C--N 1.346 0.401 0 C-N-CA 122.579 2.186 . . . . 0.0 112.293 179.954 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 64' ' ' THR . . . . . . . . . . . . . 13.4 t -165.74 36.49 0.05 Allowed 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 116.283 -0.417 . . . . 0.0 110.932 179.873 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . -99.12 -140.11 11.26 Favored Glycine 0 N--CA 1.451 -0.344 0 C-N-CA 120.78 -0.724 . . . . 0.0 112.442 -179.993 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 66' ' ' LYS . . . . . . . . . . . . . 1.7 mttm -132.21 -46.55 0.92 Allowed 'General case' 0 C--N 1.328 -0.34 0 CA-C-O 120.822 0.344 . . . . 0.0 110.87 179.97 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 67' ' ' HIS . . . . . . . . . . . . . 12.4 p80 -127.27 174.69 8.75 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.233 -0.44 . . . . 0.0 110.92 179.901 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 1.6 m-20 -98.46 48.68 0.98 Allowed 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.928 179.998 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 84.44 -61.51 4.7 Favored Glycine 0 N--CA 1.451 -0.31 0 C-N-CA 120.715 -0.755 . . . . 0.0 112.486 -179.997 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 70' ' ' SER . . . . . . . . . . . . . 31.4 p -80.26 152.15 29.22 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-O 120.774 0.321 . . . . 0.0 110.802 -179.992 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 21.5 t -134.32 118.08 26.42 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.111 179.982 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 72' ' ' PHE . . . . . . . . . . . . . 28.8 m-85 60.58 31.05 20.16 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.884 179.937 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 98.35 -28.41 14.94 Favored Glycine 0 N--CA 1.451 -0.316 0 C-N-CA 120.741 -0.742 . . . . 0.0 112.462 -179.998 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 21.5 t -73.64 130.56 35.78 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-O 120.805 0.336 . . . . 0.0 111.133 179.998 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 75' ' ' ARG . . . . . . . . . . . . . 48.4 ttt-85 -93.71 144.23 25.59 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.901 179.963 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 76' ' ' TYR . . . . . . . . . . . . . 58.4 m-85 -124.85 -44.82 1.92 Allowed 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.867 -179.985 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 77' ' ' PHE . . . . . . . . . . . . . 32.7 p90 -166.91 177.44 6.37 Favored 'General case' 0 C--N 1.327 -0.383 0 CA-C-N 116.18 -0.463 . . . . 0.0 110.908 179.978 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 1.7 t -98.96 124.83 44.18 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.833 -179.93 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 79' ' ' CYS . . . . . . . . . . . . . 27.0 p -150.98 155.01 38.2 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.847 179.952 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 80' ' ' ALA . . . . . 0.405 ' HB3' ' CD2' ' A' ' 83' ' ' HIS . . . -67.99 166.84 20.4 Favored Pre-proline 0 C--N 1.328 -0.349 0 CA-C-N 116.159 -0.473 . . . . 0.0 111.049 179.956 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 81' ' ' PRO . . . . . . . . . . . . . 53.3 Cg_exo -52.63 117.07 3.31 Favored 'Trans proline' 0 C--N 1.345 0.362 0 C-N-CA 122.538 2.159 . . . . 0.0 112.324 -179.92 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 82' ' ' ARG . . . . . . . . . . . . . 2.9 ttm180 63.12 57.7 1.56 Allowed 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.978 179.985 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 83' ' ' HIS . . . . . 0.408 ' CD2' ' HA ' ' A' ' 63' ' ' PRO . 6.3 m170 -126.96 -46.98 1.52 Allowed 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.091 -0.504 . . . . 0.0 110.94 179.957 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . -62.86 139.31 44.85 Favored Glycine 0 N--CA 1.45 -0.388 0 C-N-CA 120.722 -0.752 . . . . 0.0 112.541 179.989 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 85' ' ' VAL . . . . . . . . . . . . . 5.5 m -147.21 124.18 3.19 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.257 0 CA-C-O 120.871 0.367 . . . . 0.0 111.062 -179.942 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 86' ' ' PHE . . . . . . . . . . . . . 13.5 m-85 -100.77 121.12 41.14 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.081 -0.508 . . . . 0.0 110.9 179.999 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 87' ' ' ALA . . . . . . . . . . . . . . . -140.75 144.84 37.47 Favored Pre-proline 0 C--N 1.328 -0.33 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.161 179.975 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 88' ' ' PRO . . . . . 0.423 ' HD3' ' CZ3' ' A' ' 55' ' ' TRP . 47.6 Cg_exo -56.06 141.25 87.11 Favored 'Trans proline' 0 C--N 1.345 0.394 0 C-N-CA 122.607 2.204 . . . . 0.0 112.224 -179.9 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -47.96 -50.97 25.48 Favored 'General case' 0 CA--C 1.521 -0.149 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.295 179.854 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 90' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -55.83 -24.6 37.41 Favored 'General case' 0 C--N 1.331 -0.217 0 CA-C-N 115.68 -0.691 . . . . 0.0 109.673 178.841 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 91' ' ' ARG . . . . . 0.416 ' N ' ' O ' ' A' ' 88' ' ' PRO . 0.0 OUTLIER -87.6 -15.37 37.54 Favored 'General case' 0 N--CA 1.454 -0.244 0 CA-C-N 115.856 -0.611 . . . . 0.0 110.423 179.032 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 92' ' ' ILE . . . . . . . . . . . . . 33.0 mt -104.63 145.89 12.61 Favored 'Isoleucine or valine' 0 C--N 1.333 -0.126 0 CA-C-N 116.397 -0.365 . . . . 0.0 111.066 179.864 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 93' ' ' GLN . . . . . . . . . . . . . 0.7 OUTLIER -114.83 -179.96 3.78 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.991 -179.973 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 94' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -126.08 142.88 51.33 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.877 -179.968 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 95' ' ' ILE . . . . . . . . . . . . . 3.3 mp -117.41 -37.66 2.02 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.108 -0.496 . . . . 0.0 111.172 179.981 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . -70.22 66.9 0.71 Allowed Glycine 0 N--CA 1.453 -0.224 0 C-N-CA 120.716 -0.754 . . . . 0.0 112.513 -179.945 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 97' ' ' SER . . . . . . . . . . . . . 45.0 m -120.49 170.81 9.04 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 120.839 0.352 . . . . 0.0 110.784 179.945 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 98' ' ' GLY . . . . . . . . . . . . . . . -134.49 61.73 0.63 Allowed Glycine 0 N--CA 1.45 -0.404 0 C-N-CA 120.713 -0.756 . . . . 0.0 112.606 -179.991 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 99' ' ' PRO . . . . . . . . . . . . . 35.7 Cg_exo -57.5 -36.49 98.69 Favored 'Trans proline' 0 C--N 1.344 0.297 0 C-N-CA 122.59 2.194 . . . . 0.0 112.186 -179.995 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 100' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -105.3 -175.39 2.78 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.824 -179.96 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 1.4 m -83.4 138.54 33.45 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.856 179.963 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.249 1.067 0 CA-C-O 118.368 -1.24 . . . . 0.0 112.475 179.997 . . . . . . . . 0 0 . 1 . 010 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.207 0 N-CA-C 112.477 -0.249 . . . . 0.0 112.477 . . . . . . . . . 0 0 . 1 . 010 nuclear orig full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 17.7 t -128.49 112.31 14.21 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-O 120.79 0.329 . . . . 0.0 110.857 179.989 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 8.6 t 60.56 31.24 20.21 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.861 179.937 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -116.97 115.82 3.37 Favored Glycine 0 N--CA 1.452 -0.247 0 C-N-CA 120.794 -0.717 . . . . 0.0 112.451 -179.938 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 2.4 m -148.03 153.03 38.41 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 120.78 0.324 . . . . 0.0 110.918 179.99 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 6.2 m -96.44 141.23 29.99 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.907 179.959 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 145.83 101.33 0.3 Allowed Glycine 0 N--CA 1.451 -0.333 0 C-N-CA 120.721 -0.752 . . . . 0.0 112.503 -179.975 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 13.9 mttp -145.59 -58.54 0.33 Allowed 'General case' 0 C--N 1.33 -0.282 0 CA-C-O 120.767 0.317 . . . . 0.0 110.89 179.976 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -152.67 165.81 16.76 Favored Pre-proline 0 C--N 1.328 -0.352 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.856 -179.975 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 38.1 Cg_endo -66.44 123.22 10.84 Favored 'Trans proline' 0 C--N 1.344 0.297 0 C-N-CA 122.577 2.185 . . . . 0.0 112.297 179.933 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 69.2 m -88.11 -177.21 5.67 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.937 -179.975 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 53.0 m -127.01 144.64 51.11 Favored Pre-proline 0 C--N 1.329 -0.294 0 CA-C-N 116.263 -0.426 . . . . 0.0 110.888 179.97 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 67.9 Cg_endo -74.32 -37.17 2.68 Favored 'Trans proline' 0 C--N 1.345 0.382 0 C-N-CA 122.492 2.128 . . . . 0.0 112.35 -179.984 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 85.4 p -96.33 41.95 1.1 Allowed 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.944 179.979 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 4.3 tp -166.92 89.13 0.34 Allowed 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.919 179.942 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 101.67 -60.34 0.58 Allowed Glycine 0 N--CA 1.451 -0.306 0 C-N-CA 120.687 -0.768 . . . . 0.0 112.467 179.969 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 1.9 m 60.96 160.07 0.05 OUTLIER 'General case' 0 C--N 1.328 -0.36 0 CA-C-O 120.833 0.349 . . . . 0.0 110.858 179.987 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -109.57 -30.72 7.78 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.923 179.966 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 19' ' ' GLN . . . . . . . . . . . . . 1.6 tt0 61.24 42.45 12.02 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.838 179.94 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 20' ' ' GLN . . . . . . . . . . . . . 3.2 tt0 -157.54 -45.9 0.07 Allowed 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.895 179.911 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 9.0 ttt-85 -68.84 111.17 4.74 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.185 -0.462 . . . . 0.0 110.968 179.947 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 0.9 OUTLIER -117.16 -65.62 1.17 Allowed 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.837 -179.975 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 109.43 28.56 4.27 Favored Glycine 0 N--CA 1.451 -0.321 0 C-N-CA 120.808 -0.71 . . . . 0.0 112.488 179.99 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -136.58 -179.48 5.72 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 120.871 0.367 . . . . 0.0 111.034 179.99 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 4.0 tttp -145.59 -47.51 0.22 Allowed 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.904 -179.989 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -119.82 171.62 8.28 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.134 179.992 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 27' ' ' GLU . . . . . . . . . . . . . 28.7 mt-10 -139.41 178.31 7.29 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.946 179.972 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 28.9 t -72.31 115.7 13.18 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.219 -0.446 . . . . 0.0 111.049 -179.979 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 102.43 33.96 4.33 Favored Glycine 0 N--CA 1.452 -0.298 0 C-N-CA 120.716 -0.754 . . . . 0.0 112.443 179.969 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 13.3 m-20 -141.42 148.35 39.42 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-O 120.822 0.344 . . . . 0.0 110.912 179.92 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 31' ' ' GLN . . . . . . . . . . . . . 3.5 mp0 -72.74 137.33 45.82 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.955 179.975 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 14.8 m -146.55 177.53 1.3 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 116.262 -0.426 . . . . 0.0 111.112 179.984 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 33' ' ' LEU . . . . . . . . . . . . . 21.7 tp -134.15 112.36 11.06 Favored 'General case' 0 C--N 1.33 -0.283 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.794 -179.998 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 21.9 t -76.03 123.74 32.77 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.145 -0.479 . . . . 0.0 111.127 -179.949 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 35' ' ' ALA . . . . . . . . . . . . . . . 59.28 25.56 14.22 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.153 -0.476 . . . . 0.0 111.229 179.979 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . 55.95 27.88 51.88 Favored Glycine 0 N--CA 1.452 -0.252 0 C-N-CA 120.759 -0.734 . . . . 0.0 112.633 -179.993 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 37' ' ' GLN . . . . . . . . . . . . . 24.9 mt-30 -142.64 -69.23 0.35 Allowed 'General case' 0 C--N 1.329 -0.285 0 CA-C-O 120.885 0.374 . . . . 0.0 110.925 179.957 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 38' ' ' LYS . . . . . . . . . . . . . 19.3 mttp -67.15 119.73 12.56 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.929 179.985 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 39' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -87.09 133.03 33.65 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.886 -179.999 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -162.33 169.76 37.75 Favored Glycine 0 N--CA 1.45 -0.371 0 C-N-CA 120.742 -0.742 . . . . 0.0 112.557 -179.969 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 23.2 mt -116.03 146.22 20.75 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.352 0 CA-C-O 120.799 0.333 . . . . 0.0 111.061 -179.99 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 42' ' ' VAL . . . . . . . . . . . . . 33.3 t -69.49 124.95 26.51 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.212 -0.449 . . . . 0.0 111.042 179.946 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 43' ' ' ARG . . . . . . . . . . . . . 2.9 mmm180 -111.84 -43.39 3.62 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.894 179.99 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 44' ' ' PHE . . . . . . . . . . . . . 49.7 t80 -136.7 113.16 10.02 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.86 -179.897 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 45' ' ' TYR . . . . . 0.495 ' CE1' ' CE1' ' A' ' 56' ' ' TYR . 14.1 t80 -112.9 131.57 55.67 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.272 -0.422 . . . . 0.0 110.872 179.965 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 156.17 -172.45 34.05 Favored Glycine 0 N--CA 1.451 -0.364 0 C-N-CA 120.763 -0.732 . . . . 0.0 112.524 -179.968 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 47' ' ' LYS . . . . . 0.412 ' HG3' ' CZ ' ' A' ' 54' ' ' TYR . 98.5 mttt -69.01 155.86 39.62 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 120.768 0.318 . . . . 0.0 110.915 179.968 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 48' ' ' THR . . . . . . . . . . . . . 7.2 p -122.69 170.08 10.41 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.858 -179.943 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -102.33 -31.28 10.59 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.93 179.957 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 50' ' ' PHE . . . . . 0.413 ' CD1' ' HB2' ' A' ' 51' ' ' ALA . 18.0 p90 -73.66 -31.63 63.58 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.915 179.951 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 51' ' ' ALA . . . . . 0.413 ' HB2' ' CD1' ' A' ' 50' ' ' PHE . . . -140.51 147.95 51.45 Favored Pre-proline 0 C--N 1.33 -0.269 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.096 -179.895 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 52' ' ' PRO . . . . . . . . . . . . . 60.0 Cg_endo -72.25 176.9 7.93 Favored 'Trans proline' 0 C--N 1.344 0.32 0 C-N-CA 122.578 2.185 . . . . 0.0 112.402 179.902 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 72.45 -155.97 51.73 Favored Glycine 0 N--CA 1.45 -0.397 0 C-N-CA 120.771 -0.728 . . . . 0.0 112.592 179.947 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 54' ' ' TYR . . . . . 0.412 ' CZ ' ' HG3' ' A' ' 47' ' ' LYS . 10.8 m-85 -115.86 137.63 51.91 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-O 120.894 0.378 . . . . 0.0 110.856 -179.989 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 55' ' ' TRP . . . . . . . . . . . . . 52.0 m95 -126.37 164.25 21.48 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.835 179.977 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 56' ' ' TYR . . . . . 0.495 ' CE1' ' CE1' ' A' ' 45' ' ' TYR . 25.9 m-85 -114.42 120.88 41.81 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.968 179.963 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 57' ' ' GLY . . . . . 0.414 ' HA3' ' CE1' ' A' ' 77' ' ' PHE . . . -83.07 61.25 4.81 Favored Glycine 0 N--CA 1.45 -0.387 0 C-N-CA 120.73 -0.748 . . . . 0.0 112.401 179.995 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 58' ' ' ILE . . . . . 0.425 HG21 HD11 ' A' ' 58' ' ' ILE . 45.2 mt -69.33 145.13 13.43 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-O 120.827 0.346 . . . . 0.0 111.098 -179.899 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 5.6 tm-20 -112.83 132.77 55.13 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.797 -179.961 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 60' ' ' LEU . . . . . . . . . . . . . 39.3 mt -93.1 158.76 15.61 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.202 -0.453 . . . . 0.0 110.93 -179.994 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 32.6 t0 -100.26 31.17 3.49 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.918 179.931 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 62' ' ' GLN . . . . . . . . . . . . . 1.8 pm0 -157.46 149.05 17.02 Favored Pre-proline 0 C--N 1.33 -0.276 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.846 179.965 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 56.4 Cg_endo -70.28 63.67 2.09 Favored 'Trans proline' 0 C--N 1.344 0.314 0 C-N-CA 122.631 2.221 . . . . 0.0 112.284 -179.994 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 64' ' ' THR . . . . . . . . . . . . . 5.4 p -145.23 30.84 1.12 Allowed 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.972 179.901 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . -79.37 -159.26 15.92 Favored Glycine 0 N--CA 1.451 -0.361 0 C-N-CA 120.714 -0.755 . . . . 0.0 112.48 179.989 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 66' ' ' LYS . . . . . . . . . . . . . 7.0 mtpm? -111.53 -33.74 6.29 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 120.813 0.34 . . . . 0.0 110.928 179.969 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 67' ' ' HIS . . . . . . . . . . . . . 6.0 p80 -139.12 174.07 10.9 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.911 179.921 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 1.3 t70 -97.85 37.07 1.44 Allowed 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.951 179.973 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 95.19 -65.21 1.33 Allowed Glycine 0 N--CA 1.451 -0.337 0 C-N-CA 120.703 -0.76 . . . . 0.0 112.511 -179.965 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 70' ' ' SER . . . . . . . . . . . . . 3.1 p -89.57 133.34 34.65 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 120.807 0.337 . . . . 0.0 110.836 -179.931 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 71' ' ' VAL . . . . . 0.413 HG11 ' CD2' ' A' ' 72' ' ' PHE . 21.5 t -114.21 114.76 47.62 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.202 -0.454 . . . . 0.0 111.111 -179.982 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 72' ' ' PHE . . . . . 0.413 ' CD2' HG11 ' A' ' 71' ' ' VAL . 13.9 m-85 60.73 31.11 20.09 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.949 179.99 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 98.8 -29.36 11.81 Favored Glycine 0 N--CA 1.451 -0.324 0 C-N-CA 120.752 -0.737 . . . . 0.0 112.485 -179.956 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 21.5 t -76.97 123.56 33.74 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-O 120.797 0.332 . . . . 0.0 111.092 -179.944 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 75' ' ' ARG . . . . . . . . . . . . . 11.4 ttm180 -101.1 134.04 44.7 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.884 179.996 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 76' ' ' TYR . . . . . . . . . . . . . 51.7 m-85 -109.67 -31.15 7.57 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.998 179.922 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 77' ' ' PHE . . . . . 0.414 ' CE1' ' HA3' ' A' ' 57' ' ' GLY . 27.0 p90 -172.85 156.39 3.4 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.941 179.98 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 12.3 m -85.75 111.2 19.92 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.798 179.968 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 79' ' ' CYS . . . . . . . . . . . . . 27.1 p -134.86 164.31 27.86 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.31 -0.405 . . . . 0.0 110.995 -179.929 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 80' ' ' ALA . . . . . . . . . . . . . . . -63.55 165.86 10.72 Favored Pre-proline 0 C--N 1.328 -0.337 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.949 179.879 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 81' ' ' PRO . . . . . . . . . . . . . 20.5 Cg_endo -60.85 114.97 2.39 Favored 'Trans proline' 0 C--N 1.345 0.364 0 C-N-CA 122.58 2.187 . . . . 0.0 112.146 179.876 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 82' ' ' ARG . . . . . . . . . . . . . 49.7 mtt180 64.4 58.69 1.06 Allowed 'General case' 0 C--N 1.331 -0.232 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.752 -179.969 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 83' ' ' HIS . . . . . . . . . . . . . 5.7 m-70 -130.7 -48.56 1.05 Allowed 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.899 179.927 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . -60.48 140.29 48.06 Favored Glycine 0 N--CA 1.452 -0.273 0 C-N-CA 120.741 -0.742 . . . . 0.0 112.531 -179.99 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 85' ' ' VAL . . . . . . . . . . . . . 10.1 m -142.59 130.52 20.12 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-O 120.823 0.344 . . . . 0.0 111.096 179.937 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 86' ' ' PHE . . . . . 0.409 ' CE1' ' CA ' ' A' ' 57' ' ' GLY . 8.6 m-85 -103.66 114.0 27.93 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.924 -179.963 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 87' ' ' ALA . . . . . . . . . . . . . . . -134.28 145.4 55.23 Favored Pre-proline 0 C--N 1.331 -0.237 0 CA-C-N 116.259 -0.428 . . . . 0.0 111.067 -179.949 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 88' ' ' PRO . . . . . 0.41 ' O ' ' N ' ' A' ' 91' ' ' ARG . 36.5 Cg_exo -57.45 140.57 93.58 Favored 'Trans proline' 0 C--N 1.345 0.356 0 C-N-CA 122.527 2.151 . . . . 0.0 112.236 -179.981 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -48.24 -50.27 30.13 Favored 'General case' 0 CA--C 1.521 -0.162 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.262 179.809 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 90' ' ' SER . . . . . . . . . . . . . 2.7 m -55.9 -24.51 37.82 Favored 'General case' 0 N--CA 1.455 -0.223 0 CA-C-N 115.706 -0.679 . . . . 0.0 109.789 178.767 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 91' ' ' ARG . . . . . 0.41 ' N ' ' O ' ' A' ' 88' ' ' PRO . 0.2 OUTLIER -88.54 -14.19 38.29 Favored 'General case' 0 N--CA 1.455 -0.177 0 CA-C-N 115.865 -0.607 . . . . 0.0 110.391 179.1 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 92' ' ' ILE . . . . . . . . . . . . . 21.4 mt -108.12 139.82 28.88 Favored 'Isoleucine or valine' 0 C--O 1.232 0.154 0 CA-C-N 116.45 -0.341 . . . . 0.0 111.061 179.808 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 93' ' ' GLN . . . . . . . . . . . . . 8.7 mt-30 -106.7 171.72 7.21 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.892 179.997 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 94' ' ' ARG . . . . . . . . . . . . . 3.4 ttt-85 -111.79 154.18 25.45 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.902 179.929 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 95' ' ' ILE . . . . . . . . . . . . . 31.8 mt -122.37 -64.86 1.39 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.326 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.155 179.997 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . 123.7 161.75 11.24 Favored Glycine 0 N--CA 1.452 -0.296 0 C-N-CA 120.779 -0.725 . . . . 0.0 112.41 -179.972 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 97' ' ' SER . . . . . . . . . . . . . 93.6 p -73.21 115.81 12.99 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 120.84 0.352 . . . . 0.0 110.912 179.975 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 98' ' ' GLY . . . . . . . . . . . . . . . 93.14 83.87 1.55 Allowed Glycine 0 N--CA 1.451 -0.313 0 C-N-CA 120.725 -0.75 . . . . 0.0 112.517 179.966 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 99' ' ' PRO . . . . . . . . . . . . . 50.5 Cg_endo -69.21 -28.15 28.25 Favored 'Trans proline' 0 C--N 1.345 0.371 0 C-N-CA 122.585 2.19 . . . . 0.0 112.297 179.978 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 100' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -134.55 -48.25 0.76 Allowed 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.924 -179.987 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 20.2 t -110.94 127.75 55.59 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.922 179.998 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.249 1.065 0 CA-C-O 118.337 -1.257 . . . . 0.0 112.516 179.965 . . . . . . . . 0 0 . 1 . 011 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.181 0 N-CA-C 112.496 -0.242 . . . . 0.0 112.496 . . . . . . . . . 0 0 . 1 . 011 nuclear orig full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 1.3 p -153.32 120.93 5.95 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-O 120.769 0.319 . . . . 0.0 110.93 179.995 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER 60.54 106.6 0.02 OUTLIER 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 116.222 -0.444 . . . . 0.0 110.906 179.998 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 108.27 -70.28 0.21 Allowed Glycine 0 N--CA 1.45 -0.376 0 C-N-CA 120.768 -0.73 . . . . 0.0 112.568 -179.904 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -73.35 149.85 42.27 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-O 120.847 0.356 . . . . 0.0 110.894 179.948 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -76.71 -52.22 10.01 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.145 -0.479 . . . . 0.0 110.855 -179.977 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 69.87 118.32 0.03 OUTLIER Glycine 0 N--CA 1.45 -0.381 0 C-N-CA 120.676 -0.774 . . . . 0.0 112.549 -179.927 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 3.7 ttpp 60.44 34.55 20.51 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-O 120.821 0.343 . . . . 0.0 110.864 -179.981 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 86.9 p -175.52 90.41 0.29 Allowed Pre-proline 0 C--N 1.328 -0.341 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.835 -179.948 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 75.3 Cg_exo -50.64 118.61 4.27 Favored 'Trans proline' 0 C--N 1.345 0.343 0 C-N-CA 122.537 2.158 . . . . 0.0 112.391 -179.968 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 52.4 p -153.89 122.43 6.24 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.167 -0.469 . . . . 0.0 110.85 -179.998 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 1.3 m -87.53 147.04 40.81 Favored Pre-proline 0 C--N 1.329 -0.283 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.875 -179.986 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 63.3 Cg_endo -73.57 61.69 4.43 Favored 'Trans proline' 0 C--N 1.344 0.313 0 C-N-CA 122.559 2.173 . . . . 0.0 112.287 -179.981 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 1.3 m -170.54 72.26 0.06 Allowed 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.968 179.911 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -160.93 -45.27 0.04 OUTLIER 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.82 -179.958 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -148.18 38.84 1.02 Allowed Glycine 0 N--CA 1.451 -0.348 0 C-N-CA 120.739 -0.743 . . . . 0.0 112.463 -179.996 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 1.8 t 60.73 -176.66 0.11 Allowed 'General case' 0 C--N 1.33 -0.269 0 CA-C-O 120.807 0.337 . . . . 0.0 110.926 -179.994 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 2.2 pp -136.63 -47.01 0.61 Allowed 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.911 179.978 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 19' ' ' GLN . . . . . . . . . . . . . 35.8 tt0 -147.3 -62.58 0.28 Allowed 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.268 -0.424 . . . . 0.0 110.89 179.969 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 20' ' ' GLN . . . . . . . . . . . . . 21.8 mt-30 -127.29 -50.9 1.41 Allowed 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.892 -179.978 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 2.3 ttp180 -72.89 121.27 19.74 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.189 -0.459 . . . . 0.0 110.88 -179.987 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 4.2 pt-20 -87.48 167.31 14.1 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.809 179.951 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -102.07 30.8 9.64 Favored Glycine 0 N--CA 1.451 -0.302 0 C-N-CA 120.74 -0.743 . . . . 0.0 112.547 -179.997 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -93.99 117.05 29.57 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-O 120.795 0.331 . . . . 0.0 111.12 -179.967 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 1.1 mpmm? -69.86 -41.42 74.85 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.244 -0.435 . . . . 0.0 110.902 179.967 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -144.21 178.29 8.0 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.157 -0.474 . . . . 0.0 111.143 -179.995 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 27' ' ' GLU . . . . . . . . . . . . . 30.4 mt-10 -145.56 -178.36 6.04 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.901 -179.992 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 21.5 t -75.85 116.62 19.08 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.211 -0.449 . . . . 0.0 111.144 -179.954 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 101.35 36.65 3.77 Favored Glycine 0 N--CA 1.45 -0.416 0 C-N-CA 120.766 -0.73 . . . . 0.0 112.47 -179.992 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -144.79 151.67 39.17 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 120.778 0.323 . . . . 0.0 110.898 -179.991 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 31' ' ' GLN . . . . . . . . . . . . . 2.7 mp0 -72.11 125.78 28.14 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.233 -0.439 . . . . 0.0 110.891 179.984 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 27.5 m -127.04 174.57 10.57 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.138 -0.483 . . . . 0.0 111.143 179.964 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 33' ' ' LEU . . . . . . . . . . . . . 25.8 tp -143.22 102.54 4.0 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.852 -179.923 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 21.4 t -72.65 128.57 35.6 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.148 -0.478 . . . . 0.0 111.147 -179.92 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 35' ' ' ALA . . . . . . . . . . . . . . . 57.18 25.08 10.54 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.065 -0.516 . . . . 0.0 111.304 179.936 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . 56.38 31.22 59.53 Favored Glycine 0 N--CA 1.451 -0.344 0 C-N-CA 120.752 -0.737 . . . . 0.0 112.604 -179.986 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 37' ' ' GLN . . . . . . . . . . . . . 81.6 mt-30 -146.3 -70.86 0.25 Allowed 'General case' 0 C--N 1.329 -0.29 0 CA-C-O 120.79 0.329 . . . . 0.0 110.906 -179.92 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 38' ' ' LYS . . . . . . . . . . . . . 12.6 mttt -61.71 105.05 0.5 Allowed 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.905 -179.988 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 39' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -85.1 132.02 34.37 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.902 179.942 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -158.39 -170.19 22.78 Favored Glycine 0 N--CA 1.451 -0.358 0 C-N-CA 120.709 -0.758 . . . . 0.0 112.438 179.977 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 32.2 mt -129.55 129.74 66.87 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-O 120.798 0.332 . . . . 0.0 111.046 -179.959 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 42' ' ' VAL . . . . . . . . . . . . . 21.4 t -58.46 125.22 14.12 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.172 179.973 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 43' ' ' ARG . . . . . . . . . . . . . 36.6 mmt180 -108.18 -31.53 7.87 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.87 -179.973 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 44' ' ' PHE . . . . . . . . . . . . . 41.0 t80 -148.78 113.81 5.47 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.922 179.926 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 45' ' ' TYR . . . . . 0.471 ' CE1' ' CZ ' ' A' ' 56' ' ' TYR . 33.7 t80 -112.3 142.93 44.2 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.884 179.974 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 148.92 -168.99 29.4 Favored Glycine 0 N--CA 1.451 -0.327 0 C-N-CA 120.732 -0.747 . . . . 0.0 112.492 -179.982 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 47' ' ' LYS . . . . . 0.41 ' HE2' ' CZ ' ' A' ' 54' ' ' TYR . 22.2 mttm -87.39 141.58 28.53 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-O 120.851 0.357 . . . . 0.0 110.869 -179.98 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 48' ' ' THR . . . . . 0.441 ' CB ' ' CE2' ' A' ' 50' ' ' PHE . 63.6 p -102.18 -177.12 3.31 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.85 179.983 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 1.3 t70 -112.85 15.86 19.67 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.159 -0.473 . . . . 0.0 111.242 -179.958 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 50' ' ' PHE . . . . . 0.445 ' CD1' ' N ' ' A' ' 51' ' ' ALA . 29.2 p90 -116.38 -36.65 3.94 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-O 120.727 0.299 . . . . 0.0 110.996 179.846 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 51' ' ' ALA . . . . . 0.445 ' N ' ' CD1' ' A' ' 50' ' ' PHE . . . -140.26 146.71 47.04 Favored Pre-proline 0 C--N 1.328 -0.332 0 CA-C-N 116.249 -0.432 . . . . 0.0 111.126 179.924 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 52' ' ' PRO . . . . . . . . . . . . . 60.0 Cg_endo -72.42 170.81 18.37 Favored 'Trans proline' 0 C--N 1.345 0.388 0 C-N-CA 122.505 2.137 . . . . 0.0 112.353 -179.957 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 90.66 -154.08 23.01 Favored Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.778 -0.725 . . . . 0.0 112.525 179.939 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 54' ' ' TYR . . . . . 0.41 ' CZ ' ' HE2' ' A' ' 47' ' ' LYS . 57.4 m-85 -125.23 124.45 41.71 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 120.872 0.368 . . . . 0.0 110.867 179.963 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 55' ' ' TRP . . . . . . . . . . . . . 65.3 m95 -115.13 161.83 17.86 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.936 179.95 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 56' ' ' TYR . . . . . 0.471 ' CZ ' ' CE1' ' A' ' 45' ' ' TYR . 10.8 m-85 -117.68 120.07 36.89 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.211 -0.449 . . . . 0.0 110.92 -179.887 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 57' ' ' GLY . . . . . 0.45 ' CA ' ' CE1' ' A' ' 86' ' ' PHE . . . -84.71 63.8 4.35 Favored Glycine 0 N--CA 1.452 -0.298 0 C-N-CA 120.681 -0.771 . . . . 0.0 112.392 179.997 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 58' ' ' ILE . . . . . . . . . . . . . 3.3 mt -70.24 146.95 11.87 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.23 0 CA-C-O 120.807 0.337 . . . . 0.0 111.128 -179.966 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 3.7 tm-20 -116.91 109.8 17.51 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.841 -179.979 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 60' ' ' LEU . . . . . . . . . . . . . 96.0 mt -63.55 172.84 1.87 Allowed 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.912 179.932 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -98.5 -32.54 11.41 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.289 -0.414 . . . . 0.0 110.924 -179.978 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 62' ' ' GLN . . . . . . . . . . . . . 4.7 mm-40 -118.42 151.34 49.44 Favored Pre-proline 0 C--N 1.33 -0.264 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.94 -179.998 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 52.1 Cg_exo -54.66 99.95 0.06 OUTLIER 'Trans proline' 0 C--N 1.345 0.362 0 C-N-CA 122.485 2.123 . . . . 0.0 112.286 -179.958 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 64' ' ' THR . . . . . . . . . . . . . 9.8 t -176.98 39.01 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.872 179.983 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . -95.87 -125.43 4.73 Favored Glycine 0 N--CA 1.45 -0.37 0 C-N-CA 120.713 -0.756 . . . . 0.0 112.475 179.98 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 66' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -144.17 -47.71 0.27 Allowed 'General case' 0 C--N 1.329 -0.284 0 CA-C-O 120.825 0.345 . . . . 0.0 110.833 -179.869 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 67' ' ' HIS . . . . . . . . . . . . . 6.4 p80 -122.84 177.43 5.48 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.191 -0.458 . . . . 0.0 110.884 179.984 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -100.15 35.35 2.09 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.891 -179.987 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 100.99 -70.18 0.42 Allowed Glycine 0 N--CA 1.451 -0.365 0 C-N-CA 120.756 -0.735 . . . . 0.0 112.465 179.944 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 70' ' ' SER . . . . . . . . . . . . . 78.4 p -81.68 148.85 28.79 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 120.85 0.357 . . . . 0.0 110.868 179.987 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 27.3 t -127.67 125.94 66.17 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.167 -0.47 . . . . 0.0 111.11 179.93 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 72' ' ' PHE . . . . . . . . . . . . . 47.7 m-85 60.08 28.02 17.52 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.99 -179.929 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 95.97 -30.03 9.11 Favored Glycine 0 N--CA 1.451 -0.307 0 C-N-CA 120.628 -0.796 . . . . 0.0 112.538 179.951 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 21.6 t -80.47 122.95 36.59 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-O 120.784 0.326 . . . . 0.0 111.074 -179.939 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 75' ' ' ARG . . . . . . . . . . . . . 21.2 ttm180 -88.96 146.26 25.01 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.224 -0.443 . . . . 0.0 110.922 -179.997 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 76' ' ' TYR . . . . . 0.415 ' CE2' HG22 ' A' ' 48' ' ' THR . 37.0 m-85 -119.26 -47.75 2.45 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.185 -0.462 . . . . 0.0 110.897 -179.977 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 77' ' ' PHE . . . . . . . . . . . . . 34.8 p90 -152.79 171.4 18.3 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.922 179.972 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 4.6 p -97.26 122.56 40.42 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.904 -179.97 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 79' ' ' CYS . . . . . . . . . . . . . 27.3 p -143.87 176.74 9.03 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.906 179.963 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 80' ' ' ALA . . . . . 0.404 ' HB2' ' CD2' ' A' ' 83' ' ' HIS . . . -90.43 168.95 13.02 Favored Pre-proline 0 C--N 1.329 -0.308 0 CA-C-N 116.229 -0.441 . . . . 0.0 111.077 179.96 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 81' ' ' PRO . . . . . . . . . . . . . 52.7 Cg_exo -52.59 113.6 1.3 Allowed 'Trans proline' 0 C--N 1.344 0.303 0 C-N-CA 122.557 2.171 . . . . 0.0 112.261 179.93 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 82' ' ' ARG . . . . . . . . . . . . . 9.2 mmt180 61.27 53.59 3.47 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.907 -179.987 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 83' ' ' HIS . . . . . 0.404 ' CD2' ' HB2' ' A' ' 80' ' ' ALA . 5.5 m170 -121.17 -42.4 2.48 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.125 -0.489 . . . . 0.0 110.918 179.989 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . -63.7 154.67 45.67 Favored Glycine 0 N--CA 1.45 -0.368 0 C-N-CA 120.745 -0.741 . . . . 0.0 112.511 179.933 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 85' ' ' VAL . . . . . . . . . . . . . 15.2 m -156.27 127.27 0.87 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-O 120.84 0.352 . . . . 0.0 111.191 -179.96 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 86' ' ' PHE . . . . . 0.45 ' CE1' ' CA ' ' A' ' 57' ' ' GLY . 7.9 m-85 -112.53 102.09 10.21 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.818 179.942 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 87' ' ' ALA . . . . . . . . . . . . . . . -123.19 145.86 47.45 Favored Pre-proline 0 C--N 1.329 -0.297 0 CA-C-N 116.245 -0.434 . . . . 0.0 111.119 -179.956 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 88' ' ' PRO . . . . . 0.41 ' O ' ' N ' ' A' ' 91' ' ' ARG . 32.3 Cg_exo -58.02 141.94 96.5 Favored 'Trans proline' 0 C--N 1.346 0.4 0 C-N-CA 122.498 2.132 . . . . 0.0 112.235 179.991 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 89' ' ' ALA . . . . . 0.413 ' HB1' ' CE1' ' A' ' 56' ' ' TYR . . . -47.9 -51.44 23.24 Favored 'General case' 0 CA--C 1.522 -0.116 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.346 179.859 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 90' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -55.99 -24.29 37.84 Favored 'General case' 0 N--CA 1.454 -0.27 0 CA-C-N 115.759 -0.655 . . . . 0.0 109.789 178.836 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 91' ' ' ARG . . . . . 0.41 ' N ' ' O ' ' A' ' 88' ' ' PRO . 0.0 OUTLIER -89.77 -14.08 35.34 Favored 'General case' 0 N--CA 1.455 -0.208 0 CA-C-N 115.945 -0.571 . . . . 0.0 110.526 179.029 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 92' ' ' ILE . . . . . 0.443 HD11 HG21 ' A' ' 92' ' ' ILE . 52.4 mt -110.56 156.04 11.73 Favored 'Isoleucine or valine' 0 C--O 1.23 0.077 0 CA-C-O 120.904 0.383 . . . . 0.0 111.04 179.864 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 93' ' ' GLN . . . . . . . . . . . . . 1.9 mt-30 -124.31 179.98 4.69 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.78 179.93 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 94' ' ' ARG . . . . . . . . . . . . . 4.2 ttt180 -126.08 142.18 51.63 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.936 179.993 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 95' ' ' ILE . . . . . . . . . . . . . 3.4 mt -124.72 23.82 3.59 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.246 -0.434 . . . . 0.0 111.088 179.982 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . -96.85 161.5 21.89 Favored Glycine 0 N--CA 1.45 -0.404 0 C-N-CA 120.721 -0.752 . . . . 0.0 112.512 179.975 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 97' ' ' SER . . . . . . . . . . . . . 9.8 m -86.06 84.24 7.56 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-O 120.854 0.359 . . . . 0.0 110.902 179.986 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 98' ' ' GLY . . . . . . . . . . . . . . . -108.46 -79.9 1.19 Allowed Glycine 0 N--CA 1.451 -0.35 0 C-N-CA 120.709 -0.758 . . . . 0.0 112.511 -179.977 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 99' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_exo -52.24 103.92 0.09 OUTLIER 'Trans proline' 0 C--N 1.343 0.282 0 C-N-CA 122.623 2.215 . . . . 0.0 112.372 179.975 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 100' ' ' SER . . . . . . . . . . . . . 26.3 p -165.37 -44.22 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.86 -179.988 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER 60.84 35.65 19.31 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.811 179.959 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.249 1.069 0 CA-C-O 118.364 -1.242 . . . . 0.0 112.503 179.977 . . . . . . . . 0 0 . 1 . 012 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.275 0 N-CA-C 112.455 -0.258 . . . . 0.0 112.455 . . . . . . . . . 0 0 . 1 . 012 nuclear orig full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER -99.61 35.7 1.93 Allowed 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 120.778 0.323 . . . . 0.0 110.887 -179.962 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 2.5 m -134.8 33.94 3.18 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.264 -0.425 . . . . 0.0 110.967 -179.967 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 74.15 165.99 13.41 Favored Glycine 0 N--CA 1.451 -0.303 0 C-N-CA 120.713 -0.756 . . . . 0.0 112.64 179.985 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -141.15 -67.71 0.4 Allowed 'General case' 0 C--N 1.33 -0.276 0 CA-C-O 120.814 0.34 . . . . 0.0 110.819 -179.979 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 56.9 p -104.23 121.64 43.72 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.165 -0.471 . . . . 0.0 110.945 179.986 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 154.07 100.11 0.18 Allowed Glycine 0 N--CA 1.451 -0.349 0 C-N-CA 120.775 -0.726 . . . . 0.0 112.504 -179.972 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 9.2 tttp -162.42 127.46 3.29 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-O 120.813 0.339 . . . . 0.0 110.924 179.998 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 4.1 p -158.36 80.06 3.05 Favored Pre-proline 0 C--N 1.328 -0.339 0 CA-C-N 116.242 -0.436 . . . . 0.0 110.975 179.953 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 48.5 Cg_exo -55.81 -21.01 30.96 Favored 'Trans proline' 0 C--N 1.344 0.301 0 C-N-CA 122.669 2.246 . . . . 0.0 112.427 -179.973 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 89.2 p -54.09 -29.1 43.3 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-N 116.371 -0.377 . . . . 0.0 111.171 -179.915 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 4.0 m -112.03 73.4 1.25 Allowed Pre-proline 0 C--N 1.33 -0.276 0 CA-C-N 116.278 -0.419 . . . . 0.0 110.861 -179.974 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 61.0 Cg_endo -73.23 -37.55 3.29 Favored 'Trans proline' 0 C--N 1.344 0.32 0 C-N-CA 122.543 2.162 . . . . 0.0 112.25 -179.999 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 25.3 p -146.55 166.68 25.76 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.88 179.96 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -152.41 -58.02 0.14 Allowed 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.885 179.967 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -130.19 -77.53 0.18 Allowed Glycine 0 N--CA 1.452 -0.276 0 C-N-CA 120.774 -0.727 . . . . 0.0 112.515 179.983 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 22.1 m -161.17 96.24 1.08 Allowed 'General case' 0 C--N 1.33 -0.262 0 CA-C-O 120.869 0.366 . . . . 0.0 110.914 -179.994 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 8.2 mt -152.4 90.18 1.48 Allowed 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.154 -0.476 . . . . 0.0 110.879 179.958 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 19' ' ' GLN . . . . . . . . . . . . . 1.9 tp60 -60.31 107.43 0.65 Allowed 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.849 179.984 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 20' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -144.4 -51.97 0.3 Allowed 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.269 -0.423 . . . . 0.0 110.932 179.964 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 2.9 ttt180 -149.08 126.05 11.27 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.944 179.992 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 4.5 tt0 -142.74 153.24 43.13 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.255 -0.43 . . . . 0.0 110.904 -179.944 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -150.19 146.09 14.85 Favored Glycine 0 N--CA 1.451 -0.3 0 C-N-CA 120.694 -0.765 . . . . 0.0 112.483 179.932 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -148.35 125.76 11.63 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-O 120.803 0.335 . . . . 0.0 111.115 179.972 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 0.8 OUTLIER -83.59 -66.71 0.86 Allowed 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.917 179.97 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -122.58 -173.63 2.73 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.163 -0.472 . . . . 0.0 111.088 -179.956 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 27' ' ' GLU . . . . . . . . . . . . . 50.8 mt-10 -133.24 -177.82 4.7 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.924 179.983 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 27.4 t -71.31 121.53 21.51 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.096 179.924 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 89.72 52.98 2.51 Favored Glycine 0 N--CA 1.452 -0.293 0 C-N-CA 120.7 -0.762 . . . . 0.0 112.424 179.954 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -155.45 142.1 18.83 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 120.795 0.331 . . . . 0.0 110.887 179.968 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 31' ' ' GLN . . . . . . . . . . . . . 15.3 mt-30 -59.97 134.95 57.52 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.256 -0.429 . . . . 0.0 110.923 -179.971 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 5.5 m -141.83 179.31 2.12 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.346 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.12 -179.982 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 33' ' ' LEU . . . . . . . . . . . . . 30.6 tp -142.76 108.0 5.0 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.791 179.98 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 22.0 t -78.29 124.67 37.03 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.156 179.995 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 35' ' ' ALA . . . . . . . . . . . . . . . 58.46 26.15 13.86 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.052 -0.522 . . . . 0.0 111.231 179.952 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . 56.57 28.48 56.21 Favored Glycine 0 N--CA 1.451 -0.333 0 C-N-CA 120.773 -0.727 . . . . 0.0 112.598 -179.999 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 37' ' ' GLN . . . . . . . . . . . . . 34.3 mt-30 -140.34 -70.88 0.38 Allowed 'General case' 0 C--N 1.328 -0.327 0 CA-C-O 120.749 0.309 . . . . 0.0 110.924 -179.998 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 38' ' ' LYS . . . . . . . . . . . . . 2.1 mttt -69.76 108.45 3.93 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.263 -0.426 . . . . 0.0 110.902 -179.948 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 39' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -88.15 136.98 32.72 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.908 179.974 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -160.52 -163.49 13.89 Favored Glycine 0 N--CA 1.451 -0.319 0 C-N-CA 120.727 -0.749 . . . . 0.0 112.463 180.0 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 33.2 mt -133.67 131.6 56.9 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-O 120.742 0.306 . . . . 0.0 111.084 -179.905 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 42' ' ' VAL . . . . . . . . . . . . . 21.4 t -60.06 125.43 16.17 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.345 0 CA-C-N 116.209 -0.45 . . . . 0.0 111.123 179.988 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 43' ' ' ARG . . . . . . . . . . . . . 13.6 mmt180 -110.34 -32.72 6.85 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.908 179.951 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 44' ' ' PHE . . . . . . . . . . . . . 72.2 t80 -143.05 111.05 6.0 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.248 -0.433 . . . . 0.0 110.912 -179.919 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 45' ' ' TYR . . . . . 0.5 ' CE1' ' CZ ' ' A' ' 56' ' ' TYR . 18.6 t80 -108.0 122.95 47.88 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.855 -179.99 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 164.94 -179.61 39.47 Favored Glycine 0 N--CA 1.451 -0.32 0 C-N-CA 120.767 -0.73 . . . . 0.0 112.534 179.928 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 47' ' ' LYS . . . . . . . . . . . . . 18.6 mttt -69.4 153.18 43.97 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 120.817 0.341 . . . . 0.0 110.879 -179.975 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 48' ' ' THR . . . . . . . . . . . . . 1.3 p -111.24 177.6 4.61 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.892 179.98 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -104.5 -31.33 9.51 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.835 179.992 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 50' ' ' PHE . . . . . 0.415 ' CE2' ' HB1' ' A' ' 51' ' ' ALA . 54.1 p90 -75.53 -39.19 58.7 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.262 -0.427 . . . . 0.0 110.918 -179.965 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 51' ' ' ALA . . . . . 0.415 ' HB1' ' CE2' ' A' ' 50' ' ' PHE . . . -131.61 147.13 64.81 Favored Pre-proline 0 C--N 1.33 -0.273 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.093 -179.946 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 52' ' ' PRO . . . . . . . . . . . . . 61.0 Cg_endo -72.96 -172.58 1.01 Allowed 'Trans proline' 0 C--N 1.345 0.372 0 C-N-CA 122.508 2.138 . . . . 0.0 112.395 179.974 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 67.94 -165.48 45.23 Favored Glycine 0 N--CA 1.452 -0.291 0 C-N-CA 120.738 -0.744 . . . . 0.0 112.511 179.973 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 54' ' ' TYR . . . . . . . . . . . . . 69.3 m-85 -107.69 141.55 39.04 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-O 120.84 0.352 . . . . 0.0 110.876 -179.963 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 55' ' ' TRP . . . . . 0.418 ' CZ3' ' HD3' ' A' ' 88' ' ' PRO . 52.6 m95 -132.61 167.17 20.52 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.917 -179.897 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 56' ' ' TYR . . . . . 0.5 ' CZ ' ' CE1' ' A' ' 45' ' ' TYR . 3.7 m-85 -121.18 117.09 26.23 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.323 -0.399 . . . . 0.0 110.912 179.997 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 57' ' ' GLY . . . . . 0.446 ' N ' ' CE1' ' A' ' 86' ' ' PHE . . . -81.2 68.26 3.47 Favored Glycine 0 N--CA 1.451 -0.331 0 C-N-CA 120.789 -0.72 . . . . 0.0 112.402 -179.967 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 58' ' ' ILE . . . . . . . . . . . . . 19.6 mt -73.53 138.04 22.09 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-O 120.807 0.337 . . . . 0.0 111.113 179.998 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -103.63 114.18 28.25 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.841 -179.967 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 60' ' ' LEU . . . . . . . . . . . . . 77.8 mt -69.51 -179.94 1.87 Allowed 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.154 -0.475 . . . . 0.0 110.885 179.972 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 4.9 m-20 -109.41 -34.09 6.63 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.951 -179.977 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 62' ' ' GLN . . . . . . . . . . . . . 4.1 mm-40 -108.14 146.63 33.94 Favored Pre-proline 0 C--N 1.329 -0.3 0 CA-C-N 116.321 -0.4 . . . . 0.0 110.942 -179.975 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 31.7 Cg_exo -58.88 91.93 0.07 OUTLIER 'Trans proline' 0 C--N 1.345 0.368 0 C-N-CA 122.62 2.213 . . . . 0.0 112.172 -179.966 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 64' ' ' THR . . . . . . . . . . . . . 10.1 t -172.89 38.88 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.913 -179.979 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . -93.42 -128.97 5.1 Favored Glycine 0 N--CA 1.45 -0.37 0 C-N-CA 120.786 -0.721 . . . . 0.0 112.48 -179.976 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 66' ' ' LYS . . . . . . . . . . . . . 1.1 mtpm? -135.89 -50.8 0.72 Allowed 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 120.881 0.372 . . . . 0.0 110.874 180.0 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 67' ' ' HIS . . . . . . . . . . . . . 7.1 p80 -128.18 178.99 5.85 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.884 179.911 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 15.5 t0 -101.46 36.46 2.02 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.966 179.999 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 95.66 -37.85 3.3 Favored Glycine 0 N--CA 1.451 -0.351 0 C-N-CA 120.707 -0.759 . . . . 0.0 112.495 -179.997 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 70' ' ' SER . . . . . . . . . . . . . 75.2 p -102.73 162.33 13.02 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-O 120.947 0.403 . . . . 0.0 110.842 -179.91 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 21.4 t -148.07 117.14 1.15 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-N 116.132 -0.485 . . . . 0.0 111.168 179.953 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 72' ' ' PHE . . . . . . . . . . . . . 5.1 m-85 60.4 35.56 20.47 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.14 -0.482 . . . . 0.0 111.002 -179.977 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 80.91 28.26 46.78 Favored Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.679 -0.772 . . . . 0.0 112.597 -179.972 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 74' ' ' VAL . . . . . 0.402 ' O ' ' CE1' ' A' ' 76' ' ' TYR . 21.5 t -133.63 104.89 6.78 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-O 120.799 0.333 . . . . 0.0 111.098 -179.975 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 75' ' ' ARG . . . . . . . . . . . . . 3.6 ttt-85 -77.41 131.47 38.04 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.246 -0.433 . . . . 0.0 111.001 -179.979 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 76' ' ' TYR . . . . . 0.402 ' CE1' ' O ' ' A' ' 74' ' ' VAL . 11.7 m-85 -106.86 -45.63 4.14 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.178 -0.464 . . . . 0.0 110.858 179.956 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 77' ' ' PHE . . . . . 0.418 ' CE1' ' HA3' ' A' ' 57' ' ' GLY . 36.8 p90 -156.29 156.55 34.21 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.924 179.985 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 1.9 t -80.0 114.51 18.97 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.25 -0.432 . . . . 0.0 110.89 179.955 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 79' ' ' CYS . . . . . . . . . . . . . 29.4 p -147.15 152.48 38.5 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.973 -179.936 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 80' ' ' ALA . . . . . 0.406 ' CB ' ' HD2' ' A' ' 81' ' ' PRO . . . -58.45 166.73 2.09 Favored Pre-proline 0 C--N 1.329 -0.29 0 CA-C-N 116.143 -0.48 . . . . 0.0 111.002 179.93 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 81' ' ' PRO . . . . . 0.406 ' HD2' ' CB ' ' A' ' 80' ' ' ALA . 20.5 Cg_endo -60.76 120.95 8.95 Favored 'Trans proline' 0 C--N 1.344 0.29 0 C-N-CA 122.545 2.164 . . . . 0.0 112.168 179.936 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 82' ' ' ARG . . . . . . . . . . . . . 78.1 mtt180 63.11 50.36 3.1 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.143 -0.48 . . . . 0.0 110.876 -179.832 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 83' ' ' HIS . . . . . . . . . . . . . 5.8 m170 -123.33 -48.8 1.95 Allowed 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.934 179.933 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . -66.5 121.82 18.68 Favored Glycine 0 N--CA 1.451 -0.304 0 C-N-CA 120.629 -0.796 . . . . 0.0 112.401 179.857 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 85' ' ' VAL . . . . . . . . . . . . . 5.9 m -126.35 132.4 70.43 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-O 120.911 0.386 . . . . 0.0 111.194 -179.98 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 86' ' ' PHE . . . . . 0.446 ' CE1' ' N ' ' A' ' 57' ' ' GLY . 12.9 m-85 -103.66 118.05 35.83 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.991 179.958 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 87' ' ' ALA . . . . . . . . . . . . . . . -134.69 143.61 47.19 Favored Pre-proline 0 C--N 1.33 -0.279 0 CA-C-N 116.215 -0.448 . . . . 0.0 111.058 179.992 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 88' ' ' PRO . . . . . 0.418 ' HD3' ' CZ3' ' A' ' 55' ' ' TRP . 32.5 Cg_exo -57.71 142.1 95.81 Favored 'Trans proline' 0 C--N 1.346 0.401 0 C-N-CA 122.451 2.101 . . . . 0.0 112.397 179.972 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -47.94 -50.98 25.28 Favored 'General case' 0 CA--C 1.521 -0.156 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.255 179.867 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 90' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER -55.87 -24.39 36.72 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 115.716 -0.674 . . . . 0.0 109.801 178.859 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 91' ' ' ARG . . . . . 0.418 ' N ' ' O ' ' A' ' 88' ' ' PRO . 1.0 OUTLIER -90.98 -13.15 33.93 Favored 'General case' 0 N--CA 1.455 -0.219 0 CA-C-N 115.944 -0.571 . . . . 0.0 110.522 179.154 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 92' ' ' ILE . . . . . 0.421 HG21 HD11 ' A' ' 92' ' ' ILE . 62.9 mt -107.09 147.8 11.99 Favored 'Isoleucine or valine' 0 C--O 1.231 0.101 0 CA-C-N 116.432 -0.349 . . . . 0.0 110.895 179.836 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 93' ' ' GLN . . . . . . . . . . . . . 5.7 mt-30 -118.04 168.97 10.05 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.972 179.934 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 94' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -111.48 152.36 27.54 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.859 -179.997 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 95' ' ' ILE . . . . . . . . . . . . . 23.1 mt -132.41 -45.84 0.65 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.155 179.909 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . -59.31 179.32 1.82 Allowed Glycine 0 N--CA 1.452 -0.288 0 C-N-CA 120.81 -0.71 . . . . 0.0 112.533 179.911 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 97' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -137.94 137.29 37.83 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-O 120.797 0.332 . . . . 0.0 110.838 -179.918 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 98' ' ' GLY . . . . . . . . . . . . . . . 171.44 156.1 11.49 Favored Glycine 0 N--CA 1.451 -0.316 0 C-N-CA 120.671 -0.776 . . . . 0.0 112.476 179.905 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 99' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_exo -52.24 97.11 0.04 OUTLIER 'Trans proline' 0 C--N 1.344 0.316 0 C-N-CA 122.581 2.187 . . . . 0.0 112.311 -179.997 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 100' ' ' SER . . . . . . . . . . . . . 21.7 p -119.07 31.6 6.55 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.893 179.989 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 1.8 t -106.51 -65.97 1.04 Allowed 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.286 -0.416 . . . . 0.0 110.863 -179.97 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.25 1.095 0 CA-C-O 118.428 -1.206 . . . . 0.0 112.492 179.983 . . . . . . . . 0 0 . 1 . 013 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.216 0 N-CA-C 112.58 -0.208 . . . . 0.0 112.58 . . . . . . . . . 0 0 . 1 . 013 nuclear orig full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER 60.57 159.45 0.04 OUTLIER 'General case' 0 C--N 1.328 -0.335 0 CA-C-O 120.844 0.354 . . . . 0.0 110.911 -179.968 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 2.3 t -99.51 128.03 45.61 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.914 -179.983 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 166.31 41.7 0.02 OUTLIER Glycine 0 N--CA 1.45 -0.375 0 C-N-CA 120.791 -0.718 . . . . 0.0 112.572 -179.966 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 19.5 p -155.18 -50.0 0.09 Allowed 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 120.825 0.345 . . . . 0.0 110.893 -179.981 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 1.5 p -66.98 80.06 0.12 Allowed 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.836 179.984 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 129.81 156.25 8.7 Favored Glycine 0 N--CA 1.452 -0.28 0 C-N-CA 120.725 -0.75 . . . . 0.0 112.398 179.944 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 7.5 mttt 60.31 106.75 0.02 OUTLIER 'General case' 0 C--N 1.33 -0.248 0 CA-C-O 120.89 0.376 . . . . 0.0 110.835 -179.98 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -124.38 83.65 57.13 Favored Pre-proline 0 C--N 1.329 -0.304 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.97 179.939 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 50.2 Cg_exo -53.36 88.99 0.03 OUTLIER 'Trans proline' 0 C--N 1.345 0.38 0 C-N-CA 122.534 2.156 . . . . 0.0 112.269 179.986 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 2.9 p -152.64 102.55 2.72 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.266 -0.425 . . . . 0.0 110.878 179.987 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 0.6 OUTLIER -79.99 137.5 53.6 Favored Pre-proline 0 C--N 1.329 -0.283 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.827 179.97 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 72.8 Cg_endo -74.96 176.85 9.35 Favored 'Trans proline' 0 C--N 1.345 0.368 0 C-N-CA 122.491 2.127 . . . . 0.0 112.295 -179.994 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 8.4 t -74.63 175.89 7.44 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.844 179.939 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 22.8 mt -126.37 31.3 5.41 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.91 -179.972 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 90.52 35.13 7.53 Favored Glycine 0 N--CA 1.451 -0.346 0 C-N-CA 120.713 -0.756 . . . . 0.0 112.549 179.961 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 71.8 p -64.14 123.89 20.23 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 120.808 0.337 . . . . 0.0 110.909 -179.95 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -116.43 -42.41 3.02 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.935 -179.968 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 19' ' ' GLN . . . . . . . . . . . . . 1.4 tt0 60.18 163.65 0.06 Allowed 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.919 -179.962 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 20' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -164.67 97.32 0.76 Allowed 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.252 -0.431 . . . . 0.0 110.956 179.94 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -117.49 -39.98 3.1 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.929 -179.932 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 37.2 mt-10 57.43 32.53 21.94 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.096 -0.502 . . . . 0.0 110.899 -179.979 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -108.65 -93.34 2.28 Favored Glycine 0 N--CA 1.451 -0.329 0 C-N-CA 120.719 -0.753 . . . . 0.0 112.534 -179.953 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -80.26 144.49 32.83 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-O 120.86 0.362 . . . . 0.0 111.102 179.933 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 1.6 mmpt? -74.78 -64.15 1.1 Allowed 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.154 -0.476 . . . . 0.0 110.855 -179.986 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -88.03 -178.15 5.91 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.24 -0.436 . . . . 0.0 111.063 -179.962 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 27' ' ' GLU . . . . . . . . . . . . . 14.3 mt-10 -142.57 168.42 19.78 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.938 179.991 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 27.4 t -68.58 85.06 0.14 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.049 179.957 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 132.62 43.86 0.15 Allowed Glycine 0 N--CA 1.452 -0.265 0 C-N-CA 120.677 -0.773 . . . . 0.0 112.462 179.975 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 2.2 t0 -149.81 152.86 35.86 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 120.774 0.321 . . . . 0.0 110.902 -179.915 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 31' ' ' GLN . . . . . . . . . . . . . 1.6 mt-30 -69.03 141.92 54.72 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.918 179.943 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 5.7 m -143.27 174.84 4.43 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-N 116.247 -0.433 . . . . 0.0 111.141 179.96 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 33' ' ' LEU . . . . . . . . . . . . . 13.8 tp -141.25 105.15 4.75 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.843 179.986 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 21.7 t -73.73 123.49 28.98 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.153 -179.982 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 35' ' ' ALA . . . . . . . . . . . . . . . 56.99 25.04 10.19 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.304 179.96 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . 57.29 37.0 78.65 Favored Glycine 0 N--CA 1.45 -0.374 0 C-N-CA 120.803 -0.713 . . . . 0.0 112.572 179.912 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 37' ' ' GLN . . . . . . . . . . . . . 39.0 mt-30 -148.55 -70.17 0.21 Allowed 'General case' 0 C--N 1.33 -0.279 0 CA-C-O 120.731 0.3 . . . . 0.0 110.971 179.98 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 38' ' ' LYS . . . . . . . . . . . . . 62.3 mttt -67.73 105.78 2.03 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.913 179.973 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 39' ' ' GLN . . . . . . . . . . . . . 2.3 tm0? -82.2 132.51 35.24 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.886 -179.996 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -158.08 -174.64 28.04 Favored Glycine 0 N--CA 1.451 -0.333 0 C-N-CA 120.658 -0.782 . . . . 0.0 112.53 179.923 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 15.7 mt -127.41 135.2 63.98 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-O 120.845 0.355 . . . . 0.0 111.046 -179.967 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 42' ' ' VAL . . . . . . . . . . . . . 21.5 t -62.82 120.97 10.71 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.175 179.956 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 43' ' ' ARG . . . . . . . . . . . . . 30.9 mmt180 -110.08 -32.1 7.13 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 116.178 -0.464 . . . . 0.0 110.932 -179.991 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 44' ' ' PHE . . . . . . . . . . . . . 63.4 t80 -147.4 115.53 6.55 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.896 179.924 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 45' ' ' TYR . . . . . 0.496 ' CE1' ' CE1' ' A' ' 56' ' ' TYR . 22.1 t80 -113.1 113.54 25.55 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.967 179.887 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . -175.96 -161.06 24.51 Favored Glycine 0 N--CA 1.452 -0.293 0 C-N-CA 120.712 -0.756 . . . . 0.0 112.474 -179.967 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 47' ' ' LYS . . . . . 0.418 ' HE2' ' CE1' ' A' ' 54' ' ' TYR . 27.2 mttm -88.4 168.95 12.22 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 120.795 0.331 . . . . 0.0 110.893 -179.925 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 48' ' ' THR . . . . . 0.407 HG23 ' CE2' ' A' ' 50' ' ' PHE . 67.1 p -140.04 175.09 9.88 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.949 -179.974 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 3.9 t70 -109.2 -31.52 7.55 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.931 179.994 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 50' ' ' PHE . . . . . 0.419 ' CD1' ' N ' ' A' ' 51' ' ' ALA . 28.2 p90 -65.52 -36.07 82.74 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.97 179.959 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 51' ' ' ALA . . . . . 0.419 ' N ' ' CD1' ' A' ' 50' ' ' PHE . . . -140.98 148.13 50.8 Favored Pre-proline 0 C--N 1.329 -0.318 0 CA-C-N 116.209 -0.45 . . . . 0.0 111.097 -179.99 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 52' ' ' PRO . . . . . . . . . . . . . 59.7 Cg_endo -72.6 176.05 9.35 Favored 'Trans proline' 0 C--N 1.345 0.364 0 C-N-CA 122.508 2.139 . . . . 0.0 112.281 -179.981 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 67.72 175.19 8.33 Favored Glycine 0 N--CA 1.452 -0.286 0 C-N-CA 120.727 -0.749 . . . . 0.0 112.493 -179.934 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 54' ' ' TYR . . . . . 0.418 ' CE1' ' HE2' ' A' ' 47' ' ' LYS . 5.9 m-85 -83.71 148.91 26.81 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-O 120.829 0.347 . . . . 0.0 110.944 -179.983 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 55' ' ' TRP . . . . . . . . . . . . . 72.0 m95 -134.44 164.48 27.34 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.923 -179.978 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 56' ' ' TYR . . . . . 0.496 ' CE1' ' CE1' ' A' ' 45' ' ' TYR . 27.0 m-85 -113.55 112.41 23.5 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.908 179.979 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . -77.21 65.93 2.96 Favored Glycine 0 N--CA 1.451 -0.324 0 C-N-CA 120.727 -0.749 . . . . 0.0 112.396 179.909 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 58' ' ' ILE . . . . . . . . . . . . . 22.5 mt -74.65 152.34 6.78 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.271 0 CA-C-O 120.774 0.321 . . . . 0.0 111.215 -179.976 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 10.8 tm-20 -121.67 120.93 36.15 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 116.258 -0.428 . . . . 0.0 110.862 -179.968 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 60' ' ' LEU . . . . . . . . . . . . . 71.6 mt -79.88 -179.9 7.21 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-N 116.13 -0.486 . . . . 0.0 110.953 179.998 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -108.35 -29.0 9.08 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.028 -179.953 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 62' ' ' GLN . . . . . . . . . . . . . 8.2 mt-30 -108.63 143.41 27.46 Favored Pre-proline 0 C--N 1.329 -0.313 0 CA-C-N 116.382 -0.372 . . . . 0.0 110.973 -179.924 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 63' ' ' PRO . . . . . 0.408 ' HA ' ' CD2' ' A' ' 83' ' ' HIS . 39.4 Cg_exo -60.5 89.87 0.08 OUTLIER 'Trans proline' 0 C--N 1.346 0.4 0 C-N-CA 122.488 2.126 . . . . 0.0 112.18 179.928 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 64' ' ' THR . . . . . . . . . . . . . 10.2 t -170.89 35.97 0.02 OUTLIER 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.294 -0.412 . . . . 0.0 110.967 -179.976 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . -87.02 -95.3 0.88 Allowed Glycine 0 N--CA 1.451 -0.362 0 C-N-CA 120.684 -0.769 . . . . 0.0 112.522 -179.994 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 66' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -172.91 -47.42 0.02 OUTLIER 'General case' 0 C--N 1.328 -0.353 0 CA-C-O 120.854 0.359 . . . . 0.0 110.887 -179.982 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 67' ' ' HIS . . . . . . . . . . . . . 11.5 p80 -135.38 167.5 20.93 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.871 179.915 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -95.8 42.68 1.09 Allowed 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.898 179.945 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 87.33 -53.39 4.4 Favored Glycine 0 N--CA 1.452 -0.295 0 C-N-CA 120.717 -0.754 . . . . 0.0 112.492 179.966 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 70' ' ' SER . . . . . . . . . . . . . 93.8 p -79.05 143.82 35.23 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-O 120.773 0.32 . . . . 0.0 110.952 -179.992 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 71' ' ' VAL . . . . . 0.413 HG13 ' CD2' ' A' ' 72' ' ' PHE . 21.4 t -138.24 112.13 8.06 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.329 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.125 -179.981 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 72' ' ' PHE . . . . . 0.413 ' CD2' HG13 ' A' ' 71' ' ' VAL . 48.0 m-85 60.94 31.04 19.96 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.273 -0.421 . . . . 0.0 110.951 -179.933 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 86.11 29.49 25.36 Favored Glycine 0 N--CA 1.451 -0.304 0 C-N-CA 120.715 -0.755 . . . . 0.0 112.528 -179.997 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 21.5 t -136.77 110.33 8.82 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-O 120.849 0.357 . . . . 0.0 111.103 -179.946 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 75' ' ' ARG . . . . . . . . . . . . . 25.8 ttm-85 -81.47 143.81 31.81 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.132 -0.486 . . . . 0.0 110.91 -179.979 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 76' ' ' TYR . . . . . . . . . . . . . 24.5 m-85 -120.4 -44.48 2.47 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.837 179.992 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 77' ' ' PHE . . . . . . . . . . . . . 8.2 p90 -157.19 156.51 32.73 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.907 -179.891 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 1.2 m -84.64 95.63 8.95 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.117 -0.492 . . . . 0.0 110.883 179.912 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 79' ' ' CYS . . . . . . . . . . . . . 13.9 p -122.85 159.3 28.44 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.288 -0.414 . . . . 0.0 110.976 -179.942 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 80' ' ' ALA . . . . . 0.416 ' HB2' ' CG ' ' A' ' 83' ' ' HIS . . . -59.05 166.68 2.48 Favored Pre-proline 0 C--N 1.328 -0.343 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.011 179.944 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 81' ' ' PRO . . . . . . . . . . . . . 35.7 Cg_endo -65.09 118.26 5.28 Favored 'Trans proline' 0 C--N 1.345 0.365 0 C-N-CA 122.491 2.127 . . . . 0.0 112.196 179.958 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 82' ' ' ARG . . . . . . . . . . . . . 1.1 mtm-85 62.1 46.71 6.16 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.844 -179.944 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 83' ' ' HIS . . . . . 0.416 ' CG ' ' HB2' ' A' ' 80' ' ' ALA . 8.7 m170 -120.68 -43.36 2.48 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.899 179.98 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . -61.07 151.5 41.91 Favored Glycine 0 N--CA 1.451 -0.326 0 C-N-CA 120.708 -0.758 . . . . 0.0 112.494 -179.983 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 85' ' ' VAL . . . . . . . . . . . . . 15.2 m -151.55 129.4 2.49 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-O 120.861 0.362 . . . . 0.0 111.236 -179.929 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 86' ' ' PHE . . . . . . . . . . . . . 8.4 m-85 -102.45 121.87 43.18 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.81 179.985 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 87' ' ' ALA . . . . . . . . . . . . . . . -143.0 145.52 33.47 Favored Pre-proline 0 C--N 1.33 -0.258 0 CA-C-N 116.171 -0.468 . . . . 0.0 111.161 179.943 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 88' ' ' PRO . . . . . . . . . . . . . 32.0 Cg_exo -58.29 137.0 78.22 Favored 'Trans proline' 0 C--N 1.345 0.365 0 C-N-CA 122.575 2.183 . . . . 0.0 112.235 -179.972 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -48.38 -50.96 28.67 Favored 'General case' 0 CA--C 1.521 -0.145 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.316 179.82 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 90' ' ' SER . . . . . . . . . . . . . 51.2 p -55.96 -24.48 38.67 Favored 'General case' 0 N--CA 1.454 -0.246 0 CA-C-N 115.701 -0.681 . . . . 0.0 109.782 178.692 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 91' ' ' ARG . . . . . . . . . . . . . 1.0 OUTLIER -88.22 -14.66 37.96 Favored 'General case' 0 N--CA 1.455 -0.199 0 CA-C-N 115.808 -0.633 . . . . 0.0 110.405 179.062 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 92' ' ' ILE . . . . . . . . . . . . . 22.2 mt -108.45 150.29 11.22 Favored 'Isoleucine or valine' 0 C--O 1.231 0.114 0 CA-C-O 120.84 0.353 . . . . 0.0 111.089 179.887 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 93' ' ' GLN . . . . . . . . . . . . . 1.8 mp0 -110.95 169.68 8.6 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.87 179.98 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 94' ' ' ARG . . . . . . . . . . . . . 9.3 ttt-85 -121.59 119.27 31.42 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.189 -0.459 . . . . 0.0 110.876 -179.99 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 95' ' ' ILE . . . . . . . . . . . . . 4.5 mt -91.21 -51.75 11.26 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.185 -0.461 . . . . 0.0 111.115 -180.0 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . 59.61 61.98 6.64 Favored Glycine 0 N--CA 1.451 -0.309 0 C-N-CA 120.738 -0.744 . . . . 0.0 112.459 179.927 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 97' ' ' SER . . . . . . . . . . . . . 7.5 t -87.76 108.56 19.18 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 120.821 0.343 . . . . 0.0 110.856 179.983 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 98' ' ' GLY . . . . . . . . . . . . . . . 77.23 64.62 2.07 Favored Glycine 0 N--CA 1.45 -0.369 0 C-N-CA 120.751 -0.738 . . . . 0.0 112.501 179.962 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 99' ' ' PRO . . . . . . . . . . . . . 51.3 Cg_exo -54.28 142.44 68.28 Favored 'Trans proline' 0 C--N 1.345 0.368 0 C-N-CA 122.589 2.193 . . . . 0.0 112.282 -179.989 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 100' ' ' SER . . . . . . . . . . . . . 6.6 t 60.04 34.42 21.38 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.893 179.987 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 2.8 m -150.33 122.75 8.45 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.922 179.992 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.249 1.068 0 CA-C-O 118.318 -1.268 . . . . 0.0 112.501 -179.936 . . . . . . . . 0 0 . 1 . 014 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.243 0 N-CA-C 112.441 -0.264 . . . . 0.0 112.441 . . . . . . . . . 0 0 . 1 . 014 nuclear orig full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 5.7 t -146.3 -50.44 0.22 Allowed 'General case' 0 C--N 1.329 -0.319 0 CA-C-O 120.908 0.385 . . . . 0.0 110.91 -179.991 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 69.9 m -96.87 -31.44 12.59 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.954 179.945 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 77.15 37.61 31.92 Favored Glycine 0 N--CA 1.451 -0.352 0 C-N-CA 120.725 -0.75 . . . . 0.0 112.481 179.992 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 45.4 t -99.47 31.45 3.14 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-O 120.801 0.334 . . . . 0.0 110.855 -179.963 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 1.1 m -107.22 156.94 18.3 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.269 -0.423 . . . . 0.0 110.868 -179.976 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 132.3 -56.47 0.74 Allowed Glycine 0 N--CA 1.452 -0.283 0 C-N-CA 120.734 -0.746 . . . . 0.0 112.456 -179.99 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 31.9 mttm -114.79 144.17 43.92 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-O 120.856 0.36 . . . . 0.0 110.894 -179.994 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -172.84 85.41 0.41 Allowed Pre-proline 0 C--N 1.33 -0.269 0 CA-C-N 116.154 -0.475 . . . . 0.0 110.873 -179.99 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 52.3 Cg_endo -69.5 113.23 3.26 Favored 'Trans proline' 0 C--N 1.344 0.319 0 C-N-CA 122.475 2.117 . . . . 0.0 112.291 179.987 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 1.4 p -129.9 154.44 47.31 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.178 -0.464 . . . . 0.0 110.911 179.966 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -105.04 160.94 24.28 Favored Pre-proline 0 C--N 1.329 -0.312 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.883 179.969 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.76 -45.25 1.66 Allowed 'Trans proline' 0 C--N 1.344 0.331 0 C-N-CA 122.609 2.206 . . . . 0.0 112.223 -179.992 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 63.9 m -85.36 109.31 18.31 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.87 179.972 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -151.61 -60.18 0.17 Allowed 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.843 -179.939 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -135.1 -45.16 0.1 Allowed Glycine 0 N--CA 1.451 -0.353 0 C-N-CA 120.745 -0.741 . . . . 0.0 112.469 -179.918 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 2.0 m -156.94 167.01 31.75 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-O 120.841 0.353 . . . . 0.0 110.885 -179.907 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 39.1 mt -149.53 76.65 1.32 Allowed 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.85 179.979 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 19' ' ' GLN . . . . . . . . . . . . . 53.8 mt-30 -109.21 39.79 1.98 Allowed 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.909 -179.986 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 20' ' ' GLN . . . . . . . . . . . . . 47.1 tt0 -83.23 91.94 7.37 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.897 179.998 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -95.89 146.72 24.35 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.838 179.966 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 8.7 pt-20 -177.03 -40.13 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.875 179.96 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 97.95 93.25 1.95 Allowed Glycine 0 N--CA 1.451 -0.343 0 C-N-CA 120.692 -0.765 . . . . 0.0 112.491 179.939 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -142.27 159.55 42.0 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-O 120.871 0.367 . . . . 0.0 111.05 179.99 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -79.66 -66.19 0.9 Allowed 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.169 -0.468 . . . . 0.0 110.917 -179.999 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -105.98 174.73 5.76 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.158 -0.474 . . . . 0.0 111.075 179.953 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 27' ' ' GLU . . . . . . . . . . . . . 41.7 mt-10 -140.64 174.87 10.09 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.871 -179.972 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 21.5 t -75.27 105.48 4.27 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.247 -0.433 . . . . 0.0 111.136 179.961 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 114.51 35.63 1.4 Allowed Glycine 0 N--CA 1.452 -0.291 0 C-N-CA 120.699 -0.762 . . . . 0.0 112.537 -179.969 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -149.0 150.88 33.57 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-O 120.749 0.309 . . . . 0.0 110.934 -179.952 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 31' ' ' GLN . . . . . . . . . . . . . 8.8 mp0 -70.0 151.35 45.67 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.282 -0.417 . . . . 0.0 110.831 -179.995 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 14.0 m -152.38 179.46 0.43 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.261 -0.427 . . . . 0.0 111.153 179.998 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 33' ' ' LEU . . . . . . . . . . . . . 44.3 tp -143.39 117.86 9.71 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.856 179.943 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 21.7 t -85.57 129.6 37.7 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.207 -0.452 . . . . 0.0 111.278 -179.839 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 35' ' ' ALA . . . . . . . . . . . . . . . 53.93 25.91 5.8 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.149 -0.478 . . . . 0.0 111.394 179.893 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . 57.61 33.82 68.16 Favored Glycine 0 N--CA 1.451 -0.353 0 C-N-CA 120.725 -0.75 . . . . 0.0 112.551 179.958 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 37' ' ' GLN . . . . . . . . . . . . . 94.2 mt-30 -146.91 -70.6 0.24 Allowed 'General case' 0 C--N 1.33 -0.281 0 CA-C-O 120.847 0.356 . . . . 0.0 110.993 -179.951 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 38' ' ' LYS . . . . . . . . . . . . . 2.7 mtmp? -67.11 110.41 3.42 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.947 -179.98 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 39' ' ' GLN . . . . . . . . . . . . . 1.3 tm0? -91.35 137.98 31.94 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.921 179.964 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -164.14 -173.22 32.56 Favored Glycine 0 N--CA 1.45 -0.371 0 C-N-CA 120.82 -0.705 . . . . 0.0 112.564 179.939 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 26.6 mt -122.63 132.01 72.08 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-O 120.804 0.335 . . . . 0.0 111.146 179.958 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 42' ' ' VAL . . . . . . . . . . . . . 33.8 t -59.53 124.29 13.53 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.081 179.986 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 43' ' ' ARG . . . . . . . . . . . . . 1.6 mmm-85 -109.77 -31.11 7.56 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.957 179.985 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 44' ' ' PHE . . . . . . . . . . . . . 28.9 t80 -147.59 112.14 5.31 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.892 179.966 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 45' ' ' TYR . . . . . 0.495 ' CE1' ' CZ ' ' A' ' 56' ' ' TYR . 15.2 t80 -113.27 141.9 46.46 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.894 -179.955 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 144.95 -174.53 24.99 Favored Glycine 0 N--CA 1.451 -0.329 0 C-N-CA 120.757 -0.735 . . . . 0.0 112.501 179.951 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 47' ' ' LYS . . . . . 0.414 ' HG3' ' CD1' ' A' ' 54' ' ' TYR . 13.6 mttm -74.02 161.54 29.96 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-O 120.797 0.332 . . . . 0.0 110.88 -179.966 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 48' ' ' THR . . . . . 0.428 HG21 ' CE2' ' A' ' 50' ' ' PHE . 75.2 p -119.07 -176.91 3.22 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.853 -179.975 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 1.8 t0 -113.41 15.65 19.09 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.378 -179.985 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 50' ' ' PHE . . . . . 0.45 ' CD1' ' N ' ' A' ' 51' ' ' ALA . 42.8 p90 -124.79 -41.28 2.13 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 120.74 0.305 . . . . 0.0 110.955 -179.993 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 51' ' ' ALA . . . . . 0.45 ' N ' ' CD1' ' A' ' 50' ' ' PHE . . . -129.25 149.21 72.06 Favored Pre-proline 0 C--N 1.329 -0.306 0 CA-C-N 116.311 -0.404 . . . . 0.0 111.106 -179.995 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 52' ' ' PRO . . . . . . . . . . . . . 55.6 Cg_endo -70.19 178.04 5.25 Favored 'Trans proline' 0 C--N 1.344 0.306 0 C-N-CA 122.608 2.205 . . . . 0.0 112.274 -179.971 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 72.96 -169.91 52.35 Favored Glycine 0 N--CA 1.451 -0.345 0 C-N-CA 120.717 -0.754 . . . . 0.0 112.542 -179.95 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 54' ' ' TYR . . . . . 0.414 ' CD1' ' HG3' ' A' ' 47' ' ' LYS . 99.7 m-85 -111.28 134.38 52.91 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-O 120.849 0.357 . . . . 0.0 110.932 179.933 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 55' ' ' TRP . . . . . . . . . . . . . 42.1 m95 -120.43 157.81 28.53 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.893 179.984 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 56' ' ' TYR . . . . . 0.495 ' CZ ' ' CE1' ' A' ' 45' ' ' TYR . 4.1 m-85 -110.61 123.82 50.7 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.944 -179.901 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . -89.52 64.11 3.23 Favored Glycine 0 N--CA 1.452 -0.253 0 C-N-CA 120.768 -0.729 . . . . 0.0 112.416 179.891 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 58' ' ' ILE . . . . . . . . . . . . . 4.8 mt -71.72 144.7 13.01 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-O 120.783 0.325 . . . . 0.0 111.098 179.988 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 1.4 tm-20 -109.08 137.56 46.8 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.187 -0.461 . . . . 0.0 110.891 179.961 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 60' ' ' LEU . . . . . . . . . . . . . 65.1 mt -93.89 168.88 10.69 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.892 -179.931 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 20.2 t0 -95.79 -31.34 13.23 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.917 179.974 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 62' ' ' GLN . . . . . . . . . . . . . 5.5 pt20 -111.27 153.41 44.04 Favored Pre-proline 0 C--N 1.33 -0.274 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.865 -179.879 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 56.6 Cg_endo -70.67 80.05 1.17 Allowed 'Trans proline' 0 C--N 1.344 0.328 0 C-N-CA 122.605 2.203 . . . . 0.0 112.302 179.943 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 64' ' ' THR . . . . . . . . . . . . . 65.5 p -156.73 31.33 0.31 Allowed 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.075 -0.511 . . . . 0.0 110.823 -179.993 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . -83.85 -114.62 0.61 Allowed Glycine 0 N--CA 1.451 -0.309 0 C-N-CA 120.699 -0.762 . . . . 0.0 112.521 -179.969 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 66' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -151.68 -48.16 0.11 Allowed 'General case' 0 C--N 1.329 -0.293 0 CA-C-O 120.851 0.357 . . . . 0.0 110.904 -179.963 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 67' ' ' HIS . . . . . . . . . . . . . 7.2 p80 -124.37 175.92 6.79 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.973 -179.982 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 1.3 m-20 -97.94 37.25 1.43 Allowed 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.231 -0.44 . . . . 0.0 110.924 179.97 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 91.03 -50.94 3.14 Favored Glycine 0 N--CA 1.451 -0.325 0 C-N-CA 120.723 -0.751 . . . . 0.0 112.489 -179.998 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 70' ' ' SER . . . . . . . . . . . . . 21.4 p -88.31 143.3 27.1 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-O 120.79 0.328 . . . . 0.0 110.927 -179.938 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 71' ' ' VAL . . . . . 0.421 HG13 ' CD2' ' A' ' 72' ' ' PHE . 24.6 t -127.32 114.6 37.23 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.219 -0.446 . . . . 0.0 111.078 179.982 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 72' ' ' PHE . . . . . 0.421 ' CD2' HG13 ' A' ' 71' ' ' VAL . 25.3 m-85 60.32 31.04 20.3 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.956 -179.917 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 86.48 28.56 26.89 Favored Glycine 0 N--CA 1.451 -0.325 0 C-N-CA 120.685 -0.769 . . . . 0.0 112.475 179.969 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 21.5 t -130.16 100.2 4.92 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-O 120.91 0.386 . . . . 0.0 111.161 179.991 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 75' ' ' ARG . . . . . . . . . . . . . 4.8 ttt180 -80.26 112.37 17.52 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.116 -0.493 . . . . 0.0 110.879 -179.942 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 76' ' ' TYR . . . . . . . . . . . . . 58.0 m-85 -88.16 -40.37 13.79 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.911 -180.0 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 77' ' ' PHE . . . . . . . . . . . . . 23.3 p90 -154.1 153.39 31.78 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.889 179.892 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 5.1 t -82.97 111.56 18.95 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.145 -0.48 . . . . 0.0 110.812 -179.999 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 79' ' ' CYS . . . . . . . . . . . . . 18.4 p -143.1 170.71 15.21 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.959 -179.977 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 80' ' ' ALA . . . . . . . . . . . . . . . -70.67 167.06 30.42 Favored Pre-proline 0 C--N 1.329 -0.307 0 CA-C-N 116.121 -0.49 . . . . 0.0 110.969 179.938 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 81' ' ' PRO . . . . . . . . . . . . . 34.7 Cg_endo -64.86 126.83 17.33 Favored 'Trans proline' 0 C--N 1.345 0.356 0 C-N-CA 122.433 2.089 . . . . 0.0 112.224 179.934 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 82' ' ' ARG . . . . . . . . . . . . . 76.2 mtt180 62.03 39.34 13.32 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.132 -0.486 . . . . 0.0 110.957 -179.914 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 83' ' ' HIS . . . . . . . . . . . . . 9.1 m170 -114.55 -37.66 4.23 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.868 179.971 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . -76.91 152.77 41.03 Favored Glycine 0 N--CA 1.451 -0.332 0 C-N-CA 120.746 -0.74 . . . . 0.0 112.529 179.997 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 85' ' ' VAL . . . . . . . . . . . . . 16.1 m -153.9 135.22 5.23 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.329 0 CA-C-O 120.82 0.343 . . . . 0.0 111.12 179.934 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 86' ' ' PHE . . . . . . . . . . . . . 7.2 m-85 -111.09 117.09 32.34 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.99 -179.989 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 87' ' ' ALA . . . . . . . . . . . . . . . -135.42 145.25 52.87 Favored Pre-proline 0 C--N 1.329 -0.324 0 CA-C-N 116.262 -0.426 . . . . 0.0 111.053 179.906 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 88' ' ' PRO . . . . . 0.409 ' O ' ' N ' ' A' ' 91' ' ' ARG . 33.6 Cg_exo -59.62 145.0 99.29 Favored 'Trans proline' 0 C--N 1.344 0.337 0 C-N-CA 122.562 2.174 . . . . 0.0 112.313 -179.978 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -48.45 -50.91 29.43 Favored 'General case' 0 CA--C 1.521 -0.158 0 CA-C-N 116.187 -0.461 . . . . 0.0 110.247 179.84 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 90' ' ' SER . . . . . . . . . . . . . 1.2 m -56.0 -24.37 38.51 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 115.681 -0.69 . . . . 0.0 109.749 178.766 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 91' ' ' ARG . . . . . 0.409 ' N ' ' O ' ' A' ' 88' ' ' PRO . 0.0 OUTLIER -89.75 -13.9 35.78 Favored 'General case' 0 N--CA 1.454 -0.226 0 CA-C-N 115.926 -0.579 . . . . 0.0 110.515 179.125 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 92' ' ' ILE . . . . . . . . . . . . . 48.7 mt -110.31 153.51 12.07 Favored 'Isoleucine or valine' 0 C--O 1.23 0.074 0 CA-C-N 116.378 -0.374 . . . . 0.0 111.072 179.814 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 93' ' ' GLN . . . . . . . . . . . . . 0.6 OUTLIER -116.24 179.81 3.89 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.805 -179.98 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 94' ' ' ARG . . . . . . . . . . . . . 4.1 ttp180 -122.76 144.08 49.41 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.885 -179.983 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 95' ' ' ILE . . . . . . . . . . . . . 22.0 mt -113.42 -35.82 2.34 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 CA-C-N 116.174 -0.466 . . . . 0.0 111.177 179.931 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . 136.65 -174.11 21.74 Favored Glycine 0 N--CA 1.45 -0.377 0 C-N-CA 120.728 -0.749 . . . . 0.0 112.493 179.964 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 97' ' ' SER . . . . . . . . . . . . . 3.6 m -90.94 -57.79 2.69 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 120.793 0.33 . . . . 0.0 110.874 -179.956 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 98' ' ' GLY . . . . . . . . . . . . . . . 126.43 156.26 9.17 Favored Glycine 0 N--CA 1.451 -0.31 0 C-N-CA 120.74 -0.743 . . . . 0.0 112.526 -179.984 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 99' ' ' PRO . . . . . . . . . . . . . 52.9 Cg_endo -69.39 -28.17 27.36 Favored 'Trans proline' 0 C--N 1.344 0.295 0 C-N-CA 122.603 2.202 . . . . 0.0 112.338 179.994 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 100' ' ' SER . . . . . . . . . . . . . 3.3 p -72.38 153.43 41.45 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.884 179.981 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 23.3 t -140.84 -66.36 0.43 Allowed 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.925 179.996 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.25 1.101 0 CA-C-O 118.384 -1.231 . . . . 0.0 112.46 179.988 . . . . . . . . 0 0 . 1 . 015 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.488 2.134 0 N-CA-C 112.556 -0.217 . . . . 0.0 112.556 . . . . . . . . . 0 0 . 1 . 015 nuclear orig full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 7.6 t -168.71 -60.15 0.02 OUTLIER 'General case' 0 C--N 1.33 -0.264 0 CA-C-O 120.778 0.323 . . . . 0.0 110.845 -179.9 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 3.5 p 50.03 95.21 0.01 OUTLIER 'General case' 0 C--N 1.331 -0.236 0 CA-C-N 116.23 -0.441 . . . . 0.0 111.157 -179.943 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 90.82 -149.85 20.25 Favored Glycine 0 N--CA 1.45 -0.403 0 C-N-CA 120.742 -0.742 . . . . 0.0 112.482 -179.9 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 1.2 p -148.43 39.12 0.88 Allowed 'General case' 0 C--N 1.329 -0.321 0 CA-C-O 120.803 0.335 . . . . 0.0 110.867 179.934 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 33.3 t 61.34 162.37 0.07 Allowed 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.886 179.928 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 99.4 -29.0 12.8 Favored Glycine 0 N--CA 1.45 -0.395 0 C-N-CA 120.737 -0.744 . . . . 0.0 112.541 -179.911 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 1.4 tmtp? -62.99 118.92 8.49 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-O 120.784 0.326 . . . . 0.0 110.907 -179.993 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 2.9 m -155.38 165.2 18.83 Favored Pre-proline 0 C--N 1.328 -0.33 0 CA-C-N 116.207 -0.452 . . . . 0.0 110.923 -179.964 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 54.2 Cg_exo -51.98 118.84 4.91 Favored 'Trans proline' 0 C--N 1.344 0.302 0 C-N-CA 122.581 2.187 . . . . 0.0 112.284 179.951 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 7.8 t -125.47 137.55 53.97 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.983 -179.965 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 1.3 m -175.22 138.61 0.58 Allowed Pre-proline 0 C--N 1.329 -0.319 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.877 179.936 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 50.3 Cg_exo -53.46 -177.66 0.03 OUTLIER 'Trans proline' 0 C--N 1.344 0.332 0 C-N-CA 122.544 2.162 . . . . 0.0 112.216 -179.987 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -82.6 77.43 9.37 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.84 -179.997 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 14.6 tp -157.84 93.38 1.26 Allowed 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.897 -179.934 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 59.92 89.72 0.02 OUTLIER Glycine 0 N--CA 1.451 -0.307 0 C-N-CA 120.803 -0.713 . . . . 0.0 112.439 179.953 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -91.1 169.79 10.57 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-O 120.725 0.298 . . . . 0.0 110.96 179.983 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 3.3 mp -71.84 -38.71 70.1 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.251 -0.432 . . . . 0.0 110.888 179.993 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 19' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -122.54 90.41 3.29 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.921 179.952 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 20' ' ' GLN . . . . . . . . . . . . . 1.8 tt0 -102.87 156.0 17.96 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.845 179.999 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -135.84 88.23 2.38 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.849 179.972 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 7.4 mt-10 -158.74 126.79 5.15 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.189 -0.459 . . . . 0.0 110.92 179.918 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 171.82 -45.38 0.18 Allowed Glycine 0 N--CA 1.451 -0.344 0 C-N-CA 120.769 -0.729 . . . . 0.0 112.484 179.993 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -140.97 162.38 35.62 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 120.779 0.323 . . . . 0.0 111.054 179.972 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 1.0 OUTLIER -142.47 -47.2 0.33 Allowed 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.888 -179.948 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -122.72 170.08 10.42 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.181 -0.463 . . . . 0.0 111.121 -179.955 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 27' ' ' GLU . . . . . . . . . . . . . 4.8 mt-10 -124.31 179.51 4.88 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.953 179.976 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 21.4 t -75.21 104.98 3.83 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.241 -0.436 . . . . 0.0 111.172 179.951 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 108.13 34.55 2.72 Favored Glycine 0 N--CA 1.451 -0.328 0 C-N-CA 120.732 -0.747 . . . . 0.0 112.529 -179.941 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -138.06 145.29 41.59 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-O 120.814 0.34 . . . . 0.0 110.879 180.0 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 31' ' ' GLN . . . . . . . . . . . . . 0.7 OUTLIER -60.01 144.78 48.48 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.932 -179.962 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 12.0 m -150.02 174.46 1.08 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.372 0 CA-C-N 116.286 -0.415 . . . . 0.0 111.208 179.953 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 33' ' ' LEU . . . . . . . . . . . . . 28.8 tp -138.71 107.1 5.81 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.886 -179.958 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 21.5 t -77.32 125.58 37.17 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-N 116.236 -0.438 . . . . 0.0 111.22 -179.978 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 35' ' ' ALA . . . . . . . . . . . . . . . 58.2 26.23 13.55 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.163 -0.471 . . . . 0.0 111.333 -179.967 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . 56.14 31.39 59.01 Favored Glycine 0 C--N 1.331 0.279 0 C-N-CA 120.775 -0.726 . . . . 0.0 112.607 179.973 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 37' ' ' GLN . . . . . . . . . . . . . 37.3 mt-30 -145.3 -70.42 0.27 Allowed 'General case' 0 C--N 1.329 -0.287 0 CA-C-O 120.795 0.331 . . . . 0.0 110.877 -179.944 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 38' ' ' LYS . . . . . . . . . . . . . 32.0 mttt -67.57 104.05 1.5 Allowed 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.927 179.958 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 39' ' ' GLN . . . . . . . . . . . . . 4.2 tt0 -82.93 148.03 27.9 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.875 -179.972 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -175.68 -164.13 29.59 Favored Glycine 0 N--CA 1.451 -0.363 0 C-N-CA 120.787 -0.721 . . . . 0.0 112.541 179.945 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 3.8 mp -134.61 139.14 48.33 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-O 120.856 0.36 . . . . 0.0 111.156 179.986 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 42' ' ' VAL . . . . . . . . . . . . . 31.0 t -70.47 127.08 31.91 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.029 179.953 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 43' ' ' ARG . . . . . . . . . . . . . 15.6 mmt180 -110.72 -32.35 6.89 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.207 -0.452 . . . . 0.0 110.923 -179.957 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 44' ' ' PHE . . . . . . . . . . . . . 72.6 t80 -141.21 108.23 5.45 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.859 179.978 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 45' ' ' TYR . . . . . 0.497 ' CE1' ' CZ ' ' A' ' 56' ' ' TYR . 12.5 t80 -109.53 131.96 54.58 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.881 179.949 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 158.82 -137.71 5.33 Favored Glycine 0 N--CA 1.451 -0.36 0 C-N-CA 120.68 -0.771 . . . . 0.0 112.53 -179.968 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 47' ' ' LYS . . . . . . . . . . . . . 11.1 mttm -104.18 154.16 20.08 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-O 120.815 0.341 . . . . 0.0 110.922 179.996 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 48' ' ' THR . . . . . . . . . . . . . 25.5 p -117.86 -179.22 3.69 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.224 -0.443 . . . . 0.0 110.874 179.875 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 2.2 t0 -110.91 -26.55 9.25 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.212 -0.449 . . . . 0.0 111.026 -179.836 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 50' ' ' PHE . . . . . 0.451 ' CD1' ' N ' ' A' ' 51' ' ' ALA . 22.6 p90 -72.32 -34.12 67.86 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.422 -0.354 . . . . 0.0 111.117 -179.831 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 51' ' ' ALA . . . . . 0.451 ' N ' ' CD1' ' A' ' 50' ' ' PHE . . . -148.9 147.81 25.43 Favored Pre-proline 0 C--N 1.329 -0.3 0 CA-C-N 116.3 -0.409 . . . . 0.0 111.237 -179.931 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 52' ' ' PRO . . . . . . . . . . . . . 74.0 Cg_endo -75.3 165.34 31.06 Favored 'Trans proline' 0 C--N 1.344 0.327 0 C-N-CA 122.651 2.234 . . . . 0.0 112.366 179.954 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 99.68 -168.98 21.9 Favored Glycine 0 N--CA 1.451 -0.317 0 C-N-CA 120.734 -0.746 . . . . 0.0 112.56 179.917 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 54' ' ' TYR . . . . . . . . . . . . . 64.9 m-85 -102.31 125.87 49.15 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-O 120.825 0.345 . . . . 0.0 110.893 179.994 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 55' ' ' TRP . . . . . 0.418 ' CZ3' ' HD3' ' A' ' 88' ' ' PRO . 63.9 m95 -127.02 156.77 41.11 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.912 179.976 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 56' ' ' TYR . . . . . 0.497 ' CZ ' ' CE1' ' A' ' 45' ' ' TYR . 4.2 m-85 -113.32 122.71 48.24 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.254 -0.43 . . . . 0.0 110.95 -179.961 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 57' ' ' GLY . . . . . 0.447 ' CA ' ' CE1' ' A' ' 86' ' ' PHE . . . -84.04 68.03 3.6 Favored Glycine 0 N--CA 1.45 -0.404 0 C-N-CA 120.775 -0.726 . . . . 0.0 112.427 179.865 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 58' ' ' ILE . . . . . . . . . . . . . 19.7 mt -73.58 138.59 20.97 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-O 120.812 0.339 . . . . 0.0 111.138 -179.955 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -114.07 112.38 23.15 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.915 179.948 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 60' ' ' LEU . . . . . . . . . . . . . 8.1 mt -73.21 173.06 9.99 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.246 -0.434 . . . . 0.0 110.865 -179.972 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 8.3 p-10 -102.0 -31.59 10.58 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.856 179.957 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 62' ' ' GLN . . . . . . . . . . . . . 4.1 pt20 -106.5 157.49 34.92 Favored Pre-proline 0 C--N 1.329 -0.301 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.835 -179.974 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 37.2 Cg_endo -65.86 82.58 0.25 Allowed 'Trans proline' 0 C--N 1.345 0.345 0 C-N-CA 122.533 2.155 . . . . 0.0 112.263 179.937 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 64' ' ' THR . . . . . . . . . . . . . 9.1 t -156.01 34.55 0.34 Allowed 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.108 -0.496 . . . . 0.0 110.839 -179.995 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . -97.84 -131.51 7.15 Favored Glycine 0 N--CA 1.45 -0.407 0 C-N-CA 120.732 -0.747 . . . . 0.0 112.547 179.956 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 66' ' ' LYS . . . . . . . . . . . . . 4.3 mtmm -144.6 -58.36 0.36 Allowed 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 120.819 0.343 . . . . 0.0 110.9 -179.969 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 67' ' ' HIS . . . . . . . . . . . . . 6.9 p80 -110.72 164.51 12.68 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.887 179.945 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 45.6 t0 -97.76 36.52 1.52 Allowed 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.209 -0.451 . . . . 0.0 110.946 -179.997 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 96.75 -32.1 6.91 Favored Glycine 0 N--CA 1.45 -0.369 0 C-N-CA 120.766 -0.73 . . . . 0.0 112.47 179.955 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 70' ' ' SER . . . . . . . . . . . . . 12.2 p -114.13 141.93 46.86 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-O 120.885 0.374 . . . . 0.0 110.844 179.988 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 71' ' ' VAL . . . . . 0.403 HG13 ' CD2' ' A' ' 72' ' ' PHE . 21.6 t -131.07 111.26 19.43 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.252 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.137 179.929 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 72' ' ' PHE . . . . . 0.403 ' CD2' HG13 ' A' ' 71' ' ' VAL . 53.4 m-85 61.09 30.88 19.7 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.999 -179.952 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 98.8 -27.62 18.97 Favored Glycine 0 N--CA 1.452 -0.26 0 C-N-CA 120.728 -0.749 . . . . 0.0 112.454 -179.971 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 22.8 t -75.55 135.35 27.29 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-O 120.834 0.35 . . . . 0.0 111.09 -179.934 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 75' ' ' ARG . . . . . . . . . . . . . 19.2 ttt180 -107.71 144.44 34.81 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.911 179.992 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 76' ' ' TYR . . . . . 0.403 ' CD1' ' N ' ' A' ' 76' ' ' TYR . 3.9 m-85 -123.42 -44.06 2.15 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.944 179.932 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 77' ' ' PHE . . . . . . . . . . . . . 28.5 p90 -162.88 177.7 9.03 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.866 179.97 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -99.67 113.16 25.43 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.913 179.921 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 79' ' ' CYS . . . . . . . . . . . . . 30.2 p -142.9 152.66 42.32 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.27 -0.423 . . . . 0.0 110.924 179.955 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 80' ' ' ALA . . . . . . . . . . . . . . . -66.79 168.26 11.09 Favored Pre-proline 0 C--N 1.329 -0.325 0 CA-C-N 116.215 -0.448 . . . . 0.0 111.054 -179.984 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 81' ' ' PRO . . . . . . . . . . . . . 41.7 Cg_exo -56.91 122.49 11.91 Favored 'Trans proline' 0 C--N 1.344 0.293 0 C-N-CA 122.584 2.19 . . . . 0.0 112.306 -179.991 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 82' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER 62.37 51.91 3.23 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.169 -0.469 . . . . 0.0 111.082 179.845 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 83' ' ' HIS . . . . . . . . . . . . . 7.0 m170 -124.77 -50.42 1.72 Allowed 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.861 179.92 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . -66.05 142.36 43.04 Favored Glycine 0 N--CA 1.451 -0.338 0 C-N-CA 120.748 -0.739 . . . . 0.0 112.536 179.928 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 85' ' ' VAL . . . . . . . . . . . . . 6.9 m -146.99 129.04 6.93 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-O 120.862 0.363 . . . . 0.0 111.076 179.957 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 86' ' ' PHE . . . . . 0.447 ' CE1' ' CA ' ' A' ' 57' ' ' GLY . 17.0 m-85 -108.12 114.9 29.14 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.106 -0.497 . . . . 0.0 110.85 -179.977 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 87' ' ' ALA . . . . . . . . . . . . . . . -136.68 146.7 56.49 Favored Pre-proline 0 C--N 1.33 -0.281 0 CA-C-N 116.14 -0.482 . . . . 0.0 111.178 179.916 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 88' ' ' PRO . . . . . 0.423 ' O ' ' N ' ' A' ' 91' ' ' ARG . 34.5 Cg_exo -57.7 142.84 96.06 Favored 'Trans proline' 0 C--N 1.345 0.352 0 C-N-CA 122.561 2.174 . . . . 0.0 112.324 -179.942 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 89' ' ' ALA . . . . . 0.425 ' HB3' ' CE1' ' A' ' 56' ' ' TYR . . . -48.04 -50.75 26.82 Favored 'General case' 0 C--O 1.231 0.117 0 CA-C-N 116.101 -0.5 . . . . 0.0 110.261 179.853 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 90' ' ' SER . . . . . . . . . . . . . 42.6 m -55.75 -24.43 35.27 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 115.708 -0.678 . . . . 0.0 109.733 178.828 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 91' ' ' ARG . . . . . 0.423 ' N ' ' O ' ' A' ' 88' ' ' PRO . 3.4 mtm180 -89.41 -14.81 34.65 Favored 'General case' 0 N--CA 1.456 -0.172 0 CA-C-N 115.857 -0.611 . . . . 0.0 110.472 179.059 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 92' ' ' ILE . . . . . . . . . . . . . 48.2 mt -107.03 158.3 6.99 Favored 'Isoleucine or valine' 0 C--O 1.231 0.128 0 CA-C-N 116.379 -0.373 . . . . 0.0 111.014 179.793 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 93' ' ' GLN . . . . . . . . . . . . . 5.2 mt-30 -130.18 176.82 7.79 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.964 -179.973 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 94' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -118.16 154.23 32.51 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.903 179.971 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 95' ' ' ILE . . . . . . . . . . . . . 4.4 mt -119.54 -41.11 2.09 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.102 179.957 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . -64.85 95.11 0.19 Allowed Glycine 0 N--CA 1.451 -0.347 0 C-N-CA 120.681 -0.771 . . . . 0.0 112.496 179.982 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 97' ' ' SER . . . . . . . . . . . . . 23.2 p -86.91 169.25 12.67 Favored 'General case' 0 C--N 1.331 -0.231 0 CA-C-O 120.883 0.373 . . . . 0.0 110.872 -179.953 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 98' ' ' GLY . . . . . . . . . . . . . . . 176.12 177.89 45.49 Favored Glycine 0 N--CA 1.451 -0.346 0 C-N-CA 120.764 -0.731 . . . . 0.0 112.538 179.985 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 99' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_exo -52.31 130.98 38.1 Favored 'Trans proline' 0 C--N 1.343 0.289 0 C-N-CA 122.655 2.237 . . . . 0.0 112.253 -179.998 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 100' ' ' SER . . . . . . . . . . . . . 1.5 m -96.76 135.75 38.26 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.202 -0.453 . . . . 0.0 110.897 179.964 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 4.3 m -130.12 137.27 50.07 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.107 -0.497 . . . . 0.0 110.891 179.995 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.249 1.082 0 CA-C-O 118.305 -1.275 . . . . 0.0 112.576 -179.934 . . . . . . . . 0 0 . 1 . 016 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.191 0 N-CA-C 112.506 -0.238 . . . . 0.0 112.506 . . . . . . . . . 0 0 . 1 . 016 nuclear orig full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -113.18 -60.8 1.83 Allowed 'General case' 0 C--N 1.328 -0.338 0 CA-C-O 120.864 0.364 . . . . 0.0 110.873 -179.966 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 40.0 t -117.62 -40.39 3.04 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.887 -179.996 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 144.38 132.32 2.53 Favored Glycine 0 N--CA 1.451 -0.353 0 C-N-CA 120.781 -0.723 . . . . 0.0 112.557 -179.98 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 55.2 p -98.94 32.02 2.79 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-O 120.917 0.389 . . . . 0.0 110.953 -179.995 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 8.4 t -122.59 -178.25 3.86 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.868 179.981 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -95.64 143.18 16.5 Favored Glycine 0 N--CA 1.453 -0.216 0 C-N-CA 120.719 -0.753 . . . . 0.0 112.43 180.0 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 11.2 ttpt -85.36 158.51 20.24 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-O 120.815 0.341 . . . . 0.0 110.945 -179.995 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 9' ' ' SER . . . . . 0.422 ' CB ' ' CD ' ' A' ' 10' ' ' PRO . 1.1 m -178.52 -61.62 0.0 OUTLIER Pre-proline 0 C--N 1.329 -0.288 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.903 179.977 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 10' ' ' PRO . . . . . 0.422 ' CD ' ' CB ' ' A' ' 9' ' ' SER . 58.3 Cg_endo -71.56 114.91 4.09 Favored 'Trans proline' 0 C--N 1.345 0.378 0 C-N-CA 122.462 2.108 . . . . 0.0 112.379 179.94 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -128.39 -61.74 1.07 Allowed 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.942 -179.936 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 8.4 t -156.18 107.71 2.07 Favored Pre-proline 0 C--N 1.329 -0.287 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.911 -179.951 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 44.4 Cg_endo -68.08 85.16 0.42 Allowed 'Trans proline' 0 C--N 1.345 0.383 0 C-N-CA 122.438 2.092 . . . . 0.0 112.311 -179.952 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 0.6 OUTLIER -112.64 -66.84 1.04 Allowed 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.809 -179.991 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 2.4 mp -136.51 113.56 10.53 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.198 -0.456 . . . . 0.0 110.837 179.983 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 59.25 28.26 64.07 Favored Glycine 0 N--CA 1.451 -0.353 0 C-N-CA 120.742 -0.742 . . . . 0.0 112.533 179.957 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 0.6 OUTLIER -92.54 -45.91 7.88 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-O 120.775 0.321 . . . . 0.0 110.877 -179.951 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 13.2 mt -142.83 161.9 36.89 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.803 -179.972 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 19' ' ' GLN . . . . . . . . . . . . . 1.4 tp60 -160.27 30.63 0.17 Allowed 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.957 -180.0 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 20' ' ' GLN . . . . . . . . . . . . . 18.8 mt-30 59.59 98.03 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.189 -0.46 . . . . 0.0 111.006 -179.987 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -170.73 137.14 1.26 Allowed 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.9 179.983 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 6.4 mt-10 -122.1 -59.29 1.66 Allowed 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.968 -179.973 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -160.64 -131.02 1.18 Allowed Glycine 0 N--CA 1.451 -0.347 0 C-N-CA 120.729 -0.748 . . . . 0.0 112.506 -179.985 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -68.13 -179.47 1.26 Allowed 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.825 0.345 . . . . 0.0 111.076 179.93 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 0.7 OUTLIER -152.61 -47.45 0.1 Allowed 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.919 179.975 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -122.77 -174.54 2.95 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.984 179.947 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 27' ' ' GLU . . . . . . . . . . . . . 13.8 mt-10 -141.28 174.26 10.7 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.154 -0.476 . . . . 0.0 110.881 -179.973 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 22.1 t -76.18 117.96 21.68 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.129 179.871 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 109.39 28.65 4.25 Favored Glycine 0 N--CA 1.452 -0.281 0 C-N-CA 120.776 -0.726 . . . . 0.0 112.491 -179.95 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 7.8 t0 -143.21 142.23 31.35 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 120.807 0.336 . . . . 0.0 110.863 -179.931 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 31' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -61.62 150.35 36.6 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.843 179.931 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 15.2 m -154.14 170.6 0.81 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.351 0 CA-C-N 116.222 -0.444 . . . . 0.0 111.182 179.971 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 33' ' ' LEU . . . . . . . . . . . . . 28.9 tp -134.88 106.02 6.68 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.94 179.968 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 21.7 t -74.48 124.82 32.85 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.169 -179.918 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 35' ' ' ALA . . . . . . . . . . . . . . . 57.38 26.08 12.06 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.138 -0.483 . . . . 0.0 111.298 179.953 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . 55.81 26.95 48.76 Favored Glycine 0 N--CA 1.452 -0.284 0 C-N-CA 120.723 -0.751 . . . . 0.0 112.647 179.959 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 37' ' ' GLN . . . . . . . . . . . . . 77.9 mt-30 -138.15 -68.37 0.46 Allowed 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 120.842 0.353 . . . . 0.0 110.931 -179.949 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 38' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -69.7 111.14 5.28 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.906 -179.996 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 39' ' ' GLN . . . . . . . . . . . . . 1.9 tt0 -89.25 135.39 33.6 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.154 -0.476 . . . . 0.0 110.976 179.933 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -165.5 -167.97 26.94 Favored Glycine 0 N--CA 1.451 -0.304 0 C-N-CA 120.7 -0.762 . . . . 0.0 112.513 180.0 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 23.5 mt -129.52 143.19 41.89 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-O 120.789 0.328 . . . . 0.0 111.16 -179.959 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 42' ' ' VAL . . . . . . . . . . . . . 21.9 t -68.22 112.04 2.98 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.247 -0.433 . . . . 0.0 111.114 179.961 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 43' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -96.19 -41.21 8.8 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.965 -179.986 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 44' ' ' PHE . . . . . . . . . . . . . 21.0 t80 -135.74 119.02 16.66 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.895 179.985 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 45' ' ' TYR . . . . . 0.423 ' CE1' ' CZ ' ' A' ' 56' ' ' TYR . 38.0 t80 -123.04 136.75 54.96 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.115 -0.493 . . . . 0.0 110.844 -179.989 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 157.86 -155.3 26.31 Favored Glycine 0 N--CA 1.451 -0.346 0 C-N-CA 120.747 -0.739 . . . . 0.0 112.478 179.914 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 47' ' ' LYS . . . . . . . . . . . . . 2.1 mtpt -83.35 150.12 26.3 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-O 120.844 0.354 . . . . 0.0 110.891 179.999 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 48' ' ' THR . . . . . 0.417 HG22 ' CE2' ' A' ' 50' ' ' PHE . 6.3 p -115.04 178.01 4.44 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.814 -179.981 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -115.01 -37.48 4.13 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.974 -179.997 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 50' ' ' PHE . . . . . 0.417 ' CE2' HG22 ' A' ' 48' ' ' THR . 27.4 p90 -63.78 -32.35 73.82 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.191 -0.458 . . . . 0.0 110.951 -179.936 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 51' ' ' ALA . . . . . 0.401 ' HB1' ' CD1' ' A' ' 50' ' ' PHE . . . -149.62 152.08 34.3 Favored Pre-proline 0 C--N 1.33 -0.269 0 CA-C-N 116.226 -0.443 . . . . 0.0 111.156 -179.997 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 52' ' ' PRO . . . . . . . . . . . . . 57.6 Cg_endo -71.33 168.98 21.88 Favored 'Trans proline' 0 C--N 1.344 0.321 0 C-N-CA 122.562 2.175 . . . . 0.0 112.262 179.99 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 89.87 -160.15 28.46 Favored Glycine 0 N--CA 1.45 -0.37 0 C-N-CA 120.707 -0.758 . . . . 0.0 112.562 -179.972 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 54' ' ' TYR . . . . . . . . . . . . . 59.5 m-85 -123.67 125.73 45.31 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 120.841 0.353 . . . . 0.0 110.839 -179.928 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 55' ' ' TRP . . . . . 0.412 ' CZ3' ' HD3' ' A' ' 88' ' ' PRO . 37.3 m95 -112.34 169.8 8.62 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.22 -0.446 . . . . 0.0 110.835 179.987 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 56' ' ' TYR . . . . . 0.423 ' CZ ' ' CE1' ' A' ' 45' ' ' TYR . 9.2 m-85 -118.9 117.43 28.81 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.965 -179.96 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . -82.35 61.37 4.72 Favored Glycine 0 N--CA 1.45 -0.367 0 C-N-CA 120.752 -0.737 . . . . 0.0 112.402 179.956 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 58' ' ' ILE . . . . . . . . . . . . . 13.2 mt -69.91 137.94 23.07 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-O 120.911 0.386 . . . . 0.0 111.079 -179.949 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER -106.28 133.73 50.52 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.859 179.927 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 60' ' ' LEU . . . . . . . . . . . . . 53.5 mt -100.48 171.64 7.62 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.915 -179.969 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 61' ' ' ASP . . . . . 0.404 ' O ' ' CE1' ' A' ' 83' ' ' HIS . 0.7 OUTLIER -97.28 -30.8 12.76 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.095 -0.502 . . . . 0.0 110.919 179.987 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 62' ' ' GLN . . . . . . . . . . . . . 6.5 mm-40 -97.49 155.35 37.38 Favored Pre-proline 0 C--N 1.328 -0.331 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.974 -179.974 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 74.3 Cg_endo -75.44 60.63 5.81 Favored 'Trans proline' 0 C--N 1.344 0.324 0 C-N-CA 122.648 2.232 . . . . 0.0 112.262 -179.961 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 64' ' ' THR . . . . . . . . . . . . . 26.7 p -132.85 33.26 3.73 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.253 -0.431 . . . . 0.0 110.932 -179.95 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . -85.47 -127.51 1.86 Allowed Glycine 0 N--CA 1.451 -0.338 0 C-N-CA 120.689 -0.767 . . . . 0.0 112.489 -179.968 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 66' ' ' LYS . . . . . . . . . . . . . 0.3 OUTLIER -150.24 -49.08 0.13 Allowed 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.824 0.345 . . . . 0.0 110.865 -179.961 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 67' ' ' HIS . . . . . . . . . . . . . 5.7 p80 -119.5 169.92 9.62 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.143 -0.48 . . . . 0.0 110.854 -179.962 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -97.08 39.8 1.17 Allowed 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.87 -179.987 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 99.43 -36.34 4.13 Favored Glycine 0 N--CA 1.451 -0.337 0 C-N-CA 120.735 -0.745 . . . . 0.0 112.537 179.907 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 70' ' ' SER . . . . . . . . . . . . . 11.7 p -115.32 163.52 15.58 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 120.8 0.333 . . . . 0.0 110.957 179.986 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 21.4 t -137.88 116.25 13.62 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 116.137 -0.483 . . . . 0.0 111.125 179.984 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 72' ' ' PHE . . . . . . . . . . . . . 32.3 m-85 60.6 30.76 19.96 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.928 179.973 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 99.58 -30.03 10.8 Favored Glycine 0 N--CA 1.451 -0.341 0 C-N-CA 120.641 -0.79 . . . . 0.0 112.568 179.988 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 21.5 t -77.5 114.94 18.64 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.34 0 CA-C-O 120.896 0.379 . . . . 0.0 111.068 179.991 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 75' ' ' ARG . . . . . . . . . . . . . 12.6 ttm180 -95.27 126.49 40.62 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.911 179.967 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 76' ' ' TYR . . . . . . . . . . . . . 12.8 m-85 -100.17 -50.75 3.86 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.797 -179.96 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 77' ' ' PHE . . . . . . . . . . . . . 11.3 p90 -144.3 173.34 11.86 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.946 -179.96 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 41.6 p -103.94 122.08 44.45 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.266 -0.425 . . . . 0.0 110.904 179.917 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 79' ' ' CYS . . . . . . . . . . . . . 27.8 p -145.13 172.53 12.96 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.849 -179.988 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 80' ' ' ALA . . . . . . . . . . . . . . . -78.64 166.66 41.09 Favored Pre-proline 0 C--N 1.33 -0.268 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.115 179.988 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 81' ' ' PRO . . . . . . . . . . . . . 50.1 Cg_exo -53.57 116.35 2.93 Favored 'Trans proline' 0 C--N 1.345 0.362 0 C-N-CA 122.587 2.191 . . . . 0.0 112.333 179.959 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 82' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER 61.94 53.4 3.08 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.879 179.923 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 83' ' ' HIS . . . . . 0.404 ' CE1' ' O ' ' A' ' 61' ' ' ASP . 7.4 m170 -123.45 -44.46 2.12 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.915 179.921 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . -71.02 150.0 46.91 Favored Glycine 0 N--CA 1.451 -0.359 0 C-N-CA 120.699 -0.762 . . . . 0.0 112.535 179.948 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 85' ' ' VAL . . . . . . . . . . . . . 10.8 m -148.94 139.27 16.57 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-O 120.817 0.342 . . . . 0.0 111.157 -179.962 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 86' ' ' PHE . . . . . . . . . . . . . 4.1 m-85 -115.93 109.03 17.01 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.839 179.988 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 87' ' ' ALA . . . . . . . . . . . . . . . -130.84 142.85 47.04 Favored Pre-proline 0 C--N 1.33 -0.261 0 CA-C-N 116.259 -0.428 . . . . 0.0 111.126 -179.953 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 88' ' ' PRO . . . . . 0.421 ' O ' ' N ' ' A' ' 91' ' ' ARG . 44.3 Cg_exo -56.26 143.7 84.49 Favored 'Trans proline' 0 C--N 1.345 0.391 0 C-N-CA 122.516 2.144 . . . . 0.0 112.22 179.938 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 89' ' ' ALA . . . . . 0.417 ' HB1' ' CE1' ' A' ' 56' ' ' TYR . . . -47.89 -50.88 25.26 Favored 'General case' 0 C--N 1.333 -0.134 0 CA-C-O 121.113 0.482 . . . . 0.0 110.308 179.807 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 90' ' ' SER . . . . . . . . . . . . . 1.1 m -55.72 -24.76 36.63 Favored 'General case' 0 C--N 1.331 -0.215 0 CA-C-N 115.639 -0.71 . . . . 0.0 109.721 178.765 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 91' ' ' ARG . . . . . 0.421 ' N ' ' O ' ' A' ' 88' ' ' PRO . 0.0 OUTLIER -87.9 -16.28 34.34 Favored 'General case' 0 N--CA 1.454 -0.244 0 CA-C-N 115.833 -0.622 . . . . 0.0 110.393 179.044 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 92' ' ' ILE . . . . . . . . . . . . . 44.1 mt -104.2 153.74 6.19 Favored 'Isoleucine or valine' 0 C--O 1.231 0.114 0 CA-C-N 116.344 -0.389 . . . . 0.0 111.063 179.882 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 93' ' ' GLN . . . . . . . . . . . . . 0.3 OUTLIER -120.43 142.57 49.1 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.922 -179.976 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 94' ' ' ARG . . . . . . . . . . . . . 12.9 ttt180 -89.96 116.44 28.02 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.222 -0.444 . . . . 0.0 110.868 179.996 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 95' ' ' ILE . . . . . . . . . . . . . 35.2 mt -75.31 -54.24 14.47 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.136 -0.484 . . . . 0.0 111.143 179.99 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . -84.31 84.14 1.6 Allowed Glycine 0 N--CA 1.451 -0.311 0 C-N-CA 120.736 -0.745 . . . . 0.0 112.481 179.998 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 97' ' ' SER . . . . . . . . . . . . . 17.0 t -116.65 129.1 55.95 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-O 120.889 0.376 . . . . 0.0 110.888 179.985 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 98' ' ' GLY . . . . . . . . . . . . . . . 168.49 65.67 0.03 OUTLIER Glycine 0 N--CA 1.451 -0.334 0 C-N-CA 120.78 -0.724 . . . . 0.0 112.566 179.99 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 99' ' ' PRO . . . . . . . . . . . . . 55.4 Cg_endo -69.88 -45.81 1.39 Allowed 'Trans proline' 0 C--N 1.345 0.347 0 C-N-CA 122.543 2.162 . . . . 0.0 112.302 -179.988 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 100' ' ' SER . . . . . . . . . . . . . 1.4 p -80.81 172.68 13.44 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.872 -179.954 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 47.4 t -84.08 -36.2 23.18 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.967 179.956 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.248 1.011 0 CA-C-O 118.437 -1.202 . . . . 0.0 112.498 -179.999 . . . . . . . . 0 0 . 1 . 017 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.245 0 N-CA-C 112.546 -0.222 . . . . 0.0 112.546 . . . . . . . . . 0 0 . 1 . 017 nuclear orig full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -84.53 -171.72 3.78 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-O 120.803 0.335 . . . . 0.0 110.919 -179.962 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 18.6 p -162.95 163.59 26.13 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.809 -179.967 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -113.91 26.94 9.54 Favored Glycine 0 N--CA 1.451 -0.303 0 C-N-CA 120.727 -0.749 . . . . 0.0 112.586 -179.975 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -176.77 -65.85 0.01 OUTLIER 'General case' 0 C--N 1.33 -0.274 0 CA-C-O 120.815 0.34 . . . . 0.0 110.884 179.959 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 15.5 p -176.16 179.7 1.23 Allowed 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.877 179.952 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 80.65 152.41 8.36 Favored Glycine 0 N--CA 1.452 -0.291 0 C-N-CA 120.694 -0.765 . . . . 0.0 112.43 -179.989 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 15.0 mttp -133.02 -174.06 3.37 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 120.826 0.346 . . . . 0.0 110.931 -179.96 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 33.8 m -125.48 88.92 53.44 Favored Pre-proline 0 C--N 1.33 -0.266 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.96 -179.965 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 64.0 Cg_exo -51.16 146.47 23.14 Favored 'Trans proline' 0 C--N 1.345 0.387 0 C-N-CA 122.514 2.142 . . . . 0.0 112.383 179.919 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 1.6 p -157.38 158.25 35.56 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.895 -179.987 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 1.3 m -153.84 71.43 6.55 Favored Pre-proline 0 C--N 1.33 -0.279 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.858 -179.997 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 58.3 Cg_endo -71.71 -174.01 1.17 Allowed 'Trans proline' 0 C--N 1.343 0.28 0 C-N-CA 122.557 2.172 . . . . 0.0 112.306 179.98 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER 60.01 36.8 21.48 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.288 -0.415 . . . . 0.0 110.853 179.948 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -106.12 -39.22 6.03 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.258 -0.428 . . . . 0.0 110.836 179.93 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -136.85 13.0 3.91 Favored Glycine 0 N--CA 1.451 -0.303 0 C-N-CA 120.752 -0.737 . . . . 0.0 112.774 -179.996 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 71.2 m 55.88 34.41 23.48 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-O 120.792 0.33 . . . . 0.0 111.044 179.918 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER 61.1 89.5 0.08 Allowed 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.867 -179.992 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 19' ' ' GLN . . . . . . . . . . . . . 4.4 tt0 -172.05 105.84 0.19 Allowed 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.907 -179.989 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 20' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -150.06 160.48 43.61 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.98 -179.983 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 12.5 mtm180 60.49 157.65 0.03 OUTLIER 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.246 -0.434 . . . . 0.0 110.955 179.967 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -144.74 -70.0 0.29 Allowed 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.841 -179.996 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 72.96 157.82 4.18 Favored Glycine 0 N--CA 1.45 -0.389 0 C-N-CA 120.747 -0.739 . . . . 0.0 112.524 -179.948 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -81.62 157.07 24.83 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-O 120.816 0.341 . . . . 0.0 111.028 -179.976 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 8.7 mmtt -67.08 -62.26 1.52 Allowed 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.934 179.965 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -125.52 175.07 7.78 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.24 -0.436 . . . . 0.0 111.14 -179.957 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 27' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -123.91 168.1 13.24 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.848 -179.963 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 25.2 t -73.43 111.42 8.24 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.097 179.951 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 112.72 27.96 3.62 Favored Glycine 0 N--CA 1.452 -0.285 0 C-N-CA 120.752 -0.737 . . . . 0.0 112.516 -179.966 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -136.57 145.53 45.08 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-O 120.757 0.313 . . . . 0.0 110.895 179.995 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 31' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -68.56 136.01 52.41 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.887 179.978 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 12.7 m -136.66 179.67 3.66 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.181 -0.463 . . . . 0.0 111.093 179.993 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 33' ' ' LEU . . . . . . . . . . . . . 15.7 tp -137.91 114.1 10.11 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.914 179.959 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 21.5 t -83.82 123.22 38.67 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.343 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.104 179.997 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 35' ' ' ALA . . . . . . . . . . . . . . . 59.34 26.39 15.24 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.197 179.979 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . 56.13 27.78 52.66 Favored Glycine 0 N--CA 1.452 -0.299 0 C-N-CA 120.774 -0.727 . . . . 0.0 112.579 179.999 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 37' ' ' GLN . . . . . . . . . . . . . 41.7 mt-30 -137.17 -70.6 0.45 Allowed 'General case' 0 C--N 1.328 -0.336 0 CA-C-O 120.858 0.361 . . . . 0.0 110.987 -179.965 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 38' ' ' LYS . . . . . . . . . . . . . 11.5 mttm -70.4 124.6 24.57 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.923 179.969 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 39' ' ' GLN . . . . . . . . . . . . . 0.1 OUTLIER -99.13 129.57 45.39 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.861 179.993 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -151.88 -173.78 21.92 Favored Glycine 0 N--CA 1.452 -0.276 0 C-N-CA 120.702 -0.761 . . . . 0.0 112.49 179.955 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 32.7 mt -125.15 138.05 55.58 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-O 120.77 0.319 . . . . 0.0 111.125 -179.984 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 42' ' ' VAL . . . . . . . . . . . . . 26.5 t -67.17 113.98 3.63 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.226 -0.443 . . . . 0.0 111.02 179.956 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 43' ' ' ARG . . . . . . . . . . . . . 14.7 mmt180 -102.6 -31.45 10.38 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.933 179.995 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 44' ' ' PHE . . . . . . . . . . . . . 80.7 t80 -146.26 116.71 7.51 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.895 179.943 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 45' ' ' TYR . . . . . 0.488 ' CE1' ' CZ ' ' A' ' 56' ' ' TYR . 17.7 t80 -114.52 117.53 31.2 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.922 179.936 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 173.58 170.44 37.07 Favored Glycine 0 N--CA 1.451 -0.339 0 C-N-CA 120.746 -0.74 . . . . 0.0 112.534 -179.943 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 47' ' ' LYS . . . . . . . . . . . . . 85.5 mttt -65.33 148.27 51.99 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-O 120.819 0.342 . . . . 0.0 110.899 -179.922 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 48' ' ' THR . . . . . 0.411 HG21 ' CZ ' ' A' ' 50' ' ' PHE . 0.9 OUTLIER -103.03 -177.08 3.27 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.909 179.989 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 12.5 t0 -109.21 -31.53 7.55 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.246 -0.434 . . . . 0.0 110.985 -179.999 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 50' ' ' PHE . . . . . 0.411 ' CZ ' HG21 ' A' ' 48' ' ' THR . 19.8 p90 -80.01 -31.19 39.66 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.979 180.0 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 51' ' ' ALA . . . . . . . . . . . . . . . -134.8 139.99 33.92 Favored Pre-proline 0 C--N 1.329 -0.306 0 CA-C-N 116.269 -0.423 . . . . 0.0 111.078 -179.957 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 52' ' ' PRO . . . . . . . . . . . . . 72.0 Cg_endo -76.82 167.06 25.95 Favored 'Trans proline' 0 C--N 1.346 0.434 0 C-N-CA 122.469 2.113 . . . . 0.0 112.292 -179.974 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 92.21 -167.85 30.64 Favored Glycine 0 N--CA 1.45 -0.372 0 C-N-CA 120.734 -0.746 . . . . 0.0 112.562 179.898 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 54' ' ' TYR . . . . . . . . . . . . . 31.0 m-85 -103.31 124.27 48.34 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-O 120.868 0.366 . . . . 0.0 110.833 -179.969 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 55' ' ' TRP . . . . . . . . . . . . . 75.2 m95 -117.29 160.61 20.84 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.865 -179.997 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 56' ' ' TYR . . . . . 0.488 ' CZ ' ' CE1' ' A' ' 45' ' ' TYR . 5.7 m-85 -118.45 115.81 25.4 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.963 -179.96 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . -82.04 69.53 3.3 Favored Glycine 0 N--CA 1.452 -0.283 0 C-N-CA 120.646 -0.788 . . . . 0.0 112.437 179.933 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 58' ' ' ILE . . . . . . . . . . . . . 3.9 mt -75.67 141.05 16.36 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-O 120.8 0.333 . . . . 0.0 111.099 -179.976 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 3.1 tt0 -105.63 119.38 38.98 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.925 179.956 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 60' ' ' LEU . . . . . . . . . . . . . 92.7 mt -77.94 172.25 13.76 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.935 179.993 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -101.32 -29.2 12.19 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.895 -179.984 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 62' ' ' GLN . . . . . . . . . . . . . 0.3 OUTLIER -106.65 155.63 38.58 Favored Pre-proline 0 C--N 1.33 -0.259 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.936 179.965 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 55.0 Cg_endo -69.73 70.29 1.57 Allowed 'Trans proline' 0 C--N 1.344 0.335 0 C-N-CA 122.526 2.151 . . . . 0.0 112.296 179.993 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 64' ' ' THR . . . . . . . . . . . . . 42.9 p -147.75 43.76 1.08 Allowed 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 116.112 -0.494 . . . . 0.0 110.826 179.998 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . -95.49 -127.74 5.32 Favored Glycine 0 N--CA 1.451 -0.322 0 C-N-CA 120.777 -0.725 . . . . 0.0 112.561 179.968 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 66' ' ' LYS . . . . . . . . . . . . . 0.6 OUTLIER -148.16 -50.04 0.17 Allowed 'General case' 0 C--N 1.328 -0.346 0 CA-C-O 120.833 0.349 . . . . 0.0 110.83 179.999 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 67' ' ' HIS . . . . . . . . . . . . . 6.7 p80 -123.1 168.06 12.87 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.154 -0.476 . . . . 0.0 110.833 179.969 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 9.2 p-10 -98.89 31.29 3.02 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.253 -0.431 . . . . 0.0 110.914 -179.984 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 100.36 -28.09 17.4 Favored Glycine 0 N--CA 1.451 -0.312 0 C-N-CA 120.653 -0.784 . . . . 0.0 112.486 -179.979 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 70' ' ' SER . . . . . . . . . . . . . 33.2 p -122.47 139.74 53.53 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-O 120.795 0.331 . . . . 0.0 110.867 -179.981 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 21.5 t -124.99 116.81 48.27 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.224 -0.444 . . . . 0.0 111.029 179.988 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 72' ' ' PHE . . . . . . . . . . . . . 13.7 m-85 60.96 30.92 19.9 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.901 179.965 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 98.45 -28.52 14.5 Favored Glycine 0 N--CA 1.451 -0.33 0 C-N-CA 120.756 -0.735 . . . . 0.0 112.498 179.933 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 21.5 t -77.05 122.42 31.55 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.272 0 CA-C-O 120.876 0.369 . . . . 0.0 111.109 179.998 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 75' ' ' ARG . . . . . . . . . . . . . 3.4 ttt180 -95.3 146.34 24.44 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.925 179.982 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 76' ' ' TYR . . . . . . . . . . . . . 72.8 m-85 -122.05 -45.0 2.27 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.884 179.968 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 77' ' ' PHE . . . . . . . . . . . . . 17.1 p90 -162.23 165.25 27.06 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.883 179.945 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 1.0 OUTLIER -89.65 103.05 15.73 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.976 179.974 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 79' ' ' CYS . . . . . . . . . . . . . 28.4 p -127.69 153.73 46.14 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.887 -179.969 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 80' ' ' ALA . . . . . 0.409 ' HB2' ' CG ' ' A' ' 83' ' ' HIS . . . -61.91 164.21 10.89 Favored Pre-proline 0 C--N 1.329 -0.308 0 CA-C-N 116.136 -0.484 . . . . 0.0 111.137 179.975 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 81' ' ' PRO . . . . . . . . . . . . . 51.0 Cg_exo -54.11 115.59 2.46 Favored 'Trans proline' 0 C--N 1.345 0.385 0 C-N-CA 122.578 2.185 . . . . 0.0 112.293 -179.949 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 82' ' ' ARG . . . . . . . . . . . . . 0.7 OUTLIER 61.59 53.64 3.25 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.852 179.953 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 83' ' ' HIS . . . . . 0.409 ' CG ' ' HB2' ' A' ' 80' ' ' ALA . 6.1 m170 -125.15 -44.52 1.89 Allowed 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.145 -0.479 . . . . 0.0 110.879 179.882 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . -67.23 130.24 29.43 Favored Glycine 0 N--CA 1.451 -0.311 0 C-N-CA 120.714 -0.755 . . . . 0.0 112.434 179.934 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 85' ' ' VAL . . . . . . . . . . . . . 5.1 m -134.29 121.67 37.98 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-O 120.856 0.36 . . . . 0.0 111.174 179.966 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 86' ' ' PHE . . . . . . . . . . . . . 7.9 m-85 -96.25 112.33 24.1 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.916 179.937 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 87' ' ' ALA . . . . . . . . . . . . . . . -129.74 143.74 50.23 Favored Pre-proline 0 C--N 1.33 -0.28 0 CA-C-N 116.257 -0.429 . . . . 0.0 111.025 -179.94 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 88' ' ' PRO . . . . . 0.419 ' O ' ' N ' ' A' ' 91' ' ' ARG . 46.9 Cg_exo -56.03 140.52 86.5 Favored 'Trans proline' 0 C--N 1.346 0.406 0 C-N-CA 122.52 2.146 . . . . 0.0 112.317 -179.995 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -47.96 -51.61 22.97 Favored 'General case' 0 CA--C 1.521 -0.136 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.255 179.901 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 90' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -55.82 -24.47 36.45 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 115.76 -0.655 . . . . 0.0 109.709 178.87 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 91' ' ' ARG . . . . . 0.419 ' N ' ' O ' ' A' ' 88' ' ' PRO . 0.0 OUTLIER -87.8 -15.31 37.24 Favored 'General case' 0 N--CA 1.455 -0.225 0 CA-C-N 115.834 -0.621 . . . . 0.0 110.415 179.022 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 92' ' ' ILE . . . . . . . . . . . . . 41.7 mt -108.66 150.57 11.28 Favored 'Isoleucine or valine' 0 N--CA 1.457 -0.105 0 CA-C-N 116.376 -0.375 . . . . 0.0 111.071 179.898 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 93' ' ' GLN . . . . . . . . . . . . . 10.5 mt-30 -120.06 161.4 21.03 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.918 -179.991 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 94' ' ' ARG . . . . . . . . . . . . . 1.1 mtt180 -101.15 126.35 47.85 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.247 -0.433 . . . . 0.0 110.885 179.963 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 95' ' ' ILE . . . . . . . . . . . . . 26.1 mm -75.12 -61.79 1.57 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 116.15 -0.477 . . . . 0.0 111.171 179.968 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . -77.7 69.55 2.6 Favored Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.791 -0.719 . . . . 0.0 112.479 -179.921 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 97' ' ' SER . . . . . . . . . . . . . 20.3 p -173.19 -170.48 0.63 Allowed 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.849 0.357 . . . . 0.0 110.839 -179.978 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 98' ' ' GLY . . . . . . . . . . . . . . . 128.64 83.8 0.39 Allowed Glycine 0 N--CA 1.452 -0.239 0 C-N-CA 120.729 -0.748 . . . . 0.0 112.506 -179.921 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 99' ' ' PRO . . . . . . . . . . . . . 55.2 Cg_endo -69.79 81.33 0.83 Allowed 'Trans proline' 0 C--N 1.344 0.332 0 C-N-CA 122.557 2.171 . . . . 0.0 112.353 179.978 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 100' ' ' SER . . . . . . . . . . . . . 58.7 p -91.67 116.77 29.15 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.943 -179.933 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 56.4 p -64.45 -52.53 57.56 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.211 -0.449 . . . . 0.0 110.898 -180.0 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.25 1.116 0 CA-C-O 118.42 -1.211 . . . . 0.0 112.465 179.914 . . . . . . . . 0 0 . 1 . 018 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.231 0 N-CA-C 112.494 -0.243 . . . . 0.0 112.494 . . . . . . . . . 0 0 . 1 . 018 nuclear orig full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -160.21 126.71 4.26 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-O 120.882 0.373 . . . . 0.0 110.97 179.981 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 5.7 m -70.14 85.7 0.55 Allowed 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.899 -179.958 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -122.59 -179.66 15.92 Favored Glycine 0 N--CA 1.451 -0.353 0 C-N-CA 120.734 -0.746 . . . . 0.0 112.578 -180.0 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 25.8 t -136.02 134.4 38.47 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-O 120.804 0.335 . . . . 0.0 110.837 -179.985 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -95.26 -51.0 4.79 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.847 -179.981 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -136.39 136.08 8.16 Favored Glycine 0 N--CA 1.452 -0.288 0 C-N-CA 120.712 -0.756 . . . . 0.0 112.473 -179.946 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 7.5 pttt -60.28 -175.84 0.04 OUTLIER 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 120.766 0.317 . . . . 0.0 110.97 179.968 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 9' ' ' SER . . . . . 0.433 ' CB ' ' CD ' ' A' ' 10' ' ' PRO . 1.3 m -171.73 -63.12 0.0 OUTLIER Pre-proline 0 C--N 1.33 -0.277 0 CA-C-N 116.337 -0.392 . . . . 0.0 110.896 179.908 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 10' ' ' PRO . . . . . 0.433 ' CD ' ' CB ' ' A' ' 9' ' ' SER . 55.7 Cg_endo -69.96 113.87 3.55 Favored 'Trans proline' 0 C--N 1.347 0.448 0 C-N-CA 122.383 2.055 . . . . 0.0 112.278 179.913 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -114.56 140.0 49.13 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.255 -0.43 . . . . 0.0 110.9 -179.972 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -122.46 106.16 35.55 Favored Pre-proline 0 C--N 1.33 -0.274 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.85 -179.969 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 73.8 Cg_exo -49.21 -61.94 0.5 Allowed 'Trans proline' 0 C--N 1.346 0.431 0 C-N-CA 122.43 2.086 . . . . 0.0 112.425 179.987 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 4.6 t 56.65 -168.49 0.1 Allowed 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 116.312 -0.404 . . . . 0.0 110.924 -179.935 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 0.9 OUTLIER -157.6 81.22 0.88 Allowed 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.299 -0.41 . . . . 0.0 110.993 179.961 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 83.54 -89.09 1.52 Allowed Glycine 0 N--CA 1.451 -0.326 0 C-N-CA 120.744 -0.741 . . . . 0.0 112.548 -179.992 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 12.7 m -154.36 104.74 2.61 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-O 120.768 0.318 . . . . 0.0 110.851 -179.998 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 3.4 mt -133.19 -59.35 0.88 Allowed 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.275 -0.42 . . . . 0.0 110.958 -179.962 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 19' ' ' GLN . . . . . . . . . . . . . 5.3 mt-30 -80.54 87.99 5.7 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.971 179.97 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 20' ' ' GLN . . . . . . . . . . . . . 15.0 mt-30 -132.6 119.15 20.08 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.946 -179.958 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 5.9 ptm180 -113.75 133.76 55.17 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.906 -179.993 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -154.66 148.32 25.37 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.873 -179.969 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -69.94 135.18 26.05 Favored Glycine 0 N--CA 1.451 -0.337 0 C-N-CA 120.77 -0.729 . . . . 0.0 112.527 -179.974 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -110.34 143.62 40.3 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 120.769 0.319 . . . . 0.0 111.129 179.973 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 1.6 mmpt? -73.55 -64.12 1.06 Allowed 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.247 -0.433 . . . . 0.0 110.891 -179.957 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -131.51 -176.37 4.01 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.162 -0.472 . . . . 0.0 111.071 179.958 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 27' ' ' GLU . . . . . . . . . . . . . 3.7 mt-10 -138.84 171.38 14.42 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.084 -0.507 . . . . 0.0 110.841 -179.964 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 28.1 t -65.97 109.71 1.16 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 116.097 -0.501 . . . . 0.0 111.02 -179.999 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 112.85 29.85 2.96 Favored Glycine 0 N--CA 1.452 -0.254 0 C-N-CA 120.756 -0.735 . . . . 0.0 112.516 -179.986 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 1.2 t0 -137.48 164.69 28.09 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-O 120.823 0.344 . . . . 0.0 110.878 179.942 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 31' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -83.11 131.72 35.13 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.25 -0.432 . . . . 0.0 110.927 179.966 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 15.3 m -139.74 179.53 2.75 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 116.329 -0.396 . . . . 0.0 111.136 179.957 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 33' ' ' LEU . . . . . . . . . . . . . 22.7 tp -143.45 102.02 3.88 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.158 -0.473 . . . . 0.0 110.812 179.97 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 21.5 t -70.5 124.19 26.11 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.202 -0.454 . . . . 0.0 111.2 179.99 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 35' ' ' ALA . . . . . . . . . . . . . . . 58.57 25.51 13.24 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.228 -0.442 . . . . 0.0 111.264 179.942 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . 55.42 27.22 47.0 Favored Glycine 0 N--CA 1.452 -0.242 0 C-N-CA 120.852 -0.69 . . . . 0.0 112.587 179.984 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 37' ' ' GLN . . . . . . . . . . . . . 64.5 mt-30 -138.22 -64.86 0.52 Allowed 'General case' 0 C--N 1.329 -0.311 0 CA-C-O 120.704 0.287 . . . . 0.0 110.927 179.948 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 38' ' ' LYS . . . . . . . . . . . . . 64.3 mttt -72.38 112.64 8.62 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 116.294 -0.412 . . . . 0.0 110.877 179.954 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 39' ' ' GLN . . . . . . . . . . . . . 1.4 tm0? -91.82 117.26 29.61 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.836 179.991 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -145.14 -166.07 11.52 Favored Glycine 0 N--CA 1.451 -0.304 0 C-N-CA 120.747 -0.739 . . . . 0.0 112.468 -179.993 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 31.3 mt -131.17 132.58 63.25 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.25 0 CA-C-O 120.839 0.352 . . . . 0.0 111.105 -179.992 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 42' ' ' VAL . . . . . . . . . . . . . 21.5 t -60.4 121.46 8.27 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.261 -0.427 . . . . 0.0 111.086 179.962 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 43' ' ' ARG . . . . . . . . . . . . . 3.6 mmm-85 -104.14 -31.48 9.62 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.898 -179.941 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 44' ' ' PHE . . . . . 0.424 ' CD1' ' HB3' ' A' ' 76' ' ' TYR . 41.3 t80 -148.3 115.6 6.2 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.97 -179.947 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 45' ' ' TYR . . . . . 0.454 ' CE1' ' CE1' ' A' ' 56' ' ' TYR . 25.8 t80 -114.7 123.35 49.06 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.895 -179.986 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 171.03 -149.3 12.16 Favored Glycine 0 N--CA 1.451 -0.361 0 C-N-CA 120.671 -0.776 . . . . 0.0 112.449 179.956 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 47' ' ' LYS . . . . . . . . . . . . . 7.0 mttt -99.15 164.59 12.09 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-O 120.849 0.357 . . . . 0.0 110.975 -179.962 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 48' ' ' THR . . . . . 0.421 HG21 ' CZ ' ' A' ' 50' ' ' PHE . 13.2 p -129.68 -176.02 3.78 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.823 -179.982 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -112.98 -33.41 6.06 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.973 -179.89 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 50' ' ' PHE . . . . . 0.421 ' CZ ' HG21 ' A' ' 48' ' ' THR . 8.7 p90 -67.31 -30.51 70.37 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.24 -0.436 . . . . 0.0 111.016 -179.893 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 51' ' ' ALA . . . . . 0.42 ' N ' ' CD1' ' A' ' 50' ' ' PHE . . . -148.44 146.2 22.13 Favored Pre-proline 0 C--N 1.329 -0.314 0 CA-C-N 116.324 -0.398 . . . . 0.0 111.17 -179.906 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 52' ' ' PRO . . . . . . . . . . . . . 72.3 Cg_endo -74.95 -178.46 4.17 Favored 'Trans proline' 0 C--N 1.345 0.371 0 C-N-CA 122.584 2.189 . . . . 0.0 112.352 -179.991 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 76.78 -168.01 54.63 Favored Glycine 0 N--CA 1.451 -0.363 0 C-N-CA 120.778 -0.725 . . . . 0.0 112.515 179.954 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 54' ' ' TYR . . . . . . . . . . . . . 20.6 m-85 -101.59 149.56 23.99 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-O 120.837 0.351 . . . . 0.0 110.87 -179.929 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 55' ' ' TRP . . . . . . . . . . . . . 69.4 m95 -145.81 156.41 43.56 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.187 -0.461 . . . . 0.0 110.943 179.946 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 56' ' ' TYR . . . . . 0.454 ' CE1' ' CE1' ' A' ' 45' ' ' TYR . 25.2 m-85 -110.24 124.92 52.49 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.288 -0.415 . . . . 0.0 110.947 -179.947 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . -90.08 60.39 3.43 Favored Glycine 0 N--CA 1.45 -0.368 0 C-N-CA 120.768 -0.73 . . . . 0.0 112.414 179.9 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 58' ' ' ILE . . . . . . . . . . . . . 21.2 mt -73.53 137.68 22.82 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-O 120.871 0.367 . . . . 0.0 111.073 -179.957 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 0.2 OUTLIER -103.89 133.27 49.14 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.084 -0.507 . . . . 0.0 110.845 -179.991 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 60' ' ' LEU . . . . . . . . . . . . . 56.5 mt -88.15 174.75 8.05 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.903 179.952 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 2.7 m-20 -100.59 -30.8 11.57 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.976 179.963 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 62' ' ' GLN . . . . . . . . . . . . . 0.8 OUTLIER -106.4 153.5 40.43 Favored Pre-proline 0 C--N 1.331 -0.239 0 CA-C-N 116.178 -0.464 . . . . 0.0 110.924 -179.971 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 73.6 Cg_endo -75.81 64.22 6.72 Favored 'Trans proline' 0 C--N 1.344 0.31 0 C-N-CA 122.613 2.209 . . . . 0.0 112.323 -179.857 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 64' ' ' THR . . . . . . . . . . . . . 7.5 t -147.01 38.55 0.99 Allowed 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.899 179.975 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . -86.57 -111.72 0.86 Allowed Glycine 0 N--CA 1.451 -0.313 0 C-N-CA 120.767 -0.73 . . . . 0.0 112.559 179.98 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 66' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -147.71 -47.27 0.17 Allowed 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.819 0.343 . . . . 0.0 110.893 179.992 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 67' ' ' HIS . . . . . 0.415 ' CE1' ' CG2' ' A' ' 71' ' ' VAL . 15.7 p80 -141.99 -176.0 4.63 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.865 179.96 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -89.32 -168.83 2.28 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.833 179.987 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . -63.39 -27.6 71.01 Favored Glycine 0 N--CA 1.451 -0.363 0 C-N-CA 120.695 -0.765 . . . . 0.0 112.473 -179.934 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 70' ' ' SER . . . . . . . . . . . . . 4.0 p -116.98 147.66 42.11 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 120.8 0.333 . . . . 0.0 110.897 -179.94 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 71' ' ' VAL . . . . . 0.415 ' CG2' ' CE1' ' A' ' 67' ' ' HIS . 28.2 t -127.12 119.86 53.89 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.103 179.929 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 72' ' ' PHE . . . . . . . . . . . . . 5.4 m-85 60.57 30.82 20.02 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.887 -179.948 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 94.91 -15.76 62.72 Favored Glycine 0 N--CA 1.451 -0.318 0 C-N-CA 120.713 -0.756 . . . . 0.0 112.721 -179.999 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 25.3 t -87.9 113.08 24.48 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-O 120.807 0.337 . . . . 0.0 111.169 -179.938 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 75' ' ' ARG . . . . . . . . . . . . . 6.4 ttm105 -95.06 114.7 26.54 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.762 179.885 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 76' ' ' TYR . . . . . 0.424 ' HB3' ' CD1' ' A' ' 44' ' ' PHE . 26.0 m-85 -96.7 -34.97 11.17 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.988 -179.853 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 77' ' ' PHE . . . . . . . . . . . . . 51.6 p90 -162.6 159.52 24.7 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 116.316 -0.402 . . . . 0.0 111.021 -179.907 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 26.0 m -87.62 140.82 29.13 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.922 179.917 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 79' ' ' CYS . . . . . . . . . . . . . 30.7 p -164.67 -175.6 3.9 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.263 -0.426 . . . . 0.0 110.915 179.965 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 80' ' ' ALA . . . . . . . . . . . . . . . -96.62 166.45 14.05 Favored Pre-proline 0 C--N 1.328 -0.328 0 CA-C-N 116.166 -0.47 . . . . 0.0 111.102 -179.97 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 81' ' ' PRO . . . . . . . . . . . . . 50.6 Cg_exo -53.21 120.55 7.92 Favored 'Trans proline' 0 C--N 1.344 0.298 0 C-N-CA 122.627 2.218 . . . . 0.0 112.297 179.96 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 82' ' ' ARG . . . . . . . . . . . . . 37.8 mtp85 62.45 61.46 1.25 Allowed 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.953 -179.967 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 83' ' ' HIS . . . . . . . . . . . . . 4.5 m-70 -130.79 -51.13 1.05 Allowed 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.866 -179.985 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . -63.51 143.54 48.21 Favored Glycine 0 N--CA 1.45 -0.367 0 C-N-CA 120.753 -0.736 . . . . 0.0 112.541 179.972 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 85' ' ' VAL . . . . . . . . . . . . . 5.1 m -145.92 118.16 2.12 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-O 120.829 0.347 . . . . 0.0 111.061 -179.974 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 86' ' ' PHE . . . . . . . . . . . . . 6.6 m-85 -96.45 105.93 18.1 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.847 179.973 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 87' ' ' ALA . . . . . . . . . . . . . . . -126.0 142.76 43.35 Favored Pre-proline 0 C--N 1.328 -0.339 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.091 179.954 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 88' ' ' PRO . . . . . 0.411 ' O ' ' N ' ' A' ' 91' ' ' ARG . 31.2 Cg_exo -58.88 146.18 94.28 Favored 'Trans proline' 0 C--N 1.347 0.461 0 C-N-CA 122.468 2.112 . . . . 0.0 112.344 -179.999 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -48.38 -51.31 27.1 Favored 'General case' 0 C--N 1.333 -0.133 0 CA-C-O 121.08 0.467 . . . . 0.0 110.263 179.769 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 90' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -56.02 -24.4 38.93 Favored 'General case' 0 N--CA 1.454 -0.225 0 CA-C-N 115.648 -0.705 . . . . 0.0 109.789 178.732 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 91' ' ' ARG . . . . . 0.411 ' N ' ' O ' ' A' ' 88' ' ' PRO . 0.1 OUTLIER -88.44 -15.01 36.53 Favored 'General case' 0 N--CA 1.454 -0.254 0 CA-C-N 115.876 -0.602 . . . . 0.0 110.348 179.077 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 92' ' ' ILE . . . . . . . . . . . . . 43.1 mt -108.77 158.31 8.65 Favored 'Isoleucine or valine' 0 C--O 1.231 0.081 0 CA-C-N 116.334 -0.394 . . . . 0.0 111.017 179.784 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 93' ' ' GLN . . . . . . . . . . . . . 3.4 mt-30 -124.78 162.72 23.67 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.246 -0.434 . . . . 0.0 110.898 -179.886 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 94' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -112.65 127.17 56.03 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.113 -0.494 . . . . 0.0 110.838 -179.993 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 95' ' ' ILE . . . . . . . . . . . . . 33.0 mt -98.44 -32.01 3.8 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.187 -0.461 . . . . 0.0 111.022 179.962 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . -66.51 157.4 50.13 Favored Glycine 0 N--CA 1.451 -0.304 0 C-N-CA 120.809 -0.71 . . . . 0.0 112.408 -179.964 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 97' ' ' SER . . . . . . . . . . . . . 7.1 t -102.05 95.95 6.69 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-O 120.78 0.324 . . . . 0.0 110.949 179.972 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 98' ' ' GLY . . . . . . . . . . . . . . . -135.63 -169.8 11.92 Favored Glycine 0 N--CA 1.451 -0.3 0 C-N-CA 120.686 -0.769 . . . . 0.0 112.446 -179.985 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 99' ' ' PRO . . . . . . . . . . . . . 55.9 Cg_endo -70.1 91.1 0.55 Allowed 'Trans proline' 0 C--N 1.345 0.349 0 C-N-CA 122.576 2.184 . . . . 0.0 112.35 179.985 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 100' ' ' SER . . . . . . . . . . . . . 80.1 p -165.89 144.14 5.82 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.22 -0.446 . . . . 0.0 110.911 -179.962 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER 60.29 166.38 0.07 Allowed 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.863 179.975 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.25 1.123 0 CA-C-O 118.421 -1.211 . . . . 0.0 112.497 -180.0 . . . . . . . . 0 0 . 1 . 019 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.221 0 N-CA-C 112.487 -0.245 . . . . 0.0 112.487 . . . . . . . . . 0 0 . 1 . 019 nuclear orig full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 1.1 m -149.88 95.85 2.37 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-O 120.828 0.347 . . . . 0.0 110.906 -179.941 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 96.2 p -164.18 -44.14 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.909 -179.993 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 96.76 -29.49 10.4 Favored Glycine 0 N--CA 1.45 -0.379 0 C-N-CA 120.742 -0.742 . . . . 0.0 112.479 179.959 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 19.2 m -124.4 -61.94 1.3 Allowed 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 120.838 0.351 . . . . 0.0 110.939 -179.958 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER 59.47 89.38 0.06 Allowed 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.885 179.988 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 114.98 151.14 10.02 Favored Glycine 0 N--CA 1.451 -0.301 0 C-N-CA 120.816 -0.707 . . . . 0.0 112.45 -179.941 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER 177.06 -35.17 0.01 OUTLIER 'General case' 0 C--N 1.331 -0.238 0 CA-C-O 120.769 0.319 . . . . 0.0 110.868 -179.966 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 9' ' ' SER . . . . . 0.4 ' N ' ' CD ' ' A' ' 10' ' ' PRO . 1.1 m 64.45 53.84 1.33 Allowed Pre-proline 0 C--N 1.33 -0.247 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.979 -179.88 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 10' ' ' PRO . . . . . 0.4 ' CD ' ' N ' ' A' ' 9' ' ' SER . 71.5 Cg_endo -74.59 -39.58 1.37 Allowed 'Trans proline' 0 C--N 1.345 0.346 0 C-N-CA 122.583 2.189 . . . . 0.0 112.233 179.973 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 23.0 m -153.08 -178.08 6.71 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.81 -179.951 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -137.45 87.6 17.68 Favored Pre-proline 0 C--N 1.33 -0.279 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.941 179.971 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 53.3 Cg_exo -52.38 -34.51 61.2 Favored 'Trans proline' 0 C--N 1.345 0.367 0 C-N-CA 122.535 2.157 . . . . 0.0 112.345 179.975 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 8.5 t -130.1 139.74 50.9 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.928 179.961 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 5.3 tp -153.68 -52.72 0.1 Allowed 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.894 -179.953 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -172.29 51.95 0.17 Allowed Glycine 0 N--CA 1.452 -0.261 0 C-N-CA 120.768 -0.73 . . . . 0.0 112.439 179.976 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 7.9 t 59.39 24.62 13.23 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-O 120.752 0.311 . . . . 0.0 111.029 179.994 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 0.6 OUTLIER 56.32 22.59 6.43 Favored 'General case' 0 C--N 1.331 -0.225 0 CA-C-N 116.337 -0.392 . . . . 0.0 111.25 179.974 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 19' ' ' GLN . . . . . . . . . . . . . 1.2 tp-100 51.94 93.42 0.02 OUTLIER 'General case' 0 C--N 1.332 -0.187 0 CA-C-N 116.416 -0.356 . . . . 0.0 111.055 179.907 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 20' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -144.25 -55.37 0.35 Allowed 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.322 -0.399 . . . . 0.0 110.973 179.921 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 0.6 OUTLIER -67.74 89.55 0.26 Allowed 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.257 -0.429 . . . . 0.0 110.869 180.0 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 22.1 mm-40 -108.93 31.13 5.92 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.843 -179.943 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 65.95 90.81 0.04 OUTLIER Glycine 0 N--CA 1.451 -0.324 0 C-N-CA 120.729 -0.748 . . . . 0.0 112.489 -179.95 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -148.51 110.64 4.61 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-O 120.885 0.374 . . . . 0.0 111.095 179.968 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -68.85 -68.37 0.4 Allowed 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.869 179.924 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -109.66 174.92 5.64 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.211 -0.449 . . . . 0.0 111.105 179.998 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 27' ' ' GLU . . . . . . . . . . . . . 16.4 mt-10 -133.92 179.77 6.04 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.917 -179.975 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 21.5 t -75.32 93.16 0.85 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.091 -179.981 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 121.72 44.84 0.36 Allowed Glycine 0 N--CA 1.451 -0.36 0 C-N-CA 120.843 -0.694 . . . . 0.0 112.489 179.972 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -144.77 158.21 43.87 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-O 120.832 0.349 . . . . 0.0 110.933 -179.991 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 31' ' ' GLN . . . . . . . . . . . . . 0.2 OUTLIER -77.56 126.03 30.26 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.82 -179.911 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 16.2 m -129.34 175.63 10.11 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.262 -0.427 . . . . 0.0 111.158 179.983 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 33' ' ' LEU . . . . . . . . . . . . . 25.6 tp -144.92 101.86 3.69 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.244 -0.434 . . . . 0.0 110.926 179.936 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 21.5 t -69.42 123.02 22.13 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.171 -179.958 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 35' ' ' ALA . . . . . . . . . . . . . . . 58.2 25.73 12.93 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.279 179.977 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . 56.13 32.75 60.2 Favored Glycine 0 N--CA 1.452 -0.294 0 C-N-CA 120.731 -0.747 . . . . 0.0 112.636 -179.99 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 37' ' ' GLN . . . . . . . . . . . . . 30.9 mt-30 -142.9 -73.9 0.29 Allowed 'General case' 0 C--N 1.329 -0.319 0 CA-C-O 120.847 0.356 . . . . 0.0 110.974 -179.968 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 38' ' ' LYS . . . . . . . . . . . . . 4.6 mttp -64.35 109.6 1.97 Allowed 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.918 -179.973 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 39' ' ' GLN . . . . . . . . . . . . . 14.3 tm0? -85.32 129.38 34.82 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.254 -0.43 . . . . 0.0 110.905 179.982 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -156.13 -178.15 30.02 Favored Glycine 0 N--CA 1.45 -0.371 0 C-N-CA 120.683 -0.77 . . . . 0.0 112.524 -179.971 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 41' ' ' ILE . . . . . 0.484 HD13 HG22 ' A' ' 41' ' ' ILE . 27.9 mm -123.12 138.18 53.98 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-O 120.731 0.3 . . . . 0.0 111.114 -179.983 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 42' ' ' VAL . . . . . . . . . . . . . 26.2 t -62.79 121.11 10.96 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 116.252 -0.431 . . . . 0.0 111.101 179.982 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 43' ' ' ARG . . . . . . . . . . . . . 3.1 mmt180 -107.33 -34.16 7.17 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.922 -179.983 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 44' ' ' PHE . . . . . . . . . . . . . 25.8 t80 -145.04 116.27 7.96 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.905 -179.978 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 45' ' ' TYR . . . . . . . . . . . . . 15.4 t80 -111.09 127.1 55.45 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.901 -179.985 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 166.88 -161.49 35.3 Favored Glycine 0 N--CA 1.45 -0.384 0 C-N-CA 120.774 -0.726 . . . . 0.0 112.531 179.992 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 47' ' ' LYS . . . . . . . . . . . . . 46.5 mttt -96.88 158.11 15.58 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-O 120.816 0.341 . . . . 0.0 110.837 -179.975 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 48' ' ' THR . . . . . 0.419 ' HB ' ' CE2' ' A' ' 50' ' ' PHE . 28.4 p -120.75 168.25 11.62 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.165 -0.471 . . . . 0.0 110.848 179.895 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -91.69 -29.18 16.99 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.207 -0.452 . . . . 0.0 110.972 179.969 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 50' ' ' PHE . . . . . 0.419 ' CE2' ' HB ' ' A' ' 48' ' ' THR . 37.5 p90 -74.92 -32.33 61.77 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.273 -0.421 . . . . 0.0 111.055 -179.929 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 51' ' ' ALA . . . . . 0.418 ' HB3' ' CE1' ' A' ' 50' ' ' PHE . . . -142.1 143.35 27.55 Favored Pre-proline 0 C--N 1.33 -0.264 0 CA-C-N 116.304 -0.407 . . . . 0.0 111.128 -179.965 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 52' ' ' PRO . . . . . . . . . . . . . 73.8 Cg_endo -77.33 -168.06 0.55 Allowed 'Trans proline' 0 C--N 1.346 0.404 0 C-N-CA 122.669 2.246 . . . . 0.0 112.325 -179.978 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 70.94 -155.15 52.68 Favored Glycine 0 N--CA 1.451 -0.346 0 C-N-CA 120.722 -0.751 . . . . 0.0 112.527 179.917 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 54' ' ' TYR . . . . . . . . . . . . . 41.4 m-85 -119.04 125.23 48.85 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-O 120.793 0.33 . . . . 0.0 110.906 -179.982 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 55' ' ' TRP . . . . . 0.411 ' CZ3' ' HD3' ' A' ' 88' ' ' PRO . 63.8 m95 -117.4 168.5 10.3 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.909 179.967 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 56' ' ' TYR . . . . . 0.42 ' CE1' ' HB3' ' A' ' 89' ' ' ALA . 6.5 m-85 -124.6 119.56 29.4 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.254 -0.43 . . . . 0.0 110.939 -179.951 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 57' ' ' GLY . . . . . 0.454 ' CA ' ' CE1' ' A' ' 86' ' ' PHE . . . -84.1 62.43 4.59 Favored Glycine 0 N--CA 1.451 -0.366 0 C-N-CA 120.771 -0.728 . . . . 0.0 112.543 179.956 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 58' ' ' ILE . . . . . . . . . . . . . 7.2 mt -68.53 142.84 15.77 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-O 120.868 0.366 . . . . 0.0 111.035 179.995 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 4.7 tm-20 -109.13 110.1 21.25 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.921 179.948 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 60' ' ' LEU . . . . . . . . . . . . . 84.2 mt -68.6 176.33 3.0 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.863 -179.973 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -101.33 -32.18 10.6 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.896 -179.948 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 62' ' ' GLN . . . . . . . . . . . . . 6.3 mt-30 -102.2 162.78 19.25 Favored Pre-proline 0 C--N 1.329 -0.285 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.927 -179.97 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 98.7 Cg_endo -79.52 58.26 6.88 Favored 'Trans proline' 0 C--N 1.344 0.332 0 C-N-CA 122.663 2.242 . . . . 0.0 112.477 -179.996 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 64' ' ' THR . . . . . . . . . . . . . 20.8 p -133.4 32.12 3.69 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.949 179.993 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . -81.98 -117.28 0.48 Allowed Glycine 0 N--CA 1.451 -0.308 0 C-N-CA 120.751 -0.738 . . . . 0.0 112.454 179.976 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 66' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -155.17 -48.05 0.08 Allowed 'General case' 0 C--N 1.33 -0.263 0 CA-C-O 120.868 0.366 . . . . 0.0 110.899 179.917 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 67' ' ' HIS . . . . . . . . . . . . . 7.9 p80 -127.08 169.5 13.33 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 116.156 -0.474 . . . . 0.0 110.81 179.923 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 1.8 m-20 -97.81 36.07 1.59 Allowed 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.255 -0.43 . . . . 0.0 110.91 179.969 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 95.81 -39.57 2.81 Favored Glycine 0 N--CA 1.451 -0.355 0 C-N-CA 120.697 -0.763 . . . . 0.0 112.549 -179.984 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 70' ' ' SER . . . . . . . . . . . . . 11.6 p -101.1 127.23 47.73 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 120.741 0.305 . . . . 0.0 110.911 179.982 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 21.5 t -115.07 111.01 34.06 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.349 0 CA-C-N 116.202 -0.454 . . . . 0.0 111.128 179.964 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 72' ' ' PHE . . . . . . . . . . . . . 30.2 m-85 61.44 30.66 18.99 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.891 179.966 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 99.1 -28.79 13.66 Favored Glycine 0 N--CA 1.451 -0.356 0 C-N-CA 120.741 -0.742 . . . . 0.0 112.463 179.951 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 27.8 t -80.55 121.71 34.47 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-O 120.881 0.372 . . . . 0.0 111.075 179.952 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 75' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -106.35 142.07 36.64 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.817 -179.937 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 76' ' ' TYR . . . . . . . . . . . . . 8.2 m-85 -115.42 -46.8 2.86 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.123 -0.49 . . . . 0.0 110.855 179.954 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 77' ' ' PHE . . . . . 0.42 ' CE1' ' HA3' ' A' ' 57' ' ' GLY . 35.1 p90 -146.9 177.29 9.25 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 116.263 -0.426 . . . . 0.0 110.879 179.982 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 0.9 OUTLIER -104.69 124.36 49.23 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.875 -179.964 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 79' ' ' CYS . . . . . . . . . . . . . 10.8 p -144.97 167.42 22.68 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.118 -0.492 . . . . 0.0 110.893 179.977 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 80' ' ' ALA . . . . . . . . . . . . . . . -75.51 166.44 45.3 Favored Pre-proline 0 C--N 1.33 -0.255 0 CA-C-N 116.228 -0.442 . . . . 0.0 111.075 -179.958 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 81' ' ' PRO . . . . . . . . . . . . . 51.2 Cg_exo -52.85 116.6 3.01 Favored 'Trans proline' 0 C--N 1.345 0.346 0 C-N-CA 122.572 2.181 . . . . 0.0 112.318 179.916 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 82' ' ' ARG . . . . . . . . . . . . . 0.5 OUTLIER 61.39 56.74 2.54 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.84 179.897 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 83' ' ' HIS . . . . . . . . . . . . . 6.2 m170 -126.36 -47.76 1.58 Allowed 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.925 179.953 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . -61.91 139.33 46.43 Favored Glycine 0 N--CA 1.451 -0.353 0 C-N-CA 120.699 -0.763 . . . . 0.0 112.56 179.915 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 85' ' ' VAL . . . . . . . . . . . . . 5.8 m -140.28 127.99 24.25 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.326 0 CA-C-O 120.774 0.321 . . . . 0.0 111.126 -179.911 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 86' ' ' PHE . . . . . 0.454 ' CE1' ' CA ' ' A' ' 57' ' ' GLY . 9.1 m-85 -110.26 112.45 24.42 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.189 -0.459 . . . . 0.0 110.871 179.926 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 87' ' ' ALA . . . . . . . . . . . . . . . -134.86 149.45 70.6 Favored Pre-proline 0 C--N 1.329 -0.286 0 CA-C-N 116.303 -0.408 . . . . 0.0 111.213 179.966 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 88' ' ' PRO . . . . . 0.42 ' O ' ' N ' ' A' ' 91' ' ' ARG . 32.5 Cg_exo -58.08 140.53 94.41 Favored 'Trans proline' 0 C--N 1.345 0.356 0 C-N-CA 122.596 2.197 . . . . 0.0 112.27 -179.92 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 89' ' ' ALA . . . . . 0.42 ' HB3' ' CE1' ' A' ' 56' ' ' TYR . . . -47.79 -51.69 21.61 Favored 'General case' 0 C--N 1.332 -0.165 0 CA-C-O 121.06 0.457 . . . . 0.0 110.299 179.916 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 90' ' ' SER . . . . . . . . . . . . . 14.9 m -55.71 -24.5 35.06 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 115.731 -0.668 . . . . 0.0 109.734 178.788 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 91' ' ' ARG . . . . . 0.42 ' N ' ' O ' ' A' ' 88' ' ' PRO . 0.2 OUTLIER -88.76 -15.14 35.46 Favored 'General case' 0 N--CA 1.454 -0.229 0 CA-C-N 115.889 -0.596 . . . . 0.0 110.438 179.089 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 92' ' ' ILE . . . . . . . . . . . . . 48.4 mt -107.03 144.88 15.26 Favored 'Isoleucine or valine' 0 C--N 1.334 -0.104 0 CA-C-N 116.413 -0.358 . . . . 0.0 111.047 179.913 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 93' ' ' GLN . . . . . . . . . . . . . 9.1 mt-30 -115.65 -179.94 3.79 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.167 -0.469 . . . . 0.0 110.866 -179.997 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 94' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -125.77 134.99 51.55 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.202 -0.453 . . . . 0.0 110.996 -179.954 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 95' ' ' ILE . . . . . . . . . . . . . 5.0 mt -105.26 -37.34 4.09 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.22 -0.446 . . . . 0.0 111.108 179.952 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . 86.21 -78.23 1.96 Allowed Glycine 0 N--CA 1.45 -0.367 0 C-N-CA 120.746 -0.74 . . . . 0.0 112.449 179.925 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 97' ' ' SER . . . . . . . . . . . . . 74.3 p -126.63 127.79 45.75 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-O 120.779 0.323 . . . . 0.0 110.912 -179.981 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 98' ' ' GLY . . . . . . . . . . . . . . . -126.99 95.27 0.43 Allowed Glycine 0 N--CA 1.452 -0.259 0 C-N-CA 120.756 -0.735 . . . . 0.0 112.46 -179.953 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 99' ' ' PRO . . . . . . . . . . . . . 43.4 Cg_endo -68.1 147.22 72.85 Favored 'Trans proline' 0 C--N 1.345 0.385 0 C-N-CA 122.514 2.143 . . . . 0.0 112.261 179.972 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 100' ' ' SER . . . . . . . . . . . . . 18.3 m 63.93 136.11 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.863 -179.939 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 1.2 m 60.91 101.0 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.873 179.967 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.25 1.121 0 CA-C-O 118.384 -1.231 . . . . 0.0 112.495 -179.986 . . . . . . . . 0 0 . 1 . 020 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.241 0 N-CA-C 112.472 -0.251 . . . . 0.0 112.472 . . . . . . . . . 0 0 . 1 . 020 nuclear orig full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 3.4 m -116.83 30.75 7.15 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 120.821 0.344 . . . . 0.0 110.926 -179.971 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER 59.16 31.03 20.92 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.98 179.99 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -68.06 114.54 6.16 Favored Glycine 0 N--CA 1.451 -0.322 0 C-N-CA 120.674 -0.774 . . . . 0.0 112.511 179.948 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 43.8 t -169.36 34.3 0.02 OUTLIER 'General case' 0 C--N 1.33 -0.276 0 CA-C-O 120.82 0.343 . . . . 0.0 110.931 179.99 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 58.4 m -98.51 -32.45 11.46 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.875 -179.958 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -155.49 172.94 33.66 Favored Glycine 0 N--CA 1.451 -0.329 0 C-N-CA 120.746 -0.74 . . . . 0.0 112.509 179.998 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 0.3 OUTLIER -66.46 94.59 0.28 Allowed 'General case' 0 C--N 1.329 -0.283 0 CA-C-O 120.773 0.32 . . . . 0.0 110.843 -179.97 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -83.31 109.48 17.91 Favored Pre-proline 0 C--N 1.328 -0.346 0 CA-C-N 116.244 -0.434 . . . . 0.0 110.932 179.982 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 48.4 Cg_endo -68.51 -24.51 36.09 Favored 'Trans proline' 0 C--N 1.346 0.405 0 C-N-CA 122.441 2.094 . . . . 0.0 112.377 179.927 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 3.0 p -58.14 -52.23 66.43 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.28 -0.418 . . . . 0.0 110.904 -179.965 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 43.3 m 60.27 89.21 0.11 Allowed Pre-proline 0 C--N 1.329 -0.284 0 CA-C-N 116.198 -0.456 . . . . 0.0 110.904 179.943 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 50.4 Cg_endo -68.96 154.11 71.38 Favored 'Trans proline' 0 C--N 1.345 0.382 0 C-N-CA 122.551 2.167 . . . . 0.0 112.319 179.98 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 58.1 m -128.64 -46.62 1.29 Allowed 'General case' 0 C--N 1.327 -0.371 0 CA-C-N 116.269 -0.423 . . . . 0.0 110.825 -179.975 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -156.33 -46.33 0.07 Allowed 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.856 -179.994 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -131.11 67.95 0.56 Allowed Glycine 0 N--CA 1.45 -0.372 0 C-N-CA 120.738 -0.744 . . . . 0.0 112.499 -179.962 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 0.6 OUTLIER -88.37 132.45 34.43 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-O 120.842 0.353 . . . . 0.0 110.839 179.938 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -155.02 154.38 32.41 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.908 -179.992 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 19' ' ' GLN . . . . . . . . . . . . . 35.9 tp60 -144.29 -66.81 0.34 Allowed 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.198 -0.456 . . . . 0.0 110.941 179.916 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 20' ' ' GLN . . . . . . . . . . . . . 3.4 tt0 61.87 114.51 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.265 -0.425 . . . . 0.0 110.926 179.976 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 5.4 mtt180 -173.74 137.78 0.62 Allowed 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.259 -0.428 . . . . 0.0 110.798 179.975 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 3.8 tt0 -138.53 -53.48 0.6 Allowed 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.944 -179.996 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 102.38 105.69 2.93 Favored Glycine 0 N--CA 1.452 -0.247 0 C-N-CA 120.709 -0.758 . . . . 0.0 112.541 -179.944 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -144.81 134.81 23.87 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-O 120.817 0.341 . . . . 0.0 111.077 -179.975 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -70.62 -34.36 72.03 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.923 179.998 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -155.1 173.11 17.06 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.235 -0.439 . . . . 0.0 111.072 179.971 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 27' ' ' GLU . . . . . . . . . . . . . 7.4 mp0 -133.74 -178.63 5.1 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.955 179.994 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 25.6 t -73.43 98.96 1.05 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.061 -179.993 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 117.94 39.63 0.75 Allowed Glycine 0 N--CA 1.451 -0.327 0 C-N-CA 120.789 -0.72 . . . . 0.0 112.449 179.924 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 20.7 t70 -146.25 137.68 24.66 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-O 120.842 0.353 . . . . 0.0 110.899 -179.978 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 31' ' ' GLN . . . . . . . . . . . . . 0.8 OUTLIER -59.96 137.33 58.11 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.121 -0.491 . . . . 0.0 110.961 179.938 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 6.2 m -141.28 171.67 11.77 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 116.234 -0.439 . . . . 0.0 111.11 -179.938 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 33' ' ' LEU . . . . . . . . . . . . . 33.9 tp -136.61 111.31 8.71 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.125 -0.488 . . . . 0.0 110.875 179.943 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 21.5 t -79.15 125.77 38.64 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-N 116.226 -0.443 . . . . 0.0 111.25 -179.978 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 35' ' ' ALA . . . . . . . . . . . . . . . 56.58 25.47 9.93 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.346 179.97 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . 57.54 31.69 63.73 Favored Glycine 0 N--CA 1.451 -0.306 0 C-N-CA 120.736 -0.745 . . . . 0.0 112.565 179.898 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 37' ' ' GLN . . . . . . . . . . . . . 9.3 mt-30 -142.98 -74.28 0.28 Allowed 'General case' 0 C--N 1.33 -0.28 0 CA-C-O 120.818 0.342 . . . . 0.0 111.006 -179.971 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 38' ' ' LYS . . . . . . . . . . . . . 46.0 mttp -63.51 112.59 2.84 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.896 -179.892 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 39' ' ' GLN . . . . . . . . . . . . . 2.1 mt-30 -87.6 139.6 30.37 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.837 179.926 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -172.87 171.42 44.39 Favored Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.697 -0.763 . . . . 0.0 112.512 179.993 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 3.2 mp -111.88 143.7 21.14 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-O 120.875 0.369 . . . . 0.0 111.114 179.978 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 42' ' ' VAL . . . . . . . . . . . . . 21.5 t -69.29 123.2 22.36 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.153 -0.476 . . . . 0.0 111.138 -179.995 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 43' ' ' ARG . . . . . . . . . . . . . 4.0 mmm180 -106.73 -31.54 8.38 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.891 -179.973 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 44' ' ' PHE . . . . . 0.405 ' CG ' ' HB3' ' A' ' 76' ' ' TYR . 15.2 t80 -147.82 106.26 3.78 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.879 -179.928 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 45' ' ' TYR . . . . . 0.496 ' CE1' ' CE1' ' A' ' 56' ' ' TYR . 14.3 t80 -111.03 123.88 51.06 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.294 -0.412 . . . . 0.0 110.935 179.893 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 171.54 -142.79 7.19 Favored Glycine 0 N--CA 1.45 -0.371 0 C-N-CA 120.649 -0.786 . . . . 0.0 112.462 -179.98 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 47' ' ' LYS . . . . . . . . . . . . . 24.7 mtpt -95.06 175.01 6.8 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-O 120.773 0.321 . . . . 0.0 110.906 179.993 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 48' ' ' THR . . . . . 0.414 ' HB ' ' CE1' ' A' ' 50' ' ' PHE . 44.8 p -138.79 -177.8 5.04 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.846 -179.996 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 4.4 t70 -129.04 17.59 6.13 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.154 -0.476 . . . . 0.0 111.259 179.924 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 50' ' ' PHE . . . . . 0.418 ' CD2' ' HB3' ' A' ' 51' ' ' ALA . 49.5 p90 -126.81 -44.98 1.62 Allowed 'General case' 0 C--N 1.331 -0.217 0 CA-C-N 116.447 -0.342 . . . . 0.0 110.892 179.961 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 51' ' ' ALA . . . . . 0.418 ' HB3' ' CD2' ' A' ' 50' ' ' PHE . . . -123.5 145.37 46.72 Favored Pre-proline 0 C--N 1.329 -0.324 0 CA-C-N 116.291 -0.413 . . . . 0.0 111.122 179.944 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 52' ' ' PRO . . . . . . . . . . . . . 64.4 Cg_endo -73.59 164.7 34.26 Favored 'Trans proline' 0 C--N 1.345 0.36 0 C-N-CA 122.565 2.176 . . . . 0.0 112.32 -179.926 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 83.51 -177.2 52.65 Favored Glycine 0 N--CA 1.452 -0.287 0 C-N-CA 120.725 -0.75 . . . . 0.0 112.478 179.855 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 54' ' ' TYR . . . . . . . . . . . . . 7.8 m-85 -97.63 131.84 43.83 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-O 120.818 0.342 . . . . 0.0 110.862 -179.979 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 55' ' ' TRP . . . . . 0.423 ' CZ3' ' HD3' ' A' ' 88' ' ' PRO . 24.8 m95 -123.41 157.74 32.74 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.907 -179.994 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 56' ' ' TYR . . . . . 0.496 ' CE1' ' CE1' ' A' ' 45' ' ' TYR . 11.9 m-85 -109.69 126.84 54.12 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.977 -179.948 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . -84.46 62.08 4.62 Favored Glycine 0 N--CA 1.451 -0.36 0 C-N-CA 120.733 -0.746 . . . . 0.0 112.419 179.921 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 58' ' ' ILE . . . . . . . . . . . . . 15.9 mt -71.32 141.05 17.26 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-O 120.816 0.341 . . . . 0.0 111.108 -179.985 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER -109.89 122.14 46.85 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.885 179.951 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 60' ' ' LEU . . . . . . . . . . . . . 63.1 mt -82.69 170.3 15.26 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.945 -179.929 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 1.1 m-20 -100.6 -26.52 13.79 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.95 -179.97 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 62' ' ' GLN . . . . . . . . . . . . . 10.8 pt20 -110.41 152.16 43.13 Favored Pre-proline 0 C--N 1.329 -0.292 0 CA-C-N 116.299 -0.41 . . . . 0.0 110.922 -179.967 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 49.7 Cg_endo -68.91 84.1 0.53 Allowed 'Trans proline' 0 C--N 1.345 0.357 0 C-N-CA 122.599 2.199 . . . . 0.0 112.312 179.971 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 64' ' ' THR . . . . . . . . . . . . . 2.2 p -156.97 35.83 0.3 Allowed 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.213 -0.448 . . . . 0.0 110.894 -179.923 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . -91.65 -158.6 34.72 Favored Glycine 0 N--CA 1.451 -0.359 0 C-N-CA 120.757 -0.735 . . . . 0.0 112.443 -179.961 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 66' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -114.07 -36.69 4.67 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-O 120.735 0.303 . . . . 0.0 110.889 -179.997 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 67' ' ' HIS . . . . . . . . . . . . . 6.9 p80 -127.08 170.26 12.54 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.261 -0.427 . . . . 0.0 110.909 -179.903 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 5.4 m-20 -98.8 30.87 3.15 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.165 -0.471 . . . . 0.0 110.85 179.973 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 105.46 -42.76 1.82 Allowed Glycine 0 N--CA 1.452 -0.257 0 C-N-CA 120.667 -0.777 . . . . 0.0 112.457 179.915 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 70' ' ' SER . . . . . . . . . . . . . 63.4 p -108.62 141.76 40.08 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.798 0.333 . . . . 0.0 110.92 179.966 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 21.5 t -117.45 109.9 29.17 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 116.25 -0.432 . . . . 0.0 111.112 179.957 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 72' ' ' PHE . . . . . . . . . . . . . 40.7 m-85 60.66 30.58 19.82 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.932 -179.972 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 101.08 -30.02 11.26 Favored Glycine 0 N--CA 1.451 -0.353 0 C-N-CA 120.705 -0.759 . . . . 0.0 112.51 179.999 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 21.5 t -78.66 117.88 24.94 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-O 120.764 0.316 . . . . 0.0 111.152 -179.977 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 75' ' ' ARG . . . . . . . . . . . . . 10.3 ttm180 -98.33 145.67 26.45 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.894 -179.984 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 76' ' ' TYR . . . . . 0.405 ' HB3' ' CG ' ' A' ' 44' ' ' PHE . 12.6 m-85 -119.93 -42.36 2.61 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.852 -179.96 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 77' ' ' PHE . . . . . . . . . . . . . 26.6 p90 -153.13 158.89 42.52 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.875 179.991 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 12.0 p -89.96 99.53 12.52 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.91 -180.0 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 79' ' ' CYS . . . . . . . . . . . . . 30.5 p -117.93 173.95 6.48 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.85 179.977 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 80' ' ' ALA . . . . . . . . . . . . . . . -80.72 168.0 28.49 Favored Pre-proline 0 C--N 1.329 -0.308 0 CA-C-N 116.149 -0.478 . . . . 0.0 111.061 -179.975 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 81' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_exo -52.14 112.18 0.8 Allowed 'Trans proline' 0 C--N 1.345 0.347 0 C-N-CA 122.554 2.169 . . . . 0.0 112.296 179.974 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 82' ' ' ARG . . . . . . . . . . . . . 12.9 mtp180 59.97 56.56 3.38 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.872 179.977 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 83' ' ' HIS . . . . . . . . . . . . . 5.1 m170 -121.48 -41.78 2.48 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.949 179.967 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . -71.44 142.22 33.59 Favored Glycine 0 N--CA 1.451 -0.301 0 C-N-CA 120.786 -0.721 . . . . 0.0 112.516 179.997 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 85' ' ' VAL . . . . . . . . . . . . . 22.3 m -144.48 124.03 7.27 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-O 120.785 0.326 . . . . 0.0 111.089 179.943 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 86' ' ' PHE . . . . . . . . . . . . . 24.1 m-85 -101.28 121.26 41.56 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.974 179.927 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 87' ' ' ALA . . . . . . . . . . . . . . . -138.64 146.54 51.03 Favored Pre-proline 0 C--N 1.329 -0.3 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.102 179.981 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 88' ' ' PRO . . . . . 0.431 ' O ' ' N ' ' A' ' 91' ' ' ARG . 41.8 Cg_exo -56.92 139.15 88.79 Favored 'Trans proline' 0 C--N 1.345 0.379 0 C-N-CA 122.487 2.125 . . . . 0.0 112.313 -179.934 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -48.08 -48.39 33.58 Favored 'General case' 0 C--O 1.232 0.141 0 CA-C-N 116.076 -0.511 . . . . 0.0 110.24 179.818 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 90' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -55.53 -24.54 32.62 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 115.681 -0.69 . . . . 0.0 109.779 178.779 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 91' ' ' ARG . . . . . 0.431 ' N ' ' O ' ' A' ' 88' ' ' PRO . 0.7 OUTLIER -92.13 -13.55 30.53 Favored 'General case' 0 N--CA 1.455 -0.195 0 CA-C-N 115.877 -0.601 . . . . 0.0 110.62 179.201 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 92' ' ' ILE . . . . . 0.409 HD13 HG22 ' A' ' 92' ' ' ILE . 50.1 mt -105.74 154.39 7.01 Favored 'Isoleucine or valine' 0 C--N 1.333 -0.12 0 CA-C-O 120.836 0.35 . . . . 0.0 111.013 179.796 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 93' ' ' GLN . . . . . . . . . . . . . 0.3 OUTLIER -124.07 176.93 6.06 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.911 -179.978 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 94' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER -111.47 160.98 16.61 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.845 -179.989 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 95' ' ' ILE . . . . . . . . . . . . . 30.8 mt -139.8 -47.63 0.3 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.097 179.961 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . -66.92 -161.54 1.24 Allowed Glycine 0 N--CA 1.451 -0.329 0 C-N-CA 120.74 -0.743 . . . . 0.0 112.519 179.91 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 97' ' ' SER . . . . . . . . . . . . . 1.2 t 60.74 105.73 0.02 OUTLIER 'General case' 0 C--N 1.328 -0.35 0 CA-C-O 120.79 0.329 . . . . 0.0 110.802 179.965 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 98' ' ' GLY . . . . . . . . . . . . . . . -112.21 71.46 0.22 Allowed Glycine 0 N--CA 1.451 -0.33 0 C-N-CA 120.764 -0.732 . . . . 0.0 112.559 179.933 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 99' ' ' PRO . . . . . . . . . . . . . 55.6 Cg_endo -70.06 -44.61 1.79 Allowed 'Trans proline' 0 C--N 1.343 0.282 0 C-N-CA 122.504 2.136 . . . . 0.0 112.291 179.996 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 100' ' ' SER . . . . . . . . . . . . . 1.4 m -142.2 172.58 12.49 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.98 179.976 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 67.4 m -89.1 174.88 7.63 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.248 -0.433 . . . . 0.0 110.857 -179.992 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.25 1.145 0 CA-C-O 118.308 -1.273 . . . . 0.0 112.508 -179.994 . . . . . . . . 0 0 . 1 . 001 nuclear build core ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.231 0.11 0 CA-C-O 120.761 0.315 . . . . 0.0 111.164 . . . . . . . . . 0 0 . 1 . 001 nuclear build core ' A' A ' 27' ' ' GLU . . . . . . . . . . . . . 2.1 mm-40 -149.14 167.56 25.59 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.941 -179.992 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 21.8 t -68.6 125.02 25.54 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 CA-C-N 116.176 -0.465 . . . . 0.0 111.106 -179.975 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 98.39 29.66 7.36 Favored Glycine 0 N--CA 1.451 -0.347 0 C-N-CA 120.724 -0.751 . . . . 0.0 112.446 -179.991 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 30' ' ' ASP . . . . . 0.425 ' O ' HG23 ' A' ' 41' ' ' ILE . 0.8 OUTLIER -138.76 147.96 43.27 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-O 120.814 0.34 . . . . 0.0 110.845 -179.928 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 31' ' ' GLN . . . . . . . . . . . . . 0.7 OUTLIER -72.65 127.25 32.0 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.963 179.977 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 22.2 m -130.16 179.9 3.79 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 CA-C-N 116.265 -0.425 . . . . 0.0 111.192 179.973 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 33' ' ' LEU . . . . . 0.562 HD23 ' HA2' ' A' ' 36' ' ' GLY . 15.7 tp -139.52 109.33 6.32 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.262 -0.426 . . . . 0.0 110.963 -179.993 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 23.1 t -76.57 121.12 28.08 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.261 -0.427 . . . . 0.0 111.138 -180.0 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 35' ' ' ALA . . . . . . . . . . . . . . . 59.22 26.61 15.42 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.244 179.976 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 36' ' ' GLY . . . . . 0.562 ' HA2' HD23 ' A' ' 33' ' ' LEU . . . 56.74 36.64 73.01 Favored Glycine 0 N--CA 1.45 -0.387 0 C-N-CA 120.74 -0.743 . . . . 0.0 112.639 179.954 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 37' ' ' GLN . . . . . . . . . . . . . 35.3 mt-30 -146.98 -71.42 0.23 Allowed 'General case' 0 C--N 1.329 -0.325 0 CA-C-O 120.796 0.331 . . . . 0.0 110.948 -179.998 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 38' ' ' LYS . . . . . . . . . . . . . 13.2 mttm -67.83 114.79 6.71 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.879 -179.995 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 39' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -90.14 125.98 35.64 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.922 179.935 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -152.77 -175.61 24.45 Favored Glycine 0 N--CA 1.451 -0.347 0 C-N-CA 120.715 -0.755 . . . . 0.0 112.5 -179.971 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 41' ' ' ILE . . . . . 0.529 ' C ' HG23 ' A' ' 58' ' ' ILE . 4.3 mt -127.64 128.79 69.94 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.272 0 CA-C-O 120.8 0.333 . . . . 0.0 111.02 -179.948 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 42' ' ' VAL . . . . . . . . . . . . . 21.6 t -59.99 124.42 14.28 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.253 -0.431 . . . . 0.0 111.084 179.975 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 43' ' ' ARG . . . . . . . . . . . . . 45.0 mmt-85 -110.57 -30.24 7.71 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.23 -0.441 . . . . 0.0 111.077 -179.993 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 44' ' ' PHE . . . . . . . . . . . . . 35.7 t80 -143.61 118.6 10.02 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.318 -0.401 . . . . 0.0 110.993 -179.958 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 45' ' ' TYR . . . . . 0.455 ' CE1' ' CZ ' ' A' ' 56' ' ' TYR . 22.2 t80 -115.08 114.9 25.96 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.845 179.899 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 176.8 162.96 28.27 Favored Glycine 0 N--CA 1.45 -0.382 0 C-N-CA 120.699 -0.763 . . . . 0.0 112.441 179.944 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 47' ' ' LYS . . . . . 0.442 ' HG3' ' CE1' ' A' ' 54' ' ' TYR . 22.7 mttt -65.98 137.32 57.05 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.865 0.364 . . . . 0.0 110.852 179.97 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 48' ' ' THR . . . . . . . . . . . . . 41.2 p -95.67 -175.35 3.41 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.902 179.918 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 4.6 t70 -106.58 -30.87 8.76 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.893 179.987 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 50' ' ' PHE . . . . . . . . . . . . . 44.3 p90 -71.29 -36.22 71.58 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.867 -179.985 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 51' ' ' ALA . . . . . . . . . . . . . . . -132.69 148.17 68.48 Favored Pre-proline 0 C--N 1.33 -0.274 0 CA-C-N 116.236 -0.438 . . . . 0.0 111.188 179.978 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 52' ' ' PRO . . . . . . . . . . . . . 59.9 Cg_endo -72.25 -170.07 0.53 Allowed 'Trans proline' 0 C--N 1.344 0.34 0 C-N-CA 122.601 2.201 . . . . 0.0 112.336 -179.97 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 59.26 -161.01 15.5 Favored Glycine 0 N--CA 1.452 -0.283 0 C-N-CA 120.746 -0.74 . . . . 0.0 112.537 179.976 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 54' ' ' TYR . . . . . 0.442 ' CE1' ' HG3' ' A' ' 47' ' ' LYS . 12.8 m-85 -106.19 157.8 17.3 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-O 120.844 0.354 . . . . 0.0 110.855 -179.95 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 55' ' ' TRP . . . . . . . . . . . . . 69.5 m95 -144.37 159.71 42.27 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.898 179.988 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 56' ' ' TYR . . . . . 0.827 ' CE1' ' HB2' ' A' ' 89' ' ' ALA . 5.7 m-85 -116.36 115.26 25.55 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.878 -179.951 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 57' ' ' GLY . . . . . 0.443 ' CA ' ' CE1' ' A' ' 86' ' ' PHE . . . -82.27 65.72 4.02 Favored Glycine 0 N--CA 1.451 -0.307 0 C-N-CA 120.75 -0.738 . . . . 0.0 112.431 -179.973 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 58' ' ' ILE . . . . . 0.704 HD11 HD13 ' A' ' 92' ' ' ILE . 5.5 mt -72.67 143.66 13.75 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-O 120.816 0.341 . . . . 0.0 111.074 179.986 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 8.0 tt0 -104.23 143.04 33.49 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.836 179.95 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 60' ' ' LEU . . . . . . . . . . . . . 82.1 mt -96.11 173.18 7.54 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.929 -179.957 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 7.9 t0 -97.12 -33.19 11.6 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.954 179.991 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 62' ' ' GLN . . . . . . . . . . . . . 2.7 mt-30 -116.14 146.36 36.99 Favored Pre-proline 0 C--N 1.329 -0.319 0 CA-C-N 116.18 -0.463 . . . . 0.0 110.936 179.97 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 48.1 Cg_exo -55.83 86.75 0.04 OUTLIER 'Trans proline' 0 C--N 1.346 0.409 0 C-N-CA 122.548 2.165 . . . . 0.0 112.172 179.955 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 64' ' ' THR . . . . . . . . . . . . . 80.8 p -157.3 30.44 0.29 Allowed 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.251 -0.431 . . . . 0.0 110.984 -179.979 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . -89.62 175.54 42.29 Favored Glycine 0 N--CA 1.451 -0.363 0 C-N-CA 120.708 -0.758 . . . . 0.0 112.491 179.957 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 66' ' ' LYS . . . . . . . . . . . . . 48.5 mttm -78.61 -30.47 46.57 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 120.693 0.282 . . . . 0.0 110.865 179.94 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 67' ' ' HIS . . . . . . . . . . . . . 7.4 p80 -148.38 -178.98 6.61 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.898 -179.961 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 9.2 p30 -105.25 48.49 0.84 Allowed 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.952 179.999 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 94.02 -45.91 2.27 Favored Glycine 0 N--CA 1.452 -0.294 0 C-N-CA 120.738 -0.744 . . . . 0.0 112.512 -179.964 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 70' ' ' SER . . . . . . . . . . . . . 1.6 p -98.96 136.58 38.73 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-O 120.821 0.344 . . . . 0.0 110.901 179.985 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 71' ' ' VAL . . . . . 0.468 HG12 ' CD2' ' A' ' 72' ' ' PHE . 21.4 t -114.41 110.64 32.8 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.253 -0.431 . . . . 0.0 111.131 179.969 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 72' ' ' PHE . . . . . 0.468 ' CD2' HG12 ' A' ' 71' ' ' VAL . 60.6 m-85 60.47 31.89 20.41 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.22 -0.446 . . . . 0.0 110.961 179.967 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 98.85 -30.18 10.25 Favored Glycine 0 N--CA 1.451 -0.355 0 C-N-CA 120.685 -0.769 . . . . 0.0 112.556 -179.962 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 21.4 t -77.95 117.63 23.52 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-O 120.823 0.344 . . . . 0.0 111.127 179.904 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 75' ' ' ARG . . . . . . . . . . . . . 5.1 ttt180 -95.33 149.52 21.27 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.988 -179.864 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 76' ' ' TYR . . . . . . . . . . . . . 35.9 m-85 -129.94 -45.6 1.15 Allowed 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.25 -0.432 . . . . 0.0 110.947 179.951 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 77' ' ' PHE . . . . . . . . . . . . . 38.1 p90 -146.72 164.72 31.85 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.31 -0.405 . . . . 0.0 110.997 179.945 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 51.7 p -96.18 123.49 39.82 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.921 -179.97 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 79' ' ' CYS . . . . . . . . . . . . . 7.5 p -148.02 170.57 17.47 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.877 179.891 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 80' ' ' ALA . . . . . 0.407 ' HB1' ' HD2' ' A' ' 81' ' ' PRO . . . -71.73 162.48 72.93 Favored Pre-proline 0 C--N 1.329 -0.289 0 CA-C-N 116.163 -0.471 . . . . 0.0 111.079 -179.952 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 81' ' ' PRO . . . . . 0.407 ' HD2' ' HB1' ' A' ' 80' ' ' ALA . 53.0 Cg_exo -52.4 118.46 4.66 Favored 'Trans proline' 0 C--N 1.344 0.3 0 C-N-CA 122.632 2.221 . . . . 0.0 112.294 179.971 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 82' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER 60.27 63.53 1.38 Allowed 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.869 179.972 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 83' ' ' HIS . . . . . . . . . . . . . 3.3 m-70 -132.3 -46.02 0.91 Allowed 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.13 -0.486 . . . . 0.0 110.911 -179.975 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . -63.73 141.69 45.74 Favored Glycine 0 N--CA 1.451 -0.362 0 C-N-CA 120.709 -0.757 . . . . 0.0 112.52 179.996 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 85' ' ' VAL . . . . . . . . . . . . . 6.1 m -142.15 120.14 8.24 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-O 120.768 0.318 . . . . 0.0 111.166 -179.974 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 86' ' ' PHE . . . . . 0.443 ' CE1' ' CA ' ' A' ' 57' ' ' GLY . 12.4 m-85 -100.38 115.39 29.9 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.868 179.994 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 87' ' ' ALA . . . . . 0.609 ' O ' HD11 ' A' ' 92' ' ' ILE . . . -137.8 145.57 49.04 Favored Pre-proline 0 C--N 1.328 -0.336 0 CA-C-N 116.28 -0.418 . . . . 0.0 111.143 179.924 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 88' ' ' PRO . . . . . 0.406 ' O ' ' N ' ' A' ' 91' ' ' ARG . 47.4 Cg_exo -56.02 139.14 84.51 Favored 'Trans proline' 0 C--N 1.345 0.388 0 C-N-CA 122.454 2.103 . . . . 0.0 112.336 -179.977 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 89' ' ' ALA . . . . . 0.827 ' HB2' ' CE1' ' A' ' 56' ' ' TYR . . . -48.01 -50.91 26.03 Favored 'General case' 0 C--N 1.333 -0.122 0 CA-C-N 116.109 -0.496 . . . . 0.0 110.272 179.862 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 90' ' ' SER . . . . . . . . . . . . . 17.7 m -55.76 -24.49 35.65 Favored 'General case' 0 N--CA 1.454 -0.259 0 CA-C-N 115.687 -0.688 . . . . 0.0 109.766 178.816 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 91' ' ' ARG . . . . . 0.406 ' N ' ' O ' ' A' ' 88' ' ' PRO . 0.6 OUTLIER -88.3 -15.14 36.53 Favored 'General case' 0 N--CA 1.455 -0.188 0 CA-C-N 115.831 -0.622 . . . . 0.0 110.473 179.02 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 92' ' ' ILE . . . . . 0.704 HD13 HD11 ' A' ' 58' ' ' ILE . 33.3 mt -104.37 157.89 5.5 Favored 'Isoleucine or valine' 0 C--N 1.334 -0.097 0 CA-C-N 116.379 -0.373 . . . . 0.0 110.973 179.924 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 93' ' ' GLN . . . . . 0.482 ' N ' HG22 ' A' ' 92' ' ' ILE . 2.2 mt-30 -128.3 166.34 18.81 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.889 -179.912 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 94' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -107.15 145.36 32.64 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.846 -179.994 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 95' ' ' ILE . . . . . . . . . . . . . 23.4 mt . . . . . 0 C--N 1.329 -0.299 0 CA-C-N 116.211 -0.449 . . . . 0.0 111.13 179.902 . . . . . . . . 0 0 . 1 . 002 nuclear build core ' A' A ' 26' ' ' ALA . . . . . 0.587 ' N ' ' HH ' ' A' ' 56' ' ' TYR . . . . . . . . 0 C--O 1.231 0.101 0 CA-C-O 120.877 0.37 . . . . 0.0 111.081 . . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 27' ' ' GLU . . . . . . . . . . . . . 6.0 mt-10 -148.03 173.37 12.98 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.252 -0.431 . . . . 0.0 110.911 179.98 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 21.5 t -70.83 110.28 3.72 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.087 179.974 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 113.01 36.24 1.54 Allowed Glycine 0 N--CA 1.452 -0.296 0 C-N-CA 120.736 -0.745 . . . . 0.0 112.503 179.97 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 2.1 m-20 -150.06 138.05 20.23 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 120.852 0.358 . . . . 0.0 110.866 -179.978 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 31' ' ' GLN . . . . . . . . . . . . . 0.7 OUTLIER -62.94 132.88 53.57 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.125 -0.489 . . . . 0.0 110.871 179.998 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 32' ' ' VAL . . . . . 0.486 HG21 HG12 ' A' ' 58' ' ' ILE . 12.6 m -132.99 178.81 5.12 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.149 179.99 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 33' ' ' LEU . . . . . 0.55 HD11 ' O ' ' A' ' 37' ' ' GLN . 40.4 tp -140.14 101.22 4.1 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.9 179.931 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 34' ' ' VAL . . . . . 0.406 ' CG2' HD13 ' A' ' 58' ' ' ILE . 21.6 t -72.55 127.68 34.75 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.218 -0.446 . . . . 0.0 111.175 -179.928 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 35' ' ' ALA . . . . . . . . . . . . . . . 57.68 25.33 11.62 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.139 -0.482 . . . . 0.0 111.266 179.937 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . 56.07 27.96 52.75 Favored Glycine 0 N--CA 1.453 -0.224 0 C-N-CA 120.686 -0.769 . . . . 0.0 112.638 179.979 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 37' ' ' GLN . . . . . 0.55 ' O ' HD11 ' A' ' 33' ' ' LEU . 37.7 mt-30 -138.1 -72.83 0.41 Allowed 'General case' 0 C--N 1.33 -0.279 0 CA-C-O 120.797 0.332 . . . . 0.0 110.944 -179.906 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 38' ' ' LYS . . . . . . . . . . . . . 3.7 mttt -69.02 111.81 5.25 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.265 -0.425 . . . . 0.0 110.965 179.991 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 39' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -92.98 130.5 38.53 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.086 -0.506 . . . . 0.0 110.905 -179.997 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -152.04 -171.0 19.33 Favored Glycine 0 N--CA 1.45 -0.38 0 C-N-CA 120.812 -0.709 . . . . 0.0 112.52 -179.988 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 29.8 mt -123.4 131.92 72.29 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 CA-C-O 120.825 0.345 . . . . 0.0 111.172 179.973 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 42' ' ' VAL . . . . . . . . . . . . . 21.6 t -59.44 126.87 17.85 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.336 0 CA-C-N 116.24 -0.436 . . . . 0.0 111.105 -179.999 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 43' ' ' ARG . . . . . . . . . . . . . 8.7 mmm180 -111.81 -42.56 3.78 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.932 -179.999 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 44' ' ' PHE . . . . . . . . . . . . . 46.0 t80 -138.66 113.24 8.95 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.937 -179.937 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 45' ' ' TYR . . . . . 0.426 ' CE1' ' CE1' ' A' ' 56' ' ' TYR . 35.8 t80 -113.08 138.56 49.73 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.956 179.98 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 152.71 -169.57 31.79 Favored Glycine 0 N--CA 1.449 -0.45 0 C-N-CA 120.783 -0.722 . . . . 0.0 112.489 179.957 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 47' ' ' LYS . . . . . . . . . . . . . 28.7 mttm -78.21 147.35 34.49 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-O 120.847 0.356 . . . . 0.0 110.844 -179.954 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 48' ' ' THR . . . . . 0.654 HG22 ' CE2' ' A' ' 76' ' ' TYR . 34.8 p -118.88 171.52 8.17 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.913 179.985 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -98.88 -35.79 9.99 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.885 179.972 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 50' ' ' PHE . . . . . 0.574 ' CZ ' HG21 ' A' ' 48' ' ' THR . 27.0 p90 -61.61 -31.39 71.46 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.92 179.907 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 51' ' ' ALA . . . . . . . . . . . . . . . -152.11 146.42 18.52 Favored Pre-proline 0 C--N 1.329 -0.294 0 CA-C-N 116.26 -0.427 . . . . 0.0 111.117 179.997 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 52' ' ' PRO . . . . . . . . . . . . . 60.9 Cg_endo -72.86 175.82 9.84 Favored 'Trans proline' 0 C--N 1.345 0.368 0 C-N-CA 122.573 2.182 . . . . 0.0 112.334 179.973 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 84.11 -158.79 35.03 Favored Glycine 0 N--CA 1.45 -0.369 0 C-N-CA 120.716 -0.754 . . . . 0.0 112.541 179.986 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 54' ' ' TYR . . . . . . . . . . . . . 20.2 m-85 -118.74 124.64 47.78 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-O 120.872 0.368 . . . . 0.0 110.897 179.982 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 55' ' ' TRP . . . . . . . . . . . . . 36.4 m95 -118.19 162.89 17.49 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.911 179.988 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 56' ' ' TYR . . . . . 0.692 ' HE1' ' HB2' ' A' ' 89' ' ' ALA . 8.4 m-85 -110.69 125.37 53.4 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.934 -179.91 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 57' ' ' GLY . . . . . 0.431 ' HA3' ' CE1' ' A' ' 77' ' ' PHE . . . -88.01 53.28 4.21 Favored Glycine 0 N--CA 1.451 -0.365 0 C-N-CA 120.72 -0.752 . . . . 0.0 112.423 179.97 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 58' ' ' ILE . . . . . 0.486 HG12 HG21 ' A' ' 32' ' ' VAL . 3.8 mt -64.64 142.33 17.03 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.266 0 CA-C-O 120.834 0.349 . . . . 0.0 111.164 -179.981 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 2.4 tm-20 -115.12 108.11 16.2 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.118 -0.492 . . . . 0.0 110.836 -179.947 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 60' ' ' LEU . . . . . . . . . . . . . 48.0 mt -67.75 176.28 2.57 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.906 -179.964 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -100.86 -32.87 10.46 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.852 -179.995 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 62' ' ' GLN . . . . . . . . . . . . . 0.2 OUTLIER -101.37 154.69 37.07 Favored Pre-proline 0 C--N 1.328 -0.332 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.917 179.976 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 58.3 Cg_endo -71.85 68.13 3.09 Favored 'Trans proline' 0 C--N 1.344 0.308 0 C-N-CA 122.584 2.189 . . . . 0.0 112.275 -179.965 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 64' ' ' THR . . . . . . . . . . . . . 73.4 p -139.54 34.25 2.04 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.901 -179.994 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . -88.33 -129.11 3.15 Favored Glycine 0 N--CA 1.452 -0.295 0 C-N-CA 120.732 -0.747 . . . . 0.0 112.579 179.948 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 66' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -144.96 -47.33 0.23 Allowed 'General case' 0 C--N 1.328 -0.353 0 CA-C-O 120.785 0.326 . . . . 0.0 110.845 -179.991 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 67' ' ' HIS . . . . . . . . . . . . . 7.6 p80 -119.94 170.02 9.64 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.213 -0.448 . . . . 0.0 110.839 179.973 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 39.0 m-20 -98.42 34.04 2.09 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.862 -179.983 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 94.62 -42.72 2.39 Favored Glycine 0 N--CA 1.451 -0.329 0 C-N-CA 120.737 -0.744 . . . . 0.0 112.586 -179.939 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 70' ' ' SER . . . . . . . . . . . . . 5.6 p -100.8 134.67 43.42 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-O 120.833 0.349 . . . . 0.0 110.946 -179.984 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 71' ' ' VAL . . . . . 0.409 HG12 ' CD2' ' A' ' 72' ' ' PHE . 21.3 t -114.92 102.95 14.57 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.156 -0.474 . . . . 0.0 111.062 -179.913 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 72' ' ' PHE . . . . . 0.409 ' CD2' HG12 ' A' ' 71' ' ' VAL . 33.2 m-85 61.75 30.8 18.52 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.191 -0.458 . . . . 0.0 110.935 179.929 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 104.21 -30.09 10.81 Favored Glycine 0 N--CA 1.451 -0.362 0 C-N-CA 120.703 -0.76 . . . . 0.0 112.513 179.973 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 21.4 t -77.82 116.87 22.04 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.345 0 CA-C-O 120.749 0.309 . . . . 0.0 111.173 179.978 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 75' ' ' ARG . . . . . . . . . . . . . 10.1 ttm180 -96.62 143.24 27.77 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.272 -0.422 . . . . 0.0 110.898 -179.956 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 76' ' ' TYR . . . . . 0.654 ' CE2' HG22 ' A' ' 48' ' ' THR . 20.0 m-85 -118.69 -40.48 2.88 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.933 179.926 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 77' ' ' PHE . . . . . 0.431 ' CE1' ' HA3' ' A' ' 57' ' ' GLY . 16.0 p90 -160.07 157.55 28.79 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.956 179.972 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 18.8 m -83.9 111.51 19.3 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.836 -179.974 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 79' ' ' CYS . . . . . . . . . . . . . 30.5 p -132.74 174.24 10.52 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.901 179.941 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 80' ' ' ALA . . . . . 0.668 ' HB3' ' CD2' ' A' ' 83' ' ' HIS . . . -91.91 171.58 7.61 Favored Pre-proline 0 C--N 1.33 -0.281 0 CA-C-N 116.161 -0.472 . . . . 0.0 111.151 179.997 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 81' ' ' PRO . . . . . 0.624 ' HD2' ' HB1' ' A' ' 80' ' ' ALA . 50.7 Cg_exo -53.77 116.14 2.81 Favored 'Trans proline' 0 C--N 1.344 0.301 0 C-N-CA 122.592 2.194 . . . . 0.0 112.322 179.988 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 82' ' ' ARG . . . . . . . . . . . . . 3.4 mtp85 61.1 52.31 4.06 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.896 179.901 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 83' ' ' HIS . . . . . 0.668 ' CD2' ' HB3' ' A' ' 80' ' ' ALA . 0.9 OUTLIER -120.99 -43.02 2.47 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.793 179.936 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . -75.2 144.4 31.97 Favored Glycine 0 N--CA 1.45 -0.383 0 C-N-CA 120.817 -0.706 . . . . 0.0 112.495 179.938 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 85' ' ' VAL . . . . . . . . . . . . . 6.6 m -147.77 127.39 4.44 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-O 120.806 0.336 . . . . 0.0 111.231 179.978 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 86' ' ' PHE . . . . . . . . . . . . . 6.1 m-85 -106.71 110.74 23.01 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.886 179.975 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 87' ' ' ALA . . . . . 0.606 ' O ' HD11 ' A' ' 92' ' ' ILE . . . -132.27 150.96 77.45 Favored Pre-proline 0 C--N 1.33 -0.268 0 CA-C-N 116.189 -0.459 . . . . 0.0 111.106 -179.957 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 88' ' ' PRO . . . . . 0.405 ' O ' ' N ' ' A' ' 91' ' ' ARG . 32.1 Cg_exo -58.4 138.09 83.94 Favored 'Trans proline' 0 C--N 1.344 0.338 0 C-N-CA 122.518 2.146 . . . . 0.0 112.285 -179.972 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 89' ' ' ALA . . . . . 0.692 ' HB2' ' HE1' ' A' ' 56' ' ' TYR . . . -48.05 -51.29 24.85 Favored 'General case' 0 CA--C 1.522 -0.124 0 CA-C-N 116.106 -0.497 . . . . 0.0 110.331 179.845 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 90' ' ' SER . . . . . . . . . . . . . 70.3 p -55.96 -24.41 38.14 Favored 'General case' 0 N--CA 1.453 -0.296 0 CA-C-N 115.714 -0.675 . . . . 0.0 109.769 178.809 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 91' ' ' ARG . . . . . 0.405 ' N ' ' O ' ' A' ' 88' ' ' PRO . 1.3 mtt180 -88.43 -14.6 37.57 Favored 'General case' 0 N--CA 1.453 -0.282 0 CA-C-N 115.852 -0.613 . . . . 0.0 110.535 178.992 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 92' ' ' ILE . . . . . 0.606 HD11 ' O ' ' A' ' 87' ' ' ALA . 26.0 mt -107.02 146.01 13.85 Favored 'Isoleucine or valine' 0 C--O 1.23 0.076 0 CA-C-N 116.302 -0.408 . . . . 0.0 111.014 179.935 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 93' ' ' GLN . . . . . . . . . . . . . 2.1 mt-30 -115.53 177.2 4.75 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.904 179.973 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 94' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER -115.81 148.23 40.12 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.923 179.971 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 95' ' ' ILE . . . . . 0.482 HD11 ' HB2' ' A' ' 33' ' ' LEU . 28.8 mm . . . . . 0 C--N 1.328 -0.358 0 CA-C-N 116.259 -0.428 . . . . 0.0 111.082 -179.935 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.231 0.111 0 CA-C-O 120.784 0.326 . . . . 0.0 111.143 . . . . . . . . . 0 0 . 1 . 003 nuclear build core ' A' A ' 27' ' ' GLU . . . . . . . . . . . . . 3.0 mt-10 -115.25 -173.28 2.29 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.899 179.967 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 21.4 t -80.18 98.31 3.36 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.312 -0.404 . . . . 0.0 111.05 179.978 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 111.78 29.72 3.25 Favored Glycine 0 N--CA 1.451 -0.312 0 C-N-CA 120.807 -0.711 . . . . 0.0 112.417 179.912 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 1.2 t70 -122.81 146.03 47.91 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 120.832 0.348 . . . . 0.0 110.894 179.981 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 31' ' ' GLN . . . . . . . . . . . . . 18.1 mt-30 -60.76 131.46 50.75 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.821 179.953 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 14.5 m -140.3 171.81 12.8 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.156 -0.475 . . . . 0.0 111.137 179.978 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 33' ' ' LEU . . . . . . . . . . . . . 17.8 tp -134.21 110.54 9.61 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.903 -179.963 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 34' ' ' VAL . . . . . 0.414 HG22 ' CD1' ' A' ' 58' ' ' ILE . 21.6 t -77.95 120.43 28.68 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 116.221 -0.445 . . . . 0.0 111.09 -179.937 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 35' ' ' ALA . . . . . . . . . . . . . . . 58.25 27.05 14.65 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.163 -0.471 . . . . 0.0 111.192 179.981 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . 56.77 31.33 60.73 Favored Glycine 0 N--CA 1.452 -0.282 0 C-N-CA 120.709 -0.758 . . . . 0.0 112.606 179.931 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 37' ' ' GLN . . . . . . . . . . . . . 91.5 mt-30 -140.28 -73.27 0.36 Allowed 'General case' 0 C--N 1.33 -0.272 0 CA-C-O 120.833 0.349 . . . . 0.0 110.962 -179.992 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 38' ' ' LYS . . . . . 0.466 ' HB3' HD21 ' A' ' 60' ' ' LEU . 34.1 mttp -68.22 104.27 1.78 Allowed 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.855 179.977 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 39' ' ' GLN . . . . . . . . . . . . . 0.4 OUTLIER -85.34 136.07 33.63 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.252 -0.431 . . . . 0.0 110.839 179.905 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -164.56 -163.7 18.21 Favored Glycine 0 N--CA 1.451 -0.356 0 C-N-CA 120.771 -0.728 . . . . 0.0 112.539 179.965 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 32.4 mt -131.12 139.51 50.84 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-O 120.79 0.328 . . . . 0.0 111.156 179.994 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 42' ' ' VAL . . . . . . . . . . . . . 23.2 t -69.18 124.36 24.8 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.334 0 CA-C-N 116.187 -0.46 . . . . 0.0 111.059 -179.952 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 43' ' ' ARG . . . . . . . . . . . . . 27.8 mmt180 -105.58 -32.57 8.42 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.178 -0.464 . . . . 0.0 110.984 -179.956 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 44' ' ' PHE . . . . . . . . . . . . . 51.0 t80 -143.08 118.11 10.05 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 116.189 -0.459 . . . . 0.0 110.962 -179.93 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 45' ' ' TYR . . . . . 0.494 ' CE1' ' CZ ' ' A' ' 56' ' ' TYR . 15.5 t80 -113.02 117.94 33.41 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.867 179.965 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 172.74 170.25 36.26 Favored Glycine 0 N--CA 1.452 -0.26 0 C-N-CA 120.657 -0.782 . . . . 0.0 112.487 179.979 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 47' ' ' LYS . . . . . 0.421 ' HG3' ' CE1' ' A' ' 54' ' ' TYR . 19.5 mttt -67.09 148.08 52.33 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 120.837 0.351 . . . . 0.0 110.942 179.983 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 48' ' ' THR . . . . . 0.608 HG21 ' CZ ' ' A' ' 50' ' ' PHE . 16.6 p -109.15 170.85 7.79 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.893 179.988 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 8.3 t0 -98.3 -31.12 12.21 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.869 179.989 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 50' ' ' PHE . . . . . 0.608 ' CZ ' HG21 ' A' ' 48' ' ' THR . 18.1 p90 -66.54 -32.23 73.45 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.935 -179.962 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 51' ' ' ALA . . . . . 0.435 ' N ' ' CD1' ' A' ' 50' ' ' PHE . . . -148.94 151.72 35.34 Favored Pre-proline 0 C--N 1.329 -0.299 0 CA-C-N 116.271 -0.422 . . . . 0.0 111.096 179.996 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 52' ' ' PRO . . . . . . . . . . . . . 56.8 Cg_endo -70.67 -167.94 0.29 Allowed 'Trans proline' 0 C--N 1.344 0.31 0 C-N-CA 122.598 2.198 . . . . 0.0 112.289 179.997 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 65.2 -176.39 12.82 Favored Glycine 0 N--CA 1.45 -0.38 0 C-N-CA 120.791 -0.719 . . . . 0.0 112.481 179.971 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 54' ' ' TYR . . . . . 0.421 ' CE1' ' HG3' ' A' ' 47' ' ' LYS . 7.6 m-85 -106.57 128.97 54.55 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-O 120.828 0.347 . . . . 0.0 110.928 179.974 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 55' ' ' TRP . . . . . . . . . . . . . 35.0 m95 -116.2 174.29 6.13 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.846 -179.969 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 56' ' ' TYR . . . . . 0.73 ' HE1' ' HB2' ' A' ' 89' ' ' ALA . 16.8 m-85 -125.35 121.64 34.51 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.92 -179.963 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 57' ' ' GLY . . . . . 0.403 ' N ' ' CE1' ' A' ' 86' ' ' PHE . . . -82.11 62.03 4.61 Favored Glycine 0 N--CA 1.451 -0.33 0 C-N-CA 120.776 -0.726 . . . . 0.0 112.417 179.928 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 58' ' ' ILE . . . . . 0.541 HD11 HD13 ' A' ' 92' ' ' ILE . 21.2 mt -68.67 139.71 20.14 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-O 120.809 0.338 . . . . 0.0 111.122 -179.993 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 4.7 tm-20 -111.99 112.52 24.22 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.91 179.959 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 60' ' ' LEU . . . . . 0.466 HD21 ' HB3' ' A' ' 38' ' ' LYS . 84.7 mt -72.53 177.34 4.73 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.967 -179.992 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -100.42 -32.37 10.85 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.815 179.998 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 62' ' ' GLN . . . . . . . . . . . . . 4.7 mm100 -106.62 155.33 39.08 Favored Pre-proline 0 C--N 1.328 -0.34 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.829 179.999 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 57.7 Cg_endo -71.51 68.11 2.82 Favored 'Trans proline' 0 C--N 1.345 0.354 0 C-N-CA 122.544 2.163 . . . . 0.0 112.399 179.907 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 64' ' ' THR . . . . . . . . . . . . . 12.4 p -136.0 31.18 3.0 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.871 -179.999 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . -92.95 -139.75 9.46 Favored Glycine 0 N--CA 1.451 -0.349 0 C-N-CA 120.754 -0.736 . . . . 0.0 112.548 -179.956 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 66' ' ' LYS . . . . . 0.451 ' HD2' HG12 ' A' ' 85' ' ' VAL . 0.0 OUTLIER -128.63 -45.75 1.31 Allowed 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 120.848 0.356 . . . . 0.0 110.924 179.961 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 67' ' ' HIS . . . . . . . . . . . . . 7.2 p80 -127.1 169.89 12.93 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.233 -0.44 . . . . 0.0 110.871 179.974 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 10.3 p-10 -98.56 36.51 1.63 Allowed 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.935 179.964 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 105.88 -50.37 0.82 Allowed Glycine 0 N--CA 1.45 -0.391 0 C-N-CA 120.756 -0.735 . . . . 0.0 112.502 179.964 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 70' ' ' SER . . . . . . . . . . . . . 80.5 p -93.26 151.84 19.56 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 120.836 0.35 . . . . 0.0 110.832 -179.945 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 71' ' ' VAL . . . . . 0.622 HG12 ' CD2' ' A' ' 72' ' ' PHE . 20.0 t -141.35 110.47 2.77 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 CA-C-N 116.226 -0.443 . . . . 0.0 111.069 -180.0 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 72' ' ' PHE . . . . . 0.622 ' CD2' HG12 ' A' ' 71' ' ' VAL . 67.6 m-85 60.17 31.17 20.43 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.903 -179.968 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 87.07 28.37 25.83 Favored Glycine 0 N--CA 1.451 -0.312 0 C-N-CA 120.747 -0.739 . . . . 0.0 112.498 179.98 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 21.4 t -128.35 104.27 11.38 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-O 120.901 0.381 . . . . 0.0 111.085 -179.988 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 75' ' ' ARG . . . . . . . . . . . . . 11.3 ttt180 -84.0 134.2 34.65 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.861 -179.934 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 76' ' ' TYR . . . . . 0.594 ' CE2' HG22 ' A' ' 48' ' ' THR . 56.5 m-85 -118.2 -41.51 2.86 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.883 179.973 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 77' ' ' PHE . . . . . . . . . . . . . 12.8 p90 -158.98 163.31 36.58 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.145 -0.48 . . . . 0.0 110.87 179.987 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 1.2 p -89.6 109.1 20.08 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.926 179.97 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 79' ' ' CYS . . . . . . . . . . . . . 28.6 p -138.41 166.19 24.88 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.921 -179.988 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 80' ' ' ALA . . . . . 0.795 ' HB3' ' CD2' ' A' ' 83' ' ' HIS . . . -77.51 168.93 23.75 Favored Pre-proline 0 C--N 1.329 -0.316 0 CA-C-N 116.227 -0.442 . . . . 0.0 111.07 -179.97 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 81' ' ' PRO . . . . . 0.531 ' HD2' ' HB1' ' A' ' 80' ' ' ALA . 32.5 Cg_exo -58.11 122.93 12.55 Favored 'Trans proline' 0 C--N 1.344 0.308 0 C-N-CA 122.582 2.188 . . . . 0.0 112.29 -179.929 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 82' ' ' ARG . . . . . . . . . . . . . 14.8 mtt-85 64.17 46.54 3.59 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.155 -0.475 . . . . 0.0 111.123 179.908 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 83' ' ' HIS . . . . . 0.795 ' CD2' ' HB3' ' A' ' 80' ' ' ALA . 0.7 OUTLIER -119.29 -45.18 2.55 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.796 179.892 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . -75.49 138.96 23.99 Favored Glycine 0 N--CA 1.452 -0.295 0 C-N-CA 120.742 -0.742 . . . . 0.0 112.47 179.955 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 85' ' ' VAL . . . . . 0.451 HG12 ' HD2' ' A' ' 66' ' ' LYS . 18.0 m -141.72 119.72 8.78 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.361 0 CA-C-O 120.818 0.342 . . . . 0.0 111.108 -179.91 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 86' ' ' PHE . . . . . 0.403 ' CE1' ' N ' ' A' ' 57' ' ' GLY . 9.3 m-85 -97.69 110.57 23.11 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.872 179.928 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 87' ' ' ALA . . . . . 0.554 ' O ' HD11 ' A' ' 92' ' ' ILE . . . -128.78 151.19 76.81 Favored Pre-proline 0 C--N 1.33 -0.273 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.163 -179.989 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 88' ' ' PRO . . . . . . . . . . . . . 31.8 Cg_exo -58.72 136.24 72.53 Favored 'Trans proline' 0 C--N 1.345 0.36 0 C-N-CA 122.619 2.213 . . . . 0.0 112.252 -179.925 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 89' ' ' ALA . . . . . 0.73 ' HB2' ' HE1' ' A' ' 56' ' ' TYR . . . -48.05 -51.25 25.02 Favored 'General case' 0 C--N 1.333 -0.124 0 CA-C-N 116.154 -0.476 . . . . 0.0 110.277 179.91 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 90' ' ' SER . . . . . . . . . . . . . 5.5 m -55.94 -24.36 37.54 Favored 'General case' 0 N--CA 1.454 -0.249 0 CA-C-N 115.724 -0.671 . . . . 0.0 109.757 178.81 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 91' ' ' ARG . . . . . . . . . . . . . 0.6 OUTLIER -89.11 -14.09 37.04 Favored 'General case' 0 N--CA 1.455 -0.21 0 CA-C-N 115.818 -0.628 . . . . 0.0 110.487 179.064 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 92' ' ' ILE . . . . . 0.554 HD11 ' O ' ' A' ' 87' ' ' ALA . 28.1 mt -108.26 146.25 14.35 Favored 'Isoleucine or valine' 0 C--O 1.231 0.091 0 CA-C-N 116.391 -0.368 . . . . 0.0 111.034 179.834 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 93' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -106.19 164.49 11.96 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.218 -0.447 . . . . 0.0 110.817 -179.993 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 94' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -116.35 119.27 35.14 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.887 -179.995 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 95' ' ' ILE . . . . . . . . . . . . . 22.2 mt . . . . . 0 C--N 1.329 -0.307 0 CA-C-N 116.18 -0.464 . . . . 0.0 111.197 179.96 . . . . . . . . 0 0 . 1 . 004 nuclear build core ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.231 0.091 0 CA-C-O 120.836 0.35 . . . . 0.0 111.122 . . . . . . . . . 0 0 . 1 . 004 nuclear build core ' A' A ' 27' ' ' GLU . . . . . . . . . . . . . 1.1 pm0 -116.75 158.39 23.94 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.888 -179.988 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 36.7 t -67.85 82.69 0.11 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.035 179.911 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 136.24 43.95 0.1 OUTLIER Glycine 0 N--CA 1.451 -0.366 0 C-N-CA 120.745 -0.74 . . . . 0.0 112.537 -179.981 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -149.18 167.69 25.28 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-O 120.838 0.352 . . . . 0.0 110.893 -179.984 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 31' ' ' GLN . . . . . 0.438 ' HA ' HD13 ' A' ' 41' ' ' ILE . 0.5 OUTLIER -78.12 130.73 36.73 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.942 -179.962 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 32' ' ' VAL . . . . . 0.456 ' CG2' HD13 ' A' ' 58' ' ' ILE . 4.7 m -132.76 172.48 16.37 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.326 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.112 179.944 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 33' ' ' LEU . . . . . 0.611 ' HB2' HD11 ' A' ' 95' ' ' ILE . 16.7 tp -143.52 112.36 6.58 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.196 -0.457 . . . . 0.0 110.856 -179.942 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 34' ' ' VAL . . . . . 0.506 HG13 ' CB ' ' A' ' 87' ' ' ALA . 21.5 t -81.09 124.25 38.57 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.245 -0.434 . . . . 0.0 111.11 -179.849 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 35' ' ' ALA . . . . . . . . . . . . . . . 57.94 26.65 13.65 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.067 -0.515 . . . . 0.0 111.294 179.99 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 36' ' ' GLY . . . . . 0.541 ' HA2' HD23 ' A' ' 33' ' ' LEU . . . 57.05 33.45 64.25 Favored Glycine 0 N--CA 1.452 -0.29 0 C-N-CA 120.759 -0.734 . . . . 0.0 112.562 179.959 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 37' ' ' GLN . . . . . . . . . . . . . 37.7 mt-30 -144.36 -70.44 0.29 Allowed 'General case' 0 C--N 1.328 -0.35 0 CA-C-O 120.87 0.367 . . . . 0.0 111.075 -179.867 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 38' ' ' LYS . . . . . . . . . . . . . 2.8 mmpt? -68.08 114.61 6.74 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.925 -179.871 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 39' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -93.88 128.64 40.27 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.9 179.985 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -152.82 -172.88 21.64 Favored Glycine 0 N--CA 1.451 -0.335 0 C-N-CA 120.759 -0.734 . . . . 0.0 112.534 179.973 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 41' ' ' ILE . . . . . 0.442 ' N ' HG23 ' A' ' 58' ' ' ILE . 25.4 mm -125.33 138.07 55.57 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.269 0 CA-C-O 120.818 0.342 . . . . 0.0 111.136 -179.932 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 42' ' ' VAL . . . . . . . . . . . . . 21.5 t -69.32 122.33 20.56 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.185 -0.461 . . . . 0.0 111.082 -179.99 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 43' ' ' ARG . . . . . . . . . . . . . 8.0 mmt180 -113.55 -35.88 5.1 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.926 -179.998 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 44' ' ' PHE . . . . . . . . . . . . . 64.6 t80 -139.05 111.45 7.53 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.941 -179.983 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 45' ' ' TYR . . . . . 0.485 ' CE1' ' CE1' ' A' ' 56' ' ' TYR . 13.3 t80 -107.28 136.88 46.36 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.857 179.879 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 153.51 -163.08 30.6 Favored Glycine 0 N--CA 1.451 -0.352 0 C-N-CA 120.746 -0.74 . . . . 0.0 112.479 179.988 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 47' ' ' LYS . . . . . . . . . . . . . 21.1 mttp -88.64 167.69 13.16 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-O 120.799 0.333 . . . . 0.0 110.875 -179.944 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 48' ' ' THR . . . . . 0.672 HG21 ' CZ ' ' A' ' 50' ' ' PHE . 29.1 p -129.48 -173.88 3.13 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.846 179.965 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -110.37 -31.58 7.24 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.855 -179.97 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 50' ' ' PHE . . . . . 0.672 ' CZ ' HG21 ' A' ' 48' ' ' THR . 18.3 p90 -67.84 -36.09 79.74 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.259 -0.428 . . . . 0.0 110.992 -179.924 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 51' ' ' ALA . . . . . 0.427 ' N ' ' CD1' ' A' ' 50' ' ' PHE . . . -148.4 146.04 21.81 Favored Pre-proline 0 C--N 1.329 -0.283 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.175 179.979 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 52' ' ' PRO . . . . . . . . . . . . . 69.2 Cg_endo -74.39 173.77 13.67 Favored 'Trans proline' 0 C--N 1.345 0.391 0 C-N-CA 122.573 2.182 . . . . 0.0 112.315 -179.985 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 92.43 172.62 41.47 Favored Glycine 0 N--CA 1.452 -0.289 0 C-N-CA 120.762 -0.733 . . . . 0.0 112.48 179.905 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 54' ' ' TYR . . . . . . . . . . . . . 10.5 m-85 -90.14 110.31 21.33 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-O 120.814 0.34 . . . . 0.0 110.868 -179.993 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 55' ' ' TRP . . . . . 0.426 ' HB3' ' CD1' ' A' ' 86' ' ' PHE . 66.7 m95 -105.17 159.25 16.01 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.906 179.967 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 56' ' ' TYR . . . . . 0.607 ' CE1' ' HB2' ' A' ' 89' ' ' ALA . 12.6 m-85 -114.9 117.34 30.4 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.98 -179.824 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . -79.75 68.06 3.28 Favored Glycine 0 N--CA 1.451 -0.34 0 C-N-CA 120.684 -0.77 . . . . 0.0 112.341 179.934 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 58' ' ' ILE . . . . . 0.595 HD11 HD13 ' A' ' 92' ' ' ILE . 38.0 mt -73.3 137.89 22.44 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.39 0 CA-C-O 120.829 0.347 . . . . 0.0 111.192 -179.911 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 1.3 tm-20 -104.29 107.12 17.88 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.79 179.926 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 60' ' ' LEU . . . . . 0.568 HD11 HG11 ' A' ' 85' ' ' VAL . 36.6 mt -60.11 170.43 1.25 Allowed 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.971 -179.935 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 2.9 m-20 -100.45 -31.6 11.21 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.882 -179.991 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 62' ' ' GLN . . . . . 0.667 ' O ' HG22 ' A' ' 64' ' ' THR . 0.0 OUTLIER -120.24 147.31 44.63 Favored Pre-proline 0 C--N 1.331 -0.23 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.839 -179.93 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 50.6 Cg_exo -53.07 90.5 0.03 OUTLIER 'Trans proline' 0 C--N 1.345 0.389 0 C-N-CA 122.479 2.119 . . . . 0.0 112.405 179.949 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 64' ' ' THR . . . . . 0.667 HG22 ' O ' ' A' ' 62' ' ' GLN . 4.9 t -164.7 39.4 0.07 Allowed 'General case' 0 C--N 1.327 -0.384 0 CA-C-N 116.296 -0.411 . . . . 0.0 110.911 179.989 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . -100.66 -149.07 22.99 Favored Glycine 0 N--CA 1.451 -0.325 0 C-N-CA 120.741 -0.742 . . . . 0.0 112.515 179.946 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 66' ' ' LYS . . . . . . . . . . . . . 0.6 OUTLIER -121.47 -42.65 2.43 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-O 120.825 0.345 . . . . 0.0 110.918 -179.948 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 67' ' ' HIS . . . . . . . . . . . . . 6.8 p80 -128.53 172.15 11.44 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.917 179.964 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 4.9 m-20 -98.36 33.67 2.17 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.922 -179.971 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 99.47 -41.89 2.1 Favored Glycine 0 N--CA 1.451 -0.316 0 C-N-CA 120.636 -0.792 . . . . 0.0 112.491 179.995 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 70' ' ' SER . . . . . . . . . . . . . 77.3 p -104.82 148.62 26.44 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 120.835 0.35 . . . . 0.0 110.918 -179.974 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 21.5 t -135.45 122.59 35.31 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.146 -0.479 . . . . 0.0 111.105 179.958 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 72' ' ' PHE . . . . . . . . . . . . . 33.5 m-85 60.28 33.85 20.89 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.924 -179.992 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 80.4 27.92 50.09 Favored Glycine 0 N--CA 1.452 -0.25 0 C-N-CA 120.692 -0.766 . . . . 0.0 112.533 -179.97 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 21.4 t -131.61 100.71 4.58 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-O 120.767 0.317 . . . . 0.0 111.078 -179.997 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 75' ' ' ARG . . . . . . . . . . . . . 20.5 ttt85 -77.45 119.75 21.49 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.26 -0.427 . . . . 0.0 110.949 -179.968 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 76' ' ' TYR . . . . . . . . . . . . . 25.4 m-85 -92.28 -48.86 6.46 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.835 -179.995 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 77' ' ' PHE . . . . . . . . . . . . . 16.8 p90 -148.65 161.97 40.65 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.752 179.936 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -88.34 108.5 19.37 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.971 -179.963 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 79' ' ' CYS . . . . . . . . . . . . . 30.4 p -132.93 174.11 10.68 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.867 -179.976 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 80' ' ' ALA . . . . . 0.632 ' HB3' ' ND1' ' A' ' 83' ' ' HIS . . . -81.95 166.73 35.53 Favored Pre-proline 0 C--N 1.329 -0.311 0 CA-C-N 116.198 -0.455 . . . . 0.0 111.056 179.978 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 81' ' ' PRO . . . . . 0.518 ' HD2' ' HB1' ' A' ' 80' ' ' ALA . 51.9 Cg_exo -54.34 117.49 3.99 Favored 'Trans proline' 0 C--N 1.343 0.267 0 C-N-CA 122.57 2.18 . . . . 0.0 112.304 179.994 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 82' ' ' ARG . . . . . . . . . . . . . 3.3 mpt_? 60.99 52.97 3.86 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.116 -0.493 . . . . 0.0 110.96 179.99 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 83' ' ' HIS . . . . . 0.632 ' ND1' ' HB3' ' A' ' 80' ' ' ALA . 7.2 m170 -122.41 -42.15 2.36 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.119 -0.491 . . . . 0.0 110.915 179.989 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . -64.24 144.56 48.75 Favored Glycine 0 N--CA 1.452 -0.261 0 C-N-CA 120.632 -0.794 . . . . 0.0 112.426 179.968 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 85' ' ' VAL . . . . . 0.568 HG11 HD11 ' A' ' 60' ' ' LEU . 15.4 m -152.54 121.32 0.77 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-O 120.833 0.349 . . . . 0.0 111.101 179.997 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 86' ' ' PHE . . . . . 0.426 ' CD1' ' HB3' ' A' ' 55' ' ' TRP . 2.5 m-85 -100.69 118.73 37.4 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.945 179.971 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 87' ' ' ALA . . . . . 0.506 ' CB ' HG13 ' A' ' 34' ' ' VAL . . . -139.91 145.72 43.79 Favored Pre-proline 0 C--N 1.329 -0.316 0 CA-C-N 116.258 -0.428 . . . . 0.0 111.094 179.936 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 88' ' ' PRO . . . . . 0.411 ' O ' ' N ' ' A' ' 91' ' ' ARG . 36.0 Cg_exo -57.27 138.2 85.16 Favored 'Trans proline' 0 C--N 1.346 0.441 0 C-N-CA 122.46 2.107 . . . . 0.0 112.336 -179.952 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 89' ' ' ALA . . . . . 0.607 ' HB2' ' CE1' ' A' ' 56' ' ' TYR . . . -47.63 -51.9 19.84 Favored 'General case' 0 C--N 1.333 -0.115 0 CA-C-O 121.112 0.482 . . . . 0.0 110.367 179.902 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 90' ' ' SER . . . . . . . . . . . . . 5.9 m -55.52 -24.48 32.11 Favored 'General case' 0 N--CA 1.454 -0.246 0 CA-C-N 115.657 -0.701 . . . . 0.0 109.754 178.769 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 91' ' ' ARG . . . . . 0.411 ' N ' ' O ' ' A' ' 88' ' ' PRO . 0.6 OUTLIER -88.41 -16.36 33.1 Favored 'General case' 0 N--CA 1.454 -0.234 0 CA-C-N 115.829 -0.623 . . . . 0.0 110.416 179.066 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 92' ' ' ILE . . . . . 0.595 HD13 HD11 ' A' ' 58' ' ' ILE . 51.6 mt -104.51 145.09 13.57 Favored 'Isoleucine or valine' 0 C--N 1.333 -0.121 0 CA-C-N 116.379 -0.373 . . . . 0.0 111.035 179.869 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 93' ' ' GLN . . . . . . . . . . . . . 1.8 mt-30 -112.83 -179.96 3.8 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.228 -0.442 . . . . 0.0 111.009 -179.949 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 94' ' ' ARG . . . . . . . . . . . . . 0.6 OUTLIER -126.88 138.96 53.39 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.947 -179.895 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 95' ' ' ILE . . . . . 0.611 HD11 ' HB2' ' A' ' 33' ' ' LEU . 3.8 mp . . . . . 0 C--N 1.33 -0.252 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.059 179.967 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.23 0.06 0 CA-C-O 120.839 0.352 . . . . 0.0 111.076 . . . . . . . . . 0 0 . 1 . 005 nuclear build core ' A' A ' 27' ' ' GLU . . . . . . . . . . . . . 28.5 mt-10 -143.2 -172.59 3.72 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.918 -179.996 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 30.6 t -78.46 111.65 15.55 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.236 -0.438 . . . . 0.0 111.078 -179.979 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 106.16 42.73 1.6 Allowed Glycine 0 N--CA 1.452 -0.255 0 C-N-CA 120.729 -0.748 . . . . 0.0 112.52 179.967 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 2.3 m-20 -150.12 136.77 19.14 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-O 120.813 0.34 . . . . 0.0 110.823 179.979 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 31' ' ' GLN . . . . . . . . . . . . . 2.6 mt-30 -60.03 141.02 56.42 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.88 179.92 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 6.3 m -146.57 179.58 0.92 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.356 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.188 179.992 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 33' ' ' LEU . . . . . 0.534 HD11 ' O ' ' A' ' 37' ' ' GLN . 25.7 tp -142.09 109.89 5.8 Favored 'General case' 0 C--N 1.331 -0.239 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.846 179.991 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 34' ' ' VAL . . . . . 0.408 HG13 ' CB ' ' A' ' 87' ' ' ALA . 21.5 t -77.72 123.54 34.59 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.266 0 CA-C-N 116.181 -0.463 . . . . 0.0 111.182 -179.969 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 35' ' ' ALA . . . . . . . . . . . . . . . 57.63 26.64 13.14 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.198 -0.456 . . . . 0.0 111.235 -179.964 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . 57.07 29.38 59.42 Favored Glycine 0 N--CA 1.451 -0.327 0 C-N-CA 120.734 -0.746 . . . . 0.0 112.613 179.953 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 37' ' ' GLN . . . . . 0.534 ' O ' HD11 ' A' ' 33' ' ' LEU . 20.1 mt-30 -141.29 -74.59 0.32 Allowed 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 120.85 0.357 . . . . 0.0 110.966 -179.964 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 38' ' ' LYS . . . . . 0.465 ' HD2' HD13 ' A' ' 60' ' ' LEU . 21.8 mmtm -63.47 103.19 0.49 Allowed 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.861 -179.959 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 39' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -82.55 135.35 35.11 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.939 179.931 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -164.73 -176.01 36.04 Favored Glycine 0 N--CA 1.452 -0.288 0 C-N-CA 120.677 -0.773 . . . . 0.0 112.49 179.965 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 2.6 mt -127.34 137.01 59.03 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 CA-C-O 120.82 0.343 . . . . 0.0 111.085 -179.979 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 42' ' ' VAL . . . . . . . . . . . . . 21.4 t -59.62 123.38 11.91 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.202 -0.454 . . . . 0.0 111.12 179.971 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 43' ' ' ARG . . . . . . . . . . . . . 17.3 mmt85 -111.3 -33.99 6.27 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.902 179.903 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 44' ' ' PHE . . . . . 0.424 ' CD1' ' HB3' ' A' ' 76' ' ' TYR . 60.4 t80 -142.75 110.31 5.78 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.965 -179.979 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 45' ' ' TYR . . . . . . . . . . . . . 15.3 t80 -107.54 119.62 39.93 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.196 -0.457 . . . . 0.0 110.861 179.974 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 175.52 177.14 44.35 Favored Glycine 0 N--CA 1.451 -0.347 0 C-N-CA 120.801 -0.714 . . . . 0.0 112.561 179.971 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 47' ' ' LYS . . . . . . . . . . . . . 16.0 mtmt -77.02 168.14 20.6 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-O 120.886 0.374 . . . . 0.0 110.856 179.975 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 48' ' ' THR . . . . . 0.463 HG21 ' CE2' ' A' ' 50' ' ' PHE . 23.6 p -125.58 -179.66 4.74 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.868 179.953 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 1.5 t70 -106.74 -31.84 8.24 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.939 179.974 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 50' ' ' PHE . . . . . 0.463 ' CE2' HG21 ' A' ' 48' ' ' THR . 48.8 p90 -70.19 -35.86 74.22 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.924 -179.988 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 51' ' ' ALA . . . . . . . . . . . . . . . -141.09 144.16 33.85 Favored Pre-proline 0 C--N 1.328 -0.333 0 CA-C-N 116.218 -0.446 . . . . 0.0 111.087 -179.981 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 52' ' ' PRO . . . . . . . . . . . . . 70.8 Cg_endo -74.74 -176.85 3.02 Favored 'Trans proline' 0 C--N 1.345 0.389 0 C-N-CA 122.531 2.154 . . . . 0.0 112.309 179.99 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 76.78 -175.68 53.36 Favored Glycine 0 N--CA 1.45 -0.376 0 C-N-CA 120.745 -0.74 . . . . 0.0 112.567 179.993 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 54' ' ' TYR . . . . . . . . . . . . . 34.5 m-85 -88.58 158.35 18.31 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-O 120.847 0.356 . . . . 0.0 110.916 179.967 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 55' ' ' TRP . . . . . 0.428 ' HB3' ' CD1' ' A' ' 86' ' ' PHE . 94.2 m95 -154.06 140.96 19.21 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.154 -0.475 . . . . 0.0 110.867 179.96 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 56' ' ' TYR . . . . . 0.424 ' HE1' ' HB2' ' A' ' 89' ' ' ALA . 36.2 m-85 -102.57 122.31 44.13 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.902 -179.927 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 57' ' ' GLY . . . . . 0.447 ' N ' ' CE1' ' A' ' 86' ' ' PHE . . . -87.79 59.08 4.31 Favored Glycine 0 N--CA 1.451 -0.357 0 C-N-CA 120.754 -0.736 . . . . 0.0 112.468 -179.978 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 58' ' ' ILE . . . . . 0.67 HD11 HD13 ' A' ' 92' ' ' ILE . 7.8 mt -64.14 152.48 8.28 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-O 120.829 0.347 . . . . 0.0 110.964 -179.957 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 1.7 tm-20 -122.94 102.94 8.3 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.925 179.988 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 60' ' ' LEU . . . . . 0.465 HD13 ' HD2' ' A' ' 38' ' ' LYS . 54.8 mt -63.16 162.72 11.32 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.904 -179.957 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 2.7 t0 -92.78 -30.91 15.25 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.916 -179.981 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 62' ' ' GLN . . . . . . . . . . . . . 7.1 mt-30 -100.35 152.0 37.7 Favored Pre-proline 0 C--N 1.329 -0.311 0 CA-C-N 116.231 -0.44 . . . . 0.0 110.952 -179.994 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 71.9 Cg_endo -75.45 97.9 1.13 Allowed 'Trans proline' 0 C--N 1.344 0.316 0 C-N-CA 122.595 2.196 . . . . 0.0 112.309 -179.892 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 64' ' ' THR . . . . . . . . . . . . . 9.9 t -173.68 36.27 0.01 OUTLIER 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.9 -179.989 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . -90.09 -159.52 35.6 Favored Glycine 0 N--CA 1.451 -0.335 0 C-N-CA 120.731 -0.747 . . . . 0.0 112.544 179.985 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 66' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -110.47 -31.71 7.17 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 120.819 0.342 . . . . 0.0 110.846 -179.947 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 67' ' ' HIS . . . . . . . . . . . . . 6.6 p80 -140.83 173.57 11.36 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.893 179.954 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 2.6 m-20 -97.98 37.09 1.46 Allowed 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.834 -179.915 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 98.79 -28.61 14.33 Favored Glycine 0 N--CA 1.451 -0.362 0 C-N-CA 120.676 -0.773 . . . . 0.0 112.486 179.967 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 70' ' ' SER . . . . . . . . . . . . . 88.7 p -110.4 161.32 15.77 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-O 120.841 0.353 . . . . 0.0 110.842 -179.92 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 71' ' ' VAL . . . . . 0.524 HG12 ' HD1' ' A' ' 72' ' ' PHE . 21.5 t -146.41 126.75 6.02 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.256 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.063 -179.981 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 72' ' ' PHE . . . . . 0.524 ' HD1' HG12 ' A' ' 71' ' ' VAL . 11.3 m-85 60.58 27.05 16.73 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.163 -0.472 . . . . 0.0 111.026 179.974 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 95.65 -29.82 9.23 Favored Glycine 0 N--CA 1.452 -0.284 0 C-N-CA 120.752 -0.737 . . . . 0.0 112.537 179.952 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 25.5 t -80.98 116.58 25.53 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.343 0 CA-C-O 120.8 0.333 . . . . 0.0 111.141 -179.976 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 75' ' ' ARG . . . . . . . . . . . . . 2.1 ttt-85 -88.49 148.36 24.19 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.86 -179.933 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 76' ' ' TYR . . . . . 0.428 ' CE1' HG22 ' A' ' 48' ' ' THR . 53.8 m-85 -120.09 -50.81 2.24 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.933 -179.963 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 77' ' ' PHE . . . . . . . . . . . . . 26.9 p90 -146.04 161.78 39.35 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.9 179.978 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 4.9 m -91.93 121.98 34.03 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.099 -0.501 . . . . 0.0 110.941 179.979 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 79' ' ' CYS . . . . . . . . . . . . . 26.1 p -144.57 158.12 43.91 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.252 -0.431 . . . . 0.0 110.87 -179.952 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 80' ' ' ALA . . . . . 0.527 ' HB3' ' CG ' ' A' ' 83' ' ' HIS . . . -59.59 164.03 6.06 Favored Pre-proline 0 C--N 1.329 -0.306 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.135 179.913 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 81' ' ' PRO . . . . . 0.457 ' HD2' ' HB1' ' A' ' 80' ' ' ALA . 53.8 Cg_exo -52.31 116.19 2.67 Favored 'Trans proline' 0 C--N 1.345 0.358 0 C-N-CA 122.558 2.172 . . . . 0.0 112.322 -179.982 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 82' ' ' ARG . . . . . . . . . . . . . 16.1 mtt180 58.91 62.49 1.87 Allowed 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.874 -179.962 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 83' ' ' HIS . . . . . 0.527 ' CG ' ' HB3' ' A' ' 80' ' ' ALA . 4.3 m170 -127.12 -43.78 1.64 Allowed 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.088 -0.506 . . . . 0.0 110.859 179.957 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . -68.2 138.51 32.76 Favored Glycine 0 N--CA 1.45 -0.37 0 C-N-CA 120.706 -0.759 . . . . 0.0 112.473 179.976 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 85' ' ' VAL . . . . . 0.467 ' O ' HG23 ' A' ' 85' ' ' VAL . 16.9 m -143.3 113.91 2.43 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-O 120.894 0.378 . . . . 0.0 111.108 -179.994 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 86' ' ' PHE . . . . . 0.447 ' CE1' ' N ' ' A' ' 57' ' ' GLY . 5.4 m-85 -89.11 119.81 29.95 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.843 -179.964 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 87' ' ' ALA . . . . . 0.605 ' O ' HD11 ' A' ' 92' ' ' ILE . . . -139.48 143.86 37.41 Favored Pre-proline 0 C--N 1.329 -0.303 0 CA-C-N 116.263 -0.426 . . . . 0.0 111.146 179.991 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 88' ' ' PRO . . . . . 0.427 ' O ' ' N ' ' A' ' 91' ' ' ARG . 46.8 Cg_exo -55.94 140.45 85.85 Favored 'Trans proline' 0 C--N 1.346 0.43 0 C-N-CA 122.541 2.161 . . . . 0.0 112.379 179.959 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 89' ' ' ALA . . . . . 0.424 ' HB2' ' HE1' ' A' ' 56' ' ' TYR . . . -47.83 -50.3 26.59 Favored 'General case' 0 CA--C 1.521 -0.158 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.264 179.896 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 90' ' ' SER . . . . . . . . . . . . . 8.0 m -55.59 -24.37 32.51 Favored 'General case' 0 N--CA 1.454 -0.266 0 CA-C-N 115.769 -0.651 . . . . 0.0 109.796 178.859 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 91' ' ' ARG . . . . . 0.427 ' N ' ' O ' ' A' ' 88' ' ' PRO . 2.3 mtm-85 -89.74 -15.22 32.93 Favored 'General case' 0 N--CA 1.455 -0.19 0 CA-C-N 115.813 -0.631 . . . . 0.0 110.524 179.063 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 92' ' ' ILE . . . . . 0.67 HD13 HD11 ' A' ' 58' ' ' ILE . 49.9 mt -103.08 144.87 13.2 Favored 'Isoleucine or valine' 0 C--O 1.232 0.16 0 CA-C-N 116.402 -0.363 . . . . 0.0 111.094 179.858 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 93' ' ' GLN . . . . . . . . . . . . . 0.5 OUTLIER -115.71 154.3 29.81 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.905 -179.976 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 94' ' ' ARG . . . . . . . . . . . . . 7.6 mtp180 -96.96 138.54 34.34 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.868 179.978 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 95' ' ' ILE . . . . . . . . . . . . . 16.9 mt . . . . . 0 C--N 1.329 -0.286 0 CA-C-N 116.15 -0.477 . . . . 0.0 111.108 179.97 . . . . . . . . 0 0 . 1 . 006 nuclear build core ' A' A ' 26' ' ' ALA . . . . . 0.451 ' HB2' ' HG3' ' A' ' 94' ' ' ARG . . . . . . . . 0 C--O 1.23 0.078 0 CA-C-O 120.799 0.333 . . . . 0.0 111.142 . . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 27' ' ' GLU . . . . . . . . . . . . . 6.3 mm-40 -142.46 -179.18 6.13 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.935 179.956 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 21.5 t -66.95 123.34 19.8 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.127 -180.0 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 84.7 46.34 5.76 Favored Glycine 0 N--CA 1.451 -0.326 0 C-N-CA 120.767 -0.73 . . . . 0.0 112.529 -179.993 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 4.6 t0 -146.16 134.28 21.59 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 120.879 0.371 . . . . 0.0 110.892 -179.998 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 31' ' ' GLN . . . . . . . . . . . . . 1.9 mt-30 -60.31 139.23 57.74 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.912 179.974 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 32' ' ' VAL . . . . . 0.43 HG21 HG12 ' A' ' 58' ' ' ILE . 19.2 m -145.17 176.02 2.31 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.28 -0.418 . . . . 0.0 111.133 -179.975 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 33' ' ' LEU . . . . . 0.519 HD11 ' O ' ' A' ' 37' ' ' GLN . 30.4 tp -134.5 100.04 4.53 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.145 -0.48 . . . . 0.0 110.898 179.988 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 21.5 t -69.11 126.58 29.42 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.205 -179.853 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 35' ' ' ALA . . . . . . . . . . . . . . . 57.06 25.34 10.67 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.321 179.941 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . 56.07 35.03 63.04 Favored Glycine 0 N--CA 1.451 -0.33 0 C-N-CA 120.722 -0.751 . . . . 0.0 112.58 179.941 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 37' ' ' GLN . . . . . 0.519 ' O ' HD11 ' A' ' 33' ' ' LEU . 48.8 mt-30 -147.51 -68.3 0.25 Allowed 'General case' 0 C--N 1.329 -0.295 0 CA-C-O 120.862 0.363 . . . . 0.0 110.949 -179.929 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 38' ' ' LYS . . . . . . . . . . . . . 64.5 mttp -73.77 106.85 5.69 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.919 -179.966 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 39' ' ' GLN . . . . . 0.433 ' HG2' HD11 ' A' ' 95' ' ' ILE . 0.9 OUTLIER -85.16 135.02 34.14 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.923 179.89 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -157.87 -170.43 22.65 Favored Glycine 0 N--CA 1.45 -0.389 0 C-N-CA 120.683 -0.77 . . . . 0.0 112.505 -179.998 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 41' ' ' ILE . . . . . 0.508 ' C ' HG23 ' A' ' 58' ' ' ILE . 14.5 mt -126.38 131.54 71.33 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-O 120.842 0.353 . . . . 0.0 111.132 -179.959 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 42' ' ' VAL . . . . . . . . . . . . . 38.2 t -65.52 119.73 10.87 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.02 -179.964 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 43' ' ' ARG . . . . . . . . . . . . . 25.5 mmt180 -104.13 -31.46 9.64 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.259 -0.428 . . . . 0.0 110.966 179.895 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 44' ' ' PHE . . . . . . . . . . . . . 69.2 t80 -143.77 117.52 9.28 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.875 -179.929 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 45' ' ' TYR . . . . . 0.464 ' CE1' ' CZ ' ' A' ' 56' ' ' TYR . 21.5 t80 -113.13 133.82 54.85 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.264 -0.426 . . . . 0.0 110.925 179.988 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 154.17 174.87 24.76 Favored Glycine 0 N--CA 1.451 -0.35 0 C-N-CA 120.799 -0.715 . . . . 0.0 112.523 179.937 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 47' ' ' LYS . . . . . . . . . . . . . 1.9 mmtp -60.06 160.53 7.93 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 120.81 0.338 . . . . 0.0 110.938 -179.996 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 48' ' ' THR . . . . . 0.408 HG21 ' CZ ' ' A' ' 50' ' ' PHE . 38.4 p -124.82 -179.09 4.38 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.872 179.938 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -107.65 -34.75 6.9 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.883 -179.989 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 50' ' ' PHE . . . . . 0.435 ' CD1' ' N ' ' A' ' 51' ' ' ALA . 15.9 p90 -63.33 -31.46 72.62 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.154 -0.475 . . . . 0.0 110.986 180.0 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 51' ' ' ALA . . . . . 0.435 ' N ' ' CD1' ' A' ' 50' ' ' PHE . . . -156.27 148.16 17.28 Favored Pre-proline 0 C--N 1.33 -0.244 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.117 -179.999 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 52' ' ' PRO . . . . . . . . . . . . . 58.3 Cg_endo -71.47 162.63 41.68 Favored 'Trans proline' 0 C--N 1.344 0.326 0 C-N-CA 122.624 2.216 . . . . 0.0 112.335 179.987 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 102.28 177.42 27.57 Favored Glycine 0 N--CA 1.45 -0.407 0 C-N-CA 120.769 -0.729 . . . . 0.0 112.501 179.939 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 54' ' ' TYR . . . . . . . . . . . . . 37.1 m-85 -97.22 112.31 24.17 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 120.813 0.34 . . . . 0.0 110.958 179.996 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 55' ' ' TRP . . . . . 0.406 ' CZ3' ' HD3' ' A' ' 88' ' ' PRO . 42.1 m95 -107.93 161.76 14.63 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.898 179.989 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 56' ' ' TYR . . . . . 0.626 ' CE1' ' HB2' ' A' ' 89' ' ' ALA . 11.3 m-85 -113.61 122.49 47.37 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.26 -0.427 . . . . 0.0 110.918 -179.98 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . -84.19 56.71 5.04 Favored Glycine 0 N--CA 1.45 -0.368 0 C-N-CA 120.801 -0.714 . . . . 0.0 112.511 179.861 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 58' ' ' ILE . . . . . 0.562 HD11 HD13 ' A' ' 92' ' ' ILE . 3.7 mt -68.32 137.99 23.39 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-O 120.84 0.352 . . . . 0.0 111.092 -179.937 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 0.8 OUTLIER -101.39 141.55 34.09 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.947 179.998 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 60' ' ' LEU . . . . . 0.425 HD12 ' HA2' ' A' ' 65' ' ' GLY . 59.6 mt -97.78 174.13 6.76 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.883 179.99 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 1.3 t0 -101.55 -30.91 11.12 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.176 -0.466 . . . . 0.0 110.959 179.965 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 62' ' ' GLN . . . . . . . . . . . . . 7.5 mt-30 -104.17 153.16 39.15 Favored Pre-proline 0 C--N 1.33 -0.273 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.912 -179.972 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 66.1 Cg_endo -73.97 65.34 5.07 Favored 'Trans proline' 0 C--N 1.345 0.352 0 C-N-CA 122.576 2.184 . . . . 0.0 112.29 -179.902 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 64' ' ' THR . . . . . . . . . . . . . 3.9 t -148.76 39.38 0.86 Allowed 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.882 179.933 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 65' ' ' GLY . . . . . 0.425 ' HA2' HD12 ' A' ' 60' ' ' LEU . . . -83.64 -99.63 0.57 Allowed Glycine 0 N--CA 1.451 -0.305 0 C-N-CA 120.705 -0.759 . . . . 0.0 112.525 179.906 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 66' ' ' LYS . . . . . . . . . . . . . 5.8 mttt -168.76 -44.69 0.02 OUTLIER 'General case' 0 C--N 1.33 -0.251 0 CA-C-O 120.845 0.355 . . . . 0.0 110.871 179.952 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 67' ' ' HIS . . . . . . . . . . . . . 10.1 p80 -125.5 170.28 11.58 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.903 179.91 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 17.1 t0 -103.49 52.36 0.77 Allowed 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.934 179.951 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 90.55 -75.64 1.65 Allowed Glycine 0 N--CA 1.45 -0.403 0 C-N-CA 120.741 -0.742 . . . . 0.0 112.445 179.982 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 70' ' ' SER . . . . . . . . . . . . . 93.1 p -84.4 154.7 22.67 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-O 120.875 0.369 . . . . 0.0 110.848 179.982 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 71' ' ' VAL . . . . . 0.412 HG12 ' CD2' ' A' ' 72' ' ' PHE . 21.5 t -129.37 122.69 56.29 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.141 179.993 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 72' ' ' PHE . . . . . 0.412 ' CD2' HG12 ' A' ' 71' ' ' VAL . 37.7 m-85 60.74 30.03 19.42 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.898 179.98 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 96.5 -30.05 9.37 Favored Glycine 0 N--CA 1.451 -0.362 0 C-N-CA 120.759 -0.734 . . . . 0.0 112.573 -179.969 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 28.0 t -79.4 122.61 34.96 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-O 120.833 0.349 . . . . 0.0 111.087 -179.992 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 75' ' ' ARG . . . . . . . . . . . . . 21.8 ttt-85 -91.89 142.99 26.95 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.98 179.948 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 76' ' ' TYR . . . . . . . . . . . . . 24.3 m-85 -118.78 -41.72 2.77 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.271 -0.422 . . . . 0.0 110.869 -179.973 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 77' ' ' PHE . . . . . . . . . . . . . 50.9 p90 -160.29 161.7 33.4 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.828 -179.998 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 3.3 m -89.86 123.51 33.88 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.987 179.865 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 79' ' ' CYS . . . . . . . . . . . . . 30.3 p -145.88 -177.94 5.85 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.885 179.997 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 80' ' ' ALA . . . . . 0.477 ' HB3' ' CG ' ' A' ' 83' ' ' HIS . . . -92.1 164.47 23.23 Favored Pre-proline 0 C--N 1.329 -0.319 0 CA-C-N 116.2 -0.455 . . . . 0.0 111.124 179.988 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 81' ' ' PRO . . . . . 0.452 ' HD2' ' HB1' ' A' ' 80' ' ' ALA . 52.9 Cg_exo -52.48 116.29 2.76 Favored 'Trans proline' 0 C--N 1.345 0.344 0 C-N-CA 122.55 2.167 . . . . 0.0 112.275 179.993 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 82' ' ' ARG . . . . . . . . . . . . . 7.3 mtm180 61.9 58.79 1.85 Allowed 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.178 -0.464 . . . . 0.0 110.834 -179.997 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 83' ' ' HIS . . . . . 0.477 ' CG ' ' HB3' ' A' ' 80' ' ' ALA . 5.6 m170 -128.98 -47.55 1.23 Allowed 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.92 179.925 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . -66.64 147.58 49.82 Favored Glycine 0 N--CA 1.45 -0.4 0 C-N-CA 120.8 -0.714 . . . . 0.0 112.471 179.906 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 85' ' ' VAL . . . . . . . . . . . . . 5.2 m -152.99 123.07 0.82 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-O 120.804 0.335 . . . . 0.0 111.153 179.921 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 86' ' ' PHE . . . . . . . . . . . . . 29.8 m-85 -99.87 121.23 41.01 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.834 -179.938 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 87' ' ' ALA . . . . . 0.493 ' O ' HD11 ' A' ' 92' ' ' ILE . . . -140.56 147.38 48.94 Favored Pre-proline 0 C--N 1.33 -0.261 0 CA-C-N 116.248 -0.433 . . . . 0.0 111.093 -179.988 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 88' ' ' PRO . . . . . 0.406 ' HD3' ' CZ3' ' A' ' 55' ' ' TRP . 32.4 Cg_exo -57.97 138.33 85.46 Favored 'Trans proline' 0 C--N 1.345 0.388 0 C-N-CA 122.561 2.174 . . . . 0.0 112.258 -179.979 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 89' ' ' ALA . . . . . 0.626 ' HB2' ' CE1' ' A' ' 56' ' ' TYR . . . -47.98 -51.71 22.72 Favored 'General case' 0 C--N 1.332 -0.161 0 CA-C-O 121.137 0.494 . . . . 0.0 110.278 179.84 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 90' ' ' SER . . . . . . . . . . . . . 3.6 t -55.87 -24.45 37.07 Favored 'General case' 0 C--N 1.332 -0.186 0 CA-C-N 115.693 -0.685 . . . . 0.0 109.701 178.826 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 91' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -88.5 -14.35 38.02 Favored 'General case' 0 N--CA 1.454 -0.246 0 CA-C-N 115.911 -0.586 . . . . 0.0 110.49 179.058 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 92' ' ' ILE . . . . . 0.562 HD13 HD11 ' A' ' 58' ' ' ILE . 36.3 mt -110.83 156.13 12.05 Favored 'Isoleucine or valine' 0 C--N 1.334 -0.065 0 CA-C-O 120.908 0.385 . . . . 0.0 111.063 179.906 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 93' ' ' GLN . . . . . 0.451 ' N ' HG22 ' A' ' 92' ' ' ILE . 2.3 mp0 -123.67 173.84 7.84 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.116 -0.493 . . . . 0.0 110.811 179.987 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 94' ' ' ARG . . . . . 0.451 ' HG3' ' HB2' ' A' ' 26' ' ' ALA . 1.1 mtp180 -115.48 140.02 49.53 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.899 179.968 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 95' ' ' ILE . . . . . 0.433 HD11 ' HG2' ' A' ' 39' ' ' GLN . 21.7 mm . . . . . 0 C--N 1.33 -0.267 0 CA-C-N 116.154 -0.476 . . . . 0.0 111.124 179.946 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.231 0.13 0 CA-C-O 120.862 0.363 . . . . 0.0 111.089 . . . . . . . . . 0 0 . 1 . 007 nuclear build core ' A' A ' 27' ' ' GLU . . . . . . . . . . . . . 3.6 mm-40 -135.55 -178.73 5.25 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.841 179.946 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 21.5 t -83.08 104.98 12.42 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.164 -0.471 . . . . 0.0 111.119 179.993 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 107.35 30.58 4.07 Favored Glycine 0 N--CA 1.452 -0.288 0 C-N-CA 120.779 -0.724 . . . . 0.0 112.487 -179.948 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 3.4 m-20 -124.84 144.21 50.42 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 120.793 0.33 . . . . 0.0 110.895 179.952 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 31' ' ' GLN . . . . . . . . . . . . . 5.0 mp0 -65.28 130.4 43.19 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.806 -179.97 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 20.7 m -136.13 175.23 10.95 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 CA-C-N 116.2 -0.454 . . . . 0.0 111.079 179.993 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 33' ' ' LEU . . . . . 0.44 HD12 ' HA ' ' A' ' 39' ' ' GLN . 14.1 tp -139.11 100.06 3.92 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.105 -0.498 . . . . 0.0 110.912 179.98 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 21.5 t -64.5 121.02 12.74 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 116.234 -0.439 . . . . 0.0 111.179 179.991 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 35' ' ' ALA . . . . . . . . . . . . . . . 58.71 26.87 15.14 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.3 179.998 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . 56.66 27.79 55.61 Favored Glycine 0 N--CA 1.451 -0.32 0 C-N-CA 120.779 -0.724 . . . . 0.0 112.601 -179.976 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 37' ' ' GLN . . . . . 0.41 ' O ' HD11 ' A' ' 33' ' ' LEU . 38.9 mt-30 -139.66 -72.08 0.38 Allowed 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.775 0.321 . . . . 0.0 110.892 -179.993 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 38' ' ' LYS . . . . . 0.405 ' HB3' HD21 ' A' ' 60' ' ' LEU . 55.6 mttt -65.17 114.53 4.73 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.259 -0.428 . . . . 0.0 110.924 179.995 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 39' ' ' GLN . . . . . 0.44 ' HA ' HD12 ' A' ' 33' ' ' LEU . 5.8 tm0? -85.53 130.07 34.67 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.886 179.952 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -157.08 173.56 34.66 Favored Glycine 0 N--CA 1.451 -0.302 0 C-N-CA 120.66 -0.781 . . . . 0.0 112.481 179.993 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 41' ' ' ILE . . . . . 0.42 ' N ' HG23 ' A' ' 58' ' ' ILE . 33.5 mt -121.13 133.18 68.56 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 CA-C-O 120.802 0.334 . . . . 0.0 111.033 -179.969 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 42' ' ' VAL . . . . . . . . . . . . . 21.4 t -61.99 121.73 11.06 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.146 -0.479 . . . . 0.0 111.097 179.979 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 43' ' ' ARG . . . . . . . . . . . . . 14.8 mmt180 -108.0 -30.92 8.19 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.903 179.878 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 44' ' ' PHE . . . . . . . . . . . . . 28.9 t80 -149.73 109.57 4.07 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.25 -0.432 . . . . 0.0 110.934 -179.976 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 45' ' ' TYR . . . . . 0.49 ' CE1' ' CZ ' ' A' ' 56' ' ' TYR . 22.7 t80 -106.76 130.5 54.46 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.289 -0.414 . . . . 0.0 110.865 179.964 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 167.02 -161.17 35.02 Favored Glycine 0 N--CA 1.451 -0.35 0 C-N-CA 120.679 -0.772 . . . . 0.0 112.488 -179.976 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 47' ' ' LYS . . . . . . . . . . . . . 40.3 mttt -84.74 175.83 8.93 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 120.748 0.309 . . . . 0.0 110.949 179.94 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 48' ' ' THR . . . . . 0.46 HG21 ' CZ ' ' A' ' 50' ' ' PHE . 71.1 p -143.9 -177.42 5.42 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.938 -179.974 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 3.5 t0 -110.8 -35.03 6.08 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.284 -0.416 . . . . 0.0 110.914 -179.961 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 50' ' ' PHE . . . . . 0.46 ' CZ ' HG21 ' A' ' 48' ' ' THR . 16.1 p90 -60.06 -31.36 69.92 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.917 179.996 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 51' ' ' ALA . . . . . 0.438 ' N ' ' CD1' ' A' ' 50' ' ' PHE . . . -159.84 141.73 9.62 Favored Pre-proline 0 C--N 1.329 -0.319 0 CA-C-N 116.264 -0.426 . . . . 0.0 111.092 179.911 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 52' ' ' PRO . . . . . . . . . . . . . 72.6 Cg_endo -74.77 154.7 43.86 Favored 'Trans proline' 0 C--N 1.346 0.405 0 C-N-CA 122.497 2.131 . . . . 0.0 112.39 179.991 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 121.39 -160.34 15.75 Favored Glycine 0 N--CA 1.45 -0.393 0 C-N-CA 120.752 -0.737 . . . . 0.0 112.555 179.988 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 54' ' ' TYR . . . . . . . . . . . . . 33.4 m-85 -113.2 110.49 20.49 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-O 120.81 0.338 . . . . 0.0 110.887 179.997 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 55' ' ' TRP . . . . . . . . . . . . . 51.2 m95 -112.96 160.5 18.03 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.888 179.955 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 56' ' ' TYR . . . . . 0.6 ' HE1' ' HB2' ' A' ' 89' ' ' ALA . 4.8 m-85 -118.07 128.13 54.46 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.954 -179.972 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 57' ' ' GLY . . . . . 0.435 ' HA3' ' CE1' ' A' ' 77' ' ' PHE . . . -88.25 59.42 4.14 Favored Glycine 0 N--CA 1.451 -0.305 0 C-N-CA 120.744 -0.741 . . . . 0.0 112.344 179.855 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 58' ' ' ILE . . . . . 0.703 HD11 HD13 ' A' ' 92' ' ' ILE . 12.6 mt -68.98 148.55 11.61 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.367 0 CA-C-O 120.864 0.364 . . . . 0.0 111.113 -179.895 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -119.15 120.47 37.18 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.891 179.932 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 60' ' ' LEU . . . . . 0.405 HD21 ' HB3' ' A' ' 38' ' ' LYS . 56.7 mt -71.88 -179.96 2.93 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.852 -179.997 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 21.0 m-20 -104.96 -29.55 10.39 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.283 -0.417 . . . . 0.0 110.935 -179.928 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 62' ' ' GLN . . . . . . . . . . . . . 2.1 mt-30 -114.87 147.95 39.39 Favored Pre-proline 0 C--N 1.329 -0.31 0 CA-C-N 116.312 -0.404 . . . . 0.0 110.871 -179.907 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 36.6 Cg_exo -60.02 91.2 0.08 OUTLIER 'Trans proline' 0 C--N 1.345 0.391 0 C-N-CA 122.515 2.143 . . . . 0.0 112.264 179.924 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 64' ' ' THR . . . . . . . . . . . . . 10.1 t -172.72 39.22 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.271 -0.422 . . . . 0.0 110.992 -179.994 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . -91.37 -104.84 1.38 Allowed Glycine 0 N--CA 1.451 -0.3 0 C-N-CA 120.695 -0.764 . . . . 0.0 112.459 -179.979 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 66' ' ' LYS . . . . . . . . . . . . . 3.0 mtmt -159.99 -49.3 0.05 Allowed 'General case' 0 C--N 1.328 -0.336 0 CA-C-O 120.795 0.331 . . . . 0.0 110.791 -179.992 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 67' ' ' HIS . . . . . . . . . . . . . 7.5 p80 -128.92 171.96 11.8 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.244 -0.435 . . . . 0.0 110.868 -179.937 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 16.8 t0 -98.18 32.47 2.44 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.255 -0.43 . . . . 0.0 110.88 179.926 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 95.4 -41.47 2.48 Favored Glycine 0 N--CA 1.451 -0.32 0 C-N-CA 120.73 -0.748 . . . . 0.0 112.506 -179.936 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 70' ' ' SER . . . . . . . . . . . . . 99.2 p -98.85 126.51 44.52 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 120.762 0.315 . . . . 0.0 110.978 179.976 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 71' ' ' VAL . . . . . 0.609 HG12 ' CD2' ' A' ' 72' ' ' PHE . 21.5 t -112.88 114.27 46.49 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.354 0 CA-C-N 116.198 -0.456 . . . . 0.0 111.114 -179.908 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 72' ' ' PHE . . . . . 0.609 ' CD2' HG12 ' A' ' 71' ' ' VAL . 14.7 m-85 61.49 30.77 18.96 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.917 -179.976 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 98.42 -29.75 10.87 Favored Glycine 0 N--CA 1.452 -0.288 0 C-N-CA 120.741 -0.742 . . . . 0.0 112.511 179.985 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 21.5 t -77.2 124.22 35.22 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-O 120.752 0.311 . . . . 0.0 111.111 -179.978 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 75' ' ' ARG . . . . . . . . . . . . . 10.3 ttt180 -104.71 136.76 43.63 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.939 179.996 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 76' ' ' TYR . . . . . . . . . . . . . 36.3 m-85 -112.84 -43.47 3.42 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.965 179.963 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 77' ' ' PHE . . . . . 0.435 ' CE1' ' HA3' ' A' ' 57' ' ' GLY . 40.9 p90 -153.29 165.06 36.91 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.935 -179.995 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 2.6 t -93.6 121.62 35.2 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.176 -0.466 . . . . 0.0 110.853 -179.994 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 79' ' ' CYS . . . . . . . . . . . . . 10.0 p -142.45 154.2 44.35 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.22 -0.445 . . . . 0.0 111.002 -179.98 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 80' ' ' ALA . . . . . 0.714 ' HB1' ' HD2' ' A' ' 81' ' ' PRO . . . -58.94 165.45 3.35 Favored Pre-proline 0 C--N 1.328 -0.34 0 CA-C-N 116.166 -0.47 . . . . 0.0 111.025 179.956 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 81' ' ' PRO . . . . . 0.714 ' HD2' ' HB1' ' A' ' 80' ' ' ALA . 17.9 Cg_endo -59.6 115.94 2.95 Favored 'Trans proline' 0 C--N 1.344 0.332 0 C-N-CA 122.53 2.153 . . . . 0.0 112.095 179.985 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 82' ' ' ARG . . . . . . . . . . . . . 57.1 mtp180 63.96 55.36 1.59 Allowed 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.812 -179.883 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 83' ' ' HIS . . . . . 0.619 ' CG ' ' HB3' ' A' ' 80' ' ' ALA . 6.4 m170 -126.75 -47.43 1.54 Allowed 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.907 179.97 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . -59.04 142.41 46.51 Favored Glycine 0 N--CA 1.452 -0.261 0 C-N-CA 120.738 -0.744 . . . . 0.0 112.511 -179.99 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 85' ' ' VAL . . . . . . . . . . . . . 5.3 m -146.86 115.91 1.29 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.272 0 CA-C-O 120.804 0.335 . . . . 0.0 111.113 179.955 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 86' ' ' PHE . . . . . . . . . . . . . 10.4 m-85 -93.41 124.95 37.75 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.862 179.936 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 87' ' ' ALA . . . . . 0.515 ' O ' HD11 ' A' ' 92' ' ' ILE . . . -144.55 144.86 26.46 Favored Pre-proline 0 C--N 1.329 -0.303 0 CA-C-N 116.27 -0.423 . . . . 0.0 111.101 179.93 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 88' ' ' PRO . . . . . 0.424 ' O ' ' N ' ' A' ' 91' ' ' ARG . 31.9 Cg_exo -58.38 142.13 97.51 Favored 'Trans proline' 0 C--N 1.345 0.387 0 C-N-CA 122.429 2.086 . . . . 0.0 112.243 179.956 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 89' ' ' ALA . . . . . 0.6 ' HB2' ' HE1' ' A' ' 56' ' ' TYR . . . -47.58 -51.84 19.72 Favored 'General case' 0 C--N 1.333 -0.114 0 CA-C-O 121.088 0.471 . . . . 0.0 110.388 179.983 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 90' ' ' SER . . . . . . . . . . . . . 64.3 m -55.88 -24.29 36.28 Favored 'General case' 0 C--N 1.331 -0.235 0 CA-C-N 115.701 -0.681 . . . . 0.0 109.81 178.839 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 91' ' ' ARG . . . . . 0.424 ' N ' ' O ' ' A' ' 88' ' ' PRO . 0.5 OUTLIER -89.33 -13.83 37.06 Favored 'General case' 0 N--CA 1.455 -0.197 0 CA-C-N 115.876 -0.602 . . . . 0.0 110.484 179.095 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 92' ' ' ILE . . . . . 0.703 HD13 HD11 ' A' ' 58' ' ' ILE . 46.8 mt -109.92 141.11 26.17 Favored 'Isoleucine or valine' 0 C--O 1.231 0.126 0 CA-C-N 116.493 -0.321 . . . . 0.0 111.034 179.883 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 93' ' ' GLN . . . . . . . . . . . . . 1.4 mt-30 -107.72 171.45 7.38 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.816 179.992 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 94' ' ' ARG . . . . . . . . . . . . . 5.5 ttt180 -122.1 125.58 46.51 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.919 179.982 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 95' ' ' ILE . . . . . . . . . . . . . 5.5 mt . . . . . 0 C--N 1.329 -0.29 0 CA-C-N 116.273 -0.421 . . . . 0.0 111.037 -179.965 . . . . . . . . 0 0 . 1 . 008 nuclear build core ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.231 0.118 0 CA-C-O 120.829 0.347 . . . . 0.0 111.16 . . . . . . . . . 0 0 . 1 . 008 nuclear build core ' A' A ' 27' ' ' GLU . . . . . . . . . . . . . 5.6 mp0 -130.46 177.87 7.03 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.886 -179.96 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 26.9 t -64.9 92.21 0.11 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.231 -0.44 . . . . 0.0 111.132 179.95 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 114.86 41.86 0.82 Allowed Glycine 0 N--CA 1.452 -0.251 0 C-N-CA 120.746 -0.74 . . . . 0.0 112.403 -179.928 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 37.5 t70 -134.93 144.14 47.3 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-O 120.841 0.353 . . . . 0.0 110.945 179.979 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 31' ' ' GLN . . . . . . . . . . . . . 2.4 mp0 -64.43 134.98 55.61 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.254 -0.43 . . . . 0.0 110.811 -179.996 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 13.7 m -147.96 173.41 1.99 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.358 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.21 179.981 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 33' ' ' LEU . . . . . 0.577 HD12 ' HA ' ' A' ' 39' ' ' GLN . 15.0 tp -134.32 108.53 8.26 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.222 -0.444 . . . . 0.0 110.899 -179.969 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 34' ' ' VAL . . . . . 0.427 HG22 ' CD1' ' A' ' 58' ' ' ILE . 26.0 t -73.74 122.59 27.11 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.115 179.967 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 35' ' ' ALA . . . . . . . . . . . . . . . 59.13 25.2 13.65 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.117 -0.492 . . . . 0.0 111.194 -179.992 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 36' ' ' GLY . . . . . 0.414 ' HA2' HD23 ' A' ' 33' ' ' LEU . . . 55.27 27.49 46.97 Favored Glycine 0 N--CA 1.452 -0.253 0 C-N-CA 120.779 -0.724 . . . . 0.0 112.592 179.938 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 37' ' ' GLN . . . . . . . . . . . . . 12.8 mt-30 -141.87 -63.05 0.45 Allowed 'General case' 0 C--N 1.329 -0.286 0 CA-C-O 120.781 0.324 . . . . 0.0 110.876 -179.988 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 38' ' ' LYS . . . . . . . . . . . . . 11.4 mttp -71.26 111.97 7.03 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.25 -0.432 . . . . 0.0 110.889 179.989 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 39' ' ' GLN . . . . . 0.577 ' HA ' HD12 ' A' ' 33' ' ' LEU . 0.9 OUTLIER -82.27 131.24 35.23 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.854 -179.991 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -163.28 179.06 38.67 Favored Glycine 0 N--CA 1.451 -0.336 0 C-N-CA 120.775 -0.726 . . . . 0.0 112.504 -179.994 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 41' ' ' ILE . . . . . 0.458 ' N ' HG23 ' A' ' 58' ' ' ILE . 28.0 mt -128.63 137.74 56.49 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-O 120.842 0.354 . . . . 0.0 111.125 179.929 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 42' ' ' VAL . . . . . . . . . . . . . 21.5 t -62.19 127.16 21.68 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-N 116.174 -0.467 . . . . 0.0 111.161 -179.997 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 43' ' ' ARG . . . . . . . . . . . . . 10.1 mmt180 -111.76 -34.67 5.96 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.909 179.955 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 44' ' ' PHE . . . . . . . . . . . . . 39.4 t80 -143.52 112.28 6.53 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.897 -179.988 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 45' ' ' TYR . . . . . 0.485 ' CE1' ' CZ ' ' A' ' 56' ' ' TYR . 12.9 t80 -105.39 122.29 45.68 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.919 179.932 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 166.02 173.13 34.16 Favored Glycine 0 N--CA 1.452 -0.265 0 C-N-CA 120.757 -0.735 . . . . 0.0 112.485 179.953 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 47' ' ' LYS . . . . . . . . . . . . . 14.5 mttm -70.15 155.46 40.6 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 120.842 0.353 . . . . 0.0 110.911 -179.995 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 48' ' ' THR . . . . . 0.527 HG21 ' CE1' ' A' ' 50' ' ' PHE . 42.8 p -118.12 -177.75 3.35 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.13 -0.486 . . . . 0.0 110.874 179.969 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 4.8 t0 -105.98 -30.75 9.12 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.922 179.98 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 50' ' ' PHE . . . . . 0.527 ' CE1' HG21 ' A' ' 48' ' ' THR . 53.8 p90 -71.02 -40.75 71.58 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.941 -179.95 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 51' ' ' ALA . . . . . . . . . . . . . . . -137.0 144.47 46.5 Favored Pre-proline 0 C--N 1.329 -0.294 0 CA-C-N 116.187 -0.461 . . . . 0.0 111.211 -179.934 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 52' ' ' PRO . . . . . . . . . . . . . 73.3 Cg_endo -76.16 169.76 21.4 Favored 'Trans proline' 0 C--N 1.345 0.357 0 C-N-CA 122.54 2.16 . . . . 0.0 112.366 -179.975 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 90.39 178.78 44.07 Favored Glycine 0 N--CA 1.452 -0.294 0 C-N-CA 120.738 -0.744 . . . . 0.0 112.464 179.906 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 54' ' ' TYR . . . . . . . . . . . . . 14.1 m-85 -91.17 115.7 28.23 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-O 120.813 0.34 . . . . 0.0 110.935 179.977 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 55' ' ' TRP . . . . . . . . . . . . . 73.8 m95 -109.91 147.22 33.8 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.89 179.973 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 56' ' ' TYR . . . . . 0.579 ' CE1' ' HB2' ' A' ' 89' ' ' ALA . 8.1 m-85 -104.62 120.98 42.57 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.966 -179.89 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 57' ' ' GLY . . . . . 0.445 ' N ' ' CE1' ' A' ' 86' ' ' PHE . . . -80.72 62.78 4.34 Favored Glycine 0 N--CA 1.451 -0.325 0 C-N-CA 120.758 -0.734 . . . . 0.0 112.365 179.929 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 58' ' ' ILE . . . . . 0.757 HD11 HD13 ' A' ' 92' ' ' ILE . 21.6 mt -70.76 138.94 20.84 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-O 120.866 0.365 . . . . 0.0 111.141 -179.906 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -109.13 130.63 55.48 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.877 -179.97 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 60' ' ' LEU . . . . . 0.479 HD13 HG23 ' A' ' 64' ' ' THR . 84.2 mt -85.54 173.21 10.37 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.871 179.959 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 1.5 t70 -103.11 -31.03 10.36 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.943 -179.961 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 62' ' ' GLN . . . . . 0.401 ' HA ' ' HD3' ' A' ' 63' ' ' PRO . 2.4 mm-40 -114.43 147.81 38.82 Favored Pre-proline 0 C--N 1.33 -0.272 0 CA-C-N 116.298 -0.41 . . . . 0.0 110.911 -179.986 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 63' ' ' PRO . . . . . 0.401 ' HD3' ' HA ' ' A' ' 62' ' ' GLN . 31.9 Cg_exo -58.24 84.32 0.05 OUTLIER 'Trans proline' 0 C--N 1.346 0.399 0 C-N-CA 122.564 2.176 . . . . 0.0 112.25 179.928 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 64' ' ' THR . . . . . 0.479 HG23 HD13 ' A' ' 60' ' ' LEU . 13.4 t -157.0 35.02 0.29 Allowed 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.297 -0.411 . . . . 0.0 110.946 179.988 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . -95.96 -159.98 32.65 Favored Glycine 0 N--CA 1.452 -0.292 0 C-N-CA 120.745 -0.741 . . . . 0.0 112.503 179.911 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 66' ' ' LYS . . . . . . . . . . . . . 0.5 OUTLIER -110.03 -31.31 7.42 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 120.861 0.363 . . . . 0.0 110.922 179.977 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 67' ' ' HIS . . . . . 0.492 ' CG ' HG22 ' A' ' 71' ' ' VAL . 13.1 p80 -145.96 -178.74 6.28 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.877 -179.975 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 26.6 t0 -114.87 73.08 0.81 Allowed 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.944 179.986 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 79.41 -72.75 2.47 Favored Glycine 0 N--CA 1.451 -0.352 0 C-N-CA 120.761 -0.733 . . . . 0.0 112.476 -179.982 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 70' ' ' SER . . . . . . . . . . . . . 97.2 p -86.62 151.5 23.39 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-O 120.841 0.353 . . . . 0.0 110.907 -179.981 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 71' ' ' VAL . . . . . 0.716 HG12 ' CD2' ' A' ' 72' ' ' PHE . 21.5 t -128.03 117.9 47.08 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.162 -0.472 . . . . 0.0 111.095 179.977 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 72' ' ' PHE . . . . . 0.716 ' CD2' HG12 ' A' ' 71' ' ' VAL . 59.8 m-85 60.91 31.12 19.98 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.879 179.962 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 99.74 -30.0 10.9 Favored Glycine 0 N--CA 1.452 -0.281 0 C-N-CA 120.687 -0.768 . . . . 0.0 112.563 179.984 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 21.3 t -75.66 116.35 18.45 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-O 120.888 0.375 . . . . 0.0 111.093 179.981 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 75' ' ' ARG . . . . . . . . . . . . . 26.2 ttt85 -93.83 148.03 22.51 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.858 179.969 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 76' ' ' TYR . . . . . . . . . . . . . 89.9 m-85 -133.24 -47.69 0.84 Allowed 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.165 -0.471 . . . . 0.0 110.948 179.946 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 77' ' ' PHE . . . . . . . . . . . . . 22.5 p90 -155.2 154.67 32.6 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.9 -179.979 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 9.0 t -84.6 140.7 31.19 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.169 -0.468 . . . . 0.0 110.847 179.955 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 79' ' ' CYS . . . . . . . . . . . . . 22.7 p -164.7 162.39 21.25 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.922 179.921 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 80' ' ' ALA . . . . . 0.707 ' HB1' ' HD2' ' A' ' 81' ' ' PRO . . . -59.24 166.16 3.12 Favored Pre-proline 0 C--N 1.33 -0.254 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.002 179.949 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 81' ' ' PRO . . . . . 0.707 ' HD2' ' HB1' ' A' ' 80' ' ' ALA . 28.1 Cg_endo -62.66 122.63 11.05 Favored 'Trans proline' 0 C--N 1.346 0.397 0 C-N-CA 122.468 2.112 . . . . 0.0 112.253 -180.0 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 82' ' ' ARG . . . . . . . . . . . . . 0.5 OUTLIER 61.01 53.36 3.72 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.91 -179.875 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 83' ' ' HIS . . . . . 0.677 ' ND1' ' HB3' ' A' ' 80' ' ' ALA . 7.4 m170 -123.21 -45.54 2.1 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.11 -0.495 . . . . 0.0 110.85 179.958 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . -59.8 146.01 45.09 Favored Glycine 0 N--CA 1.451 -0.341 0 C-N-CA 120.646 -0.788 . . . . 0.0 112.501 -179.971 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 85' ' ' VAL . . . . . . . . . . . . . 6.1 m -150.04 114.88 0.67 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-O 120.815 0.34 . . . . 0.0 111.098 -179.938 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 86' ' ' PHE . . . . . 0.445 ' CE1' ' N ' ' A' ' 57' ' ' GLY . 3.7 m-85 -97.53 108.29 20.98 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.929 179.998 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 87' ' ' ALA . . . . . 0.595 ' O ' HD11 ' A' ' 92' ' ' ILE . . . -128.5 145.4 55.79 Favored Pre-proline 0 C--N 1.328 -0.344 0 CA-C-N 116.233 -0.439 . . . . 0.0 111.139 179.982 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 88' ' ' PRO . . . . . 0.417 ' O ' ' N ' ' A' ' 91' ' ' ARG . 32.3 Cg_exo -57.96 142.57 96.66 Favored 'Trans proline' 0 C--N 1.345 0.362 0 C-N-CA 122.519 2.146 . . . . 0.0 112.259 -179.984 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 89' ' ' ALA . . . . . 0.579 ' HB2' ' CE1' ' A' ' 56' ' ' TYR . . . -47.85 -51.18 23.93 Favored 'General case' 0 CA--C 1.521 -0.141 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.329 179.872 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 90' ' ' SER . . . . . . . . . . . . . 23.6 t -55.83 -24.4 36.24 Favored 'General case' 0 N--CA 1.454 -0.266 0 CA-C-N 115.747 -0.661 . . . . 0.0 109.815 178.76 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 91' ' ' ARG . . . . . 0.417 ' N ' ' O ' ' A' ' 88' ' ' PRO . 0.0 OUTLIER -89.37 -14.14 36.24 Favored 'General case' 0 N--CA 1.455 -0.215 0 CA-C-N 115.932 -0.576 . . . . 0.0 110.513 179.04 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 92' ' ' ILE . . . . . 0.757 HD13 HD11 ' A' ' 58' ' ' ILE . 48.9 mt -105.85 156.59 6.62 Favored 'Isoleucine or valine' 0 C--O 1.231 0.12 0 CA-C-N 116.396 -0.365 . . . . 0.0 110.971 179.753 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 93' ' ' GLN . . . . . 0.468 ' N ' HG22 ' A' ' 92' ' ' ILE . 50.8 mt-30 -121.42 175.0 6.4 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.262 -0.426 . . . . 0.0 110.881 -179.979 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 94' ' ' ARG . . . . . . . . . . . . . 0.6 OUTLIER -122.03 110.41 15.76 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.855 -179.972 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 95' ' ' ILE . . . . . . . . . . . . . 32.5 mt . . . . . 0 C--N 1.329 -0.317 0 CA-C-N 116.262 -0.427 . . . . 0.0 111.073 179.97 . . . . . . . . 0 0 . 1 . 009 nuclear build core ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.231 0.128 0 CA-C-O 120.827 0.346 . . . . 0.0 111.106 . . . . . . . . . 0 0 . 1 . 009 nuclear build core ' A' A ' 27' ' ' GLU . . . . . . . . . . . . . 8.8 mt-10 -125.01 167.74 14.3 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.251 -0.431 . . . . 0.0 110.885 179.992 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 28.3 t -70.55 100.41 0.73 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 CA-C-N 116.165 -0.471 . . . . 0.0 111.077 -179.963 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 116.94 39.68 0.8 Allowed Glycine 0 N--CA 1.451 -0.334 0 C-N-CA 120.692 -0.766 . . . . 0.0 112.504 -179.977 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 1.8 m-20 -142.35 146.94 35.51 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-O 120.836 0.35 . . . . 0.0 110.89 -179.992 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 31' ' ' GLN . . . . . . . . . . . . . 77.1 mt-30 -59.96 136.26 57.96 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.861 179.966 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 5.8 m -148.91 162.46 5.01 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.129 179.968 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 33' ' ' LEU . . . . . 0.506 HD23 ' HA2' ' A' ' 36' ' ' GLY . 20.5 tp -130.23 104.96 7.6 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.825 -179.956 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 34' ' ' VAL . . . . . 0.488 HG13 ' CB ' ' A' ' 87' ' ' ALA . 21.7 t -72.98 125.01 31.09 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-N 116.178 -0.464 . . . . 0.0 111.263 -179.955 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 35' ' ' ALA . . . . . . . . . . . . . . . 57.17 25.88 11.48 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.169 -0.469 . . . . 0.0 111.24 179.914 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 36' ' ' GLY . . . . . 0.506 ' HA2' HD23 ' A' ' 33' ' ' LEU . . . 56.54 32.01 60.74 Favored Glycine 0 N--CA 1.452 -0.244 0 C-N-CA 120.726 -0.749 . . . . 0.0 112.613 179.971 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 37' ' ' GLN . . . . . . . . . . . . . 29.9 mt-30 -142.2 -66.71 0.39 Allowed 'General case' 0 C--N 1.329 -0.284 0 CA-C-O 120.781 0.324 . . . . 0.0 110.975 179.96 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 38' ' ' LYS . . . . . 0.532 ' HB3' HD21 ' A' ' 60' ' ' LEU . 25.1 mmtp -72.95 112.22 8.78 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.244 -0.434 . . . . 0.0 110.902 -179.957 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 39' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -92.62 130.28 38.3 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.891 -179.967 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -161.16 -169.41 24.38 Favored Glycine 0 N--CA 1.451 -0.324 0 C-N-CA 120.749 -0.739 . . . . 0.0 112.56 179.977 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 41' ' ' ILE . . . . . 0.4 ' N ' HG23 ' A' ' 58' ' ' ILE . 8.9 mt -128.62 132.71 67.58 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-O 120.769 0.319 . . . . 0.0 111.087 -179.993 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 42' ' ' VAL . . . . . . . . . . . . . 21.5 t -59.53 125.2 15.2 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.361 0 CA-C-N 116.2 -0.454 . . . . 0.0 111.153 179.932 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 43' ' ' ARG . . . . . . . . . . . . . 10.1 mmt180 -110.51 -32.52 6.88 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.882 -179.954 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 44' ' ' PHE . . . . . . . . . . . . . 86.9 t80 -144.4 113.73 7.0 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.909 -179.995 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 45' ' ' TYR . . . . . 0.439 ' CE1' ' CZ ' ' A' ' 56' ' ' TYR . 27.1 t80 -113.15 111.73 22.6 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.925 179.989 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . -169.52 -150.38 6.76 Favored Glycine 0 N--CA 1.45 -0.391 0 C-N-CA 120.808 -0.711 . . . . 0.0 112.545 179.984 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 47' ' ' LYS . . . . . 0.411 ' HD3' ' CE1' ' A' ' 54' ' ' TYR . 2.2 mmmp? -96.77 168.84 10.26 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.792 0.33 . . . . 0.0 110.879 -179.93 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 48' ' ' THR . . . . . . . . . . . . . 64.6 p -132.43 178.15 7.05 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.837 179.947 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 32.3 t70 -112.55 -35.41 5.55 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.961 -179.975 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 50' ' ' PHE . . . . . . . . . . . . . 30.1 p90 -62.73 -31.04 71.9 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.949 -179.942 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 51' ' ' ALA . . . . . . . . . . . . . . . -151.74 151.96 29.38 Favored Pre-proline 0 C--N 1.329 -0.299 0 CA-C-N 116.237 -0.438 . . . . 0.0 111.107 -179.962 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 52' ' ' PRO . . . . . . . . . . . . . 58.2 Cg_endo -71.58 -176.89 2.17 Favored 'Trans proline' 0 C--N 1.345 0.347 0 C-N-CA 122.559 2.173 . . . . 0.0 112.3 179.928 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 75.12 -177.07 48.92 Favored Glycine 0 N--CA 1.451 -0.348 0 C-N-CA 120.756 -0.735 . . . . 0.0 112.54 -179.922 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 54' ' ' TYR . . . . . 0.411 ' CE1' ' HD3' ' A' ' 47' ' ' LYS . 10.1 m-85 -107.8 132.45 53.4 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 120.815 0.34 . . . . 0.0 110.916 179.994 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 55' ' ' TRP . . . . . 0.413 ' CZ3' ' HD3' ' A' ' 88' ' ' PRO . 19.0 m95 -120.07 173.31 7.16 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.852 -179.989 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 56' ' ' TYR . . . . . 0.615 ' HE1' ' HB2' ' A' ' 89' ' ' ALA . 10.8 m-85 -117.21 127.51 54.17 Favored 'General case' 0 C--N 1.331 -0.235 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.948 -179.904 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . -90.6 65.12 2.76 Favored Glycine 0 N--CA 1.45 -0.426 0 C-N-CA 120.746 -0.74 . . . . 0.0 112.426 -179.998 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 58' ' ' ILE . . . . . 0.444 HD12 HG22 ' A' ' 34' ' ' VAL . 25.3 mt -71.64 139.43 19.82 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-O 120.779 0.323 . . . . 0.0 111.135 -179.928 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 0.2 OUTLIER -108.49 111.0 22.64 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.826 -179.965 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 60' ' ' LEU . . . . . 0.711 HD13 HG23 ' A' ' 64' ' ' THR . 63.2 mt -63.93 167.89 5.73 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.308 -0.406 . . . . 0.0 110.846 -179.969 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -96.84 -26.1 15.23 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.947 -179.995 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 62' ' ' GLN . . . . . . . . . . . . . 64.9 mm-40 -124.26 152.36 67.56 Favored Pre-proline 0 C--N 1.329 -0.284 0 CA-C-N 116.369 -0.378 . . . . 0.0 110.908 -179.895 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 32.2 Cg_exo -58.19 92.52 0.06 OUTLIER 'Trans proline' 0 C--N 1.346 0.401 0 C-N-CA 122.579 2.186 . . . . 0.0 112.293 179.954 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 64' ' ' THR . . . . . 0.711 HG23 HD13 ' A' ' 60' ' ' LEU . 13.4 t -165.74 36.49 0.05 Allowed 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 116.283 -0.417 . . . . 0.0 110.932 179.873 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . -99.12 -140.11 11.26 Favored Glycine 0 N--CA 1.451 -0.344 0 C-N-CA 120.78 -0.724 . . . . 0.0 112.442 -179.993 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 66' ' ' LYS . . . . . . . . . . . . . 1.7 mttm -132.21 -46.55 0.92 Allowed 'General case' 0 C--N 1.328 -0.34 0 CA-C-O 120.822 0.344 . . . . 0.0 110.87 179.97 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 67' ' ' HIS . . . . . . . . . . . . . 12.4 p80 -127.27 174.69 8.75 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.233 -0.44 . . . . 0.0 110.92 179.901 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 1.6 m-20 -98.46 48.68 0.98 Allowed 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.928 179.998 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 84.44 -61.51 4.7 Favored Glycine 0 N--CA 1.451 -0.31 0 C-N-CA 120.715 -0.755 . . . . 0.0 112.486 -179.997 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 70' ' ' SER . . . . . . . . . . . . . 31.4 p -80.26 152.15 29.22 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-O 120.774 0.321 . . . . 0.0 110.802 -179.992 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 21.5 t -134.32 118.08 26.42 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.111 179.982 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 72' ' ' PHE . . . . . . . . . . . . . 28.8 m-85 60.58 31.05 20.16 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.884 179.937 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 98.35 -28.41 14.94 Favored Glycine 0 N--CA 1.451 -0.316 0 C-N-CA 120.741 -0.742 . . . . 0.0 112.462 -179.998 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 21.5 t -73.64 130.56 35.78 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-O 120.805 0.336 . . . . 0.0 111.133 179.998 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 75' ' ' ARG . . . . . . . . . . . . . 48.4 ttt-85 -93.71 144.23 25.59 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.901 179.963 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 76' ' ' TYR . . . . . . . . . . . . . 58.4 m-85 -124.85 -44.82 1.92 Allowed 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.867 -179.985 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 77' ' ' PHE . . . . . . . . . . . . . 32.7 p90 -166.91 177.44 6.37 Favored 'General case' 0 C--N 1.327 -0.383 0 CA-C-N 116.18 -0.463 . . . . 0.0 110.908 179.978 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 1.7 t -98.96 124.83 44.18 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.833 -179.93 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 79' ' ' CYS . . . . . . . . . . . . . 27.0 p -150.98 155.01 38.2 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.847 179.952 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 80' ' ' ALA . . . . . 0.524 ' HB1' ' HD2' ' A' ' 81' ' ' PRO . . . -67.99 166.84 20.4 Favored Pre-proline 0 C--N 1.328 -0.349 0 CA-C-N 116.159 -0.473 . . . . 0.0 111.049 179.956 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 81' ' ' PRO . . . . . 0.524 ' HD2' ' HB1' ' A' ' 80' ' ' ALA . 53.3 Cg_exo -52.63 117.07 3.31 Favored 'Trans proline' 0 C--N 1.345 0.362 0 C-N-CA 122.538 2.159 . . . . 0.0 112.324 -179.92 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 82' ' ' ARG . . . . . . . . . . . . . 2.9 ttm180 63.12 57.7 1.56 Allowed 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.978 179.985 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 83' ' ' HIS . . . . . 0.493 ' CE1' ' HB3' ' A' ' 80' ' ' ALA . 6.3 m170 -126.96 -46.98 1.52 Allowed 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.091 -0.504 . . . . 0.0 110.94 179.957 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . -62.86 139.31 44.85 Favored Glycine 0 N--CA 1.45 -0.388 0 C-N-CA 120.722 -0.752 . . . . 0.0 112.541 179.989 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 85' ' ' VAL . . . . . . . . . . . . . 5.5 m -147.21 124.18 3.19 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.257 0 CA-C-O 120.871 0.367 . . . . 0.0 111.062 -179.942 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 86' ' ' PHE . . . . . . . . . . . . . 13.5 m-85 -100.77 121.12 41.14 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.081 -0.508 . . . . 0.0 110.9 179.999 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 87' ' ' ALA . . . . . 0.605 ' O ' HD11 ' A' ' 92' ' ' ILE . . . -140.75 144.84 37.47 Favored Pre-proline 0 C--N 1.328 -0.33 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.161 179.975 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 88' ' ' PRO . . . . . 0.416 ' O ' ' N ' ' A' ' 91' ' ' ARG . 47.6 Cg_exo -56.06 141.25 87.11 Favored 'Trans proline' 0 C--N 1.345 0.394 0 C-N-CA 122.607 2.204 . . . . 0.0 112.224 -179.9 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 89' ' ' ALA . . . . . 0.615 ' HB2' ' HE1' ' A' ' 56' ' ' TYR . . . -47.96 -50.97 25.48 Favored 'General case' 0 CA--C 1.521 -0.149 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.295 179.854 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 90' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -55.83 -24.6 37.41 Favored 'General case' 0 C--N 1.331 -0.217 0 CA-C-N 115.68 -0.691 . . . . 0.0 109.673 178.841 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 91' ' ' ARG . . . . . 0.416 ' N ' ' O ' ' A' ' 88' ' ' PRO . 0.0 OUTLIER -87.6 -15.37 37.54 Favored 'General case' 0 N--CA 1.454 -0.244 0 CA-C-N 115.856 -0.611 . . . . 0.0 110.423 179.032 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 92' ' ' ILE . . . . . 0.605 HD11 ' O ' ' A' ' 87' ' ' ALA . 33.0 mt -104.63 145.89 12.61 Favored 'Isoleucine or valine' 0 C--N 1.333 -0.126 0 CA-C-N 116.397 -0.365 . . . . 0.0 111.066 179.864 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 93' ' ' GLN . . . . . . . . . . . . . 0.7 OUTLIER -114.83 -179.96 3.78 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.991 -179.973 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 94' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -126.08 142.88 51.33 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.877 -179.968 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 95' ' ' ILE . . . . . . . . . . . . . 3.3 mp . . . . . 0 C--N 1.329 -0.287 0 CA-C-N 116.108 -0.496 . . . . 0.0 111.172 179.981 . . . . . . . . 0 0 . 1 . 010 nuclear build core ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.231 0.1 0 CA-C-O 120.833 0.349 . . . . 0.0 111.134 . . . . . . . . . 0 0 . 1 . 010 nuclear build core ' A' A ' 27' ' ' GLU . . . . . . . . . . . . . 28.7 mt-10 -139.41 178.31 7.29 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.946 179.972 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 28.9 t -72.31 115.7 13.18 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.219 -0.446 . . . . 0.0 111.049 -179.979 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 102.43 33.96 4.33 Favored Glycine 0 N--CA 1.452 -0.298 0 C-N-CA 120.716 -0.754 . . . . 0.0 112.443 179.969 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 13.3 m-20 -141.42 148.35 39.42 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-O 120.822 0.344 . . . . 0.0 110.912 179.92 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 31' ' ' GLN . . . . . . . . . . . . . 3.5 mp0 -72.74 137.33 45.82 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.955 179.975 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 32' ' ' VAL . . . . . 0.449 ' HB ' HG22 ' A' ' 92' ' ' ILE . 14.8 m -146.55 177.53 1.3 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 116.262 -0.426 . . . . 0.0 111.112 179.984 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 33' ' ' LEU . . . . . 0.504 HD23 ' HA2' ' A' ' 36' ' ' GLY . 21.7 tp -134.15 112.36 11.06 Favored 'General case' 0 C--N 1.33 -0.283 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.794 -179.998 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 34' ' ' VAL . . . . . 0.747 HG22 HD12 ' A' ' 58' ' ' ILE . 21.9 t -76.03 123.74 32.77 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.145 -0.479 . . . . 0.0 111.127 -179.949 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 35' ' ' ALA . . . . . . . . . . . . . . . 59.28 25.56 14.22 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.153 -0.476 . . . . 0.0 111.229 179.979 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 36' ' ' GLY . . . . . 0.504 ' HA2' HD23 ' A' ' 33' ' ' LEU . . . 55.95 27.88 51.88 Favored Glycine 0 N--CA 1.452 -0.252 0 C-N-CA 120.759 -0.734 . . . . 0.0 112.633 -179.993 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 37' ' ' GLN . . . . . 0.45 ' O ' HD11 ' A' ' 33' ' ' LEU . 24.9 mt-30 -142.64 -69.23 0.35 Allowed 'General case' 0 C--N 1.329 -0.285 0 CA-C-O 120.885 0.374 . . . . 0.0 110.925 179.957 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 38' ' ' LYS . . . . . . . . . . . . . 19.3 mttp -67.15 119.73 12.56 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.929 179.985 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 39' ' ' GLN . . . . . 0.43 ' HA ' HD12 ' A' ' 33' ' ' LEU . 0.0 OUTLIER -87.09 133.03 33.65 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.886 -179.999 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -162.33 169.76 37.75 Favored Glycine 0 N--CA 1.45 -0.371 0 C-N-CA 120.742 -0.742 . . . . 0.0 112.557 -179.969 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 23.2 mt -116.03 146.22 20.75 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.352 0 CA-C-O 120.799 0.333 . . . . 0.0 111.061 -179.99 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 42' ' ' VAL . . . . . . . . . . . . . 33.3 t -69.49 124.95 26.51 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.212 -0.449 . . . . 0.0 111.042 179.946 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 43' ' ' ARG . . . . . . . . . . . . . 2.9 mmm180 -111.84 -43.39 3.62 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.894 179.99 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 44' ' ' PHE . . . . . . . . . . . . . 49.7 t80 -136.7 113.16 10.02 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.86 -179.897 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 45' ' ' TYR . . . . . 0.495 ' CE1' ' CE1' ' A' ' 56' ' ' TYR . 14.1 t80 -112.9 131.57 55.67 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.272 -0.422 . . . . 0.0 110.872 179.965 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 156.17 -172.45 34.05 Favored Glycine 0 N--CA 1.451 -0.364 0 C-N-CA 120.763 -0.732 . . . . 0.0 112.524 -179.968 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 47' ' ' LYS . . . . . 0.433 ' HG3' ' CZ ' ' A' ' 54' ' ' TYR . 98.5 mttt -69.01 155.86 39.62 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 120.768 0.318 . . . . 0.0 110.915 179.968 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 48' ' ' THR . . . . . 0.635 HG21 ' CZ ' ' A' ' 50' ' ' PHE . 7.2 p -122.69 170.08 10.41 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.858 -179.943 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -102.33 -31.28 10.59 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.93 179.957 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 50' ' ' PHE . . . . . 0.635 ' CZ ' HG21 ' A' ' 48' ' ' THR . 18.0 p90 -73.66 -31.63 63.58 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.915 179.951 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 51' ' ' ALA . . . . . . . . . . . . . . . -140.51 147.95 51.45 Favored Pre-proline 0 C--N 1.33 -0.269 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.096 -179.895 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 52' ' ' PRO . . . . . . . . . . . . . 60.0 Cg_endo -72.25 176.9 7.93 Favored 'Trans proline' 0 C--N 1.344 0.32 0 C-N-CA 122.578 2.185 . . . . 0.0 112.402 179.902 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 72.45 -155.97 51.73 Favored Glycine 0 N--CA 1.45 -0.397 0 C-N-CA 120.771 -0.728 . . . . 0.0 112.592 179.947 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 54' ' ' TYR . . . . . 0.433 ' CZ ' ' HG3' ' A' ' 47' ' ' LYS . 10.8 m-85 -115.86 137.63 51.91 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-O 120.894 0.378 . . . . 0.0 110.856 -179.989 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 55' ' ' TRP . . . . . . . . . . . . . 52.0 m95 -126.37 164.25 21.48 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.835 179.977 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 56' ' ' TYR . . . . . 0.794 ' CE1' ' HB2' ' A' ' 89' ' ' ALA . 25.9 m-85 -114.42 120.88 41.81 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.968 179.963 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 57' ' ' GLY . . . . . 0.426 ' HA3' ' CE1' ' A' ' 77' ' ' PHE . . . -83.07 61.25 4.81 Favored Glycine 0 N--CA 1.45 -0.387 0 C-N-CA 120.73 -0.748 . . . . 0.0 112.401 179.995 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 58' ' ' ILE . . . . . 0.747 HD12 HG22 ' A' ' 34' ' ' VAL . 45.2 mt -69.33 145.13 13.43 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-O 120.827 0.346 . . . . 0.0 111.098 -179.899 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 5.6 tm-20 -112.83 132.77 55.13 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.797 -179.961 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 60' ' ' LEU . . . . . . . . . . . . . 39.3 mt -93.1 158.76 15.61 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.202 -0.453 . . . . 0.0 110.93 -179.994 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 32.6 t0 -100.26 31.17 3.49 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.918 179.931 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 62' ' ' GLN . . . . . . . . . . . . . 1.8 pm0 -157.46 149.05 17.02 Favored Pre-proline 0 C--N 1.33 -0.276 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.846 179.965 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 56.4 Cg_endo -70.28 63.67 2.09 Favored 'Trans proline' 0 C--N 1.344 0.314 0 C-N-CA 122.631 2.221 . . . . 0.0 112.284 -179.994 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 64' ' ' THR . . . . . . . . . . . . . 5.4 p -145.23 30.84 1.12 Allowed 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.972 179.901 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . -79.37 -159.26 15.92 Favored Glycine 0 N--CA 1.451 -0.361 0 C-N-CA 120.714 -0.755 . . . . 0.0 112.48 179.989 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 66' ' ' LYS . . . . . . . . . . . . . 7.0 mtpm? -111.53 -33.74 6.29 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 120.813 0.34 . . . . 0.0 110.928 179.969 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 67' ' ' HIS . . . . . . . . . . . . . 6.0 p80 -139.12 174.07 10.9 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.911 179.921 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 1.3 t70 -97.85 37.07 1.44 Allowed 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.951 179.973 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 95.19 -65.21 1.33 Allowed Glycine 0 N--CA 1.451 -0.337 0 C-N-CA 120.703 -0.76 . . . . 0.0 112.511 -179.965 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 70' ' ' SER . . . . . . . . . . . . . 3.1 p -89.57 133.34 34.65 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 120.807 0.337 . . . . 0.0 110.836 -179.931 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 71' ' ' VAL . . . . . 0.691 HG12 ' CD2' ' A' ' 72' ' ' PHE . 21.5 t -114.21 114.76 47.62 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.202 -0.454 . . . . 0.0 111.111 -179.982 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 72' ' ' PHE . . . . . 0.691 ' CD2' HG12 ' A' ' 71' ' ' VAL . 13.9 m-85 60.73 31.11 20.09 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.949 179.99 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 98.8 -29.36 11.81 Favored Glycine 0 N--CA 1.451 -0.324 0 C-N-CA 120.752 -0.737 . . . . 0.0 112.485 -179.956 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 21.5 t -76.97 123.56 33.74 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-O 120.797 0.332 . . . . 0.0 111.092 -179.944 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 75' ' ' ARG . . . . . . . . . . . . . 11.4 ttm180 -101.1 134.04 44.7 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.884 179.996 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 76' ' ' TYR . . . . . . . . . . . . . 51.7 m-85 -109.67 -31.15 7.57 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.998 179.922 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 77' ' ' PHE . . . . . 0.426 ' CE1' ' HA3' ' A' ' 57' ' ' GLY . 27.0 p90 -172.85 156.39 3.4 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.941 179.98 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 12.3 m -85.75 111.2 19.92 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.798 179.968 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 79' ' ' CYS . . . . . . . . . . . . . 27.1 p -134.86 164.31 27.86 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.31 -0.405 . . . . 0.0 110.995 -179.929 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 80' ' ' ALA . . . . . 0.727 ' HB1' ' HD2' ' A' ' 81' ' ' PRO . . . -63.55 165.86 10.72 Favored Pre-proline 0 C--N 1.328 -0.337 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.949 179.879 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 81' ' ' PRO . . . . . 0.727 ' HD2' ' HB1' ' A' ' 80' ' ' ALA . 20.5 Cg_endo -60.85 114.97 2.39 Favored 'Trans proline' 0 C--N 1.345 0.364 0 C-N-CA 122.58 2.187 . . . . 0.0 112.146 179.876 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 82' ' ' ARG . . . . . . . . . . . . . 49.7 mtt180 64.4 58.69 1.06 Allowed 'General case' 0 C--N 1.331 -0.232 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.752 -179.969 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 83' ' ' HIS . . . . . 0.524 ' CG ' ' HB3' ' A' ' 80' ' ' ALA . 5.7 m-70 -130.7 -48.56 1.05 Allowed 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.899 179.927 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . -60.48 140.29 48.06 Favored Glycine 0 N--CA 1.452 -0.273 0 C-N-CA 120.741 -0.742 . . . . 0.0 112.531 -179.99 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 85' ' ' VAL . . . . . . . . . . . . . 10.1 m -142.59 130.52 20.12 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-O 120.823 0.344 . . . . 0.0 111.096 179.937 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 86' ' ' PHE . . . . . 0.409 ' CE1' ' CA ' ' A' ' 57' ' ' GLY . 8.6 m-85 -103.66 114.0 27.93 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.924 -179.963 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 87' ' ' ALA . . . . . 0.626 ' O ' HD11 ' A' ' 92' ' ' ILE . . . -134.28 145.4 55.23 Favored Pre-proline 0 C--N 1.331 -0.237 0 CA-C-N 116.259 -0.428 . . . . 0.0 111.067 -179.949 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 88' ' ' PRO . . . . . 0.41 ' O ' ' N ' ' A' ' 91' ' ' ARG . 36.5 Cg_exo -57.45 140.57 93.58 Favored 'Trans proline' 0 C--N 1.345 0.356 0 C-N-CA 122.527 2.151 . . . . 0.0 112.236 -179.981 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 89' ' ' ALA . . . . . 0.794 ' HB2' ' CE1' ' A' ' 56' ' ' TYR . . . -48.24 -50.27 30.13 Favored 'General case' 0 CA--C 1.521 -0.162 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.262 179.809 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 90' ' ' SER . . . . . . . . . . . . . 2.7 m -55.9 -24.51 37.82 Favored 'General case' 0 N--CA 1.455 -0.223 0 CA-C-N 115.706 -0.679 . . . . 0.0 109.789 178.767 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 91' ' ' ARG . . . . . 0.41 ' N ' ' O ' ' A' ' 88' ' ' PRO . 0.2 OUTLIER -88.54 -14.19 38.29 Favored 'General case' 0 N--CA 1.455 -0.177 0 CA-C-N 115.865 -0.607 . . . . 0.0 110.391 179.1 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 92' ' ' ILE . . . . . 0.704 HD13 HD11 ' A' ' 58' ' ' ILE . 21.4 mt -108.12 139.82 28.88 Favored 'Isoleucine or valine' 0 C--O 1.232 0.154 0 CA-C-N 116.45 -0.341 . . . . 0.0 111.061 179.808 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 93' ' ' GLN . . . . . . . . . . . . . 20.5 mt-30 -106.7 171.72 7.21 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.892 179.997 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 94' ' ' ARG . . . . . . . . . . . . . 3.4 ttt-85 -111.79 154.18 25.45 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.902 179.929 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 95' ' ' ILE . . . . . . . . . . . . . 31.8 mt . . . . . 0 C--N 1.328 -0.326 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.155 179.997 . . . . . . . . 0 0 . 1 . 011 nuclear build core ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.231 0.117 0 CA-C-O 120.776 0.322 . . . . 0.0 111.143 . . . . . . . . . 0 0 . 1 . 011 nuclear build core ' A' A ' 27' ' ' GLU . . . . . . . . . . . . . 30.4 mt-10 -145.56 -178.36 6.04 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.901 -179.992 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 21.5 t -75.85 116.62 19.08 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.211 -0.449 . . . . 0.0 111.144 -179.954 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 101.35 36.65 3.77 Favored Glycine 0 N--CA 1.45 -0.416 0 C-N-CA 120.766 -0.73 . . . . 0.0 112.47 -179.992 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -144.79 151.67 39.17 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 120.778 0.323 . . . . 0.0 110.898 -179.991 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 31' ' ' GLN . . . . . . . . . . . . . 2.7 mp0 -72.11 125.78 28.14 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.233 -0.439 . . . . 0.0 110.891 179.984 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 32' ' ' VAL . . . . . 0.537 HG21 HG12 ' A' ' 58' ' ' ILE . 27.5 m -127.04 174.57 10.57 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.138 -0.483 . . . . 0.0 111.143 179.964 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 33' ' ' LEU . . . . . 0.702 ' HB2' HD11 ' A' ' 95' ' ' ILE . 25.8 tp -143.22 102.54 4.0 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.852 -179.923 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 34' ' ' VAL . . . . . 0.565 ' CG2' HD13 ' A' ' 58' ' ' ILE . 21.4 t -72.65 128.57 35.6 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.148 -0.478 . . . . 0.0 111.147 -179.92 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 35' ' ' ALA . . . . . . . . . . . . . . . 57.18 25.08 10.54 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.065 -0.516 . . . . 0.0 111.304 179.936 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . 56.38 31.22 59.53 Favored Glycine 0 N--CA 1.451 -0.344 0 C-N-CA 120.752 -0.737 . . . . 0.0 112.604 -179.986 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 37' ' ' GLN . . . . . 0.616 ' O ' HD11 ' A' ' 33' ' ' LEU . 81.6 mt-30 -146.3 -70.86 0.25 Allowed 'General case' 0 C--N 1.329 -0.29 0 CA-C-O 120.79 0.329 . . . . 0.0 110.906 -179.92 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 38' ' ' LYS . . . . . . . . . . . . . 12.6 mttt -61.71 105.05 0.5 Allowed 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.905 -179.988 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 39' ' ' GLN . . . . . 0.507 ' CD ' HD13 ' A' ' 95' ' ' ILE . 0.0 OUTLIER -85.1 132.02 34.37 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.902 179.942 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -158.39 -170.19 22.78 Favored Glycine 0 N--CA 1.451 -0.358 0 C-N-CA 120.709 -0.758 . . . . 0.0 112.438 179.977 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 32.2 mt -129.55 129.74 66.87 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-O 120.798 0.332 . . . . 0.0 111.046 -179.959 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 42' ' ' VAL . . . . . . . . . . . . . 21.4 t -58.46 125.22 14.12 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.172 179.973 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 43' ' ' ARG . . . . . . . . . . . . . 36.6 mmt180 -108.18 -31.53 7.87 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.87 -179.973 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 44' ' ' PHE . . . . . . . . . . . . . 41.0 t80 -148.78 113.81 5.47 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.922 179.926 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 45' ' ' TYR . . . . . 0.471 ' CE1' ' CZ ' ' A' ' 56' ' ' TYR . 33.7 t80 -112.3 142.93 44.2 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.884 179.974 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 148.92 -168.99 29.4 Favored Glycine 0 N--CA 1.451 -0.327 0 C-N-CA 120.732 -0.747 . . . . 0.0 112.492 -179.982 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 47' ' ' LYS . . . . . 0.414 ' HE2' ' CZ ' ' A' ' 54' ' ' TYR . 22.2 mttm -87.39 141.58 28.53 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-O 120.851 0.357 . . . . 0.0 110.869 -179.98 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 48' ' ' THR . . . . . 0.666 HG21 ' CE2' ' A' ' 50' ' ' PHE . 63.6 p -102.18 -177.12 3.31 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.85 179.983 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 1.3 t70 -112.85 15.86 19.67 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.159 -0.473 . . . . 0.0 111.242 -179.958 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 50' ' ' PHE . . . . . 0.666 ' CE2' HG21 ' A' ' 48' ' ' THR . 29.2 p90 -116.38 -36.65 3.94 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-O 120.727 0.299 . . . . 0.0 110.996 179.846 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 51' ' ' ALA . . . . . 0.445 ' N ' ' CD1' ' A' ' 50' ' ' PHE . . . -140.26 146.71 47.04 Favored Pre-proline 0 C--N 1.328 -0.332 0 CA-C-N 116.249 -0.432 . . . . 0.0 111.126 179.924 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 52' ' ' PRO . . . . . . . . . . . . . 60.0 Cg_endo -72.42 170.81 18.37 Favored 'Trans proline' 0 C--N 1.345 0.388 0 C-N-CA 122.505 2.137 . . . . 0.0 112.353 -179.957 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 90.66 -154.08 23.01 Favored Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.778 -0.725 . . . . 0.0 112.525 179.939 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 54' ' ' TYR . . . . . 0.414 ' CZ ' ' HE2' ' A' ' 47' ' ' LYS . 57.4 m-85 -125.23 124.45 41.71 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 120.872 0.368 . . . . 0.0 110.867 179.963 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 55' ' ' TRP . . . . . . . . . . . . . 65.3 m95 -115.13 161.83 17.86 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.936 179.95 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 56' ' ' TYR . . . . . 0.569 ' HE1' ' HB2' ' A' ' 89' ' ' ALA . 10.8 m-85 -117.68 120.07 36.89 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.211 -0.449 . . . . 0.0 110.92 -179.887 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 57' ' ' GLY . . . . . 0.45 ' CA ' ' CE1' ' A' ' 86' ' ' PHE . . . -84.71 63.8 4.35 Favored Glycine 0 N--CA 1.452 -0.298 0 C-N-CA 120.681 -0.771 . . . . 0.0 112.392 179.997 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 58' ' ' ILE . . . . . 0.729 HD11 HD13 ' A' ' 92' ' ' ILE . 3.3 mt -70.24 146.95 11.87 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.23 0 CA-C-O 120.807 0.337 . . . . 0.0 111.128 -179.966 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 3.7 tm-20 -116.91 109.8 17.51 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.841 -179.979 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 60' ' ' LEU . . . . . 0.743 HD13 HG23 ' A' ' 64' ' ' THR . 96.0 mt -63.55 172.84 1.87 Allowed 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.912 179.932 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -98.5 -32.54 11.41 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.289 -0.414 . . . . 0.0 110.924 -179.978 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 62' ' ' GLN . . . . . 0.519 ' O ' HG22 ' A' ' 64' ' ' THR . 4.7 mm-40 -118.42 151.34 49.44 Favored Pre-proline 0 C--N 1.33 -0.264 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.94 -179.998 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 52.1 Cg_exo -54.66 99.95 0.06 OUTLIER 'Trans proline' 0 C--N 1.345 0.362 0 C-N-CA 122.485 2.123 . . . . 0.0 112.286 -179.958 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 64' ' ' THR . . . . . 0.743 HG23 HD13 ' A' ' 60' ' ' LEU . 9.8 t -176.98 39.01 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.872 179.983 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . -95.87 -125.43 4.73 Favored Glycine 0 N--CA 1.45 -0.37 0 C-N-CA 120.713 -0.756 . . . . 0.0 112.475 179.98 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 66' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -144.17 -47.71 0.27 Allowed 'General case' 0 C--N 1.329 -0.284 0 CA-C-O 120.825 0.345 . . . . 0.0 110.833 -179.869 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 67' ' ' HIS . . . . . . . . . . . . . 6.4 p80 -122.84 177.43 5.48 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.191 -0.458 . . . . 0.0 110.884 179.984 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -100.15 35.35 2.09 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.891 -179.987 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 100.99 -70.18 0.42 Allowed Glycine 0 N--CA 1.451 -0.365 0 C-N-CA 120.756 -0.735 . . . . 0.0 112.465 179.944 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 70' ' ' SER . . . . . . . . . . . . . 78.4 p -81.68 148.85 28.79 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 120.85 0.357 . . . . 0.0 110.868 179.987 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 71' ' ' VAL . . . . . 0.494 HG12 ' CD2' ' A' ' 72' ' ' PHE . 27.3 t -127.67 125.94 66.17 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.167 -0.47 . . . . 0.0 111.11 179.93 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 72' ' ' PHE . . . . . 0.494 ' CD2' HG12 ' A' ' 71' ' ' VAL . 47.7 m-85 60.08 28.02 17.52 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.99 -179.929 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 95.97 -30.03 9.11 Favored Glycine 0 N--CA 1.451 -0.307 0 C-N-CA 120.628 -0.796 . . . . 0.0 112.538 179.951 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 21.6 t -80.47 122.95 36.59 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-O 120.784 0.326 . . . . 0.0 111.074 -179.939 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 75' ' ' ARG . . . . . . . . . . . . . 21.2 ttm180 -88.96 146.26 25.01 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.224 -0.443 . . . . 0.0 110.922 -179.997 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 76' ' ' TYR . . . . . 0.424 ' CE2' HG22 ' A' ' 48' ' ' THR . 37.0 m-85 -119.26 -47.75 2.45 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.185 -0.462 . . . . 0.0 110.897 -179.977 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 77' ' ' PHE . . . . . . . . . . . . . 34.8 p90 -152.79 171.4 18.3 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.922 179.972 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 4.6 p -97.26 122.56 40.42 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.904 -179.97 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 79' ' ' CYS . . . . . . . . . . . . . 27.3 p -143.87 176.74 9.03 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.906 179.963 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 80' ' ' ALA . . . . . 0.618 ' HB3' ' CG ' ' A' ' 83' ' ' HIS . . . -90.43 168.95 13.02 Favored Pre-proline 0 C--N 1.329 -0.308 0 CA-C-N 116.229 -0.441 . . . . 0.0 111.077 179.96 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 81' ' ' PRO . . . . . 0.597 ' HD2' ' HB1' ' A' ' 80' ' ' ALA . 52.7 Cg_exo -52.59 113.6 1.3 Allowed 'Trans proline' 0 C--N 1.344 0.303 0 C-N-CA 122.557 2.171 . . . . 0.0 112.261 179.93 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 82' ' ' ARG . . . . . . . . . . . . . 9.2 mmt180 61.27 53.59 3.47 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.907 -179.987 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 83' ' ' HIS . . . . . 0.618 ' CG ' ' HB3' ' A' ' 80' ' ' ALA . 5.5 m170 -121.17 -42.4 2.48 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.125 -0.489 . . . . 0.0 110.918 179.989 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 84' ' ' GLY . . . . . 0.433 ' O ' HG13 ' A' ' 85' ' ' VAL . . . -63.7 154.67 45.67 Favored Glycine 0 N--CA 1.45 -0.368 0 C-N-CA 120.745 -0.741 . . . . 0.0 112.511 179.933 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 85' ' ' VAL . . . . . 0.433 HG13 ' O ' ' A' ' 84' ' ' GLY . 15.2 m -156.27 127.27 0.87 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-O 120.84 0.352 . . . . 0.0 111.191 -179.96 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 86' ' ' PHE . . . . . 0.45 ' CE1' ' CA ' ' A' ' 57' ' ' GLY . 7.9 m-85 -112.53 102.09 10.21 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.818 179.942 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 87' ' ' ALA . . . . . 0.454 ' CB ' HG13 ' A' ' 34' ' ' VAL . . . -123.19 145.86 47.45 Favored Pre-proline 0 C--N 1.329 -0.297 0 CA-C-N 116.245 -0.434 . . . . 0.0 111.119 -179.956 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 88' ' ' PRO . . . . . 0.41 ' O ' ' N ' ' A' ' 91' ' ' ARG . 32.3 Cg_exo -58.02 141.94 96.5 Favored 'Trans proline' 0 C--N 1.346 0.4 0 C-N-CA 122.498 2.132 . . . . 0.0 112.235 179.991 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 89' ' ' ALA . . . . . 0.569 ' HB2' ' HE1' ' A' ' 56' ' ' TYR . . . -47.9 -51.44 23.24 Favored 'General case' 0 CA--C 1.522 -0.116 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.346 179.859 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 90' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -55.99 -24.29 37.84 Favored 'General case' 0 N--CA 1.454 -0.27 0 CA-C-N 115.759 -0.655 . . . . 0.0 109.789 178.836 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 91' ' ' ARG . . . . . 0.41 ' N ' ' O ' ' A' ' 88' ' ' PRO . 0.0 OUTLIER -89.77 -14.08 35.34 Favored 'General case' 0 N--CA 1.455 -0.208 0 CA-C-N 115.945 -0.571 . . . . 0.0 110.526 179.029 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 92' ' ' ILE . . . . . 0.729 HD13 HD11 ' A' ' 58' ' ' ILE . 52.4 mt -110.56 156.04 11.73 Favored 'Isoleucine or valine' 0 C--O 1.23 0.077 0 CA-C-O 120.904 0.383 . . . . 0.0 111.04 179.864 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 93' ' ' GLN . . . . . 0.448 ' N ' HG22 ' A' ' 92' ' ' ILE . 8.5 mt-30 -124.31 179.98 4.69 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.78 179.93 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 94' ' ' ARG . . . . . . . . . . . . . 4.2 ttt180 -126.08 142.18 51.63 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.936 179.993 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 95' ' ' ILE . . . . . 0.702 HD11 ' HB2' ' A' ' 33' ' ' LEU . 3.4 mt . . . . . 0 C--N 1.329 -0.292 0 CA-C-N 116.246 -0.434 . . . . 0.0 111.088 179.982 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.457 -0.076 0 CA-C-O 120.85 0.357 . . . . 0.0 111.088 . . . . . . . . . 0 0 . 1 . 012 nuclear build core ' A' A ' 27' ' ' GLU . . . . . . . . . . . . . 50.8 mt-10 -133.24 -177.82 4.7 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.924 179.983 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 27.4 t -71.31 121.53 21.51 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.096 179.924 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 89.72 52.98 2.51 Favored Glycine 0 N--CA 1.452 -0.293 0 C-N-CA 120.7 -0.762 . . . . 0.0 112.424 179.954 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -155.45 142.1 18.83 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 120.795 0.331 . . . . 0.0 110.887 179.968 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 31' ' ' GLN . . . . . . . . . . . . . 15.3 mt-30 -59.97 134.95 57.52 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.256 -0.429 . . . . 0.0 110.923 -179.971 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 5.5 m -141.83 179.31 2.12 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.346 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.12 -179.982 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 33' ' ' LEU . . . . . 0.466 HD11 ' O ' ' A' ' 37' ' ' GLN . 30.6 tp -142.76 108.0 5.0 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.791 179.98 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 34' ' ' VAL . . . . . 0.526 HG13 ' CB ' ' A' ' 87' ' ' ALA . 22.0 t -78.29 124.67 37.03 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.156 179.995 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 35' ' ' ALA . . . . . . . . . . . . . . . 58.46 26.15 13.86 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.052 -0.522 . . . . 0.0 111.231 179.952 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . 56.57 28.48 56.21 Favored Glycine 0 N--CA 1.451 -0.333 0 C-N-CA 120.773 -0.727 . . . . 0.0 112.598 -179.999 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 37' ' ' GLN . . . . . 0.466 ' O ' HD11 ' A' ' 33' ' ' LEU . 34.3 mt-30 -140.34 -70.88 0.38 Allowed 'General case' 0 C--N 1.328 -0.327 0 CA-C-O 120.749 0.309 . . . . 0.0 110.924 -179.998 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 38' ' ' LYS . . . . . . . . . . . . . 2.1 mttt -69.76 108.45 3.93 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.263 -0.426 . . . . 0.0 110.902 -179.948 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 39' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -88.15 136.98 32.72 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.908 179.974 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -160.52 -163.49 13.89 Favored Glycine 0 N--CA 1.451 -0.319 0 C-N-CA 120.727 -0.749 . . . . 0.0 112.463 180.0 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 41' ' ' ILE . . . . . 0.406 ' C ' HG23 ' A' ' 58' ' ' ILE . 33.2 mt -133.67 131.6 56.9 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-O 120.742 0.306 . . . . 0.0 111.084 -179.905 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 42' ' ' VAL . . . . . . . . . . . . . 21.4 t -60.06 125.43 16.17 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.345 0 CA-C-N 116.209 -0.45 . . . . 0.0 111.123 179.988 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 43' ' ' ARG . . . . . . . . . . . . . 13.6 mmt180 -110.34 -32.72 6.85 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.908 179.951 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 44' ' ' PHE . . . . . . . . . . . . . 72.2 t80 -143.05 111.05 6.0 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.248 -0.433 . . . . 0.0 110.912 -179.919 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 45' ' ' TYR . . . . . 0.5 ' CE1' ' CZ ' ' A' ' 56' ' ' TYR . 18.6 t80 -108.0 122.95 47.88 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.855 -179.99 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 164.94 -179.61 39.47 Favored Glycine 0 N--CA 1.451 -0.32 0 C-N-CA 120.767 -0.73 . . . . 0.0 112.534 179.928 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 47' ' ' LYS . . . . . . . . . . . . . 18.6 mttt -69.4 153.18 43.97 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 120.817 0.341 . . . . 0.0 110.879 -179.975 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 48' ' ' THR . . . . . 0.546 HG21 ' CE1' ' A' ' 50' ' ' PHE . 1.3 p -111.24 177.6 4.61 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.892 179.98 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -104.5 -31.33 9.51 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.835 179.992 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 50' ' ' PHE . . . . . 0.546 ' CE1' HG21 ' A' ' 48' ' ' THR . 54.1 p90 -75.53 -39.19 58.7 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.262 -0.427 . . . . 0.0 110.918 -179.965 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 51' ' ' ALA . . . . . . . . . . . . . . . -131.61 147.13 64.81 Favored Pre-proline 0 C--N 1.33 -0.273 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.093 -179.946 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 52' ' ' PRO . . . . . . . . . . . . . 61.0 Cg_endo -72.96 -172.58 1.01 Allowed 'Trans proline' 0 C--N 1.345 0.372 0 C-N-CA 122.508 2.138 . . . . 0.0 112.395 179.974 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 67.94 -165.48 45.23 Favored Glycine 0 N--CA 1.452 -0.291 0 C-N-CA 120.738 -0.744 . . . . 0.0 112.511 179.973 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 54' ' ' TYR . . . . . . . . . . . . . 69.3 m-85 -107.69 141.55 39.04 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-O 120.84 0.352 . . . . 0.0 110.876 -179.963 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 55' ' ' TRP . . . . . 0.401 ' CZ3' ' HD3' ' A' ' 88' ' ' PRO . 52.6 m95 -132.61 167.17 20.52 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.917 -179.897 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 56' ' ' TYR . . . . . 0.639 ' CE1' ' HB2' ' A' ' 89' ' ' ALA . 3.7 m-85 -121.18 117.09 26.23 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.323 -0.399 . . . . 0.0 110.912 179.997 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 57' ' ' GLY . . . . . 0.446 ' N ' ' CE1' ' A' ' 86' ' ' PHE . . . -81.2 68.26 3.47 Favored Glycine 0 N--CA 1.451 -0.331 0 C-N-CA 120.789 -0.72 . . . . 0.0 112.402 -179.967 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 58' ' ' ILE . . . . . 0.723 HD11 HD13 ' A' ' 92' ' ' ILE . 19.6 mt -73.53 138.04 22.09 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-O 120.807 0.337 . . . . 0.0 111.113 179.998 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -103.63 114.18 28.25 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.841 -179.967 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 60' ' ' LEU . . . . . . . . . . . . . 77.8 mt -69.51 -179.94 1.87 Allowed 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.154 -0.475 . . . . 0.0 110.885 179.972 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 4.9 m-20 -109.41 -34.09 6.63 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.951 -179.977 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 62' ' ' GLN . . . . . 0.407 ' HA ' ' HD3' ' A' ' 63' ' ' PRO . 4.1 mm-40 -108.14 146.63 33.94 Favored Pre-proline 0 C--N 1.329 -0.3 0 CA-C-N 116.321 -0.4 . . . . 0.0 110.942 -179.975 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 63' ' ' PRO . . . . . 0.407 ' HD3' ' HA ' ' A' ' 62' ' ' GLN . 31.7 Cg_exo -58.88 91.93 0.07 OUTLIER 'Trans proline' 0 C--N 1.345 0.368 0 C-N-CA 122.62 2.213 . . . . 0.0 112.172 -179.966 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 64' ' ' THR . . . . . . . . . . . . . 10.1 t -172.89 38.88 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.913 -179.979 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . -93.42 -128.97 5.1 Favored Glycine 0 N--CA 1.45 -0.37 0 C-N-CA 120.786 -0.721 . . . . 0.0 112.48 -179.976 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 66' ' ' LYS . . . . . . . . . . . . . 1.1 mtpm? -135.89 -50.8 0.72 Allowed 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 120.881 0.372 . . . . 0.0 110.874 180.0 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 67' ' ' HIS . . . . . . . . . . . . . 7.1 p80 -128.18 178.99 5.85 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.884 179.911 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 15.5 t0 -101.46 36.46 2.02 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.966 179.999 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 95.66 -37.85 3.3 Favored Glycine 0 N--CA 1.451 -0.351 0 C-N-CA 120.707 -0.759 . . . . 0.0 112.495 -179.997 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 70' ' ' SER . . . . . . . . . . . . . 75.2 p -102.73 162.33 13.02 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-O 120.947 0.403 . . . . 0.0 110.842 -179.91 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 21.4 t -148.07 117.14 1.15 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-N 116.132 -0.485 . . . . 0.0 111.168 179.953 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 72' ' ' PHE . . . . . . . . . . . . . 5.1 m-85 60.4 35.56 20.47 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.14 -0.482 . . . . 0.0 111.002 -179.977 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 80.91 28.26 46.78 Favored Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.679 -0.772 . . . . 0.0 112.597 -179.972 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 74' ' ' VAL . . . . . 0.402 ' O ' ' CE1' ' A' ' 76' ' ' TYR . 21.5 t -133.63 104.89 6.78 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-O 120.799 0.333 . . . . 0.0 111.098 -179.975 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 75' ' ' ARG . . . . . . . . . . . . . 3.6 ttt-85 -77.41 131.47 38.04 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.246 -0.433 . . . . 0.0 111.001 -179.979 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 76' ' ' TYR . . . . . 0.402 ' CE1' ' O ' ' A' ' 74' ' ' VAL . 11.7 m-85 -106.86 -45.63 4.14 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.178 -0.464 . . . . 0.0 110.858 179.956 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 77' ' ' PHE . . . . . 0.431 ' CE1' ' HA3' ' A' ' 57' ' ' GLY . 36.8 p90 -156.29 156.55 34.21 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.924 179.985 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 1.9 t -80.0 114.51 18.97 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.25 -0.432 . . . . 0.0 110.89 179.955 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 79' ' ' CYS . . . . . . . . . . . . . 29.4 p -147.15 152.48 38.5 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.973 -179.936 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 80' ' ' ALA . . . . . 0.73 ' HB1' ' HD2' ' A' ' 81' ' ' PRO . . . -58.45 166.73 2.09 Favored Pre-proline 0 C--N 1.329 -0.29 0 CA-C-N 116.143 -0.48 . . . . 0.0 111.002 179.93 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 81' ' ' PRO . . . . . 0.73 ' HD2' ' HB1' ' A' ' 80' ' ' ALA . 20.5 Cg_endo -60.76 120.95 8.95 Favored 'Trans proline' 0 C--N 1.344 0.29 0 C-N-CA 122.545 2.164 . . . . 0.0 112.168 179.936 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 82' ' ' ARG . . . . . . . . . . . . . 78.1 mtt180 63.11 50.36 3.1 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.143 -0.48 . . . . 0.0 110.876 -179.832 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 83' ' ' HIS . . . . . 0.581 ' ND1' ' HB3' ' A' ' 80' ' ' ALA . 5.8 m170 -123.33 -48.8 1.95 Allowed 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.934 179.933 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . -66.5 121.82 18.68 Favored Glycine 0 N--CA 1.451 -0.304 0 C-N-CA 120.629 -0.796 . . . . 0.0 112.401 179.857 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 85' ' ' VAL . . . . . . . . . . . . . 5.9 m -126.35 132.4 70.43 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-O 120.911 0.386 . . . . 0.0 111.194 -179.98 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 86' ' ' PHE . . . . . 0.446 ' CE1' ' N ' ' A' ' 57' ' ' GLY . 12.9 m-85 -103.66 118.05 35.83 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.991 179.958 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 87' ' ' ALA . . . . . 0.526 ' CB ' HG13 ' A' ' 34' ' ' VAL . . . -134.69 143.61 47.19 Favored Pre-proline 0 C--N 1.33 -0.279 0 CA-C-N 116.215 -0.448 . . . . 0.0 111.058 179.992 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 88' ' ' PRO . . . . . 0.418 ' O ' ' N ' ' A' ' 91' ' ' ARG . 32.5 Cg_exo -57.71 142.1 95.81 Favored 'Trans proline' 0 C--N 1.346 0.401 0 C-N-CA 122.451 2.101 . . . . 0.0 112.397 179.972 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 89' ' ' ALA . . . . . 0.639 ' HB2' ' CE1' ' A' ' 56' ' ' TYR . . . -47.94 -50.98 25.28 Favored 'General case' 0 CA--C 1.521 -0.156 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.255 179.867 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 90' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER -55.87 -24.39 36.72 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 115.716 -0.674 . . . . 0.0 109.801 178.859 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 91' ' ' ARG . . . . . 0.418 ' N ' ' O ' ' A' ' 88' ' ' PRO . 1.0 OUTLIER -90.98 -13.15 33.93 Favored 'General case' 0 N--CA 1.455 -0.219 0 CA-C-N 115.944 -0.571 . . . . 0.0 110.522 179.154 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 92' ' ' ILE . . . . . 0.723 HD13 HD11 ' A' ' 58' ' ' ILE . 62.9 mt -107.09 147.8 11.99 Favored 'Isoleucine or valine' 0 C--O 1.231 0.101 0 CA-C-N 116.432 -0.349 . . . . 0.0 110.895 179.836 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 93' ' ' GLN . . . . . . . . . . . . . 5.7 mt-30 -118.04 168.97 10.05 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.972 179.934 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 94' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -111.48 152.36 27.54 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.859 -179.997 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 95' ' ' ILE . . . . . . . . . . . . . 23.1 mt . . . . . 0 C--N 1.329 -0.297 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.155 179.909 . . . . . . . . 0 0 . 1 . 013 nuclear build core ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.457 -0.078 0 CA-C-O 120.822 0.344 . . . . 0.0 111.063 . . . . . . . . . 0 0 . 1 . 013 nuclear build core ' A' A ' 27' ' ' GLU . . . . . . . . . . . . . 14.3 mt-10 -142.57 168.42 19.78 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.938 179.991 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 27.4 t -68.58 85.06 0.14 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.049 179.957 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 132.62 43.86 0.15 Allowed Glycine 0 N--CA 1.452 -0.265 0 C-N-CA 120.677 -0.773 . . . . 0.0 112.462 179.975 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 2.2 t0 -149.81 152.86 35.86 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 120.774 0.321 . . . . 0.0 110.902 -179.915 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 31' ' ' GLN . . . . . . . . . . . . . 1.6 mt-30 -69.03 141.92 54.72 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.918 179.943 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 5.7 m -143.27 174.84 4.43 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-N 116.247 -0.433 . . . . 0.0 111.141 179.96 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 33' ' ' LEU . . . . . . . . . . . . . 13.8 tp -141.25 105.15 4.75 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.843 179.986 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 34' ' ' VAL . . . . . 0.584 HG13 ' CB ' ' A' ' 87' ' ' ALA . 21.7 t -73.73 123.49 28.98 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.153 -179.982 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 35' ' ' ALA . . . . . . . . . . . . . . . 56.99 25.04 10.19 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.304 179.96 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . 57.29 37.0 78.65 Favored Glycine 0 N--CA 1.45 -0.374 0 C-N-CA 120.803 -0.713 . . . . 0.0 112.572 179.912 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 37' ' ' GLN . . . . . . . . . . . . . 39.0 mt-30 -148.55 -70.17 0.21 Allowed 'General case' 0 C--N 1.33 -0.279 0 CA-C-O 120.731 0.3 . . . . 0.0 110.971 179.98 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 38' ' ' LYS . . . . . . . . . . . . . 62.3 mttt -67.73 105.78 2.03 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.913 179.973 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 39' ' ' GLN . . . . . . . . . . . . . 0.2 OUTLIER -82.2 132.51 35.24 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.886 -179.996 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -158.08 -174.64 28.04 Favored Glycine 0 N--CA 1.451 -0.333 0 C-N-CA 120.658 -0.782 . . . . 0.0 112.53 179.923 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 41' ' ' ILE . . . . . 0.438 ' N ' HG23 ' A' ' 58' ' ' ILE . 15.7 mt -127.41 135.2 63.98 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-O 120.845 0.355 . . . . 0.0 111.046 -179.967 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 42' ' ' VAL . . . . . . . . . . . . . 21.5 t -62.82 120.97 10.71 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.175 179.956 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 43' ' ' ARG . . . . . . . . . . . . . 30.9 mmt180 -110.08 -32.1 7.13 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 116.178 -0.464 . . . . 0.0 110.932 -179.991 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 44' ' ' PHE . . . . . . . . . . . . . 63.4 t80 -147.4 115.53 6.55 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.896 179.924 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 45' ' ' TYR . . . . . 0.496 ' CE1' ' CE1' ' A' ' 56' ' ' TYR . 22.1 t80 -113.1 113.54 25.55 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.967 179.887 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . -175.96 -161.06 24.51 Favored Glycine 0 N--CA 1.452 -0.293 0 C-N-CA 120.712 -0.756 . . . . 0.0 112.474 -179.967 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 47' ' ' LYS . . . . . 0.424 ' HE2' ' CE1' ' A' ' 54' ' ' TYR . 27.2 mttm -88.4 168.95 12.22 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 120.795 0.331 . . . . 0.0 110.893 -179.925 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 48' ' ' THR . . . . . 0.645 HG22 ' CE2' ' A' ' 76' ' ' TYR . 67.1 p -140.04 175.09 9.88 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.949 -179.974 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 3.9 t70 -109.2 -31.52 7.55 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.931 179.994 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 50' ' ' PHE . . . . . 0.598 ' CZ ' HG21 ' A' ' 48' ' ' THR . 28.2 p90 -65.52 -36.07 82.74 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.97 179.959 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 51' ' ' ALA . . . . . 0.419 ' N ' ' CD1' ' A' ' 50' ' ' PHE . . . -140.98 148.13 50.8 Favored Pre-proline 0 C--N 1.329 -0.318 0 CA-C-N 116.209 -0.45 . . . . 0.0 111.097 -179.99 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 52' ' ' PRO . . . . . . . . . . . . . 59.7 Cg_endo -72.6 176.05 9.35 Favored 'Trans proline' 0 C--N 1.345 0.364 0 C-N-CA 122.508 2.139 . . . . 0.0 112.281 -179.981 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 67.72 175.19 8.33 Favored Glycine 0 N--CA 1.452 -0.286 0 C-N-CA 120.727 -0.749 . . . . 0.0 112.493 -179.934 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 54' ' ' TYR . . . . . 0.424 ' CE1' ' HE2' ' A' ' 47' ' ' LYS . 5.9 m-85 -83.71 148.91 26.81 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-O 120.829 0.347 . . . . 0.0 110.944 -179.983 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 55' ' ' TRP . . . . . . . . . . . . . 72.0 m95 -134.44 164.48 27.34 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.923 -179.978 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 56' ' ' TYR . . . . . 0.642 ' HE1' ' HB2' ' A' ' 89' ' ' ALA . 27.0 m-85 -113.55 112.41 23.5 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.908 179.979 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . -77.21 65.93 2.96 Favored Glycine 0 N--CA 1.451 -0.324 0 C-N-CA 120.727 -0.749 . . . . 0.0 112.396 179.909 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 58' ' ' ILE . . . . . 0.453 HD11 HD13 ' A' ' 92' ' ' ILE . 22.5 mt -74.65 152.34 6.78 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.271 0 CA-C-O 120.774 0.321 . . . . 0.0 111.215 -179.976 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 10.8 tm-20 -121.67 120.93 36.15 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 116.258 -0.428 . . . . 0.0 110.862 -179.968 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 60' ' ' LEU . . . . . . . . . . . . . 71.6 mt -79.88 -179.9 7.21 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-N 116.13 -0.486 . . . . 0.0 110.953 179.998 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -108.35 -29.0 9.08 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.028 -179.953 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 62' ' ' GLN . . . . . 0.414 ' HA ' ' HD3' ' A' ' 63' ' ' PRO . 8.2 mt-30 -108.63 143.41 27.46 Favored Pre-proline 0 C--N 1.329 -0.313 0 CA-C-N 116.382 -0.372 . . . . 0.0 110.973 -179.924 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 63' ' ' PRO . . . . . 0.414 ' HD3' ' HA ' ' A' ' 62' ' ' GLN . 39.4 Cg_exo -60.5 89.87 0.08 OUTLIER 'Trans proline' 0 C--N 1.346 0.4 0 C-N-CA 122.488 2.126 . . . . 0.0 112.18 179.928 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 64' ' ' THR . . . . . . . . . . . . . 10.2 t -170.89 35.97 0.02 OUTLIER 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.294 -0.412 . . . . 0.0 110.967 -179.976 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . -87.02 -95.3 0.88 Allowed Glycine 0 N--CA 1.451 -0.362 0 C-N-CA 120.684 -0.769 . . . . 0.0 112.522 -179.994 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 66' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -172.91 -47.42 0.02 OUTLIER 'General case' 0 C--N 1.328 -0.353 0 CA-C-O 120.854 0.359 . . . . 0.0 110.887 -179.982 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 67' ' ' HIS . . . . . . . . . . . . . 11.5 p80 -135.38 167.5 20.93 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.871 179.915 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -95.8 42.68 1.09 Allowed 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.898 179.945 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 87.33 -53.39 4.4 Favored Glycine 0 N--CA 1.452 -0.295 0 C-N-CA 120.717 -0.754 . . . . 0.0 112.492 179.966 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 70' ' ' SER . . . . . . . . . . . . . 93.8 p -79.05 143.82 35.23 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-O 120.773 0.32 . . . . 0.0 110.952 -179.992 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 71' ' ' VAL . . . . . 0.534 HG12 ' CD2' ' A' ' 72' ' ' PHE . 21.4 t -138.24 112.13 8.06 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.329 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.125 -179.981 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 72' ' ' PHE . . . . . 0.534 ' CD2' HG12 ' A' ' 71' ' ' VAL . 48.0 m-85 60.94 31.04 19.96 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.273 -0.421 . . . . 0.0 110.951 -179.933 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 86.11 29.49 25.36 Favored Glycine 0 N--CA 1.451 -0.304 0 C-N-CA 120.715 -0.755 . . . . 0.0 112.528 -179.997 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 21.5 t -136.77 110.33 8.82 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-O 120.849 0.357 . . . . 0.0 111.103 -179.946 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 75' ' ' ARG . . . . . . . . . . . . . 25.8 ttm-85 -81.47 143.81 31.81 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.132 -0.486 . . . . 0.0 110.91 -179.979 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 76' ' ' TYR . . . . . 0.645 ' CE2' HG22 ' A' ' 48' ' ' THR . 24.5 m-85 -120.4 -44.48 2.47 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.837 179.992 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 77' ' ' PHE . . . . . . . . . . . . . 8.2 p90 -157.19 156.51 32.73 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.907 -179.891 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 1.2 m -84.64 95.63 8.95 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.117 -0.492 . . . . 0.0 110.883 179.912 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 79' ' ' CYS . . . . . . . . . . . . . 13.9 p -122.85 159.3 28.44 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.288 -0.414 . . . . 0.0 110.976 -179.942 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 80' ' ' ALA . . . . . 0.742 ' HB1' ' HD2' ' A' ' 81' ' ' PRO . . . -59.05 166.68 2.48 Favored Pre-proline 0 C--N 1.328 -0.343 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.011 179.944 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 81' ' ' PRO . . . . . 0.742 ' HD2' ' HB1' ' A' ' 80' ' ' ALA . 35.7 Cg_endo -65.09 118.26 5.28 Favored 'Trans proline' 0 C--N 1.345 0.365 0 C-N-CA 122.491 2.127 . . . . 0.0 112.196 179.958 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 82' ' ' ARG . . . . . . . . . . . . . 1.1 mtm-85 62.1 46.71 6.16 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.844 -179.944 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 83' ' ' HIS . . . . . 0.711 ' CG ' ' HB3' ' A' ' 80' ' ' ALA . 8.7 m170 -120.68 -43.36 2.48 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.899 179.98 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . -61.07 151.5 41.91 Favored Glycine 0 N--CA 1.451 -0.326 0 C-N-CA 120.708 -0.758 . . . . 0.0 112.494 -179.983 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 85' ' ' VAL . . . . . . . . . . . . . 15.2 m -151.55 129.4 2.49 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-O 120.861 0.362 . . . . 0.0 111.236 -179.929 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 86' ' ' PHE . . . . . . . . . . . . . 8.4 m-85 -102.45 121.87 43.18 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.81 179.985 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 87' ' ' ALA . . . . . 0.584 ' CB ' HG13 ' A' ' 34' ' ' VAL . . . -143.0 145.52 33.47 Favored Pre-proline 0 C--N 1.33 -0.258 0 CA-C-N 116.171 -0.468 . . . . 0.0 111.161 179.943 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 88' ' ' PRO . . . . . . . . . . . . . 32.0 Cg_exo -58.29 137.0 78.22 Favored 'Trans proline' 0 C--N 1.345 0.365 0 C-N-CA 122.575 2.183 . . . . 0.0 112.235 -179.972 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 89' ' ' ALA . . . . . 0.642 ' HB2' ' HE1' ' A' ' 56' ' ' TYR . . . -48.38 -50.96 28.67 Favored 'General case' 0 CA--C 1.521 -0.145 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.316 179.82 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 90' ' ' SER . . . . . . . . . . . . . 51.2 p -55.96 -24.48 38.67 Favored 'General case' 0 N--CA 1.454 -0.246 0 CA-C-N 115.701 -0.681 . . . . 0.0 109.782 178.692 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 91' ' ' ARG . . . . . . . . . . . . . 1.0 OUTLIER -88.22 -14.66 37.96 Favored 'General case' 0 N--CA 1.455 -0.199 0 CA-C-N 115.808 -0.633 . . . . 0.0 110.405 179.062 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 92' ' ' ILE . . . . . 0.566 HD11 ' O ' ' A' ' 87' ' ' ALA . 22.2 mt -108.45 150.29 11.22 Favored 'Isoleucine or valine' 0 C--O 1.231 0.114 0 CA-C-O 120.84 0.353 . . . . 0.0 111.089 179.887 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 93' ' ' GLN . . . . . . . . . . . . . 1.8 mp0 -110.95 169.68 8.6 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.87 179.98 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 94' ' ' ARG . . . . . . . . . . . . . 9.3 ttt-85 -121.59 119.27 31.42 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.189 -0.459 . . . . 0.0 110.876 -179.99 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 95' ' ' ILE . . . . . . . . . . . . . 4.5 mt . . . . . 0 C--N 1.329 -0.289 0 CA-C-N 116.185 -0.461 . . . . 0.0 111.115 -180.0 . . . . . . . . 0 0 . 1 . 014 nuclear build core ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.231 0.119 0 CA-C-O 120.804 0.335 . . . . 0.0 111.075 . . . . . . . . . 0 0 . 1 . 014 nuclear build core ' A' A ' 27' ' ' GLU . . . . . . . . . . . . . 41.7 mt-10 -140.64 174.87 10.09 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.871 -179.972 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 21.5 t -75.27 105.48 4.27 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.247 -0.433 . . . . 0.0 111.136 179.961 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 114.51 35.63 1.4 Allowed Glycine 0 N--CA 1.452 -0.291 0 C-N-CA 120.699 -0.762 . . . . 0.0 112.537 -179.969 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -149.0 150.88 33.57 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-O 120.749 0.309 . . . . 0.0 110.934 -179.952 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 31' ' ' GLN . . . . . 0.721 ' HB3' HD12 ' A' ' 95' ' ' ILE . 8.8 mp0 -70.0 151.35 45.67 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.282 -0.417 . . . . 0.0 110.831 -179.995 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 14.0 m -152.38 179.46 0.43 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.261 -0.427 . . . . 0.0 111.153 179.998 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 33' ' ' LEU . . . . . 0.636 HD11 ' C ' ' A' ' 37' ' ' GLN . 44.3 tp -143.39 117.86 9.71 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.856 179.943 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 34' ' ' VAL . . . . . 0.411 HG13 ' CB ' ' A' ' 87' ' ' ALA . 21.7 t -85.57 129.6 37.7 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.207 -0.452 . . . . 0.0 111.278 -179.839 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 35' ' ' ALA . . . . . . . . . . . . . . . 53.93 25.91 5.8 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.149 -0.478 . . . . 0.0 111.394 179.893 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . 57.61 33.82 68.16 Favored Glycine 0 N--CA 1.451 -0.353 0 C-N-CA 120.725 -0.75 . . . . 0.0 112.551 179.958 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 37' ' ' GLN . . . . . 0.636 ' C ' HD11 ' A' ' 33' ' ' LEU . 94.2 mt-30 -146.91 -70.6 0.24 Allowed 'General case' 0 C--N 1.33 -0.281 0 CA-C-O 120.847 0.356 . . . . 0.0 110.993 -179.951 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 38' ' ' LYS . . . . . 0.467 ' O ' HD12 ' A' ' 33' ' ' LEU . 2.7 mtmp? -67.11 110.41 3.42 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.947 -179.98 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 39' ' ' GLN . . . . . . . . . . . . . 1.3 tm0? -91.35 137.98 31.94 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.921 179.964 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -164.14 -173.22 32.56 Favored Glycine 0 N--CA 1.45 -0.371 0 C-N-CA 120.82 -0.705 . . . . 0.0 112.564 179.939 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 26.6 mt -122.63 132.01 72.08 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-O 120.804 0.335 . . . . 0.0 111.146 179.958 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 42' ' ' VAL . . . . . . . . . . . . . 33.8 t -59.53 124.29 13.53 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.081 179.986 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 43' ' ' ARG . . . . . . . . . . . . . 1.6 mmm-85 -109.77 -31.11 7.56 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.957 179.985 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 44' ' ' PHE . . . . . . . . . . . . . 28.9 t80 -147.59 112.14 5.31 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.892 179.966 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 45' ' ' TYR . . . . . 0.495 ' CE1' ' CZ ' ' A' ' 56' ' ' TYR . 15.2 t80 -113.27 141.9 46.46 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.894 -179.955 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 144.95 -174.53 24.99 Favored Glycine 0 N--CA 1.451 -0.329 0 C-N-CA 120.757 -0.735 . . . . 0.0 112.501 179.951 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 47' ' ' LYS . . . . . 0.415 ' HG3' ' CD1' ' A' ' 54' ' ' TYR . 13.6 mttm -74.02 161.54 29.96 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-O 120.797 0.332 . . . . 0.0 110.88 -179.966 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 48' ' ' THR . . . . . . . . . . . . . 75.2 p -119.07 -176.91 3.22 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.853 -179.975 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 1.8 t0 -113.41 15.65 19.09 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.378 -179.985 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 50' ' ' PHE . . . . . 0.45 ' CD1' ' N ' ' A' ' 51' ' ' ALA . 42.8 p90 -124.79 -41.28 2.13 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 120.74 0.305 . . . . 0.0 110.955 -179.993 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 51' ' ' ALA . . . . . 0.45 ' N ' ' CD1' ' A' ' 50' ' ' PHE . . . -129.25 149.21 72.06 Favored Pre-proline 0 C--N 1.329 -0.306 0 CA-C-N 116.311 -0.404 . . . . 0.0 111.106 -179.995 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 52' ' ' PRO . . . . . . . . . . . . . 55.6 Cg_endo -70.19 178.04 5.25 Favored 'Trans proline' 0 C--N 1.344 0.306 0 C-N-CA 122.608 2.205 . . . . 0.0 112.274 -179.971 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 72.96 -169.91 52.35 Favored Glycine 0 N--CA 1.451 -0.345 0 C-N-CA 120.717 -0.754 . . . . 0.0 112.542 -179.95 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 54' ' ' TYR . . . . . 0.415 ' CD1' ' HG3' ' A' ' 47' ' ' LYS . 99.7 m-85 -111.28 134.38 52.91 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-O 120.849 0.357 . . . . 0.0 110.932 179.933 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 55' ' ' TRP . . . . . . . . . . . . . 42.1 m95 -120.43 157.81 28.53 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.893 179.984 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 56' ' ' TYR . . . . . 0.507 ' CE1' ' HB2' ' A' ' 89' ' ' ALA . 4.1 m-85 -110.61 123.82 50.7 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.944 -179.901 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . -89.52 64.11 3.23 Favored Glycine 0 N--CA 1.452 -0.253 0 C-N-CA 120.768 -0.729 . . . . 0.0 112.416 179.891 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 58' ' ' ILE . . . . . 0.657 HD11 HD13 ' A' ' 92' ' ' ILE . 4.8 mt -71.72 144.7 13.01 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-O 120.783 0.325 . . . . 0.0 111.098 179.988 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 1.4 tm-20 -109.08 137.56 46.8 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.187 -0.461 . . . . 0.0 110.891 179.961 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 60' ' ' LEU . . . . . . . . . . . . . 65.1 mt -93.89 168.88 10.69 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.892 -179.931 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 20.2 t0 -95.79 -31.34 13.23 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.917 179.974 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 62' ' ' GLN . . . . . . . . . . . . . 5.5 pt20 -111.27 153.41 44.04 Favored Pre-proline 0 C--N 1.33 -0.274 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.865 -179.879 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 56.6 Cg_endo -70.67 80.05 1.17 Allowed 'Trans proline' 0 C--N 1.344 0.328 0 C-N-CA 122.605 2.203 . . . . 0.0 112.302 179.943 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 64' ' ' THR . . . . . . . . . . . . . 65.5 p -156.73 31.33 0.31 Allowed 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.075 -0.511 . . . . 0.0 110.823 -179.993 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . -83.85 -114.62 0.61 Allowed Glycine 0 N--CA 1.451 -0.309 0 C-N-CA 120.699 -0.762 . . . . 0.0 112.521 -179.969 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 66' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -151.68 -48.16 0.11 Allowed 'General case' 0 C--N 1.329 -0.293 0 CA-C-O 120.851 0.357 . . . . 0.0 110.904 -179.963 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 67' ' ' HIS . . . . . . . . . . . . . 7.2 p80 -124.37 175.92 6.79 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.973 -179.982 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 1.3 m-20 -97.94 37.25 1.43 Allowed 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.231 -0.44 . . . . 0.0 110.924 179.97 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 91.03 -50.94 3.14 Favored Glycine 0 N--CA 1.451 -0.325 0 C-N-CA 120.723 -0.751 . . . . 0.0 112.489 -179.998 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 70' ' ' SER . . . . . . . . . . . . . 21.4 p -88.31 143.3 27.1 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-O 120.79 0.328 . . . . 0.0 110.927 -179.938 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 71' ' ' VAL . . . . . 0.782 HG12 ' CD2' ' A' ' 72' ' ' PHE . 24.6 t -127.32 114.6 37.23 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.219 -0.446 . . . . 0.0 111.078 179.982 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 72' ' ' PHE . . . . . 0.782 ' CD2' HG12 ' A' ' 71' ' ' VAL . 25.3 m-85 60.32 31.04 20.3 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.956 -179.917 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 86.48 28.56 26.89 Favored Glycine 0 N--CA 1.451 -0.325 0 C-N-CA 120.685 -0.769 . . . . 0.0 112.475 179.969 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 21.5 t -130.16 100.2 4.92 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-O 120.91 0.386 . . . . 0.0 111.161 179.991 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 75' ' ' ARG . . . . . . . . . . . . . 4.8 ttt180 -80.26 112.37 17.52 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.116 -0.493 . . . . 0.0 110.879 -179.942 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 76' ' ' TYR . . . . . . . . . . . . . 58.0 m-85 -88.16 -40.37 13.79 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.911 -180.0 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 77' ' ' PHE . . . . . . . . . . . . . 23.3 p90 -154.1 153.39 31.78 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.889 179.892 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 78' ' ' THR . . . . . 0.418 HG23 ' O ' ' A' ' 78' ' ' THR . 5.1 t -82.97 111.56 18.95 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.145 -0.48 . . . . 0.0 110.812 -179.999 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 79' ' ' CYS . . . . . . . . . . . . . 18.4 p -143.1 170.71 15.21 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.959 -179.977 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 80' ' ' ALA . . . . . 0.765 ' HB3' ' ND1' ' A' ' 83' ' ' HIS . . . -70.67 167.06 30.42 Favored Pre-proline 0 C--N 1.329 -0.307 0 CA-C-N 116.121 -0.49 . . . . 0.0 110.969 179.938 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 81' ' ' PRO . . . . . 0.753 ' HD2' ' HB1' ' A' ' 80' ' ' ALA . 34.7 Cg_endo -64.86 126.83 17.33 Favored 'Trans proline' 0 C--N 1.345 0.356 0 C-N-CA 122.433 2.089 . . . . 0.0 112.224 179.934 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 82' ' ' ARG . . . . . . . . . . . . . 76.2 mtt180 62.03 39.34 13.32 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.132 -0.486 . . . . 0.0 110.957 -179.914 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 83' ' ' HIS . . . . . 0.765 ' ND1' ' HB3' ' A' ' 80' ' ' ALA . 9.1 m170 -114.55 -37.66 4.23 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.868 179.971 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . -76.91 152.77 41.03 Favored Glycine 0 N--CA 1.451 -0.332 0 C-N-CA 120.746 -0.74 . . . . 0.0 112.529 179.997 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 85' ' ' VAL . . . . . . . . . . . . . 16.1 m -153.9 135.22 5.23 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.329 0 CA-C-O 120.82 0.343 . . . . 0.0 111.12 179.934 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 86' ' ' PHE . . . . . . . . . . . . . 7.2 m-85 -111.09 117.09 32.34 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.99 -179.989 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 87' ' ' ALA . . . . . 0.497 ' O ' HD11 ' A' ' 92' ' ' ILE . . . -135.42 145.25 52.87 Favored Pre-proline 0 C--N 1.329 -0.324 0 CA-C-N 116.262 -0.426 . . . . 0.0 111.053 179.906 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 88' ' ' PRO . . . . . 0.409 ' O ' ' N ' ' A' ' 91' ' ' ARG . 33.6 Cg_exo -59.62 145.0 99.29 Favored 'Trans proline' 0 C--N 1.344 0.337 0 C-N-CA 122.562 2.174 . . . . 0.0 112.313 -179.978 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 89' ' ' ALA . . . . . 0.507 ' HB2' ' CE1' ' A' ' 56' ' ' TYR . . . -48.45 -50.91 29.43 Favored 'General case' 0 CA--C 1.521 -0.158 0 CA-C-N 116.187 -0.461 . . . . 0.0 110.247 179.84 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 90' ' ' SER . . . . . . . . . . . . . 1.2 m -56.0 -24.37 38.51 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 115.681 -0.69 . . . . 0.0 109.749 178.766 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 91' ' ' ARG . . . . . 0.409 ' N ' ' O ' ' A' ' 88' ' ' PRO . 0.0 OUTLIER -89.75 -13.9 35.78 Favored 'General case' 0 N--CA 1.454 -0.226 0 CA-C-N 115.926 -0.579 . . . . 0.0 110.515 179.125 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 92' ' ' ILE . . . . . 0.657 HD13 HD11 ' A' ' 58' ' ' ILE . 48.7 mt -110.31 153.51 12.07 Favored 'Isoleucine or valine' 0 C--O 1.23 0.074 0 CA-C-N 116.378 -0.374 . . . . 0.0 111.072 179.814 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 93' ' ' GLN . . . . . 0.407 ' N ' HG22 ' A' ' 92' ' ' ILE . 0.4 OUTLIER -116.24 179.81 3.89 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.805 -179.98 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 94' ' ' ARG . . . . . . . . . . . . . 4.1 ttp180 -122.76 144.08 49.41 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.885 -179.983 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 95' ' ' ILE . . . . . 0.721 HD12 ' HB3' ' A' ' 31' ' ' GLN . 22.0 mt . . . . . 0 C--N 1.33 -0.265 0 CA-C-N 116.174 -0.466 . . . . 0.0 111.177 179.931 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.231 0.101 0 CA-C-O 120.829 0.347 . . . . 0.0 111.121 . . . . . . . . . 0 0 . 1 . 015 nuclear build core ' A' A ' 27' ' ' GLU . . . . . . . . . . . . . 4.8 mt-10 -124.31 179.51 4.88 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.953 179.976 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 21.4 t -75.21 104.98 3.83 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.241 -0.436 . . . . 0.0 111.172 179.951 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 108.13 34.55 2.72 Favored Glycine 0 N--CA 1.451 -0.328 0 C-N-CA 120.732 -0.747 . . . . 0.0 112.529 -179.941 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 30' ' ' ASP . . . . . 0.427 ' C ' HG23 ' A' ' 41' ' ' ILE . 0.8 OUTLIER -138.06 145.29 41.59 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-O 120.814 0.34 . . . . 0.0 110.879 180.0 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 31' ' ' GLN . . . . . 0.545 ' HB3' HD12 ' A' ' 95' ' ' ILE . 0.7 OUTLIER -60.01 144.78 48.48 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.932 -179.962 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 12.0 m -150.02 174.46 1.08 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.372 0 CA-C-N 116.286 -0.415 . . . . 0.0 111.208 179.953 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 33' ' ' LEU . . . . . 0.469 HD11 ' O ' ' A' ' 37' ' ' GLN . 28.8 tp -138.71 107.1 5.81 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.886 -179.958 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 34' ' ' VAL . . . . . 0.416 HG22 HD12 ' A' ' 58' ' ' ILE . 21.5 t -77.32 125.58 37.17 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-N 116.236 -0.438 . . . . 0.0 111.22 -179.978 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 35' ' ' ALA . . . . . . . . . . . . . . . 58.2 26.23 13.55 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.163 -0.471 . . . . 0.0 111.333 -179.967 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . 56.14 31.39 59.01 Favored Glycine 0 C--N 1.331 0.279 0 C-N-CA 120.775 -0.726 . . . . 0.0 112.607 179.973 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 37' ' ' GLN . . . . . 0.469 ' O ' HD11 ' A' ' 33' ' ' LEU . 37.3 mt-30 -145.3 -70.42 0.27 Allowed 'General case' 0 C--N 1.329 -0.287 0 CA-C-O 120.795 0.331 . . . . 0.0 110.877 -179.944 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 38' ' ' LYS . . . . . . . . . . . . . 32.0 mttt -67.57 104.05 1.5 Allowed 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.927 179.958 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 39' ' ' GLN . . . . . 0.4 ' NE2' HD13 ' A' ' 95' ' ' ILE . 4.2 tt0 -82.93 148.03 27.9 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.875 -179.972 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -175.68 -164.13 29.59 Favored Glycine 0 N--CA 1.451 -0.363 0 C-N-CA 120.787 -0.721 . . . . 0.0 112.541 179.945 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 41' ' ' ILE . . . . . 0.441 ' C ' HG23 ' A' ' 58' ' ' ILE . 3.8 mp -134.61 139.14 48.33 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-O 120.856 0.36 . . . . 0.0 111.156 179.986 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 42' ' ' VAL . . . . . . . . . . . . . 31.0 t -70.47 127.08 31.91 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.029 179.953 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 43' ' ' ARG . . . . . . . . . . . . . 15.6 mmt180 -110.72 -32.35 6.89 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.207 -0.452 . . . . 0.0 110.923 -179.957 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 44' ' ' PHE . . . . . . . . . . . . . 72.6 t80 -141.21 108.23 5.45 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.859 179.978 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 45' ' ' TYR . . . . . 0.497 ' CE1' ' CZ ' ' A' ' 56' ' ' TYR . 12.5 t80 -109.53 131.96 54.58 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.881 179.949 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 158.82 -137.71 5.33 Favored Glycine 0 N--CA 1.451 -0.36 0 C-N-CA 120.68 -0.771 . . . . 0.0 112.53 -179.968 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 47' ' ' LYS . . . . . . . . . . . . . 11.1 mttm -104.18 154.16 20.08 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-O 120.815 0.341 . . . . 0.0 110.922 179.996 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 48' ' ' THR . . . . . . . . . . . . . 25.5 p -117.86 -179.22 3.69 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.224 -0.443 . . . . 0.0 110.874 179.875 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 2.2 t0 -110.91 -26.55 9.25 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.212 -0.449 . . . . 0.0 111.026 -179.836 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 50' ' ' PHE . . . . . 0.451 ' CD1' ' N ' ' A' ' 51' ' ' ALA . 22.6 p90 -72.32 -34.12 67.86 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.422 -0.354 . . . . 0.0 111.117 -179.831 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 51' ' ' ALA . . . . . 0.451 ' N ' ' CD1' ' A' ' 50' ' ' PHE . . . -148.9 147.81 25.43 Favored Pre-proline 0 C--N 1.329 -0.3 0 CA-C-N 116.3 -0.409 . . . . 0.0 111.237 -179.931 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 52' ' ' PRO . . . . . . . . . . . . . 74.0 Cg_endo -75.3 165.34 31.06 Favored 'Trans proline' 0 C--N 1.344 0.327 0 C-N-CA 122.651 2.234 . . . . 0.0 112.366 179.954 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 99.68 -168.98 21.9 Favored Glycine 0 N--CA 1.451 -0.317 0 C-N-CA 120.734 -0.746 . . . . 0.0 112.56 179.917 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 54' ' ' TYR . . . . . . . . . . . . . 64.9 m-85 -102.31 125.87 49.15 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-O 120.825 0.345 . . . . 0.0 110.893 179.994 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 55' ' ' TRP . . . . . 0.408 ' CZ3' ' HD3' ' A' ' 88' ' ' PRO . 63.9 m95 -127.02 156.77 41.11 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.912 179.976 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 56' ' ' TYR . . . . . 0.576 ' CE1' ' HB2' ' A' ' 89' ' ' ALA . 4.2 m-85 -113.32 122.71 48.24 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.254 -0.43 . . . . 0.0 110.95 -179.961 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 57' ' ' GLY . . . . . 0.447 ' CA ' ' CE1' ' A' ' 86' ' ' PHE . . . -84.04 68.03 3.6 Favored Glycine 0 N--CA 1.45 -0.404 0 C-N-CA 120.775 -0.726 . . . . 0.0 112.427 179.865 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 58' ' ' ILE . . . . . 0.678 HD11 HD13 ' A' ' 92' ' ' ILE . 19.7 mt -73.58 138.59 20.97 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-O 120.812 0.339 . . . . 0.0 111.138 -179.955 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -114.07 112.38 23.15 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.915 179.948 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 60' ' ' LEU . . . . . 0.673 HD13 HG23 ' A' ' 64' ' ' THR . 8.1 mt -73.21 173.06 9.99 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.246 -0.434 . . . . 0.0 110.865 -179.972 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 8.3 p-10 -102.0 -31.59 10.58 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.856 179.957 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 62' ' ' GLN . . . . . 0.425 ' HG3' HG22 ' A' ' 64' ' ' THR . 4.1 pt20 -106.5 157.49 34.92 Favored Pre-proline 0 C--N 1.329 -0.301 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.835 -179.974 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 37.2 Cg_endo -65.86 82.58 0.25 Allowed 'Trans proline' 0 C--N 1.345 0.345 0 C-N-CA 122.533 2.155 . . . . 0.0 112.263 179.937 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 64' ' ' THR . . . . . 0.673 HG23 HD13 ' A' ' 60' ' ' LEU . 9.1 t -156.01 34.55 0.34 Allowed 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.108 -0.496 . . . . 0.0 110.839 -179.995 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . -97.84 -131.51 7.15 Favored Glycine 0 N--CA 1.45 -0.407 0 C-N-CA 120.732 -0.747 . . . . 0.0 112.547 179.956 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 66' ' ' LYS . . . . . . . . . . . . . 4.3 mtmm -144.6 -58.36 0.36 Allowed 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 120.819 0.343 . . . . 0.0 110.9 -179.969 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 67' ' ' HIS . . . . . . . . . . . . . 6.9 p80 -110.72 164.51 12.68 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.887 179.945 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 45.6 t0 -97.76 36.52 1.52 Allowed 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.209 -0.451 . . . . 0.0 110.946 -179.997 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 96.75 -32.1 6.91 Favored Glycine 0 N--CA 1.45 -0.369 0 C-N-CA 120.766 -0.73 . . . . 0.0 112.47 179.955 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 70' ' ' SER . . . . . . . . . . . . . 12.2 p -114.13 141.93 46.86 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-O 120.885 0.374 . . . . 0.0 110.844 179.988 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 71' ' ' VAL . . . . . 0.636 HG12 ' CD2' ' A' ' 72' ' ' PHE . 21.6 t -131.07 111.26 19.43 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.252 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.137 179.929 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 72' ' ' PHE . . . . . 0.636 ' CD2' HG12 ' A' ' 71' ' ' VAL . 53.4 m-85 61.09 30.88 19.7 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.999 -179.952 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 98.8 -27.62 18.97 Favored Glycine 0 N--CA 1.452 -0.26 0 C-N-CA 120.728 -0.749 . . . . 0.0 112.454 -179.971 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 22.8 t -75.55 135.35 27.29 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-O 120.834 0.35 . . . . 0.0 111.09 -179.934 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 75' ' ' ARG . . . . . 0.503 HH21 HG23 ' A' ' 78' ' ' THR . 19.2 ttt180 -107.71 144.44 34.81 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.911 179.992 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 76' ' ' TYR . . . . . 0.403 ' CD1' ' N ' ' A' ' 76' ' ' TYR . 3.9 m-85 -123.42 -44.06 2.15 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.944 179.932 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 77' ' ' PHE . . . . . . . . . . . . . 28.5 p90 -162.88 177.7 9.03 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.866 179.97 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 78' ' ' THR . . . . . 0.503 HG23 HH21 ' A' ' 75' ' ' ARG . 0.7 OUTLIER -99.67 113.16 25.43 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.913 179.921 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 79' ' ' CYS . . . . . . . . . . . . . 30.2 p -142.9 152.66 42.32 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.27 -0.423 . . . . 0.0 110.924 179.955 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 80' ' ' ALA . . . . . 0.593 ' HB3' ' CD2' ' A' ' 83' ' ' HIS . . . -66.79 168.26 11.09 Favored Pre-proline 0 C--N 1.329 -0.325 0 CA-C-N 116.215 -0.448 . . . . 0.0 111.054 -179.984 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 81' ' ' PRO . . . . . 0.527 ' HD2' ' HB1' ' A' ' 80' ' ' ALA . 41.7 Cg_exo -56.91 122.49 11.91 Favored 'Trans proline' 0 C--N 1.344 0.293 0 C-N-CA 122.584 2.19 . . . . 0.0 112.306 -179.991 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 82' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER 62.37 51.91 3.23 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.169 -0.469 . . . . 0.0 111.082 179.845 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 83' ' ' HIS . . . . . 0.593 ' CD2' ' HB3' ' A' ' 80' ' ' ALA . 1.1 m80 -124.77 -50.42 1.72 Allowed 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.861 179.92 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . -66.05 142.36 43.04 Favored Glycine 0 N--CA 1.451 -0.338 0 C-N-CA 120.748 -0.739 . . . . 0.0 112.536 179.928 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 85' ' ' VAL . . . . . . . . . . . . . 6.9 m -146.99 129.04 6.93 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-O 120.862 0.363 . . . . 0.0 111.076 179.957 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 86' ' ' PHE . . . . . 0.447 ' CE1' ' CA ' ' A' ' 57' ' ' GLY . 17.0 m-85 -108.12 114.9 29.14 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.106 -0.497 . . . . 0.0 110.85 -179.977 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 87' ' ' ALA . . . . . 0.55 ' O ' HD11 ' A' ' 92' ' ' ILE . . . -136.68 146.7 56.49 Favored Pre-proline 0 C--N 1.33 -0.281 0 CA-C-N 116.14 -0.482 . . . . 0.0 111.178 179.916 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 88' ' ' PRO . . . . . 0.423 ' O ' ' N ' ' A' ' 91' ' ' ARG . 34.5 Cg_exo -57.7 142.84 96.06 Favored 'Trans proline' 0 C--N 1.345 0.352 0 C-N-CA 122.561 2.174 . . . . 0.0 112.324 -179.942 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 89' ' ' ALA . . . . . 0.576 ' HB2' ' CE1' ' A' ' 56' ' ' TYR . . . -48.04 -50.75 26.82 Favored 'General case' 0 C--O 1.231 0.117 0 CA-C-N 116.101 -0.5 . . . . 0.0 110.261 179.853 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 90' ' ' SER . . . . . . . . . . . . . 42.6 m -55.75 -24.43 35.27 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 115.708 -0.678 . . . . 0.0 109.733 178.828 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 91' ' ' ARG . . . . . 0.423 ' N ' ' O ' ' A' ' 88' ' ' PRO . 3.4 mtm180 -89.41 -14.81 34.65 Favored 'General case' 0 N--CA 1.456 -0.172 0 CA-C-N 115.857 -0.611 . . . . 0.0 110.472 179.059 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 92' ' ' ILE . . . . . 0.678 HD13 HD11 ' A' ' 58' ' ' ILE . 48.2 mt -107.03 158.3 6.99 Favored 'Isoleucine or valine' 0 C--O 1.231 0.128 0 CA-C-N 116.379 -0.373 . . . . 0.0 111.014 179.793 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 93' ' ' GLN . . . . . 0.491 ' N ' HG22 ' A' ' 92' ' ' ILE . 5.2 mt-30 -130.18 176.82 7.79 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.964 -179.973 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 94' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -118.16 154.23 32.51 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.903 179.971 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 95' ' ' ILE . . . . . 0.545 HD12 ' HB3' ' A' ' 31' ' ' GLN . 4.4 mt . . . . . 0 C--N 1.329 -0.312 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.102 179.957 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.231 0.08 0 CA-C-O 120.9 0.381 . . . . 0.0 110.984 . . . . . . . . . 0 0 . 1 . 016 nuclear build core ' A' A ' 27' ' ' GLU . . . . . . . . . . . . . 13.8 mt-10 -141.28 174.26 10.7 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.154 -0.476 . . . . 0.0 110.881 -179.973 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 22.1 t -76.18 117.96 21.68 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.129 179.871 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 109.39 28.65 4.25 Favored Glycine 0 N--CA 1.452 -0.281 0 C-N-CA 120.776 -0.726 . . . . 0.0 112.491 -179.95 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 7.8 t0 -143.21 142.23 31.35 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 120.807 0.336 . . . . 0.0 110.863 -179.931 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 31' ' ' GLN . . . . . 0.625 ' HB3' HD12 ' A' ' 95' ' ' ILE . 0.0 OUTLIER -61.62 150.35 36.6 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.843 179.931 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 15.2 m -154.14 170.6 0.81 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.351 0 CA-C-N 116.222 -0.444 . . . . 0.0 111.182 179.971 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 33' ' ' LEU . . . . . . . . . . . . . 28.9 tp -134.88 106.02 6.68 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.94 179.968 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 34' ' ' VAL . . . . . 0.466 HG13 ' HB3' ' A' ' 87' ' ' ALA . 21.7 t -74.48 124.82 32.85 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.169 -179.918 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 35' ' ' ALA . . . . . . . . . . . . . . . 57.38 26.08 12.06 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.138 -0.483 . . . . 0.0 111.298 179.953 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . 55.81 26.95 48.76 Favored Glycine 0 N--CA 1.452 -0.284 0 C-N-CA 120.723 -0.751 . . . . 0.0 112.647 179.959 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 37' ' ' GLN . . . . . . . . . . . . . 77.9 mt-30 -138.15 -68.37 0.46 Allowed 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 120.842 0.353 . . . . 0.0 110.931 -179.949 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 38' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -69.7 111.14 5.28 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.906 -179.996 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 39' ' ' GLN . . . . . . . . . . . . . 1.9 tt0 -89.25 135.39 33.6 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.154 -0.476 . . . . 0.0 110.976 179.933 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -165.5 -167.97 26.94 Favored Glycine 0 N--CA 1.451 -0.304 0 C-N-CA 120.7 -0.762 . . . . 0.0 112.513 180.0 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 41' ' ' ILE . . . . . 0.498 ' N ' HG23 ' A' ' 58' ' ' ILE . 23.5 mt -129.52 143.19 41.89 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-O 120.789 0.328 . . . . 0.0 111.16 -179.959 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 42' ' ' VAL . . . . . . . . . . . . . 21.9 t -68.22 112.04 2.98 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.247 -0.433 . . . . 0.0 111.114 179.961 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 43' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -96.19 -41.21 8.8 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.965 -179.986 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 44' ' ' PHE . . . . . . . . . . . . . 21.0 t80 -135.74 119.02 16.66 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.895 179.985 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 45' ' ' TYR . . . . . 0.423 ' CE1' ' CZ ' ' A' ' 56' ' ' TYR . 38.0 t80 -123.04 136.75 54.96 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.115 -0.493 . . . . 0.0 110.844 -179.989 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 157.86 -155.3 26.31 Favored Glycine 0 N--CA 1.451 -0.346 0 C-N-CA 120.747 -0.739 . . . . 0.0 112.478 179.914 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 47' ' ' LYS . . . . . . . . . . . . . 2.1 mtpt -83.35 150.12 26.3 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-O 120.844 0.354 . . . . 0.0 110.891 179.999 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 48' ' ' THR . . . . . 0.535 HG22 ' CE2' ' A' ' 76' ' ' TYR . 6.3 p -115.04 178.01 4.44 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.814 -179.981 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -115.01 -37.48 4.13 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.974 -179.997 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 50' ' ' PHE . . . . . 0.427 ' CZ ' HG21 ' A' ' 48' ' ' THR . 27.4 p90 -63.78 -32.35 73.82 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.191 -0.458 . . . . 0.0 110.951 -179.936 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 51' ' ' ALA . . . . . . . . . . . . . . . -149.62 152.08 34.3 Favored Pre-proline 0 C--N 1.33 -0.269 0 CA-C-N 116.226 -0.443 . . . . 0.0 111.156 -179.997 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 52' ' ' PRO . . . . . . . . . . . . . 57.6 Cg_endo -71.33 168.98 21.88 Favored 'Trans proline' 0 C--N 1.344 0.321 0 C-N-CA 122.562 2.175 . . . . 0.0 112.262 179.99 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 89.87 -160.15 28.46 Favored Glycine 0 N--CA 1.45 -0.37 0 C-N-CA 120.707 -0.758 . . . . 0.0 112.562 -179.972 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 54' ' ' TYR . . . . . . . . . . . . . 59.5 m-85 -123.67 125.73 45.31 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 120.841 0.353 . . . . 0.0 110.839 -179.928 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 55' ' ' TRP . . . . . . . . . . . . . 37.3 m95 -112.34 169.8 8.62 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.22 -0.446 . . . . 0.0 110.835 179.987 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 56' ' ' TYR . . . . . 0.484 ' CE1' ' HB2' ' A' ' 89' ' ' ALA . 9.2 m-85 -118.9 117.43 28.81 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.965 -179.96 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . -82.35 61.37 4.72 Favored Glycine 0 N--CA 1.45 -0.367 0 C-N-CA 120.752 -0.737 . . . . 0.0 112.402 179.956 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 58' ' ' ILE . . . . . 0.514 HD11 HD13 ' A' ' 92' ' ' ILE . 13.2 mt -69.91 137.94 23.07 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-O 120.911 0.386 . . . . 0.0 111.079 -179.949 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER -106.28 133.73 50.52 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.859 179.927 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 60' ' ' LEU . . . . . . . . . . . . . 53.5 mt -100.48 171.64 7.62 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.915 -179.969 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 61' ' ' ASP . . . . . 0.404 ' O ' ' CE1' ' A' ' 83' ' ' HIS . 0.7 OUTLIER -97.28 -30.8 12.76 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.095 -0.502 . . . . 0.0 110.919 179.987 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 62' ' ' GLN . . . . . . . . . . . . . 6.5 mm-40 -97.49 155.35 37.38 Favored Pre-proline 0 C--N 1.328 -0.331 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.974 -179.974 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 74.3 Cg_endo -75.44 60.63 5.81 Favored 'Trans proline' 0 C--N 1.344 0.324 0 C-N-CA 122.648 2.232 . . . . 0.0 112.262 -179.961 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 64' ' ' THR . . . . . . . . . . . . . 26.7 p -132.85 33.26 3.73 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.253 -0.431 . . . . 0.0 110.932 -179.95 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . -85.47 -127.51 1.86 Allowed Glycine 0 N--CA 1.451 -0.338 0 C-N-CA 120.689 -0.767 . . . . 0.0 112.489 -179.968 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 66' ' ' LYS . . . . . . . . . . . . . 0.3 OUTLIER -150.24 -49.08 0.13 Allowed 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.824 0.345 . . . . 0.0 110.865 -179.961 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 67' ' ' HIS . . . . . . . . . . . . . 5.7 p80 -119.5 169.92 9.62 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.143 -0.48 . . . . 0.0 110.854 -179.962 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -97.08 39.8 1.17 Allowed 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.87 -179.987 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 99.43 -36.34 4.13 Favored Glycine 0 N--CA 1.451 -0.337 0 C-N-CA 120.735 -0.745 . . . . 0.0 112.537 179.907 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 70' ' ' SER . . . . . . . . . . . . . 11.7 p -115.32 163.52 15.58 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 120.8 0.333 . . . . 0.0 110.957 179.986 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 21.4 t -137.88 116.25 13.62 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 116.137 -0.483 . . . . 0.0 111.125 179.984 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 72' ' ' PHE . . . . . . . . . . . . . 32.3 m-85 60.6 30.76 19.96 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.928 179.973 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 99.58 -30.03 10.8 Favored Glycine 0 N--CA 1.451 -0.341 0 C-N-CA 120.641 -0.79 . . . . 0.0 112.568 179.988 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 21.5 t -77.5 114.94 18.64 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.34 0 CA-C-O 120.896 0.379 . . . . 0.0 111.068 179.991 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 75' ' ' ARG . . . . . . . . . . . . . 12.6 ttm180 -95.27 126.49 40.62 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.911 179.967 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 76' ' ' TYR . . . . . 0.535 ' CE2' HG22 ' A' ' 48' ' ' THR . 12.8 m-85 -100.17 -50.75 3.86 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.797 -179.96 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 77' ' ' PHE . . . . . . . . . . . . . 11.3 p90 -144.3 173.34 11.86 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.946 -179.96 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 41.6 p -103.94 122.08 44.45 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.266 -0.425 . . . . 0.0 110.904 179.917 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 79' ' ' CYS . . . . . . . . . . . . . 27.8 p -145.13 172.53 12.96 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.849 -179.988 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 80' ' ' ALA . . . . . 0.591 ' HB3' ' ND1' ' A' ' 83' ' ' HIS . . . -78.64 166.66 41.09 Favored Pre-proline 0 C--N 1.33 -0.268 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.115 179.988 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 81' ' ' PRO . . . . . 0.521 ' HD2' ' HB1' ' A' ' 80' ' ' ALA . 50.1 Cg_exo -53.57 116.35 2.93 Favored 'Trans proline' 0 C--N 1.345 0.362 0 C-N-CA 122.587 2.191 . . . . 0.0 112.333 179.959 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 82' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER 61.94 53.4 3.08 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.879 179.923 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 83' ' ' HIS . . . . . 0.591 ' ND1' ' HB3' ' A' ' 80' ' ' ALA . 7.4 m170 -123.45 -44.46 2.12 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.915 179.921 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . -71.02 150.0 46.91 Favored Glycine 0 N--CA 1.451 -0.359 0 C-N-CA 120.699 -0.762 . . . . 0.0 112.535 179.948 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 85' ' ' VAL . . . . . . . . . . . . . 10.8 m -148.94 139.27 16.57 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-O 120.817 0.342 . . . . 0.0 111.157 -179.962 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 86' ' ' PHE . . . . . . . . . . . . . 4.1 m-85 -115.93 109.03 17.01 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.839 179.988 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 87' ' ' ALA . . . . . 0.592 ' O ' HD11 ' A' ' 92' ' ' ILE . . . -130.84 142.85 47.04 Favored Pre-proline 0 C--N 1.33 -0.261 0 CA-C-N 116.259 -0.428 . . . . 0.0 111.126 -179.953 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 88' ' ' PRO . . . . . 0.421 ' O ' ' N ' ' A' ' 91' ' ' ARG . 44.3 Cg_exo -56.26 143.7 84.49 Favored 'Trans proline' 0 C--N 1.345 0.391 0 C-N-CA 122.516 2.144 . . . . 0.0 112.22 179.938 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 89' ' ' ALA . . . . . 0.484 ' HB2' ' CE1' ' A' ' 56' ' ' TYR . . . -47.89 -50.88 25.26 Favored 'General case' 0 C--N 1.333 -0.134 0 CA-C-O 121.113 0.482 . . . . 0.0 110.308 179.807 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 90' ' ' SER . . . . . . . . . . . . . 1.1 m -55.72 -24.76 36.63 Favored 'General case' 0 C--N 1.331 -0.215 0 CA-C-N 115.639 -0.71 . . . . 0.0 109.721 178.765 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 91' ' ' ARG . . . . . 0.421 ' N ' ' O ' ' A' ' 88' ' ' PRO . 0.0 OUTLIER -87.9 -16.28 34.34 Favored 'General case' 0 N--CA 1.454 -0.244 0 CA-C-N 115.833 -0.622 . . . . 0.0 110.393 179.044 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 92' ' ' ILE . . . . . 0.592 HD11 ' O ' ' A' ' 87' ' ' ALA . 44.1 mt -104.2 153.74 6.19 Favored 'Isoleucine or valine' 0 C--O 1.231 0.114 0 CA-C-N 116.344 -0.389 . . . . 0.0 111.063 179.882 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 93' ' ' GLN . . . . . 0.412 ' N ' HG22 ' A' ' 92' ' ' ILE . 0.3 OUTLIER -120.43 142.57 49.1 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.922 -179.976 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 94' ' ' ARG . . . . . . . . . . . . . 12.9 ttt180 -89.96 116.44 28.02 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.222 -0.444 . . . . 0.0 110.868 179.996 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 95' ' ' ILE . . . . . 0.625 HD12 ' HB3' ' A' ' 31' ' ' GLN . 35.2 mt . . . . . 0 C--N 1.329 -0.285 0 CA-C-N 116.136 -0.484 . . . . 0.0 111.143 179.99 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.231 0.107 0 CA-C-O 120.883 0.373 . . . . 0.0 111.14 . . . . . . . . . 0 0 . 1 . 017 nuclear build core ' A' A ' 27' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -123.91 168.1 13.24 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.848 -179.963 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 25.2 t -73.43 111.42 8.24 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.097 179.951 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 112.72 27.96 3.62 Favored Glycine 0 N--CA 1.452 -0.285 0 C-N-CA 120.752 -0.737 . . . . 0.0 112.516 -179.966 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -136.57 145.53 45.08 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-O 120.757 0.313 . . . . 0.0 110.895 179.995 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 31' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -68.56 136.01 52.41 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.887 179.978 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 12.7 m -136.66 179.67 3.66 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.181 -0.463 . . . . 0.0 111.093 179.993 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 33' ' ' LEU . . . . . 0.523 HD23 ' HA2' ' A' ' 36' ' ' GLY . 15.7 tp -137.91 114.1 10.11 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.914 179.959 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 34' ' ' VAL . . . . . 0.499 HG22 HD13 ' A' ' 58' ' ' ILE . 21.5 t -83.82 123.22 38.67 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.343 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.104 179.997 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 35' ' ' ALA . . . . . . . . . . . . . . . 59.34 26.39 15.24 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.197 179.979 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 36' ' ' GLY . . . . . 0.523 ' HA2' HD23 ' A' ' 33' ' ' LEU . . . 56.13 27.78 52.66 Favored Glycine 0 N--CA 1.452 -0.299 0 C-N-CA 120.774 -0.727 . . . . 0.0 112.579 179.999 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 37' ' ' GLN . . . . . . . . . . . . . 41.7 mt-30 -137.17 -70.6 0.45 Allowed 'General case' 0 C--N 1.328 -0.336 0 CA-C-O 120.858 0.361 . . . . 0.0 110.987 -179.965 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 38' ' ' LYS . . . . . . . . . . . . . 11.5 mttm -70.4 124.6 24.57 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.923 179.969 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 39' ' ' GLN . . . . . . . . . . . . . 0.1 OUTLIER -99.13 129.57 45.39 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.861 179.993 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -151.88 -173.78 21.92 Favored Glycine 0 N--CA 1.452 -0.276 0 C-N-CA 120.702 -0.761 . . . . 0.0 112.49 179.955 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 41' ' ' ILE . . . . . 0.426 ' N ' HG23 ' A' ' 58' ' ' ILE . 32.7 mt -125.15 138.05 55.58 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-O 120.77 0.319 . . . . 0.0 111.125 -179.984 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 42' ' ' VAL . . . . . . . . . . . . . 26.5 t -67.17 113.98 3.63 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.226 -0.443 . . . . 0.0 111.02 179.956 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 43' ' ' ARG . . . . . . . . . . . . . 14.7 mmt180 -102.6 -31.45 10.38 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.933 179.995 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 44' ' ' PHE . . . . . . . . . . . . . 80.7 t80 -146.26 116.71 7.51 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.895 179.943 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 45' ' ' TYR . . . . . 0.488 ' CE1' ' CZ ' ' A' ' 56' ' ' TYR . 17.7 t80 -114.52 117.53 31.2 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.922 179.936 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 173.58 170.44 37.07 Favored Glycine 0 N--CA 1.451 -0.339 0 C-N-CA 120.746 -0.74 . . . . 0.0 112.534 -179.943 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 47' ' ' LYS . . . . . . . . . . . . . 85.5 mttt -65.33 148.27 51.99 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-O 120.819 0.342 . . . . 0.0 110.899 -179.922 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 48' ' ' THR . . . . . 0.719 HG22 ' CE2' ' A' ' 76' ' ' TYR . 0.9 OUTLIER -103.03 -177.08 3.27 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.909 179.989 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 12.5 t0 -109.21 -31.53 7.55 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.246 -0.434 . . . . 0.0 110.985 -179.999 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 50' ' ' PHE . . . . . 0.494 ' CZ ' HG21 ' A' ' 48' ' ' THR . 19.8 p90 -80.01 -31.19 39.66 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.979 180.0 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 51' ' ' ALA . . . . . . . . . . . . . . . -134.8 139.99 33.92 Favored Pre-proline 0 C--N 1.329 -0.306 0 CA-C-N 116.269 -0.423 . . . . 0.0 111.078 -179.957 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 52' ' ' PRO . . . . . . . . . . . . . 72.0 Cg_endo -76.82 167.06 25.95 Favored 'Trans proline' 0 C--N 1.346 0.434 0 C-N-CA 122.469 2.113 . . . . 0.0 112.292 -179.974 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 92.21 -167.85 30.64 Favored Glycine 0 N--CA 1.45 -0.372 0 C-N-CA 120.734 -0.746 . . . . 0.0 112.562 179.898 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 54' ' ' TYR . . . . . . . . . . . . . 31.0 m-85 -103.31 124.27 48.34 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-O 120.868 0.366 . . . . 0.0 110.833 -179.969 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 55' ' ' TRP . . . . . . . . . . . . . 75.2 m95 -117.29 160.61 20.84 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.865 -179.997 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 56' ' ' TYR . . . . . 0.662 ' HE1' ' HB2' ' A' ' 89' ' ' ALA . 5.7 m-85 -118.45 115.81 25.4 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.963 -179.96 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . -82.04 69.53 3.3 Favored Glycine 0 N--CA 1.452 -0.283 0 C-N-CA 120.646 -0.788 . . . . 0.0 112.437 179.933 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 58' ' ' ILE . . . . . 0.764 HD11 HD13 ' A' ' 92' ' ' ILE . 3.9 mt -75.67 141.05 16.36 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-O 120.8 0.333 . . . . 0.0 111.099 -179.976 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 3.1 tt0 -105.63 119.38 38.98 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.925 179.956 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 60' ' ' LEU . . . . . . . . . . . . . 92.7 mt -77.94 172.25 13.76 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.935 179.993 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -101.32 -29.2 12.19 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.895 -179.984 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 62' ' ' GLN . . . . . . . . . . . . . 0.3 OUTLIER -106.65 155.63 38.58 Favored Pre-proline 0 C--N 1.33 -0.259 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.936 179.965 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 55.0 Cg_endo -69.73 70.29 1.57 Allowed 'Trans proline' 0 C--N 1.344 0.335 0 C-N-CA 122.526 2.151 . . . . 0.0 112.296 179.993 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 64' ' ' THR . . . . . . . . . . . . . 42.9 p -147.75 43.76 1.08 Allowed 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 116.112 -0.494 . . . . 0.0 110.826 179.998 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . -95.49 -127.74 5.32 Favored Glycine 0 N--CA 1.451 -0.322 0 C-N-CA 120.777 -0.725 . . . . 0.0 112.561 179.968 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 66' ' ' LYS . . . . . . . . . . . . . 0.6 OUTLIER -148.16 -50.04 0.17 Allowed 'General case' 0 C--N 1.328 -0.346 0 CA-C-O 120.833 0.349 . . . . 0.0 110.83 179.999 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 67' ' ' HIS . . . . . . . . . . . . . 6.7 p80 -123.1 168.06 12.87 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.154 -0.476 . . . . 0.0 110.833 179.969 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 9.2 p-10 -98.89 31.29 3.02 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.253 -0.431 . . . . 0.0 110.914 -179.984 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 100.36 -28.09 17.4 Favored Glycine 0 N--CA 1.451 -0.312 0 C-N-CA 120.653 -0.784 . . . . 0.0 112.486 -179.979 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 70' ' ' SER . . . . . . . . . . . . . 33.2 p -122.47 139.74 53.53 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-O 120.795 0.331 . . . . 0.0 110.867 -179.981 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 71' ' ' VAL . . . . . 0.658 HG12 ' CD2' ' A' ' 72' ' ' PHE . 21.5 t -124.99 116.81 48.27 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.224 -0.444 . . . . 0.0 111.029 179.988 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 72' ' ' PHE . . . . . 0.658 ' CD2' HG12 ' A' ' 71' ' ' VAL . 13.7 m-85 60.96 30.92 19.9 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.901 179.965 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 98.45 -28.52 14.5 Favored Glycine 0 N--CA 1.451 -0.33 0 C-N-CA 120.756 -0.735 . . . . 0.0 112.498 179.933 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 21.5 t -77.05 122.42 31.55 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.272 0 CA-C-O 120.876 0.369 . . . . 0.0 111.109 179.998 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 75' ' ' ARG . . . . . . . . . . . . . 3.4 ttt180 -95.3 146.34 24.44 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.925 179.982 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 76' ' ' TYR . . . . . 0.719 ' CE2' HG22 ' A' ' 48' ' ' THR . 72.8 m-85 -122.05 -45.0 2.27 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.884 179.968 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 77' ' ' PHE . . . . . . . . . . . . . 17.1 p90 -162.23 165.25 27.06 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.883 179.945 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 1.0 OUTLIER -89.65 103.05 15.73 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.976 179.974 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 79' ' ' CYS . . . . . . . . . . . . . 28.4 p -127.69 153.73 46.14 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.887 -179.969 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 80' ' ' ALA . . . . . 0.584 ' HB3' ' CG ' ' A' ' 83' ' ' HIS . . . -61.91 164.21 10.89 Favored Pre-proline 0 C--N 1.329 -0.308 0 CA-C-N 116.136 -0.484 . . . . 0.0 111.137 179.975 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 81' ' ' PRO . . . . . 0.443 ' HD2' ' HB1' ' A' ' 80' ' ' ALA . 51.0 Cg_exo -54.11 115.59 2.46 Favored 'Trans proline' 0 C--N 1.345 0.385 0 C-N-CA 122.578 2.185 . . . . 0.0 112.293 -179.949 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 82' ' ' ARG . . . . . . . . . . . . . 0.7 OUTLIER 61.59 53.64 3.25 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.852 179.953 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 83' ' ' HIS . . . . . 0.584 ' CG ' ' HB3' ' A' ' 80' ' ' ALA . 6.1 m170 -125.15 -44.52 1.89 Allowed 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.145 -0.479 . . . . 0.0 110.879 179.882 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . -67.23 130.24 29.43 Favored Glycine 0 N--CA 1.451 -0.311 0 C-N-CA 120.714 -0.755 . . . . 0.0 112.434 179.934 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 85' ' ' VAL . . . . . . . . . . . . . 5.1 m -134.29 121.67 37.98 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-O 120.856 0.36 . . . . 0.0 111.174 179.966 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 86' ' ' PHE . . . . . . . . . . . . . 7.9 m-85 -96.25 112.33 24.1 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.916 179.937 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 87' ' ' ALA . . . . . 0.515 ' O ' HD11 ' A' ' 92' ' ' ILE . . . -129.74 143.74 50.23 Favored Pre-proline 0 C--N 1.33 -0.28 0 CA-C-N 116.257 -0.429 . . . . 0.0 111.025 -179.94 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 88' ' ' PRO . . . . . 0.407 ' O ' ' N ' ' A' ' 91' ' ' ARG . 46.9 Cg_exo -56.03 140.52 86.5 Favored 'Trans proline' 0 C--N 1.346 0.406 0 C-N-CA 122.52 2.146 . . . . 0.0 112.317 -179.995 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 89' ' ' ALA . . . . . 0.662 ' HB2' ' HE1' ' A' ' 56' ' ' TYR . . . -47.96 -51.61 22.97 Favored 'General case' 0 CA--C 1.521 -0.136 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.255 179.901 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 90' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -55.82 -24.47 36.45 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 115.76 -0.655 . . . . 0.0 109.709 178.87 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 91' ' ' ARG . . . . . 0.407 ' N ' ' O ' ' A' ' 88' ' ' PRO . 0.0 OUTLIER -87.8 -15.31 37.24 Favored 'General case' 0 N--CA 1.455 -0.225 0 CA-C-N 115.834 -0.621 . . . . 0.0 110.415 179.022 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 92' ' ' ILE . . . . . 0.764 HD13 HD11 ' A' ' 58' ' ' ILE . 41.7 mt -108.66 150.57 11.28 Favored 'Isoleucine or valine' 0 N--CA 1.457 -0.105 0 CA-C-N 116.376 -0.375 . . . . 0.0 111.071 179.898 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 93' ' ' GLN . . . . . . . . . . . . . 32.8 mt-30 -120.06 161.4 21.03 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.918 -179.991 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 94' ' ' ARG . . . . . . . . . . . . . 1.1 mtt180 -101.15 126.35 47.85 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.247 -0.433 . . . . 0.0 110.885 179.963 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 95' ' ' ILE . . . . . 0.434 HD11 ' HB2' ' A' ' 33' ' ' LEU . 26.1 mm . . . . . 0 C--N 1.33 -0.275 0 CA-C-N 116.15 -0.477 . . . . 0.0 111.171 179.968 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 26' ' ' ALA . . . . . 0.705 ' HB2' ' HG2' ' A' ' 94' ' ' ARG . . . . . . . . 0 N--CA 1.458 -0.055 0 CA-C-O 120.861 0.362 . . . . 0.0 111.071 . . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 27' ' ' GLU . . . . . . . . . . . . . 3.7 mt-10 -138.84 171.38 14.42 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.084 -0.507 . . . . 0.0 110.841 -179.964 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 28.1 t -65.97 109.71 1.16 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 116.097 -0.501 . . . . 0.0 111.02 -179.999 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 112.85 29.85 2.96 Favored Glycine 0 N--CA 1.452 -0.254 0 C-N-CA 120.756 -0.735 . . . . 0.0 112.516 -179.986 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 30' ' ' ASP . . . . . 0.684 ' O ' HG23 ' A' ' 41' ' ' ILE . 1.2 t0 -137.48 164.69 28.09 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-O 120.823 0.344 . . . . 0.0 110.878 179.942 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 31' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -83.11 131.72 35.13 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.25 -0.432 . . . . 0.0 110.927 179.966 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 15.3 m -139.74 179.53 2.75 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 116.329 -0.396 . . . . 0.0 111.136 179.957 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 33' ' ' LEU . . . . . 0.414 HD23 ' HA2' ' A' ' 36' ' ' GLY . 22.7 tp -143.45 102.02 3.88 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.158 -0.473 . . . . 0.0 110.812 179.97 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 34' ' ' VAL . . . . . 0.49 HG22 HD12 ' A' ' 58' ' ' ILE . 21.5 t -70.5 124.19 26.11 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.202 -0.454 . . . . 0.0 111.2 179.99 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 35' ' ' ALA . . . . . . . . . . . . . . . 58.57 25.51 13.24 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.228 -0.442 . . . . 0.0 111.264 179.942 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 36' ' ' GLY . . . . . 0.414 ' HA2' HD23 ' A' ' 33' ' ' LEU . . . 55.42 27.22 47.0 Favored Glycine 0 N--CA 1.452 -0.242 0 C-N-CA 120.852 -0.69 . . . . 0.0 112.587 179.984 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 37' ' ' GLN . . . . . . . . . . . . . 64.5 mt-30 -138.22 -64.86 0.52 Allowed 'General case' 0 C--N 1.329 -0.311 0 CA-C-O 120.704 0.287 . . . . 0.0 110.927 179.948 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 38' ' ' LYS . . . . . . . . . . . . . 64.3 mttt -72.38 112.64 8.62 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 116.294 -0.412 . . . . 0.0 110.877 179.954 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 39' ' ' GLN . . . . . . . . . . . . . 1.4 tm0? -91.82 117.26 29.61 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.836 179.991 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -145.14 -166.07 11.52 Favored Glycine 0 N--CA 1.451 -0.304 0 C-N-CA 120.747 -0.739 . . . . 0.0 112.468 -179.993 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 41' ' ' ILE . . . . . 0.684 HG23 ' O ' ' A' ' 30' ' ' ASP . 31.3 mt -131.17 132.58 63.25 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.25 0 CA-C-O 120.839 0.352 . . . . 0.0 111.105 -179.992 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 42' ' ' VAL . . . . . . . . . . . . . 21.5 t -60.4 121.46 8.27 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.261 -0.427 . . . . 0.0 111.086 179.962 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 43' ' ' ARG . . . . . . . . . . . . . 3.6 mmm-85 -104.14 -31.48 9.62 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.898 -179.941 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 44' ' ' PHE . . . . . 0.427 ' CD1' ' HB3' ' A' ' 76' ' ' TYR . 41.3 t80 -148.3 115.6 6.2 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.97 -179.947 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 45' ' ' TYR . . . . . 0.454 ' CE1' ' CE1' ' A' ' 56' ' ' TYR . 25.8 t80 -114.7 123.35 49.06 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.895 -179.986 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 171.03 -149.3 12.16 Favored Glycine 0 N--CA 1.451 -0.361 0 C-N-CA 120.671 -0.776 . . . . 0.0 112.449 179.956 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 47' ' ' LYS . . . . . . . . . . . . . 7.0 mttt -99.15 164.59 12.09 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-O 120.849 0.357 . . . . 0.0 110.975 -179.962 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 48' ' ' THR . . . . . 0.428 HG21 ' CZ ' ' A' ' 50' ' ' PHE . 13.2 p -129.68 -176.02 3.78 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.823 -179.982 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -112.98 -33.41 6.06 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.973 -179.89 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 50' ' ' PHE . . . . . 0.428 ' CZ ' HG21 ' A' ' 48' ' ' THR . 8.7 p90 -67.31 -30.51 70.37 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.24 -0.436 . . . . 0.0 111.016 -179.893 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 51' ' ' ALA . . . . . 0.42 ' N ' ' CD1' ' A' ' 50' ' ' PHE . . . -148.44 146.2 22.13 Favored Pre-proline 0 C--N 1.329 -0.314 0 CA-C-N 116.324 -0.398 . . . . 0.0 111.17 -179.906 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 52' ' ' PRO . . . . . . . . . . . . . 72.3 Cg_endo -74.95 -178.46 4.17 Favored 'Trans proline' 0 C--N 1.345 0.371 0 C-N-CA 122.584 2.189 . . . . 0.0 112.352 -179.991 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 76.78 -168.01 54.63 Favored Glycine 0 N--CA 1.451 -0.363 0 C-N-CA 120.778 -0.725 . . . . 0.0 112.515 179.954 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 54' ' ' TYR . . . . . . . . . . . . . 20.6 m-85 -101.59 149.56 23.99 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-O 120.837 0.351 . . . . 0.0 110.87 -179.929 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 55' ' ' TRP . . . . . . . . . . . . . 69.4 m95 -145.81 156.41 43.56 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.187 -0.461 . . . . 0.0 110.943 179.946 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 56' ' ' TYR . . . . . 0.454 ' CE1' ' CE1' ' A' ' 45' ' ' TYR . 25.2 m-85 -110.24 124.92 52.49 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.288 -0.415 . . . . 0.0 110.947 -179.947 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . -90.08 60.39 3.43 Favored Glycine 0 N--CA 1.45 -0.368 0 C-N-CA 120.768 -0.73 . . . . 0.0 112.414 179.9 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 58' ' ' ILE . . . . . 0.533 HG23 ' C ' ' A' ' 41' ' ' ILE . 21.2 mt -73.53 137.68 22.82 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-O 120.871 0.367 . . . . 0.0 111.073 -179.957 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 0.2 OUTLIER -103.89 133.27 49.14 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.084 -0.507 . . . . 0.0 110.845 -179.991 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 60' ' ' LEU . . . . . . . . . . . . . 56.5 mt -88.15 174.75 8.05 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.903 179.952 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 2.7 m-20 -100.59 -30.8 11.57 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.976 179.963 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 62' ' ' GLN . . . . . . . . . . . . . 0.8 OUTLIER -106.4 153.5 40.43 Favored Pre-proline 0 C--N 1.331 -0.239 0 CA-C-N 116.178 -0.464 . . . . 0.0 110.924 -179.971 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 73.6 Cg_endo -75.81 64.22 6.72 Favored 'Trans proline' 0 C--N 1.344 0.31 0 C-N-CA 122.613 2.209 . . . . 0.0 112.323 -179.857 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 64' ' ' THR . . . . . . . . . . . . . 7.5 t -147.01 38.55 0.99 Allowed 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.899 179.975 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . -86.57 -111.72 0.86 Allowed Glycine 0 N--CA 1.451 -0.313 0 C-N-CA 120.767 -0.73 . . . . 0.0 112.559 179.98 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 66' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -147.71 -47.27 0.17 Allowed 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.819 0.343 . . . . 0.0 110.893 179.992 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 67' ' ' HIS . . . . . 0.514 ' ND1' HG22 ' A' ' 71' ' ' VAL . 15.7 p80 -141.99 -176.0 4.63 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.865 179.96 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -89.32 -168.83 2.28 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.833 179.987 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . -63.39 -27.6 71.01 Favored Glycine 0 N--CA 1.451 -0.363 0 C-N-CA 120.695 -0.765 . . . . 0.0 112.473 -179.934 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 70' ' ' SER . . . . . . . . . . . . . 4.0 p -116.98 147.66 42.11 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 120.8 0.333 . . . . 0.0 110.897 -179.94 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 71' ' ' VAL . . . . . 0.514 HG22 ' ND1' ' A' ' 67' ' ' HIS . 28.2 t -127.12 119.86 53.89 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.103 179.929 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 72' ' ' PHE . . . . . . . . . . . . . 5.4 m-85 60.57 30.82 20.02 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.887 -179.948 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 94.91 -15.76 62.72 Favored Glycine 0 N--CA 1.451 -0.318 0 C-N-CA 120.713 -0.756 . . . . 0.0 112.721 -179.999 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 25.3 t -87.9 113.08 24.48 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-O 120.807 0.337 . . . . 0.0 111.169 -179.938 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 75' ' ' ARG . . . . . . . . . . . . . 6.4 ttm105 -95.06 114.7 26.54 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.762 179.885 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 76' ' ' TYR . . . . . 0.427 ' HB3' ' CD1' ' A' ' 44' ' ' PHE . 26.0 m-85 -96.7 -34.97 11.17 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.988 -179.853 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 77' ' ' PHE . . . . . . . . . . . . . 51.6 p90 -162.6 159.52 24.7 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 116.316 -0.402 . . . . 0.0 111.021 -179.907 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 26.0 m -87.62 140.82 29.13 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.922 179.917 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 79' ' ' CYS . . . . . . . . . . . . . 30.7 p -164.67 -175.6 3.9 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.263 -0.426 . . . . 0.0 110.915 179.965 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 80' ' ' ALA . . . . . 0.533 ' HB1' ' HD2' ' A' ' 81' ' ' PRO . . . -96.62 166.45 14.05 Favored Pre-proline 0 C--N 1.328 -0.328 0 CA-C-N 116.166 -0.47 . . . . 0.0 111.102 -179.97 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 81' ' ' PRO . . . . . 0.533 ' HD2' ' HB1' ' A' ' 80' ' ' ALA . 50.6 Cg_exo -53.21 120.55 7.92 Favored 'Trans proline' 0 C--N 1.344 0.298 0 C-N-CA 122.627 2.218 . . . . 0.0 112.297 179.96 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 82' ' ' ARG . . . . . . . . . . . . . 37.8 mtp85 62.45 61.46 1.25 Allowed 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.953 -179.967 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 83' ' ' HIS . . . . . . . . . . . . . 4.5 m-70 -130.79 -51.13 1.05 Allowed 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.866 -179.985 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . -63.51 143.54 48.21 Favored Glycine 0 N--CA 1.45 -0.367 0 C-N-CA 120.753 -0.736 . . . . 0.0 112.541 179.972 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 85' ' ' VAL . . . . . . . . . . . . . 5.1 m -145.92 118.16 2.12 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-O 120.829 0.347 . . . . 0.0 111.061 -179.974 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 86' ' ' PHE . . . . . . . . . . . . . 6.6 m-85 -96.45 105.93 18.1 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.847 179.973 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 87' ' ' ALA . . . . . 0.562 ' O ' HD11 ' A' ' 92' ' ' ILE . . . -126.0 142.76 43.35 Favored Pre-proline 0 C--N 1.328 -0.339 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.091 179.954 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 88' ' ' PRO . . . . . 0.411 ' O ' ' N ' ' A' ' 91' ' ' ARG . 31.2 Cg_exo -58.88 146.18 94.28 Favored 'Trans proline' 0 C--N 1.347 0.461 0 C-N-CA 122.468 2.112 . . . . 0.0 112.344 -179.999 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -48.38 -51.31 27.1 Favored 'General case' 0 C--N 1.333 -0.133 0 CA-C-O 121.08 0.467 . . . . 0.0 110.263 179.769 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 90' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -56.02 -24.4 38.93 Favored 'General case' 0 N--CA 1.454 -0.225 0 CA-C-N 115.648 -0.705 . . . . 0.0 109.789 178.732 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 91' ' ' ARG . . . . . 0.411 ' N ' ' O ' ' A' ' 88' ' ' PRO . 0.1 OUTLIER -88.44 -15.01 36.53 Favored 'General case' 0 N--CA 1.454 -0.254 0 CA-C-N 115.876 -0.602 . . . . 0.0 110.348 179.077 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' A' A ' 92' ' ' ILE . . . . . 0.562 HD11 ' O ' ' A' ' 87' ' ' ALA . 43.1 mt -108.77 158.31 8.65 Favored 'Isoleucine or valine' 0 C--O 1.231 0.081 0 CA-C-N 116.334 -0.394 . . . . 0.0 111.017 179.784 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 93' ' ' GLN . . . . . 0.487 ' N ' HG22 ' A' ' 92' ' ' ILE . 3.4 mt-30 -124.78 162.72 23.67 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.246 -0.434 . . . . 0.0 110.898 -179.886 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 94' ' ' ARG . . . . . 0.705 ' HG2' ' HB2' ' A' ' 26' ' ' ALA . 0.0 OUTLIER -112.65 127.17 56.03 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.113 -0.494 . . . . 0.0 110.838 -179.993 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' A' A ' 95' ' ' ILE . . . . . . . . . . . . . 33.0 mt . . . . . 0 C--N 1.329 -0.316 0 CA-C-N 116.187 -0.461 . . . . 0.0 111.022 179.962 . . . . . . . . 0 0 . 1 . 019 nuclear build core ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.457 -0.095 0 CA-C-O 120.843 0.354 . . . . 0.0 111.105 . . . . . . . . . 0 0 . 1 . 019 nuclear build core ' A' A ' 27' ' ' GLU . . . . . . . . . . . . . 16.4 mt-10 -133.92 179.77 6.04 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.917 -179.975 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 21.5 t -75.32 93.16 0.85 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.091 -179.981 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 121.72 44.84 0.36 Allowed Glycine 0 N--CA 1.451 -0.36 0 C-N-CA 120.843 -0.694 . . . . 0.0 112.489 179.972 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -144.77 158.21 43.87 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-O 120.832 0.349 . . . . 0.0 110.933 -179.991 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 31' ' ' GLN . . . . . . . . . . . . . 0.2 OUTLIER -77.56 126.03 30.26 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.82 -179.911 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 32' ' ' VAL . . . . . 0.457 HG21 HG12 ' A' ' 58' ' ' ILE . 16.2 m -129.34 175.63 10.11 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.262 -0.427 . . . . 0.0 111.158 179.983 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 33' ' ' LEU . . . . . 0.525 HD11 ' O ' ' A' ' 37' ' ' GLN . 25.6 tp -144.92 101.86 3.69 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.244 -0.434 . . . . 0.0 110.926 179.936 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 21.5 t -69.42 123.02 22.13 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.171 -179.958 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 35' ' ' ALA . . . . . . . . . . . . . . . 58.2 25.73 12.93 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.279 179.977 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . 56.13 32.75 60.2 Favored Glycine 0 N--CA 1.452 -0.294 0 C-N-CA 120.731 -0.747 . . . . 0.0 112.636 -179.99 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 37' ' ' GLN . . . . . 0.525 ' O ' HD11 ' A' ' 33' ' ' LEU . 11.3 mt-30 -142.9 -73.9 0.29 Allowed 'General case' 0 C--N 1.329 -0.319 0 CA-C-O 120.847 0.356 . . . . 0.0 110.974 -179.968 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 38' ' ' LYS . . . . . . . . . . . . . 4.6 mttp -64.35 109.6 1.97 Allowed 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.918 -179.973 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 39' ' ' GLN . . . . . . . . . . . . . 14.3 tm0? -85.32 129.38 34.82 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.254 -0.43 . . . . 0.0 110.905 179.982 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -156.13 -178.15 30.02 Favored Glycine 0 N--CA 1.45 -0.371 0 C-N-CA 120.683 -0.77 . . . . 0.0 112.524 -179.971 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 27.9 mm -123.12 138.18 53.98 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-O 120.731 0.3 . . . . 0.0 111.114 -179.983 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 42' ' ' VAL . . . . . . . . . . . . . 26.2 t -62.79 121.11 10.96 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 116.252 -0.431 . . . . 0.0 111.101 179.982 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 43' ' ' ARG . . . . . . . . . . . . . 3.1 mmt180 -107.33 -34.16 7.17 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.922 -179.983 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 44' ' ' PHE . . . . . 0.403 ' CD1' ' HB3' ' A' ' 76' ' ' TYR . 25.8 t80 -145.04 116.27 7.96 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.905 -179.978 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 45' ' ' TYR . . . . . . . . . . . . . 15.4 t80 -111.09 127.1 55.45 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.901 -179.985 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 166.88 -161.49 35.3 Favored Glycine 0 N--CA 1.45 -0.384 0 C-N-CA 120.774 -0.726 . . . . 0.0 112.531 179.992 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 47' ' ' LYS . . . . . . . . . . . . . 46.5 mttt -96.88 158.11 15.58 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-O 120.816 0.341 . . . . 0.0 110.837 -179.975 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 48' ' ' THR . . . . . 0.453 HG21 ' CZ ' ' A' ' 50' ' ' PHE . 28.4 p -120.75 168.25 11.62 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.165 -0.471 . . . . 0.0 110.848 179.895 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -91.69 -29.18 16.99 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.207 -0.452 . . . . 0.0 110.972 179.969 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 50' ' ' PHE . . . . . 0.453 ' CZ ' HG21 ' A' ' 48' ' ' THR . 37.5 p90 -74.92 -32.33 61.77 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.273 -0.421 . . . . 0.0 111.055 -179.929 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 51' ' ' ALA . . . . . . . . . . . . . . . -142.1 143.35 27.55 Favored Pre-proline 0 C--N 1.33 -0.264 0 CA-C-N 116.304 -0.407 . . . . 0.0 111.128 -179.965 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 52' ' ' PRO . . . . . . . . . . . . . 73.8 Cg_endo -77.33 -168.06 0.55 Allowed 'Trans proline' 0 C--N 1.346 0.404 0 C-N-CA 122.669 2.246 . . . . 0.0 112.325 -179.978 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 70.94 -155.15 52.68 Favored Glycine 0 N--CA 1.451 -0.346 0 C-N-CA 120.722 -0.751 . . . . 0.0 112.527 179.917 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 54' ' ' TYR . . . . . . . . . . . . . 41.4 m-85 -119.04 125.23 48.85 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-O 120.793 0.33 . . . . 0.0 110.906 -179.982 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 55' ' ' TRP . . . . . . . . . . . . . 63.8 m95 -117.4 168.5 10.3 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.909 179.967 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 56' ' ' TYR . . . . . 0.653 ' HE1' ' HB2' ' A' ' 89' ' ' ALA . 6.5 m-85 -124.6 119.56 29.4 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.254 -0.43 . . . . 0.0 110.939 -179.951 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 57' ' ' GLY . . . . . 0.454 ' CA ' ' CE1' ' A' ' 86' ' ' PHE . . . -84.1 62.43 4.59 Favored Glycine 0 N--CA 1.451 -0.366 0 C-N-CA 120.771 -0.728 . . . . 0.0 112.543 179.956 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 58' ' ' ILE . . . . . 0.628 HD11 HD13 ' A' ' 92' ' ' ILE . 7.2 mt -68.53 142.84 15.77 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-O 120.868 0.366 . . . . 0.0 111.035 179.995 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 4.7 tm-20 -109.13 110.1 21.25 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.921 179.948 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 60' ' ' LEU . . . . . . . . . . . . . 84.2 mt -68.6 176.33 3.0 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.863 -179.973 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -101.33 -32.18 10.6 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.896 -179.948 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 62' ' ' GLN . . . . . . . . . . . . . 6.3 mt-30 -102.2 162.78 19.25 Favored Pre-proline 0 C--N 1.329 -0.285 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.927 -179.97 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 98.7 Cg_endo -79.52 58.26 6.88 Favored 'Trans proline' 0 C--N 1.344 0.332 0 C-N-CA 122.663 2.242 . . . . 0.0 112.477 -179.996 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 64' ' ' THR . . . . . . . . . . . . . 20.8 p -133.4 32.12 3.69 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.949 179.993 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . -81.98 -117.28 0.48 Allowed Glycine 0 N--CA 1.451 -0.308 0 C-N-CA 120.751 -0.738 . . . . 0.0 112.454 179.976 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 66' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -155.17 -48.05 0.08 Allowed 'General case' 0 C--N 1.33 -0.263 0 CA-C-O 120.868 0.366 . . . . 0.0 110.899 179.917 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 67' ' ' HIS . . . . . . . . . . . . . 7.9 p80 -127.08 169.5 13.33 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 116.156 -0.474 . . . . 0.0 110.81 179.923 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 1.8 m-20 -97.81 36.07 1.59 Allowed 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.255 -0.43 . . . . 0.0 110.91 179.969 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 95.81 -39.57 2.81 Favored Glycine 0 N--CA 1.451 -0.355 0 C-N-CA 120.697 -0.763 . . . . 0.0 112.549 -179.984 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 70' ' ' SER . . . . . . . . . . . . . 11.6 p -101.1 127.23 47.73 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 120.741 0.305 . . . . 0.0 110.911 179.982 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 71' ' ' VAL . . . . . 0.418 HG12 ' CD2' ' A' ' 72' ' ' PHE . 21.5 t -115.07 111.01 34.06 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.349 0 CA-C-N 116.202 -0.454 . . . . 0.0 111.128 179.964 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 72' ' ' PHE . . . . . 0.418 ' CD2' HG12 ' A' ' 71' ' ' VAL . 30.2 m-85 61.44 30.66 18.99 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.891 179.966 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 99.1 -28.79 13.66 Favored Glycine 0 N--CA 1.451 -0.356 0 C-N-CA 120.741 -0.742 . . . . 0.0 112.463 179.951 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 27.8 t -80.55 121.71 34.47 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-O 120.881 0.372 . . . . 0.0 111.075 179.952 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 75' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -106.35 142.07 36.64 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.817 -179.937 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 76' ' ' TYR . . . . . 0.403 ' HB3' ' CD1' ' A' ' 44' ' ' PHE . 8.2 m-85 -115.42 -46.8 2.86 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.123 -0.49 . . . . 0.0 110.855 179.954 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 77' ' ' PHE . . . . . 0.433 ' CE1' ' HA3' ' A' ' 57' ' ' GLY . 35.1 p90 -146.9 177.29 9.25 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 116.263 -0.426 . . . . 0.0 110.879 179.982 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 0.9 OUTLIER -104.69 124.36 49.23 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.875 -179.964 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 79' ' ' CYS . . . . . . . . . . . . . 10.8 p -144.97 167.42 22.68 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.118 -0.492 . . . . 0.0 110.893 179.977 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 80' ' ' ALA . . . . . 0.511 ' HB1' ' HD2' ' A' ' 81' ' ' PRO . . . -75.51 166.44 45.3 Favored Pre-proline 0 C--N 1.33 -0.255 0 CA-C-N 116.228 -0.442 . . . . 0.0 111.075 -179.958 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 81' ' ' PRO . . . . . 0.511 ' HD2' ' HB1' ' A' ' 80' ' ' ALA . 51.2 Cg_exo -52.85 116.6 3.01 Favored 'Trans proline' 0 C--N 1.345 0.346 0 C-N-CA 122.572 2.181 . . . . 0.0 112.318 179.916 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 82' ' ' ARG . . . . . . . . . . . . . 0.5 OUTLIER 61.39 56.74 2.54 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.84 179.897 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 83' ' ' HIS . . . . . 0.505 ' CG ' ' HB3' ' A' ' 80' ' ' ALA . 6.2 m170 -126.36 -47.76 1.58 Allowed 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.925 179.953 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . -61.91 139.33 46.43 Favored Glycine 0 N--CA 1.451 -0.353 0 C-N-CA 120.699 -0.763 . . . . 0.0 112.56 179.915 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 85' ' ' VAL . . . . . . . . . . . . . 5.8 m -140.28 127.99 24.25 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.326 0 CA-C-O 120.774 0.321 . . . . 0.0 111.126 -179.911 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 86' ' ' PHE . . . . . 0.454 ' CE1' ' CA ' ' A' ' 57' ' ' GLY . 9.1 m-85 -110.26 112.45 24.42 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.189 -0.459 . . . . 0.0 110.871 179.926 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 87' ' ' ALA . . . . . 0.526 ' O ' HD11 ' A' ' 92' ' ' ILE . . . -134.86 149.45 70.6 Favored Pre-proline 0 C--N 1.329 -0.286 0 CA-C-N 116.303 -0.408 . . . . 0.0 111.213 179.966 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 88' ' ' PRO . . . . . 0.412 ' O ' ' N ' ' A' ' 91' ' ' ARG . 32.5 Cg_exo -58.08 140.53 94.41 Favored 'Trans proline' 0 C--N 1.345 0.356 0 C-N-CA 122.596 2.197 . . . . 0.0 112.27 -179.92 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 89' ' ' ALA . . . . . 0.653 ' HB2' ' HE1' ' A' ' 56' ' ' TYR . . . -47.79 -51.69 21.61 Favored 'General case' 0 C--N 1.332 -0.165 0 CA-C-O 121.06 0.457 . . . . 0.0 110.299 179.916 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 90' ' ' SER . . . . . . . . . . . . . 14.9 m -55.71 -24.5 35.06 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 115.731 -0.668 . . . . 0.0 109.734 178.788 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 91' ' ' ARG . . . . . 0.412 ' N ' ' O ' ' A' ' 88' ' ' PRO . 0.2 OUTLIER -88.76 -15.14 35.46 Favored 'General case' 0 N--CA 1.454 -0.229 0 CA-C-N 115.889 -0.596 . . . . 0.0 110.438 179.089 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 92' ' ' ILE . . . . . 0.628 HD13 HD11 ' A' ' 58' ' ' ILE . 48.4 mt -107.03 144.88 15.26 Favored 'Isoleucine or valine' 0 C--N 1.334 -0.104 0 CA-C-N 116.413 -0.358 . . . . 0.0 111.047 179.913 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 93' ' ' GLN . . . . . . . . . . . . . 9.1 mt-30 -115.65 -179.94 3.79 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.167 -0.469 . . . . 0.0 110.866 -179.997 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 94' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -125.77 134.99 51.55 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.202 -0.453 . . . . 0.0 110.996 -179.954 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 95' ' ' ILE . . . . . . . . . . . . . 5.0 mt . . . . . 0 C--N 1.329 -0.31 0 CA-C-N 116.22 -0.446 . . . . 0.0 111.108 179.952 . . . . . . . . 0 0 . 1 . 020 nuclear build core ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.231 0.098 0 CA-C-O 120.88 0.372 . . . . 0.0 111.072 . . . . . . . . . 0 0 . 1 . 020 nuclear build core ' A' A ' 27' ' ' GLU . . . . . . . . . . . . . 7.4 mp0 -133.74 -178.63 5.1 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.955 179.994 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 25.6 t -73.43 98.96 1.05 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.061 -179.993 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 117.94 39.63 0.75 Allowed Glycine 0 N--CA 1.451 -0.327 0 C-N-CA 120.789 -0.72 . . . . 0.0 112.449 179.924 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 20.7 t70 -146.25 137.68 24.66 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-O 120.842 0.353 . . . . 0.0 110.899 -179.978 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 31' ' ' GLN . . . . . . . . . . . . . 0.8 OUTLIER -59.96 137.33 58.11 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.121 -0.491 . . . . 0.0 110.961 179.938 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 6.2 m -141.28 171.67 11.77 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 116.234 -0.439 . . . . 0.0 111.11 -179.938 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 33' ' ' LEU . . . . . 0.683 HD13 ' HG3' ' A' ' 39' ' ' GLN . 33.9 tp -136.61 111.31 8.71 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.125 -0.488 . . . . 0.0 110.875 179.943 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 21.5 t -79.15 125.77 38.64 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-N 116.226 -0.443 . . . . 0.0 111.25 -179.978 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 35' ' ' ALA . . . . . . . . . . . . . . . 56.58 25.47 9.93 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.346 179.97 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . 57.54 31.69 63.73 Favored Glycine 0 N--CA 1.451 -0.306 0 C-N-CA 120.736 -0.745 . . . . 0.0 112.565 179.898 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 37' ' ' GLN . . . . . 0.577 ' O ' HD11 ' A' ' 33' ' ' LEU . 9.3 mt-30 -142.98 -74.28 0.28 Allowed 'General case' 0 C--N 1.33 -0.28 0 CA-C-O 120.818 0.342 . . . . 0.0 111.006 -179.971 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 38' ' ' LYS . . . . . 0.414 ' O ' HD12 ' A' ' 33' ' ' LEU . 46.0 mttp -63.51 112.59 2.84 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.896 -179.892 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 39' ' ' GLN . . . . . 0.683 ' HG3' HD13 ' A' ' 33' ' ' LEU . 2.1 mt-30 -87.6 139.6 30.37 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.837 179.926 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -172.87 171.42 44.39 Favored Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.697 -0.763 . . . . 0.0 112.512 179.993 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 3.2 mp -111.88 143.7 21.14 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-O 120.875 0.369 . . . . 0.0 111.114 179.978 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 42' ' ' VAL . . . . . . . . . . . . . 21.5 t -69.29 123.2 22.36 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.153 -0.476 . . . . 0.0 111.138 -179.995 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 43' ' ' ARG . . . . . . . . . . . . . 4.0 mmm180 -106.73 -31.54 8.38 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.891 -179.973 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 44' ' ' PHE . . . . . 0.417 ' CG ' ' HB3' ' A' ' 76' ' ' TYR . 15.2 t80 -147.82 106.26 3.78 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.879 -179.928 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 45' ' ' TYR . . . . . 0.496 ' CE1' ' CE1' ' A' ' 56' ' ' TYR . 14.3 t80 -111.03 123.88 51.06 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.294 -0.412 . . . . 0.0 110.935 179.893 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 171.54 -142.79 7.19 Favored Glycine 0 N--CA 1.45 -0.371 0 C-N-CA 120.649 -0.786 . . . . 0.0 112.462 -179.98 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 47' ' ' LYS . . . . . . . . . . . . . 24.7 mtpt -95.06 175.01 6.8 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-O 120.773 0.321 . . . . 0.0 110.906 179.993 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 48' ' ' THR . . . . . . . . . . . . . 44.8 p -138.79 -177.8 5.04 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.846 -179.996 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 4.4 t70 -129.04 17.59 6.13 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.154 -0.476 . . . . 0.0 111.259 179.924 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 50' ' ' PHE . . . . . . . . . . . . . 49.5 p90 -126.81 -44.98 1.62 Allowed 'General case' 0 C--N 1.331 -0.217 0 CA-C-N 116.447 -0.342 . . . . 0.0 110.892 179.961 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 51' ' ' ALA . . . . . 0.42 ' HB1' ' CZ2' ' A' ' 55' ' ' TRP . . . -123.5 145.37 46.72 Favored Pre-proline 0 C--N 1.329 -0.324 0 CA-C-N 116.291 -0.413 . . . . 0.0 111.122 179.944 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 52' ' ' PRO . . . . . . . . . . . . . 64.4 Cg_endo -73.59 164.7 34.26 Favored 'Trans proline' 0 C--N 1.345 0.36 0 C-N-CA 122.565 2.176 . . . . 0.0 112.32 -179.926 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 83.51 -177.2 52.65 Favored Glycine 0 N--CA 1.452 -0.287 0 C-N-CA 120.725 -0.75 . . . . 0.0 112.478 179.855 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 54' ' ' TYR . . . . . . . . . . . . . 7.8 m-85 -97.63 131.84 43.83 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-O 120.818 0.342 . . . . 0.0 110.862 -179.979 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 55' ' ' TRP . . . . . 0.42 ' CZ2' ' HB1' ' A' ' 51' ' ' ALA . 24.8 m95 -123.41 157.74 32.74 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.907 -179.994 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 56' ' ' TYR . . . . . 0.658 ' HE1' ' HB2' ' A' ' 89' ' ' ALA . 11.9 m-85 -109.69 126.84 54.12 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.977 -179.948 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . -84.46 62.08 4.62 Favored Glycine 0 N--CA 1.451 -0.36 0 C-N-CA 120.733 -0.746 . . . . 0.0 112.419 179.921 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 58' ' ' ILE . . . . . 0.492 HD11 HD13 ' A' ' 92' ' ' ILE . 15.9 mt -71.32 141.05 17.26 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-O 120.816 0.341 . . . . 0.0 111.108 -179.985 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER -109.89 122.14 46.85 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.885 179.951 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 60' ' ' LEU . . . . . . . . . . . . . 63.1 mt -82.69 170.3 15.26 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.945 -179.929 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 1.1 m-20 -100.6 -26.52 13.79 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.95 -179.97 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 62' ' ' GLN . . . . . . . . . . . . . 10.8 pt20 -110.41 152.16 43.13 Favored Pre-proline 0 C--N 1.329 -0.292 0 CA-C-N 116.299 -0.41 . . . . 0.0 110.922 -179.967 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 63' ' ' PRO . . . . . 0.417 ' O ' HG23 ' A' ' 64' ' ' THR . 49.7 Cg_endo -68.91 84.1 0.53 Allowed 'Trans proline' 0 C--N 1.345 0.357 0 C-N-CA 122.599 2.199 . . . . 0.0 112.312 179.971 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 64' ' ' THR . . . . . 0.417 HG23 ' O ' ' A' ' 63' ' ' PRO . 2.2 p -156.97 35.83 0.3 Allowed 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.213 -0.448 . . . . 0.0 110.894 -179.923 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . -91.65 -158.6 34.72 Favored Glycine 0 N--CA 1.451 -0.359 0 C-N-CA 120.757 -0.735 . . . . 0.0 112.443 -179.961 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 66' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -114.07 -36.69 4.67 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-O 120.735 0.303 . . . . 0.0 110.889 -179.997 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 67' ' ' HIS . . . . . . . . . . . . . 6.9 p80 -127.08 170.26 12.54 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.261 -0.427 . . . . 0.0 110.909 -179.903 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 5.4 m-20 -98.8 30.87 3.15 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.165 -0.471 . . . . 0.0 110.85 179.973 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 105.46 -42.76 1.82 Allowed Glycine 0 N--CA 1.452 -0.257 0 C-N-CA 120.667 -0.777 . . . . 0.0 112.457 179.915 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 70' ' ' SER . . . . . . . . . . . . . 63.4 p -108.62 141.76 40.08 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.798 0.333 . . . . 0.0 110.92 179.966 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 21.5 t -117.45 109.9 29.17 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 116.25 -0.432 . . . . 0.0 111.112 179.957 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 72' ' ' PHE . . . . . . . . . . . . . 40.7 m-85 60.66 30.58 19.82 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.932 -179.972 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 101.08 -30.02 11.26 Favored Glycine 0 N--CA 1.451 -0.353 0 C-N-CA 120.705 -0.759 . . . . 0.0 112.51 179.999 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 21.5 t -78.66 117.88 24.94 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-O 120.764 0.316 . . . . 0.0 111.152 -179.977 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 75' ' ' ARG . . . . . . . . . . . . . 10.3 ttm180 -98.33 145.67 26.45 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.894 -179.984 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 76' ' ' TYR . . . . . 0.417 ' HB3' ' CG ' ' A' ' 44' ' ' PHE . 12.6 m-85 -119.93 -42.36 2.61 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.852 -179.96 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 77' ' ' PHE . . . . . . . . . . . . . 26.6 p90 -153.13 158.89 42.52 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.875 179.991 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 12.0 p -89.96 99.53 12.52 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.91 -180.0 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 79' ' ' CYS . . . . . . . . . . . . . 30.5 p -117.93 173.95 6.48 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.85 179.977 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 80' ' ' ALA . . . . . 0.644 ' HB3' ' CG ' ' A' ' 83' ' ' HIS . . . -80.72 168.0 28.49 Favored Pre-proline 0 C--N 1.329 -0.308 0 CA-C-N 116.149 -0.478 . . . . 0.0 111.061 -179.975 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 81' ' ' PRO . . . . . 0.561 ' HD2' ' HB1' ' A' ' 80' ' ' ALA . 54.1 Cg_exo -52.14 112.18 0.8 Allowed 'Trans proline' 0 C--N 1.345 0.347 0 C-N-CA 122.554 2.169 . . . . 0.0 112.296 179.974 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 82' ' ' ARG . . . . . . . . . . . . . 12.9 mtp180 59.97 56.56 3.38 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.872 179.977 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 83' ' ' HIS . . . . . 0.644 ' CG ' ' HB3' ' A' ' 80' ' ' ALA . 5.1 m170 -121.48 -41.78 2.48 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.949 179.967 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . -71.44 142.22 33.59 Favored Glycine 0 N--CA 1.451 -0.301 0 C-N-CA 120.786 -0.721 . . . . 0.0 112.516 179.997 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 85' ' ' VAL . . . . . 0.4 ' O ' HG23 ' A' ' 85' ' ' VAL . 22.3 m -144.48 124.03 7.27 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-O 120.785 0.326 . . . . 0.0 111.089 179.943 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 86' ' ' PHE . . . . . . . . . . . . . 24.1 m-85 -101.28 121.26 41.56 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.974 179.927 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 87' ' ' ALA . . . . . 0.547 ' O ' HD11 ' A' ' 92' ' ' ILE . . . -138.64 146.54 51.03 Favored Pre-proline 0 C--N 1.329 -0.3 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.102 179.981 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 88' ' ' PRO . . . . . 0.431 ' O ' ' N ' ' A' ' 91' ' ' ARG . 41.8 Cg_exo -56.92 139.15 88.79 Favored 'Trans proline' 0 C--N 1.345 0.379 0 C-N-CA 122.487 2.125 . . . . 0.0 112.313 -179.934 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 89' ' ' ALA . . . . . 0.658 ' HB2' ' HE1' ' A' ' 56' ' ' TYR . . . -48.08 -48.39 33.58 Favored 'General case' 0 C--O 1.232 0.141 0 CA-C-N 116.076 -0.511 . . . . 0.0 110.24 179.818 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 90' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -55.53 -24.54 32.62 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 115.681 -0.69 . . . . 0.0 109.779 178.779 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 91' ' ' ARG . . . . . 0.431 ' N ' ' O ' ' A' ' 88' ' ' PRO . 0.7 OUTLIER -92.13 -13.55 30.53 Favored 'General case' 0 N--CA 1.455 -0.195 0 CA-C-N 115.877 -0.601 . . . . 0.0 110.62 179.201 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' A' A ' 92' ' ' ILE . . . . . 0.547 HD11 ' O ' ' A' ' 87' ' ' ALA . 50.1 mt -105.74 154.39 7.01 Favored 'Isoleucine or valine' 0 C--N 1.333 -0.12 0 CA-C-O 120.836 0.35 . . . . 0.0 111.013 179.796 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 93' ' ' GLN . . . . . 0.424 ' N ' HG22 ' A' ' 92' ' ' ILE . 0.3 OUTLIER -124.07 176.93 6.06 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.911 -179.978 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' A' A ' 94' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER -111.47 160.98 16.61 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.845 -179.989 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 95' ' ' ILE . . . . . . . . . . . . . 30.8 mt . . . . . 0 C--N 1.329 -0.284 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.097 179.961 . . . . . . . . 0 0 . 1 . 001 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.211 0 N-CA-C 112.463 -0.255 . . . . 0.0 112.463 . . . . . . . . . 0 0 . 1 . 001 nuclear build full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 7.3 p 62.32 121.17 0.01 OUTLIER 'General case' 0 C--N 1.33 -0.252 0 CA-C-O 120.872 0.367 . . . . 0.0 110.962 -179.992 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 3.6 m -59.62 -62.54 1.8 Allowed 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.921 179.936 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -150.01 -147.63 4.58 Favored Glycine 0 N--CA 1.45 -0.387 0 C-N-CA 120.713 -0.756 . . . . 0.0 112.458 179.962 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 42.3 t -94.14 -63.11 1.23 Allowed 'General case' 0 C--N 1.329 -0.293 0 CA-C-O 120.845 0.355 . . . . 0.0 110.895 -179.967 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 20.9 p -102.05 -51.11 3.47 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.876 -179.979 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 157.16 -177.76 33.86 Favored Glycine 0 N--CA 1.452 -0.29 0 C-N-CA 120.695 -0.764 . . . . 0.0 112.464 179.949 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 10.2 tttm -157.01 31.58 0.3 Allowed 'General case' 0 C--N 1.33 -0.259 0 CA-C-O 120.827 0.346 . . . . 0.0 110.922 179.981 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 10.3 t -94.93 145.19 29.1 Favored Pre-proline 0 C--N 1.33 -0.281 0 CA-C-N 116.178 -0.464 . . . . 0.0 110.826 -179.955 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 65.5 Cg_endo -73.52 146.25 39.0 Favored 'Trans proline' 0 C--N 1.345 0.342 0 C-N-CA 122.647 2.232 . . . . 0.0 112.348 -179.972 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -81.48 -31.32 32.99 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.871 179.915 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 32.7 p -136.92 154.57 76.26 Favored Pre-proline 0 C--N 1.329 -0.312 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.847 179.879 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 39.9 Cg_endo -67.02 88.97 0.3 Allowed 'Trans proline' 0 C--N 1.345 0.363 0 C-N-CA 122.577 2.185 . . . . 0.0 112.233 179.959 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 83.6 p -123.24 147.5 46.85 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.931 179.969 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 3.8 tp -136.17 -177.04 4.53 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.174 -0.467 . . . . 0.0 110.812 179.954 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -58.28 -34.02 72.65 Favored Glycine 0 N--CA 1.451 -0.327 0 C-N-CA 120.625 -0.798 . . . . 0.0 112.43 179.982 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 3.8 p -177.49 109.32 0.07 Allowed 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.803 0.335 . . . . 0.0 110.878 179.889 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 18' ' ' LEU . . . . . 0.439 HD23 ' HA ' ' A' ' 18' ' ' LEU . 12.2 mt -153.8 31.58 0.45 Allowed 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.853 -179.988 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 19' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -154.13 31.75 0.44 Allowed 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.806 179.945 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 20' ' ' GLN . . . . . . . . . . . . . 1.9 mt-30 -87.72 176.08 7.57 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.959 179.977 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 9.8 mmt180 -100.97 105.8 17.06 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.944 -179.98 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 4.0 mt-10 60.47 31.96 20.43 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.968 179.98 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -71.07 157.58 53.55 Favored Glycine 0 N--CA 1.45 -0.37 0 C-N-CA 120.724 -0.75 . . . . 0.0 112.497 -179.992 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -170.2 155.06 5.2 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-O 120.781 0.324 . . . . 0.0 111.077 -179.945 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 0.6 OUTLIER -86.75 -46.49 9.95 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.988 179.957 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -107.84 -177.99 3.49 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.116 -0.493 . . . . 0.0 111.164 179.94 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 27' ' ' GLU . . . . . . . . . . . . . 2.1 mm-40 -149.14 167.56 25.59 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.941 -179.992 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 21.8 t -68.6 125.02 25.54 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 CA-C-N 116.176 -0.465 . . . . 0.0 111.106 -179.975 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 98.39 29.66 7.36 Favored Glycine 0 N--CA 1.451 -0.347 0 C-N-CA 120.724 -0.751 . . . . 0.0 112.446 -179.991 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 30' ' ' ASP . . . . . 0.425 ' O ' HG23 ' A' ' 41' ' ' ILE . 0.8 OUTLIER -138.76 147.96 43.27 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-O 120.814 0.34 . . . . 0.0 110.845 -179.928 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 31' ' ' GLN . . . . . . . . . . . . . 0.7 OUTLIER -72.65 127.25 32.0 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.963 179.977 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 22.2 m -130.16 179.9 3.79 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 CA-C-N 116.265 -0.425 . . . . 0.0 111.192 179.973 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 33' ' ' LEU . . . . . 0.562 HD23 ' HA2' ' A' ' 36' ' ' GLY . 15.7 tp -139.52 109.33 6.32 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.262 -0.426 . . . . 0.0 110.963 -179.993 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 23.1 t -76.57 121.12 28.08 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.261 -0.427 . . . . 0.0 111.138 -180.0 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 35' ' ' ALA . . . . . . . . . . . . . . . 59.22 26.61 15.42 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.244 179.976 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 36' ' ' GLY . . . . . 0.562 ' HA2' HD23 ' A' ' 33' ' ' LEU . . . 56.74 36.64 73.01 Favored Glycine 0 N--CA 1.45 -0.387 0 C-N-CA 120.74 -0.743 . . . . 0.0 112.639 179.954 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 37' ' ' GLN . . . . . . . . . . . . . 35.3 mt-30 -146.98 -71.42 0.23 Allowed 'General case' 0 C--N 1.329 -0.325 0 CA-C-O 120.796 0.331 . . . . 0.0 110.948 -179.998 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 38' ' ' LYS . . . . . . . . . . . . . 13.2 mttm -67.83 114.79 6.71 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.879 -179.995 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 39' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -90.14 125.98 35.64 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.922 179.935 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -152.77 -175.61 24.45 Favored Glycine 0 N--CA 1.451 -0.347 0 C-N-CA 120.715 -0.755 . . . . 0.0 112.5 -179.971 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 41' ' ' ILE . . . . . 0.529 ' C ' HG23 ' A' ' 58' ' ' ILE . 4.3 mt -127.64 128.79 69.94 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.272 0 CA-C-O 120.8 0.333 . . . . 0.0 111.02 -179.948 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 42' ' ' VAL . . . . . . . . . . . . . 21.6 t -59.99 124.42 14.28 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.253 -0.431 . . . . 0.0 111.084 179.975 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 43' ' ' ARG . . . . . . . . . . . . . 45.0 mmt-85 -110.57 -30.24 7.71 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.23 -0.441 . . . . 0.0 111.077 -179.993 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 44' ' ' PHE . . . . . . . . . . . . . 35.7 t80 -143.61 118.6 10.02 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.318 -0.401 . . . . 0.0 110.993 -179.958 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 45' ' ' TYR . . . . . 0.455 ' CE1' ' CZ ' ' A' ' 56' ' ' TYR . 22.2 t80 -115.08 114.9 25.96 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.845 179.899 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 176.8 162.96 28.27 Favored Glycine 0 N--CA 1.45 -0.382 0 C-N-CA 120.699 -0.763 . . . . 0.0 112.441 179.944 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 47' ' ' LYS . . . . . 0.442 ' HG3' ' CE1' ' A' ' 54' ' ' TYR . 22.7 mttt -65.98 137.32 57.05 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.865 0.364 . . . . 0.0 110.852 179.97 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 48' ' ' THR . . . . . . . . . . . . . 41.2 p -95.67 -175.35 3.41 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.902 179.918 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 4.6 t70 -106.58 -30.87 8.76 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.893 179.987 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 50' ' ' PHE . . . . . . . . . . . . . 44.3 p90 -71.29 -36.22 71.58 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.867 -179.985 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 51' ' ' ALA . . . . . . . . . . . . . . . -132.69 148.17 68.48 Favored Pre-proline 0 C--N 1.33 -0.274 0 CA-C-N 116.236 -0.438 . . . . 0.0 111.188 179.978 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 52' ' ' PRO . . . . . . . . . . . . . 59.9 Cg_endo -72.25 -170.07 0.53 Allowed 'Trans proline' 0 C--N 1.344 0.34 0 C-N-CA 122.601 2.201 . . . . 0.0 112.336 -179.97 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 59.26 -161.01 15.5 Favored Glycine 0 N--CA 1.452 -0.283 0 C-N-CA 120.746 -0.74 . . . . 0.0 112.537 179.976 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 54' ' ' TYR . . . . . 0.442 ' CE1' ' HG3' ' A' ' 47' ' ' LYS . 12.8 m-85 -106.19 157.8 17.3 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-O 120.844 0.354 . . . . 0.0 110.855 -179.95 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 55' ' ' TRP . . . . . . . . . . . . . 69.5 m95 -144.37 159.71 42.27 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.898 179.988 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 56' ' ' TYR . . . . . 0.827 ' CE1' ' HB2' ' A' ' 89' ' ' ALA . 5.7 m-85 -116.36 115.26 25.55 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.878 -179.951 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 57' ' ' GLY . . . . . 0.443 ' CA ' ' CE1' ' A' ' 86' ' ' PHE . . . -82.27 65.72 4.02 Favored Glycine 0 N--CA 1.451 -0.307 0 C-N-CA 120.75 -0.738 . . . . 0.0 112.431 -179.973 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 58' ' ' ILE . . . . . 0.704 HD11 HD13 ' A' ' 92' ' ' ILE . 5.5 mt -72.67 143.66 13.75 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-O 120.816 0.341 . . . . 0.0 111.074 179.986 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 8.0 tt0 -104.23 143.04 33.49 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.836 179.95 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 60' ' ' LEU . . . . . . . . . . . . . 82.1 mt -96.11 173.18 7.54 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.929 -179.957 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 7.9 t0 -97.12 -33.19 11.6 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.954 179.991 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 62' ' ' GLN . . . . . . . . . . . . . 2.7 mt-30 -116.14 146.36 36.99 Favored Pre-proline 0 C--N 1.329 -0.319 0 CA-C-N 116.18 -0.463 . . . . 0.0 110.936 179.97 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 48.1 Cg_exo -55.83 86.75 0.04 OUTLIER 'Trans proline' 0 C--N 1.346 0.409 0 C-N-CA 122.548 2.165 . . . . 0.0 112.172 179.955 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 64' ' ' THR . . . . . . . . . . . . . 80.8 p -157.3 30.44 0.29 Allowed 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.251 -0.431 . . . . 0.0 110.984 -179.979 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . -89.62 175.54 42.29 Favored Glycine 0 N--CA 1.451 -0.363 0 C-N-CA 120.708 -0.758 . . . . 0.0 112.491 179.957 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 66' ' ' LYS . . . . . . . . . . . . . 48.5 mttm -78.61 -30.47 46.57 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 120.693 0.282 . . . . 0.0 110.865 179.94 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 67' ' ' HIS . . . . . . . . . . . . . 7.4 p80 -148.38 -178.98 6.61 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.898 -179.961 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 9.2 p30 -105.25 48.49 0.84 Allowed 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.952 179.999 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 94.02 -45.91 2.27 Favored Glycine 0 N--CA 1.452 -0.294 0 C-N-CA 120.738 -0.744 . . . . 0.0 112.512 -179.964 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 70' ' ' SER . . . . . . . . . . . . . 1.6 p -98.96 136.58 38.73 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-O 120.821 0.344 . . . . 0.0 110.901 179.985 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 71' ' ' VAL . . . . . 0.468 HG12 ' CD2' ' A' ' 72' ' ' PHE . 21.4 t -114.41 110.64 32.8 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.253 -0.431 . . . . 0.0 111.131 179.969 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 72' ' ' PHE . . . . . 0.468 ' CD2' HG12 ' A' ' 71' ' ' VAL . 60.6 m-85 60.47 31.89 20.41 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.22 -0.446 . . . . 0.0 110.961 179.967 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 98.85 -30.18 10.25 Favored Glycine 0 N--CA 1.451 -0.355 0 C-N-CA 120.685 -0.769 . . . . 0.0 112.556 -179.962 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 21.4 t -77.95 117.63 23.52 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-O 120.823 0.344 . . . . 0.0 111.127 179.904 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 75' ' ' ARG . . . . . . . . . . . . . 5.1 ttt180 -95.33 149.52 21.27 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.988 -179.864 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 76' ' ' TYR . . . . . . . . . . . . . 35.9 m-85 -129.94 -45.6 1.15 Allowed 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.25 -0.432 . . . . 0.0 110.947 179.951 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 77' ' ' PHE . . . . . . . . . . . . . 38.1 p90 -146.72 164.72 31.85 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.31 -0.405 . . . . 0.0 110.997 179.945 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 51.7 p -96.18 123.49 39.82 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.921 -179.97 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 79' ' ' CYS . . . . . . . . . . . . . 7.5 p -148.02 170.57 17.47 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.877 179.891 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 80' ' ' ALA . . . . . 0.407 ' HB1' ' HD2' ' A' ' 81' ' ' PRO . . . -71.73 162.48 72.93 Favored Pre-proline 0 C--N 1.329 -0.289 0 CA-C-N 116.163 -0.471 . . . . 0.0 111.079 -179.952 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 81' ' ' PRO . . . . . 0.407 ' HD2' ' HB1' ' A' ' 80' ' ' ALA . 53.0 Cg_exo -52.4 118.46 4.66 Favored 'Trans proline' 0 C--N 1.344 0.3 0 C-N-CA 122.632 2.221 . . . . 0.0 112.294 179.971 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 82' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER 60.27 63.53 1.38 Allowed 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.869 179.972 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 83' ' ' HIS . . . . . . . . . . . . . 3.3 m-70 -132.3 -46.02 0.91 Allowed 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.13 -0.486 . . . . 0.0 110.911 -179.975 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . -63.73 141.69 45.74 Favored Glycine 0 N--CA 1.451 -0.362 0 C-N-CA 120.709 -0.757 . . . . 0.0 112.52 179.996 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 85' ' ' VAL . . . . . . . . . . . . . 6.1 m -142.15 120.14 8.24 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-O 120.768 0.318 . . . . 0.0 111.166 -179.974 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 86' ' ' PHE . . . . . 0.443 ' CE1' ' CA ' ' A' ' 57' ' ' GLY . 12.4 m-85 -100.38 115.39 29.9 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.868 179.994 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 87' ' ' ALA . . . . . 0.609 ' O ' HD11 ' A' ' 92' ' ' ILE . . . -137.8 145.57 49.04 Favored Pre-proline 0 C--N 1.328 -0.336 0 CA-C-N 116.28 -0.418 . . . . 0.0 111.143 179.924 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 88' ' ' PRO . . . . . 0.406 ' O ' ' N ' ' A' ' 91' ' ' ARG . 47.4 Cg_exo -56.02 139.14 84.51 Favored 'Trans proline' 0 C--N 1.345 0.388 0 C-N-CA 122.454 2.103 . . . . 0.0 112.336 -179.977 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 89' ' ' ALA . . . . . 0.827 ' HB2' ' CE1' ' A' ' 56' ' ' TYR . . . -48.01 -50.91 26.03 Favored 'General case' 0 C--N 1.333 -0.122 0 CA-C-N 116.109 -0.496 . . . . 0.0 110.272 179.862 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 90' ' ' SER . . . . . . . . . . . . . 17.7 m -55.76 -24.49 35.65 Favored 'General case' 0 N--CA 1.454 -0.259 0 CA-C-N 115.687 -0.688 . . . . 0.0 109.766 178.816 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 91' ' ' ARG . . . . . 0.406 ' N ' ' O ' ' A' ' 88' ' ' PRO . 0.6 OUTLIER -88.3 -15.14 36.53 Favored 'General case' 0 N--CA 1.455 -0.188 0 CA-C-N 115.831 -0.622 . . . . 0.0 110.473 179.02 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 92' ' ' ILE . . . . . 0.704 HD13 HD11 ' A' ' 58' ' ' ILE . 33.3 mt -104.37 157.89 5.5 Favored 'Isoleucine or valine' 0 C--N 1.334 -0.097 0 CA-C-N 116.379 -0.373 . . . . 0.0 110.973 179.924 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 93' ' ' GLN . . . . . 0.482 ' N ' HG22 ' A' ' 92' ' ' ILE . 2.2 mt-30 -128.3 166.34 18.81 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.889 -179.912 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 94' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -107.15 145.36 32.64 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.846 -179.994 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 95' ' ' ILE . . . . . . . . . . . . . 23.4 mt -115.58 -36.94 2.2 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.211 -0.449 . . . . 0.0 111.13 179.902 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . -105.4 146.47 16.08 Favored Glycine 0 N--CA 1.451 -0.339 0 C-N-CA 120.782 -0.723 . . . . 0.0 112.514 179.971 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 97' ' ' SER . . . . . . . . . . . . . 85.9 p -134.95 40.95 2.89 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-O 120.849 0.357 . . . . 0.0 110.841 179.998 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 98' ' ' GLY . . . . . . . . . . . . . . . 172.76 99.22 0.12 Allowed Glycine 0 N--CA 1.451 -0.32 0 C-N-CA 120.717 -0.754 . . . . 0.0 112.461 -179.994 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 99' ' ' PRO . . . . . . . . . . . . . 43.0 Cg_endo -67.75 -27.84 37.48 Favored 'Trans proline' 0 C--N 1.346 0.405 0 C-N-CA 122.431 2.088 . . . . 0.0 112.295 179.94 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 100' ' ' SER . . . . . . . . . . . . . 13.3 p -133.34 79.0 1.81 Allowed 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.949 179.974 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -144.1 170.8 15.27 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.906 -179.956 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.249 1.032 0 CA-C-O 118.335 -1.259 . . . . 0.0 112.449 -179.964 . . . . . . . . 0 0 . 1 . 002 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.17 0 N-CA-C 112.474 -0.251 . . . . 0.0 112.474 . . . . . . . . . 0 0 . 1 . 002 nuclear build full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 2.1 p -83.03 134.61 35.03 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-O 120.925 0.393 . . . . 0.0 110.941 -179.88 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -120.49 -51.28 2.18 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.075 -0.511 . . . . 0.0 110.77 179.827 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -110.31 100.69 1.31 Allowed Glycine 0 N--CA 1.451 -0.347 0 C-N-CA 120.728 -0.748 . . . . 0.0 112.488 179.9 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 9.4 p -167.79 35.1 0.03 OUTLIER 'General case' 0 C--N 1.33 -0.269 0 CA-C-O 120.746 0.308 . . . . 0.0 110.932 -179.875 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 40.1 t -76.97 -61.02 2.12 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.315 -0.402 . . . . 0.0 110.881 179.952 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 84.27 -121.2 5.47 Favored Glycine 0 N--CA 1.451 -0.326 0 C-N-CA 120.677 -0.773 . . . . 0.0 112.534 179.968 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 17.3 mmtt -148.3 127.74 13.13 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-O 120.769 0.319 . . . . 0.0 110.884 -179.945 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 12.8 p -159.99 99.78 1.46 Allowed Pre-proline 0 C--N 1.329 -0.306 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.903 -179.967 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 44.0 Cg_endo -68.01 106.32 1.32 Allowed 'Trans proline' 0 C--N 1.345 0.369 0 C-N-CA 122.44 2.093 . . . . 0.0 112.258 -179.98 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 26.7 t -115.48 44.39 1.87 Allowed 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.896 179.929 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -161.93 89.4 1.46 Allowed Pre-proline 0 C--N 1.329 -0.292 0 CA-C-N 116.1 -0.5 . . . . 0.0 110.988 179.939 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 64.7 Cg_exo -51.12 108.6 0.24 Allowed 'Trans proline' 0 C--N 1.345 0.389 0 C-N-CA 122.518 2.145 . . . . 0.0 112.29 179.951 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 23.1 t -145.86 -45.47 0.21 Allowed 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.248 -0.433 . . . . 0.0 111.062 -179.965 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 6.3 mp -116.87 -77.61 0.57 Allowed 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.268 -0.424 . . . . 0.0 110.973 -179.926 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -92.54 85.15 1.17 Allowed Glycine 0 N--CA 1.45 -0.375 0 C-N-CA 120.714 -0.755 . . . . 0.0 112.421 179.966 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -59.01 -168.53 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 120.792 0.33 . . . . 0.0 110.889 -179.945 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 1.0 OUTLIER -134.06 34.58 3.33 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.271 -0.422 . . . . 0.0 110.904 180.0 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 19' ' ' GLN . . . . . . . . . . . . . 5.4 tm0? -59.82 -38.21 81.35 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.881 179.933 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 20' ' ' GLN . . . . . . . . . . . . . 0.6 OUTLIER -133.54 145.45 50.12 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.838 -180.0 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 10.4 ptp180 -114.01 39.93 2.6 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.265 -0.425 . . . . 0.0 110.94 -179.974 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 24.6 mt-10 -106.18 178.11 4.66 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.918 179.916 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 174.28 -121.17 0.83 Allowed Glycine 0 N--CA 1.451 -0.319 0 C-N-CA 120.742 -0.742 . . . . 0.0 112.527 -179.923 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -108.92 130.9 55.45 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-O 120.81 0.338 . . . . 0.0 111.098 179.982 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 1.6 tttp -70.73 -35.49 72.73 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.874 179.985 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 26' ' ' ALA . . . . . 0.584 ' HB3' ' CE2' ' A' ' 56' ' ' TYR . . . -138.63 -176.8 4.6 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.209 -0.45 . . . . 0.0 111.081 179.985 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 27' ' ' GLU . . . . . . . . . . . . . 6.0 mt-10 -148.03 173.37 12.98 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.252 -0.431 . . . . 0.0 110.911 179.98 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 21.5 t -70.83 110.28 3.72 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.087 179.974 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 113.01 36.24 1.54 Allowed Glycine 0 N--CA 1.452 -0.296 0 C-N-CA 120.736 -0.745 . . . . 0.0 112.503 179.97 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 2.1 m-20 -150.06 138.05 20.23 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 120.852 0.358 . . . . 0.0 110.866 -179.978 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 31' ' ' GLN . . . . . . . . . . . . . 0.7 OUTLIER -62.94 132.88 53.57 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.125 -0.489 . . . . 0.0 110.871 179.998 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 32' ' ' VAL . . . . . 0.486 HG21 HG12 ' A' ' 58' ' ' ILE . 12.6 m -132.99 178.81 5.12 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.149 179.99 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 33' ' ' LEU . . . . . 0.55 HD11 ' O ' ' A' ' 37' ' ' GLN . 40.4 tp -140.14 101.22 4.1 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.9 179.931 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 34' ' ' VAL . . . . . 0.406 ' CG2' HD13 ' A' ' 58' ' ' ILE . 21.6 t -72.55 127.68 34.75 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.218 -0.446 . . . . 0.0 111.175 -179.928 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 35' ' ' ALA . . . . . . . . . . . . . . . 57.68 25.33 11.62 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.139 -0.482 . . . . 0.0 111.266 179.937 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . 56.07 27.96 52.75 Favored Glycine 0 N--CA 1.453 -0.224 0 C-N-CA 120.686 -0.769 . . . . 0.0 112.638 179.979 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 37' ' ' GLN . . . . . 0.55 ' O ' HD11 ' A' ' 33' ' ' LEU . 37.7 mt-30 -138.1 -72.83 0.41 Allowed 'General case' 0 C--N 1.33 -0.279 0 CA-C-O 120.797 0.332 . . . . 0.0 110.944 -179.906 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 38' ' ' LYS . . . . . . . . . . . . . 3.7 mttt -69.02 111.81 5.25 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.265 -0.425 . . . . 0.0 110.965 179.991 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 39' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -92.98 130.5 38.53 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.086 -0.506 . . . . 0.0 110.905 -179.997 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -152.04 -171.0 19.33 Favored Glycine 0 N--CA 1.45 -0.38 0 C-N-CA 120.812 -0.709 . . . . 0.0 112.52 -179.988 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 29.8 mt -123.4 131.92 72.29 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 CA-C-O 120.825 0.345 . . . . 0.0 111.172 179.973 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 42' ' ' VAL . . . . . . . . . . . . . 21.6 t -59.44 126.87 17.85 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.336 0 CA-C-N 116.24 -0.436 . . . . 0.0 111.105 -179.999 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 43' ' ' ARG . . . . . . . . . . . . . 8.7 mmm180 -111.81 -42.56 3.78 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.932 -179.999 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 44' ' ' PHE . . . . . . . . . . . . . 46.0 t80 -138.66 113.24 8.95 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.937 -179.937 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 45' ' ' TYR . . . . . 0.426 ' CE1' ' CE1' ' A' ' 56' ' ' TYR . 35.8 t80 -113.08 138.56 49.73 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.956 179.98 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 152.71 -169.57 31.79 Favored Glycine 0 N--CA 1.449 -0.45 0 C-N-CA 120.783 -0.722 . . . . 0.0 112.489 179.957 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 47' ' ' LYS . . . . . . . . . . . . . 28.7 mttm -78.21 147.35 34.49 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-O 120.847 0.356 . . . . 0.0 110.844 -179.954 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 48' ' ' THR . . . . . 0.654 HG22 ' CE2' ' A' ' 76' ' ' TYR . 34.8 p -118.88 171.52 8.17 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.913 179.985 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -98.88 -35.79 9.99 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.885 179.972 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 50' ' ' PHE . . . . . 0.574 ' CZ ' HG21 ' A' ' 48' ' ' THR . 27.0 p90 -61.61 -31.39 71.46 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.92 179.907 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 51' ' ' ALA . . . . . . . . . . . . . . . -152.11 146.42 18.52 Favored Pre-proline 0 C--N 1.329 -0.294 0 CA-C-N 116.26 -0.427 . . . . 0.0 111.117 179.997 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 52' ' ' PRO . . . . . . . . . . . . . 60.9 Cg_endo -72.86 175.82 9.84 Favored 'Trans proline' 0 C--N 1.345 0.368 0 C-N-CA 122.573 2.182 . . . . 0.0 112.334 179.973 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 84.11 -158.79 35.03 Favored Glycine 0 N--CA 1.45 -0.369 0 C-N-CA 120.716 -0.754 . . . . 0.0 112.541 179.986 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 54' ' ' TYR . . . . . . . . . . . . . 20.2 m-85 -118.74 124.64 47.78 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-O 120.872 0.368 . . . . 0.0 110.897 179.982 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 55' ' ' TRP . . . . . . . . . . . . . 36.4 m95 -118.19 162.89 17.49 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.911 179.988 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 56' ' ' TYR . . . . . 0.692 ' HE1' ' HB2' ' A' ' 89' ' ' ALA . 8.4 m-85 -110.69 125.37 53.4 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.934 -179.91 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 57' ' ' GLY . . . . . 0.431 ' HA3' ' CE1' ' A' ' 77' ' ' PHE . . . -88.01 53.28 4.21 Favored Glycine 0 N--CA 1.451 -0.365 0 C-N-CA 120.72 -0.752 . . . . 0.0 112.423 179.97 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 58' ' ' ILE . . . . . 0.486 HG12 HG21 ' A' ' 32' ' ' VAL . 3.8 mt -64.64 142.33 17.03 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.266 0 CA-C-O 120.834 0.349 . . . . 0.0 111.164 -179.981 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 2.4 tm-20 -115.12 108.11 16.2 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.118 -0.492 . . . . 0.0 110.836 -179.947 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 60' ' ' LEU . . . . . . . . . . . . . 48.0 mt -67.75 176.28 2.57 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.906 -179.964 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -100.86 -32.87 10.46 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.852 -179.995 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 62' ' ' GLN . . . . . . . . . . . . . 0.2 OUTLIER -101.37 154.69 37.07 Favored Pre-proline 0 C--N 1.328 -0.332 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.917 179.976 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 58.3 Cg_endo -71.85 68.13 3.09 Favored 'Trans proline' 0 C--N 1.344 0.308 0 C-N-CA 122.584 2.189 . . . . 0.0 112.275 -179.965 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 64' ' ' THR . . . . . . . . . . . . . 73.4 p -139.54 34.25 2.04 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.901 -179.994 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . -88.33 -129.11 3.15 Favored Glycine 0 N--CA 1.452 -0.295 0 C-N-CA 120.732 -0.747 . . . . 0.0 112.579 179.948 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 66' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -144.96 -47.33 0.23 Allowed 'General case' 0 C--N 1.328 -0.353 0 CA-C-O 120.785 0.326 . . . . 0.0 110.845 -179.991 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 67' ' ' HIS . . . . . . . . . . . . . 7.6 p80 -119.94 170.02 9.64 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.213 -0.448 . . . . 0.0 110.839 179.973 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 39.0 m-20 -98.42 34.04 2.09 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.862 -179.983 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 94.62 -42.72 2.39 Favored Glycine 0 N--CA 1.451 -0.329 0 C-N-CA 120.737 -0.744 . . . . 0.0 112.586 -179.939 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 70' ' ' SER . . . . . . . . . . . . . 5.6 p -100.8 134.67 43.42 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-O 120.833 0.349 . . . . 0.0 110.946 -179.984 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 71' ' ' VAL . . . . . 0.409 HG12 ' CD2' ' A' ' 72' ' ' PHE . 21.3 t -114.92 102.95 14.57 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.156 -0.474 . . . . 0.0 111.062 -179.913 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 72' ' ' PHE . . . . . 0.409 ' CD2' HG12 ' A' ' 71' ' ' VAL . 33.2 m-85 61.75 30.8 18.52 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.191 -0.458 . . . . 0.0 110.935 179.929 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 104.21 -30.09 10.81 Favored Glycine 0 N--CA 1.451 -0.362 0 C-N-CA 120.703 -0.76 . . . . 0.0 112.513 179.973 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 21.4 t -77.82 116.87 22.04 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.345 0 CA-C-O 120.749 0.309 . . . . 0.0 111.173 179.978 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 75' ' ' ARG . . . . . . . . . . . . . 10.1 ttm180 -96.62 143.24 27.77 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.272 -0.422 . . . . 0.0 110.898 -179.956 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 76' ' ' TYR . . . . . 0.654 ' CE2' HG22 ' A' ' 48' ' ' THR . 20.0 m-85 -118.69 -40.48 2.88 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.933 179.926 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 77' ' ' PHE . . . . . 0.431 ' CE1' ' HA3' ' A' ' 57' ' ' GLY . 16.0 p90 -160.07 157.55 28.79 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.956 179.972 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 18.8 m -83.9 111.51 19.3 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.836 -179.974 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 79' ' ' CYS . . . . . . . . . . . . . 30.5 p -132.74 174.24 10.52 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.901 179.941 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 80' ' ' ALA . . . . . 0.668 ' HB3' ' CD2' ' A' ' 83' ' ' HIS . . . -91.91 171.58 7.61 Favored Pre-proline 0 C--N 1.33 -0.281 0 CA-C-N 116.161 -0.472 . . . . 0.0 111.151 179.997 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 81' ' ' PRO . . . . . 0.624 ' HD2' ' HB1' ' A' ' 80' ' ' ALA . 50.7 Cg_exo -53.77 116.14 2.81 Favored 'Trans proline' 0 C--N 1.344 0.301 0 C-N-CA 122.592 2.194 . . . . 0.0 112.322 179.988 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 82' ' ' ARG . . . . . . . . . . . . . 3.4 mtp85 61.1 52.31 4.06 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.896 179.901 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 83' ' ' HIS . . . . . 0.668 ' CD2' ' HB3' ' A' ' 80' ' ' ALA . 0.9 OUTLIER -120.99 -43.02 2.47 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.793 179.936 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . -75.2 144.4 31.97 Favored Glycine 0 N--CA 1.45 -0.383 0 C-N-CA 120.817 -0.706 . . . . 0.0 112.495 179.938 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 85' ' ' VAL . . . . . . . . . . . . . 6.6 m -147.77 127.39 4.44 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-O 120.806 0.336 . . . . 0.0 111.231 179.978 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 86' ' ' PHE . . . . . . . . . . . . . 6.1 m-85 -106.71 110.74 23.01 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.886 179.975 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 87' ' ' ALA . . . . . 0.606 ' O ' HD11 ' A' ' 92' ' ' ILE . . . -132.27 150.96 77.45 Favored Pre-proline 0 C--N 1.33 -0.268 0 CA-C-N 116.189 -0.459 . . . . 0.0 111.106 -179.957 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 88' ' ' PRO . . . . . 0.405 ' O ' ' N ' ' A' ' 91' ' ' ARG . 32.1 Cg_exo -58.4 138.09 83.94 Favored 'Trans proline' 0 C--N 1.344 0.338 0 C-N-CA 122.518 2.146 . . . . 0.0 112.285 -179.972 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 89' ' ' ALA . . . . . 0.692 ' HB2' ' HE1' ' A' ' 56' ' ' TYR . . . -48.05 -51.29 24.85 Favored 'General case' 0 CA--C 1.522 -0.124 0 CA-C-N 116.106 -0.497 . . . . 0.0 110.331 179.845 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 90' ' ' SER . . . . . . . . . . . . . 70.3 p -55.96 -24.41 38.14 Favored 'General case' 0 N--CA 1.453 -0.296 0 CA-C-N 115.714 -0.675 . . . . 0.0 109.769 178.809 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 91' ' ' ARG . . . . . 0.405 ' N ' ' O ' ' A' ' 88' ' ' PRO . 1.3 mtt180 -88.43 -14.6 37.57 Favored 'General case' 0 N--CA 1.453 -0.282 0 CA-C-N 115.852 -0.613 . . . . 0.0 110.535 178.992 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 92' ' ' ILE . . . . . 0.606 HD11 ' O ' ' A' ' 87' ' ' ALA . 26.0 mt -107.02 146.01 13.85 Favored 'Isoleucine or valine' 0 C--O 1.23 0.076 0 CA-C-N 116.302 -0.408 . . . . 0.0 111.014 179.935 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 93' ' ' GLN . . . . . . . . . . . . . 2.1 mt-30 -115.53 177.2 4.75 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.904 179.973 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 94' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER -115.81 148.23 40.12 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.923 179.971 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 95' ' ' ILE . . . . . 0.482 HD11 ' HB2' ' A' ' 33' ' ' LEU . 28.8 mm -96.51 -53.95 7.58 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.358 0 CA-C-N 116.259 -0.428 . . . . 0.0 111.082 -179.935 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . -123.74 156.31 17.94 Favored Glycine 0 N--CA 1.45 -0.368 0 C-N-CA 120.775 -0.726 . . . . 0.0 112.479 -179.961 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 97' ' ' SER . . . . . . . . . . . . . 33.6 t -170.2 -173.97 1.62 Allowed 'General case' 0 C--N 1.329 -0.301 0 CA-C-O 120.852 0.358 . . . . 0.0 110.884 -179.988 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 98' ' ' GLY . . . . . . . . . . . . . . . -127.88 70.28 0.51 Allowed Glycine 0 N--CA 1.451 -0.313 0 C-N-CA 120.814 -0.708 . . . . 0.0 112.487 -179.954 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 99' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_exo -52.23 -30.47 42.1 Favored 'Trans proline' 0 C--N 1.344 0.308 0 C-N-CA 122.588 2.192 . . . . 0.0 112.359 -179.99 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 100' ' ' SER . . . . . . . . . . . . . 12.7 p 58.57 175.45 0.07 Allowed 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.108 -0.496 . . . . 0.0 110.978 179.98 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 46.0 p -168.48 35.31 0.03 OUTLIER 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.857 -179.991 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.249 1.093 0 CA-C-O 118.393 -1.226 . . . . 0.0 112.54 -179.997 . . . . . . . . 0 0 . 1 . 003 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.28 0 N-CA-C 112.482 -0.247 . . . . 0.0 112.482 . . . . . . . . . 0 0 . 1 . 003 nuclear build full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 21.8 t -158.64 167.08 30.51 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-O 120.783 0.325 . . . . 0.0 110.924 -179.952 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 32.8 t -119.76 -42.34 2.63 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.813 -179.97 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 150.02 -162.4 29.17 Favored Glycine 0 N--CA 1.451 -0.363 0 C-N-CA 120.752 -0.737 . . . . 0.0 112.471 -179.963 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 1.4 m -110.24 -42.6 4.11 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-O 120.773 0.321 . . . . 0.0 110.856 179.963 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 2.0 m -144.34 -179.32 6.46 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.797 179.978 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -169.79 -123.81 0.7 Allowed Glycine 0 N--CA 1.45 -0.368 0 C-N-CA 120.707 -0.759 . . . . 0.0 112.527 -179.999 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 12.5 tttm -91.14 130.35 37.04 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-O 120.76 0.314 . . . . 0.0 110.837 -179.958 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER 59.79 84.83 0.19 Allowed Pre-proline 0 C--N 1.329 -0.301 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.956 179.991 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 51.9 Cg_exo -52.79 151.76 18.98 Favored 'Trans proline' 0 C--N 1.345 0.35 0 C-N-CA 122.595 2.197 . . . . 0.0 112.295 -179.996 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 20.3 m -141.39 -60.54 0.48 Allowed 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.178 -0.464 . . . . 0.0 110.906 179.973 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 24.3 t -165.98 63.33 0.84 Allowed Pre-proline 0 C--N 1.329 -0.294 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.922 179.951 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 52.3 Cg_exo -52.72 -49.09 18.71 Favored 'Trans proline' 0 C--N 1.345 0.36 0 C-N-CA 122.641 2.227 . . . . 0.0 112.298 -179.959 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 1.3 m -109.87 152.94 25.14 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.147 -0.478 . . . . 0.0 110.892 -179.947 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 0.6 OUTLIER -151.67 73.98 1.1 Allowed 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.872 179.986 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 67.08 -115.35 7.11 Favored Glycine 0 N--CA 1.452 -0.291 0 C-N-CA 120.713 -0.756 . . . . 0.0 112.463 -179.971 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -177.02 37.8 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 120.856 0.36 . . . . 0.0 110.923 -179.953 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -131.16 -67.82 0.69 Allowed 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.189 -0.459 . . . . 0.0 110.938 179.944 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 19' ' ' GLN . . . . . . . . . . . . . 3.4 mp0 60.43 -178.24 0.1 Allowed 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.908 -179.976 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 20' ' ' GLN . . . . . . . . . . . . . 2.0 mt-30 -148.8 117.55 6.64 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.916 179.961 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -127.56 159.63 34.02 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.838 -179.957 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 4.3 mm-40 60.17 35.53 21.08 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.884 179.989 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 78.46 -123.89 6.45 Favored Glycine 0 N--CA 1.451 -0.327 0 C-N-CA 120.715 -0.755 . . . . 0.0 112.502 -179.963 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . 59.77 79.8 0.22 Allowed 'General case' 0 C--N 1.329 -0.325 0 CA-C-O 120.731 0.301 . . . . 0.0 111.105 179.949 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -86.86 -39.86 15.44 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.823 -179.986 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -118.41 168.16 10.9 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.176 -0.465 . . . . 0.0 111.143 179.909 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 27' ' ' GLU . . . . . . . . . . . . . 3.0 mt-10 -115.25 -173.28 2.29 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.899 179.967 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 21.4 t -80.18 98.31 3.36 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.312 -0.404 . . . . 0.0 111.05 179.978 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 111.78 29.72 3.25 Favored Glycine 0 N--CA 1.451 -0.312 0 C-N-CA 120.807 -0.711 . . . . 0.0 112.417 179.912 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 1.2 t70 -122.81 146.03 47.91 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 120.832 0.348 . . . . 0.0 110.894 179.981 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 31' ' ' GLN . . . . . . . . . . . . . 18.1 mt-30 -60.76 131.46 50.75 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.821 179.953 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 14.5 m -140.3 171.81 12.8 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.156 -0.475 . . . . 0.0 111.137 179.978 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 33' ' ' LEU . . . . . . . . . . . . . 17.8 tp -134.21 110.54 9.61 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.903 -179.963 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 34' ' ' VAL . . . . . 0.414 HG22 ' CD1' ' A' ' 58' ' ' ILE . 21.6 t -77.95 120.43 28.68 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 116.221 -0.445 . . . . 0.0 111.09 -179.937 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 35' ' ' ALA . . . . . . . . . . . . . . . 58.25 27.05 14.65 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.163 -0.471 . . . . 0.0 111.192 179.981 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . 56.77 31.33 60.73 Favored Glycine 0 N--CA 1.452 -0.282 0 C-N-CA 120.709 -0.758 . . . . 0.0 112.606 179.931 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 37' ' ' GLN . . . . . . . . . . . . . 91.5 mt-30 -140.28 -73.27 0.36 Allowed 'General case' 0 C--N 1.33 -0.272 0 CA-C-O 120.833 0.349 . . . . 0.0 110.962 -179.992 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 38' ' ' LYS . . . . . 0.466 ' HB3' HD21 ' A' ' 60' ' ' LEU . 34.1 mttp -68.22 104.27 1.78 Allowed 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.855 179.977 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 39' ' ' GLN . . . . . . . . . . . . . 0.4 OUTLIER -85.34 136.07 33.63 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.252 -0.431 . . . . 0.0 110.839 179.905 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -164.56 -163.7 18.21 Favored Glycine 0 N--CA 1.451 -0.356 0 C-N-CA 120.771 -0.728 . . . . 0.0 112.539 179.965 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 32.4 mt -131.12 139.51 50.84 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-O 120.79 0.328 . . . . 0.0 111.156 179.994 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 42' ' ' VAL . . . . . . . . . . . . . 23.2 t -69.18 124.36 24.8 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.334 0 CA-C-N 116.187 -0.46 . . . . 0.0 111.059 -179.952 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 43' ' ' ARG . . . . . . . . . . . . . 27.8 mmt180 -105.58 -32.57 8.42 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.178 -0.464 . . . . 0.0 110.984 -179.956 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 44' ' ' PHE . . . . . . . . . . . . . 51.0 t80 -143.08 118.11 10.05 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 116.189 -0.459 . . . . 0.0 110.962 -179.93 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 45' ' ' TYR . . . . . 0.494 ' CE1' ' CZ ' ' A' ' 56' ' ' TYR . 15.5 t80 -113.02 117.94 33.41 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.867 179.965 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 172.74 170.25 36.26 Favored Glycine 0 N--CA 1.452 -0.26 0 C-N-CA 120.657 -0.782 . . . . 0.0 112.487 179.979 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 47' ' ' LYS . . . . . 0.421 ' HG3' ' CE1' ' A' ' 54' ' ' TYR . 19.5 mttt -67.09 148.08 52.33 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 120.837 0.351 . . . . 0.0 110.942 179.983 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 48' ' ' THR . . . . . 0.608 HG21 ' CZ ' ' A' ' 50' ' ' PHE . 16.6 p -109.15 170.85 7.79 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.893 179.988 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 8.3 t0 -98.3 -31.12 12.21 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.869 179.989 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 50' ' ' PHE . . . . . 0.608 ' CZ ' HG21 ' A' ' 48' ' ' THR . 18.1 p90 -66.54 -32.23 73.45 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.935 -179.962 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 51' ' ' ALA . . . . . 0.435 ' N ' ' CD1' ' A' ' 50' ' ' PHE . . . -148.94 151.72 35.34 Favored Pre-proline 0 C--N 1.329 -0.299 0 CA-C-N 116.271 -0.422 . . . . 0.0 111.096 179.996 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 52' ' ' PRO . . . . . . . . . . . . . 56.8 Cg_endo -70.67 -167.94 0.29 Allowed 'Trans proline' 0 C--N 1.344 0.31 0 C-N-CA 122.598 2.198 . . . . 0.0 112.289 179.997 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 65.2 -176.39 12.82 Favored Glycine 0 N--CA 1.45 -0.38 0 C-N-CA 120.791 -0.719 . . . . 0.0 112.481 179.971 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 54' ' ' TYR . . . . . 0.421 ' CE1' ' HG3' ' A' ' 47' ' ' LYS . 7.6 m-85 -106.57 128.97 54.55 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-O 120.828 0.347 . . . . 0.0 110.928 179.974 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 55' ' ' TRP . . . . . . . . . . . . . 35.0 m95 -116.2 174.29 6.13 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.846 -179.969 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 56' ' ' TYR . . . . . 0.73 ' HE1' ' HB2' ' A' ' 89' ' ' ALA . 16.8 m-85 -125.35 121.64 34.51 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.92 -179.963 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 57' ' ' GLY . . . . . 0.403 ' N ' ' CE1' ' A' ' 86' ' ' PHE . . . -82.11 62.03 4.61 Favored Glycine 0 N--CA 1.451 -0.33 0 C-N-CA 120.776 -0.726 . . . . 0.0 112.417 179.928 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 58' ' ' ILE . . . . . 0.541 HD11 HD13 ' A' ' 92' ' ' ILE . 21.2 mt -68.67 139.71 20.14 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-O 120.809 0.338 . . . . 0.0 111.122 -179.993 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 4.7 tm-20 -111.99 112.52 24.22 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.91 179.959 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 60' ' ' LEU . . . . . 0.466 HD21 ' HB3' ' A' ' 38' ' ' LYS . 84.7 mt -72.53 177.34 4.73 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.967 -179.992 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -100.42 -32.37 10.85 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.815 179.998 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 62' ' ' GLN . . . . . . . . . . . . . 4.7 mm100 -106.62 155.33 39.08 Favored Pre-proline 0 C--N 1.328 -0.34 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.829 179.999 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 57.7 Cg_endo -71.51 68.11 2.82 Favored 'Trans proline' 0 C--N 1.345 0.354 0 C-N-CA 122.544 2.163 . . . . 0.0 112.399 179.907 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 64' ' ' THR . . . . . . . . . . . . . 12.4 p -136.0 31.18 3.0 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.871 -179.999 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . -92.95 -139.75 9.46 Favored Glycine 0 N--CA 1.451 -0.349 0 C-N-CA 120.754 -0.736 . . . . 0.0 112.548 -179.956 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 66' ' ' LYS . . . . . 0.451 ' HD2' HG12 ' A' ' 85' ' ' VAL . 0.0 OUTLIER -128.63 -45.75 1.31 Allowed 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 120.848 0.356 . . . . 0.0 110.924 179.961 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 67' ' ' HIS . . . . . . . . . . . . . 7.2 p80 -127.1 169.89 12.93 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.233 -0.44 . . . . 0.0 110.871 179.974 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 10.3 p-10 -98.56 36.51 1.63 Allowed 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.935 179.964 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 105.88 -50.37 0.82 Allowed Glycine 0 N--CA 1.45 -0.391 0 C-N-CA 120.756 -0.735 . . . . 0.0 112.502 179.964 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 70' ' ' SER . . . . . . . . . . . . . 80.5 p -93.26 151.84 19.56 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 120.836 0.35 . . . . 0.0 110.832 -179.945 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 71' ' ' VAL . . . . . 0.622 HG12 ' CD2' ' A' ' 72' ' ' PHE . 20.0 t -141.35 110.47 2.77 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 CA-C-N 116.226 -0.443 . . . . 0.0 111.069 -180.0 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 72' ' ' PHE . . . . . 0.622 ' CD2' HG12 ' A' ' 71' ' ' VAL . 67.6 m-85 60.17 31.17 20.43 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.903 -179.968 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 87.07 28.37 25.83 Favored Glycine 0 N--CA 1.451 -0.312 0 C-N-CA 120.747 -0.739 . . . . 0.0 112.498 179.98 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 21.4 t -128.35 104.27 11.38 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-O 120.901 0.381 . . . . 0.0 111.085 -179.988 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 75' ' ' ARG . . . . . . . . . . . . . 11.3 ttt180 -84.0 134.2 34.65 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.861 -179.934 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 76' ' ' TYR . . . . . 0.594 ' CE2' HG22 ' A' ' 48' ' ' THR . 56.5 m-85 -118.2 -41.51 2.86 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.883 179.973 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 77' ' ' PHE . . . . . . . . . . . . . 12.8 p90 -158.98 163.31 36.58 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.145 -0.48 . . . . 0.0 110.87 179.987 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 1.2 p -89.6 109.1 20.08 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.926 179.97 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 79' ' ' CYS . . . . . . . . . . . . . 28.6 p -138.41 166.19 24.88 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.921 -179.988 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 80' ' ' ALA . . . . . 0.795 ' HB3' ' CD2' ' A' ' 83' ' ' HIS . . . -77.51 168.93 23.75 Favored Pre-proline 0 C--N 1.329 -0.316 0 CA-C-N 116.227 -0.442 . . . . 0.0 111.07 -179.97 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 81' ' ' PRO . . . . . 0.531 ' HD2' ' HB1' ' A' ' 80' ' ' ALA . 32.5 Cg_exo -58.11 122.93 12.55 Favored 'Trans proline' 0 C--N 1.344 0.308 0 C-N-CA 122.582 2.188 . . . . 0.0 112.29 -179.929 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 82' ' ' ARG . . . . . . . . . . . . . 14.8 mtt-85 64.17 46.54 3.59 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.155 -0.475 . . . . 0.0 111.123 179.908 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 83' ' ' HIS . . . . . 0.795 ' CD2' ' HB3' ' A' ' 80' ' ' ALA . 0.7 OUTLIER -119.29 -45.18 2.55 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.796 179.892 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . -75.49 138.96 23.99 Favored Glycine 0 N--CA 1.452 -0.295 0 C-N-CA 120.742 -0.742 . . . . 0.0 112.47 179.955 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 85' ' ' VAL . . . . . 0.451 HG12 ' HD2' ' A' ' 66' ' ' LYS . 18.0 m -141.72 119.72 8.78 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.361 0 CA-C-O 120.818 0.342 . . . . 0.0 111.108 -179.91 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 86' ' ' PHE . . . . . 0.403 ' CE1' ' N ' ' A' ' 57' ' ' GLY . 9.3 m-85 -97.69 110.57 23.11 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.872 179.928 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 87' ' ' ALA . . . . . 0.554 ' O ' HD11 ' A' ' 92' ' ' ILE . . . -128.78 151.19 76.81 Favored Pre-proline 0 C--N 1.33 -0.273 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.163 -179.989 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 88' ' ' PRO . . . . . . . . . . . . . 31.8 Cg_exo -58.72 136.24 72.53 Favored 'Trans proline' 0 C--N 1.345 0.36 0 C-N-CA 122.619 2.213 . . . . 0.0 112.252 -179.925 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 89' ' ' ALA . . . . . 0.73 ' HB2' ' HE1' ' A' ' 56' ' ' TYR . . . -48.05 -51.25 25.02 Favored 'General case' 0 C--N 1.333 -0.124 0 CA-C-N 116.154 -0.476 . . . . 0.0 110.277 179.91 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 90' ' ' SER . . . . . . . . . . . . . 5.5 m -55.94 -24.36 37.54 Favored 'General case' 0 N--CA 1.454 -0.249 0 CA-C-N 115.724 -0.671 . . . . 0.0 109.757 178.81 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 91' ' ' ARG . . . . . . . . . . . . . 0.6 OUTLIER -89.11 -14.09 37.04 Favored 'General case' 0 N--CA 1.455 -0.21 0 CA-C-N 115.818 -0.628 . . . . 0.0 110.487 179.064 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 92' ' ' ILE . . . . . 0.554 HD11 ' O ' ' A' ' 87' ' ' ALA . 28.1 mt -108.26 146.25 14.35 Favored 'Isoleucine or valine' 0 C--O 1.231 0.091 0 CA-C-N 116.391 -0.368 . . . . 0.0 111.034 179.834 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 93' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -106.19 164.49 11.96 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.218 -0.447 . . . . 0.0 110.817 -179.993 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 94' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -116.35 119.27 35.14 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.887 -179.995 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 95' ' ' ILE . . . . . . . . . . . . . 22.2 mt -91.89 -61.88 1.86 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.18 -0.464 . . . . 0.0 111.197 179.96 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . 68.48 -72.36 0.34 Allowed Glycine 0 N--CA 1.451 -0.301 0 C-N-CA 120.738 -0.744 . . . . 0.0 112.413 179.89 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 97' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -155.06 -69.6 0.12 Allowed 'General case' 0 C--N 1.328 -0.34 0 CA-C-O 120.795 0.331 . . . . 0.0 110.864 -179.954 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 98' ' ' GLY . . . . . . . . . . . . . . . 99.72 -97.2 1.75 Allowed Glycine 0 N--CA 1.451 -0.304 0 C-N-CA 120.752 -0.737 . . . . 0.0 112.507 179.976 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 99' ' ' PRO . . . . . . . . . . . . . 50.0 Cg_exo -53.68 138.43 67.53 Favored 'Trans proline' 0 C--N 1.345 0.378 0 C-N-CA 122.507 2.138 . . . . 0.0 112.301 -179.986 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 100' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -81.12 152.27 27.88 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.874 -179.96 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -137.37 31.86 2.59 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.837 -179.96 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.249 1.058 0 CA-C-O 118.334 -1.259 . . . . 0.0 112.526 -179.997 . . . . . . . . 0 0 . 1 . 004 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.488 2.126 0 N-CA-C 112.518 -0.233 . . . . 0.0 112.518 . . . . . . . . . 0 0 . 1 . 004 nuclear build full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 1.3 m -149.62 -179.95 7.51 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-O 120.858 0.361 . . . . 0.0 110.827 -179.902 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -145.49 -47.45 0.22 Allowed 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.794 -179.995 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 170.54 -168.42 41.47 Favored Glycine 0 N--CA 1.451 -0.308 0 C-N-CA 120.794 -0.717 . . . . 0.0 112.501 -179.991 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 50.5 m -106.62 35.8 2.85 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-O 120.853 0.359 . . . . 0.0 110.877 179.982 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 12.3 t -122.2 93.62 4.04 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.903 179.917 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 132.06 -130.85 6.05 Favored Glycine 0 N--CA 1.451 -0.3 0 C-N-CA 120.735 -0.745 . . . . 0.0 112.415 179.939 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 15.5 tttp -60.56 91.88 0.02 OUTLIER 'General case' 0 C--N 1.328 -0.346 0 CA-C-O 120.788 0.328 . . . . 0.0 110.846 -179.877 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 9' ' ' SER . . . . . 0.405 ' N ' ' CD ' ' A' ' 10' ' ' PRO . 0.4 OUTLIER -85.63 -52.92 0.46 Allowed Pre-proline 0 C--N 1.329 -0.294 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.965 179.984 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 10' ' ' PRO . . . . . 0.405 ' CD ' ' N ' ' A' ' 9' ' ' SER . 75.5 Cg_exo -50.59 147.34 17.74 Favored 'Trans proline' 0 C--N 1.345 0.36 0 C-N-CA 122.615 2.21 . . . . 0.0 112.344 -179.963 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 17.2 p 57.84 105.76 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.98 179.972 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 45.6 t -160.6 145.58 10.85 Favored Pre-proline 0 C--N 1.329 -0.31 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.874 179.898 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 52.5 Cg_exo -54.55 -169.39 0.02 OUTLIER 'Trans proline' 0 C--N 1.346 0.43 0 C-N-CA 122.531 2.154 . . . . 0.0 112.384 179.985 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 1.2 m -150.6 -46.95 0.12 Allowed 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.868 -179.995 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -165.09 32.06 0.06 Allowed 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.871 179.979 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 109.03 41.22 1.44 Allowed Glycine 0 N--CA 1.452 -0.278 0 C-N-CA 120.686 -0.769 . . . . 0.0 112.447 -179.924 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 16.4 m -68.26 113.62 6.03 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-O 120.774 0.321 . . . . 0.0 110.907 -179.954 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 5.1 tt -151.32 -48.66 0.12 Allowed 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.282 -0.417 . . . . 0.0 110.846 179.872 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 19' ' ' GLN . . . . . . . . . . . . . 24.7 mp0 -66.39 111.9 3.77 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.926 179.925 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 20' ' ' GLN . . . . . . . . . . . . . 28.5 mt-30 -59.84 -63.86 1.15 Allowed 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.178 -0.464 . . . . 0.0 110.884 -179.929 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 2.4 mmm180 60.16 33.64 21.12 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.902 179.923 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 3.5 tt0 -167.22 -44.42 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.886 179.907 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 84.13 90.56 0.76 Allowed Glycine 0 N--CA 1.45 -0.418 0 C-N-CA 120.742 -0.742 . . . . 0.0 112.507 179.934 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -156.13 167.29 30.89 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.798 0.332 . . . . 0.0 111.021 179.985 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 5.4 mmtt -142.94 -48.55 0.33 Allowed 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.941 179.916 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -121.77 168.12 12.19 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.122 179.946 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 27' ' ' GLU . . . . . . . . . . . . . 1.1 pm0 -116.75 158.39 23.94 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.888 -179.988 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 36.7 t -67.85 82.69 0.11 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.035 179.911 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 136.24 43.95 0.1 OUTLIER Glycine 0 N--CA 1.451 -0.366 0 C-N-CA 120.745 -0.74 . . . . 0.0 112.537 -179.981 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -149.18 167.69 25.28 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-O 120.838 0.352 . . . . 0.0 110.893 -179.984 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 31' ' ' GLN . . . . . 0.438 ' HA ' HD13 ' A' ' 41' ' ' ILE . 0.5 OUTLIER -78.12 130.73 36.73 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.942 -179.962 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 32' ' ' VAL . . . . . 0.456 ' CG2' HD13 ' A' ' 58' ' ' ILE . 4.7 m -132.76 172.48 16.37 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.326 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.112 179.944 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 33' ' ' LEU . . . . . 0.611 ' HB2' HD11 ' A' ' 95' ' ' ILE . 16.7 tp -143.52 112.36 6.58 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.196 -0.457 . . . . 0.0 110.856 -179.942 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 34' ' ' VAL . . . . . 0.506 HG13 ' CB ' ' A' ' 87' ' ' ALA . 21.5 t -81.09 124.25 38.57 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.245 -0.434 . . . . 0.0 111.11 -179.849 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 35' ' ' ALA . . . . . . . . . . . . . . . 57.94 26.65 13.65 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.067 -0.515 . . . . 0.0 111.294 179.99 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 36' ' ' GLY . . . . . 0.541 ' HA2' HD23 ' A' ' 33' ' ' LEU . . . 57.05 33.45 64.25 Favored Glycine 0 N--CA 1.452 -0.29 0 C-N-CA 120.759 -0.734 . . . . 0.0 112.562 179.959 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 37' ' ' GLN . . . . . . . . . . . . . 37.7 mt-30 -144.36 -70.44 0.29 Allowed 'General case' 0 C--N 1.328 -0.35 0 CA-C-O 120.87 0.367 . . . . 0.0 111.075 -179.867 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 38' ' ' LYS . . . . . . . . . . . . . 2.8 mmpt? -68.08 114.61 6.74 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.925 -179.871 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 39' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -93.88 128.64 40.27 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.9 179.985 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -152.82 -172.88 21.64 Favored Glycine 0 N--CA 1.451 -0.335 0 C-N-CA 120.759 -0.734 . . . . 0.0 112.534 179.973 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 41' ' ' ILE . . . . . 0.442 ' N ' HG23 ' A' ' 58' ' ' ILE . 25.4 mm -125.33 138.07 55.57 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.269 0 CA-C-O 120.818 0.342 . . . . 0.0 111.136 -179.932 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 42' ' ' VAL . . . . . . . . . . . . . 21.5 t -69.32 122.33 20.56 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.185 -0.461 . . . . 0.0 111.082 -179.99 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 43' ' ' ARG . . . . . . . . . . . . . 8.0 mmt180 -113.55 -35.88 5.1 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.926 -179.998 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 44' ' ' PHE . . . . . . . . . . . . . 64.6 t80 -139.05 111.45 7.53 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.941 -179.983 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 45' ' ' TYR . . . . . 0.485 ' CE1' ' CE1' ' A' ' 56' ' ' TYR . 13.3 t80 -107.28 136.88 46.36 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.857 179.879 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 153.51 -163.08 30.6 Favored Glycine 0 N--CA 1.451 -0.352 0 C-N-CA 120.746 -0.74 . . . . 0.0 112.479 179.988 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 47' ' ' LYS . . . . . . . . . . . . . 21.1 mttp -88.64 167.69 13.16 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-O 120.799 0.333 . . . . 0.0 110.875 -179.944 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 48' ' ' THR . . . . . 0.672 HG21 ' CZ ' ' A' ' 50' ' ' PHE . 29.1 p -129.48 -173.88 3.13 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.846 179.965 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -110.37 -31.58 7.24 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.855 -179.97 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 50' ' ' PHE . . . . . 0.672 ' CZ ' HG21 ' A' ' 48' ' ' THR . 18.3 p90 -67.84 -36.09 79.74 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.259 -0.428 . . . . 0.0 110.992 -179.924 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 51' ' ' ALA . . . . . 0.427 ' N ' ' CD1' ' A' ' 50' ' ' PHE . . . -148.4 146.04 21.81 Favored Pre-proline 0 C--N 1.329 -0.283 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.175 179.979 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 52' ' ' PRO . . . . . . . . . . . . . 69.2 Cg_endo -74.39 173.77 13.67 Favored 'Trans proline' 0 C--N 1.345 0.391 0 C-N-CA 122.573 2.182 . . . . 0.0 112.315 -179.985 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 92.43 172.62 41.47 Favored Glycine 0 N--CA 1.452 -0.289 0 C-N-CA 120.762 -0.733 . . . . 0.0 112.48 179.905 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 54' ' ' TYR . . . . . . . . . . . . . 10.5 m-85 -90.14 110.31 21.33 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-O 120.814 0.34 . . . . 0.0 110.868 -179.993 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 55' ' ' TRP . . . . . 0.426 ' HB3' ' CD1' ' A' ' 86' ' ' PHE . 66.7 m95 -105.17 159.25 16.01 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.906 179.967 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 56' ' ' TYR . . . . . 0.607 ' CE1' ' HB2' ' A' ' 89' ' ' ALA . 12.6 m-85 -114.9 117.34 30.4 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.98 -179.824 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . -79.75 68.06 3.28 Favored Glycine 0 N--CA 1.451 -0.34 0 C-N-CA 120.684 -0.77 . . . . 0.0 112.341 179.934 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 58' ' ' ILE . . . . . 0.595 HD11 HD13 ' A' ' 92' ' ' ILE . 38.0 mt -73.3 137.89 22.44 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.39 0 CA-C-O 120.829 0.347 . . . . 0.0 111.192 -179.911 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 1.3 tm-20 -104.29 107.12 17.88 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.79 179.926 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 60' ' ' LEU . . . . . 0.568 HD11 HG11 ' A' ' 85' ' ' VAL . 36.6 mt -60.11 170.43 1.25 Allowed 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.971 -179.935 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 2.9 m-20 -100.45 -31.6 11.21 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.882 -179.991 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 62' ' ' GLN . . . . . 0.667 ' O ' HG22 ' A' ' 64' ' ' THR . 0.0 OUTLIER -120.24 147.31 44.63 Favored Pre-proline 0 C--N 1.331 -0.23 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.839 -179.93 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 50.6 Cg_exo -53.07 90.5 0.03 OUTLIER 'Trans proline' 0 C--N 1.345 0.389 0 C-N-CA 122.479 2.119 . . . . 0.0 112.405 179.949 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 64' ' ' THR . . . . . 0.667 HG22 ' O ' ' A' ' 62' ' ' GLN . 4.9 t -164.7 39.4 0.07 Allowed 'General case' 0 C--N 1.327 -0.384 0 CA-C-N 116.296 -0.411 . . . . 0.0 110.911 179.989 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . -100.66 -149.07 22.99 Favored Glycine 0 N--CA 1.451 -0.325 0 C-N-CA 120.741 -0.742 . . . . 0.0 112.515 179.946 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 66' ' ' LYS . . . . . . . . . . . . . 0.6 OUTLIER -121.47 -42.65 2.43 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-O 120.825 0.345 . . . . 0.0 110.918 -179.948 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 67' ' ' HIS . . . . . . . . . . . . . 6.8 p80 -128.53 172.15 11.44 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.917 179.964 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 4.9 m-20 -98.36 33.67 2.17 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.922 -179.971 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 99.47 -41.89 2.1 Favored Glycine 0 N--CA 1.451 -0.316 0 C-N-CA 120.636 -0.792 . . . . 0.0 112.491 179.995 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 70' ' ' SER . . . . . . . . . . . . . 77.3 p -104.82 148.62 26.44 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 120.835 0.35 . . . . 0.0 110.918 -179.974 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 21.5 t -135.45 122.59 35.31 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.146 -0.479 . . . . 0.0 111.105 179.958 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 72' ' ' PHE . . . . . . . . . . . . . 33.5 m-85 60.28 33.85 20.89 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.924 -179.992 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 80.4 27.92 50.09 Favored Glycine 0 N--CA 1.452 -0.25 0 C-N-CA 120.692 -0.766 . . . . 0.0 112.533 -179.97 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 21.4 t -131.61 100.71 4.58 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-O 120.767 0.317 . . . . 0.0 111.078 -179.997 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 75' ' ' ARG . . . . . . . . . . . . . 20.5 ttt85 -77.45 119.75 21.49 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.26 -0.427 . . . . 0.0 110.949 -179.968 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 76' ' ' TYR . . . . . . . . . . . . . 25.4 m-85 -92.28 -48.86 6.46 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.835 -179.995 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 77' ' ' PHE . . . . . . . . . . . . . 16.8 p90 -148.65 161.97 40.65 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.752 179.936 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -88.34 108.5 19.37 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.971 -179.963 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 79' ' ' CYS . . . . . . . . . . . . . 30.4 p -132.93 174.11 10.68 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.867 -179.976 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 80' ' ' ALA . . . . . 0.632 ' HB3' ' ND1' ' A' ' 83' ' ' HIS . . . -81.95 166.73 35.53 Favored Pre-proline 0 C--N 1.329 -0.311 0 CA-C-N 116.198 -0.455 . . . . 0.0 111.056 179.978 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 81' ' ' PRO . . . . . 0.518 ' HD2' ' HB1' ' A' ' 80' ' ' ALA . 51.9 Cg_exo -54.34 117.49 3.99 Favored 'Trans proline' 0 C--N 1.343 0.267 0 C-N-CA 122.57 2.18 . . . . 0.0 112.304 179.994 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 82' ' ' ARG . . . . . . . . . . . . . 3.3 mpt_? 60.99 52.97 3.86 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.116 -0.493 . . . . 0.0 110.96 179.99 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 83' ' ' HIS . . . . . 0.632 ' ND1' ' HB3' ' A' ' 80' ' ' ALA . 7.2 m170 -122.41 -42.15 2.36 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.119 -0.491 . . . . 0.0 110.915 179.989 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . -64.24 144.56 48.75 Favored Glycine 0 N--CA 1.452 -0.261 0 C-N-CA 120.632 -0.794 . . . . 0.0 112.426 179.968 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 85' ' ' VAL . . . . . 0.568 HG11 HD11 ' A' ' 60' ' ' LEU . 15.4 m -152.54 121.32 0.77 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-O 120.833 0.349 . . . . 0.0 111.101 179.997 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 86' ' ' PHE . . . . . 0.426 ' CD1' ' HB3' ' A' ' 55' ' ' TRP . 2.5 m-85 -100.69 118.73 37.4 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.945 179.971 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 87' ' ' ALA . . . . . 0.506 ' CB ' HG13 ' A' ' 34' ' ' VAL . . . -139.91 145.72 43.79 Favored Pre-proline 0 C--N 1.329 -0.316 0 CA-C-N 116.258 -0.428 . . . . 0.0 111.094 179.936 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 88' ' ' PRO . . . . . 0.411 ' O ' ' N ' ' A' ' 91' ' ' ARG . 36.0 Cg_exo -57.27 138.2 85.16 Favored 'Trans proline' 0 C--N 1.346 0.441 0 C-N-CA 122.46 2.107 . . . . 0.0 112.336 -179.952 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 89' ' ' ALA . . . . . 0.607 ' HB2' ' CE1' ' A' ' 56' ' ' TYR . . . -47.63 -51.9 19.84 Favored 'General case' 0 C--N 1.333 -0.115 0 CA-C-O 121.112 0.482 . . . . 0.0 110.367 179.902 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 90' ' ' SER . . . . . . . . . . . . . 5.9 m -55.52 -24.48 32.11 Favored 'General case' 0 N--CA 1.454 -0.246 0 CA-C-N 115.657 -0.701 . . . . 0.0 109.754 178.769 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 91' ' ' ARG . . . . . 0.411 ' N ' ' O ' ' A' ' 88' ' ' PRO . 0.6 OUTLIER -88.41 -16.36 33.1 Favored 'General case' 0 N--CA 1.454 -0.234 0 CA-C-N 115.829 -0.623 . . . . 0.0 110.416 179.066 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 92' ' ' ILE . . . . . 0.595 HD13 HD11 ' A' ' 58' ' ' ILE . 51.6 mt -104.51 145.09 13.57 Favored 'Isoleucine or valine' 0 C--N 1.333 -0.121 0 CA-C-N 116.379 -0.373 . . . . 0.0 111.035 179.869 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 93' ' ' GLN . . . . . . . . . . . . . 1.8 mt-30 -112.83 -179.96 3.8 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.228 -0.442 . . . . 0.0 111.009 -179.949 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 94' ' ' ARG . . . . . . . . . . . . . 0.6 OUTLIER -126.88 138.96 53.39 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.947 -179.895 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 95' ' ' ILE . . . . . 0.611 HD11 ' HB2' ' A' ' 33' ' ' LEU . 3.8 mp -113.2 -57.91 3.74 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.252 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.059 179.967 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . 73.09 167.98 12.51 Favored Glycine 0 N--CA 1.451 -0.303 0 C-N-CA 120.837 -0.697 . . . . 0.0 112.519 179.955 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 97' ' ' SER . . . . . . . . . . . . . 54.7 p -145.61 -64.75 0.32 Allowed 'General case' 0 C--N 1.33 -0.279 0 CA-C-O 120.825 0.345 . . . . 0.0 110.894 179.99 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 98' ' ' GLY . . . . . . . . . . . . . . . 127.72 143.2 5.66 Favored Glycine 0 N--CA 1.452 -0.299 0 C-N-CA 120.838 -0.696 . . . . 0.0 112.463 179.962 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 99' ' ' PRO . . . . . . . . . . . . . 50.1 Cg_exo -53.54 126.22 21.07 Favored 'Trans proline' 0 C--N 1.345 0.376 0 C-N-CA 122.569 2.18 . . . . 0.0 112.358 179.937 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 100' ' ' SER . . . . . . . . . . . . . 89.1 p -149.08 -47.52 0.14 Allowed 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.906 179.959 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER 63.77 90.5 0.08 Allowed 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.132 -0.486 . . . . 0.0 110.946 179.934 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.25 1.103 0 CA-C-O 118.365 -1.242 . . . . 0.0 112.515 179.933 . . . . . . . . 0 0 . 1 . 005 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.248 0 N-CA-C 112.502 -0.239 . . . . 0.0 112.502 . . . . . . . . . 0 0 . 1 . 005 nuclear build full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 3.5 m -150.9 166.26 31.12 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-O 120.874 0.369 . . . . 0.0 110.809 -179.952 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 14.1 m -119.43 115.16 23.5 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.125 -0.488 . . . . 0.0 110.964 -179.985 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 77.97 -131.19 10.76 Favored Glycine 0 N--CA 1.451 -0.356 0 C-N-CA 120.754 -0.736 . . . . 0.0 112.564 179.957 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 9.2 t -127.82 137.01 52.23 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-O 120.853 0.358 . . . . 0.0 110.933 -179.922 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 82.7 p -111.51 143.06 42.96 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.879 179.982 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -179.56 -45.08 0.08 OUTLIER Glycine 0 N--CA 1.451 -0.334 0 C-N-CA 120.742 -0.742 . . . . 0.0 112.485 -179.985 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 15.8 ttpt -109.42 -64.34 1.26 Allowed 'General case' 0 C--N 1.329 -0.323 0 CA-C-O 120.867 0.365 . . . . 0.0 110.93 179.955 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 2.8 m -124.66 148.08 57.93 Favored Pre-proline 0 C--N 1.33 -0.262 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.877 179.982 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 58.2 Cg_endo -71.76 -45.17 0.79 Allowed 'Trans proline' 0 C--N 1.344 0.338 0 C-N-CA 122.536 2.157 . . . . 0.0 112.342 179.971 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 1.8 p -78.06 125.26 29.08 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.248 -0.433 . . . . 0.0 110.856 -179.967 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 12' ' ' SER . . . . . 0.427 ' HB3' HD12 ' A' ' 15' ' ' LEU . 1.9 m -128.89 134.44 26.32 Favored Pre-proline 0 C--N 1.33 -0.26 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.859 179.974 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 74.1 Cg_endo -75.48 80.92 2.42 Favored 'Trans proline' 0 C--N 1.345 0.362 0 C-N-CA 122.518 2.145 . . . . 0.0 112.289 -179.958 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER 59.9 109.57 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.989 179.944 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 15' ' ' LEU . . . . . 0.427 HD12 ' HB3' ' A' ' 12' ' ' SER . 1.6 mt -141.14 30.35 1.79 Allowed 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.899 179.994 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 95.34 28.7 9.5 Favored Glycine 0 N--CA 1.451 -0.323 0 C-N-CA 120.701 -0.762 . . . . 0.0 112.539 -179.972 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 5.0 t -79.64 112.73 17.19 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-O 120.872 0.368 . . . . 0.0 110.901 -179.98 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 10.1 tp -119.79 -44.63 2.52 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.857 179.976 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 19' ' ' GLN . . . . . . . . . . . . . 3.2 mp0 -80.13 93.4 5.81 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.924 179.996 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 20' ' ' GLN . . . . . . . . . . . . . 3.4 pt20 -106.07 122.27 45.82 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.843 -179.924 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 2.1 mtt180 -108.9 80.3 1.31 Allowed 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.209 -0.451 . . . . 0.0 110.86 179.924 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 48.0 tt0 -156.92 129.46 7.54 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.931 179.95 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -175.37 141.43 5.71 Favored Glycine 0 N--CA 1.451 -0.319 0 C-N-CA 120.733 -0.746 . . . . 0.0 112.522 -179.965 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -73.13 134.16 44.36 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-O 120.733 0.301 . . . . 0.0 111.077 -179.969 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 8.7 tptp -79.37 -46.13 18.22 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.899 179.969 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -142.0 -179.37 6.18 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.277 -0.419 . . . . 0.0 111.076 179.994 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 27' ' ' GLU . . . . . . . . . . . . . 28.5 mt-10 -143.2 -172.59 3.72 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.918 -179.996 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 30.6 t -78.46 111.65 15.55 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.236 -0.438 . . . . 0.0 111.078 -179.979 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 106.16 42.73 1.6 Allowed Glycine 0 N--CA 1.452 -0.255 0 C-N-CA 120.729 -0.748 . . . . 0.0 112.52 179.967 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 2.3 m-20 -150.12 136.77 19.14 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-O 120.813 0.34 . . . . 0.0 110.823 179.979 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 31' ' ' GLN . . . . . . . . . . . . . 2.6 mt-30 -60.03 141.02 56.42 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.88 179.92 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 6.3 m -146.57 179.58 0.92 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.356 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.188 179.992 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 33' ' ' LEU . . . . . 0.534 HD11 ' O ' ' A' ' 37' ' ' GLN . 25.7 tp -142.09 109.89 5.8 Favored 'General case' 0 C--N 1.331 -0.239 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.846 179.991 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 34' ' ' VAL . . . . . 0.408 HG13 ' CB ' ' A' ' 87' ' ' ALA . 21.5 t -77.72 123.54 34.59 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.266 0 CA-C-N 116.181 -0.463 . . . . 0.0 111.182 -179.969 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 35' ' ' ALA . . . . . . . . . . . . . . . 57.63 26.64 13.14 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.198 -0.456 . . . . 0.0 111.235 -179.964 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . 57.07 29.38 59.42 Favored Glycine 0 N--CA 1.451 -0.327 0 C-N-CA 120.734 -0.746 . . . . 0.0 112.613 179.953 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 37' ' ' GLN . . . . . 0.534 ' O ' HD11 ' A' ' 33' ' ' LEU . 20.1 mt-30 -141.29 -74.59 0.32 Allowed 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 120.85 0.357 . . . . 0.0 110.966 -179.964 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 38' ' ' LYS . . . . . 0.465 ' HD2' HD13 ' A' ' 60' ' ' LEU . 21.8 mmtm -63.47 103.19 0.49 Allowed 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.861 -179.959 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 39' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -82.55 135.35 35.11 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.939 179.931 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -164.73 -176.01 36.04 Favored Glycine 0 N--CA 1.452 -0.288 0 C-N-CA 120.677 -0.773 . . . . 0.0 112.49 179.965 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 2.6 mt -127.34 137.01 59.03 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 CA-C-O 120.82 0.343 . . . . 0.0 111.085 -179.979 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 42' ' ' VAL . . . . . . . . . . . . . 21.4 t -59.62 123.38 11.91 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.202 -0.454 . . . . 0.0 111.12 179.971 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 43' ' ' ARG . . . . . . . . . . . . . 17.3 mmt85 -111.3 -33.99 6.27 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.902 179.903 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 44' ' ' PHE . . . . . 0.424 ' CD1' ' HB3' ' A' ' 76' ' ' TYR . 60.4 t80 -142.75 110.31 5.78 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.965 -179.979 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 45' ' ' TYR . . . . . . . . . . . . . 15.3 t80 -107.54 119.62 39.93 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.196 -0.457 . . . . 0.0 110.861 179.974 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 175.52 177.14 44.35 Favored Glycine 0 N--CA 1.451 -0.347 0 C-N-CA 120.801 -0.714 . . . . 0.0 112.561 179.971 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 47' ' ' LYS . . . . . . . . . . . . . 16.0 mtmt -77.02 168.14 20.6 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-O 120.886 0.374 . . . . 0.0 110.856 179.975 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 48' ' ' THR . . . . . 0.463 HG21 ' CE2' ' A' ' 50' ' ' PHE . 23.6 p -125.58 -179.66 4.74 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.868 179.953 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 1.5 t70 -106.74 -31.84 8.24 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.939 179.974 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 50' ' ' PHE . . . . . 0.463 ' CE2' HG21 ' A' ' 48' ' ' THR . 48.8 p90 -70.19 -35.86 74.22 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.924 -179.988 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 51' ' ' ALA . . . . . . . . . . . . . . . -141.09 144.16 33.85 Favored Pre-proline 0 C--N 1.328 -0.333 0 CA-C-N 116.218 -0.446 . . . . 0.0 111.087 -179.981 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 52' ' ' PRO . . . . . . . . . . . . . 70.8 Cg_endo -74.74 -176.85 3.02 Favored 'Trans proline' 0 C--N 1.345 0.389 0 C-N-CA 122.531 2.154 . . . . 0.0 112.309 179.99 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 76.78 -175.68 53.36 Favored Glycine 0 N--CA 1.45 -0.376 0 C-N-CA 120.745 -0.74 . . . . 0.0 112.567 179.993 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 54' ' ' TYR . . . . . . . . . . . . . 34.5 m-85 -88.58 158.35 18.31 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-O 120.847 0.356 . . . . 0.0 110.916 179.967 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 55' ' ' TRP . . . . . 0.428 ' HB3' ' CD1' ' A' ' 86' ' ' PHE . 94.2 m95 -154.06 140.96 19.21 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.154 -0.475 . . . . 0.0 110.867 179.96 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 56' ' ' TYR . . . . . 0.424 ' HE1' ' HB2' ' A' ' 89' ' ' ALA . 36.2 m-85 -102.57 122.31 44.13 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.902 -179.927 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 57' ' ' GLY . . . . . 0.447 ' N ' ' CE1' ' A' ' 86' ' ' PHE . . . -87.79 59.08 4.31 Favored Glycine 0 N--CA 1.451 -0.357 0 C-N-CA 120.754 -0.736 . . . . 0.0 112.468 -179.978 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 58' ' ' ILE . . . . . 0.67 HD11 HD13 ' A' ' 92' ' ' ILE . 7.8 mt -64.14 152.48 8.28 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-O 120.829 0.347 . . . . 0.0 110.964 -179.957 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 1.7 tm-20 -122.94 102.94 8.3 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.925 179.988 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 60' ' ' LEU . . . . . 0.465 HD13 ' HD2' ' A' ' 38' ' ' LYS . 54.8 mt -63.16 162.72 11.32 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.904 -179.957 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 2.7 t0 -92.78 -30.91 15.25 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.916 -179.981 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 62' ' ' GLN . . . . . . . . . . . . . 7.1 mt-30 -100.35 152.0 37.7 Favored Pre-proline 0 C--N 1.329 -0.311 0 CA-C-N 116.231 -0.44 . . . . 0.0 110.952 -179.994 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 71.9 Cg_endo -75.45 97.9 1.13 Allowed 'Trans proline' 0 C--N 1.344 0.316 0 C-N-CA 122.595 2.196 . . . . 0.0 112.309 -179.892 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 64' ' ' THR . . . . . . . . . . . . . 9.9 t -173.68 36.27 0.01 OUTLIER 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.9 -179.989 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . -90.09 -159.52 35.6 Favored Glycine 0 N--CA 1.451 -0.335 0 C-N-CA 120.731 -0.747 . . . . 0.0 112.544 179.985 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 66' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -110.47 -31.71 7.17 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 120.819 0.342 . . . . 0.0 110.846 -179.947 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 67' ' ' HIS . . . . . . . . . . . . . 6.6 p80 -140.83 173.57 11.36 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.893 179.954 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 2.6 m-20 -97.98 37.09 1.46 Allowed 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.834 -179.915 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 98.79 -28.61 14.33 Favored Glycine 0 N--CA 1.451 -0.362 0 C-N-CA 120.676 -0.773 . . . . 0.0 112.486 179.967 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 70' ' ' SER . . . . . . . . . . . . . 88.7 p -110.4 161.32 15.77 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-O 120.841 0.353 . . . . 0.0 110.842 -179.92 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 71' ' ' VAL . . . . . 0.524 HG12 ' HD1' ' A' ' 72' ' ' PHE . 21.5 t -146.41 126.75 6.02 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.256 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.063 -179.981 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 72' ' ' PHE . . . . . 0.524 ' HD1' HG12 ' A' ' 71' ' ' VAL . 11.3 m-85 60.58 27.05 16.73 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.163 -0.472 . . . . 0.0 111.026 179.974 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 95.65 -29.82 9.23 Favored Glycine 0 N--CA 1.452 -0.284 0 C-N-CA 120.752 -0.737 . . . . 0.0 112.537 179.952 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 25.5 t -80.98 116.58 25.53 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.343 0 CA-C-O 120.8 0.333 . . . . 0.0 111.141 -179.976 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 75' ' ' ARG . . . . . . . . . . . . . 2.1 ttt-85 -88.49 148.36 24.19 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.86 -179.933 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 76' ' ' TYR . . . . . 0.428 ' CE1' HG22 ' A' ' 48' ' ' THR . 53.8 m-85 -120.09 -50.81 2.24 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.933 -179.963 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 77' ' ' PHE . . . . . . . . . . . . . 26.9 p90 -146.04 161.78 39.35 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.9 179.978 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 4.9 m -91.93 121.98 34.03 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.099 -0.501 . . . . 0.0 110.941 179.979 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 79' ' ' CYS . . . . . . . . . . . . . 26.1 p -144.57 158.12 43.91 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.252 -0.431 . . . . 0.0 110.87 -179.952 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 80' ' ' ALA . . . . . 0.527 ' HB3' ' CG ' ' A' ' 83' ' ' HIS . . . -59.59 164.03 6.06 Favored Pre-proline 0 C--N 1.329 -0.306 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.135 179.913 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 81' ' ' PRO . . . . . 0.457 ' HD2' ' HB1' ' A' ' 80' ' ' ALA . 53.8 Cg_exo -52.31 116.19 2.67 Favored 'Trans proline' 0 C--N 1.345 0.358 0 C-N-CA 122.558 2.172 . . . . 0.0 112.322 -179.982 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 82' ' ' ARG . . . . . . . . . . . . . 16.1 mtt180 58.91 62.49 1.87 Allowed 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.874 -179.962 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 83' ' ' HIS . . . . . 0.527 ' CG ' ' HB3' ' A' ' 80' ' ' ALA . 4.3 m170 -127.12 -43.78 1.64 Allowed 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.088 -0.506 . . . . 0.0 110.859 179.957 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . -68.2 138.51 32.76 Favored Glycine 0 N--CA 1.45 -0.37 0 C-N-CA 120.706 -0.759 . . . . 0.0 112.473 179.976 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 85' ' ' VAL . . . . . 0.467 ' O ' HG23 ' A' ' 85' ' ' VAL . 16.9 m -143.3 113.91 2.43 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-O 120.894 0.378 . . . . 0.0 111.108 -179.994 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 86' ' ' PHE . . . . . 0.447 ' CE1' ' N ' ' A' ' 57' ' ' GLY . 5.4 m-85 -89.11 119.81 29.95 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.843 -179.964 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 87' ' ' ALA . . . . . 0.605 ' O ' HD11 ' A' ' 92' ' ' ILE . . . -139.48 143.86 37.41 Favored Pre-proline 0 C--N 1.329 -0.303 0 CA-C-N 116.263 -0.426 . . . . 0.0 111.146 179.991 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 88' ' ' PRO . . . . . 0.427 ' O ' ' N ' ' A' ' 91' ' ' ARG . 46.8 Cg_exo -55.94 140.45 85.85 Favored 'Trans proline' 0 C--N 1.346 0.43 0 C-N-CA 122.541 2.161 . . . . 0.0 112.379 179.959 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 89' ' ' ALA . . . . . 0.424 ' HB2' ' HE1' ' A' ' 56' ' ' TYR . . . -47.83 -50.3 26.59 Favored 'General case' 0 CA--C 1.521 -0.158 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.264 179.896 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 90' ' ' SER . . . . . . . . . . . . . 8.0 m -55.59 -24.37 32.51 Favored 'General case' 0 N--CA 1.454 -0.266 0 CA-C-N 115.769 -0.651 . . . . 0.0 109.796 178.859 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 91' ' ' ARG . . . . . 0.427 ' N ' ' O ' ' A' ' 88' ' ' PRO . 2.3 mtm-85 -89.74 -15.22 32.93 Favored 'General case' 0 N--CA 1.455 -0.19 0 CA-C-N 115.813 -0.631 . . . . 0.0 110.524 179.063 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 92' ' ' ILE . . . . . 0.67 HD13 HD11 ' A' ' 58' ' ' ILE . 49.9 mt -103.08 144.87 13.2 Favored 'Isoleucine or valine' 0 C--O 1.232 0.16 0 CA-C-N 116.402 -0.363 . . . . 0.0 111.094 179.858 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 93' ' ' GLN . . . . . . . . . . . . . 0.5 OUTLIER -115.71 154.3 29.81 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.905 -179.976 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 94' ' ' ARG . . . . . . . . . . . . . 7.6 mtp180 -96.96 138.54 34.34 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.868 179.978 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 95' ' ' ILE . . . . . . . . . . . . . 16.9 mt -111.02 -30.3 2.33 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.15 -0.477 . . . . 0.0 111.108 179.97 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . -58.97 -28.48 63.66 Favored Glycine 0 N--CA 1.452 -0.289 0 C-N-CA 120.745 -0.741 . . . . 0.0 112.475 179.974 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 97' ' ' SER . . . . . . . . . . . . . 7.2 p -74.78 88.27 2.26 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-O 120.778 0.323 . . . . 0.0 110.952 179.882 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 98' ' ' GLY . . . . . . . . . . . . . . . 151.13 87.13 0.06 OUTLIER Glycine 0 N--CA 1.451 -0.337 0 C-N-CA 120.736 -0.745 . . . . 0.0 112.482 179.992 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 99' ' ' PRO . . . . . . . . . . . . . 53.0 Cg_exo -52.32 -40.75 69.69 Favored 'Trans proline' 0 C--N 1.343 0.274 0 C-N-CA 122.604 2.203 . . . . 0.0 112.394 179.933 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 100' ' ' SER . . . . . . . . . . . . . 46.1 p -140.59 37.67 1.84 Allowed 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.93 179.988 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 1.3 m -132.47 -62.8 0.81 Allowed 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.145 -0.48 . . . . 0.0 110.853 -179.95 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.249 1.065 0 CA-C-O 118.344 -1.253 . . . . 0.0 112.488 179.993 . . . . . . . . 0 0 . 1 . 006 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.208 0 N-CA-C 112.476 -0.249 . . . . 0.0 112.476 . . . . . . . . . 0 0 . 1 . 006 nuclear build full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 48.3 m -139.34 162.46 34.97 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-O 120.877 0.37 . . . . 0.0 110.899 -179.971 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 15.3 m -134.64 -58.07 0.82 Allowed 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.884 179.981 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 91.86 144.92 14.24 Favored Glycine 0 N--CA 1.45 -0.406 0 C-N-CA 120.749 -0.738 . . . . 0.0 112.504 179.979 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 1.3 m -102.61 -176.02 2.98 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-O 120.817 0.342 . . . . 0.0 110.867 -179.953 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER 60.63 100.01 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.132 -0.485 . . . . 0.0 110.864 179.954 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -163.67 101.37 0.19 Allowed Glycine 0 N--CA 1.451 -0.358 0 C-N-CA 120.758 -0.734 . . . . 0.0 112.485 -179.998 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -93.45 -178.74 4.82 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-O 120.825 0.345 . . . . 0.0 110.926 179.956 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 50.7 m -128.48 59.94 45.12 Favored Pre-proline 0 C--N 1.329 -0.288 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.885 179.954 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 52.0 Cg_endo -69.49 -168.02 0.24 Allowed 'Trans proline' 0 C--N 1.344 0.317 0 C-N-CA 122.609 2.206 . . . . 0.0 112.212 -179.936 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 1.3 m -102.77 114.05 27.98 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.964 179.981 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -152.54 146.15 18.02 Favored Pre-proline 0 C--N 1.329 -0.301 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.863 179.982 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 50.9 Cg_exo -53.06 91.07 0.03 OUTLIER 'Trans proline' 0 C--N 1.344 0.338 0 C-N-CA 122.577 2.185 . . . . 0.0 112.325 179.959 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -140.93 108.25 5.53 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.944 179.998 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 9.4 tp -176.79 121.6 0.14 Allowed 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.912 -179.998 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 74.4 -70.42 1.62 Allowed Glycine 0 N--CA 1.45 -0.368 0 C-N-CA 120.745 -0.74 . . . . 0.0 112.502 -179.977 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER 64.45 -78.9 0.03 OUTLIER 'General case' 0 C--N 1.33 -0.265 0 CA-C-O 120.778 0.323 . . . . 0.0 110.934 -179.997 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -164.64 92.36 0.61 Allowed 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.274 -0.421 . . . . 0.0 110.807 179.988 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 19' ' ' GLN . . . . . . . . . . . . . 0.2 OUTLIER -145.83 127.92 15.61 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.247 -0.433 . . . . 0.0 110.973 179.995 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 20' ' ' GLN . . . . . . . . . . . . . 48.6 mm-40 -104.61 -49.46 3.53 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.877 179.986 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER 61.0 35.75 18.84 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.872 -179.989 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 2.9 tp10 -155.88 -59.51 0.1 Allowed 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.926 179.979 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 100.73 164.75 28.1 Favored Glycine 0 N--CA 1.451 -0.36 0 C-N-CA 120.705 -0.76 . . . . 0.0 112.43 179.99 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -163.08 -169.34 1.99 Allowed 'General case' 0 C--N 1.33 -0.274 0 CA-C-O 120.868 0.366 . . . . 0.0 111.057 179.966 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 1.0 OUTLIER -146.41 -50.85 0.22 Allowed 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.905 -179.992 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 26' ' ' ALA . . . . . 0.451 ' HB2' ' HG3' ' A' ' 94' ' ' ARG . . . -115.97 -178.05 3.31 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.162 -0.472 . . . . 0.0 111.142 179.992 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 27' ' ' GLU . . . . . . . . . . . . . 6.3 mm-40 -142.46 -179.18 6.13 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.935 179.956 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 21.5 t -66.95 123.34 19.8 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.127 -180.0 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 84.7 46.34 5.76 Favored Glycine 0 N--CA 1.451 -0.326 0 C-N-CA 120.767 -0.73 . . . . 0.0 112.529 -179.993 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 4.6 t0 -146.16 134.28 21.59 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 120.879 0.371 . . . . 0.0 110.892 -179.998 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 31' ' ' GLN . . . . . . . . . . . . . 1.9 mt-30 -60.31 139.23 57.74 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.912 179.974 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 32' ' ' VAL . . . . . 0.43 HG21 HG12 ' A' ' 58' ' ' ILE . 19.2 m -145.17 176.02 2.31 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.28 -0.418 . . . . 0.0 111.133 -179.975 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 33' ' ' LEU . . . . . 0.519 HD11 ' O ' ' A' ' 37' ' ' GLN . 30.4 tp -134.5 100.04 4.53 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.145 -0.48 . . . . 0.0 110.898 179.988 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 21.5 t -69.11 126.58 29.42 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.205 -179.853 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 35' ' ' ALA . . . . . . . . . . . . . . . 57.06 25.34 10.67 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.321 179.941 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . 56.07 35.03 63.04 Favored Glycine 0 N--CA 1.451 -0.33 0 C-N-CA 120.722 -0.751 . . . . 0.0 112.58 179.941 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 37' ' ' GLN . . . . . 0.519 ' O ' HD11 ' A' ' 33' ' ' LEU . 48.8 mt-30 -147.51 -68.3 0.25 Allowed 'General case' 0 C--N 1.329 -0.295 0 CA-C-O 120.862 0.363 . . . . 0.0 110.949 -179.929 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 38' ' ' LYS . . . . . . . . . . . . . 64.5 mttp -73.77 106.85 5.69 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.919 -179.966 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 39' ' ' GLN . . . . . 0.433 ' HG2' HD11 ' A' ' 95' ' ' ILE . 0.9 OUTLIER -85.16 135.02 34.14 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.923 179.89 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -157.87 -170.43 22.65 Favored Glycine 0 N--CA 1.45 -0.389 0 C-N-CA 120.683 -0.77 . . . . 0.0 112.505 -179.998 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 41' ' ' ILE . . . . . 0.508 ' C ' HG23 ' A' ' 58' ' ' ILE . 14.5 mt -126.38 131.54 71.33 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-O 120.842 0.353 . . . . 0.0 111.132 -179.959 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 42' ' ' VAL . . . . . . . . . . . . . 38.2 t -65.52 119.73 10.87 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.02 -179.964 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 43' ' ' ARG . . . . . . . . . . . . . 25.5 mmt180 -104.13 -31.46 9.64 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.259 -0.428 . . . . 0.0 110.966 179.895 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 44' ' ' PHE . . . . . . . . . . . . . 69.2 t80 -143.77 117.52 9.28 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.875 -179.929 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 45' ' ' TYR . . . . . 0.464 ' CE1' ' CZ ' ' A' ' 56' ' ' TYR . 21.5 t80 -113.13 133.82 54.85 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.264 -0.426 . . . . 0.0 110.925 179.988 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 154.17 174.87 24.76 Favored Glycine 0 N--CA 1.451 -0.35 0 C-N-CA 120.799 -0.715 . . . . 0.0 112.523 179.937 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 47' ' ' LYS . . . . . . . . . . . . . 1.9 mmtp -60.06 160.53 7.93 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 120.81 0.338 . . . . 0.0 110.938 -179.996 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 48' ' ' THR . . . . . 0.408 HG21 ' CZ ' ' A' ' 50' ' ' PHE . 38.4 p -124.82 -179.09 4.38 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.872 179.938 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -107.65 -34.75 6.9 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.883 -179.989 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 50' ' ' PHE . . . . . 0.435 ' CD1' ' N ' ' A' ' 51' ' ' ALA . 15.9 p90 -63.33 -31.46 72.62 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.154 -0.475 . . . . 0.0 110.986 180.0 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 51' ' ' ALA . . . . . 0.435 ' N ' ' CD1' ' A' ' 50' ' ' PHE . . . -156.27 148.16 17.28 Favored Pre-proline 0 C--N 1.33 -0.244 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.117 -179.999 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 52' ' ' PRO . . . . . . . . . . . . . 58.3 Cg_endo -71.47 162.63 41.68 Favored 'Trans proline' 0 C--N 1.344 0.326 0 C-N-CA 122.624 2.216 . . . . 0.0 112.335 179.987 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 102.28 177.42 27.57 Favored Glycine 0 N--CA 1.45 -0.407 0 C-N-CA 120.769 -0.729 . . . . 0.0 112.501 179.939 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 54' ' ' TYR . . . . . . . . . . . . . 37.1 m-85 -97.22 112.31 24.17 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 120.813 0.34 . . . . 0.0 110.958 179.996 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 55' ' ' TRP . . . . . 0.406 ' CZ3' ' HD3' ' A' ' 88' ' ' PRO . 42.1 m95 -107.93 161.76 14.63 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.898 179.989 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 56' ' ' TYR . . . . . 0.626 ' CE1' ' HB2' ' A' ' 89' ' ' ALA . 11.3 m-85 -113.61 122.49 47.37 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.26 -0.427 . . . . 0.0 110.918 -179.98 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . -84.19 56.71 5.04 Favored Glycine 0 N--CA 1.45 -0.368 0 C-N-CA 120.801 -0.714 . . . . 0.0 112.511 179.861 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 58' ' ' ILE . . . . . 0.562 HD11 HD13 ' A' ' 92' ' ' ILE . 3.7 mt -68.32 137.99 23.39 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-O 120.84 0.352 . . . . 0.0 111.092 -179.937 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 0.8 OUTLIER -101.39 141.55 34.09 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.947 179.998 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 60' ' ' LEU . . . . . 0.425 HD12 ' HA2' ' A' ' 65' ' ' GLY . 59.6 mt -97.78 174.13 6.76 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.883 179.99 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 1.3 t0 -101.55 -30.91 11.12 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.176 -0.466 . . . . 0.0 110.959 179.965 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 62' ' ' GLN . . . . . . . . . . . . . 7.5 mt-30 -104.17 153.16 39.15 Favored Pre-proline 0 C--N 1.33 -0.273 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.912 -179.972 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 66.1 Cg_endo -73.97 65.34 5.07 Favored 'Trans proline' 0 C--N 1.345 0.352 0 C-N-CA 122.576 2.184 . . . . 0.0 112.29 -179.902 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 64' ' ' THR . . . . . . . . . . . . . 3.9 t -148.76 39.38 0.86 Allowed 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.882 179.933 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 65' ' ' GLY . . . . . 0.425 ' HA2' HD12 ' A' ' 60' ' ' LEU . . . -83.64 -99.63 0.57 Allowed Glycine 0 N--CA 1.451 -0.305 0 C-N-CA 120.705 -0.759 . . . . 0.0 112.525 179.906 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 66' ' ' LYS . . . . . . . . . . . . . 5.8 mttt -168.76 -44.69 0.02 OUTLIER 'General case' 0 C--N 1.33 -0.251 0 CA-C-O 120.845 0.355 . . . . 0.0 110.871 179.952 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 67' ' ' HIS . . . . . . . . . . . . . 10.1 p80 -125.5 170.28 11.58 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.903 179.91 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 17.1 t0 -103.49 52.36 0.77 Allowed 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.934 179.951 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 90.55 -75.64 1.65 Allowed Glycine 0 N--CA 1.45 -0.403 0 C-N-CA 120.741 -0.742 . . . . 0.0 112.445 179.982 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 70' ' ' SER . . . . . . . . . . . . . 93.1 p -84.4 154.7 22.67 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-O 120.875 0.369 . . . . 0.0 110.848 179.982 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 71' ' ' VAL . . . . . 0.412 HG12 ' CD2' ' A' ' 72' ' ' PHE . 21.5 t -129.37 122.69 56.29 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.141 179.993 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 72' ' ' PHE . . . . . 0.412 ' CD2' HG12 ' A' ' 71' ' ' VAL . 37.7 m-85 60.74 30.03 19.42 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.898 179.98 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 96.5 -30.05 9.37 Favored Glycine 0 N--CA 1.451 -0.362 0 C-N-CA 120.759 -0.734 . . . . 0.0 112.573 -179.969 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 28.0 t -79.4 122.61 34.96 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-O 120.833 0.349 . . . . 0.0 111.087 -179.992 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 75' ' ' ARG . . . . . . . . . . . . . 21.8 ttt-85 -91.89 142.99 26.95 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.98 179.948 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 76' ' ' TYR . . . . . . . . . . . . . 24.3 m-85 -118.78 -41.72 2.77 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.271 -0.422 . . . . 0.0 110.869 -179.973 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 77' ' ' PHE . . . . . . . . . . . . . 50.9 p90 -160.29 161.7 33.4 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.828 -179.998 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 3.3 m -89.86 123.51 33.88 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.987 179.865 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 79' ' ' CYS . . . . . . . . . . . . . 30.3 p -145.88 -177.94 5.85 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.885 179.997 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 80' ' ' ALA . . . . . 0.477 ' HB3' ' CG ' ' A' ' 83' ' ' HIS . . . -92.1 164.47 23.23 Favored Pre-proline 0 C--N 1.329 -0.319 0 CA-C-N 116.2 -0.455 . . . . 0.0 111.124 179.988 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 81' ' ' PRO . . . . . 0.452 ' HD2' ' HB1' ' A' ' 80' ' ' ALA . 52.9 Cg_exo -52.48 116.29 2.76 Favored 'Trans proline' 0 C--N 1.345 0.344 0 C-N-CA 122.55 2.167 . . . . 0.0 112.275 179.993 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 82' ' ' ARG . . . . . . . . . . . . . 7.3 mtm180 61.9 58.79 1.85 Allowed 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.178 -0.464 . . . . 0.0 110.834 -179.997 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 83' ' ' HIS . . . . . 0.477 ' CG ' ' HB3' ' A' ' 80' ' ' ALA . 5.6 m170 -128.98 -47.55 1.23 Allowed 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.92 179.925 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . -66.64 147.58 49.82 Favored Glycine 0 N--CA 1.45 -0.4 0 C-N-CA 120.8 -0.714 . . . . 0.0 112.471 179.906 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 85' ' ' VAL . . . . . . . . . . . . . 5.2 m -152.99 123.07 0.82 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-O 120.804 0.335 . . . . 0.0 111.153 179.921 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 86' ' ' PHE . . . . . . . . . . . . . 29.8 m-85 -99.87 121.23 41.01 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.834 -179.938 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 87' ' ' ALA . . . . . 0.493 ' O ' HD11 ' A' ' 92' ' ' ILE . . . -140.56 147.38 48.94 Favored Pre-proline 0 C--N 1.33 -0.261 0 CA-C-N 116.248 -0.433 . . . . 0.0 111.093 -179.988 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 88' ' ' PRO . . . . . 0.406 ' HD3' ' CZ3' ' A' ' 55' ' ' TRP . 32.4 Cg_exo -57.97 138.33 85.46 Favored 'Trans proline' 0 C--N 1.345 0.388 0 C-N-CA 122.561 2.174 . . . . 0.0 112.258 -179.979 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 89' ' ' ALA . . . . . 0.626 ' HB2' ' CE1' ' A' ' 56' ' ' TYR . . . -47.98 -51.71 22.72 Favored 'General case' 0 C--N 1.332 -0.161 0 CA-C-O 121.137 0.494 . . . . 0.0 110.278 179.84 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 90' ' ' SER . . . . . . . . . . . . . 3.6 t -55.87 -24.45 37.07 Favored 'General case' 0 C--N 1.332 -0.186 0 CA-C-N 115.693 -0.685 . . . . 0.0 109.701 178.826 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 91' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -88.5 -14.35 38.02 Favored 'General case' 0 N--CA 1.454 -0.246 0 CA-C-N 115.911 -0.586 . . . . 0.0 110.49 179.058 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 92' ' ' ILE . . . . . 0.562 HD13 HD11 ' A' ' 58' ' ' ILE . 36.3 mt -110.83 156.13 12.05 Favored 'Isoleucine or valine' 0 C--N 1.334 -0.065 0 CA-C-O 120.908 0.385 . . . . 0.0 111.063 179.906 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 93' ' ' GLN . . . . . 0.451 ' N ' HG22 ' A' ' 92' ' ' ILE . 2.3 mp0 -123.67 173.84 7.84 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.116 -0.493 . . . . 0.0 110.811 179.987 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 94' ' ' ARG . . . . . 0.451 ' HG3' ' HB2' ' A' ' 26' ' ' ALA . 1.1 mtp180 -115.48 140.02 49.53 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.899 179.968 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 95' ' ' ILE . . . . . 0.433 HD11 ' HG2' ' A' ' 39' ' ' GLN . 21.7 mm -82.22 -39.92 16.75 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 CA-C-N 116.154 -0.476 . . . . 0.0 111.124 179.946 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . -87.15 -178.45 48.75 Favored Glycine 0 N--CA 1.451 -0.324 0 C-N-CA 120.714 -0.755 . . . . 0.0 112.442 -179.985 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 97' ' ' SER . . . . . . . . . . . . . 41.6 m -88.39 -48.17 7.83 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-O 120.871 0.367 . . . . 0.0 110.971 -179.922 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 98' ' ' GLY . . . . . . . . . . . . . . . 143.76 93.7 0.18 Allowed Glycine 0 N--CA 1.45 -0.381 0 C-N-CA 120.713 -0.756 . . . . 0.0 112.472 179.958 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 99' ' ' PRO . . . . . . . . . . . . . 63.5 Cg_exo -51.32 155.09 7.25 Favored 'Trans proline' 0 C--N 1.344 0.303 0 C-N-CA 122.562 2.175 . . . . 0.0 112.394 -179.997 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 100' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -119.53 100.43 7.28 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.895 -179.999 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 40.4 t -166.55 -48.05 0.03 OUTLIER 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.143 -0.48 . . . . 0.0 110.923 -179.922 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.249 1.069 0 CA-C-O 118.346 -1.252 . . . . 0.0 112.479 -179.981 . . . . . . . . 0 0 . 1 . 007 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.189 0 N-CA-C 112.547 -0.221 . . . . 0.0 112.547 . . . . . . . . . 0 0 . 1 . 007 nuclear build full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 29.1 t -171.44 -49.61 0.02 OUTLIER 'General case' 0 C--N 1.328 -0.34 0 CA-C-O 120.827 0.346 . . . . 0.0 110.968 -179.944 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 1.6 p -141.8 91.45 2.36 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.862 179.991 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -68.43 108.93 2.65 Favored Glycine 0 N--CA 1.451 -0.363 0 C-N-CA 120.694 -0.765 . . . . 0.0 112.428 -179.983 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 0.6 OUTLIER -128.55 -46.85 1.3 Allowed 'General case' 0 C--N 1.329 -0.29 0 CA-C-O 120.827 0.346 . . . . 0.0 110.845 179.993 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 1.8 m -81.57 113.89 19.9 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.911 179.998 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 141.67 53.42 0.04 OUTLIER Glycine 0 N--CA 1.451 -0.34 0 C-N-CA 120.76 -0.733 . . . . 0.0 112.526 -179.983 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 2.8 mmmm -144.69 -179.38 6.54 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 120.744 0.307 . . . . 0.0 110.951 179.967 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 45.9 m -129.39 81.06 70.96 Favored Pre-proline 0 C--N 1.329 -0.31 0 CA-C-N 116.286 -0.415 . . . . 0.0 111.032 -179.957 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 56.7 Cg_endo -70.74 -166.44 0.22 Allowed 'Trans proline' 0 C--N 1.345 0.346 0 C-N-CA 122.634 2.223 . . . . 0.0 112.29 -179.942 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 8.1 t 70.08 -67.57 0.23 Allowed 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.945 179.956 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 15.5 m -162.91 161.91 18.66 Favored Pre-proline 0 C--N 1.329 -0.302 0 CA-C-N 116.371 -0.377 . . . . 0.0 110.967 179.984 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 51.9 Cg_exo -54.37 -171.0 0.02 OUTLIER 'Trans proline' 0 C--N 1.344 0.302 0 C-N-CA 122.553 2.169 . . . . 0.0 112.286 179.937 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 3.5 t -134.48 107.43 7.55 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.899 -179.961 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 4.3 mm? -85.76 -63.45 1.32 Allowed 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.836 179.977 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -145.67 25.08 1.81 Allowed Glycine 0 N--CA 1.451 -0.301 0 C-N-CA 120.77 -0.728 . . . . 0.0 112.579 179.979 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER 58.4 174.33 0.06 Allowed 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 120.767 0.318 . . . . 0.0 110.975 179.963 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 13.3 mt 60.45 46.39 9.82 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.89 179.922 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 19' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -140.51 84.48 1.95 Allowed 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.847 -179.968 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 20' ' ' GLN . . . . . . . . . . . . . 2.5 tp-100 59.66 29.96 19.55 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.925 -179.964 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -144.26 92.13 2.28 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.262 -0.426 . . . . 0.0 110.998 179.98 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -61.74 -70.05 0.21 Allowed 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.264 -0.426 . . . . 0.0 110.852 -179.96 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 73.1 86.84 0.2 Allowed Glycine 0 N--CA 1.451 -0.303 0 C-N-CA 120.734 -0.746 . . . . 0.0 112.554 179.987 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -166.21 145.82 6.06 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 120.758 0.313 . . . . 0.0 111.097 -179.958 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 29.7 mmmt -85.45 -45.12 12.14 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.924 179.946 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -118.97 -174.76 2.77 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.089 179.983 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 27' ' ' GLU . . . . . . . . . . . . . 3.6 mm-40 -135.55 -178.73 5.25 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.841 179.946 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 21.5 t -83.08 104.98 12.42 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.164 -0.471 . . . . 0.0 111.119 179.993 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 107.35 30.58 4.07 Favored Glycine 0 N--CA 1.452 -0.288 0 C-N-CA 120.779 -0.724 . . . . 0.0 112.487 -179.948 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 3.4 m-20 -124.84 144.21 50.42 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 120.793 0.33 . . . . 0.0 110.895 179.952 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 31' ' ' GLN . . . . . . . . . . . . . 5.0 mp0 -65.28 130.4 43.19 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.806 -179.97 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 20.7 m -136.13 175.23 10.95 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 CA-C-N 116.2 -0.454 . . . . 0.0 111.079 179.993 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 33' ' ' LEU . . . . . 0.44 HD12 ' HA ' ' A' ' 39' ' ' GLN . 14.1 tp -139.11 100.06 3.92 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.105 -0.498 . . . . 0.0 110.912 179.98 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 21.5 t -64.5 121.02 12.74 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 116.234 -0.439 . . . . 0.0 111.179 179.991 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 35' ' ' ALA . . . . . . . . . . . . . . . 58.71 26.87 15.14 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.3 179.998 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . 56.66 27.79 55.61 Favored Glycine 0 N--CA 1.451 -0.32 0 C-N-CA 120.779 -0.724 . . . . 0.0 112.601 -179.976 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 37' ' ' GLN . . . . . 0.41 ' O ' HD11 ' A' ' 33' ' ' LEU . 38.9 mt-30 -139.66 -72.08 0.38 Allowed 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.775 0.321 . . . . 0.0 110.892 -179.993 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 38' ' ' LYS . . . . . 0.405 ' HB3' HD21 ' A' ' 60' ' ' LEU . 55.6 mttt -65.17 114.53 4.73 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.259 -0.428 . . . . 0.0 110.924 179.995 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 39' ' ' GLN . . . . . 0.44 ' HA ' HD12 ' A' ' 33' ' ' LEU . 5.8 tm0? -85.53 130.07 34.67 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.886 179.952 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -157.08 173.56 34.66 Favored Glycine 0 N--CA 1.451 -0.302 0 C-N-CA 120.66 -0.781 . . . . 0.0 112.481 179.993 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 41' ' ' ILE . . . . . 0.42 ' N ' HG23 ' A' ' 58' ' ' ILE . 33.5 mt -121.13 133.18 68.56 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 CA-C-O 120.802 0.334 . . . . 0.0 111.033 -179.969 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 42' ' ' VAL . . . . . . . . . . . . . 21.4 t -61.99 121.73 11.06 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.146 -0.479 . . . . 0.0 111.097 179.979 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 43' ' ' ARG . . . . . . . . . . . . . 14.8 mmt180 -108.0 -30.92 8.19 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.903 179.878 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 44' ' ' PHE . . . . . . . . . . . . . 28.9 t80 -149.73 109.57 4.07 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.25 -0.432 . . . . 0.0 110.934 -179.976 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 45' ' ' TYR . . . . . 0.49 ' CE1' ' CZ ' ' A' ' 56' ' ' TYR . 22.7 t80 -106.76 130.5 54.46 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.289 -0.414 . . . . 0.0 110.865 179.964 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 167.02 -161.17 35.02 Favored Glycine 0 N--CA 1.451 -0.35 0 C-N-CA 120.679 -0.772 . . . . 0.0 112.488 -179.976 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 47' ' ' LYS . . . . . . . . . . . . . 40.3 mttt -84.74 175.83 8.93 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 120.748 0.309 . . . . 0.0 110.949 179.94 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 48' ' ' THR . . . . . 0.46 HG21 ' CZ ' ' A' ' 50' ' ' PHE . 71.1 p -143.9 -177.42 5.42 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.938 -179.974 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 3.5 t0 -110.8 -35.03 6.08 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.284 -0.416 . . . . 0.0 110.914 -179.961 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 50' ' ' PHE . . . . . 0.46 ' CZ ' HG21 ' A' ' 48' ' ' THR . 16.1 p90 -60.06 -31.36 69.92 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.917 179.996 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 51' ' ' ALA . . . . . 0.438 ' N ' ' CD1' ' A' ' 50' ' ' PHE . . . -159.84 141.73 9.62 Favored Pre-proline 0 C--N 1.329 -0.319 0 CA-C-N 116.264 -0.426 . . . . 0.0 111.092 179.911 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 52' ' ' PRO . . . . . . . . . . . . . 72.6 Cg_endo -74.77 154.7 43.86 Favored 'Trans proline' 0 C--N 1.346 0.405 0 C-N-CA 122.497 2.131 . . . . 0.0 112.39 179.991 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 121.39 -160.34 15.75 Favored Glycine 0 N--CA 1.45 -0.393 0 C-N-CA 120.752 -0.737 . . . . 0.0 112.555 179.988 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 54' ' ' TYR . . . . . . . . . . . . . 33.4 m-85 -113.2 110.49 20.49 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-O 120.81 0.338 . . . . 0.0 110.887 179.997 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 55' ' ' TRP . . . . . . . . . . . . . 51.2 m95 -112.96 160.5 18.03 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.888 179.955 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 56' ' ' TYR . . . . . 0.6 ' HE1' ' HB2' ' A' ' 89' ' ' ALA . 4.8 m-85 -118.07 128.13 54.46 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.954 -179.972 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 57' ' ' GLY . . . . . 0.435 ' HA3' ' CE1' ' A' ' 77' ' ' PHE . . . -88.25 59.42 4.14 Favored Glycine 0 N--CA 1.451 -0.305 0 C-N-CA 120.744 -0.741 . . . . 0.0 112.344 179.855 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 58' ' ' ILE . . . . . 0.703 HD11 HD13 ' A' ' 92' ' ' ILE . 12.6 mt -68.98 148.55 11.61 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.367 0 CA-C-O 120.864 0.364 . . . . 0.0 111.113 -179.895 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -119.15 120.47 37.18 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.891 179.932 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 60' ' ' LEU . . . . . 0.405 HD21 ' HB3' ' A' ' 38' ' ' LYS . 56.7 mt -71.88 -179.96 2.93 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.852 -179.997 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 21.0 m-20 -104.96 -29.55 10.39 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.283 -0.417 . . . . 0.0 110.935 -179.928 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 62' ' ' GLN . . . . . . . . . . . . . 2.1 mt-30 -114.87 147.95 39.39 Favored Pre-proline 0 C--N 1.329 -0.31 0 CA-C-N 116.312 -0.404 . . . . 0.0 110.871 -179.907 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 36.6 Cg_exo -60.02 91.2 0.08 OUTLIER 'Trans proline' 0 C--N 1.345 0.391 0 C-N-CA 122.515 2.143 . . . . 0.0 112.264 179.924 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 64' ' ' THR . . . . . . . . . . . . . 10.1 t -172.72 39.22 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.271 -0.422 . . . . 0.0 110.992 -179.994 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . -91.37 -104.84 1.38 Allowed Glycine 0 N--CA 1.451 -0.3 0 C-N-CA 120.695 -0.764 . . . . 0.0 112.459 -179.979 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 66' ' ' LYS . . . . . . . . . . . . . 3.0 mtmt -159.99 -49.3 0.05 Allowed 'General case' 0 C--N 1.328 -0.336 0 CA-C-O 120.795 0.331 . . . . 0.0 110.791 -179.992 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 67' ' ' HIS . . . . . . . . . . . . . 7.5 p80 -128.92 171.96 11.8 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.244 -0.435 . . . . 0.0 110.868 -179.937 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 16.8 t0 -98.18 32.47 2.44 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.255 -0.43 . . . . 0.0 110.88 179.926 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 95.4 -41.47 2.48 Favored Glycine 0 N--CA 1.451 -0.32 0 C-N-CA 120.73 -0.748 . . . . 0.0 112.506 -179.936 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 70' ' ' SER . . . . . . . . . . . . . 99.2 p -98.85 126.51 44.52 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 120.762 0.315 . . . . 0.0 110.978 179.976 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 71' ' ' VAL . . . . . 0.609 HG12 ' CD2' ' A' ' 72' ' ' PHE . 21.5 t -112.88 114.27 46.49 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.354 0 CA-C-N 116.198 -0.456 . . . . 0.0 111.114 -179.908 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 72' ' ' PHE . . . . . 0.609 ' CD2' HG12 ' A' ' 71' ' ' VAL . 14.7 m-85 61.49 30.77 18.96 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.917 -179.976 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 98.42 -29.75 10.87 Favored Glycine 0 N--CA 1.452 -0.288 0 C-N-CA 120.741 -0.742 . . . . 0.0 112.511 179.985 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 21.5 t -77.2 124.22 35.22 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-O 120.752 0.311 . . . . 0.0 111.111 -179.978 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 75' ' ' ARG . . . . . . . . . . . . . 10.3 ttt180 -104.71 136.76 43.63 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.939 179.996 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 76' ' ' TYR . . . . . . . . . . . . . 36.3 m-85 -112.84 -43.47 3.42 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.965 179.963 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 77' ' ' PHE . . . . . 0.435 ' CE1' ' HA3' ' A' ' 57' ' ' GLY . 40.9 p90 -153.29 165.06 36.91 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.935 -179.995 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 2.6 t -93.6 121.62 35.2 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.176 -0.466 . . . . 0.0 110.853 -179.994 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 79' ' ' CYS . . . . . . . . . . . . . 10.0 p -142.45 154.2 44.35 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.22 -0.445 . . . . 0.0 111.002 -179.98 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 80' ' ' ALA . . . . . 0.714 ' HB1' ' HD2' ' A' ' 81' ' ' PRO . . . -58.94 165.45 3.35 Favored Pre-proline 0 C--N 1.328 -0.34 0 CA-C-N 116.166 -0.47 . . . . 0.0 111.025 179.956 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 81' ' ' PRO . . . . . 0.714 ' HD2' ' HB1' ' A' ' 80' ' ' ALA . 17.9 Cg_endo -59.6 115.94 2.95 Favored 'Trans proline' 0 C--N 1.344 0.332 0 C-N-CA 122.53 2.153 . . . . 0.0 112.095 179.985 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 82' ' ' ARG . . . . . . . . . . . . . 57.1 mtp180 63.96 55.36 1.59 Allowed 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.812 -179.883 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 83' ' ' HIS . . . . . 0.619 ' CG ' ' HB3' ' A' ' 80' ' ' ALA . 6.4 m170 -126.75 -47.43 1.54 Allowed 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.907 179.97 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . -59.04 142.41 46.51 Favored Glycine 0 N--CA 1.452 -0.261 0 C-N-CA 120.738 -0.744 . . . . 0.0 112.511 -179.99 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 85' ' ' VAL . . . . . . . . . . . . . 5.3 m -146.86 115.91 1.29 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.272 0 CA-C-O 120.804 0.335 . . . . 0.0 111.113 179.955 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 86' ' ' PHE . . . . . . . . . . . . . 10.4 m-85 -93.41 124.95 37.75 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.862 179.936 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 87' ' ' ALA . . . . . 0.515 ' O ' HD11 ' A' ' 92' ' ' ILE . . . -144.55 144.86 26.46 Favored Pre-proline 0 C--N 1.329 -0.303 0 CA-C-N 116.27 -0.423 . . . . 0.0 111.101 179.93 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 88' ' ' PRO . . . . . 0.424 ' O ' ' N ' ' A' ' 91' ' ' ARG . 31.9 Cg_exo -58.38 142.13 97.51 Favored 'Trans proline' 0 C--N 1.345 0.387 0 C-N-CA 122.429 2.086 . . . . 0.0 112.243 179.956 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 89' ' ' ALA . . . . . 0.6 ' HB2' ' HE1' ' A' ' 56' ' ' TYR . . . -47.58 -51.84 19.72 Favored 'General case' 0 C--N 1.333 -0.114 0 CA-C-O 121.088 0.471 . . . . 0.0 110.388 179.983 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 90' ' ' SER . . . . . . . . . . . . . 64.3 m -55.88 -24.29 36.28 Favored 'General case' 0 C--N 1.331 -0.235 0 CA-C-N 115.701 -0.681 . . . . 0.0 109.81 178.839 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 91' ' ' ARG . . . . . 0.424 ' N ' ' O ' ' A' ' 88' ' ' PRO . 0.5 OUTLIER -89.33 -13.83 37.06 Favored 'General case' 0 N--CA 1.455 -0.197 0 CA-C-N 115.876 -0.602 . . . . 0.0 110.484 179.095 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 92' ' ' ILE . . . . . 0.703 HD13 HD11 ' A' ' 58' ' ' ILE . 46.8 mt -109.92 141.11 26.17 Favored 'Isoleucine or valine' 0 C--O 1.231 0.126 0 CA-C-N 116.493 -0.321 . . . . 0.0 111.034 179.883 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 93' ' ' GLN . . . . . . . . . . . . . 1.4 mt-30 -107.72 171.45 7.38 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.816 179.992 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 94' ' ' ARG . . . . . . . . . . . . . 5.5 ttt180 -122.1 125.58 46.51 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.919 179.982 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 95' ' ' ILE . . . . . . . . . . . . . 5.5 mt -96.32 -58.25 3.9 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.273 -0.421 . . . . 0.0 111.037 -179.965 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . 66.6 62.7 4.37 Favored Glycine 0 N--CA 1.451 -0.311 0 C-N-CA 120.78 -0.724 . . . . 0.0 112.434 -179.992 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 97' ' ' SER . . . . . . . . . . . . . 50.6 p -108.49 158.09 17.85 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-O 120.868 0.366 . . . . 0.0 110.869 179.993 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 98' ' ' GLY . . . . . . . . . . . . . . . 140.51 -178.47 19.96 Favored Glycine 0 N--CA 1.451 -0.311 0 C-N-CA 120.739 -0.743 . . . . 0.0 112.513 179.995 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 99' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_exo -52.26 171.16 0.2 Allowed 'Trans proline' 0 C--N 1.345 0.351 0 C-N-CA 122.59 2.193 . . . . 0.0 112.28 -179.947 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 100' ' ' SER . . . . . . . . . . . . . 8.6 t -155.54 -61.43 0.11 Allowed 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.93 179.981 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 62.9 m -148.58 175.72 10.93 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.218 -0.447 . . . . 0.0 110.876 179.978 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.249 1.083 0 CA-C-O 118.357 -1.246 . . . . 0.0 112.531 179.981 . . . . . . . . 0 0 . 1 . 008 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.488 2.15 0 N-CA-C 112.57 -0.212 . . . . 0.0 112.57 . . . . . . . . . 0 0 . 1 . 008 nuclear build full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 64.0 m -139.4 142.45 37.5 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-O 120.823 0.344 . . . . 0.0 110.902 -179.982 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -102.62 98.43 8.48 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.945 179.945 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -71.31 -173.05 15.25 Favored Glycine 0 N--CA 1.451 -0.338 0 C-N-CA 120.797 -0.716 . . . . 0.0 112.478 -179.985 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -167.52 167.16 13.82 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-O 120.827 0.346 . . . . 0.0 110.946 -179.934 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 36.2 p -105.73 -53.51 2.63 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.863 -179.994 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -125.04 -77.11 0.29 Allowed Glycine 0 N--CA 1.452 -0.293 0 C-N-CA 120.726 -0.75 . . . . 0.0 112.425 179.985 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 8.0 pttt -128.75 -54.61 1.23 Allowed 'General case' 0 C--N 1.329 -0.299 0 CA-C-O 120.784 0.326 . . . . 0.0 110.85 179.919 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER 53.87 85.97 0.18 Allowed Pre-proline 0 C--N 1.329 -0.297 0 CA-C-N 116.227 -0.442 . . . . 0.0 111.054 179.861 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 52.1 Cg_exo -52.82 89.31 0.03 OUTLIER 'Trans proline' 0 C--N 1.345 0.344 0 C-N-CA 122.551 2.167 . . . . 0.0 112.254 179.987 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 20.9 m -139.52 -54.67 0.56 Allowed 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.268 -0.424 . . . . 0.0 110.923 -179.961 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 87.1 p -140.25 154.24 69.73 Favored Pre-proline 0 C--N 1.329 -0.287 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.846 179.973 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 53.2 Cg_endo -69.54 86.9 0.54 Allowed 'Trans proline' 0 C--N 1.345 0.39 0 C-N-CA 122.551 2.167 . . . . 0.0 112.24 -179.994 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -119.52 136.7 54.23 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.274 -0.421 . . . . 0.0 110.887 179.979 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 1.6 mt -165.48 -171.13 2.03 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.776 -179.995 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -55.17 106.42 0.55 Allowed Glycine 0 N--CA 1.452 -0.263 0 C-N-CA 120.796 -0.716 . . . . 0.0 112.588 179.949 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -59.4 108.39 0.7 Allowed 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 120.892 0.377 . . . . 0.0 110.944 -179.952 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 6.8 mt -112.34 -35.37 5.61 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.857 179.964 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 19' ' ' GLN . . . . . . . . . . . . . 4.3 mt-30 -65.83 136.15 55.8 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.833 -179.958 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 20' ' ' GLN . . . . . . . . . . . . . 4.1 tt0 -144.33 -47.4 0.26 Allowed 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.896 179.958 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 0.9 OUTLIER -103.64 117.01 33.42 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.18 -0.463 . . . . 0.0 110.839 179.989 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 8.4 mp0 -113.72 -62.48 1.59 Allowed 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.876 179.919 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 106.22 -59.93 0.39 Allowed Glycine 0 N--CA 1.451 -0.33 0 C-N-CA 120.715 -0.755 . . . . 0.0 112.496 179.995 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 24' ' ' ALA . . . . . 0.461 ' HB2' ' OH ' ' A' ' 45' ' ' TYR . . . -78.49 129.67 35.13 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-O 120.826 0.346 . . . . 0.0 111.116 -179.932 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -87.6 -64.19 1.19 Allowed 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.865 -179.987 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -98.83 179.85 4.52 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.185 -0.461 . . . . 0.0 111.16 179.941 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 27' ' ' GLU . . . . . . . . . . . . . 5.6 mp0 -130.46 177.87 7.03 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.886 -179.96 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 26.9 t -64.9 92.21 0.11 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.231 -0.44 . . . . 0.0 111.132 179.95 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 114.86 41.86 0.82 Allowed Glycine 0 N--CA 1.452 -0.251 0 C-N-CA 120.746 -0.74 . . . . 0.0 112.403 -179.928 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 37.5 t70 -134.93 144.14 47.3 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-O 120.841 0.353 . . . . 0.0 110.945 179.979 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 31' ' ' GLN . . . . . . . . . . . . . 2.4 mp0 -64.43 134.98 55.61 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.254 -0.43 . . . . 0.0 110.811 -179.996 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 13.7 m -147.96 173.41 1.99 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.358 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.21 179.981 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 33' ' ' LEU . . . . . 0.577 HD12 ' HA ' ' A' ' 39' ' ' GLN . 15.0 tp -134.32 108.53 8.26 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.222 -0.444 . . . . 0.0 110.899 -179.969 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 34' ' ' VAL . . . . . 0.427 HG22 ' CD1' ' A' ' 58' ' ' ILE . 26.0 t -73.74 122.59 27.11 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.115 179.967 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 35' ' ' ALA . . . . . . . . . . . . . . . 59.13 25.2 13.65 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.117 -0.492 . . . . 0.0 111.194 -179.992 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 36' ' ' GLY . . . . . 0.414 ' HA2' HD23 ' A' ' 33' ' ' LEU . . . 55.27 27.49 46.97 Favored Glycine 0 N--CA 1.452 -0.253 0 C-N-CA 120.779 -0.724 . . . . 0.0 112.592 179.938 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 37' ' ' GLN . . . . . . . . . . . . . 12.8 mt-30 -141.87 -63.05 0.45 Allowed 'General case' 0 C--N 1.329 -0.286 0 CA-C-O 120.781 0.324 . . . . 0.0 110.876 -179.988 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 38' ' ' LYS . . . . . . . . . . . . . 11.4 mttp -71.26 111.97 7.03 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.25 -0.432 . . . . 0.0 110.889 179.989 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 39' ' ' GLN . . . . . 0.577 ' HA ' HD12 ' A' ' 33' ' ' LEU . 0.9 OUTLIER -82.27 131.24 35.23 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.854 -179.991 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -163.28 179.06 38.67 Favored Glycine 0 N--CA 1.451 -0.336 0 C-N-CA 120.775 -0.726 . . . . 0.0 112.504 -179.994 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 41' ' ' ILE . . . . . 0.458 ' N ' HG23 ' A' ' 58' ' ' ILE . 28.0 mt -128.63 137.74 56.49 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-O 120.842 0.354 . . . . 0.0 111.125 179.929 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 42' ' ' VAL . . . . . . . . . . . . . 21.5 t -62.19 127.16 21.68 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-N 116.174 -0.467 . . . . 0.0 111.161 -179.997 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 43' ' ' ARG . . . . . . . . . . . . . 10.1 mmt180 -111.76 -34.67 5.96 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.909 179.955 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 44' ' ' PHE . . . . . . . . . . . . . 39.4 t80 -143.52 112.28 6.53 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.897 -179.988 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 45' ' ' TYR . . . . . 0.485 ' CE1' ' CZ ' ' A' ' 56' ' ' TYR . 12.9 t80 -105.39 122.29 45.68 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.919 179.932 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 166.02 173.13 34.16 Favored Glycine 0 N--CA 1.452 -0.265 0 C-N-CA 120.757 -0.735 . . . . 0.0 112.485 179.953 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 47' ' ' LYS . . . . . . . . . . . . . 14.5 mttm -70.15 155.46 40.6 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 120.842 0.353 . . . . 0.0 110.911 -179.995 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 48' ' ' THR . . . . . 0.527 HG21 ' CE1' ' A' ' 50' ' ' PHE . 42.8 p -118.12 -177.75 3.35 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.13 -0.486 . . . . 0.0 110.874 179.969 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 4.8 t0 -105.98 -30.75 9.12 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.922 179.98 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 50' ' ' PHE . . . . . 0.527 ' CE1' HG21 ' A' ' 48' ' ' THR . 53.8 p90 -71.02 -40.75 71.58 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.941 -179.95 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 51' ' ' ALA . . . . . . . . . . . . . . . -137.0 144.47 46.5 Favored Pre-proline 0 C--N 1.329 -0.294 0 CA-C-N 116.187 -0.461 . . . . 0.0 111.211 -179.934 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 52' ' ' PRO . . . . . . . . . . . . . 73.3 Cg_endo -76.16 169.76 21.4 Favored 'Trans proline' 0 C--N 1.345 0.357 0 C-N-CA 122.54 2.16 . . . . 0.0 112.366 -179.975 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 90.39 178.78 44.07 Favored Glycine 0 N--CA 1.452 -0.294 0 C-N-CA 120.738 -0.744 . . . . 0.0 112.464 179.906 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 54' ' ' TYR . . . . . . . . . . . . . 14.1 m-85 -91.17 115.7 28.23 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-O 120.813 0.34 . . . . 0.0 110.935 179.977 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 55' ' ' TRP . . . . . . . . . . . . . 73.8 m95 -109.91 147.22 33.8 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.89 179.973 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 56' ' ' TYR . . . . . 0.579 ' CE1' ' HB2' ' A' ' 89' ' ' ALA . 8.1 m-85 -104.62 120.98 42.57 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.966 -179.89 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 57' ' ' GLY . . . . . 0.445 ' N ' ' CE1' ' A' ' 86' ' ' PHE . . . -80.72 62.78 4.34 Favored Glycine 0 N--CA 1.451 -0.325 0 C-N-CA 120.758 -0.734 . . . . 0.0 112.365 179.929 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 58' ' ' ILE . . . . . 0.757 HD11 HD13 ' A' ' 92' ' ' ILE . 21.6 mt -70.76 138.94 20.84 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-O 120.866 0.365 . . . . 0.0 111.141 -179.906 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -109.13 130.63 55.48 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.877 -179.97 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 60' ' ' LEU . . . . . 0.479 HD13 HG23 ' A' ' 64' ' ' THR . 84.2 mt -85.54 173.21 10.37 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.871 179.959 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 1.5 t70 -103.11 -31.03 10.36 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.943 -179.961 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 62' ' ' GLN . . . . . 0.401 ' HA ' ' HD3' ' A' ' 63' ' ' PRO . 2.4 mm-40 -114.43 147.81 38.82 Favored Pre-proline 0 C--N 1.33 -0.272 0 CA-C-N 116.298 -0.41 . . . . 0.0 110.911 -179.986 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 63' ' ' PRO . . . . . 0.401 ' HD3' ' HA ' ' A' ' 62' ' ' GLN . 31.9 Cg_exo -58.24 84.32 0.05 OUTLIER 'Trans proline' 0 C--N 1.346 0.399 0 C-N-CA 122.564 2.176 . . . . 0.0 112.25 179.928 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 64' ' ' THR . . . . . 0.479 HG23 HD13 ' A' ' 60' ' ' LEU . 13.4 t -157.0 35.02 0.29 Allowed 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.297 -0.411 . . . . 0.0 110.946 179.988 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . -95.96 -159.98 32.65 Favored Glycine 0 N--CA 1.452 -0.292 0 C-N-CA 120.745 -0.741 . . . . 0.0 112.503 179.911 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 66' ' ' LYS . . . . . . . . . . . . . 0.5 OUTLIER -110.03 -31.31 7.42 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 120.861 0.363 . . . . 0.0 110.922 179.977 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 67' ' ' HIS . . . . . 0.492 ' CG ' HG22 ' A' ' 71' ' ' VAL . 13.1 p80 -145.96 -178.74 6.28 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.877 -179.975 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 26.6 t0 -114.87 73.08 0.81 Allowed 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.944 179.986 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 79.41 -72.75 2.47 Favored Glycine 0 N--CA 1.451 -0.352 0 C-N-CA 120.761 -0.733 . . . . 0.0 112.476 -179.982 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 70' ' ' SER . . . . . . . . . . . . . 97.2 p -86.62 151.5 23.39 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-O 120.841 0.353 . . . . 0.0 110.907 -179.981 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 71' ' ' VAL . . . . . 0.716 HG12 ' CD2' ' A' ' 72' ' ' PHE . 21.5 t -128.03 117.9 47.08 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.162 -0.472 . . . . 0.0 111.095 179.977 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 72' ' ' PHE . . . . . 0.716 ' CD2' HG12 ' A' ' 71' ' ' VAL . 59.8 m-85 60.91 31.12 19.98 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.879 179.962 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 99.74 -30.0 10.9 Favored Glycine 0 N--CA 1.452 -0.281 0 C-N-CA 120.687 -0.768 . . . . 0.0 112.563 179.984 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 21.3 t -75.66 116.35 18.45 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-O 120.888 0.375 . . . . 0.0 111.093 179.981 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 75' ' ' ARG . . . . . . . . . . . . . 26.2 ttt85 -93.83 148.03 22.51 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.858 179.969 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 76' ' ' TYR . . . . . . . . . . . . . 89.9 m-85 -133.24 -47.69 0.84 Allowed 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.165 -0.471 . . . . 0.0 110.948 179.946 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 77' ' ' PHE . . . . . . . . . . . . . 22.5 p90 -155.2 154.67 32.6 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.9 -179.979 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 9.0 t -84.6 140.7 31.19 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.169 -0.468 . . . . 0.0 110.847 179.955 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 79' ' ' CYS . . . . . . . . . . . . . 22.7 p -164.7 162.39 21.25 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.922 179.921 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 80' ' ' ALA . . . . . 0.707 ' HB1' ' HD2' ' A' ' 81' ' ' PRO . . . -59.24 166.16 3.12 Favored Pre-proline 0 C--N 1.33 -0.254 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.002 179.949 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 81' ' ' PRO . . . . . 0.707 ' HD2' ' HB1' ' A' ' 80' ' ' ALA . 28.1 Cg_endo -62.66 122.63 11.05 Favored 'Trans proline' 0 C--N 1.346 0.397 0 C-N-CA 122.468 2.112 . . . . 0.0 112.253 -180.0 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 82' ' ' ARG . . . . . . . . . . . . . 0.5 OUTLIER 61.01 53.36 3.72 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.91 -179.875 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 83' ' ' HIS . . . . . 0.677 ' ND1' ' HB3' ' A' ' 80' ' ' ALA . 7.4 m170 -123.21 -45.54 2.1 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.11 -0.495 . . . . 0.0 110.85 179.958 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . -59.8 146.01 45.09 Favored Glycine 0 N--CA 1.451 -0.341 0 C-N-CA 120.646 -0.788 . . . . 0.0 112.501 -179.971 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 85' ' ' VAL . . . . . . . . . . . . . 6.1 m -150.04 114.88 0.67 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-O 120.815 0.34 . . . . 0.0 111.098 -179.938 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 86' ' ' PHE . . . . . 0.445 ' CE1' ' N ' ' A' ' 57' ' ' GLY . 3.7 m-85 -97.53 108.29 20.98 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.929 179.998 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 87' ' ' ALA . . . . . 0.595 ' O ' HD11 ' A' ' 92' ' ' ILE . . . -128.5 145.4 55.79 Favored Pre-proline 0 C--N 1.328 -0.344 0 CA-C-N 116.233 -0.439 . . . . 0.0 111.139 179.982 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 88' ' ' PRO . . . . . 0.417 ' O ' ' N ' ' A' ' 91' ' ' ARG . 32.3 Cg_exo -57.96 142.57 96.66 Favored 'Trans proline' 0 C--N 1.345 0.362 0 C-N-CA 122.519 2.146 . . . . 0.0 112.259 -179.984 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 89' ' ' ALA . . . . . 0.579 ' HB2' ' CE1' ' A' ' 56' ' ' TYR . . . -47.85 -51.18 23.93 Favored 'General case' 0 CA--C 1.521 -0.141 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.329 179.872 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 90' ' ' SER . . . . . . . . . . . . . 23.6 t -55.83 -24.4 36.24 Favored 'General case' 0 N--CA 1.454 -0.266 0 CA-C-N 115.747 -0.661 . . . . 0.0 109.815 178.76 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 91' ' ' ARG . . . . . 0.417 ' N ' ' O ' ' A' ' 88' ' ' PRO . 0.0 OUTLIER -89.37 -14.14 36.24 Favored 'General case' 0 N--CA 1.455 -0.215 0 CA-C-N 115.932 -0.576 . . . . 0.0 110.513 179.04 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 92' ' ' ILE . . . . . 0.757 HD13 HD11 ' A' ' 58' ' ' ILE . 48.9 mt -105.85 156.59 6.62 Favored 'Isoleucine or valine' 0 C--O 1.231 0.12 0 CA-C-N 116.396 -0.365 . . . . 0.0 110.971 179.753 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 93' ' ' GLN . . . . . 0.468 ' N ' HG22 ' A' ' 92' ' ' ILE . 50.8 mt-30 -121.42 175.0 6.4 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.262 -0.426 . . . . 0.0 110.881 -179.979 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 94' ' ' ARG . . . . . . . . . . . . . 0.6 OUTLIER -122.03 110.41 15.76 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.855 -179.972 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 95' ' ' ILE . . . . . . . . . . . . . 32.5 mt -83.0 -32.32 9.54 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.262 -0.427 . . . . 0.0 111.073 179.97 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . -64.75 -141.8 0.02 OUTLIER Glycine 0 N--CA 1.451 -0.367 0 C-N-CA 120.783 -0.723 . . . . 0.0 112.541 179.95 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 97' ' ' SER . . . . . . . . . . . . . 5.5 m 60.23 92.44 0.05 OUTLIER 'General case' 0 C--N 1.328 -0.331 0 CA-C-O 120.862 0.363 . . . . 0.0 110.927 179.984 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 98' ' ' GLY . . . . . . . . . . . . . . . 107.62 151.98 17.27 Favored Glycine 0 N--CA 1.452 -0.297 0 C-N-CA 120.725 -0.75 . . . . 0.0 112.517 179.919 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 99' ' ' PRO . . . . . . . . . . . . . 55.4 Cg_endo -69.84 93.74 0.53 Allowed 'Trans proline' 0 C--N 1.345 0.347 0 C-N-CA 122.562 2.175 . . . . 0.0 112.3 179.962 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 100' ' ' SER . . . . . . . . . . . . . 10.7 t -72.07 139.35 48.41 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.883 -179.947 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -77.1 -173.74 2.89 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.913 179.99 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.248 1.007 0 CA-C-O 118.365 -1.242 . . . . 0.0 112.49 179.953 . . . . . . . . 0 0 . 1 . 009 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.267 0 N-CA-C 112.529 -0.228 . . . . 0.0 112.529 . . . . . . . . . 0 0 . 1 . 009 nuclear build full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 1.3 m -173.15 140.3 0.86 Allowed 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 120.871 0.367 . . . . 0.0 110.925 179.952 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 2.9 p -142.96 159.76 41.64 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.899 -179.982 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 158.44 45.8 0.01 OUTLIER Glycine 0 N--CA 1.451 -0.34 0 C-N-CA 120.777 -0.725 . . . . 0.0 112.515 -179.919 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -105.82 136.66 45.05 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 120.724 0.297 . . . . 0.0 110.926 -179.962 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -60.98 110.19 1.28 Allowed 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.864 179.994 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 140.68 154.41 6.23 Favored Glycine 0 N--CA 1.45 -0.38 0 C-N-CA 120.776 -0.726 . . . . 0.0 112.52 -179.994 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 7.6 mttt -142.71 83.18 1.8 Allowed 'General case' 0 C--N 1.328 -0.331 0 CA-C-O 120.847 0.356 . . . . 0.0 110.921 179.975 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 1.5 t -149.34 88.35 5.05 Favored Pre-proline 0 C--N 1.329 -0.316 0 CA-C-N 116.213 -0.448 . . . . 0.0 110.931 -179.993 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 49.8 Cg_endo -68.8 -28.06 30.61 Favored 'Trans proline' 0 C--N 1.345 0.358 0 C-N-CA 122.547 2.165 . . . . 0.0 112.321 179.954 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 53.2 p -82.05 128.05 33.71 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.883 -179.985 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 2.6 m -77.34 150.44 80.0 Favored Pre-proline 0 C--N 1.329 -0.3 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.878 -179.952 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_exo -52.2 -51.53 10.93 Favored 'Trans proline' 0 C--N 1.345 0.367 0 C-N-CA 122.62 2.214 . . . . 0.0 112.249 -179.96 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 1.2 m -136.2 170.5 15.92 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.275 -0.421 . . . . 0.0 110.902 179.996 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 0.6 OUTLIER -162.99 33.25 0.1 Allowed 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.211 -0.449 . . . . 0.0 110.831 -179.995 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 122.95 40.53 0.48 Allowed Glycine 0 N--CA 1.452 -0.28 0 C-N-CA 120.768 -0.73 . . . . 0.0 112.478 179.978 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 1.1 m -80.12 -42.8 22.82 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 120.733 0.302 . . . . 0.0 110.847 -179.935 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -109.9 38.96 2.24 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.884 -179.974 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 19' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -97.43 107.53 20.05 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.145 -0.48 . . . . 0.0 110.875 -179.99 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 20' ' ' GLN . . . . . . . . . . . . . 3.6 mm-40 60.31 32.37 20.7 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.114 -0.493 . . . . 0.0 110.909 179.926 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 1.0 OUTLIER -166.79 169.91 12.86 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.145 -0.48 . . . . 0.0 110.903 179.904 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 0.2 OUTLIER -111.64 165.73 11.77 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.264 -0.426 . . . . 0.0 110.899 179.989 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -112.78 112.33 2.95 Favored Glycine 0 N--CA 1.451 -0.354 0 C-N-CA 120.701 -0.762 . . . . 0.0 112.537 179.882 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -88.31 136.37 33.01 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-O 120.813 0.34 . . . . 0.0 111.125 179.94 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -91.56 -45.14 8.66 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.034 -179.986 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -108.98 166.25 10.97 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.215 -0.448 . . . . 0.0 111.106 179.981 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 27' ' ' GLU . . . . . . . . . . . . . 8.8 mt-10 -125.01 167.74 14.3 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.251 -0.431 . . . . 0.0 110.885 179.992 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 28.3 t -70.55 100.41 0.73 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 CA-C-N 116.165 -0.471 . . . . 0.0 111.077 -179.963 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 116.94 39.68 0.8 Allowed Glycine 0 N--CA 1.451 -0.334 0 C-N-CA 120.692 -0.766 . . . . 0.0 112.504 -179.977 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 1.8 m-20 -142.35 146.94 35.51 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-O 120.836 0.35 . . . . 0.0 110.89 -179.992 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 31' ' ' GLN . . . . . . . . . . . . . 77.1 mt-30 -59.96 136.26 57.96 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.861 179.966 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 5.8 m -148.91 162.46 5.01 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.129 179.968 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 33' ' ' LEU . . . . . 0.506 HD23 ' HA2' ' A' ' 36' ' ' GLY . 20.5 tp -130.23 104.96 7.6 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.825 -179.956 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 34' ' ' VAL . . . . . 0.488 HG13 ' CB ' ' A' ' 87' ' ' ALA . 21.7 t -72.98 125.01 31.09 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-N 116.178 -0.464 . . . . 0.0 111.263 -179.955 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 35' ' ' ALA . . . . . . . . . . . . . . . 57.17 25.88 11.48 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.169 -0.469 . . . . 0.0 111.24 179.914 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 36' ' ' GLY . . . . . 0.506 ' HA2' HD23 ' A' ' 33' ' ' LEU . . . 56.54 32.01 60.74 Favored Glycine 0 N--CA 1.452 -0.244 0 C-N-CA 120.726 -0.749 . . . . 0.0 112.613 179.971 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 37' ' ' GLN . . . . . . . . . . . . . 29.9 mt-30 -142.2 -66.71 0.39 Allowed 'General case' 0 C--N 1.329 -0.284 0 CA-C-O 120.781 0.324 . . . . 0.0 110.975 179.96 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 38' ' ' LYS . . . . . 0.532 ' HB3' HD21 ' A' ' 60' ' ' LEU . 25.1 mmtp -72.95 112.22 8.78 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.244 -0.434 . . . . 0.0 110.902 -179.957 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 39' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -92.62 130.28 38.3 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.891 -179.967 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -161.16 -169.41 24.38 Favored Glycine 0 N--CA 1.451 -0.324 0 C-N-CA 120.749 -0.739 . . . . 0.0 112.56 179.977 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 41' ' ' ILE . . . . . 0.4 ' N ' HG23 ' A' ' 58' ' ' ILE . 8.9 mt -128.62 132.71 67.58 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-O 120.769 0.319 . . . . 0.0 111.087 -179.993 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 42' ' ' VAL . . . . . . . . . . . . . 21.5 t -59.53 125.2 15.2 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.361 0 CA-C-N 116.2 -0.454 . . . . 0.0 111.153 179.932 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 43' ' ' ARG . . . . . . . . . . . . . 10.1 mmt180 -110.51 -32.52 6.88 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.882 -179.954 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 44' ' ' PHE . . . . . . . . . . . . . 86.9 t80 -144.4 113.73 7.0 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.909 -179.995 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 45' ' ' TYR . . . . . 0.439 ' CE1' ' CZ ' ' A' ' 56' ' ' TYR . 27.1 t80 -113.15 111.73 22.6 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.925 179.989 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . -169.52 -150.38 6.76 Favored Glycine 0 N--CA 1.45 -0.391 0 C-N-CA 120.808 -0.711 . . . . 0.0 112.545 179.984 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 47' ' ' LYS . . . . . 0.411 ' HD3' ' CE1' ' A' ' 54' ' ' TYR . 2.2 mmmp? -96.77 168.84 10.26 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.792 0.33 . . . . 0.0 110.879 -179.93 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 48' ' ' THR . . . . . . . . . . . . . 64.6 p -132.43 178.15 7.05 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.837 179.947 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 32.3 t70 -112.55 -35.41 5.55 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.961 -179.975 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 50' ' ' PHE . . . . . . . . . . . . . 30.1 p90 -62.73 -31.04 71.9 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.949 -179.942 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 51' ' ' ALA . . . . . . . . . . . . . . . -151.74 151.96 29.38 Favored Pre-proline 0 C--N 1.329 -0.299 0 CA-C-N 116.237 -0.438 . . . . 0.0 111.107 -179.962 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 52' ' ' PRO . . . . . . . . . . . . . 58.2 Cg_endo -71.58 -176.89 2.17 Favored 'Trans proline' 0 C--N 1.345 0.347 0 C-N-CA 122.559 2.173 . . . . 0.0 112.3 179.928 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 75.12 -177.07 48.92 Favored Glycine 0 N--CA 1.451 -0.348 0 C-N-CA 120.756 -0.735 . . . . 0.0 112.54 -179.922 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 54' ' ' TYR . . . . . 0.411 ' CE1' ' HD3' ' A' ' 47' ' ' LYS . 10.1 m-85 -107.8 132.45 53.4 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 120.815 0.34 . . . . 0.0 110.916 179.994 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 55' ' ' TRP . . . . . 0.413 ' CZ3' ' HD3' ' A' ' 88' ' ' PRO . 19.0 m95 -120.07 173.31 7.16 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.852 -179.989 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 56' ' ' TYR . . . . . 0.615 ' HE1' ' HB2' ' A' ' 89' ' ' ALA . 10.8 m-85 -117.21 127.51 54.17 Favored 'General case' 0 C--N 1.331 -0.235 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.948 -179.904 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . -90.6 65.12 2.76 Favored Glycine 0 N--CA 1.45 -0.426 0 C-N-CA 120.746 -0.74 . . . . 0.0 112.426 -179.998 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 58' ' ' ILE . . . . . 0.444 HD12 HG22 ' A' ' 34' ' ' VAL . 25.3 mt -71.64 139.43 19.82 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-O 120.779 0.323 . . . . 0.0 111.135 -179.928 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 0.2 OUTLIER -108.49 111.0 22.64 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.826 -179.965 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 60' ' ' LEU . . . . . 0.711 HD13 HG23 ' A' ' 64' ' ' THR . 63.2 mt -63.93 167.89 5.73 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.308 -0.406 . . . . 0.0 110.846 -179.969 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -96.84 -26.1 15.23 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.947 -179.995 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 62' ' ' GLN . . . . . . . . . . . . . 64.9 mm-40 -124.26 152.36 67.56 Favored Pre-proline 0 C--N 1.329 -0.284 0 CA-C-N 116.369 -0.378 . . . . 0.0 110.908 -179.895 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 32.2 Cg_exo -58.19 92.52 0.06 OUTLIER 'Trans proline' 0 C--N 1.346 0.401 0 C-N-CA 122.579 2.186 . . . . 0.0 112.293 179.954 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 64' ' ' THR . . . . . 0.711 HG23 HD13 ' A' ' 60' ' ' LEU . 13.4 t -165.74 36.49 0.05 Allowed 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 116.283 -0.417 . . . . 0.0 110.932 179.873 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . -99.12 -140.11 11.26 Favored Glycine 0 N--CA 1.451 -0.344 0 C-N-CA 120.78 -0.724 . . . . 0.0 112.442 -179.993 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 66' ' ' LYS . . . . . . . . . . . . . 1.7 mttm -132.21 -46.55 0.92 Allowed 'General case' 0 C--N 1.328 -0.34 0 CA-C-O 120.822 0.344 . . . . 0.0 110.87 179.97 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 67' ' ' HIS . . . . . . . . . . . . . 12.4 p80 -127.27 174.69 8.75 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.233 -0.44 . . . . 0.0 110.92 179.901 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 1.6 m-20 -98.46 48.68 0.98 Allowed 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.928 179.998 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 84.44 -61.51 4.7 Favored Glycine 0 N--CA 1.451 -0.31 0 C-N-CA 120.715 -0.755 . . . . 0.0 112.486 -179.997 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 70' ' ' SER . . . . . . . . . . . . . 31.4 p -80.26 152.15 29.22 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-O 120.774 0.321 . . . . 0.0 110.802 -179.992 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 21.5 t -134.32 118.08 26.42 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.111 179.982 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 72' ' ' PHE . . . . . . . . . . . . . 28.8 m-85 60.58 31.05 20.16 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.884 179.937 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 98.35 -28.41 14.94 Favored Glycine 0 N--CA 1.451 -0.316 0 C-N-CA 120.741 -0.742 . . . . 0.0 112.462 -179.998 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 21.5 t -73.64 130.56 35.78 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-O 120.805 0.336 . . . . 0.0 111.133 179.998 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 75' ' ' ARG . . . . . . . . . . . . . 48.4 ttt-85 -93.71 144.23 25.59 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.901 179.963 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 76' ' ' TYR . . . . . . . . . . . . . 58.4 m-85 -124.85 -44.82 1.92 Allowed 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.867 -179.985 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 77' ' ' PHE . . . . . . . . . . . . . 32.7 p90 -166.91 177.44 6.37 Favored 'General case' 0 C--N 1.327 -0.383 0 CA-C-N 116.18 -0.463 . . . . 0.0 110.908 179.978 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 1.7 t -98.96 124.83 44.18 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.833 -179.93 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 79' ' ' CYS . . . . . . . . . . . . . 27.0 p -150.98 155.01 38.2 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.847 179.952 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 80' ' ' ALA . . . . . 0.524 ' HB1' ' HD2' ' A' ' 81' ' ' PRO . . . -67.99 166.84 20.4 Favored Pre-proline 0 C--N 1.328 -0.349 0 CA-C-N 116.159 -0.473 . . . . 0.0 111.049 179.956 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 81' ' ' PRO . . . . . 0.524 ' HD2' ' HB1' ' A' ' 80' ' ' ALA . 53.3 Cg_exo -52.63 117.07 3.31 Favored 'Trans proline' 0 C--N 1.345 0.362 0 C-N-CA 122.538 2.159 . . . . 0.0 112.324 -179.92 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 82' ' ' ARG . . . . . . . . . . . . . 2.9 ttm180 63.12 57.7 1.56 Allowed 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.978 179.985 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 83' ' ' HIS . . . . . 0.493 ' CE1' ' HB3' ' A' ' 80' ' ' ALA . 6.3 m170 -126.96 -46.98 1.52 Allowed 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.091 -0.504 . . . . 0.0 110.94 179.957 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . -62.86 139.31 44.85 Favored Glycine 0 N--CA 1.45 -0.388 0 C-N-CA 120.722 -0.752 . . . . 0.0 112.541 179.989 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 85' ' ' VAL . . . . . . . . . . . . . 5.5 m -147.21 124.18 3.19 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.257 0 CA-C-O 120.871 0.367 . . . . 0.0 111.062 -179.942 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 86' ' ' PHE . . . . . . . . . . . . . 13.5 m-85 -100.77 121.12 41.14 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.081 -0.508 . . . . 0.0 110.9 179.999 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 87' ' ' ALA . . . . . 0.605 ' O ' HD11 ' A' ' 92' ' ' ILE . . . -140.75 144.84 37.47 Favored Pre-proline 0 C--N 1.328 -0.33 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.161 179.975 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 88' ' ' PRO . . . . . 0.416 ' O ' ' N ' ' A' ' 91' ' ' ARG . 47.6 Cg_exo -56.06 141.25 87.11 Favored 'Trans proline' 0 C--N 1.345 0.394 0 C-N-CA 122.607 2.204 . . . . 0.0 112.224 -179.9 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 89' ' ' ALA . . . . . 0.615 ' HB2' ' HE1' ' A' ' 56' ' ' TYR . . . -47.96 -50.97 25.48 Favored 'General case' 0 CA--C 1.521 -0.149 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.295 179.854 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 90' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -55.83 -24.6 37.41 Favored 'General case' 0 C--N 1.331 -0.217 0 CA-C-N 115.68 -0.691 . . . . 0.0 109.673 178.841 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 91' ' ' ARG . . . . . 0.416 ' N ' ' O ' ' A' ' 88' ' ' PRO . 0.0 OUTLIER -87.6 -15.37 37.54 Favored 'General case' 0 N--CA 1.454 -0.244 0 CA-C-N 115.856 -0.611 . . . . 0.0 110.423 179.032 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 92' ' ' ILE . . . . . 0.605 HD11 ' O ' ' A' ' 87' ' ' ALA . 33.0 mt -104.63 145.89 12.61 Favored 'Isoleucine or valine' 0 C--N 1.333 -0.126 0 CA-C-N 116.397 -0.365 . . . . 0.0 111.066 179.864 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 93' ' ' GLN . . . . . . . . . . . . . 0.7 OUTLIER -114.83 -179.96 3.78 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.991 -179.973 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 94' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -126.08 142.88 51.33 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.877 -179.968 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 95' ' ' ILE . . . . . . . . . . . . . 3.3 mp -117.41 -37.66 2.02 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.108 -0.496 . . . . 0.0 111.172 179.981 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . -70.22 66.9 0.71 Allowed Glycine 0 N--CA 1.453 -0.224 0 C-N-CA 120.716 -0.754 . . . . 0.0 112.513 -179.945 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 97' ' ' SER . . . . . . . . . . . . . 45.0 m -120.49 170.81 9.04 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 120.839 0.352 . . . . 0.0 110.784 179.945 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 98' ' ' GLY . . . . . 0.408 ' N ' ' HD3' ' A' ' 99' ' ' PRO . . . -134.49 61.73 0.63 Allowed Glycine 0 N--CA 1.45 -0.404 0 C-N-CA 120.713 -0.756 . . . . 0.0 112.606 -179.991 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 99' ' ' PRO . . . . . 0.408 ' HD3' ' N ' ' A' ' 98' ' ' GLY . 35.7 Cg_exo -57.5 -36.49 98.69 Favored 'Trans proline' 0 C--N 1.344 0.297 0 C-N-CA 122.59 2.194 . . . . 0.0 112.186 -179.995 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 100' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -105.3 -175.39 2.78 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.824 -179.96 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 1.4 m -83.4 138.54 33.45 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.856 179.963 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.249 1.067 0 CA-C-O 118.368 -1.24 . . . . 0.0 112.475 179.997 . . . . . . . . 0 0 . 1 . 010 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.207 0 N-CA-C 112.477 -0.249 . . . . 0.0 112.477 . . . . . . . . . 0 0 . 1 . 010 nuclear build full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 17.7 t -128.49 112.31 14.21 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-O 120.79 0.329 . . . . 0.0 110.857 179.989 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 8.6 t 60.56 31.24 20.21 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.861 179.937 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -116.97 115.82 3.37 Favored Glycine 0 N--CA 1.452 -0.247 0 C-N-CA 120.794 -0.717 . . . . 0.0 112.451 -179.938 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 2.4 m -148.03 153.03 38.41 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 120.78 0.324 . . . . 0.0 110.918 179.99 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 6.2 m -96.44 141.23 29.99 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.907 179.959 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 145.83 101.33 0.3 Allowed Glycine 0 N--CA 1.451 -0.333 0 C-N-CA 120.721 -0.752 . . . . 0.0 112.503 -179.975 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 13.9 mttp -145.59 -58.54 0.33 Allowed 'General case' 0 C--N 1.33 -0.282 0 CA-C-O 120.767 0.317 . . . . 0.0 110.89 179.976 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -152.67 165.81 16.76 Favored Pre-proline 0 C--N 1.328 -0.352 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.856 -179.975 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 38.1 Cg_endo -66.44 123.22 10.84 Favored 'Trans proline' 0 C--N 1.344 0.297 0 C-N-CA 122.577 2.185 . . . . 0.0 112.297 179.933 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 69.2 m -88.11 -177.21 5.67 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.937 -179.975 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 53.0 m -127.01 144.64 51.11 Favored Pre-proline 0 C--N 1.329 -0.294 0 CA-C-N 116.263 -0.426 . . . . 0.0 110.888 179.97 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 67.9 Cg_endo -74.32 -37.17 2.68 Favored 'Trans proline' 0 C--N 1.345 0.382 0 C-N-CA 122.492 2.128 . . . . 0.0 112.35 -179.984 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 85.4 p -96.33 41.95 1.1 Allowed 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.944 179.979 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 4.3 tp -166.92 89.13 0.34 Allowed 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.919 179.942 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 101.67 -60.34 0.58 Allowed Glycine 0 N--CA 1.451 -0.306 0 C-N-CA 120.687 -0.768 . . . . 0.0 112.467 179.969 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 1.9 m 60.96 160.07 0.05 OUTLIER 'General case' 0 C--N 1.328 -0.36 0 CA-C-O 120.833 0.349 . . . . 0.0 110.858 179.987 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -109.57 -30.72 7.78 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.923 179.966 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 19' ' ' GLN . . . . . . . . . . . . . 1.6 tt0 61.24 42.45 12.02 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.838 179.94 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 20' ' ' GLN . . . . . . . . . . . . . 3.2 tt0 -157.54 -45.9 0.07 Allowed 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.895 179.911 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 9.0 ttt-85 -68.84 111.17 4.74 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.185 -0.462 . . . . 0.0 110.968 179.947 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 0.9 OUTLIER -117.16 -65.62 1.17 Allowed 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.837 -179.975 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 109.43 28.56 4.27 Favored Glycine 0 N--CA 1.451 -0.321 0 C-N-CA 120.808 -0.71 . . . . 0.0 112.488 179.99 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -136.58 -179.48 5.72 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 120.871 0.367 . . . . 0.0 111.034 179.99 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 4.0 tttp -145.59 -47.51 0.22 Allowed 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.904 -179.989 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -119.82 171.62 8.28 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.134 179.992 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 27' ' ' GLU . . . . . . . . . . . . . 28.7 mt-10 -139.41 178.31 7.29 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.946 179.972 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 28.9 t -72.31 115.7 13.18 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.219 -0.446 . . . . 0.0 111.049 -179.979 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 102.43 33.96 4.33 Favored Glycine 0 N--CA 1.452 -0.298 0 C-N-CA 120.716 -0.754 . . . . 0.0 112.443 179.969 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 13.3 m-20 -141.42 148.35 39.42 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-O 120.822 0.344 . . . . 0.0 110.912 179.92 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 31' ' ' GLN . . . . . . . . . . . . . 3.5 mp0 -72.74 137.33 45.82 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.955 179.975 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 32' ' ' VAL . . . . . 0.449 ' HB ' HG22 ' A' ' 92' ' ' ILE . 14.8 m -146.55 177.53 1.3 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 116.262 -0.426 . . . . 0.0 111.112 179.984 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 33' ' ' LEU . . . . . 0.504 HD23 ' HA2' ' A' ' 36' ' ' GLY . 21.7 tp -134.15 112.36 11.06 Favored 'General case' 0 C--N 1.33 -0.283 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.794 -179.998 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 34' ' ' VAL . . . . . 0.747 HG22 HD12 ' A' ' 58' ' ' ILE . 21.9 t -76.03 123.74 32.77 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.145 -0.479 . . . . 0.0 111.127 -179.949 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 35' ' ' ALA . . . . . . . . . . . . . . . 59.28 25.56 14.22 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.153 -0.476 . . . . 0.0 111.229 179.979 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 36' ' ' GLY . . . . . 0.504 ' HA2' HD23 ' A' ' 33' ' ' LEU . . . 55.95 27.88 51.88 Favored Glycine 0 N--CA 1.452 -0.252 0 C-N-CA 120.759 -0.734 . . . . 0.0 112.633 -179.993 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 37' ' ' GLN . . . . . 0.45 ' O ' HD11 ' A' ' 33' ' ' LEU . 24.9 mt-30 -142.64 -69.23 0.35 Allowed 'General case' 0 C--N 1.329 -0.285 0 CA-C-O 120.885 0.374 . . . . 0.0 110.925 179.957 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 38' ' ' LYS . . . . . . . . . . . . . 19.3 mttp -67.15 119.73 12.56 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.929 179.985 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 39' ' ' GLN . . . . . 0.43 ' HA ' HD12 ' A' ' 33' ' ' LEU . 0.0 OUTLIER -87.09 133.03 33.65 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.886 -179.999 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -162.33 169.76 37.75 Favored Glycine 0 N--CA 1.45 -0.371 0 C-N-CA 120.742 -0.742 . . . . 0.0 112.557 -179.969 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 23.2 mt -116.03 146.22 20.75 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.352 0 CA-C-O 120.799 0.333 . . . . 0.0 111.061 -179.99 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 42' ' ' VAL . . . . . . . . . . . . . 33.3 t -69.49 124.95 26.51 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.212 -0.449 . . . . 0.0 111.042 179.946 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 43' ' ' ARG . . . . . . . . . . . . . 2.9 mmm180 -111.84 -43.39 3.62 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.894 179.99 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 44' ' ' PHE . . . . . . . . . . . . . 49.7 t80 -136.7 113.16 10.02 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.86 -179.897 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 45' ' ' TYR . . . . . 0.495 ' CE1' ' CE1' ' A' ' 56' ' ' TYR . 14.1 t80 -112.9 131.57 55.67 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.272 -0.422 . . . . 0.0 110.872 179.965 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 156.17 -172.45 34.05 Favored Glycine 0 N--CA 1.451 -0.364 0 C-N-CA 120.763 -0.732 . . . . 0.0 112.524 -179.968 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 47' ' ' LYS . . . . . 0.433 ' HG3' ' CZ ' ' A' ' 54' ' ' TYR . 98.5 mttt -69.01 155.86 39.62 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 120.768 0.318 . . . . 0.0 110.915 179.968 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 48' ' ' THR . . . . . 0.635 HG21 ' CZ ' ' A' ' 50' ' ' PHE . 7.2 p -122.69 170.08 10.41 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.858 -179.943 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -102.33 -31.28 10.59 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.93 179.957 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 50' ' ' PHE . . . . . 0.635 ' CZ ' HG21 ' A' ' 48' ' ' THR . 18.0 p90 -73.66 -31.63 63.58 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.915 179.951 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 51' ' ' ALA . . . . . . . . . . . . . . . -140.51 147.95 51.45 Favored Pre-proline 0 C--N 1.33 -0.269 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.096 -179.895 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 52' ' ' PRO . . . . . . . . . . . . . 60.0 Cg_endo -72.25 176.9 7.93 Favored 'Trans proline' 0 C--N 1.344 0.32 0 C-N-CA 122.578 2.185 . . . . 0.0 112.402 179.902 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 72.45 -155.97 51.73 Favored Glycine 0 N--CA 1.45 -0.397 0 C-N-CA 120.771 -0.728 . . . . 0.0 112.592 179.947 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 54' ' ' TYR . . . . . 0.433 ' CZ ' ' HG3' ' A' ' 47' ' ' LYS . 10.8 m-85 -115.86 137.63 51.91 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-O 120.894 0.378 . . . . 0.0 110.856 -179.989 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 55' ' ' TRP . . . . . . . . . . . . . 52.0 m95 -126.37 164.25 21.48 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.835 179.977 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 56' ' ' TYR . . . . . 0.794 ' CE1' ' HB2' ' A' ' 89' ' ' ALA . 25.9 m-85 -114.42 120.88 41.81 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.968 179.963 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 57' ' ' GLY . . . . . 0.426 ' HA3' ' CE1' ' A' ' 77' ' ' PHE . . . -83.07 61.25 4.81 Favored Glycine 0 N--CA 1.45 -0.387 0 C-N-CA 120.73 -0.748 . . . . 0.0 112.401 179.995 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 58' ' ' ILE . . . . . 0.747 HD12 HG22 ' A' ' 34' ' ' VAL . 45.2 mt -69.33 145.13 13.43 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-O 120.827 0.346 . . . . 0.0 111.098 -179.899 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 5.6 tm-20 -112.83 132.77 55.13 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.797 -179.961 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 60' ' ' LEU . . . . . . . . . . . . . 39.3 mt -93.1 158.76 15.61 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.202 -0.453 . . . . 0.0 110.93 -179.994 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 32.6 t0 -100.26 31.17 3.49 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.918 179.931 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 62' ' ' GLN . . . . . . . . . . . . . 1.8 pm0 -157.46 149.05 17.02 Favored Pre-proline 0 C--N 1.33 -0.276 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.846 179.965 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 56.4 Cg_endo -70.28 63.67 2.09 Favored 'Trans proline' 0 C--N 1.344 0.314 0 C-N-CA 122.631 2.221 . . . . 0.0 112.284 -179.994 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 64' ' ' THR . . . . . . . . . . . . . 5.4 p -145.23 30.84 1.12 Allowed 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.972 179.901 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . -79.37 -159.26 15.92 Favored Glycine 0 N--CA 1.451 -0.361 0 C-N-CA 120.714 -0.755 . . . . 0.0 112.48 179.989 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 66' ' ' LYS . . . . . . . . . . . . . 7.0 mtpm? -111.53 -33.74 6.29 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 120.813 0.34 . . . . 0.0 110.928 179.969 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 67' ' ' HIS . . . . . . . . . . . . . 6.0 p80 -139.12 174.07 10.9 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.911 179.921 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 1.3 t70 -97.85 37.07 1.44 Allowed 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.951 179.973 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 95.19 -65.21 1.33 Allowed Glycine 0 N--CA 1.451 -0.337 0 C-N-CA 120.703 -0.76 . . . . 0.0 112.511 -179.965 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 70' ' ' SER . . . . . . . . . . . . . 3.1 p -89.57 133.34 34.65 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 120.807 0.337 . . . . 0.0 110.836 -179.931 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 71' ' ' VAL . . . . . 0.691 HG12 ' CD2' ' A' ' 72' ' ' PHE . 21.5 t -114.21 114.76 47.62 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.202 -0.454 . . . . 0.0 111.111 -179.982 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 72' ' ' PHE . . . . . 0.691 ' CD2' HG12 ' A' ' 71' ' ' VAL . 13.9 m-85 60.73 31.11 20.09 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.949 179.99 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 98.8 -29.36 11.81 Favored Glycine 0 N--CA 1.451 -0.324 0 C-N-CA 120.752 -0.737 . . . . 0.0 112.485 -179.956 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 21.5 t -76.97 123.56 33.74 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-O 120.797 0.332 . . . . 0.0 111.092 -179.944 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 75' ' ' ARG . . . . . . . . . . . . . 11.4 ttm180 -101.1 134.04 44.7 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.884 179.996 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 76' ' ' TYR . . . . . . . . . . . . . 51.7 m-85 -109.67 -31.15 7.57 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.998 179.922 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 77' ' ' PHE . . . . . 0.426 ' CE1' ' HA3' ' A' ' 57' ' ' GLY . 27.0 p90 -172.85 156.39 3.4 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.941 179.98 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 12.3 m -85.75 111.2 19.92 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.798 179.968 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 79' ' ' CYS . . . . . . . . . . . . . 27.1 p -134.86 164.31 27.86 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.31 -0.405 . . . . 0.0 110.995 -179.929 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 80' ' ' ALA . . . . . 0.727 ' HB1' ' HD2' ' A' ' 81' ' ' PRO . . . -63.55 165.86 10.72 Favored Pre-proline 0 C--N 1.328 -0.337 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.949 179.879 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 81' ' ' PRO . . . . . 0.727 ' HD2' ' HB1' ' A' ' 80' ' ' ALA . 20.5 Cg_endo -60.85 114.97 2.39 Favored 'Trans proline' 0 C--N 1.345 0.364 0 C-N-CA 122.58 2.187 . . . . 0.0 112.146 179.876 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 82' ' ' ARG . . . . . . . . . . . . . 49.7 mtt180 64.4 58.69 1.06 Allowed 'General case' 0 C--N 1.331 -0.232 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.752 -179.969 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 83' ' ' HIS . . . . . 0.524 ' CG ' ' HB3' ' A' ' 80' ' ' ALA . 5.7 m-70 -130.7 -48.56 1.05 Allowed 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.899 179.927 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . -60.48 140.29 48.06 Favored Glycine 0 N--CA 1.452 -0.273 0 C-N-CA 120.741 -0.742 . . . . 0.0 112.531 -179.99 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 85' ' ' VAL . . . . . . . . . . . . . 10.1 m -142.59 130.52 20.12 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-O 120.823 0.344 . . . . 0.0 111.096 179.937 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 86' ' ' PHE . . . . . 0.409 ' CE1' ' CA ' ' A' ' 57' ' ' GLY . 8.6 m-85 -103.66 114.0 27.93 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.924 -179.963 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 87' ' ' ALA . . . . . 0.626 ' O ' HD11 ' A' ' 92' ' ' ILE . . . -134.28 145.4 55.23 Favored Pre-proline 0 C--N 1.331 -0.237 0 CA-C-N 116.259 -0.428 . . . . 0.0 111.067 -179.949 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 88' ' ' PRO . . . . . 0.41 ' O ' ' N ' ' A' ' 91' ' ' ARG . 36.5 Cg_exo -57.45 140.57 93.58 Favored 'Trans proline' 0 C--N 1.345 0.356 0 C-N-CA 122.527 2.151 . . . . 0.0 112.236 -179.981 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 89' ' ' ALA . . . . . 0.794 ' HB2' ' CE1' ' A' ' 56' ' ' TYR . . . -48.24 -50.27 30.13 Favored 'General case' 0 CA--C 1.521 -0.162 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.262 179.809 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 90' ' ' SER . . . . . . . . . . . . . 2.7 m -55.9 -24.51 37.82 Favored 'General case' 0 N--CA 1.455 -0.223 0 CA-C-N 115.706 -0.679 . . . . 0.0 109.789 178.767 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 91' ' ' ARG . . . . . 0.41 ' N ' ' O ' ' A' ' 88' ' ' PRO . 0.2 OUTLIER -88.54 -14.19 38.29 Favored 'General case' 0 N--CA 1.455 -0.177 0 CA-C-N 115.865 -0.607 . . . . 0.0 110.391 179.1 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 92' ' ' ILE . . . . . 0.704 HD13 HD11 ' A' ' 58' ' ' ILE . 21.4 mt -108.12 139.82 28.88 Favored 'Isoleucine or valine' 0 C--O 1.232 0.154 0 CA-C-N 116.45 -0.341 . . . . 0.0 111.061 179.808 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 93' ' ' GLN . . . . . . . . . . . . . 20.5 mt-30 -106.7 171.72 7.21 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.892 179.997 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 94' ' ' ARG . . . . . . . . . . . . . 3.4 ttt-85 -111.79 154.18 25.45 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.902 179.929 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 95' ' ' ILE . . . . . . . . . . . . . 31.8 mt -122.37 -64.86 1.39 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.326 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.155 179.997 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . 123.7 161.75 11.24 Favored Glycine 0 N--CA 1.452 -0.296 0 C-N-CA 120.779 -0.725 . . . . 0.0 112.41 -179.972 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 97' ' ' SER . . . . . . . . . . . . . 93.6 p -73.21 115.81 12.99 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 120.84 0.352 . . . . 0.0 110.912 179.975 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 98' ' ' GLY . . . . . . . . . . . . . . . 93.14 83.87 1.55 Allowed Glycine 0 N--CA 1.451 -0.313 0 C-N-CA 120.725 -0.75 . . . . 0.0 112.517 179.966 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 99' ' ' PRO . . . . . . . . . . . . . 50.5 Cg_endo -69.21 -28.15 28.25 Favored 'Trans proline' 0 C--N 1.345 0.371 0 C-N-CA 122.585 2.19 . . . . 0.0 112.297 179.978 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 100' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -134.55 -48.25 0.76 Allowed 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.924 -179.987 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 20.2 t -110.94 127.75 55.59 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.922 179.998 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.249 1.065 0 CA-C-O 118.337 -1.257 . . . . 0.0 112.516 179.965 . . . . . . . . 0 0 . 1 . 011 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.181 0 N-CA-C 112.496 -0.242 . . . . 0.0 112.496 . . . . . . . . . 0 0 . 1 . 011 nuclear build full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 1.3 p -153.32 120.93 5.95 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-O 120.769 0.319 . . . . 0.0 110.93 179.995 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER 60.54 106.6 0.02 OUTLIER 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 116.222 -0.444 . . . . 0.0 110.906 179.998 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 108.27 -70.28 0.21 Allowed Glycine 0 N--CA 1.45 -0.376 0 C-N-CA 120.768 -0.73 . . . . 0.0 112.568 -179.904 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -73.35 149.85 42.27 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-O 120.847 0.356 . . . . 0.0 110.894 179.948 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -76.71 -52.22 10.01 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.145 -0.479 . . . . 0.0 110.855 -179.977 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 69.87 118.32 0.03 OUTLIER Glycine 0 N--CA 1.45 -0.381 0 C-N-CA 120.676 -0.774 . . . . 0.0 112.549 -179.927 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 3.7 ttpp 60.44 34.55 20.51 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-O 120.821 0.343 . . . . 0.0 110.864 -179.981 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 86.9 p -175.52 90.41 0.29 Allowed Pre-proline 0 C--N 1.328 -0.341 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.835 -179.948 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 75.3 Cg_exo -50.64 118.61 4.27 Favored 'Trans proline' 0 C--N 1.345 0.343 0 C-N-CA 122.537 2.158 . . . . 0.0 112.391 -179.968 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 52.4 p -153.89 122.43 6.24 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.167 -0.469 . . . . 0.0 110.85 -179.998 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 1.3 m -87.53 147.04 40.81 Favored Pre-proline 0 C--N 1.329 -0.283 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.875 -179.986 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 63.3 Cg_endo -73.57 61.69 4.43 Favored 'Trans proline' 0 C--N 1.344 0.313 0 C-N-CA 122.559 2.173 . . . . 0.0 112.287 -179.981 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 1.3 m -170.54 72.26 0.06 Allowed 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.968 179.911 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -160.93 -45.27 0.04 OUTLIER 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.82 -179.958 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -148.18 38.84 1.02 Allowed Glycine 0 N--CA 1.451 -0.348 0 C-N-CA 120.739 -0.743 . . . . 0.0 112.463 -179.996 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 1.8 t 60.73 -176.66 0.11 Allowed 'General case' 0 C--N 1.33 -0.269 0 CA-C-O 120.807 0.337 . . . . 0.0 110.926 -179.994 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 18' ' ' LEU . . . . . 0.675 HD12 ' N ' ' A' ' 19' ' ' GLN . 2.2 pp -136.63 -47.01 0.61 Allowed 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.911 179.978 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 19' ' ' GLN . . . . . 0.675 ' N ' HD12 ' A' ' 18' ' ' LEU . 35.8 tt0 -147.3 -62.58 0.28 Allowed 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.268 -0.424 . . . . 0.0 110.89 179.969 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 20' ' ' GLN . . . . . . . . . . . . . 21.8 mt-30 -127.29 -50.9 1.41 Allowed 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.892 -179.978 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 2.3 ttp180 -72.89 121.27 19.74 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.189 -0.459 . . . . 0.0 110.88 -179.987 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 4.2 pt-20 -87.48 167.31 14.1 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.809 179.951 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -102.07 30.8 9.64 Favored Glycine 0 N--CA 1.451 -0.302 0 C-N-CA 120.74 -0.743 . . . . 0.0 112.547 -179.997 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -93.99 117.05 29.57 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-O 120.795 0.331 . . . . 0.0 111.12 -179.967 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 25' ' ' LYS . . . . . 0.5 ' HB2' ' HB1' ' A' ' 89' ' ' ALA . 1.1 mpmm? -69.86 -41.42 74.85 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.244 -0.435 . . . . 0.0 110.902 179.967 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -144.21 178.29 8.0 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.157 -0.474 . . . . 0.0 111.143 -179.995 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 27' ' ' GLU . . . . . . . . . . . . . 30.4 mt-10 -145.56 -178.36 6.04 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.901 -179.992 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 21.5 t -75.85 116.62 19.08 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.211 -0.449 . . . . 0.0 111.144 -179.954 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 101.35 36.65 3.77 Favored Glycine 0 N--CA 1.45 -0.416 0 C-N-CA 120.766 -0.73 . . . . 0.0 112.47 -179.992 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -144.79 151.67 39.17 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 120.778 0.323 . . . . 0.0 110.898 -179.991 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 31' ' ' GLN . . . . . . . . . . . . . 2.7 mp0 -72.11 125.78 28.14 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.233 -0.439 . . . . 0.0 110.891 179.984 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 32' ' ' VAL . . . . . 0.537 HG21 HG12 ' A' ' 58' ' ' ILE . 27.5 m -127.04 174.57 10.57 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.138 -0.483 . . . . 0.0 111.143 179.964 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 33' ' ' LEU . . . . . 0.702 ' HB2' HD11 ' A' ' 95' ' ' ILE . 25.8 tp -143.22 102.54 4.0 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.852 -179.923 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 34' ' ' VAL . . . . . 0.565 ' CG2' HD13 ' A' ' 58' ' ' ILE . 21.4 t -72.65 128.57 35.6 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.148 -0.478 . . . . 0.0 111.147 -179.92 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 35' ' ' ALA . . . . . . . . . . . . . . . 57.18 25.08 10.54 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.065 -0.516 . . . . 0.0 111.304 179.936 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . 56.38 31.22 59.53 Favored Glycine 0 N--CA 1.451 -0.344 0 C-N-CA 120.752 -0.737 . . . . 0.0 112.604 -179.986 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 37' ' ' GLN . . . . . 0.616 ' O ' HD11 ' A' ' 33' ' ' LEU . 81.6 mt-30 -146.3 -70.86 0.25 Allowed 'General case' 0 C--N 1.329 -0.29 0 CA-C-O 120.79 0.329 . . . . 0.0 110.906 -179.92 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 38' ' ' LYS . . . . . . . . . . . . . 12.6 mttt -61.71 105.05 0.5 Allowed 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.905 -179.988 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 39' ' ' GLN . . . . . 0.507 ' CD ' HD13 ' A' ' 95' ' ' ILE . 0.0 OUTLIER -85.1 132.02 34.37 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.902 179.942 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -158.39 -170.19 22.78 Favored Glycine 0 N--CA 1.451 -0.358 0 C-N-CA 120.709 -0.758 . . . . 0.0 112.438 179.977 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 32.2 mt -129.55 129.74 66.87 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-O 120.798 0.332 . . . . 0.0 111.046 -179.959 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 42' ' ' VAL . . . . . . . . . . . . . 21.4 t -58.46 125.22 14.12 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.172 179.973 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 43' ' ' ARG . . . . . . . . . . . . . 36.6 mmt180 -108.18 -31.53 7.87 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.87 -179.973 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 44' ' ' PHE . . . . . . . . . . . . . 41.0 t80 -148.78 113.81 5.47 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.922 179.926 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 45' ' ' TYR . . . . . 0.471 ' CE1' ' CZ ' ' A' ' 56' ' ' TYR . 33.7 t80 -112.3 142.93 44.2 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.884 179.974 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 148.92 -168.99 29.4 Favored Glycine 0 N--CA 1.451 -0.327 0 C-N-CA 120.732 -0.747 . . . . 0.0 112.492 -179.982 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 47' ' ' LYS . . . . . 0.414 ' HE2' ' CZ ' ' A' ' 54' ' ' TYR . 22.2 mttm -87.39 141.58 28.53 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-O 120.851 0.357 . . . . 0.0 110.869 -179.98 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 48' ' ' THR . . . . . 0.666 HG21 ' CE2' ' A' ' 50' ' ' PHE . 63.6 p -102.18 -177.12 3.31 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.85 179.983 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 1.3 t70 -112.85 15.86 19.67 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.159 -0.473 . . . . 0.0 111.242 -179.958 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 50' ' ' PHE . . . . . 0.666 ' CE2' HG21 ' A' ' 48' ' ' THR . 29.2 p90 -116.38 -36.65 3.94 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-O 120.727 0.299 . . . . 0.0 110.996 179.846 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 51' ' ' ALA . . . . . 0.445 ' N ' ' CD1' ' A' ' 50' ' ' PHE . . . -140.26 146.71 47.04 Favored Pre-proline 0 C--N 1.328 -0.332 0 CA-C-N 116.249 -0.432 . . . . 0.0 111.126 179.924 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 52' ' ' PRO . . . . . . . . . . . . . 60.0 Cg_endo -72.42 170.81 18.37 Favored 'Trans proline' 0 C--N 1.345 0.388 0 C-N-CA 122.505 2.137 . . . . 0.0 112.353 -179.957 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 90.66 -154.08 23.01 Favored Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.778 -0.725 . . . . 0.0 112.525 179.939 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 54' ' ' TYR . . . . . 0.414 ' CZ ' ' HE2' ' A' ' 47' ' ' LYS . 57.4 m-85 -125.23 124.45 41.71 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 120.872 0.368 . . . . 0.0 110.867 179.963 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 55' ' ' TRP . . . . . . . . . . . . . 65.3 m95 -115.13 161.83 17.86 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.936 179.95 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 56' ' ' TYR . . . . . 0.569 ' HE1' ' HB2' ' A' ' 89' ' ' ALA . 10.8 m-85 -117.68 120.07 36.89 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.211 -0.449 . . . . 0.0 110.92 -179.887 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 57' ' ' GLY . . . . . 0.45 ' CA ' ' CE1' ' A' ' 86' ' ' PHE . . . -84.71 63.8 4.35 Favored Glycine 0 N--CA 1.452 -0.298 0 C-N-CA 120.681 -0.771 . . . . 0.0 112.392 179.997 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 58' ' ' ILE . . . . . 0.729 HD11 HD13 ' A' ' 92' ' ' ILE . 3.3 mt -70.24 146.95 11.87 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.23 0 CA-C-O 120.807 0.337 . . . . 0.0 111.128 -179.966 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 3.7 tm-20 -116.91 109.8 17.51 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.841 -179.979 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 60' ' ' LEU . . . . . 0.743 HD13 HG23 ' A' ' 64' ' ' THR . 96.0 mt -63.55 172.84 1.87 Allowed 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.912 179.932 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -98.5 -32.54 11.41 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.289 -0.414 . . . . 0.0 110.924 -179.978 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 62' ' ' GLN . . . . . 0.519 ' O ' HG22 ' A' ' 64' ' ' THR . 4.7 mm-40 -118.42 151.34 49.44 Favored Pre-proline 0 C--N 1.33 -0.264 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.94 -179.998 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 52.1 Cg_exo -54.66 99.95 0.06 OUTLIER 'Trans proline' 0 C--N 1.345 0.362 0 C-N-CA 122.485 2.123 . . . . 0.0 112.286 -179.958 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 64' ' ' THR . . . . . 0.743 HG23 HD13 ' A' ' 60' ' ' LEU . 9.8 t -176.98 39.01 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.872 179.983 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . -95.87 -125.43 4.73 Favored Glycine 0 N--CA 1.45 -0.37 0 C-N-CA 120.713 -0.756 . . . . 0.0 112.475 179.98 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 66' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -144.17 -47.71 0.27 Allowed 'General case' 0 C--N 1.329 -0.284 0 CA-C-O 120.825 0.345 . . . . 0.0 110.833 -179.869 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 67' ' ' HIS . . . . . . . . . . . . . 6.4 p80 -122.84 177.43 5.48 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.191 -0.458 . . . . 0.0 110.884 179.984 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -100.15 35.35 2.09 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.891 -179.987 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 100.99 -70.18 0.42 Allowed Glycine 0 N--CA 1.451 -0.365 0 C-N-CA 120.756 -0.735 . . . . 0.0 112.465 179.944 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 70' ' ' SER . . . . . . . . . . . . . 78.4 p -81.68 148.85 28.79 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 120.85 0.357 . . . . 0.0 110.868 179.987 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 71' ' ' VAL . . . . . 0.494 HG12 ' CD2' ' A' ' 72' ' ' PHE . 27.3 t -127.67 125.94 66.17 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.167 -0.47 . . . . 0.0 111.11 179.93 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 72' ' ' PHE . . . . . 0.494 ' CD2' HG12 ' A' ' 71' ' ' VAL . 47.7 m-85 60.08 28.02 17.52 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.99 -179.929 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 95.97 -30.03 9.11 Favored Glycine 0 N--CA 1.451 -0.307 0 C-N-CA 120.628 -0.796 . . . . 0.0 112.538 179.951 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 21.6 t -80.47 122.95 36.59 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-O 120.784 0.326 . . . . 0.0 111.074 -179.939 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 75' ' ' ARG . . . . . . . . . . . . . 21.2 ttm180 -88.96 146.26 25.01 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.224 -0.443 . . . . 0.0 110.922 -179.997 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 76' ' ' TYR . . . . . 0.424 ' CE2' HG22 ' A' ' 48' ' ' THR . 37.0 m-85 -119.26 -47.75 2.45 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.185 -0.462 . . . . 0.0 110.897 -179.977 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 77' ' ' PHE . . . . . . . . . . . . . 34.8 p90 -152.79 171.4 18.3 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.922 179.972 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 4.6 p -97.26 122.56 40.42 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.904 -179.97 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 79' ' ' CYS . . . . . . . . . . . . . 27.3 p -143.87 176.74 9.03 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.906 179.963 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 80' ' ' ALA . . . . . 0.618 ' HB3' ' CG ' ' A' ' 83' ' ' HIS . . . -90.43 168.95 13.02 Favored Pre-proline 0 C--N 1.329 -0.308 0 CA-C-N 116.229 -0.441 . . . . 0.0 111.077 179.96 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 81' ' ' PRO . . . . . 0.597 ' HD2' ' HB1' ' A' ' 80' ' ' ALA . 52.7 Cg_exo -52.59 113.6 1.3 Allowed 'Trans proline' 0 C--N 1.344 0.303 0 C-N-CA 122.557 2.171 . . . . 0.0 112.261 179.93 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 82' ' ' ARG . . . . . . . . . . . . . 9.2 mmt180 61.27 53.59 3.47 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.907 -179.987 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 83' ' ' HIS . . . . . 0.618 ' CG ' ' HB3' ' A' ' 80' ' ' ALA . 5.5 m170 -121.17 -42.4 2.48 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.125 -0.489 . . . . 0.0 110.918 179.989 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 84' ' ' GLY . . . . . 0.433 ' O ' HG13 ' A' ' 85' ' ' VAL . . . -63.7 154.67 45.67 Favored Glycine 0 N--CA 1.45 -0.368 0 C-N-CA 120.745 -0.741 . . . . 0.0 112.511 179.933 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 85' ' ' VAL . . . . . 0.433 HG13 ' O ' ' A' ' 84' ' ' GLY . 15.2 m -156.27 127.27 0.87 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-O 120.84 0.352 . . . . 0.0 111.191 -179.96 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 86' ' ' PHE . . . . . 0.45 ' CE1' ' CA ' ' A' ' 57' ' ' GLY . 7.9 m-85 -112.53 102.09 10.21 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.818 179.942 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 87' ' ' ALA . . . . . 0.454 ' CB ' HG13 ' A' ' 34' ' ' VAL . . . -123.19 145.86 47.45 Favored Pre-proline 0 C--N 1.329 -0.297 0 CA-C-N 116.245 -0.434 . . . . 0.0 111.119 -179.956 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 88' ' ' PRO . . . . . 0.41 ' O ' ' N ' ' A' ' 91' ' ' ARG . 32.3 Cg_exo -58.02 141.94 96.5 Favored 'Trans proline' 0 C--N 1.346 0.4 0 C-N-CA 122.498 2.132 . . . . 0.0 112.235 179.991 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 89' ' ' ALA . . . . . 0.569 ' HB2' ' HE1' ' A' ' 56' ' ' TYR . . . -47.9 -51.44 23.24 Favored 'General case' 0 CA--C 1.522 -0.116 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.346 179.859 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 90' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -55.99 -24.29 37.84 Favored 'General case' 0 N--CA 1.454 -0.27 0 CA-C-N 115.759 -0.655 . . . . 0.0 109.789 178.836 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 91' ' ' ARG . . . . . 0.41 ' N ' ' O ' ' A' ' 88' ' ' PRO . 0.0 OUTLIER -89.77 -14.08 35.34 Favored 'General case' 0 N--CA 1.455 -0.208 0 CA-C-N 115.945 -0.571 . . . . 0.0 110.526 179.029 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 92' ' ' ILE . . . . . 0.729 HD13 HD11 ' A' ' 58' ' ' ILE . 52.4 mt -110.56 156.04 11.73 Favored 'Isoleucine or valine' 0 C--O 1.23 0.077 0 CA-C-O 120.904 0.383 . . . . 0.0 111.04 179.864 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 93' ' ' GLN . . . . . 0.448 ' N ' HG22 ' A' ' 92' ' ' ILE . 8.5 mt-30 -124.31 179.98 4.69 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.78 179.93 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 94' ' ' ARG . . . . . . . . . . . . . 4.2 ttt180 -126.08 142.18 51.63 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.936 179.993 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 95' ' ' ILE . . . . . 0.702 HD11 ' HB2' ' A' ' 33' ' ' LEU . 3.4 mt -124.72 23.82 3.59 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.246 -0.434 . . . . 0.0 111.088 179.982 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . -96.85 161.5 21.89 Favored Glycine 0 N--CA 1.45 -0.404 0 C-N-CA 120.721 -0.752 . . . . 0.0 112.512 179.975 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 97' ' ' SER . . . . . . . . . . . . . 9.8 m -86.06 84.24 7.56 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-O 120.854 0.359 . . . . 0.0 110.902 179.986 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 98' ' ' GLY . . . . . . . . . . . . . . . -108.46 -79.9 1.19 Allowed Glycine 0 N--CA 1.451 -0.35 0 C-N-CA 120.709 -0.758 . . . . 0.0 112.511 -179.977 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 99' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_exo -52.24 103.92 0.09 OUTLIER 'Trans proline' 0 C--N 1.343 0.282 0 C-N-CA 122.623 2.215 . . . . 0.0 112.372 179.975 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 100' ' ' SER . . . . . . . . . . . . . 26.3 p -165.37 -44.22 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.86 -179.988 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER 60.84 35.65 19.31 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.811 179.959 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.249 1.069 0 CA-C-O 118.364 -1.242 . . . . 0.0 112.503 179.977 . . . . . . . . 0 0 . 1 . 012 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.275 0 N-CA-C 112.455 -0.258 . . . . 0.0 112.455 . . . . . . . . . 0 0 . 1 . 012 nuclear build full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER -99.61 35.7 1.93 Allowed 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 120.778 0.323 . . . . 0.0 110.887 -179.962 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 2.5 m -134.8 33.94 3.18 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.264 -0.425 . . . . 0.0 110.967 -179.967 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 74.15 165.99 13.41 Favored Glycine 0 N--CA 1.451 -0.303 0 C-N-CA 120.713 -0.756 . . . . 0.0 112.64 179.985 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -141.15 -67.71 0.4 Allowed 'General case' 0 C--N 1.33 -0.276 0 CA-C-O 120.814 0.34 . . . . 0.0 110.819 -179.979 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 56.9 p -104.23 121.64 43.72 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.165 -0.471 . . . . 0.0 110.945 179.986 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 154.07 100.11 0.18 Allowed Glycine 0 N--CA 1.451 -0.349 0 C-N-CA 120.775 -0.726 . . . . 0.0 112.504 -179.972 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 9.2 tttp -162.42 127.46 3.29 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-O 120.813 0.339 . . . . 0.0 110.924 179.998 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 4.1 p -158.36 80.06 3.05 Favored Pre-proline 0 C--N 1.328 -0.339 0 CA-C-N 116.242 -0.436 . . . . 0.0 110.975 179.953 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 48.5 Cg_exo -55.81 -21.01 30.96 Favored 'Trans proline' 0 C--N 1.344 0.301 0 C-N-CA 122.669 2.246 . . . . 0.0 112.427 -179.973 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 89.2 p -54.09 -29.1 43.3 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-N 116.371 -0.377 . . . . 0.0 111.171 -179.915 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 4.0 m -112.03 73.4 1.25 Allowed Pre-proline 0 C--N 1.33 -0.276 0 CA-C-N 116.278 -0.419 . . . . 0.0 110.861 -179.974 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 61.0 Cg_endo -73.23 -37.55 3.29 Favored 'Trans proline' 0 C--N 1.344 0.32 0 C-N-CA 122.543 2.162 . . . . 0.0 112.25 -179.999 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 14' ' ' SER . . . . . 0.531 ' O ' HD12 ' A' ' 15' ' ' LEU . 25.3 p -146.55 166.68 25.76 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.88 179.96 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 15' ' ' LEU . . . . . 0.531 HD12 ' O ' ' A' ' 14' ' ' SER . 0.1 OUTLIER -152.41 -58.02 0.14 Allowed 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.885 179.967 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -130.19 -77.53 0.18 Allowed Glycine 0 N--CA 1.452 -0.276 0 C-N-CA 120.774 -0.727 . . . . 0.0 112.515 179.983 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 22.1 m -161.17 96.24 1.08 Allowed 'General case' 0 C--N 1.33 -0.262 0 CA-C-O 120.869 0.366 . . . . 0.0 110.914 -179.994 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 8.2 mt -152.4 90.18 1.48 Allowed 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.154 -0.476 . . . . 0.0 110.879 179.958 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 19' ' ' GLN . . . . . . . . . . . . . 1.9 tp60 -60.31 107.43 0.65 Allowed 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.849 179.984 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 20' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -144.4 -51.97 0.3 Allowed 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.269 -0.423 . . . . 0.0 110.932 179.964 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 2.9 ttt180 -149.08 126.05 11.27 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.944 179.992 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 4.5 tt0 -142.74 153.24 43.13 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.255 -0.43 . . . . 0.0 110.904 -179.944 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -150.19 146.09 14.85 Favored Glycine 0 N--CA 1.451 -0.3 0 C-N-CA 120.694 -0.765 . . . . 0.0 112.483 179.932 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -148.35 125.76 11.63 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-O 120.803 0.335 . . . . 0.0 111.115 179.972 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 0.8 OUTLIER -83.59 -66.71 0.86 Allowed 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.917 179.97 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -122.58 -173.63 2.73 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.163 -0.472 . . . . 0.0 111.088 -179.956 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 27' ' ' GLU . . . . . . . . . . . . . 50.8 mt-10 -133.24 -177.82 4.7 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.924 179.983 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 27.4 t -71.31 121.53 21.51 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.096 179.924 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 89.72 52.98 2.51 Favored Glycine 0 N--CA 1.452 -0.293 0 C-N-CA 120.7 -0.762 . . . . 0.0 112.424 179.954 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -155.45 142.1 18.83 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 120.795 0.331 . . . . 0.0 110.887 179.968 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 31' ' ' GLN . . . . . . . . . . . . . 15.3 mt-30 -59.97 134.95 57.52 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.256 -0.429 . . . . 0.0 110.923 -179.971 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 5.5 m -141.83 179.31 2.12 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.346 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.12 -179.982 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 33' ' ' LEU . . . . . 0.466 HD11 ' O ' ' A' ' 37' ' ' GLN . 30.6 tp -142.76 108.0 5.0 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.791 179.98 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 34' ' ' VAL . . . . . 0.526 HG13 ' CB ' ' A' ' 87' ' ' ALA . 22.0 t -78.29 124.67 37.03 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.156 179.995 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 35' ' ' ALA . . . . . . . . . . . . . . . 58.46 26.15 13.86 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.052 -0.522 . . . . 0.0 111.231 179.952 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . 56.57 28.48 56.21 Favored Glycine 0 N--CA 1.451 -0.333 0 C-N-CA 120.773 -0.727 . . . . 0.0 112.598 -179.999 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 37' ' ' GLN . . . . . 0.466 ' O ' HD11 ' A' ' 33' ' ' LEU . 34.3 mt-30 -140.34 -70.88 0.38 Allowed 'General case' 0 C--N 1.328 -0.327 0 CA-C-O 120.749 0.309 . . . . 0.0 110.924 -179.998 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 38' ' ' LYS . . . . . . . . . . . . . 2.1 mttt -69.76 108.45 3.93 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.263 -0.426 . . . . 0.0 110.902 -179.948 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 39' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -88.15 136.98 32.72 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.908 179.974 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -160.52 -163.49 13.89 Favored Glycine 0 N--CA 1.451 -0.319 0 C-N-CA 120.727 -0.749 . . . . 0.0 112.463 180.0 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 41' ' ' ILE . . . . . 0.406 ' C ' HG23 ' A' ' 58' ' ' ILE . 33.2 mt -133.67 131.6 56.9 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-O 120.742 0.306 . . . . 0.0 111.084 -179.905 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 42' ' ' VAL . . . . . . . . . . . . . 21.4 t -60.06 125.43 16.17 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.345 0 CA-C-N 116.209 -0.45 . . . . 0.0 111.123 179.988 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 43' ' ' ARG . . . . . . . . . . . . . 13.6 mmt180 -110.34 -32.72 6.85 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.908 179.951 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 44' ' ' PHE . . . . . . . . . . . . . 72.2 t80 -143.05 111.05 6.0 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.248 -0.433 . . . . 0.0 110.912 -179.919 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 45' ' ' TYR . . . . . 0.5 ' CE1' ' CZ ' ' A' ' 56' ' ' TYR . 18.6 t80 -108.0 122.95 47.88 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.855 -179.99 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 164.94 -179.61 39.47 Favored Glycine 0 N--CA 1.451 -0.32 0 C-N-CA 120.767 -0.73 . . . . 0.0 112.534 179.928 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 47' ' ' LYS . . . . . . . . . . . . . 18.6 mttt -69.4 153.18 43.97 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 120.817 0.341 . . . . 0.0 110.879 -179.975 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 48' ' ' THR . . . . . 0.546 HG21 ' CE1' ' A' ' 50' ' ' PHE . 1.3 p -111.24 177.6 4.61 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.892 179.98 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -104.5 -31.33 9.51 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.835 179.992 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 50' ' ' PHE . . . . . 0.546 ' CE1' HG21 ' A' ' 48' ' ' THR . 54.1 p90 -75.53 -39.19 58.7 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.262 -0.427 . . . . 0.0 110.918 -179.965 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 51' ' ' ALA . . . . . . . . . . . . . . . -131.61 147.13 64.81 Favored Pre-proline 0 C--N 1.33 -0.273 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.093 -179.946 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 52' ' ' PRO . . . . . . . . . . . . . 61.0 Cg_endo -72.96 -172.58 1.01 Allowed 'Trans proline' 0 C--N 1.345 0.372 0 C-N-CA 122.508 2.138 . . . . 0.0 112.395 179.974 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 67.94 -165.48 45.23 Favored Glycine 0 N--CA 1.452 -0.291 0 C-N-CA 120.738 -0.744 . . . . 0.0 112.511 179.973 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 54' ' ' TYR . . . . . . . . . . . . . 69.3 m-85 -107.69 141.55 39.04 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-O 120.84 0.352 . . . . 0.0 110.876 -179.963 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 55' ' ' TRP . . . . . 0.401 ' CZ3' ' HD3' ' A' ' 88' ' ' PRO . 52.6 m95 -132.61 167.17 20.52 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.917 -179.897 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 56' ' ' TYR . . . . . 0.639 ' CE1' ' HB2' ' A' ' 89' ' ' ALA . 3.7 m-85 -121.18 117.09 26.23 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.323 -0.399 . . . . 0.0 110.912 179.997 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 57' ' ' GLY . . . . . 0.446 ' N ' ' CE1' ' A' ' 86' ' ' PHE . . . -81.2 68.26 3.47 Favored Glycine 0 N--CA 1.451 -0.331 0 C-N-CA 120.789 -0.72 . . . . 0.0 112.402 -179.967 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 58' ' ' ILE . . . . . 0.723 HD11 HD13 ' A' ' 92' ' ' ILE . 19.6 mt -73.53 138.04 22.09 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-O 120.807 0.337 . . . . 0.0 111.113 179.998 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -103.63 114.18 28.25 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.841 -179.967 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 60' ' ' LEU . . . . . . . . . . . . . 77.8 mt -69.51 -179.94 1.87 Allowed 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.154 -0.475 . . . . 0.0 110.885 179.972 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 4.9 m-20 -109.41 -34.09 6.63 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.951 -179.977 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 62' ' ' GLN . . . . . 0.407 ' HA ' ' HD3' ' A' ' 63' ' ' PRO . 4.1 mm-40 -108.14 146.63 33.94 Favored Pre-proline 0 C--N 1.329 -0.3 0 CA-C-N 116.321 -0.4 . . . . 0.0 110.942 -179.975 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 63' ' ' PRO . . . . . 0.407 ' HD3' ' HA ' ' A' ' 62' ' ' GLN . 31.7 Cg_exo -58.88 91.93 0.07 OUTLIER 'Trans proline' 0 C--N 1.345 0.368 0 C-N-CA 122.62 2.213 . . . . 0.0 112.172 -179.966 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 64' ' ' THR . . . . . . . . . . . . . 10.1 t -172.89 38.88 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.913 -179.979 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . -93.42 -128.97 5.1 Favored Glycine 0 N--CA 1.45 -0.37 0 C-N-CA 120.786 -0.721 . . . . 0.0 112.48 -179.976 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 66' ' ' LYS . . . . . . . . . . . . . 1.1 mtpm? -135.89 -50.8 0.72 Allowed 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 120.881 0.372 . . . . 0.0 110.874 180.0 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 67' ' ' HIS . . . . . . . . . . . . . 7.1 p80 -128.18 178.99 5.85 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.884 179.911 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 15.5 t0 -101.46 36.46 2.02 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.966 179.999 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 95.66 -37.85 3.3 Favored Glycine 0 N--CA 1.451 -0.351 0 C-N-CA 120.707 -0.759 . . . . 0.0 112.495 -179.997 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 70' ' ' SER . . . . . . . . . . . . . 75.2 p -102.73 162.33 13.02 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-O 120.947 0.403 . . . . 0.0 110.842 -179.91 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 21.4 t -148.07 117.14 1.15 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-N 116.132 -0.485 . . . . 0.0 111.168 179.953 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 72' ' ' PHE . . . . . . . . . . . . . 5.1 m-85 60.4 35.56 20.47 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.14 -0.482 . . . . 0.0 111.002 -179.977 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 80.91 28.26 46.78 Favored Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.679 -0.772 . . . . 0.0 112.597 -179.972 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 74' ' ' VAL . . . . . 0.402 ' O ' ' CE1' ' A' ' 76' ' ' TYR . 21.5 t -133.63 104.89 6.78 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-O 120.799 0.333 . . . . 0.0 111.098 -179.975 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 75' ' ' ARG . . . . . . . . . . . . . 3.6 ttt-85 -77.41 131.47 38.04 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.246 -0.433 . . . . 0.0 111.001 -179.979 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 76' ' ' TYR . . . . . 0.402 ' CE1' ' O ' ' A' ' 74' ' ' VAL . 11.7 m-85 -106.86 -45.63 4.14 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.178 -0.464 . . . . 0.0 110.858 179.956 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 77' ' ' PHE . . . . . 0.431 ' CE1' ' HA3' ' A' ' 57' ' ' GLY . 36.8 p90 -156.29 156.55 34.21 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.924 179.985 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 1.9 t -80.0 114.51 18.97 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.25 -0.432 . . . . 0.0 110.89 179.955 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 79' ' ' CYS . . . . . . . . . . . . . 29.4 p -147.15 152.48 38.5 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.973 -179.936 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 80' ' ' ALA . . . . . 0.73 ' HB1' ' HD2' ' A' ' 81' ' ' PRO . . . -58.45 166.73 2.09 Favored Pre-proline 0 C--N 1.329 -0.29 0 CA-C-N 116.143 -0.48 . . . . 0.0 111.002 179.93 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 81' ' ' PRO . . . . . 0.73 ' HD2' ' HB1' ' A' ' 80' ' ' ALA . 20.5 Cg_endo -60.76 120.95 8.95 Favored 'Trans proline' 0 C--N 1.344 0.29 0 C-N-CA 122.545 2.164 . . . . 0.0 112.168 179.936 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 82' ' ' ARG . . . . . . . . . . . . . 78.1 mtt180 63.11 50.36 3.1 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.143 -0.48 . . . . 0.0 110.876 -179.832 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 83' ' ' HIS . . . . . 0.581 ' ND1' ' HB3' ' A' ' 80' ' ' ALA . 5.8 m170 -123.33 -48.8 1.95 Allowed 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.934 179.933 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . -66.5 121.82 18.68 Favored Glycine 0 N--CA 1.451 -0.304 0 C-N-CA 120.629 -0.796 . . . . 0.0 112.401 179.857 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 85' ' ' VAL . . . . . . . . . . . . . 5.9 m -126.35 132.4 70.43 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-O 120.911 0.386 . . . . 0.0 111.194 -179.98 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 86' ' ' PHE . . . . . 0.446 ' CE1' ' N ' ' A' ' 57' ' ' GLY . 12.9 m-85 -103.66 118.05 35.83 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.991 179.958 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 87' ' ' ALA . . . . . 0.526 ' CB ' HG13 ' A' ' 34' ' ' VAL . . . -134.69 143.61 47.19 Favored Pre-proline 0 C--N 1.33 -0.279 0 CA-C-N 116.215 -0.448 . . . . 0.0 111.058 179.992 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 88' ' ' PRO . . . . . 0.418 ' O ' ' N ' ' A' ' 91' ' ' ARG . 32.5 Cg_exo -57.71 142.1 95.81 Favored 'Trans proline' 0 C--N 1.346 0.401 0 C-N-CA 122.451 2.101 . . . . 0.0 112.397 179.972 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 89' ' ' ALA . . . . . 0.639 ' HB2' ' CE1' ' A' ' 56' ' ' TYR . . . -47.94 -50.98 25.28 Favored 'General case' 0 CA--C 1.521 -0.156 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.255 179.867 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 90' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER -55.87 -24.39 36.72 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 115.716 -0.674 . . . . 0.0 109.801 178.859 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 91' ' ' ARG . . . . . 0.418 ' N ' ' O ' ' A' ' 88' ' ' PRO . 1.0 OUTLIER -90.98 -13.15 33.93 Favored 'General case' 0 N--CA 1.455 -0.219 0 CA-C-N 115.944 -0.571 . . . . 0.0 110.522 179.154 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 92' ' ' ILE . . . . . 0.723 HD13 HD11 ' A' ' 58' ' ' ILE . 62.9 mt -107.09 147.8 11.99 Favored 'Isoleucine or valine' 0 C--O 1.231 0.101 0 CA-C-N 116.432 -0.349 . . . . 0.0 110.895 179.836 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 93' ' ' GLN . . . . . . . . . . . . . 5.7 mt-30 -118.04 168.97 10.05 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.972 179.934 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 94' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -111.48 152.36 27.54 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.859 -179.997 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 95' ' ' ILE . . . . . . . . . . . . . 23.1 mt -132.41 -45.84 0.65 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.155 179.909 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . -59.31 179.32 1.82 Allowed Glycine 0 N--CA 1.452 -0.288 0 C-N-CA 120.81 -0.71 . . . . 0.0 112.533 179.911 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 97' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -137.94 137.29 37.83 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-O 120.797 0.332 . . . . 0.0 110.838 -179.918 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 98' ' ' GLY . . . . . . . . . . . . . . . 171.44 156.1 11.49 Favored Glycine 0 N--CA 1.451 -0.316 0 C-N-CA 120.671 -0.776 . . . . 0.0 112.476 179.905 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 99' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_exo -52.24 97.11 0.04 OUTLIER 'Trans proline' 0 C--N 1.344 0.316 0 C-N-CA 122.581 2.187 . . . . 0.0 112.311 -179.997 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 100' ' ' SER . . . . . . . . . . . . . 21.7 p -119.07 31.6 6.55 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.893 179.989 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 1.8 t -106.51 -65.97 1.04 Allowed 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.286 -0.416 . . . . 0.0 110.863 -179.97 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.25 1.095 0 CA-C-O 118.428 -1.206 . . . . 0.0 112.492 179.983 . . . . . . . . 0 0 . 1 . 013 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.216 0 N-CA-C 112.58 -0.208 . . . . 0.0 112.58 . . . . . . . . . 0 0 . 1 . 013 nuclear build full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER 60.57 159.45 0.04 OUTLIER 'General case' 0 C--N 1.328 -0.335 0 CA-C-O 120.844 0.354 . . . . 0.0 110.911 -179.968 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 2.3 t -99.51 128.03 45.61 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.914 -179.983 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 166.31 41.7 0.02 OUTLIER Glycine 0 N--CA 1.45 -0.375 0 C-N-CA 120.791 -0.718 . . . . 0.0 112.572 -179.966 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 19.5 p -155.18 -50.0 0.09 Allowed 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 120.825 0.345 . . . . 0.0 110.893 -179.981 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 1.5 p -66.98 80.06 0.12 Allowed 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.836 179.984 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 129.81 156.25 8.7 Favored Glycine 0 N--CA 1.452 -0.28 0 C-N-CA 120.725 -0.75 . . . . 0.0 112.398 179.944 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 7.5 mttt 60.31 106.75 0.02 OUTLIER 'General case' 0 C--N 1.33 -0.248 0 CA-C-O 120.89 0.376 . . . . 0.0 110.835 -179.98 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -124.38 83.65 57.13 Favored Pre-proline 0 C--N 1.329 -0.304 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.97 179.939 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 50.2 Cg_exo -53.36 88.99 0.03 OUTLIER 'Trans proline' 0 C--N 1.345 0.38 0 C-N-CA 122.534 2.156 . . . . 0.0 112.269 179.986 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 2.9 p -152.64 102.55 2.72 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.266 -0.425 . . . . 0.0 110.878 179.987 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 0.6 OUTLIER -79.99 137.5 53.6 Favored Pre-proline 0 C--N 1.329 -0.283 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.827 179.97 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 72.8 Cg_endo -74.96 176.85 9.35 Favored 'Trans proline' 0 C--N 1.345 0.368 0 C-N-CA 122.491 2.127 . . . . 0.0 112.295 -179.994 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 8.4 t -74.63 175.89 7.44 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.844 179.939 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 22.8 mt -126.37 31.3 5.41 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.91 -179.972 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 90.52 35.13 7.53 Favored Glycine 0 N--CA 1.451 -0.346 0 C-N-CA 120.713 -0.756 . . . . 0.0 112.549 179.961 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 71.8 p -64.14 123.89 20.23 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 120.808 0.337 . . . . 0.0 110.909 -179.95 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -116.43 -42.41 3.02 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.935 -179.968 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 19' ' ' GLN . . . . . . . . . . . . . 1.4 tt0 60.18 163.65 0.06 Allowed 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.919 -179.962 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 20' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -164.67 97.32 0.76 Allowed 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.252 -0.431 . . . . 0.0 110.956 179.94 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -117.49 -39.98 3.1 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.929 -179.932 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 37.2 mt-10 57.43 32.53 21.94 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.096 -0.502 . . . . 0.0 110.899 -179.979 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -108.65 -93.34 2.28 Favored Glycine 0 N--CA 1.451 -0.329 0 C-N-CA 120.719 -0.753 . . . . 0.0 112.534 -179.953 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -80.26 144.49 32.83 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-O 120.86 0.362 . . . . 0.0 111.102 179.933 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 1.6 mmpt? -74.78 -64.15 1.1 Allowed 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.154 -0.476 . . . . 0.0 110.855 -179.986 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -88.03 -178.15 5.91 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.24 -0.436 . . . . 0.0 111.063 -179.962 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 27' ' ' GLU . . . . . . . . . . . . . 14.3 mt-10 -142.57 168.42 19.78 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.938 179.991 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 27.4 t -68.58 85.06 0.14 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.049 179.957 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 132.62 43.86 0.15 Allowed Glycine 0 N--CA 1.452 -0.265 0 C-N-CA 120.677 -0.773 . . . . 0.0 112.462 179.975 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 2.2 t0 -149.81 152.86 35.86 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 120.774 0.321 . . . . 0.0 110.902 -179.915 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 31' ' ' GLN . . . . . . . . . . . . . 1.6 mt-30 -69.03 141.92 54.72 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.918 179.943 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 5.7 m -143.27 174.84 4.43 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-N 116.247 -0.433 . . . . 0.0 111.141 179.96 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 33' ' ' LEU . . . . . . . . . . . . . 13.8 tp -141.25 105.15 4.75 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.843 179.986 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 34' ' ' VAL . . . . . 0.584 HG13 ' CB ' ' A' ' 87' ' ' ALA . 21.7 t -73.73 123.49 28.98 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.153 -179.982 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 35' ' ' ALA . . . . . . . . . . . . . . . 56.99 25.04 10.19 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.304 179.96 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . 57.29 37.0 78.65 Favored Glycine 0 N--CA 1.45 -0.374 0 C-N-CA 120.803 -0.713 . . . . 0.0 112.572 179.912 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 37' ' ' GLN . . . . . . . . . . . . . 39.0 mt-30 -148.55 -70.17 0.21 Allowed 'General case' 0 C--N 1.33 -0.279 0 CA-C-O 120.731 0.3 . . . . 0.0 110.971 179.98 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 38' ' ' LYS . . . . . . . . . . . . . 62.3 mttt -67.73 105.78 2.03 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.913 179.973 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 39' ' ' GLN . . . . . . . . . . . . . 0.2 OUTLIER -82.2 132.51 35.24 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.886 -179.996 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -158.08 -174.64 28.04 Favored Glycine 0 N--CA 1.451 -0.333 0 C-N-CA 120.658 -0.782 . . . . 0.0 112.53 179.923 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 41' ' ' ILE . . . . . 0.438 ' N ' HG23 ' A' ' 58' ' ' ILE . 15.7 mt -127.41 135.2 63.98 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-O 120.845 0.355 . . . . 0.0 111.046 -179.967 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 42' ' ' VAL . . . . . . . . . . . . . 21.5 t -62.82 120.97 10.71 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.175 179.956 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 43' ' ' ARG . . . . . . . . . . . . . 30.9 mmt180 -110.08 -32.1 7.13 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 116.178 -0.464 . . . . 0.0 110.932 -179.991 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 44' ' ' PHE . . . . . . . . . . . . . 63.4 t80 -147.4 115.53 6.55 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.896 179.924 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 45' ' ' TYR . . . . . 0.496 ' CE1' ' CE1' ' A' ' 56' ' ' TYR . 22.1 t80 -113.1 113.54 25.55 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.967 179.887 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . -175.96 -161.06 24.51 Favored Glycine 0 N--CA 1.452 -0.293 0 C-N-CA 120.712 -0.756 . . . . 0.0 112.474 -179.967 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 47' ' ' LYS . . . . . 0.424 ' HE2' ' CE1' ' A' ' 54' ' ' TYR . 27.2 mttm -88.4 168.95 12.22 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 120.795 0.331 . . . . 0.0 110.893 -179.925 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 48' ' ' THR . . . . . 0.645 HG22 ' CE2' ' A' ' 76' ' ' TYR . 67.1 p -140.04 175.09 9.88 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.949 -179.974 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 3.9 t70 -109.2 -31.52 7.55 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.931 179.994 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 50' ' ' PHE . . . . . 0.598 ' CZ ' HG21 ' A' ' 48' ' ' THR . 28.2 p90 -65.52 -36.07 82.74 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.97 179.959 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 51' ' ' ALA . . . . . 0.419 ' N ' ' CD1' ' A' ' 50' ' ' PHE . . . -140.98 148.13 50.8 Favored Pre-proline 0 C--N 1.329 -0.318 0 CA-C-N 116.209 -0.45 . . . . 0.0 111.097 -179.99 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 52' ' ' PRO . . . . . . . . . . . . . 59.7 Cg_endo -72.6 176.05 9.35 Favored 'Trans proline' 0 C--N 1.345 0.364 0 C-N-CA 122.508 2.139 . . . . 0.0 112.281 -179.981 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 67.72 175.19 8.33 Favored Glycine 0 N--CA 1.452 -0.286 0 C-N-CA 120.727 -0.749 . . . . 0.0 112.493 -179.934 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 54' ' ' TYR . . . . . 0.424 ' CE1' ' HE2' ' A' ' 47' ' ' LYS . 5.9 m-85 -83.71 148.91 26.81 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-O 120.829 0.347 . . . . 0.0 110.944 -179.983 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 55' ' ' TRP . . . . . . . . . . . . . 72.0 m95 -134.44 164.48 27.34 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.923 -179.978 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 56' ' ' TYR . . . . . 0.642 ' HE1' ' HB2' ' A' ' 89' ' ' ALA . 27.0 m-85 -113.55 112.41 23.5 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.908 179.979 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . -77.21 65.93 2.96 Favored Glycine 0 N--CA 1.451 -0.324 0 C-N-CA 120.727 -0.749 . . . . 0.0 112.396 179.909 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 58' ' ' ILE . . . . . 0.453 HD11 HD13 ' A' ' 92' ' ' ILE . 22.5 mt -74.65 152.34 6.78 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.271 0 CA-C-O 120.774 0.321 . . . . 0.0 111.215 -179.976 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 10.8 tm-20 -121.67 120.93 36.15 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 116.258 -0.428 . . . . 0.0 110.862 -179.968 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 60' ' ' LEU . . . . . . . . . . . . . 71.6 mt -79.88 -179.9 7.21 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-N 116.13 -0.486 . . . . 0.0 110.953 179.998 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -108.35 -29.0 9.08 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.028 -179.953 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 62' ' ' GLN . . . . . 0.414 ' HA ' ' HD3' ' A' ' 63' ' ' PRO . 8.2 mt-30 -108.63 143.41 27.46 Favored Pre-proline 0 C--N 1.329 -0.313 0 CA-C-N 116.382 -0.372 . . . . 0.0 110.973 -179.924 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 63' ' ' PRO . . . . . 0.414 ' HD3' ' HA ' ' A' ' 62' ' ' GLN . 39.4 Cg_exo -60.5 89.87 0.08 OUTLIER 'Trans proline' 0 C--N 1.346 0.4 0 C-N-CA 122.488 2.126 . . . . 0.0 112.18 179.928 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 64' ' ' THR . . . . . . . . . . . . . 10.2 t -170.89 35.97 0.02 OUTLIER 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.294 -0.412 . . . . 0.0 110.967 -179.976 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . -87.02 -95.3 0.88 Allowed Glycine 0 N--CA 1.451 -0.362 0 C-N-CA 120.684 -0.769 . . . . 0.0 112.522 -179.994 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 66' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -172.91 -47.42 0.02 OUTLIER 'General case' 0 C--N 1.328 -0.353 0 CA-C-O 120.854 0.359 . . . . 0.0 110.887 -179.982 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 67' ' ' HIS . . . . . . . . . . . . . 11.5 p80 -135.38 167.5 20.93 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.871 179.915 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -95.8 42.68 1.09 Allowed 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.898 179.945 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 87.33 -53.39 4.4 Favored Glycine 0 N--CA 1.452 -0.295 0 C-N-CA 120.717 -0.754 . . . . 0.0 112.492 179.966 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 70' ' ' SER . . . . . . . . . . . . . 93.8 p -79.05 143.82 35.23 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-O 120.773 0.32 . . . . 0.0 110.952 -179.992 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 71' ' ' VAL . . . . . 0.534 HG12 ' CD2' ' A' ' 72' ' ' PHE . 21.4 t -138.24 112.13 8.06 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.329 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.125 -179.981 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 72' ' ' PHE . . . . . 0.534 ' CD2' HG12 ' A' ' 71' ' ' VAL . 48.0 m-85 60.94 31.04 19.96 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.273 -0.421 . . . . 0.0 110.951 -179.933 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 86.11 29.49 25.36 Favored Glycine 0 N--CA 1.451 -0.304 0 C-N-CA 120.715 -0.755 . . . . 0.0 112.528 -179.997 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 21.5 t -136.77 110.33 8.82 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-O 120.849 0.357 . . . . 0.0 111.103 -179.946 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 75' ' ' ARG . . . . . . . . . . . . . 25.8 ttm-85 -81.47 143.81 31.81 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.132 -0.486 . . . . 0.0 110.91 -179.979 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 76' ' ' TYR . . . . . 0.645 ' CE2' HG22 ' A' ' 48' ' ' THR . 24.5 m-85 -120.4 -44.48 2.47 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.837 179.992 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 77' ' ' PHE . . . . . . . . . . . . . 8.2 p90 -157.19 156.51 32.73 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.907 -179.891 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 1.2 m -84.64 95.63 8.95 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.117 -0.492 . . . . 0.0 110.883 179.912 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 79' ' ' CYS . . . . . . . . . . . . . 13.9 p -122.85 159.3 28.44 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.288 -0.414 . . . . 0.0 110.976 -179.942 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 80' ' ' ALA . . . . . 0.742 ' HB1' ' HD2' ' A' ' 81' ' ' PRO . . . -59.05 166.68 2.48 Favored Pre-proline 0 C--N 1.328 -0.343 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.011 179.944 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 81' ' ' PRO . . . . . 0.742 ' HD2' ' HB1' ' A' ' 80' ' ' ALA . 35.7 Cg_endo -65.09 118.26 5.28 Favored 'Trans proline' 0 C--N 1.345 0.365 0 C-N-CA 122.491 2.127 . . . . 0.0 112.196 179.958 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 82' ' ' ARG . . . . . . . . . . . . . 1.1 mtm-85 62.1 46.71 6.16 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.844 -179.944 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 83' ' ' HIS . . . . . 0.711 ' CG ' ' HB3' ' A' ' 80' ' ' ALA . 8.7 m170 -120.68 -43.36 2.48 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.899 179.98 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . -61.07 151.5 41.91 Favored Glycine 0 N--CA 1.451 -0.326 0 C-N-CA 120.708 -0.758 . . . . 0.0 112.494 -179.983 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 85' ' ' VAL . . . . . . . . . . . . . 15.2 m -151.55 129.4 2.49 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-O 120.861 0.362 . . . . 0.0 111.236 -179.929 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 86' ' ' PHE . . . . . . . . . . . . . 8.4 m-85 -102.45 121.87 43.18 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.81 179.985 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 87' ' ' ALA . . . . . 0.584 ' CB ' HG13 ' A' ' 34' ' ' VAL . . . -143.0 145.52 33.47 Favored Pre-proline 0 C--N 1.33 -0.258 0 CA-C-N 116.171 -0.468 . . . . 0.0 111.161 179.943 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 88' ' ' PRO . . . . . . . . . . . . . 32.0 Cg_exo -58.29 137.0 78.22 Favored 'Trans proline' 0 C--N 1.345 0.365 0 C-N-CA 122.575 2.183 . . . . 0.0 112.235 -179.972 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 89' ' ' ALA . . . . . 0.642 ' HB2' ' HE1' ' A' ' 56' ' ' TYR . . . -48.38 -50.96 28.67 Favored 'General case' 0 CA--C 1.521 -0.145 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.316 179.82 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 90' ' ' SER . . . . . . . . . . . . . 51.2 p -55.96 -24.48 38.67 Favored 'General case' 0 N--CA 1.454 -0.246 0 CA-C-N 115.701 -0.681 . . . . 0.0 109.782 178.692 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 91' ' ' ARG . . . . . . . . . . . . . 1.0 OUTLIER -88.22 -14.66 37.96 Favored 'General case' 0 N--CA 1.455 -0.199 0 CA-C-N 115.808 -0.633 . . . . 0.0 110.405 179.062 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 92' ' ' ILE . . . . . 0.566 HD11 ' O ' ' A' ' 87' ' ' ALA . 22.2 mt -108.45 150.29 11.22 Favored 'Isoleucine or valine' 0 C--O 1.231 0.114 0 CA-C-O 120.84 0.353 . . . . 0.0 111.089 179.887 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 93' ' ' GLN . . . . . . . . . . . . . 1.8 mp0 -110.95 169.68 8.6 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.87 179.98 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 94' ' ' ARG . . . . . . . . . . . . . 9.3 ttt-85 -121.59 119.27 31.42 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.189 -0.459 . . . . 0.0 110.876 -179.99 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 95' ' ' ILE . . . . . . . . . . . . . 4.5 mt -91.21 -51.75 11.26 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.185 -0.461 . . . . 0.0 111.115 -180.0 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . 59.61 61.98 6.64 Favored Glycine 0 N--CA 1.451 -0.309 0 C-N-CA 120.738 -0.744 . . . . 0.0 112.459 179.927 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 97' ' ' SER . . . . . . . . . . . . . 7.5 t -87.76 108.56 19.18 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 120.821 0.343 . . . . 0.0 110.856 179.983 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 98' ' ' GLY . . . . . . . . . . . . . . . 77.23 64.62 2.07 Favored Glycine 0 N--CA 1.45 -0.369 0 C-N-CA 120.751 -0.738 . . . . 0.0 112.501 179.962 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 99' ' ' PRO . . . . . . . . . . . . . 51.3 Cg_exo -54.28 142.44 68.28 Favored 'Trans proline' 0 C--N 1.345 0.368 0 C-N-CA 122.589 2.193 . . . . 0.0 112.282 -179.989 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 100' ' ' SER . . . . . . . . . . . . . 6.6 t 60.04 34.42 21.38 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.893 179.987 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 2.8 m -150.33 122.75 8.45 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.922 179.992 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.249 1.068 0 CA-C-O 118.318 -1.268 . . . . 0.0 112.501 -179.936 . . . . . . . . 0 0 . 1 . 014 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.243 0 N-CA-C 112.441 -0.264 . . . . 0.0 112.441 . . . . . . . . . 0 0 . 1 . 014 nuclear build full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 5.7 t -146.3 -50.44 0.22 Allowed 'General case' 0 C--N 1.329 -0.319 0 CA-C-O 120.908 0.385 . . . . 0.0 110.91 -179.991 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 69.9 m -96.87 -31.44 12.59 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.954 179.945 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 77.15 37.61 31.92 Favored Glycine 0 N--CA 1.451 -0.352 0 C-N-CA 120.725 -0.75 . . . . 0.0 112.481 179.992 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 45.4 t -99.47 31.45 3.14 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-O 120.801 0.334 . . . . 0.0 110.855 -179.963 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 1.1 m -107.22 156.94 18.3 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.269 -0.423 . . . . 0.0 110.868 -179.976 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 132.3 -56.47 0.74 Allowed Glycine 0 N--CA 1.452 -0.283 0 C-N-CA 120.734 -0.746 . . . . 0.0 112.456 -179.99 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 31.9 mttm -114.79 144.17 43.92 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-O 120.856 0.36 . . . . 0.0 110.894 -179.994 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -172.84 85.41 0.41 Allowed Pre-proline 0 C--N 1.33 -0.269 0 CA-C-N 116.154 -0.475 . . . . 0.0 110.873 -179.99 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 52.3 Cg_endo -69.5 113.23 3.26 Favored 'Trans proline' 0 C--N 1.344 0.319 0 C-N-CA 122.475 2.117 . . . . 0.0 112.291 179.987 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 1.4 p -129.9 154.44 47.31 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.178 -0.464 . . . . 0.0 110.911 179.966 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 12' ' ' SER . . . . . 0.552 ' O ' HD12 ' A' ' 15' ' ' LEU . 0.1 OUTLIER -105.04 160.94 24.28 Favored Pre-proline 0 C--N 1.329 -0.312 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.883 179.969 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.76 -45.25 1.66 Allowed 'Trans proline' 0 C--N 1.344 0.331 0 C-N-CA 122.609 2.206 . . . . 0.0 112.223 -179.992 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 63.9 m -85.36 109.31 18.31 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.87 179.972 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 15' ' ' LEU . . . . . 0.552 HD12 ' O ' ' A' ' 12' ' ' SER . 0.4 OUTLIER -151.61 -60.18 0.17 Allowed 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.843 -179.939 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -135.1 -45.16 0.1 Allowed Glycine 0 N--CA 1.451 -0.353 0 C-N-CA 120.745 -0.741 . . . . 0.0 112.469 -179.918 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 2.0 m -156.94 167.01 31.75 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-O 120.841 0.353 . . . . 0.0 110.885 -179.907 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 39.1 mt -149.53 76.65 1.32 Allowed 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.85 179.979 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 19' ' ' GLN . . . . . . . . . . . . . 53.8 mt-30 -109.21 39.79 1.98 Allowed 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.909 -179.986 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 20' ' ' GLN . . . . . . . . . . . . . 47.1 tt0 -83.23 91.94 7.37 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.897 179.998 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -95.89 146.72 24.35 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.838 179.966 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 8.7 pt-20 -177.03 -40.13 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.875 179.96 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 97.95 93.25 1.95 Allowed Glycine 0 N--CA 1.451 -0.343 0 C-N-CA 120.692 -0.765 . . . . 0.0 112.491 179.939 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -142.27 159.55 42.0 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-O 120.871 0.367 . . . . 0.0 111.05 179.99 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -79.66 -66.19 0.9 Allowed 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.169 -0.468 . . . . 0.0 110.917 -179.999 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -105.98 174.73 5.76 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.158 -0.474 . . . . 0.0 111.075 179.953 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 27' ' ' GLU . . . . . . . . . . . . . 41.7 mt-10 -140.64 174.87 10.09 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.871 -179.972 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 21.5 t -75.27 105.48 4.27 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.247 -0.433 . . . . 0.0 111.136 179.961 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 114.51 35.63 1.4 Allowed Glycine 0 N--CA 1.452 -0.291 0 C-N-CA 120.699 -0.762 . . . . 0.0 112.537 -179.969 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -149.0 150.88 33.57 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-O 120.749 0.309 . . . . 0.0 110.934 -179.952 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 31' ' ' GLN . . . . . 0.721 ' HB3' HD12 ' A' ' 95' ' ' ILE . 8.8 mp0 -70.0 151.35 45.67 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.282 -0.417 . . . . 0.0 110.831 -179.995 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 14.0 m -152.38 179.46 0.43 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.261 -0.427 . . . . 0.0 111.153 179.998 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 33' ' ' LEU . . . . . 0.636 HD11 ' C ' ' A' ' 37' ' ' GLN . 44.3 tp -143.39 117.86 9.71 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.856 179.943 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 34' ' ' VAL . . . . . 0.411 HG13 ' CB ' ' A' ' 87' ' ' ALA . 21.7 t -85.57 129.6 37.7 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.207 -0.452 . . . . 0.0 111.278 -179.839 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 35' ' ' ALA . . . . . . . . . . . . . . . 53.93 25.91 5.8 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.149 -0.478 . . . . 0.0 111.394 179.893 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . 57.61 33.82 68.16 Favored Glycine 0 N--CA 1.451 -0.353 0 C-N-CA 120.725 -0.75 . . . . 0.0 112.551 179.958 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 37' ' ' GLN . . . . . 0.636 ' C ' HD11 ' A' ' 33' ' ' LEU . 94.2 mt-30 -146.91 -70.6 0.24 Allowed 'General case' 0 C--N 1.33 -0.281 0 CA-C-O 120.847 0.356 . . . . 0.0 110.993 -179.951 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 38' ' ' LYS . . . . . 0.467 ' O ' HD12 ' A' ' 33' ' ' LEU . 2.7 mtmp? -67.11 110.41 3.42 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.947 -179.98 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 39' ' ' GLN . . . . . . . . . . . . . 1.3 tm0? -91.35 137.98 31.94 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.921 179.964 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -164.14 -173.22 32.56 Favored Glycine 0 N--CA 1.45 -0.371 0 C-N-CA 120.82 -0.705 . . . . 0.0 112.564 179.939 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 26.6 mt -122.63 132.01 72.08 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-O 120.804 0.335 . . . . 0.0 111.146 179.958 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 42' ' ' VAL . . . . . . . . . . . . . 33.8 t -59.53 124.29 13.53 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.081 179.986 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 43' ' ' ARG . . . . . . . . . . . . . 1.6 mmm-85 -109.77 -31.11 7.56 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.957 179.985 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 44' ' ' PHE . . . . . . . . . . . . . 28.9 t80 -147.59 112.14 5.31 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.892 179.966 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 45' ' ' TYR . . . . . 0.495 ' CE1' ' CZ ' ' A' ' 56' ' ' TYR . 15.2 t80 -113.27 141.9 46.46 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.894 -179.955 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 144.95 -174.53 24.99 Favored Glycine 0 N--CA 1.451 -0.329 0 C-N-CA 120.757 -0.735 . . . . 0.0 112.501 179.951 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 47' ' ' LYS . . . . . 0.415 ' HG3' ' CD1' ' A' ' 54' ' ' TYR . 13.6 mttm -74.02 161.54 29.96 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-O 120.797 0.332 . . . . 0.0 110.88 -179.966 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 48' ' ' THR . . . . . . . . . . . . . 75.2 p -119.07 -176.91 3.22 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.853 -179.975 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 1.8 t0 -113.41 15.65 19.09 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.378 -179.985 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 50' ' ' PHE . . . . . 0.45 ' CD1' ' N ' ' A' ' 51' ' ' ALA . 42.8 p90 -124.79 -41.28 2.13 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 120.74 0.305 . . . . 0.0 110.955 -179.993 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 51' ' ' ALA . . . . . 0.45 ' N ' ' CD1' ' A' ' 50' ' ' PHE . . . -129.25 149.21 72.06 Favored Pre-proline 0 C--N 1.329 -0.306 0 CA-C-N 116.311 -0.404 . . . . 0.0 111.106 -179.995 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 52' ' ' PRO . . . . . . . . . . . . . 55.6 Cg_endo -70.19 178.04 5.25 Favored 'Trans proline' 0 C--N 1.344 0.306 0 C-N-CA 122.608 2.205 . . . . 0.0 112.274 -179.971 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 72.96 -169.91 52.35 Favored Glycine 0 N--CA 1.451 -0.345 0 C-N-CA 120.717 -0.754 . . . . 0.0 112.542 -179.95 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 54' ' ' TYR . . . . . 0.415 ' CD1' ' HG3' ' A' ' 47' ' ' LYS . 99.7 m-85 -111.28 134.38 52.91 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-O 120.849 0.357 . . . . 0.0 110.932 179.933 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 55' ' ' TRP . . . . . . . . . . . . . 42.1 m95 -120.43 157.81 28.53 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.893 179.984 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 56' ' ' TYR . . . . . 0.507 ' CE1' ' HB2' ' A' ' 89' ' ' ALA . 4.1 m-85 -110.61 123.82 50.7 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.944 -179.901 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . -89.52 64.11 3.23 Favored Glycine 0 N--CA 1.452 -0.253 0 C-N-CA 120.768 -0.729 . . . . 0.0 112.416 179.891 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 58' ' ' ILE . . . . . 0.657 HD11 HD13 ' A' ' 92' ' ' ILE . 4.8 mt -71.72 144.7 13.01 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-O 120.783 0.325 . . . . 0.0 111.098 179.988 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 1.4 tm-20 -109.08 137.56 46.8 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.187 -0.461 . . . . 0.0 110.891 179.961 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 60' ' ' LEU . . . . . . . . . . . . . 65.1 mt -93.89 168.88 10.69 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.892 -179.931 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 20.2 t0 -95.79 -31.34 13.23 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.917 179.974 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 62' ' ' GLN . . . . . . . . . . . . . 5.5 pt20 -111.27 153.41 44.04 Favored Pre-proline 0 C--N 1.33 -0.274 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.865 -179.879 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 56.6 Cg_endo -70.67 80.05 1.17 Allowed 'Trans proline' 0 C--N 1.344 0.328 0 C-N-CA 122.605 2.203 . . . . 0.0 112.302 179.943 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 64' ' ' THR . . . . . . . . . . . . . 65.5 p -156.73 31.33 0.31 Allowed 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.075 -0.511 . . . . 0.0 110.823 -179.993 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . -83.85 -114.62 0.61 Allowed Glycine 0 N--CA 1.451 -0.309 0 C-N-CA 120.699 -0.762 . . . . 0.0 112.521 -179.969 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 66' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -151.68 -48.16 0.11 Allowed 'General case' 0 C--N 1.329 -0.293 0 CA-C-O 120.851 0.357 . . . . 0.0 110.904 -179.963 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 67' ' ' HIS . . . . . . . . . . . . . 7.2 p80 -124.37 175.92 6.79 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.973 -179.982 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 1.3 m-20 -97.94 37.25 1.43 Allowed 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.231 -0.44 . . . . 0.0 110.924 179.97 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 91.03 -50.94 3.14 Favored Glycine 0 N--CA 1.451 -0.325 0 C-N-CA 120.723 -0.751 . . . . 0.0 112.489 -179.998 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 70' ' ' SER . . . . . . . . . . . . . 21.4 p -88.31 143.3 27.1 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-O 120.79 0.328 . . . . 0.0 110.927 -179.938 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 71' ' ' VAL . . . . . 0.782 HG12 ' CD2' ' A' ' 72' ' ' PHE . 24.6 t -127.32 114.6 37.23 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.219 -0.446 . . . . 0.0 111.078 179.982 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 72' ' ' PHE . . . . . 0.782 ' CD2' HG12 ' A' ' 71' ' ' VAL . 25.3 m-85 60.32 31.04 20.3 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.956 -179.917 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 86.48 28.56 26.89 Favored Glycine 0 N--CA 1.451 -0.325 0 C-N-CA 120.685 -0.769 . . . . 0.0 112.475 179.969 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 21.5 t -130.16 100.2 4.92 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-O 120.91 0.386 . . . . 0.0 111.161 179.991 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 75' ' ' ARG . . . . . . . . . . . . . 4.8 ttt180 -80.26 112.37 17.52 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.116 -0.493 . . . . 0.0 110.879 -179.942 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 76' ' ' TYR . . . . . . . . . . . . . 58.0 m-85 -88.16 -40.37 13.79 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.911 -180.0 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 77' ' ' PHE . . . . . . . . . . . . . 23.3 p90 -154.1 153.39 31.78 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.889 179.892 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 78' ' ' THR . . . . . 0.418 HG23 ' O ' ' A' ' 78' ' ' THR . 5.1 t -82.97 111.56 18.95 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.145 -0.48 . . . . 0.0 110.812 -179.999 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 79' ' ' CYS . . . . . . . . . . . . . 18.4 p -143.1 170.71 15.21 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.959 -179.977 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 80' ' ' ALA . . . . . 0.765 ' HB3' ' ND1' ' A' ' 83' ' ' HIS . . . -70.67 167.06 30.42 Favored Pre-proline 0 C--N 1.329 -0.307 0 CA-C-N 116.121 -0.49 . . . . 0.0 110.969 179.938 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 81' ' ' PRO . . . . . 0.753 ' HD2' ' HB1' ' A' ' 80' ' ' ALA . 34.7 Cg_endo -64.86 126.83 17.33 Favored 'Trans proline' 0 C--N 1.345 0.356 0 C-N-CA 122.433 2.089 . . . . 0.0 112.224 179.934 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 82' ' ' ARG . . . . . . . . . . . . . 76.2 mtt180 62.03 39.34 13.32 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.132 -0.486 . . . . 0.0 110.957 -179.914 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 83' ' ' HIS . . . . . 0.765 ' ND1' ' HB3' ' A' ' 80' ' ' ALA . 9.1 m170 -114.55 -37.66 4.23 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.868 179.971 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . -76.91 152.77 41.03 Favored Glycine 0 N--CA 1.451 -0.332 0 C-N-CA 120.746 -0.74 . . . . 0.0 112.529 179.997 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 85' ' ' VAL . . . . . . . . . . . . . 16.1 m -153.9 135.22 5.23 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.329 0 CA-C-O 120.82 0.343 . . . . 0.0 111.12 179.934 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 86' ' ' PHE . . . . . . . . . . . . . 7.2 m-85 -111.09 117.09 32.34 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.99 -179.989 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 87' ' ' ALA . . . . . 0.497 ' O ' HD11 ' A' ' 92' ' ' ILE . . . -135.42 145.25 52.87 Favored Pre-proline 0 C--N 1.329 -0.324 0 CA-C-N 116.262 -0.426 . . . . 0.0 111.053 179.906 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 88' ' ' PRO . . . . . 0.409 ' O ' ' N ' ' A' ' 91' ' ' ARG . 33.6 Cg_exo -59.62 145.0 99.29 Favored 'Trans proline' 0 C--N 1.344 0.337 0 C-N-CA 122.562 2.174 . . . . 0.0 112.313 -179.978 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 89' ' ' ALA . . . . . 0.507 ' HB2' ' CE1' ' A' ' 56' ' ' TYR . . . -48.45 -50.91 29.43 Favored 'General case' 0 CA--C 1.521 -0.158 0 CA-C-N 116.187 -0.461 . . . . 0.0 110.247 179.84 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 90' ' ' SER . . . . . . . . . . . . . 1.2 m -56.0 -24.37 38.51 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 115.681 -0.69 . . . . 0.0 109.749 178.766 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 91' ' ' ARG . . . . . 0.409 ' N ' ' O ' ' A' ' 88' ' ' PRO . 0.0 OUTLIER -89.75 -13.9 35.78 Favored 'General case' 0 N--CA 1.454 -0.226 0 CA-C-N 115.926 -0.579 . . . . 0.0 110.515 179.125 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 92' ' ' ILE . . . . . 0.657 HD13 HD11 ' A' ' 58' ' ' ILE . 48.7 mt -110.31 153.51 12.07 Favored 'Isoleucine or valine' 0 C--O 1.23 0.074 0 CA-C-N 116.378 -0.374 . . . . 0.0 111.072 179.814 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 93' ' ' GLN . . . . . 0.407 ' N ' HG22 ' A' ' 92' ' ' ILE . 0.4 OUTLIER -116.24 179.81 3.89 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.805 -179.98 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 94' ' ' ARG . . . . . . . . . . . . . 4.1 ttp180 -122.76 144.08 49.41 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.885 -179.983 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 95' ' ' ILE . . . . . 0.721 HD12 ' HB3' ' A' ' 31' ' ' GLN . 22.0 mt -113.42 -35.82 2.34 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 CA-C-N 116.174 -0.466 . . . . 0.0 111.177 179.931 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . 136.65 -174.11 21.74 Favored Glycine 0 N--CA 1.45 -0.377 0 C-N-CA 120.728 -0.749 . . . . 0.0 112.493 179.964 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 97' ' ' SER . . . . . . . . . . . . . 3.6 m -90.94 -57.79 2.69 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 120.793 0.33 . . . . 0.0 110.874 -179.956 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 98' ' ' GLY . . . . . . . . . . . . . . . 126.43 156.26 9.17 Favored Glycine 0 N--CA 1.451 -0.31 0 C-N-CA 120.74 -0.743 . . . . 0.0 112.526 -179.984 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 99' ' ' PRO . . . . . . . . . . . . . 52.9 Cg_endo -69.39 -28.17 27.36 Favored 'Trans proline' 0 C--N 1.344 0.295 0 C-N-CA 122.603 2.202 . . . . 0.0 112.338 179.994 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 100' ' ' SER . . . . . . . . . . . . . 3.3 p -72.38 153.43 41.45 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.884 179.981 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 23.3 t -140.84 -66.36 0.43 Allowed 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.925 179.996 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.25 1.101 0 CA-C-O 118.384 -1.231 . . . . 0.0 112.46 179.988 . . . . . . . . 0 0 . 1 . 015 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.488 2.134 0 N-CA-C 112.556 -0.217 . . . . 0.0 112.556 . . . . . . . . . 0 0 . 1 . 015 nuclear build full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 7.6 t -168.71 -60.15 0.02 OUTLIER 'General case' 0 C--N 1.33 -0.264 0 CA-C-O 120.778 0.323 . . . . 0.0 110.845 -179.9 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 3.5 p 50.03 95.21 0.01 OUTLIER 'General case' 0 C--N 1.331 -0.236 0 CA-C-N 116.23 -0.441 . . . . 0.0 111.157 -179.943 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 90.82 -149.85 20.25 Favored Glycine 0 N--CA 1.45 -0.403 0 C-N-CA 120.742 -0.742 . . . . 0.0 112.482 -179.9 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 1.2 p -148.43 39.12 0.88 Allowed 'General case' 0 C--N 1.329 -0.321 0 CA-C-O 120.803 0.335 . . . . 0.0 110.867 179.934 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 33.3 t 61.34 162.37 0.07 Allowed 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.886 179.928 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 99.4 -29.0 12.8 Favored Glycine 0 N--CA 1.45 -0.395 0 C-N-CA 120.737 -0.744 . . . . 0.0 112.541 -179.911 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 1.4 tmtp? -62.99 118.92 8.49 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-O 120.784 0.326 . . . . 0.0 110.907 -179.993 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 2.9 m -155.38 165.2 18.83 Favored Pre-proline 0 C--N 1.328 -0.33 0 CA-C-N 116.207 -0.452 . . . . 0.0 110.923 -179.964 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 54.2 Cg_exo -51.98 118.84 4.91 Favored 'Trans proline' 0 C--N 1.344 0.302 0 C-N-CA 122.581 2.187 . . . . 0.0 112.284 179.951 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 7.8 t -125.47 137.55 53.97 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.983 -179.965 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 1.3 m -175.22 138.61 0.58 Allowed Pre-proline 0 C--N 1.329 -0.319 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.877 179.936 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 50.3 Cg_exo -53.46 -177.66 0.03 OUTLIER 'Trans proline' 0 C--N 1.344 0.332 0 C-N-CA 122.544 2.162 . . . . 0.0 112.216 -179.987 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -82.6 77.43 9.37 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.84 -179.997 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 14.6 tp -157.84 93.38 1.26 Allowed 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.897 -179.934 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 59.92 89.72 0.02 OUTLIER Glycine 0 N--CA 1.451 -0.307 0 C-N-CA 120.803 -0.713 . . . . 0.0 112.439 179.953 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -91.1 169.79 10.57 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-O 120.725 0.298 . . . . 0.0 110.96 179.983 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 3.3 mp -71.84 -38.71 70.1 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.251 -0.432 . . . . 0.0 110.888 179.993 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 19' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -122.54 90.41 3.29 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.921 179.952 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 20' ' ' GLN . . . . . . . . . . . . . 1.8 tt0 -102.87 156.0 17.96 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.845 179.999 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -135.84 88.23 2.38 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.849 179.972 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 7.4 mt-10 -158.74 126.79 5.15 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.189 -0.459 . . . . 0.0 110.92 179.918 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 171.82 -45.38 0.18 Allowed Glycine 0 N--CA 1.451 -0.344 0 C-N-CA 120.769 -0.729 . . . . 0.0 112.484 179.993 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -140.97 162.38 35.62 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 120.779 0.323 . . . . 0.0 111.054 179.972 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 1.0 OUTLIER -142.47 -47.2 0.33 Allowed 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.888 -179.948 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -122.72 170.08 10.42 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.181 -0.463 . . . . 0.0 111.121 -179.955 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 27' ' ' GLU . . . . . . . . . . . . . 4.8 mt-10 -124.31 179.51 4.88 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.953 179.976 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 21.4 t -75.21 104.98 3.83 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.241 -0.436 . . . . 0.0 111.172 179.951 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 108.13 34.55 2.72 Favored Glycine 0 N--CA 1.451 -0.328 0 C-N-CA 120.732 -0.747 . . . . 0.0 112.529 -179.941 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 30' ' ' ASP . . . . . 0.427 ' C ' HG23 ' A' ' 41' ' ' ILE . 0.8 OUTLIER -138.06 145.29 41.59 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-O 120.814 0.34 . . . . 0.0 110.879 180.0 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 31' ' ' GLN . . . . . 0.545 ' HB3' HD12 ' A' ' 95' ' ' ILE . 0.7 OUTLIER -60.01 144.78 48.48 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.932 -179.962 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 12.0 m -150.02 174.46 1.08 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.372 0 CA-C-N 116.286 -0.415 . . . . 0.0 111.208 179.953 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 33' ' ' LEU . . . . . 0.469 HD11 ' O ' ' A' ' 37' ' ' GLN . 28.8 tp -138.71 107.1 5.81 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.886 -179.958 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 34' ' ' VAL . . . . . 0.416 HG22 HD12 ' A' ' 58' ' ' ILE . 21.5 t -77.32 125.58 37.17 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-N 116.236 -0.438 . . . . 0.0 111.22 -179.978 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 35' ' ' ALA . . . . . . . . . . . . . . . 58.2 26.23 13.55 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.163 -0.471 . . . . 0.0 111.333 -179.967 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . 56.14 31.39 59.01 Favored Glycine 0 C--N 1.331 0.279 0 C-N-CA 120.775 -0.726 . . . . 0.0 112.607 179.973 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 37' ' ' GLN . . . . . 0.469 ' O ' HD11 ' A' ' 33' ' ' LEU . 37.3 mt-30 -145.3 -70.42 0.27 Allowed 'General case' 0 C--N 1.329 -0.287 0 CA-C-O 120.795 0.331 . . . . 0.0 110.877 -179.944 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 38' ' ' LYS . . . . . . . . . . . . . 32.0 mttt -67.57 104.05 1.5 Allowed 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.927 179.958 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 39' ' ' GLN . . . . . 0.4 ' NE2' HD13 ' A' ' 95' ' ' ILE . 4.2 tt0 -82.93 148.03 27.9 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.875 -179.972 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -175.68 -164.13 29.59 Favored Glycine 0 N--CA 1.451 -0.363 0 C-N-CA 120.787 -0.721 . . . . 0.0 112.541 179.945 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 41' ' ' ILE . . . . . 0.441 ' C ' HG23 ' A' ' 58' ' ' ILE . 3.8 mp -134.61 139.14 48.33 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-O 120.856 0.36 . . . . 0.0 111.156 179.986 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 42' ' ' VAL . . . . . . . . . . . . . 31.0 t -70.47 127.08 31.91 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.029 179.953 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 43' ' ' ARG . . . . . . . . . . . . . 15.6 mmt180 -110.72 -32.35 6.89 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.207 -0.452 . . . . 0.0 110.923 -179.957 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 44' ' ' PHE . . . . . . . . . . . . . 72.6 t80 -141.21 108.23 5.45 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.859 179.978 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 45' ' ' TYR . . . . . 0.497 ' CE1' ' CZ ' ' A' ' 56' ' ' TYR . 12.5 t80 -109.53 131.96 54.58 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.881 179.949 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 158.82 -137.71 5.33 Favored Glycine 0 N--CA 1.451 -0.36 0 C-N-CA 120.68 -0.771 . . . . 0.0 112.53 -179.968 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 47' ' ' LYS . . . . . . . . . . . . . 11.1 mttm -104.18 154.16 20.08 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-O 120.815 0.341 . . . . 0.0 110.922 179.996 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 48' ' ' THR . . . . . . . . . . . . . 25.5 p -117.86 -179.22 3.69 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.224 -0.443 . . . . 0.0 110.874 179.875 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 2.2 t0 -110.91 -26.55 9.25 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.212 -0.449 . . . . 0.0 111.026 -179.836 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 50' ' ' PHE . . . . . 0.451 ' CD1' ' N ' ' A' ' 51' ' ' ALA . 22.6 p90 -72.32 -34.12 67.86 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.422 -0.354 . . . . 0.0 111.117 -179.831 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 51' ' ' ALA . . . . . 0.451 ' N ' ' CD1' ' A' ' 50' ' ' PHE . . . -148.9 147.81 25.43 Favored Pre-proline 0 C--N 1.329 -0.3 0 CA-C-N 116.3 -0.409 . . . . 0.0 111.237 -179.931 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 52' ' ' PRO . . . . . . . . . . . . . 74.0 Cg_endo -75.3 165.34 31.06 Favored 'Trans proline' 0 C--N 1.344 0.327 0 C-N-CA 122.651 2.234 . . . . 0.0 112.366 179.954 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 99.68 -168.98 21.9 Favored Glycine 0 N--CA 1.451 -0.317 0 C-N-CA 120.734 -0.746 . . . . 0.0 112.56 179.917 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 54' ' ' TYR . . . . . . . . . . . . . 64.9 m-85 -102.31 125.87 49.15 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-O 120.825 0.345 . . . . 0.0 110.893 179.994 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 55' ' ' TRP . . . . . 0.408 ' CZ3' ' HD3' ' A' ' 88' ' ' PRO . 63.9 m95 -127.02 156.77 41.11 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.912 179.976 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 56' ' ' TYR . . . . . 0.576 ' CE1' ' HB2' ' A' ' 89' ' ' ALA . 4.2 m-85 -113.32 122.71 48.24 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.254 -0.43 . . . . 0.0 110.95 -179.961 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 57' ' ' GLY . . . . . 0.447 ' CA ' ' CE1' ' A' ' 86' ' ' PHE . . . -84.04 68.03 3.6 Favored Glycine 0 N--CA 1.45 -0.404 0 C-N-CA 120.775 -0.726 . . . . 0.0 112.427 179.865 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 58' ' ' ILE . . . . . 0.678 HD11 HD13 ' A' ' 92' ' ' ILE . 19.7 mt -73.58 138.59 20.97 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-O 120.812 0.339 . . . . 0.0 111.138 -179.955 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -114.07 112.38 23.15 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.915 179.948 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 60' ' ' LEU . . . . . 0.673 HD13 HG23 ' A' ' 64' ' ' THR . 8.1 mt -73.21 173.06 9.99 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.246 -0.434 . . . . 0.0 110.865 -179.972 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 8.3 p-10 -102.0 -31.59 10.58 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.856 179.957 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 62' ' ' GLN . . . . . 0.425 ' HG3' HG22 ' A' ' 64' ' ' THR . 4.1 pt20 -106.5 157.49 34.92 Favored Pre-proline 0 C--N 1.329 -0.301 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.835 -179.974 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 37.2 Cg_endo -65.86 82.58 0.25 Allowed 'Trans proline' 0 C--N 1.345 0.345 0 C-N-CA 122.533 2.155 . . . . 0.0 112.263 179.937 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 64' ' ' THR . . . . . 0.673 HG23 HD13 ' A' ' 60' ' ' LEU . 9.1 t -156.01 34.55 0.34 Allowed 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.108 -0.496 . . . . 0.0 110.839 -179.995 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . -97.84 -131.51 7.15 Favored Glycine 0 N--CA 1.45 -0.407 0 C-N-CA 120.732 -0.747 . . . . 0.0 112.547 179.956 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 66' ' ' LYS . . . . . . . . . . . . . 4.3 mtmm -144.6 -58.36 0.36 Allowed 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 120.819 0.343 . . . . 0.0 110.9 -179.969 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 67' ' ' HIS . . . . . . . . . . . . . 6.9 p80 -110.72 164.51 12.68 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.887 179.945 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 45.6 t0 -97.76 36.52 1.52 Allowed 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.209 -0.451 . . . . 0.0 110.946 -179.997 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 96.75 -32.1 6.91 Favored Glycine 0 N--CA 1.45 -0.369 0 C-N-CA 120.766 -0.73 . . . . 0.0 112.47 179.955 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 70' ' ' SER . . . . . . . . . . . . . 12.2 p -114.13 141.93 46.86 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-O 120.885 0.374 . . . . 0.0 110.844 179.988 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 71' ' ' VAL . . . . . 0.636 HG12 ' CD2' ' A' ' 72' ' ' PHE . 21.6 t -131.07 111.26 19.43 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.252 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.137 179.929 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 72' ' ' PHE . . . . . 0.636 ' CD2' HG12 ' A' ' 71' ' ' VAL . 53.4 m-85 61.09 30.88 19.7 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.999 -179.952 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 98.8 -27.62 18.97 Favored Glycine 0 N--CA 1.452 -0.26 0 C-N-CA 120.728 -0.749 . . . . 0.0 112.454 -179.971 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 22.8 t -75.55 135.35 27.29 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-O 120.834 0.35 . . . . 0.0 111.09 -179.934 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 75' ' ' ARG . . . . . 0.503 HH21 HG23 ' A' ' 78' ' ' THR . 19.2 ttt180 -107.71 144.44 34.81 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.911 179.992 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 76' ' ' TYR . . . . . 0.403 ' CD1' ' N ' ' A' ' 76' ' ' TYR . 3.9 m-85 -123.42 -44.06 2.15 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.944 179.932 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 77' ' ' PHE . . . . . . . . . . . . . 28.5 p90 -162.88 177.7 9.03 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.866 179.97 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 78' ' ' THR . . . . . 0.503 HG23 HH21 ' A' ' 75' ' ' ARG . 0.7 OUTLIER -99.67 113.16 25.43 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.913 179.921 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 79' ' ' CYS . . . . . . . . . . . . . 30.2 p -142.9 152.66 42.32 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.27 -0.423 . . . . 0.0 110.924 179.955 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 80' ' ' ALA . . . . . 0.593 ' HB3' ' CD2' ' A' ' 83' ' ' HIS . . . -66.79 168.26 11.09 Favored Pre-proline 0 C--N 1.329 -0.325 0 CA-C-N 116.215 -0.448 . . . . 0.0 111.054 -179.984 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 81' ' ' PRO . . . . . 0.527 ' HD2' ' HB1' ' A' ' 80' ' ' ALA . 41.7 Cg_exo -56.91 122.49 11.91 Favored 'Trans proline' 0 C--N 1.344 0.293 0 C-N-CA 122.584 2.19 . . . . 0.0 112.306 -179.991 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 82' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER 62.37 51.91 3.23 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.169 -0.469 . . . . 0.0 111.082 179.845 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 83' ' ' HIS . . . . . 0.593 ' CD2' ' HB3' ' A' ' 80' ' ' ALA . 1.1 m80 -124.77 -50.42 1.72 Allowed 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.861 179.92 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . -66.05 142.36 43.04 Favored Glycine 0 N--CA 1.451 -0.338 0 C-N-CA 120.748 -0.739 . . . . 0.0 112.536 179.928 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 85' ' ' VAL . . . . . . . . . . . . . 6.9 m -146.99 129.04 6.93 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-O 120.862 0.363 . . . . 0.0 111.076 179.957 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 86' ' ' PHE . . . . . 0.447 ' CE1' ' CA ' ' A' ' 57' ' ' GLY . 17.0 m-85 -108.12 114.9 29.14 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.106 -0.497 . . . . 0.0 110.85 -179.977 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 87' ' ' ALA . . . . . 0.55 ' O ' HD11 ' A' ' 92' ' ' ILE . . . -136.68 146.7 56.49 Favored Pre-proline 0 C--N 1.33 -0.281 0 CA-C-N 116.14 -0.482 . . . . 0.0 111.178 179.916 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 88' ' ' PRO . . . . . 0.423 ' O ' ' N ' ' A' ' 91' ' ' ARG . 34.5 Cg_exo -57.7 142.84 96.06 Favored 'Trans proline' 0 C--N 1.345 0.352 0 C-N-CA 122.561 2.174 . . . . 0.0 112.324 -179.942 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 89' ' ' ALA . . . . . 0.576 ' HB2' ' CE1' ' A' ' 56' ' ' TYR . . . -48.04 -50.75 26.82 Favored 'General case' 0 C--O 1.231 0.117 0 CA-C-N 116.101 -0.5 . . . . 0.0 110.261 179.853 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 90' ' ' SER . . . . . . . . . . . . . 42.6 m -55.75 -24.43 35.27 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 115.708 -0.678 . . . . 0.0 109.733 178.828 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 91' ' ' ARG . . . . . 0.423 ' N ' ' O ' ' A' ' 88' ' ' PRO . 3.4 mtm180 -89.41 -14.81 34.65 Favored 'General case' 0 N--CA 1.456 -0.172 0 CA-C-N 115.857 -0.611 . . . . 0.0 110.472 179.059 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 92' ' ' ILE . . . . . 0.678 HD13 HD11 ' A' ' 58' ' ' ILE . 48.2 mt -107.03 158.3 6.99 Favored 'Isoleucine or valine' 0 C--O 1.231 0.128 0 CA-C-N 116.379 -0.373 . . . . 0.0 111.014 179.793 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 93' ' ' GLN . . . . . 0.491 ' N ' HG22 ' A' ' 92' ' ' ILE . 5.2 mt-30 -130.18 176.82 7.79 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.964 -179.973 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 94' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -118.16 154.23 32.51 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.903 179.971 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 95' ' ' ILE . . . . . 0.545 HD12 ' HB3' ' A' ' 31' ' ' GLN . 4.4 mt -119.54 -41.11 2.09 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.102 179.957 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . -64.85 95.11 0.19 Allowed Glycine 0 N--CA 1.451 -0.347 0 C-N-CA 120.681 -0.771 . . . . 0.0 112.496 179.982 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 97' ' ' SER . . . . . . . . . . . . . 23.2 p -86.91 169.25 12.67 Favored 'General case' 0 C--N 1.331 -0.231 0 CA-C-O 120.883 0.373 . . . . 0.0 110.872 -179.953 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 98' ' ' GLY . . . . . . . . . . . . . . . 176.12 177.89 45.49 Favored Glycine 0 N--CA 1.451 -0.346 0 C-N-CA 120.764 -0.731 . . . . 0.0 112.538 179.985 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 99' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_exo -52.31 130.98 38.1 Favored 'Trans proline' 0 C--N 1.343 0.289 0 C-N-CA 122.655 2.237 . . . . 0.0 112.253 -179.998 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 100' ' ' SER . . . . . . . . . . . . . 1.5 m -96.76 135.75 38.26 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.202 -0.453 . . . . 0.0 110.897 179.964 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 4.3 m -130.12 137.27 50.07 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.107 -0.497 . . . . 0.0 110.891 179.995 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.249 1.082 0 CA-C-O 118.305 -1.275 . . . . 0.0 112.576 -179.934 . . . . . . . . 0 0 . 1 . 016 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.191 0 N-CA-C 112.506 -0.238 . . . . 0.0 112.506 . . . . . . . . . 0 0 . 1 . 016 nuclear build full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -113.18 -60.8 1.83 Allowed 'General case' 0 C--N 1.328 -0.338 0 CA-C-O 120.864 0.364 . . . . 0.0 110.873 -179.966 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 40.0 t -117.62 -40.39 3.04 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.887 -179.996 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 144.38 132.32 2.53 Favored Glycine 0 N--CA 1.451 -0.353 0 C-N-CA 120.781 -0.723 . . . . 0.0 112.557 -179.98 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 55.2 p -98.94 32.02 2.79 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-O 120.917 0.389 . . . . 0.0 110.953 -179.995 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 8.4 t -122.59 -178.25 3.86 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.868 179.981 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -95.64 143.18 16.5 Favored Glycine 0 N--CA 1.453 -0.216 0 C-N-CA 120.719 -0.753 . . . . 0.0 112.43 180.0 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 11.2 ttpt -85.36 158.51 20.24 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-O 120.815 0.341 . . . . 0.0 110.945 -179.995 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 9' ' ' SER . . . . . 0.422 ' CB ' ' CD ' ' A' ' 10' ' ' PRO . 1.1 m -178.52 -61.62 0.0 OUTLIER Pre-proline 0 C--N 1.329 -0.288 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.903 179.977 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 10' ' ' PRO . . . . . 0.422 ' CD ' ' CB ' ' A' ' 9' ' ' SER . 58.3 Cg_endo -71.56 114.91 4.09 Favored 'Trans proline' 0 C--N 1.345 0.378 0 C-N-CA 122.462 2.108 . . . . 0.0 112.379 179.94 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -128.39 -61.74 1.07 Allowed 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.942 -179.936 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 8.4 t -156.18 107.71 2.07 Favored Pre-proline 0 C--N 1.329 -0.287 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.911 -179.951 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 13' ' ' PRO . . . . . 0.785 ' HB3' HD12 ' A' ' 18' ' ' LEU . 44.4 Cg_endo -68.08 85.16 0.42 Allowed 'Trans proline' 0 C--N 1.345 0.383 0 C-N-CA 122.438 2.092 . . . . 0.0 112.311 -179.952 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 14' ' ' SER . . . . . 0.809 ' HB3' HD12 ' A' ' 15' ' ' LEU . 0.6 OUTLIER -112.64 -66.84 1.04 Allowed 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.809 -179.991 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 15' ' ' LEU . . . . . 0.809 HD12 ' HB3' ' A' ' 14' ' ' SER . 2.4 mp -136.51 113.56 10.53 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.198 -0.456 . . . . 0.0 110.837 179.983 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 59.25 28.26 64.07 Favored Glycine 0 N--CA 1.451 -0.353 0 C-N-CA 120.742 -0.742 . . . . 0.0 112.533 179.957 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 0.6 OUTLIER -92.54 -45.91 7.88 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-O 120.775 0.321 . . . . 0.0 110.877 -179.951 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 18' ' ' LEU . . . . . 0.785 HD12 ' HB3' ' A' ' 13' ' ' PRO . 13.2 mt -142.83 161.9 36.89 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.803 -179.972 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 19' ' ' GLN . . . . . . . . . . . . . 1.4 tp60 -160.27 30.63 0.17 Allowed 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.957 -180.0 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 20' ' ' GLN . . . . . . . . . . . . . 18.8 mt-30 59.59 98.03 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.189 -0.46 . . . . 0.0 111.006 -179.987 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -170.73 137.14 1.26 Allowed 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.9 179.983 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 6.4 mt-10 -122.1 -59.29 1.66 Allowed 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.968 -179.973 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -160.64 -131.02 1.18 Allowed Glycine 0 N--CA 1.451 -0.347 0 C-N-CA 120.729 -0.748 . . . . 0.0 112.506 -179.985 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -68.13 -179.47 1.26 Allowed 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.825 0.345 . . . . 0.0 111.076 179.93 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 25' ' ' LYS . . . . . 0.458 ' HB2' ' HB1' ' A' ' 89' ' ' ALA . 0.7 OUTLIER -152.61 -47.45 0.1 Allowed 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.919 179.975 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -122.77 -174.54 2.95 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.984 179.947 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 27' ' ' GLU . . . . . . . . . . . . . 13.8 mt-10 -141.28 174.26 10.7 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.154 -0.476 . . . . 0.0 110.881 -179.973 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 22.1 t -76.18 117.96 21.68 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.129 179.871 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 109.39 28.65 4.25 Favored Glycine 0 N--CA 1.452 -0.281 0 C-N-CA 120.776 -0.726 . . . . 0.0 112.491 -179.95 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 7.8 t0 -143.21 142.23 31.35 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 120.807 0.336 . . . . 0.0 110.863 -179.931 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 31' ' ' GLN . . . . . 0.625 ' HB3' HD12 ' A' ' 95' ' ' ILE . 0.0 OUTLIER -61.62 150.35 36.6 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.843 179.931 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 15.2 m -154.14 170.6 0.81 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.351 0 CA-C-N 116.222 -0.444 . . . . 0.0 111.182 179.971 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 33' ' ' LEU . . . . . . . . . . . . . 28.9 tp -134.88 106.02 6.68 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.94 179.968 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 34' ' ' VAL . . . . . 0.466 HG13 ' HB3' ' A' ' 87' ' ' ALA . 21.7 t -74.48 124.82 32.85 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.169 -179.918 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 35' ' ' ALA . . . . . . . . . . . . . . . 57.38 26.08 12.06 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.138 -0.483 . . . . 0.0 111.298 179.953 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . 55.81 26.95 48.76 Favored Glycine 0 N--CA 1.452 -0.284 0 C-N-CA 120.723 -0.751 . . . . 0.0 112.647 179.959 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 37' ' ' GLN . . . . . . . . . . . . . 77.9 mt-30 -138.15 -68.37 0.46 Allowed 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 120.842 0.353 . . . . 0.0 110.931 -179.949 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 38' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -69.7 111.14 5.28 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.906 -179.996 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 39' ' ' GLN . . . . . . . . . . . . . 1.9 tt0 -89.25 135.39 33.6 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.154 -0.476 . . . . 0.0 110.976 179.933 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -165.5 -167.97 26.94 Favored Glycine 0 N--CA 1.451 -0.304 0 C-N-CA 120.7 -0.762 . . . . 0.0 112.513 180.0 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 41' ' ' ILE . . . . . 0.498 ' N ' HG23 ' A' ' 58' ' ' ILE . 23.5 mt -129.52 143.19 41.89 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-O 120.789 0.328 . . . . 0.0 111.16 -179.959 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 42' ' ' VAL . . . . . . . . . . . . . 21.9 t -68.22 112.04 2.98 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.247 -0.433 . . . . 0.0 111.114 179.961 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 43' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -96.19 -41.21 8.8 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.965 -179.986 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 44' ' ' PHE . . . . . . . . . . . . . 21.0 t80 -135.74 119.02 16.66 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.895 179.985 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 45' ' ' TYR . . . . . 0.423 ' CE1' ' CZ ' ' A' ' 56' ' ' TYR . 38.0 t80 -123.04 136.75 54.96 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.115 -0.493 . . . . 0.0 110.844 -179.989 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 157.86 -155.3 26.31 Favored Glycine 0 N--CA 1.451 -0.346 0 C-N-CA 120.747 -0.739 . . . . 0.0 112.478 179.914 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 47' ' ' LYS . . . . . . . . . . . . . 2.1 mtpt -83.35 150.12 26.3 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-O 120.844 0.354 . . . . 0.0 110.891 179.999 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 48' ' ' THR . . . . . 0.535 HG22 ' CE2' ' A' ' 76' ' ' TYR . 6.3 p -115.04 178.01 4.44 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.814 -179.981 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -115.01 -37.48 4.13 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.974 -179.997 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 50' ' ' PHE . . . . . 0.427 ' CZ ' HG21 ' A' ' 48' ' ' THR . 27.4 p90 -63.78 -32.35 73.82 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.191 -0.458 . . . . 0.0 110.951 -179.936 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 51' ' ' ALA . . . . . . . . . . . . . . . -149.62 152.08 34.3 Favored Pre-proline 0 C--N 1.33 -0.269 0 CA-C-N 116.226 -0.443 . . . . 0.0 111.156 -179.997 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 52' ' ' PRO . . . . . . . . . . . . . 57.6 Cg_endo -71.33 168.98 21.88 Favored 'Trans proline' 0 C--N 1.344 0.321 0 C-N-CA 122.562 2.175 . . . . 0.0 112.262 179.99 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 89.87 -160.15 28.46 Favored Glycine 0 N--CA 1.45 -0.37 0 C-N-CA 120.707 -0.758 . . . . 0.0 112.562 -179.972 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 54' ' ' TYR . . . . . . . . . . . . . 59.5 m-85 -123.67 125.73 45.31 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 120.841 0.353 . . . . 0.0 110.839 -179.928 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 55' ' ' TRP . . . . . . . . . . . . . 37.3 m95 -112.34 169.8 8.62 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.22 -0.446 . . . . 0.0 110.835 179.987 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 56' ' ' TYR . . . . . 0.484 ' CE1' ' HB2' ' A' ' 89' ' ' ALA . 9.2 m-85 -118.9 117.43 28.81 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.965 -179.96 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . -82.35 61.37 4.72 Favored Glycine 0 N--CA 1.45 -0.367 0 C-N-CA 120.752 -0.737 . . . . 0.0 112.402 179.956 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 58' ' ' ILE . . . . . 0.514 HD11 HD13 ' A' ' 92' ' ' ILE . 13.2 mt -69.91 137.94 23.07 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-O 120.911 0.386 . . . . 0.0 111.079 -179.949 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER -106.28 133.73 50.52 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.859 179.927 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 60' ' ' LEU . . . . . . . . . . . . . 53.5 mt -100.48 171.64 7.62 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.915 -179.969 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 61' ' ' ASP . . . . . 0.404 ' O ' ' CE1' ' A' ' 83' ' ' HIS . 0.7 OUTLIER -97.28 -30.8 12.76 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.095 -0.502 . . . . 0.0 110.919 179.987 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 62' ' ' GLN . . . . . . . . . . . . . 6.5 mm-40 -97.49 155.35 37.38 Favored Pre-proline 0 C--N 1.328 -0.331 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.974 -179.974 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 74.3 Cg_endo -75.44 60.63 5.81 Favored 'Trans proline' 0 C--N 1.344 0.324 0 C-N-CA 122.648 2.232 . . . . 0.0 112.262 -179.961 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 64' ' ' THR . . . . . . . . . . . . . 26.7 p -132.85 33.26 3.73 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.253 -0.431 . . . . 0.0 110.932 -179.95 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . -85.47 -127.51 1.86 Allowed Glycine 0 N--CA 1.451 -0.338 0 C-N-CA 120.689 -0.767 . . . . 0.0 112.489 -179.968 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 66' ' ' LYS . . . . . . . . . . . . . 0.3 OUTLIER -150.24 -49.08 0.13 Allowed 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.824 0.345 . . . . 0.0 110.865 -179.961 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 67' ' ' HIS . . . . . . . . . . . . . 5.7 p80 -119.5 169.92 9.62 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.143 -0.48 . . . . 0.0 110.854 -179.962 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -97.08 39.8 1.17 Allowed 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.87 -179.987 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 99.43 -36.34 4.13 Favored Glycine 0 N--CA 1.451 -0.337 0 C-N-CA 120.735 -0.745 . . . . 0.0 112.537 179.907 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 70' ' ' SER . . . . . . . . . . . . . 11.7 p -115.32 163.52 15.58 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 120.8 0.333 . . . . 0.0 110.957 179.986 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 21.4 t -137.88 116.25 13.62 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 116.137 -0.483 . . . . 0.0 111.125 179.984 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 72' ' ' PHE . . . . . . . . . . . . . 32.3 m-85 60.6 30.76 19.96 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.928 179.973 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 99.58 -30.03 10.8 Favored Glycine 0 N--CA 1.451 -0.341 0 C-N-CA 120.641 -0.79 . . . . 0.0 112.568 179.988 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 21.5 t -77.5 114.94 18.64 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.34 0 CA-C-O 120.896 0.379 . . . . 0.0 111.068 179.991 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 75' ' ' ARG . . . . . . . . . . . . . 12.6 ttm180 -95.27 126.49 40.62 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.911 179.967 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 76' ' ' TYR . . . . . 0.535 ' CE2' HG22 ' A' ' 48' ' ' THR . 12.8 m-85 -100.17 -50.75 3.86 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.797 -179.96 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 77' ' ' PHE . . . . . . . . . . . . . 11.3 p90 -144.3 173.34 11.86 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.946 -179.96 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 41.6 p -103.94 122.08 44.45 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.266 -0.425 . . . . 0.0 110.904 179.917 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 79' ' ' CYS . . . . . . . . . . . . . 27.8 p -145.13 172.53 12.96 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.849 -179.988 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 80' ' ' ALA . . . . . 0.591 ' HB3' ' ND1' ' A' ' 83' ' ' HIS . . . -78.64 166.66 41.09 Favored Pre-proline 0 C--N 1.33 -0.268 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.115 179.988 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 81' ' ' PRO . . . . . 0.521 ' HD2' ' HB1' ' A' ' 80' ' ' ALA . 50.1 Cg_exo -53.57 116.35 2.93 Favored 'Trans proline' 0 C--N 1.345 0.362 0 C-N-CA 122.587 2.191 . . . . 0.0 112.333 179.959 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 82' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER 61.94 53.4 3.08 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.879 179.923 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 83' ' ' HIS . . . . . 0.591 ' ND1' ' HB3' ' A' ' 80' ' ' ALA . 7.4 m170 -123.45 -44.46 2.12 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.915 179.921 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . -71.02 150.0 46.91 Favored Glycine 0 N--CA 1.451 -0.359 0 C-N-CA 120.699 -0.762 . . . . 0.0 112.535 179.948 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 85' ' ' VAL . . . . . . . . . . . . . 10.8 m -148.94 139.27 16.57 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-O 120.817 0.342 . . . . 0.0 111.157 -179.962 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 86' ' ' PHE . . . . . . . . . . . . . 4.1 m-85 -115.93 109.03 17.01 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.839 179.988 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 87' ' ' ALA . . . . . 0.592 ' O ' HD11 ' A' ' 92' ' ' ILE . . . -130.84 142.85 47.04 Favored Pre-proline 0 C--N 1.33 -0.261 0 CA-C-N 116.259 -0.428 . . . . 0.0 111.126 -179.953 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 88' ' ' PRO . . . . . 0.421 ' O ' ' N ' ' A' ' 91' ' ' ARG . 44.3 Cg_exo -56.26 143.7 84.49 Favored 'Trans proline' 0 C--N 1.345 0.391 0 C-N-CA 122.516 2.144 . . . . 0.0 112.22 179.938 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 89' ' ' ALA . . . . . 0.484 ' HB2' ' CE1' ' A' ' 56' ' ' TYR . . . -47.89 -50.88 25.26 Favored 'General case' 0 C--N 1.333 -0.134 0 CA-C-O 121.113 0.482 . . . . 0.0 110.308 179.807 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 90' ' ' SER . . . . . . . . . . . . . 1.1 m -55.72 -24.76 36.63 Favored 'General case' 0 C--N 1.331 -0.215 0 CA-C-N 115.639 -0.71 . . . . 0.0 109.721 178.765 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 91' ' ' ARG . . . . . 0.421 ' N ' ' O ' ' A' ' 88' ' ' PRO . 0.0 OUTLIER -87.9 -16.28 34.34 Favored 'General case' 0 N--CA 1.454 -0.244 0 CA-C-N 115.833 -0.622 . . . . 0.0 110.393 179.044 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 92' ' ' ILE . . . . . 0.592 HD11 ' O ' ' A' ' 87' ' ' ALA . 44.1 mt -104.2 153.74 6.19 Favored 'Isoleucine or valine' 0 C--O 1.231 0.114 0 CA-C-N 116.344 -0.389 . . . . 0.0 111.063 179.882 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 93' ' ' GLN . . . . . 0.412 ' N ' HG22 ' A' ' 92' ' ' ILE . 0.3 OUTLIER -120.43 142.57 49.1 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.922 -179.976 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 94' ' ' ARG . . . . . . . . . . . . . 12.9 ttt180 -89.96 116.44 28.02 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.222 -0.444 . . . . 0.0 110.868 179.996 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 95' ' ' ILE . . . . . 0.625 HD12 ' HB3' ' A' ' 31' ' ' GLN . 35.2 mt -75.31 -54.24 14.47 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.136 -0.484 . . . . 0.0 111.143 179.99 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . -84.31 84.14 1.6 Allowed Glycine 0 N--CA 1.451 -0.311 0 C-N-CA 120.736 -0.745 . . . . 0.0 112.481 179.998 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 97' ' ' SER . . . . . . . . . . . . . 17.0 t -116.65 129.1 55.95 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-O 120.889 0.376 . . . . 0.0 110.888 179.985 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 98' ' ' GLY . . . . . . . . . . . . . . . 168.49 65.67 0.03 OUTLIER Glycine 0 N--CA 1.451 -0.334 0 C-N-CA 120.78 -0.724 . . . . 0.0 112.566 179.99 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 99' ' ' PRO . . . . . . . . . . . . . 55.4 Cg_endo -69.88 -45.81 1.39 Allowed 'Trans proline' 0 C--N 1.345 0.347 0 C-N-CA 122.543 2.162 . . . . 0.0 112.302 -179.988 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 100' ' ' SER . . . . . . . . . . . . . 1.4 p -80.81 172.68 13.44 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.872 -179.954 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 47.4 t -84.08 -36.2 23.18 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.967 179.956 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.248 1.011 0 CA-C-O 118.437 -1.202 . . . . 0.0 112.498 -179.999 . . . . . . . . 0 0 . 1 . 017 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.245 0 N-CA-C 112.546 -0.222 . . . . 0.0 112.546 . . . . . . . . . 0 0 . 1 . 017 nuclear build full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -84.53 -171.72 3.78 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-O 120.803 0.335 . . . . 0.0 110.919 -179.962 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 18.6 p -162.95 163.59 26.13 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.809 -179.967 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -113.91 26.94 9.54 Favored Glycine 0 N--CA 1.451 -0.303 0 C-N-CA 120.727 -0.749 . . . . 0.0 112.586 -179.975 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -176.77 -65.85 0.01 OUTLIER 'General case' 0 C--N 1.33 -0.274 0 CA-C-O 120.815 0.34 . . . . 0.0 110.884 179.959 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 15.5 p -176.16 179.7 1.23 Allowed 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.877 179.952 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 80.65 152.41 8.36 Favored Glycine 0 N--CA 1.452 -0.291 0 C-N-CA 120.694 -0.765 . . . . 0.0 112.43 -179.989 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 15.0 mttp -133.02 -174.06 3.37 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 120.826 0.346 . . . . 0.0 110.931 -179.96 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 33.8 m -125.48 88.92 53.44 Favored Pre-proline 0 C--N 1.33 -0.266 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.96 -179.965 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 64.0 Cg_exo -51.16 146.47 23.14 Favored 'Trans proline' 0 C--N 1.345 0.387 0 C-N-CA 122.514 2.142 . . . . 0.0 112.383 179.919 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 1.6 p -157.38 158.25 35.56 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.895 -179.987 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 12' ' ' SER . . . . . 0.663 ' O ' HD13 ' A' ' 15' ' ' LEU . 1.3 m -153.84 71.43 6.55 Favored Pre-proline 0 C--N 1.33 -0.279 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.858 -179.997 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 58.3 Cg_endo -71.71 -174.01 1.17 Allowed 'Trans proline' 0 C--N 1.343 0.28 0 C-N-CA 122.557 2.172 . . . . 0.0 112.306 179.98 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER 60.01 36.8 21.48 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.288 -0.415 . . . . 0.0 110.853 179.948 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 15' ' ' LEU . . . . . 0.663 HD13 ' O ' ' A' ' 12' ' ' SER . 0.2 OUTLIER -106.12 -39.22 6.03 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.258 -0.428 . . . . 0.0 110.836 179.93 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -136.85 13.0 3.91 Favored Glycine 0 N--CA 1.451 -0.303 0 C-N-CA 120.752 -0.737 . . . . 0.0 112.774 -179.996 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 71.2 m 55.88 34.41 23.48 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-O 120.792 0.33 . . . . 0.0 111.044 179.918 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER 61.1 89.5 0.08 Allowed 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.867 -179.992 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 19' ' ' GLN . . . . . . . . . . . . . 4.4 tt0 -172.05 105.84 0.19 Allowed 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.907 -179.989 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 20' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -150.06 160.48 43.61 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.98 -179.983 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 12.5 mtm180 60.49 157.65 0.03 OUTLIER 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.246 -0.434 . . . . 0.0 110.955 179.967 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -144.74 -70.0 0.29 Allowed 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.841 -179.996 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 72.96 157.82 4.18 Favored Glycine 0 N--CA 1.45 -0.389 0 C-N-CA 120.747 -0.739 . . . . 0.0 112.524 -179.948 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -81.62 157.07 24.83 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-O 120.816 0.341 . . . . 0.0 111.028 -179.976 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 25' ' ' LYS . . . . . 0.695 ' HG3' ' HB1' ' A' ' 89' ' ' ALA . 8.7 mmtt -67.08 -62.26 1.52 Allowed 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.934 179.965 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -125.52 175.07 7.78 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.24 -0.436 . . . . 0.0 111.14 -179.957 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 27' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -123.91 168.1 13.24 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.848 -179.963 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 25.2 t -73.43 111.42 8.24 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.097 179.951 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 112.72 27.96 3.62 Favored Glycine 0 N--CA 1.452 -0.285 0 C-N-CA 120.752 -0.737 . . . . 0.0 112.516 -179.966 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -136.57 145.53 45.08 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-O 120.757 0.313 . . . . 0.0 110.895 179.995 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 31' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -68.56 136.01 52.41 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.887 179.978 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 12.7 m -136.66 179.67 3.66 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.181 -0.463 . . . . 0.0 111.093 179.993 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 33' ' ' LEU . . . . . 0.523 HD23 ' HA2' ' A' ' 36' ' ' GLY . 15.7 tp -137.91 114.1 10.11 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.914 179.959 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 34' ' ' VAL . . . . . 0.499 HG22 HD13 ' A' ' 58' ' ' ILE . 21.5 t -83.82 123.22 38.67 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.343 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.104 179.997 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 35' ' ' ALA . . . . . . . . . . . . . . . 59.34 26.39 15.24 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.197 179.979 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 36' ' ' GLY . . . . . 0.523 ' HA2' HD23 ' A' ' 33' ' ' LEU . . . 56.13 27.78 52.66 Favored Glycine 0 N--CA 1.452 -0.299 0 C-N-CA 120.774 -0.727 . . . . 0.0 112.579 179.999 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 37' ' ' GLN . . . . . . . . . . . . . 41.7 mt-30 -137.17 -70.6 0.45 Allowed 'General case' 0 C--N 1.328 -0.336 0 CA-C-O 120.858 0.361 . . . . 0.0 110.987 -179.965 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 38' ' ' LYS . . . . . . . . . . . . . 11.5 mttm -70.4 124.6 24.57 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.923 179.969 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 39' ' ' GLN . . . . . . . . . . . . . 0.1 OUTLIER -99.13 129.57 45.39 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.861 179.993 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -151.88 -173.78 21.92 Favored Glycine 0 N--CA 1.452 -0.276 0 C-N-CA 120.702 -0.761 . . . . 0.0 112.49 179.955 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 41' ' ' ILE . . . . . 0.426 ' N ' HG23 ' A' ' 58' ' ' ILE . 32.7 mt -125.15 138.05 55.58 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-O 120.77 0.319 . . . . 0.0 111.125 -179.984 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 42' ' ' VAL . . . . . . . . . . . . . 26.5 t -67.17 113.98 3.63 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.226 -0.443 . . . . 0.0 111.02 179.956 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 43' ' ' ARG . . . . . . . . . . . . . 14.7 mmt180 -102.6 -31.45 10.38 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.933 179.995 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 44' ' ' PHE . . . . . . . . . . . . . 80.7 t80 -146.26 116.71 7.51 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.895 179.943 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 45' ' ' TYR . . . . . 0.488 ' CE1' ' CZ ' ' A' ' 56' ' ' TYR . 17.7 t80 -114.52 117.53 31.2 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.922 179.936 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 173.58 170.44 37.07 Favored Glycine 0 N--CA 1.451 -0.339 0 C-N-CA 120.746 -0.74 . . . . 0.0 112.534 -179.943 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 47' ' ' LYS . . . . . . . . . . . . . 85.5 mttt -65.33 148.27 51.99 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-O 120.819 0.342 . . . . 0.0 110.899 -179.922 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 48' ' ' THR . . . . . 0.719 HG22 ' CE2' ' A' ' 76' ' ' TYR . 0.9 OUTLIER -103.03 -177.08 3.27 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.909 179.989 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 12.5 t0 -109.21 -31.53 7.55 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.246 -0.434 . . . . 0.0 110.985 -179.999 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 50' ' ' PHE . . . . . 0.494 ' CZ ' HG21 ' A' ' 48' ' ' THR . 19.8 p90 -80.01 -31.19 39.66 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.979 180.0 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 51' ' ' ALA . . . . . . . . . . . . . . . -134.8 139.99 33.92 Favored Pre-proline 0 C--N 1.329 -0.306 0 CA-C-N 116.269 -0.423 . . . . 0.0 111.078 -179.957 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 52' ' ' PRO . . . . . . . . . . . . . 72.0 Cg_endo -76.82 167.06 25.95 Favored 'Trans proline' 0 C--N 1.346 0.434 0 C-N-CA 122.469 2.113 . . . . 0.0 112.292 -179.974 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 92.21 -167.85 30.64 Favored Glycine 0 N--CA 1.45 -0.372 0 C-N-CA 120.734 -0.746 . . . . 0.0 112.562 179.898 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 54' ' ' TYR . . . . . . . . . . . . . 31.0 m-85 -103.31 124.27 48.34 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-O 120.868 0.366 . . . . 0.0 110.833 -179.969 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 55' ' ' TRP . . . . . . . . . . . . . 75.2 m95 -117.29 160.61 20.84 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.865 -179.997 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 56' ' ' TYR . . . . . 0.662 ' HE1' ' HB2' ' A' ' 89' ' ' ALA . 5.7 m-85 -118.45 115.81 25.4 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.963 -179.96 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . -82.04 69.53 3.3 Favored Glycine 0 N--CA 1.452 -0.283 0 C-N-CA 120.646 -0.788 . . . . 0.0 112.437 179.933 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 58' ' ' ILE . . . . . 0.764 HD11 HD13 ' A' ' 92' ' ' ILE . 3.9 mt -75.67 141.05 16.36 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-O 120.8 0.333 . . . . 0.0 111.099 -179.976 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 3.1 tt0 -105.63 119.38 38.98 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.925 179.956 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 60' ' ' LEU . . . . . . . . . . . . . 92.7 mt -77.94 172.25 13.76 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.935 179.993 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -101.32 -29.2 12.19 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.895 -179.984 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 62' ' ' GLN . . . . . . . . . . . . . 0.3 OUTLIER -106.65 155.63 38.58 Favored Pre-proline 0 C--N 1.33 -0.259 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.936 179.965 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 55.0 Cg_endo -69.73 70.29 1.57 Allowed 'Trans proline' 0 C--N 1.344 0.335 0 C-N-CA 122.526 2.151 . . . . 0.0 112.296 179.993 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 64' ' ' THR . . . . . . . . . . . . . 42.9 p -147.75 43.76 1.08 Allowed 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 116.112 -0.494 . . . . 0.0 110.826 179.998 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . -95.49 -127.74 5.32 Favored Glycine 0 N--CA 1.451 -0.322 0 C-N-CA 120.777 -0.725 . . . . 0.0 112.561 179.968 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 66' ' ' LYS . . . . . . . . . . . . . 0.6 OUTLIER -148.16 -50.04 0.17 Allowed 'General case' 0 C--N 1.328 -0.346 0 CA-C-O 120.833 0.349 . . . . 0.0 110.83 179.999 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 67' ' ' HIS . . . . . . . . . . . . . 6.7 p80 -123.1 168.06 12.87 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.154 -0.476 . . . . 0.0 110.833 179.969 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 9.2 p-10 -98.89 31.29 3.02 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.253 -0.431 . . . . 0.0 110.914 -179.984 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 100.36 -28.09 17.4 Favored Glycine 0 N--CA 1.451 -0.312 0 C-N-CA 120.653 -0.784 . . . . 0.0 112.486 -179.979 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 70' ' ' SER . . . . . . . . . . . . . 33.2 p -122.47 139.74 53.53 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-O 120.795 0.331 . . . . 0.0 110.867 -179.981 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 71' ' ' VAL . . . . . 0.658 HG12 ' CD2' ' A' ' 72' ' ' PHE . 21.5 t -124.99 116.81 48.27 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.224 -0.444 . . . . 0.0 111.029 179.988 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 72' ' ' PHE . . . . . 0.658 ' CD2' HG12 ' A' ' 71' ' ' VAL . 13.7 m-85 60.96 30.92 19.9 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.901 179.965 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 98.45 -28.52 14.5 Favored Glycine 0 N--CA 1.451 -0.33 0 C-N-CA 120.756 -0.735 . . . . 0.0 112.498 179.933 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 21.5 t -77.05 122.42 31.55 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.272 0 CA-C-O 120.876 0.369 . . . . 0.0 111.109 179.998 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 75' ' ' ARG . . . . . . . . . . . . . 3.4 ttt180 -95.3 146.34 24.44 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.925 179.982 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 76' ' ' TYR . . . . . 0.719 ' CE2' HG22 ' A' ' 48' ' ' THR . 72.8 m-85 -122.05 -45.0 2.27 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.884 179.968 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 77' ' ' PHE . . . . . . . . . . . . . 17.1 p90 -162.23 165.25 27.06 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.883 179.945 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 1.0 OUTLIER -89.65 103.05 15.73 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.976 179.974 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 79' ' ' CYS . . . . . . . . . . . . . 28.4 p -127.69 153.73 46.14 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.887 -179.969 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 80' ' ' ALA . . . . . 0.584 ' HB3' ' CG ' ' A' ' 83' ' ' HIS . . . -61.91 164.21 10.89 Favored Pre-proline 0 C--N 1.329 -0.308 0 CA-C-N 116.136 -0.484 . . . . 0.0 111.137 179.975 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 81' ' ' PRO . . . . . 0.443 ' HD2' ' HB1' ' A' ' 80' ' ' ALA . 51.0 Cg_exo -54.11 115.59 2.46 Favored 'Trans proline' 0 C--N 1.345 0.385 0 C-N-CA 122.578 2.185 . . . . 0.0 112.293 -179.949 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 82' ' ' ARG . . . . . . . . . . . . . 0.7 OUTLIER 61.59 53.64 3.25 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.852 179.953 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 83' ' ' HIS . . . . . 0.584 ' CG ' ' HB3' ' A' ' 80' ' ' ALA . 6.1 m170 -125.15 -44.52 1.89 Allowed 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.145 -0.479 . . . . 0.0 110.879 179.882 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . -67.23 130.24 29.43 Favored Glycine 0 N--CA 1.451 -0.311 0 C-N-CA 120.714 -0.755 . . . . 0.0 112.434 179.934 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 85' ' ' VAL . . . . . . . . . . . . . 5.1 m -134.29 121.67 37.98 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-O 120.856 0.36 . . . . 0.0 111.174 179.966 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 86' ' ' PHE . . . . . . . . . . . . . 7.9 m-85 -96.25 112.33 24.1 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.916 179.937 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 87' ' ' ALA . . . . . 0.515 ' O ' HD11 ' A' ' 92' ' ' ILE . . . -129.74 143.74 50.23 Favored Pre-proline 0 C--N 1.33 -0.28 0 CA-C-N 116.257 -0.429 . . . . 0.0 111.025 -179.94 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 88' ' ' PRO . . . . . 0.407 ' O ' ' N ' ' A' ' 91' ' ' ARG . 46.9 Cg_exo -56.03 140.52 86.5 Favored 'Trans proline' 0 C--N 1.346 0.406 0 C-N-CA 122.52 2.146 . . . . 0.0 112.317 -179.995 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 89' ' ' ALA . . . . . 0.695 ' HB1' ' HG3' ' A' ' 25' ' ' LYS . . . -47.96 -51.61 22.97 Favored 'General case' 0 CA--C 1.521 -0.136 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.255 179.901 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 90' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -55.82 -24.47 36.45 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 115.76 -0.655 . . . . 0.0 109.709 178.87 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 91' ' ' ARG . . . . . 0.407 ' N ' ' O ' ' A' ' 88' ' ' PRO . 0.0 OUTLIER -87.8 -15.31 37.24 Favored 'General case' 0 N--CA 1.455 -0.225 0 CA-C-N 115.834 -0.621 . . . . 0.0 110.415 179.022 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 92' ' ' ILE . . . . . 0.764 HD13 HD11 ' A' ' 58' ' ' ILE . 41.7 mt -108.66 150.57 11.28 Favored 'Isoleucine or valine' 0 N--CA 1.457 -0.105 0 CA-C-N 116.376 -0.375 . . . . 0.0 111.071 179.898 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 93' ' ' GLN . . . . . . . . . . . . . 32.8 mt-30 -120.06 161.4 21.03 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.918 -179.991 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 94' ' ' ARG . . . . . . . . . . . . . 1.1 mtt180 -101.15 126.35 47.85 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.247 -0.433 . . . . 0.0 110.885 179.963 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 95' ' ' ILE . . . . . 0.434 HD11 ' HB2' ' A' ' 33' ' ' LEU . 26.1 mm -75.12 -61.79 1.57 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 116.15 -0.477 . . . . 0.0 111.171 179.968 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . -77.7 69.55 2.6 Favored Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.791 -0.719 . . . . 0.0 112.479 -179.921 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 97' ' ' SER . . . . . . . . . . . . . 20.3 p -173.19 -170.48 0.63 Allowed 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.849 0.357 . . . . 0.0 110.839 -179.978 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 98' ' ' GLY . . . . . . . . . . . . . . . 128.64 83.8 0.39 Allowed Glycine 0 N--CA 1.452 -0.239 0 C-N-CA 120.729 -0.748 . . . . 0.0 112.506 -179.921 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 99' ' ' PRO . . . . . . . . . . . . . 55.2 Cg_endo -69.79 81.33 0.83 Allowed 'Trans proline' 0 C--N 1.344 0.332 0 C-N-CA 122.557 2.171 . . . . 0.0 112.353 179.978 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 100' ' ' SER . . . . . . . . . . . . . 58.7 p -91.67 116.77 29.15 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.943 -179.933 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 56.4 p -64.45 -52.53 57.56 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.211 -0.449 . . . . 0.0 110.898 -180.0 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.25 1.116 0 CA-C-O 118.42 -1.211 . . . . 0.0 112.465 179.914 . . . . . . . . 0 0 . 1 . 018 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.231 0 N-CA-C 112.494 -0.243 . . . . 0.0 112.494 . . . . . . . . . 0 0 . 1 . 018 nuclear build full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -160.21 126.71 4.26 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-O 120.882 0.373 . . . . 0.0 110.97 179.981 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 5.7 m -70.14 85.7 0.55 Allowed 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.899 -179.958 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -122.59 -179.66 15.92 Favored Glycine 0 N--CA 1.451 -0.353 0 C-N-CA 120.734 -0.746 . . . . 0.0 112.578 -180.0 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 25.8 t -136.02 134.4 38.47 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-O 120.804 0.335 . . . . 0.0 110.837 -179.985 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -95.26 -51.0 4.79 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.847 -179.981 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -136.39 136.08 8.16 Favored Glycine 0 N--CA 1.452 -0.288 0 C-N-CA 120.712 -0.756 . . . . 0.0 112.473 -179.946 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 7.5 pttt -60.28 -175.84 0.04 OUTLIER 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 120.766 0.317 . . . . 0.0 110.97 179.968 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 9' ' ' SER . . . . . 0.433 ' CB ' ' CD ' ' A' ' 10' ' ' PRO . 1.3 m -171.73 -63.12 0.0 OUTLIER Pre-proline 0 C--N 1.33 -0.277 0 CA-C-N 116.337 -0.392 . . . . 0.0 110.896 179.908 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 10' ' ' PRO . . . . . 0.433 ' CD ' ' CB ' ' A' ' 9' ' ' SER . 55.7 Cg_endo -69.96 113.87 3.55 Favored 'Trans proline' 0 C--N 1.347 0.448 0 C-N-CA 122.383 2.055 . . . . 0.0 112.278 179.913 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -114.56 140.0 49.13 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.255 -0.43 . . . . 0.0 110.9 -179.972 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -122.46 106.16 35.55 Favored Pre-proline 0 C--N 1.33 -0.274 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.85 -179.969 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 73.8 Cg_exo -49.21 -61.94 0.5 Allowed 'Trans proline' 0 C--N 1.346 0.431 0 C-N-CA 122.43 2.086 . . . . 0.0 112.425 179.987 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 4.6 t 56.65 -168.49 0.1 Allowed 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 116.312 -0.404 . . . . 0.0 110.924 -179.935 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 0.9 OUTLIER -157.6 81.22 0.88 Allowed 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.299 -0.41 . . . . 0.0 110.993 179.961 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 83.54 -89.09 1.52 Allowed Glycine 0 N--CA 1.451 -0.326 0 C-N-CA 120.744 -0.741 . . . . 0.0 112.548 -179.992 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 12.7 m -154.36 104.74 2.61 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-O 120.768 0.318 . . . . 0.0 110.851 -179.998 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 3.4 mt -133.19 -59.35 0.88 Allowed 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.275 -0.42 . . . . 0.0 110.958 -179.962 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 19' ' ' GLN . . . . . . . . . . . . . 5.3 mt-30 -80.54 87.99 5.7 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.971 179.97 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 20' ' ' GLN . . . . . . . . . . . . . 15.0 mt-30 -132.6 119.15 20.08 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.946 -179.958 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 5.9 ptm180 -113.75 133.76 55.17 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.906 -179.993 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -154.66 148.32 25.37 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.873 -179.969 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -69.94 135.18 26.05 Favored Glycine 0 N--CA 1.451 -0.337 0 C-N-CA 120.77 -0.729 . . . . 0.0 112.527 -179.974 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -110.34 143.62 40.3 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 120.769 0.319 . . . . 0.0 111.129 179.973 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 25' ' ' LYS . . . . . 0.404 ' HG3' ' HB1' ' A' ' 89' ' ' ALA . 1.6 mmpt? -73.55 -64.12 1.06 Allowed 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.247 -0.433 . . . . 0.0 110.891 -179.957 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 26' ' ' ALA . . . . . 0.705 ' HB2' ' HG2' ' A' ' 94' ' ' ARG . . . -131.51 -176.37 4.01 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.162 -0.472 . . . . 0.0 111.071 179.958 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 27' ' ' GLU . . . . . . . . . . . . . 3.7 mt-10 -138.84 171.38 14.42 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.084 -0.507 . . . . 0.0 110.841 -179.964 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 28.1 t -65.97 109.71 1.16 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 116.097 -0.501 . . . . 0.0 111.02 -179.999 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 112.85 29.85 2.96 Favored Glycine 0 N--CA 1.452 -0.254 0 C-N-CA 120.756 -0.735 . . . . 0.0 112.516 -179.986 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 30' ' ' ASP . . . . . 0.684 ' O ' HG23 ' A' ' 41' ' ' ILE . 1.2 t0 -137.48 164.69 28.09 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-O 120.823 0.344 . . . . 0.0 110.878 179.942 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 31' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -83.11 131.72 35.13 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.25 -0.432 . . . . 0.0 110.927 179.966 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 15.3 m -139.74 179.53 2.75 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 116.329 -0.396 . . . . 0.0 111.136 179.957 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 33' ' ' LEU . . . . . 0.414 HD23 ' HA2' ' A' ' 36' ' ' GLY . 22.7 tp -143.45 102.02 3.88 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.158 -0.473 . . . . 0.0 110.812 179.97 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 34' ' ' VAL . . . . . 0.49 HG22 HD12 ' A' ' 58' ' ' ILE . 21.5 t -70.5 124.19 26.11 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.202 -0.454 . . . . 0.0 111.2 179.99 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 35' ' ' ALA . . . . . . . . . . . . . . . 58.57 25.51 13.24 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.228 -0.442 . . . . 0.0 111.264 179.942 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 36' ' ' GLY . . . . . 0.414 ' HA2' HD23 ' A' ' 33' ' ' LEU . . . 55.42 27.22 47.0 Favored Glycine 0 N--CA 1.452 -0.242 0 C-N-CA 120.852 -0.69 . . . . 0.0 112.587 179.984 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 37' ' ' GLN . . . . . . . . . . . . . 64.5 mt-30 -138.22 -64.86 0.52 Allowed 'General case' 0 C--N 1.329 -0.311 0 CA-C-O 120.704 0.287 . . . . 0.0 110.927 179.948 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 38' ' ' LYS . . . . . . . . . . . . . 64.3 mttt -72.38 112.64 8.62 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 116.294 -0.412 . . . . 0.0 110.877 179.954 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 39' ' ' GLN . . . . . . . . . . . . . 1.4 tm0? -91.82 117.26 29.61 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.836 179.991 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -145.14 -166.07 11.52 Favored Glycine 0 N--CA 1.451 -0.304 0 C-N-CA 120.747 -0.739 . . . . 0.0 112.468 -179.993 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 41' ' ' ILE . . . . . 0.684 HG23 ' O ' ' A' ' 30' ' ' ASP . 31.3 mt -131.17 132.58 63.25 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.25 0 CA-C-O 120.839 0.352 . . . . 0.0 111.105 -179.992 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 42' ' ' VAL . . . . . . . . . . . . . 21.5 t -60.4 121.46 8.27 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.261 -0.427 . . . . 0.0 111.086 179.962 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 43' ' ' ARG . . . . . . . . . . . . . 3.6 mmm-85 -104.14 -31.48 9.62 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.898 -179.941 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 44' ' ' PHE . . . . . 0.427 ' CD1' ' HB3' ' A' ' 76' ' ' TYR . 41.3 t80 -148.3 115.6 6.2 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.97 -179.947 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 45' ' ' TYR . . . . . 0.454 ' CE1' ' CE1' ' A' ' 56' ' ' TYR . 25.8 t80 -114.7 123.35 49.06 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.895 -179.986 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 171.03 -149.3 12.16 Favored Glycine 0 N--CA 1.451 -0.361 0 C-N-CA 120.671 -0.776 . . . . 0.0 112.449 179.956 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 47' ' ' LYS . . . . . . . . . . . . . 7.0 mttt -99.15 164.59 12.09 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-O 120.849 0.357 . . . . 0.0 110.975 -179.962 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 48' ' ' THR . . . . . 0.428 HG21 ' CZ ' ' A' ' 50' ' ' PHE . 13.2 p -129.68 -176.02 3.78 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.823 -179.982 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -112.98 -33.41 6.06 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.973 -179.89 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 50' ' ' PHE . . . . . 0.428 ' CZ ' HG21 ' A' ' 48' ' ' THR . 8.7 p90 -67.31 -30.51 70.37 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.24 -0.436 . . . . 0.0 111.016 -179.893 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 51' ' ' ALA . . . . . 0.42 ' N ' ' CD1' ' A' ' 50' ' ' PHE . . . -148.44 146.2 22.13 Favored Pre-proline 0 C--N 1.329 -0.314 0 CA-C-N 116.324 -0.398 . . . . 0.0 111.17 -179.906 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 52' ' ' PRO . . . . . . . . . . . . . 72.3 Cg_endo -74.95 -178.46 4.17 Favored 'Trans proline' 0 C--N 1.345 0.371 0 C-N-CA 122.584 2.189 . . . . 0.0 112.352 -179.991 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 76.78 -168.01 54.63 Favored Glycine 0 N--CA 1.451 -0.363 0 C-N-CA 120.778 -0.725 . . . . 0.0 112.515 179.954 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 54' ' ' TYR . . . . . . . . . . . . . 20.6 m-85 -101.59 149.56 23.99 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-O 120.837 0.351 . . . . 0.0 110.87 -179.929 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 55' ' ' TRP . . . . . . . . . . . . . 69.4 m95 -145.81 156.41 43.56 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.187 -0.461 . . . . 0.0 110.943 179.946 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 56' ' ' TYR . . . . . 0.454 ' CE1' ' CE1' ' A' ' 45' ' ' TYR . 25.2 m-85 -110.24 124.92 52.49 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.288 -0.415 . . . . 0.0 110.947 -179.947 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . -90.08 60.39 3.43 Favored Glycine 0 N--CA 1.45 -0.368 0 C-N-CA 120.768 -0.73 . . . . 0.0 112.414 179.9 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 58' ' ' ILE . . . . . 0.533 HG23 ' C ' ' A' ' 41' ' ' ILE . 21.2 mt -73.53 137.68 22.82 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-O 120.871 0.367 . . . . 0.0 111.073 -179.957 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 0.2 OUTLIER -103.89 133.27 49.14 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.084 -0.507 . . . . 0.0 110.845 -179.991 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 60' ' ' LEU . . . . . . . . . . . . . 56.5 mt -88.15 174.75 8.05 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.903 179.952 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 2.7 m-20 -100.59 -30.8 11.57 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.976 179.963 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 62' ' ' GLN . . . . . . . . . . . . . 0.8 OUTLIER -106.4 153.5 40.43 Favored Pre-proline 0 C--N 1.331 -0.239 0 CA-C-N 116.178 -0.464 . . . . 0.0 110.924 -179.971 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 73.6 Cg_endo -75.81 64.22 6.72 Favored 'Trans proline' 0 C--N 1.344 0.31 0 C-N-CA 122.613 2.209 . . . . 0.0 112.323 -179.857 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 64' ' ' THR . . . . . . . . . . . . . 7.5 t -147.01 38.55 0.99 Allowed 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.899 179.975 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . -86.57 -111.72 0.86 Allowed Glycine 0 N--CA 1.451 -0.313 0 C-N-CA 120.767 -0.73 . . . . 0.0 112.559 179.98 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 66' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -147.71 -47.27 0.17 Allowed 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.819 0.343 . . . . 0.0 110.893 179.992 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 67' ' ' HIS . . . . . 0.514 ' ND1' HG22 ' A' ' 71' ' ' VAL . 15.7 p80 -141.99 -176.0 4.63 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.865 179.96 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -89.32 -168.83 2.28 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.833 179.987 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . -63.39 -27.6 71.01 Favored Glycine 0 N--CA 1.451 -0.363 0 C-N-CA 120.695 -0.765 . . . . 0.0 112.473 -179.934 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 70' ' ' SER . . . . . . . . . . . . . 4.0 p -116.98 147.66 42.11 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 120.8 0.333 . . . . 0.0 110.897 -179.94 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 71' ' ' VAL . . . . . 0.514 HG22 ' ND1' ' A' ' 67' ' ' HIS . 28.2 t -127.12 119.86 53.89 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.103 179.929 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 72' ' ' PHE . . . . . . . . . . . . . 5.4 m-85 60.57 30.82 20.02 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.887 -179.948 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 94.91 -15.76 62.72 Favored Glycine 0 N--CA 1.451 -0.318 0 C-N-CA 120.713 -0.756 . . . . 0.0 112.721 -179.999 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 25.3 t -87.9 113.08 24.48 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-O 120.807 0.337 . . . . 0.0 111.169 -179.938 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 75' ' ' ARG . . . . . . . . . . . . . 6.4 ttm105 -95.06 114.7 26.54 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.762 179.885 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 76' ' ' TYR . . . . . 0.427 ' HB3' ' CD1' ' A' ' 44' ' ' PHE . 26.0 m-85 -96.7 -34.97 11.17 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.988 -179.853 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 77' ' ' PHE . . . . . . . . . . . . . 51.6 p90 -162.6 159.52 24.7 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 116.316 -0.402 . . . . 0.0 111.021 -179.907 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 26.0 m -87.62 140.82 29.13 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.922 179.917 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 79' ' ' CYS . . . . . . . . . . . . . 30.7 p -164.67 -175.6 3.9 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.263 -0.426 . . . . 0.0 110.915 179.965 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 80' ' ' ALA . . . . . 0.533 ' HB1' ' HD2' ' A' ' 81' ' ' PRO . . . -96.62 166.45 14.05 Favored Pre-proline 0 C--N 1.328 -0.328 0 CA-C-N 116.166 -0.47 . . . . 0.0 111.102 -179.97 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 81' ' ' PRO . . . . . 0.533 ' HD2' ' HB1' ' A' ' 80' ' ' ALA . 50.6 Cg_exo -53.21 120.55 7.92 Favored 'Trans proline' 0 C--N 1.344 0.298 0 C-N-CA 122.627 2.218 . . . . 0.0 112.297 179.96 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 82' ' ' ARG . . . . . . . . . . . . . 37.8 mtp85 62.45 61.46 1.25 Allowed 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.953 -179.967 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 83' ' ' HIS . . . . . . . . . . . . . 4.5 m-70 -130.79 -51.13 1.05 Allowed 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.866 -179.985 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . -63.51 143.54 48.21 Favored Glycine 0 N--CA 1.45 -0.367 0 C-N-CA 120.753 -0.736 . . . . 0.0 112.541 179.972 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 85' ' ' VAL . . . . . . . . . . . . . 5.1 m -145.92 118.16 2.12 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-O 120.829 0.347 . . . . 0.0 111.061 -179.974 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 86' ' ' PHE . . . . . . . . . . . . . 6.6 m-85 -96.45 105.93 18.1 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.847 179.973 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 87' ' ' ALA . . . . . 0.562 ' O ' HD11 ' A' ' 92' ' ' ILE . . . -126.0 142.76 43.35 Favored Pre-proline 0 C--N 1.328 -0.339 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.091 179.954 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 88' ' ' PRO . . . . . 0.411 ' O ' ' N ' ' A' ' 91' ' ' ARG . 31.2 Cg_exo -58.88 146.18 94.28 Favored 'Trans proline' 0 C--N 1.347 0.461 0 C-N-CA 122.468 2.112 . . . . 0.0 112.344 -179.999 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 89' ' ' ALA . . . . . 0.404 ' HB1' ' HG3' ' A' ' 25' ' ' LYS . . . -48.38 -51.31 27.1 Favored 'General case' 0 C--N 1.333 -0.133 0 CA-C-O 121.08 0.467 . . . . 0.0 110.263 179.769 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 90' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -56.02 -24.4 38.93 Favored 'General case' 0 N--CA 1.454 -0.225 0 CA-C-N 115.648 -0.705 . . . . 0.0 109.789 178.732 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 91' ' ' ARG . . . . . 0.411 ' N ' ' O ' ' A' ' 88' ' ' PRO . 0.1 OUTLIER -88.44 -15.01 36.53 Favored 'General case' 0 N--CA 1.454 -0.254 0 CA-C-N 115.876 -0.602 . . . . 0.0 110.348 179.077 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 92' ' ' ILE . . . . . 0.562 HD11 ' O ' ' A' ' 87' ' ' ALA . 43.1 mt -108.77 158.31 8.65 Favored 'Isoleucine or valine' 0 C--O 1.231 0.081 0 CA-C-N 116.334 -0.394 . . . . 0.0 111.017 179.784 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 93' ' ' GLN . . . . . 0.487 ' N ' HG22 ' A' ' 92' ' ' ILE . 3.4 mt-30 -124.78 162.72 23.67 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.246 -0.434 . . . . 0.0 110.898 -179.886 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 94' ' ' ARG . . . . . 0.705 ' HG2' ' HB2' ' A' ' 26' ' ' ALA . 0.0 OUTLIER -112.65 127.17 56.03 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.113 -0.494 . . . . 0.0 110.838 -179.993 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 95' ' ' ILE . . . . . . . . . . . . . 33.0 mt -98.44 -32.01 3.8 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.187 -0.461 . . . . 0.0 111.022 179.962 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . -66.51 157.4 50.13 Favored Glycine 0 N--CA 1.451 -0.304 0 C-N-CA 120.809 -0.71 . . . . 0.0 112.408 -179.964 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 97' ' ' SER . . . . . . . . . . . . . 7.1 t -102.05 95.95 6.69 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-O 120.78 0.324 . . . . 0.0 110.949 179.972 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 98' ' ' GLY . . . . . . . . . . . . . . . -135.63 -169.8 11.92 Favored Glycine 0 N--CA 1.451 -0.3 0 C-N-CA 120.686 -0.769 . . . . 0.0 112.446 -179.985 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 99' ' ' PRO . . . . . . . . . . . . . 55.9 Cg_endo -70.1 91.1 0.55 Allowed 'Trans proline' 0 C--N 1.345 0.349 0 C-N-CA 122.576 2.184 . . . . 0.0 112.35 179.985 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 100' ' ' SER . . . . . . . . . . . . . 80.1 p -165.89 144.14 5.82 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.22 -0.446 . . . . 0.0 110.911 -179.962 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER 60.29 166.38 0.07 Allowed 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.863 179.975 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.25 1.123 0 CA-C-O 118.421 -1.211 . . . . 0.0 112.497 -180.0 . . . . . . . . 0 0 . 1 . 019 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.221 0 N-CA-C 112.487 -0.245 . . . . 0.0 112.487 . . . . . . . . . 0 0 . 1 . 019 nuclear build full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 1.1 m -149.88 95.85 2.37 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-O 120.828 0.347 . . . . 0.0 110.906 -179.941 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 96.2 p -164.18 -44.14 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.909 -179.993 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 96.76 -29.49 10.4 Favored Glycine 0 N--CA 1.45 -0.379 0 C-N-CA 120.742 -0.742 . . . . 0.0 112.479 179.959 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 19.2 m -124.4 -61.94 1.3 Allowed 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 120.838 0.351 . . . . 0.0 110.939 -179.958 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER 59.47 89.38 0.06 Allowed 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.885 179.988 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 114.98 151.14 10.02 Favored Glycine 0 N--CA 1.451 -0.301 0 C-N-CA 120.816 -0.707 . . . . 0.0 112.45 -179.941 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER 177.06 -35.17 0.01 OUTLIER 'General case' 0 C--N 1.331 -0.238 0 CA-C-O 120.769 0.319 . . . . 0.0 110.868 -179.966 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 9' ' ' SER . . . . . 0.4 ' N ' ' CD ' ' A' ' 10' ' ' PRO . 1.1 m 64.45 53.84 1.33 Allowed Pre-proline 0 C--N 1.33 -0.247 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.979 -179.88 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 10' ' ' PRO . . . . . 0.4 ' CD ' ' N ' ' A' ' 9' ' ' SER . 71.5 Cg_endo -74.59 -39.58 1.37 Allowed 'Trans proline' 0 C--N 1.345 0.346 0 C-N-CA 122.583 2.189 . . . . 0.0 112.233 179.973 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 23.0 m -153.08 -178.08 6.71 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.81 -179.951 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -137.45 87.6 17.68 Favored Pre-proline 0 C--N 1.33 -0.279 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.941 179.971 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 53.3 Cg_exo -52.38 -34.51 61.2 Favored 'Trans proline' 0 C--N 1.345 0.367 0 C-N-CA 122.535 2.157 . . . . 0.0 112.345 179.975 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 8.5 t -130.1 139.74 50.9 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.928 179.961 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 5.3 tp -153.68 -52.72 0.1 Allowed 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.894 -179.953 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -172.29 51.95 0.17 Allowed Glycine 0 N--CA 1.452 -0.261 0 C-N-CA 120.768 -0.73 . . . . 0.0 112.439 179.976 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 7.9 t 59.39 24.62 13.23 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-O 120.752 0.311 . . . . 0.0 111.029 179.994 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 0.6 OUTLIER 56.32 22.59 6.43 Favored 'General case' 0 C--N 1.331 -0.225 0 CA-C-N 116.337 -0.392 . . . . 0.0 111.25 179.974 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 19' ' ' GLN . . . . . . . . . . . . . 1.2 tp-100 51.94 93.42 0.02 OUTLIER 'General case' 0 C--N 1.332 -0.187 0 CA-C-N 116.416 -0.356 . . . . 0.0 111.055 179.907 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 20' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -144.25 -55.37 0.35 Allowed 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.322 -0.399 . . . . 0.0 110.973 179.921 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 0.6 OUTLIER -67.74 89.55 0.26 Allowed 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.257 -0.429 . . . . 0.0 110.869 180.0 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 22.1 mm-40 -108.93 31.13 5.92 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.843 -179.943 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 65.95 90.81 0.04 OUTLIER Glycine 0 N--CA 1.451 -0.324 0 C-N-CA 120.729 -0.748 . . . . 0.0 112.489 -179.95 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -148.51 110.64 4.61 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-O 120.885 0.374 . . . . 0.0 111.095 179.968 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -68.85 -68.37 0.4 Allowed 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.869 179.924 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -109.66 174.92 5.64 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.211 -0.449 . . . . 0.0 111.105 179.998 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 27' ' ' GLU . . . . . . . . . . . . . 16.4 mt-10 -133.92 179.77 6.04 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.917 -179.975 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 21.5 t -75.32 93.16 0.85 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.091 -179.981 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 121.72 44.84 0.36 Allowed Glycine 0 N--CA 1.451 -0.36 0 C-N-CA 120.843 -0.694 . . . . 0.0 112.489 179.972 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -144.77 158.21 43.87 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-O 120.832 0.349 . . . . 0.0 110.933 -179.991 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 31' ' ' GLN . . . . . . . . . . . . . 0.2 OUTLIER -77.56 126.03 30.26 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.82 -179.911 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 32' ' ' VAL . . . . . 0.457 HG21 HG12 ' A' ' 58' ' ' ILE . 16.2 m -129.34 175.63 10.11 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.262 -0.427 . . . . 0.0 111.158 179.983 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 33' ' ' LEU . . . . . 0.525 HD11 ' O ' ' A' ' 37' ' ' GLN . 25.6 tp -144.92 101.86 3.69 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.244 -0.434 . . . . 0.0 110.926 179.936 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 21.5 t -69.42 123.02 22.13 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.171 -179.958 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 35' ' ' ALA . . . . . . . . . . . . . . . 58.2 25.73 12.93 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.279 179.977 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . 56.13 32.75 60.2 Favored Glycine 0 N--CA 1.452 -0.294 0 C-N-CA 120.731 -0.747 . . . . 0.0 112.636 -179.99 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 37' ' ' GLN . . . . . 0.525 ' O ' HD11 ' A' ' 33' ' ' LEU . 11.3 mt-30 -142.9 -73.9 0.29 Allowed 'General case' 0 C--N 1.329 -0.319 0 CA-C-O 120.847 0.356 . . . . 0.0 110.974 -179.968 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 38' ' ' LYS . . . . . . . . . . . . . 4.6 mttp -64.35 109.6 1.97 Allowed 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.918 -179.973 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 39' ' ' GLN . . . . . . . . . . . . . 14.3 tm0? -85.32 129.38 34.82 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.254 -0.43 . . . . 0.0 110.905 179.982 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -156.13 -178.15 30.02 Favored Glycine 0 N--CA 1.45 -0.371 0 C-N-CA 120.683 -0.77 . . . . 0.0 112.524 -179.971 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 27.9 mm -123.12 138.18 53.98 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-O 120.731 0.3 . . . . 0.0 111.114 -179.983 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 42' ' ' VAL . . . . . . . . . . . . . 26.2 t -62.79 121.11 10.96 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 116.252 -0.431 . . . . 0.0 111.101 179.982 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 43' ' ' ARG . . . . . . . . . . . . . 3.1 mmt180 -107.33 -34.16 7.17 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.922 -179.983 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 44' ' ' PHE . . . . . 0.403 ' CD1' ' HB3' ' A' ' 76' ' ' TYR . 25.8 t80 -145.04 116.27 7.96 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.905 -179.978 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 45' ' ' TYR . . . . . . . . . . . . . 15.4 t80 -111.09 127.1 55.45 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.901 -179.985 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 166.88 -161.49 35.3 Favored Glycine 0 N--CA 1.45 -0.384 0 C-N-CA 120.774 -0.726 . . . . 0.0 112.531 179.992 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 47' ' ' LYS . . . . . . . . . . . . . 46.5 mttt -96.88 158.11 15.58 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-O 120.816 0.341 . . . . 0.0 110.837 -179.975 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 48' ' ' THR . . . . . 0.453 HG21 ' CZ ' ' A' ' 50' ' ' PHE . 28.4 p -120.75 168.25 11.62 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.165 -0.471 . . . . 0.0 110.848 179.895 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -91.69 -29.18 16.99 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.207 -0.452 . . . . 0.0 110.972 179.969 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 50' ' ' PHE . . . . . 0.453 ' CZ ' HG21 ' A' ' 48' ' ' THR . 37.5 p90 -74.92 -32.33 61.77 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.273 -0.421 . . . . 0.0 111.055 -179.929 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 51' ' ' ALA . . . . . . . . . . . . . . . -142.1 143.35 27.55 Favored Pre-proline 0 C--N 1.33 -0.264 0 CA-C-N 116.304 -0.407 . . . . 0.0 111.128 -179.965 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 52' ' ' PRO . . . . . . . . . . . . . 73.8 Cg_endo -77.33 -168.06 0.55 Allowed 'Trans proline' 0 C--N 1.346 0.404 0 C-N-CA 122.669 2.246 . . . . 0.0 112.325 -179.978 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 70.94 -155.15 52.68 Favored Glycine 0 N--CA 1.451 -0.346 0 C-N-CA 120.722 -0.751 . . . . 0.0 112.527 179.917 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 54' ' ' TYR . . . . . . . . . . . . . 41.4 m-85 -119.04 125.23 48.85 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-O 120.793 0.33 . . . . 0.0 110.906 -179.982 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 55' ' ' TRP . . . . . . . . . . . . . 63.8 m95 -117.4 168.5 10.3 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.909 179.967 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 56' ' ' TYR . . . . . 0.653 ' HE1' ' HB2' ' A' ' 89' ' ' ALA . 6.5 m-85 -124.6 119.56 29.4 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.254 -0.43 . . . . 0.0 110.939 -179.951 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 57' ' ' GLY . . . . . 0.454 ' CA ' ' CE1' ' A' ' 86' ' ' PHE . . . -84.1 62.43 4.59 Favored Glycine 0 N--CA 1.451 -0.366 0 C-N-CA 120.771 -0.728 . . . . 0.0 112.543 179.956 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 58' ' ' ILE . . . . . 0.628 HD11 HD13 ' A' ' 92' ' ' ILE . 7.2 mt -68.53 142.84 15.77 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-O 120.868 0.366 . . . . 0.0 111.035 179.995 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 4.7 tm-20 -109.13 110.1 21.25 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.921 179.948 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 60' ' ' LEU . . . . . . . . . . . . . 84.2 mt -68.6 176.33 3.0 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.863 -179.973 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -101.33 -32.18 10.6 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.896 -179.948 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 62' ' ' GLN . . . . . . . . . . . . . 6.3 mt-30 -102.2 162.78 19.25 Favored Pre-proline 0 C--N 1.329 -0.285 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.927 -179.97 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 98.7 Cg_endo -79.52 58.26 6.88 Favored 'Trans proline' 0 C--N 1.344 0.332 0 C-N-CA 122.663 2.242 . . . . 0.0 112.477 -179.996 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 64' ' ' THR . . . . . . . . . . . . . 20.8 p -133.4 32.12 3.69 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.949 179.993 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . -81.98 -117.28 0.48 Allowed Glycine 0 N--CA 1.451 -0.308 0 C-N-CA 120.751 -0.738 . . . . 0.0 112.454 179.976 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 66' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -155.17 -48.05 0.08 Allowed 'General case' 0 C--N 1.33 -0.263 0 CA-C-O 120.868 0.366 . . . . 0.0 110.899 179.917 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 67' ' ' HIS . . . . . . . . . . . . . 7.9 p80 -127.08 169.5 13.33 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 116.156 -0.474 . . . . 0.0 110.81 179.923 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 1.8 m-20 -97.81 36.07 1.59 Allowed 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.255 -0.43 . . . . 0.0 110.91 179.969 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 95.81 -39.57 2.81 Favored Glycine 0 N--CA 1.451 -0.355 0 C-N-CA 120.697 -0.763 . . . . 0.0 112.549 -179.984 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 70' ' ' SER . . . . . . . . . . . . . 11.6 p -101.1 127.23 47.73 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 120.741 0.305 . . . . 0.0 110.911 179.982 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 71' ' ' VAL . . . . . 0.418 HG12 ' CD2' ' A' ' 72' ' ' PHE . 21.5 t -115.07 111.01 34.06 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.349 0 CA-C-N 116.202 -0.454 . . . . 0.0 111.128 179.964 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 72' ' ' PHE . . . . . 0.418 ' CD2' HG12 ' A' ' 71' ' ' VAL . 30.2 m-85 61.44 30.66 18.99 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.891 179.966 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 99.1 -28.79 13.66 Favored Glycine 0 N--CA 1.451 -0.356 0 C-N-CA 120.741 -0.742 . . . . 0.0 112.463 179.951 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 27.8 t -80.55 121.71 34.47 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-O 120.881 0.372 . . . . 0.0 111.075 179.952 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 75' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -106.35 142.07 36.64 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.817 -179.937 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 76' ' ' TYR . . . . . 0.403 ' HB3' ' CD1' ' A' ' 44' ' ' PHE . 8.2 m-85 -115.42 -46.8 2.86 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.123 -0.49 . . . . 0.0 110.855 179.954 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 77' ' ' PHE . . . . . 0.433 ' CE1' ' HA3' ' A' ' 57' ' ' GLY . 35.1 p90 -146.9 177.29 9.25 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 116.263 -0.426 . . . . 0.0 110.879 179.982 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 0.9 OUTLIER -104.69 124.36 49.23 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.875 -179.964 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 79' ' ' CYS . . . . . . . . . . . . . 10.8 p -144.97 167.42 22.68 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.118 -0.492 . . . . 0.0 110.893 179.977 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 80' ' ' ALA . . . . . 0.511 ' HB1' ' HD2' ' A' ' 81' ' ' PRO . . . -75.51 166.44 45.3 Favored Pre-proline 0 C--N 1.33 -0.255 0 CA-C-N 116.228 -0.442 . . . . 0.0 111.075 -179.958 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 81' ' ' PRO . . . . . 0.511 ' HD2' ' HB1' ' A' ' 80' ' ' ALA . 51.2 Cg_exo -52.85 116.6 3.01 Favored 'Trans proline' 0 C--N 1.345 0.346 0 C-N-CA 122.572 2.181 . . . . 0.0 112.318 179.916 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 82' ' ' ARG . . . . . . . . . . . . . 0.5 OUTLIER 61.39 56.74 2.54 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.84 179.897 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 83' ' ' HIS . . . . . 0.505 ' CG ' ' HB3' ' A' ' 80' ' ' ALA . 6.2 m170 -126.36 -47.76 1.58 Allowed 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.925 179.953 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . -61.91 139.33 46.43 Favored Glycine 0 N--CA 1.451 -0.353 0 C-N-CA 120.699 -0.763 . . . . 0.0 112.56 179.915 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 85' ' ' VAL . . . . . . . . . . . . . 5.8 m -140.28 127.99 24.25 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.326 0 CA-C-O 120.774 0.321 . . . . 0.0 111.126 -179.911 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 86' ' ' PHE . . . . . 0.454 ' CE1' ' CA ' ' A' ' 57' ' ' GLY . 9.1 m-85 -110.26 112.45 24.42 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.189 -0.459 . . . . 0.0 110.871 179.926 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 87' ' ' ALA . . . . . 0.526 ' O ' HD11 ' A' ' 92' ' ' ILE . . . -134.86 149.45 70.6 Favored Pre-proline 0 C--N 1.329 -0.286 0 CA-C-N 116.303 -0.408 . . . . 0.0 111.213 179.966 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 88' ' ' PRO . . . . . 0.412 ' O ' ' N ' ' A' ' 91' ' ' ARG . 32.5 Cg_exo -58.08 140.53 94.41 Favored 'Trans proline' 0 C--N 1.345 0.356 0 C-N-CA 122.596 2.197 . . . . 0.0 112.27 -179.92 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 89' ' ' ALA . . . . . 0.653 ' HB2' ' HE1' ' A' ' 56' ' ' TYR . . . -47.79 -51.69 21.61 Favored 'General case' 0 C--N 1.332 -0.165 0 CA-C-O 121.06 0.457 . . . . 0.0 110.299 179.916 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 90' ' ' SER . . . . . . . . . . . . . 14.9 m -55.71 -24.5 35.06 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 115.731 -0.668 . . . . 0.0 109.734 178.788 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 91' ' ' ARG . . . . . 0.412 ' N ' ' O ' ' A' ' 88' ' ' PRO . 0.2 OUTLIER -88.76 -15.14 35.46 Favored 'General case' 0 N--CA 1.454 -0.229 0 CA-C-N 115.889 -0.596 . . . . 0.0 110.438 179.089 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 92' ' ' ILE . . . . . 0.628 HD13 HD11 ' A' ' 58' ' ' ILE . 48.4 mt -107.03 144.88 15.26 Favored 'Isoleucine or valine' 0 C--N 1.334 -0.104 0 CA-C-N 116.413 -0.358 . . . . 0.0 111.047 179.913 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 93' ' ' GLN . . . . . . . . . . . . . 9.1 mt-30 -115.65 -179.94 3.79 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.167 -0.469 . . . . 0.0 110.866 -179.997 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 94' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -125.77 134.99 51.55 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.202 -0.453 . . . . 0.0 110.996 -179.954 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 95' ' ' ILE . . . . . . . . . . . . . 5.0 mt -105.26 -37.34 4.09 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.22 -0.446 . . . . 0.0 111.108 179.952 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . 86.21 -78.23 1.96 Allowed Glycine 0 N--CA 1.45 -0.367 0 C-N-CA 120.746 -0.74 . . . . 0.0 112.449 179.925 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 97' ' ' SER . . . . . . . . . . . . . 74.3 p -126.63 127.79 45.75 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-O 120.779 0.323 . . . . 0.0 110.912 -179.981 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 98' ' ' GLY . . . . . . . . . . . . . . . -126.99 95.27 0.43 Allowed Glycine 0 N--CA 1.452 -0.259 0 C-N-CA 120.756 -0.735 . . . . 0.0 112.46 -179.953 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 99' ' ' PRO . . . . . . . . . . . . . 43.4 Cg_endo -68.1 147.22 72.85 Favored 'Trans proline' 0 C--N 1.345 0.385 0 C-N-CA 122.514 2.143 . . . . 0.0 112.261 179.972 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 100' ' ' SER . . . . . . . . . . . . . 18.3 m 63.93 136.11 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.863 -179.939 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 1.2 m 60.91 101.0 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.873 179.967 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.25 1.121 0 CA-C-O 118.384 -1.231 . . . . 0.0 112.495 -179.986 . . . . . . . . 0 0 . 1 . 020 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.241 0 N-CA-C 112.472 -0.251 . . . . 0.0 112.472 . . . . . . . . . 0 0 . 1 . 020 nuclear build full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 3.4 m -116.83 30.75 7.15 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 120.821 0.344 . . . . 0.0 110.926 -179.971 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER 59.16 31.03 20.92 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.98 179.99 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -68.06 114.54 6.16 Favored Glycine 0 N--CA 1.451 -0.322 0 C-N-CA 120.674 -0.774 . . . . 0.0 112.511 179.948 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 43.8 t -169.36 34.3 0.02 OUTLIER 'General case' 0 C--N 1.33 -0.276 0 CA-C-O 120.82 0.343 . . . . 0.0 110.931 179.99 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 58.4 m -98.51 -32.45 11.46 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.875 -179.958 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -155.49 172.94 33.66 Favored Glycine 0 N--CA 1.451 -0.329 0 C-N-CA 120.746 -0.74 . . . . 0.0 112.509 179.998 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 0.3 OUTLIER -66.46 94.59 0.28 Allowed 'General case' 0 C--N 1.329 -0.283 0 CA-C-O 120.773 0.32 . . . . 0.0 110.843 -179.97 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -83.31 109.48 17.91 Favored Pre-proline 0 C--N 1.328 -0.346 0 CA-C-N 116.244 -0.434 . . . . 0.0 110.932 179.982 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 48.4 Cg_endo -68.51 -24.51 36.09 Favored 'Trans proline' 0 C--N 1.346 0.405 0 C-N-CA 122.441 2.094 . . . . 0.0 112.377 179.927 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 3.0 p -58.14 -52.23 66.43 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.28 -0.418 . . . . 0.0 110.904 -179.965 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 43.3 m 60.27 89.21 0.11 Allowed Pre-proline 0 C--N 1.329 -0.284 0 CA-C-N 116.198 -0.456 . . . . 0.0 110.904 179.943 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 50.4 Cg_endo -68.96 154.11 71.38 Favored 'Trans proline' 0 C--N 1.345 0.382 0 C-N-CA 122.551 2.167 . . . . 0.0 112.319 179.98 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 58.1 m -128.64 -46.62 1.29 Allowed 'General case' 0 C--N 1.327 -0.371 0 CA-C-N 116.269 -0.423 . . . . 0.0 110.825 -179.975 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -156.33 -46.33 0.07 Allowed 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.856 -179.994 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -131.11 67.95 0.56 Allowed Glycine 0 N--CA 1.45 -0.372 0 C-N-CA 120.738 -0.744 . . . . 0.0 112.499 -179.962 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 0.6 OUTLIER -88.37 132.45 34.43 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-O 120.842 0.353 . . . . 0.0 110.839 179.938 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -155.02 154.38 32.41 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.908 -179.992 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 19' ' ' GLN . . . . . . . . . . . . . 35.9 tp60 -144.29 -66.81 0.34 Allowed 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.198 -0.456 . . . . 0.0 110.941 179.916 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 20' ' ' GLN . . . . . . . . . . . . . 3.4 tt0 61.87 114.51 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.265 -0.425 . . . . 0.0 110.926 179.976 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 5.4 mtt180 -173.74 137.78 0.62 Allowed 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.259 -0.428 . . . . 0.0 110.798 179.975 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 3.8 tt0 -138.53 -53.48 0.6 Allowed 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.944 -179.996 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 102.38 105.69 2.93 Favored Glycine 0 N--CA 1.452 -0.247 0 C-N-CA 120.709 -0.758 . . . . 0.0 112.541 -179.944 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -144.81 134.81 23.87 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-O 120.817 0.341 . . . . 0.0 111.077 -179.975 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 25' ' ' LYS . . . . . 0.523 ' HD2' ' HB1' ' A' ' 89' ' ' ALA . 0.1 OUTLIER -70.62 -34.36 72.03 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.923 179.998 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -155.1 173.11 17.06 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.235 -0.439 . . . . 0.0 111.072 179.971 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 27' ' ' GLU . . . . . . . . . . . . . 7.4 mp0 -133.74 -178.63 5.1 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.955 179.994 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 25.6 t -73.43 98.96 1.05 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.061 -179.993 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 117.94 39.63 0.75 Allowed Glycine 0 N--CA 1.451 -0.327 0 C-N-CA 120.789 -0.72 . . . . 0.0 112.449 179.924 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 20.7 t70 -146.25 137.68 24.66 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-O 120.842 0.353 . . . . 0.0 110.899 -179.978 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 31' ' ' GLN . . . . . . . . . . . . . 0.8 OUTLIER -59.96 137.33 58.11 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.121 -0.491 . . . . 0.0 110.961 179.938 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 6.2 m -141.28 171.67 11.77 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 116.234 -0.439 . . . . 0.0 111.11 -179.938 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 33' ' ' LEU . . . . . 0.683 HD13 ' HG3' ' A' ' 39' ' ' GLN . 33.9 tp -136.61 111.31 8.71 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.125 -0.488 . . . . 0.0 110.875 179.943 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 21.5 t -79.15 125.77 38.64 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-N 116.226 -0.443 . . . . 0.0 111.25 -179.978 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 35' ' ' ALA . . . . . . . . . . . . . . . 56.58 25.47 9.93 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.346 179.97 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . 57.54 31.69 63.73 Favored Glycine 0 N--CA 1.451 -0.306 0 C-N-CA 120.736 -0.745 . . . . 0.0 112.565 179.898 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 37' ' ' GLN . . . . . 0.577 ' O ' HD11 ' A' ' 33' ' ' LEU . 9.3 mt-30 -142.98 -74.28 0.28 Allowed 'General case' 0 C--N 1.33 -0.28 0 CA-C-O 120.818 0.342 . . . . 0.0 111.006 -179.971 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 38' ' ' LYS . . . . . 0.414 ' O ' HD12 ' A' ' 33' ' ' LEU . 46.0 mttp -63.51 112.59 2.84 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.896 -179.892 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 39' ' ' GLN . . . . . 0.683 ' HG3' HD13 ' A' ' 33' ' ' LEU . 2.1 mt-30 -87.6 139.6 30.37 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.837 179.926 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -172.87 171.42 44.39 Favored Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.697 -0.763 . . . . 0.0 112.512 179.993 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 3.2 mp -111.88 143.7 21.14 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-O 120.875 0.369 . . . . 0.0 111.114 179.978 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 42' ' ' VAL . . . . . . . . . . . . . 21.5 t -69.29 123.2 22.36 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.153 -0.476 . . . . 0.0 111.138 -179.995 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 43' ' ' ARG . . . . . . . . . . . . . 4.0 mmm180 -106.73 -31.54 8.38 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.891 -179.973 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 44' ' ' PHE . . . . . 0.417 ' CG ' ' HB3' ' A' ' 76' ' ' TYR . 15.2 t80 -147.82 106.26 3.78 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.879 -179.928 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 45' ' ' TYR . . . . . 0.496 ' CE1' ' CE1' ' A' ' 56' ' ' TYR . 14.3 t80 -111.03 123.88 51.06 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.294 -0.412 . . . . 0.0 110.935 179.893 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 171.54 -142.79 7.19 Favored Glycine 0 N--CA 1.45 -0.371 0 C-N-CA 120.649 -0.786 . . . . 0.0 112.462 -179.98 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 47' ' ' LYS . . . . . . . . . . . . . 24.7 mtpt -95.06 175.01 6.8 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-O 120.773 0.321 . . . . 0.0 110.906 179.993 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 48' ' ' THR . . . . . . . . . . . . . 44.8 p -138.79 -177.8 5.04 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.846 -179.996 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 4.4 t70 -129.04 17.59 6.13 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.154 -0.476 . . . . 0.0 111.259 179.924 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 50' ' ' PHE . . . . . . . . . . . . . 49.5 p90 -126.81 -44.98 1.62 Allowed 'General case' 0 C--N 1.331 -0.217 0 CA-C-N 116.447 -0.342 . . . . 0.0 110.892 179.961 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 51' ' ' ALA . . . . . 0.42 ' HB1' ' CZ2' ' A' ' 55' ' ' TRP . . . -123.5 145.37 46.72 Favored Pre-proline 0 C--N 1.329 -0.324 0 CA-C-N 116.291 -0.413 . . . . 0.0 111.122 179.944 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 52' ' ' PRO . . . . . . . . . . . . . 64.4 Cg_endo -73.59 164.7 34.26 Favored 'Trans proline' 0 C--N 1.345 0.36 0 C-N-CA 122.565 2.176 . . . . 0.0 112.32 -179.926 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 83.51 -177.2 52.65 Favored Glycine 0 N--CA 1.452 -0.287 0 C-N-CA 120.725 -0.75 . . . . 0.0 112.478 179.855 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 54' ' ' TYR . . . . . . . . . . . . . 7.8 m-85 -97.63 131.84 43.83 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-O 120.818 0.342 . . . . 0.0 110.862 -179.979 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 55' ' ' TRP . . . . . 0.42 ' CZ2' ' HB1' ' A' ' 51' ' ' ALA . 24.8 m95 -123.41 157.74 32.74 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.907 -179.994 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 56' ' ' TYR . . . . . 0.658 ' HE1' ' HB2' ' A' ' 89' ' ' ALA . 11.9 m-85 -109.69 126.84 54.12 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.977 -179.948 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . -84.46 62.08 4.62 Favored Glycine 0 N--CA 1.451 -0.36 0 C-N-CA 120.733 -0.746 . . . . 0.0 112.419 179.921 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 58' ' ' ILE . . . . . 0.492 HD11 HD13 ' A' ' 92' ' ' ILE . 15.9 mt -71.32 141.05 17.26 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-O 120.816 0.341 . . . . 0.0 111.108 -179.985 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER -109.89 122.14 46.85 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.885 179.951 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 60' ' ' LEU . . . . . . . . . . . . . 63.1 mt -82.69 170.3 15.26 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.945 -179.929 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 1.1 m-20 -100.6 -26.52 13.79 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.95 -179.97 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 62' ' ' GLN . . . . . . . . . . . . . 10.8 pt20 -110.41 152.16 43.13 Favored Pre-proline 0 C--N 1.329 -0.292 0 CA-C-N 116.299 -0.41 . . . . 0.0 110.922 -179.967 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 63' ' ' PRO . . . . . 0.417 ' O ' HG23 ' A' ' 64' ' ' THR . 49.7 Cg_endo -68.91 84.1 0.53 Allowed 'Trans proline' 0 C--N 1.345 0.357 0 C-N-CA 122.599 2.199 . . . . 0.0 112.312 179.971 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 64' ' ' THR . . . . . 0.417 HG23 ' O ' ' A' ' 63' ' ' PRO . 2.2 p -156.97 35.83 0.3 Allowed 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.213 -0.448 . . . . 0.0 110.894 -179.923 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . -91.65 -158.6 34.72 Favored Glycine 0 N--CA 1.451 -0.359 0 C-N-CA 120.757 -0.735 . . . . 0.0 112.443 -179.961 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 66' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -114.07 -36.69 4.67 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-O 120.735 0.303 . . . . 0.0 110.889 -179.997 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 67' ' ' HIS . . . . . . . . . . . . . 6.9 p80 -127.08 170.26 12.54 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.261 -0.427 . . . . 0.0 110.909 -179.903 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 5.4 m-20 -98.8 30.87 3.15 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.165 -0.471 . . . . 0.0 110.85 179.973 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 105.46 -42.76 1.82 Allowed Glycine 0 N--CA 1.452 -0.257 0 C-N-CA 120.667 -0.777 . . . . 0.0 112.457 179.915 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 70' ' ' SER . . . . . . . . . . . . . 63.4 p -108.62 141.76 40.08 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.798 0.333 . . . . 0.0 110.92 179.966 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 21.5 t -117.45 109.9 29.17 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 116.25 -0.432 . . . . 0.0 111.112 179.957 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 72' ' ' PHE . . . . . . . . . . . . . 40.7 m-85 60.66 30.58 19.82 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.932 -179.972 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 101.08 -30.02 11.26 Favored Glycine 0 N--CA 1.451 -0.353 0 C-N-CA 120.705 -0.759 . . . . 0.0 112.51 179.999 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 21.5 t -78.66 117.88 24.94 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-O 120.764 0.316 . . . . 0.0 111.152 -179.977 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 75' ' ' ARG . . . . . . . . . . . . . 10.3 ttm180 -98.33 145.67 26.45 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.894 -179.984 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 76' ' ' TYR . . . . . 0.417 ' HB3' ' CG ' ' A' ' 44' ' ' PHE . 12.6 m-85 -119.93 -42.36 2.61 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.852 -179.96 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 77' ' ' PHE . . . . . . . . . . . . . 26.6 p90 -153.13 158.89 42.52 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.875 179.991 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 12.0 p -89.96 99.53 12.52 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.91 -180.0 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 79' ' ' CYS . . . . . . . . . . . . . 30.5 p -117.93 173.95 6.48 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.85 179.977 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 80' ' ' ALA . . . . . 0.644 ' HB3' ' CG ' ' A' ' 83' ' ' HIS . . . -80.72 168.0 28.49 Favored Pre-proline 0 C--N 1.329 -0.308 0 CA-C-N 116.149 -0.478 . . . . 0.0 111.061 -179.975 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 81' ' ' PRO . . . . . 0.561 ' HD2' ' HB1' ' A' ' 80' ' ' ALA . 54.1 Cg_exo -52.14 112.18 0.8 Allowed 'Trans proline' 0 C--N 1.345 0.347 0 C-N-CA 122.554 2.169 . . . . 0.0 112.296 179.974 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 82' ' ' ARG . . . . . . . . . . . . . 12.9 mtp180 59.97 56.56 3.38 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.872 179.977 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 83' ' ' HIS . . . . . 0.644 ' CG ' ' HB3' ' A' ' 80' ' ' ALA . 5.1 m170 -121.48 -41.78 2.48 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.949 179.967 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . -71.44 142.22 33.59 Favored Glycine 0 N--CA 1.451 -0.301 0 C-N-CA 120.786 -0.721 . . . . 0.0 112.516 179.997 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 85' ' ' VAL . . . . . 0.4 ' O ' HG23 ' A' ' 85' ' ' VAL . 22.3 m -144.48 124.03 7.27 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-O 120.785 0.326 . . . . 0.0 111.089 179.943 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 86' ' ' PHE . . . . . . . . . . . . . 24.1 m-85 -101.28 121.26 41.56 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.974 179.927 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 87' ' ' ALA . . . . . 0.547 ' O ' HD11 ' A' ' 92' ' ' ILE . . . -138.64 146.54 51.03 Favored Pre-proline 0 C--N 1.329 -0.3 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.102 179.981 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 88' ' ' PRO . . . . . 0.431 ' O ' ' N ' ' A' ' 91' ' ' ARG . 41.8 Cg_exo -56.92 139.15 88.79 Favored 'Trans proline' 0 C--N 1.345 0.379 0 C-N-CA 122.487 2.125 . . . . 0.0 112.313 -179.934 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 89' ' ' ALA . . . . . 0.658 ' HB2' ' HE1' ' A' ' 56' ' ' TYR . . . -48.08 -48.39 33.58 Favored 'General case' 0 C--O 1.232 0.141 0 CA-C-N 116.076 -0.511 . . . . 0.0 110.24 179.818 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 90' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -55.53 -24.54 32.62 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 115.681 -0.69 . . . . 0.0 109.779 178.779 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 91' ' ' ARG . . . . . 0.431 ' N ' ' O ' ' A' ' 88' ' ' PRO . 0.7 OUTLIER -92.13 -13.55 30.53 Favored 'General case' 0 N--CA 1.455 -0.195 0 CA-C-N 115.877 -0.601 . . . . 0.0 110.62 179.201 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 92' ' ' ILE . . . . . 0.547 HD11 ' O ' ' A' ' 87' ' ' ALA . 50.1 mt -105.74 154.39 7.01 Favored 'Isoleucine or valine' 0 C--N 1.333 -0.12 0 CA-C-O 120.836 0.35 . . . . 0.0 111.013 179.796 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 93' ' ' GLN . . . . . 0.424 ' N ' HG22 ' A' ' 92' ' ' ILE . 0.3 OUTLIER -124.07 176.93 6.06 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.911 -179.978 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 94' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER -111.47 160.98 16.61 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.845 -179.989 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 95' ' ' ILE . . . . . . . . . . . . . 30.8 mt -139.8 -47.63 0.3 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.097 179.961 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . -66.92 -161.54 1.24 Allowed Glycine 0 N--CA 1.451 -0.329 0 C-N-CA 120.74 -0.743 . . . . 0.0 112.519 179.91 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 97' ' ' SER . . . . . . . . . . . . . 1.2 t 60.74 105.73 0.02 OUTLIER 'General case' 0 C--N 1.328 -0.35 0 CA-C-O 120.79 0.329 . . . . 0.0 110.802 179.965 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 98' ' ' GLY . . . . . . . . . . . . . . . -112.21 71.46 0.22 Allowed Glycine 0 N--CA 1.451 -0.33 0 C-N-CA 120.764 -0.732 . . . . 0.0 112.559 179.933 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 99' ' ' PRO . . . . . . . . . . . . . 55.6 Cg_endo -70.06 -44.61 1.79 Allowed 'Trans proline' 0 C--N 1.343 0.282 0 C-N-CA 122.504 2.136 . . . . 0.0 112.291 179.996 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 100' ' ' SER . . . . . . . . . . . . . 1.4 m -142.2 172.58 12.49 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.98 179.976 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 67.4 m -89.1 174.88 7.63 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.248 -0.433 . . . . 0.0 110.857 -179.992 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.25 1.145 0 CA-C-O 118.308 -1.273 . . . . 0.0 112.508 -179.994 . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.231 0.11 0 CA-C-O 120.761 0.315 . . . . 0.0 111.164 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' A' A ' 27' ' ' GLU . . . . . . . . . . . . . 2.1 mm-40 -149.14 167.56 25.59 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.941 -179.992 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 21.8 t -68.6 125.02 25.54 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 CA-C-N 116.176 -0.465 . . . . 0.0 111.106 -179.975 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 98.39 29.66 7.36 Favored Glycine 0 N--CA 1.451 -0.347 0 C-N-CA 120.724 -0.751 . . . . 0.0 112.446 -179.991 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 30' ' ' ASP . . . . . 0.425 ' O ' HG23 ' A' ' 41' ' ' ILE . 0.8 OUTLIER -138.76 147.96 43.27 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-O 120.814 0.34 . . . . 0.0 110.845 -179.928 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 31' ' ' GLN . . . . . . . . . . . . . 0.7 OUTLIER -72.65 127.25 32.0 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.963 179.977 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 22.2 m -130.16 179.9 3.79 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 CA-C-N 116.265 -0.425 . . . . 0.0 111.192 179.973 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 33' ' ' LEU . . . . . 0.562 HD23 ' HA2' ' A' ' 36' ' ' GLY . 15.7 tp -139.52 109.33 6.32 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.262 -0.426 . . . . 0.0 110.963 -179.993 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 23.1 t -76.57 121.12 28.08 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.261 -0.427 . . . . 0.0 111.138 -180.0 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 35' ' ' ALA . . . . . . . . . . . . . . . 59.22 26.61 15.42 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.244 179.976 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 36' ' ' GLY . . . . . 0.562 ' HA2' HD23 ' A' ' 33' ' ' LEU . . . 56.74 36.64 73.01 Favored Glycine 0 N--CA 1.45 -0.387 0 C-N-CA 120.74 -0.743 . . . . 0.0 112.639 179.954 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 37' ' ' GLN . . . . . . . . . . . . . 35.3 mt-30 -146.98 -71.42 0.23 Allowed 'General case' 0 C--N 1.329 -0.325 0 CA-C-O 120.796 0.331 . . . . 0.0 110.948 -179.998 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 38' ' ' LYS . . . . . . . . . . . . . 13.2 mttm -67.83 114.79 6.71 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.879 -179.995 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 39' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -90.14 125.98 35.64 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.922 179.935 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -152.77 -175.61 24.45 Favored Glycine 0 N--CA 1.451 -0.347 0 C-N-CA 120.715 -0.755 . . . . 0.0 112.5 -179.971 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 41' ' ' ILE . . . . . 0.529 ' C ' HG23 ' A' ' 58' ' ' ILE . 4.3 mt -127.64 128.79 69.94 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.272 0 CA-C-O 120.8 0.333 . . . . 0.0 111.02 -179.948 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 42' ' ' VAL . . . . . . . . . . . . . 21.6 t -59.99 124.42 14.28 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.253 -0.431 . . . . 0.0 111.084 179.975 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 43' ' ' ARG . . . . . . . . . . . . . 45.0 mmt-85 -110.57 -30.24 7.71 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.23 -0.441 . . . . 0.0 111.077 -179.993 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 44' ' ' PHE . . . . . . . . . . . . . 35.7 t80 -143.61 118.6 10.02 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.318 -0.401 . . . . 0.0 110.993 -179.958 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 45' ' ' TYR . . . . . 0.455 ' CE1' ' CZ ' ' A' ' 56' ' ' TYR . 22.2 t80 -115.08 114.9 25.96 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.845 179.899 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 176.8 162.96 28.27 Favored Glycine 0 N--CA 1.45 -0.382 0 C-N-CA 120.699 -0.763 . . . . 0.0 112.441 179.944 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 47' ' ' LYS . . . . . 0.442 ' HG3' ' CE1' ' A' ' 54' ' ' TYR . 22.7 mttt -65.98 137.32 57.05 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.865 0.364 . . . . 0.0 110.852 179.97 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 48' ' ' THR . . . . . . . . . . . . . 41.2 p -95.67 -175.35 3.41 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.902 179.918 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 4.6 t70 -106.58 -30.87 8.76 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.893 179.987 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 50' ' ' PHE . . . . . . . . . . . . . 44.3 p90 -71.29 -36.22 71.58 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.867 -179.985 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 51' ' ' ALA . . . . . . . . . . . . . . . -132.69 148.17 68.48 Favored Pre-proline 0 C--N 1.33 -0.274 0 CA-C-N 116.236 -0.438 . . . . 0.0 111.188 179.978 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 52' ' ' PRO . . . . . . . . . . . . . 59.9 Cg_endo -72.25 -170.07 0.53 Allowed 'Trans proline' 0 C--N 1.344 0.34 0 C-N-CA 122.601 2.201 . . . . 0.0 112.336 -179.97 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 59.26 -161.01 15.5 Favored Glycine 0 N--CA 1.452 -0.283 0 C-N-CA 120.746 -0.74 . . . . 0.0 112.537 179.976 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 54' ' ' TYR . . . . . 0.442 ' CE1' ' HG3' ' A' ' 47' ' ' LYS . 12.8 m-85 -106.19 157.8 17.3 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-O 120.844 0.354 . . . . 0.0 110.855 -179.95 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 55' ' ' TRP . . . . . . . . . . . . . 69.5 m95 -144.37 159.71 42.27 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.898 179.988 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 56' ' ' TYR . . . . . 0.827 ' CE1' ' HB2' ' A' ' 89' ' ' ALA . 5.7 m-85 -116.36 115.26 25.55 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.878 -179.951 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 57' ' ' GLY . . . . . 0.443 ' CA ' ' CE1' ' A' ' 86' ' ' PHE . . . -82.27 65.72 4.02 Favored Glycine 0 N--CA 1.451 -0.307 0 C-N-CA 120.75 -0.738 . . . . 0.0 112.431 -179.973 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 58' ' ' ILE . . . . . 0.704 HD11 HD13 ' A' ' 92' ' ' ILE . 5.5 mt -72.67 143.66 13.75 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-O 120.816 0.341 . . . . 0.0 111.074 179.986 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 8.0 tt0 -104.23 143.04 33.49 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.836 179.95 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 60' ' ' LEU . . . . . . . . . . . . . 82.1 mt -96.11 173.18 7.54 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.929 -179.957 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 7.9 t0 -97.12 -33.19 11.6 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.954 179.991 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 62' ' ' GLN . . . . . . . . . . . . . 2.7 mt-30 -116.14 146.36 36.99 Favored Pre-proline 0 C--N 1.329 -0.319 0 CA-C-N 116.18 -0.463 . . . . 0.0 110.936 179.97 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 48.1 Cg_exo -55.83 86.75 0.04 OUTLIER 'Trans proline' 0 C--N 1.346 0.409 0 C-N-CA 122.548 2.165 . . . . 0.0 112.172 179.955 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 64' ' ' THR . . . . . . . . . . . . . 80.8 p -157.3 30.44 0.29 Allowed 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.251 -0.431 . . . . 0.0 110.984 -179.979 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . -89.62 175.54 42.29 Favored Glycine 0 N--CA 1.451 -0.363 0 C-N-CA 120.708 -0.758 . . . . 0.0 112.491 179.957 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 66' ' ' LYS . . . . . . . . . . . . . 48.5 mttm -78.61 -30.47 46.57 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 120.693 0.282 . . . . 0.0 110.865 179.94 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 67' ' ' HIS . . . . . . . . . . . . . 7.4 p80 -148.38 -178.98 6.61 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.898 -179.961 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 9.2 p30 -105.25 48.49 0.84 Allowed 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.952 179.999 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 94.02 -45.91 2.27 Favored Glycine 0 N--CA 1.452 -0.294 0 C-N-CA 120.738 -0.744 . . . . 0.0 112.512 -179.964 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 70' ' ' SER . . . . . . . . . . . . . 1.6 p -98.96 136.58 38.73 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-O 120.821 0.344 . . . . 0.0 110.901 179.985 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 71' ' ' VAL . . . . . 0.468 HG12 ' CD2' ' A' ' 72' ' ' PHE . 21.4 t -114.41 110.64 32.8 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.253 -0.431 . . . . 0.0 111.131 179.969 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 72' ' ' PHE . . . . . 0.468 ' CD2' HG12 ' A' ' 71' ' ' VAL . 60.6 m-85 60.47 31.89 20.41 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.22 -0.446 . . . . 0.0 110.961 179.967 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 98.85 -30.18 10.25 Favored Glycine 0 N--CA 1.451 -0.355 0 C-N-CA 120.685 -0.769 . . . . 0.0 112.556 -179.962 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 21.4 t -77.95 117.63 23.52 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-O 120.823 0.344 . . . . 0.0 111.127 179.904 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 75' ' ' ARG . . . . . . . . . . . . . 5.1 ttt180 -95.33 149.52 21.27 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.988 -179.864 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 76' ' ' TYR . . . . . . . . . . . . . 35.9 m-85 -129.94 -45.6 1.15 Allowed 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.25 -0.432 . . . . 0.0 110.947 179.951 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 77' ' ' PHE . . . . . . . . . . . . . 38.1 p90 -146.72 164.72 31.85 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.31 -0.405 . . . . 0.0 110.997 179.945 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 51.7 p -96.18 123.49 39.82 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.921 -179.97 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 79' ' ' CYS . . . . . . . . . . . . . 7.5 p -148.02 170.57 17.47 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.877 179.891 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 80' ' ' ALA . . . . . 0.407 ' HB1' ' HD2' ' A' ' 81' ' ' PRO . . . -71.73 162.48 72.93 Favored Pre-proline 0 C--N 1.329 -0.289 0 CA-C-N 116.163 -0.471 . . . . 0.0 111.079 -179.952 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 81' ' ' PRO . . . . . 0.407 ' HD2' ' HB1' ' A' ' 80' ' ' ALA . 53.0 Cg_exo -52.4 118.46 4.66 Favored 'Trans proline' 0 C--N 1.344 0.3 0 C-N-CA 122.632 2.221 . . . . 0.0 112.294 179.971 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 82' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER 60.27 63.53 1.38 Allowed 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.869 179.972 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 83' ' ' HIS . . . . . . . . . . . . . 3.3 m-70 -132.3 -46.02 0.91 Allowed 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.13 -0.486 . . . . 0.0 110.911 -179.975 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . -63.73 141.69 45.74 Favored Glycine 0 N--CA 1.451 -0.362 0 C-N-CA 120.709 -0.757 . . . . 0.0 112.52 179.996 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 85' ' ' VAL . . . . . . . . . . . . . 6.1 m -142.15 120.14 8.24 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-O 120.768 0.318 . . . . 0.0 111.166 -179.974 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 86' ' ' PHE . . . . . 0.443 ' CE1' ' CA ' ' A' ' 57' ' ' GLY . 12.4 m-85 -100.38 115.39 29.9 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.868 179.994 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 87' ' ' ALA . . . . . 0.609 ' O ' HD11 ' A' ' 92' ' ' ILE . . . -137.8 145.57 49.04 Favored Pre-proline 0 C--N 1.328 -0.336 0 CA-C-N 116.28 -0.418 . . . . 0.0 111.143 179.924 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 88' ' ' PRO . . . . . 0.406 ' O ' ' N ' ' A' ' 91' ' ' ARG . 47.4 Cg_exo -56.02 139.14 84.51 Favored 'Trans proline' 0 C--N 1.345 0.388 0 C-N-CA 122.454 2.103 . . . . 0.0 112.336 -179.977 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 89' ' ' ALA . . . . . 0.827 ' HB2' ' CE1' ' A' ' 56' ' ' TYR . . . -48.01 -50.91 26.03 Favored 'General case' 0 C--N 1.333 -0.122 0 CA-C-N 116.109 -0.496 . . . . 0.0 110.272 179.862 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 90' ' ' SER . . . . . . . . . . . . . 17.7 m -55.76 -24.49 35.65 Favored 'General case' 0 N--CA 1.454 -0.259 0 CA-C-N 115.687 -0.688 . . . . 0.0 109.766 178.816 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 91' ' ' ARG . . . . . 0.406 ' N ' ' O ' ' A' ' 88' ' ' PRO . 0.6 OUTLIER -88.3 -15.14 36.53 Favored 'General case' 0 N--CA 1.455 -0.188 0 CA-C-N 115.831 -0.622 . . . . 0.0 110.473 179.02 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 92' ' ' ILE . . . . . 0.704 HD13 HD11 ' A' ' 58' ' ' ILE . 33.3 mt -104.37 157.89 5.5 Favored 'Isoleucine or valine' 0 C--N 1.334 -0.097 0 CA-C-N 116.379 -0.373 . . . . 0.0 110.973 179.924 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 93' ' ' GLN . . . . . 0.482 ' N ' HG22 ' A' ' 92' ' ' ILE . 2.2 mt-30 -128.3 166.34 18.81 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.889 -179.912 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 94' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -107.15 145.36 32.64 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.846 -179.994 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 95' ' ' ILE . . . . . . . . . . . . . 23.4 mt . . . . . 0 C--N 1.329 -0.299 0 CA-C-N 116.211 -0.449 . . . . 0.0 111.13 179.902 . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' A' A ' 26' ' ' ALA . . . . . 0.587 ' N ' ' HH ' ' A' ' 56' ' ' TYR . . . . . . . . 0 C--O 1.231 0.101 0 CA-C-O 120.877 0.37 . . . . 0.0 111.081 . . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 27' ' ' GLU . . . . . . . . . . . . . 6.0 mt-10 -148.03 173.37 12.98 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.252 -0.431 . . . . 0.0 110.911 179.98 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 21.5 t -70.83 110.28 3.72 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.087 179.974 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 113.01 36.24 1.54 Allowed Glycine 0 N--CA 1.452 -0.296 0 C-N-CA 120.736 -0.745 . . . . 0.0 112.503 179.97 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 2.1 m-20 -150.06 138.05 20.23 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 120.852 0.358 . . . . 0.0 110.866 -179.978 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 31' ' ' GLN . . . . . . . . . . . . . 0.7 OUTLIER -62.94 132.88 53.57 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.125 -0.489 . . . . 0.0 110.871 179.998 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 32' ' ' VAL . . . . . 0.486 HG21 HG12 ' A' ' 58' ' ' ILE . 12.6 m -132.99 178.81 5.12 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.149 179.99 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 33' ' ' LEU . . . . . 0.55 HD11 ' O ' ' A' ' 37' ' ' GLN . 40.4 tp -140.14 101.22 4.1 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.9 179.931 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 34' ' ' VAL . . . . . 0.406 ' CG2' HD13 ' A' ' 58' ' ' ILE . 21.6 t -72.55 127.68 34.75 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.218 -0.446 . . . . 0.0 111.175 -179.928 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 35' ' ' ALA . . . . . . . . . . . . . . . 57.68 25.33 11.62 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.139 -0.482 . . . . 0.0 111.266 179.937 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . 56.07 27.96 52.75 Favored Glycine 0 N--CA 1.453 -0.224 0 C-N-CA 120.686 -0.769 . . . . 0.0 112.638 179.979 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 37' ' ' GLN . . . . . 0.55 ' O ' HD11 ' A' ' 33' ' ' LEU . 29.5 mt-30 -138.1 -72.83 0.41 Allowed 'General case' 0 C--N 1.33 -0.279 0 CA-C-O 120.797 0.332 . . . . 0.0 110.944 -179.906 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 38' ' ' LYS . . . . . . . . . . . . . 3.7 mttt -69.02 111.81 5.25 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.265 -0.425 . . . . 0.0 110.965 179.991 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 39' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -92.98 130.5 38.53 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.086 -0.506 . . . . 0.0 110.905 -179.997 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -152.04 -171.0 19.33 Favored Glycine 0 N--CA 1.45 -0.38 0 C-N-CA 120.812 -0.709 . . . . 0.0 112.52 -179.988 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 29.8 mt -123.4 131.92 72.29 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 CA-C-O 120.825 0.345 . . . . 0.0 111.172 179.973 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 42' ' ' VAL . . . . . . . . . . . . . 21.6 t -59.44 126.87 17.85 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.336 0 CA-C-N 116.24 -0.436 . . . . 0.0 111.105 -179.999 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 43' ' ' ARG . . . . . . . . . . . . . 8.7 mmm180 -111.81 -42.56 3.78 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.932 -179.999 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 44' ' ' PHE . . . . . . . . . . . . . 46.0 t80 -138.66 113.24 8.95 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.937 -179.937 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 45' ' ' TYR . . . . . 0.426 ' CE1' ' CE1' ' A' ' 56' ' ' TYR . 35.8 t80 -113.08 138.56 49.73 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.956 179.98 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 152.71 -169.57 31.79 Favored Glycine 0 N--CA 1.449 -0.45 0 C-N-CA 120.783 -0.722 . . . . 0.0 112.489 179.957 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 47' ' ' LYS . . . . . . . . . . . . . 28.7 mttm -78.21 147.35 34.49 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-O 120.847 0.356 . . . . 0.0 110.844 -179.954 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 48' ' ' THR . . . . . 0.654 HG22 ' CE2' ' A' ' 76' ' ' TYR . 34.8 p -118.88 171.52 8.17 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.913 179.985 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -98.88 -35.79 9.99 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.885 179.972 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 50' ' ' PHE . . . . . 0.574 ' CZ ' HG21 ' A' ' 48' ' ' THR . 27.0 p90 -61.61 -31.39 71.46 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.92 179.907 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 51' ' ' ALA . . . . . . . . . . . . . . . -152.11 146.42 18.52 Favored Pre-proline 0 C--N 1.329 -0.294 0 CA-C-N 116.26 -0.427 . . . . 0.0 111.117 179.997 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 52' ' ' PRO . . . . . . . . . . . . . 60.9 Cg_endo -72.86 175.82 9.84 Favored 'Trans proline' 0 C--N 1.345 0.368 0 C-N-CA 122.573 2.182 . . . . 0.0 112.334 179.973 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 84.11 -158.79 35.03 Favored Glycine 0 N--CA 1.45 -0.369 0 C-N-CA 120.716 -0.754 . . . . 0.0 112.541 179.986 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 54' ' ' TYR . . . . . . . . . . . . . 20.2 m-85 -118.74 124.64 47.78 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-O 120.872 0.368 . . . . 0.0 110.897 179.982 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 55' ' ' TRP . . . . . . . . . . . . . 36.4 m95 -118.19 162.89 17.49 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.911 179.988 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 56' ' ' TYR . . . . . 0.692 ' HE1' ' HB2' ' A' ' 89' ' ' ALA . 8.4 m-85 -110.69 125.37 53.4 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.934 -179.91 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 57' ' ' GLY . . . . . 0.431 ' HA3' ' CE1' ' A' ' 77' ' ' PHE . . . -88.01 53.28 4.21 Favored Glycine 0 N--CA 1.451 -0.365 0 C-N-CA 120.72 -0.752 . . . . 0.0 112.423 179.97 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 58' ' ' ILE . . . . . 0.486 HG12 HG21 ' A' ' 32' ' ' VAL . 3.8 mt -64.64 142.33 17.03 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.266 0 CA-C-O 120.834 0.349 . . . . 0.0 111.164 -179.981 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 2.4 tm-20 -115.12 108.11 16.2 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.118 -0.492 . . . . 0.0 110.836 -179.947 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 60' ' ' LEU . . . . . . . . . . . . . 48.0 mt -67.75 176.28 2.57 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.906 -179.964 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -100.86 -32.87 10.46 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.852 -179.995 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 62' ' ' GLN . . . . . . . . . . . . . 0.2 OUTLIER -101.37 154.69 37.07 Favored Pre-proline 0 C--N 1.328 -0.332 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.917 179.976 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 58.3 Cg_endo -71.85 68.13 3.09 Favored 'Trans proline' 0 C--N 1.344 0.308 0 C-N-CA 122.584 2.189 . . . . 0.0 112.275 -179.965 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 64' ' ' THR . . . . . . . . . . . . . 73.4 p -139.54 34.25 2.04 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.901 -179.994 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . -88.33 -129.11 3.15 Favored Glycine 0 N--CA 1.452 -0.295 0 C-N-CA 120.732 -0.747 . . . . 0.0 112.579 179.948 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 66' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -144.96 -47.33 0.23 Allowed 'General case' 0 C--N 1.328 -0.353 0 CA-C-O 120.785 0.326 . . . . 0.0 110.845 -179.991 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 67' ' ' HIS . . . . . . . . . . . . . 7.6 p80 -119.94 170.02 9.64 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.213 -0.448 . . . . 0.0 110.839 179.973 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 39.0 m-20 -98.42 34.04 2.09 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.862 -179.983 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 94.62 -42.72 2.39 Favored Glycine 0 N--CA 1.451 -0.329 0 C-N-CA 120.737 -0.744 . . . . 0.0 112.586 -179.939 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 70' ' ' SER . . . . . . . . . . . . . 5.6 p -100.8 134.67 43.42 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-O 120.833 0.349 . . . . 0.0 110.946 -179.984 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 71' ' ' VAL . . . . . 0.409 HG12 ' CD2' ' A' ' 72' ' ' PHE . 21.3 t -114.92 102.95 14.57 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.156 -0.474 . . . . 0.0 111.062 -179.913 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 72' ' ' PHE . . . . . 0.409 ' CD2' HG12 ' A' ' 71' ' ' VAL . 33.2 m-85 61.75 30.8 18.52 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.191 -0.458 . . . . 0.0 110.935 179.929 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 104.21 -30.09 10.81 Favored Glycine 0 N--CA 1.451 -0.362 0 C-N-CA 120.703 -0.76 . . . . 0.0 112.513 179.973 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 21.4 t -77.82 116.87 22.04 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.345 0 CA-C-O 120.749 0.309 . . . . 0.0 111.173 179.978 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 75' ' ' ARG . . . . . . . . . . . . . 10.1 ttm180 -96.62 143.24 27.77 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.272 -0.422 . . . . 0.0 110.898 -179.956 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 76' ' ' TYR . . . . . 0.654 ' CE2' HG22 ' A' ' 48' ' ' THR . 20.0 m-85 -118.69 -40.48 2.88 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.933 179.926 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 77' ' ' PHE . . . . . 0.431 ' CE1' ' HA3' ' A' ' 57' ' ' GLY . 16.0 p90 -160.07 157.55 28.79 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.956 179.972 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 18.8 m -83.9 111.51 19.3 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.836 -179.974 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 79' ' ' CYS . . . . . . . . . . . . . 30.5 p -132.74 174.24 10.52 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.901 179.941 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 80' ' ' ALA . . . . . 0.624 ' HB1' ' HD2' ' A' ' 81' ' ' PRO . . . -91.91 171.58 7.61 Favored Pre-proline 0 C--N 1.33 -0.281 0 CA-C-N 116.161 -0.472 . . . . 0.0 111.151 179.997 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 81' ' ' PRO . . . . . 0.624 ' HD2' ' HB1' ' A' ' 80' ' ' ALA . 50.7 Cg_exo -53.77 116.14 2.81 Favored 'Trans proline' 0 C--N 1.344 0.301 0 C-N-CA 122.592 2.194 . . . . 0.0 112.322 179.988 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 82' ' ' ARG . . . . . . . . . . . . . 3.4 mtp85 61.1 52.31 4.06 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.896 179.901 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 83' ' ' HIS . . . . . 0.505 ' CG ' ' HB3' ' A' ' 80' ' ' ALA . 6.0 m170 -120.99 -43.02 2.47 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.793 179.936 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . -75.2 144.4 31.97 Favored Glycine 0 N--CA 1.45 -0.383 0 C-N-CA 120.817 -0.706 . . . . 0.0 112.495 179.938 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 85' ' ' VAL . . . . . . . . . . . . . 6.6 m -147.77 127.39 4.44 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-O 120.806 0.336 . . . . 0.0 111.231 179.978 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 86' ' ' PHE . . . . . . . . . . . . . 6.1 m-85 -106.71 110.74 23.01 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.886 179.975 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 87' ' ' ALA . . . . . 0.606 ' O ' HD11 ' A' ' 92' ' ' ILE . . . -132.27 150.96 77.45 Favored Pre-proline 0 C--N 1.33 -0.268 0 CA-C-N 116.189 -0.459 . . . . 0.0 111.106 -179.957 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 88' ' ' PRO . . . . . 0.405 ' O ' ' N ' ' A' ' 91' ' ' ARG . 32.1 Cg_exo -58.4 138.09 83.94 Favored 'Trans proline' 0 C--N 1.344 0.338 0 C-N-CA 122.518 2.146 . . . . 0.0 112.285 -179.972 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 89' ' ' ALA . . . . . 0.692 ' HB2' ' HE1' ' A' ' 56' ' ' TYR . . . -48.05 -51.29 24.85 Favored 'General case' 0 CA--C 1.522 -0.124 0 CA-C-N 116.106 -0.497 . . . . 0.0 110.331 179.845 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 90' ' ' SER . . . . . . . . . . . . . 70.3 p -55.96 -24.41 38.14 Favored 'General case' 0 N--CA 1.453 -0.296 0 CA-C-N 115.714 -0.675 . . . . 0.0 109.769 178.809 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 91' ' ' ARG . . . . . 0.405 ' N ' ' O ' ' A' ' 88' ' ' PRO . 1.3 mtt180 -88.43 -14.6 37.57 Favored 'General case' 0 N--CA 1.453 -0.282 0 CA-C-N 115.852 -0.613 . . . . 0.0 110.535 178.992 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 92' ' ' ILE . . . . . 0.606 HD11 ' O ' ' A' ' 87' ' ' ALA . 26.0 mt -107.02 146.01 13.85 Favored 'Isoleucine or valine' 0 C--O 1.23 0.076 0 CA-C-N 116.302 -0.408 . . . . 0.0 111.014 179.935 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 93' ' ' GLN . . . . . . . . . . . . . 2.1 mt-30 -115.53 177.2 4.75 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.904 179.973 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 94' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER -115.81 148.23 40.12 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.923 179.971 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 95' ' ' ILE . . . . . 0.482 HD11 ' HB2' ' A' ' 33' ' ' LEU . 28.8 mm . . . . . 0 C--N 1.328 -0.358 0 CA-C-N 116.259 -0.428 . . . . 0.0 111.082 -179.935 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.231 0.111 0 CA-C-O 120.784 0.326 . . . . 0.0 111.143 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' A' A ' 27' ' ' GLU . . . . . . . . . . . . . 3.0 mt-10 -115.25 -173.28 2.29 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.899 179.967 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 21.4 t -80.18 98.31 3.36 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.312 -0.404 . . . . 0.0 111.05 179.978 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 111.78 29.72 3.25 Favored Glycine 0 N--CA 1.451 -0.312 0 C-N-CA 120.807 -0.711 . . . . 0.0 112.417 179.912 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 1.2 t70 -122.81 146.03 47.91 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 120.832 0.348 . . . . 0.0 110.894 179.981 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 31' ' ' GLN . . . . . . . . . . . . . 18.1 mt-30 -60.76 131.46 50.75 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.821 179.953 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 14.5 m -140.3 171.81 12.8 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.156 -0.475 . . . . 0.0 111.137 179.978 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 33' ' ' LEU . . . . . . . . . . . . . 17.8 tp -134.21 110.54 9.61 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.903 -179.963 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 34' ' ' VAL . . . . . 0.414 HG22 ' CD1' ' A' ' 58' ' ' ILE . 21.6 t -77.95 120.43 28.68 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 116.221 -0.445 . . . . 0.0 111.09 -179.937 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 35' ' ' ALA . . . . . . . . . . . . . . . 58.25 27.05 14.65 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.163 -0.471 . . . . 0.0 111.192 179.981 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . 56.77 31.33 60.73 Favored Glycine 0 N--CA 1.452 -0.282 0 C-N-CA 120.709 -0.758 . . . . 0.0 112.606 179.931 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 37' ' ' GLN . . . . . . . . . . . . . 91.5 mt-30 -140.28 -73.27 0.36 Allowed 'General case' 0 C--N 1.33 -0.272 0 CA-C-O 120.833 0.349 . . . . 0.0 110.962 -179.992 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 38' ' ' LYS . . . . . 0.466 ' HB3' HD21 ' A' ' 60' ' ' LEU . 34.1 mttp -68.22 104.27 1.78 Allowed 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.855 179.977 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 39' ' ' GLN . . . . . . . . . . . . . 0.4 OUTLIER -85.34 136.07 33.63 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.252 -0.431 . . . . 0.0 110.839 179.905 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -164.56 -163.7 18.21 Favored Glycine 0 N--CA 1.451 -0.356 0 C-N-CA 120.771 -0.728 . . . . 0.0 112.539 179.965 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 32.4 mt -131.12 139.51 50.84 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-O 120.79 0.328 . . . . 0.0 111.156 179.994 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 42' ' ' VAL . . . . . . . . . . . . . 23.2 t -69.18 124.36 24.8 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.334 0 CA-C-N 116.187 -0.46 . . . . 0.0 111.059 -179.952 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 43' ' ' ARG . . . . . . . . . . . . . 27.8 mmt180 -105.58 -32.57 8.42 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.178 -0.464 . . . . 0.0 110.984 -179.956 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 44' ' ' PHE . . . . . . . . . . . . . 51.0 t80 -143.08 118.11 10.05 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 116.189 -0.459 . . . . 0.0 110.962 -179.93 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 45' ' ' TYR . . . . . 0.494 ' CE1' ' CZ ' ' A' ' 56' ' ' TYR . 15.5 t80 -113.02 117.94 33.41 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.867 179.965 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 172.74 170.25 36.26 Favored Glycine 0 N--CA 1.452 -0.26 0 C-N-CA 120.657 -0.782 . . . . 0.0 112.487 179.979 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 47' ' ' LYS . . . . . 0.421 ' HG3' ' CE1' ' A' ' 54' ' ' TYR . 19.5 mttt -67.09 148.08 52.33 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 120.837 0.351 . . . . 0.0 110.942 179.983 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 48' ' ' THR . . . . . 0.608 HG21 ' CZ ' ' A' ' 50' ' ' PHE . 16.6 p -109.15 170.85 7.79 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.893 179.988 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 8.3 t0 -98.3 -31.12 12.21 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.869 179.989 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 50' ' ' PHE . . . . . 0.608 ' CZ ' HG21 ' A' ' 48' ' ' THR . 18.1 p90 -66.54 -32.23 73.45 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.935 -179.962 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 51' ' ' ALA . . . . . 0.435 ' N ' ' CD1' ' A' ' 50' ' ' PHE . . . -148.94 151.72 35.34 Favored Pre-proline 0 C--N 1.329 -0.299 0 CA-C-N 116.271 -0.422 . . . . 0.0 111.096 179.996 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 52' ' ' PRO . . . . . . . . . . . . . 56.8 Cg_endo -70.67 -167.94 0.29 Allowed 'Trans proline' 0 C--N 1.344 0.31 0 C-N-CA 122.598 2.198 . . . . 0.0 112.289 179.997 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 65.2 -176.39 12.82 Favored Glycine 0 N--CA 1.45 -0.38 0 C-N-CA 120.791 -0.719 . . . . 0.0 112.481 179.971 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 54' ' ' TYR . . . . . 0.421 ' CE1' ' HG3' ' A' ' 47' ' ' LYS . 7.6 m-85 -106.57 128.97 54.55 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-O 120.828 0.347 . . . . 0.0 110.928 179.974 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 55' ' ' TRP . . . . . . . . . . . . . 35.0 m95 -116.2 174.29 6.13 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.846 -179.969 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 56' ' ' TYR . . . . . 0.73 ' HE1' ' HB2' ' A' ' 89' ' ' ALA . 16.8 m-85 -125.35 121.64 34.51 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.92 -179.963 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 57' ' ' GLY . . . . . 0.403 ' N ' ' CE1' ' A' ' 86' ' ' PHE . . . -82.11 62.03 4.61 Favored Glycine 0 N--CA 1.451 -0.33 0 C-N-CA 120.776 -0.726 . . . . 0.0 112.417 179.928 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 58' ' ' ILE . . . . . 0.541 HD11 HD13 ' A' ' 92' ' ' ILE . 21.2 mt -68.67 139.71 20.14 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-O 120.809 0.338 . . . . 0.0 111.122 -179.993 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 4.7 tm-20 -111.99 112.52 24.22 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.91 179.959 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 60' ' ' LEU . . . . . 0.466 HD21 ' HB3' ' A' ' 38' ' ' LYS . 84.7 mt -72.53 177.34 4.73 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.967 -179.992 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -100.42 -32.37 10.85 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.815 179.998 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 62' ' ' GLN . . . . . . . . . . . . . 4.7 mm100 -106.62 155.33 39.08 Favored Pre-proline 0 C--N 1.328 -0.34 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.829 179.999 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 57.7 Cg_endo -71.51 68.11 2.82 Favored 'Trans proline' 0 C--N 1.345 0.354 0 C-N-CA 122.544 2.163 . . . . 0.0 112.399 179.907 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 64' ' ' THR . . . . . . . . . . . . . 12.4 p -136.0 31.18 3.0 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.871 -179.999 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . -92.95 -139.75 9.46 Favored Glycine 0 N--CA 1.451 -0.349 0 C-N-CA 120.754 -0.736 . . . . 0.0 112.548 -179.956 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 66' ' ' LYS . . . . . 0.451 ' HD2' HG12 ' A' ' 85' ' ' VAL . 0.0 OUTLIER -128.63 -45.75 1.31 Allowed 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 120.848 0.356 . . . . 0.0 110.924 179.961 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 67' ' ' HIS . . . . . . . . . . . . . 7.2 p80 -127.1 169.89 12.93 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.233 -0.44 . . . . 0.0 110.871 179.974 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 10.3 p-10 -98.56 36.51 1.63 Allowed 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.935 179.964 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 105.88 -50.37 0.82 Allowed Glycine 0 N--CA 1.45 -0.391 0 C-N-CA 120.756 -0.735 . . . . 0.0 112.502 179.964 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 70' ' ' SER . . . . . . . . . . . . . 80.5 p -93.26 151.84 19.56 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 120.836 0.35 . . . . 0.0 110.832 -179.945 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 71' ' ' VAL . . . . . 0.622 HG12 ' CD2' ' A' ' 72' ' ' PHE . 20.0 t -141.35 110.47 2.77 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 CA-C-N 116.226 -0.443 . . . . 0.0 111.069 -180.0 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 72' ' ' PHE . . . . . 0.622 ' CD2' HG12 ' A' ' 71' ' ' VAL . 67.6 m-85 60.17 31.17 20.43 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.903 -179.968 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 87.07 28.37 25.83 Favored Glycine 0 N--CA 1.451 -0.312 0 C-N-CA 120.747 -0.739 . . . . 0.0 112.498 179.98 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 21.4 t -128.35 104.27 11.38 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-O 120.901 0.381 . . . . 0.0 111.085 -179.988 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 75' ' ' ARG . . . . . . . . . . . . . 11.3 ttt180 -84.0 134.2 34.65 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.861 -179.934 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 76' ' ' TYR . . . . . 0.594 ' CE2' HG22 ' A' ' 48' ' ' THR . 56.5 m-85 -118.2 -41.51 2.86 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.883 179.973 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 77' ' ' PHE . . . . . . . . . . . . . 12.8 p90 -158.98 163.31 36.58 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.145 -0.48 . . . . 0.0 110.87 179.987 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 1.2 p -89.6 109.1 20.08 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.926 179.97 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 79' ' ' CYS . . . . . . . . . . . . . 28.6 p -138.41 166.19 24.88 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.921 -179.988 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 80' ' ' ALA . . . . . 0.7 ' HB3' ' CE1' ' A' ' 83' ' ' HIS . . . -77.51 168.93 23.75 Favored Pre-proline 0 C--N 1.329 -0.316 0 CA-C-N 116.227 -0.442 . . . . 0.0 111.07 -179.97 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 81' ' ' PRO . . . . . 0.531 ' HD2' ' HB1' ' A' ' 80' ' ' ALA . 32.5 Cg_exo -58.11 122.93 12.55 Favored 'Trans proline' 0 C--N 1.344 0.308 0 C-N-CA 122.582 2.188 . . . . 0.0 112.29 -179.929 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 82' ' ' ARG . . . . . . . . . . . . . 14.8 mtt-85 64.17 46.54 3.59 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.155 -0.475 . . . . 0.0 111.123 179.908 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 83' ' ' HIS . . . . . 0.7 ' CE1' ' HB3' ' A' ' 80' ' ' ALA . 9.4 m170 -119.29 -45.18 2.55 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.796 179.892 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . -75.49 138.96 23.99 Favored Glycine 0 N--CA 1.452 -0.295 0 C-N-CA 120.742 -0.742 . . . . 0.0 112.47 179.955 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 85' ' ' VAL . . . . . 0.451 HG12 ' HD2' ' A' ' 66' ' ' LYS . 18.0 m -141.72 119.72 8.78 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.361 0 CA-C-O 120.818 0.342 . . . . 0.0 111.108 -179.91 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 86' ' ' PHE . . . . . 0.403 ' CE1' ' N ' ' A' ' 57' ' ' GLY . 9.3 m-85 -97.69 110.57 23.11 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.872 179.928 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 87' ' ' ALA . . . . . 0.554 ' O ' HD11 ' A' ' 92' ' ' ILE . . . -128.78 151.19 76.81 Favored Pre-proline 0 C--N 1.33 -0.273 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.163 -179.989 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 88' ' ' PRO . . . . . . . . . . . . . 31.8 Cg_exo -58.72 136.24 72.53 Favored 'Trans proline' 0 C--N 1.345 0.36 0 C-N-CA 122.619 2.213 . . . . 0.0 112.252 -179.925 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 89' ' ' ALA . . . . . 0.73 ' HB2' ' HE1' ' A' ' 56' ' ' TYR . . . -48.05 -51.25 25.02 Favored 'General case' 0 C--N 1.333 -0.124 0 CA-C-N 116.154 -0.476 . . . . 0.0 110.277 179.91 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 90' ' ' SER . . . . . . . . . . . . . 5.5 m -55.94 -24.36 37.54 Favored 'General case' 0 N--CA 1.454 -0.249 0 CA-C-N 115.724 -0.671 . . . . 0.0 109.757 178.81 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 91' ' ' ARG . . . . . . . . . . . . . 0.6 OUTLIER -89.11 -14.09 37.04 Favored 'General case' 0 N--CA 1.455 -0.21 0 CA-C-N 115.818 -0.628 . . . . 0.0 110.487 179.064 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 92' ' ' ILE . . . . . 0.554 HD11 ' O ' ' A' ' 87' ' ' ALA . 28.1 mt -108.26 146.25 14.35 Favored 'Isoleucine or valine' 0 C--O 1.231 0.091 0 CA-C-N 116.391 -0.368 . . . . 0.0 111.034 179.834 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 93' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -106.19 164.49 11.96 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.218 -0.447 . . . . 0.0 110.817 -179.993 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 94' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -116.35 119.27 35.14 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.887 -179.995 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 95' ' ' ILE . . . . . . . . . . . . . 22.2 mt . . . . . 0 C--N 1.329 -0.307 0 CA-C-N 116.18 -0.464 . . . . 0.0 111.197 179.96 . . . . . . . . 0 0 . 1 . 004 nuclear nobuild core ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.231 0.091 0 CA-C-O 120.836 0.35 . . . . 0.0 111.122 . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild core ' A' A ' 27' ' ' GLU . . . . . . . . . . . . . 1.1 pm0 -116.75 158.39 23.94 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.888 -179.988 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 36.7 t -67.85 82.69 0.11 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.035 179.911 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 136.24 43.95 0.1 OUTLIER Glycine 0 N--CA 1.451 -0.366 0 C-N-CA 120.745 -0.74 . . . . 0.0 112.537 -179.981 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -149.18 167.69 25.28 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-O 120.838 0.352 . . . . 0.0 110.893 -179.984 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 31' ' ' GLN . . . . . 0.438 ' HA ' HD13 ' A' ' 41' ' ' ILE . 0.0 OUTLIER -78.12 130.73 36.73 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.942 -179.962 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 32' ' ' VAL . . . . . 0.456 ' CG2' HD13 ' A' ' 58' ' ' ILE . 4.7 m -132.76 172.48 16.37 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.326 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.112 179.944 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 33' ' ' LEU . . . . . 0.611 ' HB2' HD11 ' A' ' 95' ' ' ILE . 16.7 tp -143.52 112.36 6.58 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.196 -0.457 . . . . 0.0 110.856 -179.942 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 34' ' ' VAL . . . . . 0.506 HG13 ' CB ' ' A' ' 87' ' ' ALA . 21.5 t -81.09 124.25 38.57 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.245 -0.434 . . . . 0.0 111.11 -179.849 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 35' ' ' ALA . . . . . . . . . . . . . . . 57.94 26.65 13.65 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.067 -0.515 . . . . 0.0 111.294 179.99 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 36' ' ' GLY . . . . . 0.541 ' HA2' HD23 ' A' ' 33' ' ' LEU . . . 57.05 33.45 64.25 Favored Glycine 0 N--CA 1.452 -0.29 0 C-N-CA 120.759 -0.734 . . . . 0.0 112.562 179.959 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 37' ' ' GLN . . . . . . . . . . . . . 37.7 mt-30 -144.36 -70.44 0.29 Allowed 'General case' 0 C--N 1.328 -0.35 0 CA-C-O 120.87 0.367 . . . . 0.0 111.075 -179.867 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 38' ' ' LYS . . . . . . . . . . . . . 2.8 mmpt? -68.08 114.61 6.74 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.925 -179.871 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 39' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -93.88 128.64 40.27 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.9 179.985 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -152.82 -172.88 21.64 Favored Glycine 0 N--CA 1.451 -0.335 0 C-N-CA 120.759 -0.734 . . . . 0.0 112.534 179.973 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 41' ' ' ILE . . . . . 0.442 ' N ' HG23 ' A' ' 58' ' ' ILE . 25.4 mm -125.33 138.07 55.57 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.269 0 CA-C-O 120.818 0.342 . . . . 0.0 111.136 -179.932 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 42' ' ' VAL . . . . . . . . . . . . . 21.5 t -69.32 122.33 20.56 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.185 -0.461 . . . . 0.0 111.082 -179.99 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 43' ' ' ARG . . . . . . . . . . . . . 8.0 mmt180 -113.55 -35.88 5.1 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.926 -179.998 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 44' ' ' PHE . . . . . . . . . . . . . 64.6 t80 -139.05 111.45 7.53 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.941 -179.983 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 45' ' ' TYR . . . . . 0.485 ' CE1' ' CE1' ' A' ' 56' ' ' TYR . 13.3 t80 -107.28 136.88 46.36 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.857 179.879 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 153.51 -163.08 30.6 Favored Glycine 0 N--CA 1.451 -0.352 0 C-N-CA 120.746 -0.74 . . . . 0.0 112.479 179.988 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 47' ' ' LYS . . . . . . . . . . . . . 21.1 mttp -88.64 167.69 13.16 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-O 120.799 0.333 . . . . 0.0 110.875 -179.944 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 48' ' ' THR . . . . . 0.672 HG21 ' CZ ' ' A' ' 50' ' ' PHE . 29.1 p -129.48 -173.88 3.13 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.846 179.965 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -110.37 -31.58 7.24 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.855 -179.97 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 50' ' ' PHE . . . . . 0.672 ' CZ ' HG21 ' A' ' 48' ' ' THR . 18.3 p90 -67.84 -36.09 79.74 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.259 -0.428 . . . . 0.0 110.992 -179.924 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 51' ' ' ALA . . . . . 0.427 ' N ' ' CD1' ' A' ' 50' ' ' PHE . . . -148.4 146.04 21.81 Favored Pre-proline 0 C--N 1.329 -0.283 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.175 179.979 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 52' ' ' PRO . . . . . . . . . . . . . 69.2 Cg_endo -74.39 173.77 13.67 Favored 'Trans proline' 0 C--N 1.345 0.391 0 C-N-CA 122.573 2.182 . . . . 0.0 112.315 -179.985 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 92.43 172.62 41.47 Favored Glycine 0 N--CA 1.452 -0.289 0 C-N-CA 120.762 -0.733 . . . . 0.0 112.48 179.905 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 54' ' ' TYR . . . . . . . . . . . . . 10.5 m-85 -90.14 110.31 21.33 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-O 120.814 0.34 . . . . 0.0 110.868 -179.993 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 55' ' ' TRP . . . . . 0.426 ' HB3' ' CD1' ' A' ' 86' ' ' PHE . 66.7 m95 -105.17 159.25 16.01 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.906 179.967 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 56' ' ' TYR . . . . . 0.607 ' CE1' ' HB2' ' A' ' 89' ' ' ALA . 12.6 m-85 -114.9 117.34 30.4 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.98 -179.824 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . -79.75 68.06 3.28 Favored Glycine 0 N--CA 1.451 -0.34 0 C-N-CA 120.684 -0.77 . . . . 0.0 112.341 179.934 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 58' ' ' ILE . . . . . 0.595 HD11 HD13 ' A' ' 92' ' ' ILE . 38.0 mt -73.3 137.89 22.44 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.39 0 CA-C-O 120.829 0.347 . . . . 0.0 111.192 -179.911 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 1.3 tm-20 -104.29 107.12 17.88 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.79 179.926 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 60' ' ' LEU . . . . . 0.568 HD11 HG11 ' A' ' 85' ' ' VAL . 36.6 mt -60.11 170.43 1.25 Allowed 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.971 -179.935 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 2.9 m-20 -100.45 -31.6 11.21 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.882 -179.991 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 62' ' ' GLN . . . . . 0.667 ' O ' HG22 ' A' ' 64' ' ' THR . 0.0 OUTLIER -120.24 147.31 44.63 Favored Pre-proline 0 C--N 1.331 -0.23 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.839 -179.93 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 50.6 Cg_exo -53.07 90.5 0.03 OUTLIER 'Trans proline' 0 C--N 1.345 0.389 0 C-N-CA 122.479 2.119 . . . . 0.0 112.405 179.949 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 64' ' ' THR . . . . . 0.667 HG22 ' O ' ' A' ' 62' ' ' GLN . 4.9 t -164.7 39.4 0.07 Allowed 'General case' 0 C--N 1.327 -0.384 0 CA-C-N 116.296 -0.411 . . . . 0.0 110.911 179.989 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . -100.66 -149.07 22.99 Favored Glycine 0 N--CA 1.451 -0.325 0 C-N-CA 120.741 -0.742 . . . . 0.0 112.515 179.946 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 66' ' ' LYS . . . . . . . . . . . . . 0.6 OUTLIER -121.47 -42.65 2.43 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-O 120.825 0.345 . . . . 0.0 110.918 -179.948 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 67' ' ' HIS . . . . . . . . . . . . . 6.8 p80 -128.53 172.15 11.44 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.917 179.964 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 4.9 m-20 -98.36 33.67 2.17 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.922 -179.971 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 99.47 -41.89 2.1 Favored Glycine 0 N--CA 1.451 -0.316 0 C-N-CA 120.636 -0.792 . . . . 0.0 112.491 179.995 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 70' ' ' SER . . . . . . . . . . . . . 77.3 p -104.82 148.62 26.44 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 120.835 0.35 . . . . 0.0 110.918 -179.974 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 21.5 t -135.45 122.59 35.31 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.146 -0.479 . . . . 0.0 111.105 179.958 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 72' ' ' PHE . . . . . . . . . . . . . 33.5 m-85 60.28 33.85 20.89 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.924 -179.992 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 80.4 27.92 50.09 Favored Glycine 0 N--CA 1.452 -0.25 0 C-N-CA 120.692 -0.766 . . . . 0.0 112.533 -179.97 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 21.4 t -131.61 100.71 4.58 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-O 120.767 0.317 . . . . 0.0 111.078 -179.997 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 75' ' ' ARG . . . . . . . . . . . . . 20.5 ttt85 -77.45 119.75 21.49 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.26 -0.427 . . . . 0.0 110.949 -179.968 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 76' ' ' TYR . . . . . . . . . . . . . 25.4 m-85 -92.28 -48.86 6.46 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.835 -179.995 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 77' ' ' PHE . . . . . . . . . . . . . 16.8 p90 -148.65 161.97 40.65 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.752 179.936 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -88.34 108.5 19.37 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.971 -179.963 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 79' ' ' CYS . . . . . . . . . . . . . 30.4 p -132.93 174.11 10.68 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.867 -179.976 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 80' ' ' ALA . . . . . 0.632 ' HB3' ' ND1' ' A' ' 83' ' ' HIS . . . -81.95 166.73 35.53 Favored Pre-proline 0 C--N 1.329 -0.311 0 CA-C-N 116.198 -0.455 . . . . 0.0 111.056 179.978 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 81' ' ' PRO . . . . . 0.518 ' HD2' ' HB1' ' A' ' 80' ' ' ALA . 51.9 Cg_exo -54.34 117.49 3.99 Favored 'Trans proline' 0 C--N 1.343 0.267 0 C-N-CA 122.57 2.18 . . . . 0.0 112.304 179.994 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 82' ' ' ARG . . . . . . . . . . . . . 3.3 mpt_? 60.99 52.97 3.86 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.116 -0.493 . . . . 0.0 110.96 179.99 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 83' ' ' HIS . . . . . 0.632 ' ND1' ' HB3' ' A' ' 80' ' ' ALA . 7.2 m170 -122.41 -42.15 2.36 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.119 -0.491 . . . . 0.0 110.915 179.989 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . -64.24 144.56 48.75 Favored Glycine 0 N--CA 1.452 -0.261 0 C-N-CA 120.632 -0.794 . . . . 0.0 112.426 179.968 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 85' ' ' VAL . . . . . 0.568 HG11 HD11 ' A' ' 60' ' ' LEU . 15.4 m -152.54 121.32 0.77 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-O 120.833 0.349 . . . . 0.0 111.101 179.997 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 86' ' ' PHE . . . . . 0.426 ' CD1' ' HB3' ' A' ' 55' ' ' TRP . 2.5 m-85 -100.69 118.73 37.4 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.945 179.971 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 87' ' ' ALA . . . . . 0.506 ' CB ' HG13 ' A' ' 34' ' ' VAL . . . -139.91 145.72 43.79 Favored Pre-proline 0 C--N 1.329 -0.316 0 CA-C-N 116.258 -0.428 . . . . 0.0 111.094 179.936 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 88' ' ' PRO . . . . . 0.411 ' O ' ' N ' ' A' ' 91' ' ' ARG . 36.0 Cg_exo -57.27 138.2 85.16 Favored 'Trans proline' 0 C--N 1.346 0.441 0 C-N-CA 122.46 2.107 . . . . 0.0 112.336 -179.952 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 89' ' ' ALA . . . . . 0.607 ' HB2' ' CE1' ' A' ' 56' ' ' TYR . . . -47.63 -51.9 19.84 Favored 'General case' 0 C--N 1.333 -0.115 0 CA-C-O 121.112 0.482 . . . . 0.0 110.367 179.902 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 90' ' ' SER . . . . . . . . . . . . . 5.9 m -55.52 -24.48 32.11 Favored 'General case' 0 N--CA 1.454 -0.246 0 CA-C-N 115.657 -0.701 . . . . 0.0 109.754 178.769 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 91' ' ' ARG . . . . . 0.411 ' N ' ' O ' ' A' ' 88' ' ' PRO . 0.6 OUTLIER -88.41 -16.36 33.1 Favored 'General case' 0 N--CA 1.454 -0.234 0 CA-C-N 115.829 -0.623 . . . . 0.0 110.416 179.066 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 92' ' ' ILE . . . . . 0.595 HD13 HD11 ' A' ' 58' ' ' ILE . 51.6 mt -104.51 145.09 13.57 Favored 'Isoleucine or valine' 0 C--N 1.333 -0.121 0 CA-C-N 116.379 -0.373 . . . . 0.0 111.035 179.869 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 93' ' ' GLN . . . . . . . . . . . . . 1.8 mt-30 -112.83 -179.96 3.8 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.228 -0.442 . . . . 0.0 111.009 -179.949 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 94' ' ' ARG . . . . . . . . . . . . . 0.6 OUTLIER -126.88 138.96 53.39 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.947 -179.895 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 95' ' ' ILE . . . . . 0.611 HD11 ' HB2' ' A' ' 33' ' ' LEU . 3.8 mp . . . . . 0 C--N 1.33 -0.252 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.059 179.967 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.23 0.06 0 CA-C-O 120.839 0.352 . . . . 0.0 111.076 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild core ' A' A ' 27' ' ' GLU . . . . . . . . . . . . . 28.5 mt-10 -143.2 -172.59 3.72 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.918 -179.996 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 30.6 t -78.46 111.65 15.55 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.236 -0.438 . . . . 0.0 111.078 -179.979 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 106.16 42.73 1.6 Allowed Glycine 0 N--CA 1.452 -0.255 0 C-N-CA 120.729 -0.748 . . . . 0.0 112.52 179.967 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 2.3 m-20 -150.12 136.77 19.14 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-O 120.813 0.34 . . . . 0.0 110.823 179.979 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 31' ' ' GLN . . . . . . . . . . . . . 2.6 mt-30 -60.03 141.02 56.42 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.88 179.92 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 6.3 m -146.57 179.58 0.92 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.356 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.188 179.992 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 33' ' ' LEU . . . . . 0.534 HD11 ' O ' ' A' ' 37' ' ' GLN . 25.7 tp -142.09 109.89 5.8 Favored 'General case' 0 C--N 1.331 -0.239 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.846 179.991 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 34' ' ' VAL . . . . . 0.408 HG13 ' CB ' ' A' ' 87' ' ' ALA . 21.5 t -77.72 123.54 34.59 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.266 0 CA-C-N 116.181 -0.463 . . . . 0.0 111.182 -179.969 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 35' ' ' ALA . . . . . . . . . . . . . . . 57.63 26.64 13.14 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.198 -0.456 . . . . 0.0 111.235 -179.964 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . 57.07 29.38 59.42 Favored Glycine 0 N--CA 1.451 -0.327 0 C-N-CA 120.734 -0.746 . . . . 0.0 112.613 179.953 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 37' ' ' GLN . . . . . 0.534 ' O ' HD11 ' A' ' 33' ' ' LEU . 20.1 mt-30 -141.29 -74.59 0.32 Allowed 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 120.85 0.357 . . . . 0.0 110.966 -179.964 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 38' ' ' LYS . . . . . 0.465 ' HD2' HD13 ' A' ' 60' ' ' LEU . 21.8 mmtm -63.47 103.19 0.49 Allowed 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.861 -179.959 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 39' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -82.55 135.35 35.11 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.939 179.931 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -164.73 -176.01 36.04 Favored Glycine 0 N--CA 1.452 -0.288 0 C-N-CA 120.677 -0.773 . . . . 0.0 112.49 179.965 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 2.6 mt -127.34 137.01 59.03 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 CA-C-O 120.82 0.343 . . . . 0.0 111.085 -179.979 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 42' ' ' VAL . . . . . . . . . . . . . 21.4 t -59.62 123.38 11.91 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.202 -0.454 . . . . 0.0 111.12 179.971 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 43' ' ' ARG . . . . . . . . . . . . . 17.3 mmt85 -111.3 -33.99 6.27 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.902 179.903 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 44' ' ' PHE . . . . . 0.424 ' CD1' ' HB3' ' A' ' 76' ' ' TYR . 60.4 t80 -142.75 110.31 5.78 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.965 -179.979 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 45' ' ' TYR . . . . . . . . . . . . . 15.3 t80 -107.54 119.62 39.93 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.196 -0.457 . . . . 0.0 110.861 179.974 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 175.52 177.14 44.35 Favored Glycine 0 N--CA 1.451 -0.347 0 C-N-CA 120.801 -0.714 . . . . 0.0 112.561 179.971 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 47' ' ' LYS . . . . . . . . . . . . . 16.0 mtmt -77.02 168.14 20.6 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-O 120.886 0.374 . . . . 0.0 110.856 179.975 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 48' ' ' THR . . . . . 0.463 HG21 ' CE2' ' A' ' 50' ' ' PHE . 23.6 p -125.58 -179.66 4.74 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.868 179.953 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 1.5 t70 -106.74 -31.84 8.24 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.939 179.974 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 50' ' ' PHE . . . . . 0.463 ' CE2' HG21 ' A' ' 48' ' ' THR . 48.8 p90 -70.19 -35.86 74.22 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.924 -179.988 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 51' ' ' ALA . . . . . . . . . . . . . . . -141.09 144.16 33.85 Favored Pre-proline 0 C--N 1.328 -0.333 0 CA-C-N 116.218 -0.446 . . . . 0.0 111.087 -179.981 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 52' ' ' PRO . . . . . . . . . . . . . 70.8 Cg_endo -74.74 -176.85 3.02 Favored 'Trans proline' 0 C--N 1.345 0.389 0 C-N-CA 122.531 2.154 . . . . 0.0 112.309 179.99 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 76.78 -175.68 53.36 Favored Glycine 0 N--CA 1.45 -0.376 0 C-N-CA 120.745 -0.74 . . . . 0.0 112.567 179.993 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 54' ' ' TYR . . . . . . . . . . . . . 34.5 m-85 -88.58 158.35 18.31 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-O 120.847 0.356 . . . . 0.0 110.916 179.967 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 55' ' ' TRP . . . . . 0.428 ' HB3' ' CD1' ' A' ' 86' ' ' PHE . 94.2 m95 -154.06 140.96 19.21 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.154 -0.475 . . . . 0.0 110.867 179.96 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 56' ' ' TYR . . . . . 0.424 ' HE1' ' HB2' ' A' ' 89' ' ' ALA . 36.2 m-85 -102.57 122.31 44.13 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.902 -179.927 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 57' ' ' GLY . . . . . 0.447 ' N ' ' CE1' ' A' ' 86' ' ' PHE . . . -87.79 59.08 4.31 Favored Glycine 0 N--CA 1.451 -0.357 0 C-N-CA 120.754 -0.736 . . . . 0.0 112.468 -179.978 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 58' ' ' ILE . . . . . 0.67 HD11 HD13 ' A' ' 92' ' ' ILE . 7.8 mt -64.14 152.48 8.28 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-O 120.829 0.347 . . . . 0.0 110.964 -179.957 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 1.7 tm-20 -122.94 102.94 8.3 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.925 179.988 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 60' ' ' LEU . . . . . 0.465 HD13 ' HD2' ' A' ' 38' ' ' LYS . 54.8 mt -63.16 162.72 11.32 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.904 -179.957 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 2.7 t0 -92.78 -30.91 15.25 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.916 -179.981 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 62' ' ' GLN . . . . . . . . . . . . . 7.1 mt-30 -100.35 152.0 37.7 Favored Pre-proline 0 C--N 1.329 -0.311 0 CA-C-N 116.231 -0.44 . . . . 0.0 110.952 -179.994 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 71.9 Cg_endo -75.45 97.9 1.13 Allowed 'Trans proline' 0 C--N 1.344 0.316 0 C-N-CA 122.595 2.196 . . . . 0.0 112.309 -179.892 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 64' ' ' THR . . . . . . . . . . . . . 9.9 t -173.68 36.27 0.01 OUTLIER 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.9 -179.989 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . -90.09 -159.52 35.6 Favored Glycine 0 N--CA 1.451 -0.335 0 C-N-CA 120.731 -0.747 . . . . 0.0 112.544 179.985 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 66' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -110.47 -31.71 7.17 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 120.819 0.342 . . . . 0.0 110.846 -179.947 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 67' ' ' HIS . . . . . . . . . . . . . 6.6 p80 -140.83 173.57 11.36 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.893 179.954 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 2.6 m-20 -97.98 37.09 1.46 Allowed 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.834 -179.915 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 98.79 -28.61 14.33 Favored Glycine 0 N--CA 1.451 -0.362 0 C-N-CA 120.676 -0.773 . . . . 0.0 112.486 179.967 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 70' ' ' SER . . . . . . . . . . . . . 88.7 p -110.4 161.32 15.77 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-O 120.841 0.353 . . . . 0.0 110.842 -179.92 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 71' ' ' VAL . . . . . 0.524 HG12 ' HD1' ' A' ' 72' ' ' PHE . 21.5 t -146.41 126.75 6.02 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.256 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.063 -179.981 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 72' ' ' PHE . . . . . 0.524 ' HD1' HG12 ' A' ' 71' ' ' VAL . 11.3 m-85 60.58 27.05 16.73 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.163 -0.472 . . . . 0.0 111.026 179.974 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 95.65 -29.82 9.23 Favored Glycine 0 N--CA 1.452 -0.284 0 C-N-CA 120.752 -0.737 . . . . 0.0 112.537 179.952 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 25.5 t -80.98 116.58 25.53 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.343 0 CA-C-O 120.8 0.333 . . . . 0.0 111.141 -179.976 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 75' ' ' ARG . . . . . . . . . . . . . 2.1 ttt-85 -88.49 148.36 24.19 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.86 -179.933 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 76' ' ' TYR . . . . . 0.428 ' CE1' HG22 ' A' ' 48' ' ' THR . 53.8 m-85 -120.09 -50.81 2.24 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.933 -179.963 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 77' ' ' PHE . . . . . . . . . . . . . 26.9 p90 -146.04 161.78 39.35 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.9 179.978 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 4.9 m -91.93 121.98 34.03 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.099 -0.501 . . . . 0.0 110.941 179.979 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 79' ' ' CYS . . . . . . . . . . . . . 26.1 p -144.57 158.12 43.91 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.252 -0.431 . . . . 0.0 110.87 -179.952 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 80' ' ' ALA . . . . . 0.527 ' HB3' ' CG ' ' A' ' 83' ' ' HIS . . . -59.59 164.03 6.06 Favored Pre-proline 0 C--N 1.329 -0.306 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.135 179.913 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 81' ' ' PRO . . . . . 0.457 ' HD2' ' HB1' ' A' ' 80' ' ' ALA . 53.8 Cg_exo -52.31 116.19 2.67 Favored 'Trans proline' 0 C--N 1.345 0.358 0 C-N-CA 122.558 2.172 . . . . 0.0 112.322 -179.982 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 82' ' ' ARG . . . . . . . . . . . . . 16.1 mtt180 58.91 62.49 1.87 Allowed 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.874 -179.962 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 83' ' ' HIS . . . . . 0.527 ' CG ' ' HB3' ' A' ' 80' ' ' ALA . 4.3 m170 -127.12 -43.78 1.64 Allowed 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.088 -0.506 . . . . 0.0 110.859 179.957 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . -68.2 138.51 32.76 Favored Glycine 0 N--CA 1.45 -0.37 0 C-N-CA 120.706 -0.759 . . . . 0.0 112.473 179.976 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 85' ' ' VAL . . . . . 0.467 ' O ' HG23 ' A' ' 85' ' ' VAL . 16.9 m -143.3 113.91 2.43 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-O 120.894 0.378 . . . . 0.0 111.108 -179.994 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 86' ' ' PHE . . . . . 0.447 ' CE1' ' N ' ' A' ' 57' ' ' GLY . 5.4 m-85 -89.11 119.81 29.95 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.843 -179.964 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 87' ' ' ALA . . . . . 0.605 ' O ' HD11 ' A' ' 92' ' ' ILE . . . -139.48 143.86 37.41 Favored Pre-proline 0 C--N 1.329 -0.303 0 CA-C-N 116.263 -0.426 . . . . 0.0 111.146 179.991 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 88' ' ' PRO . . . . . 0.427 ' O ' ' N ' ' A' ' 91' ' ' ARG . 46.8 Cg_exo -55.94 140.45 85.85 Favored 'Trans proline' 0 C--N 1.346 0.43 0 C-N-CA 122.541 2.161 . . . . 0.0 112.379 179.959 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 89' ' ' ALA . . . . . 0.424 ' HB2' ' HE1' ' A' ' 56' ' ' TYR . . . -47.83 -50.3 26.59 Favored 'General case' 0 CA--C 1.521 -0.158 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.264 179.896 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 90' ' ' SER . . . . . . . . . . . . . 8.0 m -55.59 -24.37 32.51 Favored 'General case' 0 N--CA 1.454 -0.266 0 CA-C-N 115.769 -0.651 . . . . 0.0 109.796 178.859 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 91' ' ' ARG . . . . . 0.427 ' N ' ' O ' ' A' ' 88' ' ' PRO . 2.3 mtm-85 -89.74 -15.22 32.93 Favored 'General case' 0 N--CA 1.455 -0.19 0 CA-C-N 115.813 -0.631 . . . . 0.0 110.524 179.063 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 92' ' ' ILE . . . . . 0.67 HD13 HD11 ' A' ' 58' ' ' ILE . 49.9 mt -103.08 144.87 13.2 Favored 'Isoleucine or valine' 0 C--O 1.232 0.16 0 CA-C-N 116.402 -0.363 . . . . 0.0 111.094 179.858 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 93' ' ' GLN . . . . . . . . . . . . . 0.5 OUTLIER -115.71 154.3 29.81 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.905 -179.976 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 94' ' ' ARG . . . . . . . . . . . . . 7.6 mtp180 -96.96 138.54 34.34 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.868 179.978 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 95' ' ' ILE . . . . . . . . . . . . . 16.9 mt . . . . . 0 C--N 1.329 -0.286 0 CA-C-N 116.15 -0.477 . . . . 0.0 111.108 179.97 . . . . . . . . 0 0 . 1 . 006 nuclear nobuild core ' A' A ' 26' ' ' ALA . . . . . 0.451 ' HB2' ' HG3' ' A' ' 94' ' ' ARG . . . . . . . . 0 C--O 1.23 0.078 0 CA-C-O 120.799 0.333 . . . . 0.0 111.142 . . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 27' ' ' GLU . . . . . . . . . . . . . 6.3 mm-40 -142.46 -179.18 6.13 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.935 179.956 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 21.5 t -66.95 123.34 19.8 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.127 -180.0 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 84.7 46.34 5.76 Favored Glycine 0 N--CA 1.451 -0.326 0 C-N-CA 120.767 -0.73 . . . . 0.0 112.529 -179.993 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 4.6 t0 -146.16 134.28 21.59 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 120.879 0.371 . . . . 0.0 110.892 -179.998 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 31' ' ' GLN . . . . . . . . . . . . . 1.9 mt-30 -60.31 139.23 57.74 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.912 179.974 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 32' ' ' VAL . . . . . 0.43 HG21 HG12 ' A' ' 58' ' ' ILE . 19.2 m -145.17 176.02 2.31 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.28 -0.418 . . . . 0.0 111.133 -179.975 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 33' ' ' LEU . . . . . 0.519 HD11 ' O ' ' A' ' 37' ' ' GLN . 30.4 tp -134.5 100.04 4.53 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.145 -0.48 . . . . 0.0 110.898 179.988 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 21.5 t -69.11 126.58 29.42 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.205 -179.853 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 35' ' ' ALA . . . . . . . . . . . . . . . 57.06 25.34 10.67 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.321 179.941 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . 56.07 35.03 63.04 Favored Glycine 0 N--CA 1.451 -0.33 0 C-N-CA 120.722 -0.751 . . . . 0.0 112.58 179.941 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 37' ' ' GLN . . . . . 0.519 ' O ' HD11 ' A' ' 33' ' ' LEU . 48.8 mt-30 -147.51 -68.3 0.25 Allowed 'General case' 0 C--N 1.329 -0.295 0 CA-C-O 120.862 0.363 . . . . 0.0 110.949 -179.929 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 38' ' ' LYS . . . . . . . . . . . . . 64.5 mttp -73.77 106.85 5.69 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.919 -179.966 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 39' ' ' GLN . . . . . 0.433 ' HG2' HD11 ' A' ' 95' ' ' ILE . 0.9 OUTLIER -85.16 135.02 34.14 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.923 179.89 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -157.87 -170.43 22.65 Favored Glycine 0 N--CA 1.45 -0.389 0 C-N-CA 120.683 -0.77 . . . . 0.0 112.505 -179.998 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 41' ' ' ILE . . . . . 0.508 ' C ' HG23 ' A' ' 58' ' ' ILE . 14.5 mt -126.38 131.54 71.33 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-O 120.842 0.353 . . . . 0.0 111.132 -179.959 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 42' ' ' VAL . . . . . . . . . . . . . 38.2 t -65.52 119.73 10.87 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.02 -179.964 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 43' ' ' ARG . . . . . . . . . . . . . 25.5 mmt180 -104.13 -31.46 9.64 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.259 -0.428 . . . . 0.0 110.966 179.895 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 44' ' ' PHE . . . . . . . . . . . . . 69.2 t80 -143.77 117.52 9.28 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.875 -179.929 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 45' ' ' TYR . . . . . 0.464 ' CE1' ' CZ ' ' A' ' 56' ' ' TYR . 21.5 t80 -113.13 133.82 54.85 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.264 -0.426 . . . . 0.0 110.925 179.988 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 154.17 174.87 24.76 Favored Glycine 0 N--CA 1.451 -0.35 0 C-N-CA 120.799 -0.715 . . . . 0.0 112.523 179.937 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 47' ' ' LYS . . . . . . . . . . . . . 1.9 mmtp -60.06 160.53 7.93 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 120.81 0.338 . . . . 0.0 110.938 -179.996 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 48' ' ' THR . . . . . 0.408 HG21 ' CZ ' ' A' ' 50' ' ' PHE . 38.4 p -124.82 -179.09 4.38 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.872 179.938 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -107.65 -34.75 6.9 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.883 -179.989 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 50' ' ' PHE . . . . . 0.435 ' CD1' ' N ' ' A' ' 51' ' ' ALA . 15.9 p90 -63.33 -31.46 72.62 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.154 -0.475 . . . . 0.0 110.986 180.0 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 51' ' ' ALA . . . . . 0.435 ' N ' ' CD1' ' A' ' 50' ' ' PHE . . . -156.27 148.16 17.28 Favored Pre-proline 0 C--N 1.33 -0.244 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.117 -179.999 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 52' ' ' PRO . . . . . . . . . . . . . 58.3 Cg_endo -71.47 162.63 41.68 Favored 'Trans proline' 0 C--N 1.344 0.326 0 C-N-CA 122.624 2.216 . . . . 0.0 112.335 179.987 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 102.28 177.42 27.57 Favored Glycine 0 N--CA 1.45 -0.407 0 C-N-CA 120.769 -0.729 . . . . 0.0 112.501 179.939 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 54' ' ' TYR . . . . . . . . . . . . . 37.1 m-85 -97.22 112.31 24.17 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 120.813 0.34 . . . . 0.0 110.958 179.996 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 55' ' ' TRP . . . . . 0.406 ' CZ3' ' HD3' ' A' ' 88' ' ' PRO . 42.1 m95 -107.93 161.76 14.63 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.898 179.989 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 56' ' ' TYR . . . . . 0.626 ' CE1' ' HB2' ' A' ' 89' ' ' ALA . 11.3 m-85 -113.61 122.49 47.37 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.26 -0.427 . . . . 0.0 110.918 -179.98 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . -84.19 56.71 5.04 Favored Glycine 0 N--CA 1.45 -0.368 0 C-N-CA 120.801 -0.714 . . . . 0.0 112.511 179.861 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 58' ' ' ILE . . . . . 0.562 HD11 HD13 ' A' ' 92' ' ' ILE . 3.7 mt -68.32 137.99 23.39 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-O 120.84 0.352 . . . . 0.0 111.092 -179.937 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 0.8 OUTLIER -101.39 141.55 34.09 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.947 179.998 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 60' ' ' LEU . . . . . 0.425 HD12 ' HA2' ' A' ' 65' ' ' GLY . 59.6 mt -97.78 174.13 6.76 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.883 179.99 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 1.3 t0 -101.55 -30.91 11.12 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.176 -0.466 . . . . 0.0 110.959 179.965 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 62' ' ' GLN . . . . . . . . . . . . . 7.5 mt-30 -104.17 153.16 39.15 Favored Pre-proline 0 C--N 1.33 -0.273 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.912 -179.972 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 66.1 Cg_endo -73.97 65.34 5.07 Favored 'Trans proline' 0 C--N 1.345 0.352 0 C-N-CA 122.576 2.184 . . . . 0.0 112.29 -179.902 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 64' ' ' THR . . . . . . . . . . . . . 3.9 t -148.76 39.38 0.86 Allowed 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.882 179.933 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 65' ' ' GLY . . . . . 0.425 ' HA2' HD12 ' A' ' 60' ' ' LEU . . . -83.64 -99.63 0.57 Allowed Glycine 0 N--CA 1.451 -0.305 0 C-N-CA 120.705 -0.759 . . . . 0.0 112.525 179.906 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 66' ' ' LYS . . . . . . . . . . . . . 5.8 mttt -168.76 -44.69 0.02 OUTLIER 'General case' 0 C--N 1.33 -0.251 0 CA-C-O 120.845 0.355 . . . . 0.0 110.871 179.952 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 67' ' ' HIS . . . . . . . . . . . . . 10.1 p80 -125.5 170.28 11.58 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.903 179.91 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 17.1 t0 -103.49 52.36 0.77 Allowed 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.934 179.951 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 90.55 -75.64 1.65 Allowed Glycine 0 N--CA 1.45 -0.403 0 C-N-CA 120.741 -0.742 . . . . 0.0 112.445 179.982 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 70' ' ' SER . . . . . . . . . . . . . 93.1 p -84.4 154.7 22.67 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-O 120.875 0.369 . . . . 0.0 110.848 179.982 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 71' ' ' VAL . . . . . 0.412 HG12 ' CD2' ' A' ' 72' ' ' PHE . 21.5 t -129.37 122.69 56.29 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.141 179.993 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 72' ' ' PHE . . . . . 0.412 ' CD2' HG12 ' A' ' 71' ' ' VAL . 37.7 m-85 60.74 30.03 19.42 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.898 179.98 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 96.5 -30.05 9.37 Favored Glycine 0 N--CA 1.451 -0.362 0 C-N-CA 120.759 -0.734 . . . . 0.0 112.573 -179.969 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 28.0 t -79.4 122.61 34.96 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-O 120.833 0.349 . . . . 0.0 111.087 -179.992 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 75' ' ' ARG . . . . . . . . . . . . . 21.8 ttt-85 -91.89 142.99 26.95 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.98 179.948 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 76' ' ' TYR . . . . . . . . . . . . . 24.3 m-85 -118.78 -41.72 2.77 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.271 -0.422 . . . . 0.0 110.869 -179.973 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 77' ' ' PHE . . . . . . . . . . . . . 50.9 p90 -160.29 161.7 33.4 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.828 -179.998 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 3.3 m -89.86 123.51 33.88 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.987 179.865 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 79' ' ' CYS . . . . . . . . . . . . . 30.3 p -145.88 -177.94 5.85 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.885 179.997 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 80' ' ' ALA . . . . . 0.477 ' HB3' ' CG ' ' A' ' 83' ' ' HIS . . . -92.1 164.47 23.23 Favored Pre-proline 0 C--N 1.329 -0.319 0 CA-C-N 116.2 -0.455 . . . . 0.0 111.124 179.988 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 81' ' ' PRO . . . . . 0.452 ' HD2' ' HB1' ' A' ' 80' ' ' ALA . 52.9 Cg_exo -52.48 116.29 2.76 Favored 'Trans proline' 0 C--N 1.345 0.344 0 C-N-CA 122.55 2.167 . . . . 0.0 112.275 179.993 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 82' ' ' ARG . . . . . . . . . . . . . 7.3 mtm180 61.9 58.79 1.85 Allowed 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.178 -0.464 . . . . 0.0 110.834 -179.997 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 83' ' ' HIS . . . . . 0.477 ' CG ' ' HB3' ' A' ' 80' ' ' ALA . 5.6 m170 -128.98 -47.55 1.23 Allowed 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.92 179.925 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . -66.64 147.58 49.82 Favored Glycine 0 N--CA 1.45 -0.4 0 C-N-CA 120.8 -0.714 . . . . 0.0 112.471 179.906 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 85' ' ' VAL . . . . . . . . . . . . . 5.2 m -152.99 123.07 0.82 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-O 120.804 0.335 . . . . 0.0 111.153 179.921 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 86' ' ' PHE . . . . . . . . . . . . . 29.8 m-85 -99.87 121.23 41.01 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.834 -179.938 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 87' ' ' ALA . . . . . 0.493 ' O ' HD11 ' A' ' 92' ' ' ILE . . . -140.56 147.38 48.94 Favored Pre-proline 0 C--N 1.33 -0.261 0 CA-C-N 116.248 -0.433 . . . . 0.0 111.093 -179.988 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 88' ' ' PRO . . . . . 0.406 ' HD3' ' CZ3' ' A' ' 55' ' ' TRP . 32.4 Cg_exo -57.97 138.33 85.46 Favored 'Trans proline' 0 C--N 1.345 0.388 0 C-N-CA 122.561 2.174 . . . . 0.0 112.258 -179.979 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 89' ' ' ALA . . . . . 0.626 ' HB2' ' CE1' ' A' ' 56' ' ' TYR . . . -47.98 -51.71 22.72 Favored 'General case' 0 C--N 1.332 -0.161 0 CA-C-O 121.137 0.494 . . . . 0.0 110.278 179.84 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 90' ' ' SER . . . . . . . . . . . . . 3.6 t -55.87 -24.45 37.07 Favored 'General case' 0 C--N 1.332 -0.186 0 CA-C-N 115.693 -0.685 . . . . 0.0 109.701 178.826 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 91' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -88.5 -14.35 38.02 Favored 'General case' 0 N--CA 1.454 -0.246 0 CA-C-N 115.911 -0.586 . . . . 0.0 110.49 179.058 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 92' ' ' ILE . . . . . 0.562 HD13 HD11 ' A' ' 58' ' ' ILE . 36.3 mt -110.83 156.13 12.05 Favored 'Isoleucine or valine' 0 C--N 1.334 -0.065 0 CA-C-O 120.908 0.385 . . . . 0.0 111.063 179.906 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 93' ' ' GLN . . . . . 0.451 ' N ' HG22 ' A' ' 92' ' ' ILE . 2.3 mp0 -123.67 173.84 7.84 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.116 -0.493 . . . . 0.0 110.811 179.987 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 94' ' ' ARG . . . . . 0.451 ' HG3' ' HB2' ' A' ' 26' ' ' ALA . 1.1 mtp180 -115.48 140.02 49.53 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.899 179.968 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 95' ' ' ILE . . . . . 0.433 HD11 ' HG2' ' A' ' 39' ' ' GLN . 21.7 mm . . . . . 0 C--N 1.33 -0.267 0 CA-C-N 116.154 -0.476 . . . . 0.0 111.124 179.946 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.231 0.13 0 CA-C-O 120.862 0.363 . . . . 0.0 111.089 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild core ' A' A ' 27' ' ' GLU . . . . . . . . . . . . . 3.6 mm-40 -135.55 -178.73 5.25 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.841 179.946 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 21.5 t -83.08 104.98 12.42 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.164 -0.471 . . . . 0.0 111.119 179.993 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 107.35 30.58 4.07 Favored Glycine 0 N--CA 1.452 -0.288 0 C-N-CA 120.779 -0.724 . . . . 0.0 112.487 -179.948 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 3.4 m-20 -124.84 144.21 50.42 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 120.793 0.33 . . . . 0.0 110.895 179.952 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 31' ' ' GLN . . . . . . . . . . . . . 5.0 mp0 -65.28 130.4 43.19 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.806 -179.97 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 20.7 m -136.13 175.23 10.95 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 CA-C-N 116.2 -0.454 . . . . 0.0 111.079 179.993 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 33' ' ' LEU . . . . . 0.44 HD12 ' HA ' ' A' ' 39' ' ' GLN . 14.1 tp -139.11 100.06 3.92 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.105 -0.498 . . . . 0.0 110.912 179.98 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 21.5 t -64.5 121.02 12.74 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 116.234 -0.439 . . . . 0.0 111.179 179.991 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 35' ' ' ALA . . . . . . . . . . . . . . . 58.71 26.87 15.14 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.3 179.998 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . 56.66 27.79 55.61 Favored Glycine 0 N--CA 1.451 -0.32 0 C-N-CA 120.779 -0.724 . . . . 0.0 112.601 -179.976 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 37' ' ' GLN . . . . . 0.41 ' O ' HD11 ' A' ' 33' ' ' LEU . 38.9 mt-30 -139.66 -72.08 0.38 Allowed 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.775 0.321 . . . . 0.0 110.892 -179.993 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 38' ' ' LYS . . . . . 0.405 ' HB3' HD21 ' A' ' 60' ' ' LEU . 55.6 mttt -65.17 114.53 4.73 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.259 -0.428 . . . . 0.0 110.924 179.995 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 39' ' ' GLN . . . . . 0.44 ' HA ' HD12 ' A' ' 33' ' ' LEU . 5.8 tm0? -85.53 130.07 34.67 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.886 179.952 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -157.08 173.56 34.66 Favored Glycine 0 N--CA 1.451 -0.302 0 C-N-CA 120.66 -0.781 . . . . 0.0 112.481 179.993 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 41' ' ' ILE . . . . . 0.42 ' N ' HG23 ' A' ' 58' ' ' ILE . 33.5 mt -121.13 133.18 68.56 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 CA-C-O 120.802 0.334 . . . . 0.0 111.033 -179.969 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 42' ' ' VAL . . . . . . . . . . . . . 21.4 t -61.99 121.73 11.06 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.146 -0.479 . . . . 0.0 111.097 179.979 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 43' ' ' ARG . . . . . . . . . . . . . 14.8 mmt180 -108.0 -30.92 8.19 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.903 179.878 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 44' ' ' PHE . . . . . . . . . . . . . 28.9 t80 -149.73 109.57 4.07 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.25 -0.432 . . . . 0.0 110.934 -179.976 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 45' ' ' TYR . . . . . 0.49 ' CE1' ' CZ ' ' A' ' 56' ' ' TYR . 22.7 t80 -106.76 130.5 54.46 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.289 -0.414 . . . . 0.0 110.865 179.964 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 167.02 -161.17 35.02 Favored Glycine 0 N--CA 1.451 -0.35 0 C-N-CA 120.679 -0.772 . . . . 0.0 112.488 -179.976 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 47' ' ' LYS . . . . . . . . . . . . . 40.3 mttt -84.74 175.83 8.93 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 120.748 0.309 . . . . 0.0 110.949 179.94 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 48' ' ' THR . . . . . 0.46 HG21 ' CZ ' ' A' ' 50' ' ' PHE . 71.1 p -143.9 -177.42 5.42 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.938 -179.974 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 3.5 t0 -110.8 -35.03 6.08 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.284 -0.416 . . . . 0.0 110.914 -179.961 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 50' ' ' PHE . . . . . 0.46 ' CZ ' HG21 ' A' ' 48' ' ' THR . 16.1 p90 -60.06 -31.36 69.92 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.917 179.996 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 51' ' ' ALA . . . . . 0.438 ' N ' ' CD1' ' A' ' 50' ' ' PHE . . . -159.84 141.73 9.62 Favored Pre-proline 0 C--N 1.329 -0.319 0 CA-C-N 116.264 -0.426 . . . . 0.0 111.092 179.911 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 52' ' ' PRO . . . . . . . . . . . . . 72.6 Cg_endo -74.77 154.7 43.86 Favored 'Trans proline' 0 C--N 1.346 0.405 0 C-N-CA 122.497 2.131 . . . . 0.0 112.39 179.991 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 121.39 -160.34 15.75 Favored Glycine 0 N--CA 1.45 -0.393 0 C-N-CA 120.752 -0.737 . . . . 0.0 112.555 179.988 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 54' ' ' TYR . . . . . . . . . . . . . 33.4 m-85 -113.2 110.49 20.49 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-O 120.81 0.338 . . . . 0.0 110.887 179.997 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 55' ' ' TRP . . . . . . . . . . . . . 51.2 m95 -112.96 160.5 18.03 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.888 179.955 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 56' ' ' TYR . . . . . 0.6 ' HE1' ' HB2' ' A' ' 89' ' ' ALA . 4.8 m-85 -118.07 128.13 54.46 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.954 -179.972 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 57' ' ' GLY . . . . . 0.435 ' HA3' ' CE1' ' A' ' 77' ' ' PHE . . . -88.25 59.42 4.14 Favored Glycine 0 N--CA 1.451 -0.305 0 C-N-CA 120.744 -0.741 . . . . 0.0 112.344 179.855 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 58' ' ' ILE . . . . . 0.703 HD11 HD13 ' A' ' 92' ' ' ILE . 12.6 mt -68.98 148.55 11.61 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.367 0 CA-C-O 120.864 0.364 . . . . 0.0 111.113 -179.895 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -119.15 120.47 37.18 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.891 179.932 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 60' ' ' LEU . . . . . 0.405 HD21 ' HB3' ' A' ' 38' ' ' LYS . 56.7 mt -71.88 -179.96 2.93 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.852 -179.997 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 21.0 m-20 -104.96 -29.55 10.39 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.283 -0.417 . . . . 0.0 110.935 -179.928 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 62' ' ' GLN . . . . . . . . . . . . . 2.1 mt-30 -114.87 147.95 39.39 Favored Pre-proline 0 C--N 1.329 -0.31 0 CA-C-N 116.312 -0.404 . . . . 0.0 110.871 -179.907 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 36.6 Cg_exo -60.02 91.2 0.08 OUTLIER 'Trans proline' 0 C--N 1.345 0.391 0 C-N-CA 122.515 2.143 . . . . 0.0 112.264 179.924 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 64' ' ' THR . . . . . . . . . . . . . 10.1 t -172.72 39.22 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.271 -0.422 . . . . 0.0 110.992 -179.994 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . -91.37 -104.84 1.38 Allowed Glycine 0 N--CA 1.451 -0.3 0 C-N-CA 120.695 -0.764 . . . . 0.0 112.459 -179.979 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 66' ' ' LYS . . . . . . . . . . . . . 3.0 mtmt -159.99 -49.3 0.05 Allowed 'General case' 0 C--N 1.328 -0.336 0 CA-C-O 120.795 0.331 . . . . 0.0 110.791 -179.992 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 67' ' ' HIS . . . . . . . . . . . . . 7.5 p80 -128.92 171.96 11.8 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.244 -0.435 . . . . 0.0 110.868 -179.937 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 16.8 t0 -98.18 32.47 2.44 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.255 -0.43 . . . . 0.0 110.88 179.926 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 95.4 -41.47 2.48 Favored Glycine 0 N--CA 1.451 -0.32 0 C-N-CA 120.73 -0.748 . . . . 0.0 112.506 -179.936 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 70' ' ' SER . . . . . . . . . . . . . 99.2 p -98.85 126.51 44.52 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 120.762 0.315 . . . . 0.0 110.978 179.976 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 71' ' ' VAL . . . . . 0.609 HG12 ' CD2' ' A' ' 72' ' ' PHE . 21.5 t -112.88 114.27 46.49 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.354 0 CA-C-N 116.198 -0.456 . . . . 0.0 111.114 -179.908 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 72' ' ' PHE . . . . . 0.609 ' CD2' HG12 ' A' ' 71' ' ' VAL . 14.7 m-85 61.49 30.77 18.96 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.917 -179.976 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 98.42 -29.75 10.87 Favored Glycine 0 N--CA 1.452 -0.288 0 C-N-CA 120.741 -0.742 . . . . 0.0 112.511 179.985 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 21.5 t -77.2 124.22 35.22 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-O 120.752 0.311 . . . . 0.0 111.111 -179.978 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 75' ' ' ARG . . . . . . . . . . . . . 10.3 ttt180 -104.71 136.76 43.63 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.939 179.996 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 76' ' ' TYR . . . . . . . . . . . . . 36.3 m-85 -112.84 -43.47 3.42 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.965 179.963 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 77' ' ' PHE . . . . . 0.435 ' CE1' ' HA3' ' A' ' 57' ' ' GLY . 40.9 p90 -153.29 165.06 36.91 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.935 -179.995 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 2.6 t -93.6 121.62 35.2 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.176 -0.466 . . . . 0.0 110.853 -179.994 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 79' ' ' CYS . . . . . . . . . . . . . 10.0 p -142.45 154.2 44.35 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.22 -0.445 . . . . 0.0 111.002 -179.98 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 80' ' ' ALA . . . . . 0.714 ' HB1' ' HD2' ' A' ' 81' ' ' PRO . . . -58.94 165.45 3.35 Favored Pre-proline 0 C--N 1.328 -0.34 0 CA-C-N 116.166 -0.47 . . . . 0.0 111.025 179.956 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 81' ' ' PRO . . . . . 0.714 ' HD2' ' HB1' ' A' ' 80' ' ' ALA . 17.9 Cg_endo -59.6 115.94 2.95 Favored 'Trans proline' 0 C--N 1.344 0.332 0 C-N-CA 122.53 2.153 . . . . 0.0 112.095 179.985 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 82' ' ' ARG . . . . . . . . . . . . . 57.1 mtp180 63.96 55.36 1.59 Allowed 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.812 -179.883 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 83' ' ' HIS . . . . . 0.619 ' CG ' ' HB3' ' A' ' 80' ' ' ALA . 6.4 m170 -126.75 -47.43 1.54 Allowed 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.907 179.97 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . -59.04 142.41 46.51 Favored Glycine 0 N--CA 1.452 -0.261 0 C-N-CA 120.738 -0.744 . . . . 0.0 112.511 -179.99 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 85' ' ' VAL . . . . . . . . . . . . . 5.3 m -146.86 115.91 1.29 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.272 0 CA-C-O 120.804 0.335 . . . . 0.0 111.113 179.955 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 86' ' ' PHE . . . . . . . . . . . . . 10.4 m-85 -93.41 124.95 37.75 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.862 179.936 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 87' ' ' ALA . . . . . 0.515 ' O ' HD11 ' A' ' 92' ' ' ILE . . . -144.55 144.86 26.46 Favored Pre-proline 0 C--N 1.329 -0.303 0 CA-C-N 116.27 -0.423 . . . . 0.0 111.101 179.93 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 88' ' ' PRO . . . . . 0.424 ' O ' ' N ' ' A' ' 91' ' ' ARG . 31.9 Cg_exo -58.38 142.13 97.51 Favored 'Trans proline' 0 C--N 1.345 0.387 0 C-N-CA 122.429 2.086 . . . . 0.0 112.243 179.956 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 89' ' ' ALA . . . . . 0.6 ' HB2' ' HE1' ' A' ' 56' ' ' TYR . . . -47.58 -51.84 19.72 Favored 'General case' 0 C--N 1.333 -0.114 0 CA-C-O 121.088 0.471 . . . . 0.0 110.388 179.983 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 90' ' ' SER . . . . . . . . . . . . . 64.3 m -55.88 -24.29 36.28 Favored 'General case' 0 C--N 1.331 -0.235 0 CA-C-N 115.701 -0.681 . . . . 0.0 109.81 178.839 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 91' ' ' ARG . . . . . 0.424 ' N ' ' O ' ' A' ' 88' ' ' PRO . 0.5 OUTLIER -89.33 -13.83 37.06 Favored 'General case' 0 N--CA 1.455 -0.197 0 CA-C-N 115.876 -0.602 . . . . 0.0 110.484 179.095 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 92' ' ' ILE . . . . . 0.703 HD13 HD11 ' A' ' 58' ' ' ILE . 46.8 mt -109.92 141.11 26.17 Favored 'Isoleucine or valine' 0 C--O 1.231 0.126 0 CA-C-N 116.493 -0.321 . . . . 0.0 111.034 179.883 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 93' ' ' GLN . . . . . . . . . . . . . 1.4 mt-30 -107.72 171.45 7.38 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.816 179.992 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 94' ' ' ARG . . . . . . . . . . . . . 5.5 ttt180 -122.1 125.58 46.51 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.919 179.982 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 95' ' ' ILE . . . . . . . . . . . . . 5.5 mt . . . . . 0 C--N 1.329 -0.29 0 CA-C-N 116.273 -0.421 . . . . 0.0 111.037 -179.965 . . . . . . . . 0 0 . 1 . 008 nuclear nobuild core ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.231 0.118 0 CA-C-O 120.829 0.347 . . . . 0.0 111.16 . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild core ' A' A ' 27' ' ' GLU . . . . . . . . . . . . . 5.6 mp0 -130.46 177.87 7.03 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.886 -179.96 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 26.9 t -64.9 92.21 0.11 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.231 -0.44 . . . . 0.0 111.132 179.95 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 114.86 41.86 0.82 Allowed Glycine 0 N--CA 1.452 -0.251 0 C-N-CA 120.746 -0.74 . . . . 0.0 112.403 -179.928 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 37.5 t70 -134.93 144.14 47.3 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-O 120.841 0.353 . . . . 0.0 110.945 179.979 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 31' ' ' GLN . . . . . . . . . . . . . 2.4 mp0 -64.43 134.98 55.61 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.254 -0.43 . . . . 0.0 110.811 -179.996 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 13.7 m -147.96 173.41 1.99 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.358 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.21 179.981 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 33' ' ' LEU . . . . . 0.577 HD12 ' HA ' ' A' ' 39' ' ' GLN . 15.0 tp -134.32 108.53 8.26 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.222 -0.444 . . . . 0.0 110.899 -179.969 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 34' ' ' VAL . . . . . 0.427 HG22 ' CD1' ' A' ' 58' ' ' ILE . 26.0 t -73.74 122.59 27.11 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.115 179.967 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 35' ' ' ALA . . . . . . . . . . . . . . . 59.13 25.2 13.65 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.117 -0.492 . . . . 0.0 111.194 -179.992 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 36' ' ' GLY . . . . . 0.414 ' HA2' HD23 ' A' ' 33' ' ' LEU . . . 55.27 27.49 46.97 Favored Glycine 0 N--CA 1.452 -0.253 0 C-N-CA 120.779 -0.724 . . . . 0.0 112.592 179.938 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 37' ' ' GLN . . . . . . . . . . . . . 12.8 mt-30 -141.87 -63.05 0.45 Allowed 'General case' 0 C--N 1.329 -0.286 0 CA-C-O 120.781 0.324 . . . . 0.0 110.876 -179.988 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 38' ' ' LYS . . . . . . . . . . . . . 11.4 mttp -71.26 111.97 7.03 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.25 -0.432 . . . . 0.0 110.889 179.989 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 39' ' ' GLN . . . . . 0.577 ' HA ' HD12 ' A' ' 33' ' ' LEU . 0.9 OUTLIER -82.27 131.24 35.23 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.854 -179.991 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -163.28 179.06 38.67 Favored Glycine 0 N--CA 1.451 -0.336 0 C-N-CA 120.775 -0.726 . . . . 0.0 112.504 -179.994 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 41' ' ' ILE . . . . . 0.458 ' N ' HG23 ' A' ' 58' ' ' ILE . 28.0 mt -128.63 137.74 56.49 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-O 120.842 0.354 . . . . 0.0 111.125 179.929 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 42' ' ' VAL . . . . . . . . . . . . . 21.5 t -62.19 127.16 21.68 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-N 116.174 -0.467 . . . . 0.0 111.161 -179.997 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 43' ' ' ARG . . . . . . . . . . . . . 10.1 mmt180 -111.76 -34.67 5.96 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.909 179.955 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 44' ' ' PHE . . . . . . . . . . . . . 39.4 t80 -143.52 112.28 6.53 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.897 -179.988 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 45' ' ' TYR . . . . . 0.485 ' CE1' ' CZ ' ' A' ' 56' ' ' TYR . 12.9 t80 -105.39 122.29 45.68 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.919 179.932 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 166.02 173.13 34.16 Favored Glycine 0 N--CA 1.452 -0.265 0 C-N-CA 120.757 -0.735 . . . . 0.0 112.485 179.953 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 47' ' ' LYS . . . . . . . . . . . . . 14.5 mttm -70.15 155.46 40.6 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 120.842 0.353 . . . . 0.0 110.911 -179.995 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 48' ' ' THR . . . . . 0.527 HG21 ' CE1' ' A' ' 50' ' ' PHE . 42.8 p -118.12 -177.75 3.35 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.13 -0.486 . . . . 0.0 110.874 179.969 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 4.8 t0 -105.98 -30.75 9.12 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.922 179.98 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 50' ' ' PHE . . . . . 0.527 ' CE1' HG21 ' A' ' 48' ' ' THR . 53.8 p90 -71.02 -40.75 71.58 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.941 -179.95 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 51' ' ' ALA . . . . . . . . . . . . . . . -137.0 144.47 46.5 Favored Pre-proline 0 C--N 1.329 -0.294 0 CA-C-N 116.187 -0.461 . . . . 0.0 111.211 -179.934 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 52' ' ' PRO . . . . . . . . . . . . . 73.3 Cg_endo -76.16 169.76 21.4 Favored 'Trans proline' 0 C--N 1.345 0.357 0 C-N-CA 122.54 2.16 . . . . 0.0 112.366 -179.975 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 90.39 178.78 44.07 Favored Glycine 0 N--CA 1.452 -0.294 0 C-N-CA 120.738 -0.744 . . . . 0.0 112.464 179.906 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 54' ' ' TYR . . . . . . . . . . . . . 14.1 m-85 -91.17 115.7 28.23 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-O 120.813 0.34 . . . . 0.0 110.935 179.977 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 55' ' ' TRP . . . . . . . . . . . . . 73.8 m95 -109.91 147.22 33.8 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.89 179.973 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 56' ' ' TYR . . . . . 0.579 ' CE1' ' HB2' ' A' ' 89' ' ' ALA . 8.1 m-85 -104.62 120.98 42.57 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.966 -179.89 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 57' ' ' GLY . . . . . 0.445 ' N ' ' CE1' ' A' ' 86' ' ' PHE . . . -80.72 62.78 4.34 Favored Glycine 0 N--CA 1.451 -0.325 0 C-N-CA 120.758 -0.734 . . . . 0.0 112.365 179.929 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 58' ' ' ILE . . . . . 0.757 HD11 HD13 ' A' ' 92' ' ' ILE . 21.6 mt -70.76 138.94 20.84 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-O 120.866 0.365 . . . . 0.0 111.141 -179.906 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -109.13 130.63 55.48 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.877 -179.97 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 60' ' ' LEU . . . . . 0.479 HD13 HG23 ' A' ' 64' ' ' THR . 84.2 mt -85.54 173.21 10.37 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.871 179.959 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 1.5 t70 -103.11 -31.03 10.36 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.943 -179.961 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 62' ' ' GLN . . . . . 0.401 ' HA ' ' HD3' ' A' ' 63' ' ' PRO . 2.4 mm-40 -114.43 147.81 38.82 Favored Pre-proline 0 C--N 1.33 -0.272 0 CA-C-N 116.298 -0.41 . . . . 0.0 110.911 -179.986 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 63' ' ' PRO . . . . . 0.401 ' HD3' ' HA ' ' A' ' 62' ' ' GLN . 31.9 Cg_exo -58.24 84.32 0.05 OUTLIER 'Trans proline' 0 C--N 1.346 0.399 0 C-N-CA 122.564 2.176 . . . . 0.0 112.25 179.928 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 64' ' ' THR . . . . . 0.479 HG23 HD13 ' A' ' 60' ' ' LEU . 13.4 t -157.0 35.02 0.29 Allowed 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.297 -0.411 . . . . 0.0 110.946 179.988 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . -95.96 -159.98 32.65 Favored Glycine 0 N--CA 1.452 -0.292 0 C-N-CA 120.745 -0.741 . . . . 0.0 112.503 179.911 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 66' ' ' LYS . . . . . . . . . . . . . 0.5 OUTLIER -110.03 -31.31 7.42 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 120.861 0.363 . . . . 0.0 110.922 179.977 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 67' ' ' HIS . . . . . 0.492 ' CG ' HG22 ' A' ' 71' ' ' VAL . 13.1 p80 -145.96 -178.74 6.28 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.877 -179.975 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 26.6 t0 -114.87 73.08 0.81 Allowed 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.944 179.986 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 79.41 -72.75 2.47 Favored Glycine 0 N--CA 1.451 -0.352 0 C-N-CA 120.761 -0.733 . . . . 0.0 112.476 -179.982 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 70' ' ' SER . . . . . . . . . . . . . 97.2 p -86.62 151.5 23.39 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-O 120.841 0.353 . . . . 0.0 110.907 -179.981 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 71' ' ' VAL . . . . . 0.716 HG12 ' CD2' ' A' ' 72' ' ' PHE . 21.5 t -128.03 117.9 47.08 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.162 -0.472 . . . . 0.0 111.095 179.977 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 72' ' ' PHE . . . . . 0.716 ' CD2' HG12 ' A' ' 71' ' ' VAL . 59.8 m-85 60.91 31.12 19.98 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.879 179.962 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 99.74 -30.0 10.9 Favored Glycine 0 N--CA 1.452 -0.281 0 C-N-CA 120.687 -0.768 . . . . 0.0 112.563 179.984 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 21.3 t -75.66 116.35 18.45 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-O 120.888 0.375 . . . . 0.0 111.093 179.981 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 75' ' ' ARG . . . . . . . . . . . . . 26.2 ttt85 -93.83 148.03 22.51 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.858 179.969 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 76' ' ' TYR . . . . . . . . . . . . . 89.9 m-85 -133.24 -47.69 0.84 Allowed 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.165 -0.471 . . . . 0.0 110.948 179.946 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 77' ' ' PHE . . . . . . . . . . . . . 22.5 p90 -155.2 154.67 32.6 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.9 -179.979 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 9.0 t -84.6 140.7 31.19 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.169 -0.468 . . . . 0.0 110.847 179.955 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 79' ' ' CYS . . . . . . . . . . . . . 22.7 p -164.7 162.39 21.25 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.922 179.921 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 80' ' ' ALA . . . . . 0.707 ' HB1' ' HD2' ' A' ' 81' ' ' PRO . . . -59.24 166.16 3.12 Favored Pre-proline 0 C--N 1.33 -0.254 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.002 179.949 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 81' ' ' PRO . . . . . 0.707 ' HD2' ' HB1' ' A' ' 80' ' ' ALA . 28.1 Cg_endo -62.66 122.63 11.05 Favored 'Trans proline' 0 C--N 1.346 0.397 0 C-N-CA 122.468 2.112 . . . . 0.0 112.253 -180.0 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 82' ' ' ARG . . . . . . . . . . . . . 0.5 OUTLIER 61.01 53.36 3.72 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.91 -179.875 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 83' ' ' HIS . . . . . 0.677 ' ND1' ' HB3' ' A' ' 80' ' ' ALA . 7.4 m170 -123.21 -45.54 2.1 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.11 -0.495 . . . . 0.0 110.85 179.958 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . -59.8 146.01 45.09 Favored Glycine 0 N--CA 1.451 -0.341 0 C-N-CA 120.646 -0.788 . . . . 0.0 112.501 -179.971 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 85' ' ' VAL . . . . . . . . . . . . . 6.1 m -150.04 114.88 0.67 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-O 120.815 0.34 . . . . 0.0 111.098 -179.938 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 86' ' ' PHE . . . . . 0.445 ' CE1' ' N ' ' A' ' 57' ' ' GLY . 3.7 m-85 -97.53 108.29 20.98 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.929 179.998 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 87' ' ' ALA . . . . . 0.595 ' O ' HD11 ' A' ' 92' ' ' ILE . . . -128.5 145.4 55.79 Favored Pre-proline 0 C--N 1.328 -0.344 0 CA-C-N 116.233 -0.439 . . . . 0.0 111.139 179.982 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 88' ' ' PRO . . . . . 0.417 ' O ' ' N ' ' A' ' 91' ' ' ARG . 32.3 Cg_exo -57.96 142.57 96.66 Favored 'Trans proline' 0 C--N 1.345 0.362 0 C-N-CA 122.519 2.146 . . . . 0.0 112.259 -179.984 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 89' ' ' ALA . . . . . 0.579 ' HB2' ' CE1' ' A' ' 56' ' ' TYR . . . -47.85 -51.18 23.93 Favored 'General case' 0 CA--C 1.521 -0.141 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.329 179.872 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 90' ' ' SER . . . . . . . . . . . . . 23.6 t -55.83 -24.4 36.24 Favored 'General case' 0 N--CA 1.454 -0.266 0 CA-C-N 115.747 -0.661 . . . . 0.0 109.815 178.76 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 91' ' ' ARG . . . . . 0.417 ' N ' ' O ' ' A' ' 88' ' ' PRO . 0.0 OUTLIER -89.37 -14.14 36.24 Favored 'General case' 0 N--CA 1.455 -0.215 0 CA-C-N 115.932 -0.576 . . . . 0.0 110.513 179.04 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 92' ' ' ILE . . . . . 0.757 HD13 HD11 ' A' ' 58' ' ' ILE . 48.9 mt -105.85 156.59 6.62 Favored 'Isoleucine or valine' 0 C--O 1.231 0.12 0 CA-C-N 116.396 -0.365 . . . . 0.0 110.971 179.753 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 93' ' ' GLN . . . . . 0.468 ' N ' HG22 ' A' ' 92' ' ' ILE . 50.8 mt-30 -121.42 175.0 6.4 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.262 -0.426 . . . . 0.0 110.881 -179.979 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 94' ' ' ARG . . . . . . . . . . . . . 0.6 OUTLIER -122.03 110.41 15.76 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.855 -179.972 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 95' ' ' ILE . . . . . . . . . . . . . 32.5 mt . . . . . 0 C--N 1.329 -0.317 0 CA-C-N 116.262 -0.427 . . . . 0.0 111.073 179.97 . . . . . . . . 0 0 . 1 . 009 nuclear nobuild core ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.231 0.128 0 CA-C-O 120.827 0.346 . . . . 0.0 111.106 . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild core ' A' A ' 27' ' ' GLU . . . . . . . . . . . . . 8.8 mt-10 -125.01 167.74 14.3 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.251 -0.431 . . . . 0.0 110.885 179.992 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 28.3 t -70.55 100.41 0.73 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 CA-C-N 116.165 -0.471 . . . . 0.0 111.077 -179.963 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 116.94 39.68 0.8 Allowed Glycine 0 N--CA 1.451 -0.334 0 C-N-CA 120.692 -0.766 . . . . 0.0 112.504 -179.977 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 1.8 m-20 -142.35 146.94 35.51 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-O 120.836 0.35 . . . . 0.0 110.89 -179.992 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 31' ' ' GLN . . . . . . . . . . . . . 77.1 mt-30 -59.96 136.26 57.96 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.861 179.966 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 5.8 m -148.91 162.46 5.01 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.129 179.968 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 33' ' ' LEU . . . . . 0.506 HD23 ' HA2' ' A' ' 36' ' ' GLY . 20.5 tp -130.23 104.96 7.6 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.825 -179.956 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 34' ' ' VAL . . . . . 0.488 HG13 ' CB ' ' A' ' 87' ' ' ALA . 21.7 t -72.98 125.01 31.09 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-N 116.178 -0.464 . . . . 0.0 111.263 -179.955 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 35' ' ' ALA . . . . . . . . . . . . . . . 57.17 25.88 11.48 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.169 -0.469 . . . . 0.0 111.24 179.914 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 36' ' ' GLY . . . . . 0.506 ' HA2' HD23 ' A' ' 33' ' ' LEU . . . 56.54 32.01 60.74 Favored Glycine 0 N--CA 1.452 -0.244 0 C-N-CA 120.726 -0.749 . . . . 0.0 112.613 179.971 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 37' ' ' GLN . . . . . . . . . . . . . 29.9 mt-30 -142.2 -66.71 0.39 Allowed 'General case' 0 C--N 1.329 -0.284 0 CA-C-O 120.781 0.324 . . . . 0.0 110.975 179.96 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 38' ' ' LYS . . . . . 0.532 ' HB3' HD21 ' A' ' 60' ' ' LEU . 25.1 mmtp -72.95 112.22 8.78 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.244 -0.434 . . . . 0.0 110.902 -179.957 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 39' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -92.62 130.28 38.3 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.891 -179.967 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -161.16 -169.41 24.38 Favored Glycine 0 N--CA 1.451 -0.324 0 C-N-CA 120.749 -0.739 . . . . 0.0 112.56 179.977 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 41' ' ' ILE . . . . . 0.4 ' N ' HG23 ' A' ' 58' ' ' ILE . 8.9 mt -128.62 132.71 67.58 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-O 120.769 0.319 . . . . 0.0 111.087 -179.993 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 42' ' ' VAL . . . . . . . . . . . . . 21.5 t -59.53 125.2 15.2 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.361 0 CA-C-N 116.2 -0.454 . . . . 0.0 111.153 179.932 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 43' ' ' ARG . . . . . . . . . . . . . 10.1 mmt180 -110.51 -32.52 6.88 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.882 -179.954 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 44' ' ' PHE . . . . . . . . . . . . . 86.9 t80 -144.4 113.73 7.0 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.909 -179.995 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 45' ' ' TYR . . . . . 0.439 ' CE1' ' CZ ' ' A' ' 56' ' ' TYR . 27.1 t80 -113.15 111.73 22.6 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.925 179.989 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . -169.52 -150.38 6.76 Favored Glycine 0 N--CA 1.45 -0.391 0 C-N-CA 120.808 -0.711 . . . . 0.0 112.545 179.984 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 47' ' ' LYS . . . . . 0.411 ' HD3' ' CE1' ' A' ' 54' ' ' TYR . 2.2 mmmp? -96.77 168.84 10.26 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.792 0.33 . . . . 0.0 110.879 -179.93 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 48' ' ' THR . . . . . . . . . . . . . 64.6 p -132.43 178.15 7.05 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.837 179.947 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 32.3 t70 -112.55 -35.41 5.55 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.961 -179.975 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 50' ' ' PHE . . . . . . . . . . . . . 30.1 p90 -62.73 -31.04 71.9 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.949 -179.942 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 51' ' ' ALA . . . . . . . . . . . . . . . -151.74 151.96 29.38 Favored Pre-proline 0 C--N 1.329 -0.299 0 CA-C-N 116.237 -0.438 . . . . 0.0 111.107 -179.962 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 52' ' ' PRO . . . . . . . . . . . . . 58.2 Cg_endo -71.58 -176.89 2.17 Favored 'Trans proline' 0 C--N 1.345 0.347 0 C-N-CA 122.559 2.173 . . . . 0.0 112.3 179.928 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 75.12 -177.07 48.92 Favored Glycine 0 N--CA 1.451 -0.348 0 C-N-CA 120.756 -0.735 . . . . 0.0 112.54 -179.922 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 54' ' ' TYR . . . . . 0.411 ' CE1' ' HD3' ' A' ' 47' ' ' LYS . 10.1 m-85 -107.8 132.45 53.4 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 120.815 0.34 . . . . 0.0 110.916 179.994 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 55' ' ' TRP . . . . . 0.413 ' CZ3' ' HD3' ' A' ' 88' ' ' PRO . 19.0 m95 -120.07 173.31 7.16 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.852 -179.989 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 56' ' ' TYR . . . . . 0.615 ' HE1' ' HB2' ' A' ' 89' ' ' ALA . 10.8 m-85 -117.21 127.51 54.17 Favored 'General case' 0 C--N 1.331 -0.235 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.948 -179.904 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . -90.6 65.12 2.76 Favored Glycine 0 N--CA 1.45 -0.426 0 C-N-CA 120.746 -0.74 . . . . 0.0 112.426 -179.998 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 58' ' ' ILE . . . . . 0.444 HD12 HG22 ' A' ' 34' ' ' VAL . 25.3 mt -71.64 139.43 19.82 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-O 120.779 0.323 . . . . 0.0 111.135 -179.928 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 0.2 OUTLIER -108.49 111.0 22.64 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.826 -179.965 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 60' ' ' LEU . . . . . 0.711 HD13 HG23 ' A' ' 64' ' ' THR . 63.2 mt -63.93 167.89 5.73 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.308 -0.406 . . . . 0.0 110.846 -179.969 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -96.84 -26.1 15.23 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.947 -179.995 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 62' ' ' GLN . . . . . . . . . . . . . 64.9 mm-40 -124.26 152.36 67.56 Favored Pre-proline 0 C--N 1.329 -0.284 0 CA-C-N 116.369 -0.378 . . . . 0.0 110.908 -179.895 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 32.2 Cg_exo -58.19 92.52 0.06 OUTLIER 'Trans proline' 0 C--N 1.346 0.401 0 C-N-CA 122.579 2.186 . . . . 0.0 112.293 179.954 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 64' ' ' THR . . . . . 0.711 HG23 HD13 ' A' ' 60' ' ' LEU . 13.4 t -165.74 36.49 0.05 Allowed 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 116.283 -0.417 . . . . 0.0 110.932 179.873 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . -99.12 -140.11 11.26 Favored Glycine 0 N--CA 1.451 -0.344 0 C-N-CA 120.78 -0.724 . . . . 0.0 112.442 -179.993 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 66' ' ' LYS . . . . . . . . . . . . . 1.7 mttm -132.21 -46.55 0.92 Allowed 'General case' 0 C--N 1.328 -0.34 0 CA-C-O 120.822 0.344 . . . . 0.0 110.87 179.97 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 67' ' ' HIS . . . . . . . . . . . . . 12.4 p80 -127.27 174.69 8.75 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.233 -0.44 . . . . 0.0 110.92 179.901 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 1.6 m-20 -98.46 48.68 0.98 Allowed 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.928 179.998 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 84.44 -61.51 4.7 Favored Glycine 0 N--CA 1.451 -0.31 0 C-N-CA 120.715 -0.755 . . . . 0.0 112.486 -179.997 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 70' ' ' SER . . . . . . . . . . . . . 31.4 p -80.26 152.15 29.22 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-O 120.774 0.321 . . . . 0.0 110.802 -179.992 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 21.5 t -134.32 118.08 26.42 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.111 179.982 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 72' ' ' PHE . . . . . . . . . . . . . 28.8 m-85 60.58 31.05 20.16 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.884 179.937 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 98.35 -28.41 14.94 Favored Glycine 0 N--CA 1.451 -0.316 0 C-N-CA 120.741 -0.742 . . . . 0.0 112.462 -179.998 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 21.5 t -73.64 130.56 35.78 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-O 120.805 0.336 . . . . 0.0 111.133 179.998 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 75' ' ' ARG . . . . . . . . . . . . . 48.4 ttt-85 -93.71 144.23 25.59 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.901 179.963 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 76' ' ' TYR . . . . . . . . . . . . . 58.4 m-85 -124.85 -44.82 1.92 Allowed 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.867 -179.985 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 77' ' ' PHE . . . . . . . . . . . . . 32.7 p90 -166.91 177.44 6.37 Favored 'General case' 0 C--N 1.327 -0.383 0 CA-C-N 116.18 -0.463 . . . . 0.0 110.908 179.978 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 1.7 t -98.96 124.83 44.18 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.833 -179.93 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 79' ' ' CYS . . . . . . . . . . . . . 27.0 p -150.98 155.01 38.2 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.847 179.952 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 80' ' ' ALA . . . . . 0.524 ' HB1' ' HD2' ' A' ' 81' ' ' PRO . . . -67.99 166.84 20.4 Favored Pre-proline 0 C--N 1.328 -0.349 0 CA-C-N 116.159 -0.473 . . . . 0.0 111.049 179.956 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 81' ' ' PRO . . . . . 0.524 ' HD2' ' HB1' ' A' ' 80' ' ' ALA . 53.3 Cg_exo -52.63 117.07 3.31 Favored 'Trans proline' 0 C--N 1.345 0.362 0 C-N-CA 122.538 2.159 . . . . 0.0 112.324 -179.92 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 82' ' ' ARG . . . . . . . . . . . . . 2.9 ttm180 63.12 57.7 1.56 Allowed 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.978 179.985 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 83' ' ' HIS . . . . . 0.493 ' CE1' ' HB3' ' A' ' 80' ' ' ALA . 6.3 m170 -126.96 -46.98 1.52 Allowed 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.091 -0.504 . . . . 0.0 110.94 179.957 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . -62.86 139.31 44.85 Favored Glycine 0 N--CA 1.45 -0.388 0 C-N-CA 120.722 -0.752 . . . . 0.0 112.541 179.989 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 85' ' ' VAL . . . . . . . . . . . . . 5.5 m -147.21 124.18 3.19 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.257 0 CA-C-O 120.871 0.367 . . . . 0.0 111.062 -179.942 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 86' ' ' PHE . . . . . . . . . . . . . 13.5 m-85 -100.77 121.12 41.14 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.081 -0.508 . . . . 0.0 110.9 179.999 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 87' ' ' ALA . . . . . 0.605 ' O ' HD11 ' A' ' 92' ' ' ILE . . . -140.75 144.84 37.47 Favored Pre-proline 0 C--N 1.328 -0.33 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.161 179.975 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 88' ' ' PRO . . . . . 0.416 ' O ' ' N ' ' A' ' 91' ' ' ARG . 47.6 Cg_exo -56.06 141.25 87.11 Favored 'Trans proline' 0 C--N 1.345 0.394 0 C-N-CA 122.607 2.204 . . . . 0.0 112.224 -179.9 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 89' ' ' ALA . . . . . 0.615 ' HB2' ' HE1' ' A' ' 56' ' ' TYR . . . -47.96 -50.97 25.48 Favored 'General case' 0 CA--C 1.521 -0.149 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.295 179.854 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 90' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -55.83 -24.6 37.41 Favored 'General case' 0 C--N 1.331 -0.217 0 CA-C-N 115.68 -0.691 . . . . 0.0 109.673 178.841 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 91' ' ' ARG . . . . . 0.416 ' N ' ' O ' ' A' ' 88' ' ' PRO . 0.0 OUTLIER -87.6 -15.37 37.54 Favored 'General case' 0 N--CA 1.454 -0.244 0 CA-C-N 115.856 -0.611 . . . . 0.0 110.423 179.032 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 92' ' ' ILE . . . . . 0.605 HD11 ' O ' ' A' ' 87' ' ' ALA . 33.0 mt -104.63 145.89 12.61 Favored 'Isoleucine or valine' 0 C--N 1.333 -0.126 0 CA-C-N 116.397 -0.365 . . . . 0.0 111.066 179.864 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 93' ' ' GLN . . . . . . . . . . . . . 0.7 OUTLIER -114.83 -179.96 3.78 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.991 -179.973 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 94' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -126.08 142.88 51.33 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.877 -179.968 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 95' ' ' ILE . . . . . . . . . . . . . 3.3 mp . . . . . 0 C--N 1.329 -0.287 0 CA-C-N 116.108 -0.496 . . . . 0.0 111.172 179.981 . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.231 0.1 0 CA-C-O 120.833 0.349 . . . . 0.0 111.134 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' A' A ' 27' ' ' GLU . . . . . . . . . . . . . 28.7 mt-10 -139.41 178.31 7.29 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.946 179.972 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 28.9 t -72.31 115.7 13.18 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.219 -0.446 . . . . 0.0 111.049 -179.979 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 102.43 33.96 4.33 Favored Glycine 0 N--CA 1.452 -0.298 0 C-N-CA 120.716 -0.754 . . . . 0.0 112.443 179.969 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 13.3 m-20 -141.42 148.35 39.42 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-O 120.822 0.344 . . . . 0.0 110.912 179.92 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 31' ' ' GLN . . . . . . . . . . . . . 3.5 mp0 -72.74 137.33 45.82 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.955 179.975 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 32' ' ' VAL . . . . . 0.449 ' HB ' HG22 ' A' ' 92' ' ' ILE . 14.8 m -146.55 177.53 1.3 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 116.262 -0.426 . . . . 0.0 111.112 179.984 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 33' ' ' LEU . . . . . 0.504 HD23 ' HA2' ' A' ' 36' ' ' GLY . 21.7 tp -134.15 112.36 11.06 Favored 'General case' 0 C--N 1.33 -0.283 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.794 -179.998 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 34' ' ' VAL . . . . . 0.747 HG22 HD12 ' A' ' 58' ' ' ILE . 21.9 t -76.03 123.74 32.77 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.145 -0.479 . . . . 0.0 111.127 -179.949 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 35' ' ' ALA . . . . . . . . . . . . . . . 59.28 25.56 14.22 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.153 -0.476 . . . . 0.0 111.229 179.979 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 36' ' ' GLY . . . . . 0.504 ' HA2' HD23 ' A' ' 33' ' ' LEU . . . 55.95 27.88 51.88 Favored Glycine 0 N--CA 1.452 -0.252 0 C-N-CA 120.759 -0.734 . . . . 0.0 112.633 -179.993 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 37' ' ' GLN . . . . . 0.45 ' O ' HD11 ' A' ' 33' ' ' LEU . 24.9 mt-30 -142.64 -69.23 0.35 Allowed 'General case' 0 C--N 1.329 -0.285 0 CA-C-O 120.885 0.374 . . . . 0.0 110.925 179.957 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 38' ' ' LYS . . . . . . . . . . . . . 19.3 mttp -67.15 119.73 12.56 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.929 179.985 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 39' ' ' GLN . . . . . 0.43 ' HA ' HD12 ' A' ' 33' ' ' LEU . 0.0 OUTLIER -87.09 133.03 33.65 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.886 -179.999 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -162.33 169.76 37.75 Favored Glycine 0 N--CA 1.45 -0.371 0 C-N-CA 120.742 -0.742 . . . . 0.0 112.557 -179.969 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 23.2 mt -116.03 146.22 20.75 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.352 0 CA-C-O 120.799 0.333 . . . . 0.0 111.061 -179.99 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 42' ' ' VAL . . . . . . . . . . . . . 33.3 t -69.49 124.95 26.51 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.212 -0.449 . . . . 0.0 111.042 179.946 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 43' ' ' ARG . . . . . . . . . . . . . 2.9 mmm180 -111.84 -43.39 3.62 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.894 179.99 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 44' ' ' PHE . . . . . . . . . . . . . 49.7 t80 -136.7 113.16 10.02 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.86 -179.897 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 45' ' ' TYR . . . . . 0.495 ' CE1' ' CE1' ' A' ' 56' ' ' TYR . 14.1 t80 -112.9 131.57 55.67 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.272 -0.422 . . . . 0.0 110.872 179.965 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 156.17 -172.45 34.05 Favored Glycine 0 N--CA 1.451 -0.364 0 C-N-CA 120.763 -0.732 . . . . 0.0 112.524 -179.968 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 47' ' ' LYS . . . . . 0.433 ' HG3' ' CZ ' ' A' ' 54' ' ' TYR . 98.5 mttt -69.01 155.86 39.62 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 120.768 0.318 . . . . 0.0 110.915 179.968 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 48' ' ' THR . . . . . 0.635 HG21 ' CZ ' ' A' ' 50' ' ' PHE . 7.2 p -122.69 170.08 10.41 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.858 -179.943 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -102.33 -31.28 10.59 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.93 179.957 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 50' ' ' PHE . . . . . 0.635 ' CZ ' HG21 ' A' ' 48' ' ' THR . 18.0 p90 -73.66 -31.63 63.58 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.915 179.951 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 51' ' ' ALA . . . . . . . . . . . . . . . -140.51 147.95 51.45 Favored Pre-proline 0 C--N 1.33 -0.269 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.096 -179.895 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 52' ' ' PRO . . . . . . . . . . . . . 60.0 Cg_endo -72.25 176.9 7.93 Favored 'Trans proline' 0 C--N 1.344 0.32 0 C-N-CA 122.578 2.185 . . . . 0.0 112.402 179.902 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 72.45 -155.97 51.73 Favored Glycine 0 N--CA 1.45 -0.397 0 C-N-CA 120.771 -0.728 . . . . 0.0 112.592 179.947 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 54' ' ' TYR . . . . . 0.433 ' CZ ' ' HG3' ' A' ' 47' ' ' LYS . 10.8 m-85 -115.86 137.63 51.91 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-O 120.894 0.378 . . . . 0.0 110.856 -179.989 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 55' ' ' TRP . . . . . . . . . . . . . 52.0 m95 -126.37 164.25 21.48 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.835 179.977 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 56' ' ' TYR . . . . . 0.794 ' CE1' ' HB2' ' A' ' 89' ' ' ALA . 25.9 m-85 -114.42 120.88 41.81 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.968 179.963 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 57' ' ' GLY . . . . . 0.426 ' HA3' ' CE1' ' A' ' 77' ' ' PHE . . . -83.07 61.25 4.81 Favored Glycine 0 N--CA 1.45 -0.387 0 C-N-CA 120.73 -0.748 . . . . 0.0 112.401 179.995 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 58' ' ' ILE . . . . . 0.747 HD12 HG22 ' A' ' 34' ' ' VAL . 45.2 mt -69.33 145.13 13.43 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-O 120.827 0.346 . . . . 0.0 111.098 -179.899 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 5.6 tm-20 -112.83 132.77 55.13 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.797 -179.961 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 60' ' ' LEU . . . . . . . . . . . . . 39.3 mt -93.1 158.76 15.61 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.202 -0.453 . . . . 0.0 110.93 -179.994 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 32.6 t0 -100.26 31.17 3.49 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.918 179.931 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 62' ' ' GLN . . . . . . . . . . . . . 1.8 pm0 -157.46 149.05 17.02 Favored Pre-proline 0 C--N 1.33 -0.276 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.846 179.965 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 56.4 Cg_endo -70.28 63.67 2.09 Favored 'Trans proline' 0 C--N 1.344 0.314 0 C-N-CA 122.631 2.221 . . . . 0.0 112.284 -179.994 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 64' ' ' THR . . . . . . . . . . . . . 5.4 p -145.23 30.84 1.12 Allowed 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.972 179.901 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . -79.37 -159.26 15.92 Favored Glycine 0 N--CA 1.451 -0.361 0 C-N-CA 120.714 -0.755 . . . . 0.0 112.48 179.989 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 66' ' ' LYS . . . . . . . . . . . . . 7.0 mtpm? -111.53 -33.74 6.29 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 120.813 0.34 . . . . 0.0 110.928 179.969 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 67' ' ' HIS . . . . . . . . . . . . . 6.0 p80 -139.12 174.07 10.9 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.911 179.921 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 1.3 t70 -97.85 37.07 1.44 Allowed 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.951 179.973 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 95.19 -65.21 1.33 Allowed Glycine 0 N--CA 1.451 -0.337 0 C-N-CA 120.703 -0.76 . . . . 0.0 112.511 -179.965 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 70' ' ' SER . . . . . . . . . . . . . 3.1 p -89.57 133.34 34.65 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 120.807 0.337 . . . . 0.0 110.836 -179.931 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 71' ' ' VAL . . . . . 0.691 HG12 ' CD2' ' A' ' 72' ' ' PHE . 21.5 t -114.21 114.76 47.62 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.202 -0.454 . . . . 0.0 111.111 -179.982 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 72' ' ' PHE . . . . . 0.691 ' CD2' HG12 ' A' ' 71' ' ' VAL . 13.9 m-85 60.73 31.11 20.09 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.949 179.99 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 98.8 -29.36 11.81 Favored Glycine 0 N--CA 1.451 -0.324 0 C-N-CA 120.752 -0.737 . . . . 0.0 112.485 -179.956 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 21.5 t -76.97 123.56 33.74 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-O 120.797 0.332 . . . . 0.0 111.092 -179.944 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 75' ' ' ARG . . . . . . . . . . . . . 11.4 ttm180 -101.1 134.04 44.7 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.884 179.996 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 76' ' ' TYR . . . . . . . . . . . . . 51.7 m-85 -109.67 -31.15 7.57 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.998 179.922 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 77' ' ' PHE . . . . . 0.426 ' CE1' ' HA3' ' A' ' 57' ' ' GLY . 27.0 p90 -172.85 156.39 3.4 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.941 179.98 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 12.3 m -85.75 111.2 19.92 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.798 179.968 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 79' ' ' CYS . . . . . . . . . . . . . 27.1 p -134.86 164.31 27.86 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.31 -0.405 . . . . 0.0 110.995 -179.929 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 80' ' ' ALA . . . . . 0.727 ' HB1' ' HD2' ' A' ' 81' ' ' PRO . . . -63.55 165.86 10.72 Favored Pre-proline 0 C--N 1.328 -0.337 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.949 179.879 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 81' ' ' PRO . . . . . 0.727 ' HD2' ' HB1' ' A' ' 80' ' ' ALA . 20.5 Cg_endo -60.85 114.97 2.39 Favored 'Trans proline' 0 C--N 1.345 0.364 0 C-N-CA 122.58 2.187 . . . . 0.0 112.146 179.876 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 82' ' ' ARG . . . . . . . . . . . . . 49.7 mtt180 64.4 58.69 1.06 Allowed 'General case' 0 C--N 1.331 -0.232 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.752 -179.969 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 83' ' ' HIS . . . . . 0.524 ' CG ' ' HB3' ' A' ' 80' ' ' ALA . 5.7 m-70 -130.7 -48.56 1.05 Allowed 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.899 179.927 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . -60.48 140.29 48.06 Favored Glycine 0 N--CA 1.452 -0.273 0 C-N-CA 120.741 -0.742 . . . . 0.0 112.531 -179.99 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 85' ' ' VAL . . . . . . . . . . . . . 10.1 m -142.59 130.52 20.12 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-O 120.823 0.344 . . . . 0.0 111.096 179.937 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 86' ' ' PHE . . . . . 0.409 ' CE1' ' CA ' ' A' ' 57' ' ' GLY . 8.6 m-85 -103.66 114.0 27.93 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.924 -179.963 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 87' ' ' ALA . . . . . 0.626 ' O ' HD11 ' A' ' 92' ' ' ILE . . . -134.28 145.4 55.23 Favored Pre-proline 0 C--N 1.331 -0.237 0 CA-C-N 116.259 -0.428 . . . . 0.0 111.067 -179.949 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 88' ' ' PRO . . . . . 0.41 ' O ' ' N ' ' A' ' 91' ' ' ARG . 36.5 Cg_exo -57.45 140.57 93.58 Favored 'Trans proline' 0 C--N 1.345 0.356 0 C-N-CA 122.527 2.151 . . . . 0.0 112.236 -179.981 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 89' ' ' ALA . . . . . 0.794 ' HB2' ' CE1' ' A' ' 56' ' ' TYR . . . -48.24 -50.27 30.13 Favored 'General case' 0 CA--C 1.521 -0.162 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.262 179.809 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 90' ' ' SER . . . . . . . . . . . . . 2.7 m -55.9 -24.51 37.82 Favored 'General case' 0 N--CA 1.455 -0.223 0 CA-C-N 115.706 -0.679 . . . . 0.0 109.789 178.767 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 91' ' ' ARG . . . . . 0.41 ' N ' ' O ' ' A' ' 88' ' ' PRO . 0.2 OUTLIER -88.54 -14.19 38.29 Favored 'General case' 0 N--CA 1.455 -0.177 0 CA-C-N 115.865 -0.607 . . . . 0.0 110.391 179.1 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 92' ' ' ILE . . . . . 0.704 HD13 HD11 ' A' ' 58' ' ' ILE . 21.4 mt -108.12 139.82 28.88 Favored 'Isoleucine or valine' 0 C--O 1.232 0.154 0 CA-C-N 116.45 -0.341 . . . . 0.0 111.061 179.808 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 93' ' ' GLN . . . . . . . . . . . . . 8.7 mt-30 -106.7 171.72 7.21 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.892 179.997 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 94' ' ' ARG . . . . . . . . . . . . . 3.4 ttt-85 -111.79 154.18 25.45 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.902 179.929 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 95' ' ' ILE . . . . . . . . . . . . . 31.8 mt . . . . . 0 C--N 1.328 -0.326 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.155 179.997 . . . . . . . . 0 0 . 1 . 011 nuclear nobuild core ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.231 0.117 0 CA-C-O 120.776 0.322 . . . . 0.0 111.143 . . . . . . . . . 0 0 . 1 . 011 nuclear nobuild core ' A' A ' 27' ' ' GLU . . . . . . . . . . . . . 30.4 mt-10 -145.56 -178.36 6.04 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.901 -179.992 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 21.5 t -75.85 116.62 19.08 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.211 -0.449 . . . . 0.0 111.144 -179.954 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 101.35 36.65 3.77 Favored Glycine 0 N--CA 1.45 -0.416 0 C-N-CA 120.766 -0.73 . . . . 0.0 112.47 -179.992 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -144.79 151.67 39.17 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 120.778 0.323 . . . . 0.0 110.898 -179.991 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 31' ' ' GLN . . . . . . . . . . . . . 2.7 mp0 -72.11 125.78 28.14 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.233 -0.439 . . . . 0.0 110.891 179.984 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 32' ' ' VAL . . . . . 0.537 HG21 HG12 ' A' ' 58' ' ' ILE . 27.5 m -127.04 174.57 10.57 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.138 -0.483 . . . . 0.0 111.143 179.964 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 33' ' ' LEU . . . . . 0.702 ' HB2' HD11 ' A' ' 95' ' ' ILE . 25.8 tp -143.22 102.54 4.0 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.852 -179.923 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 34' ' ' VAL . . . . . 0.565 ' CG2' HD13 ' A' ' 58' ' ' ILE . 21.4 t -72.65 128.57 35.6 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.148 -0.478 . . . . 0.0 111.147 -179.92 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 35' ' ' ALA . . . . . . . . . . . . . . . 57.18 25.08 10.54 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.065 -0.516 . . . . 0.0 111.304 179.936 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . 56.38 31.22 59.53 Favored Glycine 0 N--CA 1.451 -0.344 0 C-N-CA 120.752 -0.737 . . . . 0.0 112.604 -179.986 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 37' ' ' GLN . . . . . 0.616 ' O ' HD11 ' A' ' 33' ' ' LEU . 81.6 mt-30 -146.3 -70.86 0.25 Allowed 'General case' 0 C--N 1.329 -0.29 0 CA-C-O 120.79 0.329 . . . . 0.0 110.906 -179.92 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 38' ' ' LYS . . . . . . . . . . . . . 12.6 mttt -61.71 105.05 0.5 Allowed 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.905 -179.988 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 39' ' ' GLN . . . . . 0.507 ' CD ' HD13 ' A' ' 95' ' ' ILE . 0.0 OUTLIER -85.1 132.02 34.37 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.902 179.942 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -158.39 -170.19 22.78 Favored Glycine 0 N--CA 1.451 -0.358 0 C-N-CA 120.709 -0.758 . . . . 0.0 112.438 179.977 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 32.2 mt -129.55 129.74 66.87 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-O 120.798 0.332 . . . . 0.0 111.046 -179.959 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 42' ' ' VAL . . . . . . . . . . . . . 21.4 t -58.46 125.22 14.12 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.172 179.973 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 43' ' ' ARG . . . . . . . . . . . . . 36.6 mmt180 -108.18 -31.53 7.87 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.87 -179.973 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 44' ' ' PHE . . . . . . . . . . . . . 41.0 t80 -148.78 113.81 5.47 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.922 179.926 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 45' ' ' TYR . . . . . 0.471 ' CE1' ' CZ ' ' A' ' 56' ' ' TYR . 33.7 t80 -112.3 142.93 44.2 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.884 179.974 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 148.92 -168.99 29.4 Favored Glycine 0 N--CA 1.451 -0.327 0 C-N-CA 120.732 -0.747 . . . . 0.0 112.492 -179.982 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 47' ' ' LYS . . . . . 0.414 ' HE2' ' CZ ' ' A' ' 54' ' ' TYR . 22.2 mttm -87.39 141.58 28.53 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-O 120.851 0.357 . . . . 0.0 110.869 -179.98 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 48' ' ' THR . . . . . 0.666 HG21 ' CE2' ' A' ' 50' ' ' PHE . 63.6 p -102.18 -177.12 3.31 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.85 179.983 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 1.3 t70 -112.85 15.86 19.67 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.159 -0.473 . . . . 0.0 111.242 -179.958 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 50' ' ' PHE . . . . . 0.666 ' CE2' HG21 ' A' ' 48' ' ' THR . 29.2 p90 -116.38 -36.65 3.94 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-O 120.727 0.299 . . . . 0.0 110.996 179.846 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 51' ' ' ALA . . . . . 0.445 ' N ' ' CD1' ' A' ' 50' ' ' PHE . . . -140.26 146.71 47.04 Favored Pre-proline 0 C--N 1.328 -0.332 0 CA-C-N 116.249 -0.432 . . . . 0.0 111.126 179.924 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 52' ' ' PRO . . . . . . . . . . . . . 60.0 Cg_endo -72.42 170.81 18.37 Favored 'Trans proline' 0 C--N 1.345 0.388 0 C-N-CA 122.505 2.137 . . . . 0.0 112.353 -179.957 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 90.66 -154.08 23.01 Favored Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.778 -0.725 . . . . 0.0 112.525 179.939 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 54' ' ' TYR . . . . . 0.414 ' CZ ' ' HE2' ' A' ' 47' ' ' LYS . 57.4 m-85 -125.23 124.45 41.71 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 120.872 0.368 . . . . 0.0 110.867 179.963 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 55' ' ' TRP . . . . . . . . . . . . . 65.3 m95 -115.13 161.83 17.86 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.936 179.95 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 56' ' ' TYR . . . . . 0.569 ' HE1' ' HB2' ' A' ' 89' ' ' ALA . 10.8 m-85 -117.68 120.07 36.89 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.211 -0.449 . . . . 0.0 110.92 -179.887 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 57' ' ' GLY . . . . . 0.45 ' CA ' ' CE1' ' A' ' 86' ' ' PHE . . . -84.71 63.8 4.35 Favored Glycine 0 N--CA 1.452 -0.298 0 C-N-CA 120.681 -0.771 . . . . 0.0 112.392 179.997 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 58' ' ' ILE . . . . . 0.729 HD11 HD13 ' A' ' 92' ' ' ILE . 3.3 mt -70.24 146.95 11.87 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.23 0 CA-C-O 120.807 0.337 . . . . 0.0 111.128 -179.966 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 3.7 tm-20 -116.91 109.8 17.51 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.841 -179.979 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 60' ' ' LEU . . . . . 0.743 HD13 HG23 ' A' ' 64' ' ' THR . 96.0 mt -63.55 172.84 1.87 Allowed 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.912 179.932 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -98.5 -32.54 11.41 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.289 -0.414 . . . . 0.0 110.924 -179.978 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 62' ' ' GLN . . . . . 0.519 ' O ' HG22 ' A' ' 64' ' ' THR . 4.7 mm-40 -118.42 151.34 49.44 Favored Pre-proline 0 C--N 1.33 -0.264 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.94 -179.998 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 52.1 Cg_exo -54.66 99.95 0.06 OUTLIER 'Trans proline' 0 C--N 1.345 0.362 0 C-N-CA 122.485 2.123 . . . . 0.0 112.286 -179.958 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 64' ' ' THR . . . . . 0.743 HG23 HD13 ' A' ' 60' ' ' LEU . 9.8 t -176.98 39.01 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.872 179.983 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . -95.87 -125.43 4.73 Favored Glycine 0 N--CA 1.45 -0.37 0 C-N-CA 120.713 -0.756 . . . . 0.0 112.475 179.98 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 66' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -144.17 -47.71 0.27 Allowed 'General case' 0 C--N 1.329 -0.284 0 CA-C-O 120.825 0.345 . . . . 0.0 110.833 -179.869 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 67' ' ' HIS . . . . . . . . . . . . . 6.4 p80 -122.84 177.43 5.48 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.191 -0.458 . . . . 0.0 110.884 179.984 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -100.15 35.35 2.09 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.891 -179.987 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 100.99 -70.18 0.42 Allowed Glycine 0 N--CA 1.451 -0.365 0 C-N-CA 120.756 -0.735 . . . . 0.0 112.465 179.944 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 70' ' ' SER . . . . . . . . . . . . . 78.4 p -81.68 148.85 28.79 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 120.85 0.357 . . . . 0.0 110.868 179.987 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 71' ' ' VAL . . . . . 0.494 HG12 ' CD2' ' A' ' 72' ' ' PHE . 27.3 t -127.67 125.94 66.17 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.167 -0.47 . . . . 0.0 111.11 179.93 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 72' ' ' PHE . . . . . 0.494 ' CD2' HG12 ' A' ' 71' ' ' VAL . 47.7 m-85 60.08 28.02 17.52 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.99 -179.929 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 95.97 -30.03 9.11 Favored Glycine 0 N--CA 1.451 -0.307 0 C-N-CA 120.628 -0.796 . . . . 0.0 112.538 179.951 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 21.6 t -80.47 122.95 36.59 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-O 120.784 0.326 . . . . 0.0 111.074 -179.939 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 75' ' ' ARG . . . . . . . . . . . . . 21.2 ttm180 -88.96 146.26 25.01 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.224 -0.443 . . . . 0.0 110.922 -179.997 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 76' ' ' TYR . . . . . 0.424 ' CE2' HG22 ' A' ' 48' ' ' THR . 37.0 m-85 -119.26 -47.75 2.45 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.185 -0.462 . . . . 0.0 110.897 -179.977 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 77' ' ' PHE . . . . . . . . . . . . . 34.8 p90 -152.79 171.4 18.3 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.922 179.972 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 4.6 p -97.26 122.56 40.42 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.904 -179.97 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 79' ' ' CYS . . . . . . . . . . . . . 27.3 p -143.87 176.74 9.03 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.906 179.963 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 80' ' ' ALA . . . . . 0.618 ' HB3' ' CG ' ' A' ' 83' ' ' HIS . . . -90.43 168.95 13.02 Favored Pre-proline 0 C--N 1.329 -0.308 0 CA-C-N 116.229 -0.441 . . . . 0.0 111.077 179.96 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 81' ' ' PRO . . . . . 0.597 ' HD2' ' HB1' ' A' ' 80' ' ' ALA . 52.7 Cg_exo -52.59 113.6 1.3 Allowed 'Trans proline' 0 C--N 1.344 0.303 0 C-N-CA 122.557 2.171 . . . . 0.0 112.261 179.93 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 82' ' ' ARG . . . . . . . . . . . . . 9.2 mmt180 61.27 53.59 3.47 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.907 -179.987 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 83' ' ' HIS . . . . . 0.618 ' CG ' ' HB3' ' A' ' 80' ' ' ALA . 5.5 m170 -121.17 -42.4 2.48 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.125 -0.489 . . . . 0.0 110.918 179.989 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 84' ' ' GLY . . . . . 0.433 ' O ' HG13 ' A' ' 85' ' ' VAL . . . -63.7 154.67 45.67 Favored Glycine 0 N--CA 1.45 -0.368 0 C-N-CA 120.745 -0.741 . . . . 0.0 112.511 179.933 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 85' ' ' VAL . . . . . 0.433 HG13 ' O ' ' A' ' 84' ' ' GLY . 15.2 m -156.27 127.27 0.87 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-O 120.84 0.352 . . . . 0.0 111.191 -179.96 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 86' ' ' PHE . . . . . 0.45 ' CE1' ' CA ' ' A' ' 57' ' ' GLY . 7.9 m-85 -112.53 102.09 10.21 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.818 179.942 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 87' ' ' ALA . . . . . 0.454 ' CB ' HG13 ' A' ' 34' ' ' VAL . . . -123.19 145.86 47.45 Favored Pre-proline 0 C--N 1.329 -0.297 0 CA-C-N 116.245 -0.434 . . . . 0.0 111.119 -179.956 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 88' ' ' PRO . . . . . 0.41 ' O ' ' N ' ' A' ' 91' ' ' ARG . 32.3 Cg_exo -58.02 141.94 96.5 Favored 'Trans proline' 0 C--N 1.346 0.4 0 C-N-CA 122.498 2.132 . . . . 0.0 112.235 179.991 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 89' ' ' ALA . . . . . 0.569 ' HB2' ' HE1' ' A' ' 56' ' ' TYR . . . -47.9 -51.44 23.24 Favored 'General case' 0 CA--C 1.522 -0.116 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.346 179.859 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 90' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -55.99 -24.29 37.84 Favored 'General case' 0 N--CA 1.454 -0.27 0 CA-C-N 115.759 -0.655 . . . . 0.0 109.789 178.836 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 91' ' ' ARG . . . . . 0.41 ' N ' ' O ' ' A' ' 88' ' ' PRO . 0.0 OUTLIER -89.77 -14.08 35.34 Favored 'General case' 0 N--CA 1.455 -0.208 0 CA-C-N 115.945 -0.571 . . . . 0.0 110.526 179.029 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 92' ' ' ILE . . . . . 0.729 HD13 HD11 ' A' ' 58' ' ' ILE . 52.4 mt -110.56 156.04 11.73 Favored 'Isoleucine or valine' 0 C--O 1.23 0.077 0 CA-C-O 120.904 0.383 . . . . 0.0 111.04 179.864 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 93' ' ' GLN . . . . . 0.448 ' N ' HG22 ' A' ' 92' ' ' ILE . 1.9 mt-30 -124.31 179.98 4.69 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.78 179.93 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 94' ' ' ARG . . . . . . . . . . . . . 4.2 ttt180 -126.08 142.18 51.63 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.936 179.993 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 95' ' ' ILE . . . . . 0.702 HD11 ' HB2' ' A' ' 33' ' ' LEU . 3.4 mt . . . . . 0 C--N 1.329 -0.292 0 CA-C-N 116.246 -0.434 . . . . 0.0 111.088 179.982 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.457 -0.076 0 CA-C-O 120.85 0.357 . . . . 0.0 111.088 . . . . . . . . . 0 0 . 1 . 012 nuclear nobuild core ' A' A ' 27' ' ' GLU . . . . . . . . . . . . . 50.8 mt-10 -133.24 -177.82 4.7 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.924 179.983 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 27.4 t -71.31 121.53 21.51 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.096 179.924 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 89.72 52.98 2.51 Favored Glycine 0 N--CA 1.452 -0.293 0 C-N-CA 120.7 -0.762 . . . . 0.0 112.424 179.954 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -155.45 142.1 18.83 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 120.795 0.331 . . . . 0.0 110.887 179.968 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 31' ' ' GLN . . . . . . . . . . . . . 15.3 mt-30 -59.97 134.95 57.52 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.256 -0.429 . . . . 0.0 110.923 -179.971 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 5.5 m -141.83 179.31 2.12 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.346 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.12 -179.982 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 33' ' ' LEU . . . . . 0.466 HD11 ' O ' ' A' ' 37' ' ' GLN . 30.6 tp -142.76 108.0 5.0 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.791 179.98 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 34' ' ' VAL . . . . . 0.526 HG13 ' CB ' ' A' ' 87' ' ' ALA . 22.0 t -78.29 124.67 37.03 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.156 179.995 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 35' ' ' ALA . . . . . . . . . . . . . . . 58.46 26.15 13.86 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.052 -0.522 . . . . 0.0 111.231 179.952 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . 56.57 28.48 56.21 Favored Glycine 0 N--CA 1.451 -0.333 0 C-N-CA 120.773 -0.727 . . . . 0.0 112.598 -179.999 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 37' ' ' GLN . . . . . 0.466 ' O ' HD11 ' A' ' 33' ' ' LEU . 34.3 mt-30 -140.34 -70.88 0.38 Allowed 'General case' 0 C--N 1.328 -0.327 0 CA-C-O 120.749 0.309 . . . . 0.0 110.924 -179.998 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 38' ' ' LYS . . . . . . . . . . . . . 2.1 mttt -69.76 108.45 3.93 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.263 -0.426 . . . . 0.0 110.902 -179.948 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 39' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -88.15 136.98 32.72 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.908 179.974 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -160.52 -163.49 13.89 Favored Glycine 0 N--CA 1.451 -0.319 0 C-N-CA 120.727 -0.749 . . . . 0.0 112.463 180.0 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 41' ' ' ILE . . . . . 0.406 ' C ' HG23 ' A' ' 58' ' ' ILE . 33.2 mt -133.67 131.6 56.9 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-O 120.742 0.306 . . . . 0.0 111.084 -179.905 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 42' ' ' VAL . . . . . . . . . . . . . 21.4 t -60.06 125.43 16.17 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.345 0 CA-C-N 116.209 -0.45 . . . . 0.0 111.123 179.988 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 43' ' ' ARG . . . . . . . . . . . . . 13.6 mmt180 -110.34 -32.72 6.85 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.908 179.951 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 44' ' ' PHE . . . . . . . . . . . . . 72.2 t80 -143.05 111.05 6.0 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.248 -0.433 . . . . 0.0 110.912 -179.919 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 45' ' ' TYR . . . . . 0.5 ' CE1' ' CZ ' ' A' ' 56' ' ' TYR . 18.6 t80 -108.0 122.95 47.88 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.855 -179.99 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 164.94 -179.61 39.47 Favored Glycine 0 N--CA 1.451 -0.32 0 C-N-CA 120.767 -0.73 . . . . 0.0 112.534 179.928 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 47' ' ' LYS . . . . . . . . . . . . . 18.6 mttt -69.4 153.18 43.97 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 120.817 0.341 . . . . 0.0 110.879 -179.975 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 48' ' ' THR . . . . . 0.546 HG21 ' CE1' ' A' ' 50' ' ' PHE . 1.3 p -111.24 177.6 4.61 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.892 179.98 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -104.5 -31.33 9.51 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.835 179.992 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 50' ' ' PHE . . . . . 0.546 ' CE1' HG21 ' A' ' 48' ' ' THR . 54.1 p90 -75.53 -39.19 58.7 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.262 -0.427 . . . . 0.0 110.918 -179.965 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 51' ' ' ALA . . . . . . . . . . . . . . . -131.61 147.13 64.81 Favored Pre-proline 0 C--N 1.33 -0.273 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.093 -179.946 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 52' ' ' PRO . . . . . . . . . . . . . 61.0 Cg_endo -72.96 -172.58 1.01 Allowed 'Trans proline' 0 C--N 1.345 0.372 0 C-N-CA 122.508 2.138 . . . . 0.0 112.395 179.974 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 67.94 -165.48 45.23 Favored Glycine 0 N--CA 1.452 -0.291 0 C-N-CA 120.738 -0.744 . . . . 0.0 112.511 179.973 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 54' ' ' TYR . . . . . . . . . . . . . 69.3 m-85 -107.69 141.55 39.04 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-O 120.84 0.352 . . . . 0.0 110.876 -179.963 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 55' ' ' TRP . . . . . 0.401 ' CZ3' ' HD3' ' A' ' 88' ' ' PRO . 52.6 m95 -132.61 167.17 20.52 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.917 -179.897 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 56' ' ' TYR . . . . . 0.639 ' CE1' ' HB2' ' A' ' 89' ' ' ALA . 3.7 m-85 -121.18 117.09 26.23 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.323 -0.399 . . . . 0.0 110.912 179.997 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 57' ' ' GLY . . . . . 0.446 ' N ' ' CE1' ' A' ' 86' ' ' PHE . . . -81.2 68.26 3.47 Favored Glycine 0 N--CA 1.451 -0.331 0 C-N-CA 120.789 -0.72 . . . . 0.0 112.402 -179.967 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 58' ' ' ILE . . . . . 0.723 HD11 HD13 ' A' ' 92' ' ' ILE . 19.6 mt -73.53 138.04 22.09 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-O 120.807 0.337 . . . . 0.0 111.113 179.998 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -103.63 114.18 28.25 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.841 -179.967 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 60' ' ' LEU . . . . . . . . . . . . . 77.8 mt -69.51 -179.94 1.87 Allowed 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.154 -0.475 . . . . 0.0 110.885 179.972 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 4.9 m-20 -109.41 -34.09 6.63 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.951 -179.977 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 62' ' ' GLN . . . . . 0.407 ' HA ' ' HD3' ' A' ' 63' ' ' PRO . 4.1 mm-40 -108.14 146.63 33.94 Favored Pre-proline 0 C--N 1.329 -0.3 0 CA-C-N 116.321 -0.4 . . . . 0.0 110.942 -179.975 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 63' ' ' PRO . . . . . 0.407 ' HD3' ' HA ' ' A' ' 62' ' ' GLN . 31.7 Cg_exo -58.88 91.93 0.07 OUTLIER 'Trans proline' 0 C--N 1.345 0.368 0 C-N-CA 122.62 2.213 . . . . 0.0 112.172 -179.966 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 64' ' ' THR . . . . . . . . . . . . . 10.1 t -172.89 38.88 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.913 -179.979 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . -93.42 -128.97 5.1 Favored Glycine 0 N--CA 1.45 -0.37 0 C-N-CA 120.786 -0.721 . . . . 0.0 112.48 -179.976 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 66' ' ' LYS . . . . . . . . . . . . . 1.1 mtpm? -135.89 -50.8 0.72 Allowed 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 120.881 0.372 . . . . 0.0 110.874 180.0 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 67' ' ' HIS . . . . . . . . . . . . . 7.1 p80 -128.18 178.99 5.85 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.884 179.911 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 15.5 t0 -101.46 36.46 2.02 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.966 179.999 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 95.66 -37.85 3.3 Favored Glycine 0 N--CA 1.451 -0.351 0 C-N-CA 120.707 -0.759 . . . . 0.0 112.495 -179.997 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 70' ' ' SER . . . . . . . . . . . . . 75.2 p -102.73 162.33 13.02 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-O 120.947 0.403 . . . . 0.0 110.842 -179.91 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 21.4 t -148.07 117.14 1.15 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-N 116.132 -0.485 . . . . 0.0 111.168 179.953 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 72' ' ' PHE . . . . . . . . . . . . . 5.1 m-85 60.4 35.56 20.47 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.14 -0.482 . . . . 0.0 111.002 -179.977 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 80.91 28.26 46.78 Favored Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.679 -0.772 . . . . 0.0 112.597 -179.972 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 74' ' ' VAL . . . . . 0.402 ' O ' ' CE1' ' A' ' 76' ' ' TYR . 21.5 t -133.63 104.89 6.78 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-O 120.799 0.333 . . . . 0.0 111.098 -179.975 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 75' ' ' ARG . . . . . . . . . . . . . 3.6 ttt-85 -77.41 131.47 38.04 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.246 -0.433 . . . . 0.0 111.001 -179.979 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 76' ' ' TYR . . . . . 0.402 ' CE1' ' O ' ' A' ' 74' ' ' VAL . 11.7 m-85 -106.86 -45.63 4.14 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.178 -0.464 . . . . 0.0 110.858 179.956 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 77' ' ' PHE . . . . . 0.431 ' CE1' ' HA3' ' A' ' 57' ' ' GLY . 36.8 p90 -156.29 156.55 34.21 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.924 179.985 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 1.9 t -80.0 114.51 18.97 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.25 -0.432 . . . . 0.0 110.89 179.955 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 79' ' ' CYS . . . . . . . . . . . . . 29.4 p -147.15 152.48 38.5 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.973 -179.936 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 80' ' ' ALA . . . . . 0.73 ' HB1' ' HD2' ' A' ' 81' ' ' PRO . . . -58.45 166.73 2.09 Favored Pre-proline 0 C--N 1.329 -0.29 0 CA-C-N 116.143 -0.48 . . . . 0.0 111.002 179.93 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 81' ' ' PRO . . . . . 0.73 ' HD2' ' HB1' ' A' ' 80' ' ' ALA . 20.5 Cg_endo -60.76 120.95 8.95 Favored 'Trans proline' 0 C--N 1.344 0.29 0 C-N-CA 122.545 2.164 . . . . 0.0 112.168 179.936 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 82' ' ' ARG . . . . . . . . . . . . . 78.1 mtt180 63.11 50.36 3.1 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.143 -0.48 . . . . 0.0 110.876 -179.832 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 83' ' ' HIS . . . . . 0.581 ' ND1' ' HB3' ' A' ' 80' ' ' ALA . 5.8 m170 -123.33 -48.8 1.95 Allowed 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.934 179.933 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . -66.5 121.82 18.68 Favored Glycine 0 N--CA 1.451 -0.304 0 C-N-CA 120.629 -0.796 . . . . 0.0 112.401 179.857 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 85' ' ' VAL . . . . . . . . . . . . . 5.9 m -126.35 132.4 70.43 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-O 120.911 0.386 . . . . 0.0 111.194 -179.98 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 86' ' ' PHE . . . . . 0.446 ' CE1' ' N ' ' A' ' 57' ' ' GLY . 12.9 m-85 -103.66 118.05 35.83 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.991 179.958 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 87' ' ' ALA . . . . . 0.526 ' CB ' HG13 ' A' ' 34' ' ' VAL . . . -134.69 143.61 47.19 Favored Pre-proline 0 C--N 1.33 -0.279 0 CA-C-N 116.215 -0.448 . . . . 0.0 111.058 179.992 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 88' ' ' PRO . . . . . 0.418 ' O ' ' N ' ' A' ' 91' ' ' ARG . 32.5 Cg_exo -57.71 142.1 95.81 Favored 'Trans proline' 0 C--N 1.346 0.401 0 C-N-CA 122.451 2.101 . . . . 0.0 112.397 179.972 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 89' ' ' ALA . . . . . 0.639 ' HB2' ' CE1' ' A' ' 56' ' ' TYR . . . -47.94 -50.98 25.28 Favored 'General case' 0 CA--C 1.521 -0.156 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.255 179.867 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 90' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER -55.87 -24.39 36.72 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 115.716 -0.674 . . . . 0.0 109.801 178.859 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 91' ' ' ARG . . . . . 0.418 ' N ' ' O ' ' A' ' 88' ' ' PRO . 1.0 OUTLIER -90.98 -13.15 33.93 Favored 'General case' 0 N--CA 1.455 -0.219 0 CA-C-N 115.944 -0.571 . . . . 0.0 110.522 179.154 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 92' ' ' ILE . . . . . 0.723 HD13 HD11 ' A' ' 58' ' ' ILE . 62.9 mt -107.09 147.8 11.99 Favored 'Isoleucine or valine' 0 C--O 1.231 0.101 0 CA-C-N 116.432 -0.349 . . . . 0.0 110.895 179.836 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 93' ' ' GLN . . . . . . . . . . . . . 5.7 mt-30 -118.04 168.97 10.05 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.972 179.934 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 94' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -111.48 152.36 27.54 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.859 -179.997 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 95' ' ' ILE . . . . . . . . . . . . . 23.1 mt . . . . . 0 C--N 1.329 -0.297 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.155 179.909 . . . . . . . . 0 0 . 1 . 013 nuclear nobuild core ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.457 -0.078 0 CA-C-O 120.822 0.344 . . . . 0.0 111.063 . . . . . . . . . 0 0 . 1 . 013 nuclear nobuild core ' A' A ' 27' ' ' GLU . . . . . . . . . . . . . 14.3 mt-10 -142.57 168.42 19.78 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.938 179.991 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 27.4 t -68.58 85.06 0.14 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.049 179.957 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 132.62 43.86 0.15 Allowed Glycine 0 N--CA 1.452 -0.265 0 C-N-CA 120.677 -0.773 . . . . 0.0 112.462 179.975 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 2.2 t0 -149.81 152.86 35.86 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 120.774 0.321 . . . . 0.0 110.902 -179.915 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 31' ' ' GLN . . . . . . . . . . . . . 1.6 mt-30 -69.03 141.92 54.72 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.918 179.943 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 5.7 m -143.27 174.84 4.43 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-N 116.247 -0.433 . . . . 0.0 111.141 179.96 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 33' ' ' LEU . . . . . . . . . . . . . 13.8 tp -141.25 105.15 4.75 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.843 179.986 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 34' ' ' VAL . . . . . 0.584 HG13 ' CB ' ' A' ' 87' ' ' ALA . 21.7 t -73.73 123.49 28.98 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.153 -179.982 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 35' ' ' ALA . . . . . . . . . . . . . . . 56.99 25.04 10.19 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.304 179.96 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . 57.29 37.0 78.65 Favored Glycine 0 N--CA 1.45 -0.374 0 C-N-CA 120.803 -0.713 . . . . 0.0 112.572 179.912 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 37' ' ' GLN . . . . . . . . . . . . . 39.0 mt-30 -148.55 -70.17 0.21 Allowed 'General case' 0 C--N 1.33 -0.279 0 CA-C-O 120.731 0.3 . . . . 0.0 110.971 179.98 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 38' ' ' LYS . . . . . . . . . . . . . 62.3 mttt -67.73 105.78 2.03 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.913 179.973 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 39' ' ' GLN . . . . . . . . . . . . . 2.3 tm0? -82.2 132.51 35.24 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.886 -179.996 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -158.08 -174.64 28.04 Favored Glycine 0 N--CA 1.451 -0.333 0 C-N-CA 120.658 -0.782 . . . . 0.0 112.53 179.923 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 41' ' ' ILE . . . . . 0.438 ' N ' HG23 ' A' ' 58' ' ' ILE . 15.7 mt -127.41 135.2 63.98 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-O 120.845 0.355 . . . . 0.0 111.046 -179.967 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 42' ' ' VAL . . . . . . . . . . . . . 21.5 t -62.82 120.97 10.71 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.175 179.956 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 43' ' ' ARG . . . . . . . . . . . . . 30.9 mmt180 -110.08 -32.1 7.13 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 116.178 -0.464 . . . . 0.0 110.932 -179.991 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 44' ' ' PHE . . . . . . . . . . . . . 63.4 t80 -147.4 115.53 6.55 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.896 179.924 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 45' ' ' TYR . . . . . 0.496 ' CE1' ' CE1' ' A' ' 56' ' ' TYR . 22.1 t80 -113.1 113.54 25.55 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.967 179.887 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . -175.96 -161.06 24.51 Favored Glycine 0 N--CA 1.452 -0.293 0 C-N-CA 120.712 -0.756 . . . . 0.0 112.474 -179.967 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 47' ' ' LYS . . . . . 0.424 ' HE2' ' CE1' ' A' ' 54' ' ' TYR . 27.2 mttm -88.4 168.95 12.22 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 120.795 0.331 . . . . 0.0 110.893 -179.925 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 48' ' ' THR . . . . . 0.645 HG22 ' CE2' ' A' ' 76' ' ' TYR . 67.1 p -140.04 175.09 9.88 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.949 -179.974 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 3.9 t70 -109.2 -31.52 7.55 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.931 179.994 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 50' ' ' PHE . . . . . 0.598 ' CZ ' HG21 ' A' ' 48' ' ' THR . 28.2 p90 -65.52 -36.07 82.74 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.97 179.959 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 51' ' ' ALA . . . . . 0.419 ' N ' ' CD1' ' A' ' 50' ' ' PHE . . . -140.98 148.13 50.8 Favored Pre-proline 0 C--N 1.329 -0.318 0 CA-C-N 116.209 -0.45 . . . . 0.0 111.097 -179.99 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 52' ' ' PRO . . . . . . . . . . . . . 59.7 Cg_endo -72.6 176.05 9.35 Favored 'Trans proline' 0 C--N 1.345 0.364 0 C-N-CA 122.508 2.139 . . . . 0.0 112.281 -179.981 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 67.72 175.19 8.33 Favored Glycine 0 N--CA 1.452 -0.286 0 C-N-CA 120.727 -0.749 . . . . 0.0 112.493 -179.934 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 54' ' ' TYR . . . . . 0.424 ' CE1' ' HE2' ' A' ' 47' ' ' LYS . 5.9 m-85 -83.71 148.91 26.81 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-O 120.829 0.347 . . . . 0.0 110.944 -179.983 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 55' ' ' TRP . . . . . . . . . . . . . 72.0 m95 -134.44 164.48 27.34 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.923 -179.978 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 56' ' ' TYR . . . . . 0.642 ' HE1' ' HB2' ' A' ' 89' ' ' ALA . 27.0 m-85 -113.55 112.41 23.5 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.908 179.979 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . -77.21 65.93 2.96 Favored Glycine 0 N--CA 1.451 -0.324 0 C-N-CA 120.727 -0.749 . . . . 0.0 112.396 179.909 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 58' ' ' ILE . . . . . 0.453 HD11 HD13 ' A' ' 92' ' ' ILE . 22.5 mt -74.65 152.34 6.78 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.271 0 CA-C-O 120.774 0.321 . . . . 0.0 111.215 -179.976 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 10.8 tm-20 -121.67 120.93 36.15 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 116.258 -0.428 . . . . 0.0 110.862 -179.968 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 60' ' ' LEU . . . . . . . . . . . . . 71.6 mt -79.88 -179.9 7.21 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-N 116.13 -0.486 . . . . 0.0 110.953 179.998 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -108.35 -29.0 9.08 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.028 -179.953 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 62' ' ' GLN . . . . . 0.414 ' HA ' ' HD3' ' A' ' 63' ' ' PRO . 8.2 mt-30 -108.63 143.41 27.46 Favored Pre-proline 0 C--N 1.329 -0.313 0 CA-C-N 116.382 -0.372 . . . . 0.0 110.973 -179.924 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 63' ' ' PRO . . . . . 0.414 ' HD3' ' HA ' ' A' ' 62' ' ' GLN . 39.4 Cg_exo -60.5 89.87 0.08 OUTLIER 'Trans proline' 0 C--N 1.346 0.4 0 C-N-CA 122.488 2.126 . . . . 0.0 112.18 179.928 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 64' ' ' THR . . . . . . . . . . . . . 10.2 t -170.89 35.97 0.02 OUTLIER 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.294 -0.412 . . . . 0.0 110.967 -179.976 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . -87.02 -95.3 0.88 Allowed Glycine 0 N--CA 1.451 -0.362 0 C-N-CA 120.684 -0.769 . . . . 0.0 112.522 -179.994 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 66' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -172.91 -47.42 0.02 OUTLIER 'General case' 0 C--N 1.328 -0.353 0 CA-C-O 120.854 0.359 . . . . 0.0 110.887 -179.982 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 67' ' ' HIS . . . . . . . . . . . . . 11.5 p80 -135.38 167.5 20.93 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.871 179.915 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -95.8 42.68 1.09 Allowed 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.898 179.945 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 87.33 -53.39 4.4 Favored Glycine 0 N--CA 1.452 -0.295 0 C-N-CA 120.717 -0.754 . . . . 0.0 112.492 179.966 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 70' ' ' SER . . . . . . . . . . . . . 93.8 p -79.05 143.82 35.23 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-O 120.773 0.32 . . . . 0.0 110.952 -179.992 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 71' ' ' VAL . . . . . 0.534 HG12 ' CD2' ' A' ' 72' ' ' PHE . 21.4 t -138.24 112.13 8.06 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.329 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.125 -179.981 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 72' ' ' PHE . . . . . 0.534 ' CD2' HG12 ' A' ' 71' ' ' VAL . 48.0 m-85 60.94 31.04 19.96 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.273 -0.421 . . . . 0.0 110.951 -179.933 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 86.11 29.49 25.36 Favored Glycine 0 N--CA 1.451 -0.304 0 C-N-CA 120.715 -0.755 . . . . 0.0 112.528 -179.997 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 21.5 t -136.77 110.33 8.82 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-O 120.849 0.357 . . . . 0.0 111.103 -179.946 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 75' ' ' ARG . . . . . . . . . . . . . 25.8 ttm-85 -81.47 143.81 31.81 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.132 -0.486 . . . . 0.0 110.91 -179.979 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 76' ' ' TYR . . . . . 0.645 ' CE2' HG22 ' A' ' 48' ' ' THR . 24.5 m-85 -120.4 -44.48 2.47 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.837 179.992 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 77' ' ' PHE . . . . . . . . . . . . . 8.2 p90 -157.19 156.51 32.73 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.907 -179.891 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 1.2 m -84.64 95.63 8.95 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.117 -0.492 . . . . 0.0 110.883 179.912 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 79' ' ' CYS . . . . . . . . . . . . . 13.9 p -122.85 159.3 28.44 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.288 -0.414 . . . . 0.0 110.976 -179.942 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 80' ' ' ALA . . . . . 0.742 ' HB1' ' HD2' ' A' ' 81' ' ' PRO . . . -59.05 166.68 2.48 Favored Pre-proline 0 C--N 1.328 -0.343 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.011 179.944 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 81' ' ' PRO . . . . . 0.742 ' HD2' ' HB1' ' A' ' 80' ' ' ALA . 35.7 Cg_endo -65.09 118.26 5.28 Favored 'Trans proline' 0 C--N 1.345 0.365 0 C-N-CA 122.491 2.127 . . . . 0.0 112.196 179.958 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 82' ' ' ARG . . . . . . . . . . . . . 1.1 mtm-85 62.1 46.71 6.16 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.844 -179.944 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 83' ' ' HIS . . . . . 0.711 ' CG ' ' HB3' ' A' ' 80' ' ' ALA . 8.7 m170 -120.68 -43.36 2.48 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.899 179.98 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . -61.07 151.5 41.91 Favored Glycine 0 N--CA 1.451 -0.326 0 C-N-CA 120.708 -0.758 . . . . 0.0 112.494 -179.983 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 85' ' ' VAL . . . . . . . . . . . . . 15.2 m -151.55 129.4 2.49 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-O 120.861 0.362 . . . . 0.0 111.236 -179.929 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 86' ' ' PHE . . . . . . . . . . . . . 8.4 m-85 -102.45 121.87 43.18 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.81 179.985 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 87' ' ' ALA . . . . . 0.584 ' CB ' HG13 ' A' ' 34' ' ' VAL . . . -143.0 145.52 33.47 Favored Pre-proline 0 C--N 1.33 -0.258 0 CA-C-N 116.171 -0.468 . . . . 0.0 111.161 179.943 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 88' ' ' PRO . . . . . . . . . . . . . 32.0 Cg_exo -58.29 137.0 78.22 Favored 'Trans proline' 0 C--N 1.345 0.365 0 C-N-CA 122.575 2.183 . . . . 0.0 112.235 -179.972 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 89' ' ' ALA . . . . . 0.642 ' HB2' ' HE1' ' A' ' 56' ' ' TYR . . . -48.38 -50.96 28.67 Favored 'General case' 0 CA--C 1.521 -0.145 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.316 179.82 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 90' ' ' SER . . . . . . . . . . . . . 51.2 p -55.96 -24.48 38.67 Favored 'General case' 0 N--CA 1.454 -0.246 0 CA-C-N 115.701 -0.681 . . . . 0.0 109.782 178.692 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 91' ' ' ARG . . . . . . . . . . . . . 1.0 OUTLIER -88.22 -14.66 37.96 Favored 'General case' 0 N--CA 1.455 -0.199 0 CA-C-N 115.808 -0.633 . . . . 0.0 110.405 179.062 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 92' ' ' ILE . . . . . 0.566 HD11 ' O ' ' A' ' 87' ' ' ALA . 22.2 mt -108.45 150.29 11.22 Favored 'Isoleucine or valine' 0 C--O 1.231 0.114 0 CA-C-O 120.84 0.353 . . . . 0.0 111.089 179.887 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 93' ' ' GLN . . . . . . . . . . . . . 1.8 mp0 -110.95 169.68 8.6 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.87 179.98 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 94' ' ' ARG . . . . . . . . . . . . . 9.3 ttt-85 -121.59 119.27 31.42 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.189 -0.459 . . . . 0.0 110.876 -179.99 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 95' ' ' ILE . . . . . . . . . . . . . 4.5 mt . . . . . 0 C--N 1.329 -0.289 0 CA-C-N 116.185 -0.461 . . . . 0.0 111.115 -180.0 . . . . . . . . 0 0 . 1 . 014 nuclear nobuild core ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.231 0.119 0 CA-C-O 120.804 0.335 . . . . 0.0 111.075 . . . . . . . . . 0 0 . 1 . 014 nuclear nobuild core ' A' A ' 27' ' ' GLU . . . . . . . . . . . . . 41.7 mt-10 -140.64 174.87 10.09 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.871 -179.972 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 21.5 t -75.27 105.48 4.27 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.247 -0.433 . . . . 0.0 111.136 179.961 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 114.51 35.63 1.4 Allowed Glycine 0 N--CA 1.452 -0.291 0 C-N-CA 120.699 -0.762 . . . . 0.0 112.537 -179.969 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -149.0 150.88 33.57 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-O 120.749 0.309 . . . . 0.0 110.934 -179.952 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 31' ' ' GLN . . . . . 0.721 ' HB3' HD12 ' A' ' 95' ' ' ILE . 8.8 mp0 -70.0 151.35 45.67 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.282 -0.417 . . . . 0.0 110.831 -179.995 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 14.0 m -152.38 179.46 0.43 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.261 -0.427 . . . . 0.0 111.153 179.998 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 33' ' ' LEU . . . . . 0.636 HD11 ' C ' ' A' ' 37' ' ' GLN . 44.3 tp -143.39 117.86 9.71 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.856 179.943 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 34' ' ' VAL . . . . . 0.411 HG13 ' CB ' ' A' ' 87' ' ' ALA . 21.7 t -85.57 129.6 37.7 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.207 -0.452 . . . . 0.0 111.278 -179.839 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 35' ' ' ALA . . . . . . . . . . . . . . . 53.93 25.91 5.8 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.149 -0.478 . . . . 0.0 111.394 179.893 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . 57.61 33.82 68.16 Favored Glycine 0 N--CA 1.451 -0.353 0 C-N-CA 120.725 -0.75 . . . . 0.0 112.551 179.958 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 37' ' ' GLN . . . . . 0.636 ' C ' HD11 ' A' ' 33' ' ' LEU . 94.2 mt-30 -146.91 -70.6 0.24 Allowed 'General case' 0 C--N 1.33 -0.281 0 CA-C-O 120.847 0.356 . . . . 0.0 110.993 -179.951 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 38' ' ' LYS . . . . . 0.467 ' O ' HD12 ' A' ' 33' ' ' LEU . 2.7 mtmp? -67.11 110.41 3.42 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.947 -179.98 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 39' ' ' GLN . . . . . . . . . . . . . 1.3 tm0? -91.35 137.98 31.94 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.921 179.964 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -164.14 -173.22 32.56 Favored Glycine 0 N--CA 1.45 -0.371 0 C-N-CA 120.82 -0.705 . . . . 0.0 112.564 179.939 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 26.6 mt -122.63 132.01 72.08 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-O 120.804 0.335 . . . . 0.0 111.146 179.958 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 42' ' ' VAL . . . . . . . . . . . . . 33.8 t -59.53 124.29 13.53 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.081 179.986 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 43' ' ' ARG . . . . . . . . . . . . . 1.6 mmm-85 -109.77 -31.11 7.56 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.957 179.985 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 44' ' ' PHE . . . . . . . . . . . . . 28.9 t80 -147.59 112.14 5.31 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.892 179.966 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 45' ' ' TYR . . . . . 0.495 ' CE1' ' CZ ' ' A' ' 56' ' ' TYR . 15.2 t80 -113.27 141.9 46.46 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.894 -179.955 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 144.95 -174.53 24.99 Favored Glycine 0 N--CA 1.451 -0.329 0 C-N-CA 120.757 -0.735 . . . . 0.0 112.501 179.951 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 47' ' ' LYS . . . . . 0.415 ' HG3' ' CD1' ' A' ' 54' ' ' TYR . 13.6 mttm -74.02 161.54 29.96 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-O 120.797 0.332 . . . . 0.0 110.88 -179.966 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 48' ' ' THR . . . . . . . . . . . . . 75.2 p -119.07 -176.91 3.22 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.853 -179.975 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 1.8 t0 -113.41 15.65 19.09 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.378 -179.985 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 50' ' ' PHE . . . . . 0.45 ' CD1' ' N ' ' A' ' 51' ' ' ALA . 42.8 p90 -124.79 -41.28 2.13 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 120.74 0.305 . . . . 0.0 110.955 -179.993 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 51' ' ' ALA . . . . . 0.45 ' N ' ' CD1' ' A' ' 50' ' ' PHE . . . -129.25 149.21 72.06 Favored Pre-proline 0 C--N 1.329 -0.306 0 CA-C-N 116.311 -0.404 . . . . 0.0 111.106 -179.995 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 52' ' ' PRO . . . . . . . . . . . . . 55.6 Cg_endo -70.19 178.04 5.25 Favored 'Trans proline' 0 C--N 1.344 0.306 0 C-N-CA 122.608 2.205 . . . . 0.0 112.274 -179.971 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 72.96 -169.91 52.35 Favored Glycine 0 N--CA 1.451 -0.345 0 C-N-CA 120.717 -0.754 . . . . 0.0 112.542 -179.95 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 54' ' ' TYR . . . . . 0.415 ' CD1' ' HG3' ' A' ' 47' ' ' LYS . 99.7 m-85 -111.28 134.38 52.91 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-O 120.849 0.357 . . . . 0.0 110.932 179.933 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 55' ' ' TRP . . . . . . . . . . . . . 42.1 m95 -120.43 157.81 28.53 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.893 179.984 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 56' ' ' TYR . . . . . 0.507 ' CE1' ' HB2' ' A' ' 89' ' ' ALA . 4.1 m-85 -110.61 123.82 50.7 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.944 -179.901 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . -89.52 64.11 3.23 Favored Glycine 0 N--CA 1.452 -0.253 0 C-N-CA 120.768 -0.729 . . . . 0.0 112.416 179.891 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 58' ' ' ILE . . . . . 0.657 HD11 HD13 ' A' ' 92' ' ' ILE . 4.8 mt -71.72 144.7 13.01 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-O 120.783 0.325 . . . . 0.0 111.098 179.988 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 1.4 tm-20 -109.08 137.56 46.8 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.187 -0.461 . . . . 0.0 110.891 179.961 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 60' ' ' LEU . . . . . . . . . . . . . 65.1 mt -93.89 168.88 10.69 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.892 -179.931 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 20.2 t0 -95.79 -31.34 13.23 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.917 179.974 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 62' ' ' GLN . . . . . . . . . . . . . 5.5 pt20 -111.27 153.41 44.04 Favored Pre-proline 0 C--N 1.33 -0.274 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.865 -179.879 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 56.6 Cg_endo -70.67 80.05 1.17 Allowed 'Trans proline' 0 C--N 1.344 0.328 0 C-N-CA 122.605 2.203 . . . . 0.0 112.302 179.943 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 64' ' ' THR . . . . . . . . . . . . . 65.5 p -156.73 31.33 0.31 Allowed 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.075 -0.511 . . . . 0.0 110.823 -179.993 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . -83.85 -114.62 0.61 Allowed Glycine 0 N--CA 1.451 -0.309 0 C-N-CA 120.699 -0.762 . . . . 0.0 112.521 -179.969 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 66' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -151.68 -48.16 0.11 Allowed 'General case' 0 C--N 1.329 -0.293 0 CA-C-O 120.851 0.357 . . . . 0.0 110.904 -179.963 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 67' ' ' HIS . . . . . . . . . . . . . 7.2 p80 -124.37 175.92 6.79 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.973 -179.982 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 1.3 m-20 -97.94 37.25 1.43 Allowed 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.231 -0.44 . . . . 0.0 110.924 179.97 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 91.03 -50.94 3.14 Favored Glycine 0 N--CA 1.451 -0.325 0 C-N-CA 120.723 -0.751 . . . . 0.0 112.489 -179.998 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 70' ' ' SER . . . . . . . . . . . . . 21.4 p -88.31 143.3 27.1 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-O 120.79 0.328 . . . . 0.0 110.927 -179.938 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 71' ' ' VAL . . . . . 0.782 HG12 ' CD2' ' A' ' 72' ' ' PHE . 24.6 t -127.32 114.6 37.23 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.219 -0.446 . . . . 0.0 111.078 179.982 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 72' ' ' PHE . . . . . 0.782 ' CD2' HG12 ' A' ' 71' ' ' VAL . 25.3 m-85 60.32 31.04 20.3 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.956 -179.917 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 86.48 28.56 26.89 Favored Glycine 0 N--CA 1.451 -0.325 0 C-N-CA 120.685 -0.769 . . . . 0.0 112.475 179.969 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 21.5 t -130.16 100.2 4.92 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-O 120.91 0.386 . . . . 0.0 111.161 179.991 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 75' ' ' ARG . . . . . . . . . . . . . 4.8 ttt180 -80.26 112.37 17.52 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.116 -0.493 . . . . 0.0 110.879 -179.942 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 76' ' ' TYR . . . . . . . . . . . . . 58.0 m-85 -88.16 -40.37 13.79 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.911 -180.0 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 77' ' ' PHE . . . . . . . . . . . . . 23.3 p90 -154.1 153.39 31.78 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.889 179.892 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 78' ' ' THR . . . . . 0.418 HG23 ' O ' ' A' ' 78' ' ' THR . 5.1 t -82.97 111.56 18.95 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.145 -0.48 . . . . 0.0 110.812 -179.999 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 79' ' ' CYS . . . . . . . . . . . . . 18.4 p -143.1 170.71 15.21 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.959 -179.977 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 80' ' ' ALA . . . . . 0.765 ' HB3' ' ND1' ' A' ' 83' ' ' HIS . . . -70.67 167.06 30.42 Favored Pre-proline 0 C--N 1.329 -0.307 0 CA-C-N 116.121 -0.49 . . . . 0.0 110.969 179.938 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 81' ' ' PRO . . . . . 0.753 ' HD2' ' HB1' ' A' ' 80' ' ' ALA . 34.7 Cg_endo -64.86 126.83 17.33 Favored 'Trans proline' 0 C--N 1.345 0.356 0 C-N-CA 122.433 2.089 . . . . 0.0 112.224 179.934 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 82' ' ' ARG . . . . . . . . . . . . . 76.2 mtt180 62.03 39.34 13.32 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.132 -0.486 . . . . 0.0 110.957 -179.914 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 83' ' ' HIS . . . . . 0.765 ' ND1' ' HB3' ' A' ' 80' ' ' ALA . 9.1 m170 -114.55 -37.66 4.23 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.868 179.971 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . -76.91 152.77 41.03 Favored Glycine 0 N--CA 1.451 -0.332 0 C-N-CA 120.746 -0.74 . . . . 0.0 112.529 179.997 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 85' ' ' VAL . . . . . . . . . . . . . 16.1 m -153.9 135.22 5.23 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.329 0 CA-C-O 120.82 0.343 . . . . 0.0 111.12 179.934 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 86' ' ' PHE . . . . . . . . . . . . . 7.2 m-85 -111.09 117.09 32.34 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.99 -179.989 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 87' ' ' ALA . . . . . 0.497 ' O ' HD11 ' A' ' 92' ' ' ILE . . . -135.42 145.25 52.87 Favored Pre-proline 0 C--N 1.329 -0.324 0 CA-C-N 116.262 -0.426 . . . . 0.0 111.053 179.906 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 88' ' ' PRO . . . . . 0.409 ' O ' ' N ' ' A' ' 91' ' ' ARG . 33.6 Cg_exo -59.62 145.0 99.29 Favored 'Trans proline' 0 C--N 1.344 0.337 0 C-N-CA 122.562 2.174 . . . . 0.0 112.313 -179.978 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 89' ' ' ALA . . . . . 0.507 ' HB2' ' CE1' ' A' ' 56' ' ' TYR . . . -48.45 -50.91 29.43 Favored 'General case' 0 CA--C 1.521 -0.158 0 CA-C-N 116.187 -0.461 . . . . 0.0 110.247 179.84 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 90' ' ' SER . . . . . . . . . . . . . 1.2 m -56.0 -24.37 38.51 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 115.681 -0.69 . . . . 0.0 109.749 178.766 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 91' ' ' ARG . . . . . 0.409 ' N ' ' O ' ' A' ' 88' ' ' PRO . 0.0 OUTLIER -89.75 -13.9 35.78 Favored 'General case' 0 N--CA 1.454 -0.226 0 CA-C-N 115.926 -0.579 . . . . 0.0 110.515 179.125 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 92' ' ' ILE . . . . . 0.657 HD13 HD11 ' A' ' 58' ' ' ILE . 48.7 mt -110.31 153.51 12.07 Favored 'Isoleucine or valine' 0 C--O 1.23 0.074 0 CA-C-N 116.378 -0.374 . . . . 0.0 111.072 179.814 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 93' ' ' GLN . . . . . 0.407 ' N ' HG22 ' A' ' 92' ' ' ILE . 0.6 OUTLIER -116.24 179.81 3.89 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.805 -179.98 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 94' ' ' ARG . . . . . . . . . . . . . 4.1 ttp180 -122.76 144.08 49.41 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.885 -179.983 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 95' ' ' ILE . . . . . 0.721 HD12 ' HB3' ' A' ' 31' ' ' GLN . 22.0 mt . . . . . 0 C--N 1.33 -0.265 0 CA-C-N 116.174 -0.466 . . . . 0.0 111.177 179.931 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.231 0.101 0 CA-C-O 120.829 0.347 . . . . 0.0 111.121 . . . . . . . . . 0 0 . 1 . 015 nuclear nobuild core ' A' A ' 27' ' ' GLU . . . . . . . . . . . . . 4.8 mt-10 -124.31 179.51 4.88 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.953 179.976 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 21.4 t -75.21 104.98 3.83 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.241 -0.436 . . . . 0.0 111.172 179.951 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 108.13 34.55 2.72 Favored Glycine 0 N--CA 1.451 -0.328 0 C-N-CA 120.732 -0.747 . . . . 0.0 112.529 -179.941 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 30' ' ' ASP . . . . . 0.427 ' C ' HG23 ' A' ' 41' ' ' ILE . 0.8 OUTLIER -138.06 145.29 41.59 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-O 120.814 0.34 . . . . 0.0 110.879 180.0 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 31' ' ' GLN . . . . . 0.545 ' HB3' HD12 ' A' ' 95' ' ' ILE . 0.7 OUTLIER -60.01 144.78 48.48 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.932 -179.962 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 12.0 m -150.02 174.46 1.08 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.372 0 CA-C-N 116.286 -0.415 . . . . 0.0 111.208 179.953 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 33' ' ' LEU . . . . . 0.469 HD11 ' O ' ' A' ' 37' ' ' GLN . 28.8 tp -138.71 107.1 5.81 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.886 -179.958 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 34' ' ' VAL . . . . . 0.416 HG22 HD12 ' A' ' 58' ' ' ILE . 21.5 t -77.32 125.58 37.17 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-N 116.236 -0.438 . . . . 0.0 111.22 -179.978 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 35' ' ' ALA . . . . . . . . . . . . . . . 58.2 26.23 13.55 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.163 -0.471 . . . . 0.0 111.333 -179.967 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . 56.14 31.39 59.01 Favored Glycine 0 C--N 1.331 0.279 0 C-N-CA 120.775 -0.726 . . . . 0.0 112.607 179.973 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 37' ' ' GLN . . . . . 0.469 ' O ' HD11 ' A' ' 33' ' ' LEU . 37.3 mt-30 -145.3 -70.42 0.27 Allowed 'General case' 0 C--N 1.329 -0.287 0 CA-C-O 120.795 0.331 . . . . 0.0 110.877 -179.944 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 38' ' ' LYS . . . . . . . . . . . . . 32.0 mttt -67.57 104.05 1.5 Allowed 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.927 179.958 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 39' ' ' GLN . . . . . 0.4 ' NE2' HD13 ' A' ' 95' ' ' ILE . 4.2 tt0 -82.93 148.03 27.9 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.875 -179.972 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -175.68 -164.13 29.59 Favored Glycine 0 N--CA 1.451 -0.363 0 C-N-CA 120.787 -0.721 . . . . 0.0 112.541 179.945 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 41' ' ' ILE . . . . . 0.441 ' C ' HG23 ' A' ' 58' ' ' ILE . 3.8 mp -134.61 139.14 48.33 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-O 120.856 0.36 . . . . 0.0 111.156 179.986 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 42' ' ' VAL . . . . . . . . . . . . . 31.0 t -70.47 127.08 31.91 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.029 179.953 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 43' ' ' ARG . . . . . . . . . . . . . 15.6 mmt180 -110.72 -32.35 6.89 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.207 -0.452 . . . . 0.0 110.923 -179.957 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 44' ' ' PHE . . . . . . . . . . . . . 72.6 t80 -141.21 108.23 5.45 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.859 179.978 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 45' ' ' TYR . . . . . 0.497 ' CE1' ' CZ ' ' A' ' 56' ' ' TYR . 12.5 t80 -109.53 131.96 54.58 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.881 179.949 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 158.82 -137.71 5.33 Favored Glycine 0 N--CA 1.451 -0.36 0 C-N-CA 120.68 -0.771 . . . . 0.0 112.53 -179.968 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 47' ' ' LYS . . . . . . . . . . . . . 11.1 mttm -104.18 154.16 20.08 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-O 120.815 0.341 . . . . 0.0 110.922 179.996 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 48' ' ' THR . . . . . . . . . . . . . 25.5 p -117.86 -179.22 3.69 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.224 -0.443 . . . . 0.0 110.874 179.875 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 2.2 t0 -110.91 -26.55 9.25 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.212 -0.449 . . . . 0.0 111.026 -179.836 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 50' ' ' PHE . . . . . 0.451 ' CD1' ' N ' ' A' ' 51' ' ' ALA . 22.6 p90 -72.32 -34.12 67.86 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.422 -0.354 . . . . 0.0 111.117 -179.831 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 51' ' ' ALA . . . . . 0.451 ' N ' ' CD1' ' A' ' 50' ' ' PHE . . . -148.9 147.81 25.43 Favored Pre-proline 0 C--N 1.329 -0.3 0 CA-C-N 116.3 -0.409 . . . . 0.0 111.237 -179.931 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 52' ' ' PRO . . . . . . . . . . . . . 74.0 Cg_endo -75.3 165.34 31.06 Favored 'Trans proline' 0 C--N 1.344 0.327 0 C-N-CA 122.651 2.234 . . . . 0.0 112.366 179.954 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 99.68 -168.98 21.9 Favored Glycine 0 N--CA 1.451 -0.317 0 C-N-CA 120.734 -0.746 . . . . 0.0 112.56 179.917 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 54' ' ' TYR . . . . . . . . . . . . . 64.9 m-85 -102.31 125.87 49.15 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-O 120.825 0.345 . . . . 0.0 110.893 179.994 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 55' ' ' TRP . . . . . 0.408 ' CZ3' ' HD3' ' A' ' 88' ' ' PRO . 63.9 m95 -127.02 156.77 41.11 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.912 179.976 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 56' ' ' TYR . . . . . 0.576 ' CE1' ' HB2' ' A' ' 89' ' ' ALA . 4.2 m-85 -113.32 122.71 48.24 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.254 -0.43 . . . . 0.0 110.95 -179.961 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 57' ' ' GLY . . . . . 0.447 ' CA ' ' CE1' ' A' ' 86' ' ' PHE . . . -84.04 68.03 3.6 Favored Glycine 0 N--CA 1.45 -0.404 0 C-N-CA 120.775 -0.726 . . . . 0.0 112.427 179.865 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 58' ' ' ILE . . . . . 0.678 HD11 HD13 ' A' ' 92' ' ' ILE . 19.7 mt -73.58 138.59 20.97 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-O 120.812 0.339 . . . . 0.0 111.138 -179.955 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -114.07 112.38 23.15 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.915 179.948 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 60' ' ' LEU . . . . . 0.673 HD13 HG23 ' A' ' 64' ' ' THR . 8.1 mt -73.21 173.06 9.99 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.246 -0.434 . . . . 0.0 110.865 -179.972 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 8.3 p-10 -102.0 -31.59 10.58 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.856 179.957 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 62' ' ' GLN . . . . . 0.425 ' HG3' HG22 ' A' ' 64' ' ' THR . 4.1 pt20 -106.5 157.49 34.92 Favored Pre-proline 0 C--N 1.329 -0.301 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.835 -179.974 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 37.2 Cg_endo -65.86 82.58 0.25 Allowed 'Trans proline' 0 C--N 1.345 0.345 0 C-N-CA 122.533 2.155 . . . . 0.0 112.263 179.937 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 64' ' ' THR . . . . . 0.673 HG23 HD13 ' A' ' 60' ' ' LEU . 9.1 t -156.01 34.55 0.34 Allowed 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.108 -0.496 . . . . 0.0 110.839 -179.995 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . -97.84 -131.51 7.15 Favored Glycine 0 N--CA 1.45 -0.407 0 C-N-CA 120.732 -0.747 . . . . 0.0 112.547 179.956 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 66' ' ' LYS . . . . . . . . . . . . . 4.3 mtmm -144.6 -58.36 0.36 Allowed 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 120.819 0.343 . . . . 0.0 110.9 -179.969 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 67' ' ' HIS . . . . . . . . . . . . . 6.9 p80 -110.72 164.51 12.68 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.887 179.945 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 45.6 t0 -97.76 36.52 1.52 Allowed 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.209 -0.451 . . . . 0.0 110.946 -179.997 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 96.75 -32.1 6.91 Favored Glycine 0 N--CA 1.45 -0.369 0 C-N-CA 120.766 -0.73 . . . . 0.0 112.47 179.955 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 70' ' ' SER . . . . . . . . . . . . . 12.2 p -114.13 141.93 46.86 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-O 120.885 0.374 . . . . 0.0 110.844 179.988 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 71' ' ' VAL . . . . . 0.636 HG12 ' CD2' ' A' ' 72' ' ' PHE . 21.6 t -131.07 111.26 19.43 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.252 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.137 179.929 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 72' ' ' PHE . . . . . 0.636 ' CD2' HG12 ' A' ' 71' ' ' VAL . 53.4 m-85 61.09 30.88 19.7 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.999 -179.952 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 98.8 -27.62 18.97 Favored Glycine 0 N--CA 1.452 -0.26 0 C-N-CA 120.728 -0.749 . . . . 0.0 112.454 -179.971 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 22.8 t -75.55 135.35 27.29 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-O 120.834 0.35 . . . . 0.0 111.09 -179.934 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 75' ' ' ARG . . . . . 0.503 HH21 HG23 ' A' ' 78' ' ' THR . 19.2 ttt180 -107.71 144.44 34.81 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.911 179.992 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 76' ' ' TYR . . . . . 0.403 ' CD1' ' N ' ' A' ' 76' ' ' TYR . 3.9 m-85 -123.42 -44.06 2.15 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.944 179.932 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 77' ' ' PHE . . . . . . . . . . . . . 28.5 p90 -162.88 177.7 9.03 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.866 179.97 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 78' ' ' THR . . . . . 0.503 HG23 HH21 ' A' ' 75' ' ' ARG . 0.7 OUTLIER -99.67 113.16 25.43 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.913 179.921 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 79' ' ' CYS . . . . . . . . . . . . . 30.2 p -142.9 152.66 42.32 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.27 -0.423 . . . . 0.0 110.924 179.955 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 80' ' ' ALA . . . . . 0.527 ' HB1' ' HD2' ' A' ' 81' ' ' PRO . . . -66.79 168.26 11.09 Favored Pre-proline 0 C--N 1.329 -0.325 0 CA-C-N 116.215 -0.448 . . . . 0.0 111.054 -179.984 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 81' ' ' PRO . . . . . 0.527 ' HD2' ' HB1' ' A' ' 80' ' ' ALA . 41.7 Cg_exo -56.91 122.49 11.91 Favored 'Trans proline' 0 C--N 1.344 0.293 0 C-N-CA 122.584 2.19 . . . . 0.0 112.306 -179.991 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 82' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER 62.37 51.91 3.23 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.169 -0.469 . . . . 0.0 111.082 179.845 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 83' ' ' HIS . . . . . 0.453 ' CE1' ' HB3' ' A' ' 80' ' ' ALA . 7.0 m170 -124.77 -50.42 1.72 Allowed 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.861 179.92 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . -66.05 142.36 43.04 Favored Glycine 0 N--CA 1.451 -0.338 0 C-N-CA 120.748 -0.739 . . . . 0.0 112.536 179.928 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 85' ' ' VAL . . . . . . . . . . . . . 6.9 m -146.99 129.04 6.93 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-O 120.862 0.363 . . . . 0.0 111.076 179.957 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 86' ' ' PHE . . . . . 0.447 ' CE1' ' CA ' ' A' ' 57' ' ' GLY . 17.0 m-85 -108.12 114.9 29.14 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.106 -0.497 . . . . 0.0 110.85 -179.977 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 87' ' ' ALA . . . . . 0.55 ' O ' HD11 ' A' ' 92' ' ' ILE . . . -136.68 146.7 56.49 Favored Pre-proline 0 C--N 1.33 -0.281 0 CA-C-N 116.14 -0.482 . . . . 0.0 111.178 179.916 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 88' ' ' PRO . . . . . 0.423 ' O ' ' N ' ' A' ' 91' ' ' ARG . 34.5 Cg_exo -57.7 142.84 96.06 Favored 'Trans proline' 0 C--N 1.345 0.352 0 C-N-CA 122.561 2.174 . . . . 0.0 112.324 -179.942 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 89' ' ' ALA . . . . . 0.576 ' HB2' ' CE1' ' A' ' 56' ' ' TYR . . . -48.04 -50.75 26.82 Favored 'General case' 0 C--O 1.231 0.117 0 CA-C-N 116.101 -0.5 . . . . 0.0 110.261 179.853 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 90' ' ' SER . . . . . . . . . . . . . 42.6 m -55.75 -24.43 35.27 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 115.708 -0.678 . . . . 0.0 109.733 178.828 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 91' ' ' ARG . . . . . 0.423 ' N ' ' O ' ' A' ' 88' ' ' PRO . 3.4 mtm180 -89.41 -14.81 34.65 Favored 'General case' 0 N--CA 1.456 -0.172 0 CA-C-N 115.857 -0.611 . . . . 0.0 110.472 179.059 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 92' ' ' ILE . . . . . 0.678 HD13 HD11 ' A' ' 58' ' ' ILE . 48.2 mt -107.03 158.3 6.99 Favored 'Isoleucine or valine' 0 C--O 1.231 0.128 0 CA-C-N 116.379 -0.373 . . . . 0.0 111.014 179.793 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 93' ' ' GLN . . . . . 0.491 ' N ' HG22 ' A' ' 92' ' ' ILE . 5.2 mt-30 -130.18 176.82 7.79 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.964 -179.973 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 94' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -118.16 154.23 32.51 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.903 179.971 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 95' ' ' ILE . . . . . 0.545 HD12 ' HB3' ' A' ' 31' ' ' GLN . 4.4 mt . . . . . 0 C--N 1.329 -0.312 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.102 179.957 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.231 0.08 0 CA-C-O 120.9 0.381 . . . . 0.0 110.984 . . . . . . . . . 0 0 . 1 . 016 nuclear nobuild core ' A' A ' 27' ' ' GLU . . . . . . . . . . . . . 13.8 mt-10 -141.28 174.26 10.7 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.154 -0.476 . . . . 0.0 110.881 -179.973 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 22.1 t -76.18 117.96 21.68 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.129 179.871 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 109.39 28.65 4.25 Favored Glycine 0 N--CA 1.452 -0.281 0 C-N-CA 120.776 -0.726 . . . . 0.0 112.491 -179.95 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 7.8 t0 -143.21 142.23 31.35 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 120.807 0.336 . . . . 0.0 110.863 -179.931 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 31' ' ' GLN . . . . . 0.625 ' HB3' HD12 ' A' ' 95' ' ' ILE . 0.0 OUTLIER -61.62 150.35 36.6 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.843 179.931 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 15.2 m -154.14 170.6 0.81 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.351 0 CA-C-N 116.222 -0.444 . . . . 0.0 111.182 179.971 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 33' ' ' LEU . . . . . . . . . . . . . 28.9 tp -134.88 106.02 6.68 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.94 179.968 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 34' ' ' VAL . . . . . 0.466 HG13 ' HB3' ' A' ' 87' ' ' ALA . 21.7 t -74.48 124.82 32.85 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.169 -179.918 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 35' ' ' ALA . . . . . . . . . . . . . . . 57.38 26.08 12.06 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.138 -0.483 . . . . 0.0 111.298 179.953 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . 55.81 26.95 48.76 Favored Glycine 0 N--CA 1.452 -0.284 0 C-N-CA 120.723 -0.751 . . . . 0.0 112.647 179.959 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 37' ' ' GLN . . . . . . . . . . . . . 77.9 mt-30 -138.15 -68.37 0.46 Allowed 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 120.842 0.353 . . . . 0.0 110.931 -179.949 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 38' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -69.7 111.14 5.28 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.906 -179.996 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 39' ' ' GLN . . . . . . . . . . . . . 1.9 tt0 -89.25 135.39 33.6 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.154 -0.476 . . . . 0.0 110.976 179.933 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -165.5 -167.97 26.94 Favored Glycine 0 N--CA 1.451 -0.304 0 C-N-CA 120.7 -0.762 . . . . 0.0 112.513 180.0 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 41' ' ' ILE . . . . . 0.498 ' N ' HG23 ' A' ' 58' ' ' ILE . 23.5 mt -129.52 143.19 41.89 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-O 120.789 0.328 . . . . 0.0 111.16 -179.959 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 42' ' ' VAL . . . . . . . . . . . . . 21.9 t -68.22 112.04 2.98 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.247 -0.433 . . . . 0.0 111.114 179.961 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 43' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -96.19 -41.21 8.8 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.965 -179.986 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 44' ' ' PHE . . . . . . . . . . . . . 21.0 t80 -135.74 119.02 16.66 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.895 179.985 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 45' ' ' TYR . . . . . 0.423 ' CE1' ' CZ ' ' A' ' 56' ' ' TYR . 38.0 t80 -123.04 136.75 54.96 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.115 -0.493 . . . . 0.0 110.844 -179.989 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 157.86 -155.3 26.31 Favored Glycine 0 N--CA 1.451 -0.346 0 C-N-CA 120.747 -0.739 . . . . 0.0 112.478 179.914 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 47' ' ' LYS . . . . . . . . . . . . . 2.1 mtpt -83.35 150.12 26.3 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-O 120.844 0.354 . . . . 0.0 110.891 179.999 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 48' ' ' THR . . . . . 0.535 HG22 ' CE2' ' A' ' 76' ' ' TYR . 6.3 p -115.04 178.01 4.44 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.814 -179.981 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -115.01 -37.48 4.13 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.974 -179.997 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 50' ' ' PHE . . . . . 0.427 ' CZ ' HG21 ' A' ' 48' ' ' THR . 27.4 p90 -63.78 -32.35 73.82 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.191 -0.458 . . . . 0.0 110.951 -179.936 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 51' ' ' ALA . . . . . . . . . . . . . . . -149.62 152.08 34.3 Favored Pre-proline 0 C--N 1.33 -0.269 0 CA-C-N 116.226 -0.443 . . . . 0.0 111.156 -179.997 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 52' ' ' PRO . . . . . . . . . . . . . 57.6 Cg_endo -71.33 168.98 21.88 Favored 'Trans proline' 0 C--N 1.344 0.321 0 C-N-CA 122.562 2.175 . . . . 0.0 112.262 179.99 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 89.87 -160.15 28.46 Favored Glycine 0 N--CA 1.45 -0.37 0 C-N-CA 120.707 -0.758 . . . . 0.0 112.562 -179.972 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 54' ' ' TYR . . . . . . . . . . . . . 59.5 m-85 -123.67 125.73 45.31 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 120.841 0.353 . . . . 0.0 110.839 -179.928 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 55' ' ' TRP . . . . . . . . . . . . . 37.3 m95 -112.34 169.8 8.62 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.22 -0.446 . . . . 0.0 110.835 179.987 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 56' ' ' TYR . . . . . 0.484 ' CE1' ' HB2' ' A' ' 89' ' ' ALA . 9.2 m-85 -118.9 117.43 28.81 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.965 -179.96 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . -82.35 61.37 4.72 Favored Glycine 0 N--CA 1.45 -0.367 0 C-N-CA 120.752 -0.737 . . . . 0.0 112.402 179.956 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 58' ' ' ILE . . . . . 0.514 HD11 HD13 ' A' ' 92' ' ' ILE . 13.2 mt -69.91 137.94 23.07 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-O 120.911 0.386 . . . . 0.0 111.079 -179.949 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER -106.28 133.73 50.52 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.859 179.927 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 60' ' ' LEU . . . . . . . . . . . . . 53.5 mt -100.48 171.64 7.62 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.915 -179.969 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 61' ' ' ASP . . . . . 0.404 ' O ' ' CE1' ' A' ' 83' ' ' HIS . 0.7 OUTLIER -97.28 -30.8 12.76 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.095 -0.502 . . . . 0.0 110.919 179.987 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 62' ' ' GLN . . . . . . . . . . . . . 6.5 mm-40 -97.49 155.35 37.38 Favored Pre-proline 0 C--N 1.328 -0.331 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.974 -179.974 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 74.3 Cg_endo -75.44 60.63 5.81 Favored 'Trans proline' 0 C--N 1.344 0.324 0 C-N-CA 122.648 2.232 . . . . 0.0 112.262 -179.961 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 64' ' ' THR . . . . . . . . . . . . . 26.7 p -132.85 33.26 3.73 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.253 -0.431 . . . . 0.0 110.932 -179.95 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . -85.47 -127.51 1.86 Allowed Glycine 0 N--CA 1.451 -0.338 0 C-N-CA 120.689 -0.767 . . . . 0.0 112.489 -179.968 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 66' ' ' LYS . . . . . . . . . . . . . 0.3 OUTLIER -150.24 -49.08 0.13 Allowed 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.824 0.345 . . . . 0.0 110.865 -179.961 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 67' ' ' HIS . . . . . . . . . . . . . 5.7 p80 -119.5 169.92 9.62 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.143 -0.48 . . . . 0.0 110.854 -179.962 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -97.08 39.8 1.17 Allowed 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.87 -179.987 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 99.43 -36.34 4.13 Favored Glycine 0 N--CA 1.451 -0.337 0 C-N-CA 120.735 -0.745 . . . . 0.0 112.537 179.907 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 70' ' ' SER . . . . . . . . . . . . . 11.7 p -115.32 163.52 15.58 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 120.8 0.333 . . . . 0.0 110.957 179.986 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 21.4 t -137.88 116.25 13.62 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 116.137 -0.483 . . . . 0.0 111.125 179.984 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 72' ' ' PHE . . . . . . . . . . . . . 32.3 m-85 60.6 30.76 19.96 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.928 179.973 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 99.58 -30.03 10.8 Favored Glycine 0 N--CA 1.451 -0.341 0 C-N-CA 120.641 -0.79 . . . . 0.0 112.568 179.988 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 21.5 t -77.5 114.94 18.64 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.34 0 CA-C-O 120.896 0.379 . . . . 0.0 111.068 179.991 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 75' ' ' ARG . . . . . . . . . . . . . 12.6 ttm180 -95.27 126.49 40.62 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.911 179.967 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 76' ' ' TYR . . . . . 0.535 ' CE2' HG22 ' A' ' 48' ' ' THR . 12.8 m-85 -100.17 -50.75 3.86 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.797 -179.96 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 77' ' ' PHE . . . . . . . . . . . . . 11.3 p90 -144.3 173.34 11.86 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.946 -179.96 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 41.6 p -103.94 122.08 44.45 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.266 -0.425 . . . . 0.0 110.904 179.917 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 79' ' ' CYS . . . . . . . . . . . . . 27.8 p -145.13 172.53 12.96 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.849 -179.988 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 80' ' ' ALA . . . . . 0.591 ' HB3' ' ND1' ' A' ' 83' ' ' HIS . . . -78.64 166.66 41.09 Favored Pre-proline 0 C--N 1.33 -0.268 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.115 179.988 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 81' ' ' PRO . . . . . 0.521 ' HD2' ' HB1' ' A' ' 80' ' ' ALA . 50.1 Cg_exo -53.57 116.35 2.93 Favored 'Trans proline' 0 C--N 1.345 0.362 0 C-N-CA 122.587 2.191 . . . . 0.0 112.333 179.959 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 82' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER 61.94 53.4 3.08 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.879 179.923 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 83' ' ' HIS . . . . . 0.591 ' ND1' ' HB3' ' A' ' 80' ' ' ALA . 7.4 m170 -123.45 -44.46 2.12 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.915 179.921 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . -71.02 150.0 46.91 Favored Glycine 0 N--CA 1.451 -0.359 0 C-N-CA 120.699 -0.762 . . . . 0.0 112.535 179.948 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 85' ' ' VAL . . . . . . . . . . . . . 10.8 m -148.94 139.27 16.57 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-O 120.817 0.342 . . . . 0.0 111.157 -179.962 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 86' ' ' PHE . . . . . . . . . . . . . 4.1 m-85 -115.93 109.03 17.01 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.839 179.988 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 87' ' ' ALA . . . . . 0.592 ' O ' HD11 ' A' ' 92' ' ' ILE . . . -130.84 142.85 47.04 Favored Pre-proline 0 C--N 1.33 -0.261 0 CA-C-N 116.259 -0.428 . . . . 0.0 111.126 -179.953 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 88' ' ' PRO . . . . . 0.421 ' O ' ' N ' ' A' ' 91' ' ' ARG . 44.3 Cg_exo -56.26 143.7 84.49 Favored 'Trans proline' 0 C--N 1.345 0.391 0 C-N-CA 122.516 2.144 . . . . 0.0 112.22 179.938 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 89' ' ' ALA . . . . . 0.484 ' HB2' ' CE1' ' A' ' 56' ' ' TYR . . . -47.89 -50.88 25.26 Favored 'General case' 0 C--N 1.333 -0.134 0 CA-C-O 121.113 0.482 . . . . 0.0 110.308 179.807 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 90' ' ' SER . . . . . . . . . . . . . 1.1 m -55.72 -24.76 36.63 Favored 'General case' 0 C--N 1.331 -0.215 0 CA-C-N 115.639 -0.71 . . . . 0.0 109.721 178.765 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 91' ' ' ARG . . . . . 0.421 ' N ' ' O ' ' A' ' 88' ' ' PRO . 0.0 OUTLIER -87.9 -16.28 34.34 Favored 'General case' 0 N--CA 1.454 -0.244 0 CA-C-N 115.833 -0.622 . . . . 0.0 110.393 179.044 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 92' ' ' ILE . . . . . 0.592 HD11 ' O ' ' A' ' 87' ' ' ALA . 44.1 mt -104.2 153.74 6.19 Favored 'Isoleucine or valine' 0 C--O 1.231 0.114 0 CA-C-N 116.344 -0.389 . . . . 0.0 111.063 179.882 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 93' ' ' GLN . . . . . 0.412 ' N ' HG22 ' A' ' 92' ' ' ILE . 0.3 OUTLIER -120.43 142.57 49.1 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.922 -179.976 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 94' ' ' ARG . . . . . . . . . . . . . 12.9 ttt180 -89.96 116.44 28.02 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.222 -0.444 . . . . 0.0 110.868 179.996 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 95' ' ' ILE . . . . . 0.625 HD12 ' HB3' ' A' ' 31' ' ' GLN . 35.2 mt . . . . . 0 C--N 1.329 -0.285 0 CA-C-N 116.136 -0.484 . . . . 0.0 111.143 179.99 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.231 0.107 0 CA-C-O 120.883 0.373 . . . . 0.0 111.14 . . . . . . . . . 0 0 . 1 . 017 nuclear nobuild core ' A' A ' 27' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -123.91 168.1 13.24 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.848 -179.963 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 25.2 t -73.43 111.42 8.24 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.097 179.951 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 112.72 27.96 3.62 Favored Glycine 0 N--CA 1.452 -0.285 0 C-N-CA 120.752 -0.737 . . . . 0.0 112.516 -179.966 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -136.57 145.53 45.08 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-O 120.757 0.313 . . . . 0.0 110.895 179.995 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 31' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -68.56 136.01 52.41 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.887 179.978 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 12.7 m -136.66 179.67 3.66 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.181 -0.463 . . . . 0.0 111.093 179.993 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 33' ' ' LEU . . . . . 0.523 HD23 ' HA2' ' A' ' 36' ' ' GLY . 15.7 tp -137.91 114.1 10.11 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.914 179.959 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 34' ' ' VAL . . . . . 0.499 HG22 HD13 ' A' ' 58' ' ' ILE . 21.5 t -83.82 123.22 38.67 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.343 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.104 179.997 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 35' ' ' ALA . . . . . . . . . . . . . . . 59.34 26.39 15.24 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.197 179.979 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 36' ' ' GLY . . . . . 0.523 ' HA2' HD23 ' A' ' 33' ' ' LEU . . . 56.13 27.78 52.66 Favored Glycine 0 N--CA 1.452 -0.299 0 C-N-CA 120.774 -0.727 . . . . 0.0 112.579 179.999 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 37' ' ' GLN . . . . . . . . . . . . . 41.7 mt-30 -137.17 -70.6 0.45 Allowed 'General case' 0 C--N 1.328 -0.336 0 CA-C-O 120.858 0.361 . . . . 0.0 110.987 -179.965 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 38' ' ' LYS . . . . . . . . . . . . . 11.5 mttm -70.4 124.6 24.57 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.923 179.969 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 39' ' ' GLN . . . . . . . . . . . . . 0.1 OUTLIER -99.13 129.57 45.39 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.861 179.993 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -151.88 -173.78 21.92 Favored Glycine 0 N--CA 1.452 -0.276 0 C-N-CA 120.702 -0.761 . . . . 0.0 112.49 179.955 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 41' ' ' ILE . . . . . 0.426 ' N ' HG23 ' A' ' 58' ' ' ILE . 32.7 mt -125.15 138.05 55.58 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-O 120.77 0.319 . . . . 0.0 111.125 -179.984 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 42' ' ' VAL . . . . . . . . . . . . . 26.5 t -67.17 113.98 3.63 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.226 -0.443 . . . . 0.0 111.02 179.956 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 43' ' ' ARG . . . . . . . . . . . . . 14.7 mmt180 -102.6 -31.45 10.38 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.933 179.995 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 44' ' ' PHE . . . . . . . . . . . . . 80.7 t80 -146.26 116.71 7.51 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.895 179.943 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 45' ' ' TYR . . . . . 0.488 ' CE1' ' CZ ' ' A' ' 56' ' ' TYR . 17.7 t80 -114.52 117.53 31.2 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.922 179.936 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 173.58 170.44 37.07 Favored Glycine 0 N--CA 1.451 -0.339 0 C-N-CA 120.746 -0.74 . . . . 0.0 112.534 -179.943 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 47' ' ' LYS . . . . . . . . . . . . . 85.5 mttt -65.33 148.27 51.99 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-O 120.819 0.342 . . . . 0.0 110.899 -179.922 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 48' ' ' THR . . . . . 0.719 HG22 ' CE2' ' A' ' 76' ' ' TYR . 0.9 OUTLIER -103.03 -177.08 3.27 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.909 179.989 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 12.5 t0 -109.21 -31.53 7.55 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.246 -0.434 . . . . 0.0 110.985 -179.999 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 50' ' ' PHE . . . . . 0.494 ' CZ ' HG21 ' A' ' 48' ' ' THR . 19.8 p90 -80.01 -31.19 39.66 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.979 180.0 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 51' ' ' ALA . . . . . . . . . . . . . . . -134.8 139.99 33.92 Favored Pre-proline 0 C--N 1.329 -0.306 0 CA-C-N 116.269 -0.423 . . . . 0.0 111.078 -179.957 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 52' ' ' PRO . . . . . . . . . . . . . 72.0 Cg_endo -76.82 167.06 25.95 Favored 'Trans proline' 0 C--N 1.346 0.434 0 C-N-CA 122.469 2.113 . . . . 0.0 112.292 -179.974 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 92.21 -167.85 30.64 Favored Glycine 0 N--CA 1.45 -0.372 0 C-N-CA 120.734 -0.746 . . . . 0.0 112.562 179.898 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 54' ' ' TYR . . . . . . . . . . . . . 31.0 m-85 -103.31 124.27 48.34 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-O 120.868 0.366 . . . . 0.0 110.833 -179.969 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 55' ' ' TRP . . . . . . . . . . . . . 75.2 m95 -117.29 160.61 20.84 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.865 -179.997 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 56' ' ' TYR . . . . . 0.662 ' HE1' ' HB2' ' A' ' 89' ' ' ALA . 5.7 m-85 -118.45 115.81 25.4 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.963 -179.96 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . -82.04 69.53 3.3 Favored Glycine 0 N--CA 1.452 -0.283 0 C-N-CA 120.646 -0.788 . . . . 0.0 112.437 179.933 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 58' ' ' ILE . . . . . 0.764 HD11 HD13 ' A' ' 92' ' ' ILE . 3.9 mt -75.67 141.05 16.36 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-O 120.8 0.333 . . . . 0.0 111.099 -179.976 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 3.1 tt0 -105.63 119.38 38.98 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.925 179.956 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 60' ' ' LEU . . . . . . . . . . . . . 92.7 mt -77.94 172.25 13.76 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.935 179.993 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -101.32 -29.2 12.19 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.895 -179.984 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 62' ' ' GLN . . . . . . . . . . . . . 0.3 OUTLIER -106.65 155.63 38.58 Favored Pre-proline 0 C--N 1.33 -0.259 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.936 179.965 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 55.0 Cg_endo -69.73 70.29 1.57 Allowed 'Trans proline' 0 C--N 1.344 0.335 0 C-N-CA 122.526 2.151 . . . . 0.0 112.296 179.993 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 64' ' ' THR . . . . . . . . . . . . . 42.9 p -147.75 43.76 1.08 Allowed 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 116.112 -0.494 . . . . 0.0 110.826 179.998 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . -95.49 -127.74 5.32 Favored Glycine 0 N--CA 1.451 -0.322 0 C-N-CA 120.777 -0.725 . . . . 0.0 112.561 179.968 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 66' ' ' LYS . . . . . . . . . . . . . 0.6 OUTLIER -148.16 -50.04 0.17 Allowed 'General case' 0 C--N 1.328 -0.346 0 CA-C-O 120.833 0.349 . . . . 0.0 110.83 179.999 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 67' ' ' HIS . . . . . . . . . . . . . 6.7 p80 -123.1 168.06 12.87 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.154 -0.476 . . . . 0.0 110.833 179.969 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 9.2 p-10 -98.89 31.29 3.02 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.253 -0.431 . . . . 0.0 110.914 -179.984 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 100.36 -28.09 17.4 Favored Glycine 0 N--CA 1.451 -0.312 0 C-N-CA 120.653 -0.784 . . . . 0.0 112.486 -179.979 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 70' ' ' SER . . . . . . . . . . . . . 33.2 p -122.47 139.74 53.53 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-O 120.795 0.331 . . . . 0.0 110.867 -179.981 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 71' ' ' VAL . . . . . 0.658 HG12 ' CD2' ' A' ' 72' ' ' PHE . 21.5 t -124.99 116.81 48.27 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.224 -0.444 . . . . 0.0 111.029 179.988 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 72' ' ' PHE . . . . . 0.658 ' CD2' HG12 ' A' ' 71' ' ' VAL . 13.7 m-85 60.96 30.92 19.9 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.901 179.965 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 98.45 -28.52 14.5 Favored Glycine 0 N--CA 1.451 -0.33 0 C-N-CA 120.756 -0.735 . . . . 0.0 112.498 179.933 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 21.5 t -77.05 122.42 31.55 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.272 0 CA-C-O 120.876 0.369 . . . . 0.0 111.109 179.998 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 75' ' ' ARG . . . . . . . . . . . . . 3.4 ttt180 -95.3 146.34 24.44 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.925 179.982 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 76' ' ' TYR . . . . . 0.719 ' CE2' HG22 ' A' ' 48' ' ' THR . 72.8 m-85 -122.05 -45.0 2.27 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.884 179.968 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 77' ' ' PHE . . . . . . . . . . . . . 17.1 p90 -162.23 165.25 27.06 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.883 179.945 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 1.0 OUTLIER -89.65 103.05 15.73 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.976 179.974 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 79' ' ' CYS . . . . . . . . . . . . . 28.4 p -127.69 153.73 46.14 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.887 -179.969 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 80' ' ' ALA . . . . . 0.584 ' HB3' ' CG ' ' A' ' 83' ' ' HIS . . . -61.91 164.21 10.89 Favored Pre-proline 0 C--N 1.329 -0.308 0 CA-C-N 116.136 -0.484 . . . . 0.0 111.137 179.975 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 81' ' ' PRO . . . . . 0.443 ' HD2' ' HB1' ' A' ' 80' ' ' ALA . 51.0 Cg_exo -54.11 115.59 2.46 Favored 'Trans proline' 0 C--N 1.345 0.385 0 C-N-CA 122.578 2.185 . . . . 0.0 112.293 -179.949 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 82' ' ' ARG . . . . . . . . . . . . . 0.7 OUTLIER 61.59 53.64 3.25 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.852 179.953 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 83' ' ' HIS . . . . . 0.584 ' CG ' ' HB3' ' A' ' 80' ' ' ALA . 6.1 m170 -125.15 -44.52 1.89 Allowed 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.145 -0.479 . . . . 0.0 110.879 179.882 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . -67.23 130.24 29.43 Favored Glycine 0 N--CA 1.451 -0.311 0 C-N-CA 120.714 -0.755 . . . . 0.0 112.434 179.934 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 85' ' ' VAL . . . . . . . . . . . . . 5.1 m -134.29 121.67 37.98 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-O 120.856 0.36 . . . . 0.0 111.174 179.966 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 86' ' ' PHE . . . . . . . . . . . . . 7.9 m-85 -96.25 112.33 24.1 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.916 179.937 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 87' ' ' ALA . . . . . 0.515 ' O ' HD11 ' A' ' 92' ' ' ILE . . . -129.74 143.74 50.23 Favored Pre-proline 0 C--N 1.33 -0.28 0 CA-C-N 116.257 -0.429 . . . . 0.0 111.025 -179.94 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 88' ' ' PRO . . . . . 0.407 ' O ' ' N ' ' A' ' 91' ' ' ARG . 46.9 Cg_exo -56.03 140.52 86.5 Favored 'Trans proline' 0 C--N 1.346 0.406 0 C-N-CA 122.52 2.146 . . . . 0.0 112.317 -179.995 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 89' ' ' ALA . . . . . 0.662 ' HB2' ' HE1' ' A' ' 56' ' ' TYR . . . -47.96 -51.61 22.97 Favored 'General case' 0 CA--C 1.521 -0.136 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.255 179.901 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 90' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -55.82 -24.47 36.45 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 115.76 -0.655 . . . . 0.0 109.709 178.87 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 91' ' ' ARG . . . . . 0.407 ' N ' ' O ' ' A' ' 88' ' ' PRO . 0.0 OUTLIER -87.8 -15.31 37.24 Favored 'General case' 0 N--CA 1.455 -0.225 0 CA-C-N 115.834 -0.621 . . . . 0.0 110.415 179.022 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 92' ' ' ILE . . . . . 0.764 HD13 HD11 ' A' ' 58' ' ' ILE . 41.7 mt -108.66 150.57 11.28 Favored 'Isoleucine or valine' 0 N--CA 1.457 -0.105 0 CA-C-N 116.376 -0.375 . . . . 0.0 111.071 179.898 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 93' ' ' GLN . . . . . . . . . . . . . 10.5 mt-30 -120.06 161.4 21.03 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.918 -179.991 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 94' ' ' ARG . . . . . . . . . . . . . 1.1 mtt180 -101.15 126.35 47.85 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.247 -0.433 . . . . 0.0 110.885 179.963 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 95' ' ' ILE . . . . . 0.434 HD11 ' HB2' ' A' ' 33' ' ' LEU . 26.1 mm . . . . . 0 C--N 1.33 -0.275 0 CA-C-N 116.15 -0.477 . . . . 0.0 111.171 179.968 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 26' ' ' ALA . . . . . 0.705 ' HB2' ' HG2' ' A' ' 94' ' ' ARG . . . . . . . . 0 N--CA 1.458 -0.055 0 CA-C-O 120.861 0.362 . . . . 0.0 111.071 . . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 27' ' ' GLU . . . . . . . . . . . . . 3.7 mt-10 -138.84 171.38 14.42 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.084 -0.507 . . . . 0.0 110.841 -179.964 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 28.1 t -65.97 109.71 1.16 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 116.097 -0.501 . . . . 0.0 111.02 -179.999 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 112.85 29.85 2.96 Favored Glycine 0 N--CA 1.452 -0.254 0 C-N-CA 120.756 -0.735 . . . . 0.0 112.516 -179.986 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 30' ' ' ASP . . . . . 0.684 ' O ' HG23 ' A' ' 41' ' ' ILE . 1.2 t0 -137.48 164.69 28.09 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-O 120.823 0.344 . . . . 0.0 110.878 179.942 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 31' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -83.11 131.72 35.13 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.25 -0.432 . . . . 0.0 110.927 179.966 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 15.3 m -139.74 179.53 2.75 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 116.329 -0.396 . . . . 0.0 111.136 179.957 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 33' ' ' LEU . . . . . 0.414 HD23 ' HA2' ' A' ' 36' ' ' GLY . 22.7 tp -143.45 102.02 3.88 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.158 -0.473 . . . . 0.0 110.812 179.97 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 34' ' ' VAL . . . . . 0.49 HG22 HD12 ' A' ' 58' ' ' ILE . 21.5 t -70.5 124.19 26.11 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.202 -0.454 . . . . 0.0 111.2 179.99 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 35' ' ' ALA . . . . . . . . . . . . . . . 58.57 25.51 13.24 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.228 -0.442 . . . . 0.0 111.264 179.942 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 36' ' ' GLY . . . . . 0.414 ' HA2' HD23 ' A' ' 33' ' ' LEU . . . 55.42 27.22 47.0 Favored Glycine 0 N--CA 1.452 -0.242 0 C-N-CA 120.852 -0.69 . . . . 0.0 112.587 179.984 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 37' ' ' GLN . . . . . . . . . . . . . 64.5 mt-30 -138.22 -64.86 0.52 Allowed 'General case' 0 C--N 1.329 -0.311 0 CA-C-O 120.704 0.287 . . . . 0.0 110.927 179.948 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 38' ' ' LYS . . . . . . . . . . . . . 64.3 mttt -72.38 112.64 8.62 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 116.294 -0.412 . . . . 0.0 110.877 179.954 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 39' ' ' GLN . . . . . . . . . . . . . 1.4 tm0? -91.82 117.26 29.61 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.836 179.991 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -145.14 -166.07 11.52 Favored Glycine 0 N--CA 1.451 -0.304 0 C-N-CA 120.747 -0.739 . . . . 0.0 112.468 -179.993 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 41' ' ' ILE . . . . . 0.684 HG23 ' O ' ' A' ' 30' ' ' ASP . 31.3 mt -131.17 132.58 63.25 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.25 0 CA-C-O 120.839 0.352 . . . . 0.0 111.105 -179.992 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 42' ' ' VAL . . . . . . . . . . . . . 21.5 t -60.4 121.46 8.27 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.261 -0.427 . . . . 0.0 111.086 179.962 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 43' ' ' ARG . . . . . . . . . . . . . 3.6 mmm-85 -104.14 -31.48 9.62 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.898 -179.941 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 44' ' ' PHE . . . . . 0.427 ' CD1' ' HB3' ' A' ' 76' ' ' TYR . 41.3 t80 -148.3 115.6 6.2 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.97 -179.947 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 45' ' ' TYR . . . . . 0.454 ' CE1' ' CE1' ' A' ' 56' ' ' TYR . 25.8 t80 -114.7 123.35 49.06 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.895 -179.986 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 171.03 -149.3 12.16 Favored Glycine 0 N--CA 1.451 -0.361 0 C-N-CA 120.671 -0.776 . . . . 0.0 112.449 179.956 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 47' ' ' LYS . . . . . . . . . . . . . 7.0 mttt -99.15 164.59 12.09 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-O 120.849 0.357 . . . . 0.0 110.975 -179.962 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 48' ' ' THR . . . . . 0.428 HG21 ' CZ ' ' A' ' 50' ' ' PHE . 13.2 p -129.68 -176.02 3.78 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.823 -179.982 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -112.98 -33.41 6.06 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.973 -179.89 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 50' ' ' PHE . . . . . 0.428 ' CZ ' HG21 ' A' ' 48' ' ' THR . 8.7 p90 -67.31 -30.51 70.37 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.24 -0.436 . . . . 0.0 111.016 -179.893 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 51' ' ' ALA . . . . . 0.42 ' N ' ' CD1' ' A' ' 50' ' ' PHE . . . -148.44 146.2 22.13 Favored Pre-proline 0 C--N 1.329 -0.314 0 CA-C-N 116.324 -0.398 . . . . 0.0 111.17 -179.906 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 52' ' ' PRO . . . . . . . . . . . . . 72.3 Cg_endo -74.95 -178.46 4.17 Favored 'Trans proline' 0 C--N 1.345 0.371 0 C-N-CA 122.584 2.189 . . . . 0.0 112.352 -179.991 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 76.78 -168.01 54.63 Favored Glycine 0 N--CA 1.451 -0.363 0 C-N-CA 120.778 -0.725 . . . . 0.0 112.515 179.954 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 54' ' ' TYR . . . . . . . . . . . . . 20.6 m-85 -101.59 149.56 23.99 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-O 120.837 0.351 . . . . 0.0 110.87 -179.929 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 55' ' ' TRP . . . . . . . . . . . . . 69.4 m95 -145.81 156.41 43.56 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.187 -0.461 . . . . 0.0 110.943 179.946 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 56' ' ' TYR . . . . . 0.454 ' CE1' ' CE1' ' A' ' 45' ' ' TYR . 25.2 m-85 -110.24 124.92 52.49 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.288 -0.415 . . . . 0.0 110.947 -179.947 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . -90.08 60.39 3.43 Favored Glycine 0 N--CA 1.45 -0.368 0 C-N-CA 120.768 -0.73 . . . . 0.0 112.414 179.9 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 58' ' ' ILE . . . . . 0.533 HG23 ' C ' ' A' ' 41' ' ' ILE . 21.2 mt -73.53 137.68 22.82 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-O 120.871 0.367 . . . . 0.0 111.073 -179.957 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 0.2 OUTLIER -103.89 133.27 49.14 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.084 -0.507 . . . . 0.0 110.845 -179.991 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 60' ' ' LEU . . . . . . . . . . . . . 56.5 mt -88.15 174.75 8.05 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.903 179.952 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 2.7 m-20 -100.59 -30.8 11.57 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.976 179.963 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 62' ' ' GLN . . . . . . . . . . . . . 0.8 OUTLIER -106.4 153.5 40.43 Favored Pre-proline 0 C--N 1.331 -0.239 0 CA-C-N 116.178 -0.464 . . . . 0.0 110.924 -179.971 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 73.6 Cg_endo -75.81 64.22 6.72 Favored 'Trans proline' 0 C--N 1.344 0.31 0 C-N-CA 122.613 2.209 . . . . 0.0 112.323 -179.857 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 64' ' ' THR . . . . . . . . . . . . . 7.5 t -147.01 38.55 0.99 Allowed 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.899 179.975 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . -86.57 -111.72 0.86 Allowed Glycine 0 N--CA 1.451 -0.313 0 C-N-CA 120.767 -0.73 . . . . 0.0 112.559 179.98 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 66' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -147.71 -47.27 0.17 Allowed 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.819 0.343 . . . . 0.0 110.893 179.992 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 67' ' ' HIS . . . . . 0.514 ' ND1' HG22 ' A' ' 71' ' ' VAL . 15.7 p80 -141.99 -176.0 4.63 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.865 179.96 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -89.32 -168.83 2.28 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.833 179.987 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . -63.39 -27.6 71.01 Favored Glycine 0 N--CA 1.451 -0.363 0 C-N-CA 120.695 -0.765 . . . . 0.0 112.473 -179.934 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 70' ' ' SER . . . . . . . . . . . . . 4.0 p -116.98 147.66 42.11 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 120.8 0.333 . . . . 0.0 110.897 -179.94 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 71' ' ' VAL . . . . . 0.514 HG22 ' ND1' ' A' ' 67' ' ' HIS . 28.2 t -127.12 119.86 53.89 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.103 179.929 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 72' ' ' PHE . . . . . . . . . . . . . 5.4 m-85 60.57 30.82 20.02 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.887 -179.948 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 94.91 -15.76 62.72 Favored Glycine 0 N--CA 1.451 -0.318 0 C-N-CA 120.713 -0.756 . . . . 0.0 112.721 -179.999 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 25.3 t -87.9 113.08 24.48 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-O 120.807 0.337 . . . . 0.0 111.169 -179.938 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 75' ' ' ARG . . . . . . . . . . . . . 6.4 ttm105 -95.06 114.7 26.54 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.762 179.885 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 76' ' ' TYR . . . . . 0.427 ' HB3' ' CD1' ' A' ' 44' ' ' PHE . 26.0 m-85 -96.7 -34.97 11.17 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.988 -179.853 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 77' ' ' PHE . . . . . . . . . . . . . 51.6 p90 -162.6 159.52 24.7 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 116.316 -0.402 . . . . 0.0 111.021 -179.907 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 26.0 m -87.62 140.82 29.13 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.922 179.917 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 79' ' ' CYS . . . . . . . . . . . . . 30.7 p -164.67 -175.6 3.9 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.263 -0.426 . . . . 0.0 110.915 179.965 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 80' ' ' ALA . . . . . 0.533 ' HB1' ' HD2' ' A' ' 81' ' ' PRO . . . -96.62 166.45 14.05 Favored Pre-proline 0 C--N 1.328 -0.328 0 CA-C-N 116.166 -0.47 . . . . 0.0 111.102 -179.97 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 81' ' ' PRO . . . . . 0.533 ' HD2' ' HB1' ' A' ' 80' ' ' ALA . 50.6 Cg_exo -53.21 120.55 7.92 Favored 'Trans proline' 0 C--N 1.344 0.298 0 C-N-CA 122.627 2.218 . . . . 0.0 112.297 179.96 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 82' ' ' ARG . . . . . . . . . . . . . 37.8 mtp85 62.45 61.46 1.25 Allowed 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.953 -179.967 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 83' ' ' HIS . . . . . . . . . . . . . 4.5 m-70 -130.79 -51.13 1.05 Allowed 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.866 -179.985 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . -63.51 143.54 48.21 Favored Glycine 0 N--CA 1.45 -0.367 0 C-N-CA 120.753 -0.736 . . . . 0.0 112.541 179.972 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 85' ' ' VAL . . . . . . . . . . . . . 5.1 m -145.92 118.16 2.12 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-O 120.829 0.347 . . . . 0.0 111.061 -179.974 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 86' ' ' PHE . . . . . . . . . . . . . 6.6 m-85 -96.45 105.93 18.1 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.847 179.973 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 87' ' ' ALA . . . . . 0.562 ' O ' HD11 ' A' ' 92' ' ' ILE . . . -126.0 142.76 43.35 Favored Pre-proline 0 C--N 1.328 -0.339 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.091 179.954 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 88' ' ' PRO . . . . . 0.411 ' O ' ' N ' ' A' ' 91' ' ' ARG . 31.2 Cg_exo -58.88 146.18 94.28 Favored 'Trans proline' 0 C--N 1.347 0.461 0 C-N-CA 122.468 2.112 . . . . 0.0 112.344 -179.999 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -48.38 -51.31 27.1 Favored 'General case' 0 C--N 1.333 -0.133 0 CA-C-O 121.08 0.467 . . . . 0.0 110.263 179.769 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 90' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -56.02 -24.4 38.93 Favored 'General case' 0 N--CA 1.454 -0.225 0 CA-C-N 115.648 -0.705 . . . . 0.0 109.789 178.732 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 91' ' ' ARG . . . . . 0.411 ' N ' ' O ' ' A' ' 88' ' ' PRO . 0.1 OUTLIER -88.44 -15.01 36.53 Favored 'General case' 0 N--CA 1.454 -0.254 0 CA-C-N 115.876 -0.602 . . . . 0.0 110.348 179.077 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 92' ' ' ILE . . . . . 0.562 HD11 ' O ' ' A' ' 87' ' ' ALA . 43.1 mt -108.77 158.31 8.65 Favored 'Isoleucine or valine' 0 C--O 1.231 0.081 0 CA-C-N 116.334 -0.394 . . . . 0.0 111.017 179.784 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 93' ' ' GLN . . . . . 0.487 ' N ' HG22 ' A' ' 92' ' ' ILE . 3.4 mt-30 -124.78 162.72 23.67 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.246 -0.434 . . . . 0.0 110.898 -179.886 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 94' ' ' ARG . . . . . 0.705 ' HG2' ' HB2' ' A' ' 26' ' ' ALA . 0.0 OUTLIER -112.65 127.17 56.03 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.113 -0.494 . . . . 0.0 110.838 -179.993 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 95' ' ' ILE . . . . . . . . . . . . . 33.0 mt . . . . . 0 C--N 1.329 -0.316 0 CA-C-N 116.187 -0.461 . . . . 0.0 111.022 179.962 . . . . . . . . 0 0 . 1 . 019 nuclear nobuild core ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.457 -0.095 0 CA-C-O 120.843 0.354 . . . . 0.0 111.105 . . . . . . . . . 0 0 . 1 . 019 nuclear nobuild core ' A' A ' 27' ' ' GLU . . . . . . . . . . . . . 16.4 mt-10 -133.92 179.77 6.04 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.917 -179.975 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 21.5 t -75.32 93.16 0.85 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.091 -179.981 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 121.72 44.84 0.36 Allowed Glycine 0 N--CA 1.451 -0.36 0 C-N-CA 120.843 -0.694 . . . . 0.0 112.489 179.972 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -144.77 158.21 43.87 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-O 120.832 0.349 . . . . 0.0 110.933 -179.991 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 31' ' ' GLN . . . . . . . . . . . . . 0.2 OUTLIER -77.56 126.03 30.26 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.82 -179.911 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 32' ' ' VAL . . . . . 0.457 HG21 HG12 ' A' ' 58' ' ' ILE . 16.2 m -129.34 175.63 10.11 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.262 -0.427 . . . . 0.0 111.158 179.983 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 33' ' ' LEU . . . . . 0.525 HD11 ' O ' ' A' ' 37' ' ' GLN . 25.6 tp -144.92 101.86 3.69 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.244 -0.434 . . . . 0.0 110.926 179.936 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 21.5 t -69.42 123.02 22.13 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.171 -179.958 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 35' ' ' ALA . . . . . . . . . . . . . . . 58.2 25.73 12.93 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.279 179.977 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . 56.13 32.75 60.2 Favored Glycine 0 N--CA 1.452 -0.294 0 C-N-CA 120.731 -0.747 . . . . 0.0 112.636 -179.99 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 37' ' ' GLN . . . . . 0.525 ' O ' HD11 ' A' ' 33' ' ' LEU . 30.9 mt-30 -142.9 -73.9 0.29 Allowed 'General case' 0 C--N 1.329 -0.319 0 CA-C-O 120.847 0.356 . . . . 0.0 110.974 -179.968 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 38' ' ' LYS . . . . . . . . . . . . . 4.6 mttp -64.35 109.6 1.97 Allowed 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.918 -179.973 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 39' ' ' GLN . . . . . . . . . . . . . 14.3 tm0? -85.32 129.38 34.82 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.254 -0.43 . . . . 0.0 110.905 179.982 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -156.13 -178.15 30.02 Favored Glycine 0 N--CA 1.45 -0.371 0 C-N-CA 120.683 -0.77 . . . . 0.0 112.524 -179.971 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 27.9 mm -123.12 138.18 53.98 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-O 120.731 0.3 . . . . 0.0 111.114 -179.983 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 42' ' ' VAL . . . . . . . . . . . . . 26.2 t -62.79 121.11 10.96 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 116.252 -0.431 . . . . 0.0 111.101 179.982 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 43' ' ' ARG . . . . . . . . . . . . . 3.1 mmt180 -107.33 -34.16 7.17 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.922 -179.983 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 44' ' ' PHE . . . . . 0.403 ' CD1' ' HB3' ' A' ' 76' ' ' TYR . 25.8 t80 -145.04 116.27 7.96 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.905 -179.978 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 45' ' ' TYR . . . . . . . . . . . . . 15.4 t80 -111.09 127.1 55.45 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.901 -179.985 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 166.88 -161.49 35.3 Favored Glycine 0 N--CA 1.45 -0.384 0 C-N-CA 120.774 -0.726 . . . . 0.0 112.531 179.992 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 47' ' ' LYS . . . . . . . . . . . . . 46.5 mttt -96.88 158.11 15.58 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-O 120.816 0.341 . . . . 0.0 110.837 -179.975 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 48' ' ' THR . . . . . 0.453 HG21 ' CZ ' ' A' ' 50' ' ' PHE . 28.4 p -120.75 168.25 11.62 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.165 -0.471 . . . . 0.0 110.848 179.895 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -91.69 -29.18 16.99 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.207 -0.452 . . . . 0.0 110.972 179.969 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 50' ' ' PHE . . . . . 0.453 ' CZ ' HG21 ' A' ' 48' ' ' THR . 37.5 p90 -74.92 -32.33 61.77 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.273 -0.421 . . . . 0.0 111.055 -179.929 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 51' ' ' ALA . . . . . . . . . . . . . . . -142.1 143.35 27.55 Favored Pre-proline 0 C--N 1.33 -0.264 0 CA-C-N 116.304 -0.407 . . . . 0.0 111.128 -179.965 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 52' ' ' PRO . . . . . . . . . . . . . 73.8 Cg_endo -77.33 -168.06 0.55 Allowed 'Trans proline' 0 C--N 1.346 0.404 0 C-N-CA 122.669 2.246 . . . . 0.0 112.325 -179.978 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 70.94 -155.15 52.68 Favored Glycine 0 N--CA 1.451 -0.346 0 C-N-CA 120.722 -0.751 . . . . 0.0 112.527 179.917 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 54' ' ' TYR . . . . . . . . . . . . . 41.4 m-85 -119.04 125.23 48.85 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-O 120.793 0.33 . . . . 0.0 110.906 -179.982 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 55' ' ' TRP . . . . . . . . . . . . . 63.8 m95 -117.4 168.5 10.3 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.909 179.967 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 56' ' ' TYR . . . . . 0.653 ' HE1' ' HB2' ' A' ' 89' ' ' ALA . 6.5 m-85 -124.6 119.56 29.4 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.254 -0.43 . . . . 0.0 110.939 -179.951 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 57' ' ' GLY . . . . . 0.454 ' CA ' ' CE1' ' A' ' 86' ' ' PHE . . . -84.1 62.43 4.59 Favored Glycine 0 N--CA 1.451 -0.366 0 C-N-CA 120.771 -0.728 . . . . 0.0 112.543 179.956 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 58' ' ' ILE . . . . . 0.628 HD11 HD13 ' A' ' 92' ' ' ILE . 7.2 mt -68.53 142.84 15.77 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-O 120.868 0.366 . . . . 0.0 111.035 179.995 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 4.7 tm-20 -109.13 110.1 21.25 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.921 179.948 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 60' ' ' LEU . . . . . . . . . . . . . 84.2 mt -68.6 176.33 3.0 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.863 -179.973 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -101.33 -32.18 10.6 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.896 -179.948 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 62' ' ' GLN . . . . . . . . . . . . . 6.3 mt-30 -102.2 162.78 19.25 Favored Pre-proline 0 C--N 1.329 -0.285 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.927 -179.97 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 98.7 Cg_endo -79.52 58.26 6.88 Favored 'Trans proline' 0 C--N 1.344 0.332 0 C-N-CA 122.663 2.242 . . . . 0.0 112.477 -179.996 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 64' ' ' THR . . . . . . . . . . . . . 20.8 p -133.4 32.12 3.69 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.949 179.993 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . -81.98 -117.28 0.48 Allowed Glycine 0 N--CA 1.451 -0.308 0 C-N-CA 120.751 -0.738 . . . . 0.0 112.454 179.976 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 66' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -155.17 -48.05 0.08 Allowed 'General case' 0 C--N 1.33 -0.263 0 CA-C-O 120.868 0.366 . . . . 0.0 110.899 179.917 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 67' ' ' HIS . . . . . . . . . . . . . 7.9 p80 -127.08 169.5 13.33 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 116.156 -0.474 . . . . 0.0 110.81 179.923 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 1.8 m-20 -97.81 36.07 1.59 Allowed 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.255 -0.43 . . . . 0.0 110.91 179.969 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 95.81 -39.57 2.81 Favored Glycine 0 N--CA 1.451 -0.355 0 C-N-CA 120.697 -0.763 . . . . 0.0 112.549 -179.984 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 70' ' ' SER . . . . . . . . . . . . . 11.6 p -101.1 127.23 47.73 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 120.741 0.305 . . . . 0.0 110.911 179.982 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 71' ' ' VAL . . . . . 0.418 HG12 ' CD2' ' A' ' 72' ' ' PHE . 21.5 t -115.07 111.01 34.06 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.349 0 CA-C-N 116.202 -0.454 . . . . 0.0 111.128 179.964 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 72' ' ' PHE . . . . . 0.418 ' CD2' HG12 ' A' ' 71' ' ' VAL . 30.2 m-85 61.44 30.66 18.99 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.891 179.966 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 99.1 -28.79 13.66 Favored Glycine 0 N--CA 1.451 -0.356 0 C-N-CA 120.741 -0.742 . . . . 0.0 112.463 179.951 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 27.8 t -80.55 121.71 34.47 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-O 120.881 0.372 . . . . 0.0 111.075 179.952 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 75' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -106.35 142.07 36.64 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.817 -179.937 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 76' ' ' TYR . . . . . 0.403 ' HB3' ' CD1' ' A' ' 44' ' ' PHE . 8.2 m-85 -115.42 -46.8 2.86 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.123 -0.49 . . . . 0.0 110.855 179.954 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 77' ' ' PHE . . . . . 0.433 ' CE1' ' HA3' ' A' ' 57' ' ' GLY . 35.1 p90 -146.9 177.29 9.25 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 116.263 -0.426 . . . . 0.0 110.879 179.982 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 0.9 OUTLIER -104.69 124.36 49.23 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.875 -179.964 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 79' ' ' CYS . . . . . . . . . . . . . 10.8 p -144.97 167.42 22.68 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.118 -0.492 . . . . 0.0 110.893 179.977 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 80' ' ' ALA . . . . . 0.511 ' HB1' ' HD2' ' A' ' 81' ' ' PRO . . . -75.51 166.44 45.3 Favored Pre-proline 0 C--N 1.33 -0.255 0 CA-C-N 116.228 -0.442 . . . . 0.0 111.075 -179.958 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 81' ' ' PRO . . . . . 0.511 ' HD2' ' HB1' ' A' ' 80' ' ' ALA . 51.2 Cg_exo -52.85 116.6 3.01 Favored 'Trans proline' 0 C--N 1.345 0.346 0 C-N-CA 122.572 2.181 . . . . 0.0 112.318 179.916 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 82' ' ' ARG . . . . . . . . . . . . . 0.5 OUTLIER 61.39 56.74 2.54 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.84 179.897 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 83' ' ' HIS . . . . . 0.505 ' CG ' ' HB3' ' A' ' 80' ' ' ALA . 6.2 m170 -126.36 -47.76 1.58 Allowed 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.925 179.953 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . -61.91 139.33 46.43 Favored Glycine 0 N--CA 1.451 -0.353 0 C-N-CA 120.699 -0.763 . . . . 0.0 112.56 179.915 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 85' ' ' VAL . . . . . . . . . . . . . 5.8 m -140.28 127.99 24.25 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.326 0 CA-C-O 120.774 0.321 . . . . 0.0 111.126 -179.911 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 86' ' ' PHE . . . . . 0.454 ' CE1' ' CA ' ' A' ' 57' ' ' GLY . 9.1 m-85 -110.26 112.45 24.42 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.189 -0.459 . . . . 0.0 110.871 179.926 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 87' ' ' ALA . . . . . 0.526 ' O ' HD11 ' A' ' 92' ' ' ILE . . . -134.86 149.45 70.6 Favored Pre-proline 0 C--N 1.329 -0.286 0 CA-C-N 116.303 -0.408 . . . . 0.0 111.213 179.966 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 88' ' ' PRO . . . . . 0.412 ' O ' ' N ' ' A' ' 91' ' ' ARG . 32.5 Cg_exo -58.08 140.53 94.41 Favored 'Trans proline' 0 C--N 1.345 0.356 0 C-N-CA 122.596 2.197 . . . . 0.0 112.27 -179.92 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 89' ' ' ALA . . . . . 0.653 ' HB2' ' HE1' ' A' ' 56' ' ' TYR . . . -47.79 -51.69 21.61 Favored 'General case' 0 C--N 1.332 -0.165 0 CA-C-O 121.06 0.457 . . . . 0.0 110.299 179.916 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 90' ' ' SER . . . . . . . . . . . . . 14.9 m -55.71 -24.5 35.06 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 115.731 -0.668 . . . . 0.0 109.734 178.788 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 91' ' ' ARG . . . . . 0.412 ' N ' ' O ' ' A' ' 88' ' ' PRO . 0.2 OUTLIER -88.76 -15.14 35.46 Favored 'General case' 0 N--CA 1.454 -0.229 0 CA-C-N 115.889 -0.596 . . . . 0.0 110.438 179.089 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 92' ' ' ILE . . . . . 0.628 HD13 HD11 ' A' ' 58' ' ' ILE . 48.4 mt -107.03 144.88 15.26 Favored 'Isoleucine or valine' 0 C--N 1.334 -0.104 0 CA-C-N 116.413 -0.358 . . . . 0.0 111.047 179.913 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 93' ' ' GLN . . . . . . . . . . . . . 9.1 mt-30 -115.65 -179.94 3.79 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.167 -0.469 . . . . 0.0 110.866 -179.997 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 94' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -125.77 134.99 51.55 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.202 -0.453 . . . . 0.0 110.996 -179.954 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 95' ' ' ILE . . . . . . . . . . . . . 5.0 mt . . . . . 0 C--N 1.329 -0.31 0 CA-C-N 116.22 -0.446 . . . . 0.0 111.108 179.952 . . . . . . . . 0 0 . 1 . 020 nuclear nobuild core ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.231 0.098 0 CA-C-O 120.88 0.372 . . . . 0.0 111.072 . . . . . . . . . 0 0 . 1 . 020 nuclear nobuild core ' A' A ' 27' ' ' GLU . . . . . . . . . . . . . 7.4 mp0 -133.74 -178.63 5.1 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.955 179.994 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 25.6 t -73.43 98.96 1.05 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.061 -179.993 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 117.94 39.63 0.75 Allowed Glycine 0 N--CA 1.451 -0.327 0 C-N-CA 120.789 -0.72 . . . . 0.0 112.449 179.924 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 20.7 t70 -146.25 137.68 24.66 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-O 120.842 0.353 . . . . 0.0 110.899 -179.978 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 31' ' ' GLN . . . . . . . . . . . . . 0.8 OUTLIER -59.96 137.33 58.11 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.121 -0.491 . . . . 0.0 110.961 179.938 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 6.2 m -141.28 171.67 11.77 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 116.234 -0.439 . . . . 0.0 111.11 -179.938 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 33' ' ' LEU . . . . . 0.683 HD13 ' HG3' ' A' ' 39' ' ' GLN . 33.9 tp -136.61 111.31 8.71 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.125 -0.488 . . . . 0.0 110.875 179.943 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 21.5 t -79.15 125.77 38.64 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-N 116.226 -0.443 . . . . 0.0 111.25 -179.978 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 35' ' ' ALA . . . . . . . . . . . . . . . 56.58 25.47 9.93 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.346 179.97 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . 57.54 31.69 63.73 Favored Glycine 0 N--CA 1.451 -0.306 0 C-N-CA 120.736 -0.745 . . . . 0.0 112.565 179.898 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 37' ' ' GLN . . . . . 0.577 ' O ' HD11 ' A' ' 33' ' ' LEU . 9.3 mt-30 -142.98 -74.28 0.28 Allowed 'General case' 0 C--N 1.33 -0.28 0 CA-C-O 120.818 0.342 . . . . 0.0 111.006 -179.971 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 38' ' ' LYS . . . . . 0.414 ' O ' HD12 ' A' ' 33' ' ' LEU . 46.0 mttp -63.51 112.59 2.84 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.896 -179.892 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 39' ' ' GLN . . . . . 0.683 ' HG3' HD13 ' A' ' 33' ' ' LEU . 2.1 mt-30 -87.6 139.6 30.37 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.837 179.926 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -172.87 171.42 44.39 Favored Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.697 -0.763 . . . . 0.0 112.512 179.993 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 3.2 mp -111.88 143.7 21.14 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-O 120.875 0.369 . . . . 0.0 111.114 179.978 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 42' ' ' VAL . . . . . . . . . . . . . 21.5 t -69.29 123.2 22.36 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.153 -0.476 . . . . 0.0 111.138 -179.995 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 43' ' ' ARG . . . . . . . . . . . . . 4.0 mmm180 -106.73 -31.54 8.38 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.891 -179.973 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 44' ' ' PHE . . . . . 0.417 ' CG ' ' HB3' ' A' ' 76' ' ' TYR . 15.2 t80 -147.82 106.26 3.78 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.879 -179.928 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 45' ' ' TYR . . . . . 0.496 ' CE1' ' CE1' ' A' ' 56' ' ' TYR . 14.3 t80 -111.03 123.88 51.06 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.294 -0.412 . . . . 0.0 110.935 179.893 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 171.54 -142.79 7.19 Favored Glycine 0 N--CA 1.45 -0.371 0 C-N-CA 120.649 -0.786 . . . . 0.0 112.462 -179.98 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 47' ' ' LYS . . . . . . . . . . . . . 24.7 mtpt -95.06 175.01 6.8 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-O 120.773 0.321 . . . . 0.0 110.906 179.993 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 48' ' ' THR . . . . . . . . . . . . . 44.8 p -138.79 -177.8 5.04 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.846 -179.996 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 4.4 t70 -129.04 17.59 6.13 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.154 -0.476 . . . . 0.0 111.259 179.924 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 50' ' ' PHE . . . . . . . . . . . . . 49.5 p90 -126.81 -44.98 1.62 Allowed 'General case' 0 C--N 1.331 -0.217 0 CA-C-N 116.447 -0.342 . . . . 0.0 110.892 179.961 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 51' ' ' ALA . . . . . 0.42 ' HB1' ' CZ2' ' A' ' 55' ' ' TRP . . . -123.5 145.37 46.72 Favored Pre-proline 0 C--N 1.329 -0.324 0 CA-C-N 116.291 -0.413 . . . . 0.0 111.122 179.944 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 52' ' ' PRO . . . . . . . . . . . . . 64.4 Cg_endo -73.59 164.7 34.26 Favored 'Trans proline' 0 C--N 1.345 0.36 0 C-N-CA 122.565 2.176 . . . . 0.0 112.32 -179.926 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 83.51 -177.2 52.65 Favored Glycine 0 N--CA 1.452 -0.287 0 C-N-CA 120.725 -0.75 . . . . 0.0 112.478 179.855 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 54' ' ' TYR . . . . . . . . . . . . . 7.8 m-85 -97.63 131.84 43.83 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-O 120.818 0.342 . . . . 0.0 110.862 -179.979 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 55' ' ' TRP . . . . . 0.42 ' CZ2' ' HB1' ' A' ' 51' ' ' ALA . 24.8 m95 -123.41 157.74 32.74 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.907 -179.994 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 56' ' ' TYR . . . . . 0.658 ' HE1' ' HB2' ' A' ' 89' ' ' ALA . 11.9 m-85 -109.69 126.84 54.12 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.977 -179.948 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . -84.46 62.08 4.62 Favored Glycine 0 N--CA 1.451 -0.36 0 C-N-CA 120.733 -0.746 . . . . 0.0 112.419 179.921 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 58' ' ' ILE . . . . . 0.492 HD11 HD13 ' A' ' 92' ' ' ILE . 15.9 mt -71.32 141.05 17.26 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-O 120.816 0.341 . . . . 0.0 111.108 -179.985 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER -109.89 122.14 46.85 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.885 179.951 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 60' ' ' LEU . . . . . . . . . . . . . 63.1 mt -82.69 170.3 15.26 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.945 -179.929 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 1.1 m-20 -100.6 -26.52 13.79 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.95 -179.97 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 62' ' ' GLN . . . . . . . . . . . . . 10.8 pt20 -110.41 152.16 43.13 Favored Pre-proline 0 C--N 1.329 -0.292 0 CA-C-N 116.299 -0.41 . . . . 0.0 110.922 -179.967 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 63' ' ' PRO . . . . . 0.417 ' O ' HG23 ' A' ' 64' ' ' THR . 49.7 Cg_endo -68.91 84.1 0.53 Allowed 'Trans proline' 0 C--N 1.345 0.357 0 C-N-CA 122.599 2.199 . . . . 0.0 112.312 179.971 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 64' ' ' THR . . . . . 0.417 HG23 ' O ' ' A' ' 63' ' ' PRO . 2.2 p -156.97 35.83 0.3 Allowed 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.213 -0.448 . . . . 0.0 110.894 -179.923 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . -91.65 -158.6 34.72 Favored Glycine 0 N--CA 1.451 -0.359 0 C-N-CA 120.757 -0.735 . . . . 0.0 112.443 -179.961 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 66' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -114.07 -36.69 4.67 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-O 120.735 0.303 . . . . 0.0 110.889 -179.997 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 67' ' ' HIS . . . . . . . . . . . . . 6.9 p80 -127.08 170.26 12.54 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.261 -0.427 . . . . 0.0 110.909 -179.903 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 5.4 m-20 -98.8 30.87 3.15 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.165 -0.471 . . . . 0.0 110.85 179.973 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 105.46 -42.76 1.82 Allowed Glycine 0 N--CA 1.452 -0.257 0 C-N-CA 120.667 -0.777 . . . . 0.0 112.457 179.915 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 70' ' ' SER . . . . . . . . . . . . . 63.4 p -108.62 141.76 40.08 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.798 0.333 . . . . 0.0 110.92 179.966 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 21.5 t -117.45 109.9 29.17 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 116.25 -0.432 . . . . 0.0 111.112 179.957 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 72' ' ' PHE . . . . . . . . . . . . . 40.7 m-85 60.66 30.58 19.82 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.932 -179.972 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 101.08 -30.02 11.26 Favored Glycine 0 N--CA 1.451 -0.353 0 C-N-CA 120.705 -0.759 . . . . 0.0 112.51 179.999 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 21.5 t -78.66 117.88 24.94 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-O 120.764 0.316 . . . . 0.0 111.152 -179.977 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 75' ' ' ARG . . . . . . . . . . . . . 10.3 ttm180 -98.33 145.67 26.45 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.894 -179.984 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 76' ' ' TYR . . . . . 0.417 ' HB3' ' CG ' ' A' ' 44' ' ' PHE . 12.6 m-85 -119.93 -42.36 2.61 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.852 -179.96 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 77' ' ' PHE . . . . . . . . . . . . . 26.6 p90 -153.13 158.89 42.52 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.875 179.991 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 12.0 p -89.96 99.53 12.52 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.91 -180.0 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 79' ' ' CYS . . . . . . . . . . . . . 30.5 p -117.93 173.95 6.48 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.85 179.977 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 80' ' ' ALA . . . . . 0.644 ' HB3' ' CG ' ' A' ' 83' ' ' HIS . . . -80.72 168.0 28.49 Favored Pre-proline 0 C--N 1.329 -0.308 0 CA-C-N 116.149 -0.478 . . . . 0.0 111.061 -179.975 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 81' ' ' PRO . . . . . 0.561 ' HD2' ' HB1' ' A' ' 80' ' ' ALA . 54.1 Cg_exo -52.14 112.18 0.8 Allowed 'Trans proline' 0 C--N 1.345 0.347 0 C-N-CA 122.554 2.169 . . . . 0.0 112.296 179.974 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 82' ' ' ARG . . . . . . . . . . . . . 12.9 mtp180 59.97 56.56 3.38 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.872 179.977 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 83' ' ' HIS . . . . . 0.644 ' CG ' ' HB3' ' A' ' 80' ' ' ALA . 5.1 m170 -121.48 -41.78 2.48 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.949 179.967 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . -71.44 142.22 33.59 Favored Glycine 0 N--CA 1.451 -0.301 0 C-N-CA 120.786 -0.721 . . . . 0.0 112.516 179.997 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 85' ' ' VAL . . . . . 0.4 ' O ' HG23 ' A' ' 85' ' ' VAL . 22.3 m -144.48 124.03 7.27 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-O 120.785 0.326 . . . . 0.0 111.089 179.943 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 86' ' ' PHE . . . . . . . . . . . . . 24.1 m-85 -101.28 121.26 41.56 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.974 179.927 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 87' ' ' ALA . . . . . 0.547 ' O ' HD11 ' A' ' 92' ' ' ILE . . . -138.64 146.54 51.03 Favored Pre-proline 0 C--N 1.329 -0.3 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.102 179.981 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 88' ' ' PRO . . . . . 0.431 ' O ' ' N ' ' A' ' 91' ' ' ARG . 41.8 Cg_exo -56.92 139.15 88.79 Favored 'Trans proline' 0 C--N 1.345 0.379 0 C-N-CA 122.487 2.125 . . . . 0.0 112.313 -179.934 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 89' ' ' ALA . . . . . 0.658 ' HB2' ' HE1' ' A' ' 56' ' ' TYR . . . -48.08 -48.39 33.58 Favored 'General case' 0 C--O 1.232 0.141 0 CA-C-N 116.076 -0.511 . . . . 0.0 110.24 179.818 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 90' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -55.53 -24.54 32.62 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 115.681 -0.69 . . . . 0.0 109.779 178.779 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 91' ' ' ARG . . . . . 0.431 ' N ' ' O ' ' A' ' 88' ' ' PRO . 0.7 OUTLIER -92.13 -13.55 30.53 Favored 'General case' 0 N--CA 1.455 -0.195 0 CA-C-N 115.877 -0.601 . . . . 0.0 110.62 179.201 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 92' ' ' ILE . . . . . 0.547 HD11 ' O ' ' A' ' 87' ' ' ALA . 50.1 mt -105.74 154.39 7.01 Favored 'Isoleucine or valine' 0 C--N 1.333 -0.12 0 CA-C-O 120.836 0.35 . . . . 0.0 111.013 179.796 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 93' ' ' GLN . . . . . 0.424 ' N ' HG22 ' A' ' 92' ' ' ILE . 0.3 OUTLIER -124.07 176.93 6.06 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.911 -179.978 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 94' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER -111.47 160.98 16.61 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.845 -179.989 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 95' ' ' ILE . . . . . . . . . . . . . 30.8 mt . . . . . 0 C--N 1.329 -0.284 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.097 179.961 . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.211 0 N-CA-C 112.463 -0.255 . . . . 0.0 112.463 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 7.3 p 62.32 121.17 0.01 OUTLIER 'General case' 0 C--N 1.33 -0.252 0 CA-C-O 120.872 0.367 . . . . 0.0 110.962 -179.992 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 3.6 m -59.62 -62.54 1.8 Allowed 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.921 179.936 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -150.01 -147.63 4.58 Favored Glycine 0 N--CA 1.45 -0.387 0 C-N-CA 120.713 -0.756 . . . . 0.0 112.458 179.962 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 42.3 t -94.14 -63.11 1.23 Allowed 'General case' 0 C--N 1.329 -0.293 0 CA-C-O 120.845 0.355 . . . . 0.0 110.895 -179.967 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 20.9 p -102.05 -51.11 3.47 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.876 -179.979 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 157.16 -177.76 33.86 Favored Glycine 0 N--CA 1.452 -0.29 0 C-N-CA 120.695 -0.764 . . . . 0.0 112.464 179.949 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 10.2 tttm -157.01 31.58 0.3 Allowed 'General case' 0 C--N 1.33 -0.259 0 CA-C-O 120.827 0.346 . . . . 0.0 110.922 179.981 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 10.3 t -94.93 145.19 29.1 Favored Pre-proline 0 C--N 1.33 -0.281 0 CA-C-N 116.178 -0.464 . . . . 0.0 110.826 -179.955 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 65.5 Cg_endo -73.52 146.25 39.0 Favored 'Trans proline' 0 C--N 1.345 0.342 0 C-N-CA 122.647 2.232 . . . . 0.0 112.348 -179.972 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -81.48 -31.32 32.99 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.871 179.915 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 32.7 p -136.92 154.57 76.26 Favored Pre-proline 0 C--N 1.329 -0.312 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.847 179.879 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 39.9 Cg_endo -67.02 88.97 0.3 Allowed 'Trans proline' 0 C--N 1.345 0.363 0 C-N-CA 122.577 2.185 . . . . 0.0 112.233 179.959 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 83.6 p -123.24 147.5 46.85 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.931 179.969 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 3.8 tp -136.17 -177.04 4.53 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.174 -0.467 . . . . 0.0 110.812 179.954 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -58.28 -34.02 72.65 Favored Glycine 0 N--CA 1.451 -0.327 0 C-N-CA 120.625 -0.798 . . . . 0.0 112.43 179.982 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 3.8 p -177.49 109.32 0.07 Allowed 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.803 0.335 . . . . 0.0 110.878 179.889 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 18' ' ' LEU . . . . . 0.439 HD23 ' HA ' ' A' ' 18' ' ' LEU . 12.2 mt -153.8 31.58 0.45 Allowed 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.853 -179.988 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 19' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -154.13 31.75 0.44 Allowed 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.806 179.945 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 20' ' ' GLN . . . . . . . . . . . . . 1.9 mt-30 -87.72 176.08 7.57 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.959 179.977 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 9.8 mmt180 -100.97 105.8 17.06 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.944 -179.98 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 4.0 mt-10 60.47 31.96 20.43 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.968 179.98 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -71.07 157.58 53.55 Favored Glycine 0 N--CA 1.45 -0.37 0 C-N-CA 120.724 -0.75 . . . . 0.0 112.497 -179.992 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -170.2 155.06 5.2 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-O 120.781 0.324 . . . . 0.0 111.077 -179.945 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 0.6 OUTLIER -86.75 -46.49 9.95 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.988 179.957 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -107.84 -177.99 3.49 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.116 -0.493 . . . . 0.0 111.164 179.94 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 27' ' ' GLU . . . . . . . . . . . . . 2.1 mm-40 -149.14 167.56 25.59 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.941 -179.992 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 21.8 t -68.6 125.02 25.54 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 CA-C-N 116.176 -0.465 . . . . 0.0 111.106 -179.975 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 98.39 29.66 7.36 Favored Glycine 0 N--CA 1.451 -0.347 0 C-N-CA 120.724 -0.751 . . . . 0.0 112.446 -179.991 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 30' ' ' ASP . . . . . 0.425 ' O ' HG23 ' A' ' 41' ' ' ILE . 0.8 OUTLIER -138.76 147.96 43.27 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-O 120.814 0.34 . . . . 0.0 110.845 -179.928 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 31' ' ' GLN . . . . . . . . . . . . . 0.7 OUTLIER -72.65 127.25 32.0 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.963 179.977 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 22.2 m -130.16 179.9 3.79 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 CA-C-N 116.265 -0.425 . . . . 0.0 111.192 179.973 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 33' ' ' LEU . . . . . 0.562 HD23 ' HA2' ' A' ' 36' ' ' GLY . 15.7 tp -139.52 109.33 6.32 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.262 -0.426 . . . . 0.0 110.963 -179.993 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 23.1 t -76.57 121.12 28.08 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.261 -0.427 . . . . 0.0 111.138 -180.0 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 35' ' ' ALA . . . . . . . . . . . . . . . 59.22 26.61 15.42 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.244 179.976 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 36' ' ' GLY . . . . . 0.562 ' HA2' HD23 ' A' ' 33' ' ' LEU . . . 56.74 36.64 73.01 Favored Glycine 0 N--CA 1.45 -0.387 0 C-N-CA 120.74 -0.743 . . . . 0.0 112.639 179.954 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 37' ' ' GLN . . . . . . . . . . . . . 35.3 mt-30 -146.98 -71.42 0.23 Allowed 'General case' 0 C--N 1.329 -0.325 0 CA-C-O 120.796 0.331 . . . . 0.0 110.948 -179.998 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 38' ' ' LYS . . . . . . . . . . . . . 13.2 mttm -67.83 114.79 6.71 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.879 -179.995 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 39' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -90.14 125.98 35.64 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.922 179.935 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -152.77 -175.61 24.45 Favored Glycine 0 N--CA 1.451 -0.347 0 C-N-CA 120.715 -0.755 . . . . 0.0 112.5 -179.971 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 41' ' ' ILE . . . . . 0.529 ' C ' HG23 ' A' ' 58' ' ' ILE . 4.3 mt -127.64 128.79 69.94 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.272 0 CA-C-O 120.8 0.333 . . . . 0.0 111.02 -179.948 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 42' ' ' VAL . . . . . . . . . . . . . 21.6 t -59.99 124.42 14.28 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.253 -0.431 . . . . 0.0 111.084 179.975 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 43' ' ' ARG . . . . . . . . . . . . . 45.0 mmt-85 -110.57 -30.24 7.71 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.23 -0.441 . . . . 0.0 111.077 -179.993 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 44' ' ' PHE . . . . . . . . . . . . . 35.7 t80 -143.61 118.6 10.02 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.318 -0.401 . . . . 0.0 110.993 -179.958 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 45' ' ' TYR . . . . . 0.455 ' CE1' ' CZ ' ' A' ' 56' ' ' TYR . 22.2 t80 -115.08 114.9 25.96 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.845 179.899 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 176.8 162.96 28.27 Favored Glycine 0 N--CA 1.45 -0.382 0 C-N-CA 120.699 -0.763 . . . . 0.0 112.441 179.944 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 47' ' ' LYS . . . . . 0.442 ' HG3' ' CE1' ' A' ' 54' ' ' TYR . 22.7 mttt -65.98 137.32 57.05 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.865 0.364 . . . . 0.0 110.852 179.97 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 48' ' ' THR . . . . . . . . . . . . . 41.2 p -95.67 -175.35 3.41 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.902 179.918 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 4.6 t70 -106.58 -30.87 8.76 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.893 179.987 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 50' ' ' PHE . . . . . . . . . . . . . 44.3 p90 -71.29 -36.22 71.58 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.867 -179.985 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 51' ' ' ALA . . . . . . . . . . . . . . . -132.69 148.17 68.48 Favored Pre-proline 0 C--N 1.33 -0.274 0 CA-C-N 116.236 -0.438 . . . . 0.0 111.188 179.978 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 52' ' ' PRO . . . . . . . . . . . . . 59.9 Cg_endo -72.25 -170.07 0.53 Allowed 'Trans proline' 0 C--N 1.344 0.34 0 C-N-CA 122.601 2.201 . . . . 0.0 112.336 -179.97 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 59.26 -161.01 15.5 Favored Glycine 0 N--CA 1.452 -0.283 0 C-N-CA 120.746 -0.74 . . . . 0.0 112.537 179.976 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 54' ' ' TYR . . . . . 0.442 ' CE1' ' HG3' ' A' ' 47' ' ' LYS . 12.8 m-85 -106.19 157.8 17.3 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-O 120.844 0.354 . . . . 0.0 110.855 -179.95 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 55' ' ' TRP . . . . . . . . . . . . . 69.5 m95 -144.37 159.71 42.27 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.898 179.988 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 56' ' ' TYR . . . . . 0.827 ' CE1' ' HB2' ' A' ' 89' ' ' ALA . 5.7 m-85 -116.36 115.26 25.55 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.878 -179.951 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 57' ' ' GLY . . . . . 0.443 ' CA ' ' CE1' ' A' ' 86' ' ' PHE . . . -82.27 65.72 4.02 Favored Glycine 0 N--CA 1.451 -0.307 0 C-N-CA 120.75 -0.738 . . . . 0.0 112.431 -179.973 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 58' ' ' ILE . . . . . 0.704 HD11 HD13 ' A' ' 92' ' ' ILE . 5.5 mt -72.67 143.66 13.75 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-O 120.816 0.341 . . . . 0.0 111.074 179.986 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 8.0 tt0 -104.23 143.04 33.49 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.836 179.95 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 60' ' ' LEU . . . . . . . . . . . . . 82.1 mt -96.11 173.18 7.54 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.929 -179.957 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 7.9 t0 -97.12 -33.19 11.6 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.954 179.991 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 62' ' ' GLN . . . . . . . . . . . . . 2.7 mt-30 -116.14 146.36 36.99 Favored Pre-proline 0 C--N 1.329 -0.319 0 CA-C-N 116.18 -0.463 . . . . 0.0 110.936 179.97 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 48.1 Cg_exo -55.83 86.75 0.04 OUTLIER 'Trans proline' 0 C--N 1.346 0.409 0 C-N-CA 122.548 2.165 . . . . 0.0 112.172 179.955 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 64' ' ' THR . . . . . . . . . . . . . 80.8 p -157.3 30.44 0.29 Allowed 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.251 -0.431 . . . . 0.0 110.984 -179.979 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . -89.62 175.54 42.29 Favored Glycine 0 N--CA 1.451 -0.363 0 C-N-CA 120.708 -0.758 . . . . 0.0 112.491 179.957 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 66' ' ' LYS . . . . . . . . . . . . . 48.5 mttm -78.61 -30.47 46.57 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 120.693 0.282 . . . . 0.0 110.865 179.94 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 67' ' ' HIS . . . . . . . . . . . . . 7.4 p80 -148.38 -178.98 6.61 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.898 -179.961 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 9.2 p30 -105.25 48.49 0.84 Allowed 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.952 179.999 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 94.02 -45.91 2.27 Favored Glycine 0 N--CA 1.452 -0.294 0 C-N-CA 120.738 -0.744 . . . . 0.0 112.512 -179.964 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 70' ' ' SER . . . . . . . . . . . . . 1.6 p -98.96 136.58 38.73 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-O 120.821 0.344 . . . . 0.0 110.901 179.985 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 71' ' ' VAL . . . . . 0.468 HG12 ' CD2' ' A' ' 72' ' ' PHE . 21.4 t -114.41 110.64 32.8 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.253 -0.431 . . . . 0.0 111.131 179.969 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 72' ' ' PHE . . . . . 0.468 ' CD2' HG12 ' A' ' 71' ' ' VAL . 60.6 m-85 60.47 31.89 20.41 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.22 -0.446 . . . . 0.0 110.961 179.967 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 98.85 -30.18 10.25 Favored Glycine 0 N--CA 1.451 -0.355 0 C-N-CA 120.685 -0.769 . . . . 0.0 112.556 -179.962 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 21.4 t -77.95 117.63 23.52 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-O 120.823 0.344 . . . . 0.0 111.127 179.904 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 75' ' ' ARG . . . . . . . . . . . . . 5.1 ttt180 -95.33 149.52 21.27 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.988 -179.864 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 76' ' ' TYR . . . . . . . . . . . . . 35.9 m-85 -129.94 -45.6 1.15 Allowed 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.25 -0.432 . . . . 0.0 110.947 179.951 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 77' ' ' PHE . . . . . . . . . . . . . 38.1 p90 -146.72 164.72 31.85 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.31 -0.405 . . . . 0.0 110.997 179.945 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 51.7 p -96.18 123.49 39.82 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.921 -179.97 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 79' ' ' CYS . . . . . . . . . . . . . 7.5 p -148.02 170.57 17.47 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.877 179.891 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 80' ' ' ALA . . . . . 0.407 ' HB1' ' HD2' ' A' ' 81' ' ' PRO . . . -71.73 162.48 72.93 Favored Pre-proline 0 C--N 1.329 -0.289 0 CA-C-N 116.163 -0.471 . . . . 0.0 111.079 -179.952 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 81' ' ' PRO . . . . . 0.407 ' HD2' ' HB1' ' A' ' 80' ' ' ALA . 53.0 Cg_exo -52.4 118.46 4.66 Favored 'Trans proline' 0 C--N 1.344 0.3 0 C-N-CA 122.632 2.221 . . . . 0.0 112.294 179.971 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 82' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER 60.27 63.53 1.38 Allowed 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.869 179.972 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 83' ' ' HIS . . . . . . . . . . . . . 3.3 m-70 -132.3 -46.02 0.91 Allowed 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.13 -0.486 . . . . 0.0 110.911 -179.975 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . -63.73 141.69 45.74 Favored Glycine 0 N--CA 1.451 -0.362 0 C-N-CA 120.709 -0.757 . . . . 0.0 112.52 179.996 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 85' ' ' VAL . . . . . . . . . . . . . 6.1 m -142.15 120.14 8.24 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-O 120.768 0.318 . . . . 0.0 111.166 -179.974 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 86' ' ' PHE . . . . . 0.443 ' CE1' ' CA ' ' A' ' 57' ' ' GLY . 12.4 m-85 -100.38 115.39 29.9 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.868 179.994 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 87' ' ' ALA . . . . . 0.609 ' O ' HD11 ' A' ' 92' ' ' ILE . . . -137.8 145.57 49.04 Favored Pre-proline 0 C--N 1.328 -0.336 0 CA-C-N 116.28 -0.418 . . . . 0.0 111.143 179.924 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 88' ' ' PRO . . . . . 0.406 ' O ' ' N ' ' A' ' 91' ' ' ARG . 47.4 Cg_exo -56.02 139.14 84.51 Favored 'Trans proline' 0 C--N 1.345 0.388 0 C-N-CA 122.454 2.103 . . . . 0.0 112.336 -179.977 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 89' ' ' ALA . . . . . 0.827 ' HB2' ' CE1' ' A' ' 56' ' ' TYR . . . -48.01 -50.91 26.03 Favored 'General case' 0 C--N 1.333 -0.122 0 CA-C-N 116.109 -0.496 . . . . 0.0 110.272 179.862 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 90' ' ' SER . . . . . . . . . . . . . 17.7 m -55.76 -24.49 35.65 Favored 'General case' 0 N--CA 1.454 -0.259 0 CA-C-N 115.687 -0.688 . . . . 0.0 109.766 178.816 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 91' ' ' ARG . . . . . 0.406 ' N ' ' O ' ' A' ' 88' ' ' PRO . 0.6 OUTLIER -88.3 -15.14 36.53 Favored 'General case' 0 N--CA 1.455 -0.188 0 CA-C-N 115.831 -0.622 . . . . 0.0 110.473 179.02 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 92' ' ' ILE . . . . . 0.704 HD13 HD11 ' A' ' 58' ' ' ILE . 33.3 mt -104.37 157.89 5.5 Favored 'Isoleucine or valine' 0 C--N 1.334 -0.097 0 CA-C-N 116.379 -0.373 . . . . 0.0 110.973 179.924 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 93' ' ' GLN . . . . . 0.482 ' N ' HG22 ' A' ' 92' ' ' ILE . 2.2 mt-30 -128.3 166.34 18.81 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.889 -179.912 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 94' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -107.15 145.36 32.64 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.846 -179.994 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 95' ' ' ILE . . . . . . . . . . . . . 23.4 mt -115.58 -36.94 2.2 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.211 -0.449 . . . . 0.0 111.13 179.902 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . -105.4 146.47 16.08 Favored Glycine 0 N--CA 1.451 -0.339 0 C-N-CA 120.782 -0.723 . . . . 0.0 112.514 179.971 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 97' ' ' SER . . . . . . . . . . . . . 85.9 p -134.95 40.95 2.89 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-O 120.849 0.357 . . . . 0.0 110.841 179.998 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 98' ' ' GLY . . . . . . . . . . . . . . . 172.76 99.22 0.12 Allowed Glycine 0 N--CA 1.451 -0.32 0 C-N-CA 120.717 -0.754 . . . . 0.0 112.461 -179.994 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 99' ' ' PRO . . . . . . . . . . . . . 43.0 Cg_endo -67.75 -27.84 37.48 Favored 'Trans proline' 0 C--N 1.346 0.405 0 C-N-CA 122.431 2.088 . . . . 0.0 112.295 179.94 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 100' ' ' SER . . . . . . . . . . . . . 13.3 p -133.34 79.0 1.81 Allowed 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.949 179.974 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -144.1 170.8 15.27 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.906 -179.956 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.249 1.032 0 CA-C-O 118.335 -1.259 . . . . 0.0 112.449 -179.964 . . . . . . . . 0 0 . 1 . 002 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.17 0 N-CA-C 112.474 -0.251 . . . . 0.0 112.474 . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 2.1 p -83.03 134.61 35.03 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-O 120.925 0.393 . . . . 0.0 110.941 -179.88 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -120.49 -51.28 2.18 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.075 -0.511 . . . . 0.0 110.77 179.827 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -110.31 100.69 1.31 Allowed Glycine 0 N--CA 1.451 -0.347 0 C-N-CA 120.728 -0.748 . . . . 0.0 112.488 179.9 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 9.4 p -167.79 35.1 0.03 OUTLIER 'General case' 0 C--N 1.33 -0.269 0 CA-C-O 120.746 0.308 . . . . 0.0 110.932 -179.875 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 40.1 t -76.97 -61.02 2.12 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.315 -0.402 . . . . 0.0 110.881 179.952 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 84.27 -121.2 5.47 Favored Glycine 0 N--CA 1.451 -0.326 0 C-N-CA 120.677 -0.773 . . . . 0.0 112.534 179.968 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 17.3 mmtt -148.3 127.74 13.13 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-O 120.769 0.319 . . . . 0.0 110.884 -179.945 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 12.8 p -159.99 99.78 1.46 Allowed Pre-proline 0 C--N 1.329 -0.306 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.903 -179.967 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 44.0 Cg_endo -68.01 106.32 1.32 Allowed 'Trans proline' 0 C--N 1.345 0.369 0 C-N-CA 122.44 2.093 . . . . 0.0 112.258 -179.98 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 26.7 t -115.48 44.39 1.87 Allowed 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.896 179.929 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -161.93 89.4 1.46 Allowed Pre-proline 0 C--N 1.329 -0.292 0 CA-C-N 116.1 -0.5 . . . . 0.0 110.988 179.939 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 64.7 Cg_exo -51.12 108.6 0.24 Allowed 'Trans proline' 0 C--N 1.345 0.389 0 C-N-CA 122.518 2.145 . . . . 0.0 112.29 179.951 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 23.1 t -145.86 -45.47 0.21 Allowed 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.248 -0.433 . . . . 0.0 111.062 -179.965 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 6.3 mp -116.87 -77.61 0.57 Allowed 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.268 -0.424 . . . . 0.0 110.973 -179.926 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -92.54 85.15 1.17 Allowed Glycine 0 N--CA 1.45 -0.375 0 C-N-CA 120.714 -0.755 . . . . 0.0 112.421 179.966 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -59.01 -168.53 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 120.792 0.33 . . . . 0.0 110.889 -179.945 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 1.0 OUTLIER -134.06 34.58 3.33 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.271 -0.422 . . . . 0.0 110.904 180.0 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 19' ' ' GLN . . . . . . . . . . . . . 5.4 tm0? -59.82 -38.21 81.35 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.881 179.933 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 20' ' ' GLN . . . . . . . . . . . . . 0.6 OUTLIER -133.54 145.45 50.12 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.838 -180.0 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 10.4 ptp180 -114.01 39.93 2.6 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.265 -0.425 . . . . 0.0 110.94 -179.974 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 24.6 mt-10 -106.18 178.11 4.66 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.918 179.916 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 174.28 -121.17 0.83 Allowed Glycine 0 N--CA 1.451 -0.319 0 C-N-CA 120.742 -0.742 . . . . 0.0 112.527 -179.923 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -108.92 130.9 55.45 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-O 120.81 0.338 . . . . 0.0 111.098 179.982 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 1.6 tttp -70.73 -35.49 72.73 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.874 179.985 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 26' ' ' ALA . . . . . 0.584 ' HB3' ' CE2' ' A' ' 56' ' ' TYR . . . -138.63 -176.8 4.6 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.209 -0.45 . . . . 0.0 111.081 179.985 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 27' ' ' GLU . . . . . . . . . . . . . 6.0 mt-10 -148.03 173.37 12.98 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.252 -0.431 . . . . 0.0 110.911 179.98 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 21.5 t -70.83 110.28 3.72 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.087 179.974 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 113.01 36.24 1.54 Allowed Glycine 0 N--CA 1.452 -0.296 0 C-N-CA 120.736 -0.745 . . . . 0.0 112.503 179.97 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 2.1 m-20 -150.06 138.05 20.23 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 120.852 0.358 . . . . 0.0 110.866 -179.978 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 31' ' ' GLN . . . . . . . . . . . . . 0.7 OUTLIER -62.94 132.88 53.57 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.125 -0.489 . . . . 0.0 110.871 179.998 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 32' ' ' VAL . . . . . 0.486 HG21 HG12 ' A' ' 58' ' ' ILE . 12.6 m -132.99 178.81 5.12 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.149 179.99 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 33' ' ' LEU . . . . . 0.55 HD11 ' O ' ' A' ' 37' ' ' GLN . 40.4 tp -140.14 101.22 4.1 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.9 179.931 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 34' ' ' VAL . . . . . 0.406 ' CG2' HD13 ' A' ' 58' ' ' ILE . 21.6 t -72.55 127.68 34.75 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.218 -0.446 . . . . 0.0 111.175 -179.928 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 35' ' ' ALA . . . . . . . . . . . . . . . 57.68 25.33 11.62 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.139 -0.482 . . . . 0.0 111.266 179.937 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . 56.07 27.96 52.75 Favored Glycine 0 N--CA 1.453 -0.224 0 C-N-CA 120.686 -0.769 . . . . 0.0 112.638 179.979 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 37' ' ' GLN . . . . . 0.55 ' O ' HD11 ' A' ' 33' ' ' LEU . 29.5 mt-30 -138.1 -72.83 0.41 Allowed 'General case' 0 C--N 1.33 -0.279 0 CA-C-O 120.797 0.332 . . . . 0.0 110.944 -179.906 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 38' ' ' LYS . . . . . . . . . . . . . 3.7 mttt -69.02 111.81 5.25 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.265 -0.425 . . . . 0.0 110.965 179.991 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 39' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -92.98 130.5 38.53 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.086 -0.506 . . . . 0.0 110.905 -179.997 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -152.04 -171.0 19.33 Favored Glycine 0 N--CA 1.45 -0.38 0 C-N-CA 120.812 -0.709 . . . . 0.0 112.52 -179.988 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 29.8 mt -123.4 131.92 72.29 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 CA-C-O 120.825 0.345 . . . . 0.0 111.172 179.973 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 42' ' ' VAL . . . . . . . . . . . . . 21.6 t -59.44 126.87 17.85 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.336 0 CA-C-N 116.24 -0.436 . . . . 0.0 111.105 -179.999 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 43' ' ' ARG . . . . . . . . . . . . . 8.7 mmm180 -111.81 -42.56 3.78 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.932 -179.999 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 44' ' ' PHE . . . . . . . . . . . . . 46.0 t80 -138.66 113.24 8.95 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.937 -179.937 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 45' ' ' TYR . . . . . 0.426 ' CE1' ' CE1' ' A' ' 56' ' ' TYR . 35.8 t80 -113.08 138.56 49.73 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.956 179.98 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 152.71 -169.57 31.79 Favored Glycine 0 N--CA 1.449 -0.45 0 C-N-CA 120.783 -0.722 . . . . 0.0 112.489 179.957 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 47' ' ' LYS . . . . . . . . . . . . . 28.7 mttm -78.21 147.35 34.49 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-O 120.847 0.356 . . . . 0.0 110.844 -179.954 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 48' ' ' THR . . . . . 0.654 HG22 ' CE2' ' A' ' 76' ' ' TYR . 34.8 p -118.88 171.52 8.17 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.913 179.985 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -98.88 -35.79 9.99 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.885 179.972 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 50' ' ' PHE . . . . . 0.574 ' CZ ' HG21 ' A' ' 48' ' ' THR . 27.0 p90 -61.61 -31.39 71.46 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.92 179.907 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 51' ' ' ALA . . . . . . . . . . . . . . . -152.11 146.42 18.52 Favored Pre-proline 0 C--N 1.329 -0.294 0 CA-C-N 116.26 -0.427 . . . . 0.0 111.117 179.997 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 52' ' ' PRO . . . . . . . . . . . . . 60.9 Cg_endo -72.86 175.82 9.84 Favored 'Trans proline' 0 C--N 1.345 0.368 0 C-N-CA 122.573 2.182 . . . . 0.0 112.334 179.973 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 84.11 -158.79 35.03 Favored Glycine 0 N--CA 1.45 -0.369 0 C-N-CA 120.716 -0.754 . . . . 0.0 112.541 179.986 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 54' ' ' TYR . . . . . . . . . . . . . 20.2 m-85 -118.74 124.64 47.78 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-O 120.872 0.368 . . . . 0.0 110.897 179.982 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 55' ' ' TRP . . . . . . . . . . . . . 36.4 m95 -118.19 162.89 17.49 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.911 179.988 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 56' ' ' TYR . . . . . 0.692 ' HE1' ' HB2' ' A' ' 89' ' ' ALA . 8.4 m-85 -110.69 125.37 53.4 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.934 -179.91 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 57' ' ' GLY . . . . . 0.431 ' HA3' ' CE1' ' A' ' 77' ' ' PHE . . . -88.01 53.28 4.21 Favored Glycine 0 N--CA 1.451 -0.365 0 C-N-CA 120.72 -0.752 . . . . 0.0 112.423 179.97 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 58' ' ' ILE . . . . . 0.486 HG12 HG21 ' A' ' 32' ' ' VAL . 3.8 mt -64.64 142.33 17.03 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.266 0 CA-C-O 120.834 0.349 . . . . 0.0 111.164 -179.981 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 2.4 tm-20 -115.12 108.11 16.2 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.118 -0.492 . . . . 0.0 110.836 -179.947 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 60' ' ' LEU . . . . . . . . . . . . . 48.0 mt -67.75 176.28 2.57 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.906 -179.964 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -100.86 -32.87 10.46 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.852 -179.995 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 62' ' ' GLN . . . . . . . . . . . . . 0.2 OUTLIER -101.37 154.69 37.07 Favored Pre-proline 0 C--N 1.328 -0.332 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.917 179.976 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 58.3 Cg_endo -71.85 68.13 3.09 Favored 'Trans proline' 0 C--N 1.344 0.308 0 C-N-CA 122.584 2.189 . . . . 0.0 112.275 -179.965 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 64' ' ' THR . . . . . . . . . . . . . 73.4 p -139.54 34.25 2.04 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.901 -179.994 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . -88.33 -129.11 3.15 Favored Glycine 0 N--CA 1.452 -0.295 0 C-N-CA 120.732 -0.747 . . . . 0.0 112.579 179.948 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 66' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -144.96 -47.33 0.23 Allowed 'General case' 0 C--N 1.328 -0.353 0 CA-C-O 120.785 0.326 . . . . 0.0 110.845 -179.991 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 67' ' ' HIS . . . . . . . . . . . . . 7.6 p80 -119.94 170.02 9.64 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.213 -0.448 . . . . 0.0 110.839 179.973 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 39.0 m-20 -98.42 34.04 2.09 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.862 -179.983 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 94.62 -42.72 2.39 Favored Glycine 0 N--CA 1.451 -0.329 0 C-N-CA 120.737 -0.744 . . . . 0.0 112.586 -179.939 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 70' ' ' SER . . . . . . . . . . . . . 5.6 p -100.8 134.67 43.42 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-O 120.833 0.349 . . . . 0.0 110.946 -179.984 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 71' ' ' VAL . . . . . 0.409 HG12 ' CD2' ' A' ' 72' ' ' PHE . 21.3 t -114.92 102.95 14.57 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.156 -0.474 . . . . 0.0 111.062 -179.913 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 72' ' ' PHE . . . . . 0.409 ' CD2' HG12 ' A' ' 71' ' ' VAL . 33.2 m-85 61.75 30.8 18.52 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.191 -0.458 . . . . 0.0 110.935 179.929 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 104.21 -30.09 10.81 Favored Glycine 0 N--CA 1.451 -0.362 0 C-N-CA 120.703 -0.76 . . . . 0.0 112.513 179.973 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 21.4 t -77.82 116.87 22.04 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.345 0 CA-C-O 120.749 0.309 . . . . 0.0 111.173 179.978 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 75' ' ' ARG . . . . . . . . . . . . . 10.1 ttm180 -96.62 143.24 27.77 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.272 -0.422 . . . . 0.0 110.898 -179.956 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 76' ' ' TYR . . . . . 0.654 ' CE2' HG22 ' A' ' 48' ' ' THR . 20.0 m-85 -118.69 -40.48 2.88 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.933 179.926 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 77' ' ' PHE . . . . . 0.431 ' CE1' ' HA3' ' A' ' 57' ' ' GLY . 16.0 p90 -160.07 157.55 28.79 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.956 179.972 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 18.8 m -83.9 111.51 19.3 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.836 -179.974 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 79' ' ' CYS . . . . . . . . . . . . . 30.5 p -132.74 174.24 10.52 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.901 179.941 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 80' ' ' ALA . . . . . 0.624 ' HB1' ' HD2' ' A' ' 81' ' ' PRO . . . -91.91 171.58 7.61 Favored Pre-proline 0 C--N 1.33 -0.281 0 CA-C-N 116.161 -0.472 . . . . 0.0 111.151 179.997 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 81' ' ' PRO . . . . . 0.624 ' HD2' ' HB1' ' A' ' 80' ' ' ALA . 50.7 Cg_exo -53.77 116.14 2.81 Favored 'Trans proline' 0 C--N 1.344 0.301 0 C-N-CA 122.592 2.194 . . . . 0.0 112.322 179.988 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 82' ' ' ARG . . . . . . . . . . . . . 3.4 mtp85 61.1 52.31 4.06 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.896 179.901 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 83' ' ' HIS . . . . . 0.505 ' CG ' ' HB3' ' A' ' 80' ' ' ALA . 6.0 m170 -120.99 -43.02 2.47 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.793 179.936 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . -75.2 144.4 31.97 Favored Glycine 0 N--CA 1.45 -0.383 0 C-N-CA 120.817 -0.706 . . . . 0.0 112.495 179.938 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 85' ' ' VAL . . . . . . . . . . . . . 6.6 m -147.77 127.39 4.44 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-O 120.806 0.336 . . . . 0.0 111.231 179.978 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 86' ' ' PHE . . . . . . . . . . . . . 6.1 m-85 -106.71 110.74 23.01 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.886 179.975 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 87' ' ' ALA . . . . . 0.606 ' O ' HD11 ' A' ' 92' ' ' ILE . . . -132.27 150.96 77.45 Favored Pre-proline 0 C--N 1.33 -0.268 0 CA-C-N 116.189 -0.459 . . . . 0.0 111.106 -179.957 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 88' ' ' PRO . . . . . 0.405 ' O ' ' N ' ' A' ' 91' ' ' ARG . 32.1 Cg_exo -58.4 138.09 83.94 Favored 'Trans proline' 0 C--N 1.344 0.338 0 C-N-CA 122.518 2.146 . . . . 0.0 112.285 -179.972 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 89' ' ' ALA . . . . . 0.692 ' HB2' ' HE1' ' A' ' 56' ' ' TYR . . . -48.05 -51.29 24.85 Favored 'General case' 0 CA--C 1.522 -0.124 0 CA-C-N 116.106 -0.497 . . . . 0.0 110.331 179.845 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 90' ' ' SER . . . . . . . . . . . . . 70.3 p -55.96 -24.41 38.14 Favored 'General case' 0 N--CA 1.453 -0.296 0 CA-C-N 115.714 -0.675 . . . . 0.0 109.769 178.809 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 91' ' ' ARG . . . . . 0.405 ' N ' ' O ' ' A' ' 88' ' ' PRO . 1.3 mtt180 -88.43 -14.6 37.57 Favored 'General case' 0 N--CA 1.453 -0.282 0 CA-C-N 115.852 -0.613 . . . . 0.0 110.535 178.992 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 92' ' ' ILE . . . . . 0.606 HD11 ' O ' ' A' ' 87' ' ' ALA . 26.0 mt -107.02 146.01 13.85 Favored 'Isoleucine or valine' 0 C--O 1.23 0.076 0 CA-C-N 116.302 -0.408 . . . . 0.0 111.014 179.935 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 93' ' ' GLN . . . . . . . . . . . . . 2.1 mt-30 -115.53 177.2 4.75 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.904 179.973 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 94' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER -115.81 148.23 40.12 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.923 179.971 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 95' ' ' ILE . . . . . 0.482 HD11 ' HB2' ' A' ' 33' ' ' LEU . 28.8 mm -96.51 -53.95 7.58 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.358 0 CA-C-N 116.259 -0.428 . . . . 0.0 111.082 -179.935 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . -123.74 156.31 17.94 Favored Glycine 0 N--CA 1.45 -0.368 0 C-N-CA 120.775 -0.726 . . . . 0.0 112.479 -179.961 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 97' ' ' SER . . . . . . . . . . . . . 33.6 t -170.2 -173.97 1.62 Allowed 'General case' 0 C--N 1.329 -0.301 0 CA-C-O 120.852 0.358 . . . . 0.0 110.884 -179.988 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 98' ' ' GLY . . . . . . . . . . . . . . . -127.88 70.28 0.51 Allowed Glycine 0 N--CA 1.451 -0.313 0 C-N-CA 120.814 -0.708 . . . . 0.0 112.487 -179.954 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 99' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_exo -52.23 -30.47 42.1 Favored 'Trans proline' 0 C--N 1.344 0.308 0 C-N-CA 122.588 2.192 . . . . 0.0 112.359 -179.99 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 100' ' ' SER . . . . . . . . . . . . . 12.7 p 58.57 175.45 0.07 Allowed 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.108 -0.496 . . . . 0.0 110.978 179.98 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 46.0 p -168.48 35.31 0.03 OUTLIER 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.857 -179.991 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.249 1.093 0 CA-C-O 118.393 -1.226 . . . . 0.0 112.54 -179.997 . . . . . . . . 0 0 . 1 . 003 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.28 0 N-CA-C 112.482 -0.247 . . . . 0.0 112.482 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 21.8 t -158.64 167.08 30.51 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-O 120.783 0.325 . . . . 0.0 110.924 -179.952 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 32.8 t -119.76 -42.34 2.63 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.813 -179.97 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 150.02 -162.4 29.17 Favored Glycine 0 N--CA 1.451 -0.363 0 C-N-CA 120.752 -0.737 . . . . 0.0 112.471 -179.963 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 1.4 m -110.24 -42.6 4.11 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-O 120.773 0.321 . . . . 0.0 110.856 179.963 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 2.0 m -144.34 -179.32 6.46 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.797 179.978 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -169.79 -123.81 0.7 Allowed Glycine 0 N--CA 1.45 -0.368 0 C-N-CA 120.707 -0.759 . . . . 0.0 112.527 -179.999 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 12.5 tttm -91.14 130.35 37.04 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-O 120.76 0.314 . . . . 0.0 110.837 -179.958 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER 59.79 84.83 0.19 Allowed Pre-proline 0 C--N 1.329 -0.301 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.956 179.991 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 51.9 Cg_exo -52.79 151.76 18.98 Favored 'Trans proline' 0 C--N 1.345 0.35 0 C-N-CA 122.595 2.197 . . . . 0.0 112.295 -179.996 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 20.3 m -141.39 -60.54 0.48 Allowed 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.178 -0.464 . . . . 0.0 110.906 179.973 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 24.3 t -165.98 63.33 0.84 Allowed Pre-proline 0 C--N 1.329 -0.294 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.922 179.951 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 52.3 Cg_exo -52.72 -49.09 18.71 Favored 'Trans proline' 0 C--N 1.345 0.36 0 C-N-CA 122.641 2.227 . . . . 0.0 112.298 -179.959 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 1.3 m -109.87 152.94 25.14 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.147 -0.478 . . . . 0.0 110.892 -179.947 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 0.6 OUTLIER -151.67 73.98 1.1 Allowed 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.872 179.986 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 67.08 -115.35 7.11 Favored Glycine 0 N--CA 1.452 -0.291 0 C-N-CA 120.713 -0.756 . . . . 0.0 112.463 -179.971 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -177.02 37.8 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 120.856 0.36 . . . . 0.0 110.923 -179.953 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -131.16 -67.82 0.69 Allowed 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.189 -0.459 . . . . 0.0 110.938 179.944 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 19' ' ' GLN . . . . . . . . . . . . . 3.4 mp0 60.43 -178.24 0.1 Allowed 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.908 -179.976 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 20' ' ' GLN . . . . . . . . . . . . . 0.4 OUTLIER -148.8 117.55 6.64 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.916 179.961 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -127.56 159.63 34.02 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.838 -179.957 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 4.3 mm-40 60.17 35.53 21.08 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.884 179.989 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 78.46 -123.89 6.45 Favored Glycine 0 N--CA 1.451 -0.327 0 C-N-CA 120.715 -0.755 . . . . 0.0 112.502 -179.963 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . 59.77 79.8 0.22 Allowed 'General case' 0 C--N 1.329 -0.325 0 CA-C-O 120.731 0.301 . . . . 0.0 111.105 179.949 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -86.86 -39.86 15.44 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.823 -179.986 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -118.41 168.16 10.9 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.176 -0.465 . . . . 0.0 111.143 179.909 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 27' ' ' GLU . . . . . . . . . . . . . 3.0 mt-10 -115.25 -173.28 2.29 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.899 179.967 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 21.4 t -80.18 98.31 3.36 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.312 -0.404 . . . . 0.0 111.05 179.978 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 111.78 29.72 3.25 Favored Glycine 0 N--CA 1.451 -0.312 0 C-N-CA 120.807 -0.711 . . . . 0.0 112.417 179.912 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 1.2 t70 -122.81 146.03 47.91 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 120.832 0.348 . . . . 0.0 110.894 179.981 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 31' ' ' GLN . . . . . . . . . . . . . 18.1 mt-30 -60.76 131.46 50.75 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.821 179.953 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 14.5 m -140.3 171.81 12.8 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.156 -0.475 . . . . 0.0 111.137 179.978 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 33' ' ' LEU . . . . . . . . . . . . . 17.8 tp -134.21 110.54 9.61 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.903 -179.963 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 34' ' ' VAL . . . . . 0.414 HG22 ' CD1' ' A' ' 58' ' ' ILE . 21.6 t -77.95 120.43 28.68 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 116.221 -0.445 . . . . 0.0 111.09 -179.937 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 35' ' ' ALA . . . . . . . . . . . . . . . 58.25 27.05 14.65 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.163 -0.471 . . . . 0.0 111.192 179.981 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . 56.77 31.33 60.73 Favored Glycine 0 N--CA 1.452 -0.282 0 C-N-CA 120.709 -0.758 . . . . 0.0 112.606 179.931 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 37' ' ' GLN . . . . . . . . . . . . . 91.5 mt-30 -140.28 -73.27 0.36 Allowed 'General case' 0 C--N 1.33 -0.272 0 CA-C-O 120.833 0.349 . . . . 0.0 110.962 -179.992 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 38' ' ' LYS . . . . . 0.466 ' HB3' HD21 ' A' ' 60' ' ' LEU . 34.1 mttp -68.22 104.27 1.78 Allowed 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.855 179.977 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 39' ' ' GLN . . . . . . . . . . . . . 0.4 OUTLIER -85.34 136.07 33.63 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.252 -0.431 . . . . 0.0 110.839 179.905 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -164.56 -163.7 18.21 Favored Glycine 0 N--CA 1.451 -0.356 0 C-N-CA 120.771 -0.728 . . . . 0.0 112.539 179.965 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 32.4 mt -131.12 139.51 50.84 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-O 120.79 0.328 . . . . 0.0 111.156 179.994 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 42' ' ' VAL . . . . . . . . . . . . . 23.2 t -69.18 124.36 24.8 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.334 0 CA-C-N 116.187 -0.46 . . . . 0.0 111.059 -179.952 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 43' ' ' ARG . . . . . . . . . . . . . 27.8 mmt180 -105.58 -32.57 8.42 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.178 -0.464 . . . . 0.0 110.984 -179.956 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 44' ' ' PHE . . . . . . . . . . . . . 51.0 t80 -143.08 118.11 10.05 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 116.189 -0.459 . . . . 0.0 110.962 -179.93 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 45' ' ' TYR . . . . . 0.494 ' CE1' ' CZ ' ' A' ' 56' ' ' TYR . 15.5 t80 -113.02 117.94 33.41 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.867 179.965 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 172.74 170.25 36.26 Favored Glycine 0 N--CA 1.452 -0.26 0 C-N-CA 120.657 -0.782 . . . . 0.0 112.487 179.979 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 47' ' ' LYS . . . . . 0.421 ' HG3' ' CE1' ' A' ' 54' ' ' TYR . 19.5 mttt -67.09 148.08 52.33 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 120.837 0.351 . . . . 0.0 110.942 179.983 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 48' ' ' THR . . . . . 0.608 HG21 ' CZ ' ' A' ' 50' ' ' PHE . 16.6 p -109.15 170.85 7.79 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.893 179.988 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 8.3 t0 -98.3 -31.12 12.21 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.869 179.989 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 50' ' ' PHE . . . . . 0.608 ' CZ ' HG21 ' A' ' 48' ' ' THR . 18.1 p90 -66.54 -32.23 73.45 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.935 -179.962 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 51' ' ' ALA . . . . . 0.435 ' N ' ' CD1' ' A' ' 50' ' ' PHE . . . -148.94 151.72 35.34 Favored Pre-proline 0 C--N 1.329 -0.299 0 CA-C-N 116.271 -0.422 . . . . 0.0 111.096 179.996 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 52' ' ' PRO . . . . . . . . . . . . . 56.8 Cg_endo -70.67 -167.94 0.29 Allowed 'Trans proline' 0 C--N 1.344 0.31 0 C-N-CA 122.598 2.198 . . . . 0.0 112.289 179.997 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 65.2 -176.39 12.82 Favored Glycine 0 N--CA 1.45 -0.38 0 C-N-CA 120.791 -0.719 . . . . 0.0 112.481 179.971 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 54' ' ' TYR . . . . . 0.421 ' CE1' ' HG3' ' A' ' 47' ' ' LYS . 7.6 m-85 -106.57 128.97 54.55 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-O 120.828 0.347 . . . . 0.0 110.928 179.974 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 55' ' ' TRP . . . . . . . . . . . . . 35.0 m95 -116.2 174.29 6.13 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.846 -179.969 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 56' ' ' TYR . . . . . 0.73 ' HE1' ' HB2' ' A' ' 89' ' ' ALA . 16.8 m-85 -125.35 121.64 34.51 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.92 -179.963 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 57' ' ' GLY . . . . . 0.403 ' N ' ' CE1' ' A' ' 86' ' ' PHE . . . -82.11 62.03 4.61 Favored Glycine 0 N--CA 1.451 -0.33 0 C-N-CA 120.776 -0.726 . . . . 0.0 112.417 179.928 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 58' ' ' ILE . . . . . 0.541 HD11 HD13 ' A' ' 92' ' ' ILE . 21.2 mt -68.67 139.71 20.14 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-O 120.809 0.338 . . . . 0.0 111.122 -179.993 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 4.7 tm-20 -111.99 112.52 24.22 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.91 179.959 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 60' ' ' LEU . . . . . 0.466 HD21 ' HB3' ' A' ' 38' ' ' LYS . 84.7 mt -72.53 177.34 4.73 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.967 -179.992 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -100.42 -32.37 10.85 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.815 179.998 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 62' ' ' GLN . . . . . . . . . . . . . 4.7 mm100 -106.62 155.33 39.08 Favored Pre-proline 0 C--N 1.328 -0.34 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.829 179.999 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 57.7 Cg_endo -71.51 68.11 2.82 Favored 'Trans proline' 0 C--N 1.345 0.354 0 C-N-CA 122.544 2.163 . . . . 0.0 112.399 179.907 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 64' ' ' THR . . . . . . . . . . . . . 12.4 p -136.0 31.18 3.0 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.871 -179.999 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . -92.95 -139.75 9.46 Favored Glycine 0 N--CA 1.451 -0.349 0 C-N-CA 120.754 -0.736 . . . . 0.0 112.548 -179.956 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 66' ' ' LYS . . . . . 0.451 ' HD2' HG12 ' A' ' 85' ' ' VAL . 0.0 OUTLIER -128.63 -45.75 1.31 Allowed 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 120.848 0.356 . . . . 0.0 110.924 179.961 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 67' ' ' HIS . . . . . . . . . . . . . 7.2 p80 -127.1 169.89 12.93 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.233 -0.44 . . . . 0.0 110.871 179.974 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 10.3 p-10 -98.56 36.51 1.63 Allowed 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.935 179.964 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 105.88 -50.37 0.82 Allowed Glycine 0 N--CA 1.45 -0.391 0 C-N-CA 120.756 -0.735 . . . . 0.0 112.502 179.964 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 70' ' ' SER . . . . . . . . . . . . . 80.5 p -93.26 151.84 19.56 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 120.836 0.35 . . . . 0.0 110.832 -179.945 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 71' ' ' VAL . . . . . 0.622 HG12 ' CD2' ' A' ' 72' ' ' PHE . 20.0 t -141.35 110.47 2.77 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 CA-C-N 116.226 -0.443 . . . . 0.0 111.069 -180.0 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 72' ' ' PHE . . . . . 0.622 ' CD2' HG12 ' A' ' 71' ' ' VAL . 67.6 m-85 60.17 31.17 20.43 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.903 -179.968 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 87.07 28.37 25.83 Favored Glycine 0 N--CA 1.451 -0.312 0 C-N-CA 120.747 -0.739 . . . . 0.0 112.498 179.98 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 21.4 t -128.35 104.27 11.38 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-O 120.901 0.381 . . . . 0.0 111.085 -179.988 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 75' ' ' ARG . . . . . . . . . . . . . 11.3 ttt180 -84.0 134.2 34.65 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.861 -179.934 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 76' ' ' TYR . . . . . 0.594 ' CE2' HG22 ' A' ' 48' ' ' THR . 56.5 m-85 -118.2 -41.51 2.86 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.883 179.973 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 77' ' ' PHE . . . . . . . . . . . . . 12.8 p90 -158.98 163.31 36.58 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.145 -0.48 . . . . 0.0 110.87 179.987 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 1.2 p -89.6 109.1 20.08 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.926 179.97 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 79' ' ' CYS . . . . . . . . . . . . . 28.6 p -138.41 166.19 24.88 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.921 -179.988 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 80' ' ' ALA . . . . . 0.7 ' HB3' ' CE1' ' A' ' 83' ' ' HIS . . . -77.51 168.93 23.75 Favored Pre-proline 0 C--N 1.329 -0.316 0 CA-C-N 116.227 -0.442 . . . . 0.0 111.07 -179.97 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 81' ' ' PRO . . . . . 0.531 ' HD2' ' HB1' ' A' ' 80' ' ' ALA . 32.5 Cg_exo -58.11 122.93 12.55 Favored 'Trans proline' 0 C--N 1.344 0.308 0 C-N-CA 122.582 2.188 . . . . 0.0 112.29 -179.929 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 82' ' ' ARG . . . . . . . . . . . . . 14.8 mtt-85 64.17 46.54 3.59 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.155 -0.475 . . . . 0.0 111.123 179.908 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 83' ' ' HIS . . . . . 0.7 ' CE1' ' HB3' ' A' ' 80' ' ' ALA . 9.4 m170 -119.29 -45.18 2.55 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.796 179.892 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . -75.49 138.96 23.99 Favored Glycine 0 N--CA 1.452 -0.295 0 C-N-CA 120.742 -0.742 . . . . 0.0 112.47 179.955 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 85' ' ' VAL . . . . . 0.451 HG12 ' HD2' ' A' ' 66' ' ' LYS . 18.0 m -141.72 119.72 8.78 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.361 0 CA-C-O 120.818 0.342 . . . . 0.0 111.108 -179.91 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 86' ' ' PHE . . . . . 0.403 ' CE1' ' N ' ' A' ' 57' ' ' GLY . 9.3 m-85 -97.69 110.57 23.11 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.872 179.928 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 87' ' ' ALA . . . . . 0.554 ' O ' HD11 ' A' ' 92' ' ' ILE . . . -128.78 151.19 76.81 Favored Pre-proline 0 C--N 1.33 -0.273 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.163 -179.989 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 88' ' ' PRO . . . . . . . . . . . . . 31.8 Cg_exo -58.72 136.24 72.53 Favored 'Trans proline' 0 C--N 1.345 0.36 0 C-N-CA 122.619 2.213 . . . . 0.0 112.252 -179.925 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 89' ' ' ALA . . . . . 0.73 ' HB2' ' HE1' ' A' ' 56' ' ' TYR . . . -48.05 -51.25 25.02 Favored 'General case' 0 C--N 1.333 -0.124 0 CA-C-N 116.154 -0.476 . . . . 0.0 110.277 179.91 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 90' ' ' SER . . . . . . . . . . . . . 5.5 m -55.94 -24.36 37.54 Favored 'General case' 0 N--CA 1.454 -0.249 0 CA-C-N 115.724 -0.671 . . . . 0.0 109.757 178.81 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 91' ' ' ARG . . . . . . . . . . . . . 0.6 OUTLIER -89.11 -14.09 37.04 Favored 'General case' 0 N--CA 1.455 -0.21 0 CA-C-N 115.818 -0.628 . . . . 0.0 110.487 179.064 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 92' ' ' ILE . . . . . 0.554 HD11 ' O ' ' A' ' 87' ' ' ALA . 28.1 mt -108.26 146.25 14.35 Favored 'Isoleucine or valine' 0 C--O 1.231 0.091 0 CA-C-N 116.391 -0.368 . . . . 0.0 111.034 179.834 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 93' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -106.19 164.49 11.96 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.218 -0.447 . . . . 0.0 110.817 -179.993 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 94' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -116.35 119.27 35.14 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.887 -179.995 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 95' ' ' ILE . . . . . . . . . . . . . 22.2 mt -91.89 -61.88 1.86 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.18 -0.464 . . . . 0.0 111.197 179.96 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . 68.48 -72.36 0.34 Allowed Glycine 0 N--CA 1.451 -0.301 0 C-N-CA 120.738 -0.744 . . . . 0.0 112.413 179.89 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 97' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -155.06 -69.6 0.12 Allowed 'General case' 0 C--N 1.328 -0.34 0 CA-C-O 120.795 0.331 . . . . 0.0 110.864 -179.954 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 98' ' ' GLY . . . . . . . . . . . . . . . 99.72 -97.2 1.75 Allowed Glycine 0 N--CA 1.451 -0.304 0 C-N-CA 120.752 -0.737 . . . . 0.0 112.507 179.976 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 99' ' ' PRO . . . . . . . . . . . . . 50.0 Cg_exo -53.68 138.43 67.53 Favored 'Trans proline' 0 C--N 1.345 0.378 0 C-N-CA 122.507 2.138 . . . . 0.0 112.301 -179.986 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 100' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -81.12 152.27 27.88 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.874 -179.96 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -137.37 31.86 2.59 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.837 -179.96 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.249 1.058 0 CA-C-O 118.334 -1.259 . . . . 0.0 112.526 -179.997 . . . . . . . . 0 0 . 1 . 004 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.488 2.126 0 N-CA-C 112.518 -0.233 . . . . 0.0 112.518 . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 1.3 m -149.62 -179.95 7.51 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-O 120.858 0.361 . . . . 0.0 110.827 -179.902 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -145.49 -47.45 0.22 Allowed 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.794 -179.995 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 170.54 -168.42 41.47 Favored Glycine 0 N--CA 1.451 -0.308 0 C-N-CA 120.794 -0.717 . . . . 0.0 112.501 -179.991 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 50.5 m -106.62 35.8 2.85 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-O 120.853 0.359 . . . . 0.0 110.877 179.982 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 12.3 t -122.2 93.62 4.04 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.903 179.917 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 132.06 -130.85 6.05 Favored Glycine 0 N--CA 1.451 -0.3 0 C-N-CA 120.735 -0.745 . . . . 0.0 112.415 179.939 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 15.5 tttp -60.56 91.88 0.02 OUTLIER 'General case' 0 C--N 1.328 -0.346 0 CA-C-O 120.788 0.328 . . . . 0.0 110.846 -179.877 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 9' ' ' SER . . . . . 0.405 ' N ' ' CD ' ' A' ' 10' ' ' PRO . 0.4 OUTLIER -85.63 -52.92 0.46 Allowed Pre-proline 0 C--N 1.329 -0.294 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.965 179.984 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 10' ' ' PRO . . . . . 0.405 ' CD ' ' N ' ' A' ' 9' ' ' SER . 75.5 Cg_exo -50.59 147.34 17.74 Favored 'Trans proline' 0 C--N 1.345 0.36 0 C-N-CA 122.615 2.21 . . . . 0.0 112.344 -179.963 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 17.2 p 57.84 105.76 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.98 179.972 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 45.6 t -160.6 145.58 10.85 Favored Pre-proline 0 C--N 1.329 -0.31 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.874 179.898 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 52.5 Cg_exo -54.55 -169.39 0.02 OUTLIER 'Trans proline' 0 C--N 1.346 0.43 0 C-N-CA 122.531 2.154 . . . . 0.0 112.384 179.985 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 1.2 m -150.6 -46.95 0.12 Allowed 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.868 -179.995 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -165.09 32.06 0.06 Allowed 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.871 179.979 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 109.03 41.22 1.44 Allowed Glycine 0 N--CA 1.452 -0.278 0 C-N-CA 120.686 -0.769 . . . . 0.0 112.447 -179.924 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 16.4 m -68.26 113.62 6.03 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-O 120.774 0.321 . . . . 0.0 110.907 -179.954 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 5.1 tt -151.32 -48.66 0.12 Allowed 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.282 -0.417 . . . . 0.0 110.846 179.872 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 19' ' ' GLN . . . . . . . . . . . . . 24.7 mp0 -66.39 111.9 3.77 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.926 179.925 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 20' ' ' GLN . . . . . . . . . . . . . 28.5 mt-30 -59.84 -63.86 1.15 Allowed 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.178 -0.464 . . . . 0.0 110.884 -179.929 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 2.4 mmm180 60.16 33.64 21.12 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.902 179.923 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 3.5 tt0 -167.22 -44.42 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.886 179.907 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 84.13 90.56 0.76 Allowed Glycine 0 N--CA 1.45 -0.418 0 C-N-CA 120.742 -0.742 . . . . 0.0 112.507 179.934 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -156.13 167.29 30.89 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.798 0.332 . . . . 0.0 111.021 179.985 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 5.4 mmtt -142.94 -48.55 0.33 Allowed 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.941 179.916 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -121.77 168.12 12.19 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.122 179.946 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 27' ' ' GLU . . . . . . . . . . . . . 1.1 pm0 -116.75 158.39 23.94 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.888 -179.988 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 36.7 t -67.85 82.69 0.11 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.035 179.911 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 136.24 43.95 0.1 OUTLIER Glycine 0 N--CA 1.451 -0.366 0 C-N-CA 120.745 -0.74 . . . . 0.0 112.537 -179.981 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -149.18 167.69 25.28 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-O 120.838 0.352 . . . . 0.0 110.893 -179.984 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 31' ' ' GLN . . . . . 0.438 ' HA ' HD13 ' A' ' 41' ' ' ILE . 0.0 OUTLIER -78.12 130.73 36.73 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.942 -179.962 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 32' ' ' VAL . . . . . 0.456 ' CG2' HD13 ' A' ' 58' ' ' ILE . 4.7 m -132.76 172.48 16.37 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.326 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.112 179.944 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 33' ' ' LEU . . . . . 0.611 ' HB2' HD11 ' A' ' 95' ' ' ILE . 16.7 tp -143.52 112.36 6.58 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.196 -0.457 . . . . 0.0 110.856 -179.942 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 34' ' ' VAL . . . . . 0.506 HG13 ' CB ' ' A' ' 87' ' ' ALA . 21.5 t -81.09 124.25 38.57 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.245 -0.434 . . . . 0.0 111.11 -179.849 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 35' ' ' ALA . . . . . . . . . . . . . . . 57.94 26.65 13.65 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.067 -0.515 . . . . 0.0 111.294 179.99 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 36' ' ' GLY . . . . . 0.541 ' HA2' HD23 ' A' ' 33' ' ' LEU . . . 57.05 33.45 64.25 Favored Glycine 0 N--CA 1.452 -0.29 0 C-N-CA 120.759 -0.734 . . . . 0.0 112.562 179.959 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 37' ' ' GLN . . . . . . . . . . . . . 37.7 mt-30 -144.36 -70.44 0.29 Allowed 'General case' 0 C--N 1.328 -0.35 0 CA-C-O 120.87 0.367 . . . . 0.0 111.075 -179.867 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 38' ' ' LYS . . . . . . . . . . . . . 2.8 mmpt? -68.08 114.61 6.74 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.925 -179.871 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 39' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -93.88 128.64 40.27 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.9 179.985 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -152.82 -172.88 21.64 Favored Glycine 0 N--CA 1.451 -0.335 0 C-N-CA 120.759 -0.734 . . . . 0.0 112.534 179.973 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 41' ' ' ILE . . . . . 0.442 ' N ' HG23 ' A' ' 58' ' ' ILE . 25.4 mm -125.33 138.07 55.57 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.269 0 CA-C-O 120.818 0.342 . . . . 0.0 111.136 -179.932 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 42' ' ' VAL . . . . . . . . . . . . . 21.5 t -69.32 122.33 20.56 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.185 -0.461 . . . . 0.0 111.082 -179.99 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 43' ' ' ARG . . . . . . . . . . . . . 8.0 mmt180 -113.55 -35.88 5.1 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.926 -179.998 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 44' ' ' PHE . . . . . . . . . . . . . 64.6 t80 -139.05 111.45 7.53 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.941 -179.983 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 45' ' ' TYR . . . . . 0.485 ' CE1' ' CE1' ' A' ' 56' ' ' TYR . 13.3 t80 -107.28 136.88 46.36 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.857 179.879 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 153.51 -163.08 30.6 Favored Glycine 0 N--CA 1.451 -0.352 0 C-N-CA 120.746 -0.74 . . . . 0.0 112.479 179.988 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 47' ' ' LYS . . . . . . . . . . . . . 21.1 mttp -88.64 167.69 13.16 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-O 120.799 0.333 . . . . 0.0 110.875 -179.944 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 48' ' ' THR . . . . . 0.672 HG21 ' CZ ' ' A' ' 50' ' ' PHE . 29.1 p -129.48 -173.88 3.13 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.846 179.965 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -110.37 -31.58 7.24 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.855 -179.97 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 50' ' ' PHE . . . . . 0.672 ' CZ ' HG21 ' A' ' 48' ' ' THR . 18.3 p90 -67.84 -36.09 79.74 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.259 -0.428 . . . . 0.0 110.992 -179.924 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 51' ' ' ALA . . . . . 0.427 ' N ' ' CD1' ' A' ' 50' ' ' PHE . . . -148.4 146.04 21.81 Favored Pre-proline 0 C--N 1.329 -0.283 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.175 179.979 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 52' ' ' PRO . . . . . . . . . . . . . 69.2 Cg_endo -74.39 173.77 13.67 Favored 'Trans proline' 0 C--N 1.345 0.391 0 C-N-CA 122.573 2.182 . . . . 0.0 112.315 -179.985 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 92.43 172.62 41.47 Favored Glycine 0 N--CA 1.452 -0.289 0 C-N-CA 120.762 -0.733 . . . . 0.0 112.48 179.905 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 54' ' ' TYR . . . . . . . . . . . . . 10.5 m-85 -90.14 110.31 21.33 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-O 120.814 0.34 . . . . 0.0 110.868 -179.993 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 55' ' ' TRP . . . . . 0.426 ' HB3' ' CD1' ' A' ' 86' ' ' PHE . 66.7 m95 -105.17 159.25 16.01 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.906 179.967 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 56' ' ' TYR . . . . . 0.607 ' CE1' ' HB2' ' A' ' 89' ' ' ALA . 12.6 m-85 -114.9 117.34 30.4 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.98 -179.824 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . -79.75 68.06 3.28 Favored Glycine 0 N--CA 1.451 -0.34 0 C-N-CA 120.684 -0.77 . . . . 0.0 112.341 179.934 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 58' ' ' ILE . . . . . 0.595 HD11 HD13 ' A' ' 92' ' ' ILE . 38.0 mt -73.3 137.89 22.44 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.39 0 CA-C-O 120.829 0.347 . . . . 0.0 111.192 -179.911 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 1.3 tm-20 -104.29 107.12 17.88 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.79 179.926 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 60' ' ' LEU . . . . . 0.568 HD11 HG11 ' A' ' 85' ' ' VAL . 36.6 mt -60.11 170.43 1.25 Allowed 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.971 -179.935 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 2.9 m-20 -100.45 -31.6 11.21 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.882 -179.991 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 62' ' ' GLN . . . . . 0.667 ' O ' HG22 ' A' ' 64' ' ' THR . 0.0 OUTLIER -120.24 147.31 44.63 Favored Pre-proline 0 C--N 1.331 -0.23 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.839 -179.93 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 50.6 Cg_exo -53.07 90.5 0.03 OUTLIER 'Trans proline' 0 C--N 1.345 0.389 0 C-N-CA 122.479 2.119 . . . . 0.0 112.405 179.949 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 64' ' ' THR . . . . . 0.667 HG22 ' O ' ' A' ' 62' ' ' GLN . 4.9 t -164.7 39.4 0.07 Allowed 'General case' 0 C--N 1.327 -0.384 0 CA-C-N 116.296 -0.411 . . . . 0.0 110.911 179.989 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . -100.66 -149.07 22.99 Favored Glycine 0 N--CA 1.451 -0.325 0 C-N-CA 120.741 -0.742 . . . . 0.0 112.515 179.946 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 66' ' ' LYS . . . . . . . . . . . . . 0.6 OUTLIER -121.47 -42.65 2.43 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-O 120.825 0.345 . . . . 0.0 110.918 -179.948 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 67' ' ' HIS . . . . . . . . . . . . . 6.8 p80 -128.53 172.15 11.44 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.917 179.964 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 4.9 m-20 -98.36 33.67 2.17 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.922 -179.971 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 99.47 -41.89 2.1 Favored Glycine 0 N--CA 1.451 -0.316 0 C-N-CA 120.636 -0.792 . . . . 0.0 112.491 179.995 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 70' ' ' SER . . . . . . . . . . . . . 77.3 p -104.82 148.62 26.44 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 120.835 0.35 . . . . 0.0 110.918 -179.974 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 21.5 t -135.45 122.59 35.31 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.146 -0.479 . . . . 0.0 111.105 179.958 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 72' ' ' PHE . . . . . . . . . . . . . 33.5 m-85 60.28 33.85 20.89 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.924 -179.992 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 80.4 27.92 50.09 Favored Glycine 0 N--CA 1.452 -0.25 0 C-N-CA 120.692 -0.766 . . . . 0.0 112.533 -179.97 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 21.4 t -131.61 100.71 4.58 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-O 120.767 0.317 . . . . 0.0 111.078 -179.997 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 75' ' ' ARG . . . . . . . . . . . . . 20.5 ttt85 -77.45 119.75 21.49 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.26 -0.427 . . . . 0.0 110.949 -179.968 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 76' ' ' TYR . . . . . . . . . . . . . 25.4 m-85 -92.28 -48.86 6.46 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.835 -179.995 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 77' ' ' PHE . . . . . . . . . . . . . 16.8 p90 -148.65 161.97 40.65 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.752 179.936 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -88.34 108.5 19.37 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.971 -179.963 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 79' ' ' CYS . . . . . . . . . . . . . 30.4 p -132.93 174.11 10.68 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.867 -179.976 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 80' ' ' ALA . . . . . 0.632 ' HB3' ' ND1' ' A' ' 83' ' ' HIS . . . -81.95 166.73 35.53 Favored Pre-proline 0 C--N 1.329 -0.311 0 CA-C-N 116.198 -0.455 . . . . 0.0 111.056 179.978 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 81' ' ' PRO . . . . . 0.518 ' HD2' ' HB1' ' A' ' 80' ' ' ALA . 51.9 Cg_exo -54.34 117.49 3.99 Favored 'Trans proline' 0 C--N 1.343 0.267 0 C-N-CA 122.57 2.18 . . . . 0.0 112.304 179.994 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 82' ' ' ARG . . . . . . . . . . . . . 3.3 mpt_? 60.99 52.97 3.86 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.116 -0.493 . . . . 0.0 110.96 179.99 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 83' ' ' HIS . . . . . 0.632 ' ND1' ' HB3' ' A' ' 80' ' ' ALA . 7.2 m170 -122.41 -42.15 2.36 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.119 -0.491 . . . . 0.0 110.915 179.989 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . -64.24 144.56 48.75 Favored Glycine 0 N--CA 1.452 -0.261 0 C-N-CA 120.632 -0.794 . . . . 0.0 112.426 179.968 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 85' ' ' VAL . . . . . 0.568 HG11 HD11 ' A' ' 60' ' ' LEU . 15.4 m -152.54 121.32 0.77 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-O 120.833 0.349 . . . . 0.0 111.101 179.997 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 86' ' ' PHE . . . . . 0.426 ' CD1' ' HB3' ' A' ' 55' ' ' TRP . 2.5 m-85 -100.69 118.73 37.4 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.945 179.971 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 87' ' ' ALA . . . . . 0.506 ' CB ' HG13 ' A' ' 34' ' ' VAL . . . -139.91 145.72 43.79 Favored Pre-proline 0 C--N 1.329 -0.316 0 CA-C-N 116.258 -0.428 . . . . 0.0 111.094 179.936 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 88' ' ' PRO . . . . . 0.411 ' O ' ' N ' ' A' ' 91' ' ' ARG . 36.0 Cg_exo -57.27 138.2 85.16 Favored 'Trans proline' 0 C--N 1.346 0.441 0 C-N-CA 122.46 2.107 . . . . 0.0 112.336 -179.952 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 89' ' ' ALA . . . . . 0.607 ' HB2' ' CE1' ' A' ' 56' ' ' TYR . . . -47.63 -51.9 19.84 Favored 'General case' 0 C--N 1.333 -0.115 0 CA-C-O 121.112 0.482 . . . . 0.0 110.367 179.902 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 90' ' ' SER . . . . . . . . . . . . . 5.9 m -55.52 -24.48 32.11 Favored 'General case' 0 N--CA 1.454 -0.246 0 CA-C-N 115.657 -0.701 . . . . 0.0 109.754 178.769 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 91' ' ' ARG . . . . . 0.411 ' N ' ' O ' ' A' ' 88' ' ' PRO . 0.6 OUTLIER -88.41 -16.36 33.1 Favored 'General case' 0 N--CA 1.454 -0.234 0 CA-C-N 115.829 -0.623 . . . . 0.0 110.416 179.066 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 92' ' ' ILE . . . . . 0.595 HD13 HD11 ' A' ' 58' ' ' ILE . 51.6 mt -104.51 145.09 13.57 Favored 'Isoleucine or valine' 0 C--N 1.333 -0.121 0 CA-C-N 116.379 -0.373 . . . . 0.0 111.035 179.869 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 93' ' ' GLN . . . . . . . . . . . . . 1.8 mt-30 -112.83 -179.96 3.8 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.228 -0.442 . . . . 0.0 111.009 -179.949 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 94' ' ' ARG . . . . . . . . . . . . . 0.6 OUTLIER -126.88 138.96 53.39 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.947 -179.895 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 95' ' ' ILE . . . . . 0.611 HD11 ' HB2' ' A' ' 33' ' ' LEU . 3.8 mp -113.2 -57.91 3.74 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.252 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.059 179.967 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . 73.09 167.98 12.51 Favored Glycine 0 N--CA 1.451 -0.303 0 C-N-CA 120.837 -0.697 . . . . 0.0 112.519 179.955 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 97' ' ' SER . . . . . . . . . . . . . 54.7 p -145.61 -64.75 0.32 Allowed 'General case' 0 C--N 1.33 -0.279 0 CA-C-O 120.825 0.345 . . . . 0.0 110.894 179.99 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 98' ' ' GLY . . . . . . . . . . . . . . . 127.72 143.2 5.66 Favored Glycine 0 N--CA 1.452 -0.299 0 C-N-CA 120.838 -0.696 . . . . 0.0 112.463 179.962 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 99' ' ' PRO . . . . . . . . . . . . . 50.1 Cg_exo -53.54 126.22 21.07 Favored 'Trans proline' 0 C--N 1.345 0.376 0 C-N-CA 122.569 2.18 . . . . 0.0 112.358 179.937 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 100' ' ' SER . . . . . . . . . . . . . 89.1 p -149.08 -47.52 0.14 Allowed 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.906 179.959 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER 63.77 90.5 0.08 Allowed 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.132 -0.486 . . . . 0.0 110.946 179.934 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.25 1.103 0 CA-C-O 118.365 -1.242 . . . . 0.0 112.515 179.933 . . . . . . . . 0 0 . 1 . 005 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.248 0 N-CA-C 112.502 -0.239 . . . . 0.0 112.502 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 3.5 m -150.9 166.26 31.12 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-O 120.874 0.369 . . . . 0.0 110.809 -179.952 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 14.1 m -119.43 115.16 23.5 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.125 -0.488 . . . . 0.0 110.964 -179.985 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 77.97 -131.19 10.76 Favored Glycine 0 N--CA 1.451 -0.356 0 C-N-CA 120.754 -0.736 . . . . 0.0 112.564 179.957 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 9.2 t -127.82 137.01 52.23 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-O 120.853 0.358 . . . . 0.0 110.933 -179.922 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 82.7 p -111.51 143.06 42.96 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.879 179.982 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -179.56 -45.08 0.08 OUTLIER Glycine 0 N--CA 1.451 -0.334 0 C-N-CA 120.742 -0.742 . . . . 0.0 112.485 -179.985 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 15.8 ttpt -109.42 -64.34 1.26 Allowed 'General case' 0 C--N 1.329 -0.323 0 CA-C-O 120.867 0.365 . . . . 0.0 110.93 179.955 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 2.8 m -124.66 148.08 57.93 Favored Pre-proline 0 C--N 1.33 -0.262 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.877 179.982 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 58.2 Cg_endo -71.76 -45.17 0.79 Allowed 'Trans proline' 0 C--N 1.344 0.338 0 C-N-CA 122.536 2.157 . . . . 0.0 112.342 179.971 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 1.8 p -78.06 125.26 29.08 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.248 -0.433 . . . . 0.0 110.856 -179.967 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 12' ' ' SER . . . . . 0.427 ' HB3' HD12 ' A' ' 15' ' ' LEU . 1.9 m -128.89 134.44 26.32 Favored Pre-proline 0 C--N 1.33 -0.26 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.859 179.974 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 74.1 Cg_endo -75.48 80.92 2.42 Favored 'Trans proline' 0 C--N 1.345 0.362 0 C-N-CA 122.518 2.145 . . . . 0.0 112.289 -179.958 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER 59.9 109.57 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.989 179.944 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 15' ' ' LEU . . . . . 0.427 HD12 ' HB3' ' A' ' 12' ' ' SER . 1.6 mt -141.14 30.35 1.79 Allowed 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.899 179.994 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 95.34 28.7 9.5 Favored Glycine 0 N--CA 1.451 -0.323 0 C-N-CA 120.701 -0.762 . . . . 0.0 112.539 -179.972 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 5.0 t -79.64 112.73 17.19 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-O 120.872 0.368 . . . . 0.0 110.901 -179.98 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 10.1 tp -119.79 -44.63 2.52 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.857 179.976 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 19' ' ' GLN . . . . . . . . . . . . . 3.2 mp0 -80.13 93.4 5.81 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.924 179.996 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 20' ' ' GLN . . . . . . . . . . . . . 3.4 pt20 -106.07 122.27 45.82 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.843 -179.924 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 2.1 mtt180 -108.9 80.3 1.31 Allowed 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.209 -0.451 . . . . 0.0 110.86 179.924 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 48.0 tt0 -156.92 129.46 7.54 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.931 179.95 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -175.37 141.43 5.71 Favored Glycine 0 N--CA 1.451 -0.319 0 C-N-CA 120.733 -0.746 . . . . 0.0 112.522 -179.965 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -73.13 134.16 44.36 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-O 120.733 0.301 . . . . 0.0 111.077 -179.969 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 8.7 tptp -79.37 -46.13 18.22 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.899 179.969 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -142.0 -179.37 6.18 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.277 -0.419 . . . . 0.0 111.076 179.994 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 27' ' ' GLU . . . . . . . . . . . . . 28.5 mt-10 -143.2 -172.59 3.72 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.918 -179.996 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 30.6 t -78.46 111.65 15.55 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.236 -0.438 . . . . 0.0 111.078 -179.979 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 106.16 42.73 1.6 Allowed Glycine 0 N--CA 1.452 -0.255 0 C-N-CA 120.729 -0.748 . . . . 0.0 112.52 179.967 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 2.3 m-20 -150.12 136.77 19.14 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-O 120.813 0.34 . . . . 0.0 110.823 179.979 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 31' ' ' GLN . . . . . . . . . . . . . 2.6 mt-30 -60.03 141.02 56.42 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.88 179.92 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 6.3 m -146.57 179.58 0.92 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.356 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.188 179.992 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 33' ' ' LEU . . . . . 0.534 HD11 ' O ' ' A' ' 37' ' ' GLN . 25.7 tp -142.09 109.89 5.8 Favored 'General case' 0 C--N 1.331 -0.239 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.846 179.991 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 34' ' ' VAL . . . . . 0.408 HG13 ' CB ' ' A' ' 87' ' ' ALA . 21.5 t -77.72 123.54 34.59 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.266 0 CA-C-N 116.181 -0.463 . . . . 0.0 111.182 -179.969 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 35' ' ' ALA . . . . . . . . . . . . . . . 57.63 26.64 13.14 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.198 -0.456 . . . . 0.0 111.235 -179.964 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . 57.07 29.38 59.42 Favored Glycine 0 N--CA 1.451 -0.327 0 C-N-CA 120.734 -0.746 . . . . 0.0 112.613 179.953 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 37' ' ' GLN . . . . . 0.534 ' O ' HD11 ' A' ' 33' ' ' LEU . 20.1 mt-30 -141.29 -74.59 0.32 Allowed 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 120.85 0.357 . . . . 0.0 110.966 -179.964 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 38' ' ' LYS . . . . . 0.465 ' HD2' HD13 ' A' ' 60' ' ' LEU . 21.8 mmtm -63.47 103.19 0.49 Allowed 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.861 -179.959 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 39' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -82.55 135.35 35.11 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.939 179.931 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -164.73 -176.01 36.04 Favored Glycine 0 N--CA 1.452 -0.288 0 C-N-CA 120.677 -0.773 . . . . 0.0 112.49 179.965 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 2.6 mt -127.34 137.01 59.03 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 CA-C-O 120.82 0.343 . . . . 0.0 111.085 -179.979 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 42' ' ' VAL . . . . . . . . . . . . . 21.4 t -59.62 123.38 11.91 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.202 -0.454 . . . . 0.0 111.12 179.971 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 43' ' ' ARG . . . . . . . . . . . . . 17.3 mmt85 -111.3 -33.99 6.27 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.902 179.903 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 44' ' ' PHE . . . . . 0.424 ' CD1' ' HB3' ' A' ' 76' ' ' TYR . 60.4 t80 -142.75 110.31 5.78 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.965 -179.979 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 45' ' ' TYR . . . . . . . . . . . . . 15.3 t80 -107.54 119.62 39.93 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.196 -0.457 . . . . 0.0 110.861 179.974 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 175.52 177.14 44.35 Favored Glycine 0 N--CA 1.451 -0.347 0 C-N-CA 120.801 -0.714 . . . . 0.0 112.561 179.971 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 47' ' ' LYS . . . . . . . . . . . . . 16.0 mtmt -77.02 168.14 20.6 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-O 120.886 0.374 . . . . 0.0 110.856 179.975 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 48' ' ' THR . . . . . 0.463 HG21 ' CE2' ' A' ' 50' ' ' PHE . 23.6 p -125.58 -179.66 4.74 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.868 179.953 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 1.5 t70 -106.74 -31.84 8.24 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.939 179.974 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 50' ' ' PHE . . . . . 0.463 ' CE2' HG21 ' A' ' 48' ' ' THR . 48.8 p90 -70.19 -35.86 74.22 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.924 -179.988 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 51' ' ' ALA . . . . . . . . . . . . . . . -141.09 144.16 33.85 Favored Pre-proline 0 C--N 1.328 -0.333 0 CA-C-N 116.218 -0.446 . . . . 0.0 111.087 -179.981 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 52' ' ' PRO . . . . . . . . . . . . . 70.8 Cg_endo -74.74 -176.85 3.02 Favored 'Trans proline' 0 C--N 1.345 0.389 0 C-N-CA 122.531 2.154 . . . . 0.0 112.309 179.99 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 76.78 -175.68 53.36 Favored Glycine 0 N--CA 1.45 -0.376 0 C-N-CA 120.745 -0.74 . . . . 0.0 112.567 179.993 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 54' ' ' TYR . . . . . . . . . . . . . 34.5 m-85 -88.58 158.35 18.31 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-O 120.847 0.356 . . . . 0.0 110.916 179.967 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 55' ' ' TRP . . . . . 0.428 ' HB3' ' CD1' ' A' ' 86' ' ' PHE . 94.2 m95 -154.06 140.96 19.21 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.154 -0.475 . . . . 0.0 110.867 179.96 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 56' ' ' TYR . . . . . 0.424 ' HE1' ' HB2' ' A' ' 89' ' ' ALA . 36.2 m-85 -102.57 122.31 44.13 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.902 -179.927 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 57' ' ' GLY . . . . . 0.447 ' N ' ' CE1' ' A' ' 86' ' ' PHE . . . -87.79 59.08 4.31 Favored Glycine 0 N--CA 1.451 -0.357 0 C-N-CA 120.754 -0.736 . . . . 0.0 112.468 -179.978 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 58' ' ' ILE . . . . . 0.67 HD11 HD13 ' A' ' 92' ' ' ILE . 7.8 mt -64.14 152.48 8.28 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-O 120.829 0.347 . . . . 0.0 110.964 -179.957 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 1.7 tm-20 -122.94 102.94 8.3 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.925 179.988 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 60' ' ' LEU . . . . . 0.465 HD13 ' HD2' ' A' ' 38' ' ' LYS . 54.8 mt -63.16 162.72 11.32 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.904 -179.957 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 2.7 t0 -92.78 -30.91 15.25 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.916 -179.981 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 62' ' ' GLN . . . . . . . . . . . . . 7.1 mt-30 -100.35 152.0 37.7 Favored Pre-proline 0 C--N 1.329 -0.311 0 CA-C-N 116.231 -0.44 . . . . 0.0 110.952 -179.994 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 71.9 Cg_endo -75.45 97.9 1.13 Allowed 'Trans proline' 0 C--N 1.344 0.316 0 C-N-CA 122.595 2.196 . . . . 0.0 112.309 -179.892 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 64' ' ' THR . . . . . . . . . . . . . 9.9 t -173.68 36.27 0.01 OUTLIER 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.9 -179.989 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . -90.09 -159.52 35.6 Favored Glycine 0 N--CA 1.451 -0.335 0 C-N-CA 120.731 -0.747 . . . . 0.0 112.544 179.985 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 66' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -110.47 -31.71 7.17 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 120.819 0.342 . . . . 0.0 110.846 -179.947 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 67' ' ' HIS . . . . . . . . . . . . . 6.6 p80 -140.83 173.57 11.36 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.893 179.954 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 2.6 m-20 -97.98 37.09 1.46 Allowed 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.834 -179.915 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 98.79 -28.61 14.33 Favored Glycine 0 N--CA 1.451 -0.362 0 C-N-CA 120.676 -0.773 . . . . 0.0 112.486 179.967 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 70' ' ' SER . . . . . . . . . . . . . 88.7 p -110.4 161.32 15.77 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-O 120.841 0.353 . . . . 0.0 110.842 -179.92 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 71' ' ' VAL . . . . . 0.524 HG12 ' HD1' ' A' ' 72' ' ' PHE . 21.5 t -146.41 126.75 6.02 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.256 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.063 -179.981 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 72' ' ' PHE . . . . . 0.524 ' HD1' HG12 ' A' ' 71' ' ' VAL . 11.3 m-85 60.58 27.05 16.73 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.163 -0.472 . . . . 0.0 111.026 179.974 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 95.65 -29.82 9.23 Favored Glycine 0 N--CA 1.452 -0.284 0 C-N-CA 120.752 -0.737 . . . . 0.0 112.537 179.952 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 25.5 t -80.98 116.58 25.53 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.343 0 CA-C-O 120.8 0.333 . . . . 0.0 111.141 -179.976 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 75' ' ' ARG . . . . . . . . . . . . . 2.1 ttt-85 -88.49 148.36 24.19 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.86 -179.933 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 76' ' ' TYR . . . . . 0.428 ' CE1' HG22 ' A' ' 48' ' ' THR . 53.8 m-85 -120.09 -50.81 2.24 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.933 -179.963 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 77' ' ' PHE . . . . . . . . . . . . . 26.9 p90 -146.04 161.78 39.35 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.9 179.978 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 4.9 m -91.93 121.98 34.03 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.099 -0.501 . . . . 0.0 110.941 179.979 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 79' ' ' CYS . . . . . . . . . . . . . 26.1 p -144.57 158.12 43.91 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.252 -0.431 . . . . 0.0 110.87 -179.952 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 80' ' ' ALA . . . . . 0.527 ' HB3' ' CG ' ' A' ' 83' ' ' HIS . . . -59.59 164.03 6.06 Favored Pre-proline 0 C--N 1.329 -0.306 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.135 179.913 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 81' ' ' PRO . . . . . 0.457 ' HD2' ' HB1' ' A' ' 80' ' ' ALA . 53.8 Cg_exo -52.31 116.19 2.67 Favored 'Trans proline' 0 C--N 1.345 0.358 0 C-N-CA 122.558 2.172 . . . . 0.0 112.322 -179.982 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 82' ' ' ARG . . . . . . . . . . . . . 16.1 mtt180 58.91 62.49 1.87 Allowed 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.874 -179.962 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 83' ' ' HIS . . . . . 0.527 ' CG ' ' HB3' ' A' ' 80' ' ' ALA . 4.3 m170 -127.12 -43.78 1.64 Allowed 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.088 -0.506 . . . . 0.0 110.859 179.957 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . -68.2 138.51 32.76 Favored Glycine 0 N--CA 1.45 -0.37 0 C-N-CA 120.706 -0.759 . . . . 0.0 112.473 179.976 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 85' ' ' VAL . . . . . 0.467 ' O ' HG23 ' A' ' 85' ' ' VAL . 16.9 m -143.3 113.91 2.43 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-O 120.894 0.378 . . . . 0.0 111.108 -179.994 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 86' ' ' PHE . . . . . 0.447 ' CE1' ' N ' ' A' ' 57' ' ' GLY . 5.4 m-85 -89.11 119.81 29.95 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.843 -179.964 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 87' ' ' ALA . . . . . 0.605 ' O ' HD11 ' A' ' 92' ' ' ILE . . . -139.48 143.86 37.41 Favored Pre-proline 0 C--N 1.329 -0.303 0 CA-C-N 116.263 -0.426 . . . . 0.0 111.146 179.991 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 88' ' ' PRO . . . . . 0.427 ' O ' ' N ' ' A' ' 91' ' ' ARG . 46.8 Cg_exo -55.94 140.45 85.85 Favored 'Trans proline' 0 C--N 1.346 0.43 0 C-N-CA 122.541 2.161 . . . . 0.0 112.379 179.959 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 89' ' ' ALA . . . . . 0.424 ' HB2' ' HE1' ' A' ' 56' ' ' TYR . . . -47.83 -50.3 26.59 Favored 'General case' 0 CA--C 1.521 -0.158 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.264 179.896 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 90' ' ' SER . . . . . . . . . . . . . 8.0 m -55.59 -24.37 32.51 Favored 'General case' 0 N--CA 1.454 -0.266 0 CA-C-N 115.769 -0.651 . . . . 0.0 109.796 178.859 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 91' ' ' ARG . . . . . 0.427 ' N ' ' O ' ' A' ' 88' ' ' PRO . 2.3 mtm-85 -89.74 -15.22 32.93 Favored 'General case' 0 N--CA 1.455 -0.19 0 CA-C-N 115.813 -0.631 . . . . 0.0 110.524 179.063 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 92' ' ' ILE . . . . . 0.67 HD13 HD11 ' A' ' 58' ' ' ILE . 49.9 mt -103.08 144.87 13.2 Favored 'Isoleucine or valine' 0 C--O 1.232 0.16 0 CA-C-N 116.402 -0.363 . . . . 0.0 111.094 179.858 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 93' ' ' GLN . . . . . . . . . . . . . 0.5 OUTLIER -115.71 154.3 29.81 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.905 -179.976 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 94' ' ' ARG . . . . . . . . . . . . . 7.6 mtp180 -96.96 138.54 34.34 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.868 179.978 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 95' ' ' ILE . . . . . . . . . . . . . 16.9 mt -111.02 -30.3 2.33 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.15 -0.477 . . . . 0.0 111.108 179.97 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . -58.97 -28.48 63.66 Favored Glycine 0 N--CA 1.452 -0.289 0 C-N-CA 120.745 -0.741 . . . . 0.0 112.475 179.974 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 97' ' ' SER . . . . . . . . . . . . . 7.2 p -74.78 88.27 2.26 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-O 120.778 0.323 . . . . 0.0 110.952 179.882 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 98' ' ' GLY . . . . . . . . . . . . . . . 151.13 87.13 0.06 OUTLIER Glycine 0 N--CA 1.451 -0.337 0 C-N-CA 120.736 -0.745 . . . . 0.0 112.482 179.992 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 99' ' ' PRO . . . . . . . . . . . . . 53.0 Cg_exo -52.32 -40.75 69.69 Favored 'Trans proline' 0 C--N 1.343 0.274 0 C-N-CA 122.604 2.203 . . . . 0.0 112.394 179.933 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 100' ' ' SER . . . . . . . . . . . . . 46.1 p -140.59 37.67 1.84 Allowed 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.93 179.988 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 1.3 m -132.47 -62.8 0.81 Allowed 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.145 -0.48 . . . . 0.0 110.853 -179.95 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.249 1.065 0 CA-C-O 118.344 -1.253 . . . . 0.0 112.488 179.993 . . . . . . . . 0 0 . 1 . 006 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.208 0 N-CA-C 112.476 -0.249 . . . . 0.0 112.476 . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 48.3 m -139.34 162.46 34.97 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-O 120.877 0.37 . . . . 0.0 110.899 -179.971 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 15.3 m -134.64 -58.07 0.82 Allowed 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.884 179.981 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 91.86 144.92 14.24 Favored Glycine 0 N--CA 1.45 -0.406 0 C-N-CA 120.749 -0.738 . . . . 0.0 112.504 179.979 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 1.3 m -102.61 -176.02 2.98 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-O 120.817 0.342 . . . . 0.0 110.867 -179.953 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER 60.63 100.01 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.132 -0.485 . . . . 0.0 110.864 179.954 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -163.67 101.37 0.19 Allowed Glycine 0 N--CA 1.451 -0.358 0 C-N-CA 120.758 -0.734 . . . . 0.0 112.485 -179.998 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -93.45 -178.74 4.82 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-O 120.825 0.345 . . . . 0.0 110.926 179.956 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 50.7 m -128.48 59.94 45.12 Favored Pre-proline 0 C--N 1.329 -0.288 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.885 179.954 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 52.0 Cg_endo -69.49 -168.02 0.24 Allowed 'Trans proline' 0 C--N 1.344 0.317 0 C-N-CA 122.609 2.206 . . . . 0.0 112.212 -179.936 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 1.3 m -102.77 114.05 27.98 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.964 179.981 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -152.54 146.15 18.02 Favored Pre-proline 0 C--N 1.329 -0.301 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.863 179.982 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 50.9 Cg_exo -53.06 91.07 0.03 OUTLIER 'Trans proline' 0 C--N 1.344 0.338 0 C-N-CA 122.577 2.185 . . . . 0.0 112.325 179.959 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -140.93 108.25 5.53 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.944 179.998 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 9.4 tp -176.79 121.6 0.14 Allowed 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.912 -179.998 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 74.4 -70.42 1.62 Allowed Glycine 0 N--CA 1.45 -0.368 0 C-N-CA 120.745 -0.74 . . . . 0.0 112.502 -179.977 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER 64.45 -78.9 0.03 OUTLIER 'General case' 0 C--N 1.33 -0.265 0 CA-C-O 120.778 0.323 . . . . 0.0 110.934 -179.997 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -164.64 92.36 0.61 Allowed 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.274 -0.421 . . . . 0.0 110.807 179.988 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 19' ' ' GLN . . . . . . . . . . . . . 0.2 OUTLIER -145.83 127.92 15.61 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.247 -0.433 . . . . 0.0 110.973 179.995 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 20' ' ' GLN . . . . . . . . . . . . . 48.6 mm-40 -104.61 -49.46 3.53 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.877 179.986 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER 61.0 35.75 18.84 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.872 -179.989 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 2.9 tp10 -155.88 -59.51 0.1 Allowed 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.926 179.979 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 100.73 164.75 28.1 Favored Glycine 0 N--CA 1.451 -0.36 0 C-N-CA 120.705 -0.76 . . . . 0.0 112.43 179.99 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -163.08 -169.34 1.99 Allowed 'General case' 0 C--N 1.33 -0.274 0 CA-C-O 120.868 0.366 . . . . 0.0 111.057 179.966 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 1.0 OUTLIER -146.41 -50.85 0.22 Allowed 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.905 -179.992 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 26' ' ' ALA . . . . . 0.451 ' HB2' ' HG3' ' A' ' 94' ' ' ARG . . . -115.97 -178.05 3.31 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.162 -0.472 . . . . 0.0 111.142 179.992 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 27' ' ' GLU . . . . . . . . . . . . . 6.3 mm-40 -142.46 -179.18 6.13 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.935 179.956 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 21.5 t -66.95 123.34 19.8 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.127 -180.0 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 84.7 46.34 5.76 Favored Glycine 0 N--CA 1.451 -0.326 0 C-N-CA 120.767 -0.73 . . . . 0.0 112.529 -179.993 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 4.6 t0 -146.16 134.28 21.59 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 120.879 0.371 . . . . 0.0 110.892 -179.998 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 31' ' ' GLN . . . . . . . . . . . . . 1.9 mt-30 -60.31 139.23 57.74 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.912 179.974 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 32' ' ' VAL . . . . . 0.43 HG21 HG12 ' A' ' 58' ' ' ILE . 19.2 m -145.17 176.02 2.31 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.28 -0.418 . . . . 0.0 111.133 -179.975 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 33' ' ' LEU . . . . . 0.519 HD11 ' O ' ' A' ' 37' ' ' GLN . 30.4 tp -134.5 100.04 4.53 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.145 -0.48 . . . . 0.0 110.898 179.988 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 21.5 t -69.11 126.58 29.42 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.205 -179.853 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 35' ' ' ALA . . . . . . . . . . . . . . . 57.06 25.34 10.67 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.321 179.941 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . 56.07 35.03 63.04 Favored Glycine 0 N--CA 1.451 -0.33 0 C-N-CA 120.722 -0.751 . . . . 0.0 112.58 179.941 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 37' ' ' GLN . . . . . 0.519 ' O ' HD11 ' A' ' 33' ' ' LEU . 48.8 mt-30 -147.51 -68.3 0.25 Allowed 'General case' 0 C--N 1.329 -0.295 0 CA-C-O 120.862 0.363 . . . . 0.0 110.949 -179.929 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 38' ' ' LYS . . . . . . . . . . . . . 64.5 mttp -73.77 106.85 5.69 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.919 -179.966 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 39' ' ' GLN . . . . . 0.433 ' HG2' HD11 ' A' ' 95' ' ' ILE . 0.9 OUTLIER -85.16 135.02 34.14 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.923 179.89 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -157.87 -170.43 22.65 Favored Glycine 0 N--CA 1.45 -0.389 0 C-N-CA 120.683 -0.77 . . . . 0.0 112.505 -179.998 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 41' ' ' ILE . . . . . 0.508 ' C ' HG23 ' A' ' 58' ' ' ILE . 14.5 mt -126.38 131.54 71.33 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-O 120.842 0.353 . . . . 0.0 111.132 -179.959 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 42' ' ' VAL . . . . . . . . . . . . . 38.2 t -65.52 119.73 10.87 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.02 -179.964 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 43' ' ' ARG . . . . . . . . . . . . . 25.5 mmt180 -104.13 -31.46 9.64 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.259 -0.428 . . . . 0.0 110.966 179.895 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 44' ' ' PHE . . . . . . . . . . . . . 69.2 t80 -143.77 117.52 9.28 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.875 -179.929 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 45' ' ' TYR . . . . . 0.464 ' CE1' ' CZ ' ' A' ' 56' ' ' TYR . 21.5 t80 -113.13 133.82 54.85 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.264 -0.426 . . . . 0.0 110.925 179.988 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 154.17 174.87 24.76 Favored Glycine 0 N--CA 1.451 -0.35 0 C-N-CA 120.799 -0.715 . . . . 0.0 112.523 179.937 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 47' ' ' LYS . . . . . . . . . . . . . 1.9 mmtp -60.06 160.53 7.93 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 120.81 0.338 . . . . 0.0 110.938 -179.996 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 48' ' ' THR . . . . . 0.408 HG21 ' CZ ' ' A' ' 50' ' ' PHE . 38.4 p -124.82 -179.09 4.38 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.872 179.938 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -107.65 -34.75 6.9 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.883 -179.989 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 50' ' ' PHE . . . . . 0.435 ' CD1' ' N ' ' A' ' 51' ' ' ALA . 15.9 p90 -63.33 -31.46 72.62 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.154 -0.475 . . . . 0.0 110.986 180.0 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 51' ' ' ALA . . . . . 0.435 ' N ' ' CD1' ' A' ' 50' ' ' PHE . . . -156.27 148.16 17.28 Favored Pre-proline 0 C--N 1.33 -0.244 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.117 -179.999 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 52' ' ' PRO . . . . . . . . . . . . . 58.3 Cg_endo -71.47 162.63 41.68 Favored 'Trans proline' 0 C--N 1.344 0.326 0 C-N-CA 122.624 2.216 . . . . 0.0 112.335 179.987 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 102.28 177.42 27.57 Favored Glycine 0 N--CA 1.45 -0.407 0 C-N-CA 120.769 -0.729 . . . . 0.0 112.501 179.939 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 54' ' ' TYR . . . . . . . . . . . . . 37.1 m-85 -97.22 112.31 24.17 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 120.813 0.34 . . . . 0.0 110.958 179.996 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 55' ' ' TRP . . . . . 0.406 ' CZ3' ' HD3' ' A' ' 88' ' ' PRO . 42.1 m95 -107.93 161.76 14.63 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.898 179.989 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 56' ' ' TYR . . . . . 0.626 ' CE1' ' HB2' ' A' ' 89' ' ' ALA . 11.3 m-85 -113.61 122.49 47.37 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.26 -0.427 . . . . 0.0 110.918 -179.98 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . -84.19 56.71 5.04 Favored Glycine 0 N--CA 1.45 -0.368 0 C-N-CA 120.801 -0.714 . . . . 0.0 112.511 179.861 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 58' ' ' ILE . . . . . 0.562 HD11 HD13 ' A' ' 92' ' ' ILE . 3.7 mt -68.32 137.99 23.39 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-O 120.84 0.352 . . . . 0.0 111.092 -179.937 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 0.8 OUTLIER -101.39 141.55 34.09 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.947 179.998 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 60' ' ' LEU . . . . . 0.425 HD12 ' HA2' ' A' ' 65' ' ' GLY . 59.6 mt -97.78 174.13 6.76 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.883 179.99 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 1.3 t0 -101.55 -30.91 11.12 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.176 -0.466 . . . . 0.0 110.959 179.965 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 62' ' ' GLN . . . . . . . . . . . . . 7.5 mt-30 -104.17 153.16 39.15 Favored Pre-proline 0 C--N 1.33 -0.273 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.912 -179.972 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 66.1 Cg_endo -73.97 65.34 5.07 Favored 'Trans proline' 0 C--N 1.345 0.352 0 C-N-CA 122.576 2.184 . . . . 0.0 112.29 -179.902 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 64' ' ' THR . . . . . . . . . . . . . 3.9 t -148.76 39.38 0.86 Allowed 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.882 179.933 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 65' ' ' GLY . . . . . 0.425 ' HA2' HD12 ' A' ' 60' ' ' LEU . . . -83.64 -99.63 0.57 Allowed Glycine 0 N--CA 1.451 -0.305 0 C-N-CA 120.705 -0.759 . . . . 0.0 112.525 179.906 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 66' ' ' LYS . . . . . . . . . . . . . 5.8 mttt -168.76 -44.69 0.02 OUTLIER 'General case' 0 C--N 1.33 -0.251 0 CA-C-O 120.845 0.355 . . . . 0.0 110.871 179.952 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 67' ' ' HIS . . . . . . . . . . . . . 10.1 p80 -125.5 170.28 11.58 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.903 179.91 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 17.1 t0 -103.49 52.36 0.77 Allowed 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.934 179.951 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 90.55 -75.64 1.65 Allowed Glycine 0 N--CA 1.45 -0.403 0 C-N-CA 120.741 -0.742 . . . . 0.0 112.445 179.982 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 70' ' ' SER . . . . . . . . . . . . . 93.1 p -84.4 154.7 22.67 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-O 120.875 0.369 . . . . 0.0 110.848 179.982 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 71' ' ' VAL . . . . . 0.412 HG12 ' CD2' ' A' ' 72' ' ' PHE . 21.5 t -129.37 122.69 56.29 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.141 179.993 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 72' ' ' PHE . . . . . 0.412 ' CD2' HG12 ' A' ' 71' ' ' VAL . 37.7 m-85 60.74 30.03 19.42 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.898 179.98 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 96.5 -30.05 9.37 Favored Glycine 0 N--CA 1.451 -0.362 0 C-N-CA 120.759 -0.734 . . . . 0.0 112.573 -179.969 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 28.0 t -79.4 122.61 34.96 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-O 120.833 0.349 . . . . 0.0 111.087 -179.992 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 75' ' ' ARG . . . . . . . . . . . . . 21.8 ttt-85 -91.89 142.99 26.95 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.98 179.948 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 76' ' ' TYR . . . . . . . . . . . . . 24.3 m-85 -118.78 -41.72 2.77 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.271 -0.422 . . . . 0.0 110.869 -179.973 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 77' ' ' PHE . . . . . . . . . . . . . 50.9 p90 -160.29 161.7 33.4 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.828 -179.998 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 3.3 m -89.86 123.51 33.88 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.987 179.865 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 79' ' ' CYS . . . . . . . . . . . . . 30.3 p -145.88 -177.94 5.85 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.885 179.997 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 80' ' ' ALA . . . . . 0.477 ' HB3' ' CG ' ' A' ' 83' ' ' HIS . . . -92.1 164.47 23.23 Favored Pre-proline 0 C--N 1.329 -0.319 0 CA-C-N 116.2 -0.455 . . . . 0.0 111.124 179.988 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 81' ' ' PRO . . . . . 0.452 ' HD2' ' HB1' ' A' ' 80' ' ' ALA . 52.9 Cg_exo -52.48 116.29 2.76 Favored 'Trans proline' 0 C--N 1.345 0.344 0 C-N-CA 122.55 2.167 . . . . 0.0 112.275 179.993 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 82' ' ' ARG . . . . . . . . . . . . . 7.3 mtm180 61.9 58.79 1.85 Allowed 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.178 -0.464 . . . . 0.0 110.834 -179.997 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 83' ' ' HIS . . . . . 0.477 ' CG ' ' HB3' ' A' ' 80' ' ' ALA . 5.6 m170 -128.98 -47.55 1.23 Allowed 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.92 179.925 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . -66.64 147.58 49.82 Favored Glycine 0 N--CA 1.45 -0.4 0 C-N-CA 120.8 -0.714 . . . . 0.0 112.471 179.906 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 85' ' ' VAL . . . . . . . . . . . . . 5.2 m -152.99 123.07 0.82 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-O 120.804 0.335 . . . . 0.0 111.153 179.921 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 86' ' ' PHE . . . . . . . . . . . . . 29.8 m-85 -99.87 121.23 41.01 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.834 -179.938 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 87' ' ' ALA . . . . . 0.493 ' O ' HD11 ' A' ' 92' ' ' ILE . . . -140.56 147.38 48.94 Favored Pre-proline 0 C--N 1.33 -0.261 0 CA-C-N 116.248 -0.433 . . . . 0.0 111.093 -179.988 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 88' ' ' PRO . . . . . 0.406 ' HD3' ' CZ3' ' A' ' 55' ' ' TRP . 32.4 Cg_exo -57.97 138.33 85.46 Favored 'Trans proline' 0 C--N 1.345 0.388 0 C-N-CA 122.561 2.174 . . . . 0.0 112.258 -179.979 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 89' ' ' ALA . . . . . 0.626 ' HB2' ' CE1' ' A' ' 56' ' ' TYR . . . -47.98 -51.71 22.72 Favored 'General case' 0 C--N 1.332 -0.161 0 CA-C-O 121.137 0.494 . . . . 0.0 110.278 179.84 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 90' ' ' SER . . . . . . . . . . . . . 3.6 t -55.87 -24.45 37.07 Favored 'General case' 0 C--N 1.332 -0.186 0 CA-C-N 115.693 -0.685 . . . . 0.0 109.701 178.826 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 91' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -88.5 -14.35 38.02 Favored 'General case' 0 N--CA 1.454 -0.246 0 CA-C-N 115.911 -0.586 . . . . 0.0 110.49 179.058 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 92' ' ' ILE . . . . . 0.562 HD13 HD11 ' A' ' 58' ' ' ILE . 36.3 mt -110.83 156.13 12.05 Favored 'Isoleucine or valine' 0 C--N 1.334 -0.065 0 CA-C-O 120.908 0.385 . . . . 0.0 111.063 179.906 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 93' ' ' GLN . . . . . 0.451 ' N ' HG22 ' A' ' 92' ' ' ILE . 2.3 mp0 -123.67 173.84 7.84 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.116 -0.493 . . . . 0.0 110.811 179.987 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 94' ' ' ARG . . . . . 0.451 ' HG3' ' HB2' ' A' ' 26' ' ' ALA . 1.1 mtp180 -115.48 140.02 49.53 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.899 179.968 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 95' ' ' ILE . . . . . 0.433 HD11 ' HG2' ' A' ' 39' ' ' GLN . 21.7 mm -82.22 -39.92 16.75 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 CA-C-N 116.154 -0.476 . . . . 0.0 111.124 179.946 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . -87.15 -178.45 48.75 Favored Glycine 0 N--CA 1.451 -0.324 0 C-N-CA 120.714 -0.755 . . . . 0.0 112.442 -179.985 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 97' ' ' SER . . . . . . . . . . . . . 41.6 m -88.39 -48.17 7.83 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-O 120.871 0.367 . . . . 0.0 110.971 -179.922 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 98' ' ' GLY . . . . . . . . . . . . . . . 143.76 93.7 0.18 Allowed Glycine 0 N--CA 1.45 -0.381 0 C-N-CA 120.713 -0.756 . . . . 0.0 112.472 179.958 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 99' ' ' PRO . . . . . . . . . . . . . 63.5 Cg_exo -51.32 155.09 7.25 Favored 'Trans proline' 0 C--N 1.344 0.303 0 C-N-CA 122.562 2.175 . . . . 0.0 112.394 -179.997 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 100' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -119.53 100.43 7.28 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.895 -179.999 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 40.4 t -166.55 -48.05 0.03 OUTLIER 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.143 -0.48 . . . . 0.0 110.923 -179.922 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.249 1.069 0 CA-C-O 118.346 -1.252 . . . . 0.0 112.479 -179.981 . . . . . . . . 0 0 . 1 . 007 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.189 0 N-CA-C 112.547 -0.221 . . . . 0.0 112.547 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 29.1 t -171.44 -49.61 0.02 OUTLIER 'General case' 0 C--N 1.328 -0.34 0 CA-C-O 120.827 0.346 . . . . 0.0 110.968 -179.944 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 1.6 p -141.8 91.45 2.36 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.862 179.991 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -68.43 108.93 2.65 Favored Glycine 0 N--CA 1.451 -0.363 0 C-N-CA 120.694 -0.765 . . . . 0.0 112.428 -179.983 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 0.6 OUTLIER -128.55 -46.85 1.3 Allowed 'General case' 0 C--N 1.329 -0.29 0 CA-C-O 120.827 0.346 . . . . 0.0 110.845 179.993 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 1.8 m -81.57 113.89 19.9 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.911 179.998 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 141.67 53.42 0.04 OUTLIER Glycine 0 N--CA 1.451 -0.34 0 C-N-CA 120.76 -0.733 . . . . 0.0 112.526 -179.983 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 2.8 mmmm -144.69 -179.38 6.54 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 120.744 0.307 . . . . 0.0 110.951 179.967 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 45.9 m -129.39 81.06 70.96 Favored Pre-proline 0 C--N 1.329 -0.31 0 CA-C-N 116.286 -0.415 . . . . 0.0 111.032 -179.957 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 56.7 Cg_endo -70.74 -166.44 0.22 Allowed 'Trans proline' 0 C--N 1.345 0.346 0 C-N-CA 122.634 2.223 . . . . 0.0 112.29 -179.942 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 8.1 t 70.08 -67.57 0.23 Allowed 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.945 179.956 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 15.5 m -162.91 161.91 18.66 Favored Pre-proline 0 C--N 1.329 -0.302 0 CA-C-N 116.371 -0.377 . . . . 0.0 110.967 179.984 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 51.9 Cg_exo -54.37 -171.0 0.02 OUTLIER 'Trans proline' 0 C--N 1.344 0.302 0 C-N-CA 122.553 2.169 . . . . 0.0 112.286 179.937 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 3.5 t -134.48 107.43 7.55 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.899 -179.961 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 4.3 mm? -85.76 -63.45 1.32 Allowed 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.836 179.977 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -145.67 25.08 1.81 Allowed Glycine 0 N--CA 1.451 -0.301 0 C-N-CA 120.77 -0.728 . . . . 0.0 112.579 179.979 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER 58.4 174.33 0.06 Allowed 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 120.767 0.318 . . . . 0.0 110.975 179.963 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 13.3 mt 60.45 46.39 9.82 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.89 179.922 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 19' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -140.51 84.48 1.95 Allowed 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.847 -179.968 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 20' ' ' GLN . . . . . . . . . . . . . 2.5 tp-100 59.66 29.96 19.55 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.925 -179.964 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -144.26 92.13 2.28 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.262 -0.426 . . . . 0.0 110.998 179.98 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -61.74 -70.05 0.21 Allowed 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.264 -0.426 . . . . 0.0 110.852 -179.96 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 73.1 86.84 0.2 Allowed Glycine 0 N--CA 1.451 -0.303 0 C-N-CA 120.734 -0.746 . . . . 0.0 112.554 179.987 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -166.21 145.82 6.06 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 120.758 0.313 . . . . 0.0 111.097 -179.958 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 29.7 mmmt -85.45 -45.12 12.14 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.924 179.946 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -118.97 -174.76 2.77 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.089 179.983 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 27' ' ' GLU . . . . . . . . . . . . . 3.6 mm-40 -135.55 -178.73 5.25 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.841 179.946 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 21.5 t -83.08 104.98 12.42 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.164 -0.471 . . . . 0.0 111.119 179.993 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 107.35 30.58 4.07 Favored Glycine 0 N--CA 1.452 -0.288 0 C-N-CA 120.779 -0.724 . . . . 0.0 112.487 -179.948 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 3.4 m-20 -124.84 144.21 50.42 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 120.793 0.33 . . . . 0.0 110.895 179.952 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 31' ' ' GLN . . . . . . . . . . . . . 5.0 mp0 -65.28 130.4 43.19 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.806 -179.97 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 20.7 m -136.13 175.23 10.95 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 CA-C-N 116.2 -0.454 . . . . 0.0 111.079 179.993 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 33' ' ' LEU . . . . . 0.44 HD12 ' HA ' ' A' ' 39' ' ' GLN . 14.1 tp -139.11 100.06 3.92 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.105 -0.498 . . . . 0.0 110.912 179.98 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 21.5 t -64.5 121.02 12.74 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 116.234 -0.439 . . . . 0.0 111.179 179.991 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 35' ' ' ALA . . . . . . . . . . . . . . . 58.71 26.87 15.14 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.3 179.998 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . 56.66 27.79 55.61 Favored Glycine 0 N--CA 1.451 -0.32 0 C-N-CA 120.779 -0.724 . . . . 0.0 112.601 -179.976 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 37' ' ' GLN . . . . . 0.41 ' O ' HD11 ' A' ' 33' ' ' LEU . 38.9 mt-30 -139.66 -72.08 0.38 Allowed 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.775 0.321 . . . . 0.0 110.892 -179.993 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 38' ' ' LYS . . . . . 0.405 ' HB3' HD21 ' A' ' 60' ' ' LEU . 55.6 mttt -65.17 114.53 4.73 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.259 -0.428 . . . . 0.0 110.924 179.995 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 39' ' ' GLN . . . . . 0.44 ' HA ' HD12 ' A' ' 33' ' ' LEU . 5.8 tm0? -85.53 130.07 34.67 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.886 179.952 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -157.08 173.56 34.66 Favored Glycine 0 N--CA 1.451 -0.302 0 C-N-CA 120.66 -0.781 . . . . 0.0 112.481 179.993 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 41' ' ' ILE . . . . . 0.42 ' N ' HG23 ' A' ' 58' ' ' ILE . 33.5 mt -121.13 133.18 68.56 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 CA-C-O 120.802 0.334 . . . . 0.0 111.033 -179.969 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 42' ' ' VAL . . . . . . . . . . . . . 21.4 t -61.99 121.73 11.06 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.146 -0.479 . . . . 0.0 111.097 179.979 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 43' ' ' ARG . . . . . . . . . . . . . 14.8 mmt180 -108.0 -30.92 8.19 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.903 179.878 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 44' ' ' PHE . . . . . . . . . . . . . 28.9 t80 -149.73 109.57 4.07 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.25 -0.432 . . . . 0.0 110.934 -179.976 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 45' ' ' TYR . . . . . 0.49 ' CE1' ' CZ ' ' A' ' 56' ' ' TYR . 22.7 t80 -106.76 130.5 54.46 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.289 -0.414 . . . . 0.0 110.865 179.964 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 167.02 -161.17 35.02 Favored Glycine 0 N--CA 1.451 -0.35 0 C-N-CA 120.679 -0.772 . . . . 0.0 112.488 -179.976 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 47' ' ' LYS . . . . . . . . . . . . . 40.3 mttt -84.74 175.83 8.93 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 120.748 0.309 . . . . 0.0 110.949 179.94 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 48' ' ' THR . . . . . 0.46 HG21 ' CZ ' ' A' ' 50' ' ' PHE . 71.1 p -143.9 -177.42 5.42 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.938 -179.974 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 3.5 t0 -110.8 -35.03 6.08 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.284 -0.416 . . . . 0.0 110.914 -179.961 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 50' ' ' PHE . . . . . 0.46 ' CZ ' HG21 ' A' ' 48' ' ' THR . 16.1 p90 -60.06 -31.36 69.92 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.917 179.996 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 51' ' ' ALA . . . . . 0.438 ' N ' ' CD1' ' A' ' 50' ' ' PHE . . . -159.84 141.73 9.62 Favored Pre-proline 0 C--N 1.329 -0.319 0 CA-C-N 116.264 -0.426 . . . . 0.0 111.092 179.911 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 52' ' ' PRO . . . . . . . . . . . . . 72.6 Cg_endo -74.77 154.7 43.86 Favored 'Trans proline' 0 C--N 1.346 0.405 0 C-N-CA 122.497 2.131 . . . . 0.0 112.39 179.991 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 121.39 -160.34 15.75 Favored Glycine 0 N--CA 1.45 -0.393 0 C-N-CA 120.752 -0.737 . . . . 0.0 112.555 179.988 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 54' ' ' TYR . . . . . . . . . . . . . 33.4 m-85 -113.2 110.49 20.49 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-O 120.81 0.338 . . . . 0.0 110.887 179.997 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 55' ' ' TRP . . . . . . . . . . . . . 51.2 m95 -112.96 160.5 18.03 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.888 179.955 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 56' ' ' TYR . . . . . 0.6 ' HE1' ' HB2' ' A' ' 89' ' ' ALA . 4.8 m-85 -118.07 128.13 54.46 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.954 -179.972 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 57' ' ' GLY . . . . . 0.435 ' HA3' ' CE1' ' A' ' 77' ' ' PHE . . . -88.25 59.42 4.14 Favored Glycine 0 N--CA 1.451 -0.305 0 C-N-CA 120.744 -0.741 . . . . 0.0 112.344 179.855 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 58' ' ' ILE . . . . . 0.703 HD11 HD13 ' A' ' 92' ' ' ILE . 12.6 mt -68.98 148.55 11.61 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.367 0 CA-C-O 120.864 0.364 . . . . 0.0 111.113 -179.895 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -119.15 120.47 37.18 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.891 179.932 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 60' ' ' LEU . . . . . 0.405 HD21 ' HB3' ' A' ' 38' ' ' LYS . 56.7 mt -71.88 -179.96 2.93 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.852 -179.997 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 21.0 m-20 -104.96 -29.55 10.39 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.283 -0.417 . . . . 0.0 110.935 -179.928 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 62' ' ' GLN . . . . . . . . . . . . . 2.1 mt-30 -114.87 147.95 39.39 Favored Pre-proline 0 C--N 1.329 -0.31 0 CA-C-N 116.312 -0.404 . . . . 0.0 110.871 -179.907 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 36.6 Cg_exo -60.02 91.2 0.08 OUTLIER 'Trans proline' 0 C--N 1.345 0.391 0 C-N-CA 122.515 2.143 . . . . 0.0 112.264 179.924 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 64' ' ' THR . . . . . . . . . . . . . 10.1 t -172.72 39.22 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.271 -0.422 . . . . 0.0 110.992 -179.994 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . -91.37 -104.84 1.38 Allowed Glycine 0 N--CA 1.451 -0.3 0 C-N-CA 120.695 -0.764 . . . . 0.0 112.459 -179.979 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 66' ' ' LYS . . . . . . . . . . . . . 3.0 mtmt -159.99 -49.3 0.05 Allowed 'General case' 0 C--N 1.328 -0.336 0 CA-C-O 120.795 0.331 . . . . 0.0 110.791 -179.992 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 67' ' ' HIS . . . . . . . . . . . . . 7.5 p80 -128.92 171.96 11.8 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.244 -0.435 . . . . 0.0 110.868 -179.937 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 16.8 t0 -98.18 32.47 2.44 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.255 -0.43 . . . . 0.0 110.88 179.926 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 95.4 -41.47 2.48 Favored Glycine 0 N--CA 1.451 -0.32 0 C-N-CA 120.73 -0.748 . . . . 0.0 112.506 -179.936 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 70' ' ' SER . . . . . . . . . . . . . 99.2 p -98.85 126.51 44.52 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 120.762 0.315 . . . . 0.0 110.978 179.976 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 71' ' ' VAL . . . . . 0.609 HG12 ' CD2' ' A' ' 72' ' ' PHE . 21.5 t -112.88 114.27 46.49 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.354 0 CA-C-N 116.198 -0.456 . . . . 0.0 111.114 -179.908 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 72' ' ' PHE . . . . . 0.609 ' CD2' HG12 ' A' ' 71' ' ' VAL . 14.7 m-85 61.49 30.77 18.96 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.917 -179.976 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 98.42 -29.75 10.87 Favored Glycine 0 N--CA 1.452 -0.288 0 C-N-CA 120.741 -0.742 . . . . 0.0 112.511 179.985 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 21.5 t -77.2 124.22 35.22 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-O 120.752 0.311 . . . . 0.0 111.111 -179.978 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 75' ' ' ARG . . . . . . . . . . . . . 10.3 ttt180 -104.71 136.76 43.63 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.939 179.996 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 76' ' ' TYR . . . . . . . . . . . . . 36.3 m-85 -112.84 -43.47 3.42 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.965 179.963 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 77' ' ' PHE . . . . . 0.435 ' CE1' ' HA3' ' A' ' 57' ' ' GLY . 40.9 p90 -153.29 165.06 36.91 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.935 -179.995 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 2.6 t -93.6 121.62 35.2 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.176 -0.466 . . . . 0.0 110.853 -179.994 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 79' ' ' CYS . . . . . . . . . . . . . 10.0 p -142.45 154.2 44.35 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.22 -0.445 . . . . 0.0 111.002 -179.98 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 80' ' ' ALA . . . . . 0.714 ' HB1' ' HD2' ' A' ' 81' ' ' PRO . . . -58.94 165.45 3.35 Favored Pre-proline 0 C--N 1.328 -0.34 0 CA-C-N 116.166 -0.47 . . . . 0.0 111.025 179.956 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 81' ' ' PRO . . . . . 0.714 ' HD2' ' HB1' ' A' ' 80' ' ' ALA . 17.9 Cg_endo -59.6 115.94 2.95 Favored 'Trans proline' 0 C--N 1.344 0.332 0 C-N-CA 122.53 2.153 . . . . 0.0 112.095 179.985 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 82' ' ' ARG . . . . . . . . . . . . . 57.1 mtp180 63.96 55.36 1.59 Allowed 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.812 -179.883 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 83' ' ' HIS . . . . . 0.619 ' CG ' ' HB3' ' A' ' 80' ' ' ALA . 6.4 m170 -126.75 -47.43 1.54 Allowed 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.907 179.97 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . -59.04 142.41 46.51 Favored Glycine 0 N--CA 1.452 -0.261 0 C-N-CA 120.738 -0.744 . . . . 0.0 112.511 -179.99 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 85' ' ' VAL . . . . . . . . . . . . . 5.3 m -146.86 115.91 1.29 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.272 0 CA-C-O 120.804 0.335 . . . . 0.0 111.113 179.955 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 86' ' ' PHE . . . . . . . . . . . . . 10.4 m-85 -93.41 124.95 37.75 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.862 179.936 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 87' ' ' ALA . . . . . 0.515 ' O ' HD11 ' A' ' 92' ' ' ILE . . . -144.55 144.86 26.46 Favored Pre-proline 0 C--N 1.329 -0.303 0 CA-C-N 116.27 -0.423 . . . . 0.0 111.101 179.93 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 88' ' ' PRO . . . . . 0.424 ' O ' ' N ' ' A' ' 91' ' ' ARG . 31.9 Cg_exo -58.38 142.13 97.51 Favored 'Trans proline' 0 C--N 1.345 0.387 0 C-N-CA 122.429 2.086 . . . . 0.0 112.243 179.956 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 89' ' ' ALA . . . . . 0.6 ' HB2' ' HE1' ' A' ' 56' ' ' TYR . . . -47.58 -51.84 19.72 Favored 'General case' 0 C--N 1.333 -0.114 0 CA-C-O 121.088 0.471 . . . . 0.0 110.388 179.983 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 90' ' ' SER . . . . . . . . . . . . . 64.3 m -55.88 -24.29 36.28 Favored 'General case' 0 C--N 1.331 -0.235 0 CA-C-N 115.701 -0.681 . . . . 0.0 109.81 178.839 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 91' ' ' ARG . . . . . 0.424 ' N ' ' O ' ' A' ' 88' ' ' PRO . 0.5 OUTLIER -89.33 -13.83 37.06 Favored 'General case' 0 N--CA 1.455 -0.197 0 CA-C-N 115.876 -0.602 . . . . 0.0 110.484 179.095 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 92' ' ' ILE . . . . . 0.703 HD13 HD11 ' A' ' 58' ' ' ILE . 46.8 mt -109.92 141.11 26.17 Favored 'Isoleucine or valine' 0 C--O 1.231 0.126 0 CA-C-N 116.493 -0.321 . . . . 0.0 111.034 179.883 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 93' ' ' GLN . . . . . . . . . . . . . 1.4 mt-30 -107.72 171.45 7.38 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.816 179.992 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 94' ' ' ARG . . . . . . . . . . . . . 5.5 ttt180 -122.1 125.58 46.51 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.919 179.982 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 95' ' ' ILE . . . . . . . . . . . . . 5.5 mt -96.32 -58.25 3.9 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.273 -0.421 . . . . 0.0 111.037 -179.965 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . 66.6 62.7 4.37 Favored Glycine 0 N--CA 1.451 -0.311 0 C-N-CA 120.78 -0.724 . . . . 0.0 112.434 -179.992 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 97' ' ' SER . . . . . . . . . . . . . 50.6 p -108.49 158.09 17.85 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-O 120.868 0.366 . . . . 0.0 110.869 179.993 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 98' ' ' GLY . . . . . . . . . . . . . . . 140.51 -178.47 19.96 Favored Glycine 0 N--CA 1.451 -0.311 0 C-N-CA 120.739 -0.743 . . . . 0.0 112.513 179.995 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 99' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_exo -52.26 171.16 0.2 Allowed 'Trans proline' 0 C--N 1.345 0.351 0 C-N-CA 122.59 2.193 . . . . 0.0 112.28 -179.947 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 100' ' ' SER . . . . . . . . . . . . . 8.6 t -155.54 -61.43 0.11 Allowed 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.93 179.981 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 62.9 m -148.58 175.72 10.93 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.218 -0.447 . . . . 0.0 110.876 179.978 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.249 1.083 0 CA-C-O 118.357 -1.246 . . . . 0.0 112.531 179.981 . . . . . . . . 0 0 . 1 . 008 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.488 2.15 0 N-CA-C 112.57 -0.212 . . . . 0.0 112.57 . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 64.0 m -139.4 142.45 37.5 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-O 120.823 0.344 . . . . 0.0 110.902 -179.982 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -102.62 98.43 8.48 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.945 179.945 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -71.31 -173.05 15.25 Favored Glycine 0 N--CA 1.451 -0.338 0 C-N-CA 120.797 -0.716 . . . . 0.0 112.478 -179.985 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -167.52 167.16 13.82 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-O 120.827 0.346 . . . . 0.0 110.946 -179.934 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 36.2 p -105.73 -53.51 2.63 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.863 -179.994 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -125.04 -77.11 0.29 Allowed Glycine 0 N--CA 1.452 -0.293 0 C-N-CA 120.726 -0.75 . . . . 0.0 112.425 179.985 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 8.0 pttt -128.75 -54.61 1.23 Allowed 'General case' 0 C--N 1.329 -0.299 0 CA-C-O 120.784 0.326 . . . . 0.0 110.85 179.919 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER 53.87 85.97 0.18 Allowed Pre-proline 0 C--N 1.329 -0.297 0 CA-C-N 116.227 -0.442 . . . . 0.0 111.054 179.861 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 52.1 Cg_exo -52.82 89.31 0.03 OUTLIER 'Trans proline' 0 C--N 1.345 0.344 0 C-N-CA 122.551 2.167 . . . . 0.0 112.254 179.987 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 20.9 m -139.52 -54.67 0.56 Allowed 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.268 -0.424 . . . . 0.0 110.923 -179.961 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 87.1 p -140.25 154.24 69.73 Favored Pre-proline 0 C--N 1.329 -0.287 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.846 179.973 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 53.2 Cg_endo -69.54 86.9 0.54 Allowed 'Trans proline' 0 C--N 1.345 0.39 0 C-N-CA 122.551 2.167 . . . . 0.0 112.24 -179.994 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -119.52 136.7 54.23 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.274 -0.421 . . . . 0.0 110.887 179.979 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 1.6 mt -165.48 -171.13 2.03 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.776 -179.995 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -55.17 106.42 0.55 Allowed Glycine 0 N--CA 1.452 -0.263 0 C-N-CA 120.796 -0.716 . . . . 0.0 112.588 179.949 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -59.4 108.39 0.7 Allowed 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 120.892 0.377 . . . . 0.0 110.944 -179.952 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 6.8 mt -112.34 -35.37 5.61 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.857 179.964 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 19' ' ' GLN . . . . . . . . . . . . . 4.3 mt-30 -65.83 136.15 55.8 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.833 -179.958 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 20' ' ' GLN . . . . . . . . . . . . . 4.1 tt0 -144.33 -47.4 0.26 Allowed 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.896 179.958 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 0.9 OUTLIER -103.64 117.01 33.42 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.18 -0.463 . . . . 0.0 110.839 179.989 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 8.4 mp0 -113.72 -62.48 1.59 Allowed 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.876 179.919 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 106.22 -59.93 0.39 Allowed Glycine 0 N--CA 1.451 -0.33 0 C-N-CA 120.715 -0.755 . . . . 0.0 112.496 179.995 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 24' ' ' ALA . . . . . 0.461 ' HB2' ' OH ' ' A' ' 45' ' ' TYR . . . -78.49 129.67 35.13 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-O 120.826 0.346 . . . . 0.0 111.116 -179.932 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -87.6 -64.19 1.19 Allowed 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.865 -179.987 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -98.83 179.85 4.52 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.185 -0.461 . . . . 0.0 111.16 179.941 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 27' ' ' GLU . . . . . . . . . . . . . 5.6 mp0 -130.46 177.87 7.03 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.886 -179.96 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 26.9 t -64.9 92.21 0.11 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.231 -0.44 . . . . 0.0 111.132 179.95 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 114.86 41.86 0.82 Allowed Glycine 0 N--CA 1.452 -0.251 0 C-N-CA 120.746 -0.74 . . . . 0.0 112.403 -179.928 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 37.5 t70 -134.93 144.14 47.3 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-O 120.841 0.353 . . . . 0.0 110.945 179.979 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 31' ' ' GLN . . . . . . . . . . . . . 2.4 mp0 -64.43 134.98 55.61 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.254 -0.43 . . . . 0.0 110.811 -179.996 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 13.7 m -147.96 173.41 1.99 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.358 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.21 179.981 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 33' ' ' LEU . . . . . 0.577 HD12 ' HA ' ' A' ' 39' ' ' GLN . 15.0 tp -134.32 108.53 8.26 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.222 -0.444 . . . . 0.0 110.899 -179.969 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 34' ' ' VAL . . . . . 0.427 HG22 ' CD1' ' A' ' 58' ' ' ILE . 26.0 t -73.74 122.59 27.11 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.115 179.967 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 35' ' ' ALA . . . . . . . . . . . . . . . 59.13 25.2 13.65 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.117 -0.492 . . . . 0.0 111.194 -179.992 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 36' ' ' GLY . . . . . 0.414 ' HA2' HD23 ' A' ' 33' ' ' LEU . . . 55.27 27.49 46.97 Favored Glycine 0 N--CA 1.452 -0.253 0 C-N-CA 120.779 -0.724 . . . . 0.0 112.592 179.938 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 37' ' ' GLN . . . . . . . . . . . . . 12.8 mt-30 -141.87 -63.05 0.45 Allowed 'General case' 0 C--N 1.329 -0.286 0 CA-C-O 120.781 0.324 . . . . 0.0 110.876 -179.988 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 38' ' ' LYS . . . . . . . . . . . . . 11.4 mttp -71.26 111.97 7.03 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.25 -0.432 . . . . 0.0 110.889 179.989 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 39' ' ' GLN . . . . . 0.577 ' HA ' HD12 ' A' ' 33' ' ' LEU . 0.9 OUTLIER -82.27 131.24 35.23 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.854 -179.991 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -163.28 179.06 38.67 Favored Glycine 0 N--CA 1.451 -0.336 0 C-N-CA 120.775 -0.726 . . . . 0.0 112.504 -179.994 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 41' ' ' ILE . . . . . 0.458 ' N ' HG23 ' A' ' 58' ' ' ILE . 28.0 mt -128.63 137.74 56.49 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-O 120.842 0.354 . . . . 0.0 111.125 179.929 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 42' ' ' VAL . . . . . . . . . . . . . 21.5 t -62.19 127.16 21.68 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-N 116.174 -0.467 . . . . 0.0 111.161 -179.997 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 43' ' ' ARG . . . . . . . . . . . . . 10.1 mmt180 -111.76 -34.67 5.96 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.909 179.955 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 44' ' ' PHE . . . . . . . . . . . . . 39.4 t80 -143.52 112.28 6.53 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.897 -179.988 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 45' ' ' TYR . . . . . 0.485 ' CE1' ' CZ ' ' A' ' 56' ' ' TYR . 12.9 t80 -105.39 122.29 45.68 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.919 179.932 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 166.02 173.13 34.16 Favored Glycine 0 N--CA 1.452 -0.265 0 C-N-CA 120.757 -0.735 . . . . 0.0 112.485 179.953 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 47' ' ' LYS . . . . . . . . . . . . . 14.5 mttm -70.15 155.46 40.6 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 120.842 0.353 . . . . 0.0 110.911 -179.995 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 48' ' ' THR . . . . . 0.527 HG21 ' CE1' ' A' ' 50' ' ' PHE . 42.8 p -118.12 -177.75 3.35 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.13 -0.486 . . . . 0.0 110.874 179.969 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 4.8 t0 -105.98 -30.75 9.12 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.922 179.98 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 50' ' ' PHE . . . . . 0.527 ' CE1' HG21 ' A' ' 48' ' ' THR . 53.8 p90 -71.02 -40.75 71.58 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.941 -179.95 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 51' ' ' ALA . . . . . . . . . . . . . . . -137.0 144.47 46.5 Favored Pre-proline 0 C--N 1.329 -0.294 0 CA-C-N 116.187 -0.461 . . . . 0.0 111.211 -179.934 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 52' ' ' PRO . . . . . . . . . . . . . 73.3 Cg_endo -76.16 169.76 21.4 Favored 'Trans proline' 0 C--N 1.345 0.357 0 C-N-CA 122.54 2.16 . . . . 0.0 112.366 -179.975 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 90.39 178.78 44.07 Favored Glycine 0 N--CA 1.452 -0.294 0 C-N-CA 120.738 -0.744 . . . . 0.0 112.464 179.906 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 54' ' ' TYR . . . . . . . . . . . . . 14.1 m-85 -91.17 115.7 28.23 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-O 120.813 0.34 . . . . 0.0 110.935 179.977 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 55' ' ' TRP . . . . . . . . . . . . . 73.8 m95 -109.91 147.22 33.8 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.89 179.973 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 56' ' ' TYR . . . . . 0.579 ' CE1' ' HB2' ' A' ' 89' ' ' ALA . 8.1 m-85 -104.62 120.98 42.57 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.966 -179.89 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 57' ' ' GLY . . . . . 0.445 ' N ' ' CE1' ' A' ' 86' ' ' PHE . . . -80.72 62.78 4.34 Favored Glycine 0 N--CA 1.451 -0.325 0 C-N-CA 120.758 -0.734 . . . . 0.0 112.365 179.929 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 58' ' ' ILE . . . . . 0.757 HD11 HD13 ' A' ' 92' ' ' ILE . 21.6 mt -70.76 138.94 20.84 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-O 120.866 0.365 . . . . 0.0 111.141 -179.906 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -109.13 130.63 55.48 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.877 -179.97 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 60' ' ' LEU . . . . . 0.479 HD13 HG23 ' A' ' 64' ' ' THR . 84.2 mt -85.54 173.21 10.37 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.871 179.959 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 1.5 t70 -103.11 -31.03 10.36 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.943 -179.961 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 62' ' ' GLN . . . . . 0.401 ' HA ' ' HD3' ' A' ' 63' ' ' PRO . 2.4 mm-40 -114.43 147.81 38.82 Favored Pre-proline 0 C--N 1.33 -0.272 0 CA-C-N 116.298 -0.41 . . . . 0.0 110.911 -179.986 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 63' ' ' PRO . . . . . 0.401 ' HD3' ' HA ' ' A' ' 62' ' ' GLN . 31.9 Cg_exo -58.24 84.32 0.05 OUTLIER 'Trans proline' 0 C--N 1.346 0.399 0 C-N-CA 122.564 2.176 . . . . 0.0 112.25 179.928 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 64' ' ' THR . . . . . 0.479 HG23 HD13 ' A' ' 60' ' ' LEU . 13.4 t -157.0 35.02 0.29 Allowed 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.297 -0.411 . . . . 0.0 110.946 179.988 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . -95.96 -159.98 32.65 Favored Glycine 0 N--CA 1.452 -0.292 0 C-N-CA 120.745 -0.741 . . . . 0.0 112.503 179.911 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 66' ' ' LYS . . . . . . . . . . . . . 0.5 OUTLIER -110.03 -31.31 7.42 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 120.861 0.363 . . . . 0.0 110.922 179.977 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 67' ' ' HIS . . . . . 0.492 ' CG ' HG22 ' A' ' 71' ' ' VAL . 13.1 p80 -145.96 -178.74 6.28 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.877 -179.975 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 26.6 t0 -114.87 73.08 0.81 Allowed 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.944 179.986 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 79.41 -72.75 2.47 Favored Glycine 0 N--CA 1.451 -0.352 0 C-N-CA 120.761 -0.733 . . . . 0.0 112.476 -179.982 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 70' ' ' SER . . . . . . . . . . . . . 97.2 p -86.62 151.5 23.39 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-O 120.841 0.353 . . . . 0.0 110.907 -179.981 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 71' ' ' VAL . . . . . 0.716 HG12 ' CD2' ' A' ' 72' ' ' PHE . 21.5 t -128.03 117.9 47.08 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.162 -0.472 . . . . 0.0 111.095 179.977 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 72' ' ' PHE . . . . . 0.716 ' CD2' HG12 ' A' ' 71' ' ' VAL . 59.8 m-85 60.91 31.12 19.98 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.879 179.962 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 99.74 -30.0 10.9 Favored Glycine 0 N--CA 1.452 -0.281 0 C-N-CA 120.687 -0.768 . . . . 0.0 112.563 179.984 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 21.3 t -75.66 116.35 18.45 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-O 120.888 0.375 . . . . 0.0 111.093 179.981 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 75' ' ' ARG . . . . . . . . . . . . . 26.2 ttt85 -93.83 148.03 22.51 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.858 179.969 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 76' ' ' TYR . . . . . . . . . . . . . 89.9 m-85 -133.24 -47.69 0.84 Allowed 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.165 -0.471 . . . . 0.0 110.948 179.946 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 77' ' ' PHE . . . . . . . . . . . . . 22.5 p90 -155.2 154.67 32.6 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.9 -179.979 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 9.0 t -84.6 140.7 31.19 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.169 -0.468 . . . . 0.0 110.847 179.955 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 79' ' ' CYS . . . . . . . . . . . . . 22.7 p -164.7 162.39 21.25 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.922 179.921 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 80' ' ' ALA . . . . . 0.707 ' HB1' ' HD2' ' A' ' 81' ' ' PRO . . . -59.24 166.16 3.12 Favored Pre-proline 0 C--N 1.33 -0.254 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.002 179.949 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 81' ' ' PRO . . . . . 0.707 ' HD2' ' HB1' ' A' ' 80' ' ' ALA . 28.1 Cg_endo -62.66 122.63 11.05 Favored 'Trans proline' 0 C--N 1.346 0.397 0 C-N-CA 122.468 2.112 . . . . 0.0 112.253 -180.0 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 82' ' ' ARG . . . . . . . . . . . . . 0.5 OUTLIER 61.01 53.36 3.72 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.91 -179.875 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 83' ' ' HIS . . . . . 0.677 ' ND1' ' HB3' ' A' ' 80' ' ' ALA . 7.4 m170 -123.21 -45.54 2.1 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.11 -0.495 . . . . 0.0 110.85 179.958 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . -59.8 146.01 45.09 Favored Glycine 0 N--CA 1.451 -0.341 0 C-N-CA 120.646 -0.788 . . . . 0.0 112.501 -179.971 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 85' ' ' VAL . . . . . . . . . . . . . 6.1 m -150.04 114.88 0.67 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-O 120.815 0.34 . . . . 0.0 111.098 -179.938 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 86' ' ' PHE . . . . . 0.445 ' CE1' ' N ' ' A' ' 57' ' ' GLY . 3.7 m-85 -97.53 108.29 20.98 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.929 179.998 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 87' ' ' ALA . . . . . 0.595 ' O ' HD11 ' A' ' 92' ' ' ILE . . . -128.5 145.4 55.79 Favored Pre-proline 0 C--N 1.328 -0.344 0 CA-C-N 116.233 -0.439 . . . . 0.0 111.139 179.982 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 88' ' ' PRO . . . . . 0.417 ' O ' ' N ' ' A' ' 91' ' ' ARG . 32.3 Cg_exo -57.96 142.57 96.66 Favored 'Trans proline' 0 C--N 1.345 0.362 0 C-N-CA 122.519 2.146 . . . . 0.0 112.259 -179.984 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 89' ' ' ALA . . . . . 0.579 ' HB2' ' CE1' ' A' ' 56' ' ' TYR . . . -47.85 -51.18 23.93 Favored 'General case' 0 CA--C 1.521 -0.141 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.329 179.872 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 90' ' ' SER . . . . . . . . . . . . . 23.6 t -55.83 -24.4 36.24 Favored 'General case' 0 N--CA 1.454 -0.266 0 CA-C-N 115.747 -0.661 . . . . 0.0 109.815 178.76 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 91' ' ' ARG . . . . . 0.417 ' N ' ' O ' ' A' ' 88' ' ' PRO . 0.0 OUTLIER -89.37 -14.14 36.24 Favored 'General case' 0 N--CA 1.455 -0.215 0 CA-C-N 115.932 -0.576 . . . . 0.0 110.513 179.04 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 92' ' ' ILE . . . . . 0.757 HD13 HD11 ' A' ' 58' ' ' ILE . 48.9 mt -105.85 156.59 6.62 Favored 'Isoleucine or valine' 0 C--O 1.231 0.12 0 CA-C-N 116.396 -0.365 . . . . 0.0 110.971 179.753 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 93' ' ' GLN . . . . . 0.468 ' N ' HG22 ' A' ' 92' ' ' ILE . 50.8 mt-30 -121.42 175.0 6.4 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.262 -0.426 . . . . 0.0 110.881 -179.979 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 94' ' ' ARG . . . . . . . . . . . . . 0.6 OUTLIER -122.03 110.41 15.76 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.855 -179.972 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 95' ' ' ILE . . . . . . . . . . . . . 32.5 mt -83.0 -32.32 9.54 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.262 -0.427 . . . . 0.0 111.073 179.97 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . -64.75 -141.8 0.02 OUTLIER Glycine 0 N--CA 1.451 -0.367 0 C-N-CA 120.783 -0.723 . . . . 0.0 112.541 179.95 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 97' ' ' SER . . . . . . . . . . . . . 5.5 m 60.23 92.44 0.05 OUTLIER 'General case' 0 C--N 1.328 -0.331 0 CA-C-O 120.862 0.363 . . . . 0.0 110.927 179.984 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 98' ' ' GLY . . . . . . . . . . . . . . . 107.62 151.98 17.27 Favored Glycine 0 N--CA 1.452 -0.297 0 C-N-CA 120.725 -0.75 . . . . 0.0 112.517 179.919 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 99' ' ' PRO . . . . . . . . . . . . . 55.4 Cg_endo -69.84 93.74 0.53 Allowed 'Trans proline' 0 C--N 1.345 0.347 0 C-N-CA 122.562 2.175 . . . . 0.0 112.3 179.962 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 100' ' ' SER . . . . . . . . . . . . . 10.7 t -72.07 139.35 48.41 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.883 -179.947 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -77.1 -173.74 2.89 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.913 179.99 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.248 1.007 0 CA-C-O 118.365 -1.242 . . . . 0.0 112.49 179.953 . . . . . . . . 0 0 . 1 . 009 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.267 0 N-CA-C 112.529 -0.228 . . . . 0.0 112.529 . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 1.3 m -173.15 140.3 0.86 Allowed 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 120.871 0.367 . . . . 0.0 110.925 179.952 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 2.9 p -142.96 159.76 41.64 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.899 -179.982 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 158.44 45.8 0.01 OUTLIER Glycine 0 N--CA 1.451 -0.34 0 C-N-CA 120.777 -0.725 . . . . 0.0 112.515 -179.919 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -105.82 136.66 45.05 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 120.724 0.297 . . . . 0.0 110.926 -179.962 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -60.98 110.19 1.28 Allowed 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.864 179.994 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 140.68 154.41 6.23 Favored Glycine 0 N--CA 1.45 -0.38 0 C-N-CA 120.776 -0.726 . . . . 0.0 112.52 -179.994 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 7.6 mttt -142.71 83.18 1.8 Allowed 'General case' 0 C--N 1.328 -0.331 0 CA-C-O 120.847 0.356 . . . . 0.0 110.921 179.975 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 1.5 t -149.34 88.35 5.05 Favored Pre-proline 0 C--N 1.329 -0.316 0 CA-C-N 116.213 -0.448 . . . . 0.0 110.931 -179.993 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 49.8 Cg_endo -68.8 -28.06 30.61 Favored 'Trans proline' 0 C--N 1.345 0.358 0 C-N-CA 122.547 2.165 . . . . 0.0 112.321 179.954 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 53.2 p -82.05 128.05 33.71 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.883 -179.985 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 2.6 m -77.34 150.44 80.0 Favored Pre-proline 0 C--N 1.329 -0.3 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.878 -179.952 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_exo -52.2 -51.53 10.93 Favored 'Trans proline' 0 C--N 1.345 0.367 0 C-N-CA 122.62 2.214 . . . . 0.0 112.249 -179.96 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 1.2 m -136.2 170.5 15.92 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.275 -0.421 . . . . 0.0 110.902 179.996 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 0.6 OUTLIER -162.99 33.25 0.1 Allowed 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.211 -0.449 . . . . 0.0 110.831 -179.995 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 122.95 40.53 0.48 Allowed Glycine 0 N--CA 1.452 -0.28 0 C-N-CA 120.768 -0.73 . . . . 0.0 112.478 179.978 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 1.1 m -80.12 -42.8 22.82 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 120.733 0.302 . . . . 0.0 110.847 -179.935 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -109.9 38.96 2.24 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.884 -179.974 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 19' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -97.43 107.53 20.05 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.145 -0.48 . . . . 0.0 110.875 -179.99 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 20' ' ' GLN . . . . . . . . . . . . . 3.6 mm-40 60.31 32.37 20.7 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.114 -0.493 . . . . 0.0 110.909 179.926 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 1.0 OUTLIER -166.79 169.91 12.86 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.145 -0.48 . . . . 0.0 110.903 179.904 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 0.2 OUTLIER -111.64 165.73 11.77 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.264 -0.426 . . . . 0.0 110.899 179.989 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -112.78 112.33 2.95 Favored Glycine 0 N--CA 1.451 -0.354 0 C-N-CA 120.701 -0.762 . . . . 0.0 112.537 179.882 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -88.31 136.37 33.01 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-O 120.813 0.34 . . . . 0.0 111.125 179.94 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -91.56 -45.14 8.66 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.034 -179.986 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -108.98 166.25 10.97 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.215 -0.448 . . . . 0.0 111.106 179.981 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 27' ' ' GLU . . . . . . . . . . . . . 8.8 mt-10 -125.01 167.74 14.3 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.251 -0.431 . . . . 0.0 110.885 179.992 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 28.3 t -70.55 100.41 0.73 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 CA-C-N 116.165 -0.471 . . . . 0.0 111.077 -179.963 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 116.94 39.68 0.8 Allowed Glycine 0 N--CA 1.451 -0.334 0 C-N-CA 120.692 -0.766 . . . . 0.0 112.504 -179.977 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 1.8 m-20 -142.35 146.94 35.51 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-O 120.836 0.35 . . . . 0.0 110.89 -179.992 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 31' ' ' GLN . . . . . . . . . . . . . 77.1 mt-30 -59.96 136.26 57.96 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.861 179.966 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 5.8 m -148.91 162.46 5.01 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.129 179.968 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 33' ' ' LEU . . . . . 0.506 HD23 ' HA2' ' A' ' 36' ' ' GLY . 20.5 tp -130.23 104.96 7.6 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.825 -179.956 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 34' ' ' VAL . . . . . 0.488 HG13 ' CB ' ' A' ' 87' ' ' ALA . 21.7 t -72.98 125.01 31.09 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-N 116.178 -0.464 . . . . 0.0 111.263 -179.955 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 35' ' ' ALA . . . . . . . . . . . . . . . 57.17 25.88 11.48 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.169 -0.469 . . . . 0.0 111.24 179.914 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 36' ' ' GLY . . . . . 0.506 ' HA2' HD23 ' A' ' 33' ' ' LEU . . . 56.54 32.01 60.74 Favored Glycine 0 N--CA 1.452 -0.244 0 C-N-CA 120.726 -0.749 . . . . 0.0 112.613 179.971 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 37' ' ' GLN . . . . . . . . . . . . . 29.9 mt-30 -142.2 -66.71 0.39 Allowed 'General case' 0 C--N 1.329 -0.284 0 CA-C-O 120.781 0.324 . . . . 0.0 110.975 179.96 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 38' ' ' LYS . . . . . 0.532 ' HB3' HD21 ' A' ' 60' ' ' LEU . 25.1 mmtp -72.95 112.22 8.78 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.244 -0.434 . . . . 0.0 110.902 -179.957 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 39' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -92.62 130.28 38.3 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.891 -179.967 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -161.16 -169.41 24.38 Favored Glycine 0 N--CA 1.451 -0.324 0 C-N-CA 120.749 -0.739 . . . . 0.0 112.56 179.977 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 41' ' ' ILE . . . . . 0.4 ' N ' HG23 ' A' ' 58' ' ' ILE . 8.9 mt -128.62 132.71 67.58 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-O 120.769 0.319 . . . . 0.0 111.087 -179.993 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 42' ' ' VAL . . . . . . . . . . . . . 21.5 t -59.53 125.2 15.2 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.361 0 CA-C-N 116.2 -0.454 . . . . 0.0 111.153 179.932 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 43' ' ' ARG . . . . . . . . . . . . . 10.1 mmt180 -110.51 -32.52 6.88 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.882 -179.954 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 44' ' ' PHE . . . . . . . . . . . . . 86.9 t80 -144.4 113.73 7.0 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.909 -179.995 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 45' ' ' TYR . . . . . 0.439 ' CE1' ' CZ ' ' A' ' 56' ' ' TYR . 27.1 t80 -113.15 111.73 22.6 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.925 179.989 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . -169.52 -150.38 6.76 Favored Glycine 0 N--CA 1.45 -0.391 0 C-N-CA 120.808 -0.711 . . . . 0.0 112.545 179.984 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 47' ' ' LYS . . . . . 0.411 ' HD3' ' CE1' ' A' ' 54' ' ' TYR . 2.2 mmmp? -96.77 168.84 10.26 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.792 0.33 . . . . 0.0 110.879 -179.93 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 48' ' ' THR . . . . . . . . . . . . . 64.6 p -132.43 178.15 7.05 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.837 179.947 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 32.3 t70 -112.55 -35.41 5.55 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.961 -179.975 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 50' ' ' PHE . . . . . . . . . . . . . 30.1 p90 -62.73 -31.04 71.9 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.949 -179.942 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 51' ' ' ALA . . . . . . . . . . . . . . . -151.74 151.96 29.38 Favored Pre-proline 0 C--N 1.329 -0.299 0 CA-C-N 116.237 -0.438 . . . . 0.0 111.107 -179.962 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 52' ' ' PRO . . . . . . . . . . . . . 58.2 Cg_endo -71.58 -176.89 2.17 Favored 'Trans proline' 0 C--N 1.345 0.347 0 C-N-CA 122.559 2.173 . . . . 0.0 112.3 179.928 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 75.12 -177.07 48.92 Favored Glycine 0 N--CA 1.451 -0.348 0 C-N-CA 120.756 -0.735 . . . . 0.0 112.54 -179.922 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 54' ' ' TYR . . . . . 0.411 ' CE1' ' HD3' ' A' ' 47' ' ' LYS . 10.1 m-85 -107.8 132.45 53.4 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 120.815 0.34 . . . . 0.0 110.916 179.994 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 55' ' ' TRP . . . . . 0.413 ' CZ3' ' HD3' ' A' ' 88' ' ' PRO . 19.0 m95 -120.07 173.31 7.16 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.852 -179.989 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 56' ' ' TYR . . . . . 0.615 ' HE1' ' HB2' ' A' ' 89' ' ' ALA . 10.8 m-85 -117.21 127.51 54.17 Favored 'General case' 0 C--N 1.331 -0.235 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.948 -179.904 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . -90.6 65.12 2.76 Favored Glycine 0 N--CA 1.45 -0.426 0 C-N-CA 120.746 -0.74 . . . . 0.0 112.426 -179.998 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 58' ' ' ILE . . . . . 0.444 HD12 HG22 ' A' ' 34' ' ' VAL . 25.3 mt -71.64 139.43 19.82 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-O 120.779 0.323 . . . . 0.0 111.135 -179.928 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 0.2 OUTLIER -108.49 111.0 22.64 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.826 -179.965 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 60' ' ' LEU . . . . . 0.711 HD13 HG23 ' A' ' 64' ' ' THR . 63.2 mt -63.93 167.89 5.73 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.308 -0.406 . . . . 0.0 110.846 -179.969 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -96.84 -26.1 15.23 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.947 -179.995 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 62' ' ' GLN . . . . . . . . . . . . . 64.9 mm-40 -124.26 152.36 67.56 Favored Pre-proline 0 C--N 1.329 -0.284 0 CA-C-N 116.369 -0.378 . . . . 0.0 110.908 -179.895 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 32.2 Cg_exo -58.19 92.52 0.06 OUTLIER 'Trans proline' 0 C--N 1.346 0.401 0 C-N-CA 122.579 2.186 . . . . 0.0 112.293 179.954 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 64' ' ' THR . . . . . 0.711 HG23 HD13 ' A' ' 60' ' ' LEU . 13.4 t -165.74 36.49 0.05 Allowed 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 116.283 -0.417 . . . . 0.0 110.932 179.873 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . -99.12 -140.11 11.26 Favored Glycine 0 N--CA 1.451 -0.344 0 C-N-CA 120.78 -0.724 . . . . 0.0 112.442 -179.993 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 66' ' ' LYS . . . . . . . . . . . . . 1.7 mttm -132.21 -46.55 0.92 Allowed 'General case' 0 C--N 1.328 -0.34 0 CA-C-O 120.822 0.344 . . . . 0.0 110.87 179.97 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 67' ' ' HIS . . . . . . . . . . . . . 12.4 p80 -127.27 174.69 8.75 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.233 -0.44 . . . . 0.0 110.92 179.901 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 1.6 m-20 -98.46 48.68 0.98 Allowed 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.928 179.998 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 84.44 -61.51 4.7 Favored Glycine 0 N--CA 1.451 -0.31 0 C-N-CA 120.715 -0.755 . . . . 0.0 112.486 -179.997 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 70' ' ' SER . . . . . . . . . . . . . 31.4 p -80.26 152.15 29.22 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-O 120.774 0.321 . . . . 0.0 110.802 -179.992 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 21.5 t -134.32 118.08 26.42 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.111 179.982 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 72' ' ' PHE . . . . . . . . . . . . . 28.8 m-85 60.58 31.05 20.16 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.884 179.937 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 98.35 -28.41 14.94 Favored Glycine 0 N--CA 1.451 -0.316 0 C-N-CA 120.741 -0.742 . . . . 0.0 112.462 -179.998 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 21.5 t -73.64 130.56 35.78 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-O 120.805 0.336 . . . . 0.0 111.133 179.998 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 75' ' ' ARG . . . . . . . . . . . . . 48.4 ttt-85 -93.71 144.23 25.59 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.901 179.963 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 76' ' ' TYR . . . . . . . . . . . . . 58.4 m-85 -124.85 -44.82 1.92 Allowed 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.867 -179.985 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 77' ' ' PHE . . . . . . . . . . . . . 32.7 p90 -166.91 177.44 6.37 Favored 'General case' 0 C--N 1.327 -0.383 0 CA-C-N 116.18 -0.463 . . . . 0.0 110.908 179.978 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 1.7 t -98.96 124.83 44.18 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.833 -179.93 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 79' ' ' CYS . . . . . . . . . . . . . 27.0 p -150.98 155.01 38.2 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.847 179.952 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 80' ' ' ALA . . . . . 0.524 ' HB1' ' HD2' ' A' ' 81' ' ' PRO . . . -67.99 166.84 20.4 Favored Pre-proline 0 C--N 1.328 -0.349 0 CA-C-N 116.159 -0.473 . . . . 0.0 111.049 179.956 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 81' ' ' PRO . . . . . 0.524 ' HD2' ' HB1' ' A' ' 80' ' ' ALA . 53.3 Cg_exo -52.63 117.07 3.31 Favored 'Trans proline' 0 C--N 1.345 0.362 0 C-N-CA 122.538 2.159 . . . . 0.0 112.324 -179.92 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 82' ' ' ARG . . . . . . . . . . . . . 2.9 ttm180 63.12 57.7 1.56 Allowed 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.978 179.985 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 83' ' ' HIS . . . . . 0.493 ' CE1' ' HB3' ' A' ' 80' ' ' ALA . 6.3 m170 -126.96 -46.98 1.52 Allowed 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.091 -0.504 . . . . 0.0 110.94 179.957 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . -62.86 139.31 44.85 Favored Glycine 0 N--CA 1.45 -0.388 0 C-N-CA 120.722 -0.752 . . . . 0.0 112.541 179.989 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 85' ' ' VAL . . . . . . . . . . . . . 5.5 m -147.21 124.18 3.19 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.257 0 CA-C-O 120.871 0.367 . . . . 0.0 111.062 -179.942 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 86' ' ' PHE . . . . . . . . . . . . . 13.5 m-85 -100.77 121.12 41.14 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.081 -0.508 . . . . 0.0 110.9 179.999 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 87' ' ' ALA . . . . . 0.605 ' O ' HD11 ' A' ' 92' ' ' ILE . . . -140.75 144.84 37.47 Favored Pre-proline 0 C--N 1.328 -0.33 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.161 179.975 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 88' ' ' PRO . . . . . 0.416 ' O ' ' N ' ' A' ' 91' ' ' ARG . 47.6 Cg_exo -56.06 141.25 87.11 Favored 'Trans proline' 0 C--N 1.345 0.394 0 C-N-CA 122.607 2.204 . . . . 0.0 112.224 -179.9 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 89' ' ' ALA . . . . . 0.615 ' HB2' ' HE1' ' A' ' 56' ' ' TYR . . . -47.96 -50.97 25.48 Favored 'General case' 0 CA--C 1.521 -0.149 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.295 179.854 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 90' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -55.83 -24.6 37.41 Favored 'General case' 0 C--N 1.331 -0.217 0 CA-C-N 115.68 -0.691 . . . . 0.0 109.673 178.841 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 91' ' ' ARG . . . . . 0.416 ' N ' ' O ' ' A' ' 88' ' ' PRO . 0.0 OUTLIER -87.6 -15.37 37.54 Favored 'General case' 0 N--CA 1.454 -0.244 0 CA-C-N 115.856 -0.611 . . . . 0.0 110.423 179.032 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 92' ' ' ILE . . . . . 0.605 HD11 ' O ' ' A' ' 87' ' ' ALA . 33.0 mt -104.63 145.89 12.61 Favored 'Isoleucine or valine' 0 C--N 1.333 -0.126 0 CA-C-N 116.397 -0.365 . . . . 0.0 111.066 179.864 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 93' ' ' GLN . . . . . . . . . . . . . 0.7 OUTLIER -114.83 -179.96 3.78 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.991 -179.973 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 94' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -126.08 142.88 51.33 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.877 -179.968 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 95' ' ' ILE . . . . . . . . . . . . . 3.3 mp -117.41 -37.66 2.02 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.108 -0.496 . . . . 0.0 111.172 179.981 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . -70.22 66.9 0.71 Allowed Glycine 0 N--CA 1.453 -0.224 0 C-N-CA 120.716 -0.754 . . . . 0.0 112.513 -179.945 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 97' ' ' SER . . . . . . . . . . . . . 45.0 m -120.49 170.81 9.04 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 120.839 0.352 . . . . 0.0 110.784 179.945 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 98' ' ' GLY . . . . . 0.408 ' N ' ' HD3' ' A' ' 99' ' ' PRO . . . -134.49 61.73 0.63 Allowed Glycine 0 N--CA 1.45 -0.404 0 C-N-CA 120.713 -0.756 . . . . 0.0 112.606 -179.991 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 99' ' ' PRO . . . . . 0.408 ' HD3' ' N ' ' A' ' 98' ' ' GLY . 35.7 Cg_exo -57.5 -36.49 98.69 Favored 'Trans proline' 0 C--N 1.344 0.297 0 C-N-CA 122.59 2.194 . . . . 0.0 112.186 -179.995 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 100' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -105.3 -175.39 2.78 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.824 -179.96 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 1.4 m -83.4 138.54 33.45 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.856 179.963 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.249 1.067 0 CA-C-O 118.368 -1.24 . . . . 0.0 112.475 179.997 . . . . . . . . 0 0 . 1 . 010 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.207 0 N-CA-C 112.477 -0.249 . . . . 0.0 112.477 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 17.7 t -128.49 112.31 14.21 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-O 120.79 0.329 . . . . 0.0 110.857 179.989 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 8.6 t 60.56 31.24 20.21 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.861 179.937 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -116.97 115.82 3.37 Favored Glycine 0 N--CA 1.452 -0.247 0 C-N-CA 120.794 -0.717 . . . . 0.0 112.451 -179.938 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 2.4 m -148.03 153.03 38.41 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 120.78 0.324 . . . . 0.0 110.918 179.99 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 6.2 m -96.44 141.23 29.99 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.907 179.959 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 145.83 101.33 0.3 Allowed Glycine 0 N--CA 1.451 -0.333 0 C-N-CA 120.721 -0.752 . . . . 0.0 112.503 -179.975 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 13.9 mttp -145.59 -58.54 0.33 Allowed 'General case' 0 C--N 1.33 -0.282 0 CA-C-O 120.767 0.317 . . . . 0.0 110.89 179.976 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -152.67 165.81 16.76 Favored Pre-proline 0 C--N 1.328 -0.352 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.856 -179.975 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 38.1 Cg_endo -66.44 123.22 10.84 Favored 'Trans proline' 0 C--N 1.344 0.297 0 C-N-CA 122.577 2.185 . . . . 0.0 112.297 179.933 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 69.2 m -88.11 -177.21 5.67 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.937 -179.975 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 53.0 m -127.01 144.64 51.11 Favored Pre-proline 0 C--N 1.329 -0.294 0 CA-C-N 116.263 -0.426 . . . . 0.0 110.888 179.97 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 67.9 Cg_endo -74.32 -37.17 2.68 Favored 'Trans proline' 0 C--N 1.345 0.382 0 C-N-CA 122.492 2.128 . . . . 0.0 112.35 -179.984 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 85.4 p -96.33 41.95 1.1 Allowed 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.944 179.979 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 4.3 tp -166.92 89.13 0.34 Allowed 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.919 179.942 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 101.67 -60.34 0.58 Allowed Glycine 0 N--CA 1.451 -0.306 0 C-N-CA 120.687 -0.768 . . . . 0.0 112.467 179.969 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 1.9 m 60.96 160.07 0.05 OUTLIER 'General case' 0 C--N 1.328 -0.36 0 CA-C-O 120.833 0.349 . . . . 0.0 110.858 179.987 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -109.57 -30.72 7.78 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.923 179.966 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 19' ' ' GLN . . . . . . . . . . . . . 1.6 tt0 61.24 42.45 12.02 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.838 179.94 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 20' ' ' GLN . . . . . . . . . . . . . 3.2 tt0 -157.54 -45.9 0.07 Allowed 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.895 179.911 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 9.0 ttt-85 -68.84 111.17 4.74 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.185 -0.462 . . . . 0.0 110.968 179.947 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 0.9 OUTLIER -117.16 -65.62 1.17 Allowed 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.837 -179.975 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 109.43 28.56 4.27 Favored Glycine 0 N--CA 1.451 -0.321 0 C-N-CA 120.808 -0.71 . . . . 0.0 112.488 179.99 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -136.58 -179.48 5.72 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 120.871 0.367 . . . . 0.0 111.034 179.99 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 4.0 tttp -145.59 -47.51 0.22 Allowed 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.904 -179.989 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -119.82 171.62 8.28 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.134 179.992 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 27' ' ' GLU . . . . . . . . . . . . . 28.7 mt-10 -139.41 178.31 7.29 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.946 179.972 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 28.9 t -72.31 115.7 13.18 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.219 -0.446 . . . . 0.0 111.049 -179.979 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 102.43 33.96 4.33 Favored Glycine 0 N--CA 1.452 -0.298 0 C-N-CA 120.716 -0.754 . . . . 0.0 112.443 179.969 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 13.3 m-20 -141.42 148.35 39.42 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-O 120.822 0.344 . . . . 0.0 110.912 179.92 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 31' ' ' GLN . . . . . . . . . . . . . 3.5 mp0 -72.74 137.33 45.82 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.955 179.975 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 32' ' ' VAL . . . . . 0.449 ' HB ' HG22 ' A' ' 92' ' ' ILE . 14.8 m -146.55 177.53 1.3 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 116.262 -0.426 . . . . 0.0 111.112 179.984 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 33' ' ' LEU . . . . . 0.504 HD23 ' HA2' ' A' ' 36' ' ' GLY . 21.7 tp -134.15 112.36 11.06 Favored 'General case' 0 C--N 1.33 -0.283 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.794 -179.998 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 34' ' ' VAL . . . . . 0.747 HG22 HD12 ' A' ' 58' ' ' ILE . 21.9 t -76.03 123.74 32.77 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.145 -0.479 . . . . 0.0 111.127 -179.949 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 35' ' ' ALA . . . . . . . . . . . . . . . 59.28 25.56 14.22 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.153 -0.476 . . . . 0.0 111.229 179.979 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 36' ' ' GLY . . . . . 0.504 ' HA2' HD23 ' A' ' 33' ' ' LEU . . . 55.95 27.88 51.88 Favored Glycine 0 N--CA 1.452 -0.252 0 C-N-CA 120.759 -0.734 . . . . 0.0 112.633 -179.993 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 37' ' ' GLN . . . . . 0.45 ' O ' HD11 ' A' ' 33' ' ' LEU . 24.9 mt-30 -142.64 -69.23 0.35 Allowed 'General case' 0 C--N 1.329 -0.285 0 CA-C-O 120.885 0.374 . . . . 0.0 110.925 179.957 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 38' ' ' LYS . . . . . . . . . . . . . 19.3 mttp -67.15 119.73 12.56 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.929 179.985 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 39' ' ' GLN . . . . . 0.43 ' HA ' HD12 ' A' ' 33' ' ' LEU . 0.0 OUTLIER -87.09 133.03 33.65 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.886 -179.999 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -162.33 169.76 37.75 Favored Glycine 0 N--CA 1.45 -0.371 0 C-N-CA 120.742 -0.742 . . . . 0.0 112.557 -179.969 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 23.2 mt -116.03 146.22 20.75 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.352 0 CA-C-O 120.799 0.333 . . . . 0.0 111.061 -179.99 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 42' ' ' VAL . . . . . . . . . . . . . 33.3 t -69.49 124.95 26.51 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.212 -0.449 . . . . 0.0 111.042 179.946 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 43' ' ' ARG . . . . . . . . . . . . . 2.9 mmm180 -111.84 -43.39 3.62 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.894 179.99 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 44' ' ' PHE . . . . . . . . . . . . . 49.7 t80 -136.7 113.16 10.02 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.86 -179.897 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 45' ' ' TYR . . . . . 0.495 ' CE1' ' CE1' ' A' ' 56' ' ' TYR . 14.1 t80 -112.9 131.57 55.67 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.272 -0.422 . . . . 0.0 110.872 179.965 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 156.17 -172.45 34.05 Favored Glycine 0 N--CA 1.451 -0.364 0 C-N-CA 120.763 -0.732 . . . . 0.0 112.524 -179.968 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 47' ' ' LYS . . . . . 0.433 ' HG3' ' CZ ' ' A' ' 54' ' ' TYR . 98.5 mttt -69.01 155.86 39.62 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 120.768 0.318 . . . . 0.0 110.915 179.968 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 48' ' ' THR . . . . . 0.635 HG21 ' CZ ' ' A' ' 50' ' ' PHE . 7.2 p -122.69 170.08 10.41 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.858 -179.943 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -102.33 -31.28 10.59 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.93 179.957 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 50' ' ' PHE . . . . . 0.635 ' CZ ' HG21 ' A' ' 48' ' ' THR . 18.0 p90 -73.66 -31.63 63.58 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.915 179.951 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 51' ' ' ALA . . . . . . . . . . . . . . . -140.51 147.95 51.45 Favored Pre-proline 0 C--N 1.33 -0.269 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.096 -179.895 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 52' ' ' PRO . . . . . . . . . . . . . 60.0 Cg_endo -72.25 176.9 7.93 Favored 'Trans proline' 0 C--N 1.344 0.32 0 C-N-CA 122.578 2.185 . . . . 0.0 112.402 179.902 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 72.45 -155.97 51.73 Favored Glycine 0 N--CA 1.45 -0.397 0 C-N-CA 120.771 -0.728 . . . . 0.0 112.592 179.947 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 54' ' ' TYR . . . . . 0.433 ' CZ ' ' HG3' ' A' ' 47' ' ' LYS . 10.8 m-85 -115.86 137.63 51.91 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-O 120.894 0.378 . . . . 0.0 110.856 -179.989 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 55' ' ' TRP . . . . . . . . . . . . . 52.0 m95 -126.37 164.25 21.48 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.835 179.977 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 56' ' ' TYR . . . . . 0.794 ' CE1' ' HB2' ' A' ' 89' ' ' ALA . 25.9 m-85 -114.42 120.88 41.81 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.968 179.963 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 57' ' ' GLY . . . . . 0.426 ' HA3' ' CE1' ' A' ' 77' ' ' PHE . . . -83.07 61.25 4.81 Favored Glycine 0 N--CA 1.45 -0.387 0 C-N-CA 120.73 -0.748 . . . . 0.0 112.401 179.995 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 58' ' ' ILE . . . . . 0.747 HD12 HG22 ' A' ' 34' ' ' VAL . 45.2 mt -69.33 145.13 13.43 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-O 120.827 0.346 . . . . 0.0 111.098 -179.899 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 5.6 tm-20 -112.83 132.77 55.13 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.797 -179.961 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 60' ' ' LEU . . . . . . . . . . . . . 39.3 mt -93.1 158.76 15.61 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.202 -0.453 . . . . 0.0 110.93 -179.994 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 32.6 t0 -100.26 31.17 3.49 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.918 179.931 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 62' ' ' GLN . . . . . . . . . . . . . 1.8 pm0 -157.46 149.05 17.02 Favored Pre-proline 0 C--N 1.33 -0.276 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.846 179.965 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 56.4 Cg_endo -70.28 63.67 2.09 Favored 'Trans proline' 0 C--N 1.344 0.314 0 C-N-CA 122.631 2.221 . . . . 0.0 112.284 -179.994 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 64' ' ' THR . . . . . . . . . . . . . 5.4 p -145.23 30.84 1.12 Allowed 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.972 179.901 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . -79.37 -159.26 15.92 Favored Glycine 0 N--CA 1.451 -0.361 0 C-N-CA 120.714 -0.755 . . . . 0.0 112.48 179.989 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 66' ' ' LYS . . . . . . . . . . . . . 7.0 mtpm? -111.53 -33.74 6.29 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 120.813 0.34 . . . . 0.0 110.928 179.969 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 67' ' ' HIS . . . . . . . . . . . . . 6.0 p80 -139.12 174.07 10.9 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.911 179.921 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 1.3 t70 -97.85 37.07 1.44 Allowed 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.951 179.973 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 95.19 -65.21 1.33 Allowed Glycine 0 N--CA 1.451 -0.337 0 C-N-CA 120.703 -0.76 . . . . 0.0 112.511 -179.965 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 70' ' ' SER . . . . . . . . . . . . . 3.1 p -89.57 133.34 34.65 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 120.807 0.337 . . . . 0.0 110.836 -179.931 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 71' ' ' VAL . . . . . 0.691 HG12 ' CD2' ' A' ' 72' ' ' PHE . 21.5 t -114.21 114.76 47.62 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.202 -0.454 . . . . 0.0 111.111 -179.982 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 72' ' ' PHE . . . . . 0.691 ' CD2' HG12 ' A' ' 71' ' ' VAL . 13.9 m-85 60.73 31.11 20.09 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.949 179.99 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 98.8 -29.36 11.81 Favored Glycine 0 N--CA 1.451 -0.324 0 C-N-CA 120.752 -0.737 . . . . 0.0 112.485 -179.956 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 21.5 t -76.97 123.56 33.74 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-O 120.797 0.332 . . . . 0.0 111.092 -179.944 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 75' ' ' ARG . . . . . . . . . . . . . 11.4 ttm180 -101.1 134.04 44.7 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.884 179.996 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 76' ' ' TYR . . . . . . . . . . . . . 51.7 m-85 -109.67 -31.15 7.57 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.998 179.922 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 77' ' ' PHE . . . . . 0.426 ' CE1' ' HA3' ' A' ' 57' ' ' GLY . 27.0 p90 -172.85 156.39 3.4 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.941 179.98 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 12.3 m -85.75 111.2 19.92 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.798 179.968 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 79' ' ' CYS . . . . . . . . . . . . . 27.1 p -134.86 164.31 27.86 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.31 -0.405 . . . . 0.0 110.995 -179.929 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 80' ' ' ALA . . . . . 0.727 ' HB1' ' HD2' ' A' ' 81' ' ' PRO . . . -63.55 165.86 10.72 Favored Pre-proline 0 C--N 1.328 -0.337 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.949 179.879 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 81' ' ' PRO . . . . . 0.727 ' HD2' ' HB1' ' A' ' 80' ' ' ALA . 20.5 Cg_endo -60.85 114.97 2.39 Favored 'Trans proline' 0 C--N 1.345 0.364 0 C-N-CA 122.58 2.187 . . . . 0.0 112.146 179.876 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 82' ' ' ARG . . . . . . . . . . . . . 49.7 mtt180 64.4 58.69 1.06 Allowed 'General case' 0 C--N 1.331 -0.232 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.752 -179.969 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 83' ' ' HIS . . . . . 0.524 ' CG ' ' HB3' ' A' ' 80' ' ' ALA . 5.7 m-70 -130.7 -48.56 1.05 Allowed 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.899 179.927 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . -60.48 140.29 48.06 Favored Glycine 0 N--CA 1.452 -0.273 0 C-N-CA 120.741 -0.742 . . . . 0.0 112.531 -179.99 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 85' ' ' VAL . . . . . . . . . . . . . 10.1 m -142.59 130.52 20.12 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-O 120.823 0.344 . . . . 0.0 111.096 179.937 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 86' ' ' PHE . . . . . 0.409 ' CE1' ' CA ' ' A' ' 57' ' ' GLY . 8.6 m-85 -103.66 114.0 27.93 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.924 -179.963 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 87' ' ' ALA . . . . . 0.626 ' O ' HD11 ' A' ' 92' ' ' ILE . . . -134.28 145.4 55.23 Favored Pre-proline 0 C--N 1.331 -0.237 0 CA-C-N 116.259 -0.428 . . . . 0.0 111.067 -179.949 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 88' ' ' PRO . . . . . 0.41 ' O ' ' N ' ' A' ' 91' ' ' ARG . 36.5 Cg_exo -57.45 140.57 93.58 Favored 'Trans proline' 0 C--N 1.345 0.356 0 C-N-CA 122.527 2.151 . . . . 0.0 112.236 -179.981 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 89' ' ' ALA . . . . . 0.794 ' HB2' ' CE1' ' A' ' 56' ' ' TYR . . . -48.24 -50.27 30.13 Favored 'General case' 0 CA--C 1.521 -0.162 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.262 179.809 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 90' ' ' SER . . . . . . . . . . . . . 2.7 m -55.9 -24.51 37.82 Favored 'General case' 0 N--CA 1.455 -0.223 0 CA-C-N 115.706 -0.679 . . . . 0.0 109.789 178.767 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 91' ' ' ARG . . . . . 0.41 ' N ' ' O ' ' A' ' 88' ' ' PRO . 0.2 OUTLIER -88.54 -14.19 38.29 Favored 'General case' 0 N--CA 1.455 -0.177 0 CA-C-N 115.865 -0.607 . . . . 0.0 110.391 179.1 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 92' ' ' ILE . . . . . 0.704 HD13 HD11 ' A' ' 58' ' ' ILE . 21.4 mt -108.12 139.82 28.88 Favored 'Isoleucine or valine' 0 C--O 1.232 0.154 0 CA-C-N 116.45 -0.341 . . . . 0.0 111.061 179.808 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 93' ' ' GLN . . . . . . . . . . . . . 8.7 mt-30 -106.7 171.72 7.21 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.892 179.997 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 94' ' ' ARG . . . . . . . . . . . . . 3.4 ttt-85 -111.79 154.18 25.45 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.902 179.929 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 95' ' ' ILE . . . . . . . . . . . . . 31.8 mt -122.37 -64.86 1.39 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.326 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.155 179.997 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . 123.7 161.75 11.24 Favored Glycine 0 N--CA 1.452 -0.296 0 C-N-CA 120.779 -0.725 . . . . 0.0 112.41 -179.972 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 97' ' ' SER . . . . . . . . . . . . . 93.6 p -73.21 115.81 12.99 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 120.84 0.352 . . . . 0.0 110.912 179.975 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 98' ' ' GLY . . . . . . . . . . . . . . . 93.14 83.87 1.55 Allowed Glycine 0 N--CA 1.451 -0.313 0 C-N-CA 120.725 -0.75 . . . . 0.0 112.517 179.966 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 99' ' ' PRO . . . . . . . . . . . . . 50.5 Cg_endo -69.21 -28.15 28.25 Favored 'Trans proline' 0 C--N 1.345 0.371 0 C-N-CA 122.585 2.19 . . . . 0.0 112.297 179.978 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 100' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -134.55 -48.25 0.76 Allowed 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.924 -179.987 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 20.2 t -110.94 127.75 55.59 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.922 179.998 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.249 1.065 0 CA-C-O 118.337 -1.257 . . . . 0.0 112.516 179.965 . . . . . . . . 0 0 . 1 . 011 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.181 0 N-CA-C 112.496 -0.242 . . . . 0.0 112.496 . . . . . . . . . 0 0 . 1 . 011 nuclear nobuild full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 1.3 p -153.32 120.93 5.95 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-O 120.769 0.319 . . . . 0.0 110.93 179.995 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER 60.54 106.6 0.02 OUTLIER 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 116.222 -0.444 . . . . 0.0 110.906 179.998 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 108.27 -70.28 0.21 Allowed Glycine 0 N--CA 1.45 -0.376 0 C-N-CA 120.768 -0.73 . . . . 0.0 112.568 -179.904 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -73.35 149.85 42.27 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-O 120.847 0.356 . . . . 0.0 110.894 179.948 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -76.71 -52.22 10.01 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.145 -0.479 . . . . 0.0 110.855 -179.977 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 69.87 118.32 0.03 OUTLIER Glycine 0 N--CA 1.45 -0.381 0 C-N-CA 120.676 -0.774 . . . . 0.0 112.549 -179.927 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 3.7 ttpp 60.44 34.55 20.51 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-O 120.821 0.343 . . . . 0.0 110.864 -179.981 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 86.9 p -175.52 90.41 0.29 Allowed Pre-proline 0 C--N 1.328 -0.341 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.835 -179.948 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 75.3 Cg_exo -50.64 118.61 4.27 Favored 'Trans proline' 0 C--N 1.345 0.343 0 C-N-CA 122.537 2.158 . . . . 0.0 112.391 -179.968 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 52.4 p -153.89 122.43 6.24 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.167 -0.469 . . . . 0.0 110.85 -179.998 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 1.3 m -87.53 147.04 40.81 Favored Pre-proline 0 C--N 1.329 -0.283 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.875 -179.986 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 63.3 Cg_endo -73.57 61.69 4.43 Favored 'Trans proline' 0 C--N 1.344 0.313 0 C-N-CA 122.559 2.173 . . . . 0.0 112.287 -179.981 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 1.3 m -170.54 72.26 0.06 Allowed 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.968 179.911 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -160.93 -45.27 0.04 OUTLIER 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.82 -179.958 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -148.18 38.84 1.02 Allowed Glycine 0 N--CA 1.451 -0.348 0 C-N-CA 120.739 -0.743 . . . . 0.0 112.463 -179.996 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 1.8 t 60.73 -176.66 0.11 Allowed 'General case' 0 C--N 1.33 -0.269 0 CA-C-O 120.807 0.337 . . . . 0.0 110.926 -179.994 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 18' ' ' LEU . . . . . 0.675 HD12 ' N ' ' A' ' 19' ' ' GLN . 2.2 pp -136.63 -47.01 0.61 Allowed 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.911 179.978 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 19' ' ' GLN . . . . . 0.675 ' N ' HD12 ' A' ' 18' ' ' LEU . 35.8 tt0 -147.3 -62.58 0.28 Allowed 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.268 -0.424 . . . . 0.0 110.89 179.969 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 20' ' ' GLN . . . . . . . . . . . . . 21.8 mt-30 -127.29 -50.9 1.41 Allowed 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.892 -179.978 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 2.3 ttp180 -72.89 121.27 19.74 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.189 -0.459 . . . . 0.0 110.88 -179.987 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 4.2 pt-20 -87.48 167.31 14.1 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.809 179.951 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -102.07 30.8 9.64 Favored Glycine 0 N--CA 1.451 -0.302 0 C-N-CA 120.74 -0.743 . . . . 0.0 112.547 -179.997 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -93.99 117.05 29.57 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-O 120.795 0.331 . . . . 0.0 111.12 -179.967 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 25' ' ' LYS . . . . . 0.5 ' HB2' ' HB1' ' A' ' 89' ' ' ALA . 1.1 mpmm? -69.86 -41.42 74.85 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.244 -0.435 . . . . 0.0 110.902 179.967 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -144.21 178.29 8.0 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.157 -0.474 . . . . 0.0 111.143 -179.995 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 27' ' ' GLU . . . . . . . . . . . . . 30.4 mt-10 -145.56 -178.36 6.04 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.901 -179.992 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 21.5 t -75.85 116.62 19.08 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.211 -0.449 . . . . 0.0 111.144 -179.954 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 101.35 36.65 3.77 Favored Glycine 0 N--CA 1.45 -0.416 0 C-N-CA 120.766 -0.73 . . . . 0.0 112.47 -179.992 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -144.79 151.67 39.17 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 120.778 0.323 . . . . 0.0 110.898 -179.991 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 31' ' ' GLN . . . . . . . . . . . . . 2.7 mp0 -72.11 125.78 28.14 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.233 -0.439 . . . . 0.0 110.891 179.984 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 32' ' ' VAL . . . . . 0.537 HG21 HG12 ' A' ' 58' ' ' ILE . 27.5 m -127.04 174.57 10.57 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.138 -0.483 . . . . 0.0 111.143 179.964 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 33' ' ' LEU . . . . . 0.702 ' HB2' HD11 ' A' ' 95' ' ' ILE . 25.8 tp -143.22 102.54 4.0 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.852 -179.923 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 34' ' ' VAL . . . . . 0.565 ' CG2' HD13 ' A' ' 58' ' ' ILE . 21.4 t -72.65 128.57 35.6 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.148 -0.478 . . . . 0.0 111.147 -179.92 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 35' ' ' ALA . . . . . . . . . . . . . . . 57.18 25.08 10.54 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.065 -0.516 . . . . 0.0 111.304 179.936 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . 56.38 31.22 59.53 Favored Glycine 0 N--CA 1.451 -0.344 0 C-N-CA 120.752 -0.737 . . . . 0.0 112.604 -179.986 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 37' ' ' GLN . . . . . 0.616 ' O ' HD11 ' A' ' 33' ' ' LEU . 81.6 mt-30 -146.3 -70.86 0.25 Allowed 'General case' 0 C--N 1.329 -0.29 0 CA-C-O 120.79 0.329 . . . . 0.0 110.906 -179.92 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 38' ' ' LYS . . . . . . . . . . . . . 12.6 mttt -61.71 105.05 0.5 Allowed 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.905 -179.988 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 39' ' ' GLN . . . . . 0.507 ' CD ' HD13 ' A' ' 95' ' ' ILE . 0.0 OUTLIER -85.1 132.02 34.37 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.902 179.942 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -158.39 -170.19 22.78 Favored Glycine 0 N--CA 1.451 -0.358 0 C-N-CA 120.709 -0.758 . . . . 0.0 112.438 179.977 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 32.2 mt -129.55 129.74 66.87 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-O 120.798 0.332 . . . . 0.0 111.046 -179.959 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 42' ' ' VAL . . . . . . . . . . . . . 21.4 t -58.46 125.22 14.12 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.172 179.973 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 43' ' ' ARG . . . . . . . . . . . . . 36.6 mmt180 -108.18 -31.53 7.87 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.87 -179.973 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 44' ' ' PHE . . . . . . . . . . . . . 41.0 t80 -148.78 113.81 5.47 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.922 179.926 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 45' ' ' TYR . . . . . 0.471 ' CE1' ' CZ ' ' A' ' 56' ' ' TYR . 33.7 t80 -112.3 142.93 44.2 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.884 179.974 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 148.92 -168.99 29.4 Favored Glycine 0 N--CA 1.451 -0.327 0 C-N-CA 120.732 -0.747 . . . . 0.0 112.492 -179.982 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 47' ' ' LYS . . . . . 0.414 ' HE2' ' CZ ' ' A' ' 54' ' ' TYR . 22.2 mttm -87.39 141.58 28.53 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-O 120.851 0.357 . . . . 0.0 110.869 -179.98 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 48' ' ' THR . . . . . 0.666 HG21 ' CE2' ' A' ' 50' ' ' PHE . 63.6 p -102.18 -177.12 3.31 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.85 179.983 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 1.3 t70 -112.85 15.86 19.67 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.159 -0.473 . . . . 0.0 111.242 -179.958 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 50' ' ' PHE . . . . . 0.666 ' CE2' HG21 ' A' ' 48' ' ' THR . 29.2 p90 -116.38 -36.65 3.94 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-O 120.727 0.299 . . . . 0.0 110.996 179.846 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 51' ' ' ALA . . . . . 0.445 ' N ' ' CD1' ' A' ' 50' ' ' PHE . . . -140.26 146.71 47.04 Favored Pre-proline 0 C--N 1.328 -0.332 0 CA-C-N 116.249 -0.432 . . . . 0.0 111.126 179.924 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 52' ' ' PRO . . . . . . . . . . . . . 60.0 Cg_endo -72.42 170.81 18.37 Favored 'Trans proline' 0 C--N 1.345 0.388 0 C-N-CA 122.505 2.137 . . . . 0.0 112.353 -179.957 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 90.66 -154.08 23.01 Favored Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.778 -0.725 . . . . 0.0 112.525 179.939 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 54' ' ' TYR . . . . . 0.414 ' CZ ' ' HE2' ' A' ' 47' ' ' LYS . 57.4 m-85 -125.23 124.45 41.71 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 120.872 0.368 . . . . 0.0 110.867 179.963 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 55' ' ' TRP . . . . . . . . . . . . . 65.3 m95 -115.13 161.83 17.86 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.936 179.95 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 56' ' ' TYR . . . . . 0.569 ' HE1' ' HB2' ' A' ' 89' ' ' ALA . 10.8 m-85 -117.68 120.07 36.89 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.211 -0.449 . . . . 0.0 110.92 -179.887 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 57' ' ' GLY . . . . . 0.45 ' CA ' ' CE1' ' A' ' 86' ' ' PHE . . . -84.71 63.8 4.35 Favored Glycine 0 N--CA 1.452 -0.298 0 C-N-CA 120.681 -0.771 . . . . 0.0 112.392 179.997 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 58' ' ' ILE . . . . . 0.729 HD11 HD13 ' A' ' 92' ' ' ILE . 3.3 mt -70.24 146.95 11.87 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.23 0 CA-C-O 120.807 0.337 . . . . 0.0 111.128 -179.966 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 3.7 tm-20 -116.91 109.8 17.51 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.841 -179.979 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 60' ' ' LEU . . . . . 0.743 HD13 HG23 ' A' ' 64' ' ' THR . 96.0 mt -63.55 172.84 1.87 Allowed 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.912 179.932 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -98.5 -32.54 11.41 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.289 -0.414 . . . . 0.0 110.924 -179.978 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 62' ' ' GLN . . . . . 0.519 ' O ' HG22 ' A' ' 64' ' ' THR . 4.7 mm-40 -118.42 151.34 49.44 Favored Pre-proline 0 C--N 1.33 -0.264 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.94 -179.998 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 52.1 Cg_exo -54.66 99.95 0.06 OUTLIER 'Trans proline' 0 C--N 1.345 0.362 0 C-N-CA 122.485 2.123 . . . . 0.0 112.286 -179.958 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 64' ' ' THR . . . . . 0.743 HG23 HD13 ' A' ' 60' ' ' LEU . 9.8 t -176.98 39.01 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.872 179.983 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . -95.87 -125.43 4.73 Favored Glycine 0 N--CA 1.45 -0.37 0 C-N-CA 120.713 -0.756 . . . . 0.0 112.475 179.98 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 66' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -144.17 -47.71 0.27 Allowed 'General case' 0 C--N 1.329 -0.284 0 CA-C-O 120.825 0.345 . . . . 0.0 110.833 -179.869 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 67' ' ' HIS . . . . . . . . . . . . . 6.4 p80 -122.84 177.43 5.48 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.191 -0.458 . . . . 0.0 110.884 179.984 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -100.15 35.35 2.09 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.891 -179.987 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 100.99 -70.18 0.42 Allowed Glycine 0 N--CA 1.451 -0.365 0 C-N-CA 120.756 -0.735 . . . . 0.0 112.465 179.944 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 70' ' ' SER . . . . . . . . . . . . . 78.4 p -81.68 148.85 28.79 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 120.85 0.357 . . . . 0.0 110.868 179.987 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 71' ' ' VAL . . . . . 0.494 HG12 ' CD2' ' A' ' 72' ' ' PHE . 27.3 t -127.67 125.94 66.17 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.167 -0.47 . . . . 0.0 111.11 179.93 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 72' ' ' PHE . . . . . 0.494 ' CD2' HG12 ' A' ' 71' ' ' VAL . 47.7 m-85 60.08 28.02 17.52 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.99 -179.929 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 95.97 -30.03 9.11 Favored Glycine 0 N--CA 1.451 -0.307 0 C-N-CA 120.628 -0.796 . . . . 0.0 112.538 179.951 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 21.6 t -80.47 122.95 36.59 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-O 120.784 0.326 . . . . 0.0 111.074 -179.939 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 75' ' ' ARG . . . . . . . . . . . . . 21.2 ttm180 -88.96 146.26 25.01 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.224 -0.443 . . . . 0.0 110.922 -179.997 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 76' ' ' TYR . . . . . 0.424 ' CE2' HG22 ' A' ' 48' ' ' THR . 37.0 m-85 -119.26 -47.75 2.45 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.185 -0.462 . . . . 0.0 110.897 -179.977 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 77' ' ' PHE . . . . . . . . . . . . . 34.8 p90 -152.79 171.4 18.3 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.922 179.972 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 4.6 p -97.26 122.56 40.42 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.904 -179.97 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 79' ' ' CYS . . . . . . . . . . . . . 27.3 p -143.87 176.74 9.03 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.906 179.963 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 80' ' ' ALA . . . . . 0.618 ' HB3' ' CG ' ' A' ' 83' ' ' HIS . . . -90.43 168.95 13.02 Favored Pre-proline 0 C--N 1.329 -0.308 0 CA-C-N 116.229 -0.441 . . . . 0.0 111.077 179.96 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 81' ' ' PRO . . . . . 0.597 ' HD2' ' HB1' ' A' ' 80' ' ' ALA . 52.7 Cg_exo -52.59 113.6 1.3 Allowed 'Trans proline' 0 C--N 1.344 0.303 0 C-N-CA 122.557 2.171 . . . . 0.0 112.261 179.93 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 82' ' ' ARG . . . . . . . . . . . . . 9.2 mmt180 61.27 53.59 3.47 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.907 -179.987 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 83' ' ' HIS . . . . . 0.618 ' CG ' ' HB3' ' A' ' 80' ' ' ALA . 5.5 m170 -121.17 -42.4 2.48 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.125 -0.489 . . . . 0.0 110.918 179.989 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 84' ' ' GLY . . . . . 0.433 ' O ' HG13 ' A' ' 85' ' ' VAL . . . -63.7 154.67 45.67 Favored Glycine 0 N--CA 1.45 -0.368 0 C-N-CA 120.745 -0.741 . . . . 0.0 112.511 179.933 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 85' ' ' VAL . . . . . 0.433 HG13 ' O ' ' A' ' 84' ' ' GLY . 15.2 m -156.27 127.27 0.87 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-O 120.84 0.352 . . . . 0.0 111.191 -179.96 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 86' ' ' PHE . . . . . 0.45 ' CE1' ' CA ' ' A' ' 57' ' ' GLY . 7.9 m-85 -112.53 102.09 10.21 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.818 179.942 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 87' ' ' ALA . . . . . 0.454 ' CB ' HG13 ' A' ' 34' ' ' VAL . . . -123.19 145.86 47.45 Favored Pre-proline 0 C--N 1.329 -0.297 0 CA-C-N 116.245 -0.434 . . . . 0.0 111.119 -179.956 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 88' ' ' PRO . . . . . 0.41 ' O ' ' N ' ' A' ' 91' ' ' ARG . 32.3 Cg_exo -58.02 141.94 96.5 Favored 'Trans proline' 0 C--N 1.346 0.4 0 C-N-CA 122.498 2.132 . . . . 0.0 112.235 179.991 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 89' ' ' ALA . . . . . 0.569 ' HB2' ' HE1' ' A' ' 56' ' ' TYR . . . -47.9 -51.44 23.24 Favored 'General case' 0 CA--C 1.522 -0.116 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.346 179.859 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 90' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -55.99 -24.29 37.84 Favored 'General case' 0 N--CA 1.454 -0.27 0 CA-C-N 115.759 -0.655 . . . . 0.0 109.789 178.836 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 91' ' ' ARG . . . . . 0.41 ' N ' ' O ' ' A' ' 88' ' ' PRO . 0.0 OUTLIER -89.77 -14.08 35.34 Favored 'General case' 0 N--CA 1.455 -0.208 0 CA-C-N 115.945 -0.571 . . . . 0.0 110.526 179.029 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 92' ' ' ILE . . . . . 0.729 HD13 HD11 ' A' ' 58' ' ' ILE . 52.4 mt -110.56 156.04 11.73 Favored 'Isoleucine or valine' 0 C--O 1.23 0.077 0 CA-C-O 120.904 0.383 . . . . 0.0 111.04 179.864 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 93' ' ' GLN . . . . . 0.448 ' N ' HG22 ' A' ' 92' ' ' ILE . 1.9 mt-30 -124.31 179.98 4.69 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.78 179.93 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 94' ' ' ARG . . . . . . . . . . . . . 4.2 ttt180 -126.08 142.18 51.63 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.936 179.993 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 95' ' ' ILE . . . . . 0.702 HD11 ' HB2' ' A' ' 33' ' ' LEU . 3.4 mt -124.72 23.82 3.59 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.246 -0.434 . . . . 0.0 111.088 179.982 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . -96.85 161.5 21.89 Favored Glycine 0 N--CA 1.45 -0.404 0 C-N-CA 120.721 -0.752 . . . . 0.0 112.512 179.975 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 97' ' ' SER . . . . . . . . . . . . . 9.8 m -86.06 84.24 7.56 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-O 120.854 0.359 . . . . 0.0 110.902 179.986 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 98' ' ' GLY . . . . . . . . . . . . . . . -108.46 -79.9 1.19 Allowed Glycine 0 N--CA 1.451 -0.35 0 C-N-CA 120.709 -0.758 . . . . 0.0 112.511 -179.977 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 99' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_exo -52.24 103.92 0.09 OUTLIER 'Trans proline' 0 C--N 1.343 0.282 0 C-N-CA 122.623 2.215 . . . . 0.0 112.372 179.975 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 100' ' ' SER . . . . . . . . . . . . . 26.3 p -165.37 -44.22 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.86 -179.988 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER 60.84 35.65 19.31 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.811 179.959 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.249 1.069 0 CA-C-O 118.364 -1.242 . . . . 0.0 112.503 179.977 . . . . . . . . 0 0 . 1 . 012 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.275 0 N-CA-C 112.455 -0.258 . . . . 0.0 112.455 . . . . . . . . . 0 0 . 1 . 012 nuclear nobuild full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER -99.61 35.7 1.93 Allowed 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 120.778 0.323 . . . . 0.0 110.887 -179.962 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 2.5 m -134.8 33.94 3.18 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.264 -0.425 . . . . 0.0 110.967 -179.967 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 74.15 165.99 13.41 Favored Glycine 0 N--CA 1.451 -0.303 0 C-N-CA 120.713 -0.756 . . . . 0.0 112.64 179.985 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -141.15 -67.71 0.4 Allowed 'General case' 0 C--N 1.33 -0.276 0 CA-C-O 120.814 0.34 . . . . 0.0 110.819 -179.979 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 56.9 p -104.23 121.64 43.72 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.165 -0.471 . . . . 0.0 110.945 179.986 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 154.07 100.11 0.18 Allowed Glycine 0 N--CA 1.451 -0.349 0 C-N-CA 120.775 -0.726 . . . . 0.0 112.504 -179.972 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 9.2 tttp -162.42 127.46 3.29 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-O 120.813 0.339 . . . . 0.0 110.924 179.998 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 4.1 p -158.36 80.06 3.05 Favored Pre-proline 0 C--N 1.328 -0.339 0 CA-C-N 116.242 -0.436 . . . . 0.0 110.975 179.953 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 48.5 Cg_exo -55.81 -21.01 30.96 Favored 'Trans proline' 0 C--N 1.344 0.301 0 C-N-CA 122.669 2.246 . . . . 0.0 112.427 -179.973 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 89.2 p -54.09 -29.1 43.3 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-N 116.371 -0.377 . . . . 0.0 111.171 -179.915 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 4.0 m -112.03 73.4 1.25 Allowed Pre-proline 0 C--N 1.33 -0.276 0 CA-C-N 116.278 -0.419 . . . . 0.0 110.861 -179.974 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 61.0 Cg_endo -73.23 -37.55 3.29 Favored 'Trans proline' 0 C--N 1.344 0.32 0 C-N-CA 122.543 2.162 . . . . 0.0 112.25 -179.999 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 14' ' ' SER . . . . . 0.531 ' O ' HD12 ' A' ' 15' ' ' LEU . 25.3 p -146.55 166.68 25.76 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.88 179.96 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 15' ' ' LEU . . . . . 0.531 HD12 ' O ' ' A' ' 14' ' ' SER . 0.1 OUTLIER -152.41 -58.02 0.14 Allowed 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.885 179.967 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -130.19 -77.53 0.18 Allowed Glycine 0 N--CA 1.452 -0.276 0 C-N-CA 120.774 -0.727 . . . . 0.0 112.515 179.983 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 22.1 m -161.17 96.24 1.08 Allowed 'General case' 0 C--N 1.33 -0.262 0 CA-C-O 120.869 0.366 . . . . 0.0 110.914 -179.994 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 8.2 mt -152.4 90.18 1.48 Allowed 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.154 -0.476 . . . . 0.0 110.879 179.958 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 19' ' ' GLN . . . . . . . . . . . . . 1.9 tp60 -60.31 107.43 0.65 Allowed 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.849 179.984 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 20' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -144.4 -51.97 0.3 Allowed 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.269 -0.423 . . . . 0.0 110.932 179.964 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 2.9 ttt180 -149.08 126.05 11.27 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.944 179.992 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 4.5 tt0 -142.74 153.24 43.13 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.255 -0.43 . . . . 0.0 110.904 -179.944 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -150.19 146.09 14.85 Favored Glycine 0 N--CA 1.451 -0.3 0 C-N-CA 120.694 -0.765 . . . . 0.0 112.483 179.932 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -148.35 125.76 11.63 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-O 120.803 0.335 . . . . 0.0 111.115 179.972 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 0.8 OUTLIER -83.59 -66.71 0.86 Allowed 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.917 179.97 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -122.58 -173.63 2.73 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.163 -0.472 . . . . 0.0 111.088 -179.956 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 27' ' ' GLU . . . . . . . . . . . . . 50.8 mt-10 -133.24 -177.82 4.7 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.924 179.983 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 27.4 t -71.31 121.53 21.51 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.096 179.924 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 89.72 52.98 2.51 Favored Glycine 0 N--CA 1.452 -0.293 0 C-N-CA 120.7 -0.762 . . . . 0.0 112.424 179.954 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -155.45 142.1 18.83 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 120.795 0.331 . . . . 0.0 110.887 179.968 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 31' ' ' GLN . . . . . . . . . . . . . 15.3 mt-30 -59.97 134.95 57.52 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.256 -0.429 . . . . 0.0 110.923 -179.971 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 5.5 m -141.83 179.31 2.12 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.346 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.12 -179.982 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 33' ' ' LEU . . . . . 0.466 HD11 ' O ' ' A' ' 37' ' ' GLN . 30.6 tp -142.76 108.0 5.0 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.791 179.98 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 34' ' ' VAL . . . . . 0.526 HG13 ' CB ' ' A' ' 87' ' ' ALA . 22.0 t -78.29 124.67 37.03 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.156 179.995 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 35' ' ' ALA . . . . . . . . . . . . . . . 58.46 26.15 13.86 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.052 -0.522 . . . . 0.0 111.231 179.952 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . 56.57 28.48 56.21 Favored Glycine 0 N--CA 1.451 -0.333 0 C-N-CA 120.773 -0.727 . . . . 0.0 112.598 -179.999 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 37' ' ' GLN . . . . . 0.466 ' O ' HD11 ' A' ' 33' ' ' LEU . 34.3 mt-30 -140.34 -70.88 0.38 Allowed 'General case' 0 C--N 1.328 -0.327 0 CA-C-O 120.749 0.309 . . . . 0.0 110.924 -179.998 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 38' ' ' LYS . . . . . . . . . . . . . 2.1 mttt -69.76 108.45 3.93 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.263 -0.426 . . . . 0.0 110.902 -179.948 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 39' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -88.15 136.98 32.72 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.908 179.974 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -160.52 -163.49 13.89 Favored Glycine 0 N--CA 1.451 -0.319 0 C-N-CA 120.727 -0.749 . . . . 0.0 112.463 180.0 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 41' ' ' ILE . . . . . 0.406 ' C ' HG23 ' A' ' 58' ' ' ILE . 33.2 mt -133.67 131.6 56.9 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-O 120.742 0.306 . . . . 0.0 111.084 -179.905 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 42' ' ' VAL . . . . . . . . . . . . . 21.4 t -60.06 125.43 16.17 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.345 0 CA-C-N 116.209 -0.45 . . . . 0.0 111.123 179.988 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 43' ' ' ARG . . . . . . . . . . . . . 13.6 mmt180 -110.34 -32.72 6.85 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.908 179.951 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 44' ' ' PHE . . . . . . . . . . . . . 72.2 t80 -143.05 111.05 6.0 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.248 -0.433 . . . . 0.0 110.912 -179.919 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 45' ' ' TYR . . . . . 0.5 ' CE1' ' CZ ' ' A' ' 56' ' ' TYR . 18.6 t80 -108.0 122.95 47.88 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.855 -179.99 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 164.94 -179.61 39.47 Favored Glycine 0 N--CA 1.451 -0.32 0 C-N-CA 120.767 -0.73 . . . . 0.0 112.534 179.928 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 47' ' ' LYS . . . . . . . . . . . . . 18.6 mttt -69.4 153.18 43.97 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 120.817 0.341 . . . . 0.0 110.879 -179.975 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 48' ' ' THR . . . . . 0.546 HG21 ' CE1' ' A' ' 50' ' ' PHE . 1.3 p -111.24 177.6 4.61 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.892 179.98 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -104.5 -31.33 9.51 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.835 179.992 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 50' ' ' PHE . . . . . 0.546 ' CE1' HG21 ' A' ' 48' ' ' THR . 54.1 p90 -75.53 -39.19 58.7 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.262 -0.427 . . . . 0.0 110.918 -179.965 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 51' ' ' ALA . . . . . . . . . . . . . . . -131.61 147.13 64.81 Favored Pre-proline 0 C--N 1.33 -0.273 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.093 -179.946 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 52' ' ' PRO . . . . . . . . . . . . . 61.0 Cg_endo -72.96 -172.58 1.01 Allowed 'Trans proline' 0 C--N 1.345 0.372 0 C-N-CA 122.508 2.138 . . . . 0.0 112.395 179.974 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 67.94 -165.48 45.23 Favored Glycine 0 N--CA 1.452 -0.291 0 C-N-CA 120.738 -0.744 . . . . 0.0 112.511 179.973 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 54' ' ' TYR . . . . . . . . . . . . . 69.3 m-85 -107.69 141.55 39.04 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-O 120.84 0.352 . . . . 0.0 110.876 -179.963 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 55' ' ' TRP . . . . . 0.401 ' CZ3' ' HD3' ' A' ' 88' ' ' PRO . 52.6 m95 -132.61 167.17 20.52 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.917 -179.897 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 56' ' ' TYR . . . . . 0.639 ' CE1' ' HB2' ' A' ' 89' ' ' ALA . 3.7 m-85 -121.18 117.09 26.23 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.323 -0.399 . . . . 0.0 110.912 179.997 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 57' ' ' GLY . . . . . 0.446 ' N ' ' CE1' ' A' ' 86' ' ' PHE . . . -81.2 68.26 3.47 Favored Glycine 0 N--CA 1.451 -0.331 0 C-N-CA 120.789 -0.72 . . . . 0.0 112.402 -179.967 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 58' ' ' ILE . . . . . 0.723 HD11 HD13 ' A' ' 92' ' ' ILE . 19.6 mt -73.53 138.04 22.09 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-O 120.807 0.337 . . . . 0.0 111.113 179.998 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -103.63 114.18 28.25 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.841 -179.967 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 60' ' ' LEU . . . . . . . . . . . . . 77.8 mt -69.51 -179.94 1.87 Allowed 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.154 -0.475 . . . . 0.0 110.885 179.972 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 4.9 m-20 -109.41 -34.09 6.63 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.951 -179.977 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 62' ' ' GLN . . . . . 0.407 ' HA ' ' HD3' ' A' ' 63' ' ' PRO . 4.1 mm-40 -108.14 146.63 33.94 Favored Pre-proline 0 C--N 1.329 -0.3 0 CA-C-N 116.321 -0.4 . . . . 0.0 110.942 -179.975 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 63' ' ' PRO . . . . . 0.407 ' HD3' ' HA ' ' A' ' 62' ' ' GLN . 31.7 Cg_exo -58.88 91.93 0.07 OUTLIER 'Trans proline' 0 C--N 1.345 0.368 0 C-N-CA 122.62 2.213 . . . . 0.0 112.172 -179.966 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 64' ' ' THR . . . . . . . . . . . . . 10.1 t -172.89 38.88 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.913 -179.979 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . -93.42 -128.97 5.1 Favored Glycine 0 N--CA 1.45 -0.37 0 C-N-CA 120.786 -0.721 . . . . 0.0 112.48 -179.976 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 66' ' ' LYS . . . . . . . . . . . . . 1.1 mtpm? -135.89 -50.8 0.72 Allowed 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 120.881 0.372 . . . . 0.0 110.874 180.0 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 67' ' ' HIS . . . . . . . . . . . . . 7.1 p80 -128.18 178.99 5.85 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.884 179.911 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 15.5 t0 -101.46 36.46 2.02 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.966 179.999 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 95.66 -37.85 3.3 Favored Glycine 0 N--CA 1.451 -0.351 0 C-N-CA 120.707 -0.759 . . . . 0.0 112.495 -179.997 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 70' ' ' SER . . . . . . . . . . . . . 75.2 p -102.73 162.33 13.02 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-O 120.947 0.403 . . . . 0.0 110.842 -179.91 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 21.4 t -148.07 117.14 1.15 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-N 116.132 -0.485 . . . . 0.0 111.168 179.953 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 72' ' ' PHE . . . . . . . . . . . . . 5.1 m-85 60.4 35.56 20.47 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.14 -0.482 . . . . 0.0 111.002 -179.977 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 80.91 28.26 46.78 Favored Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.679 -0.772 . . . . 0.0 112.597 -179.972 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 74' ' ' VAL . . . . . 0.402 ' O ' ' CE1' ' A' ' 76' ' ' TYR . 21.5 t -133.63 104.89 6.78 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-O 120.799 0.333 . . . . 0.0 111.098 -179.975 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 75' ' ' ARG . . . . . . . . . . . . . 3.6 ttt-85 -77.41 131.47 38.04 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.246 -0.433 . . . . 0.0 111.001 -179.979 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 76' ' ' TYR . . . . . 0.402 ' CE1' ' O ' ' A' ' 74' ' ' VAL . 11.7 m-85 -106.86 -45.63 4.14 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.178 -0.464 . . . . 0.0 110.858 179.956 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 77' ' ' PHE . . . . . 0.431 ' CE1' ' HA3' ' A' ' 57' ' ' GLY . 36.8 p90 -156.29 156.55 34.21 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.924 179.985 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 1.9 t -80.0 114.51 18.97 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.25 -0.432 . . . . 0.0 110.89 179.955 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 79' ' ' CYS . . . . . . . . . . . . . 29.4 p -147.15 152.48 38.5 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.973 -179.936 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 80' ' ' ALA . . . . . 0.73 ' HB1' ' HD2' ' A' ' 81' ' ' PRO . . . -58.45 166.73 2.09 Favored Pre-proline 0 C--N 1.329 -0.29 0 CA-C-N 116.143 -0.48 . . . . 0.0 111.002 179.93 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 81' ' ' PRO . . . . . 0.73 ' HD2' ' HB1' ' A' ' 80' ' ' ALA . 20.5 Cg_endo -60.76 120.95 8.95 Favored 'Trans proline' 0 C--N 1.344 0.29 0 C-N-CA 122.545 2.164 . . . . 0.0 112.168 179.936 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 82' ' ' ARG . . . . . . . . . . . . . 78.1 mtt180 63.11 50.36 3.1 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.143 -0.48 . . . . 0.0 110.876 -179.832 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 83' ' ' HIS . . . . . 0.581 ' ND1' ' HB3' ' A' ' 80' ' ' ALA . 5.8 m170 -123.33 -48.8 1.95 Allowed 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.934 179.933 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . -66.5 121.82 18.68 Favored Glycine 0 N--CA 1.451 -0.304 0 C-N-CA 120.629 -0.796 . . . . 0.0 112.401 179.857 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 85' ' ' VAL . . . . . . . . . . . . . 5.9 m -126.35 132.4 70.43 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-O 120.911 0.386 . . . . 0.0 111.194 -179.98 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 86' ' ' PHE . . . . . 0.446 ' CE1' ' N ' ' A' ' 57' ' ' GLY . 12.9 m-85 -103.66 118.05 35.83 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.991 179.958 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 87' ' ' ALA . . . . . 0.526 ' CB ' HG13 ' A' ' 34' ' ' VAL . . . -134.69 143.61 47.19 Favored Pre-proline 0 C--N 1.33 -0.279 0 CA-C-N 116.215 -0.448 . . . . 0.0 111.058 179.992 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 88' ' ' PRO . . . . . 0.418 ' O ' ' N ' ' A' ' 91' ' ' ARG . 32.5 Cg_exo -57.71 142.1 95.81 Favored 'Trans proline' 0 C--N 1.346 0.401 0 C-N-CA 122.451 2.101 . . . . 0.0 112.397 179.972 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 89' ' ' ALA . . . . . 0.639 ' HB2' ' CE1' ' A' ' 56' ' ' TYR . . . -47.94 -50.98 25.28 Favored 'General case' 0 CA--C 1.521 -0.156 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.255 179.867 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 90' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER -55.87 -24.39 36.72 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 115.716 -0.674 . . . . 0.0 109.801 178.859 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 91' ' ' ARG . . . . . 0.418 ' N ' ' O ' ' A' ' 88' ' ' PRO . 1.0 OUTLIER -90.98 -13.15 33.93 Favored 'General case' 0 N--CA 1.455 -0.219 0 CA-C-N 115.944 -0.571 . . . . 0.0 110.522 179.154 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 92' ' ' ILE . . . . . 0.723 HD13 HD11 ' A' ' 58' ' ' ILE . 62.9 mt -107.09 147.8 11.99 Favored 'Isoleucine or valine' 0 C--O 1.231 0.101 0 CA-C-N 116.432 -0.349 . . . . 0.0 110.895 179.836 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 93' ' ' GLN . . . . . . . . . . . . . 5.7 mt-30 -118.04 168.97 10.05 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.972 179.934 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 94' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -111.48 152.36 27.54 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.859 -179.997 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 95' ' ' ILE . . . . . . . . . . . . . 23.1 mt -132.41 -45.84 0.65 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.155 179.909 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . -59.31 179.32 1.82 Allowed Glycine 0 N--CA 1.452 -0.288 0 C-N-CA 120.81 -0.71 . . . . 0.0 112.533 179.911 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 97' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -137.94 137.29 37.83 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-O 120.797 0.332 . . . . 0.0 110.838 -179.918 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 98' ' ' GLY . . . . . . . . . . . . . . . 171.44 156.1 11.49 Favored Glycine 0 N--CA 1.451 -0.316 0 C-N-CA 120.671 -0.776 . . . . 0.0 112.476 179.905 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 99' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_exo -52.24 97.11 0.04 OUTLIER 'Trans proline' 0 C--N 1.344 0.316 0 C-N-CA 122.581 2.187 . . . . 0.0 112.311 -179.997 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 100' ' ' SER . . . . . . . . . . . . . 21.7 p -119.07 31.6 6.55 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.893 179.989 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 1.8 t -106.51 -65.97 1.04 Allowed 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.286 -0.416 . . . . 0.0 110.863 -179.97 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.25 1.095 0 CA-C-O 118.428 -1.206 . . . . 0.0 112.492 179.983 . . . . . . . . 0 0 . 1 . 013 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.216 0 N-CA-C 112.58 -0.208 . . . . 0.0 112.58 . . . . . . . . . 0 0 . 1 . 013 nuclear nobuild full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER 60.57 159.45 0.04 OUTLIER 'General case' 0 C--N 1.328 -0.335 0 CA-C-O 120.844 0.354 . . . . 0.0 110.911 -179.968 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 2.3 t -99.51 128.03 45.61 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.914 -179.983 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 166.31 41.7 0.02 OUTLIER Glycine 0 N--CA 1.45 -0.375 0 C-N-CA 120.791 -0.718 . . . . 0.0 112.572 -179.966 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 19.5 p -155.18 -50.0 0.09 Allowed 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 120.825 0.345 . . . . 0.0 110.893 -179.981 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 1.5 p -66.98 80.06 0.12 Allowed 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.836 179.984 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 129.81 156.25 8.7 Favored Glycine 0 N--CA 1.452 -0.28 0 C-N-CA 120.725 -0.75 . . . . 0.0 112.398 179.944 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 7.5 mttt 60.31 106.75 0.02 OUTLIER 'General case' 0 C--N 1.33 -0.248 0 CA-C-O 120.89 0.376 . . . . 0.0 110.835 -179.98 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -124.38 83.65 57.13 Favored Pre-proline 0 C--N 1.329 -0.304 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.97 179.939 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 50.2 Cg_exo -53.36 88.99 0.03 OUTLIER 'Trans proline' 0 C--N 1.345 0.38 0 C-N-CA 122.534 2.156 . . . . 0.0 112.269 179.986 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 2.9 p -152.64 102.55 2.72 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.266 -0.425 . . . . 0.0 110.878 179.987 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 0.6 OUTLIER -79.99 137.5 53.6 Favored Pre-proline 0 C--N 1.329 -0.283 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.827 179.97 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 72.8 Cg_endo -74.96 176.85 9.35 Favored 'Trans proline' 0 C--N 1.345 0.368 0 C-N-CA 122.491 2.127 . . . . 0.0 112.295 -179.994 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 8.4 t -74.63 175.89 7.44 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.844 179.939 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 22.8 mt -126.37 31.3 5.41 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.91 -179.972 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 90.52 35.13 7.53 Favored Glycine 0 N--CA 1.451 -0.346 0 C-N-CA 120.713 -0.756 . . . . 0.0 112.549 179.961 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 71.8 p -64.14 123.89 20.23 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 120.808 0.337 . . . . 0.0 110.909 -179.95 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -116.43 -42.41 3.02 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.935 -179.968 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 19' ' ' GLN . . . . . . . . . . . . . 1.4 tt0 60.18 163.65 0.06 Allowed 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.919 -179.962 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 20' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -164.67 97.32 0.76 Allowed 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.252 -0.431 . . . . 0.0 110.956 179.94 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -117.49 -39.98 3.1 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.929 -179.932 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 37.2 mt-10 57.43 32.53 21.94 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.096 -0.502 . . . . 0.0 110.899 -179.979 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -108.65 -93.34 2.28 Favored Glycine 0 N--CA 1.451 -0.329 0 C-N-CA 120.719 -0.753 . . . . 0.0 112.534 -179.953 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -80.26 144.49 32.83 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-O 120.86 0.362 . . . . 0.0 111.102 179.933 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 1.6 mmpt? -74.78 -64.15 1.1 Allowed 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.154 -0.476 . . . . 0.0 110.855 -179.986 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -88.03 -178.15 5.91 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.24 -0.436 . . . . 0.0 111.063 -179.962 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 27' ' ' GLU . . . . . . . . . . . . . 14.3 mt-10 -142.57 168.42 19.78 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.938 179.991 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 27.4 t -68.58 85.06 0.14 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.049 179.957 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 132.62 43.86 0.15 Allowed Glycine 0 N--CA 1.452 -0.265 0 C-N-CA 120.677 -0.773 . . . . 0.0 112.462 179.975 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 2.2 t0 -149.81 152.86 35.86 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 120.774 0.321 . . . . 0.0 110.902 -179.915 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 31' ' ' GLN . . . . . . . . . . . . . 1.6 mt-30 -69.03 141.92 54.72 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.918 179.943 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 5.7 m -143.27 174.84 4.43 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-N 116.247 -0.433 . . . . 0.0 111.141 179.96 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 33' ' ' LEU . . . . . . . . . . . . . 13.8 tp -141.25 105.15 4.75 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.843 179.986 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 34' ' ' VAL . . . . . 0.584 HG13 ' CB ' ' A' ' 87' ' ' ALA . 21.7 t -73.73 123.49 28.98 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.153 -179.982 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 35' ' ' ALA . . . . . . . . . . . . . . . 56.99 25.04 10.19 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.304 179.96 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . 57.29 37.0 78.65 Favored Glycine 0 N--CA 1.45 -0.374 0 C-N-CA 120.803 -0.713 . . . . 0.0 112.572 179.912 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 37' ' ' GLN . . . . . . . . . . . . . 39.0 mt-30 -148.55 -70.17 0.21 Allowed 'General case' 0 C--N 1.33 -0.279 0 CA-C-O 120.731 0.3 . . . . 0.0 110.971 179.98 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 38' ' ' LYS . . . . . . . . . . . . . 62.3 mttt -67.73 105.78 2.03 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.913 179.973 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 39' ' ' GLN . . . . . . . . . . . . . 2.3 tm0? -82.2 132.51 35.24 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.886 -179.996 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -158.08 -174.64 28.04 Favored Glycine 0 N--CA 1.451 -0.333 0 C-N-CA 120.658 -0.782 . . . . 0.0 112.53 179.923 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 41' ' ' ILE . . . . . 0.438 ' N ' HG23 ' A' ' 58' ' ' ILE . 15.7 mt -127.41 135.2 63.98 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-O 120.845 0.355 . . . . 0.0 111.046 -179.967 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 42' ' ' VAL . . . . . . . . . . . . . 21.5 t -62.82 120.97 10.71 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.175 179.956 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 43' ' ' ARG . . . . . . . . . . . . . 30.9 mmt180 -110.08 -32.1 7.13 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 116.178 -0.464 . . . . 0.0 110.932 -179.991 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 44' ' ' PHE . . . . . . . . . . . . . 63.4 t80 -147.4 115.53 6.55 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.896 179.924 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 45' ' ' TYR . . . . . 0.496 ' CE1' ' CE1' ' A' ' 56' ' ' TYR . 22.1 t80 -113.1 113.54 25.55 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.967 179.887 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . -175.96 -161.06 24.51 Favored Glycine 0 N--CA 1.452 -0.293 0 C-N-CA 120.712 -0.756 . . . . 0.0 112.474 -179.967 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 47' ' ' LYS . . . . . 0.424 ' HE2' ' CE1' ' A' ' 54' ' ' TYR . 27.2 mttm -88.4 168.95 12.22 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 120.795 0.331 . . . . 0.0 110.893 -179.925 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 48' ' ' THR . . . . . 0.645 HG22 ' CE2' ' A' ' 76' ' ' TYR . 67.1 p -140.04 175.09 9.88 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.949 -179.974 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 3.9 t70 -109.2 -31.52 7.55 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.931 179.994 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 50' ' ' PHE . . . . . 0.598 ' CZ ' HG21 ' A' ' 48' ' ' THR . 28.2 p90 -65.52 -36.07 82.74 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.97 179.959 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 51' ' ' ALA . . . . . 0.419 ' N ' ' CD1' ' A' ' 50' ' ' PHE . . . -140.98 148.13 50.8 Favored Pre-proline 0 C--N 1.329 -0.318 0 CA-C-N 116.209 -0.45 . . . . 0.0 111.097 -179.99 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 52' ' ' PRO . . . . . . . . . . . . . 59.7 Cg_endo -72.6 176.05 9.35 Favored 'Trans proline' 0 C--N 1.345 0.364 0 C-N-CA 122.508 2.139 . . . . 0.0 112.281 -179.981 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 67.72 175.19 8.33 Favored Glycine 0 N--CA 1.452 -0.286 0 C-N-CA 120.727 -0.749 . . . . 0.0 112.493 -179.934 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 54' ' ' TYR . . . . . 0.424 ' CE1' ' HE2' ' A' ' 47' ' ' LYS . 5.9 m-85 -83.71 148.91 26.81 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-O 120.829 0.347 . . . . 0.0 110.944 -179.983 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 55' ' ' TRP . . . . . . . . . . . . . 72.0 m95 -134.44 164.48 27.34 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.923 -179.978 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 56' ' ' TYR . . . . . 0.642 ' HE1' ' HB2' ' A' ' 89' ' ' ALA . 27.0 m-85 -113.55 112.41 23.5 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.908 179.979 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . -77.21 65.93 2.96 Favored Glycine 0 N--CA 1.451 -0.324 0 C-N-CA 120.727 -0.749 . . . . 0.0 112.396 179.909 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 58' ' ' ILE . . . . . 0.453 HD11 HD13 ' A' ' 92' ' ' ILE . 22.5 mt -74.65 152.34 6.78 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.271 0 CA-C-O 120.774 0.321 . . . . 0.0 111.215 -179.976 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 10.8 tm-20 -121.67 120.93 36.15 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 116.258 -0.428 . . . . 0.0 110.862 -179.968 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 60' ' ' LEU . . . . . . . . . . . . . 71.6 mt -79.88 -179.9 7.21 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-N 116.13 -0.486 . . . . 0.0 110.953 179.998 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -108.35 -29.0 9.08 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.028 -179.953 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 62' ' ' GLN . . . . . 0.414 ' HA ' ' HD3' ' A' ' 63' ' ' PRO . 8.2 mt-30 -108.63 143.41 27.46 Favored Pre-proline 0 C--N 1.329 -0.313 0 CA-C-N 116.382 -0.372 . . . . 0.0 110.973 -179.924 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 63' ' ' PRO . . . . . 0.414 ' HD3' ' HA ' ' A' ' 62' ' ' GLN . 39.4 Cg_exo -60.5 89.87 0.08 OUTLIER 'Trans proline' 0 C--N 1.346 0.4 0 C-N-CA 122.488 2.126 . . . . 0.0 112.18 179.928 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 64' ' ' THR . . . . . . . . . . . . . 10.2 t -170.89 35.97 0.02 OUTLIER 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.294 -0.412 . . . . 0.0 110.967 -179.976 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . -87.02 -95.3 0.88 Allowed Glycine 0 N--CA 1.451 -0.362 0 C-N-CA 120.684 -0.769 . . . . 0.0 112.522 -179.994 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 66' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -172.91 -47.42 0.02 OUTLIER 'General case' 0 C--N 1.328 -0.353 0 CA-C-O 120.854 0.359 . . . . 0.0 110.887 -179.982 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 67' ' ' HIS . . . . . . . . . . . . . 11.5 p80 -135.38 167.5 20.93 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.871 179.915 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -95.8 42.68 1.09 Allowed 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.898 179.945 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 87.33 -53.39 4.4 Favored Glycine 0 N--CA 1.452 -0.295 0 C-N-CA 120.717 -0.754 . . . . 0.0 112.492 179.966 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 70' ' ' SER . . . . . . . . . . . . . 93.8 p -79.05 143.82 35.23 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-O 120.773 0.32 . . . . 0.0 110.952 -179.992 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 71' ' ' VAL . . . . . 0.534 HG12 ' CD2' ' A' ' 72' ' ' PHE . 21.4 t -138.24 112.13 8.06 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.329 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.125 -179.981 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 72' ' ' PHE . . . . . 0.534 ' CD2' HG12 ' A' ' 71' ' ' VAL . 48.0 m-85 60.94 31.04 19.96 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.273 -0.421 . . . . 0.0 110.951 -179.933 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 86.11 29.49 25.36 Favored Glycine 0 N--CA 1.451 -0.304 0 C-N-CA 120.715 -0.755 . . . . 0.0 112.528 -179.997 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 21.5 t -136.77 110.33 8.82 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-O 120.849 0.357 . . . . 0.0 111.103 -179.946 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 75' ' ' ARG . . . . . . . . . . . . . 25.8 ttm-85 -81.47 143.81 31.81 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.132 -0.486 . . . . 0.0 110.91 -179.979 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 76' ' ' TYR . . . . . 0.645 ' CE2' HG22 ' A' ' 48' ' ' THR . 24.5 m-85 -120.4 -44.48 2.47 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.837 179.992 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 77' ' ' PHE . . . . . . . . . . . . . 8.2 p90 -157.19 156.51 32.73 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.907 -179.891 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 1.2 m -84.64 95.63 8.95 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.117 -0.492 . . . . 0.0 110.883 179.912 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 79' ' ' CYS . . . . . . . . . . . . . 13.9 p -122.85 159.3 28.44 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.288 -0.414 . . . . 0.0 110.976 -179.942 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 80' ' ' ALA . . . . . 0.742 ' HB1' ' HD2' ' A' ' 81' ' ' PRO . . . -59.05 166.68 2.48 Favored Pre-proline 0 C--N 1.328 -0.343 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.011 179.944 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 81' ' ' PRO . . . . . 0.742 ' HD2' ' HB1' ' A' ' 80' ' ' ALA . 35.7 Cg_endo -65.09 118.26 5.28 Favored 'Trans proline' 0 C--N 1.345 0.365 0 C-N-CA 122.491 2.127 . . . . 0.0 112.196 179.958 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 82' ' ' ARG . . . . . . . . . . . . . 1.1 mtm-85 62.1 46.71 6.16 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.844 -179.944 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 83' ' ' HIS . . . . . 0.711 ' CG ' ' HB3' ' A' ' 80' ' ' ALA . 8.7 m170 -120.68 -43.36 2.48 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.899 179.98 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . -61.07 151.5 41.91 Favored Glycine 0 N--CA 1.451 -0.326 0 C-N-CA 120.708 -0.758 . . . . 0.0 112.494 -179.983 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 85' ' ' VAL . . . . . . . . . . . . . 15.2 m -151.55 129.4 2.49 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-O 120.861 0.362 . . . . 0.0 111.236 -179.929 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 86' ' ' PHE . . . . . . . . . . . . . 8.4 m-85 -102.45 121.87 43.18 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.81 179.985 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 87' ' ' ALA . . . . . 0.584 ' CB ' HG13 ' A' ' 34' ' ' VAL . . . -143.0 145.52 33.47 Favored Pre-proline 0 C--N 1.33 -0.258 0 CA-C-N 116.171 -0.468 . . . . 0.0 111.161 179.943 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 88' ' ' PRO . . . . . . . . . . . . . 32.0 Cg_exo -58.29 137.0 78.22 Favored 'Trans proline' 0 C--N 1.345 0.365 0 C-N-CA 122.575 2.183 . . . . 0.0 112.235 -179.972 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 89' ' ' ALA . . . . . 0.642 ' HB2' ' HE1' ' A' ' 56' ' ' TYR . . . -48.38 -50.96 28.67 Favored 'General case' 0 CA--C 1.521 -0.145 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.316 179.82 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 90' ' ' SER . . . . . . . . . . . . . 51.2 p -55.96 -24.48 38.67 Favored 'General case' 0 N--CA 1.454 -0.246 0 CA-C-N 115.701 -0.681 . . . . 0.0 109.782 178.692 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 91' ' ' ARG . . . . . . . . . . . . . 1.0 OUTLIER -88.22 -14.66 37.96 Favored 'General case' 0 N--CA 1.455 -0.199 0 CA-C-N 115.808 -0.633 . . . . 0.0 110.405 179.062 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 92' ' ' ILE . . . . . 0.566 HD11 ' O ' ' A' ' 87' ' ' ALA . 22.2 mt -108.45 150.29 11.22 Favored 'Isoleucine or valine' 0 C--O 1.231 0.114 0 CA-C-O 120.84 0.353 . . . . 0.0 111.089 179.887 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 93' ' ' GLN . . . . . . . . . . . . . 1.8 mp0 -110.95 169.68 8.6 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.87 179.98 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 94' ' ' ARG . . . . . . . . . . . . . 9.3 ttt-85 -121.59 119.27 31.42 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.189 -0.459 . . . . 0.0 110.876 -179.99 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 95' ' ' ILE . . . . . . . . . . . . . 4.5 mt -91.21 -51.75 11.26 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.185 -0.461 . . . . 0.0 111.115 -180.0 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . 59.61 61.98 6.64 Favored Glycine 0 N--CA 1.451 -0.309 0 C-N-CA 120.738 -0.744 . . . . 0.0 112.459 179.927 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 97' ' ' SER . . . . . . . . . . . . . 7.5 t -87.76 108.56 19.18 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 120.821 0.343 . . . . 0.0 110.856 179.983 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 98' ' ' GLY . . . . . . . . . . . . . . . 77.23 64.62 2.07 Favored Glycine 0 N--CA 1.45 -0.369 0 C-N-CA 120.751 -0.738 . . . . 0.0 112.501 179.962 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 99' ' ' PRO . . . . . . . . . . . . . 51.3 Cg_exo -54.28 142.44 68.28 Favored 'Trans proline' 0 C--N 1.345 0.368 0 C-N-CA 122.589 2.193 . . . . 0.0 112.282 -179.989 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 100' ' ' SER . . . . . . . . . . . . . 6.6 t 60.04 34.42 21.38 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.893 179.987 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 2.8 m -150.33 122.75 8.45 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.922 179.992 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.249 1.068 0 CA-C-O 118.318 -1.268 . . . . 0.0 112.501 -179.936 . . . . . . . . 0 0 . 1 . 014 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.243 0 N-CA-C 112.441 -0.264 . . . . 0.0 112.441 . . . . . . . . . 0 0 . 1 . 014 nuclear nobuild full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 5.7 t -146.3 -50.44 0.22 Allowed 'General case' 0 C--N 1.329 -0.319 0 CA-C-O 120.908 0.385 . . . . 0.0 110.91 -179.991 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 69.9 m -96.87 -31.44 12.59 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.954 179.945 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 77.15 37.61 31.92 Favored Glycine 0 N--CA 1.451 -0.352 0 C-N-CA 120.725 -0.75 . . . . 0.0 112.481 179.992 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 45.4 t -99.47 31.45 3.14 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-O 120.801 0.334 . . . . 0.0 110.855 -179.963 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 1.1 m -107.22 156.94 18.3 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.269 -0.423 . . . . 0.0 110.868 -179.976 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 132.3 -56.47 0.74 Allowed Glycine 0 N--CA 1.452 -0.283 0 C-N-CA 120.734 -0.746 . . . . 0.0 112.456 -179.99 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 31.9 mttm -114.79 144.17 43.92 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-O 120.856 0.36 . . . . 0.0 110.894 -179.994 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -172.84 85.41 0.41 Allowed Pre-proline 0 C--N 1.33 -0.269 0 CA-C-N 116.154 -0.475 . . . . 0.0 110.873 -179.99 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 52.3 Cg_endo -69.5 113.23 3.26 Favored 'Trans proline' 0 C--N 1.344 0.319 0 C-N-CA 122.475 2.117 . . . . 0.0 112.291 179.987 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 1.4 p -129.9 154.44 47.31 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.178 -0.464 . . . . 0.0 110.911 179.966 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 12' ' ' SER . . . . . 0.552 ' O ' HD12 ' A' ' 15' ' ' LEU . 0.1 OUTLIER -105.04 160.94 24.28 Favored Pre-proline 0 C--N 1.329 -0.312 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.883 179.969 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.76 -45.25 1.66 Allowed 'Trans proline' 0 C--N 1.344 0.331 0 C-N-CA 122.609 2.206 . . . . 0.0 112.223 -179.992 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 63.9 m -85.36 109.31 18.31 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.87 179.972 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 15' ' ' LEU . . . . . 0.552 HD12 ' O ' ' A' ' 12' ' ' SER . 0.4 OUTLIER -151.61 -60.18 0.17 Allowed 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.843 -179.939 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -135.1 -45.16 0.1 Allowed Glycine 0 N--CA 1.451 -0.353 0 C-N-CA 120.745 -0.741 . . . . 0.0 112.469 -179.918 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 2.0 m -156.94 167.01 31.75 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-O 120.841 0.353 . . . . 0.0 110.885 -179.907 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 39.1 mt -149.53 76.65 1.32 Allowed 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.85 179.979 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 19' ' ' GLN . . . . . . . . . . . . . 53.8 mt-30 -109.21 39.79 1.98 Allowed 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.909 -179.986 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 20' ' ' GLN . . . . . . . . . . . . . 47.1 tt0 -83.23 91.94 7.37 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.897 179.998 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -95.89 146.72 24.35 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.838 179.966 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 8.7 pt-20 -177.03 -40.13 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.875 179.96 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 97.95 93.25 1.95 Allowed Glycine 0 N--CA 1.451 -0.343 0 C-N-CA 120.692 -0.765 . . . . 0.0 112.491 179.939 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -142.27 159.55 42.0 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-O 120.871 0.367 . . . . 0.0 111.05 179.99 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -79.66 -66.19 0.9 Allowed 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.169 -0.468 . . . . 0.0 110.917 -179.999 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -105.98 174.73 5.76 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.158 -0.474 . . . . 0.0 111.075 179.953 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 27' ' ' GLU . . . . . . . . . . . . . 41.7 mt-10 -140.64 174.87 10.09 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.871 -179.972 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 21.5 t -75.27 105.48 4.27 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.247 -0.433 . . . . 0.0 111.136 179.961 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 114.51 35.63 1.4 Allowed Glycine 0 N--CA 1.452 -0.291 0 C-N-CA 120.699 -0.762 . . . . 0.0 112.537 -179.969 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -149.0 150.88 33.57 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-O 120.749 0.309 . . . . 0.0 110.934 -179.952 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 31' ' ' GLN . . . . . 0.721 ' HB3' HD12 ' A' ' 95' ' ' ILE . 8.8 mp0 -70.0 151.35 45.67 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.282 -0.417 . . . . 0.0 110.831 -179.995 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 14.0 m -152.38 179.46 0.43 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.261 -0.427 . . . . 0.0 111.153 179.998 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 33' ' ' LEU . . . . . 0.636 HD11 ' C ' ' A' ' 37' ' ' GLN . 44.3 tp -143.39 117.86 9.71 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.856 179.943 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 34' ' ' VAL . . . . . 0.411 HG13 ' CB ' ' A' ' 87' ' ' ALA . 21.7 t -85.57 129.6 37.7 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.207 -0.452 . . . . 0.0 111.278 -179.839 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 35' ' ' ALA . . . . . . . . . . . . . . . 53.93 25.91 5.8 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.149 -0.478 . . . . 0.0 111.394 179.893 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . 57.61 33.82 68.16 Favored Glycine 0 N--CA 1.451 -0.353 0 C-N-CA 120.725 -0.75 . . . . 0.0 112.551 179.958 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 37' ' ' GLN . . . . . 0.636 ' C ' HD11 ' A' ' 33' ' ' LEU . 94.2 mt-30 -146.91 -70.6 0.24 Allowed 'General case' 0 C--N 1.33 -0.281 0 CA-C-O 120.847 0.356 . . . . 0.0 110.993 -179.951 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 38' ' ' LYS . . . . . 0.467 ' O ' HD12 ' A' ' 33' ' ' LEU . 2.7 mtmp? -67.11 110.41 3.42 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.947 -179.98 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 39' ' ' GLN . . . . . . . . . . . . . 1.3 tm0? -91.35 137.98 31.94 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.921 179.964 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -164.14 -173.22 32.56 Favored Glycine 0 N--CA 1.45 -0.371 0 C-N-CA 120.82 -0.705 . . . . 0.0 112.564 179.939 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 26.6 mt -122.63 132.01 72.08 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-O 120.804 0.335 . . . . 0.0 111.146 179.958 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 42' ' ' VAL . . . . . . . . . . . . . 33.8 t -59.53 124.29 13.53 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.081 179.986 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 43' ' ' ARG . . . . . . . . . . . . . 1.6 mmm-85 -109.77 -31.11 7.56 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.957 179.985 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 44' ' ' PHE . . . . . . . . . . . . . 28.9 t80 -147.59 112.14 5.31 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.892 179.966 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 45' ' ' TYR . . . . . 0.495 ' CE1' ' CZ ' ' A' ' 56' ' ' TYR . 15.2 t80 -113.27 141.9 46.46 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.894 -179.955 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 144.95 -174.53 24.99 Favored Glycine 0 N--CA 1.451 -0.329 0 C-N-CA 120.757 -0.735 . . . . 0.0 112.501 179.951 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 47' ' ' LYS . . . . . 0.415 ' HG3' ' CD1' ' A' ' 54' ' ' TYR . 13.6 mttm -74.02 161.54 29.96 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-O 120.797 0.332 . . . . 0.0 110.88 -179.966 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 48' ' ' THR . . . . . . . . . . . . . 75.2 p -119.07 -176.91 3.22 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.853 -179.975 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 1.8 t0 -113.41 15.65 19.09 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.378 -179.985 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 50' ' ' PHE . . . . . 0.45 ' CD1' ' N ' ' A' ' 51' ' ' ALA . 42.8 p90 -124.79 -41.28 2.13 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 120.74 0.305 . . . . 0.0 110.955 -179.993 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 51' ' ' ALA . . . . . 0.45 ' N ' ' CD1' ' A' ' 50' ' ' PHE . . . -129.25 149.21 72.06 Favored Pre-proline 0 C--N 1.329 -0.306 0 CA-C-N 116.311 -0.404 . . . . 0.0 111.106 -179.995 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 52' ' ' PRO . . . . . . . . . . . . . 55.6 Cg_endo -70.19 178.04 5.25 Favored 'Trans proline' 0 C--N 1.344 0.306 0 C-N-CA 122.608 2.205 . . . . 0.0 112.274 -179.971 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 72.96 -169.91 52.35 Favored Glycine 0 N--CA 1.451 -0.345 0 C-N-CA 120.717 -0.754 . . . . 0.0 112.542 -179.95 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 54' ' ' TYR . . . . . 0.415 ' CD1' ' HG3' ' A' ' 47' ' ' LYS . 99.7 m-85 -111.28 134.38 52.91 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-O 120.849 0.357 . . . . 0.0 110.932 179.933 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 55' ' ' TRP . . . . . . . . . . . . . 42.1 m95 -120.43 157.81 28.53 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.893 179.984 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 56' ' ' TYR . . . . . 0.507 ' CE1' ' HB2' ' A' ' 89' ' ' ALA . 4.1 m-85 -110.61 123.82 50.7 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.944 -179.901 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . -89.52 64.11 3.23 Favored Glycine 0 N--CA 1.452 -0.253 0 C-N-CA 120.768 -0.729 . . . . 0.0 112.416 179.891 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 58' ' ' ILE . . . . . 0.657 HD11 HD13 ' A' ' 92' ' ' ILE . 4.8 mt -71.72 144.7 13.01 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-O 120.783 0.325 . . . . 0.0 111.098 179.988 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 1.4 tm-20 -109.08 137.56 46.8 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.187 -0.461 . . . . 0.0 110.891 179.961 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 60' ' ' LEU . . . . . . . . . . . . . 65.1 mt -93.89 168.88 10.69 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.892 -179.931 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 20.2 t0 -95.79 -31.34 13.23 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.917 179.974 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 62' ' ' GLN . . . . . . . . . . . . . 5.5 pt20 -111.27 153.41 44.04 Favored Pre-proline 0 C--N 1.33 -0.274 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.865 -179.879 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 56.6 Cg_endo -70.67 80.05 1.17 Allowed 'Trans proline' 0 C--N 1.344 0.328 0 C-N-CA 122.605 2.203 . . . . 0.0 112.302 179.943 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 64' ' ' THR . . . . . . . . . . . . . 65.5 p -156.73 31.33 0.31 Allowed 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.075 -0.511 . . . . 0.0 110.823 -179.993 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . -83.85 -114.62 0.61 Allowed Glycine 0 N--CA 1.451 -0.309 0 C-N-CA 120.699 -0.762 . . . . 0.0 112.521 -179.969 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 66' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -151.68 -48.16 0.11 Allowed 'General case' 0 C--N 1.329 -0.293 0 CA-C-O 120.851 0.357 . . . . 0.0 110.904 -179.963 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 67' ' ' HIS . . . . . . . . . . . . . 7.2 p80 -124.37 175.92 6.79 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.973 -179.982 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 1.3 m-20 -97.94 37.25 1.43 Allowed 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.231 -0.44 . . . . 0.0 110.924 179.97 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 91.03 -50.94 3.14 Favored Glycine 0 N--CA 1.451 -0.325 0 C-N-CA 120.723 -0.751 . . . . 0.0 112.489 -179.998 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 70' ' ' SER . . . . . . . . . . . . . 21.4 p -88.31 143.3 27.1 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-O 120.79 0.328 . . . . 0.0 110.927 -179.938 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 71' ' ' VAL . . . . . 0.782 HG12 ' CD2' ' A' ' 72' ' ' PHE . 24.6 t -127.32 114.6 37.23 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.219 -0.446 . . . . 0.0 111.078 179.982 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 72' ' ' PHE . . . . . 0.782 ' CD2' HG12 ' A' ' 71' ' ' VAL . 25.3 m-85 60.32 31.04 20.3 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.956 -179.917 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 86.48 28.56 26.89 Favored Glycine 0 N--CA 1.451 -0.325 0 C-N-CA 120.685 -0.769 . . . . 0.0 112.475 179.969 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 21.5 t -130.16 100.2 4.92 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-O 120.91 0.386 . . . . 0.0 111.161 179.991 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 75' ' ' ARG . . . . . . . . . . . . . 4.8 ttt180 -80.26 112.37 17.52 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.116 -0.493 . . . . 0.0 110.879 -179.942 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 76' ' ' TYR . . . . . . . . . . . . . 58.0 m-85 -88.16 -40.37 13.79 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.911 -180.0 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 77' ' ' PHE . . . . . . . . . . . . . 23.3 p90 -154.1 153.39 31.78 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.889 179.892 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 78' ' ' THR . . . . . 0.418 HG23 ' O ' ' A' ' 78' ' ' THR . 5.1 t -82.97 111.56 18.95 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.145 -0.48 . . . . 0.0 110.812 -179.999 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 79' ' ' CYS . . . . . . . . . . . . . 18.4 p -143.1 170.71 15.21 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.959 -179.977 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 80' ' ' ALA . . . . . 0.765 ' HB3' ' ND1' ' A' ' 83' ' ' HIS . . . -70.67 167.06 30.42 Favored Pre-proline 0 C--N 1.329 -0.307 0 CA-C-N 116.121 -0.49 . . . . 0.0 110.969 179.938 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 81' ' ' PRO . . . . . 0.753 ' HD2' ' HB1' ' A' ' 80' ' ' ALA . 34.7 Cg_endo -64.86 126.83 17.33 Favored 'Trans proline' 0 C--N 1.345 0.356 0 C-N-CA 122.433 2.089 . . . . 0.0 112.224 179.934 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 82' ' ' ARG . . . . . . . . . . . . . 76.2 mtt180 62.03 39.34 13.32 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.132 -0.486 . . . . 0.0 110.957 -179.914 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 83' ' ' HIS . . . . . 0.765 ' ND1' ' HB3' ' A' ' 80' ' ' ALA . 9.1 m170 -114.55 -37.66 4.23 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.868 179.971 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . -76.91 152.77 41.03 Favored Glycine 0 N--CA 1.451 -0.332 0 C-N-CA 120.746 -0.74 . . . . 0.0 112.529 179.997 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 85' ' ' VAL . . . . . . . . . . . . . 16.1 m -153.9 135.22 5.23 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.329 0 CA-C-O 120.82 0.343 . . . . 0.0 111.12 179.934 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 86' ' ' PHE . . . . . . . . . . . . . 7.2 m-85 -111.09 117.09 32.34 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.99 -179.989 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 87' ' ' ALA . . . . . 0.497 ' O ' HD11 ' A' ' 92' ' ' ILE . . . -135.42 145.25 52.87 Favored Pre-proline 0 C--N 1.329 -0.324 0 CA-C-N 116.262 -0.426 . . . . 0.0 111.053 179.906 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 88' ' ' PRO . . . . . 0.409 ' O ' ' N ' ' A' ' 91' ' ' ARG . 33.6 Cg_exo -59.62 145.0 99.29 Favored 'Trans proline' 0 C--N 1.344 0.337 0 C-N-CA 122.562 2.174 . . . . 0.0 112.313 -179.978 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 89' ' ' ALA . . . . . 0.507 ' HB2' ' CE1' ' A' ' 56' ' ' TYR . . . -48.45 -50.91 29.43 Favored 'General case' 0 CA--C 1.521 -0.158 0 CA-C-N 116.187 -0.461 . . . . 0.0 110.247 179.84 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 90' ' ' SER . . . . . . . . . . . . . 1.2 m -56.0 -24.37 38.51 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 115.681 -0.69 . . . . 0.0 109.749 178.766 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 91' ' ' ARG . . . . . 0.409 ' N ' ' O ' ' A' ' 88' ' ' PRO . 0.0 OUTLIER -89.75 -13.9 35.78 Favored 'General case' 0 N--CA 1.454 -0.226 0 CA-C-N 115.926 -0.579 . . . . 0.0 110.515 179.125 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 92' ' ' ILE . . . . . 0.657 HD13 HD11 ' A' ' 58' ' ' ILE . 48.7 mt -110.31 153.51 12.07 Favored 'Isoleucine or valine' 0 C--O 1.23 0.074 0 CA-C-N 116.378 -0.374 . . . . 0.0 111.072 179.814 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 93' ' ' GLN . . . . . 0.407 ' N ' HG22 ' A' ' 92' ' ' ILE . 0.6 OUTLIER -116.24 179.81 3.89 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.805 -179.98 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 94' ' ' ARG . . . . . . . . . . . . . 4.1 ttp180 -122.76 144.08 49.41 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.885 -179.983 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 95' ' ' ILE . . . . . 0.721 HD12 ' HB3' ' A' ' 31' ' ' GLN . 22.0 mt -113.42 -35.82 2.34 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 CA-C-N 116.174 -0.466 . . . . 0.0 111.177 179.931 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . 136.65 -174.11 21.74 Favored Glycine 0 N--CA 1.45 -0.377 0 C-N-CA 120.728 -0.749 . . . . 0.0 112.493 179.964 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 97' ' ' SER . . . . . . . . . . . . . 3.6 m -90.94 -57.79 2.69 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 120.793 0.33 . . . . 0.0 110.874 -179.956 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 98' ' ' GLY . . . . . . . . . . . . . . . 126.43 156.26 9.17 Favored Glycine 0 N--CA 1.451 -0.31 0 C-N-CA 120.74 -0.743 . . . . 0.0 112.526 -179.984 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 99' ' ' PRO . . . . . . . . . . . . . 52.9 Cg_endo -69.39 -28.17 27.36 Favored 'Trans proline' 0 C--N 1.344 0.295 0 C-N-CA 122.603 2.202 . . . . 0.0 112.338 179.994 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 100' ' ' SER . . . . . . . . . . . . . 3.3 p -72.38 153.43 41.45 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.884 179.981 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 23.3 t -140.84 -66.36 0.43 Allowed 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.925 179.996 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.25 1.101 0 CA-C-O 118.384 -1.231 . . . . 0.0 112.46 179.988 . . . . . . . . 0 0 . 1 . 015 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.488 2.134 0 N-CA-C 112.556 -0.217 . . . . 0.0 112.556 . . . . . . . . . 0 0 . 1 . 015 nuclear nobuild full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 7.6 t -168.71 -60.15 0.02 OUTLIER 'General case' 0 C--N 1.33 -0.264 0 CA-C-O 120.778 0.323 . . . . 0.0 110.845 -179.9 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 3.5 p 50.03 95.21 0.01 OUTLIER 'General case' 0 C--N 1.331 -0.236 0 CA-C-N 116.23 -0.441 . . . . 0.0 111.157 -179.943 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 90.82 -149.85 20.25 Favored Glycine 0 N--CA 1.45 -0.403 0 C-N-CA 120.742 -0.742 . . . . 0.0 112.482 -179.9 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 1.2 p -148.43 39.12 0.88 Allowed 'General case' 0 C--N 1.329 -0.321 0 CA-C-O 120.803 0.335 . . . . 0.0 110.867 179.934 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 33.3 t 61.34 162.37 0.07 Allowed 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.886 179.928 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 99.4 -29.0 12.8 Favored Glycine 0 N--CA 1.45 -0.395 0 C-N-CA 120.737 -0.744 . . . . 0.0 112.541 -179.911 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 1.4 tmtp? -62.99 118.92 8.49 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-O 120.784 0.326 . . . . 0.0 110.907 -179.993 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 2.9 m -155.38 165.2 18.83 Favored Pre-proline 0 C--N 1.328 -0.33 0 CA-C-N 116.207 -0.452 . . . . 0.0 110.923 -179.964 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 54.2 Cg_exo -51.98 118.84 4.91 Favored 'Trans proline' 0 C--N 1.344 0.302 0 C-N-CA 122.581 2.187 . . . . 0.0 112.284 179.951 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 7.8 t -125.47 137.55 53.97 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.983 -179.965 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 1.3 m -175.22 138.61 0.58 Allowed Pre-proline 0 C--N 1.329 -0.319 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.877 179.936 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 50.3 Cg_exo -53.46 -177.66 0.03 OUTLIER 'Trans proline' 0 C--N 1.344 0.332 0 C-N-CA 122.544 2.162 . . . . 0.0 112.216 -179.987 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -82.6 77.43 9.37 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.84 -179.997 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 14.6 tp -157.84 93.38 1.26 Allowed 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.897 -179.934 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 59.92 89.72 0.02 OUTLIER Glycine 0 N--CA 1.451 -0.307 0 C-N-CA 120.803 -0.713 . . . . 0.0 112.439 179.953 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -91.1 169.79 10.57 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-O 120.725 0.298 . . . . 0.0 110.96 179.983 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 3.3 mp -71.84 -38.71 70.1 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.251 -0.432 . . . . 0.0 110.888 179.993 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 19' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -122.54 90.41 3.29 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.921 179.952 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 20' ' ' GLN . . . . . . . . . . . . . 1.8 tt0 -102.87 156.0 17.96 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.845 179.999 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -135.84 88.23 2.38 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.849 179.972 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 7.4 mt-10 -158.74 126.79 5.15 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.189 -0.459 . . . . 0.0 110.92 179.918 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 171.82 -45.38 0.18 Allowed Glycine 0 N--CA 1.451 -0.344 0 C-N-CA 120.769 -0.729 . . . . 0.0 112.484 179.993 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -140.97 162.38 35.62 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 120.779 0.323 . . . . 0.0 111.054 179.972 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 1.0 OUTLIER -142.47 -47.2 0.33 Allowed 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.888 -179.948 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -122.72 170.08 10.42 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.181 -0.463 . . . . 0.0 111.121 -179.955 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 27' ' ' GLU . . . . . . . . . . . . . 4.8 mt-10 -124.31 179.51 4.88 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.953 179.976 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 21.4 t -75.21 104.98 3.83 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.241 -0.436 . . . . 0.0 111.172 179.951 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 108.13 34.55 2.72 Favored Glycine 0 N--CA 1.451 -0.328 0 C-N-CA 120.732 -0.747 . . . . 0.0 112.529 -179.941 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 30' ' ' ASP . . . . . 0.427 ' C ' HG23 ' A' ' 41' ' ' ILE . 0.8 OUTLIER -138.06 145.29 41.59 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-O 120.814 0.34 . . . . 0.0 110.879 180.0 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 31' ' ' GLN . . . . . 0.545 ' HB3' HD12 ' A' ' 95' ' ' ILE . 0.7 OUTLIER -60.01 144.78 48.48 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.932 -179.962 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 12.0 m -150.02 174.46 1.08 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.372 0 CA-C-N 116.286 -0.415 . . . . 0.0 111.208 179.953 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 33' ' ' LEU . . . . . 0.469 HD11 ' O ' ' A' ' 37' ' ' GLN . 28.8 tp -138.71 107.1 5.81 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.886 -179.958 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 34' ' ' VAL . . . . . 0.416 HG22 HD12 ' A' ' 58' ' ' ILE . 21.5 t -77.32 125.58 37.17 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-N 116.236 -0.438 . . . . 0.0 111.22 -179.978 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 35' ' ' ALA . . . . . . . . . . . . . . . 58.2 26.23 13.55 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.163 -0.471 . . . . 0.0 111.333 -179.967 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . 56.14 31.39 59.01 Favored Glycine 0 C--N 1.331 0.279 0 C-N-CA 120.775 -0.726 . . . . 0.0 112.607 179.973 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 37' ' ' GLN . . . . . 0.469 ' O ' HD11 ' A' ' 33' ' ' LEU . 37.3 mt-30 -145.3 -70.42 0.27 Allowed 'General case' 0 C--N 1.329 -0.287 0 CA-C-O 120.795 0.331 . . . . 0.0 110.877 -179.944 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 38' ' ' LYS . . . . . . . . . . . . . 32.0 mttt -67.57 104.05 1.5 Allowed 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.927 179.958 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 39' ' ' GLN . . . . . 0.4 ' NE2' HD13 ' A' ' 95' ' ' ILE . 4.2 tt0 -82.93 148.03 27.9 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.875 -179.972 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -175.68 -164.13 29.59 Favored Glycine 0 N--CA 1.451 -0.363 0 C-N-CA 120.787 -0.721 . . . . 0.0 112.541 179.945 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 41' ' ' ILE . . . . . 0.441 ' C ' HG23 ' A' ' 58' ' ' ILE . 3.8 mp -134.61 139.14 48.33 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-O 120.856 0.36 . . . . 0.0 111.156 179.986 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 42' ' ' VAL . . . . . . . . . . . . . 31.0 t -70.47 127.08 31.91 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.029 179.953 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 43' ' ' ARG . . . . . . . . . . . . . 15.6 mmt180 -110.72 -32.35 6.89 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.207 -0.452 . . . . 0.0 110.923 -179.957 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 44' ' ' PHE . . . . . . . . . . . . . 72.6 t80 -141.21 108.23 5.45 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.859 179.978 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 45' ' ' TYR . . . . . 0.497 ' CE1' ' CZ ' ' A' ' 56' ' ' TYR . 12.5 t80 -109.53 131.96 54.58 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.881 179.949 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 158.82 -137.71 5.33 Favored Glycine 0 N--CA 1.451 -0.36 0 C-N-CA 120.68 -0.771 . . . . 0.0 112.53 -179.968 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 47' ' ' LYS . . . . . . . . . . . . . 11.1 mttm -104.18 154.16 20.08 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-O 120.815 0.341 . . . . 0.0 110.922 179.996 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 48' ' ' THR . . . . . . . . . . . . . 25.5 p -117.86 -179.22 3.69 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.224 -0.443 . . . . 0.0 110.874 179.875 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 2.2 t0 -110.91 -26.55 9.25 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.212 -0.449 . . . . 0.0 111.026 -179.836 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 50' ' ' PHE . . . . . 0.451 ' CD1' ' N ' ' A' ' 51' ' ' ALA . 22.6 p90 -72.32 -34.12 67.86 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.422 -0.354 . . . . 0.0 111.117 -179.831 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 51' ' ' ALA . . . . . 0.451 ' N ' ' CD1' ' A' ' 50' ' ' PHE . . . -148.9 147.81 25.43 Favored Pre-proline 0 C--N 1.329 -0.3 0 CA-C-N 116.3 -0.409 . . . . 0.0 111.237 -179.931 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 52' ' ' PRO . . . . . . . . . . . . . 74.0 Cg_endo -75.3 165.34 31.06 Favored 'Trans proline' 0 C--N 1.344 0.327 0 C-N-CA 122.651 2.234 . . . . 0.0 112.366 179.954 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 99.68 -168.98 21.9 Favored Glycine 0 N--CA 1.451 -0.317 0 C-N-CA 120.734 -0.746 . . . . 0.0 112.56 179.917 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 54' ' ' TYR . . . . . . . . . . . . . 64.9 m-85 -102.31 125.87 49.15 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-O 120.825 0.345 . . . . 0.0 110.893 179.994 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 55' ' ' TRP . . . . . 0.408 ' CZ3' ' HD3' ' A' ' 88' ' ' PRO . 63.9 m95 -127.02 156.77 41.11 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.912 179.976 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 56' ' ' TYR . . . . . 0.576 ' CE1' ' HB2' ' A' ' 89' ' ' ALA . 4.2 m-85 -113.32 122.71 48.24 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.254 -0.43 . . . . 0.0 110.95 -179.961 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 57' ' ' GLY . . . . . 0.447 ' CA ' ' CE1' ' A' ' 86' ' ' PHE . . . -84.04 68.03 3.6 Favored Glycine 0 N--CA 1.45 -0.404 0 C-N-CA 120.775 -0.726 . . . . 0.0 112.427 179.865 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 58' ' ' ILE . . . . . 0.678 HD11 HD13 ' A' ' 92' ' ' ILE . 19.7 mt -73.58 138.59 20.97 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-O 120.812 0.339 . . . . 0.0 111.138 -179.955 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -114.07 112.38 23.15 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.915 179.948 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 60' ' ' LEU . . . . . 0.673 HD13 HG23 ' A' ' 64' ' ' THR . 8.1 mt -73.21 173.06 9.99 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.246 -0.434 . . . . 0.0 110.865 -179.972 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 8.3 p-10 -102.0 -31.59 10.58 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.856 179.957 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 62' ' ' GLN . . . . . 0.425 ' HG3' HG22 ' A' ' 64' ' ' THR . 4.1 pt20 -106.5 157.49 34.92 Favored Pre-proline 0 C--N 1.329 -0.301 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.835 -179.974 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 37.2 Cg_endo -65.86 82.58 0.25 Allowed 'Trans proline' 0 C--N 1.345 0.345 0 C-N-CA 122.533 2.155 . . . . 0.0 112.263 179.937 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 64' ' ' THR . . . . . 0.673 HG23 HD13 ' A' ' 60' ' ' LEU . 9.1 t -156.01 34.55 0.34 Allowed 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.108 -0.496 . . . . 0.0 110.839 -179.995 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . -97.84 -131.51 7.15 Favored Glycine 0 N--CA 1.45 -0.407 0 C-N-CA 120.732 -0.747 . . . . 0.0 112.547 179.956 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 66' ' ' LYS . . . . . . . . . . . . . 4.3 mtmm -144.6 -58.36 0.36 Allowed 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 120.819 0.343 . . . . 0.0 110.9 -179.969 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 67' ' ' HIS . . . . . . . . . . . . . 6.9 p80 -110.72 164.51 12.68 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.887 179.945 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 45.6 t0 -97.76 36.52 1.52 Allowed 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.209 -0.451 . . . . 0.0 110.946 -179.997 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 96.75 -32.1 6.91 Favored Glycine 0 N--CA 1.45 -0.369 0 C-N-CA 120.766 -0.73 . . . . 0.0 112.47 179.955 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 70' ' ' SER . . . . . . . . . . . . . 12.2 p -114.13 141.93 46.86 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-O 120.885 0.374 . . . . 0.0 110.844 179.988 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 71' ' ' VAL . . . . . 0.636 HG12 ' CD2' ' A' ' 72' ' ' PHE . 21.6 t -131.07 111.26 19.43 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.252 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.137 179.929 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 72' ' ' PHE . . . . . 0.636 ' CD2' HG12 ' A' ' 71' ' ' VAL . 53.4 m-85 61.09 30.88 19.7 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.999 -179.952 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 98.8 -27.62 18.97 Favored Glycine 0 N--CA 1.452 -0.26 0 C-N-CA 120.728 -0.749 . . . . 0.0 112.454 -179.971 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 22.8 t -75.55 135.35 27.29 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-O 120.834 0.35 . . . . 0.0 111.09 -179.934 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 75' ' ' ARG . . . . . 0.503 HH21 HG23 ' A' ' 78' ' ' THR . 19.2 ttt180 -107.71 144.44 34.81 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.911 179.992 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 76' ' ' TYR . . . . . 0.403 ' CD1' ' N ' ' A' ' 76' ' ' TYR . 3.9 m-85 -123.42 -44.06 2.15 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.944 179.932 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 77' ' ' PHE . . . . . . . . . . . . . 28.5 p90 -162.88 177.7 9.03 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.866 179.97 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 78' ' ' THR . . . . . 0.503 HG23 HH21 ' A' ' 75' ' ' ARG . 0.7 OUTLIER -99.67 113.16 25.43 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.913 179.921 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 79' ' ' CYS . . . . . . . . . . . . . 30.2 p -142.9 152.66 42.32 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.27 -0.423 . . . . 0.0 110.924 179.955 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 80' ' ' ALA . . . . . 0.527 ' HB1' ' HD2' ' A' ' 81' ' ' PRO . . . -66.79 168.26 11.09 Favored Pre-proline 0 C--N 1.329 -0.325 0 CA-C-N 116.215 -0.448 . . . . 0.0 111.054 -179.984 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 81' ' ' PRO . . . . . 0.527 ' HD2' ' HB1' ' A' ' 80' ' ' ALA . 41.7 Cg_exo -56.91 122.49 11.91 Favored 'Trans proline' 0 C--N 1.344 0.293 0 C-N-CA 122.584 2.19 . . . . 0.0 112.306 -179.991 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 82' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER 62.37 51.91 3.23 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.169 -0.469 . . . . 0.0 111.082 179.845 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 83' ' ' HIS . . . . . 0.453 ' CE1' ' HB3' ' A' ' 80' ' ' ALA . 7.0 m170 -124.77 -50.42 1.72 Allowed 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.861 179.92 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . -66.05 142.36 43.04 Favored Glycine 0 N--CA 1.451 -0.338 0 C-N-CA 120.748 -0.739 . . . . 0.0 112.536 179.928 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 85' ' ' VAL . . . . . . . . . . . . . 6.9 m -146.99 129.04 6.93 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-O 120.862 0.363 . . . . 0.0 111.076 179.957 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 86' ' ' PHE . . . . . 0.447 ' CE1' ' CA ' ' A' ' 57' ' ' GLY . 17.0 m-85 -108.12 114.9 29.14 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.106 -0.497 . . . . 0.0 110.85 -179.977 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 87' ' ' ALA . . . . . 0.55 ' O ' HD11 ' A' ' 92' ' ' ILE . . . -136.68 146.7 56.49 Favored Pre-proline 0 C--N 1.33 -0.281 0 CA-C-N 116.14 -0.482 . . . . 0.0 111.178 179.916 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 88' ' ' PRO . . . . . 0.423 ' O ' ' N ' ' A' ' 91' ' ' ARG . 34.5 Cg_exo -57.7 142.84 96.06 Favored 'Trans proline' 0 C--N 1.345 0.352 0 C-N-CA 122.561 2.174 . . . . 0.0 112.324 -179.942 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 89' ' ' ALA . . . . . 0.576 ' HB2' ' CE1' ' A' ' 56' ' ' TYR . . . -48.04 -50.75 26.82 Favored 'General case' 0 C--O 1.231 0.117 0 CA-C-N 116.101 -0.5 . . . . 0.0 110.261 179.853 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 90' ' ' SER . . . . . . . . . . . . . 42.6 m -55.75 -24.43 35.27 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 115.708 -0.678 . . . . 0.0 109.733 178.828 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 91' ' ' ARG . . . . . 0.423 ' N ' ' O ' ' A' ' 88' ' ' PRO . 3.4 mtm180 -89.41 -14.81 34.65 Favored 'General case' 0 N--CA 1.456 -0.172 0 CA-C-N 115.857 -0.611 . . . . 0.0 110.472 179.059 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 92' ' ' ILE . . . . . 0.678 HD13 HD11 ' A' ' 58' ' ' ILE . 48.2 mt -107.03 158.3 6.99 Favored 'Isoleucine or valine' 0 C--O 1.231 0.128 0 CA-C-N 116.379 -0.373 . . . . 0.0 111.014 179.793 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 93' ' ' GLN . . . . . 0.491 ' N ' HG22 ' A' ' 92' ' ' ILE . 5.2 mt-30 -130.18 176.82 7.79 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.964 -179.973 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 94' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -118.16 154.23 32.51 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.903 179.971 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 95' ' ' ILE . . . . . 0.545 HD12 ' HB3' ' A' ' 31' ' ' GLN . 4.4 mt -119.54 -41.11 2.09 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.102 179.957 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . -64.85 95.11 0.19 Allowed Glycine 0 N--CA 1.451 -0.347 0 C-N-CA 120.681 -0.771 . . . . 0.0 112.496 179.982 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 97' ' ' SER . . . . . . . . . . . . . 23.2 p -86.91 169.25 12.67 Favored 'General case' 0 C--N 1.331 -0.231 0 CA-C-O 120.883 0.373 . . . . 0.0 110.872 -179.953 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 98' ' ' GLY . . . . . . . . . . . . . . . 176.12 177.89 45.49 Favored Glycine 0 N--CA 1.451 -0.346 0 C-N-CA 120.764 -0.731 . . . . 0.0 112.538 179.985 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 99' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_exo -52.31 130.98 38.1 Favored 'Trans proline' 0 C--N 1.343 0.289 0 C-N-CA 122.655 2.237 . . . . 0.0 112.253 -179.998 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 100' ' ' SER . . . . . . . . . . . . . 1.5 m -96.76 135.75 38.26 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.202 -0.453 . . . . 0.0 110.897 179.964 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 4.3 m -130.12 137.27 50.07 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.107 -0.497 . . . . 0.0 110.891 179.995 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.249 1.082 0 CA-C-O 118.305 -1.275 . . . . 0.0 112.576 -179.934 . . . . . . . . 0 0 . 1 . 016 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.191 0 N-CA-C 112.506 -0.238 . . . . 0.0 112.506 . . . . . . . . . 0 0 . 1 . 016 nuclear nobuild full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -113.18 -60.8 1.83 Allowed 'General case' 0 C--N 1.328 -0.338 0 CA-C-O 120.864 0.364 . . . . 0.0 110.873 -179.966 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 40.0 t -117.62 -40.39 3.04 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.887 -179.996 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 144.38 132.32 2.53 Favored Glycine 0 N--CA 1.451 -0.353 0 C-N-CA 120.781 -0.723 . . . . 0.0 112.557 -179.98 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 55.2 p -98.94 32.02 2.79 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-O 120.917 0.389 . . . . 0.0 110.953 -179.995 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 8.4 t -122.59 -178.25 3.86 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.868 179.981 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -95.64 143.18 16.5 Favored Glycine 0 N--CA 1.453 -0.216 0 C-N-CA 120.719 -0.753 . . . . 0.0 112.43 180.0 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 11.2 ttpt -85.36 158.51 20.24 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-O 120.815 0.341 . . . . 0.0 110.945 -179.995 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 9' ' ' SER . . . . . 0.422 ' CB ' ' CD ' ' A' ' 10' ' ' PRO . 1.1 m -178.52 -61.62 0.0 OUTLIER Pre-proline 0 C--N 1.329 -0.288 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.903 179.977 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 10' ' ' PRO . . . . . 0.422 ' CD ' ' CB ' ' A' ' 9' ' ' SER . 58.3 Cg_endo -71.56 114.91 4.09 Favored 'Trans proline' 0 C--N 1.345 0.378 0 C-N-CA 122.462 2.108 . . . . 0.0 112.379 179.94 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -128.39 -61.74 1.07 Allowed 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.942 -179.936 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 8.4 t -156.18 107.71 2.07 Favored Pre-proline 0 C--N 1.329 -0.287 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.911 -179.951 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 13' ' ' PRO . . . . . 0.785 ' HB3' HD12 ' A' ' 18' ' ' LEU . 44.4 Cg_endo -68.08 85.16 0.42 Allowed 'Trans proline' 0 C--N 1.345 0.383 0 C-N-CA 122.438 2.092 . . . . 0.0 112.311 -179.952 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 14' ' ' SER . . . . . 0.809 ' HB3' HD12 ' A' ' 15' ' ' LEU . 0.6 OUTLIER -112.64 -66.84 1.04 Allowed 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.809 -179.991 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 15' ' ' LEU . . . . . 0.809 HD12 ' HB3' ' A' ' 14' ' ' SER . 2.4 mp -136.51 113.56 10.53 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.198 -0.456 . . . . 0.0 110.837 179.983 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 59.25 28.26 64.07 Favored Glycine 0 N--CA 1.451 -0.353 0 C-N-CA 120.742 -0.742 . . . . 0.0 112.533 179.957 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 0.6 OUTLIER -92.54 -45.91 7.88 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-O 120.775 0.321 . . . . 0.0 110.877 -179.951 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 18' ' ' LEU . . . . . 0.785 HD12 ' HB3' ' A' ' 13' ' ' PRO . 13.2 mt -142.83 161.9 36.89 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.803 -179.972 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 19' ' ' GLN . . . . . . . . . . . . . 1.4 tp60 -160.27 30.63 0.17 Allowed 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.957 -180.0 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 20' ' ' GLN . . . . . . . . . . . . . 18.8 mt-30 59.59 98.03 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.189 -0.46 . . . . 0.0 111.006 -179.987 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -170.73 137.14 1.26 Allowed 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.9 179.983 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 6.4 mt-10 -122.1 -59.29 1.66 Allowed 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.968 -179.973 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -160.64 -131.02 1.18 Allowed Glycine 0 N--CA 1.451 -0.347 0 C-N-CA 120.729 -0.748 . . . . 0.0 112.506 -179.985 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -68.13 -179.47 1.26 Allowed 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.825 0.345 . . . . 0.0 111.076 179.93 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 25' ' ' LYS . . . . . 0.458 ' HB2' ' HB1' ' A' ' 89' ' ' ALA . 0.7 OUTLIER -152.61 -47.45 0.1 Allowed 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.919 179.975 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -122.77 -174.54 2.95 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.984 179.947 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 27' ' ' GLU . . . . . . . . . . . . . 13.8 mt-10 -141.28 174.26 10.7 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.154 -0.476 . . . . 0.0 110.881 -179.973 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 22.1 t -76.18 117.96 21.68 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.129 179.871 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 109.39 28.65 4.25 Favored Glycine 0 N--CA 1.452 -0.281 0 C-N-CA 120.776 -0.726 . . . . 0.0 112.491 -179.95 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 7.8 t0 -143.21 142.23 31.35 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 120.807 0.336 . . . . 0.0 110.863 -179.931 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 31' ' ' GLN . . . . . 0.625 ' HB3' HD12 ' A' ' 95' ' ' ILE . 0.0 OUTLIER -61.62 150.35 36.6 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.843 179.931 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 15.2 m -154.14 170.6 0.81 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.351 0 CA-C-N 116.222 -0.444 . . . . 0.0 111.182 179.971 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 33' ' ' LEU . . . . . . . . . . . . . 28.9 tp -134.88 106.02 6.68 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.94 179.968 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 34' ' ' VAL . . . . . 0.466 HG13 ' HB3' ' A' ' 87' ' ' ALA . 21.7 t -74.48 124.82 32.85 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.169 -179.918 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 35' ' ' ALA . . . . . . . . . . . . . . . 57.38 26.08 12.06 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.138 -0.483 . . . . 0.0 111.298 179.953 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . 55.81 26.95 48.76 Favored Glycine 0 N--CA 1.452 -0.284 0 C-N-CA 120.723 -0.751 . . . . 0.0 112.647 179.959 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 37' ' ' GLN . . . . . . . . . . . . . 77.9 mt-30 -138.15 -68.37 0.46 Allowed 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 120.842 0.353 . . . . 0.0 110.931 -179.949 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 38' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -69.7 111.14 5.28 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.906 -179.996 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 39' ' ' GLN . . . . . . . . . . . . . 1.9 tt0 -89.25 135.39 33.6 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.154 -0.476 . . . . 0.0 110.976 179.933 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -165.5 -167.97 26.94 Favored Glycine 0 N--CA 1.451 -0.304 0 C-N-CA 120.7 -0.762 . . . . 0.0 112.513 180.0 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 41' ' ' ILE . . . . . 0.498 ' N ' HG23 ' A' ' 58' ' ' ILE . 23.5 mt -129.52 143.19 41.89 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-O 120.789 0.328 . . . . 0.0 111.16 -179.959 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 42' ' ' VAL . . . . . . . . . . . . . 21.9 t -68.22 112.04 2.98 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.247 -0.433 . . . . 0.0 111.114 179.961 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 43' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -96.19 -41.21 8.8 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.965 -179.986 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 44' ' ' PHE . . . . . . . . . . . . . 21.0 t80 -135.74 119.02 16.66 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.895 179.985 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 45' ' ' TYR . . . . . 0.423 ' CE1' ' CZ ' ' A' ' 56' ' ' TYR . 38.0 t80 -123.04 136.75 54.96 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.115 -0.493 . . . . 0.0 110.844 -179.989 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 157.86 -155.3 26.31 Favored Glycine 0 N--CA 1.451 -0.346 0 C-N-CA 120.747 -0.739 . . . . 0.0 112.478 179.914 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 47' ' ' LYS . . . . . . . . . . . . . 2.1 mtpt -83.35 150.12 26.3 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-O 120.844 0.354 . . . . 0.0 110.891 179.999 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 48' ' ' THR . . . . . 0.535 HG22 ' CE2' ' A' ' 76' ' ' TYR . 6.3 p -115.04 178.01 4.44 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.814 -179.981 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -115.01 -37.48 4.13 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.974 -179.997 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 50' ' ' PHE . . . . . 0.427 ' CZ ' HG21 ' A' ' 48' ' ' THR . 27.4 p90 -63.78 -32.35 73.82 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.191 -0.458 . . . . 0.0 110.951 -179.936 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 51' ' ' ALA . . . . . . . . . . . . . . . -149.62 152.08 34.3 Favored Pre-proline 0 C--N 1.33 -0.269 0 CA-C-N 116.226 -0.443 . . . . 0.0 111.156 -179.997 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 52' ' ' PRO . . . . . . . . . . . . . 57.6 Cg_endo -71.33 168.98 21.88 Favored 'Trans proline' 0 C--N 1.344 0.321 0 C-N-CA 122.562 2.175 . . . . 0.0 112.262 179.99 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 89.87 -160.15 28.46 Favored Glycine 0 N--CA 1.45 -0.37 0 C-N-CA 120.707 -0.758 . . . . 0.0 112.562 -179.972 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 54' ' ' TYR . . . . . . . . . . . . . 59.5 m-85 -123.67 125.73 45.31 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 120.841 0.353 . . . . 0.0 110.839 -179.928 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 55' ' ' TRP . . . . . . . . . . . . . 37.3 m95 -112.34 169.8 8.62 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.22 -0.446 . . . . 0.0 110.835 179.987 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 56' ' ' TYR . . . . . 0.484 ' CE1' ' HB2' ' A' ' 89' ' ' ALA . 9.2 m-85 -118.9 117.43 28.81 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.965 -179.96 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . -82.35 61.37 4.72 Favored Glycine 0 N--CA 1.45 -0.367 0 C-N-CA 120.752 -0.737 . . . . 0.0 112.402 179.956 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 58' ' ' ILE . . . . . 0.514 HD11 HD13 ' A' ' 92' ' ' ILE . 13.2 mt -69.91 137.94 23.07 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-O 120.911 0.386 . . . . 0.0 111.079 -179.949 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER -106.28 133.73 50.52 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.859 179.927 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 60' ' ' LEU . . . . . . . . . . . . . 53.5 mt -100.48 171.64 7.62 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.915 -179.969 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 61' ' ' ASP . . . . . 0.404 ' O ' ' CE1' ' A' ' 83' ' ' HIS . 0.7 OUTLIER -97.28 -30.8 12.76 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.095 -0.502 . . . . 0.0 110.919 179.987 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 62' ' ' GLN . . . . . . . . . . . . . 6.5 mm-40 -97.49 155.35 37.38 Favored Pre-proline 0 C--N 1.328 -0.331 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.974 -179.974 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 74.3 Cg_endo -75.44 60.63 5.81 Favored 'Trans proline' 0 C--N 1.344 0.324 0 C-N-CA 122.648 2.232 . . . . 0.0 112.262 -179.961 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 64' ' ' THR . . . . . . . . . . . . . 26.7 p -132.85 33.26 3.73 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.253 -0.431 . . . . 0.0 110.932 -179.95 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . -85.47 -127.51 1.86 Allowed Glycine 0 N--CA 1.451 -0.338 0 C-N-CA 120.689 -0.767 . . . . 0.0 112.489 -179.968 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 66' ' ' LYS . . . . . . . . . . . . . 0.3 OUTLIER -150.24 -49.08 0.13 Allowed 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.824 0.345 . . . . 0.0 110.865 -179.961 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 67' ' ' HIS . . . . . . . . . . . . . 5.7 p80 -119.5 169.92 9.62 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.143 -0.48 . . . . 0.0 110.854 -179.962 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -97.08 39.8 1.17 Allowed 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.87 -179.987 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 99.43 -36.34 4.13 Favored Glycine 0 N--CA 1.451 -0.337 0 C-N-CA 120.735 -0.745 . . . . 0.0 112.537 179.907 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 70' ' ' SER . . . . . . . . . . . . . 11.7 p -115.32 163.52 15.58 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 120.8 0.333 . . . . 0.0 110.957 179.986 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 21.4 t -137.88 116.25 13.62 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 116.137 -0.483 . . . . 0.0 111.125 179.984 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 72' ' ' PHE . . . . . . . . . . . . . 32.3 m-85 60.6 30.76 19.96 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.928 179.973 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 99.58 -30.03 10.8 Favored Glycine 0 N--CA 1.451 -0.341 0 C-N-CA 120.641 -0.79 . . . . 0.0 112.568 179.988 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 21.5 t -77.5 114.94 18.64 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.34 0 CA-C-O 120.896 0.379 . . . . 0.0 111.068 179.991 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 75' ' ' ARG . . . . . . . . . . . . . 12.6 ttm180 -95.27 126.49 40.62 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.911 179.967 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 76' ' ' TYR . . . . . 0.535 ' CE2' HG22 ' A' ' 48' ' ' THR . 12.8 m-85 -100.17 -50.75 3.86 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.797 -179.96 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 77' ' ' PHE . . . . . . . . . . . . . 11.3 p90 -144.3 173.34 11.86 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.946 -179.96 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 41.6 p -103.94 122.08 44.45 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.266 -0.425 . . . . 0.0 110.904 179.917 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 79' ' ' CYS . . . . . . . . . . . . . 27.8 p -145.13 172.53 12.96 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.849 -179.988 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 80' ' ' ALA . . . . . 0.591 ' HB3' ' ND1' ' A' ' 83' ' ' HIS . . . -78.64 166.66 41.09 Favored Pre-proline 0 C--N 1.33 -0.268 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.115 179.988 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 81' ' ' PRO . . . . . 0.521 ' HD2' ' HB1' ' A' ' 80' ' ' ALA . 50.1 Cg_exo -53.57 116.35 2.93 Favored 'Trans proline' 0 C--N 1.345 0.362 0 C-N-CA 122.587 2.191 . . . . 0.0 112.333 179.959 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 82' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER 61.94 53.4 3.08 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.879 179.923 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 83' ' ' HIS . . . . . 0.591 ' ND1' ' HB3' ' A' ' 80' ' ' ALA . 7.4 m170 -123.45 -44.46 2.12 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.915 179.921 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . -71.02 150.0 46.91 Favored Glycine 0 N--CA 1.451 -0.359 0 C-N-CA 120.699 -0.762 . . . . 0.0 112.535 179.948 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 85' ' ' VAL . . . . . . . . . . . . . 10.8 m -148.94 139.27 16.57 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-O 120.817 0.342 . . . . 0.0 111.157 -179.962 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 86' ' ' PHE . . . . . . . . . . . . . 4.1 m-85 -115.93 109.03 17.01 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.839 179.988 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 87' ' ' ALA . . . . . 0.592 ' O ' HD11 ' A' ' 92' ' ' ILE . . . -130.84 142.85 47.04 Favored Pre-proline 0 C--N 1.33 -0.261 0 CA-C-N 116.259 -0.428 . . . . 0.0 111.126 -179.953 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 88' ' ' PRO . . . . . 0.421 ' O ' ' N ' ' A' ' 91' ' ' ARG . 44.3 Cg_exo -56.26 143.7 84.49 Favored 'Trans proline' 0 C--N 1.345 0.391 0 C-N-CA 122.516 2.144 . . . . 0.0 112.22 179.938 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 89' ' ' ALA . . . . . 0.484 ' HB2' ' CE1' ' A' ' 56' ' ' TYR . . . -47.89 -50.88 25.26 Favored 'General case' 0 C--N 1.333 -0.134 0 CA-C-O 121.113 0.482 . . . . 0.0 110.308 179.807 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 90' ' ' SER . . . . . . . . . . . . . 1.1 m -55.72 -24.76 36.63 Favored 'General case' 0 C--N 1.331 -0.215 0 CA-C-N 115.639 -0.71 . . . . 0.0 109.721 178.765 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 91' ' ' ARG . . . . . 0.421 ' N ' ' O ' ' A' ' 88' ' ' PRO . 0.0 OUTLIER -87.9 -16.28 34.34 Favored 'General case' 0 N--CA 1.454 -0.244 0 CA-C-N 115.833 -0.622 . . . . 0.0 110.393 179.044 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 92' ' ' ILE . . . . . 0.592 HD11 ' O ' ' A' ' 87' ' ' ALA . 44.1 mt -104.2 153.74 6.19 Favored 'Isoleucine or valine' 0 C--O 1.231 0.114 0 CA-C-N 116.344 -0.389 . . . . 0.0 111.063 179.882 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 93' ' ' GLN . . . . . 0.412 ' N ' HG22 ' A' ' 92' ' ' ILE . 0.3 OUTLIER -120.43 142.57 49.1 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.922 -179.976 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 94' ' ' ARG . . . . . . . . . . . . . 12.9 ttt180 -89.96 116.44 28.02 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.222 -0.444 . . . . 0.0 110.868 179.996 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 95' ' ' ILE . . . . . 0.625 HD12 ' HB3' ' A' ' 31' ' ' GLN . 35.2 mt -75.31 -54.24 14.47 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.136 -0.484 . . . . 0.0 111.143 179.99 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . -84.31 84.14 1.6 Allowed Glycine 0 N--CA 1.451 -0.311 0 C-N-CA 120.736 -0.745 . . . . 0.0 112.481 179.998 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 97' ' ' SER . . . . . . . . . . . . . 17.0 t -116.65 129.1 55.95 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-O 120.889 0.376 . . . . 0.0 110.888 179.985 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 98' ' ' GLY . . . . . . . . . . . . . . . 168.49 65.67 0.03 OUTLIER Glycine 0 N--CA 1.451 -0.334 0 C-N-CA 120.78 -0.724 . . . . 0.0 112.566 179.99 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 99' ' ' PRO . . . . . . . . . . . . . 55.4 Cg_endo -69.88 -45.81 1.39 Allowed 'Trans proline' 0 C--N 1.345 0.347 0 C-N-CA 122.543 2.162 . . . . 0.0 112.302 -179.988 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 100' ' ' SER . . . . . . . . . . . . . 1.4 p -80.81 172.68 13.44 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.872 -179.954 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 47.4 t -84.08 -36.2 23.18 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.967 179.956 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.248 1.011 0 CA-C-O 118.437 -1.202 . . . . 0.0 112.498 -179.999 . . . . . . . . 0 0 . 1 . 017 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.245 0 N-CA-C 112.546 -0.222 . . . . 0.0 112.546 . . . . . . . . . 0 0 . 1 . 017 nuclear nobuild full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -84.53 -171.72 3.78 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-O 120.803 0.335 . . . . 0.0 110.919 -179.962 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 18.6 p -162.95 163.59 26.13 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.809 -179.967 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -113.91 26.94 9.54 Favored Glycine 0 N--CA 1.451 -0.303 0 C-N-CA 120.727 -0.749 . . . . 0.0 112.586 -179.975 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -176.77 -65.85 0.01 OUTLIER 'General case' 0 C--N 1.33 -0.274 0 CA-C-O 120.815 0.34 . . . . 0.0 110.884 179.959 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 15.5 p -176.16 179.7 1.23 Allowed 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.877 179.952 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 80.65 152.41 8.36 Favored Glycine 0 N--CA 1.452 -0.291 0 C-N-CA 120.694 -0.765 . . . . 0.0 112.43 -179.989 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 15.0 mttp -133.02 -174.06 3.37 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 120.826 0.346 . . . . 0.0 110.931 -179.96 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 33.8 m -125.48 88.92 53.44 Favored Pre-proline 0 C--N 1.33 -0.266 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.96 -179.965 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 64.0 Cg_exo -51.16 146.47 23.14 Favored 'Trans proline' 0 C--N 1.345 0.387 0 C-N-CA 122.514 2.142 . . . . 0.0 112.383 179.919 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 1.6 p -157.38 158.25 35.56 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.895 -179.987 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 12' ' ' SER . . . . . 0.663 ' O ' HD13 ' A' ' 15' ' ' LEU . 1.3 m -153.84 71.43 6.55 Favored Pre-proline 0 C--N 1.33 -0.279 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.858 -179.997 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 58.3 Cg_endo -71.71 -174.01 1.17 Allowed 'Trans proline' 0 C--N 1.343 0.28 0 C-N-CA 122.557 2.172 . . . . 0.0 112.306 179.98 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER 60.01 36.8 21.48 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.288 -0.415 . . . . 0.0 110.853 179.948 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 15' ' ' LEU . . . . . 0.663 HD13 ' O ' ' A' ' 12' ' ' SER . 0.2 OUTLIER -106.12 -39.22 6.03 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.258 -0.428 . . . . 0.0 110.836 179.93 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -136.85 13.0 3.91 Favored Glycine 0 N--CA 1.451 -0.303 0 C-N-CA 120.752 -0.737 . . . . 0.0 112.774 -179.996 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 71.2 m 55.88 34.41 23.48 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-O 120.792 0.33 . . . . 0.0 111.044 179.918 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER 61.1 89.5 0.08 Allowed 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.867 -179.992 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 19' ' ' GLN . . . . . . . . . . . . . 4.4 tt0 -172.05 105.84 0.19 Allowed 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.907 -179.989 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 20' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -150.06 160.48 43.61 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.98 -179.983 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 12.5 mtm180 60.49 157.65 0.03 OUTLIER 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.246 -0.434 . . . . 0.0 110.955 179.967 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -144.74 -70.0 0.29 Allowed 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.841 -179.996 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 72.96 157.82 4.18 Favored Glycine 0 N--CA 1.45 -0.389 0 C-N-CA 120.747 -0.739 . . . . 0.0 112.524 -179.948 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -81.62 157.07 24.83 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-O 120.816 0.341 . . . . 0.0 111.028 -179.976 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 25' ' ' LYS . . . . . 0.695 ' HG3' ' HB1' ' A' ' 89' ' ' ALA . 8.7 mmtt -67.08 -62.26 1.52 Allowed 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.934 179.965 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -125.52 175.07 7.78 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.24 -0.436 . . . . 0.0 111.14 -179.957 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 27' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -123.91 168.1 13.24 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.848 -179.963 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 25.2 t -73.43 111.42 8.24 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.097 179.951 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 112.72 27.96 3.62 Favored Glycine 0 N--CA 1.452 -0.285 0 C-N-CA 120.752 -0.737 . . . . 0.0 112.516 -179.966 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -136.57 145.53 45.08 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-O 120.757 0.313 . . . . 0.0 110.895 179.995 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 31' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -68.56 136.01 52.41 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.887 179.978 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 12.7 m -136.66 179.67 3.66 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.181 -0.463 . . . . 0.0 111.093 179.993 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 33' ' ' LEU . . . . . 0.523 HD23 ' HA2' ' A' ' 36' ' ' GLY . 15.7 tp -137.91 114.1 10.11 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.914 179.959 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 34' ' ' VAL . . . . . 0.499 HG22 HD13 ' A' ' 58' ' ' ILE . 21.5 t -83.82 123.22 38.67 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.343 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.104 179.997 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 35' ' ' ALA . . . . . . . . . . . . . . . 59.34 26.39 15.24 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.197 179.979 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 36' ' ' GLY . . . . . 0.523 ' HA2' HD23 ' A' ' 33' ' ' LEU . . . 56.13 27.78 52.66 Favored Glycine 0 N--CA 1.452 -0.299 0 C-N-CA 120.774 -0.727 . . . . 0.0 112.579 179.999 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 37' ' ' GLN . . . . . . . . . . . . . 41.7 mt-30 -137.17 -70.6 0.45 Allowed 'General case' 0 C--N 1.328 -0.336 0 CA-C-O 120.858 0.361 . . . . 0.0 110.987 -179.965 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 38' ' ' LYS . . . . . . . . . . . . . 11.5 mttm -70.4 124.6 24.57 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.923 179.969 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 39' ' ' GLN . . . . . . . . . . . . . 0.1 OUTLIER -99.13 129.57 45.39 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.861 179.993 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -151.88 -173.78 21.92 Favored Glycine 0 N--CA 1.452 -0.276 0 C-N-CA 120.702 -0.761 . . . . 0.0 112.49 179.955 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 41' ' ' ILE . . . . . 0.426 ' N ' HG23 ' A' ' 58' ' ' ILE . 32.7 mt -125.15 138.05 55.58 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-O 120.77 0.319 . . . . 0.0 111.125 -179.984 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 42' ' ' VAL . . . . . . . . . . . . . 26.5 t -67.17 113.98 3.63 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.226 -0.443 . . . . 0.0 111.02 179.956 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 43' ' ' ARG . . . . . . . . . . . . . 14.7 mmt180 -102.6 -31.45 10.38 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.933 179.995 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 44' ' ' PHE . . . . . . . . . . . . . 80.7 t80 -146.26 116.71 7.51 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.895 179.943 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 45' ' ' TYR . . . . . 0.488 ' CE1' ' CZ ' ' A' ' 56' ' ' TYR . 17.7 t80 -114.52 117.53 31.2 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.922 179.936 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 173.58 170.44 37.07 Favored Glycine 0 N--CA 1.451 -0.339 0 C-N-CA 120.746 -0.74 . . . . 0.0 112.534 -179.943 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 47' ' ' LYS . . . . . . . . . . . . . 85.5 mttt -65.33 148.27 51.99 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-O 120.819 0.342 . . . . 0.0 110.899 -179.922 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 48' ' ' THR . . . . . 0.719 HG22 ' CE2' ' A' ' 76' ' ' TYR . 0.9 OUTLIER -103.03 -177.08 3.27 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.909 179.989 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 12.5 t0 -109.21 -31.53 7.55 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.246 -0.434 . . . . 0.0 110.985 -179.999 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 50' ' ' PHE . . . . . 0.494 ' CZ ' HG21 ' A' ' 48' ' ' THR . 19.8 p90 -80.01 -31.19 39.66 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.979 180.0 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 51' ' ' ALA . . . . . . . . . . . . . . . -134.8 139.99 33.92 Favored Pre-proline 0 C--N 1.329 -0.306 0 CA-C-N 116.269 -0.423 . . . . 0.0 111.078 -179.957 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 52' ' ' PRO . . . . . . . . . . . . . 72.0 Cg_endo -76.82 167.06 25.95 Favored 'Trans proline' 0 C--N 1.346 0.434 0 C-N-CA 122.469 2.113 . . . . 0.0 112.292 -179.974 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 92.21 -167.85 30.64 Favored Glycine 0 N--CA 1.45 -0.372 0 C-N-CA 120.734 -0.746 . . . . 0.0 112.562 179.898 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 54' ' ' TYR . . . . . . . . . . . . . 31.0 m-85 -103.31 124.27 48.34 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-O 120.868 0.366 . . . . 0.0 110.833 -179.969 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 55' ' ' TRP . . . . . . . . . . . . . 75.2 m95 -117.29 160.61 20.84 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.865 -179.997 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 56' ' ' TYR . . . . . 0.662 ' HE1' ' HB2' ' A' ' 89' ' ' ALA . 5.7 m-85 -118.45 115.81 25.4 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.963 -179.96 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . -82.04 69.53 3.3 Favored Glycine 0 N--CA 1.452 -0.283 0 C-N-CA 120.646 -0.788 . . . . 0.0 112.437 179.933 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 58' ' ' ILE . . . . . 0.764 HD11 HD13 ' A' ' 92' ' ' ILE . 3.9 mt -75.67 141.05 16.36 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-O 120.8 0.333 . . . . 0.0 111.099 -179.976 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 3.1 tt0 -105.63 119.38 38.98 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.925 179.956 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 60' ' ' LEU . . . . . . . . . . . . . 92.7 mt -77.94 172.25 13.76 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.935 179.993 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -101.32 -29.2 12.19 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.895 -179.984 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 62' ' ' GLN . . . . . . . . . . . . . 0.3 OUTLIER -106.65 155.63 38.58 Favored Pre-proline 0 C--N 1.33 -0.259 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.936 179.965 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 55.0 Cg_endo -69.73 70.29 1.57 Allowed 'Trans proline' 0 C--N 1.344 0.335 0 C-N-CA 122.526 2.151 . . . . 0.0 112.296 179.993 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 64' ' ' THR . . . . . . . . . . . . . 42.9 p -147.75 43.76 1.08 Allowed 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 116.112 -0.494 . . . . 0.0 110.826 179.998 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . -95.49 -127.74 5.32 Favored Glycine 0 N--CA 1.451 -0.322 0 C-N-CA 120.777 -0.725 . . . . 0.0 112.561 179.968 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 66' ' ' LYS . . . . . . . . . . . . . 0.6 OUTLIER -148.16 -50.04 0.17 Allowed 'General case' 0 C--N 1.328 -0.346 0 CA-C-O 120.833 0.349 . . . . 0.0 110.83 179.999 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 67' ' ' HIS . . . . . . . . . . . . . 6.7 p80 -123.1 168.06 12.87 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.154 -0.476 . . . . 0.0 110.833 179.969 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 9.2 p-10 -98.89 31.29 3.02 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.253 -0.431 . . . . 0.0 110.914 -179.984 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 100.36 -28.09 17.4 Favored Glycine 0 N--CA 1.451 -0.312 0 C-N-CA 120.653 -0.784 . . . . 0.0 112.486 -179.979 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 70' ' ' SER . . . . . . . . . . . . . 33.2 p -122.47 139.74 53.53 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-O 120.795 0.331 . . . . 0.0 110.867 -179.981 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 71' ' ' VAL . . . . . 0.658 HG12 ' CD2' ' A' ' 72' ' ' PHE . 21.5 t -124.99 116.81 48.27 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.224 -0.444 . . . . 0.0 111.029 179.988 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 72' ' ' PHE . . . . . 0.658 ' CD2' HG12 ' A' ' 71' ' ' VAL . 13.7 m-85 60.96 30.92 19.9 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.901 179.965 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 98.45 -28.52 14.5 Favored Glycine 0 N--CA 1.451 -0.33 0 C-N-CA 120.756 -0.735 . . . . 0.0 112.498 179.933 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 21.5 t -77.05 122.42 31.55 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.272 0 CA-C-O 120.876 0.369 . . . . 0.0 111.109 179.998 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 75' ' ' ARG . . . . . . . . . . . . . 3.4 ttt180 -95.3 146.34 24.44 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.925 179.982 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 76' ' ' TYR . . . . . 0.719 ' CE2' HG22 ' A' ' 48' ' ' THR . 72.8 m-85 -122.05 -45.0 2.27 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.884 179.968 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 77' ' ' PHE . . . . . . . . . . . . . 17.1 p90 -162.23 165.25 27.06 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.883 179.945 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 1.0 OUTLIER -89.65 103.05 15.73 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.976 179.974 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 79' ' ' CYS . . . . . . . . . . . . . 28.4 p -127.69 153.73 46.14 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.887 -179.969 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 80' ' ' ALA . . . . . 0.584 ' HB3' ' CG ' ' A' ' 83' ' ' HIS . . . -61.91 164.21 10.89 Favored Pre-proline 0 C--N 1.329 -0.308 0 CA-C-N 116.136 -0.484 . . . . 0.0 111.137 179.975 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 81' ' ' PRO . . . . . 0.443 ' HD2' ' HB1' ' A' ' 80' ' ' ALA . 51.0 Cg_exo -54.11 115.59 2.46 Favored 'Trans proline' 0 C--N 1.345 0.385 0 C-N-CA 122.578 2.185 . . . . 0.0 112.293 -179.949 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 82' ' ' ARG . . . . . . . . . . . . . 0.7 OUTLIER 61.59 53.64 3.25 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.852 179.953 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 83' ' ' HIS . . . . . 0.584 ' CG ' ' HB3' ' A' ' 80' ' ' ALA . 6.1 m170 -125.15 -44.52 1.89 Allowed 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.145 -0.479 . . . . 0.0 110.879 179.882 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . -67.23 130.24 29.43 Favored Glycine 0 N--CA 1.451 -0.311 0 C-N-CA 120.714 -0.755 . . . . 0.0 112.434 179.934 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 85' ' ' VAL . . . . . . . . . . . . . 5.1 m -134.29 121.67 37.98 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-O 120.856 0.36 . . . . 0.0 111.174 179.966 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 86' ' ' PHE . . . . . . . . . . . . . 7.9 m-85 -96.25 112.33 24.1 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.916 179.937 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 87' ' ' ALA . . . . . 0.515 ' O ' HD11 ' A' ' 92' ' ' ILE . . . -129.74 143.74 50.23 Favored Pre-proline 0 C--N 1.33 -0.28 0 CA-C-N 116.257 -0.429 . . . . 0.0 111.025 -179.94 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 88' ' ' PRO . . . . . 0.407 ' O ' ' N ' ' A' ' 91' ' ' ARG . 46.9 Cg_exo -56.03 140.52 86.5 Favored 'Trans proline' 0 C--N 1.346 0.406 0 C-N-CA 122.52 2.146 . . . . 0.0 112.317 -179.995 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 89' ' ' ALA . . . . . 0.695 ' HB1' ' HG3' ' A' ' 25' ' ' LYS . . . -47.96 -51.61 22.97 Favored 'General case' 0 CA--C 1.521 -0.136 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.255 179.901 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 90' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -55.82 -24.47 36.45 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 115.76 -0.655 . . . . 0.0 109.709 178.87 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 91' ' ' ARG . . . . . 0.407 ' N ' ' O ' ' A' ' 88' ' ' PRO . 0.0 OUTLIER -87.8 -15.31 37.24 Favored 'General case' 0 N--CA 1.455 -0.225 0 CA-C-N 115.834 -0.621 . . . . 0.0 110.415 179.022 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 92' ' ' ILE . . . . . 0.764 HD13 HD11 ' A' ' 58' ' ' ILE . 41.7 mt -108.66 150.57 11.28 Favored 'Isoleucine or valine' 0 N--CA 1.457 -0.105 0 CA-C-N 116.376 -0.375 . . . . 0.0 111.071 179.898 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 93' ' ' GLN . . . . . . . . . . . . . 10.5 mt-30 -120.06 161.4 21.03 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.918 -179.991 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 94' ' ' ARG . . . . . . . . . . . . . 1.1 mtt180 -101.15 126.35 47.85 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.247 -0.433 . . . . 0.0 110.885 179.963 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 95' ' ' ILE . . . . . 0.434 HD11 ' HB2' ' A' ' 33' ' ' LEU . 26.1 mm -75.12 -61.79 1.57 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 116.15 -0.477 . . . . 0.0 111.171 179.968 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . -77.7 69.55 2.6 Favored Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.791 -0.719 . . . . 0.0 112.479 -179.921 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 97' ' ' SER . . . . . . . . . . . . . 20.3 p -173.19 -170.48 0.63 Allowed 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.849 0.357 . . . . 0.0 110.839 -179.978 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 98' ' ' GLY . . . . . . . . . . . . . . . 128.64 83.8 0.39 Allowed Glycine 0 N--CA 1.452 -0.239 0 C-N-CA 120.729 -0.748 . . . . 0.0 112.506 -179.921 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 99' ' ' PRO . . . . . . . . . . . . . 55.2 Cg_endo -69.79 81.33 0.83 Allowed 'Trans proline' 0 C--N 1.344 0.332 0 C-N-CA 122.557 2.171 . . . . 0.0 112.353 179.978 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 100' ' ' SER . . . . . . . . . . . . . 58.7 p -91.67 116.77 29.15 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.943 -179.933 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 56.4 p -64.45 -52.53 57.56 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.211 -0.449 . . . . 0.0 110.898 -180.0 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.25 1.116 0 CA-C-O 118.42 -1.211 . . . . 0.0 112.465 179.914 . . . . . . . . 0 0 . 1 . 018 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.231 0 N-CA-C 112.494 -0.243 . . . . 0.0 112.494 . . . . . . . . . 0 0 . 1 . 018 nuclear nobuild full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -160.21 126.71 4.26 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-O 120.882 0.373 . . . . 0.0 110.97 179.981 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 5.7 m -70.14 85.7 0.55 Allowed 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.899 -179.958 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -122.59 -179.66 15.92 Favored Glycine 0 N--CA 1.451 -0.353 0 C-N-CA 120.734 -0.746 . . . . 0.0 112.578 -180.0 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 25.8 t -136.02 134.4 38.47 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-O 120.804 0.335 . . . . 0.0 110.837 -179.985 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -95.26 -51.0 4.79 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.847 -179.981 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -136.39 136.08 8.16 Favored Glycine 0 N--CA 1.452 -0.288 0 C-N-CA 120.712 -0.756 . . . . 0.0 112.473 -179.946 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 7.5 pttt -60.28 -175.84 0.04 OUTLIER 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 120.766 0.317 . . . . 0.0 110.97 179.968 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 9' ' ' SER . . . . . 0.433 ' CB ' ' CD ' ' A' ' 10' ' ' PRO . 1.3 m -171.73 -63.12 0.0 OUTLIER Pre-proline 0 C--N 1.33 -0.277 0 CA-C-N 116.337 -0.392 . . . . 0.0 110.896 179.908 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 10' ' ' PRO . . . . . 0.433 ' CD ' ' CB ' ' A' ' 9' ' ' SER . 55.7 Cg_endo -69.96 113.87 3.55 Favored 'Trans proline' 0 C--N 1.347 0.448 0 C-N-CA 122.383 2.055 . . . . 0.0 112.278 179.913 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -114.56 140.0 49.13 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.255 -0.43 . . . . 0.0 110.9 -179.972 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -122.46 106.16 35.55 Favored Pre-proline 0 C--N 1.33 -0.274 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.85 -179.969 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 73.8 Cg_exo -49.21 -61.94 0.5 Allowed 'Trans proline' 0 C--N 1.346 0.431 0 C-N-CA 122.43 2.086 . . . . 0.0 112.425 179.987 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 4.6 t 56.65 -168.49 0.1 Allowed 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 116.312 -0.404 . . . . 0.0 110.924 -179.935 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 0.9 OUTLIER -157.6 81.22 0.88 Allowed 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.299 -0.41 . . . . 0.0 110.993 179.961 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 83.54 -89.09 1.52 Allowed Glycine 0 N--CA 1.451 -0.326 0 C-N-CA 120.744 -0.741 . . . . 0.0 112.548 -179.992 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 12.7 m -154.36 104.74 2.61 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-O 120.768 0.318 . . . . 0.0 110.851 -179.998 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 3.4 mt -133.19 -59.35 0.88 Allowed 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.275 -0.42 . . . . 0.0 110.958 -179.962 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 19' ' ' GLN . . . . . . . . . . . . . 5.3 mt-30 -80.54 87.99 5.7 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.971 179.97 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 20' ' ' GLN . . . . . . . . . . . . . 15.0 mt-30 -132.6 119.15 20.08 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.946 -179.958 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 5.9 ptm180 -113.75 133.76 55.17 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.906 -179.993 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -154.66 148.32 25.37 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.873 -179.969 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -69.94 135.18 26.05 Favored Glycine 0 N--CA 1.451 -0.337 0 C-N-CA 120.77 -0.729 . . . . 0.0 112.527 -179.974 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -110.34 143.62 40.3 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 120.769 0.319 . . . . 0.0 111.129 179.973 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 25' ' ' LYS . . . . . 0.404 ' HG3' ' HB1' ' A' ' 89' ' ' ALA . 1.6 mmpt? -73.55 -64.12 1.06 Allowed 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.247 -0.433 . . . . 0.0 110.891 -179.957 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 26' ' ' ALA . . . . . 0.705 ' HB2' ' HG2' ' A' ' 94' ' ' ARG . . . -131.51 -176.37 4.01 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.162 -0.472 . . . . 0.0 111.071 179.958 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 27' ' ' GLU . . . . . . . . . . . . . 3.7 mt-10 -138.84 171.38 14.42 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.084 -0.507 . . . . 0.0 110.841 -179.964 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 28.1 t -65.97 109.71 1.16 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 116.097 -0.501 . . . . 0.0 111.02 -179.999 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 112.85 29.85 2.96 Favored Glycine 0 N--CA 1.452 -0.254 0 C-N-CA 120.756 -0.735 . . . . 0.0 112.516 -179.986 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 30' ' ' ASP . . . . . 0.684 ' O ' HG23 ' A' ' 41' ' ' ILE . 1.2 t0 -137.48 164.69 28.09 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-O 120.823 0.344 . . . . 0.0 110.878 179.942 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 31' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -83.11 131.72 35.13 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.25 -0.432 . . . . 0.0 110.927 179.966 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 15.3 m -139.74 179.53 2.75 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 116.329 -0.396 . . . . 0.0 111.136 179.957 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 33' ' ' LEU . . . . . 0.414 HD23 ' HA2' ' A' ' 36' ' ' GLY . 22.7 tp -143.45 102.02 3.88 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.158 -0.473 . . . . 0.0 110.812 179.97 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 34' ' ' VAL . . . . . 0.49 HG22 HD12 ' A' ' 58' ' ' ILE . 21.5 t -70.5 124.19 26.11 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.202 -0.454 . . . . 0.0 111.2 179.99 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 35' ' ' ALA . . . . . . . . . . . . . . . 58.57 25.51 13.24 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.228 -0.442 . . . . 0.0 111.264 179.942 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 36' ' ' GLY . . . . . 0.414 ' HA2' HD23 ' A' ' 33' ' ' LEU . . . 55.42 27.22 47.0 Favored Glycine 0 N--CA 1.452 -0.242 0 C-N-CA 120.852 -0.69 . . . . 0.0 112.587 179.984 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 37' ' ' GLN . . . . . . . . . . . . . 64.5 mt-30 -138.22 -64.86 0.52 Allowed 'General case' 0 C--N 1.329 -0.311 0 CA-C-O 120.704 0.287 . . . . 0.0 110.927 179.948 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 38' ' ' LYS . . . . . . . . . . . . . 64.3 mttt -72.38 112.64 8.62 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 116.294 -0.412 . . . . 0.0 110.877 179.954 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 39' ' ' GLN . . . . . . . . . . . . . 1.4 tm0? -91.82 117.26 29.61 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.836 179.991 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -145.14 -166.07 11.52 Favored Glycine 0 N--CA 1.451 -0.304 0 C-N-CA 120.747 -0.739 . . . . 0.0 112.468 -179.993 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 41' ' ' ILE . . . . . 0.684 HG23 ' O ' ' A' ' 30' ' ' ASP . 31.3 mt -131.17 132.58 63.25 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.25 0 CA-C-O 120.839 0.352 . . . . 0.0 111.105 -179.992 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 42' ' ' VAL . . . . . . . . . . . . . 21.5 t -60.4 121.46 8.27 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.261 -0.427 . . . . 0.0 111.086 179.962 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 43' ' ' ARG . . . . . . . . . . . . . 3.6 mmm-85 -104.14 -31.48 9.62 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.898 -179.941 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 44' ' ' PHE . . . . . 0.427 ' CD1' ' HB3' ' A' ' 76' ' ' TYR . 41.3 t80 -148.3 115.6 6.2 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.97 -179.947 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 45' ' ' TYR . . . . . 0.454 ' CE1' ' CE1' ' A' ' 56' ' ' TYR . 25.8 t80 -114.7 123.35 49.06 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.895 -179.986 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 171.03 -149.3 12.16 Favored Glycine 0 N--CA 1.451 -0.361 0 C-N-CA 120.671 -0.776 . . . . 0.0 112.449 179.956 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 47' ' ' LYS . . . . . . . . . . . . . 7.0 mttt -99.15 164.59 12.09 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-O 120.849 0.357 . . . . 0.0 110.975 -179.962 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 48' ' ' THR . . . . . 0.428 HG21 ' CZ ' ' A' ' 50' ' ' PHE . 13.2 p -129.68 -176.02 3.78 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.823 -179.982 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -112.98 -33.41 6.06 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.973 -179.89 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 50' ' ' PHE . . . . . 0.428 ' CZ ' HG21 ' A' ' 48' ' ' THR . 8.7 p90 -67.31 -30.51 70.37 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.24 -0.436 . . . . 0.0 111.016 -179.893 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 51' ' ' ALA . . . . . 0.42 ' N ' ' CD1' ' A' ' 50' ' ' PHE . . . -148.44 146.2 22.13 Favored Pre-proline 0 C--N 1.329 -0.314 0 CA-C-N 116.324 -0.398 . . . . 0.0 111.17 -179.906 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 52' ' ' PRO . . . . . . . . . . . . . 72.3 Cg_endo -74.95 -178.46 4.17 Favored 'Trans proline' 0 C--N 1.345 0.371 0 C-N-CA 122.584 2.189 . . . . 0.0 112.352 -179.991 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 76.78 -168.01 54.63 Favored Glycine 0 N--CA 1.451 -0.363 0 C-N-CA 120.778 -0.725 . . . . 0.0 112.515 179.954 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 54' ' ' TYR . . . . . . . . . . . . . 20.6 m-85 -101.59 149.56 23.99 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-O 120.837 0.351 . . . . 0.0 110.87 -179.929 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 55' ' ' TRP . . . . . . . . . . . . . 69.4 m95 -145.81 156.41 43.56 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.187 -0.461 . . . . 0.0 110.943 179.946 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 56' ' ' TYR . . . . . 0.454 ' CE1' ' CE1' ' A' ' 45' ' ' TYR . 25.2 m-85 -110.24 124.92 52.49 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.288 -0.415 . . . . 0.0 110.947 -179.947 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . -90.08 60.39 3.43 Favored Glycine 0 N--CA 1.45 -0.368 0 C-N-CA 120.768 -0.73 . . . . 0.0 112.414 179.9 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 58' ' ' ILE . . . . . 0.533 HG23 ' C ' ' A' ' 41' ' ' ILE . 21.2 mt -73.53 137.68 22.82 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-O 120.871 0.367 . . . . 0.0 111.073 -179.957 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 0.2 OUTLIER -103.89 133.27 49.14 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.084 -0.507 . . . . 0.0 110.845 -179.991 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 60' ' ' LEU . . . . . . . . . . . . . 56.5 mt -88.15 174.75 8.05 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.903 179.952 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 2.7 m-20 -100.59 -30.8 11.57 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.976 179.963 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 62' ' ' GLN . . . . . . . . . . . . . 0.8 OUTLIER -106.4 153.5 40.43 Favored Pre-proline 0 C--N 1.331 -0.239 0 CA-C-N 116.178 -0.464 . . . . 0.0 110.924 -179.971 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 73.6 Cg_endo -75.81 64.22 6.72 Favored 'Trans proline' 0 C--N 1.344 0.31 0 C-N-CA 122.613 2.209 . . . . 0.0 112.323 -179.857 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 64' ' ' THR . . . . . . . . . . . . . 7.5 t -147.01 38.55 0.99 Allowed 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.899 179.975 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . -86.57 -111.72 0.86 Allowed Glycine 0 N--CA 1.451 -0.313 0 C-N-CA 120.767 -0.73 . . . . 0.0 112.559 179.98 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 66' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -147.71 -47.27 0.17 Allowed 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.819 0.343 . . . . 0.0 110.893 179.992 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 67' ' ' HIS . . . . . 0.514 ' ND1' HG22 ' A' ' 71' ' ' VAL . 15.7 p80 -141.99 -176.0 4.63 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.865 179.96 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -89.32 -168.83 2.28 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.833 179.987 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . -63.39 -27.6 71.01 Favored Glycine 0 N--CA 1.451 -0.363 0 C-N-CA 120.695 -0.765 . . . . 0.0 112.473 -179.934 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 70' ' ' SER . . . . . . . . . . . . . 4.0 p -116.98 147.66 42.11 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 120.8 0.333 . . . . 0.0 110.897 -179.94 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 71' ' ' VAL . . . . . 0.514 HG22 ' ND1' ' A' ' 67' ' ' HIS . 28.2 t -127.12 119.86 53.89 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.103 179.929 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 72' ' ' PHE . . . . . . . . . . . . . 5.4 m-85 60.57 30.82 20.02 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.887 -179.948 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 94.91 -15.76 62.72 Favored Glycine 0 N--CA 1.451 -0.318 0 C-N-CA 120.713 -0.756 . . . . 0.0 112.721 -179.999 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 25.3 t -87.9 113.08 24.48 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-O 120.807 0.337 . . . . 0.0 111.169 -179.938 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 75' ' ' ARG . . . . . . . . . . . . . 6.4 ttm105 -95.06 114.7 26.54 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.762 179.885 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 76' ' ' TYR . . . . . 0.427 ' HB3' ' CD1' ' A' ' 44' ' ' PHE . 26.0 m-85 -96.7 -34.97 11.17 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.988 -179.853 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 77' ' ' PHE . . . . . . . . . . . . . 51.6 p90 -162.6 159.52 24.7 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 116.316 -0.402 . . . . 0.0 111.021 -179.907 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 26.0 m -87.62 140.82 29.13 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.922 179.917 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 79' ' ' CYS . . . . . . . . . . . . . 30.7 p -164.67 -175.6 3.9 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.263 -0.426 . . . . 0.0 110.915 179.965 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 80' ' ' ALA . . . . . 0.533 ' HB1' ' HD2' ' A' ' 81' ' ' PRO . . . -96.62 166.45 14.05 Favored Pre-proline 0 C--N 1.328 -0.328 0 CA-C-N 116.166 -0.47 . . . . 0.0 111.102 -179.97 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 81' ' ' PRO . . . . . 0.533 ' HD2' ' HB1' ' A' ' 80' ' ' ALA . 50.6 Cg_exo -53.21 120.55 7.92 Favored 'Trans proline' 0 C--N 1.344 0.298 0 C-N-CA 122.627 2.218 . . . . 0.0 112.297 179.96 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 82' ' ' ARG . . . . . . . . . . . . . 37.8 mtp85 62.45 61.46 1.25 Allowed 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.953 -179.967 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 83' ' ' HIS . . . . . . . . . . . . . 4.5 m-70 -130.79 -51.13 1.05 Allowed 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.866 -179.985 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . -63.51 143.54 48.21 Favored Glycine 0 N--CA 1.45 -0.367 0 C-N-CA 120.753 -0.736 . . . . 0.0 112.541 179.972 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 85' ' ' VAL . . . . . . . . . . . . . 5.1 m -145.92 118.16 2.12 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-O 120.829 0.347 . . . . 0.0 111.061 -179.974 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 86' ' ' PHE . . . . . . . . . . . . . 6.6 m-85 -96.45 105.93 18.1 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.847 179.973 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 87' ' ' ALA . . . . . 0.562 ' O ' HD11 ' A' ' 92' ' ' ILE . . . -126.0 142.76 43.35 Favored Pre-proline 0 C--N 1.328 -0.339 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.091 179.954 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 88' ' ' PRO . . . . . 0.411 ' O ' ' N ' ' A' ' 91' ' ' ARG . 31.2 Cg_exo -58.88 146.18 94.28 Favored 'Trans proline' 0 C--N 1.347 0.461 0 C-N-CA 122.468 2.112 . . . . 0.0 112.344 -179.999 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 89' ' ' ALA . . . . . 0.404 ' HB1' ' HG3' ' A' ' 25' ' ' LYS . . . -48.38 -51.31 27.1 Favored 'General case' 0 C--N 1.333 -0.133 0 CA-C-O 121.08 0.467 . . . . 0.0 110.263 179.769 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 90' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -56.02 -24.4 38.93 Favored 'General case' 0 N--CA 1.454 -0.225 0 CA-C-N 115.648 -0.705 . . . . 0.0 109.789 178.732 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 91' ' ' ARG . . . . . 0.411 ' N ' ' O ' ' A' ' 88' ' ' PRO . 0.1 OUTLIER -88.44 -15.01 36.53 Favored 'General case' 0 N--CA 1.454 -0.254 0 CA-C-N 115.876 -0.602 . . . . 0.0 110.348 179.077 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 92' ' ' ILE . . . . . 0.562 HD11 ' O ' ' A' ' 87' ' ' ALA . 43.1 mt -108.77 158.31 8.65 Favored 'Isoleucine or valine' 0 C--O 1.231 0.081 0 CA-C-N 116.334 -0.394 . . . . 0.0 111.017 179.784 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 93' ' ' GLN . . . . . 0.487 ' N ' HG22 ' A' ' 92' ' ' ILE . 3.4 mt-30 -124.78 162.72 23.67 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.246 -0.434 . . . . 0.0 110.898 -179.886 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 94' ' ' ARG . . . . . 0.705 ' HG2' ' HB2' ' A' ' 26' ' ' ALA . 0.0 OUTLIER -112.65 127.17 56.03 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.113 -0.494 . . . . 0.0 110.838 -179.993 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 95' ' ' ILE . . . . . . . . . . . . . 33.0 mt -98.44 -32.01 3.8 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.187 -0.461 . . . . 0.0 111.022 179.962 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . -66.51 157.4 50.13 Favored Glycine 0 N--CA 1.451 -0.304 0 C-N-CA 120.809 -0.71 . . . . 0.0 112.408 -179.964 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 97' ' ' SER . . . . . . . . . . . . . 7.1 t -102.05 95.95 6.69 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-O 120.78 0.324 . . . . 0.0 110.949 179.972 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 98' ' ' GLY . . . . . . . . . . . . . . . -135.63 -169.8 11.92 Favored Glycine 0 N--CA 1.451 -0.3 0 C-N-CA 120.686 -0.769 . . . . 0.0 112.446 -179.985 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 99' ' ' PRO . . . . . . . . . . . . . 55.9 Cg_endo -70.1 91.1 0.55 Allowed 'Trans proline' 0 C--N 1.345 0.349 0 C-N-CA 122.576 2.184 . . . . 0.0 112.35 179.985 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 100' ' ' SER . . . . . . . . . . . . . 80.1 p -165.89 144.14 5.82 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.22 -0.446 . . . . 0.0 110.911 -179.962 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER 60.29 166.38 0.07 Allowed 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.863 179.975 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.25 1.123 0 CA-C-O 118.421 -1.211 . . . . 0.0 112.497 -180.0 . . . . . . . . 0 0 . 1 . 019 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.221 0 N-CA-C 112.487 -0.245 . . . . 0.0 112.487 . . . . . . . . . 0 0 . 1 . 019 nuclear nobuild full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 1.1 m -149.88 95.85 2.37 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-O 120.828 0.347 . . . . 0.0 110.906 -179.941 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 96.2 p -164.18 -44.14 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.909 -179.993 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 96.76 -29.49 10.4 Favored Glycine 0 N--CA 1.45 -0.379 0 C-N-CA 120.742 -0.742 . . . . 0.0 112.479 179.959 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 19.2 m -124.4 -61.94 1.3 Allowed 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 120.838 0.351 . . . . 0.0 110.939 -179.958 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER 59.47 89.38 0.06 Allowed 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.885 179.988 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 114.98 151.14 10.02 Favored Glycine 0 N--CA 1.451 -0.301 0 C-N-CA 120.816 -0.707 . . . . 0.0 112.45 -179.941 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER 177.06 -35.17 0.01 OUTLIER 'General case' 0 C--N 1.331 -0.238 0 CA-C-O 120.769 0.319 . . . . 0.0 110.868 -179.966 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 9' ' ' SER . . . . . 0.4 ' N ' ' CD ' ' A' ' 10' ' ' PRO . 1.1 m 64.45 53.84 1.33 Allowed Pre-proline 0 C--N 1.33 -0.247 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.979 -179.88 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 10' ' ' PRO . . . . . 0.4 ' CD ' ' N ' ' A' ' 9' ' ' SER . 71.5 Cg_endo -74.59 -39.58 1.37 Allowed 'Trans proline' 0 C--N 1.345 0.346 0 C-N-CA 122.583 2.189 . . . . 0.0 112.233 179.973 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 23.0 m -153.08 -178.08 6.71 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.81 -179.951 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -137.45 87.6 17.68 Favored Pre-proline 0 C--N 1.33 -0.279 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.941 179.971 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 53.3 Cg_exo -52.38 -34.51 61.2 Favored 'Trans proline' 0 C--N 1.345 0.367 0 C-N-CA 122.535 2.157 . . . . 0.0 112.345 179.975 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 8.5 t -130.1 139.74 50.9 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.928 179.961 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 5.3 tp -153.68 -52.72 0.1 Allowed 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.894 -179.953 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -172.29 51.95 0.17 Allowed Glycine 0 N--CA 1.452 -0.261 0 C-N-CA 120.768 -0.73 . . . . 0.0 112.439 179.976 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 7.9 t 59.39 24.62 13.23 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-O 120.752 0.311 . . . . 0.0 111.029 179.994 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 0.6 OUTLIER 56.32 22.59 6.43 Favored 'General case' 0 C--N 1.331 -0.225 0 CA-C-N 116.337 -0.392 . . . . 0.0 111.25 179.974 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 19' ' ' GLN . . . . . . . . . . . . . 1.2 tp-100 51.94 93.42 0.02 OUTLIER 'General case' 0 C--N 1.332 -0.187 0 CA-C-N 116.416 -0.356 . . . . 0.0 111.055 179.907 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 20' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -144.25 -55.37 0.35 Allowed 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.322 -0.399 . . . . 0.0 110.973 179.921 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 0.6 OUTLIER -67.74 89.55 0.26 Allowed 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.257 -0.429 . . . . 0.0 110.869 180.0 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 22.1 mm-40 -108.93 31.13 5.92 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.843 -179.943 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 65.95 90.81 0.04 OUTLIER Glycine 0 N--CA 1.451 -0.324 0 C-N-CA 120.729 -0.748 . . . . 0.0 112.489 -179.95 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -148.51 110.64 4.61 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-O 120.885 0.374 . . . . 0.0 111.095 179.968 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -68.85 -68.37 0.4 Allowed 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.869 179.924 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -109.66 174.92 5.64 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.211 -0.449 . . . . 0.0 111.105 179.998 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 27' ' ' GLU . . . . . . . . . . . . . 16.4 mt-10 -133.92 179.77 6.04 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.917 -179.975 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 21.5 t -75.32 93.16 0.85 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.091 -179.981 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 121.72 44.84 0.36 Allowed Glycine 0 N--CA 1.451 -0.36 0 C-N-CA 120.843 -0.694 . . . . 0.0 112.489 179.972 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -144.77 158.21 43.87 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-O 120.832 0.349 . . . . 0.0 110.933 -179.991 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 31' ' ' GLN . . . . . . . . . . . . . 0.2 OUTLIER -77.56 126.03 30.26 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.82 -179.911 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 32' ' ' VAL . . . . . 0.457 HG21 HG12 ' A' ' 58' ' ' ILE . 16.2 m -129.34 175.63 10.11 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.262 -0.427 . . . . 0.0 111.158 179.983 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 33' ' ' LEU . . . . . 0.525 HD11 ' O ' ' A' ' 37' ' ' GLN . 25.6 tp -144.92 101.86 3.69 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.244 -0.434 . . . . 0.0 110.926 179.936 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 21.5 t -69.42 123.02 22.13 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.171 -179.958 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 35' ' ' ALA . . . . . . . . . . . . . . . 58.2 25.73 12.93 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.279 179.977 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . 56.13 32.75 60.2 Favored Glycine 0 N--CA 1.452 -0.294 0 C-N-CA 120.731 -0.747 . . . . 0.0 112.636 -179.99 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 37' ' ' GLN . . . . . 0.525 ' O ' HD11 ' A' ' 33' ' ' LEU . 30.9 mt-30 -142.9 -73.9 0.29 Allowed 'General case' 0 C--N 1.329 -0.319 0 CA-C-O 120.847 0.356 . . . . 0.0 110.974 -179.968 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 38' ' ' LYS . . . . . . . . . . . . . 4.6 mttp -64.35 109.6 1.97 Allowed 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.918 -179.973 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 39' ' ' GLN . . . . . . . . . . . . . 14.3 tm0? -85.32 129.38 34.82 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.254 -0.43 . . . . 0.0 110.905 179.982 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -156.13 -178.15 30.02 Favored Glycine 0 N--CA 1.45 -0.371 0 C-N-CA 120.683 -0.77 . . . . 0.0 112.524 -179.971 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 27.9 mm -123.12 138.18 53.98 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-O 120.731 0.3 . . . . 0.0 111.114 -179.983 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 42' ' ' VAL . . . . . . . . . . . . . 26.2 t -62.79 121.11 10.96 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 116.252 -0.431 . . . . 0.0 111.101 179.982 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 43' ' ' ARG . . . . . . . . . . . . . 3.1 mmt180 -107.33 -34.16 7.17 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.922 -179.983 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 44' ' ' PHE . . . . . 0.403 ' CD1' ' HB3' ' A' ' 76' ' ' TYR . 25.8 t80 -145.04 116.27 7.96 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.905 -179.978 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 45' ' ' TYR . . . . . . . . . . . . . 15.4 t80 -111.09 127.1 55.45 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.901 -179.985 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 166.88 -161.49 35.3 Favored Glycine 0 N--CA 1.45 -0.384 0 C-N-CA 120.774 -0.726 . . . . 0.0 112.531 179.992 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 47' ' ' LYS . . . . . . . . . . . . . 46.5 mttt -96.88 158.11 15.58 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-O 120.816 0.341 . . . . 0.0 110.837 -179.975 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 48' ' ' THR . . . . . 0.453 HG21 ' CZ ' ' A' ' 50' ' ' PHE . 28.4 p -120.75 168.25 11.62 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.165 -0.471 . . . . 0.0 110.848 179.895 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -91.69 -29.18 16.99 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.207 -0.452 . . . . 0.0 110.972 179.969 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 50' ' ' PHE . . . . . 0.453 ' CZ ' HG21 ' A' ' 48' ' ' THR . 37.5 p90 -74.92 -32.33 61.77 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.273 -0.421 . . . . 0.0 111.055 -179.929 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 51' ' ' ALA . . . . . . . . . . . . . . . -142.1 143.35 27.55 Favored Pre-proline 0 C--N 1.33 -0.264 0 CA-C-N 116.304 -0.407 . . . . 0.0 111.128 -179.965 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 52' ' ' PRO . . . . . . . . . . . . . 73.8 Cg_endo -77.33 -168.06 0.55 Allowed 'Trans proline' 0 C--N 1.346 0.404 0 C-N-CA 122.669 2.246 . . . . 0.0 112.325 -179.978 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 70.94 -155.15 52.68 Favored Glycine 0 N--CA 1.451 -0.346 0 C-N-CA 120.722 -0.751 . . . . 0.0 112.527 179.917 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 54' ' ' TYR . . . . . . . . . . . . . 41.4 m-85 -119.04 125.23 48.85 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-O 120.793 0.33 . . . . 0.0 110.906 -179.982 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 55' ' ' TRP . . . . . . . . . . . . . 63.8 m95 -117.4 168.5 10.3 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.909 179.967 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 56' ' ' TYR . . . . . 0.653 ' HE1' ' HB2' ' A' ' 89' ' ' ALA . 6.5 m-85 -124.6 119.56 29.4 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.254 -0.43 . . . . 0.0 110.939 -179.951 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 57' ' ' GLY . . . . . 0.454 ' CA ' ' CE1' ' A' ' 86' ' ' PHE . . . -84.1 62.43 4.59 Favored Glycine 0 N--CA 1.451 -0.366 0 C-N-CA 120.771 -0.728 . . . . 0.0 112.543 179.956 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 58' ' ' ILE . . . . . 0.628 HD11 HD13 ' A' ' 92' ' ' ILE . 7.2 mt -68.53 142.84 15.77 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-O 120.868 0.366 . . . . 0.0 111.035 179.995 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 4.7 tm-20 -109.13 110.1 21.25 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.921 179.948 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 60' ' ' LEU . . . . . . . . . . . . . 84.2 mt -68.6 176.33 3.0 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.863 -179.973 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -101.33 -32.18 10.6 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.896 -179.948 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 62' ' ' GLN . . . . . . . . . . . . . 6.3 mt-30 -102.2 162.78 19.25 Favored Pre-proline 0 C--N 1.329 -0.285 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.927 -179.97 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 98.7 Cg_endo -79.52 58.26 6.88 Favored 'Trans proline' 0 C--N 1.344 0.332 0 C-N-CA 122.663 2.242 . . . . 0.0 112.477 -179.996 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 64' ' ' THR . . . . . . . . . . . . . 20.8 p -133.4 32.12 3.69 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.949 179.993 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . -81.98 -117.28 0.48 Allowed Glycine 0 N--CA 1.451 -0.308 0 C-N-CA 120.751 -0.738 . . . . 0.0 112.454 179.976 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 66' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -155.17 -48.05 0.08 Allowed 'General case' 0 C--N 1.33 -0.263 0 CA-C-O 120.868 0.366 . . . . 0.0 110.899 179.917 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 67' ' ' HIS . . . . . . . . . . . . . 7.9 p80 -127.08 169.5 13.33 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 116.156 -0.474 . . . . 0.0 110.81 179.923 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 1.8 m-20 -97.81 36.07 1.59 Allowed 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.255 -0.43 . . . . 0.0 110.91 179.969 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 95.81 -39.57 2.81 Favored Glycine 0 N--CA 1.451 -0.355 0 C-N-CA 120.697 -0.763 . . . . 0.0 112.549 -179.984 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 70' ' ' SER . . . . . . . . . . . . . 11.6 p -101.1 127.23 47.73 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 120.741 0.305 . . . . 0.0 110.911 179.982 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 71' ' ' VAL . . . . . 0.418 HG12 ' CD2' ' A' ' 72' ' ' PHE . 21.5 t -115.07 111.01 34.06 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.349 0 CA-C-N 116.202 -0.454 . . . . 0.0 111.128 179.964 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 72' ' ' PHE . . . . . 0.418 ' CD2' HG12 ' A' ' 71' ' ' VAL . 30.2 m-85 61.44 30.66 18.99 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.891 179.966 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 99.1 -28.79 13.66 Favored Glycine 0 N--CA 1.451 -0.356 0 C-N-CA 120.741 -0.742 . . . . 0.0 112.463 179.951 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 27.8 t -80.55 121.71 34.47 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-O 120.881 0.372 . . . . 0.0 111.075 179.952 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 75' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -106.35 142.07 36.64 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.817 -179.937 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 76' ' ' TYR . . . . . 0.403 ' HB3' ' CD1' ' A' ' 44' ' ' PHE . 8.2 m-85 -115.42 -46.8 2.86 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.123 -0.49 . . . . 0.0 110.855 179.954 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 77' ' ' PHE . . . . . 0.433 ' CE1' ' HA3' ' A' ' 57' ' ' GLY . 35.1 p90 -146.9 177.29 9.25 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 116.263 -0.426 . . . . 0.0 110.879 179.982 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 0.9 OUTLIER -104.69 124.36 49.23 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.875 -179.964 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 79' ' ' CYS . . . . . . . . . . . . . 10.8 p -144.97 167.42 22.68 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.118 -0.492 . . . . 0.0 110.893 179.977 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 80' ' ' ALA . . . . . 0.511 ' HB1' ' HD2' ' A' ' 81' ' ' PRO . . . -75.51 166.44 45.3 Favored Pre-proline 0 C--N 1.33 -0.255 0 CA-C-N 116.228 -0.442 . . . . 0.0 111.075 -179.958 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 81' ' ' PRO . . . . . 0.511 ' HD2' ' HB1' ' A' ' 80' ' ' ALA . 51.2 Cg_exo -52.85 116.6 3.01 Favored 'Trans proline' 0 C--N 1.345 0.346 0 C-N-CA 122.572 2.181 . . . . 0.0 112.318 179.916 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 82' ' ' ARG . . . . . . . . . . . . . 0.5 OUTLIER 61.39 56.74 2.54 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.84 179.897 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 83' ' ' HIS . . . . . 0.505 ' CG ' ' HB3' ' A' ' 80' ' ' ALA . 6.2 m170 -126.36 -47.76 1.58 Allowed 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.925 179.953 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . -61.91 139.33 46.43 Favored Glycine 0 N--CA 1.451 -0.353 0 C-N-CA 120.699 -0.763 . . . . 0.0 112.56 179.915 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 85' ' ' VAL . . . . . . . . . . . . . 5.8 m -140.28 127.99 24.25 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.326 0 CA-C-O 120.774 0.321 . . . . 0.0 111.126 -179.911 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 86' ' ' PHE . . . . . 0.454 ' CE1' ' CA ' ' A' ' 57' ' ' GLY . 9.1 m-85 -110.26 112.45 24.42 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.189 -0.459 . . . . 0.0 110.871 179.926 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 87' ' ' ALA . . . . . 0.526 ' O ' HD11 ' A' ' 92' ' ' ILE . . . -134.86 149.45 70.6 Favored Pre-proline 0 C--N 1.329 -0.286 0 CA-C-N 116.303 -0.408 . . . . 0.0 111.213 179.966 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 88' ' ' PRO . . . . . 0.412 ' O ' ' N ' ' A' ' 91' ' ' ARG . 32.5 Cg_exo -58.08 140.53 94.41 Favored 'Trans proline' 0 C--N 1.345 0.356 0 C-N-CA 122.596 2.197 . . . . 0.0 112.27 -179.92 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 89' ' ' ALA . . . . . 0.653 ' HB2' ' HE1' ' A' ' 56' ' ' TYR . . . -47.79 -51.69 21.61 Favored 'General case' 0 C--N 1.332 -0.165 0 CA-C-O 121.06 0.457 . . . . 0.0 110.299 179.916 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 90' ' ' SER . . . . . . . . . . . . . 14.9 m -55.71 -24.5 35.06 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 115.731 -0.668 . . . . 0.0 109.734 178.788 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 91' ' ' ARG . . . . . 0.412 ' N ' ' O ' ' A' ' 88' ' ' PRO . 0.2 OUTLIER -88.76 -15.14 35.46 Favored 'General case' 0 N--CA 1.454 -0.229 0 CA-C-N 115.889 -0.596 . . . . 0.0 110.438 179.089 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 92' ' ' ILE . . . . . 0.628 HD13 HD11 ' A' ' 58' ' ' ILE . 48.4 mt -107.03 144.88 15.26 Favored 'Isoleucine or valine' 0 C--N 1.334 -0.104 0 CA-C-N 116.413 -0.358 . . . . 0.0 111.047 179.913 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 93' ' ' GLN . . . . . . . . . . . . . 9.1 mt-30 -115.65 -179.94 3.79 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.167 -0.469 . . . . 0.0 110.866 -179.997 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 94' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -125.77 134.99 51.55 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.202 -0.453 . . . . 0.0 110.996 -179.954 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 95' ' ' ILE . . . . . . . . . . . . . 5.0 mt -105.26 -37.34 4.09 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.22 -0.446 . . . . 0.0 111.108 179.952 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . 86.21 -78.23 1.96 Allowed Glycine 0 N--CA 1.45 -0.367 0 C-N-CA 120.746 -0.74 . . . . 0.0 112.449 179.925 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 97' ' ' SER . . . . . . . . . . . . . 74.3 p -126.63 127.79 45.75 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-O 120.779 0.323 . . . . 0.0 110.912 -179.981 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 98' ' ' GLY . . . . . . . . . . . . . . . -126.99 95.27 0.43 Allowed Glycine 0 N--CA 1.452 -0.259 0 C-N-CA 120.756 -0.735 . . . . 0.0 112.46 -179.953 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 99' ' ' PRO . . . . . . . . . . . . . 43.4 Cg_endo -68.1 147.22 72.85 Favored 'Trans proline' 0 C--N 1.345 0.385 0 C-N-CA 122.514 2.143 . . . . 0.0 112.261 179.972 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 100' ' ' SER . . . . . . . . . . . . . 18.3 m 63.93 136.11 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.863 -179.939 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 1.2 m 60.91 101.0 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.873 179.967 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.25 1.121 0 CA-C-O 118.384 -1.231 . . . . 0.0 112.495 -179.986 . . . . . . . . 0 0 . 1 . 020 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.241 0 N-CA-C 112.472 -0.251 . . . . 0.0 112.472 . . . . . . . . . 0 0 . 1 . 020 nuclear nobuild full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 3.4 m -116.83 30.75 7.15 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 120.821 0.344 . . . . 0.0 110.926 -179.971 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER 59.16 31.03 20.92 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.98 179.99 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -68.06 114.54 6.16 Favored Glycine 0 N--CA 1.451 -0.322 0 C-N-CA 120.674 -0.774 . . . . 0.0 112.511 179.948 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 43.8 t -169.36 34.3 0.02 OUTLIER 'General case' 0 C--N 1.33 -0.276 0 CA-C-O 120.82 0.343 . . . . 0.0 110.931 179.99 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 58.4 m -98.51 -32.45 11.46 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.875 -179.958 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -155.49 172.94 33.66 Favored Glycine 0 N--CA 1.451 -0.329 0 C-N-CA 120.746 -0.74 . . . . 0.0 112.509 179.998 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 0.3 OUTLIER -66.46 94.59 0.28 Allowed 'General case' 0 C--N 1.329 -0.283 0 CA-C-O 120.773 0.32 . . . . 0.0 110.843 -179.97 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -83.31 109.48 17.91 Favored Pre-proline 0 C--N 1.328 -0.346 0 CA-C-N 116.244 -0.434 . . . . 0.0 110.932 179.982 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 48.4 Cg_endo -68.51 -24.51 36.09 Favored 'Trans proline' 0 C--N 1.346 0.405 0 C-N-CA 122.441 2.094 . . . . 0.0 112.377 179.927 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 3.0 p -58.14 -52.23 66.43 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.28 -0.418 . . . . 0.0 110.904 -179.965 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 43.3 m 60.27 89.21 0.11 Allowed Pre-proline 0 C--N 1.329 -0.284 0 CA-C-N 116.198 -0.456 . . . . 0.0 110.904 179.943 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 50.4 Cg_endo -68.96 154.11 71.38 Favored 'Trans proline' 0 C--N 1.345 0.382 0 C-N-CA 122.551 2.167 . . . . 0.0 112.319 179.98 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 58.1 m -128.64 -46.62 1.29 Allowed 'General case' 0 C--N 1.327 -0.371 0 CA-C-N 116.269 -0.423 . . . . 0.0 110.825 -179.975 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -156.33 -46.33 0.07 Allowed 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.856 -179.994 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -131.11 67.95 0.56 Allowed Glycine 0 N--CA 1.45 -0.372 0 C-N-CA 120.738 -0.744 . . . . 0.0 112.499 -179.962 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 0.6 OUTLIER -88.37 132.45 34.43 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-O 120.842 0.353 . . . . 0.0 110.839 179.938 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -155.02 154.38 32.41 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.908 -179.992 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 19' ' ' GLN . . . . . . . . . . . . . 35.9 tp60 -144.29 -66.81 0.34 Allowed 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.198 -0.456 . . . . 0.0 110.941 179.916 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 20' ' ' GLN . . . . . . . . . . . . . 3.4 tt0 61.87 114.51 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.265 -0.425 . . . . 0.0 110.926 179.976 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 5.4 mtt180 -173.74 137.78 0.62 Allowed 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.259 -0.428 . . . . 0.0 110.798 179.975 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 3.8 tt0 -138.53 -53.48 0.6 Allowed 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.944 -179.996 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 102.38 105.69 2.93 Favored Glycine 0 N--CA 1.452 -0.247 0 C-N-CA 120.709 -0.758 . . . . 0.0 112.541 -179.944 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -144.81 134.81 23.87 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-O 120.817 0.341 . . . . 0.0 111.077 -179.975 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 25' ' ' LYS . . . . . 0.523 ' HD2' ' HB1' ' A' ' 89' ' ' ALA . 0.1 OUTLIER -70.62 -34.36 72.03 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.923 179.998 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -155.1 173.11 17.06 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.235 -0.439 . . . . 0.0 111.072 179.971 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 27' ' ' GLU . . . . . . . . . . . . . 7.4 mp0 -133.74 -178.63 5.1 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.955 179.994 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 25.6 t -73.43 98.96 1.05 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.061 -179.993 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 117.94 39.63 0.75 Allowed Glycine 0 N--CA 1.451 -0.327 0 C-N-CA 120.789 -0.72 . . . . 0.0 112.449 179.924 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 20.7 t70 -146.25 137.68 24.66 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-O 120.842 0.353 . . . . 0.0 110.899 -179.978 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 31' ' ' GLN . . . . . . . . . . . . . 0.8 OUTLIER -59.96 137.33 58.11 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.121 -0.491 . . . . 0.0 110.961 179.938 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 6.2 m -141.28 171.67 11.77 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 116.234 -0.439 . . . . 0.0 111.11 -179.938 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 33' ' ' LEU . . . . . 0.683 HD13 ' HG3' ' A' ' 39' ' ' GLN . 33.9 tp -136.61 111.31 8.71 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.125 -0.488 . . . . 0.0 110.875 179.943 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 21.5 t -79.15 125.77 38.64 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-N 116.226 -0.443 . . . . 0.0 111.25 -179.978 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 35' ' ' ALA . . . . . . . . . . . . . . . 56.58 25.47 9.93 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.346 179.97 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . 57.54 31.69 63.73 Favored Glycine 0 N--CA 1.451 -0.306 0 C-N-CA 120.736 -0.745 . . . . 0.0 112.565 179.898 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 37' ' ' GLN . . . . . 0.577 ' O ' HD11 ' A' ' 33' ' ' LEU . 9.3 mt-30 -142.98 -74.28 0.28 Allowed 'General case' 0 C--N 1.33 -0.28 0 CA-C-O 120.818 0.342 . . . . 0.0 111.006 -179.971 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 38' ' ' LYS . . . . . 0.414 ' O ' HD12 ' A' ' 33' ' ' LEU . 46.0 mttp -63.51 112.59 2.84 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.896 -179.892 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 39' ' ' GLN . . . . . 0.683 ' HG3' HD13 ' A' ' 33' ' ' LEU . 2.1 mt-30 -87.6 139.6 30.37 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.837 179.926 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -172.87 171.42 44.39 Favored Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.697 -0.763 . . . . 0.0 112.512 179.993 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 3.2 mp -111.88 143.7 21.14 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-O 120.875 0.369 . . . . 0.0 111.114 179.978 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 42' ' ' VAL . . . . . . . . . . . . . 21.5 t -69.29 123.2 22.36 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.153 -0.476 . . . . 0.0 111.138 -179.995 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 43' ' ' ARG . . . . . . . . . . . . . 4.0 mmm180 -106.73 -31.54 8.38 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.891 -179.973 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 44' ' ' PHE . . . . . 0.417 ' CG ' ' HB3' ' A' ' 76' ' ' TYR . 15.2 t80 -147.82 106.26 3.78 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.879 -179.928 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 45' ' ' TYR . . . . . 0.496 ' CE1' ' CE1' ' A' ' 56' ' ' TYR . 14.3 t80 -111.03 123.88 51.06 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.294 -0.412 . . . . 0.0 110.935 179.893 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 171.54 -142.79 7.19 Favored Glycine 0 N--CA 1.45 -0.371 0 C-N-CA 120.649 -0.786 . . . . 0.0 112.462 -179.98 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 47' ' ' LYS . . . . . . . . . . . . . 24.7 mtpt -95.06 175.01 6.8 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-O 120.773 0.321 . . . . 0.0 110.906 179.993 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 48' ' ' THR . . . . . . . . . . . . . 44.8 p -138.79 -177.8 5.04 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.846 -179.996 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 4.4 t70 -129.04 17.59 6.13 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.154 -0.476 . . . . 0.0 111.259 179.924 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 50' ' ' PHE . . . . . . . . . . . . . 49.5 p90 -126.81 -44.98 1.62 Allowed 'General case' 0 C--N 1.331 -0.217 0 CA-C-N 116.447 -0.342 . . . . 0.0 110.892 179.961 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 51' ' ' ALA . . . . . 0.42 ' HB1' ' CZ2' ' A' ' 55' ' ' TRP . . . -123.5 145.37 46.72 Favored Pre-proline 0 C--N 1.329 -0.324 0 CA-C-N 116.291 -0.413 . . . . 0.0 111.122 179.944 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 52' ' ' PRO . . . . . . . . . . . . . 64.4 Cg_endo -73.59 164.7 34.26 Favored 'Trans proline' 0 C--N 1.345 0.36 0 C-N-CA 122.565 2.176 . . . . 0.0 112.32 -179.926 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 83.51 -177.2 52.65 Favored Glycine 0 N--CA 1.452 -0.287 0 C-N-CA 120.725 -0.75 . . . . 0.0 112.478 179.855 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 54' ' ' TYR . . . . . . . . . . . . . 7.8 m-85 -97.63 131.84 43.83 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-O 120.818 0.342 . . . . 0.0 110.862 -179.979 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 55' ' ' TRP . . . . . 0.42 ' CZ2' ' HB1' ' A' ' 51' ' ' ALA . 24.8 m95 -123.41 157.74 32.74 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.907 -179.994 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 56' ' ' TYR . . . . . 0.658 ' HE1' ' HB2' ' A' ' 89' ' ' ALA . 11.9 m-85 -109.69 126.84 54.12 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.977 -179.948 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . -84.46 62.08 4.62 Favored Glycine 0 N--CA 1.451 -0.36 0 C-N-CA 120.733 -0.746 . . . . 0.0 112.419 179.921 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 58' ' ' ILE . . . . . 0.492 HD11 HD13 ' A' ' 92' ' ' ILE . 15.9 mt -71.32 141.05 17.26 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-O 120.816 0.341 . . . . 0.0 111.108 -179.985 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER -109.89 122.14 46.85 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.885 179.951 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 60' ' ' LEU . . . . . . . . . . . . . 63.1 mt -82.69 170.3 15.26 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.945 -179.929 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 1.1 m-20 -100.6 -26.52 13.79 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.95 -179.97 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 62' ' ' GLN . . . . . . . . . . . . . 10.8 pt20 -110.41 152.16 43.13 Favored Pre-proline 0 C--N 1.329 -0.292 0 CA-C-N 116.299 -0.41 . . . . 0.0 110.922 -179.967 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 63' ' ' PRO . . . . . 0.417 ' O ' HG23 ' A' ' 64' ' ' THR . 49.7 Cg_endo -68.91 84.1 0.53 Allowed 'Trans proline' 0 C--N 1.345 0.357 0 C-N-CA 122.599 2.199 . . . . 0.0 112.312 179.971 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 64' ' ' THR . . . . . 0.417 HG23 ' O ' ' A' ' 63' ' ' PRO . 2.2 p -156.97 35.83 0.3 Allowed 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.213 -0.448 . . . . 0.0 110.894 -179.923 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . -91.65 -158.6 34.72 Favored Glycine 0 N--CA 1.451 -0.359 0 C-N-CA 120.757 -0.735 . . . . 0.0 112.443 -179.961 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 66' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -114.07 -36.69 4.67 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-O 120.735 0.303 . . . . 0.0 110.889 -179.997 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 67' ' ' HIS . . . . . . . . . . . . . 6.9 p80 -127.08 170.26 12.54 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.261 -0.427 . . . . 0.0 110.909 -179.903 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 5.4 m-20 -98.8 30.87 3.15 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.165 -0.471 . . . . 0.0 110.85 179.973 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 105.46 -42.76 1.82 Allowed Glycine 0 N--CA 1.452 -0.257 0 C-N-CA 120.667 -0.777 . . . . 0.0 112.457 179.915 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 70' ' ' SER . . . . . . . . . . . . . 63.4 p -108.62 141.76 40.08 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.798 0.333 . . . . 0.0 110.92 179.966 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 21.5 t -117.45 109.9 29.17 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 116.25 -0.432 . . . . 0.0 111.112 179.957 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 72' ' ' PHE . . . . . . . . . . . . . 40.7 m-85 60.66 30.58 19.82 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.932 -179.972 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 101.08 -30.02 11.26 Favored Glycine 0 N--CA 1.451 -0.353 0 C-N-CA 120.705 -0.759 . . . . 0.0 112.51 179.999 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 21.5 t -78.66 117.88 24.94 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-O 120.764 0.316 . . . . 0.0 111.152 -179.977 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 75' ' ' ARG . . . . . . . . . . . . . 10.3 ttm180 -98.33 145.67 26.45 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.894 -179.984 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 76' ' ' TYR . . . . . 0.417 ' HB3' ' CG ' ' A' ' 44' ' ' PHE . 12.6 m-85 -119.93 -42.36 2.61 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.852 -179.96 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 77' ' ' PHE . . . . . . . . . . . . . 26.6 p90 -153.13 158.89 42.52 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.875 179.991 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 12.0 p -89.96 99.53 12.52 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.91 -180.0 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 79' ' ' CYS . . . . . . . . . . . . . 30.5 p -117.93 173.95 6.48 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.85 179.977 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 80' ' ' ALA . . . . . 0.644 ' HB3' ' CG ' ' A' ' 83' ' ' HIS . . . -80.72 168.0 28.49 Favored Pre-proline 0 C--N 1.329 -0.308 0 CA-C-N 116.149 -0.478 . . . . 0.0 111.061 -179.975 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 81' ' ' PRO . . . . . 0.561 ' HD2' ' HB1' ' A' ' 80' ' ' ALA . 54.1 Cg_exo -52.14 112.18 0.8 Allowed 'Trans proline' 0 C--N 1.345 0.347 0 C-N-CA 122.554 2.169 . . . . 0.0 112.296 179.974 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 82' ' ' ARG . . . . . . . . . . . . . 12.9 mtp180 59.97 56.56 3.38 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.872 179.977 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 83' ' ' HIS . . . . . 0.644 ' CG ' ' HB3' ' A' ' 80' ' ' ALA . 5.1 m170 -121.48 -41.78 2.48 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.949 179.967 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . -71.44 142.22 33.59 Favored Glycine 0 N--CA 1.451 -0.301 0 C-N-CA 120.786 -0.721 . . . . 0.0 112.516 179.997 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 85' ' ' VAL . . . . . 0.4 ' O ' HG23 ' A' ' 85' ' ' VAL . 22.3 m -144.48 124.03 7.27 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-O 120.785 0.326 . . . . 0.0 111.089 179.943 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 86' ' ' PHE . . . . . . . . . . . . . 24.1 m-85 -101.28 121.26 41.56 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.974 179.927 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 87' ' ' ALA . . . . . 0.547 ' O ' HD11 ' A' ' 92' ' ' ILE . . . -138.64 146.54 51.03 Favored Pre-proline 0 C--N 1.329 -0.3 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.102 179.981 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 88' ' ' PRO . . . . . 0.431 ' O ' ' N ' ' A' ' 91' ' ' ARG . 41.8 Cg_exo -56.92 139.15 88.79 Favored 'Trans proline' 0 C--N 1.345 0.379 0 C-N-CA 122.487 2.125 . . . . 0.0 112.313 -179.934 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 89' ' ' ALA . . . . . 0.658 ' HB2' ' HE1' ' A' ' 56' ' ' TYR . . . -48.08 -48.39 33.58 Favored 'General case' 0 C--O 1.232 0.141 0 CA-C-N 116.076 -0.511 . . . . 0.0 110.24 179.818 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 90' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -55.53 -24.54 32.62 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 115.681 -0.69 . . . . 0.0 109.779 178.779 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 91' ' ' ARG . . . . . 0.431 ' N ' ' O ' ' A' ' 88' ' ' PRO . 0.7 OUTLIER -92.13 -13.55 30.53 Favored 'General case' 0 N--CA 1.455 -0.195 0 CA-C-N 115.877 -0.601 . . . . 0.0 110.62 179.201 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 92' ' ' ILE . . . . . 0.547 HD11 ' O ' ' A' ' 87' ' ' ALA . 50.1 mt -105.74 154.39 7.01 Favored 'Isoleucine or valine' 0 C--N 1.333 -0.12 0 CA-C-O 120.836 0.35 . . . . 0.0 111.013 179.796 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 93' ' ' GLN . . . . . 0.424 ' N ' HG22 ' A' ' 92' ' ' ILE . 0.3 OUTLIER -124.07 176.93 6.06 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.911 -179.978 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 94' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER -111.47 160.98 16.61 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.845 -179.989 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 95' ' ' ILE . . . . . . . . . . . . . 30.8 mt -139.8 -47.63 0.3 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.097 179.961 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . -66.92 -161.54 1.24 Allowed Glycine 0 N--CA 1.451 -0.329 0 C-N-CA 120.74 -0.743 . . . . 0.0 112.519 179.91 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 97' ' ' SER . . . . . . . . . . . . . 1.2 t 60.74 105.73 0.02 OUTLIER 'General case' 0 C--N 1.328 -0.35 0 CA-C-O 120.79 0.329 . . . . 0.0 110.802 179.965 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 98' ' ' GLY . . . . . . . . . . . . . . . -112.21 71.46 0.22 Allowed Glycine 0 N--CA 1.451 -0.33 0 C-N-CA 120.764 -0.732 . . . . 0.0 112.559 179.933 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 99' ' ' PRO . . . . . . . . . . . . . 55.6 Cg_endo -70.06 -44.61 1.79 Allowed 'Trans proline' 0 C--N 1.343 0.282 0 C-N-CA 122.504 2.136 . . . . 0.0 112.291 179.996 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 100' ' ' SER . . . . . . . . . . . . . 1.4 m -142.2 172.58 12.49 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.98 179.976 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 67.4 m -89.1 174.88 7.63 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.248 -0.433 . . . . 0.0 110.857 -179.992 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.25 1.145 0 CA-C-O 118.308 -1.273 . . . . 0.0 112.508 -179.994 . . . . . . . . 0 0 . 1 stop_ save_